human
prolactin
hprl
kda
polypeptide
hormone
produce
primarily
anterior
pituitary
gland
expression
hprl
pituitary
regulate
multiple
signal
pathway
mediate
epidermal
growth
factor
egf
second
messenger
camp
hormone
hormone
hormone
estrogen
glucocorticoid
baudhuin
freeman
pleiotropic
hormone
prl
exercise
much
biological
activity
binding
cognate
receptor
goffin
human
well
know
function
prl
stimulate
growth
development
mammary
gland
ultimately
lead
milk
production
secretion
goffin
mounting
evidence
cell
culture
animal
study
well
epidemiological
study
hankinson
vonderhaar
vonderhaar
llovera
llovera
clevenger
allow
appreciate
contribution
hprl
pathogenesis
progression
human
breast
cancer
however
anticancer
therapy
design
block
expression
secretion
pituitary
hormone
hprl
growth
hormone
little
effect
patient
human
breast
cancer
research
well
clevenger
clevenger
provide
explanation
observation
local
expression
hprl
create
autocrine
paracrine
loop
within
human
breast
addition
mammary
gland
prl
also
produce
locally
multiple
extrapituitary
site
include
placenta
uterus
bone
prostate
brain
immune
system
freeman
clevenger
prl
mrna
detect
normal
neoplastic
human
breast
tissue
well
human
mammary
cell
line
include
derived
breast
epithelial
carcinoma
clevenger
ginsburg
vonderhaar
vonderhaar
human
prl
protein
also
detect
cell
derivative
cell
ginsburg
vonderhaar
additionally
cell
contain
vladusic
vonderhaar
make
excellent
candidate
study
estrogen
regulation
synthesis
hprl
breast
cancer
cell
hprl
antagonist
block
cultured
mammary
tumor
cell
growth
far
support
existence
autocrine
paracrine
loop
fuh
wells
ginsburg
vonderhaar
chen
whereas
mammary
prl
may
play
role
normal
mammary
development
human
breast
cancer
progression
regulation
hprl
mammary
tissue
human
breast
cancer
cell
understand
extrapituitary
prl
expression
mainly
regulate
distal
promoter
locate
kb
upstream
pituitary
promoter
berwaer
gellersen
result
alternative
promoter
usage
extrapituitary
prl
regulate
different
signal
pathway
different
hormone
cytokine
neuropeptide
compare
regulation
pituitary
goffin
prl
expression
via
extrapituitary
distal
prl
promoter
also
demonstrate
primary
leukocyte
leukemic
cell
line
also
report
distal
promoter
functional
many
human
breast
cancer
cell
cell
baudhuin
present
evidence
estrogen
directly
induce
hprl
gene
expression
human
breast
cancer
cell
identify
functional
estrogen
responsive
element
site
locate
hprl
distal
promoter
estradiol
act
gel
shift
chromatin
immunoprecipitation
assay
show
directly
bind
interact
protein
bind
site
hprl
distal
promoter
promoter
reporter
gene
study
demonstrate
site
require
full
induction
promoter
activity
study
suggest
interaction
estrogen
transcription
factor
regulation
autocrine
paracrine
prl
human
breast
may
critical
oncogenesis
may
contribute
progression
breast
cancer
material
cell
culture
reagent
human
breast
cancer
cell
line
obtain
american
type
culture
collection
manassas
va
usa
cell
routinely
maintain
rpmi
supplement
fetal
bovine
serum
fbs
invitrogen
gaithersburg
md
usa
insulin
ml
sigma
aldrich
louis
usa
penicillin
ml
streptomycin
ml
invitrogen
cyclohexamide
chx
estradiol
genistein
actinomycin
purchase
sigma
ici
obtain
astrazeneca
pharmaceutical
lp
wilmington
usa
ppt
bis
dpn
purchase
tocris
cookson
ellisville
usa
hcl
mpp
obtain
research
usa
total
rna
extract
ethanol
etoh
vehicle
control
cell
trizol
reagent
invitrogen
invitrogen
treat
rna
reverse
transcribe
mmlv
reverse
transcriptase
invitrogen
prime
random
final
volume
cdna
subject
pcr
amplification
specific
gene
primer
pcr
master
mix
roche
molecular
biochemical
indianapolis
usa
negative
control
reverse
transcription
lack
enzyme
control
perform
absence
product
primer
hprl
forward
reverse
pcr
condition
min
follow
min
min
min
cycle
final
extension
min
gene
expression
level
determine
express
relative
constitutive
level
human
gapdh
determine
primer
forward
reverse
pcr
condition
min
final
extension
min
give
experiment
pcr
perform
predetermine
number
cycle
span
linear
range
sample
test
cycle
product
resolve
agarose
gel
electrophoresis
visualize
ethidium
bromide
quantify
nih
image
analysis
conduct
triplicate
replicate
least
two
separate
experiment
previously
show
method
consistently
robust
reproducible
result
comparable
sybr
green
quantitative
method
plasmids
transient
transfection
luciferase
assay
plasmids
contain
splice
variant
cdna
gift
safe
texas
university
richard
miksicek
physiology
department
state
university
respectively
hprl
promoter
luc
reporter
construct
luc
luc
vector
kindly
provide
university
western
ontario
ontario
canada
deletion
mutation
analysis
deletion
construct
span
produce
digestion
luc
plus
dna
separately
mutation
introduce
site
promoter
fragment
ii
xl
kit
usa
mutate
primer
follow
transient
transfection
perform
reagent
roche
applied
science
indianapolis
usa
ratio
dna
cell
seed
plate
cell
ml
phenol
red
free
medium
charcoal
strip
fbs
gemini
usa
prior
transfection
well
transfected
empty
vector
ev
variant
lack
dna
binding
domain
cell
dprl
luc
medium
change
cell
treat
without
indicate
cell
extract
prepare
wash
cell
twice
phosphate
buffer
saline
ph
lysed
reporter
lysis
buffer
promega
centrifuged
rpm
min
supernatant
reporter
gene
assay
store
firefly
renilla
luciferase
activity
measure
dual
luciferase
assay
system
promega
madison
usa
luminometer
electrophoretic
mobility
shift
assay
emsa
nuclear
extract
obtain
cell
treat
without
extraction
nuclear
protein
emsa
perform
describe
briefly
sense
antisense
oligonucleotide
corresponding
erep
sense
antisense
sense
antisense
dprl
promoter
consensus
sense
antisense
promega
anneal
label
amersham
nj
usa
presence
kinase
promega
emsa
perform
gel
shift
assay
core
system
promega
reaction
resolve
polyacrylamide
gel
electrophoresis
prior
autoradiography
emsa
experiment
perform
least
three
time
chromatin
immunoprecipitation
chip
assay
chip
assay
perform
chip
assay
kit
active
motif
carlsbad
usa
cell
either
treat
etoh
vehicle
concentration
etoh
never
exceed
protein
bind
dna
formaldehyde
final
concentration
min
protein
dna
complex
subsequently
immunoprecipitated
primary
antibody
igg
santa
cruz
biotechnology
santa
cruz
usa
reverse
heating
dna
recover
analyzed
pcr
pcr
perform
primer
amplify
dprl
promoter
region
include
either
forward
reverse
site
forward
reverse
amplification
condition
follow
min
follow
cycle
min
final
extension
min
sample
run
agarose
gel
visualize
ethidium
bromide
staining
chip
analysis
perform
three
time
similar
result
statistical
analysis
statistical
analysis
perform
anova
compare
significance
treat
untreated
group
result
express
mean
estrogen
regulation
human
prolactin
expression
previous
study
show
hprl
produce
secrete
human
breast
cancer
cell
confirm
investigator
clevenger
since
estrogen
play
important
role
regulation
hprl
expression
pituitary
gland
examine
effect
hprl
expression
human
breast
cancer
cell
cell
choose
synthesize
significant
quantity
hprl
express
show
consistently
induce
hprl
mrna
level
concentration
nm
great
manner
physiological
concentration
nm
induce
hprl
mrna
level
much
time
course
treatment
indicate
hprl
expression
rapidly
induce
upon
hormone
addition
increase
mrna
level
obtain
treatment
maximal
induction
rapid
effect
hprl
mrna
level
suggest
directly
regulate
expression
hprl
cell
stimulate
absence
presence
protein
synthesis
inhibitor
cycloheximide
chx
treatment
cell
chx
result
slight
increase
hprl
mrna
expression
suggest
transcriptional
activation
dependent
novo
synthesis
intermediate
protein
rather
directly
regulate
transcription
level
datum
confirm
activation
hprl
occur
transcriptional
level
since
actinomycin
inhibitor
rna
synthesis
completely
abolish
induction
hprl
mrna
image
directly
regulate
hprl
expression
cell
cell
cultured
presence
absence
indicate
concentration
without
nm
indicate
time
period
triplicate
sample
analyzed
hprl
gapdh
mrna
expression
ethidium
agarose
gel
electrophoresis
effect
cyclohexamide
chx
actinomycin
act
ml
hprl
expression
cell
cell
treat
without
chx
act
min
add
control
vehicle
etoh
subsequently
analysis
hprl
gapdh
perform
data
mean
present
digitized
nih
image
normalize
gapdh
representative
obtain
three
separate
experiment
chx
act
negative
control
positive
control
hprl
plasmid
view
within
article
estrogen
stimulation
human
prolactin
distal
promoter
activity
order
investigate
whether
directly
stimulate
hprl
promoter
activity
cell
transiently
transfected
luc
promoter
reporter
construct
internal
control
plasmid
treat
presence
absence
follow
measurement
luciferase
activity
luciferase
activity
cell
transfected
plasmid
manner
peak
induction
nm
plasmid
datum
show
time
course
treatment
cell
transiently
transfected
luc
promoter
reporter
construct
plasmid
show
induce
increase
luciferase
activity
rapidly
result
suggest
regulate
hprl
gene
expression
distal
promoter
image
stimulate
hprl
hprl
distal
promoter
activity
location
fragment
distal
proximal
pituitary
promoter
cell
transfected
luc
internal
control
vector
construct
treat
without
indicate
concentration
nm
indicate
time
period
follow
measurement
luciferase
activity
dual
luciferase
reporter
system
result
show
arbitrary
unit
control
etoh
vehicle
set
bar
mean
representative
experiment
carry
compare
control
view
within
article
mediate
hprl
distal
promoter
activity
estrogen
regulate
gene
expression
binding
cognate
receptor
two
subtype
identify
therefore
utilize
agonist
antagonist
different
receptor
specificity
examine
effect
promoter
activity
ici
identify
ligand
ppt
mpp
identify
specific
ligand
harris
sun
genistein
dpn
complete
antagonist
agonist
thus
agonist
ppt
genistein
dpn
induce
luciferase
activity
manner
antagonist
mpp
completely
block
ppt
induction
promoter
activity
partially
inhibit
induction
luciferase
activity
contrast
pure
antiestrogen
ici
completely
abolish
activity
interestingly
induce
luciferase
activity
partially
inhibit
activity
result
suggest
subtype
mediate
estrogen
induction
dprl
promoter
activity
cell
address
issue
transiently
transfected
either
human
breast
cancer
cell
line
along
luc
find
mediate
induction
dprl
promoter
induction
lesser
extent
domain
deletion
variant
also
fail
fully
induce
dprl
promoter
result
show
pathway
able
fully
activate
hprl
distal
promoter
pathway
confer
partial
activation
suggest
multiple
mechanism
involve
one
require
direct
dna
binding
image
mediate
hprl
distal
promoter
specific
ligand
stimulate
hprl
distal
promoter
activity
cell
transfected
luc
construct
treat
without
ppt
genistein
indicate
effect
antagonist
hprl
distal
promoter
activity
cell
transfected
treat
ethanol
vehicle
nm
ppt
nm
mpp
ici
alone
combination
effect
specific
ligand
hprl
distal
promoter
activity
cell
transfected
treat
ethanol
vehicle
dpn
ici
alone
combination
subsequently
dual
luciferase
assay
perform
result
show
arbitrary
unit
control
etoh
vehicle
set
bar
mean
representative
experiment
carry
effect
variant
cell
cell
transfected
empty
vector
ev
dprl
luc
cell
treat
without
nm
follow
measurement
luciferase
activity
dual
luciferase
reporter
system
result
show
arbitrary
unit
control
etoh
vehicle
set
bar
mean
representative
experiment
carry
compare
compare
ppt
dpn
view
within
article
estrogen
stimulation
dprl
promoter
activity
site
upon
binding
estrogen
regulate
gene
expression
variety
mechanism
include
genomic
pathway
order
elucidate
dna
element
responsible
induction
promoter
activity
perform
computational
analysis
promoter
prepare
two
deletion
mutant
show
responsiveness
luc
similar
luc
however
elicit
response
empty
vector
proximal
hprl
promoter
luc
element
confer
responsiveness
paech
jakacka
safe
fujimoto
therefore
introduce
mutation
site
test
responsiveness
demonstrate
mutation
either
site
alone
decrease
induction
significant
induction
luciferase
still
observe
however
mutation
site
completely
abolish
induction
result
suggest
site
present
dprl
promoter
responsible
induction
hprl
cell
image
maximal
induction
hprl
distal
promoter
activity
require
computational
analysis
kb
fragment
regulatory
region
human
dprl
promoter
demonstrate
presence
potential
binding
site
two
site
mutate
emsa
see
indicate
arrow
cell
transfected
luc
luc
mutation
construct
cell
treat
without
nm
follow
measurement
luciferase
activity
dual
luciferase
reporter
system
result
show
arbitrary
unit
control
etoh
vehicle
set
bar
mean
representative
experiment
carry
triplicate
mutation
site
mutation
ae
mutation
compare
control
view
within
article
bind
interact
complex
comparison
present
dprl
promoter
consensus
reveal
one
order
investigate
whether
bind
dprl
promoter
perform
emsa
sequence
dprl
promoter
chip
assay
show
treatment
lead
formation
two
complex
compete
away
unlabelled
consensus
dprl
promoter
mutate
additionally
treatment
increase
protein
dna
complex
formation
emsa
sequence
dprl
promoter
compete
away
unlabelled
consensus
oligonucleotide
sequence
dprl
promoter
mutate
site
chip
assay
antibody
pull
fragment
however
well
antibody
pull
dna
fragment
suggest
bind
present
dprl
promoter
interact
protein
bind
site
present
dprl
promoter
image
induce
protein
dna
complex
formation
site
present
hprl
distal
analysis
site
present
hprl
distal
promoter
present
dprl
promoter
compare
gene
adapt
basis
indicate
letter
nuclear
extract
prepare
cell
treat
without
nm
emsa
perform
erep
site
distal
prl
promoter
site
distal
prl
promoter
mutation
site
mutation
recruitment
site
dprl
promoter
chip
assay
perform
describe
section
protein
dna
complex
immunoprecipitated
indicate
primary
antibody
reversal
dna
recover
analyzed
pcr
pcr
perform
primer
target
site
dprl
promoter
view
within
article
taken
together
result
demonstrate
estrogen
directly
induce
hprl
gene
expression
human
breast
cancer
cell
cooperative
action
site
present
hprl
distal
promoter
site
discussion
pituitary
gland
think
exclusive
source
hprl
however
variety
study
prove
hprl
also
produce
locally
several
extrapituitary
site
include
notably
mammary
gland
freeman
prl
mrna
detect
normal
neoplastic
human
breast
tissue
well
human
mammary
cell
line
derived
breast
epithelial
carcinoma
clevenger
ginsburg
vonderhaar
increasing
evidence
support
existence
autocrine
paracrine
loop
human
breast
tissue
cancer
cell
line
fuh
wells
ginsburg
vonderhaar
chen
several
study
demonstrate
prl
might
play
role
normal
mammary
development
human
breast
cancer
progression
underscore
importance
understand
regulation
expression
extrapituitary
prl
expression
primarily
regulate
distal
promoter
berwaer
gellersen
functional
human
breast
cancer
cell
well
primary
leukocyte
leukemic
cell
line
contrast
report
egf
stimulate
hprl
pituitary
promoter
human
breast
cancer
cell
proximal
responsive
element
present
evidence
estrogen
stimulate
hprl
distal
promoter
human
breast
cancer
cell
site
estrogen
via
cognate
receptor
regulate
gene
expression
multiple
mechanism
classical
model
upon
binding
bind
specific
dna
element
transactivate
transcription
target
recently
several
alternative
pathway
describe
include
response
element
bind
directly
rather
result
interaction
transcriptional
factor
paech
jakacka
safe
fujimoto
several
signal
transduction
cascade
activate
estrogen
various
tissue
cell
line
estrogen
upregulation
prl
gene
expression
pituitary
cell
via
protein
kinase
signal
transduction
pathway
kinase
pathway
appear
activate
estrogen
include
pka
pkc
pathway
analysis
hprl
distal
promoter
many
potential
dna
responsive
element
find
activate
estrogen
however
deletion
mutation
study
demonstrate
promoter
region
include
responsive
estrogen
site
require
full
induction
promoter
activity
fujimoto
coworkers
report
environmental
estrogenic
chemical
activate
consistent
work
consistent
observation
find
pathway
confer
much
robust
induction
hprl
distal
promoter
pathway
cell
interaction
study
find
bind
present
dprl
promoter
interact
protein
bind
site
well
document
play
key
role
breast
development
carcinogenesis
identification
presence
variant
human
breast
cancer
cell
make
process
gene
regulation
estrogen
even
much
complicate
miksicek
vladusic
mounting
evidence
show
hprl
cognate
receptor
prlr
implicate
development
progression
human
breast
cancer
hankinson
vonderhaar
llovera
clevenger
complex
interaction
prl
estrogen
relationship
protein
human
breast
cancer
extensively
address
human
expose
hormone
simultaneously
addition
induction
autocrine
paracrine
prl
demonstrate
herein
estrogen
also
stimulate
prlr
gene
expression
human
breast
cancer
cell
ormandy
although
correlation
prlr
consistent
within
literature
bonneterre
placido
ormandy
recently
report
estradiol
hprlr
gene
expression
novel
transcriptional
mechanism
ebp
transcription
factor
involve
moreover
clinical
study
show
reduce
expression
hprlr
breast
tumor
patient
give
tamoxifen
work
laboratory
demonstrate
expression
prl
prlr
find
much
female
breast
carcinoma
high
normal
breast
tissue
reynolds
report
interaction
hprl
estrogen
enhance
activity
breast
cancer
cell
mapk
pathway
thus
interaction
among
prl
prlr
estrogen
protein
may
significant
increase
entire
prl
prlr
autocrine
system
breast
cancer
additional
study
prl
pathway
human
breast
cancer
cell
will
increase
understanding
key
interaction
occur
development
disease
potentially
lead
improve
treatment
modality
acknowledgement
research
support
research
program
nih
center
cancer
research
nci
addition
role
transcription
nuclear
process
role
chromatin
modification
dna
break
dsb
repair
recently
first
histone
modification
discover
specifically
associate
dsb
phosphorylation
term
chromatin
mark
induce
kinase
relate
encompass
chromatin
region
span
thousand
million
base
pair
surround
lesion
histone
gene
essential
genomic
instability
sensitivity
agent
observe
absence
report
two
independent
study
mouse
reveal
significantly
increase
incidence
tumorigenesis
absence
gene
inactivate
tumor
suppressor
gene
breast
cancer
represent
one
much
heterogeneous
form
cancer
morphologically
genetically
addition
gene
identify
breast
cancer
susceptibility
gene
atm
also
know
function
dna
damage
response
pathway
hence
speculate
dna
damage
response
pathway
possible
major
target
inactivation
breast
cancer
several
study
attempt
identify
mutation
dna
damage
response
gene
also
numerous
association
study
candidate
polymorphism
clear
major
target
emerge
study
provide
enough
evidence
key
gene
pivotal
role
neoplastic
progression
histone
gene
map
region
commonly
delete
translocated
several
hematologic
malignancy
solid
tumor
mouse
model
study
raise
possibility
may
serve
tumor
suppressor
human
haploinsufficiency
cancer
predisposition
mouse
recent
study
demonstrate
activate
cell
suppress
progression
dsb
chromosomal
break
translocation
study
fortify
tumor
suppressor
role
human
present
study
screen
dna
sporadic
breast
cancer
patient
presence
mutation
gene
estimate
relative
gene
copy
number
pair
study
quantitative
polymerase
chain
reaction
pcr
investigation
reveal
although
gene
sequence
conserve
significant
alteration
term
gene
copy
number
tumor
sample
compare
adjacent
normal
tissue
material
sample
collection
according
instruction
institutional
review
board
freeze
mastectomy
specimen
tumor
pair
adjacent
tissue
consecutive
patient
invasive
ductal
carcinoma
breast
obtain
dharamshila
cancer
hospital
research
institute
delhi
clinicopathologic
variable
measure
diagnosis
obtain
patient
record
describe
detail
table
enrolled
patient
receive
chemotherapy
radiation
therapy
operation
free
distant
metastases
accord
preoperative
evaluation
table
association
alter
copy
number
clinicopathologic
feature
sporadic
breast
cancer
patient
amplification
age
yr
menopausal
status
tumor
size
nodal
status
stage
grade
estrogen
receptora
progesterone
receptora
somatic
mutation
table
significant
value
show
bold
face
data
available
six
tumor
sample
view
within
article
total
dna
extraction
total
dna
tumor
adjacent
normal
tissue
hela
cell
line
extract
mammalian
genomic
dna
kit
louis
accord
manufacturer
instruction
quantity
measure
nanodrop
nanodrop
technology
wilmington
sample
purity
range
nm
ratio
highly
efficient
amplification
dna
dilute
final
concentration
mutation
detection
pcr
follow
primer
amplify
gene
promoter
untranslated
region
forward
reverse
coding
region
forward
reverse
forward
reverse
pcr
perform
dna
thermal
pcr
system
applied
biosystems
foster
city
reaction
mixture
contain
genomic
dna
pmol
forward
reverse
primer
mol
dntp
amplification
buffer
contain
mmol
unit
taq
dna
polymerase
bangalore
genei
bangalore
india
pcr
condition
follow
initial
denaturation
step
minute
follow
cycle
consist
step
minute
anneal
three
region
gene
respectively
minute
minute
final
extension
step
perform
minute
thereafter
pcr
product
check
agarose
gel
electrophoresis
purified
product
direct
dna
sequencing
automate
dna
sequencer
genetic
analyzer
applied
biosystems
heterozygosity
loh
analysis
marker
region
amplify
primer
sequence
give
genomic
data
base
pcr
perform
condition
similar
mention
except
anneal
temperature
follow
simple
sequence
length
polymorphism
high
performance
liquid
chromatography
analysis
ne
determination
copy
number
relative
change
copy
number
normal
tumor
pair
gapdh
reference
gene
determine
pcr
follow
comparative
threshold
cycle
method
sequence
primer
ttg
gta
aca
ggc
aca
tct
tcc
forward
primer
ttc
aaa
acg
act
ctt
reverse
primer
accession
aac
agc
gac
acc
cat
cct
forward
primer
cat
acc
agg
aaa
tga
gct
tga
caa
reverse
primer
accession
primer
gene
correspond
base
pair
bp
amplicon
locate
region
gene
target
reference
gene
amplify
separately
abi
prism
sequence
detection
system
pe
applied
biosystems
foster
city
usa
pcr
perform
total
volume
well
contain
sybr
green
pcr
master
mix
pe
applied
biosystems
genomic
dna
pmol
primer
pcr
condition
consist
initial
denaturation
step
minute
follow
cycle
second
minute
reaction
carry
duplicate
negative
control
template
keep
every
pcr
run
pcr
reaction
threshold
cycle
ct
number
establish
sds
software
applied
biosystems
copy
number
normalize
reference
gene
gapdh
relative
calibrator
normal
sample
respective
pair
determine
formula
twofold
increase
decrease
copy
number
tumor
sample
corresponding
pair
normal
sample
consider
amplification
deletion
respectively
comparison
copy
number
hela
cell
line
carry
similarly
statistical
analysis
analyze
correlation
tumor
alter
copy
number
clinicopathologic
parameter
pearson
test
fisher
exact
test
apply
evaluate
difference
group
consider
statistically
significant
sequencing
gene
present
study
sporadic
breast
cancer
patient
reveal
alteration
whole
coding
region
promoter
part
gene
gene
copy
number
alteration
breast
tumor
copy
number
analysis
gene
perform
sporadic
breast
cancer
sample
adjacent
normal
tissue
gapdh
reference
gene
exponential
growth
curve
gapdh
gene
five
value
range
copy
show
dissociation
curve
show
single
sharp
peak
corresponding
amplification
single
size
product
primer
dimer
formation
either
case
regression
curve
show
good
linearity
correlation
coefficient
whereas
slope
gapdh
standard
curve
respectively
indicate
nearly
pcr
efficiency
gene
ensure
acceptable
degree
precision
comparative
ct
method
determine
relative
copy
number
representative
graph
alteration
deletion
amplification
gene
copy
number
show
quantitative
pcr
analysis
pair
sporadic
breast
cancer
tissue
show
alteration
case
among
alteration
observe
amplification
deletion
respect
normal
sample
deletion
account
case
amplification
sample
image
exponential
growth
curve
five
serial
dilution
dissociation
curve
standard
curve
gapdh
respectively
view
within
article
image
representative
amplification
plot
show
alteration
deletion
amplification
gene
copy
number
sporadic
breast
tumor
sample
compare
match
normal
tissue
view
within
article
image
copy
number
analysis
gene
quantitative
pcr
pair
sporadic
breast
cancer
sample
bar
represent
copy
number
tumor
tissue
relative
normal
tissue
calculate
gapdh
reference
gene
pair
normal
calibrator
value
twofold
difference
show
dot
line
consider
amplification
deletion
respectively
comparison
normal
value
set
show
continuous
line
view
within
article
deletion
gene
copy
number
comparison
gene
copy
number
alteration
dna
hela
breast
cancer
cell
line
cell
reveal
twofold
deletion
gene
copy
number
gapdh
gene
copy
number
remain
constant
image
amplification
plot
show
alteration
gene
copy
number
compare
hela
cell
line
view
within
article
association
clinicopathologic
feature
association
copy
number
alteration
sample
patient
age
histologic
grade
stage
lymph
node
metastasis
hormone
receptor
status
marker
instability
mutation
status
datum
show
analyzed
patient
estrogen
progesterone
receptor
positive
tumor
significantly
alter
copy
number
pr
negative
tumor
respectively
table
compare
deletion
separately
however
trend
maintain
tumor
though
highly
significant
borderline
association
obtain
histologic
grade
association
gene
alteration
loh
marker
locate
megabase
mb
end
gene
reveal
despite
absence
significant
correlation
tumor
positive
marker
instability
gene
alteration
positive
compare
deletion
alone
association
somatic
mutation
gene
alteration
nonsignificant
table
discussion
rationale
investigate
status
gene
sporadic
breast
cancer
patient
based
finding
mouse
present
feature
genomic
instability
syndrome
gene
locate
mb
telomeric
atm
region
commonly
delete
human
cancer
include
breast
cancer
absence
gene
mutation
sequence
variation
dna
pair
breast
cancer
sample
match
result
make
two
previous
report
one
familial
breast
cancer
case
another
malignancy
suggest
highly
conserve
gene
germline
somatic
mutation
common
gene
however
rare
disease
mutation
still
possibility
interestingly
quantitative
pcr
analysis
show
gene
copy
number
alteration
tumor
tissue
case
somatic
event
involve
amplification
deletion
gene
dosage
effect
reflect
observation
make
know
developmental
defect
model
organism
certain
inherit
human
disease
implication
tumor
biology
context
haploinsufficiency
atm
key
dna
damage
response
gene
report
play
role
tumorigenesis
observation
alteration
copy
number
gene
majority
show
deletion
allelic
instability
loh
marker
emphasize
genomic
instability
region
observe
tumor
sample
furthermore
breast
cancer
cell
line
also
show
twofold
deletion
gene
copy
number
corroborate
observation
breast
carcinoma
tissue
suggest
deletion
gene
copy
number
role
breast
carcinogenesis
protein
know
get
phosphorylated
within
minute
dsb
induction
essential
tether
two
break
end
together
thereby
prevent
progression
deleterious
translocation
event
phosphorylated
molecule
per
dsb
require
large
amount
cover
megabase
chromatin
thousand
reduction
amount
protein
account
break
dna
end
problem
retention
repair
factor
completion
repair
process
distal
region
long
know
associate
human
cancer
analysis
comparative
genome
hybridization
show
deletion
region
several
cancer
however
copy
number
variation
particular
gene
region
explore
context
knowledge
present
study
first
report
alteration
copy
number
gene
locate
sporadic
breast
cancer
patient
although
majority
case
study
show
deletion
case
show
amplification
gene
speculate
deletion
amplification
probably
lead
insufficiency
overexpression
respectively
sporadic
breast
cancer
suggest
proper
gene
balance
dosage
gene
may
critical
normal
cellular
function
however
show
previous
report
overexpression
effect
cell
therefore
implication
overexpression
amplification
gene
still
remain
elusive
datum
demonstrate
significant
association
copy
number
alteration
tumor
furthermore
compare
deletion
alone
trend
maintain
histologic
grade
also
show
positive
association
fact
obtain
high
significance
value
histologic
grade
tumor
stage
probably
number
tumor
show
alteration
early
stage
well
know
pr
expression
increase
early
stage
tumorigenesis
speculate
dysregulation
hormone
receptor
expression
together
alteration
early
force
uncontrolled
proliferation
lead
accumulation
threshold
level
mutation
require
tumor
development
whether
alteration
associate
event
consequence
increase
receptor
expression
remain
explore
however
correlation
alter
copy
number
prevalence
somatic
mutation
generally
know
occur
tumor
based
preliminary
result
likely
mutation
alteration
involve
different
step
breast
cancer
progression
conclusion
present
study
first
demonstration
gene
copy
number
alteration
sporadic
breast
cancer
possibly
contribute
tumor
heterogeneity
aspect
explore
date
may
help
classify
tumor
accordingly
achieve
well
chemotherapeutic
intervention
acknowledgment
cooperation
doctor
staff
dharamshila
cancer
hospital
patient
involve
study
acknowledge
support
fellowship
department
biotechnology
india
support
fellowship
council
scientific
industrial
research
india
work
fund
grant
provide
university
grant
commission
ugc
national
center
applied
human
genetic
university
potential
excellence
project
school
life
science
university
breast
cancer
much
common
malignancy
woman
death
per
year
although
recent
advance
make
tumor
detection
treatment
development
clinical
metastasis
remain
significant
morbidity
mortality
disease
thus
control
tumor
metastasis
crucial
goal
successful
treatment
cancer
hgf
also
call
scatter
factor
control
genetic
program
know
invasive
growth
involve
critical
step
tumor
metastasis
factor
demonstrate
ability
stimulate
proliferation
dissociation
migration
invasion
wide
variety
tumor
cell
also
potent
angiogenic
factor
clinical
significance
hgf
receptor
met
human
mammary
cancer
begin
emerge
last
year
overexpression
hgf
receptor
met
human
mammary
tumor
compare
normal
mammary
tissue
clinical
importance
hgf
receptor
far
demonstrate
recent
study
show
level
met
mammary
cancer
tissue
level
circulate
hgf
patient
mammary
cancer
associate
survival
development
distant
metastasis
lung
liver
bone
frequent
site
breast
cancer
metastasis
indeed
patient
multiple
metastatic
site
liver
metastasis
exhibit
high
hgf
level
furthermore
increase
serum
hgf
level
significantly
associate
tumor
size
nodal
status
histological
evidence
venous
invasion
observation
suggest
importance
well
insight
role
hgf
met
tumor
metastasis
potential
targeting
pathway
therapeutic
strategy
hgf
met
signaling
pathway
responsible
invasive
growth
mostly
elucidate
downstream
signaling
component
include
akt
ras
mapk
jak
stat
pathway
activation
pathway
associate
increase
scatter
motility
invasion
proliferation
survival
morphogenesis
interaction
activate
met
may
enhance
activity
implicate
cytoskeletal
require
cell
motility
formation
focal
adhesion
change
actin
organization
cell
include
formation
highly
meshwork
actin
filament
lead
edge
cell
call
lamellipodia
membrane
ruffle
formation
short
bundle
actin
filament
cell
surface
call
moreover
akt
pathway
may
activate
ib
kinase
complex
ib
result
promote
nfb
liberate
nfb
translocated
nucleus
bind
cognate
sequence
promoter
region
many
target
gene
activate
gene
transcription
mmp
upa
degrade
basement
membrane
stromal
connective
tissue
believe
play
important
role
cancer
metastasis
addition
digest
extracellular
matrix
ecm
progression
invasion
carcinoma
require
constant
dynamic
remodeling
adhesive
contact
ecm
follow
invasion
interstitial
matrix
compose
subunits
major
family
cell
surface
receptor
mediate
attachment
ecm
link
ecm
intracellular
cytoskeletal
structure
hgf
may
promote
cell
adhesion
invasion
increase
avidity
integrin
specific
ligand
mechanism
suggest
aggregate
integrin
form
complex
endow
enhance
avidity
matrix
substrate
potentiate
adhesion
migration
efficiency
integrin
help
enhance
met
oncogenic
potential
receptor
various
isoform
basement
membrane
component
laminin
met
activation
result
tyrosine
phosphorylation
cytoplasmic
domain
thereafter
hgf
establish
study
model
flavonoid
breast
cancer
cell
effect
function
investigate
flavonoids
common
constituent
human
diet
present
much
fruit
vegetable
comprise
several
class
include
flavonol
flavone
isoflavone
several
case
flavonoid
report
possess
anticancer
potential
apigenin
toxicity
flavone
widely
distribute
many
fruit
vegetable
include
orange
sprout
tea
show
induce
apoptosis
cancer
cell
exert
effect
inhibit
invasive
process
mechanism
unclear
previous
report
show
luteolin
flavone
inhibit
cell
invasion
involve
mapk
erk
akt
pathway
aim
study
evaluate
inhibitory
effect
apigenin
invasion
metastasis
breast
cancer
cell
investigate
molecular
mechanism
involve
material
method
antibody
reagent
sapk
antibody
purchase
cell
signaling
technology
beverly
ma
jnk
sapk
akt
antibody
obtain
santa
cruz
biotechnology
santa
cruz
mab
chemicon
international
matrigel
collaborative
research
bedford
ma
solubilized
basement
membrane
preparation
extract
mouse
sarcoma
contain
laminin
collagen
type
iv
proteoglycans
growth
factor
recombinant
hgf
purchase
louis
inhibitor
wortmannin
obtain
calbiochem
la
jolla
four
flavonoid
namely
naringenin
apigenin
genistein
kaempferol
purchase
louis
image
image
effect
flavonoid
migration
invasion
chemical
structure
hgf
ml
apply
chamber
chemoattractive
agent
cell
seed
onto
upper
chamber
consist
filter
coat
without
migration
assay
matrigel
basement
membrane
matrix
invasion
assay
incubate
various
type
flavonoid
cell
migrate
invade
surface
membrane
count
light
microscope
datum
represent
mean
sd
three
independent
analysis
view
within
article
cell
culture
human
breast
carcinoma
cell
lung
carcinoma
cell
carcinoma
cell
invasive
cell
line
obtain
atcc
maintain
dulbecco
modify
eagle
medium
dmem
gibco
brl
grand
island
fetal
bovine
serum
fbs
penicillin
streptomycin
amino
acid
cell
line
maintain
incubator
air
addition
hgf
cell
incubate
overnight
without
serum
human
umbilical
vein
endothelial
cell
huvec
isolate
term
umbilical
cord
maintain
complete
medium
medium
mm
hepes
ph
fetal
calf
serum
mm
glutamine
ml
heparin
ml
crude
endothelial
cell
growth
supplement
ml
penicillin
ml
streptomycin
tissue
culture
dish
cell
passage
cell
viability
assay
cell
seed
well
plate
cell
well
cultured
complete
grow
medium
grow
medium
another
cell
treat
without
naringenin
apigenin
genistein
kaempferol
thereafter
medium
change
incubate
bromide
mtt
dye
solution
promega
southampton
uk
number
viable
cell
directly
proportional
production
formazan
dissolve
dmso
measure
spectrophotometrically
nm
microplate
reader
molecular
devices
sunnyvale
comparative
cell
viability
flavonoid
control
cell
evaluate
effective
dose
express
vitro
cell
migration
invasion
assay
matrigel
bd
transduction
laboratory
contain
laminin
collagen
type
iv
proteoglycans
growth
factor
dilute
dmem
diluted
matrigel
plate
top
boyden
chamber
allow
gel
cell
pretreated
without
indicate
concentration
flavonoid
integrin
mab
wortmannin
cell
cell
ml
suspend
medium
suspend
cell
place
top
well
dmem
without
ml
hgf
place
chamber
incubation
cell
upper
surface
filter
wipe
cotton
swab
cell
surface
filter
fix
min
methanol
stain
giemsa
cell
invade
surface
filter
count
microscope
replicate
cell
five
random
select
field
determine
count
average
migration
assay
procedure
except
polycarbonate
filter
coat
matrigel
scratch
motility
assay
cell
plate
well
plate
grow
overnight
confluency
medium
cell
serum
starve
monolayer
scratch
pipette
tip
wash
pbs
remove
float
cell
medium
photograph
various
concentration
apigenin
without
combination
hgf
ml
apply
number
cell
migrate
scratch
area
day
photograph
count
randomly
select
field
mean
value
per
field
express
analysis
cell
morphology
distribution
cell
seed
well
plate
density
well
cultured
dmem
contain
fbs
medium
replace
medium
another
pretreatment
apigenin
hgf
apply
incubation
cell
fix
paraformaldehyde
block
bsa
stain
phalloidin
observe
actin
cytoskeleton
mg
ml
dapi
add
visualize
nucleus
image
take
nikon
fluorescence
microscope
objective
preparation
total
cell
extract
immunoblot
analysis
cell
wash
pbs
plus
zinc
ion
mm
lysed
radio
immunoprecipitation
assay
ripa
buffer
mm
tris
buffer
mm
edta
mm
nacl
np
acid
mm
sodium
orthovanadate
ml
ml
leupeptin
ml
pmsf
ph
mix
min
mixture
centrifuged
min
supernatant
collect
extract
protein
content
determine
protein
assay
reagent
bovine
serum
albumin
standard
sample
contain
protein
boil
laemmli
sample
buffer
separate
sds
polyacrylamide
gel
transfer
nitrocellulose
membrane
amersham
arlington
heights
blot
indicate
primary
antibody
protein
visualize
horseradish
secondary
antibody
laboratory
south
san
francisco
follow
chemiluminescence
detection
santa
cruz
biotechnology
immunofluorescence
microscopy
cell
plate
onto
well
plate
costar
contain
glass
coverslip
previously
coat
describe
adhesion
assay
cell
pretreated
apigenin
wortmannin
incubation
min
presence
absence
hgf
ml
cell
fix
freshly
prepare
solution
contain
formaldehyde
sucrose
pbs
ph
min
room
temperature
cell
permeabilized
coverslip
buffer
mm
hepes
ph
mm
sucrose
mm
nacl
mm
triton
min
room
temperature
immunofluorescence
perform
previously
report
luca
brief
saturation
pbs
bsa
min
primary
antibody
layer
onto
cell
incubate
moist
chamber
min
rinsing
pbs
bsa
coverslip
incubate
appropriate
secondary
antibody
min
mount
hoechst
specimen
observe
inverted
model
hc
leica
fluorescence
image
capture
cool
digital
ccd
camera
digitally
record
imaging
software
cell
matrix
adhesion
assay
first
well
plate
coat
pbs
block
bsa
pbs
wash
pbs
air
dry
cell
pretreated
without
apigenin
integrin
mab
wortmannin
cell
harvest
wash
twice
medium
add
well
concentration
cell
ml
medium
incubation
min
presence
absence
hgf
unbound
cell
remove
wash
pbs
adherent
cell
fix
paraformaldehyde
stain
crystal
violet
min
wash
three
time
pbs
lysed
acetic
acid
solution
relative
cell
adhesion
quantify
monitor
absorbance
dye
nm
nonspecific
cell
adhesion
measure
well
subtract
cell
cell
adhesion
assay
cell
pretreated
without
apigenin
labeled
carboxyethyl
ester
min
labeled
cell
deposit
onto
huvec
monolayer
incubation
presence
absence
hgf
min
adhesion
determine
ex
nm
nm
sirna
transfection
small
interfere
rna
sirna
inhibition
akt
expression
achieve
akt
sirna
kit
accord
manufacturer
instruction
cell
signaling
technology
beverly
ma
briefly
cell
confluence
incubate
akt
sirna
negative
control
nonspecific
sirna
assess
transfection
efficiency
nm
transfection
efficiency
verify
cell
pretreated
without
apigenin
presence
absence
hgf
indicate
time
knockdown
protein
follow
sirna
transfection
confirm
western
blot
blot
strip
reprobed
well
monitor
protein
loading
nonspecific
rna
interference
effect
parallel
experiment
cell
perform
invasion
assay
describe
previously
experimental
metastasis
assay
nude
mouse
female
nude
mouse
experimental
metastasis
assay
generate
metastases
nude
mouse
cell
without
various
treatment
resuspended
pbs
contain
without
hgf
inject
tail
vein
day
mouse
sacrifice
week
injection
cancer
cell
organ
examination
find
disseminate
tumor
form
principally
lung
size
weight
lung
assess
addition
tumor
metastasis
assay
measure
lung
section
stain
hematoxylin
chick
embryo
metastasis
assay
similar
cell
pretreatment
nude
mouse
study
cell
suspend
medium
contain
without
hgf
seed
chick
chorioallantoic
membrane
cam
day
resected
ability
tumor
cell
primary
tumor
circulation
follow
spontaneous
metastasis
lung
liver
assess
detection
human
tumor
cell
cam
lung
liver
detection
human
tumor
cell
tissue
based
quantitative
detection
human
alu
sequence
present
dna
extract
tissue
genomic
dna
extract
harvest
tissue
dna
purification
system
system
minneapolis
mn
detect
human
tumor
cell
chick
tissue
primer
specific
human
alu
sequence
sense
acg
cct
gta
atc
cca
ctt
antisense
tcg
agg
ctg
gag
tgc
employ
amplify
human
alu
repeat
present
genomic
dna
extract
chick
tissue
pcr
employ
amplify
detect
alu
sequence
contain
genomic
dna
mm
primer
dntp
platinum
taq
polymerase
invitrogen
corporation
carlsbad
dilution
sybr
green
dye
molecular
probes
pcr
perform
final
volume
mineral
oil
laboratory
hercules
follow
condition
polymerase
activation
min
follow
cycle
quantitative
measure
chick
dna
obtain
amplification
chick
gapdh
genomic
dna
sequence
primer
sense
gag
gaa
agg
tcg
cct
ggt
gga
tcg
antisense
ggt
gag
gac
aag
cag
tga
gga
acg
pcr
condition
describe
alu
fluorescence
emit
reporter
dye
detect
online
threshold
cycle
ct
sample
record
quantitative
measure
amount
pcr
product
sample
ct
number
cycle
fluorescence
generate
reporter
dye
exceed
fix
level
baseline
indicate
alu
signal
normalize
relative
quantity
gapdh
express
ct
change
alu
signal
relative
total
amount
genomic
dna
hence
change
quantity
human
dna
chick
tissue
express
ct
data
show
relative
expression
alu
level
untreated
group
normalize
one
assay
include
negative
control
positive
control
control
experimental
sample
duplicate
statistical
analysis
statistical
significance
analyzed
analysis
variance
anova
post
hoc
dunnett
test
value
little
consider
statistically
significant
scientific
san
usa
result
cytotoxicity
flavonoid
cell
first
determine
cytotoxicity
flavonoid
include
naringenin
apigenin
genistein
kaempferol
treat
cell
various
concentration
follow
mtt
assay
compared
control
alone
percentage
cell
viability
flavonoid
determine
result
demonstrate
significant
difference
cell
viability
concentration
range
value
flavonoid
show
table
concentration
flavonoid
apply
subsequent
experiment
table
evaluation
flavonoid
cell
viability
cell
table
cell
viability
determine
mtt
assay
three
independent
experiment
describe
material
method
comparative
effect
control
evaluate
flavonoid
express
view
within
article
effect
flavonoid
cell
migration
invasion
cell
hgf
show
promote
proliferation
invasion
various
cancer
cell
trypan
blue
dye
exclusion
assay
demonstrate
hgf
ml
promote
cell
proliferation
compare
control
however
promote
cell
invasion
treatment
cell
datum
show
examine
whether
select
flavonoid
able
prevent
cell
migration
invasion
boyden
chamber
assay
find
select
flavonoid
exhibit
significant
inhibitory
effect
migration
invasion
cell
apigenin
much
potent
effect
apigenin
cell
motility
scatter
migration
invasion
since
stimulation
hgf
signaling
implicate
cancer
cell
invasive
growth
involve
sequential
series
critical
step
include
increase
motility
cell
scatter
cell
cell
branch
morphogenesis
migration
invasion
well
understand
inhibitory
effect
apigenin
invasive
growth
cell
investigate
effect
apigenin
cell
motility
cell
scatter
scratch
motility
assay
starve
untreated
cell
exhibit
limited
wound
closure
activity
contrast
cell
show
acceleration
wound
closure
observe
treatment
cell
form
multiple
sheet
cell
stretch
area
notably
cell
form
protrusion
apigenin
markedly
decrease
wound
closure
activity
result
wound
closure
assay
quantitated
visual
analysis
wound
five
distinct
view
field
per
sample
randomly
select
number
cell
count
cell
scatter
important
component
several
physiological
process
embryonic
morphogenesis
tissue
regeneration
tumor
invasion
see
cell
cultured
show
tight
junction
moderately
treatment
hgf
cell
show
remarkable
scatter
morphology
pretreatment
apigenin
effective
block
cell
scatter
modulation
cytoskeleton
protein
link
cell
invasion
proceed
investigate
cytoskeleton
change
staining
phalloidin
membrane
protrusion
lamellipodia
responsible
cell
move
attachment
see
pretreatment
apigenin
cytoskeleton
change
inhibit
however
difference
nuclear
image
image
image
image
evaluation
apigenin
cell
motility
scatter
migration
invasion
monolayer
cell
scratch
pipette
tip
pretreated
without
apigenin
api
apply
hgf
ml
result
observe
phase
contrast
microscope
photograph
scale
bar
number
cell
migrate
scratch
area
count
randomly
select
field
represent
mean
monolayer
cell
pretreated
without
apigenin
api
apply
hgf
ml
cell
observe
phase
contrast
microscopy
nucleus
stain
dapi
display
blue
fluorescence
stain
phalloidin
display
red
fluorescence
arrowhead
indicate
membrane
ruffle
scale
bar
migration
invasion
assay
perform
boyden
chamber
ml
hgf
chemoattractive
agent
chamber
cell
fix
stain
count
describe
text
datum
represent
mean
sd
three
independent
analysis
view
within
article
also
examine
dose
effect
apigenin
prevent
cell
migration
invasion
stimulate
hgf
anticipate
apigenin
inhibit
cell
migration
invasion
manner
subject
boyden
chamber
assay
effect
apigenin
met
phosphorylation
hgf
met
signaling
pathway
deregulated
numerous
type
cancer
include
breast
cancer
however
mechanism
apigenin
inhibit
signaling
remain
unknown
therefore
first
investigate
whether
apigenin
inhibit
met
phosphorylation
western
blot
analysis
reveal
hgf
treatment
induce
met
phosphorylation
early
min
phosphorylated
form
remain
sustain
however
apigenin
repress
phosphorylation
met
suggest
directly
inhibit
met
activation
image
image
effect
apigenin
phosphorylation
met
mapk
cell
stimulate
ml
hgf
min
cell
lysate
subject
western
blot
analysis
probe
antibody
addition
cell
pretreated
various
concentration
apigenin
incubate
hgf
additional
min
cell
lysate
subject
western
blot
analysis
probe
time
course
effect
hgf
phosphorylation
mapk
akt
analyzed
cell
pretreated
various
concentration
apigenin
incubate
hgf
additional
min
cell
lysate
subject
western
blot
analysis
effect
apigenin
phosphorylation
mapk
invasion
assay
perform
boyden
chamber
assay
cell
pretreated
apigenin
wortmannin
without
hgf
chemoattractive
agent
cell
count
triplicate
well
three
independent
experiment
datum
represent
mean
cell
pretreated
without
apigenin
incubate
without
ml
hgf
additional
min
cell
lysate
subject
western
blot
analysis
probe
view
within
article
effect
apigenin
akt
phosphorylation
remain
determine
pathway
downstream
hgf
met
signaling
inhibit
apigenin
order
address
molecular
mechanism
apigenin
inhibit
invasive
growth
cell
evaluate
extent
activation
downstream
transducer
phosphorylation
jnk
sapk
mapk
akt
follow
hgf
stimulation
analyzed
western
blot
even
case
phosphorylated
within
min
hgf
stimulation
maximal
tyrosine
phosphorylation
observe
min
jnk
sapk
activate
early
min
activation
sustain
much
follow
hgf
treatment
akt
act
downstream
multifunctional
regulator
cell
survival
growth
invasion
also
phosphorylated
within
min
hgf
stimulation
phosphorylation
maintain
total
protein
level
jnk
sapk
akt
remain
unchanged
treatment
however
mapk
activate
treatment
hgf
though
kinase
present
cell
observation
suggest
activation
jnk
sapk
akt
hgf
may
play
role
invasive
activity
cell
far
investigate
effect
apigenin
phosphorylation
jnk
sapk
akt
show
apigenin
suppress
akt
activation
sapk
activation
result
far
confirm
different
inhibitor
include
mek
inhibitor
jnk
inhibitor
inhibitor
wortmannin
datum
show
addition
treatment
wortmannin
like
apigenin
inhibit
loss
cellular
junction
actin
organization
datum
show
decrease
number
invasive
cell
stimulate
hgf
combination
treatment
wortmannin
apigenin
promote
effect
cell
result
indicate
block
akt
pathway
apigenin
contribute
inhibit
invasive
activity
furthermore
investigate
whether
apigenin
selectively
inhibit
akt
phosphorylation
cancer
cell
show
apigenin
exhibit
potential
suppress
akt
phosphorylation
human
hepatocellular
carcinoma
cell
human
lung
carcinoma
cell
inhibitory
effect
apigenin
cell
invasion
decrease
integrin
avidity
adhesion
mechanism
tumor
invasion
tumor
cell
escape
tumor
mass
degrade
surround
ecm
variety
protease
produce
tumor
cell
implicate
ecm
degradation
proceed
determine
protease
expression
hgf
stimulation
consistent
report
hgf
alter
protein
level
mmp
inhibitor
include
datum
show
presence
integrin
seem
necessary
efficiently
respond
invasion
metastasis
several
carcinoma
cell
line
hgf
promote
cell
adhesion
invasiveness
increase
avidity
integrin
therefore
investigate
inhibition
effect
apigenin
cell
invasiveness
involve
integrin
avidity
first
perform
immunofluorescence
experiment
cell
adhere
onto
specific
matrix
ligand
absence
presence
hgf
alone
combination
apigenin
wortmannin
monitor
integrin
subcellular
distribution
cell
plate
onto
basement
membrane
minor
aggregation
integrin
treatment
clustering
integrin
adhesive
site
lamellipodia
redistribution
membrane
ruffle
inhibit
apigenin
wortmannin
outcome
independent
apoptosis
confirm
dapi
nuclear
stain
cell
serum
starve
detach
plate
onto
plastic
substrate
coat
cell
adhesion
enhance
treatment
hgf
compare
untreated
cell
inhibit
presence
apigenin
inhibitor
wortmannin
mab
integrin
result
suggest
signaling
pathway
play
crucial
role
block
integrin
avidity
cell
adhesion
apigenin
image
image
effect
apigenin
integrin
cluster
adhesion
cell
seed
well
plate
pretreated
apigenin
wortmannin
treat
hgf
min
analysis
immunofluorescence
microscopy
perform
describe
text
integrin
display
green
fluorescence
stain
phalloidin
display
red
fluorescence
nucleus
stain
dapi
display
blue
fluorescence
arrowhead
indicate
integrin
cluster
green
area
red
scale
bar
cell
treatment
indicate
agent
add
microplate
coat
incubation
presence
absence
hgf
min
cell
matrix
adhesion
quantify
elisa
plate
reader
describe
text
data
represent
mean
invasion
assay
perform
boyden
chamber
surface
membrane
coat
hgf
chemoattractive
agent
membrane
count
triplicate
well
three
independent
experiment
datum
represent
mean
treatment
indicate
agent
cell
labeled
carboxyethyl
ester
min
deposit
onto
huvec
monolayer
incubate
without
hgf
additional
min
adhesion
quantify
fluorescent
plate
reader
ex
nm
nm
data
present
mean
raw
fluorescent
count
per
well
mean
data
mean
compare
control
compare
hgf
treat
alone
view
within
article
critical
step
metastatic
process
attachment
tumor
cell
basement
membrane
bm
alter
cell
ecm
interaction
clearly
critical
acquisition
invasive
phenotype
experiment
prompt
investigate
whether
inhibition
cell
adhesion
integrin
avidity
also
affect
invasion
perform
assay
hgf
expect
significantly
increase
invasive
cancer
cell
decrease
pretreatment
apigenin
wortmannin
treatment
combine
apigenin
wortmannin
enhance
effect
observation
indicate
suppression
avidity
apigenin
crucial
effect
moreover
demonstrate
colonization
lung
human
breast
cancer
cell
correlated
cell
adhesion
human
endothelial
cell
luminal
surface
pulmonary
artery
arterioles
venules
mediate
integrin
thus
investigate
whether
integrin
function
inhibit
apigenin
fact
contribute
suppression
cell
adhesion
endothelial
cell
perform
adhesion
assay
measure
adherence
cell
cultured
endothelial
cell
result
indicate
cell
adhesion
compare
untreated
cell
apigenin
wortmannin
pretreated
cell
exhibit
inhibit
adhesion
activity
compare
alone
group
pharmacological
inhibitor
may
exhibit
nonspecific
effect
perform
confirm
crucial
role
akt
pathway
invasion
immunoblot
analysis
lysate
cell
transfected
control
sirna
pretreated
without
apigenin
presence
absence
hgf
demonstrate
protein
level
total
akt
cell
diminish
parallel
sample
transfected
sirna
akt
control
pretreated
without
apigenin
invasion
assay
perform
show
hgf
enhance
cell
invasiveness
effect
cell
cell
however
cell
significantly
inhibit
invasion
inhibitory
effect
promote
combination
apigenin
together
result
strongly
suggest
apigenin
inhibit
akt
phosphorylation
crucial
step
prevent
cell
invasion
image
image
effect
apigenin
invasion
sirna
transfected
cell
transfected
nm
akt
sirna
control
sirna
cell
pretreated
without
apigenin
incubate
without
hgf
lysate
probe
confirm
silence
akt
expression
antibody
erk
control
monitor
protein
loading
nonspecific
rna
interference
effect
immunoblot
transfected
cell
pretreated
without
apigenin
apply
hgf
invasion
assay
describe
data
represent
mean
untreated
cell
cell
treat
hgf
alone
view
within
article
inhibitory
effect
apigenin
lung
colonization
cell
nude
mouse
hgf
significantly
increase
lung
metastasis
report
previously
although
cell
inefficient
form
spontaneous
metastasis
female
nude
mouse
datum
show
able
generate
experimental
lung
metastasis
week
intravenous
injection
tumor
cell
model
evaluate
inhibitory
effect
apigenin
lung
colonization
cell
nude
mouse
four
week
cell
injection
group
mouse
treat
hgf
alone
exhibit
sign
respiratory
distress
experiment
terminate
mouse
euthanized
pulmonary
colonization
examine
develop
lung
metastasis
size
total
weight
lung
significantly
increase
group
compare
control
group
moreover
presence
hgf
group
pretreated
apigenin
wortmannin
show
decrease
size
total
weight
lung
furthermore
number
size
metastatic
lung
nodule
significantly
reduce
apigenin
wortmannin
pretreated
group
histological
examination
lung
confirm
gross
finding
upon
intravenous
injection
cell
nude
mouse
hgf
promote
production
massive
tumor
solid
histological
appearance
lack
sign
tissue
organization
group
pretreated
apigenin
wortmannin
reduce
metastatic
phenomenon
state
taken
together
finding
strongly
support
idea
block
akt
function
apigenin
play
crucial
role
suppress
metastasis
cell
image
image
effect
apigenin
lung
colonization
breast
cancer
cell
nude
mouse
cell
pretreated
indicate
agent
inject
without
hgf
lateral
tail
vein
female
nude
mouse
mice
sacrifice
week
later
lung
cut
representative
lung
size
view
gross
lung
metastatic
nodule
histological
view
lung
section
photograph
right
upper
square
histograms
correspond
magnification
select
lung
section
scale
bar
view
within
article
table
effect
apigenin
lung
colonization
nodule
range
mm
nodule
mean
range
lung
weight
table
effect
apigenin
lung
colonization
determine
describe
text
mouse
euthanized
week
cell
injection
number
size
lung
metastasis
whole
lung
weight
measure
lung
nodule
mm
diameter
count
compare
normal
compare
control
compare
alone
group
view
within
article
inhibitory
effect
apigenin
spontaneous
intravasation
metastasis
cell
chick
embryo
intravasation
tumor
cell
invade
blood
vessel
wall
bloodstream
key
step
carcinoma
process
lead
metastasis
thus
assess
whether
function
integrin
require
apigenin
suppress
spontaneous
cam
vasculature
metastasizing
host
liver
lung
tissue
vivo
incubate
cell
apigenin
wortmannin
seed
tumor
cell
together
without
hgf
chick
chorioallantoic
membrane
cam
chick
embryo
model
tumor
cell
dissemination
liver
lung
exhibit
incidence
spontaneous
liver
lung
metastasis
detect
pcr
human
alu
decrease
pretreated
though
incidence
spontaneous
lcam
intravasation
show
apparent
difference
experimental
group
pretreated
group
apigenin
wortmannin
decrease
human
alu
expression
lcam
significantly
pcr
analysis
taken
together
observation
indicate
apigenin
prevent
metastasis
block
akt
pathway
integrin
function
table
effect
apigenin
spontaneous
metastasis
chick
embryo
organ
display
human
alu
metastasis
total
table
effect
apigenin
spontaneous
metastasis
chick
embryo
determine
describe
text
incidence
intravasation
breast
cancer
lcam
metastasis
liver
lung
tissue
evaluate
pcr
analysis
total
tissue
dna
presence
human
alu
sequence
chick
gapdh
control
respectively
view
within
article
image
image
effect
apigenin
breast
cancer
cell
spontaneous
intravasation
metastasis
chick
embryo
cell
pretreated
indicate
agent
cell
resuspended
seed
together
without
ml
hgf
onto
cam
chick
embryo
day
tissue
chorioallantoic
membrane
lcam
liver
lung
harvest
quantitative
pcr
amplification
human
alu
chick
gapdh
perform
dna
extract
lcam
lung
liver
describe
text
datum
representative
two
consecutive
experiment
view
within
article
discussion
suggest
breast
cancer
incidence
asia
western
country
may
attributed
asian
dietary
regimen
rich
plant
think
many
cancer
include
cancer
colon
breast
lung
show
express
kinase
enzyme
activity
flavonoids
know
modulate
protein
kinase
protein
kinase
pkc
protein
tyrosine
kinase
ptk
play
key
role
cancer
biology
lin
test
flavonoid
exhibit
inhibitory
effect
migration
invasion
apigenin
present
much
potent
involve
block
activity
interestingly
tea
polyphenol
directly
inhibit
met
activation
cell
apigenin
treatment
capable
block
response
suggest
apigenin
may
inhibit
hgf
met
signaling
level
receptor
ability
block
downstream
signaling
akt
pathway
sufficient
inhibit
invasion
hgf
met
signaling
pathway
deregulated
majority
cancer
associate
poor
prognosis
breast
cancer
downstream
activation
akt
ras
erk
pathway
find
necessary
motility
well
adherence
junction
disassembly
activate
small
rac
activated
rac
turn
control
organization
actin
cytoskeleton
demonstrate
hgf
induce
phosphorylation
met
erk
jnk
akt
cell
apigenin
inhibit
akt
phosphorylation
thereafter
apigenin
inhibit
cell
scatter
motility
migration
invasion
block
akt
pathway
addition
involve
avidity
integrin
locate
membrane
ruffle
lamellipodia
increasing
avidity
integrin
may
enhance
invasiveness
isolate
matrix
protein
well
reconstitute
base
membrane
datum
show
block
signaling
apigenin
wortmannin
prevent
integrin
avidity
addition
cell
also
express
integrin
subunits
report
hgf
potentiate
cell
adhesion
ecm
component
fibronectin
affect
integrin
therefore
perform
adhesion
assay
two
substrate
find
apigenin
reduce
enhancement
effect
stimulate
hgf
datum
show
although
apigenin
suppress
avidity
akt
pathway
involve
cell
adhesion
invasion
molecular
mechanism
integrin
need
far
investigation
furthermore
colonization
lung
metastatic
human
breast
cancer
cell
correlated
cell
surface
expression
integrin
cell
adhesion
endothelial
cell
luminal
surface
pulmonary
artery
arterioles
venules
suggest
effect
apigenin
may
involve
lung
metastasis
block
function
notion
confirm
nude
mouse
experiment
decrease
metastasis
tumor
invasion
play
crucial
role
metastasis
involve
number
important
step
include
adhesion
tumor
cell
basement
membrane
bm
enzymatic
digestion
bm
proteolytic
enzyme
follow
migration
ecm
subsequent
growth
proliferation
cell
new
site
event
largely
regulate
extracellular
signal
include
growth
factor
hgf
hgf
show
increase
upa
mmp
expression
secretion
cancer
cell
correlated
enhance
invasiveness
induce
hgf
moreover
many
protease
regulate
nfb
activation
akt
require
nfb
activation
hgf
human
prostate
cell
several
study
demonstrate
hgf
activate
nfb
transcription
fail
observe
cell
datum
show
though
hgf
induce
akt
activation
thus
considerable
difference
nfb
activation
among
different
cell
type
response
hgf
result
may
reflect
importance
cell
context
signal
transduction
one
possibility
key
adaptor
link
akt
transactivation
domain
might
miss
cell
furthermore
hgf
neither
alter
substantially
production
activity
ecm
protease
upa
nfb
signaling
pathway
apigenin
able
decrease
basal
level
protease
cell
unpublished
datum
finding
indicate
reduction
upa
apigenin
might
contribute
prevention
invasive
growth
result
previous
paper
demonstrate
dysregulation
akt
signaling
pathway
lead
tumor
progression
efficacious
inhibitor
may
develop
promise
chemopreventor
suggest
major
structural
requirement
potent
inhibition
flavonoid
derivative
presence
double
bond
hydroxyl
group
structural
point
view
double
bond
result
plane
might
critical
access
kinase
substrate
binding
site
polar
oh
group
require
suppress
kinase
activity
according
investigation
apigenin
contain
single
hydroxyl
double
bond
show
much
potent
effect
test
flavonoid
furthermore
significant
difference
effect
apigenin
contain
single
hydroxyl
luteolin
contain
hydroxyl
cancer
cell
datum
show
thus
association
inhibition
property
display
flavonoid
need
far
investigation
conclusion
paper
demonstrate
apigenin
inhibit
invasive
growth
cell
include
motility
scatter
migration
invasion
block
akt
pathway
furthermore
apigenin
inhibitor
wortmannin
ability
reduce
cell
invasion
adhesion
decrease
integrin
avidity
addition
first
establish
two
distinct
model
confirm
apigenin
activation
akt
pathway
integrin
function
thus
reduce
lung
colonization
metastasis
tumor
cell
nude
mouse
spontaneous
intravasation
organ
metastasis
chick
embryo
finding
support
apigenin
may
considerable
potential
develop
breast
cancer
chemopreventor
acknowledgment
study
support
national
science
council
grant
nsc
matrix
metalloproteinase
mmp
kda
gelatinase
large
mmp
family
relate
tumor
invasion
metastasis
capacity
tissue
remodeling
via
extracellular
matrix
basement
membrane
degradation
indeed
secrete
zymogen
cleave
active
form
function
tightly
regulate
several
multistep
mechanism
previous
study
indicate
mmp
express
breast
cancer
tissue
aberrant
overexpression
associate
increase
potential
breast
cancer
cell
date
many
study
investigate
importance
breast
cancer
metastasis
aberrant
expression
oncogene
relate
disease
progression
increase
invasive
capacity
breast
cancer
may
due
increased
mmp
expression
positive
expression
correlate
overexpression
estrogen
receptor
disease
ubiquitous
transmembrane
tyrosine
kinase
implicate
different
process
critical
development
progression
malignant
tumor
proliferation
survival
growth
well
cell
adhesion
migration
invasion
amplification
overexpression
neu
find
breast
ovarian
gastric
prostate
carcinoma
recent
study
demonstrate
growth
factor
express
breast
cancer
malignancy
activate
receptor
via
induction
heterodimeric
complex
high
level
major
signaling
molecule
correlated
tumor
size
short
survival
tumor
dimerization
strong
mitogen
many
breast
cancer
cell
line
find
epithelial
stromal
component
breast
tumor
induce
follow
activation
receptor
increase
expression
invasiveness
breast
cancer
cell
overexpression
also
able
expression
enhance
invasive
capacity
tumor
cell
observation
suggest
cell
signaling
pathway
critical
metastatic
cell
spread
recent
study
tissue
inhibitor
metalloproteinase
protein
timp
report
natural
mmp
inhibitor
prevent
degradation
extracellular
matrix
protein
abolish
activity
activate
member
metalloproteinase
family
particular
selective
type
iv
thus
negatively
regulate
activity
however
multifunctional
role
also
correlate
expression
mammary
malignancy
resveratrol
major
component
exhibit
potential
anticarcinogenic
activity
many
type
cancer
chemotherapeutic
role
resveratrol
act
several
stage
multistep
malignancy
process
however
inhibitory
effect
resveratrol
expression
study
well
yet
study
investigate
whether
resveratrol
affect
expression
suppress
expression
breast
cancer
cell
invasion
material
reagent
antibody
recombinant
protein
antiphosphorylation
antibody
monoclonal
antibody
purchase
rd
system
minneapolis
mn
antiphosphorylation
monoclonal
antibody
purchase
cell
signaling
danvers
ma
antiactin
monoclonal
antibody
purchase
santa
cruz
biotech
santa
cruz
resveratrol
sodium
bicarbonate
sodium
pyruvate
amino
acid
neaa
gelatin
purchase
sigma
louis
dulbecco
modify
eagle
medium
dmem
insulin
purchase
invitrogen
carlsbad
human
breast
cancer
cell
purchase
american
type
culture
collection
manassas
va
cell
culture
briefly
cell
cultured
humidify
incubator
grow
confluency
fetal
bovine
serum
fbs
dmem
dmem
supplement
fbs
mm
sodium
bicarbonate
mm
sodium
pyruvate
mm
neaa
ml
insulin
supplementation
resveratrol
human
breast
cancer
cell
incubate
different
concentration
resveratrol
efficient
uptake
resveratrol
cell
resveratrol
dissolve
dimethyl
sulfoxide
carrier
vehicle
incorporate
fbs
min
mix
dmem
gelatin
zymography
protein
supernatant
cultured
breast
cancer
cell
load
polyacrylamide
gel
contain
wt
gelatin
gel
incubate
room
temperature
presence
triton
subsequently
overnight
buffer
contain
mm
nacl
mm
tris
ph
gel
stain
protein
coomassie
blue
photograph
light
box
proteolysis
detect
white
dark
field
western
blot
analysis
human
breast
cancer
cell
cultured
fbs
culture
medium
presence
absence
resveratrol
various
length
time
min
phosphorylation
expression
timp
cell
lysed
buffer
contain
follow
saline
sigma
sodium
deoxycholate
sodium
dodecyl
sulfate
aprotinin
specific
phosphatase
inhibitor
sodium
orthovanadate
cell
lysate
clear
centrifugation
cellular
protein
sodium
dodecyl
sulfate
polyacrylamide
gel
electrophoresis
transfer
nitrocellulose
membrane
blot
antiphosphorylation
antibody
accord
manufacturer
instruction
blot
strip
reprobed
antiactin
antibody
loading
control
timp
phosphorylated
measure
procedure
describe
cell
invasion
assay
invasion
tumor
cell
analyzed
transwell
boyden
chamber
polyvinyl
polycarbonate
filter
pore
size
filter
coat
dilute
matrigel
cold
dmem
form
thin
continuous
film
top
filter
human
breast
cancer
cell
stimulate
ml
add
triplicate
well
dmem
cell
well
incubation
cell
randomly
selective
field
count
number
cell
invade
side
filter
measure
invasive
activity
invasive
index
statistical
analysis
statistical
software
analyze
determine
difference
invasive
capability
experimental
set
invasive
cancer
cell
control
set
cancer
cell
brief
statistical
analysis
difference
invasive
capability
among
triplicate
set
experimental
condition
perform
sas
confirmation
difference
invasion
statistically
significant
require
rejection
null
hypothesis
difference
mean
invasive
index
obtain
triplicate
set
level
student
test
effect
resveratrol
activation
breast
cancer
cell
previous
study
indicate
strong
mitogen
many
breast
cancer
cell
line
find
epithelial
stromal
component
breast
tumor
however
effect
resveratrol
signaling
pathway
demonstrate
yet
therefore
present
study
investigate
whether
resveratrol
inhibit
expression
human
breast
cancer
cell
initially
examine
effect
resveratrol
activation
show
significantly
induce
phosphorylation
receptor
however
resveratrol
negligible
effect
activation
receptor
protein
without
change
total
actin
protein
level
image
effect
resveratrol
activation
breast
cancer
cell
postconfluent
human
breast
cancer
cell
cultured
cm
petri
dish
incubate
dmem
fbs
wash
medium
breast
cancer
cell
preincubated
dmem
fbs
various
concentration
resveratrol
stimulate
ml
min
total
cell
lysate
blot
antibody
describe
material
method
level
detection
represent
amount
breast
cancer
cell
blot
strip
reprobed
monoclonal
antibody
loading
control
immunoreactive
band
note
arrow
densitometric
analysis
show
datum
show
representative
three
independent
experiment
view
within
article
protein
kinase
mapk
signaling
molecule
play
important
role
expression
breast
cancer
cell
since
promoter
consist
site
plausible
investigate
important
role
mapk
signaling
pathway
activation
different
specific
kinase
inhibitor
examine
important
role
mapk
signaling
pathway
regulation
expression
among
find
inhibitor
concentration
significantly
suppress
expression
human
breast
cancer
cell
lane
inhibitory
effect
observe
presence
resveratrol
lane
inhibitory
effect
observe
treatment
concentration
wortmannin
inhibitor
inhibitor
inhibitor
datum
show
suggest
expression
part
regulate
signaling
pathway
resveratrol
still
potential
compound
suppression
expression
image
mapk
signaling
molecule
play
important
role
expression
breast
cancer
cell
postconfluent
breast
cancer
cell
cultured
well
plate
incubate
dmem
fbs
wash
medium
breast
cancer
cell
incubate
condition
medium
dmem
mek
signaling
inhibitor
stimulate
ml
conditioned
medium
collect
load
zymogram
gel
gel
stain
coomassie
blue
stain
describe
material
method
level
detection
represent
zymogen
expression
breast
cancer
cell
band
note
arrow
densitometric
analysis
show
asterisk
represent
statistically
significant
difference
compare
group
datum
show
representative
three
independent
experiment
view
within
article
effect
resveratrol
activation
breast
cancer
cell
explore
possible
mechanism
resveratrol
suppression
activity
investigate
inhibitory
effect
resveratrol
mapk
erk
activation
show
resveratrol
suppress
phosphorylation
without
change
total
actin
protein
suggest
resveratrol
block
expression
via
suppression
activity
image
effect
resveratrol
activation
breast
cancer
cell
postconfluent
human
breast
cancer
cell
cultured
cm
petri
dish
incubate
dmem
fbs
wash
medium
breast
cancer
cell
preincubated
dmem
fbs
various
concentration
resveratrol
stimulate
ml
min
total
cell
lysate
blot
antibody
describe
material
method
level
detection
represent
amount
breast
cancer
cell
blot
strip
reprobed
antiactin
monoclonal
antibody
loading
control
immunoreactive
band
note
arrow
densitometric
analysis
show
asterisk
represent
statistically
significant
difference
compare
group
datum
show
representative
three
independent
experiment
view
within
article
effect
resveratrol
expression
breast
cancer
cell
far
examine
whether
resveratrol
suppress
expression
invasion
breast
cancer
cell
result
zymogram
gel
indicate
resveratrol
potentially
block
mmp
expression
human
breast
cancer
cell
concentration
result
suggest
resveratrol
play
crucial
role
expression
image
effect
resveratrol
expression
breast
cancer
cell
postconfluent
breast
cancer
cell
cultured
well
plate
incubate
dmem
fbs
wash
medium
breast
cancer
cell
incubate
condition
medium
dmem
different
concentration
resveratrol
stimulate
ml
conditioned
medium
collect
load
zymogram
gel
gel
stain
coomassie
blue
stain
describe
material
method
level
detection
represent
zymogen
expression
breast
cancer
cell
zymogen
band
note
arrow
densitometric
analysis
show
asterisk
represent
statistically
significant
difference
compare
group
datum
show
representative
three
independent
experiment
view
within
article
effect
resveratrol
human
breast
cancer
cell
invasion
result
experiment
show
resveratrol
inhibit
expression
via
suppression
mapk
erk
signaling
pathway
since
mmp
include
play
important
role
cellular
invasion
far
examine
effect
resveratrol
human
breast
cancer
cell
invasion
result
show
resveratrol
significantly
inhibit
breast
cancer
cell
invasion
presence
result
suggest
resveratrol
inhibit
activity
also
prevent
invasion
breast
cancer
cell
stimulation
therefore
resveratrol
function
chemotherapeutic
therapeutic
agent
prevent
suppress
spread
breast
cancer
cell
image
effect
resveratrol
human
breast
cancer
cell
invasion
invasion
tumor
cell
analyzed
transwell
boyden
chamber
polyvinyl
polycarbonate
filter
pore
size
filter
coat
dilute
matrigel
cold
dmem
form
thin
continuous
layer
top
filter
confluent
human
breast
cancer
cell
cultured
dmem
fbs
wash
medium
breast
cancer
cell
trypsinized
transfer
transwell
boyden
chamber
human
breast
cancer
cell
cell
well
stimulate
ml
add
triplicate
well
dmem
contain
various
concentration
resveratrol
incubation
cell
stain
count
describe
number
cell
invade
side
filter
measure
invasive
microphotographs
invasive
breast
cancer
number
invasive
cell
asterisk
represent
statistically
significant
difference
compare
unstimulated
group
datum
show
representative
three
independent
experiment
view
within
article
effect
resveratrol
expression
human
breast
cancer
recent
study
demonstrate
suppress
tumor
angiogenesis
however
contrast
role
growth
mammary
carcinoma
identify
therefore
investigate
possibility
resveratrol
affect
expression
suppress
breast
cancer
invasion
show
resveratrol
effect
expression
human
breast
cancer
cell
suggest
inhibitory
effect
resveratrol
cell
invasion
occur
pathway
image
effect
resveratrol
expression
human
breast
cancer
postconfluent
human
breast
cancer
cell
cultured
cm
petri
dish
incubate
dmem
fbs
wash
medium
breast
cancer
cell
incubate
dmem
fbs
various
concentration
resveratrol
stimulate
ml
total
cell
lysate
blot
antibody
describe
material
method
level
detection
represent
amount
timp
breast
cancer
cell
blot
strip
reprobed
antiactin
monoclonal
antibody
loading
control
immunoreactive
band
note
arrow
densitometric
analysis
show
datum
show
representative
three
independent
experiment
view
within
article
discussion
tumor
angiogenesis
invasion
metastasis
require
control
degradation
extracellular
matrix
increase
expression
mmp
associate
tumor
invasion
metastasis
malignant
tumor
neu
amplification
show
correlate
expression
tumor
invasion
although
resveratrol
indicate
strong
anticarcinogenic
compound
effect
expression
cellular
invasion
investigate
yet
initially
test
possibility
resveratrol
inhibit
signaling
pathway
show
resveratrol
suppress
phosphorylation
receptor
since
pathway
play
important
role
regulation
expression
far
test
downstream
signaling
pathway
previous
study
show
activate
heterodimer
induce
activation
downstream
signaling
pathway
include
mapk
pathway
investigate
whether
mediate
activation
signaling
pathway
test
hypothesis
concentration
different
specific
kinase
inhibitor
include
mek
inhibitor
wortmannin
inhibitor
inhibitor
inhibitor
even
concentration
mek
inhibitor
alone
effectively
block
expression
however
change
little
change
expression
observe
treatment
kinase
inhibitor
datum
show
result
suggest
expression
sensitive
phosphorylation
status
activation
mapk
erk
cascade
play
important
role
regulation
expression
thus
far
test
whether
resveratrol
suppress
activation
mapk
erk
signaling
molecule
block
expression
show
find
resveratrol
concentration
significantly
inhibit
activation
mapk
erk
signaling
pathway
interestingly
also
find
basal
phosphorylation
cell
although
comparable
total
detect
datum
show
suggest
compromise
extent
resveratrol
inhibit
phosphorylation
one
plausible
explanation
early
stage
cell
cell
rather
later
stage
cell
transform
moderate
malignancy
cell
study
currently
investigate
discrepancy
based
different
stage
cell
result
suggest
resveratrol
inhibit
activation
mapk
erk
molecule
spite
absence
effect
receptor
joint
treatment
resveratrol
slightly
inhibit
expression
zymogram
analysis
therefore
result
rule
possibility
resveratrol
also
partially
inhibit
signaling
pathway
far
block
expression
test
hypothesis
resveratrol
effectively
suppress
cell
invasion
part
investigate
inhibitory
effect
resveratrol
expression
human
breast
cancer
cell
show
study
resveratrol
significantly
suppress
expression
human
breast
cancer
cell
also
find
level
resveratrol
slightly
induce
expression
might
suggest
resveratrol
agonistic
effect
induce
expression
although
currently
investigate
possibility
confirm
anticarcinogenic
role
resveratrol
investigate
effect
resveratrol
cellular
invasion
show
resveratrol
significantly
inhibit
cellular
invasion
manner
recent
study
suggest
timp
gene
expression
negatively
inhibit
mmp
activity
suppress
cell
angiogenesis
however
emerge
multifunctional
role
contrast
role
inhibit
enzyme
promote
mammary
growth
test
important
role
examine
whether
resveratrol
affect
expression
block
cell
invasion
show
resveratrol
negligible
effect
expression
human
breast
cancer
cell
also
find
slightly
induce
expression
suggest
expression
might
correlate
activation
receptor
currently
investigate
molecular
mechanism
mammary
malignancy
demonstrate
resveratrol
suppress
expression
well
invasion
breast
cancer
recent
study
also
indicate
resveratrol
also
fail
modulate
receptor
tyrosine
kinase
vascular
endothelial
growth
factor
consistent
finding
resveratrol
act
chemotherapeutic
agent
targeting
intracellular
signaling
molecule
thus
resveratrol
regulate
activity
part
suppression
mapk
signaling
pathway
previous
study
indicate
site
exist
promoter
region
transcriptional
factor
mainly
regulate
activation
mapk
signaling
pathway
result
show
blockade
mapk
signaling
pathway
contribute
inhibition
expression
reduced
activation
resveratrol
correlate
level
breast
cancer
invasion
present
study
recently
suggest
anticancer
property
therapeutic
potential
resveratrol
vivo
previous
study
also
indicate
phytochemical
compound
inhibit
tumor
angiogenesis
metastasis
since
resveratrol
long
demonstrate
anticancer
effect
plausible
mixture
extract
resveratrol
might
much
effective
single
compound
suppress
tumor
growth
invasion
metastasis
present
study
demonstrate
resveratrol
inhibit
expression
blockade
cell
invasion
human
breast
cancer
cell
resveratrol
might
act
therapeutic
agent
inhibition
cancer
development
finding
provide
novel
mechanistic
insight
potential
effect
resveratrol
suppression
tumor
invasion
metastasis
acknowledgment
material
based
work
support
part
department
health
grant
agreement
national
science
council
grant
agreement
nsc
china
medical
university
grant
agreement
thank
shih
pan
datum
analysis
neoadjuvant
chemotherapy
important
tool
treatment
breast
cancer
patient
locally
advance
disease
however
woman
receive
preoperative
cytotoxic
therapy
respond
treatment
ellis
ellis
need
identify
patient
will
respond
certain
chemotherapy
offer
treatment
strategy
spite
different
mechanism
action
much
cytotoxic
drug
clinic
induce
apoptosis
among
molecular
mechanism
involve
chemoresistance
alteration
critical
pathway
apoptosis
cascade
initiate
cytotoxic
drug
two
principal
pathway
lead
apoptosis
one
begin
plasma
membrane
presence
death
receptor
begin
mitochondria
mitochondrial
pathway
regulate
member
protein
family
function
promoter
bax
inhibitor
member
protein
family
interact
form
heterodimer
ratio
protein
rather
either
alone
example
instead
alone
dictate
ultimate
sensitivity
resistance
tumor
cell
apoptosis
gene
encode
two
protein
isoform
commonly
detect
isoform
molecular
weight
kda
whereas
protein
molecular
weight
kda
rarely
detect
protein
localized
inner
surface
plasma
membrane
outer
inner
mitochondrial
membrane
nuclear
membrane
breast
cancer
expression
associate
presence
marker
differentiation
long
survival
patient
daidone
daidone
since
positive
correlation
estrogen
receptor
alpha
status
raise
possibility
gene
fact
find
expression
marker
tamoxifen
sensitivity
breast
cancer
patient
elledge
elledge
widely
demonstrate
prevent
apoptosis
induce
chemotherapeutic
drug
include
doxorubicin
cancer
cell
line
however
breast
cancer
patient
role
predictive
marker
resistance
sensitivity
chemotherapy
still
controversial
report
evaluate
prognostic
marker
neoadjuvant
therapy
prognostic
factor
measurement
associate
clinical
outcome
absence
therapy
application
standard
therapy
patient
likely
receive
predictive
factor
measurement
associate
benefit
lack
benefit
particular
therapy
study
adjuvant
therapy
high
expression
find
relate
good
response
chemotherapy
whereas
author
find
association
resistance
chemotherapy
study
neoadjuvant
chemotherapy
author
find
correlation
response
treatment
daidone
daidone
observe
absence
tumor
chemotherapy
correlated
well
pathological
response
bax
protein
x
proapoptotic
protein
family
bax
gene
produce
different
protein
mrna
alternative
splice
mechanism
include
isoform
bax
commonly
detect
isoform
molecular
weight
kda
move
cytoplasm
mitochondria
follow
apoptotic
stimulus
form
heterodimeric
complex
metastatic
breast
cancer
patient
reduce
bax
expression
associate
short
survival
tumor
suppressor
gene
involve
regulation
apoptosis
wt
protein
induce
cell
cycle
arrest
apoptosis
wt
expression
gene
activate
expression
bax
gene
human
breast
carcinoma
inverse
correlation
immunostaining
surrogate
mutant
protein
describe
elsewhere
expression
report
krajewski
order
advance
knowledge
usefulness
evaluate
expression
level
breast
cancer
patient
conduct
study
correlate
expression
protein
clinical
pathological
response
chemotherapy
survival
patient
effect
neoadjuvant
chemotherapy
expression
part
study
principal
goal
perform
match
sample
fac
fec
group
fluorouracil
adriamycin
epirubicin
cyclophosphamide
match
sample
group
doxorubicin
epirubicin
sample
enough
material
biopsy
obtain
core
biopsy
destine
analysis
staining
confine
cytoplasm
tumor
cell
section
tumor
sample
observe
area
infiltrate
lymphocyte
internal
positive
control
cell
express
cytoplasm
fac
fec
group
markedly
positive
stain
cell
tumor
remove
chemotherapy
chemotherapy
protein
remain
unchanged
case
decrease
case
increase
case
negative
case
high
apoptotic
index
much
frequently
find
among
case
expression
compare
case
high
content
inverse
correlation
statistically
significant
mean
evaluate
hematoxylin
eosin
range
range
chemotherapy
respectively
similar
mean
value
obtain
tunel
range
range
pre
biopsy
respectively
four
patient
show
increase
evaluate
follow
chemotherapy
whereas
case
value
decrease
change
case
eight
patient
show
increase
evaluate
tunel
follow
chemotherapy
whereas
case
value
decrease
value
remain
unchanged
case
find
trend
correlation
sample
spearman
rank
correlation
coefficient
image
figure
immunoreactivity
cytoplasm
tumor
cell
negative
expression
tumor
cell
expression
cytoplasm
infiltrate
lymphocyte
bax
immunoreactivity
cytoplasm
tumor
cell
bax
immunoreactivity
nucleus
tumor
cell
immunostaining
repeat
three
time
obtain
result
scale
bar
view
within
article
group
markedly
positive
stain
cell
tumor
remove
chemotherapy
chemotherapy
protein
remain
unchanged
case
decrease
case
induce
match
sample
order
know
antibody
might
also
reveal
presence
fragment
generate
apoptosis
molecule
decide
perform
western
blot
study
corroborate
specific
reaction
band
kda
time
exposition
chemiluminescence
reagent
increase
min
min
two
greater
molecular
weight
band
small
band
observe
image
figure
western
blot
analysis
test
specificity
antibody
study
time
exposition
chemiluminescence
reagent
increase
lane
min
lane
min
lane
note
specific
reaction
band
kda
presence
two
greater
molecular
weight
band
small
band
lane
molecular
weight
calculate
protein
molecular
weight
marker
kit
amersham
life
science
england
view
within
article
study
bax
expression
match
sample
fac
fec
group
protein
present
cytoplasm
tumor
remove
chemotherapy
protein
remain
unchanged
treatment
case
whereas
decrease
case
increase
case
one
case
bax
expression
disappear
chemotherapy
important
mention
case
bax
present
nucleus
tumor
cell
chemotherapy
intensity
nuclear
bax
expression
weak
moderate
change
significantly
drug
administration
since
wt
tend
activate
bax
explore
correlation
bax
expression
observe
mutate
correlated
bax
content
biopsy
spearman
rank
correlation
coefficient
relationship
tumor
clinical
response
tumor
patient
treat
fac
fec
present
end
neoadjuvant
chemotherapy
clinical
response
tumor
evaluate
partial
response
pr
patient
patient
present
stable
disease
sd
expression
bax
evaluate
chemotherapy
correlate
clinical
response
tumor
table
correlation
molecular
marker
chemotherapy
clinical
response
fac
value
responders
sdb
responders
pr
crc
sdb
bax
pgr
table
pr
partial
response
sd
stable
disease
cr
complete
response
significant
ne
evaluate
total
score
view
within
article
group
patient
attain
pr
patient
present
sd
patient
group
show
complete
response
cr
expression
evaluate
chemotherapy
correlate
clinical
response
tumor
study
statistical
analysis
show
clinical
response
tumor
correlate
survival
patient
fisher
exact
test
significant
pathological
response
fac
fec
group
specimen
macroscopic
residual
disease
mar
group
absent
specimen
pathological
complete
response
specimen
mar
relationship
expression
clinical
outcome
fac
fec
group
none
marker
study
biopsy
chemotherapy
correlated
disease
free
survival
dfs
overall
survival
however
biopsy
expression
significantly
associate
long
dfs
respectively
ratio
favor
associate
long
dfs
respectively
expression
chemotherapy
show
tendency
correlate
long
dfs
neither
expression
surgical
specimen
correlated
survival
patient
image
figure
disease
free
survival
dfs
overall
survival
curve
accord
expression
biopsy
fac
fec
group
analyses
dfs
perform
kaplan
meier
method
difference
curve
evaluate
test
censor
survival
event
observation
view
within
article
group
expression
biopsy
chemotherapy
correlate
dfs
biopsy
expression
significantly
associate
long
dfs
show
tendency
correlate
long
expression
chemotherapy
associate
long
dfs
image
figure
disease
free
survival
dfs
overall
survival
curve
accord
expression
biopsy
group
analyses
dfs
perform
kaplan
meier
method
difference
curve
evaluate
test
censor
survival
event
observation
view
within
article
interesting
note
patient
group
well
dfs
patient
fac
fec
group
cox
model
respectively
however
interaction
two
treatment
regimen
status
statistically
significant
predictive
significance
study
discussion
previous
researcher
explore
value
protein
predictive
prognostic
factor
adjuvant
treatment
breast
cancer
bonetti
lee
however
analysis
homogeneous
group
patient
treat
neoadjuvant
chemotherapy
study
find
statistically
significant
change
expression
bax
chemotherapy
complete
fac
fec
group
analyzed
difference
individual
patient
note
group
surgical
specimen
follow
chemotherapy
ellis
report
reduce
expression
show
significant
increase
ellis
ellis
discrepancy
result
may
explain
fact
combination
cytotoxic
drug
cisplatin
epirubicin
fluorouracil
dose
schedule
administration
patient
different
report
bax
rise
follow
therapy
study
happen
surgical
specimen
interesting
note
observe
nuclear
expression
bax
breast
cancer
sample
unusual
localization
previously
observe
cultured
cell
include
human
breast
cancer
cell
wang
show
circumstance
bax
nucleus
may
involve
protein
study
nuclear
expression
bax
correlate
clinical
response
tumor
outcome
patient
study
will
necessary
elucidate
role
bax
nuclear
compartment
breast
tumor
cell
drug
administration
find
correlation
expression
clinical
pathological
response
consistent
previous
report
important
mention
find
absence
expression
specimen
associate
much
frequent
complete
pathological
response
despite
consideration
remember
study
clinical
response
tumor
good
parameter
predict
survival
patient
present
study
high
expression
time
surgery
correlated
well
dfs
fac
fec
group
clear
represent
molecular
marker
well
prognosis
breast
cancer
patient
treat
neoadjuvant
chemotherapy
point
consideration
take
account
determination
status
alone
sufficient
assess
protein
apoptosis
pathway
form
heterodimer
family
member
study
ratio
fac
fec
group
observe
ratio
also
correlated
well
dfs
therefore
believe
necessary
determine
expression
member
family
interact
know
real
implication
protein
apoptotic
pathway
induce
chemotherapy
induction
apoptosis
activate
caspase
cleave
transform
protein
inducer
cell
death
perform
western
blot
know
biopsy
recognize
whole
molecule
proapoptotic
fragment
corroborate
antibody
recognize
whole
molecule
level
expression
crucial
determine
role
apoptosis
describe
author
perform
cell
transfection
study
show
high
expression
proapoptotic
relatively
expression
antiapoptotic
discuss
molecular
mechanism
effect
true
tumor
cell
high
expression
escape
primary
tumor
may
much
sensitive
chemotherapy
explain
well
dfs
however
remember
remain
cell
tumor
neoadjuvant
chemotherapy
mainly
become
resistant
drug
alternatively
also
possible
cell
reach
drug
cell
completely
remove
surgery
chemotherapy
radiation
therapy
will
responsible
treatment
failure
local
level
local
recurrence
perhaps
will
source
metastasis
examine
primary
tumor
know
happen
cell
already
escape
primary
tumor
hypothesize
breast
tumor
cell
overexpressing
become
much
resistant
chemotherapy
least
see
surgical
specimen
obtain
induction
chemotherapy
little
aggressive
behavior
little
able
produce
metastasis
reason
primary
tumor
contain
overexpression
relate
well
survival
explanation
consistent
result
obtain
may
indicate
expression
marker
breast
cancer
reduce
capability
distant
colonization
even
presence
lymphovascular
invasion
word
support
conclusion
bonetti
positive
tumor
response
chemotherapy
well
survival
one
explanation
may
activity
show
may
negatively
regulate
transition
mechanism
involve
increase
expression
antioxidant
enzyme
superoxide
dismutase
catalase
turn
reduce
intracellular
reactive
species
level
dependent
phosphorylation
status
examine
cell
proliferation
positive
tumor
know
whether
tumor
overexpressing
protein
proliferation
compare
pcna
cell
nuclear
antigen
expression
expression
observe
significant
correlation
datum
show
finally
well
survival
patient
positive
tumor
may
explain
correlation
content
group
patient
whose
tumor
receive
hormone
therapy
chemotherapy
explanation
sufficient
explain
good
survival
patient
positive
tumor
fac
fec
status
correlate
expression
marginally
useful
predict
interval
useful
predict
overall
survival
find
high
expression
predictive
value
prognostic
value
breast
cancer
patient
treat
doxorubicin
epirubicin
neoadjuvant
chemotherapy
study
will
necessary
elucidate
protein
important
prognostic
marker
breast
cancer
patient
experimental
patient
one
hundred
ten
patient
bear
primary
breast
cancer
stage
ii
iii
enrolled
study
patient
require
histological
proof
invasive
carcinoma
least
year
age
performance
status
scale
serum
level
mg
dl
serum
creatinine
level
mg
dl
normal
cardiac
function
patient
assess
metastasis
free
time
diagnosis
careful
clinical
evaluation
chest
bone
scintigraphy
liver
ultrasound
none
patient
previously
receive
treatment
disease
main
clinical
pathological
characteristic
patient
show
table
research
protocol
approve
ethic
committee
hospital
written
inform
consent
obtain
subject
initial
diagnosis
make
aspiration
case
core
biopsy
case
incision
biopsy
case
table
main
clinical
pathological
characteristic
patient
study
fec
number
age
year
clinical
stage
presentation
tumor
size
cm
histological
type
infiltrating
infiltrating
infiltrating
mucinous
sarcoma
poor
differentiate
clinical
pathological
cr
mir
table
sd
stable
disease
pr
partial
response
cr
complete
response
cr
complete
response
mir
microscopic
residual
disease
mar
macroscopic
residual
disease
view
within
article
neoadjuvant
chemotherapy
first
consecutive
patient
receive
combination
therapy
fac
fec
fluorouracil
mg
adriamycin
epirubicin
mg
cyclophosphamide
mg
cycle
surgery
case
maximally
reduce
tumor
bulk
patient
receive
much
cycle
case
cycle
administer
high
toxicity
initial
diagnosis
make
aspiration
case
incision
biopsy
case
surgery
patient
receive
additional
cycle
fac
fec
next
patient
receive
consist
doxorubicin
mg
epirubicin
mg
cycle
surgery
initial
diagnosis
make
core
biopsy
surgery
patient
receive
cycle
cyclophosphamide
methotrexate
fluorouracil
cmf
surgical
excision
tumor
perform
patient
even
present
clinical
complete
response
case
area
tumor
excise
adjuvant
administer
patient
chemotherapy
accord
medical
doctor
judgment
evaluate
progesterone
receptor
clinical
response
assess
measurement
change
product
two
large
diameter
record
baseline
end
chemotherapy
surgery
tumor
progression
tp
define
increase
least
tumor
size
stable
disease
sd
tumor
size
increase
little
reduction
little
equal
partial
response
pr
tumor
shrinkage
great
complete
response
cr
total
disappearance
clinical
sign
disease
lumpectomy
mastectomy
perform
approximately
week
last
cycle
neoadjuvant
chemotherapy
patient
chemotherapy
much
cycle
radiation
therapy
apply
case
gy
chest
wall
gy
lymph
node
table
show
main
characteristic
patient
study
specimen
surgery
carefully
evaluate
presence
residual
disease
pathologist
pathological
complete
response
pcr
define
absence
invasive
carcinoma
breast
microscopic
residual
disease
mir
define
mm
invasive
carcinoma
macroscopic
residual
disease
mar
define
mm
multiple
focus
invasive
carcinoma
throughout
specimen
periodically
perform
clinically
diagnostic
tool
mention
median
time
define
time
death
last
visit
month
month
fac
fec
group
month
month
group
dfs
calculate
period
diagnosis
date
first
distant
recurrence
last
calculate
period
diagnosis
date
death
histopathology
sample
immediately
fix
buffer
formalin
embed
paraffin
serial
section
mount
onto
sigma
louis
slide
subsequent
analysis
apoptotic
figure
identify
histological
section
stain
hematoxylin
eosin
establish
morphological
criterion
part
tumor
sample
store
western
blot
analysis
perform
apoptosis
assay
tunel
apoptosis
detection
perform
improve
tunel
technique
briefly
tissue
section
pretreated
k
promega
madison
ml
phosphate
buffer
saline
ph
min
room
temperature
follow
microwave
irradiation
citrate
buffer
ph
endogenous
peroxidase
block
incubate
section
sodium
azide
hoechst
argentina
buffer
mm
tris
hcl
mm
tris
brij
ph
add
min
room
temperature
bovine
serum
albumin
block
staining
min
room
temperature
plus
peroxidase
situ
apoptosis
kit
reaction
buffer
tdt
equilibration
buffer
buffer
section
incubate
mouse
monoclonal
antibody
mab
digoxigenin
sigma
dilute
pbs
ph
overnight
humidify
chamber
incubate
biotinylated
rabbit
mouse
igg
dako
carpinteria
dilute
pbs
min
room
temperature
finally
section
incubate
streptavidin
dako
dilute
min
room
temperature
diaminobenzidine
mg
ml
peroxide
chromogen
substrate
tissue
section
counterstained
methyl
green
reveal
nucleus
observe
microscope
zeiss
oberkochen
germany
section
pair
biopsy
always
process
together
negative
control
slide
incubate
without
tdt
include
step
procedure
percentage
apoptotic
cell
evaluate
count
least
cell
slide
cutoff
value
choose
slide
review
score
separate
two
observer
blind
clinical
outcome
patient
immunohistochemistry
follow
primary
antibody
mouse
mab
clone
protein
dako
identification
sheet
dako
provide
information
specificity
antibody
state
label
solely
band
kda
corresponding
oncoprotein
reduce
condition
sure
test
antibody
western
blot
kda
band
label
mouse
mab
bax
recombinant
human
bax
protein
japan
mouse
mab
protein
upon
uk
mouse
mab
estrogen
receptor
dako
mouse
mab
mpri
progesterone
receptor
pgr
paris
france
antibody
clone
recognize
protein
positive
nuclear
immunostaining
surrogate
mutant
tissue
lack
mutant
detectable
signal
protein
short
present
level
contrast
mutant
accumulate
nucleus
detectable
immunohistochemistry
antigen
retrieval
protocol
microwave
unmask
bax
pr
antigen
min
citrate
buffer
ph
tissue
section
incubate
primary
antibody
overnight
humidity
chamber
follow
dilution
bax
mpri
second
antibody
igg
whole
molecule
conjugate
dako
dilution
min
lab
complex
dako
apply
dilution
diaminobenzidine
mg
ml
peroxide
chromogen
substrate
slide
lightly
counterstained
methyl
green
reveal
nucleus
observe
microscope
zeiss
oberkochen
germany
section
pair
biopsy
always
process
together
negative
control
slide
process
exclude
primary
antibody
include
step
procedure
slide
review
score
separate
two
observer
blind
clinical
outcome
patient
discordant
case
resolve
consensus
cutoff
determine
marker
positive
negative
choose
based
upon
previous
study
demonstrate
clinical
significance
immunoreactive
cell
dichotomized
two
group
cutoff
bax
krajewski
immunoreactive
cell
hormone
receptor
dichotomized
two
group
total
score
intensity
proportion
intensity
score
staining
weak
staining
moderate
staining
strong
staining
proportion
score
western
blot
part
breast
cancer
sample
store
western
blot
analysis
perform
total
protein
sample
subject
follow
transfer
onto
nitrocellulose
filter
previously
describe
antibody
dilute
detection
chemiluminescence
reagent
follow
manufacturer
instruction
dupont
boston
ma
statistical
analysis
wilcoxon
sign
rank
test
determine
whether
difference
find
biopsy
significant
strength
association
tunel
well
correlation
marker
study
calculate
spearman
rank
correlation
coefficient
fisher
exact
test
determine
whether
expression
marker
study
correlated
significantly
clinical
pathological
response
outcome
patient
analyses
dfs
perform
kaplan
meier
method
difference
curve
evaluate
test
censor
survival
event
observation
predictive
significance
evaluate
logistic
regression
cox
model
contain
term
main
effect
treatment
statistical
analysis
perform
prism
computer
program
graph
pad
software
san
diego
spss
program
consider
significant
acknowledgment
want
thank
dr
help
advice
statistical
analysis
datum
technical
assistance
work
support
grant
national
research
council
argentine
argentine
foundation
cancer
research
breast
cancer
much
common
major
malignancy
woman
second
leading
cancer
death
treatment
hinge
effective
surgical
removal
primary
tumor
recurrence
occur
significant
portion
patient
even
good
technique
tumor
surgery
usually
associate
release
tumor
cell
lymphatic
blood
stream
large
fraction
patient
already
harbor
micrometastases
scatter
tumor
cell
time
surgery
whether
minimal
residual
disease
result
clinical
metastases
depend
largely
balance
immune
activity
tumor
ability
seed
proliferate
attract
new
blood
vessel
practice
immune
system
host
defense
frequently
fail
neutralize
minimal
residual
disease
consequently
local
metastatic
disease
remain
common
breast
cancer
surgery
least
three
perioperative
factor
shift
balance
toward
progression
minimal
residual
disease
first
surgery
per
possibly
release
tumor
cell
circulation
depress
immunity
include
cytotoxic
cell
natural
killer
nk
cell
function
reduce
circulate
concentration
factor
increase
concentration
factor
vegf
release
growth
factor
promote
local
distant
growth
malignant
tissue
second
factor
anesthesia
per
impair
numerous
immune
component
include
neutrophil
macrophage
cell
function
third
opioid
give
control
surgical
pain
opioids
inhibit
cellular
humoral
immune
function
human
furthermore
morphine
promote
breast
tumor
growth
rodent
consequently
analgesia
help
preserve
natural
killer
cell
function
animal
human
reduce
metastatic
spread
cancer
rodent
regional
anesthesia
analgesia
attenuate
prevent
adverse
effect
example
regional
anesthesia
moderate
neuroendocrine
stress
response
surgery
block
neural
transmission
reach
central
nervous
system
activate
stress
response
block
descend
activation
sympathetic
nervous
system
might
thus
expect
surgical
stress
attenuate
well
regional
general
anesthesia
consequently
nk
cell
function
well
preserve
metastatic
load
lung
reduce
spinal
analgesia
rat
model
breast
cancer
metastasis
regional
general
anesthesia
combine
amount
general
anesthetic
require
much
reduce
presumably
immune
suppression
furthermore
regional
analgesia
provide
pain
relief
usually
need
postoperative
opioid
consequent
adverse
effect
immune
function
promotion
tumor
growth
regional
analgesia
also
reduce
release
endogenous
opioid
available
datum
thus
suggest
regional
anesthesia
analgesia
help
preserve
effective
defense
tumor
progression
attenuate
surgical
stress
response
reduce
general
anesthesia
requirement
spare
postoperative
opioid
animal
study
consistent
theory
show
regional
anesthesia
optimum
postoperative
analgesia
independently
reduce
metastatic
burden
animal
inoculate
breast
adenocarcinoma
cell
preliminary
datum
cancer
patient
also
support
theory
paravertebral
anesthesia
analgesia
breast
cancer
surgery
associate
approximately
reduce
risk
recurrence
metastasis
year
period
ci
hazard
ratio
furthermore
patient
epidural
analgesia
open
radical
prostate
surgery
significantly
little
likely
suffer
recurrence
unpublished
datum
consistent
observation
retrospective
analysis
suggest
general
anesthesia
augment
recurrence
melanoma
will
thus
conduct
clinical
trial
compare
recurrence
rate
patient
primary
breast
cancer
will
randomly
assign
paravertebral
epidural
analgesia
combine
sedation
light
anesthesia
sevoflurane
anesthesia
postoperative
opioid
analgesia
specifically
will
test
follow
hypothesis
primary
hypothesis
recurrence
local
metastatic
cancer
primary
breast
cancer
surgery
reduce
patient
give
regional
analgesia
combine
sedation
light
anesthesia
rather
sevoflurane
anesthesia
postoperative
opioid
analgesia
secondary
hypothesis
mortality
reduce
patient
give
regional
analgesia
rather
general
anesthesia
opioid
analgesia
report
outline
approach
study
protocol
purpose
establish
priori
record
principal
method
primary
endpoint
study
setting
population
study
clinical
trial
coordinated
department
outcomes
research
cleveland
clinic
register
protocol
approve
institutional
review
board
cleveland
clinic
university
louisville
medical
university
vienna
hospital
university
dublin
application
submit
participate
center
will
recruit
patient
primary
breast
cancer
without
know
extension
beyond
breast
axillary
node
believe
tumor
stage
node
schedule
unilateral
bilateral
mastectomy
without
implant
partial
mastectomy
axillary
node
dissection
isolate
lumpectomy
qualify
patient
follow
exclusion
criterion
will
previous
surgery
breast
cancer
except
diagnostic
biopsy
inflammatory
breast
cancer
little
much
year
old
schedule
free
flap
reconstruction
american
society
physical
status
great
contraindication
epidural
paravertebral
anesthesia
analgesia
include
abnormal
anatomy
contraindication
midazolam
propofol
sevoflurane
fentanyl
morphine
cancer
accord
attend
surgeon
remission
systemic
disease
estimate
mortality
protocol
patient
will
mg
intravenous
midazolam
kg
fentanyl
patient
meet
inclusion
exclusion
criterion
consent
study
will
assign
randomly
general
anesthesia
postoperative
opioid
analgesia
regional
thoracic
epidural
paravertebral
anesthesia
analgesia
anesthesia
assignment
proc
plan
sas
statistical
software
will
stratified
study
site
randomly
size
block
individual
randomization
shortly
surgery
will
obtain
secure
system
will
automatically
record
assignment
randomization
number
purpose
image
trial
profile
view
within
article
general
anesthesia
opioid
analgesia
patient
assign
general
anesthesia
opioid
analgesia
general
anesthesia
group
general
anesthesia
will
induce
kg
fentanyl
mg
kg
propofol
will
facilitate
muscle
relaxant
alternatively
supraglottic
airway
mask
additional
muscle
relaxant
will
administer
deem
necessary
attend
anesthesiologist
anesthesia
will
maintain
sevoflurane
oxygen
balance
nitrogen
fentanyl
sevoflurane
fentanyl
administration
will
adjust
maintain
blood
pressure
heart
rate
within
value
lung
will
mechanically
maintain
near
mm
hg
impair
immune
function
will
keep
patient
distal
esophageal
temperature
warming
will
completion
surgery
morphine
sulfate
will
postoperative
pain
first
near
end
surgery
anesthesiologist
will
morphine
administration
patient
respiratory
rate
per
minute
morphine
will
provide
subsequently
postoperative
analgesia
need
intravenously
mg
boluses
min
lockout
period
background
infusion
although
morphine
will
drug
opioid
substitute
equivalent
dose
patient
tolerate
morphine
approximately
patient
will
transitioned
acetaminophen
analgesic
oral
opioid
will
also
permit
necessary
regional
anesthesia
analgesia
patient
assign
regional
anesthesia
analgesia
regional
anesthesia
group
analgesia
will
provide
either
thoracic
epidural
paravertebral
block
ameliorate
surgical
stress
response
reduce
eliminate
need
general
anesthesia
postoperative
opioid
choice
will
discretion
attend
anesthesiologist
based
patient
anesthesiologist
surgeon
preference
epidural
anesthesia
choose
epidural
catheter
will
insert
standard
technique
insertion
prove
difficult
catheter
insertion
will
attempt
negative
aspiration
blood
patient
will
give
test
dose
ml
lidocaine
epinephrine
catheter
will
repositioned
necessary
aspiration
test
dose
negative
patient
will
give
additional
bolus
similar
solution
provide
intraoperative
analgesia
catheter
will
repositioned
necessary
block
temperature
confirm
surgical
additional
boluses
bupivacaine
ropivacaine
epinephrine
will
give
hourly
surgery
maintain
anesthesia
additional
boluses
permit
discretion
attend
anesthesiologist
postoperatively
epidural
analgesia
will
provide
infusion
ropivacaine
ml
fentanyl
epinephrine
start
shortly
patient
emerge
general
anesthesia
basal
infusion
rate
will
set
ml
ml
per
demand
lockout
period
min
local
anesthetic
concentration
infusion
rate
demand
volume
adjust
clinically
indicate
provide
excellent
analgesia
avoid
paravertebral
anesthesia
will
provide
either
thoracic
interspace
catheter
injection
thoracic
interspace
clinically
appropriate
depending
anticipate
scope
surgery
catheter
will
insert
ipsilateral
paravertebral
space
level
standard
technique
patient
will
give
bolus
bupivacaine
ropivacaine
epinephrine
test
dose
lidocaine
epinephrine
near
end
surgery
infusion
ml
either
solution
will
start
infusion
drug
concentration
rate
modify
deem
necessary
attend
anesthesiologist
local
anesthetic
infusion
will
continue
clinically
necessary
long
catheter
will
remove
hospital
discharge
technique
separate
injection
thoracic
interspace
will
perform
gauge
needle
needle
will
insert
cm
lateral
superior
aspect
process
ipsilateral
side
surgery
walk
transverse
process
caudal
direction
cm
distal
transverse
process
ropivacaine
ml
will
give
five
level
via
extension
attach
additionally
injection
ropivacaine
will
give
surgeon
block
cervical
contralateral
thoracic
nerve
also
contribute
breast
epidural
paravertebral
anesthesia
will
supplement
propofol
usually
kg
min
also
administer
insertion
block
clinically
necessary
general
anesthetic
practical
supraglottic
airway
will
minimize
airway
stimulation
minimize
eliminate
need
muscle
relaxant
sort
anesthetic
much
close
deep
sedation
full
anesthetic
describe
general
anesthesia
opioid
group
opioids
judge
clinically
necessary
will
avoid
extent
practical
patient
assign
regional
anesthesia
postoperatively
analgesia
will
provide
primarily
either
type
regional
block
supplement
acetaminophen
analgesic
need
per
individual
site
routine
protocol
however
supplemental
morphine
provide
pain
relief
inadequate
either
infusion
need
soon
practical
usually
patient
will
transitioned
acetaminophen
analgesic
necessary
oral
opioid
anesthesiologist
participate
study
will
experience
high
thoracic
epidural
paravertebral
block
even
experience
hand
anticipate
block
will
fail
failure
rate
preliminary
study
patient
unsuccessful
block
will
switch
alternative
regional
technique
practical
give
general
anesthesia
morphine
postoperative
analgesia
describe
overall
trial
profile
show
transfusion
management
target
minimum
hematocrit
hct
will
determine
prospectively
based
patient
age
cardiovascular
status
target
hematocrit
hct
will
patient
young
year
significant
cardiovascular
disease
great
patient
year
old
cardiovascular
disease
great
patient
old
year
significant
cardiovascular
disease
define
significant
cardiovascular
disease
previous
myocardial
infarction
congestive
heart
failure
cardiomyopathy
hypertension
require
treatment
blood
pressure
exceed
peripheral
vascular
disease
allogeneic
blood
will
administer
necessary
maintain
prospectively
determine
target
hct
boluses
mg
give
necessary
discretion
attend
anesthesiologist
dexamethasone
postoperative
nausea
vomit
prohibit
protocol
steroid
immune
however
will
provide
mg
need
patient
experience
nausea
measurement
morphometric
demographic
characteristic
patient
will
record
purpose
will
obtain
contact
information
patient
family
member
name
patient
oncologist
primary
physician
date
last
menstruation
will
obtain
woman
since
cycle
phase
influence
natural
killer
cell
function
metastasis
risk
perioperative
inhibitor
will
record
since
impact
immunosuppressive
effect
surgery
intraoperative
postoperative
datum
will
collect
present
table
prognostic
factor
relate
risk
breast
cancer
recurrence
collect
list
table
table
perioperative
datum
collect
general
group
upper
block
type
regional
anesthesia
epidural
paravertebral
x
initial
dose
local
amount
local
anesthetic
ml
x
total
dose
propofol
mg
xx
bispectral
blood
loss
ml
xx
fluid
ml
xx
total
fentanyl
xx
total
mg
postoperative
hoursx
postoperative
hoursx
postoperative
hoursx
arterial
blood
pressure
mm
hg
xx
heart
rate
beat
per
min
xx
core
temperature
xx
pain
vas
surgeryxx
surgeryxx
morning
surgeryxx
morning
surgeryxx
surgeryxx
morning
surgeryxx
morning
duration
hospitalization
xx
table
bispectral
index
bis
aspect
medical
ma
much
case
will
record
min
interval
includes
allogeneic
blood
analysis
purpose
postoperative
opioid
convert
equivalent
morphine
sulphate
factor
principles
analgesic
treatment
acute
chronic
cancer
pain
vas
visual
scale
mm
pain
mm
ill
pain
patient
pain
nausea
assess
numeric
rating
scale
patient
vomit
consider
synonymous
patient
long
hospital
second
postoperative
morning
investigator
will
call
ask
pain
nausea
vomit
opioid
view
within
article
table
prognostic
factor
tumor
size
shape
estrogen
receptor
status
extent
nodal
involvement
preoperative
postoperative
adjuvant
chemotherapy
radiotherapy
endocrine
therapy
nottingham
prognostic
resection
margin
clear
tumor
table
national
cancer
institute
will
stage
score
prognosis
breast
cancer
based
formula
tumor
size
histological
grade
grade
least
aggressive
histology
grade
intermediate
histology
grade
much
aggressive
histology
axillary
lymph
node
involvement
node
involve
three
node
involve
much
three
node
involve
score
suggest
good
outcome
whereas
score
suggest
intermediate
prognosis
view
within
article
cancer
recurrence
mortality
will
evaluate
track
patient
interval
throughout
study
patient
provider
will
contact
interval
confirm
recurrence
status
obtain
detail
recurrence
one
will
also
obtain
result
yearly
mammogram
preformed
routinely
patient
biopsy
result
will
obtain
whenever
possible
site
initial
detect
recurrence
will
determine
contact
will
determine
additional
surgery
require
reason
surgery
kind
anesthesia
general
regional
monitor
anesthesia
care
contact
patient
family
caregivers
will
conduct
investigator
strictly
blind
group
assignment
intraoperative
management
question
might
investigator
will
specifically
avoid
healthcare
provider
will
contact
confirm
mortality
provide
death
list
death
social
security
index
will
also
determine
mortality
patient
otherwise
completely
lose
case
apparent
recurrence
will
evaluate
adjudication
committee
will
make
final
determination
take
account
available
laboratory
clinical
evidence
adjudication
committee
strictly
blind
randomization
actual
perioperative
management
committee
will
consist
site
director
however
director
will
case
site
discuss
keep
process
completely
blind
data
analysis
primary
outcome
time
metastatic
spread
local
cancer
recurrence
secondary
outcome
mortality
randomized
group
will
compare
baseline
variable
summary
statistic
mean
standard
deviation
median
quartile
frequency
percent
appropriate
test
will
significance
level
primary
analysis
will
sas
statistical
software
will
datum
analysis
primary
analysis
primary
analysis
will
subject
analyzed
group
randomized
expect
regional
block
will
fail
patient
will
convert
general
anesthesia
case
will
analyzed
group
randomized
will
assess
effect
regional
versus
general
anesthesia
time
recurrence
local
metastatic
cancer
compare
randomized
group
kaplan
meier
analysis
test
stratify
clinical
center
equal
precision
confidence
band
will
construct
plot
randomized
group
along
kaplan
meier
estimate
usual
survival
analysis
patient
lose
due
factor
study
will
censor
time
last
contact
patient
die
without
local
recurrence
metastatic
disease
will
also
censor
time
death
secondary
analysis
large
randomized
trial
true
confound
factor
relate
intervention
outcome
expect
randomized
group
will
likely
well
balanced
baseline
factor
however
multivariable
analysis
will
important
secondary
analysis
order
adjust
estimate
treatment
effect
baseline
covariables
may
significantly
relate
outcome
analysis
usually
increase
precision
estimate
treatment
effect
thus
add
power
trial
multivariable
analysis
will
include
cox
proportional
hazard
regression
adjust
treatment
effect
clinical
center
baseline
factor
find
associate
cancer
recurrence
will
also
include
covariate
chemotherapy
radiotherapy
patient
receive
index
surgery
patient
recurrence
much
sophisticated
approach
accounting
variable
consider
outcome
will
consider
potentially
adapt
method
survival
analysis
will
assess
proportional
hazard
assumption
cox
model
statistically
latter
via
test
interaction
time
individual
covariate
proportional
hazard
assumption
appear
grossly
particular
continuous
covariate
will
attempt
transformation
variable
categorization
covariables
will
adjust
significant
level
include
age
race
ethnicity
red
cell
transfusion
tumor
size
grade
type
estrogen
receptor
status
type
surgery
whether
preoperative
postoperative
adjuvant
chemotherapy
radiotherapy
endocrine
therapy
secondary
analysis
will
also
test
interaction
treatment
effect
follow
select
covariables
red
cell
transfusion
tumor
size
grade
type
estrogen
receptor
status
whether
preoperative
postoperative
adjuvant
chemotherapy
radiotherapy
endocrine
therapy
analysis
may
help
identify
specific
subgroup
patient
intervention
appear
especially
helpful
helpful
will
compare
randomized
group
length
time
mortality
multivariable
survival
analytic
method
describe
primary
outcome
analysis
will
conduct
method
describe
analysis
calculation
sequential
primary
outcome
cancer
recurrence
hypothesize
control
group
general
anesthesia
opioid
will
pattern
recurrence
similar
report
stage
will
similar
patient
treat
previously
cleveland
clinic
give
hazard
rate
general
anesthesia
group
will
need
observe
maximum
recurrence
power
significance
level
detect
reduction
risk
cancer
recurrence
hazard
ratio
allow
three
interim
analysis
maximum
number
event
plus
final
analysis
calculation
include
rate
per
year
assumption
regional
block
will
fail
thus
convert
general
anesthesia
dilute
treatment
effect
although
analyzed
far
assume
will
patient
first
year
second
year
patient
per
year
additional
three
year
total
will
accordingly
patient
five
year
enrollment
expect
accrual
assume
hazard
rate
general
anesthesia
group
alternative
hypothesis
treatment
effect
interim
analysis
will
occur
year
event
year
event
year
event
final
analysis
need
year
event
usual
survival
statistic
interim
analysis
based
number
recurrence
event
enrollment
elapse
time
alternative
hypothesis
probability
stop
trial
either
efficacy
futility
interim
analysis
probability
continue
final
look
larger
true
treatment
effect
large
probability
stop
efficacy
final
look
image
expect
accrual
assume
hazard
rate
general
anesthesia
group
alternative
hypothesis
treatment
effect
interim
analysis
will
occur
year
event
year
event
year
event
final
analysis
need
year
event
view
within
article
calculation
assume
stopping
rule
data
safety
monitoring
board
will
ultimate
authority
account
monitor
null
alternative
hypothesis
gamma
family
spending
function
hwang
shih
parameter
gamma
control
fast
alpha
beta
spend
throughout
trial
gamma
efficacy
alpha
spending
gamma
futility
beta
spending
thus
spend
beta
somewhat
fast
alpha
trial
boundary
meet
end
maximum
accrual
decision
either
efficacy
futility
will
make
point
trial
stopping
boundary
efficacy
futility
parenthesis
follow
look
look
look
last
look
analogous
calculation
perform
secondary
outcome
mortality
image
gamma
family
spending
function
hwang
parameter
gamma
control
fast
alpha
beta
spend
throughout
trial
gamma
efficacy
alpha
spending
closely
resemble
fleming
spending
function
gamma
futility
beta
spending
pocock
fleming
approach
view
within
article
image
stopping
boundary
efficacy
futility
parenthesis
trial
follow
look
look
look
last
look
view
within
article
discussion
preliminary
retrospective
study
suggest
regional
analgesia
reduce
risk
cancer
recurrence
example
cancer
recurrence
rate
find
reduce
woman
breast
cancer
give
paravertebral
analgesia
rather
morphine
postoperative
analgesia
however
large
outcome
study
one
describe
adequately
test
hypothesis
hypothesis
regional
analgesia
breast
cancer
surgery
reduce
risk
recurrence
immediately
applicable
since
paravertebral
thoracic
epidural
block
routine
procedure
familiar
many
anesthesiologist
study
potential
demonstrate
minor
trivial
modification
anesthetic
management
one
implement
little
risk
cost
will
reduce
risk
metastases
complication
ultimately
lethal
much
case
similar
study
test
hypothesis
recurrence
endometrial
colon
cancer
reduce
patient
give
regional
analgesia
combine
sedation
light
anesthesia
rather
general
anesthesia
postoperative
opioid
analgesia
will
start
third
quarter
acknowledgement
outcomes
research
institute
university
louisville
edit
manuscript
estrogen
receptor
attractive
target
treatment
breast
cancer
development
breast
cancer
imaging
agent
diagnostic
biomedical
imaging
technique
positron
emission
tomography
pet
positron
labeled
steroidal
estrogen
estradiol
derivative
radioligand
indicate
develop
pet
breast
cancer
imaging
agent
number
selective
estrogen
receptor
modulator
serm
tamoxifen
hydroxytamoxifen
currently
advance
clinical
trial
market
treatment
breast
cancer
recently
series
tetrahydroisoquinoline
derivative
develop
new
potent
serm
find
bind
high
affinity
two
currently
know
specificity
exhibit
fold
tetrahydroisoquinoline
derivative
labeled
positron
emit
radionuclide
may
enable
monitoring
expression
breast
cancer
breast
cancer
response
hormone
therapy
interested
development
pet
breast
cancer
imaging
agent
previous
work
develop
labeled
derivative
new
potential
pet
estrogen
radioligand
imaging
expression
breast
cancer
ongoing
study
develop
new
serm
radioligand
develop
therapeutic
agent
diagnostic
first
design
synthesize
evaluate
labeled
tetrahydroisoquinoline
derivative
methyl
fluorophenyl
phenoxy
ethyl
methyl
chlorophenyl
phenoxy
ethyl
new
potential
serm
radioligand
pet
imaging
expression
breast
cancer
image
chemical
structure
estrogen
serm
view
within
article
result
chemistry
synthesis
precursor
reference
standard
design
accomplish
chemical
modification
previously
report
procedure
synthetic
approach
outline
scheme
treat
ethyl
chloroformate
furnish
compound
yield
subsequent
cyclization
compound
polyphosphoric
acid
ppa
provide
lactam
compound
yield
compound
condition
cui
dmf
afford
compound
yield
respectively
treatment
compound
subsequent
give
intermediate
iminium
salt
quantitative
yield
iminium
salt
subsequently
treat
memgbr
thf
give
yield
respectively
debenzylation
presence
compound
yield
phenol
yield
respectively
alkylation
compound
furnish
compound
yield
compound
treat
methyl
give
ester
yield
respectively
cleavage
methyl
ether
compound
presence
etsh
provide
target
tetrahydroisoquinoline
compound
reference
standard
yield
respectively
hydrolysis
compound
afford
acid
precursor
yield
respectively
image
scheme
synthesis
tetrahydroisoquinoline
derivative
reagent
condition
ii
ppa
iii
cui
dmf
reflux
iv
generate
thf
memgbr
thf
vii
reflux
butanone
reflux
viii
methyl
reflux
etsh
x
meoh
hcl
view
within
article
compound
select
lead
candidate
pet
radioligand
development
reason
selectivity
potency
feasibility
chemical
modification
incorporate
group
ester
moiety
group
serve
platform
radiolabeling
series
methyl
ester
compound
positron
emit
radioisotope
potential
pet
radiopharmaceutical
compound
x
x
compound
labeling
another
positron
emit
radioisotope
conventional
substitution
k
new
pet
agent
regard
compound
precursor
compound
radiolabeling
reaction
radiochemistry
synthesis
target
tracer
labeled
tetrahydroisoquinoline
derivative
outline
scheme
precursor
labeled
methyl
triflate
methylation
isolate
simplified
extraction
spe
purification
produce
corresponding
pure
target
radiolabeled
compound
radiochemical
yield
based
decay
correct
end
eob
large
polarity
difference
acid
precursor
labeled
ester
product
permit
spe
technique
purification
labeled
product
radiolabeling
reaction
mixture
either
light
cartridge
guard
cartridge
column
spe
purification
technique
reaction
mixture
load
onto
cartridge
gas
pressure
cartridge
wash
water
remove
acid
precursor
reaction
solvent
final
labeled
product
eluted
ethanol
overall
synthesis
time
min
eob
spe
technique
fast
efficient
convenient
work
well
tracer
production
radiosynthesis
perform
automate
module
allow
measurement
specific
activity
synthesis
specific
activity
estimate
range
gbq
mol
end
synthesis
eos
based
compound
produce
condition
measure
technique
actual
measurement
specific
activity
eos
analytical
high
pressure
liquid
chromatography
hplc
method
agreement
estimation
specific
activity
obtain
automate
synthesis
module
high
since
methylation
reagent
high
specific
activity
produce
production
method
silver
triflate
agotf
column
addition
small
amount
precursor
mg
radiosynthesis
also
improve
specific
activity
datum
chemical
purity
radiochemical
purity
determine
analytical
hplc
method
chemical
purity
precursor
reference
standard
radiochemical
purity
target
tracer
determine
nai
flow
detector
chemical
purity
target
tracer
determine
hplc
uv
flow
detector
image
scheme
synthesis
labeled
tetrahydroisoquinoline
derivative
reagent
condition
naoh
view
within
article
methylation
phenolic
hydroxyl
position
precursor
form
undesired
radiolabeled
ether
byproduct
potential
compete
reaction
however
previous
result
indicate
methylation
acid
position
precursor
form
desire
radiolabeled
ester
product
will
major
reaction
result
consistent
theoretical
explanation
acid
position
precursor
much
easy
phenolic
hydroxyl
position
precursor
since
acid
position
precursor
great
phenolic
hydroxyl
position
precursor
methylation
precursor
will
prefer
occur
acid
position
rather
phenolic
hydroxyl
position
addition
minimal
formation
undesired
labeled
byproduct
estimate
will
wash
acid
precursor
reaction
solvent
water
spe
purification
since
polarity
similar
prove
alkylation
indeed
occur
control
experiment
design
conduct
previously
report
procedure
laboratory
briefly
precursor
mg
dissolve
ml
solution
add
naoh
mm
mixture
stir
room
temperature
min
reaction
monitor
analytical
hplc
method
aforementioned
result
show
precursor
completely
convert
compound
respectively
indicate
retention
time
tr
min
tr
min
tr
min
tr
min
hplc
chromatograms
chromatographic
datum
support
conclusion
cell
proliferation
assay
compound
design
synthesize
slight
structural
modification
based
novel
series
tetrahydroisoquinoline
derivative
potent
serm
recently
develop
fully
evaluate
radioligand
binding
assay
estrogen
response
element
assay
inhibition
cell
proliferation
assay
thus
assume
slight
structural
modification
compound
significantly
change
biological
activity
light
structure
activity
relationship
sar
preliminary
biological
evaluation
synthesize
new
tetrahydroisoquinoline
derivative
perform
via
cell
proliferation
assay
compare
hydroxytamoxifen
nm
cell
much
potent
serm
parent
compound
tamoxifen
nm
cell
cell
line
positive
human
breast
cancer
cell
line
result
show
indicate
proliferation
cell
inhibit
nm
hydroxytamoxifen
also
high
concentration
cell
proliferation
inhibit
nm
compound
high
concentration
similar
hydroxytamoxifen
proliferation
cell
inhibit
nm
compound
also
high
concentration
taken
collectively
result
suggest
new
compound
prove
potent
serm
high
binding
affinity
comparable
reference
compound
hydroxytamoxifen
assay
condition
image
cell
proliferation
assay
hydroxytamoxifen
new
tetrahydroisoquinoline
derivative
represent
blank
cell
control
carrier
different
concentration
nm
represent
average
inhibition
intensity
cell
measure
optical
density
od
nm
assay
demonstrate
new
tetrahydroisoquinoline
derivative
similar
potency
human
breast
cancer
cell
line
compare
reference
compound
view
within
article
conclusion
efficient
convenient
synthesis
new
labeled
tetrahydroisoquinoline
derivative
well
develop
synthetic
methodology
employ
classical
organic
chemistry
cyclization
debenzylation
alkylation
hydrolysis
reaction
synthesize
unlabeled
tetrahydroisoquinoline
derivative
labeling
oxygen
position
precursor
methylation
incorporate
efficiently
signature
reaction
radiochemistry
laboratory
radiosynthesis
produce
new
radioligand
amount
purity
suitable
preclinical
application
animal
study
pet
labeled
product
suitable
injection
high
specific
radioactivity
range
gbq
mol
eos
obtain
within
min
eob
include
fast
efficient
spe
purification
formulation
preliminary
finding
vitro
biological
assay
indicate
synthesize
new
tetrahydroisoquinoline
derivative
display
similar
potency
human
breast
cancer
cell
line
comparison
reference
compound
hydroxytamoxifen
result
encourage
far
vivo
evaluation
labeled
tetrahydroisoquinoline
derivative
new
potential
serm
radioligand
pet
imaging
expression
breast
cancer
general
commercial
reagent
solvent
aldrich
sigma
without
far
prepare
accord
literature
procedure
melting
point
determine
ii
capillary
tube
apparatus
uncorrected
nmr
spectrum
record
bruker
nmr
spectrometer
tms
internal
standard
chemical
shift
datum
proton
resonance
report
part
per
million
ppm
scale
relative
internal
standard
tms
couple
constant
j
report
hz
resolution
mass
spectrum
obtain
bruker
iii
mass
spectrometer
high
resolution
mass
spectrum
hrms
obtain
spectrometer
chromatographic
solvent
proportion
indicate
ratio
thin
layer
chromatography
run
silica
gel
plates
visualize
uv
light
normal
phase
flash
chromatography
carry
science
silica
gel
mesh
force
flow
indicate
solvent
system
proportion
describe
reaction
perform
positive
pressure
nitrogen
maintain
direct
line
nitrogen
source
analytical
hplc
perform
column
mm
mm
ph
buffer
solution
mobile
phase
flow
rate
ml
min
uv
nm
nai
flow
detector
light
cartridge
obtain
water
corporate
ma
guard
cartridge
column
cm
obtain
industry
berlin
nj
part
number
sterile
vent
filter
unit
obtain
millipore
corporation
bedford
ma
ethyl
mmol
dissolve
ml
ml
mmol
ethyl
chloroformate
ml
mmol
add
stir
continue
reaction
mixture
wash
water
ml
dry
filter
organic
phase
evaporate
reduce
pressure
give
compound
rf
meoh
nmr
j
hz
j
hz
dd
j
hz
dd
j
hz
j
hz
compound
mmol
treat
polyphosphoric
acid
ppa
atmosphere
reaction
mixture
cool
add
ml
extract
etoac
ml
ml
wash
brine
dry
combined
organic
layer
evaporate
residue
recrystallized
etoac
purify
column
chromatography
silica
gel
afford
colorless
solid
mp
rf
etoac
nmr
j
hz
dt
j
hz
j
hz
j
hz
j
hz
j
hz
mixture
compound
mmol
mmol
mmol
cui
mmol
dmf
ml
heat
atmosphere
second
portion
cui
mg
mmol
add
heating
continue
another
mixture
pour
aqueous
ml
etoac
ml
layer
separate
aqueous
layer
extract
etoac
ml
combine
organic
phase
wash
brine
ml
dry
concentrate
vacuo
crystallization
start
hexanes
add
slowly
solution
crystallization
provide
white
solid
mp
rf
etoac
hexanes
nmr
j
hz
j
hz
j
hz
dd
j
hz
j
hz
dd
j
hz
j
hz
chlorophenyl
according
procedure
preparation
compound
prepare
compound
yield
white
solid
mp
rf
etoac
hexanes
nmr
j
hz
j
hz
j
hz
dd
j
hz
j
hz
benzyloxy
phenyl
fluorophenyl
cold
solution
mmol
anhydrous
thf
ml
add
solution
ml
mmol
period
min
resultant
suspension
stir
min
solution
compound
mmol
anhydrous
thf
ml
add
min
continue
min
reaction
mixture
pour
water
ml
etoac
ml
ml
add
mixture
stir
min
ph
value
aqueous
layer
adjust
addition
aqueous
layer
separate
aqueous
layer
extract
etoac
ml
combine
organic
layer
wash
brine
ml
dry
solution
concentrate
vacuo
obtain
yellowish
solid
directly
next
step
without
far
purification
mp
rf
nmr
j
hz
j
hz
j
hz
j
hz
esi
benzyloxy
phenyl
chlorophenyl
according
procedure
preparation
compound
prepare
compound
yield
yellowish
solid
mp
rf
nmr
j
hz
j
hz
esi
fluorophenyl
cold
solution
compound
mmol
anhydrous
thf
ml
add
solution
memgbr
ml
mmol
min
resultant
mixture
stir
min
allow
warm
suspension
pour
saturate
aqueous
ml
stir
aqueous
layer
extract
ml
combine
organic
phase
wash
brine
ml
dry
concentrate
vacuo
crude
product
recrystallized
etoac
hexanes
purify
column
chromatography
silica
gel
provide
white
solid
mp
rf
etoac
hexanes
nmr
j
hz
chlorophenyl
according
procedure
preparation
compound
prepare
compound
yield
white
solid
mp
rf
etoac
hexanes
nmr
dt
j
hz
chh
j
hz
chh
chh
chh
j
hz
j
hz
j
hz
j
hz
fluorophenyl
phenol
solution
compound
mmol
mmol
mmol
ml
stir
water
ml
ml
add
reaction
mixture
ph
value
aqueous
layer
adjust
aqueous
layer
separate
aqueous
layer
extract
ml
etoac
ml
combine
organic
phase
wash
brine
dry
concentrate
vacuo
resultant
oil
purify
column
chromatography
silica
gel
afford
white
solid
product
mp
rf
etoac
hexanes
nmr
dt
j
hz
chh
chh
oh
j
hz
chlorophenyl
phenol
according
procedure
preparation
compound
prepare
compound
yield
white
solid
mp
rf
etoac
hexanes
nmr
dt
j
hz
chh
chh
oh
j
hz
phenyl
fluorophenyl
method
solution
compound
mg
mmol
mg
mmol
mg
mmol
ml
heat
reflux
day
reaction
mixture
filter
concentrate
residue
purify
column
chromatography
silica
gel
give
white
solid
mg
method
solution
compound
mmol
mmol
mmol
butanone
ml
heat
reflux
day
reaction
mixture
filter
concentrate
residue
purify
column
chromatography
silica
gel
give
white
solid
mp
rf
etoac
hexanes
nmr
dt
j
hz
chh
chh
j
hz
j
hz
j
hz
phenyl
chlorophenyl
according
method
preparation
compound
prepare
compound
yield
white
solid
mp
rf
etoac
hexanes
nmr
dt
j
hz
chh
chh
j
hz
j
hz
j
hz
j
hz
j
hz
j
hz
methyl
fluorophenyl
phenoxy
ethyl
solution
compound
mg
mmol
methyl
mg
mmol
mg
mmol
ml
heat
reflux
day
reaction
mixture
filter
concentrate
residue
purify
column
chromatography
silica
gel
give
white
solid
mg
mp
rf
etoac
hexanes
nmr
j
hz
j
hz
j
hz
ci
hrms
ci
calcd
find
methyl
chlorophenyl
phenoxy
ethyl
according
procedure
preparation
compound
prepare
compound
yield
white
solid
mp
rf
etoac
hexanes
nmr
j
hz
j
hz
j
hz
j
hz
j
hz
ci
hrms
ci
calcd
find
methyl
fluorophenyl
phenoxy
ethyl
cold
solution
compound
mg
mmol
etsh
ml
ml
add
mg
mmol
mixture
stir
reaction
quench
add
water
ph
value
solution
adjust
aqueous
mixture
extract
ml
combine
organic
layer
wash
brine
dry
concentrate
vacuo
residue
purify
column
chromatography
silica
gel
afford
white
solid
mg
mp
rf
nmr
j
hz
j
hz
esi
hrms
ci
calcd
find
methyl
chlorophenyl
phenoxy
ethyl
according
procedure
preparation
compound
prepare
compound
yield
white
solid
mp
rf
nmr
j
hz
j
hz
j
hz
j
hz
esi
hrms
ci
calcd
find
phenoxy
ethyl
acid
solution
compound
mg
mmol
potassium
mg
mmol
methanol
ml
stir
mixture
evaporate
vacuo
add
water
ml
adjust
ph
hcl
mixture
solution
extract
etoac
ml
wash
brine
dry
concentrate
vacuo
residue
purify
column
chromatography
give
yellow
compound
mg
mp
rf
nmr
j
hz
j
hz
esi
hrms
ci
calcd
find
phenoxy
ethyl
acid
according
procedure
preparation
compound
prepare
compound
yield
yellow
solid
mp
rf
nmr
j
hz
j
hz
j
hz
j
hz
oh
esi
hrms
ci
calcd
find
general
method
preparation
labeled
tetrahydroisoquinoline
derivative
methyl
fluorophenyl
phenoxy
ethyl
methyl
chlorophenyl
phenoxy
ethyl
produce
nuclear
reaction
small
volume
gas
target
mev
proton
research
purity
nitrogen
siemens
radionuclide
delivery
system
eclipse
acid
precursor
mg
dissolve
solution
add
naoh
mixture
transfer
small
reaction
produce
agotf
column
pass
reaction
vial
cool
radioactivity
reach
maximum
min
reaction
vial
isolate
heat
min
content
reaction
vial
dilute
ml
reaction
tube
connect
either
light
cartridge
guard
cartridge
column
labeled
product
mixture
solution
pass
onto
cartridge
spe
purification
gas
pressure
cartridge
wash
ml
aqueous
washing
discard
product
eluted
column
etoh
ml
pass
onto
solvent
remove
labeled
product
formulate
saline
sterile
vent
acetate
membrane
collect
sterile
vial
whose
volume
dependent
upon
labeled
product
tissue
study
ml
ml
pet
imaging
study
ml
total
radioactivity
assay
total
volume
ml
note
overall
synthesis
time
include
spe
purification
formulation
min
radiochemical
yield
decay
correct
eob
eos
respectively
retention
time
analytical
hplc
system
tr
min
tr
min
tr
min
tr
min
tr
min
tr
min
cell
proliferation
assay
cell
proliferation
assay
perform
follow
literature
procedure
briefly
cell
proliferation
perform
kit
proliferation
assay
medium
contain
breast
cancer
cell
plate
well
microplate
becton
dickinson
park
nj
incubate
presence
nm
reference
compound
hydroxytamoxifen
synthesize
new
compound
following
treatment
reagent
tetrazolium
compound
mts
promega
madison
add
well
incubation
continue
absorbance
measure
wavelength
nm
control
cell
incubate
hydroxytamoxifen
series
perform
triplicate
acknowledgment
work
partially
support
susan
komen
cure
grant
breast
cancer
research
foundation
indiana
genomic
initiative
indiana
university
support
part
lilly
endowment
inc
author
like
thank
bruce
mock
barbara
assistance
production
referee
criticism
editor
comment
revision
manuscript
greatly
appreciate
many
practical
situation
main
objective
understand
effect
continuous
predictor
binary
response
instance
however
relationship
covariate
xj
vary
accord
value
take
remain
variable
xk
moreover
joint
effect
pair
response
may
vary
turn
among
subset
define
level
categorical
covariate
regression
framework
consideration
might
well
give
logistic
generalized
additive
model
gam
hastie
tibshirani
include
interaction
express
conditional
probability
unknown
constant
set
smooth
unknown
bivariate
partial
function
clearly
representation
give
unique
restriction
impose
order
avoid
different
combination
fjk
lead
model
ensure
identification
model
follow
two
condition
require
effect
pair
continuous
covariate
ii
sum
specific
effect
across
level
zero
specifically
give
sample
follow
model
two
condition
give
ii
note
condition
represent
restriction
model
since
possible
modify
conform
condition
purpose
constraint
define
clearly
part
function
fjk
main
effect
part
interaction
note
model
formulation
quite
general
nest
interesting
regression
model
instance
logistic
gam
include
interaction
obtain
interaction
interaction
gam
obtain
moreover
fjk
xj
pure
logistic
gam
without
interaction
term
obtain
recent
year
number
paper
appear
address
problem
estimate
testing
gam
interaction
term
hastie
tibshirani
discuss
various
approach
smooth
spline
present
method
based
marginal
integration
among
propose
smooth
spline
anova
method
investigate
alternative
method
based
spline
also
propose
wood
thin
plate
regression
spline
work
paper
lang
also
develop
bayesian
version
gam
extension
generalized
structure
additive
regression
paper
mainly
focused
gam
include
interaction
although
may
find
statistical
contribution
gam
include
interaction
see
wood
several
package
like
package
write
wood
allow
fitting
type
model
practice
model
still
scarce
main
reason
lack
close
theory
address
interesting
issue
either
testing
interaction
construct
confidence
interval
practical
difficulty
final
interpretation
model
main
goal
paper
propose
nonparametric
method
estimate
testing
interaction
type
model
retain
interpretation
practical
point
view
aim
propose
generalization
procedure
suggest
recently
estimate
testing
general
model
also
ii
curve
obtain
final
biomedical
interpretation
model
propose
estimation
algorithm
adapt
version
local
scoring
algorithm
based
bivariate
local
linear
kernel
smoothers
detect
bivariate
continuous
effect
depended
group
associate
factor
likelihood
test
since
theory
yet
formulate
field
hypothesis
testing
particular
context
therefore
suggest
technique
approximate
distribution
propose
test
know
however
bootstrap
resampling
technique
involve
estimate
model
great
number
time
also
process
connection
reliance
local
linear
bivariate
kernel
estimator
enable
binning
technique
fan
marron
wand
considerably
reduce
computational
time
render
procedure
practical
situation
especially
sample
size
large
methodology
develop
work
employ
diagnosis
cad
system
dedicate
early
detection
breast
cancer
usually
system
produce
result
suspicious
area
extract
breast
may
recognize
true
lesion
false
detection
characteristic
area
relate
brightness
shape
extract
term
continuous
variable
feature
employ
different
image
processing
algorithm
however
process
detect
structure
within
image
always
influence
contrast
image
contrast
one
much
important
feature
image
define
difference
image
gray
level
scale
closely
adjacent
region
contrast
large
influence
structure
within
region
hard
human
eye
computer
detect
contrast
structure
within
region
image
mammograms
classify
dense
high
gray
level
value
fatty
gray
level
value
term
breast
tissue
therefore
detection
suspicious
area
usually
represent
relative
high
level
value
will
influence
surround
tissue
area
contrast
suspicious
area
will
dense
mammogram
although
work
will
focused
regression
model
binary
response
procedure
explain
paper
easily
generalizable
response
belong
exponential
family
paper
follow
new
procedure
test
interaction
logistic
gam
suggest
section
bootstrap
technique
approximate
distribution
test
statistic
section
propose
nonparametric
estimation
algorithm
discuss
bandwidth
selection
procedure
assess
validity
test
statistic
simulation
study
provide
section
section
apply
propose
methodology
cad
system
dedicate
detection
mass
digital
mammogram
approach
yield
immediately
interpretable
result
calculate
one
much
widely
effect
measure
biomedical
research
finally
conclude
discussion
section
testing
interaction
logistic
gam
section
bootstrap
resampling
technique
test
interaction
model
pair
continuous
covariate
interest
center
null
hypothesis
namely
bivariate
effect
depend
level
factor
aim
propose
likelihood
ratio
test
based
statistic
denote
estimate
obtain
null
hypothesis
deviance
define
log
word
test
statistic
represent
increment
deviance
null
model
remark
null
hypothesis
verify
close
zero
will
generally
positive
thus
test
rule
check
asymptotic
significance
level
null
hypothesis
reject
tt
tp
percentile
distribution
null
hypothesis
theory
ascertain
asymptotic
distribution
difficult
turn
render
difficult
calculate
critical
value
binary
bootstrap
thus
calculate
critical
value
technique
adapt
version
bootstrap
consider
obtain
response
belong
exponential
family
specifically
testing
procedure
consist
follow
step
step
estimate
null
regression
model
null
hypothesis
obtain
bootstrap
pilot
estimate
step
generate
sample
calculate
bootstrap
test
statistic
way
original
calculate
test
rule
consist
reject
null
hypothesis
tt
empirical
value
estimation
algorithm
paper
develop
new
algorithm
enable
estimate
propose
algorithm
modify
version
local
scoring
algorithm
backfitting
backfitting
algorithm
cycle
combination
estimate
obtain
apply
local
linear
kernel
smoothers
corresponding
partial
residual
residual
obtain
remove
estimate
effect
covariate
step
estimation
algorithm
follow
compute
initial
estimate
step
form
adjust
dependent
variable
weight
step
fit
additive
model
interaction
backfitting
compute
update
follow
step
cycle
calculate
partial
residual
compute
local
linear
polynomial
estimator
update
see
appendix
detail
bandwidth
associate
estimation
fjk
bandwidth
associate
estimation
level
factor
step
process
repeat
replace
small
threshold
step
repeat
step
replace
small
threshold
note
case
one
continuous
covariate
backfitting
avoid
local
scoring
procedure
result
estimate
satisfy
identification
condition
explain
section
way
estimate
consider
centered
version
form
estimate
constant
consider
way
estimate
model
give
equivalent
original
estimate
model
satisfying
identification
condition
bandwidth
selection
computational
aspect
well
know
probability
estimate
obtain
model
heavily
depend
bandwidth
local
linear
kernel
estimate
partial
function
fjk
respectively
bandwidth
bias
variance
result
estimate
various
proposal
optimal
selection
suggest
gam
yet
difficulty
asymptotic
theory
backfitting
context
mean
nowadays
optimal
selection
still
challenge
open
problem
moreover
distinction
draw
bandwidth
choice
estimation
testing
computational
experience
show
whereas
interaction
term
tend
smooth
null
hypothesis
interaction
never
reject
case
large
bandwidth
case
small
bandwidth
interaction
term
tend
prove
significant
automatic
choice
bandwidth
cycle
algorithm
bandwidth
obtain
estimate
automatically
select
minimize
follow
weighted
error
criterion
obtain
sample
similarly
bandwidth
obtain
estimate
select
minimize
obtain
leave
datum
point
implementation
test
previously
explain
estimate
obtain
employ
window
initial
sample
window
fix
bootstrap
procedure
way
estimate
obtain
window
initial
estimate
bootstrap
resampling
technique
process
necessary
estimate
model
great
number
time
case
moreover
imply
high
computational
cost
necessary
repeat
estimation
operation
several
time
order
select
optimal
bandwidth
speed
process
acceleration
technique
fan
marron
wand
obtain
binning
approximation
estimation
algorithm
see
appendix
detail
like
estimation
algorithm
binning
technique
error
cvjk
approximate
similarly
obtain
without
element
binning
sample
previous
expression
grid
point
along
xj
xk
direction
empirical
matrix
obtain
set
j
k
distance
consecutive
grid
kth
direction
respectively
approximation
reduce
notably
compute
time
calculation
cvjk
error
necessary
evaluate
kernel
k
maximum
different
point
choice
bandwidth
addition
account
take
grid
point
zero
weight
simulation
study
section
describe
simulation
study
conduct
assess
validity
propose
interaction
test
logistic
gam
give
z
factor
bivariate
vector
continuous
covariate
binary
outcome
variable
generate
accord
z
factor
select
accord
covariate
choose
independent
random
variable
uniformly
distribute
uniform
one
thousand
independent
sample
generate
model
remark
constant
control
interaction
exist
model
correspond
situation
interaction
mean
value
increase
degree
interaction
model
rise
average
result
show
figure
true
probability
surface
well
corresponding
mean
based
sample
size
repetition
show
image
true
probability
surface
plot
plot
mean
estimate
based
repetition
plot
plot
view
within
article
regarding
issue
testing
consider
null
hypothesis
test
explain
section
determine
critical
value
test
apply
bootstrap
describe
total
bootstrap
sample
type
error
well
power
calculate
proportion
rejection
run
size
power
test
determine
different
level
different
sample
size
first
study
type
error
test
result
obtain
express
show
table
table
estimated
type
error
table
view
within
article
observe
table
test
perform
well
general
type
error
relatively
close
nominal
one
moreover
difference
among
obtain
type
error
nominal
level
decrease
sample
size
increase
sample
size
small
test
reject
much
expect
nominal
level
sample
size
increase
obtain
type
error
similar
nominal
level
power
curve
show
display
expect
behavior
pattern
probability
rejection
approximately
nominal
level
probability
rise
value
increase
however
see
power
test
strongly
depend
sample
size
consider
thus
power
test
poor
reduce
sample
size
test
register
notable
improvement
power
sample
size
grow
simulation
study
consider
two
continuous
covariate
factor
two
level
much
complex
situation
clear
power
test
will
strongly
depend
sample
size
consider
thus
practical
situation
deal
several
covariate
several
level
factor
large
simple
size
recommend
ensure
validity
mechanism
propose
paper
image
percentage
rejection
increase
nominal
level
sample
size
view
within
article
application
radiology
datum
propose
methodology
apply
cad
system
dedicate
detection
mass
small
medium
size
digital
mammogram
database
consist
mammogram
select
file
patient
undergo
biopsy
hospital
health
spain
total
number
mammogram
correspond
abnormal
image
lesion
present
rest
mammogram
classify
normal
image
lesion
present
criterion
employ
radiologist
select
malignant
case
biopsy
prove
malignant
mass
exist
mammogram
location
mass
mark
original
film
radiologist
moreover
mammogram
classify
dense
fatty
radiologist
based
general
appearance
tissue
mammogram
briefly
fatty
tissue
mean
high
contrast
mass
surround
tissue
thereby
mass
relative
easy
detect
dense
tissue
mean
contrast
represent
difficult
detection
task
cad
scheme
employ
study
describe
detection
procedure
perform
total
region
suspicious
malignant
mass
detect
original
mammogram
set
algorithm
apply
region
reduce
eliminate
number
false
positive
detection
result
set
feature
extract
region
employ
input
classifier
two
feature
associate
maximum
minimum
gray
level
value
pixels
belong
detect
region
candidate
malignant
mass
gray
feature
play
important
role
discriminate
breast
mass
normal
tissue
fact
breast
mass
usually
homogeneous
relative
high
gray
level
value
moreover
dense
breast
superimpose
tissue
reduce
contrast
make
difficult
detection
mass
even
radiologist
main
goal
present
analysis
investigate
relationship
probability
malignant
mass
continuous
feature
depended
type
tissue
task
total
detect
region
provide
datum
set
consist
follow
information
tp
represent
true
positive
malignant
mass
first
analyzed
probability
tp
value
without
distinguish
case
fatty
dense
tissue
global
analysis
fitting
logistic
gam
follow
fix
parameter
bivariate
function
estimate
probability
surface
plot
image
estimated
probability
positive
surface
global
analysis
fatty
tissue
dense
tissue
region
represent
high
probability
positive
view
within
article
test
interaction
term
significant
likelihood
ratio
test
previously
propose
assuming
logistic
gam
consider
null
hypothesis
univariate
function
depending
respectively
apply
likelihood
ratio
test
datum
corresponding
render
interaction
term
statistically
significant
next
investigate
possibility
probability
tp
associate
might
vary
type
tissue
corresponding
surface
interaction
term
add
fit
logistic
gam
give
fix
parameter
bivariate
function
moreover
correspond
global
surface
without
discriminate
among
tissue
surface
relate
fatty
tissue
correspond
dense
tissue
corresponding
estimate
probability
surface
tissue
plot
separately
applying
interaction
test
outline
section
obtain
thereby
interaction
term
statistically
significant
mean
joint
effect
continuous
covariate
select
study
behave
different
fatty
dense
tissue
interaction
include
model
assess
association
probability
tp
type
breast
tissue
propose
one
much
widely
effect
measure
biomedical
research
accordance
model
present
define
surface
pair
value
take
dense
tissue
reference
category
accordance
model
present
expression
simplified
context
lead
decide
type
tissue
allow
well
discrimination
true
detection
true
positive
false
detection
false
positive
estimate
probability
true
positive
show
nature
upper
boundary
reflect
absence
real
datum
value
shape
three
curve
quite
similar
reflect
complexity
problem
however
model
introduce
clear
difference
high
probability
level
shade
region
curve
high
comparison
represent
compromise
fatty
dense
tissue
respectively
nevertheless
ascertain
much
clearly
functional
form
bivariate
surface
vary
value
decide
plot
estimate
surface
separately
way
leave
column
show
estimate
surface
four
different
value
figure
right
column
also
add
estimate
curve
corresponding
pointwise
confidence
band
construction
confidence
interval
bootstrap
resampling
technique
specifically
give
point
step
construction
confidence
interval
true
follow
image
estimate
surface
associate
curve
corresponding
pointwise
confidence
band
different
value
view
within
article
step
estimate
model
obtain
bootstrap
pilot
estimate
pilot
estimate
step
generate
sample
process
complete
limit
confidence
interval
true
give
estimate
obtain
original
sample
represent
difference
see
value
probability
tp
small
statistically
significant
difference
appear
tissue
increase
probability
tp
increase
dense
tissue
difference
statistically
significant
significant
difference
probability
tp
high
tissue
finally
high
probability
fatty
tissue
difference
statistically
significant
value
observe
high
probability
relate
high
value
expect
since
high
value
represent
high
gray
level
value
detect
region
thereby
great
discrimination
rest
breast
tissue
however
surface
different
behavior
depending
type
tissue
fatty
tissue
probability
detect
region
tp
high
value
interval
moreover
change
high
probability
fatty
tissue
surface
large
dense
tissue
value
increase
interval
thus
density
breast
tissue
increase
fatty
little
dense
dense
brightness
mass
rise
high
value
essential
preserve
contrast
mass
relate
surround
tissue
detection
result
coherent
fact
observe
radiologist
dense
mammogram
superimpose
breast
tissue
reduce
visibility
mass
remark
work
logistic
regression
model
bivariate
effect
pair
continuous
covariate
response
may
depend
group
define
level
covariate
factor
consider
main
goal
development
statistical
test
detect
type
interaction
namely
interaction
local
scoring
backfitting
based
kernel
smoothers
estimate
model
smooth
window
select
employ
technique
since
backfitting
theory
difficult
gam
context
procedure
implementation
test
technique
involve
estimate
model
great
number
time
case
bootstrap
replicate
therefore
binning
acceleration
technique
speed
process
methodology
flexible
extension
much
complex
interaction
model
possible
note
however
introduce
high
order
interaction
gradually
bring
back
problem
interpretation
apply
novel
approach
result
yield
cad
system
dedicate
detection
breast
mass
differentiate
lesion
result
show
different
behavior
detect
region
breast
tissue
take
account
thus
indicate
factor
relevant
perform
discrimination
study
breast
region
computational
point
view
binning
acceleration
make
possible
estimation
testing
process
conclude
min
sample
size
iii
mb
conclusion
method
develop
paper
together
curve
allow
possibility
obtain
model
behavior
feature
extract
suspicious
area
include
distortion
introduce
surround
tissue
result
may
help
improve
performance
cad
system
program
implement
propose
methodology
outline
paper
obtain
contact
first
author
acknowledgment
author
grateful
anonymous
referee
helpful
comment
result
improve
version
manuscript
technical
assistance
comment
work
carmen
support
grant
european
support
include
spanish
ministry
education
grant
final
step
cancer
progression
metastasis
accord
prevail
view
based
several
clinical
experimental
observation
first
much
cancer
patient
die
metastases
primary
disease
second
early
surgery
often
cure
third
somatic
genetic
change
accumulate
local
progression
extrapolate
systemic
progression
since
rare
variant
cell
within
tumor
give
rise
metastases
fourth
repeat
round
vivo
selection
lead
cell
line
increase
metastasis
formation
however
several
clinical
experimental
observation
inconsistent
model
example
metastasis
develop
small
cancer
even
absence
detectable
primary
tumor
cancer
unknown
primary
rank
among
much
frequent
cancer
diagnosis
furthermore
epidemiological
analysis
much
breast
cancer
patient
indicate
metastasis
might
initiate
already
year
diagnosis
primary
tumor
suggest
cancer
cell
capable
metastasize
necessarily
develop
within
large
tumor
also
notion
early
metastasis
indirectly
support
gene
expression
study
reveal
patient
poor
prognosis
identify
manifestation
metastasis
thus
metastatic
spread
seem
somehow
genetically
predetermine
time
point
metastatic
dissemination
resolve
doubt
deep
understanding
metastasis
critical
design
much
effective
therapy
systemic
cancer
example
metastatic
spread
occur
late
progression
inhibitor
invasion
able
prevent
however
observe
several
clinical
trial
testing
inhibitor
however
tumor
cell
dissemination
occur
early
question
need
address
tumor
cell
survive
quiescent
state
year
ectopic
site
tumor
dormancy
metastatic
outgrowth
regulate
last
least
disseminate
tumor
cell
dtc
develop
parallel
primary
tumor
prolong
time
molecular
target
dtc
need
urgently
identify
previously
address
issue
early
versus
late
metastatic
spread
analyzing
dtc
bone
marrow
breast
cancer
patient
year
metastatic
manifestation
cell
display
different
fewer
aberration
match
primary
tumor
find
suggestive
early
dissemination
among
dtc
identify
cancer
cell
spread
onset
chromosomal
instability
though
chromosomal
instability
observe
histological
cancer
invasion
breast
cancer
cell
may
still
disseminate
become
prior
microscopic
invasion
interestingly
subpopulation
normal
cancer
cell
bone
marrow
display
amplification
marker
particularly
aggressive
disease
therefore
think
search
dtc
transgenic
model
breast
cancer
early
time
point
atypical
epithelial
transformation
direct
comparison
report
finding
dtc
breast
cancer
patient
include
patient
situ
carcinoma
result
epithelial
cell
disseminate
premalignant
phase
murine
breast
cancer
study
tumor
progression
much
closely
choose
balb
mouse
transgenic
activate
rat
neu
gene
mouse
carlo
model
mimic
progression
gene
expression
profile
human
breast
cancer
female
strain
constitutively
activate
rat
gene
control
mmtv
promoter
develop
invasive
mammary
cancer
negative
sibling
balb
mouse
remain
tumor
free
female
mammary
epithelia
start
express
oncogene
onset
puberty
week
age
mouse
become
responsive
steroid
sex
hormone
epithelial
hyperplasia
detect
microscopically
mammary
gland
week
carlo
progress
situ
carcinoma
occur
week
around
week
tumor
mammary
gland
become
palpable
visible
week
invasive
cancer
become
apparent
mice
euthanized
week
primary
tumor
exceed
size
cm
diameter
lung
metastases
macroscopically
detectable
image
image
figure
tumor
progression
systemic
disease
left
panel
whole
mount
mammary
gland
mouse
week
show
absence
tumor
branch
ductal
tree
indicate
lymph
node
arrow
point
nipple
arrowhead
show
side
bud
around
mammary
duct
middle
panel
histological
section
mammary
gland
week
show
side
bud
display
morphology
atypical
ductal
hyperplasia
adh
epithelial
cell
arrange
small
nodule
around
duct
right
panel
histology
invasive
cancer
week
neoplastic
epithelial
cell
form
scarcely
define
solid
nest
invade
surround
stroma
left
panel
detection
micrometastases
antibody
lung
mouse
right
panel
eight
micro
metastasis
lung
three
transgenic
mouse
week
two
sample
normal
lung
tissue
microdissected
analyzed
transcript
lactalbumin
microdissected
tissue
normal
mammary
gland
progression
local
systemic
disease
mouse
time
left
panel
increase
tumor
area
triangle
indicate
mean
value
whisker
confidence
interval
solid
line
triangle
indicate
well
fit
curve
right
panel
number
red
dot
blue
dot
cell
per
bone
marrow
cell
whisker
indicate
confidence
interval
dash
red
blue
line
depict
result
nontransgenic
control
mouse
ck
respectively
double
staining
bone
marrow
cell
ck
red
green
expression
left
right
small
ck
single
cell
small
aggregate
cell
table
summarize
result
analyzed
cell
view
within
article
principal
goal
study
find
cell
express
transgene
disseminate
emigrate
breast
epithelia
since
receptor
express
neither
normal
lung
tissue
bone
marrow
concentrate
organ
preferred
site
metastasis
breast
cancer
patient
addition
detection
early
human
cancer
spread
bone
marrow
staining
ck
antibody
specific
sensitive
demonstrate
numerous
study
braun
klein
include
simultaneous
staining
antibody
show
cell
surprisingly
mouse
cytokeratin
positive
cell
express
cell
become
detectable
bone
marrow
early
week
age
much
meticulous
analysis
mammary
gland
detect
area
atypical
ductal
hyperplasia
adh
solely
figure
figure
available
article
online
lung
tissue
single
tumor
cell
become
detectable
week
micrometastases
first
visible
around
week
table
figure
furthermore
descent
lung
micrometastases
mammary
tissue
confirm
demonstration
alpha
lactalbumin
transcript
specificity
tumor
cell
detection
antibody
direct
cytokeratin
far
control
sample
nontransgenic
sibling
despite
exponential
growth
primary
site
depict
sum
total
tumor
area
ten
mammary
gland
mouse
figure
number
cell
bone
marrow
rise
marginally
course
time
respectively
figure
total
number
cell
positive
ck
congruent
perform
double
staining
two
antigen
indeed
tumor
cell
express
marker
suggest
either
existence
heterogeneous
tumor
cell
population
disseminate
distant
site
different
cellular
state
disseminate
tumor
cell
dtc
interestingly
majority
detect
dtc
cell
mouse
express
little
similar
datum
obtain
blood
sample
table
although
detection
rate
dtc
bone
marrow
test
whether
early
dissemination
characteristic
mouse
also
screen
bone
marrow
sample
transgenic
mouse
though
unable
establish
detection
tumor
cell
antibody
direct
pymt
antigen
tumor
cell
detect
week
bone
marrow
staining
figure
adh
dcis
find
mammary
tissue
figure
lung
micrometastases
although
difficult
detect
hematoxylin
eosin
staining
alone
find
start
week
age
figure
mouse
observe
significant
increase
number
dtc
bone
marrow
tumor
growth
table
tumor
cell
emigrate
transgenic
mammary
gland
transplant
although
cytokeratin
expression
bone
marrow
provide
strong
evidence
cell
indeed
derived
epithelia
seek
direct
evidence
cell
disseminate
transform
breast
tissue
detection
positive
cell
due
transgene
expression
therefore
transplant
mammary
gland
fragment
transgenic
mouse
onto
sibling
recipient
receive
one
clear
fat
pad
one
tissue
fragment
one
donor
gland
bone
marrow
recipient
screen
cell
week
later
recipient
mouse
transplant
find
transgene
express
graft
dissection
image
image
figure
dtc
derived
transformed
mammary
tissue
staining
grafted
tissue
autopsy
week
transplantation
transgenic
tissue
mouse
numerous
epithelial
cell
atypical
ductal
hyperplasia
adh
focus
express
brown
cell
bone
marrow
recipient
mouse
respectively
box
plot
display
number
cell
per
bone
marrow
cell
balb
mouse
recipient
transplant
transgenic
mammary
tissue
transplant
box
plot
display
number
cell
per
bone
marrow
cell
recipient
transplant
transgenic
mammary
tissue
invasive
cancer
representative
result
cgh
analysis
isolate
single
cell
different
model
chromosomal
region
designate
accord
aberration
show
left
column
depict
identifiers
mouse
letter
indicate
antigen
detection
cytokeratin
cell
isolate
week
mouse
cell
isolate
week
mouse
cell
isolate
bone
marrow
mouse
mammary
tissue
transplantation
cell
isolate
bone
marrow
mouse
bone
marrow
view
within
article
transplant
animal
number
cell
per
bone
marrow
cell
mouse
respectively
figure
significantly
rare
cell
number
control
mouse
average
bone
marrow
cell
ck
cell
figure
much
likely
reflect
reduce
total
number
transgenic
mammary
cell
recipient
mouse
carry
single
transgenic
gland
compare
mouse
carry
ten
transgenic
mammary
gland
transgenic
mouse
analyzed
histology
large
tumor
ignore
remain
mammary
gland
transplant
recipient
mouse
scrutinize
single
tumor
arise
transgenic
mammary
graft
sign
invasiveness
exact
staging
transplant
based
histology
complete
serial
sectioning
increase
dtc
bone
marrow
observe
stage
adh
stage
invasive
cancer
cell
cell
figure
malignant
origin
disseminate
cell
detect
bone
marrow
establish
comparative
genomic
hybridization
cgh
cell
isolate
bone
marrow
display
multiple
chromosomal
aberration
contrast
single
leukocyte
normal
cgh
profile
figure
figure
thus
cgh
ascertain
malignancy
cell
originate
single
transplant
mammary
gland
gene
expression
program
associated
early
tumor
spread
pymt
tumor
model
dissemination
begin
shortly
expression
oncogenic
transgene
without
histologically
detectable
sign
invasion
light
microscopy
underlie
basement
membrane
show
gross
interruption
raise
question
transform
epithelial
cell
get
atypical
hyperplastic
area
however
examine
electron
microscopy
epithelial
cell
cross
basement
membrane
clearly
identify
figure
mouse
figure
sibling
neither
basement
membrane
lesion
emigrate
cell
discern
observation
basement
membrane
underlie
hyperplastic
epithelia
appear
disrupt
mouse
question
whether
local
activation
proteolytic
enzyme
verify
therefore
apply
cdna
array
analysis
laser
microdissected
sample
assess
expression
protease
adh
week
large
carcinoma
week
recently
establish
mrna
amplification
method
klein
klein
hybridize
sample
onto
small
dedicate
cdna
array
array
comprise
cdna
encode
mmp
cathepsin
early
imply
invasion
metastasis
high
expression
cathepsin
ctsz
ctsb
ctsl
ctsd
ctsh
metalloproteases
caspase
observe
early
lesion
false
discovery
rate
q
week
compare
week
increase
ctsz
ctsd
ctsh
ctsb
expression
significant
wilcoxon
test
correct
accord
gene
expression
pattern
week
separate
week
cluster
analysis
cluster
index
figure
except
outliers
find
immunohistochemistry
protein
express
normal
tissue
young
mouse
week
figure
strongly
express
adh
week
transgenic
mouse
image
image
figure
electron
microscopical
analyses
mammary
tissue
activation
invasive
adh
electron
microscopical
analysis
mammary
mammary
duct
sibling
balb
mouse
line
polygonal
large
dark
light
cell
luminal
microvilli
dark
myoepithelial
cell
locate
basal
surface
without
luminal
contact
throughout
duct
surround
basal
membrane
arrowhead
continuously
outline
basal
border
epithelial
myoepithelial
mammary
duct
mouse
line
polygonal
irregularly
arrange
cell
without
luminal
contact
frequently
show
aspect
stromal
invasiveness
disrupt
basal
membrane
myoepithelial
cell
scarcely
higher
magnification
basal
membrane
arrowhead
intact
basal
membrane
arrow
disrupt
basal
membrane
cluster
analysis
expression
datum
cdna
array
dedicate
molecule
proteolytic
system
sample
identifiers
right
consist
age
week
number
mouse
sample
take
sample
number
individual
sample
one
animal
isolate
different
mammary
gland
note
cluster
sample
mouse
third
figure
display
upregulation
various
proteolytic
enzyme
immunohistochemistry
antibody
show
scarce
expression
balb
mouse
week
age
strong
expression
brown
side
bud
duct
adh
mouse
quantitative
twist
mrna
microdissected
tissue
sample
isolate
transgenic
animal
week
adh
tumor
edge
center
balb
normal
asterisk
indicate
significant
upregulation
twist
adh
sample
view
within
article
abundant
protease
expression
hyperplastic
lesion
may
provide
mechanism
early
tumor
spread
may
part
gene
regulatory
program
therefore
determine
expression
transcription
factor
twist
regulator
affect
cell
migration
marker
undifferentiated
mammary
cell
apparently
play
role
metastasis
regulate
cell
invasion
intravasation
howe
yang
compare
mrna
expression
several
gland
mouse
lesion
adh
area
invasive
cancer
dissect
central
part
invasion
front
quantitative
pcr
sample
normal
mammary
gland
central
tumor
area
microdissected
area
invasion
front
display
level
twist
mrna
contrast
adh
lesion
express
twist
mrna
significantly
much
often
medium
high
level
pearson
df
figure
keep
notion
genetic
program
govern
cell
dissemination
activate
early
transformation
evidence
cell
grow
metastases
finding
tumor
cell
disseminate
preinvasive
mammary
lesion
raise
question
whether
also
may
grow
metastases
although
time
point
dissemination
metastatic
founder
cell
determine
directly
vivo
obtain
evidence
early
systemic
spread
founder
cell
follow
different
type
experiment
assess
onset
metastasis
relative
primary
tumor
growth
histological
section
lung
therefore
take
detect
presence
micrometastases
measure
increase
time
detect
week
onward
time
point
mostly
situ
carcinoma
present
primary
site
since
metastases
need
time
grow
increase
size
parallel
primary
lesion
support
conclusion
least
case
founder
cell
metastases
disseminate
early
start
proliferate
image
image
figure
progression
lung
metastasis
mice
recipients
transgenic
mammary
tissue
progression
lung
metastasis
mouse
without
removal
primary
tumor
increase
tumor
area
time
figure
plot
next
size
large
lung
metastases
note
logarithmic
scale
detect
individual
mouse
blue
square
indicate
average
size
metastases
mouse
various
time
point
red
triangle
indicate
average
size
metastases
operate
animal
week
surgery
whisker
indicate
confidence
interval
tumor
progression
transplantation
noncancerous
mammary
tissue
mouse
histology
graft
tissue
surgery
week
transplantation
resemble
adh
small
invasive
carcinoma
staining
lung
micrometastasis
week
experimental
design
assess
tumor
progression
recipient
mammary
gland
surgery
primary
tumor
analyzed
week
euthanized
operate
mouse
asterisk
indicate
time
point
lung
bone
marrow
sample
result
transplantation
experiment
mouse
treat
curative
intention
surgery
adh
atypical
ductal
hyperplasia
invasive
carcinoma
note
small
size
resected
tumor
compare
tumor
mouse
unusually
high
number
cell
bm
diagnose
adh
view
within
article
address
point
much
directly
perform
surgery
mouse
try
remove
entire
milk
line
mouse
old
week
survive
radical
procedure
however
none
four
mouse
display
situ
carcinoma
prevent
reduce
number
size
lung
metastases
week
age
test
whether
dtc
large
tumor
differ
tumor
cell
compare
chromosomal
aberration
reason
dissemination
occur
early
genetically
cancer
cell
able
grow
metastases
therefore
analyzed
cgh
profile
tumor
cell
isolate
bone
marrow
mouse
week
old
week
hierarchical
cluster
analysis
classification
figure
separate
tumor
cell
young
old
animal
detect
significant
increase
aberration
young
old
animal
exact
wilcoxon
rank
sum
test
final
set
experiment
direct
tumor
progression
female
receive
graft
mammary
gland
transgenic
sibling
mouse
lung
micro
metastases
become
detectable
week
age
female
autochthonous
primary
cancer
develop
lung
metastases
week
average
next
excise
gland
various
time
point
follow
operate
recipient
recipient
grafted
gland
excise
week
primary
transplantation
mammary
tissue
diagnose
atypical
ductal
hyperplasia
adh
two
recipient
small
invasive
cancer
four
recipient
invasive
cancer
measure
remain
two
recipient
tumor
female
week
week
respectively
figure
additional
week
operate
recipient
sacrifice
screen
local
relapse
tumor
cell
bone
marrow
lung
none
animal
observe
local
relapse
display
sign
either
minimal
residual
disease
lung
metastasis
even
animal
small
primary
lesion
resected
gland
carry
micrometastasis
lung
figure
compare
incidence
lung
micro
metastases
animal
diagnose
invasive
cancer
either
sacrifice
operate
week
mammary
tissue
transplantation
animal
sacrifice
time
point
one
mouse
harbored
lung
micrometastasis
contrast
six
animal
resection
transplant
mammary
tissue
surgery
week
four
diagnose
metastatic
growth
micrometastasis
metastases
lung
week
later
fisher
exact
test
figure
find
indicate
disseminate
cancer
cell
continue
progress
underscore
single
case
adh
lung
micrometastasis
indeed
represent
progressive
minimal
residual
disease
early
dtc
growth
arrest
obviously
tumor
cell
dissemination
occur
early
additional
mechanism
regulate
outgrowth
example
time
point
observe
manifest
bone
metastasis
frequency
tumor
cell
much
bone
marrow
mouse
therefore
ask
whether
dtc
bone
marrow
young
mouse
proliferate
generate
progeny
stimulation
endogenous
growth
factor
chemokine
consequence
irradiation
transplant
bone
marrow
transgenic
mouse
lethally
irradiate
nontransgenic
sibling
three
transgenic
donor
week
old
euthanized
bone
marrow
cell
transplant
littermates
bone
marrow
one
balb
mouse
transplant
three
sibling
control
staining
ck
antibody
reveal
presence
positive
cell
per
bone
marrow
cell
inoculum
transgenic
mouse
indicate
total
cell
per
recipient
mouse
nineteen
week
later
bone
marrow
transplant
recipient
become
four
animal
find
dead
bone
marrow
analyzed
autopsy
show
massive
infiltration
bone
marrow
cell
comprise
nucleated
cell
mouse
receive
bone
marrow
balb
sibling
healthy
sacrifice
week
respectively
harbored
cell
bone
marrow
far
isolate
single
cell
recipient
animal
display
cgh
abnormality
demonstrate
malignant
origin
interestingly
metastases
detect
site
experiment
demonstrate
tumor
cell
disseminate
adh
establish
bone
marrow
carcinosis
upon
transplantation
image
image
figure
dtc
transgenic
mice
form
bone
marrow
carcinosis
recipients
bone
marrow
sample
full
cell
dark
cell
indicate
bone
marrow
carcinosis
summary
bone
marrow
transplantation
experiment
transgenic
control
mouse
sibling
balb
mouse
view
within
article
dissemination
tumor
cell
associated
tumor
size
human
breast
cancer
one
provocative
finding
study
mouse
model
breast
cancer
large
tumor
seed
neither
much
genetically
cancer
cell
small
lesion
figure
figure
respectively
thus
ability
metastatic
dissemination
appear
result
selection
tumor
cell
within
tumor
rather
datum
suggest
tumor
cell
disseminate
early
will
select
outgrowth
distant
site
analyzed
sample
breast
cancer
patient
test
hypothesis
breast
cancer
patient
screen
bone
marrow
sample
presence
dtc
assess
number
dtc
different
size
primary
tumor
find
association
tumor
stage
presence
disseminate
cell
pearson
df
figure
specifically
finding
cell
patient
ductal
carcinoma
situ
dcis
patient
statistically
different
pearson
test
however
number
cell
seed
bone
marrow
dcis
patient
significantly
high
observe
control
patient
stain
antibody
mab
pearson
test
side
image
image
figure
number
karyotype
dtc
detected
bone
marrow
breast
cancer
patient
number
detect
cell
per
bone
marrow
cell
patient
different
tumor
stage
dcis
karyotype
cell
bone
marrow
breast
cancer
patient
patient
harboring
dtc
normal
abnormal
normal
abnormal
karyotype
differentially
distribute
tumor
patient
dtc
patient
dtc
patient
dtc
view
within
article
finally
model
rule
tumor
cell
bone
marrow
patient
large
primary
tumor
genetically
far
advance
disseminate
cancer
cell
patient
small
tumor
previously
show
bone
marrow
sample
breast
cancer
patient
contain
tumor
cell
without
chromosomal
aberration
match
primary
tumor
display
abnormal
karyotype
cell
apparently
disseminate
onset
chromosomal
instability
primary
site
think
occur
stroma
invasion
furthermore
malignant
origin
cell
normal
karyotype
establish
demonstration
loss
heterozygosity
conclude
cell
represent
early
stage
genetic
tumor
development
follow
lead
examine
chromosomal
aberration
dtc
bone
marrow
take
patient
various
tumor
stage
patient
classify
harboring
cell
cgh
abnormality
cell
without
cgh
abnormality
harboring
type
tumor
cell
bone
marrow
analyzed
single
cell
isolate
patient
observe
significant
difference
patient
small
large
cancer
figure
pearson
df
indicate
association
large
tumor
size
development
manifest
metastasis
explain
increase
frequency
genetically
progress
cancer
cell
bone
marrow
discussion
provide
evidence
dissemination
tumor
cell
mouse
model
breast
cancer
well
human
disease
occur
preinvasive
stage
tumor
progression
number
genotype
seed
tumor
cell
associate
tumor
size
finding
modify
prevail
view
metastatic
dissemination
late
event
association
tumor
size
risk
metastasis
reflect
high
frequency
tumor
cell
seed
implicit
view
extend
period
genetic
progression
within
primary
tumor
require
metastatic
dissemination
finding
support
chromosomal
aberration
mouse
model
human
breast
associate
increase
tumor
size
though
accumulate
time
human
cancer
show
mouse
model
human
sample
therefore
concur
observation
relative
total
number
tumor
cell
primary
lesion
dissemination
high
early
transformation
interestingly
model
activation
proteolytic
system
breast
epithelia
associate
young
age
adh
moreover
quantitative
analysis
twist
expression
compare
lesion
adh
central
peripheral
region
large
tumor
normal
sample
reveal
significant
upregulation
breast
cancer
cell
exceed
even
expression
level
invasion
front
primary
tumor
twist
expression
associate
transition
migration
invasion
deregulation
yang
activation
specific
genetic
program
early
expression
transform
oncogene
may
thus
initiate
microinvasion
detect
transmission
electron
microscopy
breast
lesion
early
stage
adh
lesion
define
noninvasive
evidence
invasion
detect
careful
inspection
experience
pathologist
yet
pymt
mouse
harbored
dtc
lung
bone
marrow
cell
bone
marrow
adh
evidence
malignant
origin
provide
comparative
genomic
hybridization
ectopic
transgene
expression
site
exclude
transplantation
experiment
mammary
graft
grow
background
also
epithelial
cell
disseminate
bone
marrow
lung
stage
adh
display
genetic
aberration
existence
genetic
program
associate
dissemination
transiently
activate
early
lesion
might
explain
human
breast
cancer
twist
expression
rarely
find
invasive
ductal
carcinoma
perform
several
experiment
assess
whether
mouse
model
cancer
cell
may
give
rise
metastasis
first
growth
metastasis
occur
transition
primary
lesion
noninvasive
invasive
indicate
tumor
cell
disseminate
much
early
start
grow
distant
site
second
week
situ
carcinoma
present
resection
gland
neither
prevent
reduce
number
lung
metastases
third
dissemination
early
lung
colonization
find
also
female
transiently
carry
single
transgenic
mammary
graft
resection
much
graft
display
small
invasive
cancer
one
two
case
transplant
surgically
remove
stage
adh
cell
start
form
metastatic
colony
analyzed
week
surgery
thus
number
experiment
currently
quantify
frequency
manifest
metastasis
consequence
adh
safe
state
tumor
cell
occasionally
metastatic
potential
however
note
course
disease
transplant
sibling
prolong
compare
transgenic
animal
autochthonous
tumor
female
metastases
regularly
present
week
mouse
micro
metastases
appear
much
week
transplantation
transgenic
gland
least
two
possibility
may
account
observation
although
transplant
mammary
tissue
expression
transgene
recipient
mouse
result
peripheral
immunological
tolerance
exclude
rat
transgene
product
slow
systemic
cancer
progression
alternatively
surgical
removal
primary
lesion
early
time
point
may
cancer
cell
systemically
act
factor
important
outgrowth
factor
secrete
primary
tumor
may
prepare
metastatic
niche
foster
early
cancerous
colony
recently
suggest
thus
large
primary
breast
cancer
patient
may
support
metastasis
seed
much
cancer
cell
provide
unknown
systemically
act
factor
stimulate
colonization
previously
disseminate
tumor
cell
ectopic
site
reasoning
back
finding
patient
small
tumor
harbor
similar
number
disseminate
cancer
cell
patient
late
stage
tumor
present
cohort
patient
several
study
dtc
breast
cancer
employ
however
rather
different
technique
dtc
detection
much
patient
braun
coworkers
observe
increase
positive
bone
marrow
sample
stage
stage
datum
give
far
support
conclusion
large
tumor
relation
small
tumor
seed
far
little
tumor
cell
bone
marrow
average
primary
tumor
comprise
time
much
cancer
cell
tumor
percentage
patient
dtc
bone
marrow
increase
marginally
thus
poor
prognosis
patient
breast
cancer
explain
increased
dtc
number
far
unknown
external
trigger
may
responsible
metastatic
outgrowth
currently
rather
underestimate
context
noteworthy
high
number
dtc
bone
marrow
lifetime
mouse
never
exceed
bone
marrow
cell
transplantation
transgenic
bone
marrow
contain
total
tumor
cell
per
inoculum
take
mouse
inject
irradiate
animal
result
bone
marrow
carcinosis
much
cell
cancerous
origin
since
donor
bone
marrow
take
mouse
adh
suggest
tumor
cell
may
release
dormancy
type
consequence
stimulatory
microenvironment
repopulation
irradiate
bone
marrow
eventually
grow
though
finding
microinvasion
stage
adh
may
apply
patient
breast
cancer
detection
disseminate
cancer
cell
dcis
suggest
conventional
histopathological
analysis
may
miss
tumor
spread
human
cancer
well
although
rare
metastasis
dcis
patient
observe
despite
complete
resection
mammary
tissue
clinical
finding
cancer
unknown
primary
well
transfer
cancer
organ
transplant
donor
small
undiagnosed
malignant
lesion
equally
consistent
early
dissemination
potential
metastatic
outgrowth
taken
together
finding
suggest
concept
cancer
progression
accord
metastatic
dissemination
distinct
early
step
cancer
progression
necessary
sufficient
metastatic
outgrowth
interaction
cancer
cell
ectopic
microenvironment
lead
selection
adaptation
within
early
metastatic
niche
ill
understand
present
may
require
different
experimental
approach
frequent
cell
line
derived
late
stage
tumor
previous
work
present
work
demonstrate
essential
step
genetic
progression
take
place
ectopic
site
within
primary
tumor
understanding
mechanism
promote
outgrowth
dtc
often
extend
period
cancer
latency
might
key
prevention
lethal
metastases
experimental
procedure
mice
mouse
transgenic
mouse
maintain
facility
accord
european
union
guideline
animal
experiment
perform
accord
eu
national
institutional
regulation
mice
screen
week
age
negative
littermates
serve
balb
mouse
control
mammary
gland
female
mouse
twice
week
arise
tumor
measure
caliper
two
perpendicular
diameter
tissue
sample
transgenic
mouse
strain
obtain
christoph
peters
thomas
reinheckel
institute
molecular
medicine
university
freiburg
bone
marrow
preparation
sterile
preparation
femur
bone
marrow
rinse
needle
ml
pbs
density
gradient
centrifugation
interphase
cell
drop
adhesion
slide
menzel
germany
least
cell
per
mouse
stain
positive
cell
isolate
immunostaining
detection
disseminate
cell
germany
germany
antibody
concentration
ml
visualize
abc
complex
ap
dako
denmark
ap
substrate
biorad
germany
immunohistochemistry
solid
tissue
primary
tumor
lung
tissue
stain
immunohistochemistry
tissue
embed
paraffin
rabbit
polyclonal
chemicon
international
apply
dilution
laser
microdissection
dna
mrna
preparation
laser
microdissection
isolation
nucleic
acid
preparation
dna
mrna
perform
describe
previously
klein
klein
small
piece
sample
catapult
cap
pcr
oil
centrifuged
reaction
tube
dna
mrna
analysis
tissue
catapult
reaction
tube
contain
bead
suspension
lysis
buffer
quantitative
pcr
pcr
perform
roche
fast
start
master
sybr
green
kit
roche
analysis
software
roche
pcr
efficiency
reference
sample
include
every
run
pooled
mrna
cell
serve
positive
control
measurement
show
product
curve
analysis
discard
far
analysis
expression
level
give
relative
gapdh
primer
sequence
provide
table
comparative
genomic
hybridization
image
acquisition
analysis
murine
control
dna
tumor
dna
labeled
roche
germany
respectively
detect
hybridization
metaphase
chromosome
ml
roche
germany
biotinylated
normal
dna
usa
image
record
leica
microscope
leica
acquisition
program
equip
ccd
camera
usa
processing
karyotyping
leica
software
package
array
hybridization
analysis
global
mrna
amplification
cdna
fragment
digoxigenin
labeled
hybridize
filter
scanning
significance
analysis
perform
publish
clustering
protease
euclidean
distance
complete
linkage
protease
average
linkage
case
cluster
assessment
perform
develop
richard
peng
calculation
tumor
progression
time
tumor
area
calculate
mammary
gland
mouse
assume
shape
circle
tumor
tumor
size
area
mammary
gland
without
tumor
set
zero
curve
fit
friedman
smooth
cell
sample
mouse
cell
sample
mouse
calculate
sum
single
disseminate
cell
number
aggregate
measurement
similar
time
point
week
consolidated
offset
week
draw
cell
one
plot
number
cell
nontransgenic
balb
mouse
measure
mouse
ck
mouse
five
time
point
week
connect
dot
line
area
lung
metastases
measure
software
calculate
sum
metastases
find
value
average
two
tissue
section
size
metastases
measure
four
mouse
mouse
without
surgery
measurement
similar
time
point
week
consolidated
surgery
mammary
tumor
mice
mg
mg
sufficient
min
thorax
abdomen
shave
skin
caudal
cranial
midline
subcutaneous
tissue
prepare
breast
gland
together
fatty
tissue
resected
vessel
skin
close
suture
ethicon
germany
surgery
take
usually
min
mouse
keep
warming
postoperative
analgesia
achieve
mg
every
day
suture
remove
tissue
transplantation
surgical
technique
transplantation
procedure
previously
describe
daniel
briefly
nipple
region
fourth
fat
pad
right
side
recipient
balb
mouse
remove
anesthesia
piece
donor
mammary
tissue
approximately
mm
size
mouse
implant
clear
mammary
fat
pad
recipient
mouse
bone
marrow
transplantation
eleven
mouse
euthanized
bone
marrow
harvest
femur
x
bone
marrow
cell
inject
tail
vein
lethally
irradiate
split
dose
day
day
sibling
remain
bone
marrow
slide
prepare
describe
determine
tumor
load
ck
staining
analysis
breast
cancer
patient
previous
study
disseminate
breast
cancer
cell
include
nonmetastatic
patient
information
available
four
patient
dcis
cell
detect
isolate
genetic
analysis
dna
amplify
comparative
genomic
hybridization
describe
addition
breast
cancer
patient
unilateral
primary
breast
cancer
patient
dcis
undergo
surgery
department
oncology
obstetrics
university
germany
include
bone
marrow
sampling
preparation
staining
screening
perform
accord
consensus
protocol
detection
disseminate
cancer
cell
apply
mab
antibody
germany
bone
marrow
sample
take
approval
local
ethic
committee
obtain
inform
consent
patient
data
control
group
normal
individual
include
patient
nonmalignant
disease
patient
benign
lesion
breast
fibroadenoma
abscess
cyst
simple
cyst
ovary
cervical
neoplasm
grade
ii
take
study
acknowledgment
gratefully
acknowledge
generous
help
provide
mouse
cdna
array
thomas
reinheckel
christoph
peters
help
pymt
mouse
thank
andrea
excellent
animal
care
melanie
help
bone
marrow
transplantation
experiment
work
support
grant
german
federal
ministry
education
science
grant
state
ministry
science
research
arts
italian
association
cancer
research
italian
ministry
education
university
research
scholarship
hamburg
natural
history
early
breast
cancer
depend
nodal
status
biological
characteristic
primary
tumour
oestrogen
receptor
status
excise
primary
tumour
oestrogen
receptor
ie
year
recurrence
rate
high
hormonal
therapy
little
effect
therefore
effect
adjuvant
chemotherapy
particular
interest
advance
breast
cancer
effect
chemotherapy
macroscopic
primary
secondary
lesion
observe
directly
early
disease
however
effect
chemotherapy
directly
individual
patient
trial
need
one
trial
adjuvant
chemotherapy
include
patient
disease
statistical
stability
effect
treatment
recurrence
mortality
woman
especially
long
term
well
study
periodically
update
relevant
randomised
trial
early
breast
cancer
trialists
collaborative
group
ebctcg
set
coordinate
yearly
centrally
collect
datum
woman
randomised
trial
treatment
early
breast
cancer
report
second
third
cycle
collaboration
indicate
take
type
primary
tumour
together
effect
adjuvant
chemotherapy
outcome
average
great
woman
young
year
old
age
mainly
year
since
woman
old
study
report
fourth
show
age
year
effect
chemotherapy
mortality
average
somewhat
greater
indicate
previous
ebctcg
report
however
still
difficult
determine
reliably
effect
particular
type
patient
unless
indicate
otherwise
present
report
term
chemotherapy
denote
prolong
adjuvant
treatment
various
standard
combination
old
drug
eg
six
course
cmf
randomised
woman
six
course
fac
fec
randomised
woman
also
call
adriamycin
none
regimen
study
deliberately
various
hypothesis
raise
efficacy
chemotherapy
breast
cancer
vitro
study
suggest
presence
tamoxifen
might
reduce
uptake
cytotoxic
activity
fluorouracil
breast
cancer
cell
observational
study
woman
advance
disease
conclude
objective
response
chemotherapy
much
likely
later
study
replicate
find
conclude
either
response
chemotherapy
correlate
even
increase
trial
perioperative
polychemotherapy
pect
versus
adjuvant
include
patient
disease
indicate
effect
survival
little
definite
trial
much
prolong
polychemotherapy
pect
trial
include
premenopausal
postmenopausal
woman
irrespective
status
give
adjuvant
tamoxifen
one
pect
trial
however
recurrence
reduce
subgroup
postmenopausal
woman
view
suggest
chemotherapy
might
particularly
effective
old
woman
disease
tamoxifen
ebctcg
analysis
prolong
chemotherapy
address
therefore
agree
first
report
fifth
cycle
address
evidence
regard
effect
adjuvant
polychemotherapy
versus
chemotherapy
disease
include
trial
tamoxifen
give
also
tamoxifen
give
woman
group
method
method
seek
collaboration
datum
collection
check
presentation
previous
ebctcg
ebctcg
receive
ethical
approval
oxford
research
ethic
committee
present
cycle
trial
eligible
begin
range
actual
start
date
much
late
available
information
oxford
analyses
allocate
treatment
previously
recurrence
define
first
detection
randomisation
breast
cancer
local
contralateral
distant
present
cycle
information
available
woman
disease
trial
chemotherapy
tamoxifen
table
trial
polychemotherapy
versus
chemotherapy
alone
versus
adjuvant
therapy
woman
chemotherapy
tamoxifen
versus
tamoxifen
alone
woman
trial
tamoxifen
versus
mostly
chemotherapy
tamoxifen
versus
chemotherapy
alone
number
woman
disease
age
trial
polychemotherapy
tamoxifen
begin
age
entry
year
polychemotherapy
versus
adjuvant
chemotherapy
polychemotherapy
alone
tamoxifen
ie
tamoxifen
alone
total
polychemotherapy
trial
tamoxifen
versus
adjuvant
tamoxifen
tamoxifen
alone
polychemotherapy
ie
polychemotherapy
alone
total
tamoxifen
trial
table
control
patient
trial
trial
stratum
count
number
give
webfigure
tamoxifen
polychemotherapy
give
concurrently
woman
trial
sequentially
remainder
percentage
woman
trial
regimen
contain
anthracycline
includes
six
age
know
tamoxifen
polychemotherapy
give
concurrently
woman
trial
sequentially
remainder
includes
nine
age
know
view
within
article
forest
plot
accompany
give
separately
trial
four
trial
perioperative
polychemotherapy
brief
summary
treatment
regimen
test
whether
active
treatment
group
allocate
chemotherapy
tamoxifen
number
woman
disease
treatment
versus
control
main
result
woman
detail
trial
treatment
regimen
give
webappendix
previous
ebctcg
report
tumour
define
receptor
measurement
done
many
year
ago
different
technique
different
trial
sometimes
even
trial
therefore
include
tumour
expression
also
tumour
little
expression
per
mg
cytosol
protein
quantitative
measurement
available
perhaps
much
strongly
tumour
false
negative
receptor
measurement
statistical
analysis
detailed
description
main
statistical
method
previously
also
available
logrank
statistic
assess
effect
active
versus
control
outcome
estimate
method
event
rate
ratio
confidence
result
fine
plot
black
square
horizontal
line
denote
ci
rather
ci
help
make
allowance
multiple
testing
result
total
subtotal
plot
white
denote
ci
test
trend
stratum
eg
age
effect
treatment
suppose
stratum
number
logrank
statistic
grand
total
stratum
define
mean
stratum
number
sum
one
term
per
stratum
define
sum
one
term
per
stratum
variance
var
sum
one
term
per
stratum
trend
test
statistic
ie
change
one
stratum
next
log
event
rate
ratio
var
variance
var
test
whether
two
trend
involve
corresponding
trend
test
statistic
statistic
one
degree
freedom
testing
whether
quantity
q
differ
significantly
zero
give
var
q
follow
two
question
formally
equivalent
whether
tamoxifen
reduce
proportional
efficacy
chemotherapy
whether
chemotherapy
reduce
proportional
efficacy
tamoxifen
illustrate
consider
hypothetical
factorial
trial
chemotherapy
tamoxifen
neither
suppose
one
particular
stratum
duration
patient
characteristic
event
rate
four
treatment
group
respectively
chem
tam
nil
two
different
chemotherapy
comparison
make
compare
efficacy
chemotherapy
rate
ratio
nil
efficacy
chemotherapy
presence
tamoxifen
ie
tamoxifen
group
rate
ratio
tam
comparing
answer
first
question
value
will
tend
little
tamoxifen
reduce
efficacy
chemotherapy
likewise
two
different
tamoxifen
comparison
make
compare
efficacy
tamoxifen
rate
ratio
nil
efficacy
tamoxifen
presence
chemotherapy
ie
chemotherapy
group
rate
ratio
chem
comparing
answer
second
question
value
will
tend
little
chemotherapy
reduce
efficacy
tamoxifen
however
equal
illustrate
equivalence
principle
question
role
funding
source
collaboration
fund
general
financial
support
ctsu
organisation
role
study
design
datum
collection
datum
analysis
datum
interpretation
write
report
organisation
list
acknowledgement
ebctcg
secretariat
see
full
access
datum
analysis
final
decision
submit
publication
responsibility
collaborator
result
figure
figure
figure
figure
describe
various
analysis
time
first
recurrence
webfigure
show
recurrence
analysis
also
give
corresponding
analysis
breast
cancer
mortality
death
image
image
figure
polychemotherapy
versus
disease
subdivide
first
type
comparison
absence
presence
tamoxifen
treatment
group
age
randomisation
event
rate
ratio
recurrence
significant
difference
trend
view
within
article
image
image
figure
polychemotherapy
versus
disease
subdivide
first
age
randomisation
type
comparison
absence
presence
tamoxifen
treatment
group
event
rate
ratio
recurrence
significant
view
within
article
image
image
figure
tamoxifen
versus
disease
subdivide
first
age
randomisation
type
comparison
absence
presence
chemotherapy
treatment
group
event
rate
ratio
recurrence
significant
polychemotherapy
trial
chemotherapy
three
view
within
article
image
image
figure
polychemotherapy
versus
disease
type
comparison
absence
presence
tamoxifen
treatment
group
age
randomisation
year
probability
recurrence
view
within
article
trial
polychemotherapy
versus
recurrence
rate
ratio
subdivide
figure
figure
age
randomised
entry
age
year
old
tamoxifen
ie
absence
presence
adjuvant
tamoxifen
treatment
regimen
compare
figure
analysis
subdivide
first
tamoxifen
age
whereas
figure
analysis
subdivide
first
age
tamoxifen
figure
describe
trial
polychemotherapy
alone
ie
absence
tamoxifen
suggest
substantial
proportional
risk
reduction
approximately
independent
age
although
age
range
consider
separately
confidence
interval
effect
age
year
wide
contrast
aggregate
trial
polychemotherapy
versus
section
part
figure
proportional
risk
reduction
appear
twice
great
entry
age
little
entry
age
conventionally
significant
trend
towards
great
efficacy
chemotherapy
young
age
treatment
versus
control
recurrence
rate
ratio
entry
age
year
entry
age
year
test
trend
great
effect
young
age
presence
tamoxifen
trend
towards
great
effect
chemotherapy
young
age
figure
apparent
difference
trend
age
figure
however
conventionally
significant
footnote
figure
apparently
null
trend
age
figure
apparently
strong
trend
age
figure
compatible
moderate
trend
age
overall
result
figure
within
age
range
woman
young
year
figure
tamoxifen
significantly
modify
effect
chemotherapy
first
two
age
range
figure
chemotherapy
appear
somewhat
much
effective
presence
tamoxifen
whereas
third
figure
appear
somewhat
little
effective
presence
tamoxifen
age
range
however
apparent
difference
efficacy
statistically
significant
overall
test
whether
tamoxifen
influence
efficacy
chemotherapy
figure
although
figure
take
evidence
tamoxifen
reduce
efficacy
chemotherapy
woman
age
figure
provide
evidence
figure
effect
tamoxifen
plus
chemotherapy
actually
appear
somewhat
well
chemotherapy
alone
opposite
expect
tamoxifen
reduce
efficacy
chemotherapy
taken
together
opposite
interaction
figure
figure
neither
statistically
significant
suggest
tamoxifen
little
relevance
efficacy
chemotherapy
disease
statistical
method
section
illustrate
equivalence
two
question
result
breast
cancer
mortality
death
webfigure
similar
recurrence
except
trend
age
reach
statistical
significance
also
age
range
consider
mortality
reduction
trial
chemotherapy
conventionally
significant
absence
tamoxifen
presence
tamoxifen
combine
age
overall
relative
risk
breast
cancer
mortality
death
figure
show
year
recurrence
risk
polychemotherapy
versus
subdivide
figure
figure
age
tamoxifen
whereas
figure
show
corresponding
year
result
death
year
difference
just
breast
cancer
mortality
similar
death
webfigure
image
image
figure
polychemotherapy
versus
disease
type
comparison
absence
presence
tamoxifen
treatment
group
age
randomisation
year
probability
death
view
within
article
figure
figure
figure
upper
part
give
result
absence
tamoxifen
middle
part
give
result
presence
tamoxifen
part
give
overall
result
age
range
difference
significant
absolute
effect
chemotherapy
absence
tamoxifen
absolute
effect
chemotherapy
presence
tamoxifen
overall
result
ie
part
figure
figure
figure
course
based
large
number
alone
even
information
available
woman
three
age
range
year
still
enough
result
individual
age
range
numerically
stable
particularly
mortality
old
age
range
thus
although
mortality
reduction
age
conventionally
significant
interpret
context
highly
significant
mortality
reduction
age
assess
effect
chemotherapy
old
woman
might
appropriate
consider
datum
two
year
age
range
together
give
small
number
randomised
overall
result
year
age
range
young
woman
give
figure
webfigure
compare
finding
recurrence
breast
cancer
mortality
death
age
range
year
effect
chemotherapy
year
probability
death
highly
significant
age
year
dead
absolute
difference
age
year
dead
absolute
difference
effect
death
effect
breast
cancer
mortality
figure
suggest
little
effect
regimen
year
mortality
even
year
age
image
image
figure
trial
polychemotherapy
versus
disease
patient
age
randomisation
year
probability
recurrence
ii
breast
cancer
mortality
iii
death
comparison
figure
figure
pool
datum
randomised
trial
prolong
adjuvant
polychemotherapy
irrespective
whether
tamoxifen
include
treatment
regimen
compare
view
within
article
young
woman
year
trial
disease
disease
whereas
age
year
disease
recurrence
rate
much
high
woman
despite
neither
proportional
risk
reduction
significantly
affect
nodal
status
respectively
corresponding
result
breast
cancer
mortality
death
give
webfigure
three
part
webfigure
give
far
subgroup
analysis
respect
type
chemotherapy
menopausal
status
stratified
age
nodal
status
stratified
age
tamoxifen
treatment
group
tumour
size
woman
just
woman
disease
tumour
differentiation
woman
just
woman
disease
progesterone
receptor
status
none
factor
significantly
modify
proportional
risk
reduction
produce
chemotherapy
although
fac
fec
regimen
appear
somewhat
much
promising
old
regimen
cmf
much
reliable
evidence
conclusion
come
much
large
number
directly
randomised
comparison
regimen
versus
webfigure
also
show
recurrence
specify
local
contralateral
one
also
local
contralateral
proportional
reduction
local
distant
recurrence
similar
main
effect
recurrence
just
first
year
randomisation
already
see
figure
webfigure
give
result
separately
trial
chemotherapy
versus
webfigure
give
result
separately
trial
tamoxifen
versus
completeness
webfigure
give
result
separately
four
trial
single
course
polychemotherapy
versus
adjuvant
chemotherapy
discussion
large
amount
datum
previous
trial
now
available
present
result
show
trial
continue
yield
useful
result
effect
adjuvant
polychemotherapy
recurrence
mortality
substantial
statistically
definite
woman
disease
age
little
age
year
figure
finding
inform
current
future
care
woman
chemotherapy
probably
give
intensively
now
particularly
old
woman
none
patient
present
analysis
receive
new
drug
taxane
hence
current
future
adjuvant
regimen
well
produce
substantially
greater
proportional
risk
reduction
recurrence
breast
cancer
mortality
regimen
test
trial
although
tamoxifen
now
disease
give
many
woman
trial
estimate
absolute
effect
chemotherapy
recurrence
mortality
see
trial
tamoxifen
two
approach
possible
one
chiefly
emphasise
just
upper
part
figure
figure
figure
ground
chemotherapy
comparison
tamoxifen
give
chiefly
emphasise
overall
result
part
figure
ground
tamoxifen
little
relevance
effect
chemotherapy
disease
randomised
evidence
compare
chemotherapy
versus
chemotherapy
first
approach
advantage
simplicity
also
disadvantage
small
number
woman
hence
larger
random
error
particularly
age
range
year
woman
year
woman
consider
isolation
age
range
little
year
relative
risk
year
similar
upper
part
part
figure
figure
figure
approach
yield
similar
estimate
benefit
although
finding
age
young
year
much
highly
significant
large
number
part
age
range
year
independent
evidence
tamoxifen
directly
indirectly
eg
modify
compliance
reduce
efficacy
chemotherapy
age
range
figure
therefore
might
much
appropriate
emphasise
randomised
evidence
part
woman
rather
just
fraction
part
woman
overall
result
mortality
reduction
highly
significant
age
range
year
combine
figure
together
significant
recurrence
reduction
age
range
see
figure
indicate
appreciable
mortality
reduction
age
also
age
year
even
though
reduction
late
age
might
somewhat
small
present
little
direct
information
benefit
hazard
chemotherapy
woman
age
year
old
woman
randomised
trial
least
quarter
recurrence
isolate
local
contralateral
recurrence
year
reduction
mortality
great
year
reduction
recurrence
figure
age
range
figure
year
absolute
reduction
year
risk
death
great
reduction
breast
cancer
mortality
line
evidence
chemotherapy
regimen
average
little
adverse
effect
mortality
first
year
consider
general
implication
trial
result
appropriate
consider
mortality
breast
cancer
mortality
separately
breast
cancer
proportional
risk
reduction
might
well
much
stable
absolute
risk
reduction
case
nodal
status
webfigure
therefore
much
likely
widely
approximate
proportional
risk
reduction
obtain
ratio
treatment
versus
control
year
breast
cancer
mortality
risk
figure
mortality
breast
cancer
will
depend
mainly
age
various
epidemiological
risk
factor
whether
disease
breast
cancer
already
present
woman
little
year
age
diagnosis
ratio
year
breast
cancer
mortality
risk
whereas
woman
year
age
figure
ratio
suggest
absence
death
year
breast
cancer
mortality
might
reduce
age
age
year
risk
might
reduce
age
age
year
risk
reduction
approximately
indicate
regimen
fac
fec
previous
ebctcg
however
good
drug
combination
test
trial
give
appreciably
well
result
might
achieve
overall
tamoxifen
appear
slightly
protective
woman
classify
disease
event
rate
ratio
endpoint
webfigure
however
well
woman
classify
disease
early
trial
fact
expression
hence
treatment
effect
apparent
protective
effect
somewhat
strong
trial
year
tamoxifen
typically
begin
around
whilst
trial
much
mean
year
tamoxifen
versus
typically
begin
much
recently
involve
woman
classify
disease
apparent
protective
effect
webfigure
suggest
even
year
tamoxifen
little
effect
disease
really
current
future
chemotherapy
regimen
substantially
much
effective
regimen
trial
therefore
yield
substantially
well
proportional
risk
reduction
future
ebctcg
report
will
address
directly
category
patient
disease
example
small
tumour
absolute
risk
even
without
adjuvant
chemotherapy
absolute
benefit
give
proportional
risk
reduction
will
also
however
risk
recurrence
category
untreated
disease
substantial
even
old
regimen
produce
appreciable
absolute
reduction
indicate
figure
contributors
write
committee
paper
order
clarke
coates
sc
darby
davies
rd
gelber
j
godwin
goldhirsch
gray
peto
pritchard
wood
accept
full
responsibility
overall
content
report
steering
committee
meeting
k
albain
anderson
arriagada
barlow
j
bergh
j
bliss
buyse
cameron
clarke
coates
collins
j
costantino
j
cuzick
darby
davidson
davies
leo
dowsett
ewertz
kvistgaard
gelber
geyer
goldhirsch
gray
hayes
hill
j
ingle
jakesz
kaufmann
mcgale
norton
ohashi
paik
perez
peto
piccart
k
pritchard
raina
ravdin
j
robertson
rutgers
yf
shao
taylor
valagussa
viale
whelan
winer
wang
wood
executive
group
secretariat
ebctcg
collaborator
list
alphabetically
institution
alphabetically
name
tokyo
japano
abe
abe
k
k
kikuchi
nomura
ohashi
k
k
j
hospital
cambridge
ukj
trial
collaborative
study
group
oxford
davies
j
sayer
breast
cancer
study
group
new
j
tm
zealand
breast
cancer
trial
group
forbes
austrian
breast
cancer
study
group
vienna
gnant
jakesz
lang
marth
menzel
j
thaler
j
oncology
centre
glasgow
belgian
adjuvant
breast
cancer
project
birmingham
general
hospital
ukg
j
institut
francem
institute
brussels
belgiuma
leo
j
piccart
bradford
royal
infirmary
ukm
j
j
price
breast
cancer
study
group
comprehensive
cancer
centre
j
british
columbia
cancer
agency
jackson
j
cancer
leukemia
group
washington
dc
usad
berry
norton
weiss
cancer
care
ontario
cancer
research
centre
academy
medical
science
cancer
research
uk
london
ukm
baum
j
cuzick
dowsett
j
cardiff
trialists
group
ukr
case
western
reserve
university
cleveland
oh
gordon
central
oncology
group
milwaukee
davis
centre
j
centre
romestaing
centre
paul
francej
centre
regional
j
centre
huguenin
paris
francep
university
czech
general
hospital
ukj
chemo
trial
group
harbeck
jnicke
chicago
university
meier
hospital
radium
institute
manchester
uka
howell
swindell
clinical
trial
service
unit
oxford
uk
ie
ebctcg
secretariat
clarke
collins
darby
davies
evans
j
godwin
gray
james
mcgale
peto
j
sayer
taylor
wang
instituto
j
copenhagen
radium
centre
mouridsen
cancer
institute
boston
ma
usad
hayes
j
harris
shapiro
winer
danish
breast
cancer
cooperative
group
copenhagen
ewertz
kvistgaard
mouridsen
mller
danish
cancer
registry
copenhagen
university
germanyh
j
dutch
working
party
autologous
bone
marrow
transplant
solid
tumour
vries
van
eastern
cooperative
oncology
group
boston
ma
usar
davidson
gray
robert
wood
edinburgh
breast
unit
cameron
hospital
hamburg
erasmus
mc
daniel
den
hoed
cancer
center
rotterdam
netherlandsj
j
van
european
institute
oncology
milan
italya
veronesi
viale
european
organization
research
treatment
cancer
brussels
rutgers
j
van
velde
j
van
hospital
fox
cancer
centre
philadelphia
pa
j
french
adjuvant
study
group
francej
bonneterre
german
adjuvant
breast
group
kaufmann
schumacher
von
german
breast
cancer
study
group
freiburg
sauerbrei
schumacher
university
hospital
belgiuma
group
cancer
care
evaluation
glasgow
infirmary
smith
gruppo
oncologico
del
gruppo
ricerca
genova
hospital
cape
town
south
hacking
murray
hospital
j
university
japanm
hospital
london
fentiman
j
hayward
heidelberg
university
germanyh
heidelberg
university
ii
kaufmann
cooperative
oncology
group
athens
helsinki
medical
centre
helsinki
university
university
institut
curie
paris
j
salmon
j
institut
paris
arriagada
hill
l
amsterdam
netherlandsj
van
velde
j
van
j
international
breast
cancer
study
group
ludwig
bern
switzerlandm
castiglione
coates
j
collins
j
forbes
gelber
goldhirsch
j
lindtner
k
price
raina
j
senn
international
collaborative
cancer
group
cross
hospital
london
ukj
bliss
hall
international
drug
development
institute
buyse
israel
tel
aviv
robinson
istituto
nazionale
per
la
ricerca
genova
venturini
istituto
nazionale
per
la
milan
italyg
palo
mg
valagussa
istituto
oncologico
italian
cooperative
group
italya
italian
oncology
group
clinical
research
parma
cocconi
japan
clinical
oncology
group
breast
cancer
study
group
japank
japanese
foundation
multidisciplinary
treatment
cancer
tokyo
japano
abe
k
k
kikuchi
k
sawa
medical
school
japanh
institute
oncology
j
university
group
japanm
ogawa
j
yamashita
leuven
ziekenhuis
van
den
francep
martin
memorial
cancer
center
new
york
norton
memorial
cancer
hospital
athens
national
medical
centre
city
la
national
cancer
institute
bethesda
md
usar
k
k
j
j
pierce
j
national
cancer
institute
italya
national
cancer
institute
canada
clinical
trial
group
ontario
canadaj
levine
j
j
k
pritchard
shepherd
tu
whelan
zee
national
cancer
center
nomura
national
surgical
adjuvant
breast
bowel
project
nsabp
pittsburgh
pa
anderson
brown
j
bryant
deceased
j
costantino
j
fisher
geyer
paik
redmond
nolvadex
adjuvant
trial
organisation
london
ukm
baum
jackson
deceased
k
palmer
north
central
cancer
treatment
group
clinic
rochester
mn
perez
j
ingle
j
north
sweden
breast
cancer
group
jonsson
british
surgeon
manchester
ukj
swindell
park
hospital
london
ukm
norwegian
breast
cancer
group
oslo
norwayb
erikstein
hannisdal
jacobsen
j
norwegian
radium
hospital
oslo
norwayb
erikstein
hst
jacobsen
nottingham
city
hospital
ukr
k
mitchell
j
robertson
paris
francem
j
ontario
clinical
oncology
group
hamilton
clark
levine
k
pritchard
whelan
osaka
city
university
japank
osaka
national
hospital
japank
sawa
hospital
oxford
harris
taylor
parma
hospital
italyg
cocconi
research
institute
oncology
oncology
association
usaj
cooper
hospital
japanh
university
south
royal
hospital
institute
cancer
research
london
ukr
j
smith
j
george
hospital
london
ukj
hospital
dublin
oncology
hospital
martino
international
trialists
cape
town
south
douglas
hacking
hst
lindtner
cancer
foundation
j
bryant
j
scandinavian
adjuvant
chemotherapy
study
group
oslo
cancer
therapy
network
edinburgh
foster
george
j
south
sweden
breast
cancer
group
mller
sweden
breast
cancer
group
swedenj
cancer
study
group
alabama
breast
cancer
project
birmingham
usaj
carpenter
oncology
group
san
antonio
tx
usak
albain
barlow
j
green
martino
k
ravdin
southampton
oncology
centre
murray
stockholm
breast
cancer
study
group
glas
swiss
group
clinical
cancer
research
bern
gallen
switzerlandm
castiglione
goldhirsch
j
senn
tel
aviv
university
tokyo
cancer
institute
hospital
japanm
breast
cancer
study
group
paterson
k
pritchard
toronto
margaret
hospital
canadaj
k
pritchard
tumour
hospital
chinese
academy
medical
science
beijing
people
republic
china
collaboration
oxford
ctsu
shao
x
wang
zhao
ctsu
chen
hc
pan
institut
uk
multicentre
cancer
chemotherapy
study
group
london
ukm
uk
asia
collaborative
breast
cancer
group
london
ukg
university
ii
italya
placido
university
texas
md
anderson
cancer
center
houston
tx
usak
breast
cancer
study
group
swedenj
bergh
j
vienna
university
hospital
department
west
oncology
association
birmingham
ukj
dunn
k
hill
lee
j
morrison
west
scotland
breast
trial
group
glasgow
uka
western
cancer
study
group
usar
university
germanyh
conflict
interest
statement
write
committee
secretariat
declare
conflict
interest
acknowledgment
main
acknowledgment
ten
thousand
woman
take
part
trial
review
funding
ebctcg
secretariat
direct
support
uk
medical
research
council
cancer
research
uk
clinical
trial
service
unit
epidemiological
study
unit
ctsu
university
oxford
angiogenesis
important
growth
progression
metastasis
solid
tumor
vascular
endothelial
growth
factor
vegf
play
central
role
process
act
angiogenic
inducer
endothelial
mitogen
mediator
vascular
permeability
evidence
important
role
vegf
breast
cancer
vegf
mrna
protein
expression
show
increase
invasive
breast
cancer
tissue
comparison
adjacent
normal
breast
tissue
addition
vegf
expression
level
report
increase
estrogen
breast
cancer
cell
isolate
endometrial
cell
support
notion
vegf
play
significant
role
development
breast
cancer
moreover
high
level
vegf
expression
appear
correlate
poor
prognosis
decrease
overall
survival
patient
breast
cancer
advance
ovarian
carcinoma
vegf
gene
highly
much
single
nucleotide
polymorphism
snp
describe
literature
particular
interest
snp
locate
regulatory
region
associate
alter
gene
expression
one
polymorphism
untranslated
region
cytosine
change
position
result
variant
long
potential
binding
site
activator
protein
transcription
factor
correlate
plasma
level
vegf
healthy
man
woman
allele
also
find
associate
reduce
uptake
detection
stage
breast
cancer
provide
additional
evidence
functional
role
polymorphism
association
functional
polymorphism
risk
sporadic
breast
cancer
describe
various
study
however
result
remain
controversial
study
reproduce
finding
respect
hereditary
breast
ovarian
cancer
datum
potential
role
polymorphism
modifier
disease
risk
publish
evidence
indicate
regulate
vegf
gene
transcriptional
activation
secretion
breast
cancer
cell
via
interaction
various
transcription
factor
one
study
demonstrate
presence
wild
type
wt
protein
vegf
expression
vegf
secretion
inhibit
whereas
inhibition
observe
presence
mutate
protein
study
report
increase
level
enhance
vegf
promoter
activity
vegf
mrna
level
whereas
mutate
protein
partially
completely
lose
ability
stimulate
transcriptional
activity
finding
line
small
polish
breast
cancer
study
report
significantly
serum
level
vegf
mutation
carrier
thus
association
polymorphism
vegf
level
mutation
status
vegf
level
suggest
assessment
possible
functional
consequence
polymorphism
breast
cancer
require
elucidate
role
functional
vegf
polymorphism
breast
ovarian
cancer
perform
case
control
study
among
polish
woman
carry
one
three
common
founder
mutation
include
breast
cancer
case
ovarian
cancer
case
control
material
study
participant
hereditary
cancer
registry
pomeranian
medical
university
szczecin
poland
contain
clinical
epidemiological
datum
collect
individual
carry
one
three
common
polish
founder
mutation
tg
mutation
carrier
select
family
least
one
breast
cancer
diagnose
year
age
ovarian
cancer
age
strong
history
breast
ovarian
cancer
questionnaire
collect
information
potential
risk
factor
research
approve
ethic
committee
pomeranian
medical
university
szczecin
poland
participant
give
inform
consent
prior
enrolling
study
woman
receive
genetic
counseling
prior
provision
test
result
register
carrier
female
mutation
carrier
dna
sample
available
include
study
include
breast
cancer
case
ovarian
cancer
case
unaffected
individual
breast
ovarian
cancer
case
diagnose
invasive
primary
disease
undergo
prophylactic
mastectomy
adnexectomy
breast
cancer
case
prophylactic
mastectomy
adnexectomy
tubal
ligation
ovarian
cancer
case
prior
cancer
diagnosis
control
breast
cancer
unaffected
breast
cancer
situ
breast
carcinoma
type
cancer
undergo
prophylactic
mastectomy
adnexectomy
control
ovarian
cancer
case
unaffected
ovarian
cancer
type
cancer
undergo
prophylactic
mastectomy
adnexectomy
tubal
ligation
number
subject
various
subgroup
median
age
case
diagnosis
breast
ovarian
cancer
control
time
interview
present
table
table
study
group
median
age
case
diagnosis
breast
ovarian
cancer
control
time
interview
case
factor
datum
age
case
cancer
diagnosis
year
range
median
age
control
time
interview
year
range
breast
cancer
case
control
total
ovarian
cancer
case
control
total
table
control
control
breast
ovarian
cancer
case
view
within
article
genetic
analysis
genomic
dna
isolate
peripheral
blood
leukocyte
accord
genotyping
polymorphism
perform
pcr
analysis
pcr
primer
condition
report
previously
fragment
digest
restriction
enzyme
promega
germany
separate
agarose
gel
contain
ethidium
bromide
steinheim
germany
score
uv
visualization
fragment
size
bp
allele
bp
bp
allele
genotyping
perform
laboratory
personnel
blind
case
control
status
blind
sample
repeat
concordance
quality
control
sample
genotyping
success
rate
great
statistical
analysis
risk
estimate
calculate
odd
ratio
confidence
interval
ci
univariate
multivariate
unconditional
logistic
regression
crude
orcrude
calculate
breast
cancer
case
control
ovarian
cancer
case
control
two
hundred
breast
cancer
case
control
ovarian
cancer
case
control
adjust
potential
breast
ovarian
cancer
risk
factor
referred
adjust
oradj
risk
factor
include
age
first
live
birth
year
parity
lifetime
cumulative
month
breastfeed
month
age
menarche
oral
contraceptive
oc
year
smoking
body
mass
index
bmi
age
breast
cancer
diagnosis
case
time
interview
control
year
birth
mutation
multivariate
unconditional
logistic
regression
model
age
comparison
among
carrier
different
genotype
perform
mann
whitney
statistical
analysis
perform
sas
stat
software
version
procedure
logistic
order
account
potential
bias
due
presence
relative
also
perform
cluster
multivariate
logistic
regression
analysis
sas
programme
value
little
consider
statistically
significant
due
proportion
woman
tt
genotype
patient
control
ct
tt
genotype
combine
analysis
result
distribution
select
cancer
risk
factor
include
age
menarche
age
first
live
birth
parity
breastfeed
oc
smoking
bmi
year
birth
mutation
show
previously
similar
breast
ovarian
cancer
case
corresponding
control
overall
prevalence
allele
carrier
among
breast
cancer
patient
ovarian
cancer
patient
comparison
unaffected
individual
genotype
frequency
polymorphism
case
control
association
genotype
breast
ovarian
cancer
risk
present
table
table
association
polymorphism
breast
ovarian
cancer
risk
genotype
cancer
case
control
orcrudea
ci
pcases
control
oradjb
ci
reference
reference
ct
allele
ovarian
cancer
case
control
orcrudea
ci
pcases
control
oradjb
ci
reference
reference
ct
allele
table
orcrude
crude
odd
ratio
oradj
odd
ratio
adjust
age
menarche
age
first
live
birth
parity
breastfeed
oc
smoking
bmi
year
birth
mutation
allele
genotype
frequency
agreement
previously
publish
healthy
caucasian
view
within
article
genotype
frequency
among
breast
cancer
case
control
reveal
association
tt
genotype
reduce
breast
cancer
risk
oradj
ci
correction
relate
study
subject
statistically
significant
association
remain
ct
tt
cc
orclustered
ci
comparison
genotype
frequency
ovarian
cancer
case
control
show
similar
decrease
ovarian
cancer
risk
compare
observe
breast
cancer
case
among
tt
genotype
carrier
statistically
significant
oradj
ci
however
correct
family
cluster
statistically
significant
association
observe
ct
tt
cc
orclustered
ci
mean
age
breast
cancer
diagnosis
woman
allele
similar
year
although
age
difference
small
statistically
significant
mann
whitney
show
tendency
line
observe
protective
effect
allele
also
difference
mean
age
ovarian
cancer
diagnosis
carrier
year
mann
whitney
discussion
study
investigate
effect
polymorphism
risk
breast
ovarian
cancer
woman
predispose
mutation
gene
several
investigation
polymorphism
sporadic
breast
cancer
population
previously
report
nothing
know
effect
polymorphism
disease
risk
good
knowledge
one
first
report
show
possible
influence
polymorphism
breast
ovarian
cancer
risk
woman
harbor
predispose
mutation
result
indicate
allele
associate
decrease
risk
breast
cancer
polish
mutation
carrier
association
remain
affect
polymorphism
adjust
know
putative
risk
factor
include
age
first
live
birth
parity
breastfeed
age
menarche
oc
smoking
status
bmi
year
birth
mutation
correct
relate
study
participant
protective
affect
polymorphism
remain
imply
observe
risk
modification
much
likely
attributed
polymorphism
vegf
gene
outside
context
similar
association
report
one
austrian
case
control
study
breast
cancer
case
control
find
association
allele
decrease
breast
cancer
risk
ci
another
large
case
control
study
include
case
control
shanghai
genotype
associate
decrease
breast
cancer
risk
ci
inverse
correlation
restrict
premenopausal
woman
ci
finding
however
reproduce
three
case
control
study
sporadic
familial
breast
cancer
furthermore
one
study
report
opposite
effect
association
allele
increase
risk
situ
breast
cancer
current
study
decrease
risk
ovarian
cancer
also
observe
take
confound
effect
consideration
however
reach
statistical
significance
much
likely
due
insufficient
number
case
nevertheless
family
cluster
consider
confounder
significant
effect
observe
thus
influence
polymorphism
ovarian
cancer
risk
pursue
large
study
study
population
consist
woman
harbored
mutation
gene
know
confer
high
risk
disease
group
woman
harbor
germ
line
mutation
develop
malignancy
study
highlight
potential
benefit
investigate
modifier
breast
ovarian
cancer
risk
population
difference
presence
absence
disease
limitation
present
study
take
account
general
selection
bias
may
occur
due
study
participant
registry
due
inclusion
incident
prevalent
case
polish
registry
presence
prevalent
case
among
study
participant
may
lead
general
limitation
kind
retrospective
study
effect
change
gene
expression
result
decrease
vegf
level
consequence
reduce
angiogenesis
suggest
polymorphism
may
modify
disease
risk
however
also
possible
observe
effect
due
another
functional
polymorphism
elsewhere
linkage
polymorphism
present
study
provide
evidence
functional
polymorphism
modify
risk
breast
cancer
may
potentially
alter
risk
ovarian
cancer
polish
woman
carry
founder
mutation
due
explorative
nature
study
far
confirmatory
study
warrant
acknowledgement
work
support
heidelberg
anna
jakubowska
researcher
pomeranian
medical
university
szczecin
poland
support
fellowship
anna
jakubowska
support
memorial
uicc
international
cancer
study
grant
plasminogen
activator
system
complex
system
multiple
interaction
member
participate
fibrinolysis
cell
migration
angiogenesis
wound
healing
embryogenesis
tumor
cell
dissemination
metastasis
variety
solid
tumor
increased
level
upa
primary
tumor
tissue
breast
cancer
patient
correlate
tumor
aggressiveness
poor
clinical
outcome
patient
high
tumor
tissue
antigen
content
upa
ill
probability
overall
survival
patient
level
biomarker
serve
prognostic
marker
clinical
utility
upa
prove
high
level
evidence
next
clinically
useful
prognostic
factor
allow
estimate
course
disease
early
breast
cancer
upa
may
also
serve
predictive
factor
predict
response
systemic
therapy
primary
breast
cancer
patient
high
upa
level
benefit
significantly
adjuvant
chemotherapy
aim
ongoing
trial
determine
benefit
sequential
anthracycline
docetaxel
regimen
breast
cancer
patient
compare
current
standard
chemotherapy
present
upa
provide
unique
opportunity
allow
validate
clinically
relevant
risk
assessment
breast
cancer
patient
provide
established
risk
factor
therefore
annually
update
ago
guideline
breast
cancer
management
german
working
group
gynecological
oncology
ago
recommend
biomarker
marker
routine
clinical
decision
make
breast
cancer
next
establish
clinical
histomorphological
factor
upa
system
plasminogen
activator
system
also
know
system
consist
serine
plasminogen
activator
upa
plasminogen
activator
tpa
plasminogen
activator
cell
receptor
upa
plasminogen
activator
inhibitor
type
plasminogen
activate
upa
tpa
active
serine
protease
plasmin
although
upa
tpa
quite
similar
structure
common
inhibitor
physiological
substrate
physiological
role
distinct
system
highly
specific
plasminogen
plasmin
tpa
present
blood
stream
presence
fibrin
also
effective
tissue
upa
attach
cellular
receptor
upar
lead
activation
nearby
plasminogen
subsequently
degradation
extracellular
fibrin
matrix
protein
newly
generate
plasmin
plasminogen
activator
system
complex
system
multiple
interaction
among
member
also
constituent
extracellular
matrix
traditionally
role
tpa
primarily
fibrinolysis
upa
cell
migration
especially
angiogenesis
wound
healing
embryogenesis
tumor
cell
dissemination
metastasis
functional
role
plasminogen
inhibitor
long
simply
inhibit
plasminogen
activator
role
promote
cycle
attachment
cell
extracellular
matrix
independent
role
enzymatic
inhibitor
upa
reveal
role
regulation
cell
death
alter
gene
expression
influence
rate
cell
proliferation
differentiation
inhibit
programme
cell
death
apoptosis
manner
independent
inhibition
production
activation
upa
system
component
therefore
lead
change
degradation
extracellular
matrix
also
affect
cell
adhesion
angiogenesis
cell
proliferation
cell
invasion
physiological
condition
also
pathological
condition
cancer
expression
upa
often
high
epithelial
stromal
cell
tumor
tissue
surround
normal
tissue
point
fact
cancer
regulation
extracellular
proteolysis
involve
complex
interplay
cancer
cell
nonmalignant
stroma
cell
component
plasminogen
activation
system
image
key
role
upa
system
tumor
invasion
metastasis
view
within
article
clinical
relevance
upa
breast
cancer
elevated
expression
upa
mrna
protein
level
demonstrate
every
solid
malignant
tumor
type
examine
cancer
breast
ovary
esophagus
stomach
kidney
lung
liver
increased
level
upa
primary
tumor
tissue
correlate
tumor
aggressiveness
poor
patient
outcome
among
article
publish
scientific
literature
subject
much
datum
regard
prognostic
predictive
value
upa
impact
clinical
decision
make
available
breast
cancer
datum
consistently
show
high
level
upa
determine
primary
tumor
tissue
extract
protein
analysis
mrna
screening
associate
poor
clinical
outcome
patient
prognostic
impact
upa
primary
breast
cancer
validation
process
demonstrate
clinical
utility
upa
achieve
several
mostly
european
research
center
duffy
first
show
serine
protease
upa
prognostic
impact
breast
cancer
patient
demonstrate
high
enzymatic
activity
upa
primary
breast
cancer
tissue
correlate
tumor
size
number
lymph
node
involve
short
survival
compare
patient
upa
activity
soon
initial
observation
jnicke
demonstrate
determination
upa
antigen
content
primary
tumor
tissue
immunosorbent
assay
elisa
also
allow
prediction
course
disease
patient
receive
adjuvant
treatment
time
also
become
apparent
antigen
level
upa
also
possess
prognostic
value
breast
cancer
patient
model
develop
still
clinical
relevance
patient
high
tumor
tissue
antigen
content
upa
ill
probability
overall
survival
patient
level
biomarker
regarding
assessment
combination
upa
either
high
find
superior
either
factor
take
alone
furthermore
based
multivariate
analysis
upa
statistically
independent
establish
prognostic
factor
tumor
size
tumor
grade
steroid
hormone
receptor
status
menopausal
status
prognostic
factor
upa
superior
oncoprotein
thus
render
statistically
independent
clinically
important
information
international
research
group
report
similar
prognostic
impact
upa
breast
cancer
moreover
publish
interaction
vascular
endothelial
growth
factor
vegf
warrant
far
investigation
relationship
biomarker
angiogenesis
protease
cascade
order
achieve
high
level
evidence
clinical
utility
biomarker
accord
asco
tumor
marker
utility
grade
system
clinical
significance
prognostic
predictive
cancer
biomarker
evaluate
either
prospective
randomized
clinical
trial
large
regarding
guideline
upa
criterion
fulfil
prospective
randomized
multicenter
breast
cancer
therapy
trial
chemo
total
patient
enrolled
study
center
germany
slovenia
large
conduct
eortc
receptor
biomarker
group
comprise
breast
cancer
patient
independent
dataset
eortc
european
organisation
research
treatment
cancer
cancer
foundation
based
brussels
belgium
chemo
trial
upa
antigen
content
determine
primary
tumor
tissue
extract
commercially
available
elisa
kit
obtain
american
diagnostica
ct
usa
patient
upa
content
allocate
observation
arm
patient
high
upa
content
randomized
either
adjuvant
chemotherapy
six
cycle
cmf
cyclophosphamide
observation
compare
two
observation
arm
high
upa
prognostic
impact
upa
evaluate
prospective
fashion
first
interim
analysis
chemo
trial
median
time
month
demonstrate
statistically
independent
prognostic
impact
upa
regard
survival
also
previously
optimized
value
upa
discriminate
high
upa
confirm
second
analysis
median
time
month
comprise
patient
prognostic
impact
upa
regard
overall
survival
analysis
reveal
breast
cancer
patient
present
upa
primary
tumor
tissue
profile
year
overall
survival
rate
even
absence
adjuvant
systemic
therapy
image
study
design
chemo
trial
view
within
article
predictive
impact
upa
next
clinically
useful
prognostic
factor
allow
estimate
course
disease
early
breast
cancer
upa
may
also
serve
predictive
factor
predict
response
systemic
therapy
yet
study
publish
look
predictive
impact
upa
regard
response
failure
chemotherapy
endocrine
therapy
breast
cancer
instance
palliative
setting
show
metastasized
breast
cancer
patient
high
level
upa
primary
tumor
tissue
respond
poorly
palliative
endocrine
tamoxifen
therapy
compare
patient
level
factor
neoadjuvant
setting
look
correlation
level
determine
biopsy
tumor
tissue
sample
take
neoadjuvant
chemotherapy
tumor
biopsy
take
chemotherapy
time
primary
surgery
small
collective
patient
association
find
initial
level
clinical
response
primary
chemotherapy
early
breast
cancer
improvement
clinical
risk
assessment
therapy
benefit
prediction
combine
upa
evaluate
upa
level
prospectively
measure
elisa
tumor
tissue
extract
patient
primary
breast
cancer
criterion
either
alone
factor
identify
high
sensitivity
patient
high
risk
disease
recurrence
keep
much
half
patient
group
much
interestingly
significant
interaction
upa
adjuvant
systemic
therapy
demonstrate
suggest
benefit
adjuvant
therapy
breast
cancer
patient
define
upa
harbeck
subsequent
study
primary
breast
cancer
patient
breast
cancer
center
munich
germany
rotterdam
netherlands
evaluate
predictive
impact
upa
regard
response
adjuvant
endocrine
therapy
show
patient
high
upa
level
enhance
benefit
adjuvant
chemotherapy
compare
level
biomarker
corresponding
interaction
endocrine
therapy
high
upa
level
observe
upa
benefit
adjuvant
chemotherapy
subsequently
validate
pool
analysis
collective
eortc
receptor
biomarker
group
prospective
multicenter
chemo
trial
primary
breast
cancer
patient
high
upa
level
either
randomized
chemotherapy
observation
thereby
look
clinical
value
therapeutic
intervention
high
upa
patient
already
short
period
month
considerable
statistically
significant
benefit
adjuvant
cmf
chemotherapy
also
observe
high
upa
breast
cancer
patient
still
valid
long
median
time
month
prospective
randomized
multicenter
clinical
trial
therefore
validate
prognostic
value
upa
breast
cancer
patient
also
demonstrate
predictive
impact
high
level
evidence
method
determination
upa
majority
publish
retrospective
study
quantification
upa
antigen
level
tumor
tissue
extract
perform
commercially
available
elisa
kit
assay
also
prospective
chemo
clinical
trial
routine
tissue
analysis
clinical
decision
make
within
trial
conduct
six
different
laboratory
consequently
routine
quantitative
determination
upa
antigen
content
elisa
assay
recommend
employ
protein
extract
primary
breast
cancer
tissue
sample
assay
also
apply
assess
protein
extract
obtain
small
breast
cancer
biopsy
core
biopsy
specimen
section
upa
elisa
test
standardized
quality
assure
receptor
biomarker
group
pathobiology
group
eortc
present
mrna
analysis
upa
messenger
expression
reach
level
clinical
routine
mainly
due
lack
validate
multicenter
clinical
study
still
study
encourage
recent
publication
although
patient
collective
indicate
feasibility
test
system
breast
cancer
tissue
upa
analysis
independent
protein
expression
internalization
upa
complex
cell
likewise
validate
multicenter
clinically
relevant
breast
cancer
immunohistochemistry
study
upa
direct
antibody
routinely
process
breast
cancer
specimen
conduct
far
consequently
various
detection
quantification
system
upa
gene
protein
level
one
current
task
eortc
pathobiology
group
context
like
mention
addition
mrna
protein
expression
epigenetic
modification
cpg
island
within
promoter
region
upa
gene
also
indicator
tumor
aggressiveness
still
prospective
breast
cancer
trial
observe
upa
stratification
factor
yet
conduct
clinical
trial
consequence
result
chemo
breast
cancer
trial
number
clinical
question
answer
still
remain
open
regard
prognosis
therapy
response
prediction
breast
cancer
patient
breast
cancer
patient
level
upa
comprise
half
breast
cancer
patient
rather
risk
disease
recurrence
therefore
subject
adjuvant
systemic
chemotherapy
contrast
patient
high
upa
level
risk
develop
metastasis
benefit
adjuvant
systemic
therapy
second
prospective
multicenter
phase
iii
therapy
trial
trial
node
negative
breast
cancer
trial
now
open
patient
recruitment
principal
investigator
christoph
accord
german
law
university
harbeck
technical
university
munich
germany
two
main
aim
trial
compare
risk
assessment
clinical
outcome
based
tumor
biological
factor
upa
based
establish
clinical
histomorphological
factor
optimize
adjuvant
chemotherapy
regimen
breast
cancer
patient
trial
intergroup
trial
conduct
cooperation
ago
german
eortc
pathobiology
group
german
breast
group
end
october
recruitment
patient
come
clinical
center
germany
france
primary
breast
cancer
patient
age
year
tumor
size
cm
eligible
trial
recruitment
center
allow
select
risk
assessment
criterion
either
establish
clinical
histomorphological
criterion
determination
upa
primary
tumor
tissue
extract
risk
assessment
established
factor
take
recommendation
gallen
consensus
meeting
account
criterion
breast
cancer
patient
fulfil
follow
criterion
regard
high
risk
disease
recurrence
age
year
vascular
invasion
tumor
grade
steroid
hormone
receptor
pgr
pgr
tumor
grade
tumor
size
cm
image
trial
clinical
histomorphological
risk
trial
tumor
biological
risk
assessment
view
within
article
second
option
risk
assessment
based
presence
tumor
biological
factor
upa
primary
tumor
tissue
however
risk
assessment
primary
breast
cancer
patient
first
classify
accord
tumor
grade
patient
tumor
consider
risk
allocate
observation
arm
tumor
patient
consider
high
risk
therefore
randomized
chemotherapy
arm
patient
tumor
far
risk
stratification
accord
upa
appropriate
patient
year
age
upa
consider
risk
thus
allocate
observation
arm
patient
year
age
high
upa
young
year
age
randomized
one
two
chemotherapy
regimen
trial
patient
define
high
risk
disease
recurrence
randomized
either
six
cycle
cyclophosphamide
every
three
week
three
cycle
follow
three
cycle
docetaxel
every
three
week
patient
define
risk
disease
recurrence
allocate
observation
arm
receive
endocrine
therapy
accord
ago
guideline
applicable
overall
aim
trial
compare
risk
stratification
clinical
histomorphological
tumor
biological
determine
benefit
sequential
anthracycline
docetaxel
regimen
breast
cancer
patient
like
mention
another
clinical
therapy
trial
adebar
trial
adjuvant
docetaxel
versus
regimen
trial
already
complete
breast
cancer
patient
much
three
involve
axillary
lymph
node
enrolled
patient
recruit
center
randomized
either
six
cycle
six
cycle
sequential
anthracycline
docetaxel
regimen
testing
upa
optional
translational
research
subprotocol
intend
evaluate
benefit
add
taxane
chemotherapy
two
risk
group
accord
upa
status
adebar
trial
close
patient
recruitment
spring
clinical
result
thus
also
result
upa
subprotocol
still
current
upa
clinical
decision
making
tumor
biological
factor
upa
validate
high
level
evidence
regard
prognostic
predictive
impact
primary
breast
cancer
therefore
german
working
group
gynecological
oncology
ago
recommend
biomarker
routine
clinical
decision
make
breast
cancer
next
establish
clinical
histomorphological
factor
recommendation
first
issue
annually
update
ago
guideline
image
ago
breast
cancer
treatment
guidelines
prognostic
predictive
factor
clinical
routine
view
within
article
still
although
substantial
consistent
datum
publish
prospective
clinical
therapy
trial
evidence
validate
prognostic
factor
demonstrate
benefit
adjuvant
chemotherapy
high
upa
breast
cancer
patient
available
tumor
biological
marker
recently
integrate
international
guideline
gallen
conference
consensus
clinical
validity
dispute
one
reason
limited
worldwide
acceptance
certainly
necessity
tumor
tissue
preparation
tumor
tissue
extract
elisa
testing
available
standard
care
many
country
world
include
usa
rather
surprising
since
many
year
breast
cancer
tissue
set
aside
steroid
hormone
receptor
testing
eia
test
moreover
mrna
testing
employ
technology
also
require
fresh
breast
cancer
tissue
analysis
based
level
evidence
much
recent
asco
guideline
include
upa
marker
recommend
practice
want
stress
date
upa
breast
biomarker
whose
clinical
utility
demonstrate
prospective
clinical
trial
chemo
second
confirmatory
trial
way
regarding
prospective
gene
signature
validation
breast
cancer
patient
first
clinical
therapy
trial
just
launch
tailorx
trial
assigning
individualized
options
treatment
rx
gene
disease
recurrence
score
mindact
microarray
disease
may
avoid
chemo
therapy
gene
signature
risk
assessment
thus
present
upa
provide
unique
opportunity
allow
validate
clinically
relevant
risk
assessment
breast
cancer
patient
provide
traditional
establish
risk
factor
numerous
epidemiological
biological
clinical
study
indicate
strong
correlation
dietary
factor
prevention
human
cancer
therefore
chemoprevention
cancer
phytochemical
become
field
research
past
decade
ginger
rhizome
commonly
know
ginger
utilize
worldwide
flavoring
agent
long
history
medicinal
ginger
contain
pungent
phenolic
substance
collectively
know
one
major
pungent
element
ginger
find
exhibit
antioxidant
activity
determine
inhibition
peroxidation
induce
system
confirm
many
vitro
vivo
system
gingerol
also
find
inhibit
platelet
aggregation
formation
ginger
oil
single
oral
dose
mg
kg
significantly
suppress
severe
chronic
adjuvant
arthritis
rat
ginger
consumption
ameliorate
pain
symptom
disorder
lower
platelet
production
human
recently
cancer
chemopreventive
potential
ginger
determine
inhibition
inhibition
virus
activation
cell
suppression
intestinal
carcinogenesis
rat
mouse
skin
tumor
also
gingerol
show
exhibit
anticancer
activity
induction
apoptosis
cancer
metastasis
consist
complex
cascade
event
ultimately
allow
tumor
cell
escape
seed
ectopic
environment
breast
cancer
cell
manifest
malignant
potential
develop
ability
break
dissolve
extracellular
matrix
ecm
particularly
basement
membrane
bm
degradation
bm
ecm
concerted
action
several
class
enzyme
one
important
class
enzyme
include
matrix
metalloproteinase
mmp
mmp
implicate
possible
mediator
invasion
metastasis
cancer
recently
show
inhibit
formation
lung
metastases
melanoma
experimental
mouse
model
however
limited
knowledge
regard
effect
term
metastasis
mmp
may
exert
antitumor
effect
study
investigate
effect
tumor
metastasis
thus
far
study
undertake
assess
effect
ginger
metastasis
breast
cancer
therefore
examine
effect
human
breast
cancer
cell
material
material
reagent
purchase
biomol
usa
dissolve
ethanol
dilute
cell
culture
medium
cell
purchase
american
type
culture
collection
rockville
md
usa
follow
reagent
chemical
obtain
respective
dulbecco
modify
eagle
medium
nutrient
mixture
ham
dmem
streptomycin
penicillin
gibco
brl
bovine
serum
albumin
bsa
transferrin
sigma
louis
usa
mmp
purchase
santa
cruz
biotechnology
santa
cruz
usa
reagent
obtain
sigma
cell
culture
human
breast
cancer
cell
line
maintain
dmem
contain
ml
fetal
bovine
serum
fbs
penicillin
mg
streptomycin
examine
effect
cell
plate
dmem
contain
fbs
human
breast
cancer
cell
treat
cell
monolayer
rinse
starve
serum
dmem
supplement
mg
transferrin
bsa
selenium
medium
sfm
serum
starvation
fresh
sfm
without
indicate
concentration
replace
viable
cell
number
estimate
cell
expose
bromide
mtt
assay
describe
previously
brief
mtt
solution
mg
ml
add
cell
incubate
allow
cleavage
tetrazolium
mitochondrial
dehydrogenase
formation
blue
formazan
crystal
residual
mtt
carefully
remove
crystal
dissolve
absorbance
nm
measure
spectrophotometry
adhesion
assay
plate
coat
fibronectin
bd
bioscience
massachusetts
usa
ml
pbs
incubate
coated
well
wash
twice
pbs
incubate
sfm
well
pbs
dry
clean
cell
cell
well
suspend
medium
contain
seed
coat
well
incubate
adherent
cell
wash
three
time
pbs
medium
contain
mg
ml
mtt
absorbance
measure
nm
microplate
reader
molecular
devices
sunnyvale
usa
experiment
perform
independently
three
time
matrigel
invasion
assay
wells
matrigel
chamber
bd
bioscience
fill
sfm
adapt
room
temperature
cell
cell
ml
resuspended
medium
contain
carefully
transfer
upper
chamber
lower
chamber
fill
fbs
medium
attract
cell
matrigel
chamber
incubate
cell
upper
surface
filter
remove
wipe
paper
filter
stain
stain
solution
dade
behring
nj
usa
cell
surface
filter
fix
onto
glass
slide
cell
five
randomly
select
microscopic
field
slide
count
experiment
perform
independently
three
time
wound
healing
migration
assay
migration
assay
based
repopulation
wound
culture
cell
seed
well
culture
plate
cell
ml
cultured
medium
contain
fbs
near
confluence
cell
monolayer
confluent
cell
monolayer
incubate
ml
stop
cell
proliferation
monolayer
carefully
wound
yellow
pipette
tip
cellular
debris
present
remove
wash
pbs
wound
monolayer
incubate
sfm
contain
photograph
exact
wound
area
take
initially
take
boyden
chamber
motility
assay
filter
diameter
pore
size
coat
gelatin
solution
room
temperature
chamber
fill
fbs
medium
attract
cell
cell
cell
ml
resuspended
medium
contain
carefully
transfer
upper
chamber
chamber
fill
fbs
medium
attract
cell
boyden
chamber
incubate
gentle
removal
filter
chamber
cell
upper
side
filter
remove
wipe
paper
filter
stain
stain
solution
dade
behring
cell
surface
filter
penetrate
pore
filter
fix
onto
glass
slide
cell
five
randomly
select
microscopic
field
slide
count
experiment
perform
independently
three
time
matrix
metalloproteinase
activity
gelatin
zymography
cell
seed
plate
cell
ml
incubate
medium
contain
fbs
supernatants
collect
concentrate
centricon
mmp
activity
supernatant
investigate
gelatin
zymography
supernatant
mix
sample
buffer
invitrogen
zymography
perform
gel
polyacrylamide
gelatin
mmp
activity
visualize
staining
coomassie
blue
matrix
metalloproteinase
amount
assay
cell
seed
plate
cell
ml
incubate
medium
contain
fbs
supernatants
collect
concentrate
centricon
next
well
plate
coat
buffer
solution
mg
mg
ml
ph
coated
well
incubate
dilute
primary
monoclonal
antibody
supernatant
add
well
incubate
room
temperature
wells
wash
twice
pbs
ph
contain
nacl
block
bsa
solution
wash
wells
incubate
secondary
mouse
antibody
wash
tbm
substrate
solution
tbm
dmso
ml
add
well
well
incubate
overnight
dark
reaction
stop
addition
absorbance
measure
nm
microplate
reader
molecular
devices
reverse
transcriptase
polymerase
chain
reaction
total
rna
isolate
sigma
cdna
synthesize
total
rna
ii
reverse
transcriptase
invitrogen
amplification
cdna
primer
upstream
primer
downstream
primer
primer
upstream
primer
downstream
primer
anneal
min
cycle
expression
human
transcript
examine
internal
control
describe
previously
pcr
product
separate
agarose
gel
stain
ethidium
bromide
bands
corresponding
specific
pcr
product
quantify
densitometric
scanning
expose
film
application
statistical
analysis
statistical
analysis
perform
statistical
analysis
system
software
sas
institute
cary
usa
data
express
mean
standard
deviation
analyzed
via
analysis
variance
anova
statistically
significant
difference
among
mean
group
test
duncan
multiple
range
test
effect
growth
adhesion
viable
cell
number
differ
treatment
within
elucidate
effect
metastasis
first
examine
effect
cell
show
effect
cell
adhesion
effect
cell
adhesion
result
reduction
compare
image
effect
cell
proliferation
cell
cell
plate
density
cell
ml
well
plate
dmem
supplement
fbs
monolayer
serum
starve
dmem
supplement
ml
transferrin
ml
selenium
mg
ml
bovine
serum
albumin
serum
starvation
monolayer
incubate
medium
viable
cell
number
estimate
mtt
assay
bar
represent
calculate
three
independent
experiment
view
within
article
image
effect
adhesion
cell
cell
ml
suspend
dmem
contain
plate
well
well
plate
medium
gently
remove
attach
cell
assay
mtt
assay
bar
represent
calculate
three
independent
experiment
comparison
among
different
concentration
yield
statistically
significant
difference
indicate
different
letter
bar
view
within
article
effect
invasion
motility
invasion
motility
human
breast
carcinoma
cell
line
show
inhibitory
effect
cell
invasion
matrigel
chamber
cell
migration
motility
critical
process
invasion
allow
primary
tumor
metastasize
treatment
cell
increase
concentration
lead
decrease
wound
healing
cell
migration
cell
motility
boyden
chamber
assay
image
effect
invasion
cell
cell
cultured
presence
various
concentration
within
matrigel
invasion
chamber
microphotographs
filter
quantitative
analysis
matrigel
chamber
invasion
assay
show
invasion
express
percentage
control
bar
represent
calculate
three
independent
experiment
comparison
among
different
concentration
yield
statistically
significant
difference
indicate
different
letter
bar
view
within
article
image
effect
migration
cell
cell
plate
well
plate
density
cell
well
dmem
supplement
fbs
confluent
monolayer
wound
incubate
medium
presence
wound
cell
photograph
phase
contrast
microscope
view
within
article
image
effect
cell
motility
cell
cell
cultured
presence
various
concentration
within
boyden
chamber
microphotographs
filter
quantitative
analysis
boyden
chamber
assay
show
motility
express
percentage
control
bar
represent
calculate
three
independent
experiment
view
within
article
effect
activity
amount
mrna
expression
mmp
invasion
bm
principally
mediate
gelatinase
matrix
metalloproteases
determine
whether
affect
activity
amount
mrna
expression
show
activity
cell
decrease
manner
amount
protein
culture
supernatant
detect
decrease
manner
result
cell
culture
various
concentration
reverse
transcriptase
polymerase
chain
reaction
analysis
cell
mrna
suggest
expression
decrease
cell
upon
treatment
although
change
protein
level
mrna
expression
decrease
treatment
image
effect
activity
cell
cell
plate
plate
density
cell
well
dmem
supplement
fbs
monolayer
incubate
medium
absence
presence
medium
collect
activity
measure
photograph
mmp
band
representative
three
independent
experiment
quantitative
analysis
band
bar
represent
calculate
three
independent
experiment
comparison
among
different
concentration
yield
statistically
significant
difference
indicate
different
letter
bar
view
within
article
image
effect
amount
cell
cell
plate
plate
density
cell
well
dmem
supplement
fbs
monolayer
incubate
medium
absence
presence
medium
collect
protein
amount
estimate
elisa
bar
represent
calculate
three
independent
experiment
comparison
among
different
concentration
yield
statistically
significant
difference
indicate
different
letter
bar
view
within
article
image
effect
mrna
expression
cell
cell
treat
total
rna
isolate
perform
investigate
mrna
expression
photograph
ethidium
gel
representative
three
independent
experiment
quantitative
analysis
relative
abundance
band
estimate
densitometric
analysis
bar
represent
calculate
three
independent
experiment
comparison
among
different
concentration
yield
statistically
significant
difference
indicate
different
letter
bar
view
within
article
discussion
investigation
attempt
address
role
metastasis
may
exert
antitumor
effect
metastasis
complex
process
involve
cell
adhesion
invasion
motility
hence
interruption
one
much
step
one
approach
therapy
date
direct
evidence
show
exert
effect
development
breast
cancer
metastasis
present
study
first
demonstrate
significantly
inhibit
metastatic
process
human
breast
cancer
cell
initial
invasive
action
metastatic
cell
involve
interaction
tumor
cell
ecm
process
cell
matrix
adhesion
malignant
cell
detach
primary
tumor
surround
bm
adhere
meshwork
type
iv
collagen
laminin
fibronectin
show
manuscript
inhibit
attachment
fibronectin
one
major
component
bm
dose
process
tumor
cell
invasion
metastasis
require
degradation
connective
tissue
associate
vascular
bm
interstitial
connective
tissue
bm
large
barrier
free
malignant
cell
bloodstream
traverse
malignant
cell
enter
circulate
blood
therefore
invasion
bm
critical
step
metastasis
breast
cancer
cell
invasiveness
investigate
study
transwell
chamber
system
successfully
penetrate
filter
membrane
cell
successfully
adhere
degrade
traverse
insert
present
study
show
inhibit
invasion
breast
cancer
cell
manner
however
study
cell
proliferation
affect
treatment
although
cell
invasion
decrease
period
therefore
datum
suggest
effect
inhibition
cell
invasion
take
priority
decrease
cell
proliferation
motility
another
property
cancer
cell
need
migration
primary
site
secondary
organ
alteration
property
interrupt
metastatic
cascade
present
study
show
treatment
various
concentration
reduce
motility
cell
mechanism
inhibit
cell
adhesion
invasion
migration
yet
clear
several
line
evidence
strongly
implicate
mmp
particularly
process
tumor
cell
invasion
metastasis
include
positive
correlation
expression
invasive
potential
inhibition
metastasis
formation
mmp
inhibitor
vivo
mmp
family
enzyme
consist
propeptide
catalytic
hinge
domain
mmp
produce
latent
form
require
catalytic
removal
propeptide
domain
function
unique
inclusion
three
fibronectin
type
ii
repeat
within
catalytic
domain
demonstrate
significantly
contribute
invasion
bone
marrow
fibroblast
cell
investigator
exclude
possibility
contact
breast
cancer
cell
bone
marrow
fibroblast
result
rapid
release
inactive
release
may
associate
breast
cancer
membrane
type
mmp
tissue
inhibitor
complex
facilitate
activation
subsequent
invasion
normal
tissue
malignant
cell
much
malignant
cell
contain
fibronectin
likely
important
mechanism
development
metastases
many
cancer
report
plasma
concentration
activity
significantly
control
compare
cancer
benign
patient
expression
describe
positive
prognostic
marker
breast
cancer
show
activity
decrease
treatment
suggest
level
mrna
decrease
cell
treat
additionally
find
decrease
amount
protein
culture
supernatant
result
treatment
cell
level
level
remain
unchanged
conclusion
describe
first
time
inhibit
metastasis
breast
cancer
cell
line
suggest
anticancer
effect
may
contribute
inhibition
metastasis
decrease
activity
expression
ginger
considerable
amount
human
diet
mg
day
consider
ginger
contain
derivative
concentration
study
achieve
vivo
may
useful
prevent
treat
cancer
despite
considerable
attention
research
focus
breast
cancer
remain
much
common
cancer
among
woman
ethnic
background
one
two
lead
cancer
death
among
woman
numerous
study
show
overall
breast
cancer
incidence
high
white
woman
african
american
hispanic
woman
two
latter
group
disadvantaged
respect
stage
diagnosis
survival
recent
study
link
neighborhood
indicator
poverty
disadvantage
difference
stage
diagnosis
individual
live
socioeconomic
status
ses
area
increase
probability
diagnosis
individual
level
datum
characteristic
income
education
often
available
sample
cancer
registry
datum
thus
area
level
indicator
ses
often
predictive
model
examine
relationship
ses
stage
cancer
diagnosis
much
study
examine
link
neighborhood
ses
health
however
recent
change
urban
neighborhood
raise
question
assumption
area
concentrate
poverty
stable
total
number
people
live
neighborhood
poverty
rate
high
common
definition
neighborhood
decrease
two
major
factor
contribute
trend
first
income
rise
many
nation
poor
urban
area
especially
south
second
last
two
decade
young
professional
suburb
many
metropolitan
area
include
chicago
increasingly
choose
live
city
center
process
loosely
referred
gentrification
addition
change
public
housing
policy
include
destruction
many
large
building
increase
economic
power
among
recent
lead
increased
ethnic
diversity
surround
neighborhood
despite
interest
neighborhood
effect
health
virtually
study
examine
impact
rapid
neighborhood
level
social
change
health
outcome
change
positive
negative
effect
example
increase
neighborhood
property
value
lead
increased
perception
safety
increase
private
public
investment
decrease
barrier
receive
health
care
safety
transportation
increase
quality
life
resident
afford
take
advantage
change
hand
rapid
social
change
may
also
source
stress
individual
financially
increase
property
become
socially
isolate
friend
family
member
leave
change
neighborhood
neighborhood
social
change
also
disrupt
access
healthcare
service
alteration
designation
medically
area
mua
impact
availability
clinic
service
illinois
state
cancer
registry
iscr
datum
conjunction
census
tract
level
datum
examine
association
rapid
residential
area
economic
change
likelihood
distant
metastasis
diagnosis
breast
cancer
among
woman
chicago
area
method
study
population
analysis
employ
breast
cancer
stage
diagnosis
datum
iscr
analysis
based
breast
cancer
case
diagnose
among
woman
reside
cook
county
iscr
datum
estimate
complete
year
based
north
american
association
central
cancer
registry
method
cancer
registry
record
provide
standardized
information
age
race
hispanic
ethnicity
surveillance
epidemiology
end
result
seer
general
summary
stage
diagnosis
exclude
small
number
patient
identify
white
black
hispanic
case
case
unknown
diagnostic
stage
report
case
respectively
also
exclude
analysis
demographic
characteristic
include
case
show
table
outcome
variable
distant
metastasis
diagnosis
code
local
regional
stage
diagnosis
code
cancer
case
cancer
registry
census
block
level
residential
address
time
diagnosis
complete
valid
address
information
available
much
cook
county
breast
cancer
case
information
code
case
cook
county
census
tract
table
frequency
distribution
included
analysis
mean
sd
individual
level
seer
stage
diagnosis
mean
age
yr
race
ethnicity
african
neighborhood
tract
level
mean
concentrate
mean
concentrate
mean
concentrate
mean
upward
table
sd
standard
deviation
view
within
article
measurement
neighborhood
characteristic
measure
indicator
census
bureau
summary
tape
file
respectively
cook
county
develop
scale
measure
neighborhood
characteristic
census
datum
concentrate
disadvantage
concentrate
affluence
concentrate
immigration
based
work
sampson
concentrated
disadvantage
define
percentage
family
census
tract
income
poverty
line
percentage
family
receive
public
assistance
percentage
person
unemployed
percentage
household
child
concentrated
affluence
measure
percentage
family
income
much
percentage
adult
college
education
much
percentage
civilian
labor
force
professional
managerial
occupation
finally
concentrate
immigration
scale
compose
percent
hispanic
among
population
percent
percent
isolate
household
percent
household
lack
least
one
member
speak
english
well
principal
component
analysis
confirm
variable
scale
highly
load
single
factor
following
sampson
colleague
first
calculate
z
score
variable
census
tract
cook
county
scale
average
equal
weighting
create
scale
scale
table
bottom
panel
mean
close
zero
standard
deviation
close
one
slightly
census
tract
case
female
breast
cancer
exclude
multilevel
analysis
number
measure
neighborhood
change
propose
literature
gentrification
city
establish
change
ses
consider
level
census
variable
principal
component
analysis
reveal
load
strongly
single
factor
consequently
assess
neighborhood
change
composite
score
percent
change
housing
value
percent
civilian
labor
force
professional
managerial
occupation
percent
adult
college
education
factor
loading
variable
respectively
scale
score
calculate
average
equally
weighted
z
score
data
analysis
utilize
multilevel
logistic
regression
predict
log
odd
distant
metastasis
diagnosis
accounting
woman
within
census
tract
model
consist
compositional
characteristic
concentrate
disadvantage
concentrate
affluence
concentrate
immigration
neighborhood
change
residential
area
level
patient
age
race
ethnicity
individual
level
model
examine
effect
neighborhood
change
likelihood
distant
metastasis
diagnosis
breast
cancer
control
neighborhood
socioeconomic
demographic
characteristic
result
show
table
residential
area
socioeconomic
upward
change
significantly
associate
probability
distant
metastasis
diagnosis
breast
cancer
specifically
unit
increase
one
standard
deviation
rate
neighborhood
change
odd
distant
metastasis
diagnosis
increase
odd
ratio
neighborhood
compositional
factor
also
relate
distant
metastasis
diagnosis
greater
concentrate
disadvantage
concentrate
immigration
associate
great
odd
distant
metastasis
diagnosis
neighborhood
affluence
associate
reduce
odd
distant
metastasis
diagnosis
individual
level
odd
distant
metastasis
diagnosis
breast
cancer
positively
associate
age
increase
per
year
age
african
american
compare
white
also
much
likely
distant
metastasis
diagnosis
contrast
hispanic
woman
little
likely
distant
metastasis
diagnosis
compare
white
woman
table
multilevel
logistic
regression
model
neighborhood
upward
change
distant
breast
cancer
stage
diagnosis
value
upward
african
table
ci
confidence
interval
view
within
article
discussion
result
reveal
upward
economic
change
local
area
measure
increase
property
value
professional
employment
education
among
neighborhood
resident
associate
increase
risk
distant
metastasis
diagnosis
breast
cancer
consistent
ongoing
research
unpublished
previous
study
find
level
neighborhood
affluence
disadvantage
strongly
relate
distant
metastasis
diagnosis
breast
cancer
significant
positive
effect
neighborhood
ses
might
imply
betterment
economic
status
residential
area
lead
early
diagnosis
breast
cancer
well
chance
survival
among
neighborhood
resident
however
study
show
upward
neighborhood
ses
change
actually
associate
increase
risk
distant
metastasis
diagnosis
breast
cancer
possible
effect
result
influx
woman
risk
distant
metastasis
diagnosis
improve
area
however
think
unlikely
new
neighborhood
resident
likely
young
employ
woman
good
healthcare
coverage
instead
much
likely
woman
distant
metastasis
diagnosis
breast
cancer
resident
neighborhood
upward
neighborhood
economic
change
woman
may
result
disruption
pattern
interaction
social
network
access
healthcare
service
result
social
isolation
concern
relocation
socioeconomic
area
stress
decrease
social
support
result
neighborhood
change
may
impact
health
via
reduction
utilization
health
care
include
cancer
screening
several
study
find
increase
social
tie
receive
support
relate
increased
mammography
study
find
much
modest
insignificant
relationship
indicator
social
support
mammography
recent
study
show
woman
income
education
even
little
likely
mammogram
reside
metropolitan
statistical
area
high
overall
level
education
income
regular
mammography
clinical
breast
exam
place
woman
risk
diagnose
much
advance
breast
cancer
addition
upward
neighborhood
ses
change
may
disrupt
access
health
care
particularly
poor
woman
impact
federally
qualify
health
center
fqhcs
designation
residential
area
mua
reduction
percentage
resident
live
poverty
percentage
resident
old
year
age
expect
directly
affect
important
federal
designation
fqhcs
locate
formerly
disadvantaged
neighborhood
may
struggle
provide
service
increasingly
geographically
disperse
extent
distant
metastasis
diagnosis
breast
cancer
relate
difference
screening
access
care
result
may
public
health
policy
implication
suggest
cancer
screening
resource
direct
area
undergo
change
term
debate
among
urban
specialist
effect
neighborhood
change
health
result
suggest
neighborhood
improvement
may
lead
early
diagnosis
breast
cancer
rather
effect
seem
just
reverse
result
much
consistent
speculation
regard
social
effect
poverty
much
optimistic
view
however
important
note
expect
eventually
economic
betterment
census
tract
positive
effect
early
diagnosis
breast
cancer
yet
process
upward
neighborhood
change
temporary
effect
put
woman
neighborhood
high
risk
late
diagnosis
woman
unchanged
neighborhood
whether
effect
temporary
empirical
finding
deserving
far
research
limitation
finding
great
individual
level
datum
measure
individual
experience
neighborhood
change
particular
know
long
woman
live
residential
area
prior
breast
cancer
diagnosis
hence
long
expose
neighborhood
environment
finding
also
based
datum
chicago
urban
area
particularly
large
differential
breast
cancer
survival
thus
may
generalizable
city
replicate
analysis
collaboration
researcher
center
population
health
health
disparity
university
boston
area
university
pennsylvania
philadelphia
area
state
university
detroit
area
rand
corporation
washington
suburban
maryland
angeles
area
metropolitan
area
vary
racial
ethnic
socioeconomic
characteristic
finally
datum
available
allow
directly
examine
issue
stress
social
support
change
access
care
neighborhood
experience
upward
ses
change
much
clearly
elucidate
mechanism
change
impact
cancer
diagnosis
future
research
focus
understanding
neighborhood
change
impact
woman
across
ses
probable
woman
resource
may
much
impact
neighborhood
change
consistent
recent
finding
suggest
individual
ses
live
area
high
level
ses
receive
health
benefit
area
fact
exhibit
high
level
mortality
also
consistent
literature
examine
effect
differential
socioeconomic
status
measure
disease
outcome
literature
claim
income
inequality
negative
effect
health
usually
relied
comparison
large
area
state
census
tract
future
research
also
differentiate
endogenous
improvement
ses
resident
exogenous
improvement
result
high
ses
new
resident
change
examine
health
impact
research
fund
national
cancer
institute
warnecke
pi
cancer
incidence
datum
study
supply
illinois
department
public
health
department
specifically
responsibility
analysis
interpretation
conclusion
thank
james
help
prepare
census
datum
philip
give
valuable
advice
process
social
change
cook
county
tumor
suppressor
gene
localized
short
arm
chromosome
play
critical
role
prevention
onset
progression
breast
cancer
expression
induce
upon
cellular
stress
include
dna
damage
oncogene
activation
overexpression
arrest
cell
cycle
induce
dna
repair
apoptosis
germ
line
mutation
lead
development
cancer
early
stage
inactivate
mutation
associate
initiation
progression
much
malignancy
human
mutation
gene
inhibit
activity
increase
breast
cancer
incidence
single
nucleotide
polymorphism
codon
gene
replace
arginine
also
alter
protein
activity
similarly
substitution
bp
downstream
may
also
alter
activity
close
functional
relationship
murine
double
oncogene
locate
long
arm
chromosome
gene
well
know
protein
negatively
regulate
function
multiple
independent
way
binding
transcription
activation
domain
inhibit
promote
nuclear
export
much
importantly
promote
degradation
activate
transcription
inhibit
function
interaction
relative
ratio
regulate
cell
division
overexpression
enable
damage
cell
escape
cell
cycle
checkpoint
become
carcinogenic
naturally
occur
sequence
variation
promoter
result
alter
protein
expression
lead
alteration
mediate
tumor
suppression
activity
polymorphism
promoter
increase
affinity
stimulatory
protein
subsequently
attenuate
pathway
study
association
polymorphism
breast
cancer
risk
show
positive
result
whereas
much
investigator
demonstrate
lack
association
snp
regulate
expression
codon
critical
function
combination
polymorphism
expect
determine
risk
breast
cancer
much
accurately
alone
polymorphism
gene
relationship
breast
cancer
susceptibility
vary
one
population
another
one
ethnic
group
another
depending
upon
residential
locality
level
environmental
exposure
present
investigation
therefore
undertake
investigate
association
polymorphism
breast
cancer
risk
indian
woman
material
method
chemical
agarose
methylene
boric
acid
blue
chloroform
acid
formamide
glycerol
chloride
sodium
chloride
sodium
carbonate
sucrose
trisodium
citrate
tris
base
triton
phenol
purchase
sigma
aldrich
louis
polymerase
chain
reaction
pcr
purification
kit
procure
germany
acetic
acid
formaldehyde
taq
polymerase
hot
start
taq
polymerase
dntp
pcr
primer
pcr
reaction
kit
chemical
require
study
procure
locally
either
bangalore
genei
research
laboratory
india
selection
subjects
medical
ethic
committee
participate
institution
approve
study
write
consent
obtain
blood
collection
individual
involve
study
blood
sample
collect
control
breast
cancer
patient
expert
clinician
institute
medical
science
sgpgims
lucknow
case
prevalent
identify
sgpgims
total
female
control
female
breast
cancer
patient
range
year
age
recruit
blood
collection
case
control
ethnic
group
resident
lucknow
adjacent
locality
north
india
special
emphasis
give
recruit
patient
control
similar
locality
avoid
difference
environmental
factor
control
female
possess
type
tumor
cancer
also
exhibit
genetic
disorder
visible
disease
sample
collect
unrelated
family
rule
possibility
direct
involvement
genetic
variable
patient
clinically
define
symptom
breast
cancer
consider
study
patient
history
breast
cancer
family
consider
study
avoid
involvement
know
familial
factor
properly
assess
contribution
single
nucleotide
polymorphism
snp
patient
classify
premenopausal
postmenopausal
group
based
case
history
information
give
basic
demographic
patient
control
summarize
table
table
table
basic
demographic
control
breast
cancer
patient
recruit
study
basic
control
age
mean
sd
year
year
smoking
habit
body
mass
index
mean
kg
kg
menopausal
status
number
age
menarche
mean
year
table
view
within
article
table
characteristic
tumor
treatment
regimen
patient
recruit
study
total
patient
tumor
histology
number
nodal
status
number
stage
diagnosis
number
stage
stage
stage
surgery
number
chemotherapy
number
radiotherapy
number
hormonal
therapy
tamoxifen
number
neoadjuvant
chemotherapy
number
table
view
within
article
blood
collection
dna
extraction
blood
draw
venous
puncture
control
breast
cancer
patient
collect
vial
contain
trisodium
citrate
ph
anticoagulant
genomic
dna
extract
whole
blood
mix
anticoagulant
salt
procedure
describe
dna
precipitate
aqueous
phase
ethanol
store
till
far
dna
amplify
desire
gene
segment
specific
primer
pcr
pcr
snp
genotyping
forward
reverse
primer
synthesize
exon
include
region
gene
amplify
separately
sequenced
forward
reverse
primer
promoter
synthesize
dna
segment
contain
amplify
amplification
refractory
mutation
system
positive
negative
control
essential
dna
sequencing
pcr
amplicon
purify
sequenced
automate
dna
sequencer
centre
genomic
application
tcga
new
delhi
india
sequence
analysis
perform
dna
available
online
software
single
strand
conformation
polymorphism
assess
codon
variant
also
perform
statistical
analysis
statistical
analysis
epi
software
allelic
genotypic
frequency
calculate
express
two
decimal
haplotype
frequency
case
control
calculate
online
software
unadjusted
odd
ratio
calculate
contingency
table
statistical
significance
calculate
test
however
fisher
exact
test
also
expect
cell
frequency
little
five
calculate
separately
confidence
interval
genotype
frequency
total
premenopausal
postmenopausal
breast
cancer
patient
compare
respective
control
minimum
detectable
power
level
significance
sample
size
case
control
prevail
percent
homozygous
wild
type
control
case
protective
association
case
increase
risk
equilibrium
snp
case
control
calculate
although
study
based
application
highly
reproducible
molecular
technique
three
experiment
sample
still
perform
confirm
reproducibility
result
gene
allele
total
premenopausal
postmenopausal
case
control
analyzed
neither
snp
genotype
associate
significantly
breast
cancer
risk
combined
genotype
also
associate
breast
cancer
risk
table
allelic
genotypic
frequency
polymorphism
position
gene
case
control
breast
cancer
patient
indian
woman
patient
frequency
patient
case
control
frequency
control
odds
ratio
value
total
womenn
allele
frequency
total
number
allele
genotypic
frequency
total
number
genotype
reference
total
premenopausal
womenn
allele
frequency
total
number
allele
genotypic
frequency
total
number
genotype
reference
total
postmenopausal
allele
frequency
total
number
allele
genotypic
frequency
total
number
genotype
reference
table
view
within
article
codon
polymorphism
gene
significant
protective
association
heterozygous
arginine
variant
breast
cancer
risk
find
total
postmenopausal
woman
arg
pro
genotype
total
postmenopausal
woman
ci
ci
respectively
pro
pro
genotype
alone
associate
breast
cancer
risk
study
population
arg
pro
pro
pro
genotype
combination
show
significant
protective
association
total
postmenopausal
woman
table
allelic
genotypic
frequency
polymorphism
codon
gene
case
control
breast
cancer
patient
indian
woman
patient
frequency
patient
case
control
frequency
control
odds
ratio
value
total
allele
frequency
total
number
allele
genotypic
frequency
total
number
genotype
reference
total
premenopausal
womenn
allele
frequency
total
number
allele
genotypic
frequency
total
number
genotype
reference
total
postmenopausal
womenn
allele
frequency
total
number
allele
genotypic
frequency
total
number
genotype
reference
table
view
within
article
polymorphism
gene
polymorphism
associate
significantly
breast
cancer
risk
total
premenopausal
postmenopausal
woman
genotype
alone
combination
also
associate
significantly
breast
cancer
risk
however
frequency
genotype
great
postmenopausal
control
woman
table
allelic
genotypic
frequency
polymorphism
gene
case
control
breast
cancer
patient
indian
woman
patient
frequency
patient
case
control
frequency
control
odds
ratio
value
total
womenn
allele
frequency
total
number
allele
genotypic
frequency
total
number
genotype
reference
total
premenopausal
womenn
allele
frequency
total
number
allele
genotypic
frequency
total
number
genotype
reference
total
postmenopausal
allele
frequency
total
number
allele
genotypic
frequency
total
number
genotype
reference
table
view
within
article
estimation
haplotype
among
haplotype
haplotype
show
high
frequency
control
postmenopausal
woman
compare
respective
patient
table
haplotype
distribution
case
control
estimated
haplotype
frequency
patient
control
odds
ratio
value
total
woman
total
allele
reference
total
premenopausal
woman
total
allele
reference
total
postmenopausal
woman
total
allele
reference
table
view
within
article
association
polymorphism
combination
possible
genotypic
combination
gene
analyzed
total
premenopausal
postmenopausal
woman
genotype
associate
postmenopausal
breast
cancer
risk
analyzed
alone
however
significant
protective
association
breast
cancer
risk
premenopausal
woman
observe
analyzed
combination
arg
pro
ci
although
frequency
codon
genotype
combination
total
patient
control
calculate
significant
association
breast
cancer
risk
observe
arg
pro
combination
exhibit
significant
association
total
postmenopausal
breast
cancer
risk
ci
total
ci
value
postmenopausal
woman
combine
genotype
combination
arginine
heterozygous
variant
show
significant
protective
association
premenopausal
woman
genotype
combination
also
associate
breast
cancer
risk
combine
total
premenopausal
woman
ci
ci
respectively
present
study
none
postmenopausal
control
woman
exhibit
genotype
combination
table
combinational
genotypic
frequency
polymorphism
case
control
breast
cancer
patient
indian
woman
underlined
letter
indicate
genotype
patient
frequency
patient
case
control
frequency
control
odds
ratio
value
total
womenn
genotypic
frequency
total
number
genotype
reference
total
premenopausal
genotypic
frequency
total
number
genotype
reference
total
postmenopausal
genotypic
frequency
total
number
genotype
reference
table
view
within
article
association
polymorphism
combination
statistical
analysis
possible
combination
polymorphism
show
significant
association
breast
cancer
risk
total
premenopausal
postmenopausal
woman
although
combination
show
difference
frequency
case
control
total
premenopausal
postmenopausal
woman
lack
significant
association
breast
cancer
risk
table
combinational
genotypic
frequency
polymorphism
case
control
breast
cancer
patient
indian
woman
underlined
letter
indicate
genotype
patient
frequency
patient
case
control
frequency
control
odds
ratio
value
total
womenn
genotypic
frequency
total
number
genotype
reference
total
premenopausal
genotypic
frequency
total
number
genotype
reference
total
postmenopausal
genotypic
frequency
total
number
genotype
reference
table
view
within
article
equilibrium
genotypic
frequency
snp
case
control
show
statistically
significant
deviation
expect
frequency
except
polymorphism
total
postmenopausal
control
observe
frequency
total
control
expect
frequency
similarly
postmenopausal
control
observe
frequency
expect
respectively
discussion
breast
cancer
second
much
common
cancer
among
female
uterine
cervix
india
women
germ
line
mutation
gene
high
risk
develop
breast
cancer
polymorphism
codon
gene
significantly
affect
function
arg
much
susceptible
degradation
human
papilloma
virus
hpv
protein
suppress
cellular
transformation
much
effectively
pro
hand
arg
much
efficient
induce
apoptosis
ability
induce
apoptosis
vitro
pro
speculate
associate
breast
cancer
risk
however
several
contradictory
report
available
within
outside
caucasian
japanese
population
racial
ethnic
environmental
difference
play
critical
role
pathogenesis
breast
cancer
probably
responsible
differential
finding
india
country
diverse
racial
ethnic
environmental
exposure
therefore
assessment
contribution
germ
line
mutation
gene
association
breast
cancer
risk
inevitable
indian
population
tumor
suppressor
protein
regulate
level
normally
divide
cell
interaction
incidence
breast
cancer
great
population
possess
reduce
activity
polymorphism
along
increase
expression
due
polymorphism
gene
reverse
combination
within
population
attenuate
breast
cancer
risk
although
various
investigator
demonstrate
independent
association
lack
association
polymorphism
gene
breast
cancer
risk
report
available
combinational
study
report
available
indian
population
study
increase
frequency
decrease
frequency
lack
significant
difference
frequency
genotype
find
case
control
indian
compare
japanese
woman
hand
jew
control
exhibit
decrease
frequency
jew
control
show
increase
frequency
genotype
compare
indian
control
lack
significant
difference
genotypic
frequency
decrease
frequency
find
turkish
control
compare
indian
control
frequency
indian
control
show
similarity
chinese
mark
dissimilarity
british
white
control
population
association
allele
breast
cancer
risk
observe
study
although
statistically
significant
allele
induce
apoptosis
biologically
weak
ability
prevent
cellular
transformation
allele
probably
act
breast
cancer
prone
allele
indian
population
even
caucasian
turkish
homozygous
increase
breast
cancer
risk
contradictory
report
also
available
literature
implicate
involvement
pro
pro
genotype
breast
cancer
risk
especially
estrogen
receptor
positive
postmenopausal
woman
japanese
although
lack
association
arg
arg
genotype
breast
cancer
risk
observe
frequency
arginine
homozygous
combination
variant
high
indian
breast
cancer
patient
compare
control
also
explain
basis
predominantly
regulate
activation
arginine
allele
cancer
development
variable
environmental
condition
unique
food
habit
life
style
factor
india
although
control
patient
properly
age
match
similar
pattern
expect
properly
age
match
control
snp
germline
mutation
significantly
change
age
population
molecular
epidemiological
study
association
combination
snp
gene
breast
cancer
risk
perform
since
genetic
variation
gene
play
critical
role
pathogenesis
breast
cancer
inhibit
activity
regulate
location
stability
transcription
although
significant
protective
association
arg
pro
genotype
breast
cancer
risk
find
total
postmenopausal
woman
lack
statistically
significant
association
observe
breast
cancer
risk
total
premenopausal
postmenopausal
indian
woman
present
study
provide
evidence
early
finding
polymorphism
alone
significantly
associate
sporadic
heritable
breast
cancer
risk
polymorphism
alone
exhibit
significant
protective
association
total
premenopausal
postmenopausal
breast
cancer
risk
however
significant
protective
association
observe
premenopausal
woman
contain
heterozygous
arginine
homozygous
variant
find
associate
early
onset
familial
breast
cancer
british
german
population
sporadic
breast
cancer
onset
chinese
white
turkish
population
sequence
analysis
single
nucleotide
polymorphism
see
gene
also
report
investigator
population
polymorphism
also
analyzed
alone
combination
assess
association
breast
cancer
risk
indian
woman
individual
combine
genotype
analysis
show
association
breast
cancer
risk
indian
woman
discrepancy
association
polymorphism
various
gene
breast
cancer
risk
due
ethnic
variation
difference
environmental
factor
life
style
among
various
population
conclusion
polymorphism
alone
predictive
factor
assess
breast
cancer
risk
indian
population
report
population
however
alone
combination
may
help
assess
breast
cancer
risk
indian
woman
study
show
protective
association
heterozygous
variant
postmenopausal
homozygous
variant
along
heterozygous
variant
premenopausal
breast
cancer
risk
indian
woman
result
obtain
thus
suggest
variable
association
pattern
polymorphism
premenopausal
postmenopausal
breast
cancer
risk
indian
population
expression
gene
depend
several
intrinsic
extrinsic
factor
therefore
polymorphism
gene
alone
predict
breast
cancer
risk
absolute
confidence
effect
polymorphism
gene
might
counteract
variable
include
genetic
environmental
factor
understanding
polymorphism
gene
various
pathway
involve
breast
cancer
onset
regulatory
gene
combination
may
probably
assess
accurate
breast
cancer
risk
thank
university
grant
commission
ugc
new
delhi
india
provide
research
fellowship
also
thank
tcga
new
delhi
india
sequencing
pcr
amplicon
communication
number
article
drug
efflux
transporter
atp
binding
cassette
abc
family
protein
play
critical
role
determine
pharmacokinetic
pharmacodynamic
property
drug
particular
treatment
multidrug
resistance
mdr
tumor
cell
become
resistant
different
drug
attributed
part
efflux
transporter
pgp
breast
cancer
resistance
protein
bcrp
protein
actively
efflux
drug
target
cell
thus
limit
therapeutic
efficacy
several
compound
evaluate
inhibitor
abc
transporter
recent
anticipate
inhibitor
drug
will
improve
oral
bioavailability
agent
recently
study
show
drug
topotecan
elacridar
inhibitor
pgp
bcrp
significantly
increase
bioavailability
topotecan
reduce
recent
transport
inhibitor
like
elacridar
inhibit
multiple
abc
transporter
since
much
cell
express
host
transporter
just
specific
member
dual
broad
spectrum
inhibitor
may
offer
advantage
find
compound
target
single
transport
protein
hand
broad
spectrum
inhibitor
may
give
rise
much
side
hence
relative
merit
specific
versus
multiple
inhibitor
still
widely
flavonoids
derivative
receive
considerable
attention
abc
transporter
flavonol
action
doxorubicin
multidrug
resistant
cell
lead
proposal
might
inhibitor
growing
interest
potential
flavonoid
pgp
inhibitor
lead
synthesis
flavonoid
derivative
side
well
investigation
flavonoid
subfamilies
like
much
recently
several
flavonoid
find
inhibitor
breast
cancer
resistance
protein
comparison
structural
requirement
flavonoid
bcrp
interaction
show
similar
identical
establish
flavonoid
pgp
boumendjel
propose
active
flavonoid
strong
affinity
binding
domain
pgp
chromenone
bear
similarity
adenine
moiety
atp
effort
enhance
adenine
replace
oxygen
chromenone
nitrogen
result
compound
diminish
may
nitrogen
atom
result
compound
extensively
protonated
physiological
ph
importance
cationic
centre
like
protonated
amino
function
emphasize
several
structure
activity
relationship
sar
investigation
several
chalcone
basic
functionality
evaluate
inhibitor
pgp
bcrp
chalcone
flavonoid
associate
pgp
inhibitory
one
chalcone
report
inhibit
bcrp
well
lipophilicity
chalcone
commonly
cite
important
parameter
pgp
inhibitory
comparison
little
know
inhibitory
potential
chalcone
cationic
functionality
spite
acknowledge
importance
motif
activity
structural
requirement
bcrp
inhibitory
activity
receive
even
little
attention
thus
objective
assess
cationic
functionality
chalcone
template
will
affect
ability
compound
inhibit
pgp
bcrp
show
different
structural
requirement
require
inhibition
functionally
relate
protein
achieve
objective
library
chalcone
basic
functionality
evaluate
inhibition
pgp
vitro
assay
carry
mardin
darby
canine
kidney
mdck
cell
transfected
human
cdna
compound
find
promising
inhibitory
activity
far
evaluate
ability
increase
doxorubicin
accumulation
human
breast
cancer
cell
line
select
pgp
protein
finally
compound
test
bcrp
inhibition
mitoxantrone
accumulation
assay
carry
cell
select
bcrp
chalcone
test
inhibitory
activity
synthesis
library
chalcone
describe
early
briefly
synthesis
achieve
condensation
appropriately
substitute
compound
characterize
purify
purity
confirm
hplc
analysis
biological
testing
structure
library
member
give
table
except
compound
compound
arrange
group
based
substitution
pattern
compound
member
group
basic
functionality
unlike
compound
group
compound
substitute
basic
group
replace
basic
pyridine
chalcone
basic
group
either
one
chalcone
chalcone
represent
library
table
structure
chalcone
investigate
inhibition
pgp
bcrp
efflux
activity
pyridinylc
pyridinylc
pyridinylc
pyridinylc
table
compound
describe
group
follow
substituents
image
pyridine
substitute
place
view
within
article
effect
uptake
mdckii
cell
calcein
acetoxymethyl
ester
substrate
pgp
extremely
lipid
soluble
rapid
entry
cell
cell
endogenous
give
fluorescent
calcein
substrate
pgp
thus
retain
cytosol
cell
express
high
level
pgp
rapidly
extrude
plasma
membrane
lead
reduce
accumulation
fluorescent
calcein
hand
cell
pgp
accumulate
high
level
fluorescent
calcein
way
ability
compound
inhibit
pgp
activity
assess
measure
increase
intracellular
calcein
fluorescence
incubate
pgp
cell
line
compare
parental
cell
line
two
cell
line
assay
parental
mdckii
wt
transfected
clone
mdckii
express
high
level
pgp
expression
pgp
cell
line
determine
western
blot
constitutive
level
pgp
detect
parental
cell
line
strong
band
observe
mdckii
cell
protein
load
thus
mdckii
cell
high
level
pgp
accumulate
little
parental
cell
image
figure
western
blot
analysis
pgp
expression
mdckii
wt
mdckii
cell
protein
loading
sample
determine
protein
assay
actin
positive
control
view
within
article
figure
show
output
representative
assay
accumulation
concurrently
monitor
mdckii
wt
cell
mdckii
cell
period
min
linear
increase
fluorescence
note
time
period
fast
rate
increase
observe
parental
mdckii
wt
cell
average
fluorescent
unit
min
run
compare
transfected
mdckii
cell
average
fluorescent
unit
min
run
keep
pgp
transfected
cell
two
know
pgp
inhibitor
verapamil
cyclosporin
positive
control
cell
line
inhibitor
increase
accumulation
two
cell
line
general
great
increase
observe
transfected
cell
line
compare
parental
cell
line
control
determination
routinely
carry
well
plate
along
test
compound
screening
purpose
test
fix
concentration
effect
test
compound
transfected
cell
line
monitor
min
two
parameter
determine
plot
accumulation
min
eq
ii
rate
uptake
min
time
interval
result
give
table
two
parameter
find
significantly
correlated
pearson
correlation
coefficient
three
compound
find
increase
accumulation
significantly
great
degree
verapamil
two
compound
far
investigate
concentration
dependent
effect
accumulation
process
ability
increase
doxorubicin
dox
level
human
breast
cancer
cell
select
pgp
also
test
inhibition
bcrp
describe
follow
section
compound
include
spite
good
activity
structurally
similar
two
compound
instead
include
comparable
verapamil
term
ability
accumulate
one
compound
far
investigation
basic
methoxy
group
thus
different
compound
interest
see
difference
affect
activity
image
figure
accumulation
mdckii
wt
mdckii
cell
min
without
presence
cyclosporin
csa
verapamil
view
within
article
table
effect
test
compound
accumulation
mdckii
cell
clogp
value
calcein
cyclosporin
table
compound
test
accumulation
test
compound
fluorescence
calcein
minute
value
mean
much
separate
determination
sd
bracket
determination
rate
uptake
assess
plot
calcein
fluorescence
versus
time
value
mean
sd
sd
give
determination
clogp
determine
sybyl
tripos
louis
significantly
different
verapamil
anova
way
tukey
origin
originlab
ma
significant
difference
uptake
among
indicate
compound
anova
way
tukey
origin
originlab
ma
view
within
article
concentration
dependent
effect
select
compound
accumulation
figure
show
effect
different
concentration
promising
compound
accumulation
latter
express
eq
measure
extent
test
compound
increase
uptake
transfected
cell
line
compare
maximum
increase
uptake
expect
assay
system
denominator
fmdckii
wt
without
drug
fmdckii
without
drug
determine
parental
transfected
cell
line
represent
maximum
difference
calcein
fluorescence
prevail
experimental
condition
numerator
represent
increase
calcein
fluorescence
mdckii
cell
due
inhibitory
effect
test
compound
measurement
make
minute
image
figure
increase
accumulation
mdckii
cell
minute
presence
test
compound
view
within
article
figure
show
fairly
linear
increase
fluorescence
increase
concentration
compound
sustain
rise
fluorescence
associate
compound
suggest
much
potent
two
little
active
compound
include
comparison
show
gradual
increase
concentration
effect
compound
accumulation
doxorubicin
cell
pgp
adr
cell
line
adr
select
pgp
continuous
exposure
doxorubicin
western
blot
analysis
confirm
presence
pgp
bcrp
cell
line
parental
cell
line
detectable
level
pgp
bcrp
result
serve
confirm
appropriateness
cell
line
model
assess
effect
compound
pgp
transporter
image
figure
western
blot
analysis
pgp
bcrp
expression
wt
adr
mx
cell
protein
loading
sample
determine
protein
assay
actin
positive
control
view
within
article
section
compound
test
effect
uptake
mdckii
cell
since
different
cell
line
adr
reporter
molecule
dox
instead
section
different
concentration
may
require
hence
determine
value
test
compound
doxorubicin
arrive
concentration
dox
substrate
pgp
adr
cell
approximately
fold
high
parental
cell
line
hand
value
test
compound
two
cell
line
differ
significantly
imply
likely
substrate
pgp
based
determination
concentration
subsequent
experiment
image
figure
test
compound
adr
uptake
doxorubicin
adr
wt
cell
presence
test
compound
verapamil
cyclosporin
csa
ctr
control
cell
expose
dox
absence
test
significant
difference
dox
wt
adr
cell
anova
follow
tukey
test
compound
two
cell
line
find
differ
significant
difference
uptake
dox
adr
cell
treat
test
compound
compare
untreated
control
ctr
adr
cell
anova
follow
tukey
bar
represent
mean
sd
determination
view
within
article
uptake
dox
cell
readily
monitor
measure
intrinsic
fluorescence
intracellular
compartment
calibration
curve
level
fluorescence
correlated
amount
dox
take
cell
show
figure
five
time
much
doxorubicin
accumulate
parental
wt
cell
adr
cell
cell
cyclosporin
verapamil
expose
dox
another
hour
uptake
dox
increase
significantly
adr
cell
almost
comparable
level
parental
cell
similar
observation
make
cell
test
compound
test
result
far
confirm
pgp
inhibitory
property
chalcone
effect
compound
accumulation
mitoxantrone
mx
mitoxantrone
resistant
cell
mx
mx
cell
select
bcrp
continuous
exposure
mitoxantrone
western
blot
analysis
confirm
bcrp
express
status
mx
detectable
level
pgp
observe
cell
line
state
early
neither
pgp
bcrp
detect
parental
cell
line
mitoxantrone
mx
substrate
bcrp
cellular
accumulation
determine
method
involve
flow
cytometry
cell
typical
experiment
follow
monitor
autofluorescence
wt
cell
curve
ii
mx
fluorescence
mx
cell
expose
mx
curve
respectively
iii
mx
fluorescence
mx
cell
presence
bcrp
inhibitor
ftc
positive
control
curve
iv
similar
iii
presence
test
compound
depict
image
figure
flow
cytometry
analysis
mx
wt
mx
cell
wt
mx
mx
mx
mx
mx
ftc
wt
vertical
marker
area
right
define
area
define
region
view
within
article
show
figure
vertical
marker
set
autofluorescence
curve
wt
cell
curve
facs
plot
marker
adjust
area
right
area
referred
area
define
region
parental
cell
wt
accumulate
much
mx
mx
cell
result
stronger
fluorescent
signal
thus
large
area
define
region
show
curve
ftc
much
mx
accumulation
mx
cell
curve
right
hand
shift
position
fluorescent
peak
compare
curve
table
list
area
define
region
accumulation
mx
mx
cell
presence
compound
datum
analyzed
significant
difference
control
untreated
mx
cell
way
anova
follow
tukey
statistical
difference
observe
compound
marginally
great
uptake
detect
compare
control
chalcone
ftc
significant
increase
mx
accumulation
compare
control
untreated
cell
chalcone
increase
accumulation
control
compare
ftc
table
accumulation
mitoxantrone
mx
mx
cell
presence
test
compound
cell
line
test
define
region
accumulation
wt
mx
wt
mx
mx
mx
mx
mx
mx
mx
mx
mx
mx
mx
table
concentration
mx
test
compound
ftc
area
define
region
part
curve
right
vertical
marker
autofluorescence
curve
wt
cell
mx
value
mean
sd
except
ftc
give
eq
mx
uptake
presence
test
compound
significantly
different
uptake
untreated
mx
cell
test
anova
way
tukey
origin
originlab
ma
view
within
article
pgp
inhibitory
property
chalcone
library
chalcone
investigate
enhance
accumulation
three
compound
significantly
increase
uptake
great
degree
know
inhibitor
verapamil
compound
belong
group
substitute
two
methoxy
group
since
also
little
active
compound
group
presence
motif
per
ensure
good
inhibitory
activity
basic
substituents
pyridine
place
phenyl
check
compound
table
show
basic
group
consistently
lead
poor
activity
irrespective
substitution
hand
role
basic
functionality
little
present
finding
show
necessary
sufficient
feature
pgp
inhibitory
activity
example
much
active
compound
group
group
although
basic
chalcone
addition
chalcone
like
compound
uptake
level
significantly
different
basic
chalcone
like
well
understanding
difference
exhibit
library
consider
lipophilicity
compound
since
property
widely
cite
important
requirement
pgp
inhibitory
clog
value
compound
determine
correlation
clogp
rate
uptake
assess
find
significant
correlation
pearson
correlation
note
compound
basic
group
among
least
lipophilic
respective
group
may
account
part
poor
pgp
inhibitory
activity
also
consider
proposal
pgp
inhibitor
characterize
electron
donor
hydrogen
bond
acceptor
group
separate
distance
namely
nm
type
nm
type
ii
addition
compound
large
number
type
ii
recognition
pattern
generally
associate
greater
inhibitory
potency
compound
examine
presence
recognition
pattern
two
type
ii
recognition
pattern
group
find
involve
dimethoxy
group
nm
oxygen
atom
carbonyl
oxygen
methoxy
oxygen
nm
nitrogen
atom
piperidine
electron
donor
protonated
ph
electron
aromatic
type
ii
recognition
pattern
find
group
except
compound
dimethoxy
group
otherwise
compound
fast
rate
uptake
respective
group
compound
also
illustrate
importance
type
ii
recognition
pattern
compound
three
type
ii
distance
methoxy
group
yet
great
degree
accumulation
among
chalcone
qualitative
picture
structural
requirement
pgp
inhibitory
activity
among
basic
chalcone
may
summarize
follow
first
clear
indication
basic
group
present
one
chalcone
template
preferably
basic
group
adversely
affect
activity
possibly
result
compound
lipophilicity
second
motif
either
important
feature
activity
electron
donor
type
ii
spatial
distance
pgp
inhibitor
propose
seelig
motif
present
distance
oxygen
atom
carbonyl
moiety
methoxy
group
also
fall
within
require
type
ii
spatial
distance
chalcone
two
feature
sufficient
ensure
good
inhibitory
activity
see
poor
activity
group
compound
three
type
ii
feature
like
compound
comparable
activity
verapamil
contrast
basic
chalcone
require
one
two
type
ii
feature
good
accumulation
evident
compound
significantly
well
verapamil
compound
comparable
verapamil
however
stage
clear
type
ii
requirement
differ
basic
chalcone
bcrp
inhibitory
property
chalcone
library
four
compound
test
bcrp
inhibitory
activity
mx
accumulation
assay
compound
good
pgp
inhibitory
profile
chalcone
poor
pgp
inhibitory
activity
result
show
contrast
mark
effect
pgp
efflux
activity
compound
increase
mx
accumulation
bcrp
cell
line
rather
compound
significantly
increase
mx
accumulation
keen
interest
develop
bcrp
inhibitor
many
compound
know
inhibit
moreover
inhibitor
bcrp
abc
transporter
protein
seem
different
structural
also
observe
study
based
contrast
activity
basic
chalcone
chalcone
however
much
example
require
far
confirmation
observation
compound
may
offer
potential
dual
inhibitor
pgp
bcrp
comparable
verapamil
increase
uptake
nearly
efficient
ftc
increase
mx
accumulation
order
develop
molecule
pharmaceutical
interest
desirable
candidate
compound
present
significant
cytotoxicity
compound
value
able
increase
dox
accumulation
adr
cell
concentration
comparison
compound
associate
great
cytotoxicity
conclusion
conclusion
identify
several
basic
chalcone
exhibit
promising
reverse
effect
transport
property
pgp
sar
show
basic
group
necessary
sufficient
feature
inhibitory
activity
presence
motif
chalcone
framework
also
require
presumably
introduce
electron
donor
atom
optimal
spatial
distance
postulate
important
activity
main
difference
basic
chalcone
basic
group
present
fewer
electron
donor
group
require
great
inhibition
pgp
efflux
activity
note
one
advantage
associate
fewer
electron
donor
group
may
improve
permeability
oral
bioavailability
state
lipinski
rule
according
mnemonic
compound
much
hydrogen
bond
acceptor
equivalent
electron
donor
group
likely
poor
oral
absorption
also
find
chalcone
good
pgp
inhibitor
generally
poor
bcrp
inhibitor
converse
may
true
much
compound
need
confirm
trend
spite
contrast
structural
requirement
one
compound
inhibit
transport
protein
suggest
careful
structural
manipulation
dual
inhibitor
pgp
bcrp
may
develop
chalcone
template
chalcone
library
synthesis
chalcone
report
compound
characterize
nmr
nmr
purify
confirm
hplc
analysis
column
chromatography
crystallization
detail
provide
cite
material
calcein
acetoxymethyl
ester
doxorubicin
mitoxantrone
verapamil
cyclosporin
bromide
mtt
ftc
purchase
sigma
aldrich
chemical
singapore
mouse
monoclonal
antibody
western
blot
analysis
pgp
bcrp
signet
laboratory
inc
dedham
ma
reagent
analytical
grade
cell
line
parental
mardin
darby
canine
kidney
cell
mdckii
wt
mdckii
cell
transfected
human
cdna
generous
gift
dr
bern
netherlands
cancer
institute
antoni
van
leeuwenhoek
hospital
amsterdam
netherlands
mdckii
mdckii
wt
cell
grow
dmem
contain
fetal
bovine
serum
fbs
penicillin
streptomycin
sulfate
cell
reach
confluency
passage
assay
human
breast
cancer
cell
purchase
american
type
cell
culture
manassas
va
usa
drug
select
doxorubicin
adriamycin
resistant
adr
mitoxantrone
resistant
mx
cell
line
obtain
department
pharmacy
national
university
singapore
cell
cultured
rpmi
medium
supplement
fbs
penicillin
streptomycin
sulfate
medium
adr
mx
cell
contain
doxorubicin
nm
mitoxantrone
respectively
western
blot
analysis
determine
pgp
level
mdckii
wt
mdckii
adr
mx
cell
bcrp
level
similarly
determine
parental
drug
select
cell
western
blot
analysis
western
blot
analysis
pgp
carry
mdckii
wt
mdckii
adr
mx
cell
bcrp
level
similarly
determine
parental
drug
select
cell
cell
line
grow
confluence
trypsinized
transfer
eppendorf
tube
rinse
pbs
content
tube
suspend
lysis
buffer
extraction
buffer
presence
protease
inhibitor
protease
inhibitor
cocktail
roche
cell
suspension
incubate
min
centrifuged
min
k
rpm
give
clear
supernatant
aliquots
prepare
different
cell
line
way
protein
content
aliquot
determine
commercial
reagent
dye
reagent
concentrate
western
blot
analysis
protein
extract
dilute
laemmli
buffer
analyzed
sds
gel
electrophoresis
appropriate
polyacrylamide
gel
protein
load
lane
protein
gel
transfer
pvdf
membrane
transfer
method
block
tris
buffer
saline
contain
milk
membrane
probe
primary
antibody
pgp
signet
mouse
monoclonal
antibody
cat
bcrp
signet
mouse
monoclonal
antibody
cat
clone
antibody
purchase
signet
laboratory
inc
dedham
ma
dilution
membrane
blot
react
secondary
antibody
horseradish
peroxidase
igg
horseradish
peroxidase
igg
wash
extensively
tris
buffer
saline
min
mixture
horse
peroxidase
substrate
supersignal
west
pico
pierce
lightly
dry
expose
vary
period
min
autoradiography
film
develop
visualize
antibody
antigen
complex
determination
growth
inhibitory
value
tetrazolium
assay
previously
describe
method
briefly
wt
adr
cell
incubate
test
compound
medium
decant
replace
mtt
solution
incubate
another
cell
wash
saline
pbs
dmso
add
cell
dissolve
formazan
crystal
absorbance
read
nm
microplate
reader
determination
make
concentration
test
compound
value
determine
prism
graph
pad
san
diego
usa
uptake
mdckii
cell
previously
describe
method
follow
briefly
mdckii
mdckii
wt
cell
confluency
trypsinized
seed
well
plate
cell
density
cell
well
incubate
atmosphere
cell
monolayer
well
carefully
wash
pbs
follow
incubation
test
compound
prepare
dmso
hank
saline
solution
min
atmosphere
min
incubation
aliquot
dmso
add
well
give
final
concentration
maximum
concentration
dmso
per
well
incubation
min
fluorescence
well
measure
min
interval
min
microplate
reader
excitation
nm
emission
nm
concurrent
determination
make
positive
control
verapamil
cyclosporin
accumulation
calculate
minute
rate
accumulation
presence
test
compound
also
determine
gradient
linear
increase
calcein
fluorescence
time
microsoft
office
excel
doxorubicin
accumulation
adr
cell
previously
describe
method
briefly
adr
passage
wt
passage
grow
flask
confluency
cell
trypsinized
resuspended
rpmi
cell
density
cell
ml
seed
well
plate
incubate
attachment
monolayer
test
compound
add
ml
dmso
rpmi
incubation
well
incubate
follow
dox
distil
water
incubate
another
hour
uptake
stop
wash
well
pbs
ml
thrice
cell
triton
sds
pbs
incubation
min
aliquot
well
transfer
well
plate
intracellular
level
dox
determine
analyzing
cell
lysate
fluorescence
plate
reader
wavelength
excitation
nm
emission
nm
obtain
dox
standard
curve
cell
lysate
prepare
describe
absence
test
compound
lysate
transfer
well
plate
add
aliquot
freshly
prepare
doxorubicin
distil
water
give
final
concentration
range
ml
ml
fluorescence
intensity
solution
determine
calibration
curve
construct
fluorescence
intensity
dox
concentration
express
doxorubicin
cell
good
linearity
obtain
plot
determine
intracellular
level
dox
mitoxantrone
accumulation
mx
cell
method
describe
zhang
follow
accumulation
mitoxantrone
mx
investigate
wt
mx
cell
flow
cytometry
briefly
cell
grow
flask
confluence
trypsinized
wash
twice
pbs
resuspended
rpmi
medium
cell
density
cell
ml
accumulation
mx
investigate
incubate
ml
cell
test
compound
vehicle
dmso
rpmi
falcon
tube
min
follow
addition
mx
final
concentration
test
compound
mx
respectively
incubation
min
uptake
stop
add
ml
pbs
centrifugation
rpm
min
cell
wash
twice
pbs
intracellular
concentration
mx
determine
facscan
flow
cytometer
coulter
elite
equip
solid
state
argon
laser
excitation
nm
filter
nm
detect
mx
fluorescence
data
process
version
software
accumulation
mx
express
eq
footnote
table
molecular
modeling
chem
pro
ma
sybyl
tripos
louis
determine
distance
clogp
test
compound
respectively
measurement
make
geometry
optimized
conformation
compound
standard
force
field
software
statistical
analysis
data
analyzed
significant
difference
anova
follow
tukey
test
origin
originlab
ma
acknowledgment
work
make
possible
funding
research
scholarship
national
university
singapore
reference
note
beijnen
schellens
pharmacol
sci
article
|
pdf
k
|
view
record
scopus
|
cited
scopus
gottesman
bates
nat
rev
cancer
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
robert
med
chem
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
pozza
boumendjel
pietro
drug
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
beijnen
ten
bokkel
huinink
paul
schellens
clin
oncol
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
paterson
ludwig
gottesman
nat
rev
drug
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
boumendjel
pietro
dumontet
barron
med
res
rev
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
cancer
chemother
pharmacol
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
shapiro
biochem
pharmacol
article
|
pdf
k
|
view
record
scopus
|
cited
scopus
med
chem
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
conseil
dumontet
pietro
barron
med
chem
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
boumendjel
beney
mariotte
pietro
chem
pharm
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
boumendjel
gut
bioorg
med
chem
article
|
pdf
k
|
view
record
scopus
|
cited
scopus
mariotte
boumendjel
med
chem
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
bois
beney
boumendjel
mariotte
conseil
pietro
med
chem
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
bois
boumendjel
mariotte
conseil
pietro
bioorg
med
chem
article
|
pdf
k
|
view
record
scopus
|
cited
scopus
pozza
bates
pietro
cancer
res
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
cancer
res
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
zhang
yang
biochem
pharmacol
article
|
pdf
k
|
view
record
scopus
|
cited
scopus
beck
mol
pharmacol
view
record
scopus
|
cited
scopus
seelig
eur
med
chem
article
|
pdf
k
|
view
record
scopus
|
cited
scopus
liu
go
bioorg
med
chem
article
|
pdf
k
|
view
record
scopus
|
cited
scopus
liu
go
bioorg
med
chem
article
|
pdf
k
|
view
record
scopus
|
cited
scopus
liu
go
med
chem
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
gottesman
biol
chem
view
record
scopus
|
cited
scopus
cancer
res
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
zhang
yang
pan
eur
cancer
article
|
pdf
k
|
view
record
scopus
|
cited
scopus
seelig
eur
biochem
view
record
scopus
|
cited
scopus
bates
ross
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
lipinski
pharmacol
toxicol
method
article
|
pdf
k
|
view
record
scopus
|
cited
scopus
corresponding
author
fax
bioorganic
medicinal
chemistry
volume
issue
january
nucleic
acid
modification
list
|
previous
next
home
browse
search
select
setting
alerts
help
sciencedirect
|
contact
|
terms
&
conditions
|
privacy
policycopyright
elsevier
right
reserve
sciencedirect
register
trademark
elsevier
var
hidediv
collabboxcontent
inflammation
common
breast
cancer
associate
cancer
onset
progression
several
important
peripheral
marker
inflammation
breast
cancer
provide
unique
insight
inflammatory
process
include
vegf
crp
vwf
vegf
angiogenic
cytokine
stimulate
formation
new
blood
vessel
necessary
tumor
growth
metastasis
circulating
level
vegf
elevate
breast
cancer
independent
predictor
poor
survival
nishimura
wu
expression
adhesion
molecule
aid
host
immune
surveillance
tumor
cell
ogawa
implicate
tumor
progression
metastases
great
expression
associate
growth
potential
negative
lymph
node
involvement
good
prognosis
contrast
soluble
form
elevate
breast
cancer
klein
predictive
poor
response
chemotherapy
poor
prognosis
zhang
reflect
generalized
inflammation
exert
immunomodulatory
effect
suppression
natural
killer
cell
function
inhibition
leukocyte
binding
target
cell
include
formation
natural
killer
cell
tumor
cell
conjugate
cho
several
component
reaction
also
elevate
breast
cancer
include
inflammatory
cytokine
crp
blann
effect
breast
cancer
high
serum
level
breast
cancer
independent
predictor
poor
survival
independent
predictor
progression
free
survival
metastatic
breast
cancer
patient
receive
chemotherapy
secrete
macrophage
monocyte
stimulate
breast
cancer
proliferation
along
find
breast
cancer
tissue
elevated
serum
level
correlate
breast
cancer
recurrence
level
high
old
breast
cancer
patient
whose
cancer
lack
estrogen
receptor
reactant
crp
produce
liver
response
inflammation
elevated
crp
level
predictive
poor
survival
metastatic
breast
cancer
addition
elevate
crp
level
correlate
provide
evidence
elevate
level
reflect
acute
phase
response
generalized
inflammation
von
factor
vwf
find
body
secretory
endothelial
cell
platelet
play
key
role
elevate
breast
cancer
blann
blann
elevated
vwf
level
appear
reflect
platelet
activation
rather
endothelial
activation
damage
blann
blann
soluble
hand
reflect
platelet
activation
breast
cancer
blann
fox
platelet
expression
support
formation
blood
cell
complex
circulation
facilitate
metastases
chemotherapy
breast
cancer
lead
increase
inflammatory
mediator
case
decrease
three
cycle
standard
chemotherapy
stage
patient
lead
increase
circulate
level
vegf
chemotherapy
taxane
paclitaxel
docetaxel
increase
level
decrease
level
much
pronounce
effect
docetaxel
three
course
neoadjuvant
chemotherapy
stage
breast
cancer
lead
decrease
level
effect
great
patient
complete
versus
partial
response
single
agent
paclitaxel
therapy
fluorouracil
plus
doxorubicin
cyclophosphamide
chemotherapy
increase
level
although
several
marker
disease
associate
inflammation
breast
cancer
study
prospectively
examine
disease
treatment
factor
might
relate
change
inflammation
response
chemotherapy
breast
cancer
examine
circulate
level
vegf
growth
factor
prior
follow
adjuvant
chemotherapy
patient
positive
node
breast
cancer
significant
reduction
vegf
level
patient
large
tumor
patient
positive
hormone
receptor
status
primary
aim
study
examine
effect
chemotherapy
breast
cancer
measure
inflammation
test
potential
predictor
inflammation
response
chemotherapy
measure
inflammation
include
panel
eight
circulate
marker
know
clinical
relevance
breast
cancer
hypothesized
four
vegf
increase
response
chemotherapy
potential
predictor
inflammation
test
panel
demographic
breast
cancer
treatment
regimen
characteristic
method
women
breast
cancer
recruit
ucsd
moore
cancer
center
oncologist
san
diego
area
diagnose
stage
breast
cancer
referred
adjuvant
chemotherapy
invite
participate
exclusion
criterion
include
pregnancy
woman
undergo
bone
marrow
transplant
metastatic
breast
cancer
confound
underlie
medical
illness
include
renal
failure
significant
anemia
physical
psychological
impairment
limit
participation
study
approve
ucsd
human
research
protection
program
ucsd
cancer
center
human
research
protection
program
oncologist
breast
cancer
disease
stage
perform
referring
medical
oncologist
typically
utilize
american
joint
committee
cancer
staging
manual
edition
patient
receive
adjuvant
chemotherapy
clinical
staging
definitive
surgical
treatment
either
lumpectomy
mastectomy
axillary
staging
sentinel
node
biopsy
axillary
lymph
node
dissection
accord
institutional
standard
individual
anthracycline
regimen
study
include
standard
clinical
dose
adriamycin
cyclophosphamide
alone
adriamycin
cyclophosphamide
taxane
epirubicin
cytoxan
chemotherapy
woman
complete
study
obtain
large
pool
woman
initially
request
information
study
effect
chemotherapy
breast
cancer
disturb
sleep
fatigue
interested
participate
eligible
participate
drop
study
completion
remain
participant
complete
design
examine
effect
chemotherapy
inflammation
participant
study
prior
follow
three
week
cycle
adjuvant
chemotherapy
nine
woman
treat
hormone
prior
chemotherapy
none
woman
radiation
therapy
chemotherapy
blood
sampling
assay
blood
sample
collect
breast
cancer
clinic
hour
pm
immediately
prior
administration
cycle
chemotherapy
immediately
prior
start
cycle
chemotherapy
whole
blood
preserve
either
edta
vegf
crp
sodium
citrate
vwf
following
centrifugation
plasma
serum
store
vegf
determine
duplicate
commercial
elisa
internal
control
rd
system
mn
von
precision
assay
follow
cv
vegf
respectively
cv
respectively
sensitivity
value
ml
pg
ml
ml
pg
ml
pg
ml
pg
ml
vwf
determine
duplicate
commercial
elisa
internal
control
diagnostica
parsippany
new
cv
vwf
cv
sensitivity
crp
level
determine
duplicate
high
sensitivity
assay
internal
control
cv
crp
cv
sensitivity
mg
sample
give
patient
assay
together
data
analysis
prior
chemotherapy
simple
correlation
analysis
anova
run
examine
relationship
among
inflammatory
marker
demographic
age
bmi
breast
cancer
disease
characteristic
include
cancer
type
infiltrate
lobular
carcinoma
infiltrate
ductal
carcinoma
infiltrate
mix
carcinoma
estrogen
receptor
expression
progesterone
receptor
expression
human
epidermal
growth
factor
expression
tumor
size
presence
absence
positive
node
primary
aim
study
order
test
whether
significant
pre
post
chemotherapy
change
overall
inflammatory
marker
panel
adjust
multiple
comparison
run
manova
include
eight
inflammatory
marker
dependent
variable
analysis
take
account
correlation
among
different
marker
manova
significant
hence
follow
fisher
least
significant
difference
paradigm
conduct
separate
repeat
measure
analysis
variance
marker
individual
analysis
serve
tease
potential
chemotherapy
treatment
effect
inflammatory
marker
multiple
linear
regression
analysis
run
determine
extent
variable
independently
predict
level
inflammatory
marker
potential
predictor
variable
enter
regression
model
separate
block
age
bmi
force
enter
first
block
level
respective
inflammatory
marker
prior
chemotherapy
force
enter
second
block
factor
relate
breast
cancer
diagnosis
describe
enter
third
block
disease
stage
enter
separate
potential
predictor
variable
factor
determine
stage
tumor
size
lymph
node
status
enter
model
treatment
information
include
chemotherapy
regimen
adriamycin
cyclophosphamide
alone
adriamycin
cyclophosphamide
taxane
epirubicin
cytoxan
chemotherapy
enter
fourth
block
among
patient
adriamycin
cyclophosphamide
taxane
group
patient
receive
taxol
receive
among
patient
mastectomy
group
receive
double
mastectomy
mastectomy
data
analyzed
spss
windows
spss
chicago
present
mean
sd
level
statistical
significance
set
borderline
significance
also
present
show
trend
may
help
well
illustrate
overall
relationship
result
table
present
individual
patient
characteristic
age
bmi
ethnicity
breast
cancer
stage
cancer
type
tumor
size
presence
positive
node
estrogen
receptor
progesterone
receptor
expression
expression
chemotherapy
regimen
type
surgery
mean
age
sample
year
sd
compared
patient
complete
large
study
chemotherapy
disturb
sleep
fatigue
patient
complete
inflammatory
marker
significantly
differ
characteristic
appear
table
table
patient
disease
treatment
characteristic
age
year
sd
range
american
ii
iii
type
lobular
carcinoma
ductal
carcinoma
mix
carcinoma
mean
tumor
size
cm
positive
receptor
receptor
chemotherapy
cyclophosphamide
alone
cyclophosphamide
taxanes
cytoxan
table
view
within
article
inflammatory
marker
circulating
level
inflammatory
marker
present
table
prior
chemotherapy
level
high
individual
negative
versus
positive
estrogen
receptor
expression
pg
ml
sd
versus
pg
ml
sd
respectively
individual
negative
versus
positive
progesterone
receptor
expression
pg
ml
sd
versus
pg
ml
sd
respectively
significant
correlation
crp
level
bmi
table
level
inflammatory
marker
prior
chemotherapy
mean
sd
value
crp
mg
pg
ml
pg
ml
vegf
pg
ml
ml
pg
ml
ml
vwf
table
view
within
article
inflammatory
marker
chemotherapy
manova
significant
individual
repeat
measure
anova
show
chemotherapy
lead
significant
elevation
circulate
level
vegf
vwf
crp
level
significantly
change
response
chemotherapy
result
multiple
regression
analysis
present
table
level
inflammatory
marker
predict
level
case
except
crp
level
start
cycle
predict
high
level
crp
model
similarly
level
start
cycle
predict
high
level
model
table
multiple
regression
predictor
inflammation
response
chemotherapy
inflammatory
predictor
variable
coefficient
value
model
adjust
value
crp
status
vegf
tumor
size
tumor
size
tumor
size
chemotherapy
vwf
table
view
within
article
level
vegf
start
cycle
predict
high
level
vegf
well
small
tumor
size
model
cycle
level
predict
level
cycle
model
level
cycle
predict
high
level
well
large
tumor
size
model
level
cycle
predict
small
tumor
size
type
chemotherapy
treatment
model
post
hoc
analysis
chemotherapy
treatment
effect
show
cycle
level
high
individual
receive
epirubicin
cytoxan
ml
sd
versus
adriamycin
cyclophosphamide
alone
ml
sd
adriamycin
cyclophosphamide
taxane
ml
sd
image
multiple
regression
analysis
level
predict
type
chemotherapy
regimen
level
high
patient
receive
epirubicin
cytoxan
versus
adriamycin
cyclophosphamide
alone
adriamycin
cyclophosphamide
taxane
act
view
within
article
circulating
level
vwf
cycle
predict
high
level
vwf
model
regression
model
cycle
statistically
significant
model
discussion
among
eight
inflammatory
marker
examine
four
find
elevate
response
chemotherapy
consistent
prior
study
level
vegf
vwf
significantly
high
circulation
follow
three
cycle
chemotherapy
study
suggest
elevate
level
breast
cancer
reflect
acute
phase
response
elevate
vwf
level
reflect
endothelial
activation
damage
respectively
elevation
believe
reflect
platelet
endothelial
activation
clear
whether
elevation
vwf
observe
follow
chemotherapy
reflect
endothelial
platelet
source
see
breast
cancer
prior
treatment
finding
elevate
marker
endothelial
platelet
activation
may
provide
explanation
observation
increase
risk
thrombosis
patient
undergo
chemotherapy
link
yet
clear
long
chemotherapy
elevate
level
might
persist
report
compare
radiotherapy
chemotherapy
breast
cancer
lead
significant
reduction
circulate
vegf
level
month
month
follow
treatment
current
study
vegf
level
level
elevate
chemotherapy
unfortunately
long
term
datum
patient
address
duration
elevation
find
significant
difference
versus
level
crp
finding
consistent
prior
report
previous
study
find
increase
decrease
advance
breast
cancer
patient
response
chemotherapy
although
effect
observe
follow
long
treatment
regimen
full
cycle
chemotherapy
taxane
inflammatory
factor
long
duration
treatment
need
induce
activation
report
stage
iii
breast
cancer
patient
adjuvant
neoadjuvant
every
week
paclitaxel
chemotherapy
lead
significant
increase
circulate
level
contrast
adriamycin
cyclophosphamide
chemotherapy
day
interval
six
full
cycle
stage
iii
breast
cancer
patient
significant
effect
serum
level
primary
aim
study
identify
factor
might
relate
level
inflammatory
marker
follow
chemotherapy
six
eight
marker
examine
study
significantly
relate
respective
level
prior
start
chemotherapy
imply
degree
inflammation
present
patient
follow
chemotherapy
part
determine
degree
inflammation
exist
begin
chemotherapy
hold
true
marker
vegf
vwf
crp
change
significantly
response
chemotherapy
addition
among
several
demographic
disease
relate
variable
examine
estrogen
receptor
status
tumor
size
chemotherapy
regimen
also
relate
one
much
inflammatory
marker
follow
chemotherapy
report
neoadjuvant
chemotherapy
stage
breast
cancer
lead
reduction
circulate
level
great
patient
partial
complete
response
suggest
degree
clinical
response
relate
level
consistent
finding
circulate
level
inflammatory
marker
find
relate
expression
estrogen
progesterone
receptor
tumor
cell
report
old
breast
cancer
patient
significantly
high
concentration
proinflammatory
cytokine
tumor
lack
progesterone
receptor
high
concentration
lack
estrogen
receptor
prior
chemotherapy
find
level
high
patient
negative
estrogen
progesterone
receptor
express
tumor
consistent
observation
follow
chemotherapy
find
level
marginally
high
patient
negative
estrogen
receptor
express
tumor
also
find
tumor
size
positively
relate
level
negatively
relate
vegf
level
report
positive
negative
association
tumor
size
plasma
vegf
level
breast
cancer
nishimura
wu
expression
typically
associate
tumor
size
estrogen
progesterone
receptor
expression
observe
study
prior
chemotherapy
particular
aspect
finding
suggest
endothelial
versus
immune
cell
response
chemotherapy
differentially
relate
initial
severity
disease
effect
also
observe
chemotherapy
regimen
level
high
woman
receive
epirubicin
cytoxan
treatment
aware
literature
suggest
epirubicin
cytoxan
treatment
differentially
activate
platelet
compare
adriamycin
several
potential
limitation
study
breast
cancer
patient
finding
might
generalize
much
severe
disease
minimum
number
cycle
chemotherapy
time
study
four
week
cycle
study
limited
woman
receive
regimen
result
therefore
may
generalizable
woman
week
cycle
get
much
four
cycle
treatment
addition
obtain
single
blood
sample
study
ideal
factor
display
variability
attempt
address
limitation
sampling
blood
within
fix
time
testing
day
context
clinic
set
limit
blood
sampling
time
within
range
approximately
possible
therefore
biomarker
level
fully
representative
endogenous
level
finally
study
restrict
examine
marker
endothelial
platelet
activation
markers
cell
activation
destruction
merit
study
context
examine
inflammatory
effect
chemotherapy
breast
cancer
summary
result
study
indicate
three
cycle
chemotherapy
breast
cancer
lead
elevation
inflammatory
marker
associate
endothelial
platelet
activation
circulating
level
inflammatory
marker
chemotherapy
much
significantly
relate
level
exist
prior
chemotherapy
also
potentially
disease
characteristic
estrogen
receptor
status
tumor
size
also
type
chemotherapy
treatment
acknowledgment
thank
johnson
coordinating
study
help
datum
collection
chemotherapy
consider
cornerstone
treatment
many
type
cancer
however
many
chemotherapeutic
agent
exhibit
toxicity
include
congestive
heart
failure
myelosuppression
neutropenia
alopecia
mucositis
diarrhea
well
mutagenic
carcinogenic
effect
addition
majority
cancer
patient
treat
chemotherapy
relapse
die
disease
therefore
particular
interest
explore
therapeutic
approach
reduce
toxicity
chemotherapeutic
agent
conjunction
safe
natural
agent
act
incorporate
little
toxic
yet
effective
treatment
may
thus
provide
answer
urgent
need
natural
product
obtain
react
rice
bran
hemicellulose
multiple
carbohydrate
hydrolyzing
enzyme
shiitake
mushroom
main
chemical
structure
arabinoxylan
xylose
main
chain
arabinose
polymer
side
chain
previously
present
evidence
role
potent
activator
human
nk
cell
healthy
subject
cancer
patient
recently
demonstrate
sensitize
human
leukemic
hut
cell
apoptosis
study
examine
sensitize
ability
toward
chemotherapeutic
agent
daunorubicin
dnr
human
breast
cancer
cell
bcc
examine
possible
mechanism
underlie
effect
material
tumor
cell
line
culture
condition
human
breast
cancer
cell
line
cell
present
study
cell
purchase
american
tissue
culture
collection
atcc
manassas
va
tumor
cell
maintain
laboratory
complete
medium
cm
consist
supplement
fetal
calf
serum
fcs
mm
glutamine
ml
streptomycin
penicillin
drug
chemical
dnr
bromide
mtt
obtain
sigma
denatured
hemicellulose
obtain
react
rice
bran
hemicellulose
multiple
carbohydrate
hydrolyzing
enzyme
shiitake
mushroom
main
chemical
structure
arabinoxylan
xylose
main
chain
arabinose
polymer
side
chain
dissolve
cm
concentration
mg
ml
provide
daiwa
pharmaceutical
tokyo
japan
drug
sensitivity
assay
drug
sensitivity
determine
colorimetric
mtt
assay
assay
based
reduction
tetrazolium
salt
mtt
bromide
mitochondrial
dehydrogenase
viable
cell
colorless
formazan
product
viable
cell
measure
amount
formazan
produce
proportional
number
live
cell
cell
seed
well
plate
cultured
triplicate
presence
absence
various
concentration
ml
without
select
concentration
dnr
final
volume
medium
well
addition
dnr
culture
incubate
day
mtt
add
well
culture
incubate
additional
plate
centrifuged
medium
carefully
remove
formazan
crystal
solubilized
acid
alcohol
plate
read
nm
elisa
plate
reader
molecular
devices
park
inhibitory
concentration
determine
drug
concentration
result
reduction
cell
viability
determine
plot
logarithm
drug
concentration
versus
survival
rate
treat
cell
daunorubicin
accumulation
dnr
fluorescent
compound
accumulation
cell
study
flow
cytometry
previously
describe
briefly
cell
incubate
presence
absence
ml
min
dnr
add
cell
gently
mix
incubate
min
accumulation
dnr
measure
flow
cytometry
facscan
becton
dickinson
fluorescence
intensity
record
histograms
datum
express
mean
fluorescence
channel
mfc
number
kinetics
drug
uptake
presence
carry
cell
cultured
dnr
presence
absence
ml
drug
accumulation
examine
min
interval
min
flow
cytometry
statistical
analysis
statistical
significance
determine
student
difference
consider
significant
level
effect
bcc
survival
bcc
ml
day
treatment
cell
result
significant
decrease
cell
survival
follow
fashion
data
show
percentage
cell
survival
concentration
ml
respectively
hand
response
cell
apoptotic
effect
little
remarkable
image
effect
alone
survival
breast
cancer
cell
cell
seed
well
plate
cultured
triplicate
presence
absence
various
concentration
mg
ml
day
survival
cell
determine
mtt
assay
cell
survival
show
percent
control
untreated
cell
datum
represent
mean
six
experiment
experiment
cell
datum
represent
mean
three
experiment
experiment
compare
control
untreated
cell
view
within
article
effect
sensitivity
bcc
dnr
bcc
cultured
dnr
different
concentration
presence
absence
day
cell
survival
value
determine
dnr
expect
inhibit
survival
cell
manner
dnr
however
cell
dnr
dnr
cell
significantly
reduce
data
show
concentration
ml
decrease
dnr
cell
fold
respectively
compare
dnr
alone
also
enhance
sensitivity
cell
dnr
lesser
extent
compare
cell
data
show
decrease
dnr
cell
fold
image
effect
dnr
cytotoxicity
bcc
cell
seed
well
plate
dnr
presence
absence
mg
ml
day
cell
survival
determine
mtt
cell
datum
represent
mean
six
experiment
experiment
cell
datum
represent
mean
three
experiment
experiment
triplicate
view
within
article
effect
accumulation
dnr
bcc
determine
observe
enhancement
dnr
cytotoxicity
relate
alteration
drug
transport
study
accumulation
dnr
flow
cytometry
result
show
concentration
ml
significantly
enhance
accumulation
dnr
cell
cell
compare
control
unlabelled
cell
figure
include
graph
unlabelled
cell
control
image
effect
accumulation
dnr
bcc
cell
incubate
dnr
without
ml
drug
accumulation
assess
flow
cell
view
within
article
kinetics
drug
uptake
presence
dnr
accumulation
cell
examine
presence
absence
min
show
difference
dnr
accumulation
detect
min
far
increase
accumulation
min
presence
enhance
drug
accumulation
mean
fluorescence
channel
number
image
kinetics
dnr
uptake
presence
accumulation
dnr
cell
examine
presence
absence
ml
min
interval
min
flow
express
mean
fluorescence
channel
mfc
number
view
within
article
discussion
study
examine
sensitize
effect
human
breast
cancer
cell
chemotherapeutic
agent
daunorubicin
treatment
significantly
increase
susceptibility
cell
dnr
fold
respectively
compare
cell
treat
dnr
alone
study
show
potential
reduce
effect
murine
cancer
patient
beneficial
effect
adverse
action
anticancer
drug
report
include
protection
severe
weight
loss
mouse
due
cisplatin
cis
rat
due
cis
adriamycin
adr
demonstrate
gross
gastrointestinal
pathological
change
prevention
death
induce
cis
addition
result
clinical
trial
progressive
cancer
patient
treat
chemotherapy
presence
absence
show
treatment
result
high
survival
rate
mark
improvement
appetite
patient
receive
chemo
compare
patient
treat
chemo
alone
previous
study
also
show
food
supplement
soy
isoflavone
genistein
increase
induction
apoptosis
cancer
cell
line
inhibit
growth
breast
tumor
mouse
administer
combination
tamoxifen
addition
green
belong
alleviate
side
effect
fluorouracil
treatment
animal
experiment
vitamin
supplementation
effect
peripheral
nerve
damage
report
examine
mechanism
increase
sensitivity
bcc
dnr
human
breast
cancer
cell
result
show
treatment
increase
accumulation
dnr
cell
several
agent
enhance
cytotoxic
effect
chemotherapeutic
cancer
cell
via
increase
intracellular
drug
accumulation
reverse
multidrug
resistance
mdr
cancer
cell
include
calcium
channel
alkaloid
agent
synthetic
isothiocyanate
addition
nutritional
intervention
toward
tumor
responsiveness
chemotherapy
recently
examine
report
enhancement
tumor
responsiveness
chemotherapy
polyunsaturated
fatty
acid
also
increase
intracellular
drug
accumulation
finally
show
reverse
multidrug
resistance
cell
research
last
two
decade
reveal
many
anticancer
drug
function
induce
apoptosis
recently
examine
role
caspase
activation
result
show
treatment
result
increase
number
cancer
cell
active
caspase
addition
sensitize
effect
human
leukemic
hut
cell
apoptosis
also
correlated
increase
number
cell
active
caspase
suggest
sensitize
cancer
cell
dnr
mechanism
involve
caspase
cascade
similar
finding
recently
report
whereby
increase
intracellular
platinum
accumulation
synthetic
isothiocyanate
derivative
ethyl
accompany
stimulation
activity
promise
activity
rice
rice
bran
derivative
recently
focus
much
research
arabinoxylan
extract
rice
bran
prove
potent
biological
response
modifier
ability
boost
function
different
arm
immune
system
nk
cell
cell
macrophage
production
addition
demonstrate
additional
characteristic
novel
agent
able
sensitize
human
leukemia
cell
death
receptor
apoptosis
cancer
cell
apoptosis
human
myeloid
leukemia
cell
adr
treatment
human
breast
cancer
cell
dnr
treatment
show
current
study
rice
bran
product
demonstrate
activity
include
polysaccharide
lipoprotein
fraction
addition
recent
study
show
rice
inhibit
growth
human
leukemic
cell
activation
peripheral
blood
mononuclear
cell
conclude
treatment
human
breast
cancer
cell
significantly
sensitize
cell
chemotherapeutic
agent
daunorubicin
datum
may
suggest
food
supplement
conjunction
chemotherapy
may
useful
treatment
breast
cancer
conflict
interest
none
declare
acknowledgement
author
like
acknowledge
daiwa
pharmaceutical
tokyo
japan
financial
support
project
publish
study
provide
information
breast
cancer
screening
practice
respect
chamorro
indigenous
population
guam
however
behavioral
risk
factor
surveillance
system
initiate
center
disease
control
track
female
cancer
screening
test
guam
since
information
indicate
mammography
increase
steadily
woman
year
age
report
high
rate
within
previous
two
year
guam
behavioral
risk
factor
surveillance
guam
department
public
health
social
service
unpublished
elsewhere
issue
colleague
find
chamorro
woman
age
year
guam
report
mammography
within
previous
two
year
rate
high
pacific
islander
population
example
native
american
age
year
report
receive
mammogram
within
time
frame
however
little
know
breast
cancer
screening
practice
among
chamorro
woman
live
mainland
important
research
question
breast
cancer
lead
death
chamorro
woman
guam
age
immigration
pattern
mainland
warrant
attention
question
since
guam
organic
act
resident
guam
continue
migration
chamorro
family
mainland
particularly
california
western
state
migration
stimulate
many
factor
include
depressed
guam
government
sponsor
attrition
program
offer
early
retirement
option
employee
addition
large
number
chamorro
san
diego
area
numerous
military
facility
due
military
relocation
base
closure
city
desirable
location
exist
chamorro
population
nearby
military
proximity
international
return
guam
indeed
san
diego
home
large
group
chamorro
mainland
chamorro
live
mainland
estimate
chamorro
san
diego
associate
military
active
duty
reserve
retire
spouse
dependent
pertinent
current
study
military
provide
excellent
health
insurance
coverage
medical
center
clinic
conduct
breast
health
monitor
mammogram
factor
encourage
breast
cancer
screening
based
relatively
high
rate
screening
mammography
strong
affiliation
military
among
chamorro
research
group
postulate
factor
connect
therefore
purpose
present
study
two
fold
assess
knowledge
attitude
breast
cancer
screening
behavior
among
chamorro
woman
san
diego
determine
whether
affiliation
military
well
knowledge
attitude
behavior
relate
breast
cancer
associate
mammogram
method
conduct
survey
among
chamorro
woman
san
diego
california
achieve
study
objective
preparation
survey
conduct
two
focus
group
determine
knowledge
attitude
cancer
might
unique
chamorro
woman
participants
response
supplement
develop
culturally
relevant
question
survey
university
california
human
subject
review
committee
approve
protocol
study
research
design
sampling
strategy
sampling
method
participant
recruit
son
daughter
guam
sdgc
well
group
sdgc
participate
pacific
islander
cancer
control
network
provide
support
pilot
research
project
inclusion
criterion
include
chamorro
female
age
year
history
breast
cancer
also
ask
whether
associate
military
order
recruit
even
number
participant
without
military
affiliation
based
priori
assumption
access
breast
cancer
screening
may
differ
two
group
women
interested
participate
invite
social
gathering
complete
survey
written
inform
consent
obtain
prior
questionnaire
administration
survey
instrument
survey
instrument
contain
question
derived
national
health
interview
survey
nhis
nhis
cancer
control
supplement
focus
group
result
survey
include
knowledge
attitude
behavior
question
specific
breast
cancer
addition
mammography
utilization
demographic
information
knowledge
question
score
point
scale
strongly
disagree
somewhat
disagree
somewhat
agree
strongly
agree
know
attitudinal
question
measure
important
concept
cancer
control
belief
importance
early
detection
prevention
cancer
fear
disease
attitudinal
question
employ
point
scale
include
know
question
knowledge
attitude
dichotomized
disagree
versus
agree
important
versus
important
outcome
variable
assess
much
recent
mammogram
dichotomized
yes
respect
mammogram
past
year
know
response
include
bivariate
analysis
since
context
response
option
likely
reflect
true
status
respondent
knowledge
attitude
actually
knowledge
attitude
give
issue
statistical
analysis
descriptive
statistic
calculate
participant
socioeconomic
variable
health
status
access
medical
care
breast
cancer
relate
knowledge
attitude
screening
behavior
initial
analysis
reveal
minor
difference
variable
exist
respondent
without
military
affiliation
therefore
combine
response
presentation
result
section
point
difference
exist
bivariate
association
aforementioned
variable
mammography
within
past
two
year
examine
predictor
variable
much
two
level
series
analysis
contingency
table
conduct
examine
source
difference
combination
level
guard
type
error
adapt
bonferroni
correction
set
significant
level
number
analysis
result
bivariate
association
based
upon
different
sample
size
vary
number
respondent
answer
different
survey
item
result
table
present
sociodemographic
characteristic
chamorro
female
reside
san
diego
country
design
approximately
half
woman
affiliate
military
among
much
affiliation
spouse
active
duty
majority
respondent
born
guam
half
woman
little
year
old
least
college
education
majority
marry
currently
employ
report
form
health
insurance
table
sociodemographic
characteristic
variablen
place
age
yr
high
high
school
college
household
income
k
ever
affiliate
active
reserve
active
spouse
serve
list
type
employment
marital
common
separated
never
language
speak
general
language
read
chamorro
well
english
well
form
health
type
health
sponsor
military
va
private
one
table
total
indicate
number
respondent
answer
question
variable
percentage
may
total
due
round
error
view
within
article
level
access
medical
care
notable
specifically
indicate
regular
source
medical
care
report
visit
place
usual
source
care
little
year
ago
much
common
site
usual
source
care
doctor
office
table
health
status
access
medical
care
variablen
health
general
access
medical
usual
source
medical
type
usual
source
doctor
hospital
emergence
hospital
outpatient
health
health
maintenance
last
time
visit
usual
source
less
one
year
year
year
year
table
total
indicate
number
respondent
answer
question
variable
percentage
may
total
due
round
error
view
within
article
specific
participant
knowledge
cancer
general
report
cancer
detect
early
cure
likely
likewise
large
majority
undergo
painful
unpleasant
treatment
improve
chance
live
long
note
respondent
believe
cancer
taotaomonas
spirit
suruhano
traditional
healer
treat
cancer
however
one
third
believe
cancer
god
give
table
knowledge
attitude
cancer
general
variablen
cancer
detect
early
likely
rather
know
cancer
taotaomonas
spirit
getting
cancer
god
give
one
get
cancer
past
age
need
worry
cancer
spread
suruhano
traditional
healer
treat
faith
god
will
cure
cancer
bring
chamorro
faith
god
will
help
get
people
get
cancer
neglect
god
give
power
medical
doctor
treat
undergo
painful
unpleasant
treatment
improve
chance
live
cancer
environmental
cancer
cancer
table
total
indicate
number
respondent
answer
question
variable
may
total
due
round
error
view
within
article
majority
chamorro
woman
agree
aging
diet
high
fat
blood
relative
breast
cancer
increase
woman
risk
get
breast
cancer
furthermore
much
woman
agree
birth
control
pill
expose
medical
increase
woman
risk
get
breast
cancer
contrast
majority
chamorro
woman
disagree
give
birth
first
child
age
start
age
relate
increased
risk
breast
cancer
approximately
one
third
respondent
believe
trauma
breast
increase
risk
breast
cancer
table
knowledge
attitude
breast
cancer
risk
factor
variablen
getting
old
increase
risk
get
breast
diet
high
fat
increase
risk
get
breast
giving
birth
first
child
age
increase
risk
get
breast
blood
relative
breast
cancer
increase
risk
get
breast
birth
control
pill
increase
risk
get
breast
expose
medical
increase
risk
get
breast
starting
menstruation
age
increase
risk
get
breast
trauma
breast
increase
risk
get
breast
active
excessive
sexual
stimulation
table
total
indicate
number
respondent
answer
question
variable
percentage
may
total
due
round
error
risk
factor
biomedical
community
accept
risk
factor
biomedical
community
view
within
article
table
present
result
regard
breast
cancer
screening
knowledge
behavior
prevalence
rate
mammogram
ever
mammogram
rate
much
recent
mammogram
within
past
two
year
year
old
report
much
recent
mammogram
within
past
two
year
large
majority
believe
mammogram
detect
breast
cancer
early
stage
mammogram
accurate
somewhat
accurate
find
lump
table
knowledge
behavior
regard
breast
cancer
screening
variablen
ever
hear
ever
much
recent
within
last
year
year
much
year
make
decision
doctor
frequently
woman
without
symptom
every
every
every
every
year
age
doctor
recommend
woman
start
start
give
mammogram
detect
breast
cancer
early
accurate
mammogram
find
breast
somewhat
table
total
indicate
number
respondent
answer
question
variable
percentage
may
total
due
round
error
view
within
article
bivariate
analysis
difference
rate
mammography
among
woman
without
affiliation
military
statistically
significant
versus
hand
woman
military
insurance
much
likely
mammography
within
time
frame
none
sociodemographic
characteristic
associate
mammogram
likewise
knowledge
risk
factor
breast
cancer
correlated
outcome
variable
however
several
important
factor
show
correlate
mammography
utilization
general
access
medical
care
significantly
relate
likelihood
mammogram
within
past
two
year
analysis
show
chamorro
woman
rate
general
access
medical
care
good
good
excellent
significantly
much
likely
mammogram
report
access
medical
care
poor
fair
respectively
furthermore
mammogram
differ
chamorro
woman
indicate
visit
regular
source
care
little
one
year
ago
year
ago
year
ago
much
year
ago
analysis
show
visit
source
care
within
past
year
much
likely
mammogram
visit
source
year
ago
much
year
ago
respectively
addition
woman
whose
doctor
nurse
recommend
mammogram
significantly
much
likely
mammogram
within
past
two
year
whose
doctor
nurse
recommend
participants
perception
likelihood
cancer
cure
detect
early
also
relate
mammogram
analysis
show
woman
report
cancer
likely
cure
detect
early
much
likely
mammogram
within
past
two
year
report
cancer
unlikely
cure
detect
early
finally
participant
perception
frequency
woman
get
screening
mammogram
relate
mammogram
specifically
compare
woman
report
know
frequently
screening
mammogram
report
one
annually
much
likely
test
discussion
compared
pacific
islander
certain
asian
population
screening
rate
within
san
diego
cohort
chamorro
exceed
approximately
chamorro
woman
age
old
report
receive
mammogram
within
precede
two
year
figure
high
list
one
health
objective
healthy
people
however
additional
study
intervention
promote
utilization
mammogram
necessary
meet
recommendation
nci
every
woman
age
old
receive
mammogram
least
every
year
determine
chamorro
study
well
rate
mammography
pacific
islander
population
however
participant
relatively
high
socioeconomic
status
least
college
education
household
income
least
moreover
report
form
health
insurance
perceive
least
good
access
medical
care
finding
consistent
previous
study
may
part
explain
relatively
large
proportion
chamorro
woman
date
breast
cancer
screening
number
factor
associate
mammography
within
study
population
statistically
insignificant
trend
toward
increase
mammography
affiliate
military
however
military
insurance
time
interview
significantly
associate
mammography
difference
utilization
mammography
military
insurance
due
mammogram
coverage
military
insurance
insurance
cover
mammography
one
possible
explanation
military
health
provider
may
much
proactive
individual
mammogram
mailing
brochure
benefit
mammogram
future
targeted
research
empirically
investigate
possibility
surprisingly
whose
doctor
nurse
recommend
mammogram
much
likely
mammogram
whose
doctor
nurse
recommend
furthermore
chamorro
woman
possess
knowledge
often
woman
get
mammogram
much
likely
one
compare
knowledge
frequency
hand
none
sociodemographic
characteristic
associate
mammogram
taken
together
result
suggest
although
socioeconomic
status
may
increase
chamorro
woman
access
mammography
service
may
sufficient
ensure
actual
mammogram
furthermore
knowledge
risk
factor
breast
cancer
relate
likelihood
get
mammogram
may
suggest
possess
knowledge
risk
factor
may
modify
individual
health
behavior
much
directly
link
chance
get
breast
cancer
knowledge
may
affect
one
utilization
mammography
example
know
diet
high
fat
increase
risk
breast
cancer
may
motivate
individual
change
eat
behavior
consume
food
fat
tanjasiri
conduct
study
date
chamorro
woman
mainland
examine
breast
cancer
risk
knowledge
screening
behavior
study
conduct
angeles
orange
country
chamorro
woman
survey
report
screening
mammogram
within
past
year
woman
age
year
report
mammography
within
past
two
year
note
woman
form
health
insurance
slightly
high
rate
study
bivariate
analysis
health
insurance
old
age
great
income
marry
traditional
healer
associate
high
screening
rate
tanjasiri
study
several
limitation
present
study
first
result
obtain
sample
generalized
chamorro
woman
although
trend
datum
may
well
represent
san
diego
chamorro
perspective
second
bias
inherent
design
subject
report
error
future
longitudinal
study
examine
trend
mammogram
utilization
explore
predictor
compliance
population
conclusion
remain
room
improvement
chamorro
woman
san
diego
relatively
high
rate
breast
cancer
screening
mammography
find
may
due
part
relatively
high
rate
health
insurance
coverage
particularly
military
insurance
good
access
medical
care
among
chamorro
compare
pacific
islander
population
based
upon
result
educational
effort
targeted
toward
assure
woman
know
breast
cancer
cure
detect
early
screening
mammogram
recommend
woman
year
age
old
pacific
islander
cancer
control
network
begin
address
issue
publication
culturally
appropriate
breast
cancer
educational
brochure
focusing
breast
health
chamorro
community
based
organization
health
fair
venue
conflict
interest
conflict
interest
acknowledgement
source
support
grant
national
cancer
institute
content
manuscript
solely
responsibility
author
necessarily
represent
view
funding
agency
breast
cancer
much
common
invasive
cancer
second
leading
death
among
woman
north
america
etiology
breast
cancer
complex
several
risk
factor
identify
numerous
epidemiological
laboratory
study
reveal
effect
dietary
pattern
food
group
well
single
nutrient
nutritional
determinant
sporadic
breast
cancer
risk
much
breast
cancer
consider
sporadic
estimate
due
inherit
susceptibility
individual
sporadic
breast
cancer
may
inherit
mutation
parent
instead
certain
cell
undergo
mutation
lead
cancer
mutation
sun
exposure
radiation
certain
chemical
yet
unknown
factor
case
hereditary
cancer
tumor
cell
usually
contain
mutation
find
elsewhere
body
also
harbor
critical
mutation
every
cell
share
people
born
mutation
much
likely
develop
cancer
especially
young
age
without
inherit
mutation
autosomal
dominant
alteration
two
gene
chromosome
chromosome
likely
account
familial
case
breast
cancer
suspect
genetic
factor
mutation
mutation
cell
kinase
gene
well
pten
general
role
nutritional
factor
etiology
breast
cancer
remain
controversial
number
dietary
factor
include
consumption
fruit
vegetable
dairy
product
meat
poultry
fish
dietary
pattern
feature
high
intake
fat
combination
essential
fatty
acid
antioxidant
vitamin
intensively
assess
relation
breast
cancer
risk
objective
paper
provide
overview
effect
consumption
certain
food
group
breast
cancer
risk
among
gene
mutation
carrier
woman
inherit
alter
form
gene
well
sporadic
breast
cancer
table
provide
overview
study
representative
review
literature
paper
table
selected
study
representative
literature
review
nutritional
breast
cancer
risk
fruits
cohort
ci
eight
cohort
ci
van
cohort
epic
ci
dairy
eight
large
prospective
ci
paper
publish
case
controlsrr
ci
statistical
analysis
show
study
eight
large
prospective
ci
nurse
health
study
prospective
ci
case
controlsor
ci
prospective
ci
prospective
ci
total
cohort
study
national
breast
screening
study
ci
case
controlsrr
ci
total
case
controlsor
ci
paper
publish
case
controlsrr
ci
saturated
prospective
ci
controlsor
ci
study
cohort
ci
case
controlsor
ci
prospective
study
nurse
health
study
ii
ci
vitamin
prospective
study
nurse
health
study
ii
rr
ci
vitamin
rr
ci
vitamin
rr
ci
clinical
premenopausal
woman
vitamin
calcium
breast
density
prospective
study
epic
ci
case
controlsor
ci
nested
case
controlsor
ci
table
view
within
article
method
identify
study
relationship
nutrition
breast
cancer
among
sporadic
case
gene
mutation
carrier
literature
search
conduct
follow
electronic
database
current
institute
scientific
information
philadelphia
pa
medline
national
library
medicine
bethesda
md
year
publication
consider
reporting
consumption
fruit
vegetable
dairy
product
meat
poultry
fish
total
energy
total
fat
fatty
acid
vitamin
mineral
phytoestrogen
relation
breast
cancer
risk
also
study
choose
accord
sample
size
standard
methodology
publish
know
institution
paper
cite
relevant
article
also
examine
dietary
factor
breast
cancer
fruits
vegetable
many
fruit
vegetable
contain
protective
substance
fiber
antioxidant
vitamin
mineral
potentially
anticarcinogenic
compound
include
isothiocyanate
flavonol
among
association
fruit
vegetable
intake
breast
cancer
risk
subject
many
limited
number
cohort
study
extensive
summary
world
cancer
research
fund
conclude
vegetable
intake
breast
cancer
risk
protective
association
woman
breast
cancer
risk
relative
risk
rr
ci
confidence
interval
find
high
versus
consumption
vegetable
decrease
risk
contrast
recent
prospective
study
woman
year
show
evidence
protective
effect
fruit
vegetable
breast
cancer
risk
pooled
analysis
eight
cohort
study
include
woman
reveal
weak
association
fruit
vegetable
breast
cancer
risk
association
establish
green
vegetable
eight
botanical
group
specific
fruit
vegetable
result
suggest
fruit
vegetable
consumption
significantly
associate
reduce
breast
cancer
risk
moreover
pool
project
subject
publication
bias
weakness
often
arise
heavy
reliance
publish
study
show
significant
datum
finding
little
likely
publish
interpret
outcome
addition
although
statistical
analysis
perform
original
datum
standardized
way
dietary
assessment
methodology
apply
may
different
instance
study
food
frequency
questionnaire
ffq
ffq
characterize
several
inaccuracy
will
discuss
later
overview
cohort
study
implement
diet
recall
either
overestimate
underestimate
dietary
intake
argue
absence
association
vegetable
fruit
intake
cancer
risk
due
method
measure
diet
however
one
advantage
cohort
study
general
large
sample
size
even
strength
relationship
dilute
look
food
group
whole
addition
evidence
protective
effect
fruit
vegetable
strong
woman
family
history
breast
cancer
woman
estrogen
receptor
tumor
dairy
product
cohort
study
dairy
food
breast
cancer
yield
conflict
result
inverse
association
milk
breast
cancer
find
several
recent
investigation
part
dietary
fat
breast
cancer
risk
concentrate
two
dairy
category
milk
study
cheese
study
detect
significant
association
breast
cancer
conduct
pool
analysis
subject
project
prospective
study
diet
cancer
relationship
note
dairy
product
breast
cancer
risk
recently
summarize
result
cohort
study
evaluate
association
dairy
product
consumption
breast
cancer
risk
conclude
available
epidemiological
evidence
support
strong
association
consumption
milk
dairy
product
risk
breast
cancer
nurse
health
study
ii
conduct
among
premenopausal
high
consumption
dairy
product
inverse
association
breast
cancer
risk
rr
ci
however
total
dairy
intake
associate
risk
breast
cancer
dairy
intake
positively
associate
risk
rr
ci
serving
per
day
complicate
interpretation
result
another
recent
examination
datum
much
study
cohort
study
also
support
association
dairy
product
consumption
breast
cancer
risk
research
address
theory
association
dairy
product
consumption
breast
cancer
via
fat
insulin
growth
growth
hormone
estrogen
weight
evidence
support
propose
link
although
estrogen
axis
play
critical
role
mammary
gland
development
breast
cancer
mechanism
complex
cancer
probably
influence
much
autocrine
paracrine
secretion
circulate
hormone
level
since
believe
daily
contribution
factor
dairy
product
consumption
far
small
exert
physiological
effect
compare
daily
endogenous
secretion
calcium
vitamin
important
regulation
cell
growth
addition
vitamin
active
metabolite
vitamin
essential
calcium
homeostasis
absorption
cell
animal
study
suggest
hyperplasia
mammary
epithelial
cell
reduce
dietary
calcium
vitamin
number
possible
mechanism
antiproliferative
action
calcium
example
calcium
may
neutralize
fatty
acid
mutagenic
acid
rapidly
pass
intestine
breast
affect
induce
protein
manner
similar
estradiol
also
know
increase
breast
density
strongly
link
breast
cancer
risk
recent
research
reveal
augment
intake
calcium
vitamin
associate
decrease
breast
density
presence
rumenic
vaccenic
butyric
branch
chain
fatty
acid
bcfas
whey
protein
calcium
vitamin
milk
may
reduce
breast
cancer
risk
rumenic
acid
ra
predominant
natural
conjugate
linoleic
acid
milk
fat
rich
natural
source
vaccenic
acid
va
major
fatty
acid
milk
fat
convert
ra
animal
human
normal
rat
mammary
epithelial
cell
ra
observe
inhibit
cell
growth
induce
apoptosis
physiological
concentration
ra
va
milk
fat
stop
cell
growth
breast
cancer
cell
action
ra
may
mediate
induction
apoptosis
inhibition
angiogenesis
associate
decrease
serum
glandular
level
vascular
endothelial
growth
factor
receptor
bcfas
synthesize
bacterium
particularly
chain
length
carbon
atom
find
milk
fat
initially
report
acid
also
induce
cell
death
human
breast
cancer
cell
rapid
induction
apoptosis
recently
test
activity
series
two
human
breast
cancer
cell
line
find
bcfas
slightly
inhibit
fatty
acid
synthetase
significantly
dehydrogenase
main
system
breast
cancer
cell
thus
study
suggest
bcfas
fatty
acid
reduce
precursor
addition
direct
inhibitory
effect
fatty
acid
synthetase
butyric
acid
ba
present
milk
fat
potent
agent
induce
differentiation
apoptosis
inhibit
proliferation
angiogenesis
case
milk
fat
butyrate
milk
fat
contain
butyrate
thus
although
butyrate
short
circulation
increase
present
small
compound
also
synergy
dietary
agent
like
vitamin
vitamin
resveratrol
reduce
plasma
concentration
butyrate
require
modulate
cell
growth
two
study
show
dietary
butyrate
significantly
inhibit
chemically
induce
mammary
tumor
development
rat
evidence
animal
vitro
study
human
breast
cancer
cell
indicate
milk
protein
especially
associate
whey
fraction
property
whey
protein
rich
source
essential
synthesis
glutathione
potent
cellular
antioxidant
act
agent
via
relate
enzyme
facilitate
elimination
mutagen
carcinogen
body
lead
current
hypothesis
dairy
product
may
reduce
breast
cancer
risk
based
vitamin
content
food
naturally
contain
significant
amount
vitamin
vitamin
dairy
product
mostly
result
fortification
although
fortification
dairy
product
cereal
common
type
product
fortify
amount
vitamin
add
vary
country
difference
indicate
study
country
different
regulation
practice
regard
vitamin
fortification
strictly
comparable
vitamin
component
dairy
product
influence
breast
cancer
risk
comparison
take
account
specific
dairy
product
also
level
vitamin
fortification
overall
publish
study
review
provide
consistent
evidence
association
dairy
product
consumption
breast
cancer
risk
meat
poultry
meat
several
study
examine
relationship
meat
breast
cancer
risk
conflict
result
woman
significant
association
find
intake
total
meat
red
meat
white
meat
breast
cancer
risk
contrary
study
among
woman
case
control
disclose
increase
risk
breast
cancer
intake
much
beef
per
week
odd
ratio
ci
moreover
recent
study
perform
cohort
woman
reveal
large
effect
size
postmenopausal
woman
meat
type
significant
association
total
process
red
meat
consumption
meat
show
strong
hazard
ratio
ci
high
consumption
compare
none
postmenopausal
woman
consume
much
meat
day
high
risk
breast
cancer
ci
meat
compose
fat
protein
also
contain
essential
nutrient
vitamin
vitamin
micronutrients
major
source
due
either
high
concentration
great
bioavailability
folate
selenium
zinc
regional
difference
discern
meat
component
also
preparation
western
country
meat
mainly
whereas
boil
meat
preparation
asian
african
country
concentration
aromatic
hydrocarbon
increase
markedly
therefore
steak
contain
whereas
compound
find
boil
meat
retrospective
women
health
study
innovative
method
determine
technique
involve
series
color
photograph
represent
range
meat
cooking
level
extremely
rare
risk
develop
breast
cancer
observe
significantly
great
woman
prefer
meat
compare
favour
medium
cook
raw
meat
recent
datum
indicate
heterocyclic
amine
steak
increase
breast
cancer
risk
presence
genetic
polymorphism
high
activity
homozygous
deletion
glutathione
mi
gene
recently
assess
red
meat
intake
breast
cancer
risk
among
premenopausal
woman
nurse
health
study
ii
year
premenopausal
woman
note
greater
red
meat
intake
strongly
relate
elevate
risk
breast
cancer
estrogen
progesterone
pr
rr
breast
cancer
ci
woman
eat
much
serving
per
week
compare
eat
three
fewer
serving
per
week
red
meat
rr
ci
much
five
serving
per
week
ci
fewer
serving
per
day
finally
rr
ci
much
serving
per
day
test
trend
association
pr
breast
cancer
several
biological
mechanism
may
explain
positive
association
red
meat
intake
hormone
breast
cancer
risk
first
heterocyclic
amine
estrogenic
stimulate
gene
expression
well
pr
expression
vitro
animal
study
show
heterocyclic
amine
elevate
serum
prolactin
level
second
exogenous
hormone
treatment
growth
promotion
european
country
united
state
concern
although
health
effect
hormone
residue
beef
investigate
theoretically
may
preferentially
affect
hormone
tumor
third
red
meat
source
iron
highly
bioavailable
form
iron
major
source
store
body
iron
find
enhance
tumor
finally
postulate
fat
intake
may
breast
cancer
risk
augment
circulate
estrogen
level
poultry
two
publish
cohort
study
conclude
association
poultry
consumption
breast
cancer
risk
hand
study
case
control
note
decrease
breast
cancer
risk
ci
versus
day
protective
effect
white
meat
consumption
may
amino
acid
content
white
meat
support
well
immune
function
thereby
enhance
tumor
surveillance
high
level
intake
however
far
study
need
confirm
protective
effect
white
meat
fish
vitro
animal
study
show
inhibitory
effect
marine
fatty
acid
breast
cancer
growth
several
epidemiological
investigation
examine
association
fish
consumption
breast
cancer
risk
human
review
seven
cohort
study
fish
consumption
marine
fatty
acid
breast
cancer
risk
report
inconsistent
result
author
find
association
suggest
decrease
risk
high
consumption
fish
fatty
acid
still
postulate
inverse
association
subgroup
define
menopausal
status
one
study
include
review
detect
slightly
elevate
risk
breast
cancer
rr
ci
associate
high
dietary
marine
fatty
acid
cohort
woman
record
significantly
reduce
risk
breast
cancer
rr
ci
high
consumption
fish
marine
fatty
acid
similarly
significant
inverse
association
fish
intake
breast
cancer
risk
observe
japanese
woman
breast
cancer
case
reference
group
ci
examine
association
fatty
lean
fish
breast
cancer
risk
large
study
sweden
find
weak
inverse
association
fish
breast
cancer
clear
difference
outcome
fish
species
study
norwegian
woman
association
salmon
consumption
breast
cancer
risk
note
positive
association
daily
total
fish
intake
breast
cancer
risk
rr
ci
difference
association
detect
type
fish
preparation
method
suggest
factor
fish
fat
responsible
observation
recently
find
evidence
association
fish
intake
breast
cancer
risk
rr
ci
study
sample
woman
recruitment
european
prospective
investigation
cancer
nutrition
limitation
much
study
fish
consumption
breast
cancer
risk
distinguish
lean
fatty
fish
lean
fish
contain
small
amount
fatty
acid
since
much
fat
store
liver
fish
beneficial
effect
fatty
acid
may
association
apparent
fatty
fish
consumption
furthermore
indeed
protective
effect
fish
consumption
breast
cancer
risk
may
also
counterbalance
harmful
impact
contaminants
fish
may
contaminate
substance
present
environment
heavy
metal
pesticide
may
estrogenic
effect
influence
pesticide
breast
cancer
risk
evaluate
recent
review
human
epidemiological
study
limitation
review
differ
level
detail
available
questionnaire
assess
fish
consumption
different
research
center
country
make
difficult
distinguish
different
type
fish
fish
product
true
cooking
method
way
fish
consume
smoke
salt
moreover
additional
consideration
fish
intake
fish
good
dietary
source
vitamin
good
source
vitamin
vitamin
mineral
calcium
iron
trace
element
selenium
zinc
component
associate
breast
cancer
risk
vitamin
calcium
selenium
hypothesized
play
beneficial
role
reduce
breast
cancer
risk
calcium
vitamin
show
interact
promote
growth
inhibition
breast
cancer
cell
moreover
selenium
antioxidant
also
effective
reduce
breast
cancer
risk
inhibit
angiogenesis
view
factor
clear
evidence
yet
emerge
association
fish
consumption
breast
cancer
risk
total
energy
number
experimental
epidemiological
investigation
assess
relationship
energy
intake
breast
cancer
cohort
study
canada
observe
increase
risk
breast
cancer
premenopausal
woman
daily
total
energy
intake
kcal
much
based
upon
study
shanghai
case
control
report
increase
premenopausal
breast
cancer
risk
among
woman
consume
total
energy
intake
much
kcal
per
day
compare
consume
kcal
per
day
recently
study
among
french
canadian
case
control
positive
association
find
total
energy
intake
breast
cancer
risk
ci
among
woman
consume
kcal
day
compare
consume
kcal
day
result
independent
age
body
mass
index
bmi
physical
activity
addition
consistent
evidence
experimental
animal
study
indicate
energy
restriction
lead
inhibition
induce
breast
cancer
restriction
energy
intake
reduce
mammary
tumor
although
study
mention
concentrate
different
population
different
sample
size
detect
positive
association
high
energy
intake
breast
cancer
risk
several
mechanism
propose
energy
restriction
decrease
breast
cancer
risk
evidence
effect
dietary
restriction
mediate
via
change
availability
turn
inhibit
tumor
development
decrease
cell
proliferation
diet
show
suppress
estrogen
secretion
therefore
attenuate
mammary
tumor
development
furthermore
may
lead
decrease
free
radical
production
mitochondria
reduce
oxidative
stress
inflammation
diminish
energy
restriction
also
reduce
dna
replication
enhance
rate
apoptosis
thus
diminish
tissue
susceptibility
carcinogen
total
fat
preclinical
human
ecological
study
suggest
association
increase
dietary
fat
intake
breast
cancer
risk
cohort
study
reveal
little
consistent
effect
instance
study
case
control
find
association
breast
cancer
dietary
fat
intake
similarly
observational
study
influence
dietary
fat
breast
cancer
recurrence
produce
mix
result
variable
association
may
due
difference
fat
intake
study
population
difficulty
accurately
measure
fat
intake
method
high
correlation
dietary
fat
diet
lifestyle
variable
much
investigator
assume
observe
effect
dietary
fat
need
adjust
statistically
energy
intake
however
straightforward
issue
change
fat
composition
diet
may
alteration
energy
intake
thus
high
energy
intake
result
change
fat
intake
may
consider
one
mechanism
fat
affect
tumor
development
dietary
fat
may
also
play
role
development
breast
cancer
via
hormone
metabolism
may
particularly
relevant
cancer
elevation
endogenous
estrogen
level
increase
fat
intake
think
relate
breast
cancer
alternatively
role
dietary
fat
breast
cancer
may
little
direct
example
diet
may
lead
great
body
mass
obesity
probable
risk
factor
postmenopausal
breast
cancer
postmenopausal
woman
intake
may
increase
level
bioavailable
estrogen
thus
elevate
risk
breast
cancer
furthermore
intake
childhood
adolescence
may
promote
fast
growth
early
onset
menarche
establish
risk
factor
breast
cancer
fatty
saturated
fat
giving
much
weight
prospective
study
find
relationship
saturate
fat
intake
breast
cancer
risk
subject
japan
collaborative
cohort
study
hand
combine
analysis
study
reveal
increase
risk
postmenopausal
breast
cancer
high
saturate
fat
intake
give
overall
quintile
intake
estimate
adjust
total
fat
intake
also
associate
increase
risk
view
relationship
breast
cancer
food
high
saturate
fat
meat
dairy
product
may
observe
association
breast
cancer
saturate
fat
study
may
due
component
meat
saturate
fat
food
preparation
method
hand
observe
association
meat
consumption
may
reflect
true
effect
saturate
fat
mufas
olive
oil
rich
source
mufas
study
show
risk
breast
cancer
decrease
consumption
much
olive
oil
per
day
ci
antioxidant
present
olive
oil
vitamin
suggest
one
protective
constituent
however
eight
cohort
study
find
association
mufas
breast
cancer
risk
relationship
mufas
intake
breast
cancer
risk
appear
depend
contribute
food
polyunsaturated
fatty
acid
pufa
conduct
study
case
control
observe
overall
association
pufa
breast
cancer
risk
similarly
combine
analysis
study
indicate
statistically
significant
association
postmenopausal
breast
cancer
risk
pufa
intake
moreover
another
cohort
study
note
similar
absence
association
diet
high
pufa
may
link
breast
cancer
risk
independently
contribution
total
fat
intake
thus
contrary
datum
animal
experiment
human
study
show
increase
breast
cancer
risk
pufa
intake
risk
associate
pufa
intake
remain
difficult
food
composition
table
fatty
acid
incomplete
vitamin
mineral
antioxidant
property
dietary
carotenoids
vitamin
neutralize
reactive
oxygen
species
reduce
oxidative
dna
damage
genetic
mutation
may
also
enhance
host
immunological
function
reaction
help
protect
breast
carcinogenesis
preformed
vitamin
retinol
ester
involve
cell
differentiation
certain
carotenoids
fruit
vegetable
retinol
study
diet
breast
cancer
support
weak
protective
effect
carotenoids
rather
preformed
vitamin
cohort
study
woman
demonstrate
consumption
fruit
vegetable
high
specific
carotenoids
vitamin
may
reduce
breast
cancer
rr
ci
hand
cohort
study
find
evidence
high
intake
vitamin
diminish
risk
breast
cancer
vitamin
calcium
emerge
promising
chemopreventive
chemotherapeutic
agent
breast
cancer
aside
supplement
vitamin
find
certain
food
good
natural
source
fish
oil
egg
liver
vitamin
food
milk
obtain
exposure
uv
light
conversion
skin
furthermore
recent
datum
nurse
health
study
suggest
among
premenopausal
woman
dietary
vitamin
might
protect
breast
cancer
independently
sun
exposure
intake
milk
constituent
include
calcium
vitamin
also
play
major
role
calcium
homeostasis
calcium
important
mineral
find
primarily
dairy
product
cellular
proliferation
differentiation
modulate
calcium
cell
function
also
involve
carcinogenesis
cohort
study
suggest
calcium
intake
may
associate
decrease
breast
cancer
risk
hand
find
association
vitamin
breast
density
among
premenopausal
postmenopausal
woman
however
note
increase
vitamin
calcium
intake
associate
decrease
breast
density
suggest
augment
dietary
vitamin
calcium
reduce
breast
cancer
risk
change
breast
tissue
morphology
however
remain
controversial
issue
phytoestrogens
intake
phytoestrogen
much
high
among
asian
woman
compare
woman
live
western
world
hence
role
genetic
probably
relatively
small
compare
environmental
lifestyle
factor
dietary
habit
therefore
hypothesized
high
phytoestrogen
intake
protect
breast
cancer
estrogen
estradiol
particular
know
strong
mitogenic
property
experimental
epidemiological
study
circulate
estrogen
level
breast
cancer
indicate
increase
risk
high
level
estrone
estradiol
although
postmenopausal
woman
however
also
compete
endogenous
estrogen
way
inhibit
binding
much
potent
endogenous
estrogen
postulate
situation
circulate
level
endogenous
estrogen
phytoestrogen
may
act
weak
estrogen
antiestrogenic
effect
environment
high
circulate
level
endogenous
estrogen
hence
protect
premenopausal
breast
cancer
increase
breast
cancer
risk
menopause
prospective
study
soy
intake
breast
cancer
risk
find
significant
protective
effect
high
intake
enterolactone
mammalian
lignan
genistein
isoflavone
concentration
plasma
sample
premenopausal
case
control
study
germany
show
median
plasma
enterolactone
concentration
case
control
nmol
respectively
median
genistein
concentration
nmol
respectively
premenopausal
breast
cancer
risk
decrease
increase
plasma
enterolactone
concentration
overall
ci
ci
trend
woman
third
fourth
quartile
plasma
enterolactone
compare
quartile
association
plasma
genistein
concentration
premenopausal
breast
cancer
risk
direct
association
demonstrate
either
den
urinary
isoflavone
level
postmenopausal
woman
prospective
epidemiological
study
assess
circulate
urinary
excretion
level
lignan
also
give
conflict
result
premenopausal
woman
increase
decrease
breast
cancer
risk
report
recently
nest
study
case
control
show
genistein
ci
indicate
around
decrease
risk
comparable
protective
effect
although
statistically
significant
see
isoflavone
lignan
level
appear
relate
breast
cancer
risk
result
similar
premenopausal
postmenopausal
woman
isoflavone
lignan
level
plasma
measure
liquid
chromatography
tandem
mass
incorporating
triple
standard
perform
analysis
clear
explanation
advance
oppose
effect
isoflavone
absence
association
isoflavone
breast
cancer
decrease
risk
breast
cancer
isoflavone
study
may
serum
level
isoflavone
aside
effect
also
marker
dietary
compound
soy
protein
antioxidant
addition
variant
gene
involve
metabolism
sex
steroid
hormone
may
important
effect
phytoestrogen
breast
cancer
risk
example
decrease
breast
cancer
risk
woman
high
dietary
genistein
intake
woman
high
plasma
concentration
lignan
observe
certain
variant
gene
study
premenopausal
breast
cancer
patient
control
hypothesis
phytoestrogen
protect
breast
cancer
situation
high
circulate
level
endogenous
estrogen
premenopausal
woman
increase
risk
environment
relatively
level
endogenous
estrogen
menopause
generally
support
result
prospective
study
publish
far
furthermore
endogenous
estrogen
level
severely
decrease
menopause
excess
circulate
level
phytoestrogen
circulate
estradiol
level
much
large
postmenopausal
compare
premenopausal
woman
hence
phytoestrogen
estradiol
may
much
effective
menopause
moreover
obese
postmenopausal
woman
estrogen
convert
active
form
body
fat
thus
high
circulation
estrogen
level
however
phytoestrogen
antiestrogenic
effect
competitive
binding
consequently
diminish
binding
stronger
endogenous
estrogen
mechanism
dietary
phytoestrogen
may
attenuate
adverse
outcome
obesity
development
postmenopausal
breast
cancer
circulating
level
isoflavone
woman
live
western
country
much
asian
woman
however
compare
endogenous
estrogen
phytoestrogen
level
western
woman
show
phytoestrogen
level
time
high
endogenous
estrogen
hence
effect
expect
even
circulate
level
isoflavone
similar
observe
european
american
population
propose
mechanism
action
phytoestrogen
scavenge
free
radical
induction
apoptosis
tyrosine
kinase
activity
may
also
result
decrease
breast
cancer
risk
however
effect
note
vitro
experiment
much
high
phytoestrogen
level
report
vivo
study
inhibition
aromatic
enzyme
however
describe
level
reach
diet
effect
particularly
interesting
menopause
estrogen
produce
ovary
aromatic
conversion
androgen
fat
tissue
main
pathway
estrogen
synthesis
according
national
cancer
institute
surveillance
epidemiology
end
result
registry
evidence
potential
health
benefit
phytoestrogen
increase
hormone
replacement
therapy
decrease
discussion
methodological
issue
epidemiological
study
may
harbor
bias
influence
outcome
bias
result
dietary
assessment
method
employ
cohort
prospective
study
typically
employ
recall
diet
record
ffq
much
study
administer
ffq
retrospectively
assess
dietary
pattern
consumption
frequency
food
nutrient
food
group
believe
relate
etiology
disease
investigation
interpret
datum
several
factor
consider
much
importantly
assessment
diet
outcome
relation
cancer
risk
subject
bias
example
subject
may
accurately
report
food
consumption
ffq
food
list
may
miss
key
dietary
element
moreover
different
dietary
assessment
method
may
yield
different
result
standard
develop
permit
detection
association
consumption
food
product
breast
cancer
risk
certainty
method
epidemiological
study
include
ffq
dietary
record
food
diary
achieve
modest
validity
misclassification
intake
unavoidable
however
result
generally
take
indicative
dietary
pattern
ffq
diet
recall
food
record
remain
reliable
method
epidemiological
study
another
challenge
evaluate
food
nutrient
relate
disease
risk
high
among
food
nutrient
diet
result
food
combination
instance
person
high
consumption
cheese
dairy
product
may
also
much
likely
consume
large
amount
meat
food
contribute
increase
risk
breast
cancer
even
total
energy
intake
control
analysis
may
impossible
completely
separate
effect
dairy
intake
example
dietary
factor
include
intake
various
type
fat
conversely
person
may
consume
milk
dairy
product
part
overall
healthy
diet
also
high
fruit
vegetable
fat
may
difficult
separate
effect
particular
food
product
food
group
alter
breast
cancer
risk
noteworthy
relatively
study
adjust
dietary
factor
alcohol
consumption
total
energy
intake
analysis
fruit
vegetable
dairy
product
meat
poultry
fish
fatty
acid
vitamin
mineral
phytoestrogen
risk
protective
factor
breast
cancer
etiology
add
difficulty
inherent
compare
study
accord
dietary
variable
consider
analysis
nonetheless
result
study
adjust
estimate
wide
range
variable
include
alcohol
consumption
oral
contraceptive
parity
family
history
breast
cancer
age
menopause
age
first
birth
bmi
parity
differ
systematically
study
adjust
many
factor
adjustment
covariate
within
study
often
appreciably
alter
crude
estimate
consumption
particular
food
however
adjustment
necessary
confirm
significance
result
variation
level
food
consumption
report
different
population
another
important
consideration
evaluate
epidemiological
datum
standard
method
currently
available
categorize
intake
level
particular
food
product
type
fruit
vegetable
cheese
meat
fish
oil
average
intake
vary
considerably
population
level
consumption
consider
high
one
population
might
another
consequently
many
researcher
make
comparison
based
quintile
intake
within
specific
study
population
hand
approach
take
epidemiological
investigation
may
affect
finding
link
breast
cancer
nutrition
example
state
early
major
limitation
study
recall
bias
exposure
among
case
may
food
believe
may
contribute
diagnosis
healthy
food
believe
may
prevent
disease
bias
rr
far
null
value
observe
prospective
study
relationship
selection
bias
may
result
distortion
evidence
datum
arise
way
collect
bias
may
drive
case
find
disease
likely
contribute
high
participation
rate
control
epidemiological
study
addition
control
participate
may
much
perhaps
consume
much
fruit
vegetable
little
fat
refuse
take
part
study
effect
recall
selection
bias
trivial
lead
apparent
inverse
association
fruit
vegetable
positive
association
dietary
fat
finally
difference
finding
epidemiological
study
may
due
dissimilarity
study
population
duration
choice
nutrient
database
range
nutrient
intake
capture
ffq
moreover
identify
role
extent
dietary
habit
development
disease
usually
easy
much
efficient
compare
contrast
population
ethnic
group
lifestyle
difference
however
rarely
logistical
practical
issue
among
group
wide
variation
food
eat
conclusion
since
breast
cancer
may
latent
initiation
genetic
environment
diet
lifestyle
therefore
consider
potential
factor
etiology
numerous
study
test
theory
association
dairy
product
consumption
breast
cancer
risk
via
role
play
fat
dairy
product
relation
estrogen
although
estrogen
axis
play
critical
role
mammary
gland
development
mechanism
complex
cancer
probably
influence
much
autocrine
paracrine
secretion
circulate
level
nevertheless
daily
contribution
factor
dairy
product
consumption
far
small
exert
physiological
effect
compare
daily
endogenous
secretion
presence
ra
va
ba
bcfas
whey
protein
calcium
vitamin
milk
potential
help
prevent
breast
cancer
although
diet
per
elevate
breast
cancer
risk
meat
rule
risk
factor
individual
evidence
point
overall
protective
effect
high
fruit
vegetable
consumption
speculation
remain
potentially
anticarcinogenic
agent
present
fruit
vegetable
include
numerous
micronutrients
carotenoids
vitamin
flavonoid
regional
difference
breast
cancer
incidence
likely
partially
attributable
environmental
risk
factor
particularly
dietary
habit
appear
advisable
time
counsel
woman
adopt
dietary
pattern
region
world
mediterranean
diet
protect
breast
cancer
traditional
western
diet
also
beneficial
ingredient
regular
constituent
meal
overview
conclude
fruit
vegetable
dairy
product
fish
mufas
pufa
vitamin
calcium
phytoestrogen
may
protect
risk
breast
cancer
however
far
research
need
well
understand
dietary
contribution
underlie
nutrient
constituent
disease
ultimate
goal
research
contribute
novel
prevention
strategy
decrease
number
woman
risk
develop
breast
cancer
conflict
interest
none
declare
acknowledgment
funding
study
receive
montreal
cancer
institute
author
acknowledge
editorial
assistance
da
research
support
office
research
centre
montreal
canada
acute
myeloid
leukemia
clinical
syndrome
occur
exposure
chemotherapy
radiotherapy
majority
result
alkylating
agent
dna
topoisomerase
ii
inhibitor
alkylating
agent
relate
aml
often
occur
average
interval
year
myelodysplastic
syndrome
frequently
describe
associate
abnormality
chromosome
alternatively
result
dna
topoisomerase
ii
inhibitor
treatment
appear
frequently
short
interval
associate
translocation
chromosome
less
often
associate
chromosomal
translocation
result
mll
gene
rearrangement
often
associate
diagnosis
treatment
topoisomerase
ii
inhibitor
survival
patient
generally
poor
region
genetically
unstable
subsequent
translocation
insertion
chromosome
report
multiple
chromosome
break
region
likely
induce
chemo
radiotherapy
mutagen
associate
subgroup
patient
extremely
bad
prognosis
previously
tel
gene
transcription
factor
transform
specific
family
essential
establish
definitive
hematopoiesis
bone
marrow
find
case
several
rearrangement
result
fusion
gene
much
different
partner
include
also
report
cell
harboring
translocation
gene
allele
often
delete
inactivate
clinical
consequence
loss
function
aml
however
define
yet
although
region
genetically
unstable
subsequent
translocation
chromosome
rare
cytogenetic
abnormality
report
seven
leukemia
case
good
knowledge
never
detect
acute
leukemia
thus
datum
regard
clinical
course
outcome
patient
limited
report
case
breast
cancer
chemo
radiotherapy
rare
reciprocal
secondary
cytogenetic
abnormality
addition
translocated
gene
find
disrupt
case
report
june
woman
diagnose
leave
breast
cancer
undergo
wide
local
excision
sentinel
lymph
node
dissection
receive
adjuvant
chemotherapy
consist
two
cycle
epirubicin
four
cycle
fluorouracil
epirubicin
cyclophosphamide
well
local
radiation
therapy
total
dose
hormonal
maintenance
treatment
follow
four
year
later
december
admit
investigation
full
peripheral
blood
cell
count
show
white
blood
cell
wbc
count
neutrophil
lymphocyte
monocyte
platelet
hemoglobin
dl
hematocrit
mean
corpuscular
volume
fl
mean
corpuscular
hemoglobin
pg
routine
biochemistry
screen
reveal
elevate
lactate
dehydrogenase
iu
normal
range
iu
clinically
absence
palpable
lymph
node
note
bone
marrow
aspirate
show
infiltration
blast
consist
nucleated
cell
morphology
suggestive
myeloid
origin
well
trilineage
dysplasia
present
little
cell
three
line
immunophenotypic
analysis
flow
cytometry
demonstrate
positivity
consistent
acute
myeloid
leukaemia
chromosome
analysis
bone
marrow
cell
show
induction
chemotherapy
cytarabine
idarubicin
cytarabine
administer
complete
remission
achieve
patient
undergo
three
course
consolidation
therapy
first
course
consist
cytarabine
idarubicin
second
course
consist
cytarabine
etoposide
third
course
consist
cytarabine
eight
month
later
october
relapse
morphologic
immunophenotypic
finding
new
cytogenetic
analysis
show
salvage
chemotherapy
consist
etoposide
cytarabine
administer
day
later
peripheral
blood
cell
count
show
wbc
neutrophil
lymphocyte
monocyte
new
bone
marrow
aspirate
consistent
morphologic
remission
blast
mark
trilineage
dysplasia
due
fact
impossible
identify
suitable
donor
international
donor
pool
allogeneic
bone
marrow
transplant
patient
sister
schedule
unfortunately
bone
marrow
transplantation
postpone
patient
continuous
relapse
last
month
material
chromosome
study
chromosome
study
perform
unstimulated
bone
marrow
cell
cultured
hour
cytogenetic
analysis
perform
trypsin
band
chromosome
preparation
imaging
karyotyping
perform
microscopy
computer
imaging
technique
least
metaphase
cell
time
karyotype
describe
accord
international
system
human
cytogenetic
nomenclature
fluorescence
situ
hybridization
fish
fish
study
perform
bone
marrow
cytogenetic
specimen
follow
specific
dna
probe
lsi
mll
rearrangement
probe
lsi
tel
translocation
probe
lsi
tel
rearrangement
probe
lsi
chop
rearrangement
probe
molecular
plain
chromosome
probe
cambridge
uk
fish
image
digitally
generate
isis
fish
imaging
software
germany
cytogenetic
result
chromosomal
analysis
bone
marrow
cell
diagnosis
show
abnormal
clone
contain
reciprocal
translocation
long
arm
chromosome
short
arm
chromosome
breakpoint
respectively
metaphase
cell
evaluate
karyotype
thus
describe
patient
relapse
new
cytogenetic
analysis
bone
marrow
reveal
two
abnormal
clone
first
clone
one
detect
diagnosis
metaphase
evaluate
evolutionary
clone
carry
additional
reciprocal
translocation
short
arm
chromosome
long
arm
homologue
breakpoint
respectively
detect
metaphase
cell
evaluate
karyotype
describe
image
bone
marrow
show
view
within
article
fish
mll
probe
show
split
signal
interphase
nucleus
analyzed
metaphase
fish
analysis
reveal
primer
one
mll
gene
translocated
confirm
reciprocal
exchange
chromosome
tel
probe
gene
show
normal
pattern
hybridization
interphase
nucleus
metaphase
analysis
detect
signal
corresponding
two
allele
gene
normally
locate
short
derivative
chromosome
investigate
whether
gene
translocated
intact
lsi
tel
rearrangement
probe
split
hybridization
signal
detect
interphase
metaphase
cell
interphase
fish
analysis
detect
nucleus
score
split
signal
metaphase
cell
primer
one
gene
find
small
primer
remain
large
probe
specific
chop
gene
show
normal
hybridization
pattern
interphase
nucleus
analyzed
chop
allele
find
large
interphase
fish
image
fish
metaphase
cell
show
red
probe
correspond
end
mll
whereas
green
probe
correspond
end
mll
intact
mll
associate
overlap
red
green
yellow
fusion
signal
telomeric
part
mll
red
translocated
chromosome
indicate
long
arrow
whereas
end
mll
remain
indicate
short
arrow
chromosome
probe
green
give
signal
centromere
normal
chromosome
well
centromere
view
within
article
image
fish
result
lsi
tel
translocation
probe
label
gene
previously
tel
green
gene
previously
red
arrow
show
two
green
signal
corresponding
two
gene
view
within
article
image
fish
analysis
demonstrate
rearrangement
gene
view
inverted
dapi
filter
red
probe
correspond
end
whereas
green
probe
correspond
end
intact
associate
overlap
red
green
yellow
fusion
signal
primer
red
large
translocated
small
arrow
view
within
article
image
fish
analysis
lsi
chop
rearrangement
probe
two
yellow
fusion
signal
observe
reflect
two
intact
copy
chop
gene
arrow
result
translocation
chop
gene
homologue
chromosome
large
view
within
article
discussion
case
diagnose
year
intensive
chemo
radiotherapy
breast
cancer
reciprocal
detect
diagnosis
cytogenetic
analysis
far
characterize
fish
analysis
primary
chromosomal
abnormality
often
associate
diagnosis
mainly
time
present
case
seem
result
topoisomerase
ii
inhibitor
agent
anthracycline
rather
alkylating
agent
precede
phase
mds
show
balanced
translocation
involve
chromosome
band
present
rather
short
interval
chemotherapy
moreover
young
age
patient
age
specific
type
dna
topoisomerase
ii
inhibitor
seem
predispose
specifically
development
translocation
chromosome
band
evolutionary
clone
detect
upon
disease
relapse
month
consolidation
therapy
characterize
additionally
thus
secondary
cytogenetic
change
growth
advantage
evolutionary
clone
since
secondary
abnormality
closely
associate
progression
leukemia
detect
upon
disease
relapse
likely
play
important
role
progression
leukemia
review
literature
reveal
report
seven
leukemia
case
limited
clinical
datum
case
include
two
case
one
case
cml
three
case
aml
one
case
mds
progress
rapidly
aml
although
acute
leukemia
case
rearrangement
report
patient
history
chemotherapy
radiotherapy
patient
associate
unfavorable
prognosis
none
report
case
available
medical
history
appear
therapy
relate
like
patient
however
report
patient
aml
bad
outcome
unfavourable
prognosis
except
one
whose
outcome
available
since
much
report
case
treatment
patient
available
cytogenetic
aberration
prognosis
sole
aberration
currently
unknown
patient
continuous
relapse
last
month
poor
prognosis
also
associate
diagnosis
table
demographic
clinical
cytogenetic
characteristic
report
case
yr
early
nrnr
del
nrnr
first
treatment
month
later
induction
chemotherapy
three
course
consolidation
therapy
breast
relapse
induction
chemotherapy
three
course
consolidation
therapy
salvage
case
table
abbreviation
pt
patient
male
female
nr
report
aml
acute
leukaemia
cml
chronic
myeloid
leukaemia
ph
philadelphia
mds
myelodysplastic
syndrome
acute
lymphoblastic
leukemia
chronic
lymphoblastic
leukemia
ifn
alive
view
within
article
current
case
result
split
gene
demonstrate
breakpoint
large
locate
within
gene
thus
gene
disrupt
make
expression
product
indicate
possible
formation
new
fusion
gene
know
fusion
gene
may
lead
formation
chimeric
protein
activation
partner
gene
case
formation
protein
rearrangements
gene
detect
another
case
relapse
disease
case
report
fusion
generate
rearrangement
expect
produce
chimeric
protein
truncate
form
pediatric
acute
lymphoblastic
leukemia
characterization
rearrangement
important
may
reveal
new
fusion
gene
increase
understanding
functional
property
may
also
identify
new
breakpoint
may
disclose
previously
oncogene
translocation
chop
gene
large
indicate
breakpoint
small
proximal
chop
fact
translocated
intact
reveal
chop
gene
fuse
however
determine
however
whether
change
position
chop
gene
affect
normal
expression
balanced
translocation
long
arm
chromosome
describe
myelofibrosis
myeloid
metaplasia
implicate
region
pathogenesis
malignant
myeloproliferative
disease
since
approximately
myelofibrosis
myeloproliferative
disease
transform
acute
leukemia
gene
region
may
play
important
role
predisposition
aml
investigation
emphasize
role
fish
detection
submicroscopic
chromosome
leukemia
especially
target
gene
multiple
partner
gene
mll
gene
fish
approach
detect
deletion
one
part
gene
translocation
independently
involve
partner
gene
moreover
allow
identification
partner
gene
partner
chromosome
region
metaphase
present
high
level
false
positivity
range
conclusion
finding
suggest
gene
rearrangement
may
reveal
new
fusion
gene
involve
new
partner
gene
band
disruption
gene
may
involve
progression
disease
good
knowledge
case
also
represent
first
report
rare
associate
emphasize
role
fish
detection
submicroscopic
chromosome
leukemia
cd
heavy
metal
widely
distribute
throughout
environment
result
pollution
variety
source
environmental
exposure
cd
occur
contaminate
food
cigarette
smoke
general
population
tobacco
smoking
important
source
cd
exposure
cd
classify
category
carcinogen
international
agency
research
cancer
iarc
however
comparison
carcinogenic
metal
cd
strong
cancer
instead
weak
mutagen
stimulation
cellular
signaling
various
stage
mitogenic
cascade
expression
dna
synthesis
cell
proliferation
various
mammalian
cell
system
think
mechanism
carcinogenic
action
metal
last
decade
grow
body
evidence
accumulate
suggest
certain
cell
type
micromolar
concentration
cd
able
initiate
series
rapid
signaling
event
include
generation
second
camp
within
smith
yamagami
increase
intracellular
calcium
within
min
smith
yamagami
activation
certain
kinase
hung
misra
misra
induction
early
response
gene
within
min
misra
misra
since
signal
generate
soon
cd
exposure
argue
physiological
interaction
cd
intracellular
protein
postulate
cd
might
bind
activate
putative
cell
membrane
receptor
trigger
downstream
signaling
event
however
limited
number
study
misra
misra
explore
possibility
definitive
study
elucidate
nature
receptor
might
possibly
mediate
effect
estrogen
modulate
cellular
function
action
initiate
cell
membrane
two
propose
model
rapid
response
estrogen
action
first
model
propose
estrogen
receptor
alpha
mer
associate
cell
membrane
protein
include
protein
receptor
tyrosine
kinase
mediate
rapid
signaling
induce
estrogen
razandi
razandi
razandi
pedram
second
model
propose
another
membrane
protein
involve
process
filardo
filardo
norman
thomas
although
nature
mer
still
debate
song
evidence
certain
cell
type
small
fraction
associate
cell
membrane
originate
transcript
classical
require
rapid
effect
estrogen
razandi
razandi
razandi
song
pedram
relatively
dose
kg
ip
cd
able
increase
uterine
weight
promote
growth
development
mammary
gland
induce
gene
ovariectomized
rat
xenoestrogen
cd
ability
bind
high
affinity
kd
activate
alter
estrogen
target
gene
transcription
expression
effect
estradiol
mediate
mer
cd
may
also
trigger
rapid
signaling
cascade
mechanism
mitogen
activate
protein
kinase
mapk
serine
threonine
protein
kinase
play
important
role
signaling
cascade
regulate
cellular
process
cell
proliferation
differentiation
apoptosis
three
major
subfamilies
describe
kinase
erk
kinase
jnk
kinase
depending
cellular
context
stimulator
significant
cross
talk
transduction
module
respond
common
upstream
activator
phosphorylate
common
stream
target
general
erk
pathway
preferentially
activate
response
growth
differentiation
factor
jnk
kinase
much
sensitive
stress
stimulus
include
heat
shock
inflammatory
cytokine
ultraviolet
gamma
irradiation
cell
show
different
temporal
pattern
cd
treatment
term
activation
mapk
among
three
major
subfamilies
mapk
usually
activate
cd
much
early
jnk
kinase
chuang
chuang
yang
huang
iryo
additionally
rapid
activation
widely
endpoint
reflect
effect
variety
cell
type
filardo
filardo
razandi
razandi
razandi
pedram
activation
either
akt
kinase
prevent
cell
undergo
apoptosis
induce
certain
chemical
physical
agent
serine
threonine
protein
kinase
akt
also
activate
various
growth
survival
factor
akt
promote
cell
survival
two
distinct
pathway
inhibition
apoptosis
phosphorylation
bad
component
bad
bcl
xl
complex
dissociation
bad
bcl
xl
complex
allow
cell
survival
activation
ikk
ultimately
lead
activation
cell
survival
induce
activation
akt
endothelial
cell
wild
type
mouse
within
min
cell
mouse
report
prostate
cell
akt
activate
cd
within
min
present
study
design
investigate
rapid
signaling
response
cd
three
human
breast
cancer
cell
line
different
expression
profile
material
method
chemical
biochemical
phenol
dmem
ham
obtain
louis
fetal
bovine
serum
fbs
purchase
hyclone
logan
synthetic
estrogen
antagonist
ici
purchase
louis
antibody
akt
purchase
cell
signaling
technology
danvers
ma
antibody
purchase
santa
cruz
biotechnology
santa
cruz
california
blocking
buffer
obtain
lincon
ne
sirna
study
pool
sirna
human
sirna
obtain
dharmacon
tech
lafayette
sirna
transfection
reagent
lipid
purchase
austin
tx
chemical
reagent
either
louis
fisher
scientific
cell
culture
three
breast
cancer
cell
line
positive
purchase
american
type
culture
collection
va
cell
grow
maintain
phenol
dmem
ham
medium
contain
sodium
bicarbonate
fbs
mg
gentamicin
filardo
filardo
stock
culture
maintain
complete
medium
humidify
atmosphere
air
employ
experiment
within
serial
passage
cell
every
day
mixture
trypsin
edta
cell
exposure
preparation
cell
extract
cell
seed
flask
well
cell
culture
plate
phenol
dmem
medium
contain
fbs
next
day
medium
replace
phenol
medium
cell
maintain
treatment
quiescent
cell
confluence
cd
carry
phenol
medium
describe
legend
since
cd
commonly
researcher
study
effect
cd
mapk
chuang
chuang
yang
huang
iryo
concentration
present
study
comparison
early
report
determine
mtt
trypan
blue
exclusion
assay
treatment
cell
cd
min
cytotoxicity
datum
show
end
cd
treatment
cell
wash
twice
saline
pbs
lysed
ripa
buffer
mm
sodium
chloride
mm
tris
ph
sodium
sodium
dodecyl
sulfate
sds
triton
mm
sodium
pyrophosphate
mm
mm
pmsf
mm
naf
mm
edta
plus
protease
inhibitor
cocktail
ratio
cell
lysate
centrifuged
min
supernatant
store
analyzed
protein
concentration
determine
micro
bca
reagent
kit
pierce
biotechnology
rockford
accord
manufacturer
instruction
western
blot
analysis
prior
electrophoresis
cell
extract
heat
min
laemmli
buffer
contain
amount
protein
extract
electrophoresis
keep
constant
experiment
vary
experiment
electrophoresis
protein
nitrocellulose
membrane
min
sd
transfer
cell
hercules
membrane
block
block
buffer
room
temperature
incubate
primary
antibody
dilute
contain
bsa
overnight
room
temperature
nitrocellulose
membrane
wash
incubate
secondary
antibody
labeled
dilute
block
buffer
contain
follow
extensive
washing
wash
membrane
scan
lincon
ne
optical
density
band
quantify
application
software
version
transfection
small
interfere
rna
sirna
sirna
transfection
conduct
accord
instruction
provide
dharmacon
tech
lafayette
briefly
cell
transfected
either
sirna
control
sirna
human
allow
recover
overnight
cell
prior
treatment
cd
data
analysis
experiment
repeat
three
time
optical
density
datum
statistically
analyzed
significant
difference
anova
follow
tukey
test
result
activation
presence
phosphorylated
threonine
tyrosine
residue
mapk
correlate
activity
kinase
thus
assess
activate
level
cell
extract
process
western
blot
analysis
antibody
phosphorylated
peptide
encompass
residue
first
activation
compare
cell
positive
control
response
pattern
comparison
make
nm
cd
effect
medium
change
phosphorylation
examine
untreated
cell
significant
change
observe
datum
show
depict
temporal
response
pattern
activation
induce
cd
cell
similar
induce
maximal
activation
cd
observe
min
follow
gradual
decrease
min
period
contrast
cell
neither
cd
activate
cell
express
however
cell
express
cd
transient
activation
similar
observe
cell
result
indicate
mer
important
rapid
signaling
image
image
activation
cd
three
different
breast
cancer
cell
cell
cell
cell
quiescent
cell
treat
cd
nm
min
comparison
temporal
response
pattern
activation
three
cell
line
show
data
present
mean
sd
three
independent
experiment
significantly
high
basal
level
respective
cell
view
within
article
datum
cell
cd
show
cell
expose
concentration
cd
min
show
significant
increase
fold
activation
maximum
activation
fold
see
cd
image
image
pattern
activation
cd
cell
quiescent
cell
treat
cd
min
data
present
mean
sd
three
independent
experiment
significantly
high
basal
level
view
within
article
activation
akt
since
akt
activate
phosphorylation
threonine
upstream
kinase
activation
akt
detect
western
blot
analysis
antibody
recognize
peptide
contain
threonine
residue
medium
change
significant
effect
phosphorylation
akt
untreated
cell
datum
show
show
cd
significantly
increase
fold
phosphorylated
akt
cell
within
min
continue
fold
duration
experiment
induce
akt
activation
exhibit
similar
pattern
cell
cd
induce
moderate
activation
akt
min
comparison
akt
phosphorylation
cell
affect
either
cd
time
similar
response
cell
phosphorylation
thus
datum
also
point
involvement
mer
akt
signaling
cd
image
image
akt
activation
cd
three
different
breast
cancer
cell
cell
cell
cell
quiescent
cell
treat
cd
nm
min
comparison
temporal
response
pattern
akt
activation
three
cell
line
show
data
present
mean
sd
three
independent
experiment
significantly
high
basal
level
respective
cell
view
within
article
phosphorylation
result
obtain
akt
phosphorylation
cell
suggest
mer
might
play
role
rapid
signaling
thus
delineate
involvement
signaling
process
phosphorylation
investigate
quiescent
cell
treatment
cd
show
cd
transiently
elevate
fold
level
phosphorylated
receptor
min
comparison
gradual
much
sustain
phosphorylation
image
image
phosphorylation
cd
cell
phosphorylation
quiescent
cell
cd
nm
temporal
response
pattern
cd
show
data
present
mean
sd
three
independent
experiment
significantly
high
basal
level
view
within
article
effect
estrogen
antagonist
akt
activation
since
rapid
activation
cell
mer
ici
estrogen
antagonist
able
antagonize
genomic
rapid
signaling
effect
present
study
possible
role
mer
rapid
signaling
examine
antagonist
quiescent
cell
pretreated
ici
min
treat
cd
nm
min
presence
antagonist
ici
stock
solution
mm
prepare
ethanol
thus
control
cell
incubate
medium
contain
ethanol
depict
whereas
antagonist
complete
block
phosphorylation
kinase
significant
effect
phosphorylation
either
kinase
lack
effect
activation
akt
receptor
antagonist
contrary
result
obtain
thus
far
suggest
mechanism
image
image
effect
antagonist
activation
akt
cell
quiescent
cell
pretreated
ici
vehicle
ethanol
min
treat
either
cd
nm
presence
antagonist
phosphorylation
phosphorylation
akt
data
present
mean
sd
three
independent
experiment
significantly
high
control
cell
cell
treat
alone
view
within
article
effect
sirna
activation
evaluate
role
mer
rapid
activation
akt
second
approach
utilize
specific
sirna
knockdown
expression
receptor
transfection
sirna
markedly
completely
suppress
expression
quiescent
cell
level
suppression
expression
sufficient
completely
block
rapid
activation
akt
comparison
partially
block
activation
completely
block
activation
akt
result
suggest
addition
mer
receptor
might
also
involve
interact
cd
image
image
effect
suppression
expression
activation
akt
cell
forty
eight
hour
transfection
specific
sirna
quiescent
cell
treat
either
cd
nm
phosphorylation
phosphorylation
akt
data
present
mean
sd
three
independent
experiment
significantly
high
respective
control
cell
respective
cell
transfected
sirna
view
within
article
discussion
cd
describe
endocrine
disrupt
chemical
number
investigator
henson
xenoestrogen
cd
alter
expression
certain
estrogen
target
gene
affect
breast
tissue
development
ovariectomized
rat
metal
also
evaluate
reproductive
tissue
effect
cd
one
demonstrate
effect
mammary
proliferation
johnson
although
definitive
epidemiological
evidence
show
positive
relationship
cd
exposure
breast
cancer
incidence
general
population
nagata
xenoestrogen
cd
may
play
role
cancer
promotion
progression
cancer
initiate
davidson
mechanism
cd
disrupt
endocrine
function
remain
poorly
understand
result
obtain
present
study
demonstrate
cell
relatively
benign
breast
cancer
cell
line
cd
able
rapidly
activate
akt
micromolar
concentration
within
min
exposure
condition
cell
moderately
malignant
breast
cancer
cell
line
respond
bit
much
slowly
min
term
activation
comparison
highly
invasive
breast
cancer
cell
line
show
rapid
response
cd
treatment
dramatic
response
difference
three
cell
line
speculate
sensitivity
cd
might
associate
relative
invasiveness
breast
cancer
cell
since
activation
akt
play
role
regulate
various
cellular
process
cell
growth
cell
differentiation
apoptosis
induce
certain
chemical
physical
agent
much
study
need
perform
elucidate
rapid
signaling
affect
normal
function
breast
tissue
susceptibility
certain
stress
present
study
cd
also
induce
rapid
phosphorylation
might
make
cell
much
sensitive
relatively
level
although
downstream
effect
investigate
present
study
result
akt
phosphorylation
suggest
even
occasional
exposure
cd
might
transient
effect
normal
physiology
breast
tissue
might
disrupt
normal
homeostasis
especially
exposure
occur
early
critical
period
breast
development
potential
exposure
concentration
cd
environmental
health
importance
may
biological
significance
especially
subject
chemical
physical
stress
agent
result
present
study
also
show
cd
like
rapid
phosphorylation
cell
min
treatment
suggest
cd
possibly
share
similar
downstream
signal
transduction
pathway
regulatory
mechanism
rapid
inactivation
imply
existence
tightly
control
regulatory
mechanism
contrast
result
report
cd
induce
significant
activation
cell
min
treatment
period
although
difference
biological
characteristic
sensitivity
endocrine
disruptors
among
various
cell
stock
may
partially
contribute
difference
rapid
activation
also
possible
cd
concentration
detect
significant
effect
regard
present
study
provide
much
comprehensive
datum
rapid
signaling
cell
concentration
report
increase
phosphorylation
cell
response
cd
start
min
peak
variant
cell
partly
account
result
report
present
study
secondly
investigator
dmem
contain
phenol
red
perform
serum
starvation
exposure
present
study
utilize
phenol
dmem
medium
serum
starve
cell
show
without
serum
starvation
cd
induce
significant
phosphorylation
cell
exposure
furthermore
weak
estrogen
mimic
interfere
effect
estrogen
therefore
exclude
medium
study
effect
estrogen
endocrine
disruptors
additionally
since
activate
rapidly
early
time
point
need
consider
design
study
observe
short
treatment
murine
cell
biphasic
activation
peak
induction
min
early
phase
second
phase
similarly
report
treatment
cell
also
biphasic
phosphorylation
akt
peak
min
respectively
furthermore
first
wave
activation
whereas
second
study
activation
akt
cell
report
maximum
activation
conclude
activation
occur
mechanism
fully
block
ici
comparison
present
study
cd
rapid
activation
min
cell
block
ici
partially
block
cell
transfected
thus
cd
like
appear
induce
biphasic
activation
early
late
phase
possibly
involve
besides
breast
cancer
cell
activation
cd
report
several
cell
type
include
human
cell
lung
carcinoma
cell
line
mouse
epidermal
cell
iryo
chuang
chuang
yang
huang
phosphorylation
cell
treat
cd
occur
min
exposure
lung
carcinoma
cell
line
high
concentration
cd
induce
phosphorylation
treatment
similarly
mouse
epidermal
cell
report
cd
induce
sustain
activation
min
wang
report
activation
rat
cell
involve
mrna
transcription
inhibition
partially
attenuate
transcription
thus
different
cell
line
show
variation
response
activation
term
likely
multiple
mechanism
involve
mediate
effect
certain
biological
response
cell
type
specific
important
finding
study
cell
express
respond
cd
involvement
receptor
cd
signaling
another
membrane
receptor
show
involve
rapid
signaling
event
filardo
filardo
since
cell
contain
respond
cd
receptor
also
appear
interact
cd
conclusion
result
present
provide
evidence
micromolar
concentration
cd
rapidly
activate
akt
cell
process
seem
involve
mer
plausible
cd
also
bind
membrane
receptor
upstream
kinase
couple
protein
associate
specialized
cell
membrane
structural
complex
rapid
activation
downstream
kinase
cascade
study
need
elucidate
mechanism
rapid
signaling
well
understand
cd
interfere
cell
signaling
network
affect
normal
physiological
function
homeostasis
acknowledgment
author
thank
dr
valuable
assistance
various
technique
liu
yu
receive
fellowship
grant
nih
research
make
possible
research
core
facility
support
grant
view
express
manuscript
author
necessarily
represent
view
nih
breast
cancer
second
leading
cancer
death
woman
incidence
rate
breast
cancer
increase
much
country
particularly
asia
annual
increase
incidence
compare
rest
world
incidence
breast
cancer
rise
particularly
develop
country
india
molecular
mechanism
underlie
breast
carcinogenesis
understand
completely
cell
line
provide
unlimited
source
cell
widely
distribute
facilitate
comparative
study
continuous
cell
line
establish
primary
tumour
provide
important
experimental
system
study
biology
genetic
change
associate
tumour
initiation
progression
since
establishment
first
human
breast
carcinoma
cell
line
many
attempt
make
establish
permanent
breast
tumour
cell
line
however
limited
success
achieve
cultivate
epithelial
cell
culture
human
primary
breast
tumour
wang
date
majority
breast
cancer
derived
cell
line
obtain
secondary
tumour
pleural
effusion
patient
advance
stage
breast
cancer
culture
establish
secondary
deposit
collect
late
development
disease
time
may
modification
original
tumour
although
human
breast
cancer
line
describe
literature
number
breast
tumour
cell
line
adequately
characterised
widely
young
herein
report
establishment
characterisation
two
oestrogen
receptor
negative
breast
cancer
cell
line
one
familial
sporadic
primary
breast
carcinoma
material
tissue
specimen
establishment
primary
culture
breast
carcinoma
tissue
collect
process
set
primary
culture
describe
previously
except
culture
propagate
dmem
medium
culture
monitor
cell
growth
propagate
trypsinisation
purification
epithelial
cell
epithelial
cell
population
enrich
differential
trypsinisation
describe
previously
kaur
ralhan
rohatgi
thereafter
fibroblast
reduce
selective
chemical
elimination
sulphate
ml
gibco
brl
grand
island
describe
epithelial
cell
purify
macs
epithelial
column
biotech
gmbh
germany
eluted
purify
epithelial
cell
plate
culture
flask
contain
dmem
gibco
invitrogen
cell
culture
grand
island
medium
supplement
fbs
gibco
invitrogen
cell
culture
bovine
insulin
ml
sigma
aldrich
bangalore
india
epidermal
growth
factor
ml
gibco
invitrogen
cell
culture
propagate
regularly
cell
maintain
medium
supplement
growth
factor
passage
growth
factor
withdraw
gradually
medium
cell
grow
without
growth
factor
passage
light
electron
microscopic
analysis
breast
cancer
cell
various
passage
examine
photograph
inverted
microscope
olympus
tokyo
japan
cell
grow
coverslip
fix
glutaraldehyde
sodium
cacodylate
buffer
ph
process
cell
surface
characterisation
scanning
electron
microscopy
sem
leo
field
emission
scanning
electron
microscope
see
kaur
ralhan
cell
monolayer
fix
glutaraldehyde
sodium
cacodylate
buffer
ph
process
examine
internal
cell
structure
transmission
electron
microscope
tem
see
kaur
ralhan
rohatgi
growth
rate
colony
formation
soft
agar
cell
plate
triplicate
cell
density
cell
per
well
well
plate
cell
cell
number
count
regular
time
interval
growth
curve
plot
double
time
calculate
exponential
phase
growth
assess
suspend
cell
ml
soft
agar
laboratory
detroit
mi
usa
layer
base
agar
mm
dish
agar
supplement
dmem
fbs
formation
colony
determine
inverted
microscopy
week
immunocytochemistry
cell
grow
coverslip
fix
process
immunocytochemical
analysis
briefly
cell
primary
antibody
ml
follow
biotinylated
secondary
antibody
ml
dako
glostrup
denmark
incubate
streptavidin
conjugate
horseradish
peroxidase
colour
develop
diaminobenzidine
chromogen
slide
counterstained
mayer
haematoxylin
mount
examine
light
microscope
mutational
analysis
genomic
dna
isolate
cell
standard
phenol
chloroform
method
polymerase
chain
reaction
pcr
amplify
product
encompass
exon
gene
harbour
mutational
analyse
mutation
direct
automate
sequencing
abi
prism
sequencer
applied
biosystems
foster
city
usa
analysis
expression
total
rna
prepare
trizol
reagent
invitrogen
rockville
md
five
micrograms
total
rna
mer
mmlv
invitrogen
volume
two
microlitres
cdna
template
subject
pcr
amplification
control
cdna
integrity
pcr
carry
cdna
primer
specific
condition
mention
elsewhere
mizuno
bisulphite
treatment
methylation
specific
pcr
genomic
dna
isolate
cell
phenol
chloroform
method
subject
bisulphite
treatment
describe
previously
methylation
specific
pcr
carry
bisulphite
treat
dna
pcr
mixture
contain
mm
ammonium
sulphate
mm
tris
ph
mm
mm
mm
dntp
primer
reaction
reaction
hot
start
min
addition
taq
polymerase
sequence
primer
purchase
gene
list
methylate
forward
tgg
cgg
aaa
agc
gc
reverse
tct
caa
cga
act
cac
product
size
bp
unmethylated
forward
gtt
ttt
gtg
gta
atg
gaa
reverse
caa
aaa
atc
tca
aca
aac
tca
cac
product
size
bp
methylate
forward
acg
cga
gcg
att
reverse
caa
tcc
aac
cga
aac
product
size
bp
unmethylated
forward
caa
tcc
aac
caa
aac
reverse
atg
tga
gtg
att
product
size
bp
methylate
forward
agc
ggt
ggc
gtt
reverse
cga
ctt
cga
atc
acg
product
size
bp
unmethylated
forward
gtg
aag
ttg
ggt
reverse
aca
act
tca
cac
ata
product
size
bp
methylate
forward
ggt
att
cgt
tgg
gcg
reverse
cca
cgt
ata
cgt
aac
product
size
bp
unmethylated
forward
tgt
att
tgg
ttg
gag
reverse
caa
acc
ttt
aca
cac
aac
product
size
bp
establishment
novel
human
breast
cancer
cell
line
bca
breast
carcinoma
establish
year
female
patient
diagnose
situ
ductal
carcinoma
breast
patient
family
history
breast
cancer
bca
breast
carcinoma
derived
year
female
stage
iib
invasive
ductal
carcinoma
breast
epithelial
cell
emerge
tissue
piece
within
day
initiation
culture
day
primary
culture
confluent
fibroblast
remove
epithelial
cell
purify
describe
section
cell
show
morphology
observe
light
microscope
cell
grow
rapidly
vitro
confluent
cell
grow
multilayers
suggestive
loss
contact
inhibition
characteristic
transform
cell
cell
passage
cell
passage
image
breast
cancer
cell
line
breast
cell
emerge
tissue
within
day
culturing
population
cell
epithelial
cell
purification
macs
original
magnification
culture
day
depict
emergence
different
cell
type
tissue
population
cell
epithelial
cell
purification
macs
column
note
allow
grow
confluency
cell
form
multilayers
indicate
loss
contact
original
magnification
view
within
article
characterisation
cell
ultrastructural
analysis
verify
epithelial
characteristic
establish
cell
analysis
carry
scanning
electron
microscopy
reveal
irregular
cell
surface
morphology
intercellular
cell
cell
connect
structure
cell
line
cell
also
show
structure
long
cytoplasmic
process
microvilli
cell
surface
image
ultrastructural
analysis
establish
breast
cancer
cell
line
electron
microscopy
scanning
electron
micrographs
original
magnification
original
magnification
cell
line
display
irregular
cell
surface
intercellular
connect
structure
microvilli
indicate
arrowhead
combination
letter
respectively
transmission
electron
micrographs
original
magnification
original
magnification
reveal
cytoplasmic
filament
arrow
within
cell
cell
cell
attachment
tight
junction
arrow
microvilli
arrow
cell
surface
view
within
article
transmission
electron
microscopic
evaluation
reveal
polygonal
cell
connect
tight
junction
microvilli
locate
cell
surface
furthermore
bundle
cytoplasmic
tonofilaments
also
observe
electron
micrographs
cell
reveal
desmosomes
cytoplasmic
filament
expression
epithelial
marker
epithelial
membrane
antigen
ema
cytokeratin
express
much
epithelial
cancer
cell
serve
epithelial
marker
immunocytochemical
analysis
cell
demonstrate
presence
epithelial
membrane
antigen
ema
contain
cytokeratin
confirm
epithelial
origin
culture
image
immunocytochemical
analysis
establish
breast
cancer
cell
line
epithelial
membrane
antigen
ema
vimentin
cell
respectively
original
magnification
view
within
article
cell
vimentin
however
cell
show
presence
vimentin
mesenchymal
cell
marker
marker
mesenchymal
epithelial
lineage
suggestive
epithelial
metaplastic
transition
emt
cell
growth
characteristic
population
double
time
cell
line
determine
trypan
blue
exclusion
method
count
cell
number
different
time
period
cell
grow
slowly
culture
population
double
time
cell
grow
much
rapidly
population
double
time
datum
show
confluent
cell
grow
multilayers
suggestive
loss
contact
inhibition
characteristic
transform
cell
cell
passage
cell
passage
next
cell
grow
independent
condition
assess
growth
potential
anchorage
free
environment
culture
grow
agar
enlarge
colony
demonstrate
anchorage
independent
growth
human
breast
cancer
cell
line
positive
control
form
colony
soft
agar
human
breast
cell
line
negative
control
form
colony
soft
agar
form
large
colony
compare
colony
form
culture
contain
average
cell
per
colony
respectively
compare
colony
cell
image
photomicrograph
colony
form
soft
agar
cell
plate
soft
agar
observe
colony
formation
experiment
twice
triplicate
positive
control
form
colony
soft
agar
show
growth
characteristic
cell
whereas
breast
cell
line
form
colony
indicate
anchorage
dependent
growth
view
within
article
mutational
analysis
mutational
analysis
gene
exon
show
wild
type
sequence
cell
line
analysis
transcript
gene
expression
reduce
many
sporadic
breast
cancer
rice
rice
therefore
mrna
level
analyse
determine
reduction
level
transcript
gene
specific
primer
transcript
observe
cell
suggest
alteration
expression
may
critically
involve
process
cell
line
image
transcript
breast
cancer
cell
line
cell
line
show
expression
mrna
albeit
different
internal
control
respective
cell
line
lane
negative
control
lane
bp
dna
ladder
view
within
article
expression
biological
marker
expression
various
cell
cycle
regulatory
gene
cell
surface
receptor
oncogene
tumour
suppressor
gene
product
neu
prb
analyse
insight
molecular
mechanism
involve
breast
carcinogenesis
cell
line
expression
status
protein
cell
line
summarised
table
table
immunocytochemical
analysis
molecular
marker
line
faint
positive
cyclin
table
cytoplasmic
consider
positive
nuclear
observe
cytoplasmic
staining
consider
negative
view
within
article
expression
dna
methyl
dnmts
expression
dnmts
elevate
many
cancer
marzo
girault
mizuno
robertson
hence
analyse
expression
dnmts
transcript
level
compare
breast
cancer
cell
line
mammary
cell
line
transcript
amplify
gene
specific
primer
housekeeping
gene
control
cell
line
show
expression
transcript
level
elevate
cell
line
similar
breast
cancer
cell
line
compare
breast
cell
line
image
expression
dnmts
transcript
breast
cell
line
dnmts
transcript
express
breast
cancer
cell
line
compare
cell
line
mcf
particularly
transcript
elevate
breast
cancer
cell
line
lane
negative
control
lane
bp
dna
ladder
view
within
article
table
relative
ratio
dnmts
expression
breast
cancer
cell
line
cell
table
view
within
article
epigenetic
alteration
promoter
methylation
one
mechanism
silence
tumour
suppressor
gene
exist
neoplastic
cell
therefore
carry
promoter
methylation
analysis
gene
commonly
know
methylate
breast
cancer
methylation
specific
pcr
analysis
gene
promoter
show
promoter
methylate
cell
methylation
observe
cell
gene
promoter
methylate
promoter
unmethylated
promoter
exon
unmethylated
cell
line
comparison
breast
cancer
cell
line
cell
line
mcf
also
analyse
methylate
breast
cancer
cell
line
breast
cell
line
show
promoter
methylation
gene
analyse
study
image
promoter
methylation
status
breast
cell
methylation
product
size
bp
bp
um
methylation
product
size
bp
bp
um
methylation
product
size
bp
bp
um
methylation
product
size
bp
bp
um
methylation
product
size
bp
bp
um
lane
negative
control
lane
bp
dna
ladder
methylate
unmethylated
view
within
article
discussion
two
breast
cancer
cell
line
one
family
history
breast
cancer
sporadic
breast
carcinoma
establish
oestrogen
receptor
negative
tumour
knowledge
familial
breast
cancer
cell
line
establish
one
vitro
model
familial
origin
date
therefore
cell
line
will
provide
new
experimental
model
study
hereditary
breast
cancer
also
understand
molecular
pathogenesis
negative
breast
cancer
cell
line
establish
patient
ductal
origin
one
culture
establish
patient
ductal
carcinoma
situ
family
history
breast
cancer
carcinoma
situ
early
stage
cancer
therefore
difficult
establish
cell
line
stage
intriguingly
although
culture
establish
situ
ductal
carcinoma
cell
lack
oestrogen
receptor
prb
epithelial
nature
cell
line
establish
morphological
characteristic
marker
epithelial
origin
epithelial
membrane
antigen
ema
cytokeratin
cytokeratin
intermediate
filament
express
epithelial
cell
presence
intercellular
connect
structure
well
develop
desmosomes
observe
electron
microscopy
suggest
epithelial
nature
cell
line
presence
intermediate
filament
tonofilaments
far
support
epithelial
phenotype
interact
meshwork
form
keratin
filament
desmosomes
plasma
membrane
produce
integrate
network
throughout
epithelial
tissue
however
one
cell
line
also
show
expression
mesenchymal
cell
marker
vimentin
suggest
partial
transition
epithelial
mesenchymal
cell
type
call
metaplastic
transition
hence
culture
may
classify
metaplastic
cancer
cell
line
vimentin
expression
epithelial
cell
report
marker
high
grade
malignancy
vimentin
keratin
often
see
epithelial
cancer
cell
line
two
kind
filament
segregate
distinct
network
cell
line
establish
study
show
growth
pattern
characteristic
feature
transform
cell
strongly
correlated
invasiveness
several
cell
type
furthermore
cell
grow
multilayers
suggestive
loss
contact
inhibition
taken
together
characteristic
feature
indicative
malignant
potential
role
prb
pathway
cell
cycle
regulation
well
establish
hence
study
expression
protein
involve
pathway
interestingly
observe
loss
important
target
protein
cell
cycle
regulatory
pathway
namely
prb
increase
expression
cyclin
cell
suggestive
deregulated
prb
cyclin
pathway
may
give
growth
advantage
cell
cell
show
defect
one
component
pathway
loss
prb
nevertheless
result
suggest
deregulation
prb
pathway
might
account
least
contribute
loss
growth
control
thereby
lead
neoplastic
transformation
two
cell
line
key
tumour
suppressor
gene
involve
regulation
many
cellular
pathway
cell
cycle
regulation
dna
damage
repair
mutate
many
cancer
include
breast
cancer
therefore
additionally
analyse
mutation
establish
cell
line
sequencing
exon
cell
reveal
cell
line
harbour
wild
type
sequence
exon
bear
majority
mutation
mutation
exist
gene
may
lie
outside
region
furthermore
undetectable
protein
expression
immunocytochemistry
expression
protein
downstream
target
suggestive
existence
wild
type
functionality
pathway
cell
cell
line
show
detectable
expression
nucleus
however
cytoplasmic
accumulation
observe
consistent
characteristic
negative
breast
cancer
cell
review
furthermore
cell
line
show
cytoplasmic
localisation
protein
protein
nucleus
cell
reduce
nuclear
expression
cell
implicate
defect
dna
repair
pathway
may
eventually
lead
accumulation
genetic
defect
cell
overexpression
cytoplasmic
mediate
cytoplasmic
sequestration
breast
cancer
furthermore
aberrant
expression
breast
ovarian
cancer
correlated
poor
prognosis
whether
involve
cytoplasmic
sequestration
protein
cell
remain
determine
dna
methylation
pattern
mammalian
cell
establish
embryogenesis
alter
upon
differentiation
somatic
cell
however
methylation
pattern
alter
cancer
cell
thus
cpg
repeat
hypermethylation
cpg
island
common
phenomenon
occur
much
cancer
jones
dna
methylation
family
protein
call
dna
methyltransferases
dnmts
maintenance
enzyme
prefer
substrate
may
responsible
establish
methylation
pattern
template
dependent
manner
dna
replication
consider
novo
methyltransferases
based
ability
modify
totally
unmethylated
dna
vitro
expression
dnmts
alter
different
human
cancer
marzo
girault
lee
lin
mizuno
robertson
compare
expression
dnmts
breast
cancer
cell
line
indian
origin
transcript
level
three
dnmts
cancer
cell
line
comparable
malignant
cell
line
high
compare
cell
line
much
observe
substantially
overexpressed
malignant
cell
line
compare
line
increased
expression
protein
different
breast
cancer
cell
line
also
report
additionally
notice
increase
level
dnmts
particularly
breast
tumour
specimen
parallel
study
observe
high
ratio
associate
high
methylation
index
cell
line
unpublished
datum
culture
describe
present
work
show
high
ratio
result
far
suggest
deregulation
epigenetic
pathway
cell
similar
cancer
cell
line
promoter
hypermethylation
occur
frequently
breast
cancer
cell
mammary
epithelial
cell
detailed
analysis
promoter
reveal
presence
several
consensus
binding
site
protein
responsive
expression
significantly
reduce
high
proportion
primary
breast
carcinoma
attributable
aberrant
methylation
promoter
limit
basal
expression
mrna
epigenetic
silence
thus
represent
novel
important
mechanism
signal
attenuate
breast
cancer
hence
specifically
analyse
promoter
hypermethylation
gene
cell
promoter
hypermethylation
gene
find
cell
suggest
firstly
involvement
promoter
hypermethylation
mediate
silence
gene
neoplastic
transformation
cell
secondly
support
neoplastic
origin
cell
line
however
promoter
hypermethylation
detect
cell
compatible
detection
protein
via
immunohistochemistry
suggest
culturing
cell
loss
may
extremely
difficult
part
may
explain
absence
promoter
methylation
cell
line
however
methylation
observe
sporadic
breast
tumour
parallel
study
primary
breast
tumour
author
laboratory
datum
show
expression
may
essential
survival
cell
hence
promoter
unmethylated
breast
cancer
cell
line
furthermore
disruption
homologous
mouse
gene
targeting
show
embryo
become
die
early
development
suggest
gene
indispensable
embryogenesis
methylation
observe
either
cell
line
establish
present
study
parallel
study
author
laboratory
methylation
observe
establish
breast
cancer
cell
line
similar
observe
present
study
conclusion
report
establishment
characterisation
two
cell
line
will
serve
vitro
model
understanding
mechanism
underlie
familial
sporadic
breast
carcinogenesis
cell
line
also
provide
model
design
test
new
drug
large
proportion
breast
tumour
negative
neu
require
novel
drug
effective
management
acknowledgement
author
express
staff
electron
microscope
facility
india
institute
medical
science
support
help
conduct
ultrastructural
analysis
grateful
lisa
germany
expert
advice
suggestion
prepare
manuscript
study
support
grant
indian
council
medical
research
new
delhi
india
germany
council
scientific
industrial
research
award
research
fellowship
senior
research
fellowship
endocrine
therapy
mainstay
treatment
patient
hormone
early
advance
breast
cancer
letrozole
femara
novartis
pharmaceutical
east
nj
aromatase
inhibitor
show
superior
efficacy
tamoxifen
early
adjuvant
endocrine
therapy
advance
breast
furthermore
letrozole
superior
placebo
give
extend
adjuvant
treatment
follow
year
widespread
aromatase
inhibitor
initial
acquire
resistance
agent
pose
major
clinical
problem
research
mechanism
resistance
show
various
signal
transduction
pathway
activate
breast
cancer
cell
escape
effect
endocrine
therapy
example
activation
kinase
mtor
pathway
key
adaptive
change
drive
endocrine
mammalian
target
rapamycin
mtor
inhibition
restore
responsiveness
tamoxifen
breast
cancer
cell
constitutively
express
akt
effect
occur
partly
blockade
oestrogen
receptor
mediate
role
mtor
breast
cancer
proliferation
suggest
combine
aromatase
inhibitor
mtor
inhibitor
beneficial
patient
tumour
orally
bioavailable
inhibitor
mtor
pathway
effect
cancer
cell
include
reduce
growth
proliferation
inhibition
protein
translation
vascular
endothelial
growth
factor
vegf
consistent
activity
inhibitor
mtor
particularly
active
tumour
cell
high
level
active
form
akt
namely
associate
much
aggressive
tumour
cell
growth
early
clinical
study
alone
characterised
pharmacokinetic
pk
show
much
adverse
event
ae
mild
moderate
severity
toxicity
dlt
grade
stomatitis
fatigue
neutropaenia
molecular
pharmacodynamic
study
advance
cancer
patient
treatment
show
complete
target
inhibition
dose
mg
day
dose
well
tolerate
produce
blood
level
comparable
effect
demonstrate
treatment
aro
breast
cancer
cell
letrozole
inhibit
modulation
mtor
pathway
letrozole
also
inhibit
proliferation
effect
significantly
enhance
agent
combine
combination
treatment
associate
profound
disruption
cell
cycle
progression
reduce
cell
viability
increase
apoptosis
similar
effect
combination
cell
proliferation
survival
also
observe
aro
breast
cancer
primary
objective
phase
ib
study
report
investigate
safety
potential
pk
interaction
associate
combination
mg
day
letrozole
mg
day
patient
advance
breast
cancer
secondary
objective
find
evidence
activity
patient
objective
response
letrozole
alone
patient
method
phase
ib
trial
sequential
cohort
define
dose
combine
register
dose
letrozole
mg
day
mg
day
previously
identify
optimal
biologically
active
dose
dose
escalation
plan
stop
feasibility
combine
mg
day
letrozole
establish
even
maximum
tolerate
dose
reach
toxicity
assess
national
cancer
institute
common
terminology
criteria
adverse
version
dlt
define
grade
toxicity
occur
within
first
day
suspect
relate
study
drug
exception
grade
hypercholesterolaemia
hypertriglyceridaemia
lead
treatment
interruption
week
duration
first
cohort
patient
receive
mg
day
absence
dlt
second
cohort
receive
mg
day
much
patient
experience
dlt
additional
recruit
expand
cohort
patient
estimate
probability
detect
ae
occur
individual
ae
occur
patient
remain
combination
treatment
long
progression
free
absence
unacceptable
toxicity
reason
investigator
patient
opinion
require
termination
participation
protocol
approve
local
ethic
committee
patient
sign
inform
consent
form
study
inclusion
patient
inclusion
exclusion
criterion
eligible
patient
postmenopausal
woman
man
year
histologically
confirm
metastatic
recurrent
advance
breast
cancer
receive
endocrine
therapy
letrozole
mg
day
month
without
objective
response
stable
progressive
disease
exclude
patient
bulky
symptomatic
disease
consider
urgent
indication
chemotherapy
inclusion
requirement
life
expectancy
month
world
health
organization
performance
status
hypercholesterolaemia
hypertriglyceridaemia
grade
drug
permit
adequate
bone
marrow
function
absolute
neutrophil
count
platelet
dl
normal
liver
renal
function
serum
albumin
within
reference
range
serum
bilirubin
upper
limit
normal
uln
serum
uln
serum
creatinine
mol
creatinine
clearance
ml
min
formula
exclusion
criterion
include
treatment
strong
inhibitor
inducer
know
central
nervous
system
metastases
uncontrolled
infection
know
human
virus
infection
anticoagulant
medication
antineoplastic
therapy
within
week
radiation
therapy
within
week
surgery
within
week
prior
study
individual
active
bleeding
also
exclude
patient
concurrent
severe
uncontrolled
medical
disease
diabetes
hypertension
congestive
heart
failure
ventricular
arrhythmias
active
heart
disease
myocardial
infarction
within
month
chronic
liver
renal
disease
active
ulceration
upper
gastrointestinal
gi
tract
impairment
gi
function
gi
disease
might
significantly
alter
absorption
ineligible
laboratory
examination
safety
assessment
laboratory
examination
vital
sign
physical
examination
perform
locally
accord
schedule
visit
include
analysis
blood
chemistry
standard
method
performance
status
assess
standard
scale
abnormal
laboratory
value
record
ae
associate
clinical
sign
symptom
require
therapy
report
ae
serious
ae
record
follow
serious
ae
follow
day
treatment
discontinuation
pharmacokinetic
assessment
pk
parameter
derived
concentration
time
datum
standard
analysis
method
include
peak
concentration
cmax
time
reach
cmax
tmax
trough
concentration
cmin
area
curve
dose
interval
auclast
letrozole
measure
plasma
automate
extraction
liquid
chromatography
fluorescence
detection
blood
ml
freeze
within
min
collection
sample
process
automate
extraction
liquid
chromatography
fluorescence
detection
calibration
range
nmol
limit
letrozole
quantification
nmol
ml
plasma
blood
concentration
determine
liquid
liquid
extraction
follow
liquid
chromatography
mass
edta
blood
ml
store
within
min
collection
limit
quantification
ml
blood
sample
take
pk
profile
letrozole
steady
state
day
immediately
thereafter
day
prior
administration
baseline
pk
profile
letrozole
alone
obtain
baseline
obtain
interruption
letrozole
adequate
washout
consider
pk
datum
patient
advance
cancer
obtain
another
phase
study
mg
day
single
blood
sample
collect
day
determination
letrozole
trough
level
efficacy
assessment
tumour
response
assess
every
month
standard
radiography
compute
tomography
magnetic
resonance
imaging
clinical
examination
accord
response
evaluation
criteria
solid
tumor
recist
statistical
analysis
data
analyse
based
analysis
descriptive
statistic
patient
datum
laboratory
value
effect
letrozole
pk
vice
versa
assess
result
eighteen
eligible
caucasian
patient
female
male
median
age
year
range
breast
cancer
metastases
bone
lung
liver
kidney
superficial
lymph
node
skin
enrolled
five
patient
performance
status
status
patient
receive
letrozole
study
entry
thirteen
patient
also
receive
chemotherapy
mg
day
cohort
mg
day
cohort
patient
receive
least
one
dose
study
medication
seven
patient
remain
therapy
month
receive
study
medication
year
patient
mg
day
cohort
patient
mg
day
cohort
table
key
demographic
background
characteristic
treatment
group
mg
mg
day
total
number
patient
median
age
range
performance
status
prior
antineoplastic
therapy
hormonal
therapy
totalb
letrozole
tamoxifen
chemotherapy
totalb
adjuvant
metastatic
time
since
diagnosis
localisation
target
lesion
lung
without
mediastinum
superficial
lymph
table
one
patient
withdraw
consent
prior
end
period
patient
hormonal
therapy
chemotherapy
indication
count
total
patient
several
localisation
count
localisation
view
within
article
safety
result
combination
well
tolerate
dose
level
detailed
safety
result
appear
table
table
one
patient
mg
day
cohort
experience
dlt
grade
thrombocytopaenia
grade
neutropaenia
recover
within
week
letrozole
interruption
four
much
frequent
ae
stomatitis
grade
patient
mg
day
cohort
patient
mg
day
cohort
fatigue
patient
mg
day
cohort
patient
mg
day
cohort
diarrhoea
patient
mg
day
cohort
anorexia
decrease
appetite
patient
mg
day
concomitant
gi
disturbance
diarrhoea
bowel
syndrome
gi
infection
consider
relate
study
drug
thrombocytopaenia
grade
occur
patient
receive
mg
day
patient
receive
mg
day
patient
platelet
count
return
normal
level
despite
ongoing
treatment
grade
neutropaenia
observe
patient
receive
either
cohort
grade
neutropaenia
observe
patient
receive
mg
day
grade
neutropaenia
observe
patient
receive
mg
day
also
experience
grade
thrombocytopaenia
increase
hepatic
enzyme
common
grade
elevation
alkaline
phosphatase
patient
grade
increase
enzyme
occur
patient
respectively
bilirubin
level
remain
within
normal
range
patient
table
key
study
parameter
mg
mg
day
total
number
patient
exposure
median
duration
range
due
adverse
event
ae
disease
ae
total
total
ae
grade
total
ae
dose
adjustment
total
serious
total
serious
ae
suspect
relation
study
table
grade
ae
occur
study
grade
ae
mg
day
cohort
peripheral
oedema
mass
right
breast
patient
grade
ae
mg
day
cohort
fatigue
patient
thrombocytopaenia
neutropaenia
patient
anorexia
diarrhoea
patient
view
within
article
table
adverse
event
ae
patient
letrozole
treatment
group
patient
patient
mg
day
mg
day
ae
total
number
patient
anorexia
decrease
oedema
dry
bone
dry
weight
table
one
grade
ae
two
grade
ae
grade
ae
view
within
article
amongst
patient
receive
mg
day
discontinue
disease
progression
suspect
ae
see
table
patient
develop
grade
oedema
experience
chronic
hepatitis
enrollment
patient
study
note
protocol
violation
much
common
ae
mg
day
cohort
stomatitis
fatigue
nausea
see
table
amongst
patient
give
mg
day
discontinue
treatment
disease
progression
withdraw
consent
discontinue
suspect
ae
grade
bone
pain
experience
recurrent
general
weakness
see
table
much
common
ae
report
mg
day
cohort
anorexia
decrease
appetite
diarrhoea
stomatitis
fatigue
headache
peripheral
oedema
dry
skin
see
table
patient
mg
day
cohort
reduce
mg
day
ae
either
follow
interruption
patient
stomatitis
general
weakness
thrombocytopaenia
without
interruption
patient
stomatitis
pharmacokinetic
evaluation
thirteen
patient
provide
blood
sample
pk
analysis
evaluable
letrozole
pk
evaluable
pk
data
pk
take
patient
advance
cancer
involve
another
unpublished
phase
study
receive
mg
day
monotherapy
pk
letrozole
change
presence
see
table
ratio
patient
range
cmax
auclast
pk
presence
letrozole
generally
comparable
absence
letrozole
see
table
significant
alteration
plasma
whole
blood
level
letrozole
respectively
observe
agent
table
letrozole
pharmacokinetic
parameter
mg
mg
letrozole
tmax
cmax
nmol
cmin
nmol
auclast
nmol
mg
day
mg
day
mg
day
tmax
cmax
ml
cmin
ml
auclast
ml
table
applicable
value
mean
standard
deviation
except
tmax
median
range
view
within
article
image
mean
letrozole
plasma
concentration
nmol
standard
deviation
patient
letrozole
mg
day
alone
mg
mean
whole
blood
concentration
ml
standard
deviation
patient
mg
day
alone
letrozole
mg
day
datum
obtain
previous
study
view
within
article
efficacy
evaluation
much
patient
good
response
letrozole
report
stable
disease
good
response
combine
treatment
letrozole
evaluate
patient
one
patient
lesion
skin
sole
site
disease
receive
mg
day
experience
complete
response
month
duration
disease
progress
letrozole
monotherapy
seven
month
mg
day
add
complete
response
observe
patient
treat
letrozole
week
addition
mg
day
table
disease
status
letrozole
alone
good
response
combine
treatment
letrozole
patient
mg
day
mg
day
disease
status
letrozole
alone
duration
letrozole
alone
median
range
best
response
letrozole
alone
stable
progressive
best
response
combine
treatment
overall
response
cr
pr
complete
response
duration
partial
response
stable
disease
stable
disease
duration
progressive
disease
unknown
table
cr
complete
response
pr
partial
response
patient
little
month
letrozole
therapy
inclusion
patient
mg
cohort
month
mg
cohort
month
respectively
time
first
confirm
cr
progression
including
patient
reduction
liver
metastasis
time
first
treatment
progression
three
patient
classify
unknown
tumour
assessment
report
discontinuation
stable
disease
report
day
minimum
week
require
classify
good
response
stable
disease
reach
view
within
article
partial
response
observe
one
patient
receive
mg
day
reduction
liver
metastases
just
short
recist
definition
partial
response
reduction
reduction
observe
day
first
dose
patient
meet
recist
criterion
stable
disease
month
patient
receive
letrozole
year
prior
study
liver
metastases
enlarge
month
period
letrozole
monotherapy
without
meet
criterion
progressive
disease
addition
prolong
stable
disease
month
study
entry
observe
patient
receive
mg
day
patient
receive
mg
day
see
table
discussion
result
phase
ib
study
indicate
combination
daily
oral
dose
novel
mtor
inhibitor
aromatase
inhibitor
letrozole
involve
pk
interaction
overall
tolerability
combination
satisfactory
patient
discontinue
ae
safety
profile
combination
generally
consistent
observe
monotherapy
publish
safety
datum
temsirolimus
another
mtor
inhibitor
monotherapy
advance
breast
cancer
much
thrombocytopaenia
neutropaenia
event
occur
within
week
treatment
subsequent
study
combination
therefore
include
blood
count
day
patient
experience
toxicity
need
stop
treatment
patient
mg
day
cohort
dose
interrupt
adjust
ae
continue
month
reduce
dose
mg
day
dose
reduction
delay
algorithm
will
include
subsequent
study
combination
therapy
aim
develop
recommendation
management
toxicity
amongst
patient
experience
toxicity
lead
dose
reduction
interruption
within
first
week
combination
treatment
frequently
feasible
prolong
time
period
patient
treat
combination
month
treat
month
study
result
suggest
combination
letrozole
activity
one
complete
response
month
one
near
partial
response
month
mg
day
cohort
based
clinical
finding
study
oral
dose
mg
day
combination
letrozole
recommend
far
trial
dose
identify
provide
complete
target
inhibition
initial
model
subsequent
molecular
pathology
study
tumour
treat
future
challenge
will
identify
patient
much
likely
benefit
combination
letrozole
letrozole
aromatase
inhibitor
know
excellent
tolerability
mtor
inhibitor
aromatase
inhibitor
add
side
effect
particularly
mucositis
also
fatigue
skin
gi
ae
result
phase
iii
trial
mtor
inhibitor
temsirolimus
administer
oral
dose
mg
day
day
every
week
combine
letrozole
comparison
letrozole
alone
recently
unselected
population
postmenopausal
woman
advance
breast
cancer
combination
temsirolimus
letrozole
improve
survival
finding
illustrate
need
investigate
way
distinguish
patient
benefit
addition
mtor
inhibitor
subsequent
clinical
development
accept
complexity
correlative
study
help
identify
predictive
biomarker
randomised
phase
ii
study
ongoing
compare
efficacy
letrozole
monotherapy
combination
letrozole
mg
day
neoadjuvant
breast
cancer
treatment
tumour
biopsy
perform
baseline
day
month
treatment
major
study
objective
assess
whether
molecular
characteristic
tumour
predict
benefit
combination
therapy
identify
molecular
marker
may
serve
patient
selection
parameter
phase
iii
development
amongst
marker
directly
reflect
mtor
inhibition
associate
mtor
activation
kinase
mutation
cyclin
will
analyse
study
establish
feasibility
combine
letrozole
pk
interaction
observe
safety
profile
appear
satisfactory
side
effect
compromise
tolerability
characteristic
class
drug
similar
targeted
therapy
manageable
acceptable
oral
therapy
sufficiently
benefit
patient
daily
dose
oral
mg
day
recommend
far
study
combination
letrozole
combination
dose
level
signal
suggestive
activity
see
patient
achieve
objective
response
letrozole
alone
development
combination
focus
identify
predictive
biomarker
allow
selection
patient
benefit
novel
treatment
approach
conflict
interest
statement
jutta
steinseifer
chiaki
tanaka
ulrike
zoellner
tang
employee
novartis
pharma
belgian
jutta
steinseifer
chiaki
tanaka
ulrike
zoellner
stock
novartis
pharma
luc
receive
research
funding
novartis
pharma
study
piccart
receive
honorarium
novartis
pharma
conflict
interest
report
acknowledgement
study
support
novartis
pharma
author
acknowledge
assistance
preparation
clinical
study
report
richard
edit
manuscript
current
treatment
breast
cancer
early
surgery
systemic
hormone
therapy
chemotherapy
reduce
risk
death
although
much
recently
aromatase
inhibitor
inhibit
oestrogen
receptor
breast
cancer
tumour
largely
unresponsive
hormonal
novel
promising
agent
prevent
breast
cancer
recurrence
growth
factor
receptor
tyrosine
kinase
include
epidermal
growth
factor
receptor
egfr
inhibitor
although
good
tolerability
potential
synergy
treatment
largely
demonstrate
disease
minor
response
clinical
trial
unselected
breast
cancer
adrenergic
receptor
bind
catecholamines
epinephrine
regulate
vascular
tone
cardiac
adrenergic
receptor
antagonist
include
prazosin
doxazosin
terazosin
therapy
additionally
extensive
vitro
vivo
study
demonstrate
doxazosin
terazosin
induce
prostate
cancer
propose
mechanism
include
action
via
induction
reduce
focal
adhesion
based
prior
study
prostate
cancer
study
inhibition
vitro
pituitary
tumour
proliferation
seek
test
effect
far
elucidate
mechanism
doxazosin
action
breast
cancer
cell
study
demonstrate
doxazosin
dox
treatment
inhibit
proliferation
induce
apoptosis
breast
cancer
cell
action
largely
independent
adrenergic
receptor
expression
result
reduce
inhibition
signal
additionally
doxazosin
egfr
iressa
synergistically
induce
increase
apoptosis
breast
cancer
cell
material
cell
culture
human
breast
cancer
cell
normal
breast
cell
cultured
accord
american
type
culture
collection
rockville
md
usa
recommendation
pcr
adrenergic
receptor
cell
proliferation
assay
cell
cycle
analysis
pcr
receptor
perform
previously
cell
proliferation
measure
mts
assay
promega
madison
usa
cell
cycle
analysis
carry
facscan
becton
dickinson
nj
usa
cell
treat
either
doxazosin
dox
vehicle
dmso
transfection
apoptosis
assay
egfr
signal
experiment
separate
aliquot
cell
first
dominant
gifted
jeffery
kudlow
gifted
eduardo
arzt
transfectant
cell
treat
vehicle
ml
egf
ml
tnf
alone
combination
dox
oestrogen
experiment
cell
cultured
dmem
supplement
charcoal
strip
serum
css
cell
aliquot
treat
dox
vehicle
either
css
medium
css
plus
nm
estradiol
cell
wash
incubate
propidium
iodide
annexin
antibody
pharmingen
san
diego
usa
prior
flow
cytometric
analysis
quantify
apoptotic
western
blot
analysis
treated
cell
lysed
ripa
buffer
protein
electrophoresed
immunoblotted
standard
technique
antibody
cleave
total
egfr
santa
cruz
biotechnology
usa
phosphorylated
cell
beverly
ma
egfr
phosphorylation
study
egfr
immunoprecipitated
antibody
transduction
laboratory
bind
protein
agarose
prior
application
gel
vitro
sre
cre
transcriptional
activity
mda
breast
cancer
cell
transiently
transfected
cre
sre
luciferase
plasmid
laboratory
inc
negative
control
treat
either
dox
vehicle
luciferase
activity
determine
statistical
analysis
experiment
perform
triplicate
three
separate
experiment
analyse
anova
kruskal
wallis
dunn
multiple
comparison
test
test
value
consider
significant
adrenergic
receptor
antagonist
doxazosin
inhibit
human
breast
cancer
proliferation
first
set
experiment
investigate
breast
cancer
cell
proliferation
follow
doxazosin
treatment
depict
inhibit
breast
cancer
proliferation
manner
proliferation
inhibit
dox
proliferative
rate
far
inhibit
likewise
cell
inhibit
proliferation
increase
image
doxazosin
dox
treatment
breast
cancer
cell
inhibit
breast
cancer
cell
proliferation
lead
decrease
cell
population
decrease
prb
expression
vehicle
dox
doxazosin
prb
phosphorylated
retinoblastoma
protein
view
within
article
lead
cell
cycle
arrest
insight
mechanism
inhibition
proliferation
next
perform
cell
cycle
analysis
breast
cancer
cell
result
fold
increase
cell
doxazosin
dose
high
datum
show
along
decrease
cell
population
western
blot
analysis
cell
reveal
decrease
phosphorylated
retinoblastoma
prb
protein
expression
provide
potential
mechanism
cell
cycle
arrest
doxazosin
induce
breast
cancer
apoptosis
vitro
next
investigate
effect
breast
cancer
cell
apoptosis
following
facs
demonstrate
fold
increase
positive
apoptotic
cell
contrast
significant
increase
apoptosis
evident
normal
breast
epithelial
cell
previous
study
report
differential
effect
dox
positive
negative
prostate
cancer
cell
examine
apoptosis
express
cell
incubate
either
charcoal
strip
serum
css
alone
css
plus
nm
estradiol
higher
apoptotic
rate
demonstrate
cell
css
medium
alone
compare
css
dox
cell
also
result
fold
increase
apoptosis
additionally
western
blot
analysis
reveal
fold
increase
mda
cleave
expression
implicate
breast
cancer
cell
apoptosis
image
increase
breast
cancer
cell
apoptotic
rate
comparison
normal
breast
cell
apoptosis
much
mark
express
cell
also
evident
negative
cell
associate
increase
cleave
expression
vehicle
dox
doxazosin
view
within
article
action
independent
adrenergic
receptor
doxazosin
action
due
ability
bind
adrenergic
receptor
mechanism
action
cancer
cell
well
understand
elucidate
issue
adrenergic
receptor
mrna
expression
examine
breast
cancer
cell
line
mrna
expression
demonstrate
mda
cell
detectable
cell
suggest
doxazosin
induce
effect
entirely
dependent
adrenergic
receptor
expression
additionally
express
mda
cell
doxazosin
block
dose
irreversible
receptor
antagonist
phenoxybenzamine
abrogate
action
doxazosin
image
demonstrate
receptor
expression
mda
cell
line
expression
absent
cell
apoptosis
abrogate
breast
cancer
cell
antagonist
vehicle
phenoxybenzamine
dox
doxazosin
rna
serve
internal
control
view
within
article
doxazosin
reduce
egfr
phosphorylation
inhibit
map
kinase
signal
doxazosin
structure
similar
egfr
tyrosine
kinase
inhibitor
iressa
potential
interaction
doxazosin
via
egfr
breast
cancer
cell
alone
significantly
alter
apoptotic
rate
contrast
doxazosin
treatment
alone
result
fold
increase
apoptosis
combination
treatment
result
fold
increase
apoptosis
compare
apoptotic
rate
mda
cell
suggest
synergistic
action
drug
next
examine
total
phosphorylated
perk
expression
western
blot
cell
epidermal
growth
factor
egf
treatment
expect
egf
treatment
ml
min
expression
mean
sem
fold
lane
intriguingly
min
inhibit
breast
cancer
perk
expression
lane
min
also
potently
inhibit
expression
lane
unexpectedly
doxazosin
min
plus
iressa
min
result
far
decrease
level
breast
cancer
cell
lane
image
induce
breast
cancer
cell
apoptosis
whereas
iressa
alone
alter
apoptotic
rate
iressa
far
increase
apoptosis
compare
doxazosin
doxazosin
inhibit
lane
breast
cancer
expression
compare
egf
alone
lane
partially
inhibit
lane
combination
far
decrease
perk
level
lane
induce
phosphorylated
egfr
expression
lane
inhibit
iressa
lane
dox
treatment
also
inhibit
expression
lane
vehicle
view
within
article
give
finding
next
examine
activate
egfr
expression
predict
ml
min
lead
fold
increase
breast
cancer
level
lane
compare
vehicle
treatment
completely
inhibit
iressa
treatment
min
lane
however
doxazosin
treatment
alone
min
also
decrease
egf
induce
phosphorylated
egfr
level
mda
cell
lane
suggest
like
iressa
doxazosin
act
inhibit
breast
cancer
egfr
activation
doxazosin
inhibit
transcription
activity
characterise
action
signal
transduction
transiently
transfected
activator
protein
element
sre
element
cre
luciferase
reporter
plasmid
breast
cancer
cell
treat
transfectant
dox
vehicle
determine
luciferase
activity
lead
fold
fold
fold
fold
decrease
sre
cre
promoter
luciferase
activity
respectively
mda
breast
cancer
cell
transfectant
compare
vehicle
treatment
demonstrate
inhibit
image
change
mapk
breast
cancer
cell
follow
cell
transiently
transfected
cre
sre
promoter
reporter
construct
phosphorylated
expression
follow
vehicle
dox
doxazosin
view
within
article
doxazosin
inhibit
transcription
show
reduce
phosphorylated
inhibitor
kappa
kinase
ikk
level
dox
inhibit
transcriptional
target
sre
cre
breast
cancer
cell
examine
baseline
stimulate
phosphorylated
kinase
level
dox
treatment
expect
tnf
ml
min
induce
phosphorylated
expression
fold
lane
whereas
min
decrease
constitutive
breast
cancer
expression
lane
abrogate
tnf
induce
kinase
level
lane
suggest
also
transcriptional
target
doxazosin
combination
egf
tnf
require
block
breast
cancer
apoptosis
characterise
contribution
signal
apoptosis
transiently
transfected
mutant
dominant
negative
construct
breast
cancer
cell
examine
apoptotic
rate
baseline
follow
vehicle
treatment
follow
egf
ml
tnf
ml
mediate
respectively
depict
transfection
gene
mda
cell
alter
base
line
apoptotic
rate
breast
cancer
cell
group
although
expression
increase
breast
cancer
cell
sensitivity
apoptosis
group
ml
group
egf
ml
group
treatment
alone
combination
ml
egf
ml
group
alter
baseline
apoptotic
rate
breast
cancer
cell
furthermore
express
breast
cancer
cell
egf
alone
plus
doxazosin
totally
abrogate
breast
cancer
apoptotic
rate
although
apoptotic
rate
treat
express
cell
cell
vehicle
treat
group
egf
block
apoptosis
express
cell
group
indicate
breast
cancer
apoptosis
involve
signal
similar
result
see
parallel
experiment
cell
datum
show
image
change
breast
cancer
apoptosis
follow
transient
expression
construct
presence
absence
dominant
negative
egfr
dominant
negative
vehicle
dox
doxazosin
view
within
article
discussion
effectively
reduce
oestrogen
receptor
breast
cancer
recurrence
additional
agent
prevent
breast
cancer
urgently
several
previous
study
report
clinically
approve
dose
antagonist
doxazosin
terazosin
inhibit
proliferation
induce
apoptosis
prostate
cancer
cell
clear
concept
far
pursue
human
clinical
extend
finding
demonstrate
doxazosin
inhibit
human
breast
cancer
cell
proliferation
potently
increase
apoptosis
vitro
breast
cancer
cell
via
multiple
mechanism
entirely
mediate
via
alpha
prostate
cancer
study
doxazosin
terazosin
treatment
appear
primarily
induce
apoptosis
lesser
effect
prostate
cancer
cell
proliferation
different
response
describe
androgen
receptor
expression
compare
prostate
cancer
based
observe
reduce
population
decrease
prb
expression
significantly
inhibit
breast
cancer
cell
proliferation
addition
potently
induce
apoptosis
effect
much
pronounce
breast
cancer
cell
compare
normal
breast
epithelial
cell
much
mark
absence
oestrogen
cell
unexpectedly
effect
observe
breast
cancer
cell
exhibit
significant
expression
blockade
abrogate
effect
suggest
apoptotic
action
entirely
mediate
via
receptor
demonstrate
reduce
phosphorylated
egfr
phosphorylated
erk
level
inhibit
signal
transduction
doxazosin
iressa
action
overlap
increase
breast
cancer
apoptotic
rate
compare
either
drug
alone
however
inactivation
totally
abrogate
breast
cancer
apoptosis
additional
study
demonstrate
also
reduce
constitutive
breast
cancer
level
however
blockade
nfb
signal
alone
totally
abrogate
breast
cancer
apoptosis
require
inhibit
effect
doxazosin
speculate
different
apoptotic
response
cancer
versus
normal
cell
may
due
great
activation
signal
pathway
breast
cancer
versus
normal
breast
cell
give
multiple
mechanism
action
inhibit
action
well
establish
safety
profile
comparatively
cost
clinically
approve
doxazosin
dose
may
ultimately
offer
novel
therapeutic
option
positive
negative
breast
cancer
patient
however
far
vivo
breast
cancer
study
now
necessary
way
clinical
trial
doxazosin
therapy
patient
breast
cancer
conflict
interest
statement
none
declare
acknowledgement
thank
jeffery
kudlow
eduardo
arzt
kind
donation
mutant
egfr
plasmid
respectively
work
support
foundation
seed
grant
margaret
early
foundation
research
institute
recent
decade
breast
cancer
become
highly
visible
disease
united
state
pink
ribbon
symbolize
breast
cancer
event
raise
money
breast
cancer
research
ubiquitous
part
cultural
represent
dramatic
previously
attach
breast
cancer
king
leopold
sontag
instead
succumb
shameful
disease
woman
breast
cancer
today
openly
honored
survivor
intuitively
make
sense
cultural
image
breast
cancer
will
shape
experience
woman
disease
fact
breast
cancer
culture
imply
woman
disease
readily
embrace
identity
survivor
however
study
examine
change
cultural
representation
breast
cancer
black
brown
fosket
king
klawiter
leopold
patterson
sontag
murray
researcher
empirically
consider
new
survivor
identity
shape
disease
experience
woman
breast
cancer
article
consider
extent
woman
embrace
survivor
identity
follow
breast
cancer
treatment
begin
overview
dominant
representation
breast
cancer
survivor
criticism
representation
summarize
two
complementary
approach
understanding
construction
breast
cancer
affect
woman
first
approach
posit
survivorship
tool
woman
frame
disease
experience
swidler
swidler
according
second
approach
survivorship
craftwork
whereby
woman
construct
life
meaning
cancer
describe
research
method
provide
datum
interview
woman
united
state
recently
complete
treatment
breast
cancer
datum
present
number
woman
embrace
survivor
identity
woman
craft
new
meaning
survivorship
additionally
woman
explicitly
reject
label
fail
account
possibility
recurrence
heroic
public
identity
discuss
implication
finding
woman
breast
cancer
sociology
health
illness
breast
cancer
survivor
dominant
image
survivor
term
survivor
enter
cancer
discourse
mullan
describe
cancer
experience
new
england
journal
medicine
article
survival
mullan
mullan
later
establish
national
cancer
survivorship
nccs
work
shift
perception
cancer
patient
victim
survivor
formally
define
survivor
time
diagnosis
balance
life
nccs
word
survivor
arguably
much
often
associate
breast
cancer
breast
cancer
survivor
much
often
represent
happy
healthy
feminine
batt
king
breast
cancer
medical
treatment
now
hold
place
honor
cancer
world
ehrenreich
klawiter
image
consistent
positive
tone
characteristic
early
campaign
united
state
batt
patterson
also
reflect
history
breast
cancer
movement
subsequent
corporate
interest
breast
cancer
breast
cancer
movement
consist
large
diverse
group
woman
include
feminist
seek
radical
change
woman
simply
want
greater
medical
investment
disease
many
movement
ultimately
secure
widespread
support
portray
breast
cancer
patient
survivor
deserving
mother
work
within
medicine
demand
great
research
cancer
treatment
medical
cure
breast
cancer
kaufert
king
short
goal
reform
movement
become
ehrenreich
king
within
framework
breast
cancer
survivor
represent
power
medicine
beat
breast
cancer
return
woman
fulfil
life
federal
funding
breast
cancer
research
million
dollar
million
influx
money
seen
cancer
king
breast
cancer
continue
portray
medicalized
disease
approach
fear
optimism
breast
cancer
survivor
take
center
stage
image
breast
cancer
patient
feminine
deserving
medical
cure
make
breast
cancer
perfect
charity
associate
product
breast
cancer
fundraising
relate
company
build
brand
secure
brand
differentiate
brand
without
cut
price
innovative
company
countless
adopt
breast
cancer
lead
influx
symbol
breast
cancer
market
ehrenreich
king
number
product
corporation
contribution
breast
cancer
grow
large
organization
breast
cancer
action
launch
think
pink
campaign
think
pink
consumer
learn
much
little
money
purchase
go
breast
cancer
breast
cancer
action
king
breast
cancer
corporate
federal
support
breast
cancer
survivor
take
center
stage
breast
cancer
run
walk
around
country
forefront
physical
activity
susan
komen
race
cure
race
cure
km
run
walk
raise
fund
awareness
breast
cancer
first
take
place
texas
race
expand
location
united
state
well
one
million
participant
year
race
survivor
pink
honored
special
survivor
king
klawiter
race
message
advance
treatment
ensure
cancer
detect
early
will
cure
according
klawiter
survivor
race
honored
fight
breast
cancer
willingness
demonstrate
woman
rejection
cultural
code
silence
breast
cancer
shameful
neither
disfigure
notably
mastectomy
scar
disfigure
body
hide
race
prostheses
cosmetic
company
race
breast
cancer
walk
encourage
woman
project
image
alternative
image
criticism
survivorship
alternative
construction
life
breast
cancer
dominant
image
survivorship
example
woman
reject
title
survivor
favor
breast
cancer
choose
conceal
effect
cancer
model
matuschka
mastectomy
scar
cover
new
york
time
magazine
next
look
away
according
matuschka
keep
quiet
cancer
woman
body
refuse
accept
woman
body
whatever
condition
lorde
choose
wear
prosthesis
follow
mastectomy
battle
right
define
present
body
way
account
breast
cancer
lorde
william
serve
place
woman
express
pain
fear
disclose
reality
breast
cancer
kaufert
leopold
potts
alternative
dominant
survivor
image
exist
level
well
area
women
cancer
walk
show
woman
body
follow
mastectomy
without
prostheses
color
black
instead
pink
welcome
discussion
death
display
anger
toxic
cancer
industry
attack
industry
produce
carcinogen
embrace
term
cancer
victim
emphasize
woman
get
cancer
larger
social
force
organization
like
mainstream
counterpart
want
inform
woman
raise
awareness
breast
cancer
however
one
hand
inform
empower
mean
question
status
quo
show
dark
side
cancer
hand
inform
raise
awareness
mean
educate
woman
screening
encourage
fundraising
research
display
highly
intact
body
batt
king
dominant
breast
cancer
image
also
directly
criticize
breast
cancer
survivor
criticize
grateful
image
breast
cancer
survivor
failure
mention
image
cancer
injection
tumor
site
nipple
radiation
barbara
ehrenreich
breast
cancer
culture
survivorship
pink
disease
criticize
breast
cancer
culture
abundance
product
market
breast
cancer
absence
mainstream
breast
cancer
culture
emphasis
cheerful
representation
breast
cancer
effectively
silence
emotion
anger
survivorship
criticize
encourage
woman
conceal
physical
effect
cancer
stigmatize
person
long
work
pass
unnoticed
society
survivor
simultaneously
encourage
status
via
pink
ribbon
disguise
true
nature
body
follow
treatment
via
reconstruction
prostheses
batt
enact
reverse
pass
survivor
become
mirror
body
attempt
recreate
image
healthy
body
moreover
disguise
survivor
experience
frank
call
experience
solitary
separate
survivor
women
work
project
image
perfect
health
follow
cancer
pay
emotional
price
well
whole
also
survivorship
fail
capture
uncertainty
inherent
cancer
experience
language
win
consistent
acute
model
illness
however
cancer
typically
experience
acute
episode
disease
fosket
frank
little
sontag
rather
follow
treatment
patient
often
struggle
inability
define
healthy
ill
frank
endure
ongoing
screening
medication
struggle
fear
recurrence
breast
cancer
william
want
avoid
yet
another
cancer
patient
publicly
declare
survivor
later
die
disease
rather
choose
see
cancer
one
form
another
survivorship
story
diagnosis
treatment
recovery
make
restitution
narrative
restitution
narrative
powerful
medicine
individual
support
optimism
oncology
clarke
good
like
person
disability
exceptional
image
breast
cancer
survivor
one
exceptional
health
strength
face
success
story
may
may
also
alienate
mayer
potts
particularly
experience
ongoing
effect
cancer
poor
prognosis
ultimately
die
disease
batt
ehrenreich
frank
analysis
narrative
content
form
breast
cancer
survivor
story
cancer
find
element
restitution
narrative
well
element
frank
narrative
story
never
end
problem
quest
narrative
story
change
result
indicate
story
survivorship
may
work
many
people
short
meaning
survivorship
criticize
particularly
within
account
breast
cancer
despite
critique
researcher
consider
typical
breast
cancer
patient
view
survivorship
research
contribute
understanding
process
adjustment
follow
cancer
augment
sociology
health
illness
two
key
way
first
although
sociology
health
illness
examine
impact
cultural
meaning
disease
illness
experience
bury
charmaz
charmaz
conrad
strauss
karp
karp
research
overwhelmingly
focused
effect
stigmatize
negative
disease
meaning
reynolds
fife
goffman
link
phelan
link
phelan
thus
know
little
illness
experience
positive
cultural
meaning
intuitively
positive
meaning
facilitate
healthy
adjustment
produce
feeling
pride
social
worth
however
criticism
survivorship
shed
doubt
benefit
survivor
identity
thus
prior
consider
possible
psychological
benefit
survivor
identity
qualitative
research
need
establish
whether
woman
embrace
identity
second
follow
tradition
learn
great
deal
entry
sick
role
pay
little
attention
recovery
illness
particular
cancer
patient
live
possibility
recurrence
represent
boundary
recovery
health
conrad
frank
work
attempt
clarify
woman
relationship
survivor
identity
next
discuss
two
theoretical
framework
conceptualize
woman
relationship
survivorship
survivorship
cultural
tool
survivorship
craftwork
cultural
sociology
provide
framework
conceptualize
meaning
survivorship
impact
woman
breast
cancer
according
swidler
individual
possess
knowledge
variety
cultural
meaning
talk
love
swidler
interested
people
cultural
material
reject
especially
attempt
retool
life
follow
major
life
event
transition
identity
breast
cancer
survivor
conceive
tool
woman
become
certain
kind
person
give
disruption
bring
cancer
stam
nelson
make
sense
woman
survivorship
organize
life
furthermore
accord
swidler
becoming
certain
kind
person
learn
practiced
sustain
culture
woman
breast
cancer
culture
provide
clear
guideline
mean
survivor
well
opportunity
breast
cancer
walk
practice
survivor
however
woman
question
reject
survivorship
unclear
alternative
meaning
embrace
give
image
breast
cancer
largely
negative
little
available
survivorship
deem
inadequate
cultural
tool
woman
may
work
construct
alternative
meaning
word
may
enact
survivorship
craftwork
according
frank
survivorship
craftwork
embody
exacting
skill
building
something
make
something
work
precise
way
much
importantly
craftwork
require
practice
construction
one
life
frank
primarily
interested
individual
construct
role
service
follow
cancer
extend
notion
craftwork
include
craft
meaning
survivorship
together
swidler
frank
conception
cultural
tool
craftwork
provide
conceptual
framework
understanding
individual
may
embrace
reject
survivorship
actively
construct
meaning
follow
cancer
thus
article
consider
two
question
first
woman
embrace
survivor
identity
way
make
sense
life
follow
cancer
second
extent
woman
craft
new
meaning
experience
method
data
come
interview
conduct
woman
complete
treatment
breast
cancer
month
prior
interview
treatment
define
surgery
chemotherapy
radiation
sample
include
individual
undergo
adjuvant
treatment
take
tamoxifen
one
advantage
sample
woman
interview
within
month
treatment
whereas
sample
much
survivorship
literature
include
individual
many
different
survival
duration
week
year
respondents
referred
study
cancer
support
center
small
city
personal
referral
mean
age
sample
woman
range
year
age
woman
receive
chemotherapy
sixteen
woman
lumpectomy
remove
cancer
remain
woman
undergo
either
unilateral
bilateral
mastectomy
woman
interview
caucasian
least
high
school
degree
general
education
high
school
equivalent
least
degree
woman
sample
currently
employ
two
woman
eight
woman
retire
remain
six
woman
sample
unemployed
hope
return
work
future
sample
largely
middle
class
class
determination
based
upon
education
occupation
author
observation
many
home
interview
three
woman
unusual
employ
blue
assembly
line
worker
sample
largely
white
middle
class
represent
woman
much
likely
identify
survivor
culture
flexible
interview
guide
allow
respondent
talk
freely
cancer
experience
include
diagnosis
treatment
life
treatment
two
question
assess
respondent
view
towards
survivorship
first
woman
ask
referred
survivor
woman
also
ask
word
survivor
mean
question
survivorship
pose
near
end
interview
woman
talk
survivorship
prior
direct
question
survivorship
interviews
last
average
minute
woman
pay
participate
interview
interviews
transcribe
enter
scientific
software
development
woman
assign
author
analysis
combine
deductive
inductive
strategy
first
transcript
corresponding
field
note
read
sense
respondent
experience
whole
preliminary
working
datum
utilize
ground
theory
method
consist
set
flexible
principle
construct
theory
analysis
rich
datum
charmaz
glaser
strauss
glaser
strauss
become
familiar
datum
much
deductive
strategy
adopt
first
datum
relate
identity
cancer
survivor
code
apply
code
survivor
text
respondent
word
survivor
well
response
question
refer
cancer
survivor
term
survivor
mean
datum
extract
interview
create
complete
picture
woman
view
survivorship
examine
pattern
across
woman
initially
woman
transcript
code
one
two
identify
survivor
among
reject
survivorship
three
distinct
reason
reject
identity
quickly
emerge
datum
additional
work
datum
reveal
among
woman
identify
survivor
embrace
dominant
meaning
survivorship
express
towards
survivorship
deeper
analysis
latter
group
reveal
often
modify
meaning
survivorship
thus
discussion
woman
accept
survivorship
distinguish
woman
embrace
survivorship
identify
survivor
alter
meaning
survivorship
result
survivor
identity
rarely
woman
spontaneously
refer
survivor
instead
title
survivor
typically
describe
example
woman
might
say
aunt
survivor
ask
refer
survivor
twenty
woman
say
yes
even
among
woman
identify
survivor
meaning
survivor
identity
vary
woman
clearly
embrace
dominant
meaning
survivorship
mary
age
year
one
woman
ask
referred
cancer
survivor
mary
reply
confidence
without
survivor
explain
survivor
mean
beat
strong
win
battle
hard
imagine
mary
breast
cancer
fundraising
event
pink
survivor
proudly
publicly
mark
breast
cancer
survivor
visually
embody
identity
otherwise
apparent
klawiter
consistent
swidler
culture
much
obvious
period
life
mary
new
cultural
skill
exaggerate
proudly
declare
survivor
also
describe
breast
cancer
pin
ribbon
exhibit
careful
culture
definition
survivorship
create
national
cancer
survivor
survivor
day
diagnose
woman
sample
draw
much
selectively
survivor
discourse
age
year
see
survivor
strong
enough
make
experience
say
test
really
strong
strong
faith
respondent
name
kim
age
year
feel
proud
survivor
breast
cancer
walk
attend
year
according
kim
think
proud
survive
fall
apart
find
inner
strength
explain
part
go
something
else
come
surgeon
might
take
give
different
something
happen
quiet
little
kim
say
find
inner
strength
kim
story
fit
quest
bring
new
aspect
make
well
person
frank
lisa
age
year
say
absolutely
identify
survivor
like
woman
quote
feel
pride
strength
make
treatment
proudly
wear
pink
symbol
breast
cancer
however
lisa
poignantly
describe
ongoing
fear
ache
pain
think
wonder
feel
like
buoy
large
body
water
chemo
feel
like
something
kill
now
take
tamoxifen
will
good
feel
little
bit
like
buoy
water
feel
like
get
throw
around
little
bit
wave
life
know
way
notion
beat
cancer
fear
cancer
linger
contradictory
lisa
able
identify
survivor
believe
cancer
may
behind
every
ache
pain
one
possibility
lisa
thoroughly
examine
culture
view
go
unnoticed
rather
lisa
specific
definition
survivorship
allow
linger
fear
lisa
definition
entail
see
cancer
ongoing
survivorship
mean
win
huge
battle
war
will
last
rest
life
lisa
adopt
definition
survivorship
acknowledge
successful
treatment
fear
recurrence
brooke
construction
survivorship
far
remove
dominant
meaning
brooke
age
year
initially
see
survivorship
empower
feel
part
great
people
feeling
develop
part
character
sex
city
successfully
undergo
treatment
breast
cancer
however
brooke
identification
survivorship
allow
notice
breast
cancer
death
around
read
morning
interview
brooke
confidence
ability
survive
cancer
shake
however
craft
new
meaning
around
survivorship
enable
retain
survivor
identity
explain
survivor
mean
come
really
family
survivor
long
become
cancer
survivor
really
screw
mother
treatment
long
communicate
one
thing
think
much
cancer
survivor
survivor
general
mean
cancer
just
one
much
thing
add
term
cancer
survivor
much
now
just
one
much
notch
survival
emphasis
add
brooke
alter
meaning
survivorship
fit
personal
biography
someone
overcome
difficulty
survivorship
retain
significance
like
brooke
name
lauren
also
fear
recurrence
breast
mean
one
thing
just
stand
people
say
oh
cure
like
people
get
cure
die
heart
attack
know
cure
breast
cancer
rest
life
question
mark
never
know
will
come
back
labeled
threat
cancer
recurrence
syndrome
character
beneath
suspend
single
hair
lauren
life
cancer
feature
life
nonetheless
see
survivor
definition
survivorship
center
good
fight
think
just
mean
treatment
done
everything
keep
come
back
go
live
life
like
whatever
happen
go
happen
walk
around
say
go
come
back
guard
much
come
back
totally
throw
loop
always
leave
like
little
thing
mind
come
back
datum
demonstrate
group
woman
identify
survivor
include
woman
feel
beat
disease
well
view
cancer
permanent
feature
life
late
group
dominant
notion
survival
incongruent
belief
medicine
guarantee
permanent
removal
cancerous
cell
body
thus
alter
meaning
survivorship
account
possibility
recurrence
next
turn
woman
identify
survivor
fear
recurrence
also
weigh
heavily
woman
however
rather
accept
survivor
title
modify
fit
fear
woman
accept
survivor
identity
addition
present
datum
two
additional
reason
reject
sick
enough
want
part
survivor
group
survivorship
rejecting
due
fear
struggle
feeling
survivorship
know
always
question
think
woman
speak
like
well
wait
minute
cancer
cancer
survivor
warrior
really
good
answer
technically
day
diagnose
call
survivor
feel
really
somehow
guess
still
feel
like
battle
sophia
age
year
quote
aware
available
cultural
definition
however
sophia
among
woman
sample
identify
survivor
many
woman
believe
survivor
identity
incongruent
uncertainty
feel
whereas
first
group
woman
keep
survivor
title
tailor
meaning
view
woman
accept
identity
example
kathleen
age
year
poignantly
describe
possibility
recurrence
make
term
survivor
like
term
know
beat
sure
really
survive
survive
whole
month
know
guess
think
way
plane
crash
survive
survive
plane
crash
gonna
get
back
plane
crash
cancer
make
treatment
go
now
mean
gonna
come
back
possibility
crash
kathleen
instead
refer
cancer
free
now
phrase
well
capture
tentative
nature
health
age
year
also
view
cancer
linger
ask
identify
survivor
reply
like
word
explain
mean
never
go
problem
think
maybe
practical
think
survive
cancer
mean
die
something
else
ultimately
choose
classify
accordance
reality
experience
say
phrase
treat
breast
cancer
figure
really
fact
know
true
quote
age
year
explain
reluctance
identify
survivor
highlight
contrast
exacting
medicalized
period
diagnosis
treatment
uncertain
vague
period
follow
want
positive
end
say
yes
gonna
beat
gonna
survivor
life
time
just
wonder
know
get
online
check
conclusive
evidence
risk
recurrence
want
somebody
tell
great
candidate
recur
nobody
tell
look
oncologist
like
go
know
much
definition
cancer
know
cancer
grade
estrogen
receptor
positive
age
factor
everything
precise
now
like
back
unknown
like
like
emphasis
add
sophia
whose
early
quote
express
difficulty
term
survivor
explain
see
technically
call
survivor
kind
guess
think
warrior
breast
cancer
warrior
symbolize
point
recognize
struggle
may
still
still
ongoing
just
know
come
close
enough
death
survivor
give
cultural
fear
associate
cancer
medicine
inability
prevent
breast
cancer
cure
metastatic
breast
cancer
leopold
patterson
altogether
surprising
woman
face
difficulty
reconcile
fear
recurrence
message
beat
cancer
much
unexpected
several
woman
sample
reject
survivorship
believe
sick
enough
survivor
respondent
name
olivia
explain
see
close
death
know
term
go
relay
event
say
survivor
may
look
like
one
lady
say
instead
survivor
probably
tend
much
believe
end
like
woman
olivia
craft
definition
survivorship
come
close
enough
die
martha
age
year
reject
survivorship
survivor
mean
just
deathly
ill
feel
like
deathly
ill
probably
within
six
month
however
neither
woman
easy
cancer
undergo
surgery
chemotherapy
radiation
women
like
olivia
martha
suggest
breast
cancer
culture
emphasize
heroic
battle
cancer
extent
alienate
woman
breast
cancer
culture
rejecting
social
identity
survivor
final
group
woman
explicitly
refuse
part
social
identity
breast
cancer
individual
face
chronic
stigmatize
severe
debilitating
illness
risk
socially
identify
disease
bury
charmaz
goffman
response
ill
person
may
work
define
much
just
illness
charmaz
charmaz
case
survivorship
desire
identify
one
illness
extend
even
identity
positive
age
year
explain
need
symbol
around
remind
say
kind
person
wear
honor
like
think
much
complex
term
age
year
describe
sometimes
hate
remind
cancer
pink
ribbon
license
plate
see
around
perhaps
well
articulate
discomfort
public
nature
breast
like
part
group
know
mean
like
like
part
like
part
society
like
individual
like
link
label
uncomfortable
piece
mind
tell
breast
cancer
want
commit
march
across
want
commit
know
mean
woman
name
joanna
take
reluctance
identify
survivor
far
refuse
labeled
refuse
ignore
large
factor
believe
just
feel
like
see
survivor
like
buy
like
come
home
iraq
tell
prosthesis
mind
arm
war
now
like
government
medical
establishment
labeling
something
interviewer
think
label
mean
imply
cancer
survivor
somebody
screw
government
reason
get
cancer
due
pollution
lack
care
human
culture
cancer
survivor
just
mean
convince
look
somebody
think
reason
survive
know
anything
globally
event
stand
just
survive
label
joanna
woman
sample
cultural
definition
survivor
consider
definition
preclude
consideration
structural
factor
joanna
draw
upon
tradition
within
native
american
culture
craft
conception
breast
get
part
native
american
certain
thing
think
time
like
sundance
put
chest
pull
prove
love
fellow
man
show
suffer
love
view
like
really
come
give
device
way
look
make
cancer
victim
cancer
survivor
someone
go
sundance
live
stronger
now
joanna
articulate
sundance
represent
meaning
want
associate
breast
chest
suffer
life
survivor
framework
final
group
woman
survivorship
salient
part
cancer
experience
ask
consider
survivor
age
year
reply
know
never
really
think
guess
woman
survivorship
lack
age
year
survivorship
unavailable
undesirable
instead
relied
discourse
aging
body
martha
age
year
explain
really
anything
mean
live
year
know
bind
something
like
discussion
finding
suggest
dominant
representation
disease
pose
challenge
individual
attempt
make
sense
illness
even
disease
meaning
positive
frank
refer
good
story
much
desire
positive
cheerful
story
breast
cancer
good
story
acknowledge
role
cancer
woman
life
fear
recurrence
framework
reduce
separation
private
public
experience
cancer
draw
woman
close
body
accept
contingency
life
exhibit
suffer
openly
share
pain
framework
also
entail
shift
terminology
survivor
live
cancer
cancer
recent
call
recognize
cancer
chronic
disease
institute
medicine
report
cancer
patient
cancer
survivor
transition
detail
need
cancer
patient
however
datum
present
demonstrate
woman
breast
cancer
face
conflict
cultural
definition
survivorship
ongoing
battle
cancer
good
cancer
story
also
acknowledge
variation
response
breast
cancer
women
response
survivorship
vary
even
among
relatively
sample
capture
similar
point
diversity
woman
response
survivorship
present
challenge
clinician
responsible
address
need
cancer
patient
clearly
labeling
woman
survivor
will
assist
adjustment
leave
feeling
uncomfortable
moreover
finding
add
understanding
culture
woman
process
retool
life
process
building
meaning
around
illness
evident
set
cultural
meaning
salient
however
meaning
simply
reject
accept
rather
individual
work
modify
cultural
meaning
fit
life
craft
meaning
woman
agency
medical
event
highly
impersonal
abstract
technical
women
meaning
important
framework
attach
experience
shape
subsequent
action
woman
seek
meaning
support
ongoing
effort
prevent
recurrence
quickly
detect
new
cancer
explain
woman
adopt
survivor
identity
neither
disease
stage
treatment
modality
predict
view
survivorship
sample
future
work
examine
influence
disease
person
characteristic
identification
survivorship
women
color
woman
socioeconomic
status
may
view
survivorship
differently
may
draw
upon
salient
cultural
framework
mitchell
future
work
also
examine
woman
relationship
survivor
identity
point
illness
experience
survivorship
may
shift
time
woman
work
effect
treatment
feel
great
distance
disease
face
recurrence
addition
study
systematically
examine
survivor
culture
shape
woman
physical
however
prior
work
suggest
breast
cancer
culture
send
clear
message
woman
conceal
effect
cancer
therefore
future
work
pursue
connection
survivorship
woman
body
political
feminist
response
breast
cancer
largely
absent
datum
may
reflect
sample
future
work
consider
whether
sample
articulate
perspective
even
woman
identify
breast
cancer
culture
draw
upon
limited
way
dominant
model
may
affect
limit
way
think
disease
word
cultural
construction
breast
cancer
may
feminist
political
response
disease
batt
leopold
current
image
survivor
persist
work
many
woman
social
level
contemporary
construction
breast
cancer
secure
funding
respect
disease
narrative
survivorship
support
medical
model
wherein
illness
diagnose
treat
cure
batt
frank
individual
level
woman
opportunity
dominant
culture
via
pink
ribbon
symbol
fewer
opportunity
exist
act
alternative
way
mean
embrace
new
construction
survivorship
recognize
last
effect
breast
cancer
diversity
response
breast
cancer
first
mean
acknowledge
physical
sensation
management
appearance
effect
treatment
fosket
second
mean
acknowledge
limit
medicine
control
cancer
according
batt
woman
breast
cancer
understand
medicine
limited
ability
control
disease
reliance
physician
test
medical
intervention
enormously
reduce
power
institution
accordingly
without
filter
breast
cancer
culture
woman
breast
cancer
right
map
future
within
real
constraint
impose
disease
conclusion
view
breast
cancer
change
dramatically
recent
decade
women
breast
cancer
today
will
face
little
access
great
information
disease
openly
receive
support
overwhelmingly
positive
change
breast
cancer
patient
however
construct
positive
definition
survivorship
breast
cancer
culture
leave
many
woman
search
representation
acknowledge
fear
continue
presence
cancer
life
moreover
woman
response
breast
cancer
vary
thus
well
model
life
cancer
acknowledge
variety
response
disease
ongoing
significance
disease
woman
life
acknowledgment
article
based
work
support
national
science
foundation
grant
national
cancer
institute
like
thank
follow
people
helpful
comment
paper
armstrong
fife
richard
warnecke
carol
breast
cancer
much
frequent
malignancy
much
common
death
woman
worldwide
approximately
death
year
approximately
patient
diagnose
breast
cancer
risk
develop
tumor
recurrence
time
within
course
disease
therefore
early
diagnosis
accurate
restage
recurrent
breast
cancer
important
define
appropriate
therapeutic
strategy
identify
patient
limited
disease
potentially
benefit
curative
treatment
primary
staging
breast
cancer
usually
perform
imaging
approach
conventional
radiograph
ultrasound
compute
tomography
ct
magnetic
resonance
imaging
mri
based
change
density
size
contrast
enhancement
however
sequential
imaging
approach
potential
finding
may
delay
appropriate
therapy
report
fdg
positron
emission
tomography
pet
clinical
value
search
breast
cancer
metastases
especially
suggest
presence
clinical
symptom
progressive
increase
biochemical
marker
combination
metabolic
datum
pet
detail
anatomical
information
compute
tomography
scanner
markedly
increase
lesion
localization
diagnostic
accuracy
compare
modality
application
recently
combine
pet
ct
introduce
imaging
modality
screening
patient
suspicion
recurrent
breast
cancer
indicate
improve
restage
accuracy
possible
impact
therapy
mri
lack
ionize
radiation
high
soft
tissue
contrast
spatial
resolution
useful
application
tumor
detection
stage
malignant
disease
high
sensitivity
report
detection
organ
metastases
especially
tumor
frequently
metastasizing
liver
bone
brain
like
breast
cancer
however
different
requirement
coil
setup
sequence
design
slice
position
well
patient
repositioning
procedure
past
delay
clinical
application
introduction
scanner
cover
patient
anatomy
head
toe
mri
become
promising
candidate
body
tumor
imaging
now
dedicate
assessment
individual
organ
various
soft
tissue
contrast
image
orientation
spatial
resolution
contrast
medium
dynamic
combine
anatomic
coverage
recently
approve
clinical
mr
system
field
strength
become
available
potential
snr
either
acquisition
acceleration
increase
spatial
resolution
compromise
result
even
short
total
examination
time
increase
patient
comfort
acceptance
various
study
group
report
improve
diagnostic
accuracy
image
quality
different
dedicate
organ
system
like
functional
morphologic
imaging
brain
vessel
define
structure
yet
scientific
study
describe
system
part
body
include
chest
abdomen
even
application
purpose
study
compare
diagnostic
potential
fdg
pet
ct
patient
breast
cancer
suspicion
tumor
recurrence
additionally
high
field
condition
introduce
new
feasible
application
within
clinical
setting
material
method
study
include
female
patient
mean
age
year
range
year
history
breast
cancer
treat
primarily
curative
approach
patient
referred
hospital
within
time
period
month
either
clinical
suspicion
tumor
recurrence
conspicuous
finding
another
imaging
modality
newly
elevate
tumor
marker
level
patient
examine
consecutively
pet
gemini
philip
medical
system
cleveland
ohio
within
diagnostic
algorithm
clinical
routine
patient
also
undergo
within
maximum
day
average
day
mri
perform
agreement
patient
well
clinician
charge
approval
institutional
review
board
write
patient
consent
obtain
beforehand
pet
ct
irrespective
apply
field
strength
well
tolerate
patient
avoid
bias
diagnostic
accuracy
pet
ct
due
suppress
metabolic
activity
patient
receive
chemotherapy
radiotherapy
immediately
prior
examination
exclude
statistical
analysis
table
overview
selection
criterion
patient
include
imaging
aftercare
algorithm
patient
selection
criterion
imaging
algorithm
pet
ct
clinical
bone
pain
abdominal
pain
pathologic
liver
enzyme
pathologic
fracture
elevated
tumor
marker
cea
suspicious
imaging
radiograph
abdominal
ultrasound
ultrasound
table
view
within
article
mri
patient
perform
mt
min
slew
rate
scanner
magnetom
siemens
medical
solution
erlangen
germany
integrate
parallel
acquisition
technique
ipat
scanner
allow
connection
receiver
coil
element
multiple
surface
coil
cover
patient
head
toe
simultaneous
signal
independent
receiver
channel
automate
table
motion
parallel
imaging
three
spatial
direction
total
scan
range
cm
perform
without
patient
repositioning
patient
examine
head
proximal
calf
four
body
level
coronal
orientation
head
neck
pelvis
thigh
calf
tr
well
thorax
abdomen
tr
technique
prospective
correction
pace
prospective
acquisition
correction
subsequently
body
scan
coronal
tr
thorax
abdomen
tr
technique
lung
examine
axial
orientation
tr
tr
follow
scan
liver
tr
coronal
haste
abdomen
tr
sagittal
imaging
upper
spine
tr
tr
perform
application
magnevist
bayer
schering
pharma
berlin
germany
ml
mmol
kg
ml
saline
dynamic
portal
late
venous
phase
axial
volume
exam
liver
scan
accomplish
tr
include
late
venous
scan
breast
lung
level
tr
axial
tr
tr
brain
perform
finally
fat
saturate
whole
abdomen
axial
orientation
tr
perform
table
give
overview
apply
scan
protocol
table
mri
sequence
protocol
matrix
resolution
acquisition
time
min
matrix
resolution
acquisition
time
min
free
breathing
stat
table
alternatively
apply
coronal
imaging
head
neck
region
breast
late
venous
phase
perform
extend
anatomic
coverage
entire
lung
replace
axial
lung
axial
imaging
brain
perform
gradient
echo
sequence
view
within
article
coronal
imaging
except
calf
sagittal
imaging
spine
pat
apply
axial
imaging
thorax
abdomen
also
choose
mri
patient
perform
mt
min
slew
rate
scanner
magnetom
tim
siemens
medical
solution
erlangen
germany
ipat
within
migration
describe
establish
protocol
condition
adaptation
scan
parameter
different
field
strength
perform
far
adjustment
optimization
spatial
resolution
make
preserve
two
protocol
see
table
coronal
perform
four
body
level
tr
thorax
abdomen
tr
follow
haste
lung
tr
abdomen
tr
include
scan
liver
tr
due
change
relaxation
time
increase
compare
achieve
adequate
fat
suppress
bone
marrow
signal
contrast
comprise
coronal
body
level
tr
tr
head
neck
region
tr
achieve
adequate
image
contrast
detail
brain
parenchyma
complex
soft
tissue
structure
neck
shoulder
sagittal
tr
sequence
tr
spine
perform
due
increased
sar
pulse
technique
variable
rate
selective
excitation
verse
select
verse
allow
substantial
sar
reduction
without
significant
increase
tr
negligible
change
image
contrast
contrast
protocol
sequence
tr
replace
axial
already
establish
brain
imaging
choice
high
cnr
robust
image
quality
high
field
strength
contrast
enhance
imaging
perform
dynamic
liver
tr
late
venous
scan
lung
breast
tr
fat
saturate
perform
abdomen
pelvis
tr
additionally
dielectric
pad
place
patient
body
fat
avoid
dielectric
artifact
axial
lung
perform
due
severe
impairment
image
quality
pulsation
artifact
fdg
pet
ct
imaging
examination
perform
row
pet
gemini
philip
medical
system
cleveland
ohio
injection
mbq
patient
ask
fast
least
examination
assure
blood
glucose
level
mg
dl
apply
intravenously
avoid
uptake
fdg
smooth
muscle
additionally
mg
furosemide
give
increase
renal
excretion
tracer
avoid
accumulation
cell
ct
scan
shallow
breathing
perform
correction
cover
neck
thorax
abdomen
pelvis
ma
kv
collimation
mm
mm
pitch
emission
scan
follow
row
action
maximum
likelihood
algorithm
reconstruction
bed
position
fov
cm
matrix
finally
diagnostic
ct
conduct
ma
kv
collimation
mm
mm
pitch
application
ml
agent
bayer
schering
pharma
berlin
germany
venous
phase
delay
diagnostic
fuse
special
software
philip
medical
system
cleveland
ohio
usa
whole
examination
average
dose
ionize
radiation
calculate
table
give
overview
apply
scan
protocol
table
protocol
fdg
pet
ct
imaging
row
scanner
ct
attenuation
correction
fdg
pet
ct
protocol
patient
ct
ma
kv
ma
kv
mbq
fdg
collimation
mm
mm
matrix
collimation
mm
mm
mg
furosemide
position
pitch
mg
cm
fov
ml
delay
time
min
table
view
within
article
data
analysis
two
radiologist
much
year
experience
read
mri
scan
another
radiologist
one
nuclear
medicine
physician
year
experience
read
pet
ct
image
consensus
reader
group
fully
blind
modality
information
previous
current
diagnostic
imaging
result
location
extension
number
suspect
malignant
lesion
record
established
size
criterion
apply
determine
tumor
involvement
assess
lymph
hard
criterion
malignancy
modality
sign
aggressive
expansion
lesion
like
border
infiltration
neighboring
anatomical
structure
hemorrhage
sign
necrosis
mri
malignancy
determine
based
establish
signal
change
bone
marrow
signal
imaging
combination
hyperintense
signal
stir
case
bone
lesion
furthermore
classic
finding
abnormal
static
ct
dynamic
mri
contrast
uptake
characteristic
consult
like
early
enhancement
case
malignant
liver
lesion
addition
malignancy
pet
ct
define
focally
increase
glucose
uptake
standard
uptake
value
reference
indicate
malignancy
progressive
change
size
number
lesion
within
give
time
period
increase
pathological
tracer
uptake
consider
hard
criterion
malignancy
focal
mass
count
case
present
diffuse
infiltration
pattern
especially
metastatic
disease
bone
evaluation
system
anatomical
region
apply
lesion
count
bone
region
affect
diffuse
infiltration
one
femur
diffuse
infiltration
case
disseminate
metastatic
disease
liver
lung
define
much
five
metastases
degree
metastatic
spread
describe
affect
lung
lobe
liver
segment
respectively
disseminate
metastatic
disease
lung
lobe
liver
segment
detect
lesion
include
discordant
finding
modality
radiological
nuclear
medicine
study
within
least
month
average
month
month
standard
reference
follow
study
perform
mammography
breast
ultrasound
mri
pet
ct
ct
bone
scintigraphy
radiograph
abdominal
ultrasound
case
suppose
local
recurrent
tumor
find
histological
clarification
achieve
statistical
analysis
assess
diagnostic
accuracy
modality
sensitivity
specificity
well
negative
predictive
value
calculate
describe
lesion
concordance
assessment
mri
pet
calculate
statistical
analysis
perform
spss
windows
version
spss
chicago
illinois
result
tumor
recurrence
find
patient
altogether
pet
ct
detect
lesion
classify
malignant
lesion
consider
benign
thirteen
patient
visible
malignant
pathology
also
negative
examination
correlation
modality
detect
lesion
describe
lesion
observe
within
common
fov
modality
skull
base
proximal
bone
discordant
finding
classify
examination
fdg
pet
ct
show
overall
diagnostic
accuracy
sensitivity
specificity
altogether
achieve
equal
overall
diagnostic
accuracy
sensitivity
specificity
two
patient
tumor
recurrence
breast
detect
pet
ct
one
local
recurrence
one
recurrence
breast
one
patient
rate
local
recurrence
sign
tumor
recurrence
find
pet
ct
month
patient
image
woman
breast
cancer
suspicion
tumor
recurrence
breast
radiograph
ultrasound
routine
coronal
four
body
level
show
large
hyperintense
bone
marrow
lesion
indicate
metastasis
right
proximal
femur
arrow
late
venous
phase
anatomic
level
breast
show
enhance
mass
right
breast
suspicious
contralateral
tumor
recurrence
additionally
large
sternal
bone
metastasis
depict
arrowhead
pet
ct
thorax
reveal
pathologic
right
breast
lesion
suv
well
sternal
mass
indicate
malignancy
bilateral
uptake
facet
joint
breast
ultrasound
correlation
confirm
lesion
mm
diagnose
tumor
recurrence
carcinoma
view
within
article
pet
ct
detect
lymph
node
metastases
sensitivity
equal
specificity
diagnostic
accuracy
reveal
malignant
lymph
node
sensitivity
yield
specificity
diagnostic
accuracy
pet
ct
detect
much
lymph
node
metastases
especially
axilla
mediastinal
region
pet
ct
versus
table
table
summary
detect
malignant
lesion
detect
mri
pet
ct
anatomical
distribution
detected
local
malignant
lymph
distant
table
overall
malignant
focus
detect
modality
correlation
view
within
article
image
woman
breast
cancer
elevate
tumor
axial
lung
show
round
hyperintense
structure
upper
ventral
mediastinum
indicative
lymph
node
difficult
distinguish
vessel
pulsation
artifact
another
hyperintense
structure
region
hardly
interpretable
arrow
ct
show
two
lymph
node
describe
site
borderline
size
cm
arrow
pet
ct
reveal
pathologic
tracer
uptake
ventral
lymph
node
suv
node
show
significant
uptake
progressive
multifocal
metastatic
disease
secondary
lymphedema
trunk
arm
well
additional
brain
metastases
diagnose
patient
view
within
article
detection
distant
metastatic
disease
pet
ct
demonstrate
sensitivity
specificity
diagnostic
accuracy
show
sensitivity
specificity
diagnostic
accuracy
reveal
much
metastases
bone
versus
pet
ct
liver
versus
show
even
performance
detection
lung
metastases
table
one
patient
indicate
focal
bone
metastasis
confirm
image
woman
increase
liver
enzyme
suspicious
mass
abdominal
pet
ct
show
focal
liver
metastasis
increase
liver
portal
venous
phase
confirm
large
liver
metastasis
show
additional
multiple
small
satellite
another
focal
liver
metastasis
mm
find
different
liver
segment
arrow
large
metastasis
show
pet
ct
small
satellite
lesion
mask
physiological
background
uptake
lesion
describe
different
liver
segment
mri
visualize
month
reveal
morphological
increase
lesion
despite
chemotherapy
view
within
article
consider
full
field
view
examination
cover
body
head
calf
total
additional
focal
malignant
focus
find
five
patient
nine
previously
unknown
brain
metastases
describe
four
patient
two
bone
metastases
distal
femur
one
patient
another
patient
pathologic
meningeal
contrast
uptake
describe
confirm
meningeosis
carcinomatosa
image
woman
breast
cancer
newly
occur
high
contrast
display
soft
tissue
abdominal
structure
substantial
artifact
especially
thorax
abdomen
observe
axial
brain
post
contrast
show
multifocal
small
brain
metastases
right
arrow
arrow
another
patient
post
contrast
mri
brain
show
pathologic
meningeal
contrast
uptake
indicate
meningeosis
carcinomatosa
arrow
view
within
article
image
woman
breast
cancer
newly
occur
bone
pain
well
elevate
liver
spine
show
small
bone
metastases
mm
size
arrow
multiple
lumbar
vertebral
high
contrast
fat
saturate
depict
large
metastasis
fourth
dorsal
lumbar
body
infiltration
right
facet
joint
paravertebral
soft
corresponding
pet
ct
show
pathologic
much
small
bone
metastases
find
right
joint
leave
bone
arrow
large
metastasis
show
visible
osteolytic
defect
arrow
imaging
liver
additionally
reveal
liver
metastasis
right
liver
lobe
high
resolution
typical
late
enhancement
view
within
article
examination
time
pet
ct
min
min
patient
preparation
scan
time
min
total
acquisition
time
min
mean
room
time
min
total
acquisition
time
reduce
min
identical
image
resolution
time
axial
lung
additionally
perform
min
overall
scan
time
reduce
min
mean
room
time
min
discussion
basic
imaging
approach
breast
cancer
support
german
cancer
society
date
consist
regular
mammography
clinical
examination
well
imaging
strategy
procedure
large
based
assumption
study
perform
early
necessarily
correlate
increase
survival
benefit
unfortunately
approach
mainly
comprise
modality
know
poor
sensitivity
chest
radiograph
examination
strong
variation
sensitivity
abdominal
ultrasound
procedure
limited
specificity
like
bone
scintigraphy
especially
last
year
numerous
promising
concept
develop
therapy
metastasized
breast
cancer
include
hormonal
drug
immune
therapy
indicate
improvement
patient
survival
new
surgical
interventional
technique
management
unifocal
metastases
demonstrate
effectiveness
local
therapeutic
approach
report
promising
survival
rate
background
imaging
modality
pet
ct
mri
appear
new
promising
tool
detect
tumor
recurrence
high
accuracy
initial
stage
provide
much
effective
therapeutic
strategy
patient
study
find
high
prevalence
recurrent
disease
fdg
pet
ct
show
overall
diagnostic
accuracy
detection
tumor
recurrence
previous
study
describe
efficacy
pet
ct
cancer
restage
yet
much
case
heterogeneous
tumor
cohort
analyzed
recent
study
breast
cancer
restage
strategy
exist
pet
ct
examine
woman
history
breast
cancer
elevate
tumor
marker
fdg
pet
ct
report
similarly
high
tumor
recurrence
patient
accuracy
observe
pet
ct
different
group
describe
even
well
performance
pet
ct
diagnostic
accuracy
however
patient
history
study
rather
heterogeneous
consist
woman
referred
primary
staging
restage
well
evaluation
treatment
response
limit
result
interpretation
contrast
study
much
homogeneous
group
patient
increase
likelihood
tumor
recurrence
analyzed
compose
either
increase
breast
cancer
marker
level
cea
newly
occur
clinical
symptom
indicate
recurrence
suspicious
finding
within
aftercare
may
also
explain
high
tumor
prevalence
find
cohort
far
study
exist
directly
compare
pet
ct
concept
tumor
restage
none
focused
breast
cancer
patient
alone
still
equally
high
diagnostic
accuracy
observe
modality
subgroup
breast
cancer
patient
correlate
well
result
previous
study
perform
scanner
stage
different
primary
tumor
comparable
imaging
concept
protocol
initial
report
patient
analyzed
total
lesion
result
overall
accuracy
pet
ct
calculate
retrospective
give
datum
current
finding
pet
ct
regard
overall
diagnostic
accuracy
balanced
similar
observation
make
pilot
study
mention
yet
tendency
slightly
well
performance
modality
probably
heterogeneous
tumor
cohort
initial
analysis
variation
biological
nature
tumor
well
tracer
uptake
characteristic
may
influence
factor
basis
one
finding
local
breast
tumor
recurrence
describe
otherwise
healthy
patient
round
enhance
mass
adjacent
scar
tissue
describe
show
tracer
uptake
pet
ct
certainly
clinically
feasible
approach
present
protocol
setup
supine
position
patient
make
impossible
imply
dedicate
mri
breast
lack
contrast
imaging
adequate
breast
compression
concept
impair
diagnostic
accuracy
local
tumor
recurrence
furthermore
anatomic
metabolic
information
provide
fdg
pet
ct
scan
advantage
interpret
focal
breast
mass
far
enhance
diagnostic
accuracy
ct
datum
alone
otherwise
suffer
soft
tissue
contrast
breast
additional
metabolic
information
pet
ct
become
much
apparent
analyzing
result
lymph
node
detection
study
pet
ct
detect
much
lymph
node
metastases
high
diagnostic
accuracy
versus
especially
typical
anatomical
region
metastatic
dissemination
breast
cancer
like
mediastinum
along
internal
artery
image
quality
may
affect
susceptibility
artifact
mri
potentially
may
worsen
condition
additionally
small
lymph
node
harboring
micrometastases
may
impair
diagnostic
sensitivity
imaging
based
morphological
criterion
alone
recently
publish
study
introduce
staging
lymphoma
lack
sensitivity
detection
small
lymph
node
metastases
mm
become
evident
report
decline
sensitivity
compare
pet
ct
pilot
study
patient
various
primary
tumor
observe
superior
diagnostic
accuracy
fdg
pet
ct
compare
assessment
correct
comparable
observation
make
study
several
concept
presently
develop
enhance
diagnostic
accuracy
malignant
lymph
node
detection
adequate
fat
suppression
dwibs
prove
promising
enhance
display
pathologic
lymph
node
high
resolution
recently
show
feasibility
technique
application
condition
diagnostic
image
quality
describe
good
correlation
lymph
node
metastases
depict
dwibs
visualize
fdg
pet
author
calculation
signal
intensity
ratio
compare
saline
phantom
report
excellent
result
detection
lymph
node
metastases
lung
cancer
due
excellent
contrast
soft
tissue
structure
main
performance
certainly
lie
within
detection
distant
metastatic
disease
especially
abdominal
organ
brain
bone
represent
frequent
route
metastasis
breast
cancer
although
modality
perform
reliable
detection
organ
metastases
show
high
diagnostic
accuracy
versus
pet
ct
similar
trend
report
previously
describe
initial
study
tumor
stage
perform
group
scanner
yield
even
performance
pet
ct
accuracy
compare
current
study
advantage
especially
detection
versus
liver
metastases
versus
find
similar
observation
make
site
combination
fat
suppress
present
protocol
prove
much
accurate
detection
malignant
bone
marrow
disorder
excellent
value
especially
describe
literature
recently
study
perform
bone
marrow
screening
compare
fdg
pet
ct
total
body
matrix
coil
concept
resolution
parameter
within
study
significantly
high
diagnostic
accuracy
versus
confirm
mainly
due
significantly
high
sensitivity
sensitivity
pet
ct
impair
small
bone
lesion
show
visible
morphologic
change
ct
significant
tracer
uptake
especially
lesion
double
size
spatial
resolution
usually
mm
mention
study
indeed
much
small
lesion
mm
detect
however
state
first
generation
pet
ct
scanner
study
current
analysis
today
largely
upgrade
much
significantly
increase
imaging
performance
diagnostic
potential
due
enhance
resolution
reconstruction
result
diagnostic
accuracy
small
size
lesion
organ
soft
tissue
contrast
high
density
like
liver
bone
expect
increase
excellent
depiction
liver
pathology
report
contrast
enhance
abdomen
vibe
well
performance
especially
lesion
compare
fdg
pet
ct
fdg
pet
ct
show
even
performance
detection
lung
metastases
may
effect
implementation
fast
pat
prove
highly
efficient
detection
small
lung
pathology
important
benefit
pat
significant
reduction
blur
increase
image
single
pulse
sequence
time
length
echo
train
reduce
tissue
high
thus
avoid
loss
ratio
report
technical
feasibility
lung
mri
observe
neither
substantially
different
image
characteristic
significantly
increase
artifact
high
field
condition
high
cnr
nodule
find
vibe
cnr
infiltrate
haste
lung
sequence
implement
protocol
indeed
image
patient
examine
fully
diagnostic
without
noticeable
impairment
artifact
larger
anatomical
coverage
compare
pet
ct
skull
base
proximal
femur
reveal
additional
finding
prognostic
importance
previously
unknown
brain
metastases
describe
four
patient
meningeosis
detect
another
patient
due
high
cns
pet
scan
cerebral
pathology
easily
miss
fdg
pet
ct
exam
protocol
fact
cerebral
metastases
image
high
resolution
clear
advantage
especially
tumor
frequently
spread
cns
like
breast
cancer
report
similar
finding
comparable
protocol
mr
scanner
considerable
number
additional
diagnosis
include
previously
unknown
cerebral
tumor
spread
soft
tissue
metastases
make
compare
standard
staging
method
lead
change
therapy
patient
propose
protocol
show
pat
enable
flexible
imaging
protocol
various
soft
tissue
contrast
image
orientation
spatial
resolution
contrast
medium
dynamic
within
clinically
feasible
examination
time
total
scan
time
min
exam
tolerate
well
patient
making
increase
snr
keep
identical
resolution
parameter
total
scan
time
even
far
reduce
min
patient
discomfort
report
thus
introduce
effective
application
high
field
condition
several
modification
image
parameter
describe
method
section
perform
adapt
concept
high
field
condition
preclinical
step
platform
migration
study
group
analyzed
image
quality
criterion
artifact
propose
protocol
healthy
volunteer
resolution
parameter
result
show
comparably
good
performance
scanner
slightly
increase
artifact
without
significantly
influence
image
quality
fact
basis
difference
detection
tumor
recurrence
find
pet
ct
indicator
successful
introduction
platform
migration
clinical
setting
limit
aspect
study
unchanged
resolution
parameter
order
trade
snr
far
scan
time
reduction
allow
analyze
effect
enhance
spatial
resolution
diagnostic
accuracy
especially
comparison
diagnostic
performance
scanner
possible
due
sample
number
differ
patient
subgroup
match
lesion
type
furthermore
lack
histological
proof
true
gold
standard
detect
lesion
verification
based
radiological
alone
represent
another
limit
aspect
reference
standard
based
imaging
alone
may
arise
small
slowly
grow
lesion
absence
significant
morphological
change
hand
comparable
numerous
study
similar
design
obtain
multiple
biopsy
tissue
verification
unacceptable
altogether
important
take
account
diagnostic
accuracy
imaging
modality
considerably
influence
several
condition
one
hand
susceptible
chemotherapy
hand
lesion
successful
chemotherapy
remain
virtually
unchanged
morphology
signal
mri
minimize
bias
exclude
patient
prior
systemic
chemotherapy
examination
summary
robust
performance
pet
ct
may
significantly
improve
diagnostic
accuracy
breast
cancer
patient
suspicion
tumor
recurrence
represent
promising
alternative
algorithm
consequence
patient
might
benefit
early
much
accurate
tumor
detection
improve
therapeutic
option
although
pet
ct
advantage
assessment
local
tumor
recurrence
lymph
node
detection
scanner
pat
show
excellent
performance
detection
distant
metastatic
disease
finally
high
field
condition
clinically
feasible
reduce
examination
time
whether
snr
far
resolution
enhancement
will
impact
diagnostic
accuracy
yet
determine
present
study
initiate
norwegian
breast
cancer
group
address
aspect
endocrine
therapy
breast
cancer
patient
report
mid
focused
systemic
adjuvant
treatment
patient
operable
breast
study
aim
control
eliminate
subclinical
residual
disease
order
draw
appropriate
conclusion
based
available
clinical
observation
datum
collect
trial
group
overall
survival
benefit
demonstrate
patient
receive
either
tamoxifen
tam
polychemotherapy
several
study
adjuvant
endocrine
therapy
start
late
adjuvant
tam
treatment
show
significant
effect
postmenopausal
patient
year
age
reduce
risk
death
approximately
wide
range
treatment
policy
employ
early
breast
cancer
patient
mostly
due
lack
evidence
survival
advantage
various
treatment
policy
understand
mechanism
action
endocrine
treatment
achieve
demonstration
estrogen
receptor
tumour
possible
importance
fluctuation
steroid
receptor
level
progesterone
receptor
pgr
induce
treatment
tam
information
possible
steroid
receptor
modulation
treat
advance
breast
cancer
patient
cyclic
tam
high
dose
acetate
mpa
high
response
rate
cyclic
arm
versus
versus
tam
alone
treatment
arm
find
significant
difference
duration
remission
survival
test
possible
clinical
effect
steroid
receptor
fluctuation
theoretical
assumption
combination
drug
different
mechanism
action
well
single
drug
therapy
present
multicenter
randomized
study
postmenopausal
node
positive
breast
cancer
patient
design
address
effect
cyclic
tam
acetate
ma
survival
rfs
overall
survival
document
possible
long
endocrine
responsiveness
hypothesis
cyclic
treatment
reduce
receptor
activity
result
well
outcome
due
long
tam
cycle
week
reduce
overlap
therapeutic
action
sequential
therapy
ma
instead
mpa
due
document
effect
minor
side
effect
advance
material
method
patient
march
december
postmenopausal
define
age
diagnosis
year
year
woman
operable
breast
cancer
stage
ii
include
randomized
prospective
adjuvant
study
study
recommend
regional
committee
ethic
norwegian
medicine
agency
patient
inform
write
give
inform
consent
patient
exclude
study
due
protocol
violation
exclusion
criterion
concomitant
previous
malignancy
illness
seriously
affect
life
expectancy
thirteen
patient
tumour
six
another
cancer
time
randomization
table
patient
exclude
due
protocol
violation
time
randomization
variabletam
matamtotal
randomized
cancer
node
metastatic
receptor
evaluable
table
view
within
article
median
age
range
study
population
year
main
clinical
characteristic
well
balanced
two
group
table
patient
tumour
characteristic
variabletam
matamtotal
age
year
median
range
patient
pt
stage
category
pt
size
cm
median
range
pn
stage
median
examine
range
pn
stage
miss
patient
table
view
within
article
patient
normal
chest
normal
liver
blood
test
inclusion
study
surgical
treatment
adjuvant
radiotherapy
surgical
procedure
perform
different
hospital
fifteen
participate
hospital
treat
least
patient
half
study
population
treat
six
hospital
breast
conservation
surgery
bcs
perform
patient
rest
mastectomy
axillary
dissection
level
ii
perform
four
patient
biopsy
perform
inclusion
period
patient
year
age
offer
standard
adjuvant
intravenous
chemotherapy
half
patient
include
study
receive
postoperative
chemotherapy
mg
day
cyclophosphamide
mg
day
mg
day
methotrexate
mg
day
patient
arm
receive
postoperative
standard
cmf
every
third
week
cyclophosphamide
mg
methotrexate
mg
mg
adjuvant
treatment
table
treatment
surgery
breast
postoperative
chemotherapy
postoperative
cmf
duration
study
medication
month
median
range
table
chemotherapy
give
day
postoperatively
information
miss
one
patient
view
within
article
radiotherapy
give
bcs
patient
patient
metastatic
axillary
lymph
node
total
patient
randomization
adjuvant
endocrine
treatment
randomization
phone
study
center
perform
block
randomization
block
size
five
health
region
norway
represent
stratum
patient
allocate
receive
either
tam
nolvadex
mg
daily
cyclic
tam
ma
nolvadex
mg
daily
week
alternate
mg
daily
week
arm
adjuvant
treatment
continue
year
first
confirmation
recurrent
disease
standard
length
treatment
time
oppose
present
day
year
treatment
primary
tumour
axillary
nodal
status
steroid
hormone
receptor
classification
tumour
accord
uicc
tnm
classification
malignant
tumour
edition
revise
distribution
pt
classification
size
axillary
nodal
status
pn
two
treatment
group
show
table
tumour
grade
give
case
miss
case
hormone
receptor
measure
dextran
coat
charcoal
method
report
pgr
level
fmol
mg
protein
criterion
positivity
level
fmol
mg
regard
negative
study
also
include
tumour
unknown
receptor
status
patient
tumour
know
negative
time
randomization
include
status
equally
distribute
two
arm
median
level
pgr
high
tam
ma
group
table
hormone
receptor
variabletam
ma
tam
total
receptor
median
fmol
range
pgr
median
fmol
range
pgr
pgr
table
view
within
article
patient
clinical
examination
every
third
month
year
every
sixth
month
year
thereafter
annual
basis
death
month
tumour
month
tumour
recur
clinical
form
complete
every
visit
initial
site
recurrence
distant
metastases
record
confirm
confirmation
make
wall
regional
node
cytology
histology
whenever
possible
bone
conventional
radiology
bone
scan
lung
chest
computer
tomography
ct
appropriate
liver
ultrasound
ct
confirm
cytology
necessary
novel
breast
cancer
define
new
malignant
tumour
contralateral
breast
new
malignant
tumour
locate
different
quadrant
ipsilateral
breast
patient
previously
treat
breast
conservation
final
complete
june
statistic
primary
end
point
rfs
detect
difference
power
significance
level
give
estimate
year
rfs
tam
arm
estimate
patient
arm
need
rfs
calculate
randomization
recurrence
patient
recurrence
censor
time
death
end
observation
alive
secondary
end
point
time
diagnosis
novel
malignant
breast
tumour
calculate
randomization
death
analysis
time
novel
breast
tumour
patient
treat
censor
end
observation
period
dead
alive
case
event
occur
survival
time
event
specify
estimate
kaplan
meier
method
two
treatment
group
compare
log
rank
test
due
similar
result
two
treatment
arm
cox
proportional
regression
test
perform
interim
analysis
perform
year
end
inclusion
pay
attention
pocock
termination
difference
find
result
duration
medication
analysis
intention
treat
basis
compliance
take
study
medication
fairly
good
median
month
arm
range
wide
tam
ma
month
tam
month
table
tam
ma
arm
patient
treat
little
month
much
month
tam
arm
patient
treat
little
month
patient
much
month
median
range
time
eligible
patient
year
patient
still
alive
median
range
time
year
survival
mortality
difference
rfs
median
rfs
year
tam
ma
arm
reach
tam
arm
figure
see
tam
curve
level
just
survival
mean
rfs
year
tam
ma
tam
group
respectively
rfs
rate
tam
ma
tam
arm
respectively
image
figure
time
start
treatment
first
recurrence
tam
group
blue
dash
line
compare
tam
ma
group
green
dash
line
number
patient
still
risk
year
tam
group
tam
ma
group
view
within
article
similar
two
treatment
group
median
survival
year
tam
ma
tam
group
respectively
image
figure
overall
survival
tam
group
blue
dash
line
tam
ma
group
green
dash
line
number
patient
still
risk
year
tam
group
tam
ma
group
view
within
article
median
time
cancer
specific
survival
year
total
patient
group
new
contralateral
quadrant
ipsilateral
breast
breast
cancer
new
ipsilateral
breast
cancer
diagnose
patient
tam
ma
group
tam
group
median
time
new
breast
cancer
year
tam
ma
tam
group
respectively
rate
tam
ma
tam
group
respectively
table
status
allocate
treatment
variabletam
ma
tam
total
main
location
first
recurrence
recurrence
ipsilateral
supraclavicular
systemic
recurrence
missing
total
contralateral
breast
new
death
breast
table
view
within
article
breast
cancer
death
patient
study
population
deceased
patient
total
number
death
main
location
relapse
similar
two
treatment
group
side
effect
side
effect
assess
every
visit
expect
event
vaginal
bleeding
slightly
much
common
tam
ma
group
side
effect
lead
cessation
medication
patient
stop
therapy
whole
treatment
period
table
side
effect
lead
cessation
medication
tam
matamtotal
patient
fluid
vaginal
table
view
within
article
discussion
treatment
background
mid
first
report
appear
focusing
systemic
adjuvant
treatment
patient
operable
breast
systemic
treatment
strategy
breast
cancer
patient
depend
tumour
extent
histological
grade
steroid
receptor
level
pgr
age
patient
postmenopausal
axillary
nodal
status
adjuvant
treatment
postmenopausal
breast
cancer
patient
tam
show
improve
rfs
compare
control
optimal
treatment
cancer
patient
still
increase
treatment
effect
different
strategy
prolong
treatment
period
year
year
far
year
lately
long
year
adjuvant
treatment
patient
standard
time
trial
start
oppose
year
level
tumour
predict
response
endocrine
treatment
patient
advance
breast
cancer
well
adjuvant
early
stage
length
treatment
response
difficult
predict
one
major
problem
medical
cancer
treatment
resistance
sequential
combination
drug
different
mechanism
action
attempt
delay
development
hormonal
resistance
try
increase
rfs
combination
treatment
hormone
receptor
combination
frequently
examine
past
tam
progestin
adjuvant
treatment
tam
show
increase
level
pgr
short
time
significant
change
mean
content
find
pgr
androgen
week
tam
treatment
possible
explanation
well
response
cyclic
treatment
compare
single
drug
therapy
increase
binding
ma
assume
increase
pgr
progestin
will
decrease
level
show
breast
cancer
thereby
induce
relative
tissue
endogenous
estrogen
advance
breast
cancer
patient
cyclic
tam
mpa
show
high
response
rate
cyclic
arm
versus
versus
tam
alone
treatment
arm
difference
duration
remission
another
study
long
median
survival
find
group
give
cyclic
treatment
versus
week
significant
difference
overall
response
cr
pr
positive
effect
cyclic
treatment
tam
mpa
advance
situation
find
present
study
adjuvant
setting
possible
verify
possible
fluctuation
tumour
steroid
receptor
measure
serum
content
tam
ma
ma
treatment
possibly
reduce
tam
serum
level
tam
ma
arm
report
mpa
possibly
influence
response
cyclic
arm
include
patient
pgr
positive
status
unknown
tumour
prove
negative
tumour
study
time
end
point
rfs
hope
increase
end
point
parameter
investigational
arm
study
due
possible
different
mechanism
action
two
drug
postpone
development
resistance
crossover
ma
tam
arm
plan
study
protocol
treatment
group
treatment
group
well
balanced
randomization
regard
patient
characteristic
pt
classification
primary
treatment
type
surgery
perioperative
adjuvant
chemotherapy
small
difference
two
group
receptor
level
number
patient
receptor
status
unknown
trial
size
randomization
procedure
suppose
handle
kind
analysis
also
perform
case
know
receptor
positive
tumour
without
different
outcome
datum
show
relapse
mortality
difference
treatment
arm
regard
rfs
observe
study
observe
median
rfs
year
study
population
patient
compare
well
number
location
first
event
relapse
also
expect
statistical
significant
difference
two
treatment
group
regard
new
contralateral
cancer
year
survival
rate
study
population
comprise
node
positive
breast
cancer
patient
great
proportion
eligible
postmenopausal
breast
cancer
patient
norway
recruitment
period
include
study
cancer
registry
norway
datum
show
hospital
treat
breast
cancer
patient
enter
patient
conclusion
prospective
randomized
population
based
study
postmenopausal
node
positive
woman
pgr
positive
unknown
operable
breast
cancer
rather
long
time
median
year
reveal
statistically
significant
difference
year
adjuvant
cyclic
tam
ma
treatment
versus
tam
monotherapy
regard
rfs
demonstrate
equivalence
two
treatment
arm
however
large
number
patient
need
trial
conflict
interest
author
financial
personal
relationship
people
organisation
inappropriately
influence
work
acknowledgement
work
financially
support
norwegian
cancer
society
want
thank
hannisdal
cancer
clinic
medical
center
oslo
important
help
randomization
datum
statistical
analysis
cancer
registry
oslo
estimate
amount
patient
available
randomization
trial
physician
enrolling
patient
study
follow
hospital
name
norwegian
study
include
patient
study
fsh
fsh
fsh
vos
fsh
fsh
fsh
fsh
fsh
moss
ssh
ssh
rit
rit
ssh
ssh
og
ssh
ssh
og
ssh
ssh
ssh
breast
cancer
second
deadly
form
cancer
woman
united
state
largely
due
tendency
metastasize
metastasis
occur
relative
year
survival
rate
drop
little
depending
site
metastasis
breast
cancer
skeleton
preferred
site
metastasis
nearly
primary
secondary
metastases
target
bone
within
skeletal
system
breast
cancer
cell
much
frequently
colonize
end
long
bone
rib
area
contain
rich
microvasculature
closely
metabolically
active
bone
surface
metaphyseal
area
end
long
bone
contain
complex
network
bone
cell
hematopoietic
cell
stromal
cell
entry
breast
cancer
cell
marrow
cavity
disturb
status
quo
particular
interaction
osteoblast
osteoclast
adult
skeleton
two
cell
type
responsible
slow
continuous
turnover
bone
metastatic
breast
cancer
cell
invade
bone
microenvironment
balance
upset
favor
net
bone
loss
indeed
breast
cancer
metastasis
usually
result
osteolytic
lesion
due
activate
osteoclast
degrade
bone
matrix
bone
loss
severe
pain
pathologic
fracture
spinal
cord
nerve
compression
bone
marrow
suppression
addition
growth
factor
release
matrix
promote
cancer
cell
proliferation
contribute
describe
vicious
cycle
particular
transform
growth
insulin
growth
release
matrix
bone
degradation
stimulate
production
parathyroid
protein
pthrp
foster
cancer
cell
growth
furthermore
growth
factor
release
matrix
substance
secrete
cancer
cell
osteoblast
contribute
metastatic
microenvironment
osteoblast
factor
receptor
activator
nuclear
factor
kappa
ligand
rankl
opg
part
normal
signaling
cross
talk
monocyte
chemoattractant
may
indicate
osteoblast
inflammatory
response
know
long
time
chronic
inflammation
occur
part
cancer
cell
interaction
stromal
environment
support
cancer
progression
metastasis
endothelial
cell
cell
blood
lymph
vasculature
well
transient
cell
innate
adaptive
immune
system
affect
cancer
cell
growth
metastasis
condition
communication
within
stromal
network
carry
cytokine
chemokine
peptide
disruption
homeostasis
trauma
microorganism
material
cancer
cell
result
change
level
type
cytokine
express
stromal
environment
metaphyseal
bone
exception
circumstance
change
balance
osteoblast
osteoclast
may
lead
bone
loss
example
osteomyelitis
bring
tuberculosis
aureus
associate
uncontrolled
inflammation
especially
high
level
rantes
bone
loss
trace
osteoblast
stress
response
high
level
cytokine
show
attract
activate
osteoclast
well
cell
immune
system
thus
perpetuate
bone
loss
likely
lymphocyte
neutrophil
macrophage
potent
source
inflammatory
molecule
present
evidence
paper
metastatic
breast
cancer
cell
directly
induce
osteoblast
express
increase
level
inflammatory
stress
response
molecule
specifically
macrophage
inflammatory
kc
moreover
osteoblast
response
mediate
soluble
factor
occur
independently
direct
cancer
cell
osteoblast
contact
ultimate
target
osteoclast
current
therapy
direct
block
osteoclast
activity
bisphosphonates
zoledronic
acid
current
standard
care
much
metastases
bone
synthetic
analogue
pyrophosphate
inhibit
osteoclast
activity
slow
lesion
formation
although
reduce
event
curative
lead
restoration
bone
eliminate
cancer
cell
osteoblast
appear
functionally
previously
report
osteoblast
expose
metastatic
breast
cancer
cell
condition
medium
show
increase
apoptosis
suppression
production
bone
matrix
protein
change
morphology
result
study
indicate
osteoblast
also
switch
inflammatory
mode
presence
breast
cancer
cell
inflammatory
cytokine
different
make
cancer
cell
target
osteoclast
precursor
effector
osteolysis
therefore
osteoblast
contribute
osteolytic
phenotype
due
loss
bone
deposition
function
well
increased
production
osteoclast
activate
cytokine
material
method
cell
line
osteoblast
hfob
cell
human
fetal
osteoblast
immortalize
large
antigen
temperature
proliferate
incubation
show
growth
foster
osteoblast
differentiation
cell
gift
thomas
cultured
hfob
growth
medium
consist
dulbecco
modified
eagle
medium
dmem
sigma
louis
fetal
bovine
serum
fbs
sigma
penicillin
streptomycin
ml
sigma
experiment
hfob
osteoblast
confluency
cultured
day
hfob
differentiation
medium
fbs
penicillin
streptomycin
ml
vitamin
biomol
plymouth
meeting
pa
vitamin
k
sigma
ml
vitamin
ascorbic
acid
sigma
indicate
various
experiment
hfob
cell
plate
approximately
cell
flask
mm
well
culture
plate
cell
murine
line
capable
differentiation
mineralization
culture
gift
norman
university
cell
maintain
growth
medium
alpha
minimum
essential
medium
mem
mediatech
va
neonatal
fbs
ontario
penicillin
streptomycin
ml
experiment
indicate
cell
plate
cell
differentiation
medium
mem
fbs
penicillin
streptomycin
ml
ml
ascorbic
acid
mm
sigma
breast
cancer
cell
cell
human
metastatic
breast
cancer
line
derived
pleural
effusion
gift
welch
university
alabama
birmingham
cell
maintain
breast
cancer
growth
medium
dmem
fbs
penicillin
streptomycin
ml
primary
osteoblast
neonatal
mouse
calvariae
osteoblast
isolate
neonatal
mouse
calvariae
cultured
describe
animal
approve
pennsylvania
state
university
briefly
calvariae
dissect
day
mouse
calvariae
rinse
pbs
cut
piece
incubate
digestion
solution
mg
ml
collagenase
type
ia
sigma
trypsin
pbs
min
shake
immediately
incubation
min
min
incubation
solution
contain
cell
collect
fbs
add
calvariae
piece
wash
ml
dmem
wash
add
digestion
solution
contain
cell
centrifuged
min
cell
pellet
resuspended
calvariae
growth
medium
dmem
fbs
penicillin
streptomycin
ml
ml
ascorbic
acid
plate
well
plate
ml
cell
suspension
per
well
pool
procedure
repeat
three
much
time
pool
follow
day
culture
medium
replace
fresh
growth
medium
cell
monitor
confluency
reach
cell
trypsinized
trypsin
mm
edta
hank
balanced
salt
solution
mediatech
va
combine
pool
combine
cell
plate
cell
density
cell
calvariae
growth
medium
next
day
culture
medium
remove
calvariae
differentiation
medium
dmem
fbs
penicillin
streptomycin
ml
ml
ascorbic
acid
ml
dexamethasone
add
cell
change
twice
week
desire
osteoblast
age
reach
combined
pool
day
addition
differentiation
medium
experiment
describe
study
conditioned
medium
preparation
breast
cancer
cell
grow
confluency
breast
cancer
growth
medium
remove
culture
rinse
pbs
hfob
cell
mem
cell
add
cancer
cell
ml
flask
cell
culture
incubate
breast
cancer
cell
condition
medium
bccm
collect
centrifuged
min
remove
cellular
debris
store
hfob
cell
condition
medium
prepare
hfob
cell
confluent
rinse
one
time
pbs
penicillin
streptomycin
ml
add
collect
incubation
centrifuged
remove
debris
store
conditioned
medium
treatment
osteoblast
vehicle
medium
vm
consist
differentiation
medium
appropriate
cell
line
differentiation
medium
formulate
osteoblast
cell
line
hfob
medium
consist
dmem
ham
fbs
vitamin
k
ml
ascorbic
acid
iu
ml
penicillin
ml
streptomycin
medium
consist
mem
neonatal
fbs
ml
ascorbic
acid
mm
iu
ml
penicillin
ml
streptomycin
conditioned
medium
cm
comprise
one
half
volume
bccm
one
half
volume
osteoblast
differentiation
medium
appropriate
osteoblast
line
experiment
scheme
ensure
concentration
serum
differentiation
factor
identical
vm
cm
peptide
cytokine
antibody
purchase
rd
system
minneapolis
mn
concentration
indicate
antibody
incubate
vm
cm
prior
culturing
osteoblast
parathyroid
hormone
obtain
sigma
louis
cytokine
analysis
cytokine
culture
medium
detect
raybio
mouse
cytokine
antibody
array
iii
system
raybio
human
array
system
hfob
cell
cytokine
protein
level
quantitated
elisa
follow
protocol
recommend
rd
system
variation
typically
little
select
cytokine
quantitated
mouse
human
cytokine
assay
system
hercules
california
statistical
analysis
statistical
analysis
carry
sas
windows
sas
version
sas
institute
cary
main
effect
evaluate
analysis
variance
anova
data
analysis
variable
statistical
significance
define
probability
analysis
value
individual
experiment
provide
figure
legend
result
production
hfob
cell
increase
presence
breast
cancer
condition
medium
hfob
approximately
confluent
rinse
pbs
treat
either
vm
cm
hour
later
culture
medium
collect
screen
raybio
human
cytokine
array
among
cytokine
screen
level
readily
detect
array
cytokine
detect
bccm
alone
medium
osteoblast
also
detectable
level
cytokine
array
datum
show
image
image
hfob
secrete
cytokine
detect
cytokine
hfob
cell
grow
growth
medium
reach
approximately
confluency
growth
medium
remove
cell
rinse
pbs
subsequently
treat
vm
cm
resultant
culture
supernatant
collect
centrifuged
remove
debris
analyzed
raybio
human
cytokine
protein
array
system
array
result
culture
supernatant
hfob
cell
treat
cm
leave
right
positive
control
positive
control
array
result
bccm
alone
positive
control
cytokine
detect
view
within
article
order
detect
cytokine
level
standard
elisa
carry
bccm
assay
presence
human
assay
pg
ml
pg
ml
pg
ml
detect
basal
level
cytokine
subtract
datum
follow
late
time
assay
bccm
assay
find
pg
ml
pg
ml
pg
ml
define
osteoblast
cytokine
response
bccm
determine
whether
stage
osteoblast
differentiation
important
response
hfob
treat
cm
various
day
hfob
grow
confluency
day
transfer
allow
differentiation
day
transfer
cell
treat
either
vm
cm
hour
later
culture
medium
collect
assay
elisa
human
day
hfob
cell
treat
vm
contain
undetectable
level
osteoblast
treat
cm
contain
ml
ml
respectively
however
difference
much
pronounce
osteoblast
differentiate
example
exposure
osteoblast
cm
lead
fold
increase
ml
time
cytokine
level
cell
treat
vm
increase
ml
image
image
increase
secretion
hfob
various
stage
differentiation
presence
breast
cancer
condition
hfob
grow
confluency
day
change
differentiation
condition
indicate
method
section
hour
prior
indicate
day
osteoblast
treat
either
vm
cm
resultant
culture
supernatant
collect
assay
concentration
bccm
alone
approximately
pg
ml
pg
ml
undetectable
pg
ml
baseline
cytokine
level
subtract
value
obtain
hfob
treatment
cm
experiment
perform
twice
day
eight
time
day
similar
result
shown
representative
experiment
pair
total
separate
experiment
total
separate
experiment
value
calculation
include
datum
show
view
within
article
similar
pattern
find
cytokine
concentration
osteoblast
treat
vm
ml
early
differentiation
stage
however
concentration
increase
ml
day
treatment
cm
increase
osteoblast
production
nearly
five
time
ml
compare
treatment
vm
time
ml
osteoblast
production
display
different
pattern
expression
increase
cell
treat
vm
cm
however
concentration
high
culture
osteoblast
treat
cm
vm
increase
maintain
throughout
stage
osteoblast
differentiation
day
osteoblast
treat
vm
ml
cm
ml
day
osteoblast
treat
vm
ml
cm
ml
dose
response
osteoblast
cytokine
expression
determine
treat
hfob
bccm
resultant
culture
supernatant
collect
assay
elisa
osteoblast
production
increase
percentage
bccm
increase
image
image
hfob
increase
cytokine
secretion
breast
cancer
condition
medium
dose
hfob
cell
plate
grow
confluency
change
differentiation
condition
indicate
method
section
day
osteoblast
treat
vm
cm
either
bccm
resultant
culture
supernatant
collect
cytokine
level
determine
elisa
view
within
article
determine
alter
cytokine
production
specific
breast
cancer
condition
medium
osteoblast
culture
treat
osteoblast
cm
significant
change
osteoblast
production
compare
treatment
vm
datum
show
direct
hfob
breast
cancer
cell
direct
model
test
determine
change
similar
treatment
cm
occur
cell
contact
cell
add
differentiate
day
monolayer
hfob
ratio
hfob
cell
hfob
cell
cultured
separately
control
culture
supernatant
collect
assay
elisa
supernatant
cell
contain
nearly
ml
ml
hfob
cell
alone
express
ml
ml
breast
cancer
cell
cultured
alone
express
pg
ml
therefore
fold
increase
fold
increase
production
condition
believe
cytokine
produce
osteoblast
possible
situation
osteoblast
may
stimulate
breast
cancer
cell
increase
cytokine
production
image
image
increase
cytokine
production
hfob
directly
hfob
plate
grow
day
confluent
culture
move
day
cell
count
metastatic
breast
cancer
cell
add
exist
hfob
osteoblast
culture
ratio
breast
cancer
cell
osteoblast
cell
also
plate
alone
culture
incubate
resultant
culture
supernatant
collect
assay
elisa
medium
cell
cultured
alone
undetectable
level
solid
bar
hfob
cell
check
bar
cell
hfob
cell
ratio
view
within
article
osteoblast
increase
cytokine
production
presence
condition
medium
due
nature
hfob
cell
complication
two
human
cell
line
also
test
murine
osteoblast
line
initial
experiment
cell
cultured
day
osteoblast
differentiation
medium
treat
vm
cm
resultant
culture
supernatant
collect
assay
raybio
mouse
cytokine
array
iii
system
visible
increase
well
lix
macrophage
inflammatory
rantes
similar
increase
observe
cell
treat
cm
day
culture
time
osteoblast
early
stage
datum
show
assay
follow
murine
elisa
confirm
quantify
expression
increase
murine
substantial
example
osteoblast
treat
vm
contain
ml
whereas
treatment
cm
yield
ml
increase
murine
however
little
dramatic
ml
compare
ml
datum
show
since
mouse
express
assay
murine
cytokine
think
function
similarly
detect
concentration
pg
ml
increase
exposure
cm
pg
ml
datum
show
thus
exposure
bccm
elicit
similar
cytokine
response
human
murine
osteoblast
line
additionally
increase
response
demonstrate
primary
mouse
osteoblast
isolate
neonatal
due
consistent
dramatic
increase
murine
production
treat
osteoblast
designate
signature
cytokine
inflammatory
response
image
image
conditioned
medium
breast
cancer
cell
induce
osteoblast
cytokine
production
cell
day
culture
osteoblast
treat
either
vm
cm
hour
later
resultant
culture
supernatant
collect
raybio
mouse
cytokine
antibody
array
iii
detect
change
osteoblast
cytokine
production
shown
result
day
day
result
murine
osteoblast
vm
cytokine
murine
osteoblast
cytokine
production
treatment
cm
leave
right
lix
rantes
osteoblast
secretion
cytokine
induce
lix
increase
rantes
treat
cm
view
within
article
image
image
conditioned
medium
breast
cancer
cell
rapidly
induce
osteoblast
production
day
culture
osteoblast
treat
vm
cm
resultant
culture
supernatant
collect
murine
level
measure
elisa
shown
range
concentration
hour
exposure
cm
treatment
box
plot
black
bar
vehicle
medium
check
bar
condition
medium
per
condition
view
within
article
image
image
primary
murine
osteoblast
secrete
response
breast
cancer
condition
medium
primary
osteoblast
isolate
calvariae
neonatal
mouse
describe
method
section
cell
cultured
calvariae
differentiation
medium
day
medium
change
vm
cm
culture
medium
collect
murine
quantitated
elisa
shown
mean
standard
deviation
per
condition
view
within
article
determine
response
time
bccm
cell
cultured
day
treat
vm
cm
resultant
culture
supernatant
assay
murine
little
exposure
cm
elicit
fold
increase
murine
secretion
osteoblast
vm
treatment
ml
cm
treatment
ml
increase
nearly
fold
vm
treatment
ml
cm
treatment
ml
parathyroid
peptide
transform
growth
candidate
factor
mediate
expression
osteoblast
cytokine
pthrp
report
present
breast
cancer
condition
medium
report
induce
least
one
cytokine
interest
therefore
consider
possible
factor
secrete
cell
may
promote
osteoblast
cytokine
expression
detect
therefore
eliminate
far
consideration
pthrp
present
pg
ml
approximately
andrea
penn
state
similar
value
report
concentration
bring
increase
expression
osteoblast
datum
show
however
find
present
ml
depending
batch
condition
medium
also
see
concentration
sufficient
stimulate
production
osteoblast
see
test
combination
suboptimal
concentration
ml
pthrp
find
synergistic
production
datum
show
therefore
focused
breast
cancer
cell
condition
medium
image
image
partially
responsible
expression
cell
cultured
day
conditioned
medium
cell
contain
ml
tgf
later
determine
elisa
add
cell
incubate
ml
neutralize
antibody
addition
culture
incubate
ml
ml
antibody
one
set
culture
incubate
vehicle
medium
incubation
culture
medium
collect
assay
black
bar
vehicle
medium
check
bar
condition
medium
shown
mean
standard
deviation
representative
experiment
experiment
conduct
three
time
duplicate
similar
result
per
condition
view
within
article
determine
effect
add
neutralize
antibody
breast
cancer
cell
condition
medium
addition
condition
medium
increase
production
nearly
fold
compare
addition
regular
differentiation
medium
vm
treatment
condition
medium
excess
ml
neutralize
antibody
reduce
osteoblast
expression
compare
untreated
condition
medium
addition
tgf
ml
osteoblast
increase
production
approximately
fold
value
reduce
follow
incubation
tgf
antibody
tgf
addition
cell
later
determine
condition
medium
contain
approximately
ml
tgf
thus
antibody
far
excess
require
neutralize
antigen
similar
result
see
inhibitor
tocris
tgf
receptor
datum
show
discussion
find
osteoblast
respond
condition
medium
human
metastatic
breast
cancer
cell
enhance
cytokine
expression
specifically
osteoblast
increase
production
human
three
cytokine
characterize
osteoblast
inflammatory
stress
protein
molecule
may
help
provide
favorable
tumor
cell
environment
well
initiate
osteoclastogenesis
find
support
idea
breast
cancer
metastases
create
unique
niche
bone
microenvironment
normal
cell
bone
favor
tumor
growth
development
cell
type
undoubtedly
involve
metastatic
tumorigenic
process
demonstrate
direct
effect
metastatic
breast
cancer
cell
osteoblast
breast
cancer
metastasis
bone
predominantly
osteolytic
disease
whereby
osteoclast
cancer
cell
bone
degradation
according
vicious
cycle
paradigm
cancer
pthrp
activate
osteoblast
express
rankl
bind
receptor
activator
nuclear
factor
kappa
rank
osteoclast
lead
activation
subsequent
bone
loss
osteoclast
resorption
bone
matrix
release
act
tumor
cell
stimulate
much
pthrp
however
osteoclast
solely
responsible
sustain
bone
loss
administration
bisphosphonate
inhibit
osteoclast
activity
result
resolution
bone
lesion
lesion
formation
slow
lesion
heal
clearly
impact
metastatic
breast
cancer
cell
osteoblast
ignore
close
examination
fate
osteoblast
find
presence
breast
cancer
cell
condition
medium
cultured
osteoblast
exhibit
increase
apoptosis
change
morphology
suppression
differentiation
mineralization
evidence
lack
expression
alkaline
phosphatase
bone
increase
osteoblast
apoptosis
decrease
alkaline
phosphatase
expression
also
detect
vivo
mouse
model
addition
phenotypic
effect
current
study
demonstrate
osteoblast
exhibit
increase
inflammatory
cytokine
presence
metastatic
breast
cancer
cell
cytokine
array
reveal
three
cytokine
particular
increase
dramatically
hfob
human
osteoblast
treat
cm
also
elevate
hfob
cell
murine
osteoblast
display
similar
increase
murine
expose
metastatic
breast
cancer
cell
condition
medium
far
evidence
also
see
increase
kc
murine
homologue
human
vitro
ex
vivo
unpublished
datum
exposure
primary
murine
osteoblast
breast
cancer
condition
medium
also
elicit
increase
murine
cytokine
express
high
level
osteoblast
osteolysis
occur
particle
device
chronic
state
inflammation
bone
microenvironment
additionally
osteoblast
expose
tuberculosis
aureus
vitro
vivo
undergo
inflammatory
stress
response
produce
infection
bone
two
microbe
elicit
chronic
inflammatory
response
bone
damage
observe
osteomyelitis
thus
present
study
indicate
breast
cancer
cell
evoke
similar
stress
response
osteoblast
pleiotropic
cytokine
influence
many
biological
event
include
bone
remodeling
particular
play
role
formation
activation
osteoclast
vitro
vivo
implicate
pathogenesis
bone
resorption
associate
paget
disease
disappear
bone
disease
syndrome
multiple
myeloma
interest
study
show
induce
production
pthrp
human
osteoblastic
cell
soluble
pthrp
also
derived
tumor
cell
stimulate
production
additional
feedback
loop
facilitate
osteoclastogenesis
decrease
production
opg
increase
osteoblast
expression
rankl
bone
resorption
subsequently
follow
release
store
bone
matrix
turn
enhance
breast
cancer
cell
production
pthrp
addition
play
role
osteoclastogenesis
bone
resorption
function
may
contribute
cancer
progression
although
involvement
regulate
growth
apoptosis
breast
cancer
cell
unclear
know
growth
factor
myeloma
cell
act
factor
human
esophageal
carcinoma
multiple
myeloma
cell
addition
downregulate
expression
chemokine
property
cell
also
report
enhance
migration
breast
cancer
cell
vitro
furthermore
importance
cancer
progression
demonstrate
study
signaling
breast
cancer
cell
block
inhibition
result
significantly
decrease
tumor
size
metastasis
nude
mouse
model
finally
level
breast
cancer
patient
correlated
clinical
stage
rate
recurrence
particular
high
serum
level
patient
advance
recurrent
breast
cancer
find
unfavorable
prognosis
indicator
besides
act
cell
tumor
bone
microenvironment
also
find
increase
osteoblast
production
another
cytokine
identify
study
monomeric
polypeptide
member
cc
chemokine
superfamily
principle
cytokine
involve
inflammation
bone
remodeling
know
recruit
cell
involve
inflammation
osteoclast
precursor
angiogenesis
three
process
clearly
involve
breast
cancer
tumorigenesis
lesion
formation
bone
also
normally
produce
osteoblast
also
increase
metastatic
cell
line
find
particularly
important
cancer
cell
migration
metastasis
study
utilize
metastatic
lncap
bone
metastatic
lncap
prostate
cancer
cell
find
increase
proliferation
invasion
interestingly
receptor
receptor
find
present
prostate
cancer
cell
line
examine
addition
prostate
cancer
cell
find
produce
high
level
compare
primary
prostate
epithelial
cell
study
show
mediate
prostate
cancer
osteoclastogenesis
bone
resorption
breast
ovarian
cancer
patient
serum
level
correlated
advance
tumor
stage
addition
expression
squamous
cell
carcinoma
esophagus
equate
venous
invasion
metastasis
furthermore
show
act
chemoattractant
myeloma
cell
thus
evident
key
mediator
involve
inflammation
cancer
cell
progression
inflammatory
cytokine
produce
many
cell
type
include
osteoblast
first
identify
neutrophil
chemoattractant
now
know
attract
monocyte
osteoclast
precursor
well
promote
angiogenesis
bone
show
directly
inhibit
alkaline
phosphatase
expression
well
decrease
normal
bone
resorption
increase
motility
osteoclast
new
resorption
site
interestingly
human
osteoclast
also
show
secrete
high
level
indicate
molecule
importance
normal
bone
remodeling
along
also
find
important
cancer
cell
progression
secrete
many
tumor
cell
line
metastatic
osteolytic
addition
appear
play
role
cell
motility
invasion
metastatic
potential
human
tumor
concerning
present
study
increase
bone
metastatic
potential
human
breast
cancer
cell
associate
cancer
cell
ability
express
several
study
metastatic
breast
cancer
find
directly
stimulate
osteoclastogenesis
via
rankl
dependent
independent
mechanism
particular
propose
play
important
role
vicious
cycle
breast
cancer
cell
metastasis
bone
breast
cancer
increase
rankl
expression
osteoblast
turn
facilitate
osteoclast
formation
addition
soluble
directly
promote
osteoclastogenesis
lead
bone
resorption
release
bone
matrix
continue
drive
vicious
cycle
amplify
osteolysis
support
breast
cancer
bone
metastases
also
implicate
clinical
outcome
patient
breast
cancer
study
involve
woman
operable
advance
breast
cancer
elevate
serum
level
find
directly
associate
clinical
stage
breast
cancer
find
indicative
poor
prognosis
cytokine
feedback
directly
onto
tumor
cell
seem
unlikely
since
cell
receptor
cytokine
specifically
report
literature
cell
express
receptor
express
level
mrna
nonetheless
neutralize
antibody
affect
growth
cell
cell
express
receptor
find
consistent
lack
response
one
report
expression
mrna
receptor
none
protein
report
take
together
indicate
cancer
cell
expect
respond
cytokine
hypothesis
osteoblast
produce
cytokine
response
cancer
cell
cytokine
go
activate
osteoclast
well
document
literature
osteoclast
stimulate
property
summary
show
osteoblast
display
inflammatory
response
expose
breast
cancer
cell
condition
medium
inflammatory
cytokine
target
osteoclast
precursor
osteoclast
bring
bone
matrix
destruction
thus
osteoblast
contribute
osteolytic
phenotype
suppression
bone
deposition
production
cytokine
recruit
activate
osteoclast
acknowledgment
work
support
medical
material
research
breast
cancer
program
national
foundation
cancer
research
center
metastasis
research
susan
komen
breast
cancer
foundation
american
institute
cancer
research
sigma
xi
research
grant
fund
college
research
award
author
like
thank
richard
immunomodulation
core
penn
state
work
support
nih
technical
advice
regard
elisa
editorial
assistance
paper
describe
knowledge
based
system
kbs
intend
assist
clinician
assessment
management
patient
suspect
breast
cancer
system
build
part
credo
project
fox
patkar
thomas
design
support
entire
journey
breast
cancer
patient
initial
presentation
diagnosis
treatment
part
credo
project
formal
model
breast
cancer
care
pathway
develop
fox
patkar
rose
black
show
may
many
separate
decision
point
breast
cancer
journey
significant
potential
patient
harm
least
failure
achieve
good
outcome
unless
clinician
apply
good
practice
system
describe
triple
assessment
decision
support
system
design
assist
breast
clinician
four
decision
point
genetic
risk
assessment
selection
imaging
technique
choice
biopsy
modality
final
management
decision
system
create
tallis
implementation
proforma
knowledge
representation
language
user
interface
implement
java
server
page
servlets
javascript
cascading
style
describe
analyse
system
commonkads
methodology
first
section
paper
provide
background
information
triple
assessment
commonkads
proforma
tallis
next
three
section
commonkads
methodology
analyse
describe
system
analysis
first
examine
organisational
context
system
describe
requirement
meet
finally
outline
design
final
section
paper
discuss
analysis
perform
outline
conclusion
triple
assessment
breast
cancer
breast
cancer
much
commonly
diagnose
cancer
woman
accounting
cancer
one
nine
woman
will
develop
breast
cancer
point
life
year
total
woman
newly
diagnose
breast
cancer
england
uk
office
national
statistic
uk
woman
breast
relate
symptom
raise
suspicion
breast
cancer
referred
gp
designate
breast
clinic
local
hospital
single
year
average
gp
patient
list
expect
see
one
two
new
case
breast
cancer
will
see
considerably
much
patient
benign
breast
problem
hospital
responsible
population
will
deal
perhaps
new
gp
referral
week
plus
maybe
two
woman
referred
screening
mammography
period
one
year
typical
breast
clinic
will
approximately
breast
referral
approximately
patient
will
diagnose
breast
cancer
increase
accuracy
diagnosis
combination
clinical
examination
imaging
biopsy
know
together
triple
assessment
recommend
qualify
woman
imaging
achieve
either
mammography
ultrasound
biopsy
may
take
form
core
biopsy
fine
needle
aspiration
fna
commonkads
commonkads
provide
complete
methodology
development
knowledge
based
system
kbs
methodology
describe
principle
technique
model
language
document
structure
assist
three
phase
construction
kbs
contextual
analysis
phase
focuses
organisation
will
eventually
system
describe
business
process
resource
knowledge
asset
organisation
well
describe
impact
kbs
will
system
one
aim
contextual
analysis
demonstrate
propose
kbs
feasible
bring
benefit
organisation
cost
implement
adopt
second
conceptual
analysis
phase
methodology
clarify
knowledge
kbs
will
require
represent
reasoning
will
require
perform
knowledge
interaction
will
require
perform
user
external
agent
third
design
phase
methodology
create
design
kbs
easily
translated
code
appropriate
language
analysis
produce
set
model
illustrate
contextual
analysis
phase
produce
organisation
model
first
cut
description
organisation
system
also
produce
task
agent
model
provide
much
detail
task
organisation
perform
people
system
perform
task
conceptual
analysis
phase
produce
knowledge
model
describe
knowledge
representation
reasoning
requirement
system
communication
model
describe
require
information
flow
system
various
agent
interact
design
phase
produce
design
model
model
may
omit
inappropriate
system
analyse
image
commonkads
model
view
within
article
proforma
tallis
proforma
knowledge
representation
language
create
process
description
description
process
time
require
cooperation
various
actor
clinician
medical
personnel
language
benefit
graphical
editor
obtain
agreement
research
team
develop
language
proforma
process
description
compose
object
draw
class
set
uml
class
diagram
class
object
set
name
property
avoid
property
show
instance
give
class
will
different
value
property
one
class
object
connect
another
kind
relationship
much
specific
class
inherit
property
much
general
class
instance
proforma
component
property
name
description
hence
data
items
kind
proforma
component
will
also
property
image
proforma
component
view
within
article
proforma
process
description
set
proforma
component
proforma
component
among
thing
task
data
item
task
action
enquiry
decision
plan
action
generally
represent
request
external
actor
something
prescribe
drug
perform
clinical
intervention
enquiry
represent
request
external
actor
provide
value
datum
item
source
enquiry
decision
represent
choice
one
much
candidate
choice
candidate
may
perform
external
actor
may
make
automatically
system
engine
keep
record
candidate
choose
information
control
subsequent
execution
process
candidate
associate
one
much
argument
logical
expression
whose
truth
influence
choice
candidate
will
recommend
external
actor
make
engine
external
actor
involve
proforma
include
expression
language
define
among
thing
true
order
task
activate
criterion
fulfil
order
argument
true
proforma
expression
language
include
usual
logical
comparison
operator
well
function
evaluate
value
datum
item
execution
state
task
whether
need
perform
proforma
language
give
precise
semantics
sutton
fox
semantics
define
value
return
expression
evaluate
well
operation
perform
run
process
change
occur
process
state
operation
perform
two
implementation
proforma
engine
exist
implementation
available
commercially
london
uk
tallis
implementation
cancer
research
uk
contextual
analysis
commonkads
contextual
analysis
describe
effect
propose
kbs
will
organisation
provide
mean
judge
improvement
kbs
will
bring
well
cost
implement
adopt
essential
part
contextual
analysis
development
organisation
model
model
five
section
first
section
problem
organisation
face
set
solution
problem
involve
kbs
briefly
outline
second
variant
aspect
organisation
organisational
structure
business
process
knowledge
asset
outline
third
section
describe
individual
task
perform
part
organisation
business
process
fourth
identify
describe
evaluate
knowledge
asset
process
fifth
section
set
initial
judgement
feasibility
propose
kbs
problem
problem
statement
case
consider
main
problem
face
make
sure
assessment
technique
available
clinician
appropriately
technique
form
part
triple
assessment
process
may
risk
harm
patient
term
miss
cancer
resource
exhaustion
recent
policy
document
audit
emphasised
importance
evidence
based
guideline
ensure
consistency
quality
cancer
care
express
concern
extent
policy
follow
transparent
manner
audit
commission
calman
hine
propose
kbs
aim
provide
assistance
clinical
staff
involve
triple
assessment
assistance
intend
accord
evidence
based
guideline
ensure
consistent
safe
practice
problem
examine
context
wide
project
credo
whose
aim
provide
support
breast
cancer
patient
stage
management
proposed
solution
propose
solution
proforma
language
tallis
toolset
implement
distribute
computerised
decision
support
system
assist
triple
assessment
process
primary
user
system
will
breast
surgeon
radiologist
nurse
practitioner
system
will
make
datum
provide
cytologist
pathologist
organisational
context
essential
part
commonkads
organisational
model
description
aspect
organisational
context
likely
affect
decision
whether
adopt
propose
kbs
include
overall
goal
principle
organisation
strategy
adopt
order
achieve
goal
external
factor
oblige
consider
reason
include
information
model
propose
kbs
conform
respect
aspect
organisational
context
order
successfully
adopt
section
set
goal
principle
underlie
provision
cancer
care
england
wales
strategy
employ
order
achieve
goal
external
factor
affect
provision
service
mission
goal
principle
expert
advisory
group
cancer
calman
hine
recommend
follow
principle
govern
provision
cancer
care
england
wales
care
uniformly
high
quality
provide
close
patient
home
compatible
high
quality
safe
effective
treatment
early
recognition
symptom
encourage
public
professional
education
program
screening
program
patient
family
carers
give
clear
information
assistance
stage
diagnosis
treatment
cancer
care
patient
centre
take
account
patient
family
carers
view
primary
care
team
continue
provide
central
role
provision
care
patient
family
psychosocial
aspect
cancer
care
consider
stage
cancer
registration
careful
monitoring
treatment
outcome
essential
principles
specific
diagnosis
breast
cancer
set
national
institute
health
clinical
excellence
nice
include
increase
speed
accuracy
breast
disease
diagnosis
reduction
cost
reduce
unnecessary
open
biopsy
rate
survival
quality
life
benefit
associate
appropriate
treatment
adequate
early
diagnosis
improvement
patient
experience
time
number
visit
require
get
diagnosis
strategies
strategies
adopt
achieve
goal
include
provision
paper
guideline
care
see
example
baso
sign
encouragement
write
protocol
concentration
resource
centre
unit
large
enough
ensure
sufficient
volume
work
maintain
expertise
professional
training
include
training
nurse
practitioner
introduction
audit
cycle
expert
advisory
group
nice
note
although
will
variation
pattern
practice
across
country
cancer
unit
cancer
centre
different
method
treatment
expect
justify
scientific
logistical
ground
external
factor
breast
cancer
diagnosis
treatment
subject
considerable
interest
public
press
government
political
organization
pharmaceutical
industry
external
factor
affect
provision
cancer
care
therefore
include
patient
group
industry
body
political
campaign
government
policy
commitment
variant
aspect
goal
strategy
set
first
section
organisation
model
assume
sense
will
change
result
adoption
propose
kbs
second
section
model
set
aspect
organisation
least
potentially
subject
change
variant
aspect
include
structure
organisation
concern
business
process
agent
involve
process
resource
knowledge
asset
structure
structure
organisation
provide
care
suspect
breast
cancer
patient
united
kingdom
outline
patient
first
point
contact
system
likely
visit
gp
screening
programme
contact
give
reason
concern
patient
will
referred
specialist
breast
clinic
local
hospital
manage
nhs
acute
trust
acute
trust
provide
service
commission
primary
care
trust
operate
strategic
direction
provide
local
strategic
health
authority
image
organisational
structure
view
within
article
breast
clinic
will
facility
examination
biopsy
procedure
report
consultation
radiology
resource
ultrasound
mammography
close
hand
easy
access
report
breast
clinic
work
closely
designate
multidisciplinary
team
mdt
discuss
case
recommend
far
course
action
process
primary
business
process
set
figure
illustrate
various
task
perform
individual
patient
progress
diagnosis
treatment
process
set
uml
activity
diagram
rectangle
represent
task
perform
rectangle
represent
information
object
produce
task
solid
line
task
indicate
control
flow
whereas
dash
line
represent
datum
flow
control
flow
follow
path
datum
flow
show
separately
image
overall
business
process
view
within
article
patient
initial
point
contact
system
will
visit
gp
via
screening
initial
contact
give
concern
patient
will
referred
triple
assessment
triple
assessment
process
set
much
detail
image
triple
assessment
process
view
within
article
triple
assessment
produce
diagnosis
will
examine
multidisciplinary
team
will
arrive
definitive
diagnosis
fine
needle
aspiration
core
biopsy
may
perform
part
triple
assessment
process
appropriate
however
case
mdt
may
request
much
extensive
open
biopsy
perform
patient
whose
history
indicate
high
genetic
risk
cancer
may
referred
geneticist
addition
primary
process
set
secondary
business
process
design
quality
assurance
review
public
education
professional
training
management
coordination
triple
assessment
process
outline
first
element
assessment
consist
clinical
examination
gathering
patient
history
demographic
datum
initial
examination
reveal
abnormality
patient
will
referred
imaging
ultrasound
mammography
needle
biopsy
biopsy
may
fine
needle
aspiration
fna
large
sample
may
obtain
core
biopsy
case
patient
will
initially
referred
fna
biopsy
inconclusive
result
procedure
will
necessitate
core
biopsy
well
mammograms
generally
take
radiographer
later
interpret
radiologist
ultrasound
image
take
radiologist
will
interpret
time
triple
assessment
may
differ
shown
result
availability
datum
resource
instance
image
datum
may
already
available
surgeon
time
first
visit
allow
imaging
task
omit
integration
kbs
business
process
kbs
will
provide
decision
support
four
point
business
process
will
assist
determination
risk
category
genetic
risk
assessment
task
will
assist
choice
imaging
modality
mammography
ultrasound
neither
perform
clinical
assessment
task
will
also
biopsy
decision
task
assist
decision
nature
biopsy
perform
finally
will
management
decision
task
order
decide
manage
patient
people
triple
assessment
collaborative
activity
involve
follow
participant
baso
surgeon
primary
care
patient
breast
cancer
currently
responsibility
surgeon
radiologist
part
diagnostic
team
involve
appropriate
imaging
report
radiographer
joint
responsibility
monitoring
maintain
standard
procedure
equipment
report
set
nhsbsp
cytologist
part
diagnostic
team
work
closely
breast
surgeon
report
result
fine
needle
aspiration
fna
biopsy
maintain
standard
set
nhs
breast
screening
programme
nhsbsp
pathologist
work
closely
breast
surgeon
radiologist
report
core
biopsy
per
nhsbsp
standard
breast
care
nurse
present
time
give
positive
result
patient
discuss
treatment
option
general
nurse
may
act
chaperone
geneticist
part
cancer
treatment
team
rather
breast
cancer
team
direct
involvement
day
day
activity
breast
team
clinical
staff
adequate
support
require
maintain
good
communication
patient
gp
member
breast
team
resources
setting
dedicate
diagnostic
service
offer
triple
assessment
single
visit
involve
human
resource
cost
include
equipment
dedicate
mammotome
machine
ultrasound
machine
space
extra
man
hour
immediate
reporting
image
cytology
equipment
assist
multidisciplinary
team
discussion
individual
case
support
additional
resource
will
require
computerised
decision
support
include
datum
capture
storage
facility
electronic
patient
record
epr
picture
system
pacs
image
pathology
datum
knowledge
knowledge
resource
particular
importance
kbs
describe
separately
resource
principal
knowledge
asset
business
process
describe
guideline
set
organisation
national
institute
health
clinical
excellence
nice
various
tacit
skill
involve
surgical
task
communication
patient
knowledge
asset
describe
evaluate
follow
two
section
process
breakdown
organisation
model
include
breakdown
task
involve
business
process
outline
previous
section
task
identify
perform
task
within
organisational
structure
perform
also
identify
knowledge
asset
task
determine
whether
task
describe
knowledge
intensive
give
indication
significance
term
significance
leave
deliberately
vague
specification
commonkads
methodology
different
definition
may
appropriate
different
case
present
case
take
significance
subjective
measure
likelihood
physical
patient
harm
arise
task
perform
significance
express
numerical
estimate
scale
least
risk
great
risk
task
involve
triple
assessment
process
describe
table
table
process
breakdown
triple
assessment
process
clinical
clinictacit
skill
baso
sign
sign
genetic
risk
assessmentsurgeonbreast
clinic
nice
care
nurse
surgeonbreast
clinical
assessmentsurgeonbreast
clinic
baso
sign
nccn
clinic
breast
clinic
nhsbsp
tacit
clinic
nhsbsp
nhsbsp
tacit
clinic
breast
clinic
tacit
clinic
breast
clinic
nhsbsp
biopsy
surgeonbreast
clinic
mammography
clinic
ultrasound
clinic
baso
nccn
nhsbsp
sign
cytologist
surgeonbreast
clinictacit
fna
skill
nhsbsp
core
clinictacit
management
clinic
baso
sign
nccn
table
view
within
article
knowledge
asset
knowledge
asset
involve
business
process
resource
importance
give
section
organisation
model
complete
analysis
list
knowledge
asset
involve
business
process
describe
task
identify
limitation
availability
quality
particular
evaluate
whether
form
knowledge
asset
provide
paper
digital
appropriate
task
whether
knowledge
make
available
right
place
right
time
whether
quality
sufficient
knowledge
asset
triple
assessment
process
already
identify
table
list
separately
similar
comment
make
knowledge
asset
high
quality
available
right
time
place
asset
task
kbs
provide
support
convert
suitable
digital
form
feasibility
analysis
organisation
model
conclude
set
initial
observation
feasibility
propose
kbs
feasibility
assess
along
three
axis
business
feasibility
concern
benefit
cost
business
risk
result
adoption
kbs
technical
feasibility
express
technical
difficulty
risk
involve
project
feasibility
deal
possible
problem
involve
acquire
necessary
commitment
resource
implement
kbs
internal
external
communication
will
necessary
development
process
case
concern
might
make
follow
initial
observation
business
feasibility
principal
benefit
result
adoption
kbs
propose
reduction
number
error
arise
triple
assessment
demonstrate
general
computerised
decision
support
system
improve
practitioner
compliance
guideline
disease
management
prototype
implementation
triple
assessment
kbs
create
initial
trial
implementation
paper
patient
indicate
result
significant
reduction
number
error
make
triple
assessment
process
likely
business
feasibility
propose
system
depend
electronic
patient
record
epr
system
existence
otherwise
cost
datum
entry
technical
feasibility
considerable
body
experience
build
computerised
representation
medical
guideline
many
framework
design
create
representation
sutton
fox
proforma
language
associate
tallis
toolset
encapsulate
clinical
guideline
variety
setting
bury
sutton
technical
feasibility
system
strongly
link
existence
epr
system
business
feasibility
trial
pilot
study
possible
without
system
comprehensive
deployment
kbs
describe
likely
impractical
project
feasibility
initial
consultation
clinician
participate
first
trial
system
reveal
number
factor
likely
favour
acceptance
system
number
acceptance
general
agreement
kbs
improve
patient
care
clinician
respond
positively
question
trial
become
much
confident
trial
feel
kbs
definitely
reduce
variation
practice
also
feel
kbs
helpful
point
view
document
decision
well
underlie
medical
evidence
however
clinician
feel
kbs
might
slow
process
assessment
particular
clinical
staff
involve
comfortable
computer
question
need
kbs
argue
assessment
pathway
involve
already
give
adequate
paper
definition
clinician
also
point
kbs
affect
doctor
patient
relationship
system
generally
fit
well
mission
goal
principle
strategy
outline
previous
section
paper
effective
kbs
potential
facilitate
early
diagnosis
uniformity
standard
care
monitoring
treatment
kbs
may
also
provide
much
effective
way
disseminate
guideline
method
comment
elicit
clinician
however
highlight
need
consider
psychosocial
effect
kbs
effect
doctor
patient
relationship
also
raise
possibility
kbs
may
conflict
aim
minimize
time
require
diagnosis
particularly
staff
train
effectively
required
change
variant
aspect
kbs
follow
change
necessary
variant
aspect
identify
precede
section
people
new
role
create
clinician
need
train
kbs
structure
business
process
unchanged
kbs
provide
decision
support
various
point
previously
describe
knowledge
asset
knowledge
asset
triple
assessment
analyse
suitable
proforma
process
description
create
already
creation
kbs
initial
trial
domain
expert
check
result
process
description
consistent
original
paper
guideline
resources
reason
previously
mention
kbs
need
integrate
epr
routine
manner
conceptual
analysis
conceptual
modelling
stage
commonkads
analysis
knowledge
model
create
describe
knowledge
system
will
require
represent
reasoning
will
need
perform
commonkads
methodology
divide
knowledge
intensive
task
number
basic
type
describe
template
knowledge
model
type
adapt
create
knowledge
model
specific
particular
task
system
perform
task
perform
system
consider
describe
commonkads
terminology
compound
four
separate
assessment
task
assessment
task
one
case
assess
number
criterion
place
one
number
category
first
four
assessment
task
system
perform
assessment
patient
genetic
risk
breast
cancer
classify
high
great
lifetime
risk
medium
lifetime
risk
little
lifetime
risk
second
assessment
task
choice
appropriate
imaging
modality
mammography
ultrasound
neither
third
task
choose
type
biopsy
appropriate
final
task
choose
manage
patient
option
include
referral
geneticist
referral
multidisciplinary
team
meeting
commonkads
knowledge
model
three
component
first
component
domain
knowledge
consist
domain
schema
describe
type
knowledge
kbs
represent
knowledge
base
describe
particular
instance
knowledge
type
second
component
inference
knowledge
describe
reasoning
kbs
capable
perform
knowledge
third
component
task
knowledge
describe
system
reasoning
representation
capability
order
perform
knowledge
intensive
task
design
domain
schema
four
assessment
task
perform
system
model
domain
schema
set
simple
adaptation
schema
propose
commonkads
template
model
model
patient
state
set
separate
patient
datum
datum
interpret
provide
set
argument
various
decision
candidate
image
domain
schema
view
within
article
argument
include
warrant
describe
reason
apply
argument
identify
research
finding
guideline
support
argument
indicate
strength
evidence
favour
argument
weight
describe
importance
give
argument
choose
decision
candidate
instance
argument
may
sufficient
require
rule
particular
candidate
need
consider
alongside
argument
example
argument
perform
mammography
apply
patient
age
little
warrant
argument
increase
risk
radiation
hazard
sensitivity
mammography
age
group
back
british
association
surgical
oncology
baso
guideline
document
make
recommendation
evidence
grade
iii
meaning
support
well
design
descriptive
study
case
control
study
correlation
study
weight
argument
absolute
contraindication
schema
show
commonkads
graphical
language
extension
modelling
language
uml
principal
extension
make
uml
introduction
rule
type
represent
oval
rule
type
represent
set
constraint
exist
relationship
instance
class
schema
rule
type
argumentation
rule
represent
set
constraint
determine
whether
give
argument
relevant
give
patient
state
decision
rule
set
constraint
determine
whether
give
decision
candidate
adopt
give
argument
candidate
knowledge
base
knowledge
base
kbs
consist
instance
argument
decision
candidate
class
along
instance
two
rule
type
diagram
example
knowledge
base
second
two
assessment
task
system
perform
choose
appropriate
imaging
modality
include
follow
instance
among
many
instance
decision
candidate
class
represent
option
perform
mammography
breast
instance
argument
class
become
relevant
woman
high
genetic
risk
breast
cancer
year
old
instance
decision
rule
type
indicate
argument
sufficient
aforementioned
candidate
recommend
long
argument
possibility
patient
pregnant
inference
knowledge
inference
knowledge
section
describe
reasoning
step
kbs
able
perform
inference
knowledge
system
consider
describe
inference
structure
describe
adapt
commonkads
template
model
assessment
task
image
inference
structure
view
within
article
oval
figure
represent
inference
system
capable
perform
specifically
give
patient
state
system
capable
work
argument
need
evaluate
represent
specify
inference
system
capable
evaluate
argument
see
true
represent
evaluate
inference
system
capable
evaluate
argument
arrive
appropriate
decision
candidate
represent
match
inference
task
knowledge
task
knowledge
section
knowledge
model
describe
goal
task
kbs
require
perform
method
require
adopt
order
achieve
goal
goal
four
task
perform
triple
assessment
system
already
outline
make
assessment
genetic
risk
patient
run
appropriate
imaging
biopsy
perform
strategy
manage
patient
task
achieve
straightforward
combination
inference
describe
appropriate
argument
specify
evaluate
sufficient
datum
available
match
inference
arrive
decision
candidate
task
perform
design
commonkads
methodology
describe
strategy
transform
requirement
identify
conceptual
modelling
phase
design
kbs
first
identify
general
software
architecture
system
hardware
software
architecture
implement
architecture
separate
component
describe
element
identify
conceptual
analysis
domain
schema
inference
implement
within
architecture
methodology
include
control
various
phase
process
prototype
version
system
architecture
adopt
model
implement
tallis
implementation
proforma
view
controller
implement
java
server
page
servlets
javascript
cascading
style
show
screenshot
system
image
screenshot
prototype
system
view
within
article
order
construct
system
necessary
translate
element
identify
conceptual
modelling
domain
schema
knowledge
basis
inference
task
method
proforma
task
candidate
argument
much
part
straightforward
exercise
since
four
assessment
task
decision
candidate
argument
identify
conceptual
analysis
map
fairly
directly
proforma
task
argument
candidate
however
problem
occur
translate
commonkads
rule
proforma
due
limitation
way
proforma
argument
arrive
decision
instance
proforma
allow
argument
associate
much
one
candidate
mean
difficult
represent
case
argument
favour
one
candidate
argument
another
discussion
commonkads
methodology
analyse
requirement
design
kbs
implement
proforma
knowledge
representation
language
exercise
reveal
strength
weakness
methodology
knowledge
representation
language
major
advantage
commonkads
methodology
lie
emphasis
place
analysis
organisation
will
kbs
clear
picture
generate
aim
strategy
business
process
knowledge
asset
organisation
allow
knowledge
engineer
project
manager
arrive
well
inform
judgement
feasibility
kbs
good
way
integrate
organisation
operation
particular
importance
case
consider
kbs
will
form
part
much
large
process
involve
many
separate
participant
however
methodology
specifically
design
medical
system
may
require
extension
deal
particular
intervene
medically
necessary
produce
hard
evidence
efficacy
intervention
usually
form
clinical
trial
mean
feasibility
analysis
take
place
contextual
analysis
ideally
include
analysis
whether
trial
fact
possible
deal
question
whether
feasible
recruit
sufficient
number
patient
trial
general
proforma
language
prove
project
describe
paper
task
kbs
require
perform
assessment
task
involve
choice
set
candidate
proforma
well
suit
task
directly
represent
argument
candidate
decision
class
describe
problem
occur
proforma
represent
operation
require
examination
set
complex
entity
example
see
consider
knowledge
representation
requirement
first
assessment
task
kbs
perform
assess
patient
genetic
risk
argument
argumentation
rule
task
require
examination
medical
history
patient
relative
example
patient
two
second
degree
relative
diagnose
breast
cancer
age
consider
argument
assess
medium
risk
provide
argument
assess
degree
risk
high
proforma
datum
structure
allow
datum
item
simple
value
integer
real
number
text
string
also
allow
datum
item
whose
value
set
simple
value
set
integer
however
consider
patient
relative
natural
regard
relative
complex
entity
say
entity
property
date
birth
date
diagnosis
risk
much
easily
calculate
evaluate
set
entity
determine
many
possess
particular
property
proforma
lack
facility
represent
set
entity
representation
argumentation
involve
genetic
risk
assessment
somewhat
similar
problem
arise
necessary
represent
lesion
reveal
examination
patient
lesion
naturally
represent
complex
entity
patient
might
set
lesion
resultant
complexity
proforma
expression
reason
collection
entity
create
difficulty
one
attempt
verify
implementation
correctly
implement
requirement
system
however
inherent
reason
proforma
language
extend
represent
set
complex
entity
expression
involve
set
weakness
discuss
section
might
therefore
good
consider
sign
proforma
require
far
development
rather
evidence
basic
structural
problem
conclusion
commonkads
analysis
kbs
describe
feature
clarify
reasoning
knowledge
representation
requirement
also
enable
clear
picture
build
manner
kbs
fit
exist
business
process
allow
reason
feasibility
adopt
feasibility
system
dependent
availability
suitable
epr
system
also
necessary
address
training
user
interface
order
ensure
slow
assessment
patient
limitation
proforma
language
may
create
problem
ensure
proforma
implementation
correctly
implement
reasoning
requirement
system
problem
describe
previous
overcome
kbs
along
line
describe
paper
provide
useful
assistance
meet
state
objective
early
diagnosis
uniformity
standard
care
monitoring
treatment
process
datum
mining
find
pattern
relationship
datum
relatively
large
amount
datum
cancer
patient
collect
last
year
result
datum
mining
directly
affect
quantity
quality
datum
price
joshua
lederberg
state
data
building
block
knowledge
seed
discovery
challenge
develop
new
concept
theory
model
make
sense
pattern
see
successful
application
datum
mining
cancer
patient
datum
result
new
knowledge
assist
cancer
diagnosis
choice
treatment
one
million
people
diagnose
worldwide
breast
cancer
year
accord
international
agency
research
cancer
iarc
extensive
database
number
new
case
increase
last
decade
especially
western
part
world
iceland
number
newly
diagnose
patient
steadily
increase
since
whilst
number
patient
die
breast
cancer
remain
nearly
survival
five
year
initial
diagnosis
change
little
year
year
make
prognosis
patient
breast
cancer
one
good
among
cancer
purpose
study
build
predictive
outcome
model
pom
accurately
classify
newly
diagnose
patient
either
follow
two
class
cancer
five
year
diagnosis
research
based
datum
set
rose
assemble
cooperation
cancer
centre
research
development
university
hospital
iceland
year
rose
database
include
relative
small
number
instance
large
number
feature
feature
study
fact
collect
time
patient
first
diagnose
treat
clinical
practice
patient
classify
risk
group
diagnose
breast
cancer
therefore
interest
able
conduct
experiment
result
classifier
model
compare
result
obtain
clinical
practice
result
introduction
new
feature
name
risk
rose
dataset
risk
feature
estimate
evaluate
doctor
risk
newly
diagnose
patient
show
mark
disease
within
five
year
diagnosis
medical
doctor
group
patient
three
risk
group
high
intermediate
risk
recurrence
expect
performance
pom
improve
add
feature
datum
set
secondary
objective
specialist
risk
estimate
patient
class
attribute
see
whether
pom
simulate
pattern
implicitly
medical
doctor
estimate
risk
prediction
pom
build
training
set
instance
whereas
instance
characterize
set
give
feature
building
valid
reliable
pom
difficult
time
consume
firstly
modeller
need
clean
datum
select
much
appropriate
feature
class
attribute
secondly
datum
instance
learn
process
will
based
upon
choose
learn
method
select
range
algorithm
currently
available
finally
modeller
need
assess
reliability
obtain
result
herein
model
selection
tool
mst
construct
order
ease
process
build
effective
pom
already
mention
result
pom
predict
five
year
outcome
newly
diagnose
breast
cancer
patient
appropriate
information
patient
tool
implement
top
datum
mining
package
weka
witten
frank
important
aspect
study
well
understanding
relative
importance
feature
include
prepare
datum
datum
mining
task
specific
question
address
many
type
feature
select
reach
satisfactory
prediction
whether
learn
algorithm
significantly
well
type
datum
whether
subjective
evaluation
doctor
mark
influence
result
brief
review
relate
work
lee
linear
support
vector
machine
svm
extract
feature
datum
set
include
breast
cancer
patient
datum
set
wpbcc
prognostic
breast
cancer
chemotherapy
database
publicly
available
wolberg
lee
mangasarian
contain
feature
obtain
surgery
classification
based
divide
patient
disease
lymph
node
metastases
disease
lymph
node
metastases
patient
patient
cluster
three
prognostic
group
good
intermediate
lymph
node
metastases
poor
much
lymph
node
metastases
whereas
group
distinct
survival
curve
based
select
feature
model
assign
new
patient
one
three
prognostic
group
associate
survival
curve
lee
mangasarian
wolberg
improve
cluster
selection
method
even
far
result
classifier
classify
breast
cancer
instance
three
survival
category
accuracy
mangasarian
carry
numerical
test
wpbcc
datum
set
month
cut
predict
recurrence
recurrence
breast
cancer
support
vector
machine
report
test
accuracy
fold
cross
validation
another
publicly
available
datum
set
contain
information
breast
cancer
breast
cancer
data
set
zwitter
soklic
originally
collect
university
medical
center
institute
oncology
slovenia
outcome
class
accuracy
obtain
different
classification
method
tsai
king
decision
tree
classify
datum
set
result
maximum
accuracy
indicate
approach
comparable
optimal
inductive
learning
approach
breast
cancer
data
set
widely
compare
different
classifier
pendharkar
rodger
apply
bayesian
network
classifier
datum
analysis
dea
dataset
collect
breast
cancer
patient
large
hospital
pennsylvania
order
discover
pattern
datum
result
experiment
indicate
dea
bayesian
network
classifier
outperform
statistical
linear
discriminate
analysis
pendharkar
rodger
previously
show
datum
mining
breast
cancer
diagnosis
report
accuracy
artificial
neural
network
decision
tree
respectively
large
dataset
contain
much
case
collect
year
prediction
accuracy
well
report
literature
far
size
dataset
time
big
size
dataset
report
outcome
class
define
incidence
breast
cancer
person
still
live
month
year
date
diagnosis
remainder
paper
organize
follow
section
feature
selection
process
present
different
classification
algorithm
will
review
section
testing
method
measure
testing
performance
different
classifier
describe
section
section
present
experimental
design
result
real
medical
datum
rose
database
present
section
discussion
conclusion
follow
section
section
respectively
feature
selection
quality
datum
important
datum
mining
project
number
quality
indicator
accuracy
consistency
two
much
important
indicator
datum
quality
definition
feature
database
analyzed
feature
sufficiently
well
define
definition
correct
improve
otherwise
delete
database
result
likely
exclude
many
feature
database
know
rule
statistic
number
instance
exponential
number
feature
rule
quite
clear
datum
mining
fewer
input
feature
classifier
simple
result
classifier
model
will
become
chance
overfitting
decrease
turn
enhance
usefulness
model
prognostic
tool
choice
feature
large
great
effort
usually
put
consider
number
feature
report
goal
feature
selection
method
reduce
cost
complexity
classifier
improve
model
accuracy
improve
visualization
induce
concept
one
way
select
relevant
feature
database
select
based
estimate
importance
rating
scheme
construct
evaluate
quality
relevance
feature
wide
range
automatic
feature
selection
method
also
available
either
way
size
datum
reduce
significantly
irrelevant
feature
delete
datum
aim
feature
selection
part
study
mst
identify
dataset
contain
small
number
feature
give
good
result
algorithm
classification
variety
learn
algorithm
classification
amongst
much
commonly
apply
classifier
naive
bayes
nb
algorithm
john
decision
tree
algorithm
along
wide
variety
meta
algorithm
meta
algorithm
algorithm
combine
result
base
classifier
naive
bayes
nb
algorithm
based
bayes
simple
probabilistic
classifier
widely
real
datum
set
nb
algorithm
fairly
number
feature
apply
type
witten
frank
implementation
mst
tool
weka
environment
knowledge
analysis
software
access
different
classifier
witten
frank
weka
include
several
standard
method
enable
user
apply
machine
learn
derive
useful
knowledge
database
large
analyzed
hand
machine
learn
algorithm
differ
way
feature
datum
set
much
design
learn
much
appropriate
feature
ignore
irrelevant
redundant
feature
performance
classifier
practice
improve
feature
reduction
example
type
algorithm
possible
feature
decision
tree
algorithm
relevant
feature
ignore
irrelevant
one
testing
performance
value
select
feature
even
algorithm
improve
reduce
amount
feature
witten
frank
hall
simple
naive
bayes
nb
classifier
study
reference
algorithm
algorithm
nb
work
well
test
actual
datum
set
often
much
sophisticated
one
design
nb
assume
feature
independent
one
another
redundant
feature
present
dependency
feature
datum
set
result
result
reduce
irrelevant
redundant
feature
show
well
performance
nb
classifier
witten
frank
testing
measure
performance
different
classifier
time
model
construct
train
important
test
validity
reliability
training
testing
perform
datum
set
result
usually
optimistic
since
training
algorithm
learn
record
involve
therefore
well
independent
supply
test
set
testing
training
test
datum
assume
representative
sample
datum
set
differ
nature
generally
large
training
datum
set
well
classifier
build
much
accurate
error
estimate
good
error
estimate
hard
achieve
small
datum
set
cross
validation
repeat
holdout
procedure
testing
splitting
stratified
stratification
mean
class
represent
approximately
proportion
instance
subset
stratified
cross
validation
group
become
standard
method
evaluation
witten
frank
training
testing
method
mention
mst
fold
cross
validation
much
common
claim
give
much
reliable
result
witten
frank
compare
two
learn
scheme
measure
evaluate
performance
introduce
one
common
measure
literature
hall
accuracy
define
correct
classify
instance
divide
total
number
instance
value
give
percent
correct
pc
classification
value
addition
pc
value
mst
include
kappa
parameter
cohen
eugenio
glas
true
positive
rate
sensitivity
true
negative
rate
specificity
receiver
operating
characteristic
roc
area
roc
curve
auc
accept
performance
metric
roc
curve
remain
subsections
section
will
explain
method
far
detail
interpretation
result
classifier
confusion
matrix
calculate
classifier
confusion
matrix
simple
table
show
table
upper
row
show
actual
result
positive
class
row
show
result
negative
class
reliability
test
estimated
calculate
sensitivity
specificity
sensitivity
equal
true
positive
rate
sensitivity
tp
tp
fn
specificity
equal
true
negative
rate
specificity
fp
imbalanced
datum
set
two
class
include
high
proportion
false
record
value
confusion
matrix
highly
dependent
number
instance
class
classifier
show
high
value
show
tp
value
vice
versa
good
prediction
model
medicine
result
fn
value
possible
patient
true
class
sick
patient
will
miss
high
however
model
predict
instance
true
result
value
thus
measure
performance
fp
false
positive
also
kappa
kappa
parameter
measure
pair
wise
agreement
two
different
observer
correct
expect
chance
agreement
value
kappa
complete
agreement
classifier
real
world
kappa
value
calculate
confusion
matrix
show
table
kappa
value
calculate
follow
equation
whereas
total
number
instance
percentage
agreement
classifier
underlie
truth
chance
agreement
whereas
k
indicate
perfect
agreement
k
indicate
agreement
expect
chance
k
mean
perfect
disagreement
eugenio
glas
list
two
main
way
calculate
practice
two
give
similar
result
formula
study
kappa
value
also
calculate
case
class
attribute
much
two
value
get
confusion
matrix
scale
kappa
allow
tentative
conclusion
kappa
definitive
conclusion
kappa
consider
kappa
value
indicator
fair
agreement
kappa
value
kappa
indicate
moderate
agreement
value
kappa
indicate
substantial
agreement
roc
auc
alternative
method
compare
performance
different
classifier
evaluate
area
receiver
operating
characteristic
roc
curve
auc
roc
curve
plot
observe
sensitivity
plot
function
specificity
possible
threshold
auc
area
roc
curve
measure
difference
two
class
distribution
compare
quality
classifier
compare
class
generalized
calculation
auc
multiple
class
classification
problem
roc
analysis
relate
cost
benefit
analysis
diagnostic
medicine
many
year
recently
estimate
result
datum
mining
experiment
roc
analysis
provide
tool
select
good
model
independently
class
distribution
furthermore
auc
show
well
evaluation
measure
accuracy
context
misclassification
include
cost
imbalanced
dataset
hand
till
kappa
versus
roc
auc
obvious
relationship
kappa
auc
since
auc
measure
ranking
ability
kappa
measure
hard
classification
agreement
categorical
william
find
practice
kappa
parameter
highly
significantly
correlated
auc
conclude
kappa
provide
simple
effective
test
predictive
performance
experimental
design
study
tool
build
keep
track
preparation
dataset
training
testing
process
model
algorithm
small
breast
cancer
dataset
datum
mining
process
model
selection
tool
model
selection
tool
mst
implement
top
weka
package
incorporate
follow
six
analyze
feature
database
assess
datum
define
class
attribute
divide
set
instance
appropriate
class
extract
potential
feature
classification
select
subset
feature
learn
process
investigate
possible
imbalance
select
datum
set
may
counteract
select
subset
instance
record
learn
based
choose
classifier
algorithm
learn
process
decide
testing
method
estimate
performance
select
algorithm
mst
include
choice
seventeen
different
classifier
step
five
table
list
name
classifier
along
short
description
classifier
group
follow
group
bayes
tree
function
meta
rule
show
table
algorithm
deal
binary
target
feature
numeric
nominal
feature
miss
fold
stratified
cross
validation
procedure
method
training
testing
mst
pom
model
generate
output
six
step
illustrate
along
select
learn
algorithm
result
pom
classify
new
patient
survival
group
much
detail
explanation
six
step
conduct
herein
already
database
construction
datum
preparation
step
start
include
analysis
feature
definition
possible
class
attribute
experience
medical
cancer
specialist
datum
miner
manually
reduce
number
feature
rating
accord
rating
scheme
prognostic
factor
similar
feature
author
work
zwitter
soklic
holte
tsai
wolberg
lee
also
feature
reduction
datum
miner
first
author
involve
definition
feature
database
thus
learn
know
characteristic
based
upon
characteristic
base
feature
include
date
feature
manually
select
original
feature
base
datum
set
name
include
instance
create
select
previously
choose
feature
help
rating
scheme
different
dataset
automatically
generate
mst
select
various
feature
automatic
feature
selection
method
list
table
associate
search
method
best
first
rank
search
genetic
search
also
include
simple
method
one
find
good
rule
include
just
one
feature
witten
frank
medical
doctor
select
feature
dataset
include
new
dataset
name
feature
list
table
along
short
description
table
name
feature
datum
set
short
description
diagnose
yes
indicator
tumor
find
medical
examination
yes
indicator
node
palpateble
suspicious
yes
indicator
node
palpateble
suspicious
yes
indicator
affect
breast
exhibit
skin
experience
pain
localized
heat
yes
indicator
metastasis
confirm
lung
film
yes
indicator
metastasis
confirm
isotope
bone
scan
numeric
result
laboratory
test
tumor
marker
numeric
result
laboratory
test
tumor
marker
cea
type
structural
pattern
cancer
cell
define
diagnosis
yes
indicator
ask
small
thin
lymphatic
invasion
detect
tumor
specimen
yes
indicator
ask
large
vessel
vascular
invasion
detect
tumor
specimen
field
report
percentage
value
cell
total
number
lymph
node
micrometastases
yes
indicator
cancer
growth
include
skin
combination
feature
indicate
patient
diagnose
define
disease
type
pgr
hormone
receptor
test
presence
sample
primary
tumor
size
measurement
primary
tumor
pathologist
yes
indicator
chemotherapy
give
pre
operation
yes
indicator
indicate
patient
get
adjuvant
radiotherapy
yes
indicator
indicate
patient
get
adjuvant
chemotherapy
yes
indicator
indicate
patient
get
adjuvant
hormonal
therapy
table
view
within
article
small
dataset
name
also
generate
include
five
manually
select
feature
feature
include
follow
age
nodespos
metbone
chemother
class
attribute
two
class
attribute
include
class
value
respectively
classify
instance
dataset
main
class
attribute
real
status
outcome
patient
disease
measure
five
year
diagnosis
instance
supervise
two
class
feature
class
attribute
two
class
value
nominal
type
true
instance
false
instance
indicate
patient
without
sign
disease
five
year
cancer
diagnose
class
attribute
risk
estimate
doctor
risk
feature
select
class
attribute
feature
exclude
dataset
mst
tool
train
test
seventeen
different
algorithm
standard
fold
cross
validation
procedure
generate
dataset
medical
estimation
risk
recurrence
result
kappa
value
much
original
result
turn
rather
medical
doctor
ask
add
one
feature
datum
set
feature
estimate
individual
risk
patient
categorize
patient
medical
doctor
ask
follow
question
risk
recurrence
death
patient
occur
within
five
year
diagnosis
date
high
risk
probability
intermediate
risk
probability
risk
probability
ten
new
datum
set
risk
feature
include
build
mst
ten
datum
set
train
test
mst
since
kappa
often
medical
study
order
investigate
relationship
kappa
auc
auc
kappa
calculate
half
datum
set
study
auc
value
plot
function
kappa
value
see
approximate
linear
relationship
formula
good
line
least
square
sense
auc
kappa
value
regression
formula
thus
get
approximation
auc
value
give
kappa
value
class
variable
case
class
three
value
class
variable
case
risk
class
image
linear
regression
individual
prediction
interval
auc
function
kappa
statistic
multiple
datum
set
classifier
view
within
article
distribution
value
risk
feature
list
table
distribution
instance
much
balanced
previous
class
value
distribution
instance
true
instance
versus
negative
instance
also
list
table
distribution
value
attribute
risk
value
table
distribution
instance
risk
group
accord
subjective
estimate
doctor
risk
instance
false
high
risk
intermediate
risk
risk
table
distribution
instance
group
also
list
view
within
article
table
feature
selection
method
namea
brief
way
rating
feature
estimate
importance
quality
local
medical
cancer
specialist
select
global
result
mine
database
breast
find
good
rule
include
just
one
based
feature
selection
subset
weighting
algorithm
ranking
feature
table
view
within
article
experimental
result
section
describe
result
obtain
three
follow
dataset
result
generate
risk
feature
include
dataset
also
assess
performance
result
dataset
display
table
table
table
naive
bayes
algorithm
decision
tree
simple
part
rule
selection
algorithm
table
show
prediction
outcome
risk
feature
table
show
prediction
outcome
risk
feature
table
show
prediction
value
risk
attribute
table
seem
result
depend
partly
performance
parameter
judge
performance
classifier
table
predicting
outcome
risk
feature
data
setalgorithmnumber
featurespc
kappa
valueaucsensitivityspecificitysize
tree
leavesnumber
rule
table
view
within
article
table
predicting
outcome
risk
feature
data
setalgorithmnumber
featurespc
kappa
valueaucsensitivityspecificitysize
tree
leavesnumber
rule
table
view
within
article
table
predicting
outcome
risk
feature
data
setalgorithmnumber
featurespc
kappa
rule
table
view
within
article
datum
set
datum
set
contain
feature
class
attribute
result
prune
decision
tree
datum
set
tree
size
include
leave
pc
kappa
auc
sensitivity
specificity
size
tree
show
just
small
part
available
feature
evaluation
result
based
fold
cross
validation
tree
give
based
training
datum
result
naive
bayes
classifier
pc
kappa
auc
sensitivity
specificity
include
feature
choose
doctor
make
risk
assessment
class
attribute
result
prune
decision
tree
node
include
leave
pc
value
kappa
value
auc
sensitivity
specificity
evaluation
result
based
fold
cross
validation
tree
give
based
training
datum
result
naive
bayes
classifier
pc
kappa
auc
sensitivity
specificity
feature
belong
list
table
comparing
subset
base
datum
set
order
find
optional
datum
set
distribution
result
pc
value
nb
classifier
analyzed
time
pc
value
show
high
value
time
result
pc
value
decision
tree
show
time
pc
value
high
time
value
pc
value
classifier
give
similar
result
many
datum
set
show
high
pc
value
classify
decision
tree
algorithm
result
small
decision
tree
size
include
leave
tree
two
feature
feature
nodespos
metbone
typical
pc
value
kappa
value
decision
tree
contain
leave
build
include
feature
result
pc
value
kappa
auc
sensitivity
specificity
definite
optimal
datum
set
find
neither
automatic
feature
selection
method
local
global
knowledge
performance
risk
feature
include
datum
set
result
prune
decision
tree
datum
set
include
risk
feature
tree
without
risk
feature
tree
size
include
leave
result
pc
kappa
auc
sensitivity
specificity
include
risk
feature
neither
node
leaf
decision
tree
datum
set
prune
decision
tree
present
datum
set
include
risk
feature
result
tree
size
include
leave
one
leaf
original
tree
datum
set
replace
two
new
node
leave
performance
classifier
similar
pc
value
kappa
value
auc
sensitivity
specificity
image
prune
decision
tree
risk
feature
include
datum
set
view
within
article
effect
include
additional
feature
subjective
risk
assessment
medical
doctor
give
well
classification
result
two
datum
set
neither
insert
risk
feature
datum
set
result
well
performance
predicting
subjective
assessment
doctor
risk
assessment
class
attribute
result
high
kappa
value
mean
classifier
general
seem
much
successful
predict
doctor
risk
assessment
actual
outcome
datum
set
higher
kappa
value
might
fact
risk
class
class
attribute
compare
class
attribute
difference
percent
correct
value
negligible
prune
decision
tree
risk
assessment
feature
class
attribute
size
leave
pc
value
kappa
value
auc
value
calculate
risk
group
group
respectively
show
instance
hard
classify
instance
belong
intermediate
risk
class
sensitivity
tp
rate
risk
group
show
similar
trend
high
pc
value
range
standard
deviation
seventeen
classifier
datum
set
just
feature
include
exactly
many
true
false
instance
high
value
kappa
indicate
moderate
agreement
test
class
show
kappa
value
discussion
testing
much
different
datum
set
become
clear
difficult
find
one
datum
set
outperform
prediction
recurrence
cancer
furthermore
number
feature
include
datum
set
seem
large
impact
result
since
similar
result
obtain
regardless
whether
dataset
contain
five
much
high
number
feature
simplicity
usually
preferred
avoid
overfitting
small
datum
set
well
suit
build
effective
efficient
additionally
clinical
cost
time
require
collect
many
feature
reduce
small
dataset
none
select
classifier
list
table
show
significantly
well
performance
standard
nb
classifier
performance
simple
decision
tree
classifier
come
close
performance
nb
classifier
therefore
good
classifier
select
seem
either
naive
bayes
decision
tree
benefit
simple
decision
tree
result
easily
visualize
build
small
dataset
however
note
performance
classifier
based
support
vector
machine
critically
depend
proper
parameter
pay
close
attention
study
table
classifier
namea
brief
naive
simple
approach
probabilistic
decision
tree
extension
decision
tree
logistic
model
tree
logistic
regression
function
rep
treea
decision
regression
tree
information
variance
random
forest
random
tree
support
vector
sequential
minimal
optimization
algorithm
function
logistic
regression
model
simple
logistic
regression
simple
regression
function
base
meta
classifier
schememeta
meta
classifier
schememeta
meta
classifier
creation
artificial
training
example
bagging
rep
treea
meta
bagging
classifier
rep
decision
decision
simple
decision
table
majority
error
feature
rule
rule
voting
feature
interval
feature
projection
voting
table
view
within
article
table
confusion
matrix
actual
patient
state
classified
true
positive
classified
false
negative
class
true
positive
class
false
negative
table
view
within
article
including
risk
feature
improve
result
classifier
somewhat
surprising
since
risk
feature
build
know
prognostic
factor
clinical
practice
may
show
yet
find
right
prognostic
factor
however
result
classify
instance
risk
class
show
well
algorithm
approximate
medical
doctor
estimate
risk
recurrence
individual
patient
direct
prediction
value
real
outcome
patient
state
patient
five
year
diagnosis
predict
risk
group
moderate
kappa
value
study
show
medical
information
include
diagnosis
treatment
information
predict
outcome
newly
diagnose
patient
predictive
accuracy
pc
kappa
value
preferred
evaluate
classifier
performance
result
value
show
fair
agreement
reporting
kappa
value
unusual
since
much
study
report
performance
model
accuracy
sensitivity
specificity
much
learn
algorithm
treat
true
false
example
equally
important
aim
maximize
accuracy
work
imbalanced
datum
set
imbalance
misclassification
cost
relate
one
way
counteract
imbalance
datum
set
study
imbalanced
datum
set
raise
cost
misclassifying
false
class
holte
classifier
typically
evaluate
predictive
accuracy
pc
datum
set
imbalanced
might
appropriate
parameter
least
important
interpret
result
classifier
correctly
classify
instance
study
kappa
value
auc
value
also
compute
result
show
high
kappa
value
auc
value
necessarily
consistent
high
pc
value
recent
year
new
biological
datum
element
measure
every
new
cancer
patient
future
study
feature
include
collect
soon
available
datum
publish
control
standard
form
datum
easily
understand
share
gray
cooperation
different
scientific
domain
standardization
datum
eventually
establish
develop
large
medical
database
include
valuable
information
vital
compare
result
mining
effort
research
study
respect
feature
selection
performance
study
whereas
database
relatively
small
high
classification
accuracy
obtain
goal
create
model
much
reliable
current
one
even
build
small
database
pom
create
research
study
view
final
model
step
towards
reach
goal
conclusion
case
study
instance
available
result
study
give
rise
continue
work
collect
datum
patient
diagnose
year
later
five
year
pass
diagnosis
respective
patient
also
valuable
collect
select
information
year
create
new
class
attribute
year
instead
year
survival
status
month
also
class
attribute
big
dataset
instead
outcome
disease
great
need
continue
work
conduct
research
study
model
selection
tool
develop
prove
useful
construction
much
reliable
predictive
outcome
model
model
build
larger
standardized
database
one
study
new
biological
datum
feature
also
include
good
prospect
practical
predictive
outcome
model
acknowledgement
author
thank
critical
reading
assistance
manuscript
preparation
taiwan
breast
cancer
second
much
occur
cancer
death
rate
breast
cancer
increase
year
cancer
registry
annual
report
overview
public
health
almost
woman
breast
cancer
diagnose
age
woman
breast
cancer
diagnose
age
cheng
liu
average
woman
diagnose
breast
cancer
taiwan
young
recognize
factor
will
increase
risk
breast
cancer
however
still
unknown
hence
difficult
medical
professional
treat
breast
cancer
appropriate
preventive
method
yu
cook
howe
miller
investigate
risk
factor
fibroadenoma
study
involve
fibroadenoma
case
australia
study
show
fibroadenoma
share
risk
factor
breast
cancer
estimate
dna
virus
emerge
major
causal
factor
contribute
occurrence
human
cancer
dimmock
primrose
dna
virus
closely
relate
human
cancer
part
factor
dna
virus
include
specific
type
virus
type
ebv
virus
cmv
cytomegalovirus
hpv
human
human
dimmock
primrose
study
biological
breast
cancer
cell
attenuate
human
hematopoietic
stem
cell
transplantation
develop
second
generation
genetically
modify
paclitaxel
treatment
breast
cancer
vitro
wang
vos
study
hybrid
herpesvirus
infectious
vector
based
ebv
gene
transfer
human
cell
vitro
vivo
study
indicate
ebv
hybridoma
technique
offer
several
advantage
hybridoma
system
generate
cancer
human
monoclonal
antibody
establish
line
breast
tumor
tissue
also
clark
ward
peripheral
blood
mononuclear
cell
individual
breast
cancer
construction
human
immunoglobulin
gene
library
study
frequency
genome
load
ebv
breast
cancer
various
geographical
area
recently
demonstrate
ebv
carcinoma
breast
lung
site
xue
griffin
also
study
ebv
gene
human
breast
cancer
huang
chen
ambinder
hayward
suggest
sporadic
ebv
infection
might
contribute
polymerase
chain
reaction
based
detection
ebv
traditionally
associate
epithelial
malignancy
addition
garcia
study
whether
relationship
latent
infection
ebv
expression
breast
carcinoma
lastly
compare
radiation
response
ebv
cell
line
derived
breast
cancer
patient
without
mutation
reveal
significant
difference
previous
study
cmv
breast
cancer
study
group
patient
undergo
modify
radical
mastectomy
breast
cancer
lee
oh
campbell
find
caveolin
expression
significantly
reduce
human
breast
cancer
cell
provide
caveolin
cdna
link
cmv
promoter
transfected
human
mammary
cancer
cell
still
hamilton
indicate
constitutive
expression
gene
control
cmv
promoter
mouse
fibroblast
result
cellular
transformation
growth
analyzed
impact
chemotherapy
cell
responsive
cmv
immunity
breast
cancer
patient
zhang
tang
study
cytotoxic
effect
adenoviral
vector
carry
promoter
regulate
cytosine
gene
cancer
breast
ovary
colon
similar
vector
drive
cmv
promoter
also
construct
control
treatment
result
decrease
tumor
size
decrease
tumor
cell
growth
rate
demonstrate
inhibition
survival
pathway
promote
apoptosis
malignant
breast
cancer
cell
relative
spare
normal
counterpart
show
expression
luciferase
compare
cmv
promoter
mouse
live
vivo
prove
good
candidate
promoter
cancer
gene
therapy
melanoma
breast
cancer
recent
study
reveal
possible
role
hpv
pathogenesis
breast
cancer
although
definitive
interaction
observe
type
oral
contraceptive
recognize
risk
factor
breast
cancer
oral
contraceptive
may
act
promoter
carcinogenesis
la
demonstrate
high
frequency
abnormality
gene
human
breast
cancer
find
genomic
deletion
rearrangement
spite
presence
abnormal
transcript
definite
relationship
abnormal
transcript
hpv
infection
show
type
breast
cancer
identify
hpv
positive
pcr
dot
blot
analysis
hpv
primer
set
marth
suggest
hpv
dna
might
transport
original
site
infection
breast
tissue
bloodstream
possibly
exist
carcinogenesis
breast
patient
finally
research
breast
cancer
citation
literature
klein
klein
study
surveillance
tumor
relevant
viral
agent
context
find
kaposi
sarcoma
high
incidence
population
relate
literature
review
see
important
evaluate
association
among
dna
virus
ebv
cmv
hpv
breast
cancer
fibroadenoma
order
obtain
relationship
dna
virus
breast
tumor
paper
support
vector
machine
svm
find
pertinent
bioinformatics
support
vector
machine
first
suggest
recently
range
problem
include
pattern
recognition
bioinformatics
yu
text
categorization
cancer
diagnosis
lee
lee
lee
liu
svm
two
problem
confront
choose
optimal
input
feature
subset
svm
set
good
kernel
parameter
two
problem
crucial
feature
subset
choice
influence
appropriate
kernel
parameter
vice
versa
feature
selection
important
issue
building
classification
system
advantageous
limit
number
input
feature
classifier
order
good
predictive
little
computationally
intensive
model
small
feature
set
explanation
rationale
classification
decision
much
readily
realize
addition
feature
selection
proper
model
parameter
set
improve
svm
classification
accuracy
parameter
optimized
include
penalty
parameter
kernel
function
parameter
gamma
radial
basis
function
rbf
kernel
design
svm
one
choose
kernel
function
set
kernel
parameter
determine
soft
margin
constant
grid
algorithm
alternative
find
good
gamma
rbf
kernel
function
hsu
lin
explore
five
dna
virus
ebv
cmv
hpv
affect
breast
tumor
diagnose
support
vector
machine
study
try
grid
search
find
good
svm
model
parameter
calculation
select
input
feature
paper
organize
follow
section
describe
basic
svm
concept
section
describe
three
strategy
research
section
present
experimental
result
propose
method
diagnose
real
world
breast
cancer
datum
set
section
give
remark
provide
conclusion
basic
concept
svm
classifier
section
will
briefly
describe
basic
svm
concept
typical
classification
problem
concept
also
find
give
training
set
pair
xi
yi
xi
yi
svm
find
optimal
separate
hyperplane
maximum
margin
solve
follow
optimization
problem
know
solve
quadratic
optimization
problem
one
find
saddle
point
lagrange
function
denote
lagrange
multipliers
hence
search
optimal
saddle
point
necessary
lp
minimize
respect
variable
maximize
respect
dual
variable
differentiate
respect
introduce
condition
optimum
constrain
function
transform
dual
lagrangian
find
optimal
hyperplane
dual
lagrangian
maximize
respect
solution
dual
optimization
problem
determine
parameter
optimal
hyperplane
thus
optimal
hyperplane
decision
function
x
x
write
typical
classification
task
small
subset
lagrange
multipliers
usually
tend
great
zero
vector
close
optimal
hyperplane
respective
training
vector
call
support
vector
optimal
decision
hyperplane
x
depend
exclusively
concept
also
extend
case
linear
generalized
svm
term
slack
variable
problem
find
hyperplane
provide
minimum
number
training
error
keep
constraint
violation
small
possible
formal
expression
follow
penalty
parameter
training
error
slack
variable
svm
find
hyperplane
provide
minimum
number
training
error
keep
constraint
violation
small
possible
optimization
model
solve
lagrangian
method
almost
equivalent
method
solve
optimization
problem
case
one
maximize
dual
variable
lagrangian
find
optimal
hyperplane
dual
lagrangian
maximize
respect
constraint
penalty
parameter
now
upper
bind
determine
user
finally
form
optimal
hyperplane
decision
function
nonlinear
svm
map
training
sample
input
space
feature
space
via
mapping
function
kernel
function
k
xi
xj
define
inner
product
k
xi
xj
xi
xj
dual
lagrange
inner
product
replace
kernel
function
nonlinear
svm
dual
lagrangian
similar
linear
generalized
case
step
describe
linear
generalized
case
obtain
decision
function
follow
form
kernel
function
explore
experiment
radial
basis
function
rbf
define
k
experiment
data
collection
datum
partition
source
datum
point
tissue
sample
include
specimen
invasive
ductal
breast
cancer
woman
mammary
fibroadenoma
medical
university
hospital
pcr
southern
hybridization
screen
presence
discover
specimen
screen
dna
virus
positive
negative
presence
internal
control
guarantee
present
result
valid
generalized
make
prediction
regard
new
datum
datum
set
far
randomly
partition
training
independent
testing
set
via
stratified
fold
cross
validation
subset
act
independent
holdout
test
set
model
train
rest
subset
advantage
cross
validation
impact
datum
dependency
minimize
reliability
result
improve
addition
classification
model
develop
huge
portion
accessible
datum
case
datum
utilize
test
train
model
pair
training
testing
set
call
fold
group
study
show
table
due
number
case
positive
negative
divide
size
fold
number
case
fold
table
datum
set
far
randomly
partition
training
independent
testing
set
via
stratified
fold
cross
validation
size
training
testing
set
fold
fold
fold
fold
fold
table
view
within
article
feature
selection
feature
selection
important
issue
building
classification
system
advantageous
limit
number
input
feature
classifier
order
good
predictive
little
computationally
intensive
model
small
feature
set
explanation
rationale
classification
decision
much
easily
realize
area
medical
diagnosis
small
feature
subset
mean
test
diagnosis
cost
chen
lin
simple
technique
measure
discrimination
two
set
real
number
give
training
vector
xk
k
number
positive
negative
instance
respectively
feature
define
follow
chen
lin
average
feature
whole
positive
negative
datum
set
respectively
feature
kth
positive
instance
feature
kth
negative
instance
numerator
indicate
discrimination
positive
negative
set
denominator
indicate
one
within
two
set
large
much
likely
feature
much
discriminative
chen
lin
setting
model
parameter
addition
feature
subset
selection
proper
model
parameter
set
improve
svm
classification
accuracy
parameter
optimized
include
penalty
parameter
kernel
function
parameter
gamma
radial
basis
function
rbf
kernel
design
svm
one
choose
kernel
function
set
kernel
parameter
determine
soft
margin
constant
rbf
kernel
two
parameter
determine
svm
model
gamma
grid
search
approach
hsu
chang
lin
alternative
find
good
gamma
rbf
kernel
function
grid
search
approach
pair
try
one
good
accuracy
choose
identify
well
region
grid
fine
grid
search
region
conduct
get
good
generalization
ability
grid
search
approach
validation
process
decide
parameter
k
subset
datum
set
create
training
set
k
run
process
follow
chen
lin
hsu
consider
grid
space
step
pair
search
space
conduct
cross
validation
training
set
step
choose
parameter
lead
cv
cross
validation
error
classification
rate
step
good
parameter
create
model
predictor
overall
accuracy
average
across
k
partition
k
accuracy
value
also
give
estimate
accuracy
variance
algorithm
setting
model
parameter
grid
search
select
input
feature
build
diagnosis
model
successfully
study
try
strategy
grid
search
optimize
model
parameter
calculation
select
input
feature
see
procedure
grid
search
shown
section
approach
k
also
conduct
avoid
overfitting
training
process
overall
testing
accuracy
average
across
k
partition
k
subset
datum
create
training
set
k
run
process
calculate
sort
step
possible
number
feature
total
number
feature
datum
set
follow
keep
first
feature
accord
sort
training
set
calculate
average
svm
accuracy
fold
cross
validation
step
choose
large
average
accuracy
svm
training
set
predict
test
accuracy
test
set
image
strategy
grid
search
optimize
model
parameter
calculation
select
input
feature
view
within
article
experimental
result
experimental
result
experiment
importance
feature
measure
svm
parameter
optimized
grid
search
table
show
relative
feature
importance
feature
fold
average
cmv
ebv
hpv
high
respectively
degree
breast
tumor
associate
dna
virus
high
cmv
ebv
hpv
therefore
five
model
different
number
feature
construct
far
obtain
svm
classification
model
show
table
five
model
different
feature
subset
based
cmv}
cmv
ebv}
cmv
ebv
table
relative
feature
importance
table
view
within
article
image
relative
importance
dna
virus
based
view
within
article
table
five
feature
subset
based
select
cmv
cmv
ebv
cmv
ebv
hpv
table
view
within
article
table
table
show
training
testing
accuracy
five
model
model
achieve
high
average
overall
accuracy
among
five
model
two
model
feature
subset
cmv}
achieve
high
training
testing
accuracy
two
model
cmv}
table
show
detail
good
svm
parameter
gamma
training
accuracy
testing
accuracy
fold
average
negative
positive
overall
hit
rate
model
achieve
respectively
table
overall
training
accuracy
feature
subset
number
select
featuressvm
gs
fs
training
accuracy
fold
deviation
table
view
within
article
table
overall
testing
accuracy
feature
subset
number
select
featuressvm
gs
fs
testing
accuracy
fold
deviation
table
view
within
article
table
detail
testing
accuracy
feature
subset
size
feature
size
size
negative
hit
ratiopositive
hit
ratiooverall
hit
rationegative
hit
ratiopositive
hit
ratiooverall
hit
ratio
fold
fold
fold
fold
fold
table
view
within
article
two
three
attribute
cmv}
achieve
identical
high
accuracy
necessary
include
feature
sake
cost
save
accuracy
positive
hit
ratio
high
negative
hit
ratio
average
overall
hit
ratio
highly
accurate
result
reveal
svm
model
good
performance
diagnose
breast
cancer
accord
datum
set
comparison
linear
discriminate
analysis
experiment
importance
feature
classificatory
accuracy
measure
linear
discriminate
analysis
lda
table
show
significance
attribute
feature
subset
ebv}
include
lda
model
except
fold
attribute
ebv
slightly
insignificant
model
fold
therefore
two
attribute
include
table
show
detail
training
testing
accuracy
fold
average
negative
positive
overall
hit
rate
model
achieve
respectively
table
attribute
lda
fold
fold
fold
fold
fold
table
view
within
article
table
training
testing
accuracy
lda
negative
hit
ratiopositive
hit
ratiooverall
hit
rationegative
hit
ratiopositive
hit
ratiooverall
hit
ratio
fold
fold
fold
fold
fold
table
view
within
article
table
show
accuracy
svm
slightly
superior
accuracy
lda
select
feature
svm
include
cmv}
lda
include
ebv}
table
comparison
summary
svm
lda
negative
hit
ratiopositive
hit
ratiooverall
hit
feature
cmv}
ebv}
}
table
view
within
article
discussion
conclusion
paper
explore
five
dna
virus
ebv
cmv
hpv
affect
breast
tumor
diagnose
support
vector
machine
order
find
correlation
dna
virus
breast
tumor
achieve
high
classificatory
accuracy
adapt
find
important
feature
grid
search
approach
search
optimal
svm
parameter
result
reveal
model
good
performance
diagnose
breast
cancer
accord
datum
set
present
study
result
also
show
attribute
cmv}
achieve
identical
high
accuracy
average
overall
hit
rate
although
two
model
identical
high
accuracy
consider
diagnosis
cost
accuracy
study
suggest
simultaneously
consider
feasible
however
consider
little
accurate
svm
model
lda
author
find
common
important
feature
breast
tumor
distinguish
breast
cancer
fibroadenoma
development
viral
therapy
breast
cancer
mutant
result
also
indicate
mutant
hold
significant
potential
cancer
therapeutic
agent
detect
two
woman
develop
kaposi
sarcoma
arm
many
year
surgery
breast
cancer
kaposi
herpesvirus
suggest
associate
breast
cancer
additionally
svm
model
cmv
also
important
feature
breast
tumor
investigate
association
ebv
cmv
immunoglobulin
level
risk
breast
cancer
age
australian
breast
cancer
family
result
cmv
risk
factor
breast
cancer
furthermore
richardson
suggest
cmv
risk
factor
breast
carcinoma
antibody
activity
cmv
increase
several
patient
none
patient
however
develop
sign
cmv
infection
lda
show
ebv
important
feature
breast
tumor
first
report
positive
effect
ebv
breast
cancer
fentiman
chen
chang
study
presence
ebv
breast
cancer
suggest
may
play
significant
role
etiology
breast
cancer
taiwan
glaser
ambinder
hsu
conclude
ebv
transcript
commonly
express
breast
cancer
based
broadly
representative
case
series
investigate
presence
ebv
human
breast
cancer
indicate
ebv
might
development
breast
cancer
research
nine
study
ebv
breast
cancer
find
one
case
test
positive
ebv
conclude
ebv
regularly
detect
whole
section
breast
cancer
viral
copy
number
based
svm
model
lda
neglect
factor
hpv
find
klein
klein
klein
klein
also
show
hpv
associate
breast
cancer
report
conclude
product
hpv
genome
induce
human
breast
epithelial
cell
reduce
growth
factor
requirement
present
study
show
classifier
fibroadenoma
breast
cancer
diagnosis
classification
model
satisfactory
classificatory
accuracy
find
important
feature
discriminate
fibroadenoma
breast
cancer
practical
obstacle
well
neural
network
classification
model
nature
possible
solution
issue
svm
rule
extraction
technique
model
combine
much
interpretable
model
issue
remain
solve
future
research
increase
interest
attract
phenolic
recent
year
significant
bioactivity
scavenge
free
radical
chelating
metal
regulate
enzyme
activity
modulate
cell
proliferation
miller
kim
packer
associate
beneficial
effect
diet
human
health
recent
investigation
show
antioxidant
activity
plant
tissue
correlated
oxidative
stress
defense
different
human
disease
include
cancer
aging
process
manosroi
polyphenolic
antioxidant
interfere
oxidation
process
react
free
radical
chelating
free
catalytic
metal
act
oxygen
scavenger
thus
antioxidant
system
aerobic
metabolism
counteract
oxidative
damage
reactive
oxygen
species
breast
cancer
much
common
diagnose
invasive
cancer
woman
consider
one
lead
death
due
cancer
breast
cancer
extremely
difficult
treat
due
several
distinct
class
tumor
exhibit
different
treatment
response
epidemiological
study
indicate
relationship
flavonoid
intake
reduce
risk
certain
cancer
many
study
dietary
prevention
cancer
model
breast
cancer
establish
assess
impact
wide
variety
flavonoid
efficacy
inhibit
cancer
wang
zhang
decrease
risk
breast
cancer
incidence
associate
high
intake
genistein
moderate
consumption
red
wine
biological
pharmacological
property
chinese
herb
receive
much
attention
recent
year
attributed
fact
chinese
herb
contain
significant
amount
phytochemical
antioxidant
bioactive
compound
lamb
also
name
chinese
red
pine
pine
green
pine
belong
one
species
pine
bark
extract
unique
mixture
flavonoid
comprise
flavonoid
condensed
flavonoid
identify
mainly
procyanidins
procyanidins
mainly
constitute
link
together
dimer
report
bark
extract
french
marine
pine
protect
fraction
human
plasma
lipoprotein
oxidation
dna
iron
damage
nelson
lau
rong
moreover
french
marine
pine
also
protect
cellular
system
increase
activity
endogenous
antioxidant
enzyme
glutathione
redox
enzyme
gsh
gsh
peroxidase
superoxide
dismutase
catalase
rong
li
lau
unfortunately
limited
formation
antioxidant
activity
biological
activity
pepb
present
study
inhibition
effect
peroxidation
reduce
power
metal
chelating
ability
dpph
radical
scavenge
activity
pepb
investigate
immunomodulatory
cancer
activity
pepb
also
evaluate
material
chemical
linoleic
acid
ferrozine
dpph
purchase
sigma
aldrich
steinheim
germany
butylated
bht
butylated
bha
vitamin
vitamin
ammonium
thiocyanate
tbhq
purchase
nanjing
chemical
nanjing
china
sulfanilamide
dihydrochloride
ethylenediaminetetraacetic
acid
edta
purchase
merck
germany
bromide
mtt
dimethyl
sulfoxide
dmso
paclitaxel
rutin
purchase
sigma
chemical
louis
usa
medium
purchase
gibco
brl
invitrogen
md
fetal
calf
serum
penicillin
streptomycin
obtain
zhongshan
university
guangzhou
china
chemical
analytical
grade
preparation
pepb
bark
lamb
mature
stage
ground
powder
powder
extract
ethanol
ratio
extract
filter
evaporate
reduce
pressure
follow
bioassays
yield
pepb
reference
dry
bark
determination
antioxidant
activity
ftc
method
antioxidant
activity
pepb
inhibition
peroxidation
determine
ftc
method
solution
ml
sample
mix
ml
emulsion
phosphate
buffer
ph
reaction
mixture
incubate
accelerate
oxidation
process
ml
ethanol
ml
ammonium
thiocyanate
add
ml
solution
precisely
min
addition
ml
ferrous
chloride
acid
reaction
mixture
peroxide
value
determine
read
absorbance
nm
every
absorbance
blank
extract
sample
ml
reach
maximum
solution
without
pepb
control
distilled
water
blank
antioxidant
activity
vitamin
standard
reference
also
assay
percent
inhibition
lipid
peroxidation
emulsion
calculate
follow
absorbance
control
absorbance
presence
sample
test
carry
triplicate
assay
dpph
radical
scavenge
activity
assay
dpph
radical
scavenge
activity
carry
method
modification
briefly
ml
mm
dpph
ethanol
solution
add
ml
pepb
solution
ethanol
ml
mixture
solution
maintain
min
dark
absorbance
measure
nm
absorbance
reaction
mixture
indicate
high
radical
scavenge
activity
antioxidant
activity
vitamin
tbhq
standard
reference
also
assay
solution
without
pepb
control
ethanol
blank
test
perform
triplicate
inhibition
dpph
radical
sample
calculate
follow
reducing
power
reduce
power
pepb
determine
method
yen
duh
tsai
different
concentration
pepb
dissolve
methanol
mix
ml
phosphate
buffer
ph
ml
potassium
mixture
incubate
min
incubation
ml
acid
add
mixture
follow
centrifugation
min
supernatant
ml
collect
mix
ml
distil
water
ml
chloride
absorbance
result
solution
measure
nm
antioxidant
activity
vitamin
vitamin
bha
standard
reference
also
assay
distilled
water
blank
test
carry
triplicate
metal
chelating
ability
chelating
ability
ferrous
ion
pepb
estimate
method
briefly
pepb
solution
ml
add
ml
mm
reaction
initiate
addition
ml
mm
ferrozine
mixture
shake
keep
room
temperature
min
absorbance
solution
measure
nm
antioxidant
activity
bha
bht
edta
standard
reference
also
assay
distilled
water
blank
test
carry
triplicate
assay
scavenge
activity
scavenge
activity
pepb
measure
accord
method
packer
method
based
principle
sodium
nitroprusside
aqueous
solution
physiological
ph
spontaneously
generate
interact
oxygen
produce
nitrite
ion
estimate
griess
reagent
act
oxygen
lead
reduce
production
nitrite
ion
experiment
ml
pepb
add
ml
mm
sodium
nitroprusside
snp
solution
mixture
incubate
room
temperature
min
griess
reagent
ml
sulfanilamide
naphthylethylenediamine
dihydrochloride
add
mixture
absorbance
form
nitrite
sulfanilamide
subsequent
coupling
naphthylethylenediamine
dihydrochloride
immediately
record
nm
antioxidant
activity
bha
bht
standard
reference
also
assay
distilled
water
blank
test
carry
triplicate
determination
total
phenolic
content
total
phenolic
content
determine
folin
method
singleton
briefly
extract
dissolve
methanol
extract
solution
ml
mix
ml
folin
reagent
min
ml
add
mixture
allow
stand
intermittent
room
temperature
absorbance
measure
nm
total
phenolic
content
express
mg
equivalent
gce
dry
weight
dw
basis
animal
normal
female
balb
mouse
month
old
zhongshan
university
guangzhou
china
maintain
environment
allow
continuous
free
access
standard
laboratory
chow
fresh
water
mouse
allow
day
prior
experiment
cell
line
culture
human
breast
cancer
helf
cell
line
obtain
immune
system
analysis
laboratory
zhongshan
university
guangzhou
china
cell
maintain
complete
medium
humidify
atmosphere
mice
kill
cervical
dislocation
spleen
remove
single
cell
prepare
spleen
fragment
press
stainless
mesh
screen
rpmi
complete
medium
complete
medium
supplement
fetal
calf
serum
mm
penicillin
ml
streptomycin
ml
amount
cell
place
mm
well
incubate
humidify
supernatant
together
cell
collect
centrifugation
rpm
min
cell
pellet
rpmi
complete
medium
adjust
cell
ml
manosroi
manosroi
vitro
proliferation
assay
proliferation
stimulatory
effect
pepb
splenocyte
cytotoxicity
helf
cell
evaluate
bromide
mtt
assay
method
describe
previously
sun
pan
briefly
ml
pepb
paclitaxel
rutin
dissolve
ethanol
dilute
rpmi
add
well
add
cell
suspension
cell
ml
rpmi
well
plate
control
cell
incubate
medium
contain
equivalent
solvent
amount
without
test
material
final
solvent
concentration
range
experiment
find
concentration
level
alter
cell
growth
plate
incubate
humidify
atmosphere
mtt
solution
mg
ml
add
well
incubate
supernatant
remove
carefully
well
without
disturbing
attach
cell
formazan
crystal
solubilized
add
well
shake
min
absorbance
nm
measure
microplate
reader
richmond
well
without
cell
control
experiment
perform
triplicate
pepb
proliferation
helf
calculate
follow
formula
stimulatory
effect
pepb
proliferation
splenocyte
calculate
follow
statistical
analysis
datum
express
mean
standard
deviation
sd
three
replicate
determination
statistical
calculation
version
software
originlab
corporation
usa
carry
one
way
variance
analysis
apply
determine
difference
result
sample
value
consider
significantly
different
result
antioxidant
activity
pepb
linoleic
acid
peroxidation
study
total
phenolic
content
pepb
measure
mg
gce
dw
show
pine
bark
rich
source
polyphenol
antioxidant
activity
pepb
measure
ftc
system
ftc
method
measure
peroxide
level
initial
stage
lipid
oxidation
oxidation
peroxide
form
result
maximum
absorbance
nm
absorbance
value
indicate
high
level
antioxidant
activity
duh
tu
yen
show
table
pepb
exhibit
antioxidant
activity
concentration
ml
pepb
high
percent
inhibition
follow
vitamin
suggest
antioxidant
activity
pepb
linoleic
acid
peroxidation
high
vitamin
table
vitro
antioxidant
activity
pepb
standard
antioxidant
vitamin
peroxidation
system
ftc
pepb
ml
absorbance
vitamin
vitamin
table
data
represent
mean
sd
mean
indicate
significantly
different
vitamin
view
within
article
dpph
radical
scavenge
activity
dpph
assay
evaluate
ability
antioxidant
scavenge
free
radical
show
scavenge
activity
pepb
vitamin
tbhq
dpph
radical
compare
pepb
strong
scavenge
activity
dpph
radical
effect
enhance
increase
concentration
range
ml
however
significant
difference
observe
scavenge
activity
ml
pepb
exhibit
high
scavenge
activity
follow
vitamin
tbhq
ml
image
free
radical
scavenge
activity
pepb
tbhq
vitamin
result
mean
sd
three
replicate
measurement
view
within
article
assay
scavenge
activity
important
role
various
type
inflammatory
process
animal
body
scavenge
activity
may
help
arrest
chain
reaction
initiate
excess
generation
detrimental
human
health
scavenge
activity
pepb
bht
bha
radical
evaluate
respectively
show
pepb
stronger
scavenge
activity
ml
inhibition
effect
enhance
increase
concentration
pepb
exhibit
radical
scavenge
activity
ml
significantly
high
bha
bht
image
vitro
activity
pepb
bha
bht
result
mean
sd
three
replicate
measurement
view
within
article
reducing
power
good
correlation
antioxidant
activity
reduce
power
plant
extract
prove
yen
chen
peng
therefore
reduce
capacity
may
indicator
potential
antioxidant
show
reduce
power
pepb
compare
bha
vitamin
pepb
reducing
power
concentration
reduce
power
pepb
high
bha
vitamin
image
reducing
power
pepb
vitamin
vitamin
bha
result
mean
sd
three
replicate
measurement
view
within
article
metal
chelating
ability
metal
chelating
ability
pepb
standard
antioxidant
determine
evaluate
capacity
compete
ferrozine
ferrous
ion
ferrozine
quantitatively
form
complex
presence
chelating
agent
complex
formation
disrupt
result
reduce
red
colour
complex
therefore
measurement
rate
colour
reduction
allow
estimation
chelating
ability
show
formation
complex
complete
presence
pepb
furthermore
ability
chelating
ferrous
ion
enhance
increase
pepb
concentration
metal
chelating
ability
pepb
great
bht
bha
difference
pepb
edta
statistically
significant
ml
bha
bht
edta
show
chelating
ability
respectively
report
chelating
agent
effective
secondary
antioxidant
reduce
redox
potential
thereby
oxidized
form
metal
ion
yen
datum
study
exhibit
pepb
effective
ability
iron
binding
image
chelating
effect
pepb
bha
edta
bht
ferrous
ion
result
mean
sd
three
replicate
measurement
view
within
article
immunomodulatory
activity
pepb
immunomodulatory
activity
pepb
investigate
proliferation
splenocyte
show
ml
pepb
markedly
stimulate
proliferation
splenocyte
manner
concentration
pepb
ml
concentration
study
exhibit
significantly
stimulatory
effect
splenocyte
proliferation
concentration
ml
study
pepb
exhibit
stimulatory
effect
proliferation
splenocyte
respectively
rutin
show
stimulatory
effect
respectively
result
reveal
pepb
exhibit
stronger
stimulatory
effect
proliferation
mouse
splenocyte
rutin
similar
result
report
plant
extract
flavone
lin
image
stimulatory
effect
pepb
rutin
proliferation
splenocyte
result
mean
sd
three
replicate
measurement
view
within
article
cancer
activity
lamb
bark
extract
table
present
cytotoxicity
cell
pepb
paclitaxel
various
concentration
treatment
pepb
significantly
inhibit
cell
proliferation
manner
high
concentration
ml
cytotoxicity
pepb
ml
observe
respectively
median
effective
dose
pepb
inhibition
cell
proliferation
ml
hand
paclitaxel
approve
fda
anticancer
drug
show
strong
cytotoxicity
helf
cytotoxicity
paclitaxel
ml
beyond
ml
cytotoxicity
helf
paclitaxel
respectively
result
suggest
paclitaxel
exhibit
good
inhibitory
effect
cancer
cell
proliferation
damage
normal
cell
table
cytotoxicity
human
breast
cancer
cell
pepb
paclitaxel
various
concentration
treatment
pepb
concentration
ml
absorbance
nmcytotoxicity
paclitaxel
concentration
ml
absorbance
nmcytotoxicity
table
data
represent
mean
sd
mean
indicate
significantly
different
paclitaxel
level
view
within
article
show
table
concentration
test
pepb
exhibit
different
helf
cell
effect
cell
viability
proliferation
furthermore
pepb
relatively
safe
cell
little
cytotoxicity
observe
range
ml
paclitaxel
observation
suggest
pepb
attractive
component
may
potentially
anticancer
agent
table
cytotoxicity
helf
pepb
paclitaxel
various
concentration
treatment
determine
tetrazolium
dye
mtt
assay
pepb
concentration
ml
absorbance
nmcytotoxicity
paclitaxel
ml
absorbance
nmcytotoxicity
table
data
represent
mean
sd
mean
indicate
significantly
different
paclitaxel
level
view
within
article
conclusion
pepb
exhibit
strong
antioxidant
activity
five
model
study
include
total
antioxidant
activity
free
radical
scavenge
activity
metal
chelating
ability
scavenge
activity
antioxidant
activity
pepb
might
attributed
effective
ability
capability
effectiveness
good
scavenger
hydrogen
peroxide
free
radical
pepb
also
show
stronger
stimulatory
effect
proliferation
mouse
splenocyte
rutin
addition
pepb
inhibit
growth
human
breast
cancer
cell
ml
toxicity
helf
paclitaxel
result
obtain
study
suggest
pepb
easy
accessible
source
natural
antioxidant
possible
supplement
pharmaceutical
industry
major
component
responsible
immunomodulatory
anticancer
activity
need
far
investigate
acknowledgement
financial
support
provide
national
natural
science
foundation
china
national
key
technology
program
research
foundation
greatly
appreciate
term
life
cycle
within
biomedical
discipline
describe
much
rigid
phase
biological
organism
travel
throughout
life
within
nursing
research
long
recognised
patient
need
differ
dependent
life
stage
nursing
develop
specifically
target
intervention
aim
promote
maintain
health
childhood
school
year
adolescence
adulthood
old
age
life
course
research
represent
group
methodology
conceptual
issue
relevant
research
question
involve
various
era
life
course
little
within
nursing
health
service
research
however
application
study
suggest
technique
may
benefit
healthcare
research
attempt
understand
complex
health
behaviour
many
approach
examine
historical
experience
event
history
experience
evaluation
interpretation
event
prospective
retrospective
design
strength
weakness
prospective
design
facilitate
selection
representative
sample
ability
collect
current
datum
however
often
associate
problem
attrition
conditioning
expense
methodological
strength
retrospective
design
lie
allow
researcher
cover
lengthy
time
period
access
longitudinal
datum
unfortunately
may
cost
recall
memory
possible
survivor
bias
risk
past
event
filter
present
experience
need
participant
secure
social
acceptance
concept
life
course
introduce
contribution
history
sociology
medicine
evidence
empirical
research
method
historical
sociology
aging
life
history
longitudinal
survey
influence
current
perspective
life
course
research
much
research
centre
large
prospective
panel
survey
british
birth
cohort
study
whose
follow
individual
age
year
indicate
inequality
health
relate
social
difference
material
circumstance
difference
individual
skill
resource
acquire
early
life
perspective
life
course
remain
controversial
emphasised
human
historical
context
pattern
behaviour
call
question
regularity
universal
stage
development
propose
developmental
psychologist
life
cycle
life
course
perspective
associate
method
datum
collection
favour
last
year
due
change
biographical
method
general
last
year
biographical
method
move
away
focusing
present
situation
individual
perspective
whole
life
across
whole
family
several
generation
today
life
course
framework
span
traditional
interest
quality
course
human
life
alternate
approach
precision
observation
analysis
state
key
building
block
element
new
life
course
paradigm
event
combine
event
history
trajectory
compare
across
person
group
note
difference
timing
duration
rate
change
argue
new
perspective
constructivist
approach
life
course
study
individual
social
change
mutual
influence
methodological
guidance
specifically
relate
life
course
study
publish
elder
much
recent
information
contain
life
course
life
course
paradigm
paradigm
state
point
life
span
view
consequence
past
experience
future
expectation
include
location
time
place
history
social
structure
culture
link
life
influence
institution
group
human
agency
individual
goal
sense
timing
chronological
event
image
four
key
element
life
course
paradigm
diagram
show
four
key
element
life
course
paradigm
show
four
element
location
time
place
link
life
human
agency
timing
four
element
determine
possible
different
trajectory
take
life
course
diagram
author
cb
design
giele
view
within
article
first
domain
relate
location
time
place
describe
individual
cultural
background
period
time
individual
social
behaviour
involve
different
level
social
physical
context
result
general
individual
experience
phenomenon
term
social
sociology
literature
practice
continue
time
second
link
life
relate
social
integration
level
social
interaction
cultural
institutional
psychological
interact
mutually
influence
individual
behaviour
social
expectation
norm
differ
individual
may
also
similar
share
family
background
experience
exist
see
cohort
study
third
human
agency
concern
individual
goal
orientation
age
marker
individual
development
therefore
link
human
agency
however
relationship
age
human
behaviour
life
course
complex
number
psychological
control
theory
exist
explain
human
behaviour
much
rely
human
wish
produce
behaviour
link
event
elicit
control
environment
control
fail
relate
negative
affect
face
anticipate
actual
loss
control
theory
development
suggest
emergence
transformation
behaviour
life
course
influence
primary
secondary
control
state
primary
control
relate
behaviour
direct
external
environment
involve
attempt
change
world
fit
need
desire
individual
secondary
control
attempt
minimize
loss
due
failure
boost
primary
control
function
suggest
life
course
control
will
differ
due
opportunity
barrier
encounter
constructivist
perspective
connection
age
human
agency
rigid
although
influence
age
norm
also
affect
many
factor
show
great
variation
demonstrate
study
developmental
regulation
across
adulthood
individual
group
meet
need
result
active
decision
make
organising
life
around
personal
group
goal
example
economically
secure
avoid
pain
life
course
perspective
include
final
dimension
timing
life
strategic
adaptation
accomplish
goal
individual
group
respond
timing
external
event
undertake
behaviour
resource
available
timing
life
event
therefore
see
passive
active
adaptation
reach
individual
group
goal
bring
together
three
element
integrate
historical
social
individual
activity
giele
elder
suggest
model
look
individual
adaptation
certain
event
situation
seek
methodology
describe
explore
circumstance
referral
due
family
history
breast
cancer
life
course
paradigm
provide
useful
theoretical
framework
explore
referral
event
majority
study
health
behaviour
context
genetic
risk
develop
cancer
tend
focus
psychological
harm
benefit
new
information
study
indicate
likely
factor
also
influence
behaviour
interest
try
understand
much
complex
psychological
interpretation
information
social
political
context
person
family
understand
health
behaviour
context
genetic
risk
therefore
important
select
methodology
capable
take
account
wide
context
view
individual
family
systematic
review
life
course
paradigm
healthcare
literature
stage
study
become
aware
although
life
course
paradigm
appear
particularly
relevant
study
little
publish
health
research
utilised
approach
systematic
search
follow
electronic
database
perform
psychinfo
medline
web
science
identify
life
course
paradigm
within
nursing
literature
review
term
database
clear
none
term
life
course
major
therefore
search
perform
term
life
course
nursing
combine
produce
result
examine
abstract
result
evidence
life
course
paradigm
eight
result
within
health
literature
element
life
course
paradigm
five
paper
report
empirical
research
life
course
perspective
whilst
four
paper
either
review
paper
three
paper
life
course
framework
review
exist
healthcare
literature
within
specific
field
oral
healthcare
mental
health
childhood
onset
disability
evidence
life
course
paradigm
prospective
study
patient
diagnose
coronary
artery
disease
show
approach
alongside
quantitative
method
give
rich
insight
live
chronic
disease
lukkarinen
lukkarinen
two
paper
look
aspect
care
family
member
throughout
life
course
demonstrate
retrospective
approach
application
life
course
paradigm
increase
genetic
research
last
decade
result
discovery
affect
ability
health
professional
give
individualised
risk
information
based
family
history
dna
testing
following
identification
gene
responsible
much
inherit
breast
cancer
sudden
demand
referral
threaten
oncology
service
uk
australia
europe
technique
create
life
course
chart
describe
context
study
aim
explore
woman
risk
little
lifetime
risk
develop
breast
cancer
due
family
history
represent
least
quarter
referral
specialist
centre
referral
family
history
breast
cancer
part
study
woman
interview
explore
experience
referral
event
also
prior
interaction
health
professional
research
review
local
ethical
review
committee
woman
study
referred
family
history
clinic
assessment
personal
risk
develop
breast
cancer
clinic
locate
within
acute
surgical
outpatient
department
cancer
centre
sampling
strategy
follow
purposeful
approach
aim
maximum
variation
allow
far
expansion
theme
emerge
total
referral
letter
receive
hospital
clinic
review
chronologically
write
referral
general
practitioner
batch
one
consist
first
letter
review
sample
choose
meet
follow
criterion
woman
without
personal
history
breast
cancer
whose
family
represent
range
genetic
risk
batch
two
consist
referral
choose
meet
criterion
plus
sample
likely
genetic
risk
emerge
interesting
area
investigation
batch
three
consist
referral
sample
criterion
also
select
old
woman
age
year
unusual
case
occur
previous
sample
sampling
procedure
ensure
interesting
phenomenon
emerge
initial
interview
similar
also
dissimilar
case
select
increase
evidence
dispute
emerge
idea
woman
approach
agree
participate
two
interview
able
complete
week
referral
interview
require
study
allow
recent
referral
event
women
send
letter
patient
information
sheet
clinician
reply
researcher
make
certain
information
fully
understand
prior
arrange
interview
time
interview
none
woman
see
clinic
techniques
procedure
life
course
charting
research
retrospective
design
interview
transcribe
analyse
constant
comparison
technique
also
within
separate
complementary
life
course
paradigm
study
interview
transcript
analyse
ground
theory
approach
ground
theory
choose
ability
qualitative
methodology
produce
explanatory
linkage
concept
allow
sensitivity
emerge
area
interest
rather
purely
rich
description
research
based
within
constructivist
paradigm
analysis
follow
ground
theory
approach
analysis
strategy
study
fully
describe
consist
purposeful
sampling
open
coding
constant
comparison
new
datum
axial
coding
selective
coding
theoretical
saturation
ground
theory
analysis
construction
life
chart
life
chart
author
cb
interpretation
based
construct
story
event
describe
woman
interview
participants
ask
towards
end
interview
describe
life
experience
breast
cancer
childhood
present
day
encourage
mention
specific
event
feeling
datum
standardised
coding
framework
organised
text
chronologically
time
incidence
breast
cancer
diagnosis
clinic
referral
also
chronological
age
also
important
collection
subjective
information
relate
feeling
woman
time
objective
information
onward
referral
make
initially
diagram
make
paper
indicate
event
mention
life
course
paradigm
bring
theoretical
sensitivity
term
life
course
participant
analysis
add
complementary
perspective
ground
theory
analysis
study
woman
ask
discuss
prior
experience
breast
cancer
family
therefore
woman
study
talk
reconstruction
past
situate
past
within
immediate
historical
social
circumstance
present
term
presently
understand
past
form
research
life
review
reveal
individual
repeatedly
past
event
light
point
present
situate
discussion
regard
family
history
breast
cancer
referral
event
context
evoke
presence
author
study
research
take
narrative
approach
biography
oppose
approach
describe
miller
study
true
historical
situation
past
wish
study
current
day
perception
past
experience
relation
breast
cancer
thus
take
constructivist
perspective
recognition
individual
relay
interpretation
presently
understand
past
one
researcher
select
component
story
tell
reconstruct
order
convey
meaning
intend
take
story
historical
truth
individual
account
event
primary
issue
novel
methodology
draw
life
course
chart
knowledge
within
health
service
research
datum
collection
life
chart
create
alongside
coding
interview
help
inform
sampling
strategy
construction
life
chart
chart
construct
igrafix
microsoft
draw
package
woman
chronological
age
historical
context
along
note
social
historical
event
start
nhs
provide
free
healthcare
start
human
genome
project
isolation
first
hereditary
breast
ovarian
cancer
gene
availability
specialist
family
history
breast
screening
clinic
hoc
basis
chart
indicate
affective
period
concern
subjective
point
identify
woman
motherhood
significant
period
change
objective
datum
period
knowledge
breast
cancer
family
interaction
health
professional
white
circle
represent
diagnosis
event
usually
breast
cancer
friend
family
member
black
circle
death
arrow
represent
interaction
healthcare
provider
discuss
family
history
raise
knowledge
breast
cancer
history
show
green
line
light
grey
period
concern
show
red
line
dark
grey
example
baseline
chart
provide
chart
allow
researcher
timing
significant
event
across
life
course
identify
context
term
historical
significance
breast
cancer
gene
identify
period
individual
life
adolescence
event
interest
referral
study
place
significant
event
motherhood
personal
illness
event
chart
depend
perspective
researcher
main
research
question
pose
study
chart
powerful
technique
help
develop
interpretation
possible
interplay
event
image
example
life
chart
show
structure
chart
woman
age
x
historical
time
period
event
trajectory
woman
remember
experience
relation
familial
breast
cancer
turn
point
specific
event
time
diagnosis
family
member
explicit
knowledge
make
available
family
member
diagnosis
level
concern
interaction
health
professional
view
within
article
igrafix
software
also
facilitate
superimpose
multiple
individual
chart
create
technique
possible
one
woman
chart
another
enable
similarity
variation
experience
referral
pathway
contrast
compare
one
example
compare
chart
woman
know
breast
cancer
much
recently
compare
knowledge
number
year
enhance
understanding
pattern
emerge
although
show
variation
time
take
knowledge
breast
cancer
family
referred
emerge
group
woman
motivate
seek
interaction
health
professional
quickly
knowledge
whilst
show
wait
number
year
image
multiple
life
course
know
breast
cancer
family
number
year
referral
multiple
life
course
chart
show
woman
long
period
knowledge
breast
cancer
family
show
variation
number
interaction
health
professional
single
double
arrow
time
know
risk
green
light
grey
line
time
period
concern
red
dark
grey
line
age
time
diagnosis
relative
white
circle
age
relative
death
black
circle
view
within
article
contribution
life
course
chart
identification
psychosocial
process
realisation
risk
twenty
four
woman
approach
agree
interview
response
rate
total
woman
interview
referred
primary
care
one
hospital
breast
clinic
nineteen
woman
one
two
affect
family
member
either
mother
sister
affect
lifetime
risk
develop
breast
cancer
individual
calculate
thirteen
woman
little
risk
medium
risk
high
risk
woman
describe
white
age
range
year
woman
age
year
first
relative
diagnose
breast
cancer
woman
relative
diagnose
family
close
affect
family
member
woman
mother
six
case
sister
remain
three
case
involve
much
distant
family
member
unlike
study
explore
woman
attend
family
history
clinic
majority
woman
study
social
class
range
half
woman
formal
education
age
study
referral
event
core
seem
benefit
greatly
inclusion
life
course
chart
contribute
identification
psychosocial
process
realisation
risk
psychosocial
process
develop
ground
theory
analysis
conjunction
review
life
chart
process
example
give
datum
intend
show
full
analysis
six
initial
category
identify
personal
know
mother
history
never
really
bother
initiation
close
home
social
family
start
look
want
old
know
action
make
first
step
now
healthcare
think
think
hope
expectation
want
mammogram
process
realisation
risk
find
main
behind
woman
health
professional
reason
initiate
referral
image
psychosocial
risk
view
within
article
one
woman
story
see
ability
observe
chart
multiple
domain
powerful
identify
conceptual
process
year
old
woman
move
house
register
local
doctor
routine
new
patient
interview
doctor
ask
cancer
heart
disease
list
ask
heart
disease
good
thing
kind
cover
lot
thing
kind
really
stick
cancer
mention
mother
image
example
life
chart
confirm
realisation
risk
process
view
within
article
woman
explain
mother
die
year
ago
breast
cancer
gp
ask
age
onset
say
wise
check
inherit
instance
present
focused
realisation
risk
hold
health
professional
previously
present
woman
order
make
referral
gp
ask
much
information
relate
family
member
ask
woman
return
surgery
say
like
tell
go
away
think
tell
first
information
sort
want
know
many
people
breast
cancer
age
information
drop
raise
present
focused
realisation
risk
woman
initiate
referral
woman
go
away
concern
feel
able
face
issue
soon
mother
death
wish
raise
issue
family
evoke
cope
mechanism
allow
level
concern
result
much
unfocused
realisation
think
much
shock
first
dr
gp
start
explain
want
get
done
just
know
soon
mother
die
know
sick
cancer
just
want
hear
know
sometimes
say
sometimes
think
like
sleep
lie
happen
happen
just
want
back
mind
four
year
later
number
instance
trigger
feeling
personal
friend
back
home
recently
undergo
aggressive
therapy
bone
cancer
father
sister
diagnose
breast
cancer
age
year
detect
late
go
go
early
might
even
breast
remove
wait
month
go
know
get
shock
family
might
want
put
back
mind
put
back
mind
know
go
always
feel
now
time
act
go
back
think
much
like
time
go
get
old
know
run
away
everything
like
definitely
want
now
now
recently
friend
mine
get
cancer
home
think
check
now
something
hear
information
mother
aunt
just
now
just
know
health
now
much
now
specifically
make
appointment
see
gp
unavailable
see
another
doctor
instead
keen
take
issue
seriously
say
know
much
available
hold
unfocused
realisation
risk
however
referral
letter
write
woman
feel
please
something
now
face
problem
feel
relieve
now
care
expect
get
surveillance
reality
woman
genetic
risk
lifetime
risk
offer
extra
surveillance
attend
clinic
contribution
life
chart
identify
two
element
realisation
risk
process
life
chart
facilitate
identification
two
important
concept
drive
referral
process
anticipate
onset
generational
transference
show
highlight
box
process
diagram
onset
term
anticipate
onset
apply
describe
concept
woman
feel
acknowledge
perceive
threat
health
breast
cancer
specific
life
stage
demonstrate
see
bother
know
think
worry
nothing
like
start
turn
start
much
mind
sit
think
worry
go
start
reach
now
start
worry
much
now
thing
mind
like
much
active
like
now
get
old
understand
much
much
wise
much
remember
mum
see
go
mind
next
year
get
thing
mind
will
get
cancer
convince
will
get
frightening
year
old
medium
risk
whose
mother
develop
cancer
anticipate
onset
relied
upon
woman
knowledge
age
breast
cancer
occur
relative
describe
much
specific
chronological
age
example
include
close
age
now
age
group
mother
will
happen
age
onset
affect
family
member
often
motivation
seek
referral
see
another
study
relate
decision
pursue
genetic
testing
inherit
bowel
cancer
susceptibility
term
age
correlation
age
referral
age
close
family
member
diagnose
recently
demonstrate
however
current
study
negative
example
woman
describe
concern
even
similar
age
affect
relative
condition
present
prevent
woman
think
possible
vulnerability
anticipate
onset
describe
reason
woman
associate
feeling
vulnerability
likely
due
contextual
factor
life
map
help
highlight
concept
highlight
particular
event
care
sick
relative
financial
difficulty
therefore
feel
able
address
personal
health
concern
also
ability
chart
age
affect
relative
onto
woman
personal
chart
powerful
indicator
life
period
feeling
vulnerability
often
arise
ability
link
life
help
formulate
development
theory
realisation
risk
generational
transference
woman
study
create
meaning
current
event
seem
draw
upon
past
experience
similar
event
experience
history
sometimes
articulate
remember
relative
begin
put
place
often
social
role
become
similar
motherhood
term
generational
transference
describe
concept
personally
relate
affect
family
member
social
role
appearance
personal
situation
result
raise
concern
circumstance
relation
vulnerability
illness
death
women
describe
phenomenon
often
approach
similar
stage
life
course
age
onset
cancer
relative
anticipate
describe
similar
social
role
child
similar
age
child
affect
relative
time
illness
family
responsibility
even
just
similar
personal
appearance
example
give
importance
personal
family
experience
highlight
many
study
similar
concept
likeness
recently
describe
walter
emery
part
propose
model
familial
risk
big
worry
see
mum
young
see
mum
pass
away
feel
go
happen
go
take
illness
child
go
leave
young
like
get
young
well
like
mum
pass
away
happen
get
little
one
year
old
woman
year
old
son
example
generational
transference
occur
story
woman
occurrence
often
lead
feeling
increase
personal
vulnerability
health
behaviour
associate
feeling
often
facilitate
constrain
contextual
factor
availability
clinical
service
life
chart
show
rapid
pace
development
scientific
understanding
inherit
breast
cancer
also
scientific
discovery
availability
specialist
clinical
service
initiation
referral
fifty
eight
interaction
health
professional
describe
woman
study
interaction
lead
current
referral
event
historical
interaction
interaction
code
belong
one
three
group
women
appointment
directly
discuss
family
history
woman
initiate
discussion
attend
another
reason
woman
whose
interaction
initiate
action
health
professional
initiate
focused
risk
realisation
presence
personal
vulnerability
seem
drive
referral
process
towards
much
active
pathway
onward
referral
level
personal
vulnerability
express
woman
seem
correlated
pathway
women
travel
active
pathway
referral
initiate
interaction
directly
seem
much
likely
perceive
personal
vulnerability
women
without
feeling
personal
vulnerability
tend
travel
inactive
path
referred
advice
health
professional
travel
much
passive
pathway
amount
vulnerability
feel
woman
seem
drive
referral
process
forward
woman
travel
active
pathway
likely
onward
referral
referral
oppose
woman
travel
inactive
opportunistic
pathway
referral
case
woman
express
feeling
high
vulnerability
seek
referral
case
important
highlight
circumstance
woman
high
level
concern
vulnerability
also
hold
unfocused
view
risk
seem
little
likely
onward
referral
case
referral
make
nearly
always
due
woman
perceive
health
professional
risk
feeling
oblige
refer
onwards
case
woman
perceive
health
professional
feel
risk
absent
realisation
risk
discuss
issue
woman
hold
focused
idea
expect
referral
result
onward
referral
make
model
suggest
likelihood
referral
initiation
show
study
interview
woman
follow
referral
event
health
professional
state
risk
realisation
show
health
professional
subjective
measure
image
proposed
model
predict
likelihood
referral
event
take
place
primary
care
specialist
service
view
within
article
discussion
life
course
paradigm
theoretical
framework
novel
development
life
chart
help
define
core
psychosocial
process
occur
initiate
referral
context
perceive
familial
risk
life
chart
allow
visualisation
number
factor
include
historical
context
current
age
life
stage
timing
relevant
event
death
relative
diagnosis
chronic
disease
choice
item
relevant
plot
depend
upon
research
question
event
individual
researcher
wish
mark
relevant
analytical
approach
complementary
ground
theory
gather
information
question
representation
life
chart
methodology
address
many
nursing
healthcare
relate
research
question
complex
interplay
health
social
psychological
historical
factor
life
course
paradigm
already
theoretically
chart
chronic
illness
life
course
chart
develop
help
understand
health
behaviour
many
chronic
disease
life
chart
conjunction
participant
draw
together
life
course
chart
therefore
strong
utility
understanding
management
risk
field
health
promotion
beneficial
propose
construction
life
course
chart
beneficial
explore
life
experience
patient
area
nursing
practice
diagram
family
dynamic
currently
part
family
therapy
possible
historical
context
provide
life
chart
approach
helpful
discuss
change
event
history
within
family
especially
ability
layer
individual
chart
create
multiple
chart
family
nursing
practice
often
require
exploration
circumstance
lead
illness
also
trajectory
illness
healing
process
ability
discuss
patient
ask
tell
story
already
prove
important
part
nursing
possible
life
chart
allow
representation
story
contrast
explore
patient
journey
study
life
chart
help
demonstrate
referral
rather
motivate
valid
genetic
risk
greatly
influence
psychological
social
health
concern
woman
model
likelihood
initiation
referral
test
far
see
combination
risk
realisation
woman
health
professional
predict
likelihood
referral
study
provide
evidence
suggest
health
professional
knowledgeable
genetic
risk
time
elicit
personal
concern
concern
often
resolve
within
primary
care
woman
make
inform
decision
agree
onward
referral
recent
review
qualitative
research
relate
familial
risk
highlight
number
concept
identify
research
study
confirm
importance
qualitative
methodology
identify
issue
important
individual
context
qualitative
quantitative
method
utilised
within
life
course
paradigm
tool
method
depend
upon
basic
belief
enquiry
hold
researcher
study
describe
ground
theory
methodology
life
course
charting
within
constructivist
framework
allow
woman
construct
life
story
experience
relate
referral
primary
care
dual
approach
allow
technique
enhance
theoretical
sensitivity
ground
theory
analytical
apply
life
chart
question
compare
look
exceptional
case
action
woman
study
suggest
appraise
situation
term
threat
concern
often
approach
health
professional
directly
outcome
approach
seem
upon
availability
national
health
service
resource
term
knowledgeable
health
professional
specialist
clinic
plot
interaction
health
professional
onto
chart
find
study
contrast
two
questionnaire
study
woman
easily
articulate
service
referred
especially
referred
follow
advice
health
professional
range
motivation
seek
referral
find
van
ask
woman
postal
questionnaire
select
list
motive
attend
cancer
genetic
clinic
conclude
woman
unique
combination
motive
attend
often
influence
sociodemographic
factor
age
whether
young
child
much
detail
insight
study
individual
referred
hospital
doctor
gp
uk
cancer
genetic
service
study
ask
participant
select
scale
importance
set
factor
report
screening
rate
much
important
child
along
perceive
risk
develop
cancer
much
high
average
categorised
high
level
cancer
worry
similar
find
old
people
much
interested
attend
order
find
risk
family
member
study
difficult
assess
participant
motivation
prompt
select
list
one
study
primarily
involve
woman
genetic
risk
referred
primary
care
effect
group
represent
far
large
population
affect
family
history
breast
cancer
total
adult
woman
uk
close
relative
develop
breast
cancer
although
group
necessarily
expect
benefit
intensive
surveillance
research
provide
evidence
many
woman
genetic
risk
worry
seek
information
health
professional
agreement
woman
risk
little
satisfy
receive
information
regard
risk
assessment
letter
want
much
information
moderate
risk
highlight
important
concern
health
professional
sometimes
raise
concern
unnecessarily
due
provision
inappropriate
advice
kirk
kirk
kirk
metcalfe
study
identify
interaction
health
professional
result
onward
referral
currently
new
technology
develop
computer
programme
allow
health
professional
primary
care
access
information
base
accurate
risk
assessment
pilot
nurse
doctor
work
healthcare
setting
much
frequently
become
face
question
concern
familial
risk
important
able
potential
motivation
behind
referral
specialist
risk
assessment
make
judgment
based
solely
statistical
risk
result
life
course
study
raise
much
question
complex
area
divide
many
exist
theory
health
behaviour
rely
start
point
either
illness
health
health
behaviour
often
represent
theoretical
approach
stress
cognitive
process
determinant
behaviour
meta
analysis
study
model
theory
action
theory
behaviour
show
variance
intention
variance
behaviour
explain
model
evidence
study
show
woman
feel
risk
different
illness
carry
faulty
gene
loss
ability
maintain
social
role
perhaps
important
consider
design
instrument
measure
health
behaviour
context
family
history
illness
model
familial
risk
perception
develop
walter
emery
interview
individual
risk
chronic
disease
due
family
history
study
concur
many
finding
model
concept
anticipate
onset
generational
transference
also
similar
theme
likeness
perceive
mention
walter
emery
study
psychosocial
process
realisation
risk
model
familial
risk
perception
element
common
theoretical
work
common
sense
model
regulation
arise
observation
cognitive
emotional
representation
threat
appraise
attempt
make
control
threat
walter
recently
map
result
study
onto
element
model
helpful
way
understanding
familial
risk
conclusion
two
question
lie
much
traditional
social
science
life
course
research
individual
affect
social
change
life
course
situation
group
actually
influence
social
change
purpose
article
highlight
value
life
course
research
methodology
bring
nursing
research
possible
question
consider
patient
affect
healthcare
system
life
course
situation
certain
patient
influence
healthcare
change
article
show
life
course
paradigm
allow
broad
understanding
health
behaviour
place
behaviour
social
political
context
also
focus
purely
psychological
determinant
include
temporal
element
well
environmental
economic
social
behavioural
determinant
chronic
disease
life
chart
study
draw
computer
package
however
possible
discuss
draw
individual
life
chart
paper
interesting
develop
technique
far
option
much
dynamic
life
charting
time
interview
conclude
novel
method
life
course
chart
help
highlight
similarity
difference
relate
common
event
make
valuable
method
examine
nursing
practice
patient
experience
acknowledgement
wish
thank
woman
participate
study
metcalfe
advice
helpful
comment
manuscript
breast
cancer
remain
major
public
health
problem
several
establish
risk
factor
parity
age
first
pregnancy
identify
relate
breast
cancer
etiology
factor
diet
alcohol
consumption
great
interest
constitute
modifiable
risk
factor
breast
cancer
association
alcohol
consumption
breast
cancer
largely
investigate
result
publish
entirely
consistent
study
find
evidence
increase
risk
alcohol
consumption
report
significant
positive
association
agree
high
alcohol
consumption
increase
breast
cancer
risk
even
consensus
harmful
causal
effect
alcohol
consumption
breast
cancer
risk
issue
still
remain
one
issue
role
drinking
pattern
breast
cancer
risk
apart
two
recent
study
previous
study
investigate
effect
average
intake
without
take
account
pattern
consumption
southern
france
mediterranean
region
wine
integral
part
population
dietary
habit
although
much
study
investigate
effect
wine
consumption
breast
cancer
risk
date
study
investigate
link
breast
cancer
risk
drinking
pattern
beverage
principal
aim
study
evaluate
effect
drinking
pattern
alcoholic
beverage
breast
cancer
risk
focused
study
particularly
wine
consumption
investigate
average
wine
consumption
take
account
whether
wine
consume
frequently
whether
high
intake
fewer
occasion
analysis
remain
key
approach
epidemiological
study
traditional
analysis
usually
based
threshold
value
represent
quintile
dietary
variable
study
population
southern
france
choose
examine
association
alcohol
consumption
breast
cancer
mean
new
statistical
approach
based
detection
consumption
threshold
value
accord
breast
cancer
odd
ratio
variation
statistical
method
draw
adaptation
free
knot
spline
function
logistic
model
provide
different
way
look
relation
disease
risk
factor
since
quantitative
risk
factor
determine
much
precisely
show
advantage
new
method
compare
classical
method
alternative
statistical
spline
method
examine
association
drinking
pattern
alcoholic
beverage
risk
breast
cancer
method
study
population
conduct
study
among
french
woman
year
age
eligible
case
subject
woman
reside
southern
france
hrault
former
history
breast
cancer
attempt
recruit
patient
newly
diagnose
primary
breast
cancer
confirm
histologically
june
december
patient
identify
surgical
ward
medical
information
department
record
median
time
diagnosis
interview
month
control
subject
randomized
list
resident
supply
roll
case
recruit
two
control
match
accord
age
year
area
residence
among
respondent
rate
participation
case
control
four
hundred
eligible
case
eligible
control
enrolled
study
case
control
sign
write
consent
form
enrolment
study
study
protocol
approve
two
ethical
committee
study
human
subject
committee
data
processing
medical
research
national
commission
data
processing
right
require
medical
information
anonymous
data
collection
data
obtain
mean
structure
questionnaire
administer
two
train
interviewer
first
part
questionnaire
relate
demographic
characteristic
reproductive
menstrual
factor
oral
contraception
hormone
replacement
therapy
hrt
family
history
cancer
anthropometric
factor
physical
activity
smoking
history
women
consider
menopausal
menstruation
cease
naturally
month
prior
interview
follow
bilateral
addition
estimate
activity
subtract
cumulative
number
month
pregnancy
oral
contraception
number
year
menarche
menopause
date
interview
case
premenopausal
woman
question
physical
activity
draw
previous
study
subjects
ask
indicate
type
leisure
activity
time
spend
per
week
household
occupational
activity
value
score
accord
time
spend
per
week
household
activity
level
occupational
activity
second
part
questionnaire
relate
diet
alcohol
consumption
assess
subject
usual
drinking
habit
subjects
ask
report
drinking
status
nondrinker
current
drinker
define
woman
never
control
define
woman
stop
drinking
study
start
case
breast
cancer
diagnose
current
ask
drinking
habit
previous
year
habit
change
recently
otherwise
habit
change
take
account
alcohol
consumption
assessment
separate
three
category
first
concern
consumption
week
second
deal
consumption
weekend
last
relate
party
family
gathering
specific
type
alcoholic
beverage
wine
aperitif
beer
spirit
subject
ask
indicate
much
drink
often
five
category
frequency
thus
define
alcohol
intake
exceptional
consumption
little
month
occasional
consumption
much
month
little
week
regular
consumption
least
week
almost
every
day
consumption
much
five
time
week
compare
result
publish
study
investigate
link
drinking
pattern
alcoholic
beverage
breast
cancer
risk
three
group
drinker
form
sporadic
frequent
drinker
frequent
drinker
define
woman
consume
alcohol
five
time
week
much
often
sporadic
drinker
comprise
woman
drink
four
time
per
week
little
alcohol
consumption
standardized
record
accord
drink
unit
one
unit
correspond
ethanol
fl
oz
wine
fl
oz
aperitif
fortify
wine
alcohol
contain
alcohol
volume
fl
oz
beer
fl
oz
spirit
alcohol
beverage
contain
around
alcohol
volume
information
frequency
amount
consumption
allow
describe
consumption
habit
study
population
total
period
consumption
alcoholic
beverage
calculate
age
woman
begin
drinking
age
cease
drinking
age
time
interview
continue
drink
alcohol
change
drinking
pattern
period
consumption
take
consideration
example
woman
claim
drinking
time
interview
fact
previous
point
alcoholic
sporadic
motivate
cessation
drinking
case
long
typical
phase
consumption
individual
history
study
diet
measure
validate
food
frequency
questionnaire
organize
mainly
food
group
food
frequency
questionnaire
already
diet
study
assess
subject
usual
diet
previous
year
habit
change
recently
otherwise
dietary
habit
change
take
account
statistical
analysis
multivariate
conditional
logistic
regression
employ
analyze
association
breast
cancer
alcohol
consumption
associate
confidence
interval
ci
across
exposure
level
alcohol
intake
calculate
adjust
potential
confounder
factor
factor
choose
accord
statistical
significance
take
separately
univariate
analysis
potential
confounder
include
multivariate
logistic
model
education
parity
age
first
pregnancy
duration
ovulatory
activity
family
history
breast
cancer
mother
sister
body
mass
index
bmi
physical
activity
dietary
factor
also
analyzed
association
breast
cancer
risk
adjust
confounder
factor
total
energy
intake
dietary
factor
relate
breast
cancer
also
include
multivariate
logistic
model
study
match
accord
age
interval
year
therefore
statistical
adjustment
age
require
furthermore
menopausal
identify
need
statistical
adjustment
group
drinking
pattern
sporadic
frequent
drinker
instead
transform
continuous
variable
ordinal
variable
accord
distribution
quartile
sole
function
form
different
group
homogeneous
size
free
knot
spline
logistic
model
threshold
selection
method
provide
well
mean
split
continuous
variable
several
group
group
form
estimate
threshold
value
vary
accord
breast
cancer
furthermore
extreme
threshold
locate
quartile
quartile
reveal
method
statistical
method
recently
apply
clinical
trial
vitro
program
provide
convincing
result
unlike
logistic
model
assess
linear
effect
risk
factor
logit
function
suppose
unit
change
one
component
x
effect
patient
whole
range
component
spline
method
provide
interesting
way
look
relationship
disease
explanatory
variable
relieve
linearity
assumption
logit
function
risk
factor
x
enter
logistic
model
via
set
linear
spline
function
degree
spline
function
restrict
differ
accord
number
knot
include
case
number
knot
null
spline
function
without
knot
correspond
linear
function
function
good
fit
datum
select
information
criterion
bayesian
information
criterion
moreover
knot
spline
function
estimate
give
risk
factor
consider
threshold
value
breast
cancer
change
thus
good
model
linear
model
continuous
variable
transform
ordinal
variable
threshold
value
method
apply
datum
package
version
test
linear
trend
appropriate
conduct
consider
variable
conditional
logistic
model
value
degree
significance
variable
model
value
two
side
value
little
consider
statistically
significant
test
test
parameter
multivariate
conditional
logistic
regression
produce
mean
phreg
procedure
statistical
software
package
sas
version
result
mean
age
case
year
year
control
year
significant
difference
two
group
find
association
much
accept
risk
factor
breast
cancer
parity
tend
decrease
risk
breast
cancer
family
history
breast
cancer
tend
increase
breast
cancer
risk
education
leisure
physical
activity
inversely
associate
breast
cancer
risk
conversely
late
first
pregnancy
long
duration
ovulatory
activity
high
bmi
well
household
occupational
physical
activity
increase
breast
cancer
risk
table
distribution
select
risk
factor
breast
cancer
associate
odd
ratio
confidence
interval
controlsunadjusted
ci
family
history
breast
age
first
yr
duration
ovulatory
physical
activity
leisure
physical
activity
household
physical
activity
occupation
total
energy
table
odd
ratio
ci
confidence
interval
bmi
body
mass
index
view
within
article
various
food
intake
relate
breast
cancer
risk
result
support
role
play
high
consumption
red
meat
increase
breast
cancer
risk
cereal
olive
oil
reduction
nonsignificant
decrease
associate
cook
vegetable
intake
well
fish
consumption
dairy
product
raw
vegetable
fruit
intake
appear
associate
breast
cancer
risk
table
odds
ratio
confidence
interval
breast
cancer
associate
select
food
adjust
total
energy
breast
cancer
risk
factor
controlsor
ci
total
q
q
q
q
q
q
q
fish
q
olive
q
q
q
dairy
table
odd
ratio
ci
confidence
interval
q
quantity
alcohol
intake
adjusted
total
energy
intake
education
parity
age
first
pregnancy
duration
ovulatory
activity
body
mass
index
physical
activity
family
history
breast
cancer
energy
intake
food
measure
gram
per
day
view
within
article
woman
study
case
control
report
alcohol
consumption
month
prior
diagnosis
case
prior
interview
control
addition
woman
case
control
drink
alcoholic
beverage
little
five
time
week
woman
case
control
report
consumption
much
five
time
week
association
find
frequency
alcohol
consumption
breast
cancer
risk
table
association
frequency
alcohol
consumption
breast
cancer
risk
intake
control
unadjusted
ci
ci
table
adjusted
education
parity
age
first
pregnancy
duration
ovulatory
activity
body
mass
index
physical
activity
family
history
breast
cancer
consumption
cereal
meat
olive
oil
total
energy
intake
total
alcohol
consumption
duration
consumption
view
within
article
average
amount
total
alcohol
consumption
split
accord
level
consumption
establish
previous
study
alcoholic
beverage
consume
little
average
per
day
standard
drink
per
day
case
control
case
control
consume
average
per
day
average
much
per
day
standard
drink
consume
case
control
women
report
average
consumption
day
total
alcohol
intake
drink
day
ci
compare
nondrinker
reference
group
association
persist
adjustment
establish
risk
factor
dietary
factor
duration
consumption
drink
per
day
risk
rise
association
nonsignificant
relationship
alcohol
consumption
breast
cancer
risk
show
nonsignificant
association
day
total
alcohol
intake
ci
see
table
table
show
breast
cancer
associate
total
alcohol
consumption
categorised
accord
drinking
pattern
level
consumption
sporadic
frequent
drinker
obtain
two
method
classic
method
median
threshold
spline
method
estimate
threshold
neither
two
method
reveal
association
drinking
pattern
total
alcohol
consumption
risk
breast
cancer
table
odds
ratio
confidence
interval
breast
cancer
risk
accord
average
alcohol
consumption
alcohol
control
unadjusted
ci
ci
q
q
q
q
q
total
intake
table
odd
ratio
ci
confidence
interval
q
quantity
alcohol
intake
measure
gram
per
day
adjusted
education
parity
age
first
pregnancy
duration
ovulatory
activity
body
mass
index
physical
activity
family
history
breast
cancer
consumption
cereal
meat
olive
oil
total
energy
intake
total
duration
alcohol
consumption
view
within
article
intake
alcohol
wine
beer
aperitif
spirit
associate
breast
cancer
risk
result
modify
occasional
drinker
exclude
analysis
datum
show
table
association
breast
cancer
drinking
pattern
alcoholic
beverage
level
drinking
obtain
two
method
classic
spline
alcohol
intakeintake
level
median
controlsunadjusted
ci
ci
intake
level
spline
threshold
table
adjusted
education
parity
age
first
pregnancy
duration
ovulatory
activity
body
mass
index
physical
activity
family
history
breast
cancer
consumption
cereal
meat
olive
oil
total
energy
intake
view
within
article
wine
predominant
type
alcoholic
beverage
population
represent
total
alcohol
consume
spirit
beer
represent
respectively
total
alcohol
consume
average
consumption
wine
whereas
average
consumption
aperitif
spirit
beer
respectively
datum
show
average
wine
consumption
separate
three
category
drinking
pattern
never
sporadic
frequent
consumption
median
threshold
choose
create
different
group
level
consumption
association
sporadic
frequent
wine
consumption
breast
cancer
nonsignificant
adjustment
potential
confounder
factor
table
odds
ratio
confidence
interval
breast
cancer
per
average
intake
alcohol
type
ci
ci
value
heterogeneity
total
table
adjusted
education
parity
age
first
pregnancy
duration
ovulatory
activity
body
mass
index
physical
activity
family
history
breast
cancer
consumption
cereal
meat
olive
oil
total
energy
intake
mutually
adjust
specific
beverage
wine
beer
aperitif
spirit
view
within
article
spline
threshold
nonsignificant
increase
ci
find
sporadic
wine
consumption
breast
cancer
contrast
significant
decrease
breast
cancer
associate
woman
frequent
consumption
wine
compare
non
wine
drinker
ci
moreover
association
remain
significant
adjustment
ci
result
also
modify
non
wine
drinker
sporadic
wine
drinker
consider
referent
ci
datum
show
wine
consumption
risk
breast
cancer
increase
association
illustrate
variation
breast
cancer
accord
spline
threshold
regular
wine
consumption
table
association
breast
cancer
pattern
drinking
wine
level
drinking
obtain
classic
spline
method
wine
intakeintake
level
median
controlsunadjusted
ci
ci
intake
level
spline
threshold
table
adjusted
education
parity
first
pregnancy
duration
ovulatory
activity
body
mass
index
physical
activity
family
history
breast
cancer
consumption
cereal
meat
olive
oil
total
energy
intake
total
consumption
alcoholic
beverage
wine
view
within
article
image
figure
variation
breast
cancer
accord
spline
threshold
regular
wine
consumption
view
within
article
adjust
analysis
drinking
pattern
alcoholic
beverage
exclude
wine
show
risk
associate
frequent
drinker
differ
nondrinker
contrast
significant
association
sporadic
consumption
breast
cancer
risk
find
level
consumption
obtain
mean
median
threshold
breast
cancer
risk
associate
consumption
reduce
ci
compare
risk
associate
nondrinker
apart
estimate
threshold
value
similar
result
find
level
consumption
obtain
spline
method
table
association
breast
cancer
pattern
drinking
alcohol
beverage
wine
level
drinking
obtain
classic
spline
method
alcohol
intake
level
median
controlsunadjusted
ci
ci
intake
level
spline
threshold
table
adjusted
education
parity
first
pregnancy
duration
ovulatory
activity
body
mass
index
physical
activity
family
history
breast
cancer
consumption
cereal
meat
olive
oil
total
energy
intake
total
consumption
wine
view
within
article
discussion
previous
study
result
support
hypothesis
threshold
effect
indeed
exist
since
risk
breast
cancer
decrease
modify
consumption
certain
threshold
increase
threshold
value
different
study
exceed
average
consumption
standard
drink
study
woman
average
consumption
drink
per
day
ethanol
risk
compare
nondrinker
drink
per
day
risk
rise
association
nonsignificant
unlike
study
find
significant
increase
risk
breast
cancer
consumption
study
agree
find
significant
association
recent
study
suggest
importance
drinking
pattern
alcohol
consumption
breast
cancer
etiology
however
date
two
study
examine
association
drinking
pattern
alcohol
breast
cancer
find
previous
study
drinking
frequency
influence
breast
cancer
risk
study
total
consumption
duration
consumption
alcohol
woman
sporadic
consumption
risk
woman
frequent
consumption
however
far
investigation
conduct
direction
order
confirm
result
find
many
study
investigate
effect
different
type
alcoholic
beverage
breast
cancer
significant
association
find
different
type
alcoholic
beverage
breast
cancer
risk
however
although
association
pattern
consumption
total
alcohol
breast
cancer
find
type
alcoholic
beverage
seem
play
important
role
association
study
risk
associate
woman
consume
approximately
one
drink
ethanol
wine
per
day
decrease
significantly
compare
risk
associate
non
wine
drinker
sporadic
wine
drinker
association
remain
unchanged
adjustment
potential
confounder
factor
establish
factor
breast
cancer
dietary
factor
alcoholic
beverage
beer
aperitif
spirit
wine
consumption
risk
breast
cancer
increase
association
non
significant
protective
effect
regular
wine
consumption
breast
cancer
plausible
since
wine
particularly
red
wine
contain
high
level
antioxidant
well
resveratrol
phytoestrogen
anticancer
property
also
likely
high
regular
level
alcohol
intake
beneficial
effect
last
hypothesis
explain
previous
result
concern
deleterious
effect
moderate
high
wine
consumption
breast
cancer
however
study
confirm
hypothesis
case
control
study
population
consume
much
two
drink
wine
per
day
hand
study
may
explain
protective
effect
alcohol
consumption
find
since
wine
predominant
type
alcoholic
beverage
population
study
population
frequent
wine
drinker
pattern
consumption
alcoholic
beverage
wine
also
associate
breast
cancer
risk
adjustment
wine
consumption
risk
associate
woman
consume
much
alcoholic
beverage
wine
decrease
compare
risk
associate
nondrinker
contrast
risk
associate
frequent
drinker
differ
nondrinker
result
study
suggest
association
alcohol
consumption
modify
hrt
whereas
finding
study
support
difference
hrt
user
present
study
estimate
association
average
alcohol
intake
identical
hrt
user
association
drinking
pattern
breast
cancer
risk
differ
within
either
group
hrt
user
although
find
hrt
significance
alcohol
breast
cancer
association
exclude
possible
effect
fact
take
separately
factor
may
register
association
however
may
necessarily
case
consider
together
effect
alcohol
various
biological
mechanism
breast
cancer
widely
discuss
investigator
suggest
alcohol
consumption
increase
risk
breast
cancer
among
woman
influence
estrogen
metabolism
promotion
growth
breast
cancer
may
also
explain
increase
production
liver
growth
factor
associate
moderate
alcohol
intake
likewise
alcohol
may
exhibit
mutagenic
oxidative
effect
breast
tissue
affect
folate
level
lead
damage
dna
although
several
possible
mechanism
link
chronic
alcohol
consumption
breast
cancer
possible
critical
effect
alcohol
cancer
depend
threshold
value
absence
adverse
effect
alcohol
consumption
cancer
find
study
therefore
plausible
strength
study
ability
examine
association
breast
cancer
drinking
pattern
alcoholic
beverage
particularly
wine
furthermore
several
confound
factor
take
account
much
particularly
dietary
factor
total
duration
consumption
educational
level
study
associate
breast
cancer
represent
indicator
socioeconomic
status
population
study
study
observe
high
level
education
associate
high
alcohol
intake
none
report
significant
interaction
avoid
possible
confound
effect
alcohol
breast
cancer
due
socioeconomic
status
analysis
adjust
educational
level
frequent
moderate
heavy
consumption
alcohol
rare
population
adequate
statistical
power
examine
relationship
heavy
alcohol
consumption
breast
cancer
risk
although
case
control
interview
similar
condition
avoid
possible
recall
bias
inherent
retrospective
study
attribute
unexpected
finding
protective
effect
alcohol
consumption
possible
recall
bias
since
case
modify
response
concern
alcohol
consumption
owing
knowledge
disease
however
although
alcohol
consumption
particularly
wine
mediterranean
region
common
discuss
alcohol
consumption
remain
among
case
control
lead
minimize
bias
comparison
participant
particular
concern
alcohol
consumption
possible
study
case
control
refuse
participate
consent
give
information
relate
questionnaire
limit
scope
study
statistical
point
view
spline
logistic
model
provide
practical
tool
investigate
relationship
create
optimal
group
exposure
risk
factor
furthermore
method
allow
accurate
estimation
consumption
risk
breast
cancer
vary
significantly
summary
drinking
pattern
type
specific
beverage
particularly
wine
seem
important
alcohol
breast
cancer
association
regular
consumption
wine
reduce
risk
breast
cancer
risk
associate
woman
consume
approximately
one
drink
wine
per
day
decrease
significantly
compare
risk
associate
nondrinker
sporadic
wine
drinker
ratio
alcohol
consumption
complex
ignore
benefit
consumption
overall
mortality
cardiovascular
disease
perhaps
suitable
systematically
advise
alcohol
consumer
especially
wine
drinker
reduce
alcohol
intake
suggest
previous
study
interesting
investigate
effect
alcohol
subpopulation
combine
profile
subpopulation
high
predisposition
breast
cancer
predisposition
cardiovascular
disease
vice
versa
constitute
different
group
without
predisposition
breast
cancer
cardiovascular
disease
predisposition
one
disease
predisposition
disease
predisposition
assess
consider
exposure
establish
risk
factor
disease
first
degree
family
history
parity
age
pregnancy
breast
cancer
result
study
improve
public
health
recommendation
work
support
grant
national
cancer
institute
france
hrault
regional
council
wish
thank
valuable
contribution
role
incomplete
pregnancy
breast
cancer
hypothesized
biology
hormone
elevation
pregnancy
suggest
preliminary
epidemiologic
study
methodologic
issue
retrospective
study
include
potential
report
bias
inappropriate
referent
group
selection
lack
differentiation
spontaneous
induce
abortion
identify
limitation
internal
validity
finding
study
prospectively
collect
datum
ameliorate
potential
introduction
report
bias
show
evidence
association
spontaneous
induce
abortion
breast
cancer
risk
collaborative
group
hormonal
factor
breast
cancer
publish
pool
analysis
prospective
study
show
significant
overall
increase
breast
cancer
risk
associate
one
much
pregnancy
end
either
spontaneous
induce
abortion
subsequently
european
prospective
investigation
cancer
nutrition
report
association
induce
abortion
breast
cancer
risk
positive
association
spontaneous
abortion
report
nurse
health
study
ii
show
association
either
type
incomplete
pregnancy
breast
cancer
risk
although
weight
evidence
shift
toward
association
continue
substantial
public
debate
regard
question
evaluate
hypothesis
incomplete
pregnancy
associate
breast
cancer
risk
california
teachers
study
cts
large
prospective
cohort
study
detail
pregnancy
history
datum
material
study
population
detail
description
cts
publish
previously
brief
cts
prospectively
follow
cohort
current
recent
retire
female
public
school
teacher
administrator
member
california
state
teachers
retirement
system
time
study
inception
cohort
participant
complete
detail
questionnaire
collect
information
personal
medical
history
family
history
breast
cancer
reproductive
history
hormone
therapy
medication
recreational
physical
activity
diet
alcohol
consumption
smoking
history
reproductive
history
section
include
detail
assessment
age
outcome
pregnancy
include
miscarriage
induce
abortion
separately
human
subject
datum
study
approve
institutional
review
board
participate
institution
accord
assurance
file
approve
united
state
department
health
human
services
total
woman
comprise
cts
cohort
analysis
exclude
woman
follow
order
live
outside
california
time
complete
baseline
questionnaire
prior
history
breast
cancer
whose
history
breast
cancer
unknown
year
old
baseline
currently
pregnant
first
pregnancy
incomplete
information
critical
breast
cancer
risk
factor
unknown
age
menarche
unknown
ever
pregnant
unknown
number
pregnancy
result
analytic
cohort
report
consist
woman
table
selected
baseline
characteristic
cts
relation
ever
miscarriage
induce
abortion
total
column
never
pregnancy
pregnancy
outcome
number
number
invasive
breast
cancer
age
baseline
year
race
ethnicity
african
asian
pacific
family
history
breast
cancer
age
menarche
year
menopausal
status
never
estrogen
combined
estrogen
progesterone
unknown
menopausal
ever
miscarriage
ever
induce
abortion
table
limited
woman
age
prior
history
breast
cancer
baseline
includes
estrogen
progesterone
unknown
view
within
article
case
newly
diagnose
case
invasive
breast
cancer
identify
annual
linkage
california
cancer
registry
california
cancer
registry
receive
report
cancer
diagnosis
occur
california
resident
regional
registry
datum
share
agreement
neighboring
state
part
state
cts
participant
consider
eligible
analysis
diagnose
invasive
breast
cancer
time
interval
begin
date
baseline
questionnaire
complete
continue
first
diagnosis
breast
cancer
first
occurrence
censor
event
move
outside
california
diagnosis
carcinoma
situ
breast
death
december
residence
california
determine
annual
mailing
questionnaire
annual
linkage
united
state
postal
service
national
change
address
database
submit
participant
death
obtain
california
state
mortality
file
national
death
index
social
security
administration
death
master
file
measure
incomplete
pregnancy
participants
provide
detail
information
baseline
questionnaire
regard
pregnancy
history
include
age
outcome
pregnancy
addition
outcome
first
pregnancy
never
pregnant
induce
abortion
miscarriage
tubal
pregnancy
live
birth
design
follow
measure
capture
various
aspect
induce
abortion
ever
never
induce
abortion
ever
abortion
never
pregnant
among
nulliparous
woman
pregnancy
among
parous
woman
total
number
induce
abortion
never
pregnant
pregnancy
induce
abortion
induce
abortion
age
first
induce
abortion
never
pregnant
pregnancy
first
abortion
age
year
first
abortion
age
year
first
abortion
age
year
first
abortion
age
year
old
year
first
induce
abortion
never
pregnant
pregnancy
first
abortion
year
federally
abortion
first
abortion
later
design
follow
variable
characterize
miscarriage
history
ever
never
miscarriage
ever
miscarriage
never
pregnant
pregnancy
total
number
miscarriage
never
pregnant
pregnancy
miscarriage
miscarriage
age
first
miscarriage
never
pregnant
pregnancy
first
miscarriage
age
year
first
miscarriage
age
year
first
miscarriage
age
year
first
miscarriage
age
year
old
assessment
breast
cancer
risk
factor
consider
establish
breast
cancer
risk
factor
potential
confounder
include
race
ethnicity
white
african
american
asian
pacific
islander
unknown
family
history
breast
cancer
yes
adopt
unknown
age
menarche
year
age
first
pregnancy
year
number
pregnancy
woman
consider
postmenopausal
meet
one
follow
criterion
report
period
stop
much
month
ago
report
ovary
remove
age
baseline
already
classify
perimenopausal
women
prior
last
menstrual
period
year
young
consider
unknown
menopausal
status
question
ask
conjugate
estrogen
well
estrogen
progestin
combination
menopausal
status
variable
construct
follow
premenopausal
perimenopausal
postmenopausal
never
postmenopausal
estrogen
postmenopausal
combine
estrogen
progestin
therapy
postmenopausal
estrogen
estrogen
plus
progestin
different
period
time
postmenopausal
progestin
postmenopausal
unknown
unknown
menopausal
status
statistical
analysis
multivariable
cox
proportional
hazard
regression
assess
whether
measure
incomplete
pregnancy
associate
breast
cancer
incidence
multivariable
adjust
hazard
rate
ratio
present
relative
hazard
confidence
interval
ci
estimate
age
day
start
end
end
point
time
observation
model
evaluate
relationship
measure
incomplete
pregnancy
breast
cancer
risk
stratified
parity
status
nulliparous
parous
order
address
strong
possibility
confound
factor
model
also
stratified
age
year
datum
show
analysis
perform
sas
version
sas
institute
cary
usa
result
show
table
woman
analytic
dataset
parous
parous
woman
old
baseline
nulliparous
woman
woman
report
ever
miscarriage
proportion
woman
report
ever
miscarriage
vary
baseline
age
age
group
year
proportion
respectively
woman
overall
report
ever
induce
abortion
proportion
woman
report
ever
induce
abortion
vary
baseline
age
category
history
miscarriage
high
year
age
group
age
group
year
proportion
respectively
breast
cancer
risk
associate
outcome
first
pregnancy
among
nulliparous
woman
observe
relationship
induce
abortion
miscarriage
tubal
pregnancy
outcome
first
pregnancy
risk
invasive
breast
cancer
observe
association
outcome
first
pregnancy
risk
breast
cancer
among
parous
woman
observe
statistically
significant
association
breast
cancer
risk
induce
abortion
history
measure
number
induce
abortion
age
first
induce
abortion
either
nulliparous
parous
woman
examine
risk
induce
abortion
united
state
observe
association
breast
cancer
risk
timing
first
induce
abortion
breast
cancer
risk
associate
history
miscarriage
number
miscarriage
age
first
miscarriage
among
nulliparous
parous
woman
analysis
restrict
woman
find
breast
cancer
risk
significantly
elevate
hazard
ratio
race
adjust
ci
among
woman
pregnancy
end
abortion
compare
woman
pregnancy
end
live
birth
model
also
run
stratified
age
year
result
differ
show
woman
datum
show
table
multivariable
relative
hazarda
ci
breast
cancer
associate
outcome
first
pregnancy
among
woman
cts
parity
status
variablenulliparousparous
outcome
first
pregnancy
reference
induced
tubal
table
model
adjust
race
family
history
breast
cancer
age
menarche
combination
variable
menopausal
status
model
parous
woman
additionally
adjust
age
first
pregnancy
number
pregnancy
reference
group
nulliparous
woman
woman
never
pregnant
reference
group
parous
woman
woman
pregnancy
outcome
first
pregnancy
value
show
rha
ci
case
view
within
article
table
relative
hazarda
ci
breast
cancer
associate
induce
abortion
among
woman
cts
parity
status
variablenulliparousparous
ever
never
induce
abortion
reference
ever
total
number
induce
abortion
reference
age
first
induce
abortion
reference
first
abortion
age
year
first
induce
abortion
reference
first
abortion
first
abortion
table
model
adjust
race
family
history
breast
cancer
age
menarche
combination
variable
menopausal
status
model
parous
woman
additionally
adjust
age
first
pregnancy
number
pregnancy
reference
group
nulliparous
woman
woman
never
pregnant
reference
group
parous
woman
woman
pregnancy
value
show
rha
ci
case
view
within
article
table
relative
hazarda
ci
breast
cancer
associate
miscarriage
among
woman
cts
parity
status
variablenulliparousparous
ever
never
miscarriage
reference
ever
total
number
miscarriage
reference
age
first
reference
first
miscarriage
age
table
model
adjust
race
family
history
breast
cancer
age
menarche
combination
variable
menopausal
status
model
parous
woman
additionally
adjust
age
first
pregnancy
number
pregnancy
reference
group
nulliparous
woman
woman
never
pregnant
reference
group
parous
woman
woman
pregnancy
value
show
rha
ci
case
view
within
article
discussion
neither
induce
abortion
miscarriage
associate
breast
cancer
risk
prospective
cohort
female
california
teacher
administrator
result
consistent
report
nurse
health
study
ii
cohort
female
register
nurse
age
year
old
baseline
cohort
adjust
hazard
ratio
breast
cancer
among
woman
one
much
induce
abortion
ci
adjust
hazard
ratio
breast
cancer
among
woman
one
much
miscarriage
ci
public
concern
regard
relationship
induce
abortion
breast
cancer
risk
continue
despite
mount
evidence
association
exist
much
datum
prompt
concern
come
study
many
may
affect
bias
design
much
recently
publish
study
report
positive
association
induce
abortion
breast
cancer
risk
prospective
cohort
study
minimize
potential
biased
risk
estimate
also
find
association
induce
abortion
breast
cancer
risk
datum
appear
refute
two
mechanism
hypothesized
underlie
association
induce
abortion
breast
cancer
risk
first
woman
undergo
abortion
experience
protection
breast
cancer
pregnancy
provide
support
observation
similar
risk
among
woman
whose
pregnancy
end
abortion
woman
whose
pregnancy
end
live
birth
second
hypothesis
breast
woman
undergo
induce
abortion
expose
high
hormone
level
typical
early
normal
pregnancy
experience
terminal
cell
differentiation
occur
late
normal
pregnancy
leave
breast
tissue
much
vulnerable
carcinogen
also
support
result
woman
cohort
may
underreported
induce
abortion
abortion
ratio
among
cohort
member
per
pregnancy
end
induce
abortion
live
birth
woman
age
baseline
compare
per
pregnancy
united
state
time
period
socioeconomic
status
strong
predictor
measure
abortion
include
abortion
birth
ratio
figure
least
among
woman
college
education
economically
disadvantaged
cts
participant
highly
educate
represent
range
socioeconomic
stratum
thus
number
pregnancy
end
induce
abortion
live
birth
woman
age
baseline
may
reflect
underreporting
furthermore
among
woman
cts
age
year
baseline
report
least
one
induce
abortion
percentage
consistent
estimate
woman
united
state
will
induce
abortion
age
year
level
underreporting
study
appear
addition
effect
underreporting
prospective
cohort
study
expect
nondifferential
since
time
report
reproductive
history
woman
aware
future
breast
cancer
diagnosis
unlikely
breast
cancer
population
woman
study
undiagnosed
rate
screening
study
high
percent
woman
year
age
baseline
woman
year
age
baseline
report
least
one
mammogram
proportion
woman
two
age
group
report
mammogram
year
prior
baseline
respectively
another
potential
limitation
pertinent
analysis
datum
abortion
miscarriage
tubal
pregnancy
measure
baseline
possible
woman
experience
another
event
breast
cancer
diagnosis
however
stratify
analysis
age
thereby
compare
group
much
little
likely
experience
additional
event
respectively
find
difference
result
current
result
may
limited
generalizability
addition
limited
racial
ethnic
diversity
relative
general
female
population
united
state
cts
characterize
high
level
education
associate
characteristic
late
age
first
pregnancy
nevertheless
result
provide
far
strong
evidence
neither
induce
abortion
miscarriage
associate
breast
cancer
risk
may
help
resolve
remain
uncertainty
whether
relationship
exist
acknowledgment
author
like
thank
participant
california
teachers
study
cts
addition
thank
richard
carmen
responsible
overall
datum
collection
datum
management
maintenance
cohort
member
cts
steering
committee
responsible
formation
maintenance
cohort
within
study
conduct
include
author
current
article
dennis
daniel
west
estimate
new
diagnosis
death
will
occur
breast
cancer
united
state
breast
cancer
represent
heterogeneous
population
tumor
characterize
marker
age
stage
nodal
status
pathologic
grade
pr
status
status
marker
help
define
need
adjuvant
therapy
molecular
marker
potential
refine
prognosis
response
therapy
study
indicate
young
woman
early
stage
breast
cancer
experience
poorer
local
distant
survival
old
counterpart
interest
establish
biologic
factor
identify
pattern
failure
young
woman
undergo
breast
conservation
cdna
microarray
profile
study
categorize
breast
carcinoma
follow
five
distinct
subtype
luminal
luminal
overexpressing
ck
normal
breast
tissue
study
show
poorer
local
survival
tumor
represent
cancer
blc
nielson
far
characterize
blc
via
triple
negative
phenotype
comprise
tumor
express
pr
neu
immunohistochemistry
outcome
heterogeneous
cohort
conservatively
manage
breast
cancer
function
classification
scheme
recently
demonstrate
depict
phenotype
significant
independent
predictor
distant
metastasis
poorer
survival
difference
local
relapse
blc
also
characterize
cytokeratin
marker
contrast
breast
cancer
luminal
origin
pr
positive
represent
epithelial
marker
basal
cytokeratin
marker
ck
associate
overexpression
epidermal
growth
factor
receptor
egfr
correlated
poor
clinical
outcome
gene
expression
array
analysis
reveal
mutate
genotype
display
similar
genetic
profile
blc
current
study
examine
cohort
young
woman
undergo
surgery
radiotherapy
local
distant
overall
survival
function
status
surrogate
marker
blc
seek
compare
negativity
standard
clinicopathologic
variable
independent
risk
factor
aggressive
disease
method
material
patient
patient
select
current
study
specific
inclusion
requirement
include
follow
patient
conservatively
manage
stage
ii
breast
cancer
treat
lumpectomy
adjuvant
radiotherapy
patient
age
year
young
time
breast
cancer
diagnosis
tissue
block
primary
breast
cancer
hospital
referring
hospital
available
processing
total
patient
meet
inclusion
criterion
state
protocol
chart
review
archived
tumor
specimen
review
approve
institutional
review
board
patient
study
treat
surgically
surgery
without
axillary
lymph
node
dissection
standard
radiation
treatment
parameter
follow
deliver
whole
intact
breast
regional
nodal
irradiation
deliver
clinically
indicate
photon
daily
fraction
size
gy
total
median
dose
approximately
gy
adjuvant
systemic
chemotherapy
adjuvant
hormone
therapy
administer
clinically
indicate
accordance
standard
practice
time
interval
immunohistochemical
analysis
tissue
microarray
expression
pr
tissue
microarray
construct
analysis
pathologist
examine
hematoxylin
eosin
stain
slide
archived
paraffin
block
circle
representative
tumor
section
tumor
section
two
mm
core
extract
tissue
instruments
silver
spring
md
area
tumor
distinct
normal
epithelium
identify
stain
slide
pathologist
mark
subsequent
analysis
section
microarray
thick
cut
tissue
transfer
system
hackensack
nj
process
describe
previously
promise
tissue
microarray
biopsy
previously
validate
variety
tumor
include
head
neck
colorectal
lung
immunohistochemical
analysis
perform
tissue
section
prepare
archival
tissue
resected
primary
tumor
tissue
section
quench
hydrogen
peroxide
methanol
solution
slide
incubate
overnight
follow
antibody
mouse
monoclonal
antihuman
dako
pr
mouse
monoclonal
antihuman
pr
dako
neu
rabbit
polyclonal
neu
oncoprotein
dako
mouse
monoclonal
antihuman
oncoprotein
dako
mouse
monoclonal
az
next
day
slide
incubate
secondary
antibody
labeled
complex
elite
vector
laboratory
incubate
chromogen
diaminobenzidine
counterstained
hematoxylin
dehydrated
ethanol
mount
assessment
five
biomarker
stain
quantitative
qualitative
single
experience
pathologist
blind
patient
outcome
core
region
predominant
staining
intensity
score
pr
assess
number
positive
stain
nucleus
neu
membrane
staining
score
positive
numeric
score
range
reflect
staining
intensity
pattern
much
tumor
status
numeric
score
consider
positive
staining
intensity
score
none
faint
focal
moderate
strong
percent
distribution
cytoplasmic
staining
core
tissue
loss
lack
tumor
cell
score
applicable
give
see
figure
status
consider
positive
staining
intensity
epithelial
distribution
assessment
staining
similar
except
nuclear
reactivity
score
little
nuclear
reactivity
tumor
cell
score
expression
greater
nuclear
reactivity
score
high
expression
image
staining
characteristic
cytokeratin
antibody
tissue
microarray
phenotype
phenotype
view
within
article
statistical
analysis
status
relevant
assemble
database
analyzed
sas
user
guide
version
sas
institute
cary
test
statistical
significance
value
consider
statistically
significant
study
endpoint
local
relapse
distant
survival
overall
survival
include
death
recurrence
define
clinically
relapse
ipsilateral
breast
distant
metastases
define
clinical
evidence
distant
disease
based
clinical
radiographic
evidence
endpoint
calculate
date
radiation
therapy
completion
represent
start
continuous
risk
relapse
median
calculate
reverse
method
independent
variable
analysis
include
race
degree
family
history
histology
stage
nodal
status
status
status
expression
mutation
molecular
profile
patient
correlated
factor
local
distant
overall
survival
association
outcome
assess
multivariate
model
bivariate
analysis
association
status
status
include
test
fisher
exact
test
bivariate
analysis
association
predictor
variable
local
distant
recurrence
overall
survival
conduct
kaplan
meier
test
test
linear
trend
univariate
survival
analysis
cox
proportional
hazard
model
calculate
unadjusted
relative
risk
year
local
relapse
lr
year
distant
survival
dmfs
year
poor
overall
survival
multivariate
analysis
cox
proportional
hazard
regression
determine
significant
predictor
survival
overall
survival
level
final
model
result
descriptive
statistic
patient
cohort
treat
surgery
adjuvant
radiation
therapy
invasive
breast
cancer
also
patient
young
year
age
median
age
year
time
diagnosis
treatment
median
year
total
patient
experience
local
relapse
first
site
failure
result
year
actuarial
rate
total
distant
metastases
year
dmfs
year
actuarial
overall
survival
rate
entire
cohort
table
summarize
frequency
statistic
characteristic
patient
cohort
include
demographic
stage
molecular
marker
status
positive
expression
pr
neu
respectively
table
patient
characteristic
age
median
race
ethnicity
family
history
unknown
moderate
histology
tumor
size
cm
nodal
status
status
pr
status
status
status
status
cytokeratin
status
mutation
mutation
adjuvant
treatment
hormonal
table
view
within
article
patient
cohort
undergo
genetic
testing
positive
mutation
deleterious
mutation
family
history
consider
one
much
relative
diagnose
breast
cancer
time
diagnosis
approximately
two
third
patient
pathologic
stage
disease
much
two
third
patient
node
negative
status
evenly
split
cohort
adjuvant
cytotoxic
chemotherapy
patient
whereas
patient
receive
hormonal
therapy
status
follow
staining
faint
focal
staining
moderate
staining
strong
staining
accordance
analysis
parameter
sample
define
remain
define
see
figure
tumor
sufficiently
immunoreactive
antibody
show
cytoplasmic
staining
negative
control
show
staining
expression
phenotype
define
staining
intensity
core
positive
analysis
analysis
fisher
exact
test
status
significantly
associate
phenotype
see
table
prognostic
variable
race
ethnicity
family
history
tumor
histology
stage
nodal
status
significantly
associate
phenotype
also
status
correlate
molecular
marker
expression
mutation
table
association
cytokeratin
status
status
prognostic
factor
status
prognostic
value
race
family
unknown
moderate
tumor
nodal
table
statistically
significant
view
within
article
expect
patient
exhibit
mutation
phenotype
although
lobular
histology
equally
distribute
ductal
histology
much
prevalent
phenotype
compare
phenotype
phenotype
correlate
parameter
show
table
univariate
analysis
depict
univariate
analysis
table
stage
significant
predictor
year
dmfs
rr
ci
year
rr
ci
nodal
status
also
significantly
associate
dmfs
rr
ci
rr
ci
adjuvant
chemotherapy
associate
local
distant
overall
benefit
entire
cohort
phenotype
correlated
lr
dmfs
study
table
univariate
analysis
prognostic
factor
year
local
relapse
distant
metastasis
free
survival
dmfs
overall
survival
prognostic
factorrr
ci
valuerr
ci
valuerr
ci
value
race
family
unknown
moderate
tumor
nodal
table
abbreviation
adj
ci
confidence
interval
lr
local
relapse
overall
survival
reference
group
rr
risk
ratio
statistically
significant
view
within
article
phenotype
statistically
significant
predictor
poor
lr
rr
ci
dmfs
rr
ci
rr
ci
survival
curve
year
survival
dmfs
respect
status
present
respectively
show
figure
year
survival
tumor
patient
negative
experience
year
dmfs
versus
positive
wilcoxon
test
addition
overexpression
show
borderline
significance
predict
year
lr
rr
ci
however
significant
predictor
dmfs
rr
ci
rr
ci
image
effect
status
year
local
recurrence
lr
rate
young
woman
breast
cancer
treat
cs
year
survival
tumor
tumor
test
view
within
article
image
distant
metastasis
free
survival
dmfs
function
status
young
woman
breast
cancer
treat
cs
year
dmfs
tumor
tumor
wilcoxon
test
view
within
article
image
overall
survival
young
woman
breast
cancer
treat
cs
year
tumor
tumor
test
view
within
article
multivariate
analysis
multivariate
survival
estimate
based
cox
proportional
hazard
model
assume
interaction
significant
variable
final
model
status
tumor
size
nodal
status
status
enter
multivariate
model
determine
relationship
year
lr
dmfs
analysis
see
table
stage
lose
prognostic
significance
relation
dmfs
rr
ci
overall
survival
rr
ci
nodal
status
demonstrate
relative
risk
ci
poor
overall
survival
multivariate
analysis
negativity
maintain
statistical
significance
predictor
tumor
much
likely
recur
locally
rr
ci
note
relative
risk
poor
overall
survival
negative
phenotype
increase
univariate
value
multivariate
value
ci
remain
significant
thus
patient
status
approximately
two
time
little
likely
survive
year
compare
patient
tumor
table
multivariate
analysis
prognostic
factor
local
recurrence
distant
survival
overall
survival
local
survival
prognostic
factorrr
ci
valuerr
ci
valuerr
ci
value
tumor
nodal
table
abbreviation
ci
confidence
interval
reference
group
rr
risk
ratio
statistically
significant
view
within
article
discussion
tissue
microarray
young
woman
stage
ii
breast
cancer
treat
surgery
radiotherapy
find
negativity
significantly
predict
poor
lr
dmfs
univariate
multivariate
model
stage
nodal
status
additional
predictor
distant
overall
survival
yet
statistically
inferior
status
univariate
multivariate
analysis
although
phenotype
associate
poor
prognosis
lr
dmfs
cohort
correlated
negativity
overexpression
within
classification
breast
carcinoma
heterogeneous
group
tumor
correlation
via
phenotype
simplified
identification
genetically
unstable
breast
cancer
although
nielson
report
absence
lack
overexpression
case
phenotype
observe
case
current
study
difference
note
versus
phenotype
current
study
perhaps
cohort
consist
homogenous
group
young
woman
early
stage
disease
disparity
frequency
report
blc
may
inherent
biologic
difference
young
patient
cohort
study
consistent
previously
report
finding
considerable
genetic
overlap
mutation
cancer
blc
expect
correlation
status
per
ihc
status
per
genetic
testing
expect
six
patient
carry
mutation
exhibit
phenotype
conversely
association
observe
phenotype
mutation
consistent
much
tumor
associate
mutation
turner
show
study
breast
tumor
mutation
generally
negative
associate
compromise
distant
survival
current
study
phenotype
also
associate
overexpression
turner
describe
previously
just
study
observe
overexpression
correlate
poor
overall
distant
survival
show
borderline
significance
local
relapse
univariate
analysis
however
status
significant
independent
prognostic
factor
see
multivariate
analysis
study
although
patient
treat
systemic
adjuvant
chemotherapy
year
actuarial
overall
survival
rate
entire
cohort
subset
analysis
lr
dmfs
patient
phenotype
function
chemotherapy
conduct
relatively
small
number
propose
analysis
contrast
previous
study
prognostic
utility
phenotype
limited
select
patient
much
aggressive
relapse
rate
either
locally
distantly
thus
prognosis
patient
cohort
may
refined
addition
cytokeratin
expression
datum
negativity
significant
predictor
aggressive
disease
study
patient
argue
poor
prognosis
associate
phenotype
influence
ck
expression
rather
absence
study
three
basal
cytokeratin
alone
marker
blc
may
prognostic
value
attain
study
combine
status
phenotype
may
ill
outcome
preclude
adjuvant
hormonal
molecular
therapy
available
estrogen
tumor
although
basal
luminal
cytokeratin
status
may
aid
validate
phenotype
single
basal
luminal
marker
alone
identify
subset
patient
poor
outcome
may
fail
identify
several
cancer
current
study
may
support
staining
obtain
tumor
specimen
basal
marker
egfr
much
accurately
identify
blc
although
expression
specific
blc
combine
marker
ck
show
contribute
accurate
identification
blc
course
confirmation
luminal
versus
cancer
obtain
via
cdna
microarray
analysis
intrinsic
gene
set
describe
group
relatively
early
stage
cancer
treat
surgery
radiation
able
validate
lack
luminal
cytokeratin
staining
independent
risk
factor
poor
prognosis
respect
lr
dmfs
risk
factor
validate
large
study
across
much
heterogeneous
cohort
consider
addition
great
radiation
boost
dose
whole
breast
irradiation
additional
chemotherapy
agent
aggressive
adjuvant
modality
patient
desire
breast
conservation
patient
disease
relatively
high
risk
local
relapse
status
may
also
serve
stratify
patient
poor
candidate
protocol
employ
accelerate
partial
breast
irradiation
recent
datum
also
suggest
blc
much
responsive
taxane
neoadjuvant
chemotherapy
subtype
therefore
negativity
represent
biologically
distinct
subtype
breast
cancer
may
also
select
tumor
distinct
chemotherapy
sensitivity
therapeutic
monoclonal
antibody
treatment
potential
option
patient
neu
negative
tumor
characteristic
blc
drug
iressa
show
vivo
vitro
effective
breast
tumor
cell
express
egfr
effect
cell
line
although
size
series
reasonable
uniformly
treat
homogeneous
population
young
woman
number
event
may
relatively
small
define
role
molecular
factor
clinical
process
woman
breast
cancer
nevertheless
putative
marker
blc
negativity
important
risk
factor
predict
local
distant
overall
prognosis
young
woman
disease
evaluation
outcome
young
woman
breast
carcinoma
treat
surgery
radiation
warrant
larger
prospective
clinical
trial
much
aggressive
adjuvant
radiotherapy
chemotherapy
without
biologic
modifier
postmastectomy
radiation
pmrt
indicate
select
breast
cancer
patient
traditional
indication
pmrt
include
tumor
cm
four
much
involve
axillary
lymph
node
however
number
patient
receive
treatment
grow
new
datum
suggest
local
control
survival
advantage
patient
even
one
positive
axillary
lymph
node
time
many
woman
wish
pursue
breast
reconstruction
whether
will
undergo
pmrt
need
pmrt
determine
pathologic
stage
disease
role
patient
management
often
know
definitive
surgery
decision
proceed
immediate
reconstruction
may
therefore
make
information
available
integration
pmrt
overall
management
patient
proceed
immediate
reconstruction
pose
treatment
dilemma
well
study
algorithm
develop
memorial
cancer
center
manage
patient
determine
need
pmrt
undergo
immediate
breast
reconstruction
technique
figure
depict
algorithm
treatment
begin
definitive
surgery
consist
mastectomy
axillary
lymph
node
dissection
alnd
placement
subpectoral
tissue
expander
tissue
expansion
occur
period
adjuvant
chemotherapy
completion
chemotherapy
patient
take
back
operate
room
exchange
permanent
implant
finally
radiation
deliver
chest
wall
supraclavicular
fossa
image
memorial
algorithm
integration
radiation
immediate
reconstruction
alnd
axillary
lymph
node
dissection
view
within
article
radiotherapy
immediately
reconstructed
breast
particular
technique
remain
highly
controversial
criticism
technique
focused
three
major
concern
potential
inferior
cosmetic
outcome
increase
complication
rate
compromise
radiation
design
risk
inferior
disease
control
due
delay
initiation
radiation
first
two
concern
previously
examine
however
issue
timing
radiation
reconstructive
algorithm
resultant
disease
control
poorly
study
focus
article
memorial
cancer
center
treatment
algorithm
incorporate
delay
completion
chemotherapy
initiation
radiation
allow
exchange
permanent
implant
first
aim
study
determine
actual
interval
component
treatment
patient
treat
algorithm
assess
actual
length
incorporate
delay
clinical
practice
second
aim
evaluate
local
regional
distant
disease
control
well
overall
survival
patient
treat
algorithm
assess
whether
clinical
outcome
seem
acceptable
group
patient
method
material
obtain
institutional
review
board
approval
study
retrospectively
review
chart
patient
initiate
treatment
memorial
cancer
center
accord
algorithm
depict
patient
undergo
definitive
surgery
december
include
initial
review
patient
receive
component
treatment
institution
complete
entire
treatment
algorithm
include
analysis
data
collect
regard
patient
characteristic
disease
characteristic
treatment
detail
treatment
outcome
patient
stage
accord
american
joint
committee
cancer
edition
category
patient
undergo
total
mastectomy
tm
affect
breast
ipsilateral
alnd
case
patient
undergo
one
much
lumpectomy
tm
alnd
time
prior
lumpectomy
patient
time
tm
subpectoral
place
plastic
surgeon
one
two
week
surgery
tissue
expansion
begin
care
plastic
surgeon
week
surgery
adjuvant
chemotherapy
initiate
care
medical
oncologist
length
period
depended
chemotherapy
regimen
select
approximately
week
completion
chemotherapy
patient
take
back
operate
room
exchange
permanent
saline
implant
approximately
week
exchange
patient
initiate
radiation
gather
information
chart
review
patient
treatment
include
surgery
chemotherapy
radiation
regimen
examine
time
interval
component
treatment
examine
clinical
outcome
include
local
regional
distant
disease
control
well
survival
clinical
outcome
evaluate
physical
examination
well
imaging
posttreatment
imaging
include
ct
scan
contralateral
mammogram
applicable
tumor
marker
follow
discretion
medical
oncologist
failure
document
tissue
biopsy
perform
univariate
analysis
follow
factor
outcome
distant
metastasis
survival
age
year
year
stage
stage
extranodal
extension
tumor
histology
invasive
ductal
disease
presence
vascular
invasion
presence
perineural
invasion
margin
status
chest
wall
involvement
estrogen
receptor
status
progesterone
receptor
pr
status
chemotherapy
regimen
adjuvant
chemotherapy
based
hormone
therapy
interval
chemotherapy
radiation
week
week
survival
time
define
time
mastectomy
date
death
last
local
control
define
time
mastectomy
date
local
failure
last
distant
survival
time
define
time
mastectomy
date
distant
metastasis
last
survival
curve
estimate
survival
methodology
estimate
survival
time
various
group
compare
log
rank
test
result
december
mastectomy
perform
memorial
cancer
center
include
immediate
reconstruction
placement
transverse
rectus
abdominus
tram
flap
latissimus
dorsi
flap
total
patient
undergo
immediate
placement
deem
require
pmrt
initiate
treatment
accord
algorithm
describe
patient
undergo
definitive
surgery
institution
receive
either
chemotherapy
radiotherapy
component
treatment
outside
institution
remain
patient
receive
component
treatment
institution
constitute
study
group
treatment
march
patient
select
treatment
algorithm
team
treat
physician
specific
inclusion
exclusion
criterion
algorithm
deem
suitable
treatment
procedure
table
table
summarize
disease
characteristic
median
patient
age
time
diagnosis
year
range
year
case
inflammatory
breast
cancer
patient
treat
neoadjuvant
chemotherapy
patient
undergo
tm
alnd
status
evaluate
immunohistochemistry
patient
increase
staining
case
evaluate
fluorescent
situ
hybridization
patient
amplify
case
median
number
lymph
node
dissect
range
table
tumor
characteristic
characteristicn
invasive
ductal
invasive
lobular
vascular
invasion
perineural
invasion
direct
skin
invasion
chest
wall
invasion
positive
surgical
estrogen
receptor
progesterone
receptor
extranodal
extension
multifocal
table
view
within
article
table
patient
stage
table
view
within
article
adjuvant
chemotherapy
administer
patient
chemotherapy
doxorubicin
patient
fluorouracil
patient
cyclophosphamide
patient
three
patient
receive
trastuzumab
positive
fluorescent
situ
hybridization
positive
immunohistochemistry
chemotherapy
patient
receive
hormone
therapy
patient
receive
tamoxifen
alone
receive
aromatase
inhibitor
alone
receive
sequence
tamoxifen
aromatase
inhibitor
patient
positive
receive
hormone
therapy
patient
negative
receive
hormone
therapy
chemoprevention
adjuvant
radiation
deliver
patient
indication
radiation
disease
patient
extranodal
extension
patient
large
tumor
cm
pathology
patient
gross
multifocality
multicentricity
patient
positive
margin
patient
two
lymph
node
involve
without
another
adverse
pathologic
feature
patient
treat
strong
preference
comprehensive
therapy
radiation
deliver
chest
wall
tangent
photon
beam
conformal
radiotherapy
patient
one
receive
radiation
supraclavicular
fossa
anterior
oblique
photon
beam
internal
mammary
node
imn
specifically
targeted
additional
electron
field
patient
ten
patient
receive
posterior
axillary
boost
photon
field
median
radiation
dose
field
cgy
range
cgy
fraction
cgy
one
patient
receive
electron
scar
boost
remain
patient
scar
boost
cm
bolus
daily
chest
wall
patient
five
patient
terminate
treatment
early
skin
desquamation
patient
receive
minimum
cgy
chest
wall
patient
complete
chest
wall
treatment
without
bolus
last
fraction
desquamation
interval
component
treatment
algorithm
also
evaluate
interval
depict
median
interval
definitive
surgery
initiation
chemotherapy
week
range
week
median
duration
chemotherapy
month
range
month
median
interval
completion
chemotherapy
exchange
permanent
implant
week
range
week
median
interval
exchange
initiation
radiation
week
range
week
median
total
interval
completion
chemotherapy
initiation
radiation
week
range
week
median
interval
mastectomy
initiation
radiation
month
range
month
image
median
treatment
interval
patient
treat
memorial
algorithm
integration
postmastectomy
radiation
immediate
reconstruction
alnd
axillary
lymph
node
dissection
radiotherapy
view
within
article
median
date
definitive
surgery
month
range
month
median
completion
radiotherapy
month
range
month
perform
interval
every
month
annually
depending
length
time
since
treatment
seven
patient
lose
much
month
since
last
visit
median
lose
month
range
month
visit
whether
perform
radiation
oncologist
medical
oncologist
surgeon
include
physical
examination
chest
wall
regional
lymph
node
also
include
ct
scanning
contralateral
mammogram
applicable
serum
tumor
marker
discretion
treat
physician
case
local
regional
failure
detect
result
locoregional
disease
control
rate
twenty
patient
chest
wall
skin
biopsy
suspect
local
recurrence
negative
fifteen
patient
develop
distant
metastases
year
distant
survival
rate
confidence
interval
ci
distant
survival
consider
date
completion
radiation
year
rate
ci
last
patient
note
rise
tumor
marker
radiographic
evidence
disease
recurrence
five
patient
die
year
overall
survival
rate
ci
four
patient
die
metastatic
breast
cancer
die
unknown
figure
depict
curve
locoregional
control
distant
survival
overall
survival
seven
patient
diagnose
contralateral
breast
cancer
either
subsequent
treatment
index
cancer
three
patient
develop
subsequent
cancer
contralateral
stage
ia
lung
cancer
localized
melanoma
heel
carcinoma
situ
cervix
seven
patient
undergo
prophylactic
bilateral
treatment
patient
undergo
contralateral
prophylactic
mastectomy
either
time
original
mastectomy
treatment
image
curve
demonstrate
locoregional
control
distant
survival
overall
survival
probability
patient
treat
algorithm
median
time
mastectomy
month
view
within
article
statistically
significant
association
distant
survival
follow
patient
tumor
treatment
characteristic
age
year
year
stage
stage
extranodal
extension
tumor
histology
invasive
ductal
presence
vascular
invasion
presence
perineural
invasion
margin
status
chest
wall
involvement
pr
status
chemotherapy
regimen
adjuvant
chemotherapy
based
hormone
therapy
interval
chemotherapy
radiation
week
week
negative
status
cancer
right
breast
leave
breast
significantly
associate
poorer
distant
survival
outcome
discussion
postmastectomy
radiation
traditionally
deliver
breast
cancer
patient
tumor
cm
four
much
involve
axillary
lymph
node
however
pathologic
stage
disease
particular
nodal
staging
often
difficult
predict
definitive
surgery
need
pmrt
may
know
time
surgery
however
decision
regard
immediate
reconstruction
make
surgery
traditionally
bias
pmrt
patient
undergo
immediate
reconstruction
patient
know
need
pmrt
time
surgery
discourage
proceeding
immediate
reconstruction
treatment
patient
discover
require
pmrt
surgery
pose
management
dilemma
memorial
cancer
center
treatment
algorithm
develop
mean
manage
patient
identify
need
pmrt
surgery
however
much
recent
datum
suggest
survival
advantage
pmrt
patient
one
three
positive
lymph
node
pmrt
also
become
much
common
many
woman
also
opt
reconstruction
psychosocial
reason
thus
pmrt
setting
reconstruction
become
much
prevalent
ability
safely
integrate
pmrt
reconstructive
algorithm
become
much
important
number
reconstructive
option
patient
undergo
mastectomy
breast
cancer
two
general
category
reconstructive
technique
autologous
tissue
reconstruction
implant
reconstruction
autologous
reconstruction
much
commonly
involve
placement
pedicled
free
tram
flap
chest
wall
technique
breast
reconstructed
tissue
abdomen
include
skin
subcutaneous
fat
rectus
abdominus
muscle
procedure
lengthy
associate
significant
morbidity
require
long
healing
period
patient
able
undergo
type
reconstruction
comorbid
condition
obesity
diabetes
prior
surgery
radiation
collagen
vascular
disease
smoking
consider
relative
contraindication
type
reconstruction
also
thin
woman
may
enough
tissue
autologous
reconstruction
therefore
many
woman
eligible
autologous
reconstruction
elect
procedure
morbidity
implant
reconstruction
hand
involve
placement
permanent
implant
muscle
technique
require
little
operative
time
tolerate
great
percentage
woman
donor
site
require
reconstruction
generally
perform
two
stage
initial
placement
expand
saline
period
time
follow
exchange
permanent
implant
reconstructive
technique
perform
immediate
delay
basis
immediate
reconstruction
perform
time
mastectomy
whereas
delay
reconstruction
perform
separate
surgical
procedure
complete
healing
mastectomy
occur
several
disadvantage
immediate
reconstruction
first
final
pathology
know
time
procedure
role
future
radiation
may
unknown
second
implant
autologous
tissue
technique
prolong
therefore
increase
risk
surgery
however
many
woman
prefer
delay
reconstruction
psychosocial
reason
reconstruction
also
necessitate
additional
surgical
procedure
consequent
risk
furthermore
tissue
expansion
irradiate
mastectomy
wound
usually
possible
limit
feasibility
reconstruction
perform
delay
basis
integration
radiation
technique
complex
controversial
american
society
clinical
oncology
guideline
conclude
insufficient
evidence
make
recommendation
respect
integration
pmrt
reconstruction
discuss
implication
study
pertinent
review
principal
pmrt
setting
immediate
reconstruction
controversy
surround
primary
concern
express
regard
treatment
incorporate
breast
reconstruction
pmrt
relate
increased
complication
rate
poor
cosmesis
great
debate
whether
autologous
implant
reconstruction
result
good
outcome
conclude
tram
reconstruction
radiation
contraindicate
one
study
report
late
complication
rate
patient
treat
tram
reconstruction
follow
radiation
believe
reconstruction
inferior
tram
combine
radiation
retrospective
review
patient
reconstruction
either
radiation
report
significantly
increase
complication
rate
reconstruction
compare
tram
reconstruction
another
study
report
grade
capsular
contracture
patient
undergo
radiation
implant
conclude
adjuvant
radiotherapy
contraindication
immediate
implant
reconstruction
aesthetic
point
view
however
another
study
patient
pmrt
either
reconstruction
show
equal
rate
major
complication
tram
reconstruction
conclude
pmrt
consider
eligible
patient
setting
either
type
reconstruction
study
irradiate
patient
reconstructed
technique
examine
rate
complication
well
patient
satisfaction
outcome
show
comparable
patient
assessment
cosmetic
outcome
woman
treat
reconstruction
without
radiation
though
high
rate
complication
irradiate
patient
series
limited
small
patient
number
heterogeneous
population
despite
fact
several
article
conclude
integration
reconstruction
feasible
wide
range
conclusion
draw
different
study
feel
immediate
reconstruction
contraindicate
patient
may
need
pmrt
addition
cosmetic
concern
study
raise
concern
irradiation
immediately
reconstructed
breast
result
inferior
quality
radiation
study
show
majority
radiation
plan
term
provide
broad
coverage
chest
wall
imn
adequately
spare
heart
lung
need
treat
imn
controversial
irradiation
imn
show
confer
benefit
survival
rate
distant
metastasis
datum
suggest
radiation
plan
compromise
case
imn
targeted
finally
timing
integration
pmrt
reconstructive
algorithm
well
study
concern
delay
initiation
radiation
result
inferior
disease
control
conflict
datum
regard
significance
delay
initiation
radiotherapy
setting
adjuvant
chemotherapy
mastectomy
study
report
increase
local
failure
rate
radiation
delay
favor
deliver
adjuvant
chemotherapy
whereas
show
increase
odd
ratio
mortality
radiation
delay
much
month
start
chemotherapy
setting
therapy
delay
week
surgery
start
radiation
absence
chemotherapy
acceptable
datum
aware
suggest
appropriate
delay
chemotherapy
radiation
setting
mastectomy
reconstruction
one
study
report
similar
rate
local
failure
distant
metastasis
patient
treat
pmrt
without
immediate
implant
reconstruction
mean
month
interval
component
treatment
describe
another
study
report
significant
difference
incidence
local
failure
distant
metastasis
patient
undergo
pmrt
immediate
tram
reconstruction
compare
undergo
reconstruction
interval
surgery
radiation
study
similar
whether
reconstruction
perform
approximately
month
one
algorithm
propose
address
issue
describe
reconstruction
approach
patient
undergo
mastectomy
placement
fully
expand
final
pathology
available
patient
may
undergo
reconstruction
autologous
tissue
permanent
implant
radiation
indicate
radiation
indicate
radiation
deliver
expander
subsequently
final
autologous
reconstruction
perform
limited
datum
outcome
treatment
approach
report
patient
treat
pmrt
algorithm
downside
reconstruction
need
patient
will
receive
pmrt
undergo
two
operation
require
general
anesthesia
close
patient
require
pmrt
algorithm
involve
irradiation
rather
permanent
implant
although
irradiation
feasible
ideal
magnetic
component
port
interfere
radiation
delivery
potential
problem
approach
fact
tissue
expansion
radiation
complication
formation
expander
capsule
mastectomy
radiation
may
allow
datum
also
limited
one
potential
advantage
algorithm
patient
receive
adjuvant
chemotherapy
likely
result
short
time
interval
completion
chemotherapy
initiation
radiation
aware
study
specifically
report
time
interval
memorial
cancer
center
algorithm
alternative
approach
reconstruction
also
address
concern
raise
regard
integration
pmrt
reconstructive
algorithm
reconstruction
rather
autologous
tissue
reconstruction
algorithm
much
widely
applicable
much
woman
eligible
reconstruction
autologous
reconstruction
much
streamlined
approach
fewer
invasive
procedure
believe
experience
treatment
algorithm
sufficient
concern
raise
regard
pmrt
setting
immediate
reconstruction
although
center
report
inferior
cosmetic
outcome
radiation
immediately
reconstructed
breast
technique
institution
publish
datum
cosmetic
outcome
complication
large
series
patient
treat
algorithm
many
patient
also
represent
present
study
although
complete
overlap
patient
receive
radiation
outside
institution
include
study
address
cosmesis
study
patient
study
demonstrate
good
excellent
aesthetic
result
case
develop
grade
moderate
capsular
contracture
develop
grade
severe
capsular
contracture
percent
patient
report
choose
form
reconstruction
series
include
large
number
patient
much
homogeneous
population
publish
series
believe
one
reason
acceptable
outcome
report
institution
surgical
technique
implant
completely
cover
tissue
center
additional
reconstruction
may
perform
time
exchange
improve
cosmesis
much
recent
datum
institution
continue
support
timing
radiation
immediate
reconstruction
term
complication
aesthetic
outcome
prospective
study
patient
undergo
bilateral
immediate
reconstruction
unilateral
pmrt
compare
outcome
two
breast
nonirradiated
breast
control
group
difference
identify
two
breast
grade
contracture
increase
one
grade
modify
scale
increase
grade
finally
datum
single
surgeon
experience
reconstruction
institution
address
early
complication
complication
publish
majority
patient
study
receive
radiation
also
include
small
number
patient
receive
radiation
reconstruction
early
complication
examine
include
skin
flap
necrosis
infection
delay
wound
healing
seroma
fail
expansion
expander
late
complication
examine
include
capsular
contracture
implant
loss
increase
early
complication
rate
note
patient
undergo
chest
wall
radiation
reconstruction
increase
early
complication
patient
receive
chemotherapy
tissue
expansion
term
outcome
increase
incidence
capsular
contracture
patient
receive
radiation
decrease
overall
aesthetic
score
difference
consider
acceptable
successful
outcome
achievable
patient
receive
radiation
reconstruction
none
publication
institution
report
oncologic
outcome
instead
focused
exclusively
cosmetic
outcome
complication
issue
radiation
design
setting
immediate
reconstruction
centered
around
need
include
imn
target
practice
specifically
target
imn
case
radiographic
evidence
imn
involvement
case
high
index
suspicion
involvement
accomplish
either
additional
electron
field
targeting
imn
deep
tangent
cover
superior
aspect
radiation
field
two
technique
institution
treat
imn
pmrt
case
design
spare
normal
heart
lung
tissue
target
imn
approximately
pmrt
patient
although
none
patient
study
imn
targeted
electron
field
possible
case
deeper
tangent
field
select
cover
imn
record
treatment
summary
imn
targeted
minimal
difficulty
targeting
chest
wall
spare
normal
tissue
final
concern
respect
irradiation
immediately
reconstructed
breast
time
pmrt
treatment
sequence
memorial
cancer
center
algorithm
result
week
interval
completion
chemotherapy
initiation
radiotherapy
allow
exchange
permanent
implant
healing
surgical
procedure
first
study
aware
specifically
examine
disease
control
time
interval
patient
receive
pmrt
immediate
reconstruction
median
week
interval
chemotherapy
radiation
disease
control
rate
acceptable
accord
parameter
include
local
regional
control
distant
control
survival
disease
control
rate
compare
historical
control
report
rate
local
failure
patient
treat
pmrt
range
depending
extent
disease
menopausal
status
length
among
factor
excellent
control
rate
suggest
week
delay
chemotherapy
radiation
month
delay
surgery
radiation
setting
adjuvant
chemotherapy
detrimental
effect
local
disease
control
combination
previously
report
acceptable
cosmetic
outcome
believe
immediate
breast
reconstruction
mastectomy
technique
acceptable
sequenced
accord
algorithm
association
status
increase
rate
distant
metastasis
concordant
expect
outcome
explain
increase
rate
distant
metastasis
patient
disease
likely
represent
statistical
anomaly
based
small
number
study
limited
possibility
selection
bias
relatively
small
patient
number
short
median
although
majority
local
failure
will
occur
first
year
treatment
distant
failure
may
occur
later
patient
study
remain
risk
locoregional
distant
failure
women
think
poor
prognosis
due
locally
advance
disease
detect
surgery
may
immediate
reconstruction
undergo
neoadjuvant
chemotherapy
introduce
bias
study
toward
patient
much
favorable
prognosis
finally
possible
patient
metastatic
disease
receive
surveillance
local
failure
remain
disease
free
therefore
possible
local
failure
occur
document
group
patient
fail
distantly
also
acknowledge
lack
control
group
study
preclude
comparison
patient
outcome
patient
undergo
immediate
reconstruction
despite
limitation
report
represent
important
evidence
algorithm
basis
provide
much
woman
opportunity
elect
immediate
reconstruction
even
setting
pmrt
conclusion
mastectomy
immediate
reconstruction
adjuvant
chemotherapy
radiation
deliver
accord
memorial
cancer
center
algorithm
result
median
interval
week
completion
chemotherapy
initiation
radiotherapy
treatment
algorithm
result
acceptable
local
regional
control
distant
survival
overall
survival
year
complex
factor
contribute
challenge
demonstrate
clear
role
progesterone
breast
cancer
first
progesterone
difficult
study
isolation
hormone
growth
factor
prolactin
also
contribute
breast
cancer
biology
second
progesterone
receptor
pr
isoform
express
response
estrogen
mediate
transcriptional
event
also
occur
independently
subset
mammary
epithelial
cell
mec
breast
express
also
express
estrogen
usually
require
order
induce
robust
expression
pr
cell
estrogen
also
potent
breast
mitogen
make
difficult
separate
effect
progesterone
alone
estrogen
indeed
pr
isoform
grossly
relative
normal
neoplastic
breast
study
steroid
hormone
receptor
mouse
reveal
concerted
action
estrogen
progesterone
require
normal
mammary
gland
development
estrogen
promote
growth
duct
invade
mammary
fat
pad
nipple
estrogen
progesterone
pr
require
development
terminal
acini
locate
end
duct
later
become
milk
produce
structure
lactate
mammary
gland
additional
require
hormone
know
epidermal
growth
factor
egf
growth
factor
augment
proliferation
terminal
normal
breast
development
promote
ductal
outgrowth
side
branch
induce
estrogen
plus
progesterone
fact
pr
isoform
expression
response
estrogen
require
presence
egf
suggest
existence
important
cross
talk
egf
receptor
egfr
family
member
steroid
hormone
receptor
image
mammary
gland
acini
locate
end
duct
adult
mammary
gland
functional
unit
lactate
mammary
gland
luminal
epithelial
cell
apical
exist
polar
cell
contact
myoepithelial
cell
basal
epithelial
cell
population
separate
stroma
basement
steroid
hormone
receptor
positive
cell
occur
adjacent
proliferate
cell
normal
mammary
gland
communication
paracrine
signaling
epithelial
stromal
compartment
mediate
proliferation
pr
negative
cell
early
event
breast
cancer
development
may
mediate
switch
paracrine
autocrine
mechanism
proliferation
cell
view
within
article
another
limitation
decipher
role
progesterone
pr
action
breast
cancer
development
normal
proliferate
breast
epithelial
cell
steroid
hormone
receptor
negative
normal
adult
mammary
gland
cell
represent
luminal
epithelial
cell
population
cell
much
often
usually
lie
adjacent
proliferate
cell
much
current
information
suggest
cell
capable
proliferate
expression
inhibitory
molecule
high
level
endogenous
inhibitor
protein
kinase
cdk
communication
breast
epithelial
stromal
compartment
mediate
proliferation
nearby
adjacent
cell
expression
secretion
locally
active
molecule
wnts
hepatocyte
growth
factor
hgf
recent
evidence
suggest
cell
may
act
cell
provide
substance
wnts
nearby
progenitor
stem
cell
population
contrast
normal
breast
proliferate
cell
much
often
devoid
steroid
hormone
receptor
majority
breast
cancer
express
pr
time
diagnosis
although
steroid
hormone
tumor
much
often
slow
grow
relative
tumor
breast
epithelial
cell
may
undergo
early
switch
autocrine
paracrine
signaling
mechanism
whereby
negative
control
proliferation
somehow
lift
another
set
cell
clearly
divide
pregnant
mammary
gland
cyclin
divide
cell
thus
pathway
involve
normal
mammary
gland
growth
development
may
inappropriately
breast
cancer
progression
experimental
evidence
model
organism
primate
mouse
rat
human
suggest
role
progestin
herein
review
status
progesterone
pr
action
breast
cancer
model
suggest
potential
future
development
pr
antagonist
part
combine
breast
cancer
therapy
integration
pr
classical
rapid
signaling
pr
isoform
define
transcription
factor
member
large
family
relate
steroid
hormone
receptor
include
androgen
receptor
glucocorticoid
receptor
gr
mineralocorticoid
receptor
pr
activate
upon
binding
naturally
occur
ovarian
steroid
hormone
progesterone
via
binding
synthetic
ligand
progestin
regulate
gene
expression
binding
directly
indirectly
specific
site
dna
three
pr
isoform
distinct
protein
product
single
gene
locate
chromosome
transcription
pr
isoform
govern
distal
proximal
promoter
region
presence
internal
translational
start
site
within
common
mrna
result
creation
three
protein
isoform
consist
full
length
kda
truncate
kda
kda
cell
much
often
isoform
receptor
exhibit
different
transcriptional
activity
within
promoter
context
also
recognize
entirely
different
gene
promoter
essential
normal
mammary
gland
development
require
uterine
development
reproductive
function
devoid
transcriptional
activity
express
enhance
pr
activity
breast
cancer
cell
function
dominant
inhibitor
uterus
image
progesterone
integrate
ligand
activate
transcription
factor
contain
hormone
binding
domain
hinge
region
domain
dbd
amino
terminus
activation
function
represent
site
interaction
require
transcription
regulatory
site
response
progestin
mitogenic
signaling
pathway
modify
pr
phosphorylation
specific
site
pr
couple
multiple
receptor
mediate
dissociation
protein
hsp
nuclear
accumulation
nuclear
pr
regulate
gene
expression
via
classical
pathway
phosphorylated
pr
recruit
regulatory
molecule
may
function
one
much
process
transcription
localization
turnover
pr
growth
factor
activate
mapk
via
pathway
may
result
positive
regulation
pr
transcriptional
activity
via
regulation
direct
phosphorylation
liganded
pr
occur
absence
presence
ligand
gene
activation
mapk
pr
provide
regulation
gene
whose
promoter
contain
pre
otherwise
independent
activity
utilize
response
progestin
phosphorylation
pr
mediate
tether
selective
regulation
growth
promote
gene
via
site
egfr
view
within
article
pr
complexed
chaperone
molecule
include
heat
shock
protein
hsp
interaction
allow
proper
protein
fold
assembly
stable
pr
molecule
competent
bind
hormone
also
mediate
important
aspect
pr
protein
trafficking
binding
progesterone
receptor
change
induce
dimerization
hsp
dissociation
activated
receptor
associate
include
steroid
receptor
withhold
nucleus
bind
directly
specific
progesterone
response
element
pre
sequence
promoter
region
target
gene
fatty
acid
synthetase
mmtv
treatment
progestin
also
result
upregulation
gene
without
pre
proximal
promoter
region
epidermal
growth
factor
receptor
cyclin
regulation
gene
without
pre
pre
sequence
occur
pr
tether
transcription
factor
specificity
protein
activate
protein
signal
transducer
activator
transcription
stat
genomic
classical
action
steroid
hormone
treatment
delay
several
minute
hour
dictate
time
require
transcription
translation
target
gene
recently
however
rapidly
occur
within
minute
extranuclear
effect
cell
steroid
hormone
receptor
enter
forefront
example
progestin
treatment
breast
cancer
cell
rapid
transient
min
activation
cytoplasmic
protein
kinase
include
protein
kinase
mapk
kinase
similar
activity
report
effect
mediate
direct
binding
steroid
hormone
receptor
protein
protein
interaction
domain
signaling
molecule
locate
near
plasma
membrane
close
proximity
growth
factor
receptor
immediate
effector
human
pr
contain
pxxp
motif
mediate
direct
binding
three
domain
signaling
molecule
kinase
family
manner
vitro
experiment
demonstrate
purify
directly
activate
protein
kinase
hck
activate
mapk
vivo
mutation
pxxp
sequence
disrupt
pr
interaction
block
activation
hck
mapk
furthermore
mutation
domain
dbd
abolish
pr
transcriptional
activity
without
block
map
kinase
activation
thus
mapk
activation
progestin
complex
much
likely
occur
way
mechanism
involve
ras
activation
mapk
module
association
signaling
adaptor
molecule
suspect
reside
similar
cytoplasmic
signaling
complex
possibly
association
pr
study
human
breast
prostate
cancer
cell
line
rapid
signaling
action
pr
show
contribute
regulation
cell
proliferation
response
respective
hormone
ligand
potential
role
human
physiology
whole
organism
little
clear
steroid
hormone
activation
cytoplasmic
signaling
molecule
may
primarily
serve
potentiate
nuclear
function
receptor
example
amplification
pr
nuclear
function
likely
occur
rapid
direct
phosphorylation
pr
protein
receptor
response
activation
cytoplasmic
pathway
couple
ligand
binding
thus
appropriately
phosphorylated
activate
receptor
complex
efficiently
direct
select
target
gene
clearly
positive
feedback
explain
dramatic
influence
activate
signaling
pathway
pr
nuclear
function
indeed
several
progestin
event
mapk
include
upregulation
cyclin
activation
entry
cell
growth
direct
phosphorylation
pr
require
pr
tether
transcription
factor
bind
egfr
promoter
pr
tether
upon
mapk
pathway
activation
predict
alter
pr
promoter
selectivity
favoring
promoter
within
gene
kinase
also
confer
phosphorylated
example
mapk
mediate
pr
hypersensitivity
ligand
phosphorylation
pr
event
receptor
activity
prevent
pr
sumoylation
activated
loss
induce
pr
activity
via
phosphorylation
although
much
study
need
become
clear
activation
cytoplasmic
protein
kinase
integral
feature
pr
nuclear
action
phosphorylation
event
require
gene
regulation
lead
change
cell
biology
thus
rapid
phosphorylation
event
may
primarily
act
alter
pr
transcriptional
activity
clearly
also
mediate
promoter
selectivity
might
signaling
action
steroid
hormone
receptor
include
pr
contribute
deregulated
breast
cancer
cell
growth
increase
breast
cancer
risk
perhaps
link
steroid
hormone
action
expression
gene
endpoint
mapk
signaling
phosphorylation
transcription
factor
support
concept
extranuclear
action
liganded
induce
state
adaptive
hypersensitivity
endocrine
therapy
growth
factor
signaling
pathway
upregulated
model
mapk
activation
liganded
localized
cell
membrane
interact
protein
induce
phosphorylation
lead
recruitment
adaptor
molecule
activation
ras
mapk
module
mapk
regulate
gene
via
direct
phosphorylation
ets
factor
component
independently
transcriptional
activity
activation
mapk
explain
many
tumor
respond
well
aromatase
inhibitor
yet
fail
respond
selective
estrogen
receptor
modulator
design
inhibit
transcriptional
activity
nucleus
mapk
activation
cytoplasm
breast
cancer
often
exhibit
heighten
mapk
activity
elevate
cyclin
target
gene
whose
expression
sensitive
multiple
kinase
input
steroid
hormone
receptor
include
pr
may
contribute
constitutive
signaling
cytoplasmic
mitogenic
protein
kinase
via
activity
thereby
antiestrogen
therapy
pr
action
animal
model
study
rodent
demonstrate
differentially
express
mammary
gland
development
predominantly
express
ductal
expression
coincide
formation
alveoli
express
proliferate
cell
proliferate
cell
compartment
suggest
progesterone
may
induce
proliferation
either
direct
paracrine
mechanism
contrast
cell
adult
virgin
gland
pr
cyclin
positive
fail
proliferate
possibly
due
high
level
protein
kinase
inhibitor
menstrual
cycle
mec
undergo
sequential
wave
proliferation
apoptosis
notably
primate
macaques
human
increase
terminal
duct
lobular
unit
cell
proliferation
coincide
peak
serum
progesterone
occur
phase
suggest
paracrine
mechanism
hormone
adult
tissue
upregulation
local
may
factor
regard
animal
model
postmenopausal
hormone
replacement
therapy
parous
nulliparous
early
late
postmenopausal
mouse
subject
estrogen
alone
estrogen
plus
progestin
produce
greater
proliferative
response
relative
alone
regardless
parity
treatment
time
also
show
act
directly
mammary
gland
rather
via
systemic
effect
similar
result
occur
surgically
postmenopausal
macaques
postmenopausal
human
although
breast
cancer
development
animal
study
result
increase
proliferation
consistent
human
clinical
datum
reveal
increase
tumor
number
size
woman
take
alone
significantly
alter
breast
cancer
risk
tumor
size
progesterone
may
act
via
growth
factor
affect
breast
cell
proliferation
breast
cancer
etiology
majority
early
breast
cancer
lesion
express
pr
receptor
remain
high
least
advance
early
event
may
include
switch
ability
normally
quiescent
cell
respond
directly
steroid
hormone
proliferate
notably
deregulation
cell
cycle
hallmark
breast
cancer
breast
cancer
overexpress
cyclin
least
lose
contain
activate
mutation
loss
also
frequent
occurrence
numerous
vitro
study
demonstrate
linkage
pr
action
cell
cycle
regulation
namely
pr
interact
directly
cyclin
pr
activity
high
dna
synthesis
phase
cell
cycle
activity
peak
furthermore
pr
transcriptional
activity
become
upon
loss
progestin
act
transcription
induce
cyclin
expression
cell
cycle
breast
cancer
cell
suggest
breast
progesterone
pr
action
tightly
couple
mechanism
cell
cycle
control
breast
cancer
mitogenic
potential
activate
pr
may
manifest
particularly
loss
checkpoint
control
elevation
cdk
mitogenic
kinase
activity
example
egfr
ligand
transgenic
mouse
develop
proliferative
hyperplasia
early
lesion
rapidly
progress
tumor
recent
vitro
study
demonstrate
enhance
pr
transcriptional
activity
mec
proliferation
increase
genetically
engineer
mouse
lack
mammary
gland
related
finding
recent
study
mouse
lack
mammary
gland
expression
pr
protein
level
dramatically
increase
development
aggressive
tumor
virgin
mouse
completely
block
future
study
will
important
define
negative
regulation
cell
proliferation
normal
mec
somehow
lift
allow
progression
early
lesion
malignant
cancer
early
event
include
loss
checkpoint
control
alteration
dna
damage
repair
pathway
cell
pr
action
human
breast
cancer
cell
model
biochemistry
pr
action
well
characterize
largely
define
human
breast
cancer
cell
line
cell
modify
pr
numerous
study
focused
pr
interaction
regulatory
protein
change
pr
subcellular
localization
modification
pr
phosphorylation
sumoylation
condition
affect
pr
transcriptional
activity
usually
measure
artificial
gene
promoter
reporter
gene
contain
one
much
tandem
pre
site
growth
factor
include
egf
promote
transcriptional
synergy
presence
progestin
gene
discuss
phosphorylation
event
primarily
serve
augment
pr
action
promoter
selective
manner
despite
depth
basic
understanding
detail
gene
regulation
associate
change
cell
biology
response
pr
activation
remain
elusive
handful
endogenous
gene
describe
detail
majority
gene
regulate
response
progesterone
lack
consensus
sequence
progesterone
responsive
element
pre
presence
one
much
pre
pre
fail
accurately
predict
regulation
many
gene
regulate
upon
pr
expression
independently
progesterone
furthermore
several
gene
downregulated
response
progesterone
transcriptional
largely
unknown
mechanism
much
case
regulation
specific
gene
response
progesterone
pr
loosely
tie
correlation
change
cell
tumor
biology
example
many
gene
associate
aspect
tumor
progression
towards
aggressive
tumor
phenotype
addition
ratio
frequently
alter
away
breast
tumor
relative
normal
tissue
condition
predict
dramatically
alter
genetic
program
role
progesterone
breast
cancer
find
progesterone
biphasic
effect
proliferation
breast
cancer
cell
line
grow
vitro
cell
grow
plastic
culture
dish
supplement
medium
cultured
cell
line
undergo
initial
proliferation
characterize
increased
entry
peak
progesterone
treatment
cell
cycle
progression
drive
successive
upregulation
cyclin
elevate
activity
follow
one
three
cell
cycle
later
cell
growth
inhibition
upregulated
cell
ultimately
arrest
boundary
thus
response
cultured
breast
cancer
cell
progesterone
proliferative
inhibitory
contrast
clear
mitogenic
effect
estrogen
cell
line
model
reason
suggest
progesterone
act
primarily
prime
agent
growth
promote
activity
dependent
upon
cellular
context
presence
secondary
agent
example
progestin
upregulate
select
component
growth
signaling
pathway
include
egfr
family
member
ligand
breast
cancer
cell
much
responsive
proliferation
cell
thus
progesterone
may
act
part
sensitize
breast
cancer
cell
growth
factor
cytokine
signal
note
progesterone
treatment
breast
cancer
cell
grow
culture
also
implicate
resistance
apoptosis
tumor
cell
differentiation
luminal
myoepithelial
phenotype
minimal
effect
tumor
growth
transition
associate
poor
clinical
prognosis
similarly
epithelial
mesenchymal
transition
emt
early
event
precede
tumor
cell
invasion
metastasis
may
occur
independently
change
proliferation
emt
stationary
epithelial
cell
become
acquire
ability
migrate
invade
locally
interestingly
many
gene
encode
molecule
involve
signal
transduction
cell
adhesion
extracellular
matrix
ecm
basement
membrane
component
gene
mediator
increase
cell
motility
effect
progestin
recently
evaluate
type
culture
system
allow
breast
cancer
cell
grow
colony
much
similar
organization
acini
find
vivo
contrast
culture
progestin
clearly
mitogenic
system
wherein
induce
transcriptional
upregulation
lead
sustain
mapk
activity
upregulation
cyclin
formation
abundant
large
colony
suggest
mitogenic
action
progesterone
require
establishment
cell
polarity
property
support
culture
system
addition
far
insight
role
appear
excessive
cross
talk
progesterone
pr
signaling
pathway
component
clear
definition
specific
action
progesterone
pr
relevant
much
advance
breast
cancer
cell
biology
tumor
progression
metastasis
include
emt
need
may
require
study
condition
mimic
preserve
breast
epithelial
cell
architecture
luminal
epithelial
cell
contact
basement
membrane
component
support
concept
normal
mec
respond
differently
estrogen
progesterone
cultured
presence
variable
ecm
component
collagen
type
fibronectin
laminin
ecm
protein
increase
expression
egf
receptor
context
estrogen
plus
progestin
inhibit
egf
mec
proliferation
manner
clearly
pr
interaction
ecm
complex
deregulation
ecm
protein
expression
integrin
signaling
early
event
cancer
progression
likely
dramatically
alter
hormone
responsiveness
future
perspective
many
aspect
pr
action
originally
discover
animal
cell
line
model
breast
cancer
establish
human
however
direct
role
pr
breast
cancer
illustrate
clinical
finding
women
health
initiative
million
women
study
demonstrate
woman
take
progestin
combination
estrogen
part
hormone
replacement
therapy
ept
experience
great
breast
cancer
risk
relative
estrogen
alone
tumor
large
high
grade
million
women
study
also
find
woman
much
likely
die
breast
cancer
take
ept
time
diagnosis
thus
substantial
preclinical
datum
suggest
important
role
pr
function
modulate
breast
cancer
biology
validation
finding
dependent
clinical
strategy
disrupt
pr
function
human
breast
cancer
will
important
decipher
contribution
nuclear
membrane
pr
activity
target
appropriately
selective
pr
modulator
addition
targeting
relevant
kinase
mapk
require
steroid
hormone
receptor
action
suggest
pr
activity
routinely
targeted
part
combination
therapy
aim
block
along
associate
essential
protein
kinase
acknowledgement
study
role
progesterone
breast
cancer
fund
nih
nci
grant
formerly
thank
andrea
daniel
douglas
helpful
comment
sentinel
node
biopsy
allow
accurate
staging
lymph
node
status
breast
cancer
previous
axillary
surgery
long
consider
contraindication
mapping
due
disruption
lymphatic
vessel
drain
tumour
axilla
removal
potential
axillary
datum
available
experimental
study
find
disruption
lymphatic
vessel
may
temporary
lymphatic
within
certain
period
surgery
although
period
never
evaluate
regeneration
lymphatic
vessel
may
result
new
lymphatic
network
connect
tumour
current
lymphatic
furthermore
original
lymphatic
vessel
interrupt
due
surgery
lymphatic
drainage
tumour
may
follow
previously
little
retain
open
lymphatic
channel
lymph
node
basin
however
often
different
basin
find
without
axillary
surgery
result
much
patient
unexpected
lymphatic
lymphatic
drainage
previous
axillary
surgery
interest
patient
primary
recurrent
breast
cancer
lymphatic
mapping
patient
evaluate
however
follow
principle
patient
without
prior
axillary
surgery
lymphatic
drainage
cancer
map
injection
radiocolloid
vital
blue
dye
possible
advantage
successful
mapping
lymph
node
biopsy
much
thorough
examination
map
lymph
node
reduce
morbidity
case
negative
lymph
node
find
complete
lymph
node
dissection
lymphatic
basin
require
study
determine
feasibility
accuracy
lymphatic
mapping
follow
previous
axillary
surgery
look
parameter
associate
failure
mapping
procedure
patient
patient
method
patient
lymphatic
mapping
attempt
patient
primary
recurrent
breast
cancer
history
previous
axillary
surgery
indication
lymphatic
mapping
type
previous
breast
axillary
surgery
see
table
clinical
pathologic
parameter
patient
see
table
eight
patient
history
previous
chemotherapy
patient
history
radiation
follow
breast
conservation
surgery
accord
standard
treatment
protocol
diagnosis
breast
cancer
make
core
needle
biopsy
patient
clinical
evaluation
axilla
prior
lymphatic
mapping
find
negative
axillary
lymph
node
patient
table
indication
lymph
node
mapping
type
previous
breast
axillary
surgery
result
lymph
node
biopsy
indication
ln
previous
breast
previous
axillary
patient
successful
ln
ln
perform
primary
bc
mastectomy
sampling
incision
recurrent
bc
snb
table
abbreviation
bc
breast
cancer
ln
lymph
node
snb
sentinel
node
biopsy
alnd
axillary
lymph
node
dissection
one
patient
undergo
axillary
tissue
resection
due
recurrent
abscess
formation
patient
undergo
resection
malignant
melanoma
upper
arm
hand
shoulder
view
within
article
table
clinicopathologic
characteristic
patient
undergo
lymph
node
mapping
previous
axillary
surgery
recurrent
primary
breast
cancer
mean
sd
age
year
menopausal
status
breast
quadrant
upper
lower
lower
upper
histology
breast
tumour
intraductal
carcinoma
situ
high
tumour
differentiation
estrogen
receptor
status
progesterone
receptor
status
neu
status
table
view
within
article
lymph
node
mapping
lymphatic
mapping
injection
radiocolloid
mbq
volume
ml
prior
surgery
preoperative
lymphoscintigraphy
gamma
camera
determine
lymphatic
drainage
intraoperatively
map
lymph
node
identify
hand
hold
gamma
probe
neoprobe
neoprobe
dublin
oh
usa
vital
blue
vital
dye
ml
blue
venue
bedford
oh
usa
lymph
node
regard
map
node
either
blue
blue
stain
lymphatic
channel
lead
directly
node
hot
node
find
gamma
probe
lymph
node
regard
hot
node
excise
node
reveal
count
great
time
count
axilla
removal
patient
positive
node
suggest
alnd
alnd
also
suggest
patient
negative
lymph
node
evaluate
false
negative
rate
far
lymph
node
dissection
map
lymph
node
internal
mammary
node
lymphatic
mapping
approve
local
ethic
committee
review
board
hospital
write
inform
consent
participate
lymphatic
mapping
procedure
obtain
patient
pathological
examination
lymph
node
intraoperative
freeze
section
examination
map
lymph
node
patient
postoperatively
negative
lymph
node
examine
serial
section
interval
stain
haematoxylin
eosin
negative
far
investigate
cytokeratin
immunohistochemical
ihc
stain
antibody
dpc
uk
cytokeratin
section
map
lymph
node
regard
negative
tumour
find
permanent
section
lymph
node
remove
alnd
examine
section
stain
immunohistochemical
stain
statistical
analysis
addition
explorative
datum
analysis
follow
test
perform
two
group
frequency
table
analyzed
fisher
exact
test
normally
distribute
metric
variable
analyzed
mann
whitney
test
normally
distribute
metric
variable
test
normality
kolmogorov
smirnov
test
significance
analyzed
mean
test
independent
sample
spss
package
version
calculation
test
confidence
level
many
hypothesis
test
error
rate
increase
adjustment
therefore
descriptive
result
result
lymphoscintigraphy
lymph
node
biopsy
preoperative
lymphoscintigraphy
reveal
drainage
lymph
node
basin
patient
mean
sd
number
map
lymph
node
range
node
remove
patient
identification
rate
three
patient
positive
lymph
node
one
ihc
micrometastasis
undergo
alnd
two
patient
map
lymph
node
positive
lymph
node
whereas
one
patient
another
positive
node
axillary
specimen
one
patient
isolate
tumour
cell
find
permanent
examination
one
two
node
node
find
level
iii
axilla
previous
alnd
far
lymph
node
find
patient
fifteen
patient
negative
lymph
node
two
patient
far
lymph
node
remove
negative
lymph
node
remove
internal
mammary
basin
current
lymphatic
drainage
exclusively
internal
mammary
node
patient
previous
alnd
thirteen
patient
completion
alnd
find
mean
sd
number
lymph
node
range
lymph
node
positive
lymph
node
find
axillary
specimen
false
negative
rate
five
patient
drainage
lymph
node
significantly
patient
prior
alnd
compare
patient
prior
biopsy
versus
fisher
exact
test
table
lymphatic
drainage
pattern
patient
previous
axillary
surgery
successful
lymph
node
mapping
biopsy
type
previous
axillary
alnd
contralateral
snb
node
sampling
ii
axillary
incision
table
abbreviation
internal
mammary
artery
node
level
axilla
snb
sentinel
node
biopsy
alnd
axillary
lymph
node
dissection
view
within
article
lymph
node
status
patient
lymph
node
find
lymphatic
mapping
patient
preoperative
lymphoscintigraphy
find
drainage
lymphatic
basin
hot
spot
blue
node
find
intraoperatively
eight
patient
history
previous
alnd
exploration
axilla
reveal
lymph
node
patient
whereas
negative
node
remove
one
patient
three
patient
prior
biopsy
alnd
find
negative
node
axillary
specimen
negative
node
remove
positive
node
patient
associate
failure
lymphatic
mapping
mean
sd
time
previous
axillary
surgery
mapping
procedure
month
range
month
patient
successful
mapping
compare
month
range
month
patient
node
find
lymphatic
mapping
mann
whitney
test
patient
previous
chemotherapy
previous
radiation
show
significant
identification
rate
table
number
previously
remove
lymph
node
associate
decrease
identification
rate
statistically
significant
much
lymph
node
remove
prior
axillary
surgery
positive
lymphoscintigraphy
lymphatic
drainage
see
lymphoscintigram
significantly
associate
successful
lymphatic
mapping
table
correlation
previous
chemotherapy
previous
radiation
previous
chemotherapy
radiation
perform
successful
lymph
node
mapping
patient
previous
axillary
surgery
successful
mappingmapping
patient
previous
previous
fisher
exact
test
patient
previous
previous
fisher
exact
test
patient
previous
radiation
previous
radiation
fisher
exact
test
table
view
within
article
table
correlation
number
previously
remove
node
successful
lymph
node
mapping
patient
previous
axillary
surgery
number
node
mappingmapping
fisher
exact
test
table
view
within
article
table
correlation
positive
lymphoscintigraphy
successful
lymph
node
mapping
successful
mappingmapping
patient
positive
patient
negative
fisher
exact
test
table
view
within
article
discussion
lymphatic
mapping
successfully
identify
lymph
node
patient
previous
axillary
surgery
considerably
identification
rate
report
mapping
breast
cancer
patient
without
prior
axillary
surgery
comparable
study
find
identification
rate
study
publish
european
cancer
institute
milan
describe
identification
rate
patient
high
identification
rate
find
study
may
relate
fact
patient
study
prior
biopsy
leave
almost
unaltered
drainage
axillary
lymph
node
correlation
prior
alnd
biopsy
identification
rate
also
see
study
patient
prior
biopsy
identification
rate
compare
alnd
show
success
lymph
node
mapping
axillary
surgery
depend
number
previously
remove
lymph
node
similar
study
port
study
find
number
much
lymph
node
remove
previously
axilla
significantly
associate
unsuccessful
mapping
decrease
identification
rate
see
lymphatic
mapping
previous
axillary
surgery
attributed
disruption
lymphatic
vessel
drain
breast
tumour
regional
lymph
node
surgery
chemotherapy
radiation
regeneration
disrupt
lymphatic
vessel
follow
surgery
describe
experimental
study
never
evaluate
patient
furthermore
remain
unknown
whether
regeneration
lymphatic
associate
length
time
surgery
however
study
time
previous
axillary
surgery
lymphatic
mapping
impact
success
mapping
procedure
lymphatic
mapping
patient
prior
axillary
surgery
follow
lymphatic
ipsilateral
axillary
node
much
lymphatic
drainage
exclusively
outside
axilla
see
small
number
patient
number
patient
positive
without
involvement
axillary
node
even
may
expect
lymphatic
drainage
lymph
node
see
much
often
patient
prior
axillary
surgery
patient
without
axillary
perre
report
lymphatic
drainage
pattern
patient
follow
either
alnd
radiotherapy
study
identify
prior
surgery
mapping
week
follow
surgery
lymphatic
drainage
find
mapping
ipsilateral
axilla
much
patient
also
ipsilateral
contralateral
internal
mammary
chain
contralateral
report
four
patient
recurrent
primary
breast
cancer
history
prior
alnd
lymphoscintigraphy
find
lymphatic
drainage
node
outside
ipsilateral
axilla
four
patient
report
two
patient
find
contralateral
axilla
roumen
find
successfully
map
either
internal
mammary
chain
contralateral
axilla
study
lymphatic
drainage
lymphatic
node
find
patient
drainage
much
often
previous
alnd
prior
biopsy
success
lymphatic
mapping
significantly
associate
positive
lymphoscintigraphy
lymph
node
map
patient
negative
lymphoscintigram
hot
spot
find
intraoperatively
despite
vital
blue
dye
every
patient
therefore
patient
primary
recurrent
breast
cancer
history
prior
axillary
surgery
schedule
preoperative
lymphoscintigraphy
lymphatic
mapping
plan
contrary
mapping
patient
previously
untreated
axillae
blue
dye
alone
allow
successful
mapping
large
number
study
find
patient
history
previous
chemotherapy
radiation
treatment
axillary
surgery
identification
rate
compare
patient
previous
axillary
surgery
however
lack
statistical
significance
associate
factor
simply
due
small
sample
size
far
evaluate
large
group
patient
effect
radiotherapy
lymphatic
drainage
pattern
breast
cancer
patient
describe
yet
however
histopathological
change
fibrosis
breast
tissue
commonly
radiation
treatment
result
distortion
lymphatic
vessel
decrease
identification
rate
negative
impact
chemotherapy
identification
rate
describe
patient
undergo
mapping
preoperative
chemotherapy
may
relate
lymphatic
drainage
lymphatic
tissue
replace
crucial
issue
however
come
implement
lymphatic
node
mapping
previous
axillary
surgery
clinical
practice
false
negative
rate
procedure
order
become
clinically
applicable
false
negative
rate
comparable
current
study
biopsy
patient
without
prior
axillary
surgery
experience
hand
little
study
false
negative
result
find
yet
number
patient
small
draw
definitive
conclusion
issue
may
require
different
institution
conclusion
lymphatic
mapping
axillary
surgery
associate
decrease
identification
rate
false
negative
rate
zero
lymphatic
drainage
pattern
patient
radionuclide
mapping
prerequisite
successful
mapping
procedure
conflict
interest
conflict
interest
author
manuscript
financial
personal
relationship
people
organisation
inappropriately
influence
work
commercial
funding
study
acknowledgement
statistical
analysis
support
grant
ludwig
institute
surgical
clinicopathologic
characteristic
breast
cancer
patient
heterogeneous
consequently
survival
time
different
subgroup
patient
generally
survival
range
population
breast
cancer
patient
purpose
study
apply
novel
analytical
method
breast
cancer
patient
identify
prognostic
factor
explore
interaction
clinical
variable
impact
survival
decision
tree
algorithm
allow
relation
predictive
factor
outcome
mix
datum
type
numerical
categorical
isolate
outliers
incorporate
prune
process
alternative
testing
second
datum
set
literature
several
report
separation
patient
subgroup
different
prognosis
survival
sauerbrei
decision
tree
recursive
partitioning
assess
effect
specific
variable
survival
thereby
ultimately
generate
group
patient
similar
clinical
feature
survival
time
partitioning
patient
group
differ
survival
time
clinical
variable
generate
model
analyzed
assess
clinical
utility
therefore
decision
tree
method
classification
regression
tree
crt
automatic
interaction
detector
chaid
quick
unbiased
efficient
statistical
tree
quest
commercial
version
interactive
dichotomizer
version
much
suitable
classical
statistical
method
analyzed
simultaneous
relationship
among
risk
factor
breast
cancer
five
decision
tree
algorithm
study
compare
relative
effect
risk
factor
breast
cancer
multivariate
analysis
model
try
discover
significant
pattern
relationship
among
risk
factor
make
decision
rule
management
breast
cancer
patient
patient
retrospective
analysis
perform
breast
cancer
patient
diagnose
investigation
prognostic
factor
age
menopausal
status
age
menarche
age
first
delivery
presence
abortus
hormone
replacement
therapy
family
history
cancer
histologic
tumor
type
quadrant
tumor
tumor
size
estrogen
progesterone
receptor
status
histologic
nuclear
grading
accord
richardson
criterion
bloom
richardson
type
surgery
axillary
nodal
status
pericapsular
involvement
lymph
node
stage
disease
accord
ajcc
american
joint
committee
cancer
lymphovascular
perineural
invasion
radiotherapy
chemotherapy
hormonal
therapy
complete
datum
patient
form
basis
study
primary
local
treatment
surgery
modify
radical
mastectomy
breast
conserve
surgery
median
age
range
whole
patient
population
tumor
consider
positive
estrogen
progesterone
receptor
much
tumor
cell
show
nuclear
staining
zhang
descriptive
statistic
clinical
pathologic
datum
entire
patient
population
list
table
perform
classical
statistical
analysis
examine
difference
distribution
variable
patient
recurrence
kolmogorov
smirnov
test
assess
normality
numeric
variable
numeric
variable
distribute
comparison
two
group
make
mann
whitney
result
express
median
interquartile
range
association
recurrence
nominal
variable
assess
test
table
clinical
laboratory
characteristic
study
group
independent
absent
present
age
median
irq
age
menarche
median
irq
tumor
size
cm
median
irq
hormone
replacement
age
first
delivery
menopausal
presence
stage
situ
early
stage
locally
advance
nuclear
estrogen
receptor
progesterone
receptor
type
radical
breast
conserve
hormonal
family
history
breast
perineural
lymphovascular
axillary
nodal
lymph
node
lymph
node
histologic
histologic
tumor
quadrant
pericapsular
involvement
lymph
table
view
within
article
adjuvant
radiotherapy
give
patient
chemotherapy
administer
patient
chemotherapy
deliver
prior
radiotherapy
hormonal
therapy
initiate
completion
radiotherapy
typically
continue
year
hormone
receptor
positive
patient
recurrence
disease
consist
clinical
assessment
every
three
month
first
three
year
two
year
annual
five
year
statistical
analysis
variable
decision
tree
algorithm
identify
optimal
cut
point
datum
fold
analysis
perform
initial
evaluation
test
error
algorithm
briefly
process
involve
splitting
dataset
random
segment
training
test
set
algorithm
survival
analysis
perform
survival
time
initial
diagnosis
first
recurrence
disease
local
regional
distant
terminal
node
good
decision
tree
method
survival
curve
estimate
kaplan
meier
method
difference
curve
evaluate
test
mantel
cox
time
patient
calculate
month
last
day
initial
treatment
date
death
date
last
visit
statistical
test
little
consider
significant
decision
tree
classification
regression
tree
crt
recursive
partitioning
method
regression
classification
crt
construct
splitting
subset
datum
set
predictor
variable
create
two
child
node
repeatedly
begin
entire
datum
set
good
predictor
choose
variety
impurity
diversity
measure
gini
twoing
order
twoing
deviation
goal
produce
subset
datum
homogeneous
possible
respect
target
variable
friedman
study
measure
gini
impurity
categorical
target
variable
gini
impurity
measure
gini
index
node
define
j
category
target
variable
equation
gini
index
also
write
thus
case
node
evenly
distribute
across
category
gini
index
take
maximum
value
k
k
number
category
target
variable
case
node
belong
category
gini
index
equal
cost
misclassification
specify
gini
index
compute
probability
misclassifying
category
j
case
category
gini
criterion
function
split
node
define
tl
tr
proportion
case
send
leave
child
node
pr
proportion
send
right
child
node
split
choose
maximize
value
value
report
improvement
tree
automatic
interaction
detection
chaid
method
based
test
association
chaid
tree
decision
tree
construct
repeatedly
split
subset
space
two
much
child
node
begin
entire
datum
set
michael
gordon
determine
good
split
node
allowable
pair
category
predictor
variable
merge
statistically
significant
difference
within
pair
respect
target
variable
chaid
method
naturally
deal
interaction
independent
variable
directly
available
examination
tree
final
node
identify
subgroup
define
different
set
independent
variable
magidson
spss
chaid
algorithm
accept
nominal
ordinal
categorical
predictor
predictor
continuous
transform
ordinal
predictor
follow
algorithm
predictor
variable
x
merge
category
final
category
x
will
result
one
child
node
x
split
node
merge
step
also
calculate
adjust
splitting
x
category
stop
set
adjust
x
category
go
step
else
find
allowable
pair
category
x
allowable
pair
category
ordinal
predictor
two
adjacent
category
nominal
predictor
two
category
least
significantly
different
much
similar
pair
pair
whose
test
statistic
give
large
respect
dependent
variable
calculate
various
situation
will
describe
late
section
pair
large
check
large
merge
pair
merge
single
compound
category
new
set
category
x
form
go
step
optional
newly
form
compound
category
consist
three
much
original
category
find
good
binary
split
within
compound
category
small
perform
binary
split
large
split
merge
go
step
optional
category
observation
compare
minimum
segment
size
merge
much
similar
category
measure
large
adjust
compute
merge
category
apply
bonferroni
adjustment
discuss
magidson
spss
quick
unbiased
efficient
statistical
tree
quest
decision
tree
algorithm
classification
datum
mining
quest
univariate
linear
combination
split
unique
feature
attribute
selection
method
negligible
bias
attribute
respect
class
attribute
approximately
change
select
split
node
loh
shih
quest
tree
grow
process
consist
selection
split
predictor
selection
split
point
select
predictor
stop
algorithm
univariate
split
consider
selection
split
predictor
follow
continuous
predictor
x
perform
anova
test
different
class
dependent
variable
mean
x
calculate
accord
statistic
categorical
predictor
perform
pearson
test
x
independence
calculate
accord
statistic
find
predictor
small
denote
small
little
level
significance
total
number
predictor
variable
predictor
x
select
split
predictor
node
go
continuous
predictor
x
compute
statistic
based
absolute
deviation
x
class
mean
test
variance
x
different
class
calculate
test
find
predictor
small
denote
small
little
number
continuous
predictor
x
select
split
predictor
node
otherwise
node
split
loh
shih
commercial
version
supervise
learn
classification
algorithm
construct
decision
tree
datum
much
empirical
learning
system
give
set
case
describe
vector
attribute
value
construct
mapping
attribute
value
class
one
system
learn
decision
tree
classifier
approach
grow
decision
tree
main
difference
similar
decision
tree
building
algorithm
test
selection
evaluation
process
attribute
denote
case
denote
class
denote
set
case
test
split
based
attribute
split
mutually
exclusive
subset
subset
case
collection
case
test
choose
decision
tree
consist
node
identify
test
one
branch
possible
subset
subset
new
test
choose
far
split
satisfy
stop
criterion
tree
leaf
associate
much
frequent
class
one
reason
stop
case
belong
one
class
decision
tree
algorithm
modify
splitting
criterion
call
ratio
arg
max
arg
max
ratio
choose
test
split
ci
denote
proportion
case
belong
class
select
test
maximize
ratio
value
initial
decision
tree
construct
prune
procedure
initiate
decrease
overall
tree
size
decrease
estimate
error
rate
tree
interactive
dichotomizer
version
simple
decision
tree
learn
algorithm
develop
quinlan
algorithm
build
decision
tree
greedy
search
procedure
represent
core
quinlan
highly
successful
decision
tree
algorithm
basic
idea
algorithm
construct
decision
tree
employ
greedy
search
give
set
test
attribute
every
tree
node
order
select
attribute
much
useful
classify
give
set
introduce
metric
information
algorithm
work
follow
cheng
shao
suppose
pe
ne
pe
set
positive
example
ne
set
negative
example
pe
ne
example
will
determine
belong
pe
probability
ne
probability
employ
information
heuristic
decision
tree
consider
source
message
pe
ne
expect
information
need
generate
message
give
attribute
x
value
domain
root
decision
tree
will
partition
contain
example
value
contain
pi
example
pe
ni
expect
information
require
pi
ni
expect
information
require
tree
x
root
x
obtain
weigh
average
weight
branch
proportion
example
belong
information
branch
x
x
therefore
x
x
examine
candidate
attribute
choose
x
maximize
x
construct
tree
process
construct
decision
tree
residual
subset
example
positive
create
yes
node
halt
example
negative
create
node
halt
otherwise
select
another
attribute
way
give
early
multidimensional
scaling
mds
mds
method
represent
measurement
similarity
dissimilarity
among
pair
object
distance
point
space
help
represent
similarity
object
distance
euclidean
space
effect
much
dissimilar
two
object
large
distance
object
euclidean
space
object
study
different
classification
technique
describe
characteristic
term
classification
performance
measurement
location
technique
map
based
position
variable
space
similar
measure
regression
analysis
calculate
mds
equal
percentage
sum
dissimilarity
explain
model
another
measure
projection
stress
factor
stress
factor
consider
good
borg
kruskal
kaplan
meier
survival
analysis
kaplan
meier
analysis
technique
estimate
event
kaplan
meier
test
statistical
significance
difference
survival
curve
associate
two
different
circumstance
apply
analyzing
distribution
patient
survival
time
follow
recruitment
study
analysis
express
term
proportion
patient
still
alive
give
time
follow
recruitment
graphical
term
plot
proportion
patient
survive
time
characteristic
decline
often
exponential
curve
indicate
efficacy
treatment
investigate
much
shallow
survival
curve
much
effective
treatment
variety
test
may
compare
two
much
kaplan
meier
curve
certain
circumstance
median
remission
time
time
cohort
reach
remission
well
quantity
probability
remission
also
generate
kaplan
meier
analysis
provide
sufficient
characteristic
study
subject
median
month
percentile
month
patient
least
one
event
survival
recurrence
distant
metastases
second
cancer
tumor
size
axillary
nodal
status
stage
disease
lymphovascular
invasion
quadrant
tumor
progesterone
receptor
status
pericapsular
involvement
lymph
node
type
surgery
hormonal
therapy
find
statistically
significant
prognostic
factor
recurrence
comparison
decision
tree
method
error
rate
training
set
monitor
prediction
performance
method
table
give
performance
measure
crt
chaid
quest
algorithm
error
rate
value
training
set
range
error
rate
value
range
see
table
application
crt
take
small
error
rate
value
training
set
rank
second
chaid
rank
third
follow
quest
table
comparison
error
rate
model
rate
training
table
view
within
article
comparison
predictive
value
sensitivity
specificity
positive
predictive
value
ppv
negative
predictive
value
npv
predictive
rate
pr
training
set
decision
tree
method
show
table
model
sensitivity
specificity
ppv
npv
pr
training
set
range
respectively
table
comparison
performance
model
training
set
specificity
ppv
npv
pr
table
view
within
article
predictive
value
training
set
input
variable
mds
identify
homogenous
group
classification
technique
based
predictive
value
find
stress
factor
mds
plot
see
perform
well
chaid
quest
crt
predict
breast
cancer
image
find
good
method
multidimensional
scaling
view
within
article
classification
tree
rule
prediction
rfs
breast
cancer
analysis
identify
variable
play
important
role
explain
recurrence
indicate
tumor
size
much
important
factor
recurrence
split
produce
two
initial
branch
classification
tree
cm
versus
cm
table
terminal
node
tumor
size
cm
node
tumor
size
cm
age
node
tumor
size
cm
age
axillary
nodal
status
negative
lymph
node
positive
node
tumor
size
cm
age
axillary
nodal
status
lymph
node
positive
hormonal
therapy
absent
node
tumor
size
cm
age
axillary
nodal
status
lymph
node
positive
hormonal
therapy
present
axillary
nodal
status
negative
lymph
node
positive
quadrant
tumor
multicentric
node
axillary
nodal
status
lymph
node
positive
radiotherapy
absent
node
axillary
nodal
status
negative
lymph
node
positive
quadrant
tumor
unicentric
hormonal
therapy
absent
node
axillary
nodal
status
negative
lymph
node
positive
quadrant
tumor
unicentric
hormonal
therapy
present
node
axillary
nodal
status
lymph
node
positive
radiotherapy
present
progesterone
receptor
status
negative
node
axillary
nodal
status
lymph
node
positive
radiotherapy
present
progesterone
receptor
status
positive
tumor
size
cm
node
tumor
size
cm
presence
abortus
present
node
tumor
size
cm
presence
abortus
present
nodal
status
lymph
node
positive
node
tumor
size
cm
presence
abortus
present
axillary
nodal
status
negative
lymph
node
positive
age
menarche
node
tumor
size
cm
presence
abortus
present
axillary
nodal
status
negative
lymph
node
positive
age
menarche
tumor
type
ductal
node
tumor
size
cm
presence
abortus
present
axillary
nodal
status
negative
lymph
node
positive
age
menarche
hystologic
tumor
type
tumor
size
cm
age
menarche
hormonal
therapy
absent
axillary
nodal
status
lymph
node
positive
node
tumor
size
cm
age
menarche
hormonal
therapy
absent
axillary
nodal
status
negative
node
tumor
size
cm
age
menarche
hormonal
therapy
absent
axillary
nodal
status
lymph
node
positive
node
tumor
size
cm
age
menarche
hormonal
therapy
present
node
tumor
size
cm
age
menarche
node
tumor
size
cm
hormonal
therapy
absent
node
tumor
size
cm
hormonal
therapy
present
hystologic
grade
ii
node
tumor
size
cm
hormonal
therapy
present
hystologic
grade
iii
tumor
size
cm
node
tumor
size
cm
axillary
nodal
status
lymph
node
positive
hormonal
therapy
absent
node
tumor
size
cm
axillary
nodal
status
lymph
node
positive
hormonal
therapy
present
pericapsular
involvement
lymph
node
positive
node
tumor
size
cm
axillary
nodal
status
lymph
node
positive
hormonal
therapy
present
pericapsular
involvement
lymph
node
negative
node
tumor
size
cm
axillary
nodal
status
negative
node
tumor
size
cm
axillary
nodal
status
lymph
node
positive
table
view
within
article
see
difference
two
tumor
size
cm
age
menarche
prove
good
predict
variable
age
menarche
branch
include
hormonal
therapy
much
prominent
tumor
size
cm
age
menarche
absent
hormonal
therapy
axillary
nodal
status
lymph
none
positive
much
prominent
tumor
size
cm
present
hormonal
therapy
histological
grade
much
prominent
classification
tree
chart
illustrate
decision
rule
decision
rule
provide
specific
information
risk
factor
based
rule
induction
begin
one
root
node
contain
observation
sample
leaf
node
terminal
node
survival
analysis
breast
cancer
patient
tree
initial
split
breast
cancer
eight
terminal
node
form
variable
determine
structure
tree
include
tumor
size
age
menarche
hormonal
therapy
histological
grade
axillary
nodal
status
long
survive
terminal
node
node
include
three
event
patient
tumor
size
cm
age
menarche
patient
month
median
survival
second
terminal
node
node
relatively
long
median
survival
month
include
two
event
patient
tumor
size
cm
age
menarche
hormonal
therapy
give
axillary
nodal
status
negative
third
terminal
node
node
median
survival
month
include
nine
event
patient
tumor
size
cm
age
menarche
hormonal
therapy
give
axillary
nodal
status
lymph
node
positive
one
short
survive
terminal
node
node
include
event
patient
tumor
size
cm
hormonal
therapy
give
patient
median
survival
month
table
descriptive
statistic
survival
rfs
node
rfs
size
cm
age
menarche
size
cm
hormonal
therapy
absent
size
cm
age
menarche
hormonal
therapy
present
size
cm
hormonal
therapy
present
hystologic
grade
ii
size
cm
hormonal
therapy
present
hystologic
grade
iii
size
cm
age
menarche
hormonal
therapy
absent
axillary
nodal
status
lymph
node
positive
size
cm
age
menarche
hormonal
therapy
absent
axillary
nodal
status
negative
size
cm
age
menarche
hormonal
therapy
absent
axillary
nodal
status
lymph
node
positive
table
view
within
article
kaplan
meier
estimate
survival
whole
patient
show
estimate
survival
rate
accord
decision
tree
method
based
analysis
test
statistical
significance
difference
survival
curve
two
terminal
node
test
survival
curve
node
statistically
different
node
node
statistically
different
node
except
node
survival
curve
node
statistically
different
node
survival
curve
node
statistically
different
node
survival
curve
node
statistically
different
node
finally
node
statistically
different
node
image
kaplan
meier
survival
curve
eight
terminal
node
generate
view
within
article
table
comparison
mantel
cox
node
node
node
node
node
node
node
node
table
view
within
article
discussion
study
report
research
develop
several
prediction
model
predict
risk
factor
breast
cancer
specially
five
decision
tree
method
furthermore
evaluate
performance
model
accord
predictive
value
mds
identify
homogenous
group
classification
technique
estimate
rfs
rate
accord
decision
tree
method
based
analysis
current
evidence
support
clear
association
clinical
pathologic
factor
reduce
rfs
breast
cancer
prognostic
factor
influence
recurrence
survival
divide
intrinsic
relate
characteristic
tumor
histologic
feature
axillary
lymph
node
metastases
tumor
size
hormonal
receptor
status
histologic
nuclear
grade
stage
lymphovascular
invasion
pericapsular
involvement
lymph
node
perineural
invasion
extrinsic
host
menopausal
status
age
menarche
family
history
cancer
type
adequacy
radiotherapy
chemotherapy
hormonal
therapy
incidence
recurrence
great
survival
decrease
large
tumor
size
high
histologic
grade
presence
lymphovascular
invasion
involvement
axillary
node
tumor
negative
estrogen
receptor
status
young
age
henson
generally
survival
range
population
breast
cancer
patient
cox
regression
model
much
common
tool
investigate
simultaneously
influence
several
factor
survival
time
patient
give
estimate
degree
separation
different
subgroup
literature
several
report
separation
patient
subgroup
different
prognosis
survival
report
clinician
often
experience
difficulty
apply
standard
statistical
method
assess
interaction
clinical
variable
determine
cumulative
effect
variable
survival
translate
information
appropriate
management
complex
presentation
patient
unknown
primary
carcinoma
hence
show
kaplan
meier
analysis
together
crt
patient
unknown
primary
carcinoma
show
determine
src
activity
marker
poor
clinical
prognosis
colon
carcinoma
patient
analyzed
significant
association
elevate
src
activity
short
overall
survival
patient
kaplan
meier
analysis
report
classification
tree
chaid
crt
exploratory
datum
analysis
complex
datum
set
epidemiology
report
new
prognostic
classification
scheme
node
negative
breast
cancer
patient
according
crt
analysis
rfs
find
tumor
size
grade
much
important
factor
prognosis
group
patient
additionally
age
estrogen
receptor
status
factor
study
find
similar
prognostic
factor
rfs
breast
cancer
patient
node
tumor
large
cm
hormonal
treatment
consist
patient
bad
prognosis
recurrence
rfs
median
month
rfs
patient
grade
hg
breast
cancer
well
prognosis
high
grade
carcinoma
present
study
show
statistically
significant
short
rfs
patient
high
grade
hg
iii
tumor
grade
tumor
breast
cancer
patient
tumor
metastasis
axillary
lymph
node
significant
risk
factor
survival
outcome
development
metastatic
disease
present
study
patient
positive
axillary
lymph
node
node
statistically
significant
survival
node
respectively
age
menarche
show
risk
factor
development
primary
breast
cancer
evidence
indicate
lifetime
estrogen
exposure
may
critical
factor
breast
carcinogenesis
however
prognostic
influence
breast
cancer
present
uncertain
study
find
association
age
menarche
outcome
patient
primary
breast
cancer
contrary
report
early
age
menarche
modestly
increase
mortality
study
find
age
menarche
second
important
risk
factor
survival
study
find
perform
well
chaid
quest
crt
technique
furthermore
estimate
rfs
rate
kaplan
meier
analysis
accord
analysis
result
recommend
decision
tree
method
together
kaplan
meier
analysis
determine
risk
factor
effect
factor
survival
compare
method
real
datum
set
order
provide
information
general
tendency
datum
structure
assess
effect
specific
variable
survival
datum
set
help
researcher
select
good
method
solve
problem
classification
limited
datum
classification
effort
one
method
basis
consideration
suggest
datum
well
explore
process
high
performance
model
method
researchers
avoid
assessment
datum
one
method
future
study
focusing
breast
cancer
clinical
condition
fatty
acid
fas
catalyzes
synthesis
palmitate
play
central
role
conversion
dietary
storage
form
energy
numerous
clinical
basic
study
indicate
high
level
fas
present
variety
human
cancer
associate
poor
prognosis
demonstrate
inhibition
fas
synthetic
inhibitor
sirna
selectively
cytotoxic
human
cancer
cell
lead
significant
effect
various
cancer
xenograft
furthermore
high
level
fas
find
various
cancer
precursor
lesion
colon
stomach
esophagus
oral
cavity
prostate
breast
suggest
activation
fatty
acid
synthesis
require
carcinogenesis
collectively
fas
occur
wide
variety
human
cancerous
lesion
suggest
fas
potential
drug
target
chemoprevention
chemotherapy
show
regulate
fas
expression
akt
signal
transduction
pathway
reveal
molecular
connection
fas
human
breast
cancer
cell
alternatively
know
neu
member
egfr
family
transmembrane
receptor
tyrosine
kinase
overexpressed
breast
cancer
overexpression
show
correlated
poor
prognosis
enhance
metastatic
potential
increase
chemoresistance
human
cancer
notably
inhibition
fas
preferentially
induce
apoptosis
cancer
cell
delay
tumor
progression
transgenic
mouse
suggest
upregulation
fas
expression
might
play
role
cell
survival
tumorigenesis
taken
together
targeting
fas
might
novel
approach
treat
prevent
breast
cancer
recent
year
global
trend
toward
natural
substance
present
fruit
vegetable
herb
antioxidant
agent
chemically
plant
steroid
series
solasodine
tomatidine
occur
much
plant
tissue
think
play
protective
role
certain
previous
study
show
solasodine
effective
treatment
skin
cancer
tomatidine
may
benefit
cancer
chemotherapy
inhibit
resistance
human
cancer
cell
addition
diosgenin
member
steroidal
find
several
plant
include
species
importance
recently
diosgenin
show
favorable
effect
lipid
metabolism
also
effect
cancer
cell
although
datum
suggest
diosgenin
possess
strong
activity
effect
cancer
cell
seldom
mention
based
fact
fas
expression
play
important
role
survival
tumorigenesis
breast
cancer
plant
steroid
favorable
effect
lipid
metabolism
promote
investigate
whether
plant
steroid
diminish
fas
expression
breast
cancer
structurally
relate
plant
steroid
reveal
diosgenin
much
effective
suppression
fas
expression
breast
cancer
cell
diosgenin
preferentially
inhibit
proliferation
induce
apoptosis
cancer
cell
furthermore
show
modulate
akt
mtor
jnk
phosphorylation
potentially
require
fas
suppression
finally
diosgenin
specifically
sensitize
cytotoxicity
cancer
cell
result
indicate
diosgenin
fas
expression
induce
apoptosis
cancer
cell
modulate
akt
mtor
jnk
phosphorylation
far
suggest
diosgenin
therapeutic
implication
cancer
cell
material
chemical
diosgenin
solasodine
tomatidine
rapamycin
acid
fatty
bovine
serum
albumin
bsa
mtt
purchase
sigma
chemical
louis
usa
purchase
calbiochem
san
diego
usa
antibody
fas
purchase
bd
bioscience
angeles
antibody
akt
mtor
mapk
mapk
mapk
mapk
purchase
cell
signaling
technology
beverly
ma
antibody
abcam
cambridge
ma
antibody
conjugate
horseradish
peroxidase
obtain
santa
cruz
biotechnology
santa
cruz
reagent
chemical
purchase
sigma
analytical
grade
image
image
image
image
effect
diosgenin
solasodine
tomatidine
fas
expression
proliferation
breast
cancer
chemical
structure
diosgenin
solasodine
cell
incubate
dmso
con
tomatidine
dg
diosgenin
sd
solasodine
immunoblotting
measure
protein
level
fas
cell
viability
determine
mtt
assay
continuous
exposure
different
concentration
diosgenin
solasodine
tomatidine
number
viable
cell
treatment
express
percentage
control
data
mean
three
independent
experiment
bar
represent
left
column
immunoblotting
measure
fas
cell
fas
expression
upregulated
cell
right
column
cell
treat
various
concentration
diosgenin
cell
viability
determine
mtt
assay
number
viable
cell
treatment
express
percentage
control
data
mean
three
independent
experiment
bar
represent
view
within
article
cell
culture
human
cancer
cell
line
breast
adenocarcinoma
cell
line
expression
include
breast
adenocarcinoma
derived
normal
human
breast
tissue
transform
large
antigen
obtain
american
type
culture
collection
manassas
va
cell
grow
dmem
supplement
fetal
calf
serum
hyclone
laboratory
logan
penicillin
streptomycin
transfectant
kindly
provide
hung
university
texas
anderson
cancer
center
houston
tx
cultured
describe
cell
grow
humidify
atmosphere
culturing
cell
presence
serum
albumin
complex
palmitate
sigma
first
complexed
fatty
bovine
serum
albumin
describe
briefly
four
volume
bovine
serum
albumin
solution
nacl
add
volume
mm
palmitate
ethanol
incubate
obtain
mm
stock
solution
bovine
serum
palmitate
western
blot
analysis
cell
seed
onto
mm
tissue
culture
dish
contain
fcs
dmem
cultured
cell
incubate
fcs
dmem
treat
various
agent
indicate
figure
legend
treatment
cell
place
ice
wash
cold
pbs
lysed
lysis
buffer
western
blot
describe
previously
intensity
band
scan
quantify
nih
image
software
cell
proliferation
assay
flow
cytometry
describe
previously
effect
diosgenin
solasodine
tomatidine
taxol
cell
proliferation
examine
mtt
method
cell
cycle
analysis
peak
detection
apoptotic
effect
determine
flow
cytometry
staining
statistical
analysis
value
express
mean
value
mean
least
three
separate
experiment
group
student
statistical
comparison
value
significantly
different
effect
diosgenin
solasodine
tomatidine
expression
fas
breast
cancer
cell
diosgenin
solasodine
tomatidine
naturally
occur
plant
steroid
show
activity
investigate
possible
relationship
chemical
structure
biological
activity
determine
inhibitory
activity
protein
level
fas
breast
cancer
cell
line
treat
separately
human
breast
cancer
cell
compound
level
fas
protein
analyzed
show
among
test
compound
diosgenin
much
effective
compound
suppress
fas
expression
diosgenin
preferentially
inhibit
proliferation
breast
cancer
cell
assess
biological
activity
diosgenin
solasodine
tomatidine
term
cell
proliferation
cell
treat
plant
steroid
different
concentration
growth
inhibition
test
cell
line
manner
various
extent
cell
overexpress
show
high
susceptibility
diosgenin
cell
result
cell
viability
cell
sensitive
solasodine
tomatidine
contrast
show
high
cytotoxicity
cell
avoid
genetic
complexity
associate
establish
cancer
cell
line
compare
sensitivity
cell
establish
transfecting
neomycin
resistance
gene
alone
cell
consistent
expectation
cell
much
sensitive
diosgenin
cell
overall
result
suggest
diosgenin
preferentially
suppress
growth
cancer
cell
line
diosgenin
preferentially
promote
apoptotic
cell
death
breast
cancer
cell
next
examine
whether
loss
cell
viability
due
increase
apoptotic
cell
death
percentage
apoptotic
cell
peak
cell
measure
flow
cytometry
show
compare
control
diosgenin
dramatically
increase
amount
apoptotic
cell
cell
cancer
cell
line
contrast
cell
line
level
apoptotic
cell
similar
either
vehicle
diosgenin
treatment
addition
also
find
diosgenin
preferentially
induce
apoptosis
cell
compare
cell
therefore
diosgenin
preferentially
induce
apoptosis
cancer
cell
line
image
image
diosgenin
induce
apoptosis
cancer
cell
line
cancer
cell
line
cell
treat
vehicle
diosgenin
harvest
subject
dna
content
analysis
level
apoptosis
induce
vehicle
set
level
apoptosis
induce
diosgenin
express
relative
value
average
three
independent
experiment
bar
represent
view
within
article
palmitate
suppress
cytotoxicity
cancer
cell
confirm
cell
cytotoxicity
induce
diosgenin
relate
fas
inhibition
cell
expose
diosgenin
presence
palmitate
palmitate
markedly
reduce
cytotoxic
effect
diosgenin
percentage
viable
cell
significantly
decrease
addition
exogenous
palmitate
poly
polymerase
parp
cleave
caspase
apoptosis
produce
mr
fragment
measure
marker
apoptosis
immunoblotting
diosgenin
induce
corresponding
increase
parp
cleavage
addition
exogenous
palmitate
reduce
cleavage
test
whether
suppression
fas
really
critical
diosgenin
ability
inhibit
proliferation
cancer
cell
line
cell
treat
synthetic
fas
inhibitor
different
concentration
growth
inhibition
cell
manner
contrast
suppression
fas
mimic
diosgenin
effect
image
image
exogenous
palmitate
suppress
cancer
cell
cell
expose
vehicle
control
diosgenin
presence
absence
palmitate
cell
viability
determine
mtt
assay
bar
represent
cell
expose
vehicle
control
diosgenin
presence
absence
palmitate
parp
cleavage
assess
western
blot
cell
viability
determine
mtt
assay
continuous
exposure
different
concentration
synthetic
fas
inhibitor
number
viable
cell
treatment
express
percentage
control
data
mean
three
independent
experiment
bar
represent
view
within
article
diosgenin
downregulate
upregulate
level
breast
cancer
cell
akt
erk
jnk
show
involve
fas
regulation
various
cell
type
examine
whether
activity
akt
mapk
affect
diosgenin
analyzed
phosphorylation
akt
mapk
cell
treatment
diosgenin
immunoblot
analysis
antibody
perform
show
diosgenin
inhibit
phosphorylation
akt
downstream
mtor
contrast
diosgenin
enhance
jnk
phosphorylation
diosgenin
affect
erk
phosphorylation
image
image
effect
diosgenin
akt
mtor
map
kinase
phosphorylation
breast
cancer
cell
cell
treat
inhibitor
inhibitor
pd
diosgenin
level
phosphorylated
akt
mtor
mapk
analyzed
immunoblotting
mtor
mapk
mapk
antibody
immunoblotting
antibody
demonstrate
equivalent
protein
cell
incubate
inhibitor
jnk
inhibitor
mtor
inhibitor
rapamycin
nm
presence
absence
diosgenin
cell
harvest
immunoblotting
measure
level
fas
protein
cell
incubate
jnk
inhibitor
presence
absence
diosgenin
cell
harvest
parp
cleavage
assess
western
blot
analysis
view
within
article
effect
kinase
inhibitor
fas
expression
breast
cancer
cell
far
study
examine
whether
inhibition
fas
expression
diosgenin
mediate
modulation
akt
mtor
jnk
phosphorylation
show
treat
cell
inhibitor
mtor
rapamycin
significantly
reduce
fas
protein
expression
treatment
jnk
inhibitor
render
diosgenin
unable
suppress
fas
expression
also
inhibit
diosgenin
ability
induce
apoptosis
taken
together
suggest
diosgenin
inhibit
fas
expression
repress
phosphorylation
akt
mtor
activate
jnk
phosphorylation
cell
diosgenin
enhance
chemosensitivity
breast
cancer
cell
previous
study
show
overexpression
confer
resistance
chemotherapeutic
agent
breast
cancer
cell
inhibition
fas
sensitize
cancer
cell
paclitaxel
diosgenin
inhibit
fas
expression
cancer
cell
thus
evaluate
whether
diosgenin
sensitize
cancer
cell
chemotherapeutic
agent
paclitaxel
determine
effect
diosgenin
cytotoxicity
treat
cell
increase
concentration
paclitaxel
nm
absence
presence
diosgenin
treatment
cell
viability
measure
mtt
assay
show
diosgenin
enhance
cytotoxicity
cell
cell
taken
together
datum
show
diosgenin
specifically
enhance
cytotoxicity
induce
paclitaxel
cancer
cell
express
cancer
cell
image
image
diosgenin
enhance
growth
inhibition
cancer
cell
cell
treat
either
vehicle
diosgenin
combination
indicate
concentration
paclitaxel
cell
viability
measure
mtt
assay
view
within
article
discussion
practice
dietary
agent
treat
disease
well
know
time
recently
light
focused
steroid
like
compound
present
number
dietary
agent
study
demonstrate
among
test
naturally
occur
steroid
diosgenin
show
much
effective
inhibition
fas
expression
cancer
cell
analysis
indicate
diosgenin
preferentially
inhibit
proliferation
cancer
cell
addition
diosgenin
specifically
sensitize
cancer
cell
cytotoxicity
interestingly
diosgenin
solasodine
effective
inhibition
proliferation
cell
tomatidine
suggest
presence
absence
may
lead
major
modification
biological
activity
cell
result
will
provide
new
information
study
functional
group
future
hypothesized
increase
exposure
exogenous
estrogen
dietary
phytoestrogen
may
reduce
breast
cancer
risk
main
class
isoflavone
lignan
genistein
example
show
inhibit
growth
wide
range
cancer
cell
diosgenin
important
compound
pharmaceutical
industry
natural
source
steroidal
hormone
attention
recently
study
suggest
absorb
gut
activity
effect
diosgenin
demonstrate
mediate
disruption
homeostasis
inhibition
activation
modulation
activity
demonstrate
first
time
fatty
acid
synthesis
require
cytotoxicity
cancer
cell
cancer
cell
overexpress
fas
thus
sensitive
treatment
target
fas
concept
oncogene
suggest
cancer
cell
often
physiologically
dependent
continue
activity
specific
activate
overexpressed
oncogene
maintenance
malignant
phenotype
provide
heel
tumor
cancer
therapy
fas
overexpressed
cancer
cell
reasonable
assume
diosgenin
suppress
survival
cancer
cell
activation
akt
signaling
demonstrate
upregulate
expression
fas
various
cell
type
include
breast
prostate
ovarian
cancer
cell
study
phosphorylation
akt
suppress
diosgenin
cell
overexpress
furthermore
expression
fas
also
inhibit
inhibitor
show
regulate
fas
expression
mechanism
give
akt
either
activate
negatively
regulate
pten
investigation
possible
involvement
pten
akt
currently
progress
noteworthy
result
illustrate
mtor
signaling
play
important
role
upregulation
fas
cancer
cell
consistent
recent
report
clear
association
mtor
activation
overexpression
breast
cancer
activation
signaling
pathway
associate
poor
prognosis
many
report
suggest
mtor
pathway
play
important
role
susceptibility
chemopreventive
chemotherapeutic
agent
kill
cancer
cell
accordance
concept
diosgenin
sensitize
cytotoxicity
cancer
cell
kinase
jnk
pathway
represent
one
map
kinase
activate
cytokine
exposure
environmental
stress
jnk
report
role
induction
apoptosis
also
implicate
enhance
cell
survival
proliferation
interestingly
apoptosis
find
relate
activation
jnk
phosphorylation
increase
caspase
activity
support
role
jnk
facilitate
apoptosis
result
suggest
jnk
may
play
role
fas
suppression
apoptosis
datum
show
contrast
suppress
fas
expression
inhibit
jnk
signaling
also
demonstrate
laboratory
taken
together
alteration
jnk
activity
may
lead
change
fas
level
cell
survival
role
jnk
regulation
fas
expression
apoptosis
still
controversial
merit
far
investigation
conclusion
elevate
fas
expression
associate
overexpression
regard
poor
prognostic
marker
breast
cancer
cell
provide
experimental
evidence
first
time
demonstrate
diosgenin
suppress
fas
expression
modulate
akt
mtor
jnk
phosphorylation
cancer
cell
result
highlight
potential
diosgenin
unique
chemotherapeutic
modulator
prevention
treatment
cancer
acknowledgement
author
like
thank
hung
generous
provide
cancer
cell
line
study
support
national
science
council
nsc
isolated
local
recurrence
ilr
mastectomy
conservative
surgery
cs
associate
increase
risk
distant
metastasis
death
breast
cancer
ilr
may
source
distant
metastasis
marker
systemic
dissemination
occur
initial
number
factor
interval
initial
tumor
lymph
node
stage
patient
age
extent
histology
recurrent
tumor
identify
may
influence
risk
mortality
local
recurrence
patient
invasive
breast
breast
cancer
specific
event
uncommon
much
five
year
salvage
treatment
local
recurrence
however
author
publish
year
result
multivariate
analysis
examine
factor
affect
outcome
three
study
evaluate
survival
local
relapse
respect
initial
surgical
purpose
study
evaluate
survival
patient
salvage
treatment
ilr
respect
primary
surgical
treatment
prognostic
factor
material
method
january
december
patient
stage
ii
breast
cancer
treat
consecutively
modify
radical
mastectomy
cs
national
institute
oncology
detail
regard
baseline
characteristic
adjuvant
treatment
describe
one
hundred
twenty
four
patient
subsequent
ilr
mastectomy
cs
ilr
define
appearance
histologically
verify
new
breast
tumor
invasive
adenocarcinoma
chest
wall
surgical
flap
scar
operate
breast
parenchyma
overlying
skin
least
three
month
prior
regional
relapse
distant
metastasis
ipsilateral
relapse
classify
either
new
primary
np
tumor
true
local
recurrence
tr
np
diagnose
recurrence
different
primary
tumor
respect
histological
type
recurrence
location
different
anatomical
clearly
distinct
location
salvage
treatment
consist
surgery
radiation
chemotherapy
hormone
therapy
combination
following
cs
decision
repeat
wide
excision
mastectomy
make
patient
treat
surgical
oncologist
generally
wide
tumor
excision
suggest
technically
feasible
skin
involvement
sixteen
patient
salvage
surgery
consider
inoperable
due
disease
extension
affect
whole
breast
skin
lesion
table
type
salvage
treatment
conservative
table
radiotherapy
hormonal
therapy
view
within
article
survival
analysis
carry
kaplan
meier
time
ilr
calculate
initial
surgery
occurrence
ilr
time
second
local
recurrence
calculate
salvage
surgery
occurrence
second
local
recurrence
survival
calculate
date
histological
diagnosis
ilr
death
breast
cancer
last
actuarial
curve
compare
test
difference
consider
significant
independent
prognostic
significance
variable
prove
significant
factor
univariate
analysis
test
proportional
hazard
regression
model
describe
estimate
model
give
relative
risk
rr
confidence
interval
ci
separate
analysis
also
perform
original
surgical
treatment
group
mastectomy
cs
investigate
possibility
difference
prognostic
factor
either
treatment
result
initial
presentation
ilr
invasive
three
situ
cancer
cs
patient
median
time
initial
surgery
ilr
month
range
month
median
time
survive
patient
onset
ilr
month
range
month
last
patient
alive
two
distant
disease
patient
die
breast
cancer
patient
die
internal
disease
cancer
actuarial
rate
year
survival
ilr
mastectomy
patient
much
advance
initial
stage
cs
patient
axillary
lymph
node
metastasis
primary
respectively
table
show
time
initial
surgery
local
recurrence
subset
patient
interval
significantly
short
patient
subsequent
distant
failure
follow
local
recurrence
node
positive
primary
inoperable
local
recurrence
grade
recurrent
tumor
table
delay
initial
surgery
local
recurrence
month
patientsmedian
mean
subsequent
distant
metastasis
age
first
initial
tumor
initial
lymph
node
pn
pn
initial
conservative
adjuvant
operability
recurrent
tumor
table
test
view
within
article
prognostic
variable
patient
result
univariate
analysis
test
prognostic
variable
show
table
adjuvant
radiotherapy
seven
potential
prognostic
variable
significantly
relate
survival
local
recurrence
patient
inoperable
local
recurrence
die
within
year
year
survival
year
survival
rate
also
poor
young
node
positive
woman
short
time
ilr
multivariate
analysis
inoperable
recurrence
rr
young
age
initial
diagnosis
rr
short
time
recurrence
rr
remain
independent
negative
predictor
survival
axillary
lymph
node
stage
initial
diagnosis
show
borderline
significance
table
year
specific
survival
follow
isolate
local
recurrence
type
initial
surgery
prognostic
factor
patient
patientssurvival
age
first
initial
tumor
initial
lymph
node
stage
pn
pn
initial
conservative
adjuvant
time
local
recurrence
operability
recurrent
tumor
table
year
survival
view
within
article
table
multivariate
proportional
hazard
model
death
follow
local
recurrence
age
first
treatment
initial
tumor
stage
initial
lymph
node
stage
pn
negative
initial
surgery
conservative
surgery
time
local
relapse
operability
recurrence
operable
recurrent
tumor
grade
table
rr
relative
risk
ci
confidence
interval
view
within
article
second
step
multivariate
analysis
type
initial
surgery
operability
local
recurrence
include
model
potential
independent
risk
factor
operability
recurrence
affect
whole
breast
chest
wall
surgical
flap
recurrence
skin
infiltration
may
subject
operator
skill
obvious
marker
distant
dissemination
follow
factor
increase
risk
death
treatment
ilr
positive
lymph
node
stage
rr
ci
short
time
month
ilr
rr
ci
combination
variable
strengthen
prognostic
value
year
survival
treatment
ilr
node
negative
stage
month
ilr
node
positive
stage
month
ilr
respectively
prognostic
variable
mastectomy
patient
patient
die
breast
cancer
rate
year
survival
patient
ilr
develop
year
follow
initial
operation
result
univariate
analysis
test
prognostic
variable
show
table
woman
inoperable
ilr
die
within
year
year
survival
number
young
patient
risk
insufficient
give
reliable
estimate
year
year
survival
rate
year
survival
also
poor
patient
lymph
node
metastasis
short
time
local
relapse
respectively
lymph
node
negative
stage
single
scar
recurrence
predict
relatively
good
survival
year
respectively
patient
single
scar
recurrence
initial
lymph
node
negative
stage
excellent
survival
rate
year
year
survival
rate
surgery
ilr
patient
initial
lymph
node
negative
stage
month
ilr
operable
patient
group
patient
initial
lymph
node
metastasis
month
ilr
poor
survival
rate
year
table
year
specific
survival
isolate
local
recurrence
prognostic
factor
mastectomy
patient
patientssurvival
age
first
initial
tumor
initial
lymph
node
pn
pn
adjuvant
time
local
operability
type
operable
single
recurrent
tumor
table
year
survival
rate
year
survival
rate
multiple
thoracic
wall
view
within
article
prognostic
variable
cs
patient
patient
die
breast
cancer
rate
year
survival
patient
ilr
develop
year
follow
initial
operation
np
develop
node
negative
patient
four
patient
inoperable
ilr
affect
whole
breast
diffuse
skin
infiltration
average
recurrent
tumor
size
salvage
excision
mastectomy
patient
mm
range
mm
mm
range
mm
respectively
result
univariate
analysis
test
prognostic
factor
show
table
age
time
ilr
type
recurrence
operability
recurrence
size
recurrence
significant
impact
survival
type
salvage
surgery
mastectomy
repeat
lumpectomy
significant
impact
survival
neither
patient
cm
year
estimate
survival
rate
patient
cm
year
estimate
survival
rate
local
recurrence
np
develop
month
initial
surgery
median
time
ilr
np
tr
month
respectively
older
patient
year
np
good
survival
rate
follow
surgery
ilr
year
survival
rate
year
young
patient
year
np
three
patient
belong
group
table
year
specific
survival
isolate
local
recurrence
prognostic
factor
conservative
surgery
patient
patientssurvival
age
first
initial
tumor
initial
lymph
node
pn
pn
adjuvant
time
local
type
new
operability
size
operable
type
salvage
wide
recurrent
tumor
table
one
tumor
bed
recurrence
ductal
carcinoma
situ
two
new
primary
paget
disease
affecting
whole
breast
skin
infiltration
year
survival
view
within
article
second
local
recurrence
sixteen
patient
never
free
local
disease
systemic
treatment
inoperable
ilr
patient
treat
surgery
initial
local
recurrence
develop
second
local
recurrence
mean
time
second
local
recurrence
month
range
month
second
local
recurrence
increase
risk
death
rr
ci
year
survival
follow
treatment
ilr
without
second
local
recurrence
respectively
rate
second
local
recurrence
follow
initial
mastectomy
cs
respectively
mastectomy
patient
half
second
local
recurrence
synchronous
event
distant
relapse
come
distant
relapse
cs
patient
rate
second
local
recurrence
follow
salvage
excision
mastectomy
respectively
rate
second
local
recurrence
follow
salvage
surgery
tr
np
respectively
local
recurrence
size
cm
cm
significant
impact
rate
second
local
recurrence
second
local
recurrence
rate
patient
cm
recurrence
treat
salvage
excision
mastectomy
respectively
patient
cm
recurrence
rate
salvage
modality
discussion
series
patient
stage
ii
breast
cancer
develop
ilr
mastectomy
cs
year
actuarial
rate
survival
event
study
pool
result
mastectomy
cs
patient
report
survival
rate
similar
study
van
year
survival
rate
local
recurrence
similar
mastectomy
cs
patient
respectively
series
year
survival
significantly
well
cs
patient
respectively
study
characteristic
mastectomy
cs
group
similar
respect
initial
prognostic
factor
series
mastectomy
patient
significantly
much
advance
initial
stage
multivariate
analysis
type
initial
surgery
remain
independent
predictor
survival
multivariate
analysis
l
outcome
patient
also
affect
type
initial
surgery
match
pair
analysis
janni
primary
surgical
treatment
modality
marginal
statistical
significance
year
survival
chest
wall
recurrence
respectively
series
time
local
recurrence
operability
local
recurrence
age
remain
independent
predictor
survival
initial
axillary
lymph
node
status
show
borderline
significance
series
institut
short
interval
month
old
age
diagnosis
primary
tumor
high
histologic
grade
primary
tumor
pool
result
two
randomized
short
time
local
recurrence
initial
axillary
lymph
node
metastasis
increase
risk
recurrence
mortality
match
pair
study
janni
initial
lymph
node
status
time
local
recurrence
much
significant
prognostic
factor
subsequent
survival
local
recurrence
study
combination
two
variable
strengthen
prognostic
value
year
survival
treatment
ilr
node
negative
stage
month
ilr
node
positive
stage
month
ilr
respectively
survival
rate
recurrence
report
survival
rate
patient
invasive
recurrence
case
survival
rate
find
patient
old
age
initial
diagnosis
long
interval
ilr
np
operable
ilr
much
favorable
prognosis
much
frequently
report
prognostic
factor
survival
local
recurrence
time
extent
recurrence
also
find
significant
prognostic
study
patient
undergo
surgery
local
recurrence
high
risk
death
compare
patient
subject
surgery
patient
inoperable
recurrence
die
within
year
report
survival
year
patient
small
cm
recurrence
according
analysis
year
survival
cm
recurrence
study
type
salvage
surgery
mastectomy
repeat
wide
tumor
excision
significant
predictor
survival
patient
cm
recurrence
year
survival
salvage
modality
base
publish
survival
result
mastectomy
appear
however
patient
recurrence
already
fail
cs
safe
selection
criterion
repeat
lumpectomy
well
define
patient
rate
second
local
recurrence
follow
salvage
excision
mastectomy
respectively
study
rate
second
local
recurrence
repeat
lumpectomy
report
high
study
show
non
significant
tendency
patient
subject
salvage
mastectomy
well
local
control
compare
patient
subject
repeat
however
repeat
lumpectomy
regard
survival
mastectomy
irreversible
therefore
motivate
patient
small
cm
recurrence
repeat
cs
might
carry
ipsilateral
breast
tumor
recurrence
represent
two
distinct
type
entity
tr
np
patient
np
generally
much
favorable
series
year
survival
rate
ilr
tr
np
smith
report
similar
year
survival
rate
respectively
patient
np
develop
month
primary
surgery
find
two
indicator
good
prognosis
patient
old
age
year
np
good
survival
rate
follow
salvage
surgery
ilr
year
author
find
difference
prognosis
two
publish
proportion
np
vary
patient
rate
lack
standardized
classification
rule
might
explain
controversy
chest
wall
recurrence
mastectomy
generally
prognosis
survival
possible
patient
survival
rate
year
find
patient
negative
initial
lymph
node
stage
long
time
ilr
single
scar
recurrence
operable
ilr
much
favorable
prognosis
node
negative
patient
single
scar
recurrence
excellent
survival
rate
year
much
commonly
report
prognostic
factor
survival
local
recurrence
mastectomy
patient
time
local
recurrence
initial
lymph
node
chagpar
demonstrate
initially
patient
develop
ilr
month
diagnosis
primary
tumor
favorable
prognosis
observation
year
survival
rate
subset
patient
study
year
survival
rate
local
recurrence
patient
initial
lymph
node
metastasis
month
ilr
patient
rate
second
chest
wall
recurrence
salvage
surgery
chagpar
report
result
young
woman
early
invasive
breast
cancer
generally
poor
prognosis
treat
cs
high
risk
local
high
frequency
local
recurrence
among
young
patient
represent
problem
study
find
survival
significantly
different
young
woman
undergo
cs
compare
subject
multivariate
analysis
age
remain
independent
predictor
mortality
young
year
patient
poor
survival
rate
year
study
pool
result
mastectomy
cs
patient
young
age
significant
negative
predictor
find
median
time
ilr
short
subsequent
distant
metastasis
aggressive
tumor
short
time
median
month
ilr
observe
patient
inoperable
local
recurrence
none
survive
year
salvage
therapy
interval
initial
surgery
ilr
also
relatively
short
median
month
young
node
positive
patient
time
ilr
long
median
month
cs
patient
np
tumor
excellent
survival
rate
year
shorten
interval
event
suggest
distant
metastases
already
exist
time
initial
conclusion
current
study
demonstrate
patient
develop
ilr
mastectomy
cs
early
invasive
breast
cancer
long
time
local
recurrence
initial
node
negative
stage
old
age
confer
good
prognosis
inoperable
ilr
initial
node
positive
stage
short
time
ilr
indicator
systemic
dissemination
type
initial
surgery
independent
predictor
survival
node
negative
mastectomy
patient
single
scar
recurrence
good
estimate
survival
patient
undergo
cs
repeat
complete
tumor
excision
deleterious
effect
survival
np
confer
significantly
well
survival
tr
conflict
interest
statement
none
declare
breast
cancer
much
common
type
cancer
woman
much
common
death
woman
diagnosis
intervention
key
successful
therapy
whereby
drug
treatment
mostly
based
anthracycline
taxane
commonly
precede
follow
surgery
reduce
tumor
bulk
prevent
metastatic
spread
growth
respectively
however
breast
cancer
become
metastatic
response
agent
often
markedly
reduce
possibly
consequence
widespread
adjuvant
therapy
novel
treatment
regimen
incorporating
agent
trastuzumab
gemcitabine
capecitabine
show
potential
overcome
problem
restore
tumor
cell
sensitivity
anthracycline
taxane
modulation
signaling
pathway
may
provide
different
complementary
approach
clinical
management
disease
present
study
focuses
role
play
signal
transducer
activator
transcription
response
highly
metastatic
human
breast
adenocarcinoma
cell
line
doxorubicin
dox
drug
anthracycline
family
belong
family
latent
cytoplasmic
transcription
factor
activate
phosphorylation
critical
tyrosine
residue
dimerization
nuclear
translocation
upon
binding
cytokine
growth
factor
membrane
receptor
number
experimental
finding
support
hypothesis
role
oncogenesis
tumor
progression
based
ability
transactivate
number
gene
whose
product
involve
cell
proliferation
survival
invasion
metastasis
angiogenesis
recent
review
see
constitutive
activation
frequent
occurrence
breast
tumor
demonstrate
number
breast
cancer
cell
line
possibly
consequence
overexpression
constitutive
activation
upstream
receptor
egfr
src
tyrosine
kinase
thus
emerge
important
target
cancer
therapy
high
level
activity
also
find
predict
intrinsic
drug
resistance
chemotherapy
possibly
upregulation
antiapoptotic
factor
survivin
inhibition
evaluate
possible
strategy
increase
tumor
cell
response
cytotoxic
agent
however
conflict
result
report
suggest
outcome
may
highly
dependent
tumor
type
drug
consider
result
present
study
confirm
finding
author
indicate
metastatic
breast
cancer
cell
exhibit
increase
baseline
level
activity
far
enhance
follow
dox
treatment
inhibition
cell
address
three
different
approach
inhibition
upstream
janus
kinase
jak
major
tyrosine
kinase
involve
activation
transfection
form
treatment
satraplatin
platinum
derivative
similar
compound
class
inhibit
activity
three
approach
increase
proapoptotic
effect
dox
albeit
different
extent
latter
two
also
interfere
antiapoptotic
protein
expression
suggest
inhibitor
activity
might
prove
valuable
addition
therapeutic
protocol
currently
clinical
management
metastatic
breast
cancer
material
reagent
standard
chemical
cell
culture
reagent
purchase
sigma
aldrich
milan
italy
unless
otherwise
indicate
purchase
alexis
corporation
switzerland
doxorubicin
dox
kindly
provide
nerviano
medical
science
nerviano
italy
synthesize
several
step
via
homologous
pt
ii
derivative
accord
publish
procedure
follow
antibody
rabbit
polyclonal
santa
cruz
biotechnology
santa
cruz
usa
rabbit
polyclonal
cell
signaling
technology
danvers
ma
usa
rabbit
polyclonal
abcam
cambridge
uk
rabbit
polyclonal
medical
biological
laboratory
japan
cell
line
treatment
human
breast
adenocarcinoma
cell
line
estrogen
estrogen
metastatic
harboring
mutant
form
well
overexpression
egf
receptor
obtain
atcc
rockville
md
usa
maintain
dmem
supplement
fetal
bovine
serum
fbs
milan
italy
atmosphere
preparation
cell
lysate
immunoprecipitation
immunoblotting
intracellular
level
total
assess
immunoprecipitation
western
blot
baseline
condition
follow
different
treatment
cell
lysed
buffer
contain
nacl
mm
naf
mm
edta
mm
egta
mm
sodium
pyrophosphate
mm
tris
hcl
mm
ph
pmsf
mm
mm
oxide
mm
protease
inhibitor
cocktail
sigma
protein
concentration
determine
acid
assay
pierce
rockford
usa
protein
incubate
overnight
rabbit
polyclonal
antibody
follow
morning
immune
complex
immunoprecipitated
follow
incubation
protein
immunoprecipitates
dissolve
laemmli
sample
buffer
separate
sds
page
transfer
onto
immobilon
membrane
millipore
bedford
ma
usa
western
blot
analysis
perform
standard
technique
rabbit
polyclonal
antibody
total
protein
level
obtain
incubate
membrane
rabbit
polyclonal
antibody
intracellular
level
survivin
assess
western
blot
total
cell
lysate
fifty
micrograms
protein
separate
transfer
previously
describe
pvdf
membrane
incubate
overnight
rabbit
polyclonal
antibody
verify
equal
protein
loading
blot
reprobed
mouse
monoclonal
antibody
sigma
aldrich
however
western
blot
perform
immunoprecipitates
therefore
experiment
repeat
time
order
assess
reliability
reproducibility
result
obtain
immunoreactive
band
visualize
secondary
antibody
supersignal
west
pico
substrate
system
pierce
biotechnology
rockford
usa
accord
manufacturer
instruction
cytotoxicity
assay
mtt
assay
assess
antiproliferative
effect
dox
briefly
cell
ml
seed
onto
well
plate
allow
grow
subsequently
expose
dox
mtt
bromide
mg
ml
pbs
add
well
reduction
mtt
viable
cell
measure
nm
universal
microplate
reader
instruments
usa
combination
treatment
dox
satraplatin
cell
treat
simultaneously
different
dox
concentration
fix
satraplatin
concentration
approximately
corresponding
value
concentration
yield
cell
survival
assess
preliminary
experiment
cell
end
experimental
period
cell
process
mtt
assay
describe
flow
cytometric
analysis
apoptotic
cell
following
different
treatment
cell
harvest
wash
saline
pbs
fix
ethanol
min
room
temperature
far
wash
pbs
dna
stain
ml
propidium
iodide
pbs
presence
ml
room
temperature
min
cell
sample
cell
analyzed
facscalibur
flow
cytometer
becton
dickinson
franklin
nj
usa
equip
mw
nm
argon
ion
laser
datum
process
cellquest
software
becton
dickinson
fluorescent
emission
collect
nm
filter
least
event
analyzed
sample
percentage
apoptotic
cell
sample
determine
based
peak
detect
histograms
vector
transfection
cell
transiently
transfected
expression
plasmid
contain
cdna
encode
peptide
form
replace
expression
vector
originally
provide
nagata
university
osaka
medical
school
control
cell
generous
gift
molecular
oncology
university
osaka
medical
school
grow
cell
harvest
transfected
dna
system
uk
condition
optimized
accord
manufacturer
instruction
experiment
perform
start
transfection
efficiency
persistence
transfection
check
immunoprecipitation
western
blot
analysis
cell
lysate
describe
subsequently
thereafter
statistical
analysis
statistical
analysis
datum
perform
graphpad
prism
software
graphpad
san
diego
usa
value
concentration
yield
cell
survival
estimate
vitro
dose
response
curve
regression
analysis
difference
analyzed
student
test
independent
sample
analysis
variance
tukey
multiple
comparison
much
two
experimental
group
involve
analysis
drug
interaction
analyzed
software
cambridge
uk
develop
chou
effect
dox
cell
show
value
estimate
dose
response
curve
obtain
follow
exposure
dox
well
percentage
apoptotic
cell
induce
two
cell
line
exposure
dox
datum
indicate
cell
slightly
significantly
much
resistant
dox
add
characteristic
cell
metastatic
trait
mutation
egf
receptor
overexpression
define
highly
aggressive
phenotype
image
effect
dox
cell
survival
apoptosis
phosphorylation
value
estimate
dose
response
curve
obtain
follow
exposure
different
dox
concentration
percentage
apoptotic
cell
determine
follow
exposure
dox
mean
independent
experiment
air
apoptosis
treat
untreated
cell
western
blot
cell
extract
immunoprecipitated
obtain
antibody
follow
exposure
dox
view
within
article
show
protein
level
cell
expose
dox
untreated
cell
exhibit
high
baseline
level
form
untreated
cell
confirm
presence
constitutive
activation
exposure
dox
modify
level
either
cell
line
whereas
increase
much
notably
cell
indicate
drug
treatment
far
enhance
activation
effect
treatment
show
effect
exposure
expression
activation
indicate
even
concentration
tyrphostin
partially
inhibit
phosphorylation
activation
leave
total
protein
level
show
simultaneous
exposure
dox
induce
significant
albeit
modest
increase
proapoptotic
effect
observe
concentration
dox
alone
image
effect
level
effect
proapoptotic
action
dox
mean
independent
control
dox
view
within
article
effect
transfection
vector
show
level
cell
follow
transfection
vector
encode
negative
dominant
form
empty
vector
protein
extract
transfected
cell
prepare
start
transfection
every
thereafter
observe
total
protein
level
unmodified
cell
line
time
point
level
also
unmodified
cell
whereas
decrease
become
undetectable
level
also
assess
transfected
cell
line
unaltered
datum
show
indicate
cell
much
sensitive
cytotoxic
effect
dox
cell
term
percentage
apoptotic
cell
different
drug
exposure
time
value
exposure
dox
response
cell
dox
similar
exhibit
parental
cell
line
nm
respectively
finally
show
survivin
protein
level
decrease
concomitantly
level
cell
unmodified
cell
image
level
cell
different
time
follow
transfection
baseline
determination
perform
induction
apoptosis
dox
cell
mean
independent
experiment
datum
normalize
percent
apoptotic
cell
observe
untreated
sample
time
value
obtain
cell
mean
independent
survivin
protein
level
view
within
article
effect
treatment
satraplatin
satraplatin
find
decrease
cell
proliferation
estimate
value
combination
dox
satraplatin
latter
concentration
approximately
correspond
value
show
significantly
reduce
level
exposure
cell
satraplatin
significantly
enhance
antiproliferative
effect
dox
indicate
dramatic
decrease
value
analysis
interaction
dox
satraplatin
perform
accord
model
develop
chou
yield
ci
value
dox
combine
satraplatin
respectively
indicate
strong
synergy
two
agent
result
confirm
datum
induction
apoptosis
show
dox
satraplatin
combination
yield
significantly
high
percentage
apoptotic
cell
either
agent
alone
accordingly
treatment
satraplatin
markedly
reduce
protein
level
however
reduction
observe
survivin
expression
follow
satraplatin
treatment
image
effect
satraplatin
dox
percentage
apoptotic
cell
observe
follow
exposure
dox
survivin
level
unless
otherwise
indicate
concentration
satraplatin
mean
independent
experiment
dox
alone
view
within
article
discussion
increase
body
evidence
cell
line
mouse
model
human
tissue
implicate
constitutive
activation
breast
cancer
oncogenesis
review
result
preliminary
experiment
compare
level
antiproliferative
effect
dox
metastatic
cell
indicate
activation
also
associate
reduce
response
tumor
drug
treatment
interestingly
exposure
dox
induce
far
mark
enhancement
baseline
level
cell
whereas
change
observe
cell
suggest
activation
may
represent
early
defense
mechanism
lead
impair
response
cytotoxic
treatment
may
argue
observe
difference
percent
apoptotic
cell
two
cell
line
although
significant
trifling
compare
induce
acquire
resistance
level
however
increasingly
recognize
even
apparently
trifling
reduction
drug
effectiveness
lead
therapeutic
failure
encounter
clinic
datum
agreement
report
real
parental
breast
cancer
cell
metastatic
derived
show
activation
pathway
reduce
response
paclitaxel
dox
metastatic
cell
line
number
antiapoptotic
gene
identify
direct
indirect
target
transcriptional
activity
much
notably
encode
antiapoptotic
family
member
survivin
thus
activation
contribute
breast
cancer
cell
resistance
potential
target
chemosensitizing
strategy
verify
hypothesis
focused
different
intervention
aim
block
activation
cell
constitutive
activation
also
much
likely
drive
egfr
overexpression
first
approach
based
inhibition
janus
kinase
probably
major
upstream
activator
stat
protein
tyrphostin
derivative
compound
show
reduce
level
induce
apoptosis
variety
cancer
cell
line
well
sensitize
lymphoma
multiple
myeloma
cell
host
cytotoxic
agent
assess
sensitize
effect
independent
direct
cytotoxic
effect
decide
concentration
per
induce
apoptosis
cell
still
able
partially
abrogate
phosphorylation
condition
modest
effect
dox
observe
indicate
partial
inhibition
activation
sufficient
jeopardize
antiapoptotic
function
alternatively
jak
simultaneously
phosphorylate
substrate
besides
turn
might
affect
survival
breast
cancer
cell
inhibit
jak
function
much
notably
main
target
action
involve
well
phosphorylation
since
generally
report
play
proapoptotic
role
review
see
concomitant
inhibition
mask
effect
induce
inhibition
achieve
much
complete
phosphorylation
without
interfere
function
transfected
cell
plasmid
construct
encode
form
transfected
cell
indeed
exhibit
decrease
level
become
undetectable
accompany
concurrent
decrease
survivin
protein
level
expect
reduction
antiapoptotic
protein
expression
transfected
cell
also
sensitize
cytotoxic
effect
dox
indicate
significant
decrease
follow
exposure
dox
significant
increase
percentage
apoptotic
cell
death
induce
dox
exposure
post
transfection
compare
cell
thus
interfere
constitutive
activation
seem
viable
approach
breast
cancer
cell
dox
especially
function
show
many
normal
cell
tissue
thereby
reduce
risk
severe
side
toxicity
approach
take
advantage
several
small
molecule
inhibitor
identify
q
resveratrol
specifically
design
target
interestingly
turkson
recently
report
novel
platinum
compound
able
interfere
transcriptional
activity
along
line
decide
test
capability
chemosensitizing
property
satraplatin
orally
active
platinum
iv
drug
already
well
advance
clinical
trial
phase
iii
activity
prostate
cancer
study
satraplatin
concentration
induce
inhibition
cell
growth
cell
follow
exposure
concentration
observe
mark
inhibition
phosphorylation
well
protein
level
whereas
survivin
level
modify
treatment
last
observation
rather
hard
explain
view
inhibition
survivin
expression
observe
cell
transfected
form
one
possible
explanation
demonstrate
frank
coworkers
neither
survivin
gene
direct
target
transcriptional
activity
thus
transcription
two
gene
involve
transcription
factor
may
different
requirement
activation
turn
emphasize
satraplatin
contrast
transfection
completely
abolish
phosphorylation
much
interestingly
spite
unaltered
survivin
level
satraplatin
induce
dramatic
increase
dox
cytotoxicity
cell
evidence
value
percentage
apoptotic
cell
indicate
two
drug
highly
synergistic
impressive
effect
role
play
currently
investigation
laboratory
datum
indicate
satraplatin
owing
much
antitumor
activity
vivo
platinum
ii
metabolite
rapidly
form
upon
oral
administration
exhibit
modest
intrinsic
cytotoxic
activity
vitro
may
exert
yet
chemosensitizing
effect
breast
cancer
cell
thus
vivo
effect
administration
drug
breast
tumor
constitutively
active
may
well
worthy
far
investigation
conclude
result
confirm
role
intrinsic
resistance
dox
exhibit
metastatic
breast
cancer
cell
indicate
transcription
factor
valid
target
strategy
aim
sensitize
tumor
effect
chemotherapy
addition
suggest
possible
novel
therapeutic
application
satraplatin
acknowledgement
financial
support
italian
ministry
university
research
breast
cancer
estrogen
receptor
expression
marker
hormone
responsiveness
present
indicate
likely
success
endocrine
manipulation
form
treatment
much
commonly
therapeutic
endocrine
agent
breast
cancer
target
significance
progesterone
receptor
pr
primarily
derive
fact
pr
synthesize
response
provide
evidence
intact
pathway
regard
relative
prognostic
importance
pr
expression
breast
cancer
numerous
study
perform
investigate
relationship
receptor
breast
cancer
prognosis
result
inconsistent
pr
well
interpretation
complicate
adjuvant
endocrine
therapy
chemotherapy
however
one
study
include
patient
receive
systemic
adjuvant
therapy
assess
relationship
pr
expression
prognosis
small
significant
difference
disease
dfs
survival
find
year
tumor
compare
tumor
study
similar
result
find
tumor
survival
advantage
compare
tumor
year
furthermore
study
note
trend
well
clinical
outcome
high
dfs
versus
dfs
tumor
pr
level
note
high
dfs
versus
dfs
tumor
level
thus
give
unknown
whether
pr
expression
important
marker
breast
cancer
prognosis
fact
sensitive
specific
quantitative
assay
measurement
widely
clinical
practice
important
investigate
relationship
outcome
assessment
prognosis
strong
correlative
survival
breast
cancer
stage
diagnosis
remove
confound
introduce
adjuvant
endocrine
treatment
chemotherapy
furthermore
stage
breast
cancer
diagnosis
much
widely
method
predict
prognosis
patient
breast
cancer
regional
lymph
node
metastasis
tumor
size
two
strong
correlate
survival
patient
without
obvious
distant
metastasis
correlation
pr
expression
breast
tumor
size
status
regional
lymph
node
metastasis
examine
independently
two
study
show
pr
expression
individually
inversely
associate
tumor
size
association
expression
significant
small
study
however
important
mention
one
study
neither
pr
expression
find
associate
tumor
size
patient
distant
metastatic
disease
moreover
study
assess
association
expression
combination
pr
expression
regional
nodal
status
metastasis
none
study
find
expression
correlate
regional
lymph
node
metastasis
find
pr
expression
combination
pr
expression
alone
negatively
correlate
regional
lymph
node
metastasis
study
assess
relationship
thus
although
datum
limited
result
study
provide
support
inverse
association
pr
expression
breast
tumor
size
pr
expression
regional
lymph
node
metastasis
result
possible
significant
inverse
association
pr
expression
possibly
expression
stage
breast
cancer
diagnosis
since
include
tumor
size
status
regional
lymph
node
metastasis
well
presence
absence
distant
metastasis
according
thorough
literature
review
several
study
investigate
relationship
pr
expression
stage
breast
cancer
diagnosis
study
indicate
pr
expression
individually
associate
stage
breast
cancer
diagnosis
however
three
study
assess
association
pr
expression
individually
stage
breast
cancer
diagnosis
one
study
four
stage
grouping
invasive
breast
cancer
define
american
joint
committee
cancer
ajcc
collapse
two
group
ii
versus
iii
iv
reduce
accuracy
stage
represent
anatomic
extent
breast
cancer
addition
pr
expression
report
either
positive
negative
rather
grade
level
expression
statistical
reason
reduce
chance
find
significant
inverse
association
pr
expression
perhaps
expression
stage
breast
cancer
diagnosis
adequate
testing
relationship
study
far
jeopardize
account
histology
histological
grade
extent
differentiation
tumor
assess
lethality
well
patient
characteristic
influence
time
diagnosis
since
breast
cancer
stage
relate
tumor
growth
rate
metastatic
potential
duration
existence
thus
since
pr
expression
may
stronger
inverse
association
stage
breast
cancer
expression
conduct
study
include
woman
invasive
ductal
carcinoma
breast
determine
relationship
pr
expression
stage
breast
cancer
diagnosis
strong
correlate
survival
affect
intervene
endocrine
therapy
chemotherapy
study
design
also
account
patient
breast
tumor
characteristic
previously
note
influence
stage
breast
cancer
diagnose
material
study
design
study
involve
woman
invasive
ductal
carcinoma
breast
purpose
study
determine
association
breast
tumor
pr
expression
study
outcome
stage
breast
cancer
diagnosis
study
conduct
southwestern
medical
center
southwestern
institutional
review
board
approve
protocol
inform
consent
obtain
study
subject
prior
collection
clinical
datum
breast
tumor
specimen
select
ductal
carcinoma
case
represent
majority
breast
cancer
eliminate
variable
effect
different
breast
tumor
histology
may
stage
breast
cancer
diagnosis
study
covariate
select
age
race
ethnicity
menopausal
status
body
mass
index
bmi
breast
tumor
grade
human
epidermal
growth
factor
receptor
neu
expression
based
thorough
literature
review
indicate
association
stage
breast
cancer
diagnosis
breast
cancer
prognosis
subjects
tissue
invasive
ductal
breast
carcinoma
study
represent
consecutive
series
female
patient
referral
population
southwestern
tissue
specimen
collect
surgical
resection
open
core
biopsy
diagnosis
october
november
store
southwestern
tissue
repository
paraffin
embed
tissue
section
southwestern
tissue
repository
also
provide
clinical
tumoral
datum
relate
tissue
specimen
collect
time
histology
stage
nottingham
scheme
determine
breast
tumor
histological
grade
iii
ajcc
stage
system
classify
stage
breast
cancer
case
iv
number
case
stage
ii
iii
iv
respectively
due
small
number
stage
iv
case
include
stage
iii
analysis
relate
outcome
breast
cancer
stage
diagnosis
immunohistochemistry
assay
quantitation
method
quantitative
immunohistochemistry
determine
breast
tumor
pr
neu
expression
immunohistochemistry
staining
perform
room
temperature
carry
dako
carpinteria
describe
previously
reagent
supply
universal
kit
biocare
medical
biocare
ph
previously
describe
optimum
primary
antibody
dilution
predetermine
know
positive
control
tissue
know
positive
control
section
include
run
assure
proper
staining
quantitative
information
staining
obtain
automate
microscopy
method
automated
cellular
imaging
system
acis
medical
system
san
juan
acis
federal
drug
administration
fda
approve
detection
pr
acis
system
consist
automate
robotic
microscope
module
computer
windows
software
interface
robotic
microscope
module
scan
stain
slide
computer
monitor
display
digitalized
tissue
image
view
image
acis
computer
one
much
subregions
digitalized
tissue
image
select
analysis
acis
assess
level
tissue
pr
expression
acis
provide
percentage
positively
stain
cell
pr
select
subregions
manufacture
guideline
acis
determine
tissue
pr
neu
expression
tissue
consider
positive
pr
expression
percentage
cell
staining
positive
pr
select
subregions
tissue
assess
neu
overexpression
acis
provide
average
score
select
subregions
tissue
high
staining
intensity
neu
tissue
average
score
consider
neu
overexpression
image
acis
breast
breast
view
within
article
statistical
analysis
microsoft
access
create
study
database
fisher
exact
test
kruskal
wallis
statistic
determine
association
covariate
age
race
ethnicity
menopausal
status
bmi
breast
tumor
grade
neu
expression
study
outcome
stage
breast
cancer
diagnosis
logistic
regression
analysis
determine
association
study
predictor
variable
breast
tumor
pr
expression
adjust
covariate
logistic
regression
analysis
elimination
procedure
covariate
keep
final
model
statistical
analysis
software
version
analysis
result
clinical
tumoral
datum
patient
association
datum
stage
breast
cancer
diagnosis
present
table
much
patient
year
old
white
postmenopausal
overweight
kg
nearly
half
breast
tumor
positive
pr
expression
positive
neu
overexpression
result
univariate
analysis
present
table
indicate
following
breast
tumor
histological
grade
neu
expression
significantly
positively
associate
stage
breast
cancer
diagnosis
addition
although
pr
expression
together
inversely
significantly
associate
stage
breast
cancer
diagnosis
pr
expression
consider
separately
pr
expression
expression
inversely
significantly
associate
stage
breast
cancer
diagnosis
however
although
pr
expression
inversely
associate
tumor
grade
level
statistical
significance
illustrate
breast
tumor
pr
expression
significantly
inversely
associate
stage
breast
cancer
diagnosis
demonstrate
pr
expression
decline
much
rapidly
advance
stage
breast
cancer
diagnosis
expression
table
selected
patient
breast
tumor
characteristic
associate
stage
breast
cancer
diagnosis
mean
sd
age
year
bmi
kg
pr
number
race
african
table
inverse
association
stage
breast
cancer
diagnosis
positive
association
stage
breast
cancer
diagnosis
view
within
article
image
breast
tumor
expression
pr
breast
tumor
expression
significantly
inversely
associate
breast
tumor
grade
diagnosis
view
within
article
image
pr
breast
tumor
expression
breast
tumor
expression
significantly
inversely
associate
stage
breast
cancer
diagnosis
view
within
article
show
table
multivariate
logistic
regression
analysis
also
indicate
pr
expression
significantly
inversely
associate
stage
breast
cancer
diagnosis
odd
ratio
confidence
interval
ci
without
ci
neu
expression
covariate
whereas
association
expression
stage
breast
cancer
diagnosis
insignificant
weak
unclear
direction
ci
without
ci
neu
expression
covariate
note
neu
expression
appear
final
logistic
regression
model
since
statistically
significant
ci
calculate
per
unit
increment
table
association
pr
expression
stage
breast
cancer
diagnosis
ci
ci
table
adjusted
race
ethnicity
breast
tumor
grade
adjusted
race
ethnicity
breast
tumor
grade
neu
expression
neu
statistically
significant
ci
view
within
article
discussion
univariate
result
study
indicate
although
pr
expression
significantly
inversely
associate
breast
tumor
grade
breast
tumor
pr
expression
significantly
inversely
associate
stage
breast
cancer
diagnosis
finding
consistent
result
past
study
favorable
prognosis
associate
breast
tumor
expression
lose
disappear
year
fact
study
focused
issue
expression
find
loose
breast
cancer
relapse
year
point
prognosis
begin
decline
furthermore
multivariate
result
study
indicate
pr
expression
expression
regardless
neu
expression
status
significantly
inversely
associate
stage
breast
cancer
diagnosis
strong
correlative
survival
affect
intervene
endocrine
therapy
chemotherapy
thus
finding
indicate
although
pr
expression
favorable
effect
breast
tumor
differentiation
measure
tumor
grade
pr
expression
marker
breast
cancer
prognosis
measure
stage
breast
cancer
diagnosis
result
pr
expression
may
useful
therapeutic
tool
well
inform
decision
adjuvant
chemotherapy
select
patient
much
specifically
national
consensus
guideline
currently
recommend
consideration
adjuvant
chemotherapy
breast
tumor
cm
diameter
associate
regional
lymph
node
metastasis
however
emerge
evidence
suggest
regardless
regional
lymph
node
status
metastasis
benefit
adjuvant
chemotherapy
term
dfs
breast
tumor
small
compare
breast
tumor
tend
since
pr
synthesize
response
therefore
adjuvant
chemotherapy
may
beneficial
patient
breast
tumor
cm
diameter
occur
least
time
furthermore
pr
may
potential
therapeutic
target
since
study
indicate
pr
positive
prognostic
marker
breast
cancer
recent
vitro
study
indicate
pr
expression
may
serve
protective
role
breast
cancer
progression
via
mechanism
several
recent
study
show
potential
benefit
pr
presence
progesterone
reduce
breast
cancer
progression
study
conduct
vitro
model
system
pr
cdna
stably
transfected
breast
cancer
cell
line
one
study
pr
presence
progesterone
markedly
inhibit
growth
breast
cancer
cell
induce
spread
adherence
property
finding
study
indicate
pr
presence
progesterone
may
play
significant
role
block
tumor
invasion
metastasis
another
study
find
progesterone
substantially
inhibit
breast
tumor
growth
scid
mouse
inoculate
breast
cancer
cell
stably
transfected
pr
cdna
final
study
progesterone
find
induce
cellular
differentiation
breast
cancer
cell
transfected
pr
cdna
much
recent
study
demonstrate
progesterone
treatment
breast
cancer
cell
transfected
pr
cdna
result
whole
genome
expression
profile
strong
antiproliferative
antineoplastic
feature
thus
finding
study
overall
suggest
progesterone
act
pr
may
play
role
decrease
breast
tumor
proliferation
invasiveness
regulate
expression
gene
furthermore
study
indicate
pr
may
therapeutic
target
breast
cancer
lend
support
conduct
future
vitro
study
determine
threshold
level
pr
expression
necessary
induce
favorable
tumor
effect
also
evidence
suggest
pr
may
serve
protective
role
breast
cancer
progression
via
mechanism
recent
study
observe
knockdown
pr
breast
cancer
cell
activation
fold
induction
mrna
observe
absence
exogenous
progesterone
suggest
pr
exert
action
inhibit
activation
induce
proinflammatory
cytokine
growth
factor
tumor
promoter
link
carcinogenesis
find
overexpressed
significant
portion
breast
cancer
particularly
express
neu
addition
transcription
factor
mediate
action
proinflammatory
cytokine
induce
expression
appear
play
important
role
breast
carcinogenesis
moreover
selective
ablation
pr
cell
condition
also
lead
increase
expression
cytoskeletal
protein
highly
correlated
tumor
cell
invasiveness
metastasis
far
demonstrate
increase
expression
pr
absence
ligand
breast
cancer
cell
diminish
expression
also
note
glucocorticoid
receptor
pr
mediate
focal
adhesion
breast
cancer
cell
transfected
pr
cdna
reduce
potential
tumor
metastasis
thus
protective
action
pr
may
great
significance
case
postmenopausal
woman
circulate
level
progesterone
absent
negligible
possible
limitation
study
account
confounder
important
variable
breast
cancer
case
may
influence
breast
cancer
stage
diagnosis
however
account
much
important
confounder
based
thorough
literature
review
also
aware
although
result
study
indicate
pr
expression
important
marker
early
stage
breast
cancer
one
conclude
result
pr
decrease
breast
cancer
progression
however
finding
pr
expression
significantly
inversely
associate
stage
breast
cancer
diagnosis
strong
predictor
breast
cancer
prognosis
also
suggest
pr
activate
reactivate
may
therapeutic
benefit
light
potential
protective
role
pr
breast
cancer
indicate
mechanistic
study
mention
conclusion
study
provide
new
information
indicate
pr
expression
marker
early
stage
breast
cancer
indicate
pr
expression
important
prognostic
marker
breast
cancer
will
likely
enhance
ability
effectively
treat
select
patient
addition
based
current
experimental
research
indicate
pr
may
play
role
reduce
progression
breast
cancer
pr
also
potential
target
therapy
breast
cancer
thus
finding
emphasize
importance
conduct
future
study
test
importance
pr
prognostic
marker
breast
cancer
well
determine
whether
activation
decrease
breast
cancer
progression
knowledge
may
help
identify
new
strategy
breast
cancer
treatment
acknowledgement
thank
provide
datum
southwestern
tissue
repository
manage
study
database
carry
datum
analysis
study
john
review
manuscript
protein
kinase
isozymes
consist
family
different
serine
threonine
kinase
classify
three
group
ii
pkc
isozymes
implicate
variety
cellular
function
include
cell
proliferation
apoptosis
metastasis
pkc
originally
find
overexpressed
breast
tumour
biopsy
highly
overexpressed
aggressive
oestrogen
pkc
isozymes
identify
human
mammary
cell
line
vary
expression
level
association
cancer
development
connect
breast
cancer
growth
modify
form
upregulated
resistant
cell
comparison
also
implicate
malignant
transformation
proliferation
mammary
tissue
regulate
control
apoptosis
well
associate
much
aggressive
previous
study
also
show
activity
protect
cell
undergo
critical
role
regulation
basic
fibroblast
growth
factor
gene
expression
transcription
factor
confirm
activation
novel
cell
inhibit
apoptosis
suggest
kinase
specific
therefore
may
represent
potential
target
inhibit
growth
metastasis
breast
cancer
addition
direct
effect
evidence
suggest
inhibition
potentiate
beneficial
effect
radiotherapy
ionising
radiation
show
activate
multiple
signal
pathway
egfr
mapk
jnk
pkc
strongly
activate
gamma
irradiation
play
important
role
tumour
pathway
signal
several
study
different
cancer
cell
line
demonstrate
activation
pkc
gamma
irradiation
link
cellular
response
soh
show
cell
inhibit
overexpression
regulatory
domain
much
sensitive
gamma
irradiation
normal
cell
work
important
role
two
isoform
radiotherapy
suggest
suppression
isoform
may
enhance
radiosensitivity
breast
cancer
enzastaurin
selective
inhibitor
nmol
also
suppress
nmol
nmol
high
enzastaurin
combination
radiotherapy
synergistic
effect
glioma
however
molecular
mechanism
responsible
synergy
require
far
present
study
investigate
mechanism
enzastaurin
gamma
irradiation
achieve
synergy
seem
exert
effect
block
apoptosis
human
tumour
perform
vivo
activity
assay
pkc
isoform
evaluate
change
pkc
cellular
localisation
irradiation
also
show
combination
treatment
influence
clonogenic
cell
survival
induce
apoptosis
increase
activity
material
cell
culture
human
breast
carcinoma
cell
line
obtain
american
type
culture
collection
atcc
manassas
va
cell
grow
modify
eagle
minimum
essential
medium
supplement
mg
ml
bovine
insulin
foetal
calf
serum
maintain
humidify
atmosphere
contain
clonogenic
cell
death
assay
enzastaurin
eli
lilly
company
indianapolis
amount
mg
dissolve
ml
dimethyl
dmso
store
stock
solution
dilute
medium
concentration
vitro
experiment
range
cultured
cell
pretreated
enzastaurin
later
cell
irradiate
irradiator
model
shepherd
associates
glenwood
dose
rate
gy
min
cell
incubate
medium
clonogenic
cell
death
assay
treatment
group
prepare
previously
describe
choi
treatment
group
cultured
cell
harvest
suspend
matrigel
becton
dickinson
bedford
ma
fifty
microliter
suspension
contain
tumour
cell
inject
subcutaneously
right
thigh
female
scid
mouse
seven
day
injection
tumour
palpable
mouse
randomised
four
group
consist
three
mouse
per
group
twice
daily
oral
administration
enzastaurin
mg
kg
day
ii
single
dose
irradiation
tumour
gy
iii
combination
follow
later
ii
iv
vehicle
control
group
receive
twice
daily
oral
administration
dmso
saline
solution
day
irradiation
tumour
mouse
intraperitoneal
injection
mixture
mg
kg
ketamine
mg
kg
entire
body
mouse
cover
lead
shield
exception
tumour
area
tumour
irradiate
philip
orthovoltage
unit
philip
medical
system
dose
gy
min
total
deliver
dose
gy
animal
procedure
care
compliance
animal
care
committee
university
minnesota
pkc
assay
tumour
remove
mouse
completion
last
treatment
place
ml
lysis
buffer
mm
tris
hcl
ph
mm
nacl
mm
mm
egta
triton
mm
sodium
pyrophosphate
mm
mm
ml
leupeptin
mm
pmsf
cell
signaling
boston
ma
sample
sonicated
ice
centrifuged
rpm
min
protein
concentration
determine
biorad
protein
assay
biorad
laboratory
hercules
sample
contain
equal
amount
protein
detection
pkc
activity
protein
kinase
assay
kit
bioscience
darmstadt
germany
previously
specific
isoform
activity
sample
contain
protein
resuspended
lysis
buffer
incubate
antibody
santa
cruz
biotechnology
santa
cruz
cell
signal
boston
ma
incubation
protein
santa
cruz
biotechnology
santa
cruz
add
accord
manufacturer
instruction
leave
overnight
incubation
supernatant
remove
immunoprecipitated
pellet
resuspended
sample
preparation
buffer
mm
tris
hcl
mm
mm
egta
mm
mm
edta
mm
pmsf
ph
pkc
isoform
detect
sample
triplicate
kinase
assay
describe
protein
concentration
assess
immunoblotting
actin
antibody
santa
cruz
biotechnology
santa
cruz
western
blot
cell
seed
tissue
culture
dish
mm
pretreated
enzastaurin
prior
irradiation
cell
irradiate
gy
irradiator
model
shepherd
associates
glenwood
incubate
medium
cytosolic
membrane
nuclear
fraction
separate
treat
sample
collect
initiation
treatment
briefly
cell
resuspended
ml
buffer
hepes
ph
kcl
edta
sucrose
glycerol
sodium
orthovanadate
agitate
min
centrifuged
rpm
min
supernatant
obtain
contain
cytoplasmic
protein
pellet
resuspended
ml
buffer
hepes
ph
kcl
edta
sucrose
glycerol
sodium
orthovanadate
agitate
min
centrifuged
rpm
min
supernatants
drain
pellet
resuspended
buffer
hepes
ph
nacl
edta
glycerol
sodium
orthovanadate
agitate
min
centrifuged
describe
previously
nuclear
protein
dissolve
supernatant
collect
pellet
resuspended
buffer
hepes
ph
kcl
edta
sucrose
glycerol
sodium
deoxycholate
sodium
orthovanadate
ml
solution
centrifuged
membrane
protein
remove
buffer
protein
extraction
include
protein
extraction
kit
institute
hayward
protein
concentration
sample
determine
biorad
protein
assay
biorad
laboratory
hercules
blotting
perform
describe
follow
primary
antibody
antibody
santa
cruz
biotechnology
santa
cruz
egf
receptor
antibody
cell
signal
boston
ma
actin
antibody
santa
cruz
biotechnology
santa
cruz
quantity
control
protein
extraction
vitro
study
activate
cell
signal
boston
ma
control
enzastaurin
activity
annexin
apoptosis
detection
assay
cell
plate
tissue
culture
dish
mm
fbs
medium
cell
incubate
enzastaurin
irradiate
later
gy
gamma
radiation
cell
collect
irradiation
count
resuspended
binding
buffer
guava
technology
hayward
incubate
annexin
presence
aminoactinomycin
guava
technologie
hayward
cell
screen
flow
cytometer
facscalibur
becton
dickinson
san
jose
annexin
cell
score
early
apoptotic
cell
annexin
cell
score
apoptotic
cell
camptothecin
ml
positive
control
caspase
activity
assay
activity
analyse
assay
accord
manufacturer
instruction
promega
corporation
cell
seed
well
white
plate
corresponding
clear
well
plate
cell
allow
adhere
overnight
treat
enzastaurin
solvent
vehicle
enzastaurin
gy
gamma
radiation
incubate
end
incubation
time
appropriate
reagent
add
well
contain
blank
negative
control
treat
cell
culture
medium
plates
gently
mix
incubate
room
temperature
luminescence
read
luminometer
corresponding
well
clear
plate
measure
number
viable
cell
reagent
molecular
technology
gaithersburg
md
caspase
activity
normalised
value
statistical
analysis
statistical
analysis
perform
anova
unpaired
student
software
graphpad
software
san
diego
minimal
level
significance
experiment
repeat
least
three
independent
time
except
vivo
study
value
express
mean
clonogenic
survival
enzastaurin
exposure
irradiation
survival
curve
cell
treat
various
dose
irradiation
show
exponential
decrease
increase
dose
irradiation
cell
survival
gy
gy
gy
gy
treatment
enzastaurin
alone
result
cell
survival
enzastaurin
combination
irradiation
produce
synergistic
decline
cell
survival
gy
gy
gy
gy
extent
cell
death
enzastaurin
irradiation
every
irradiate
dose
great
expect
additive
effect
confirm
enzastaurin
synergistically
enhance
cell
death
image
radiosensitising
effect
enzastaurin
survival
breast
cancer
cell
cultured
cell
pretreated
enzastaurin
later
irradiate
deliver
dose
gy
radiation
cell
incubate
medium
survive
fraction
assess
colony
formation
day
irradiation
data
show
mean
independent
experiment
radiation
dose
group
combination
enzastaurin
versus
radiation
dose
alone
view
within
article
apoptosis
induction
enzastaurin
exposure
irradiation
determine
mode
cell
death
responsible
cellular
radiosensitivity
examine
whether
apoptotic
machinery
activate
cell
follow
enzastaurin
exposure
irradiation
cell
stain
annexin
detection
indicator
apoptosis
aminoactinomycin
detection
dna
fragment
indicator
apoptosis
treatment
enzastaurin
alone
induce
apoptosis
dose
versus
vehicle
control
enzastaurin
dose
follow
gy
irradiation
cell
undergo
high
rate
programme
cell
death
combination
treatment
group
versus
concentration
enzastaurin
alone
difference
much
rate
apoptosis
consider
evidence
point
towards
synergistic
activity
enzastaurin
dose
result
confirm
synergy
cytotoxicity
achieve
enzastaurin
irradiation
trigger
fashion
induction
apoptosis
image
radiosensitising
effect
enzastaurin
apoptosis
activation
cell
pretreated
different
enzastaurin
concentration
prior
irradiation
gy
incubate
induction
cell
apoptosis
detect
annexin
aminoactinomycin
staining
cell
annexin
negative
positive
upper
leave
late
apoptotic
cell
annexin
positive
positive
live
cell
annexin
negative
negative
leave
early
apoptotic
cell
annexin
positive
negative
right
data
representative
three
independent
experiment
treatment
effect
activity
assess
average
three
experiment
six
replicate
perform
datum
show
versus
untreated
control
versus
gy
group
view
within
article
activity
enzastaurin
exposure
irradiation
significantly
increase
cell
treat
enzastaurin
dose
versus
vehicle
control
fig
high
concentration
activity
fold
high
vehicle
control
activity
far
increase
cell
pretreated
enzastaurin
irradiation
drug
dose
versus
gy
irradiation
alone
high
dose
result
activity
fold
high
vehicle
control
irradiation
alone
induction
usually
activate
prior
show
increase
activity
treatment
combination
enzastaurin
alone
significantly
increase
activity
fold
fold
compare
vehicle
control
combination
treatment
drug
concentration
gy
radiation
significantly
increase
activity
fold
fold
respectively
compare
radiation
alone
versus
gy
irradiation
alone
irradiation
alone
significant
increase
activity
compare
vehicle
control
incubation
period
cytosol
membrane
bind
enzastaurin
exposure
irradiation
western
blot
indicate
enzastaurin
inhibitory
effect
pkc
isoform
cytosolic
membrane
fraction
cell
pkc
isoform
also
inhibit
combination
treatment
irradiation
gy
effect
either
isoform
activity
cell
either
cellular
locale
irradiation
image
enzastaurin
inhibit
isoform
cytosolic
membrane
fraction
sample
collect
vitro
drug
exposure
irradiation
cell
lysate
separate
immunoblotted
antibody
actin
egfr
loading
control
cytosol
membrane
lysate
respectively
view
within
article
enzastaurin
reverse
activity
vivo
elucidate
pkc
inhibitory
effect
enzastaurin
three
much
important
pkc
isoform
ii
test
vivo
irradiation
gy
alone
significantly
induce
increase
activity
versus
untreated
control
enzastaurin
alone
inhibit
ii
isoform
versus
untreated
control
statistical
difference
untreated
group
combination
treatment
group
however
significant
difference
irradiate
group
combination
treatment
group
indicate
enzastaurin
reverse
activity
similar
pattern
kinase
activity
see
total
pkc
notable
difference
pattern
pkc
isoform
response
see
activity
increase
response
irradiation
versus
untreated
control
addition
statistical
difference
observe
total
pkc
activity
untreated
control
combination
treatment
group
control
quantitative
protein
concentration
experiment
western
blot
actin
antibody
image
enzastaurin
reverse
activity
human
tumour
xenograft
mice
pretreated
enzastaurin
mg
kg
twice
daily
irradiate
gy
one
time
hour
post
irradiation
tumour
extract
lysate
immunoprecipitated
pkc
activity
activity
unpaired
compare
significant
change
group
three
mouse
per
treatment
group
sample
prepare
triplicate
bar
versus
vehicle
control
versus
irradiation
alone
actin
quantitative
control
protein
amount
show
view
within
article
image
enzastaurin
inhibitory
effect
phosphorylation
vivo
hour
post
irradiation
tumour
extract
lysate
detection
status
actin
quantitative
control
protein
amount
histograms
show
relative
optical
density
phosphorylated
view
within
article
enzastaurin
suppress
phosphorylation
vivo
pkc
activity
connect
different
signal
pathway
kinase
akt
ras
however
report
suppression
phosphorylated
early
event
enzastaurin
activity
vitro
vivo
inhibition
pathway
suggest
pharmacodynamic
marker
enzastaurin
activity
determine
enzastaurin
gamma
irradiation
may
influence
phosphorylation
status
western
blot
analysis
perform
sample
pkc
activity
assay
optical
density
measurement
show
inhibitory
effect
group
well
combination
treatment
group
irradiation
gy
result
minimal
change
expression
compare
vehicle
control
discussion
pkc
become
therapeutic
target
treat
different
malignancy
pkc
inhibitor
enzastaurin
already
test
clinical
trial
patient
diffuse
large
lymphoma
lung
preclinical
trial
human
breast
carcinoma
tumour
xenograft
colleague
show
tumour
response
radiotherapy
enzastaurin
present
study
show
enzastaurin
combine
gamma
irradiation
therapy
synergistic
radiosensitising
effect
human
cancer
cell
line
vitro
also
demonstrate
vivo
model
enzastaurin
reverse
activation
three
different
isoform
pkc
nakajima
colleague
kim
colleague
conclude
vitro
study
activation
two
isoform
pkc
occur
shortly
irradiation
critical
regulation
apoptosis
vitro
study
demonstrate
pkc
isoform
inhibit
cytosolic
membrane
fraction
cell
response
enzastaurin
treatment
irradiation
irradiation
gy
alone
change
pkc
activity
either
cellular
locale
confirm
result
nakajima
colleague
lymphoma
consistent
vitro
result
detect
elevate
activity
three
pkc
isoform
tumour
xenograft
gamma
irradiation
notably
activity
dramatically
increase
response
gamma
irradiation
gy
compare
suggest
isoform
may
critical
mechanism
breast
cancer
cell
soh
colleague
suggest
play
important
role
upregulation
protein
expression
increase
cell
survival
inhibition
observation
show
overexpression
strongly
involve
malignant
cell
transformation
animal
inhibition
link
inhibition
mapk
activation
suggest
block
isoform
may
positive
effect
metastasis
tumour
result
clearly
show
enzastaurin
influence
activity
isoform
vivo
provide
rational
explanation
molecular
pathway
enzastaurin
may
render
tumour
xenograft
much
sensitive
gamma
irradiation
treatment
cell
vitro
enzastaurin
synergistically
interact
ionising
radiation
clonogenic
cell
death
contrast
previous
study
rodent
breast
cancer
show
enzastaurin
treatment
synergistically
induce
cell
apoptosis
combination
gamma
irradiation
detect
staining
although
combination
treatment
additive
effect
activity
effect
consistent
previous
finding
show
caspase
activity
least
partially
require
cell
vitro
vivo
study
human
breast
cancer
cell
line
clearly
show
enzastaurin
radiosensitising
agent
mostly
inhibition
activity
based
promising
effect
combination
therapy
believe
far
study
radiosensitising
effect
enzastaurin
warrant
conflict
interest
statement
declare
conflict
interest
relate
member
bureau
eli
lilly
company
acknowledgement
study
partially
support
experimental
therapeutic
fund
university
minnesota
grateful
dennis
anderson
ongoing
support
fund
like
thank
michael
franklin
editorial
support
diabetes
mellitus
dm
associate
development
progression
pathological
change
various
organ
system
include
central
nervous
system
however
specific
effect
diabetes
blood
brain
barrier
bbb
remain
controversial
study
utilize
model
diabetes
assess
effect
bbb
indicate
physical
barrier
remain
intact
whereas
recent
study
indicate
bbb
permeability
substance
increase
diabetes
however
report
show
contradictory
outcome
explanation
conflict
result
barrier
transport
component
bbb
function
attributed
dysfunction
cerebral
microvasculature
paracellular
transcellular
permeability
bbb
differentially
regulate
diabetes
permeability
much
small
molecule
limited
paracellular
pathway
tight
junction
transcellular
movement
molecule
organic
ion
highly
regulate
numerous
transporter
include
efflux
transporter
efflux
transporter
mainly
belong
abc
superfamily
include
breast
cancer
resistance
protein
bcrp
first
describe
component
acquire
multidrug
resistance
mdr
mechanism
tumor
cell
now
know
present
physiologically
luminal
membrane
brain
capillary
endothelial
cell
actively
expel
wide
spectrum
drug
brain
blood
lead
decrease
uptake
brain
bcrp
first
call
now
designate
nomenclature
confer
resistance
many
drug
include
mitoxantrone
prazosin
camptothecin
derivative
range
may
overlap
substrate
multidrug
protein
bcrp
identify
human
porcine
brain
capillary
endothelial
cell
find
responsible
vitro
export
daunorubicin
porcine
brain
capillary
endothelial
cell
present
brain
endothelial
cell
indicate
bcrp
may
influence
efflux
drug
bbb
vivo
study
knockout
mouse
show
involve
brain
penetration
imatinib
series
study
show
disease
include
diabetes
mellitus
affect
expression
function
efflux
transporter
result
change
bbb
permeability
previous
study
show
expression
function
brain
diabetic
rat
damage
accompany
increase
brain
penetration
substrate
vincristine
without
mark
change
bbb
integrity
similar
also
find
diabetic
mouse
induce
stz
contrast
expression
function
find
brain
diabetic
rat
induce
stz
accompany
decrease
fluorescein
brain
penetration
bcrp
one
important
efflux
transporter
restrict
substance
brain
however
little
know
regulation
expression
function
diabetes
mellitus
purpose
study
firstly
investigate
whether
dm
change
bcrp
function
expression
brain
cortex
diabetic
rat
western
blot
two
typical
substrate
prazosin
cimetidine
typical
substrate
bcrp
widely
evaluate
bcrp
function
secondly
clarify
whether
agent
treatment
reverse
change
bcrp
expression
function
induce
dm
thirdly
study
factor
may
contribute
change
function
expression
bcrp
brain
cortex
material
animal
preparation
male
rat
purchase
center
experimental
animal
china
pharmaceutical
university
study
house
control
room
humidity
temperature
rat
fast
prior
intraperitoneal
injection
mg
kg
stz
dissolve
sodium
citrate
buffer
ph
following
injection
animal
return
cage
maintain
standard
dark
condition
give
food
water
remainder
study
normal
rat
receive
citrate
buffer
development
diabetes
confirm
blood
glucose
analysis
reagent
kit
jiancheng
biotech
nanjing
china
rats
serum
glucose
level
high
mm
consider
diabetic
rat
include
study
animal
experiment
perform
license
grant
jiangsu
science
technology
office
china
approval
animal
ethic
committee
china
pharmaceutical
university
every
effort
make
minimize
stress
animal
experimental
protocol
diabetic
rat
randomly
divide
group
group
serve
diabetic
control
model
receive
saline
solution
group
ii
serve
insulin
treatment
subcutaneously
inject
kg
insulin
twice
day
group
iii
serve
metformin
treatment
receive
orally
mg
kg
metformin
jiangsu
pharmaceutical
group
twice
day
group
iv
serve
aminoguanidine
inhibitor
advance
glycation
end
product
treatment
orally
receive
mg
kg
aminoguanidine
hydrogen
carbonate
gmbh
kg
steinheim
germany
twice
day
normal
rat
receive
saline
solution
week
treatment
rat
group
randomly
choose
evaluation
function
expression
bcrp
brain
cortex
rest
rat
continue
treat
another
week
distribution
prazosin
cimetidine
elucidate
effect
dm
bcrp
function
bbb
two
typical
substrate
bcrp
prazosin
cimetidine
give
intravenously
experimental
rat
normal
rat
prazosin
min
injection
mg
kg
prazosin
national
institute
control
pharmaceutical
biological
product
beijing
china
rat
sacrifice
light
ether
anesthesia
blood
brain
sample
immediately
collect
analysis
cimetidine
min
injection
mg
kg
cimetidine
national
institute
control
pharmaceutical
biological
product
beijing
china
rat
sacrifice
light
ether
anesthesia
blood
brain
sample
immediately
collect
analysis
blood
sample
immediately
centrifuged
yield
plasma
cerebral
cortex
obtain
weigh
plasma
brain
sample
store
analysis
concentration
ratio
cimetidine
calculate
serve
brain
penetration
drug
western
blot
analysis
rats
sacrifice
light
ether
anesthesia
brain
cortex
quickly
remove
brain
cortex
lysed
lysis
buffer
contain
mm
nacl
sodium
azide
ml
pmsf
mm
tris
hcl
ph
lysate
incubate
ice
min
centrifuged
min
supernatant
collect
protein
concentration
determine
bradford
assay
hercules
usa
protein
assay
reagent
addition
sample
loading
buffer
min
denatured
protein
sample
electrophoresed
subsequently
transfer
pvdf
membrane
roche
membrane
incubate
fresh
blocking
buffer
saline
ph
contain
nonfat
dry
milk
room
temperature
min
probe
goat
polyclonal
antibody
santa
cruz
usa
block
buffer
overnight
wash
membrane
pbst
pbs
three
time
min
incubate
appropriate
donkey
secondary
antibody
room
temperature
another
wash
three
time
pbst
buffer
transfer
protein
incubate
ecl
substrate
solution
cell
signaling
usa
min
accord
manufacturer
instruction
visualize
autoradiography
blot
strip
reprobed
polyclonal
antibody
biotech
china
ascertain
equal
loading
protein
drug
assay
concentration
prazosin
cimetidine
plasma
brain
cortex
measure
hplc
shimadzu
system
shimadzu
japan
mm
mm
particle
size
column
richmond
hill
usa
select
determination
prazosin
ml
plasma
ml
purify
water
contain
homogenize
brain
cortex
mix
terazosin
solution
ml
alkalized
ml
sodium
carbonate
solution
extraction
ml
ml
organic
layer
transfer
clean
tube
evaporate
dryness
nitrogen
gas
stream
residue
reconstitute
ml
methanol
sample
inject
hplc
system
mobile
phase
consist
acetonitrile
ph
flow
rate
ml
min
concentration
prazosin
measure
fluorescence
detector
set
excitation
wavelength
nm
emission
wavelength
nm
limit
quantitation
prazosin
brain
cortex
plasma
brain
cortex
ml
respectively
concentration
quantify
area
ratio
prazosin
internal
standard
terazosin
standard
curve
linear
concentration
range
brain
cortex
ml
plasma
respectively
recovery
high
relative
standard
derivation
intraday
interday
determination
cimetidine
ml
plasma
purify
water
contain
homogenize
brain
cortex
mix
ml
internal
standard
alkalized
ml
sodium
carbonate
solution
extraction
ml
ethyl
acetate
mixture
centrifuged
rpm
min
min
ml
organic
layer
collect
evaporate
dryness
gentle
stream
nitrogen
gas
residue
reconstitute
ml
methanol
sample
inject
hplc
system
ultraviolet
detector
set
wavelength
nm
hplc
assay
utilize
mobile
phase
contain
ph
flow
rate
ml
min
limit
quantitation
cimetidine
brain
cortex
plasma
brain
cortex
ml
respectively
recovery
high
relative
standard
derivation
intraday
interday
linear
range
cimetidine
brain
cortex
plasma
brain
cortex
ml
respectively
measurement
physiological
biochemical
parameter
blood
sample
take
vein
fast
overnight
centrifuged
rpm
min
min
serum
sample
obtain
serum
glucose
level
insulin
level
measure
reagent
kit
elisa
kit
jiancheng
biotech
respectively
serum
advance
glycation
end
product
ages
measure
method
describe
previously
brief
fluorescence
measurement
fold
saline
dilute
serum
perform
triplicate
shimadzu
japan
excitation
wavelength
nm
emission
wavelength
nm
fluorescence
intensity
sample
express
mg
protein
protein
measure
protein
assay
kit
jiancheng
biotech
statistical
analysis
result
express
mean
standard
deviation
overall
difference
among
group
determine
analysis
variance
anova
analysis
significant
difference
group
estimate
student
newman
multiple
comparison
post
hoc
test
little
indicate
significant
difference
physiological
biochemical
parameter
experimental
rat
physiological
parameter
body
weight
blood
glucose
level
insulin
level
serum
ages
level
week
week
experimental
rat
measure
list
table
compared
normal
rat
level
insulin
high
level
blood
glucose
ages
find
serum
diabetic
rat
induce
stz
accompany
body
weight
treatment
insulin
reverse
change
physiological
biochemical
parameter
diabetic
rat
metformin
treatment
partly
reverse
change
physiological
biochemical
parameter
diabetic
rat
aminoguanidine
inhibitor
advance
glycation
significantly
decrease
ages
serum
diabetic
rat
effect
physiological
biochemical
parameter
table
biochemical
parameter
week
week
rat
controldmdm
insulindm
agdm
met
week
body
weight
serum
glucose
mmol
serum
ages
mg
protein
serum
insulin
week
body
weight
serum
glucose
mmol
serum
ages
mg
protein
serum
insulin
table
dm
diabetes
mellitus
aminoguanidine
met
metformin
value
represent
mean
rat
versus
control
versus
diabetes
view
within
article
brain
distribution
prazosin
cimetidine
experiment
design
investigate
whether
dm
affect
function
bcrp
brain
two
typical
substrate
bcrp
prazosin
since
brain
concentration
prazosin
cimetidine
affect
plasma
concentration
concentration
ratio
prazosin
cimetidine
calculate
serve
brain
penetration
significant
high
concentration
ratio
two
substrate
diabetic
rat
find
compare
normal
rat
concentration
ratio
prazosin
increase
week
diabetic
rat
week
diabetic
rat
compare
normal
rat
respectively
similarly
concentration
ratio
cimetidine
increase
week
diabetic
rat
week
diabetic
rat
compare
normal
rat
respectively
report
physical
structure
bbb
remain
intact
diabetic
rat
induce
stz
result
indicate
increase
ratio
typical
substrate
may
result
damage
bcrp
function
induce
dm
impairment
bcrp
function
dependent
duration
diabetes
table
effect
dm
drug
treatment
distribution
prazosin
brain
cortex
week
week
rat
controldmdm
insulindm
agdm
met
week
plasma
level
ml
brain
level
brain
cortex
kp
value
ml
brain
week
plasma
level
ml
brain
level
brain
cortex
kp
value
ml
brain
table
change
distribution
prazosin
brain
cortex
diabetic
rat
drug
treat
diabetic
rat
prazosin
mg
kg
administer
week
week
nontreated
diabetic
rat
drug
treat
diabetic
rat
control
rat
respectively
blood
whole
brain
cortex
sample
collect
measure
follow
min
prazosin
injection
concentration
ratio
prazosin
calculate
value
represent
mean
rat
dm
diabetes
mellitus
aminoguanidine
met
metformin
kp
ratio
versus
control
versus
diabetes
view
within
article
table
effect
dm
drug
treatment
distribution
cimetidine
brain
cortex
week
week
rat
controldmdm
insulindm
week
plasma
level
ml
brain
level
brain
cortex
kp
value
ml
brain
week
plasma
level
ml
brain
level
brain
cortex
kp
value
ml
brain
table
change
distribution
cimetidine
brain
cortex
diabetic
rat
drug
treat
diabetic
rat
mg
kg
administer
week
week
nontreated
diabetic
rat
drug
treat
diabetic
rat
normal
rat
respectively
blood
whole
brain
cortex
sample
collect
measure
follow
min
cimetidine
injection
concentration
ratio
cimetidine
calculate
value
represent
mean
rat
dm
diabetes
mellitus
aminoguanidine
met
metformin
kp
ratio
versus
control
versus
diabetes
view
within
article
order
investigate
whether
drug
treatment
attenuate
impairment
bcrp
function
induce
dm
diabetic
rat
treat
insulin
metformin
aminoguanidine
respectively
show
table
table
insulin
treatment
may
attenuate
impairment
bcrp
function
brain
cortex
diabetic
rat
accompany
increase
serum
insulin
level
decrease
blood
glucose
level
metformin
although
significantly
decrease
glucose
ages
level
serum
show
improvement
bcrp
function
follow
week
week
treatment
similarly
aminoguanidine
inhibitor
advance
glycation
end
product
significantly
decrease
ages
level
serum
reverse
decrease
bcrp
function
induce
diabetes
result
indicate
impairment
bcrp
may
partly
result
insulin
level
high
ages
high
glucose
level
bcrp
expression
brain
cortex
experiment
design
investigate
whether
dm
affect
expression
bcrp
brain
cortex
bcrp
level
cerebral
cortex
measure
western
blot
result
reveal
band
kda
identify
bcrp
antibody
corresponding
bcrp
bcrp
level
cerebral
cortex
diabetic
rat
significant
normal
rat
bcrp
level
brain
cortex
week
week
diabetic
rat
bcrp
level
corresponding
control
rat
respectively
result
indicate
dm
may
expression
bcrp
brain
cortex
diabetic
rat
impair
expression
bcrp
bbb
diabetic
rat
dependent
duration
diabetes
image
change
bcrp
expression
level
brain
cortex
represent
western
blot
bcrp
brain
cortex
week
week
rat
respectively
ratio
relative
staining
intensity
bcrp
week
week
rat
describe
respectively
datum
represent
mean
three
independent
experiment
dm
diabetes
mellitus
aminoguanidine
met
metformin
versus
control
versus
diabetes
view
within
article
order
investigate
whether
drug
treatment
attenuate
impairment
bcrp
expression
induce
dm
diabetic
rat
treat
insulin
metformin
aminoguanidine
respectively
find
insulin
reverse
decrease
expression
bcrp
week
week
diabetic
rat
contrary
aminoguanidine
metformin
show
effect
restoration
bcrp
expression
week
week
diabetic
rat
discussion
present
study
first
design
explore
whether
dm
affect
bcrp
function
expression
brain
cortex
diabetic
rat
typical
substrate
prazosin
cimetidine
western
blot
analysis
lower
level
bcrp
brain
cortex
diabetic
rat
parallel
increase
ratio
prazosin
cimetidine
prazosin
typical
substrate
bcrp
widely
evaluate
bcrp
function
cimetidine
initially
recognize
inhibitor
organic
cation
transporter
recently
many
report
also
identify
cimetidine
novel
efficiently
transport
substrate
murine
bcrp
brain
concentration
drug
affect
plasma
concentration
ratio
study
though
note
concentration
cimetidine
prazosin
cerebral
cortex
plasma
diabetic
rat
control
rat
identify
high
ratio
prazosin
cimetidine
diabetic
rat
compare
control
rat
previous
study
show
dm
destroy
integrity
bbb
murine
human
diabetes
tight
junction
appear
alter
previous
study
also
show
significant
difference
brain
cortex
concentration
evans
blue
diabetic
rat
control
rat
histopathological
examination
show
mark
change
apical
membrane
brain
microvessel
endothelium
experimental
condition
result
suggest
increase
ratio
prazosin
cimetidine
brain
cortex
may
result
impairment
bcrp
brain
neither
impairment
bbb
integrity
damage
brain
microvessel
endothelium
induce
dm
cimetidine
prazosin
report
undergo
significant
metabolism
male
rat
via
handful
liver
induction
hepatic
recognize
experimental
diabetes
may
partly
contribute
decrease
cimetidine
prazosin
plasma
concentration
investigate
whether
decrease
bcrp
function
brain
cortex
diabetic
rat
due
alter
expression
bcrp
western
blot
accomplish
protein
extract
brain
cortex
study
confirm
bcrp
expression
significantly
decrease
cerebral
cortex
week
week
diabetic
rat
compare
control
rat
respectively
result
impairment
bcrp
function
result
clearly
demonstrate
dm
increase
ratio
cimetidine
prazosin
via
impair
expression
function
bcrp
brain
lower
level
insulin
high
level
ages
high
level
blood
glucose
significant
feature
dm
order
investigate
whether
factor
impair
bcrp
function
expression
brain
cortex
diabetic
rat
treat
aminoguanidine
metformin
insulin
respectively
previous
study
show
decrease
protein
level
ages
impair
expression
organic
cation
transporter
kidney
experimental
dm
however
find
treatment
aminoguanidine
reduce
serum
ages
level
improve
impair
bcrp
function
expression
diabetic
rat
although
metformin
modify
high
blood
glucose
ages
level
treatment
metformin
still
improve
function
expression
bcrp
diabetic
rat
result
indicate
high
level
ages
blood
glucose
may
play
minor
role
regulate
bcrp
function
expression
brain
treatment
insulin
reverse
impair
expression
function
bcrp
brain
cortex
associate
normalize
level
insulin
serum
ages
blood
glucose
serum
diabetic
rat
consider
poor
effect
high
blood
glucose
ages
regulate
bcrp
expression
function
insulin
level
important
influential
factor
associate
impairment
conclusion
experiment
confirm
function
expression
bcrp
brain
cortex
diabetic
rat
impair
lower
level
insulin
may
contribute
mechanism
brain
cortex
bcrp
dysfunction
ages
may
play
minor
role
alteration
acknowledgement
work
support
national
science
foundation
china
project
innovation
graduate
education
jiangsu
cancer
stem
cell
hypothesis
suggest
many
cancer
maintain
hierarchical
organization
rare
slowly
divide
cancer
stem
cell
cell
rapidly
divide
amplify
cell
early
precursor
cell
epc
differentiate
tumor
cell
tentatively
define
identify
hematologic
brain
breast
prostate
liver
pancreas
colon
cancer
renew
differentiate
multiple
lineage
highly
tumorigenic
immunodeficient
mouse
according
hypothesis
source
tumor
also
may
responsible
tumor
progression
metastasis
resistance
therapy
subsequent
tumor
recurrence
breast
enrich
sort
cell
select
sp
cell
efflux
hoechst
dye
isolate
cluster
cell
mammosphere
suspension
culture
however
method
purify
epc
ponti
since
mirna
regulate
differentiation
function
either
tumor
suppressor
oncogene
regulate
tumor
development
prognosis
look
whether
difference
mirna
expression
might
distinguish
epc
much
differentiate
mirna
know
contribute
preserve
stemness
embryonic
stem
cell
cell
deficient
mirna
processing
maintain
previous
study
show
overall
reduction
mirna
expression
embryonic
tissue
stem
cell
change
specific
mirna
associate
cell
renewal
differentiation
moreover
profile
help
characterize
stage
subtype
prognosis
cancer
relatively
resistant
chemotherapy
able
generate
large
number
cell
vivo
passage
breast
cancer
cell
nod
scid
mouse
treat
chemotherapy
find
mirna
expression
globally
reduce
compare
much
differentiate
cancer
cell
particular
family
express
generate
cell
line
patient
tumor
increase
differentiation
express
differentially
express
oncomirs
antagonize
much
differentiate
cell
find
regulate
key
feature
breast
cancer
stem
renewal
vitro
multipotent
differentiation
ability
form
tumor
serially
transplant
metastasize
nod
scid
mouse
protein
expression
target
ras
high
silence
differentiation
ras
silence
contribute
loss
renewal
affect
multipotent
differentiation
silence
enhance
multilineage
differentiation
effect
renewal
result
chemotherapy
selectively
breast
cancer
cell
resistance
chemotherapy
distinguish
cancer
cell
examine
whether
chemotherapy
might
enrich
compare
proportion
vitro
cancer
cell
breast
cancer
patient
receive
neoadjuvant
chemotherapy
tumor
resected
patient
table
freshly
isolate
cell
cultured
suspension
generate
mammosphere
method
culturing
mammary
gland
progenitor
cell
mammosphere
generation
vitro
assay
potential
day
tumor
cell
neoadjuvant
chemotherapy
patient
form
mammosphere
compare
patient
fold
increase
figure
furthermore
mammosphere
chemotherapy
patient
passaged
least
eight
ten
generation
endpoint
study
patient
without
chemotherapy
within
two
three
generation
breast
cancer
tumor
cell
patient
cell
untreated
patient
phenotype
ascribed
ponti
figure
enrichment
chemotherapy
confirm
study
pair
specimen
seven
patient
obtain
biopsy
prior
chemotherapy
surgery
follow
neoadjuvant
chemotherapy
tumor
cell
chemotherapy
cell
obtain
chemotherapy
form
mammosphere
day
suspension
culture
figure
similarly
proportion
cell
fold
high
sample
chemotherapy
table
another
patient
group
metastatic
pleural
effusion
receive
chemotherapy
year
pleural
cancer
cell
highly
enrich
cell
table
datum
three
cohort
suggest
chemotherapy
selectively
enhance
survival
image
image
figure
breast
cancer
cell
pressure
chemotherapy
enriched
breast
cancer
patient
receive
neoadjuvant
chemotherapy
substantially
enrich
cell
expect
property
compare
untreated
patient
representative
image
show
increase
number
mammosphere
day
culture
high
percentage
cell
freshly
isolate
tumor
patient
receive
tumor
resected
eight
patient
receive
chemotherapy
five
patient
receive
neoadjuvant
chemotherapy
analyzed
table
similarly
passaging
human
breast
cancer
line
nod
scid
mouse
enrich
cell
property
cell
third
passage
xenograft
form
much
mammosphere
parent
line
mammosphere
passaged
vitro
large
shown
number
generate
dissociate
sphere
generate
dissociate
sphere
mammosphere
day
compare
error
bar
correspond
mean
sd
mammosphere
generate
culture
image
indicate
day
suspension
culture
shown
mean
sd
number
cell
sphere
compare
error
bar
correspond
mean
sd
majority
freshly
isolate
cell
expect
cell
phenotype
rare
representative
datum
five
experiment
show
cell
cultured
sphere
differentiate
adherent
culture
gradually
assume
parental
phenotype
somewhat
much
rapidly
mammosphere
sphere
dissociate
remove
growth
factor
plate
collagen
top
express
luminal
myoepithelial
differentiation
marker
far
differentiation
bottom
develop
elongate
cell
subpopulation
staining
either
differentiate
subtype
freshly
isolate
cell
enrich
sp
cell
compare
cell
view
within
article
take
advantage
find
see
enrich
consecutively
passaging
breast
cancer
cell
nod
scid
mouse
treat
chemotherapy
mice
inject
mammary
fat
pad
cell
treat
epirubicin
weekly
week
xenograft
reach
cm
diameter
cell
third
passage
cultured
suspension
generate
mammosphere
number
mammosphere
reflect
quantity
cell
capable
vitro
renewal
number
cell
sphere
measure
capacity
cell
dontu
dontu
form
fold
much
sphere
versus
figure
moreover
dissociate
cell
mammosphere
generate
equivalent
proportion
sphere
demonstrate
vitro
potential
mammosphere
culture
maintain
passage
within
three
four
passage
mammosphere
fail
generate
sphere
become
adherent
differentiate
finding
confirm
figure
mammosphere
observe
begin
day
increase
size
cell
number
day
mammosphere
passaged
time
clone
however
mammosphere
appear
day
parental
cell
fold
fewer
number
much
small
addition
freshly
isolate
form
fold
much
colony
assay
correlate
renewal
figure
percent
freshly
isolate
cell
compare
cell
moreover
sphere
cell
cell
plate
collagen
differentiate
condition
serum
remain
day
similarly
freshly
isolate
mammospheric
cell
day
differentiate
condition
maintain
phenotype
furthermore
cell
parental
cell
highly
express
stem
decline
vitro
differentiation
figure
therefore
mammospheric
cell
differentiate
capability
vitro
also
phenotype
expect
mammosphere
cell
however
may
different
mammosphere
although
initially
similar
proportion
cell
mammosphere
lose
phenotype
much
day
differentiation
mammospheric
cell
versus
cell
staining
bright
differentiate
cell
large
proportion
cell
taken
together
slow
growth
small
size
mammosphere
inability
passage
sphere
datum
suggest
mammosphere
may
undergo
first
step
toward
lose
capacity
key
property
multipotency
mammospheric
cell
round
stain
cytokeratin
ck
differentiation
marker
actin
even
adhere
collagen
however
far
differentiation
develop
elongate
cell
subpopulation
staining
either
myoepithelial
luminal
epithelial
marker
expect
differentiate
cell
also
lose
potential
since
cell
maintain
differentiate
condition
day
form
sphere
fold
reduction
compare
cell
grow
sphere
also
believe
resistant
chemotherapy
part
overexpressing
cassette
property
correlate
ability
expel
dye
define
flow
cytometry
side
population
sp
freshly
isolate
cell
contain
fold
much
sp
cell
versus
figure
line
mammospheric
differentiate
stain
immunoblot
figure
reduced
direct
consequence
chemotherapy
similar
reduction
observe
mammospheric
mammospheric
mrna
parallel
difference
protein
show
moreover
mammospheric
cell
relatively
resistant
epirubicin
compare
differentiate
show
important
feature
efficient
xenograft
formation
mammospheric
cell
inoculate
nod
scid
mouse
eight
ten
mouse
generate
tumor
animal
inject
fold
much
cell
develop
tumor
contrast
mouse
inoculate
cell
develop
tumor
tumor
develop
three
ten
animal
inoculate
cell
therefore
mammospheric
cell
least
fold
much
tumorigenic
importantly
mammospheric
tumor
cell
xenograft
serially
passaged
recipient
unselected
cell
table
potent
tumorigenic
capability
mammospheric
cell
upon
serial
xenotransplantation
suggest
vivo
capacity
table
incidence
tumor
metastasis
mammospheric
cell
cell
nod
scid
mice
number
cell
metastasisliver
metastasistumorslung
metastasisliver
metastasistumorslung
metastasisliver
metastasis
mammospheric
parent
table
$
compare
untransduced
mammospheric
cell
view
within
article
hypothesized
cancer
cell
property
initiate
metastases
therefore
compare
lung
liver
metastases
xenograft
five
week
inoculation
mammospheric
cell
massive
lung
metastases
visualize
microscopy
eight
ten
mouse
mouse
inject
number
develop
microscopic
lung
metastases
analyzed
tumor
reach
size
cm
diameter
xenograft
similarly
mammospheric
cell
generate
liver
micrometastases
six
ten
mouse
cell
produce
none
determine
whether
chemotherapy
need
maintain
stable
percentage
cell
compare
mammospheric
tumor
far
passaged
nod
scid
mouse
treat
chemotherapy
respectively
contain
equal
percentage
cell
table
figure
suggest
proportion
already
third
passage
contrast
cell
generate
fold
fewer
sphere
imply
selective
pressure
chemotherapy
require
maintain
proportion
cell
vivo
cell
inject
nod
scid
mouse
tumor
develop
virtually
animal
majority
metastasized
table
significant
difference
tumor
formation
metastasis
mammospheric
cell
unselected
cell
whether
mouse
generally
generate
tumor
number
cell
therefore
chemotherapy
select
prevent
differentiation
xenograft
responsible
capacity
collectively
datum
show
vivo
passaging
breast
cancer
line
chemotherapy
pressure
enrich
least
cell
display
expect
property
vitro
stable
mammosphere
formation
growth
nonadherent
condition
multipotent
differentiation
phenotype
sp
high
rate
form
tumor
capable
serial
transplantation
xenograft
mammospheric
cell
reduced
mirna
help
regulate
cell
differentiation
take
advantage
ability
obtain
large
number
cell
compare
mirna
expression
mammospheric
vitro
differentiate
progeny
much
mirna
express
background
line
reduce
expression
mammospheric
cell
either
freshly
dissociate
figure
lane
briefly
adhere
lane
compare
cell
differentiate
adherent
condition
day
lane
day
lane
lane
differentiation
much
reduce
mirna
gradually
increase
level
cluster
analysis
multiple
sample
show
clear
distinction
mammospheric
versus
differentiate
cell
show
anova
analysis
normalize
chip
datum
identify
number
mirna
whose
expression
mammosphere
significantly
different
differentiate
parent
cell
among
family
emerge
much
consistently
significantly
reduce
mirna
mirna
include
show
expression
pattern
initially
identify
mirna
regulate
development
target
key
gene
include
ras
homolog
human
family
member
differentially
express
different
tissue
believe
redundant
target
function
downregulated
human
cancer
associate
poor
lung
cancer
prognosis
target
ras
encode
protein
implicate
mesenchymal
cell
differentiation
tumor
formation
paper
focused
know
tumor
suppressor
image
image
figure
mirna
reduced
mammospheric
cell
tumor
mirna
array
analysis
show
mirna
differentially
express
cell
cultured
mammosphere
adhere
day
parent
much
mirna
include
homolog
reduce
cultured
mammosphere
just
adhere
increase
differentiation
similar
level
northern
blot
probe
amplify
mean
sd
relative
verify
microarray
result
derived
either
show
similar
expression
increase
gradually
begin
day
follow
induction
differentiation
within
compare
cell
cultured
sphere
error
bar
correspond
mean
sd
function
assay
luciferase
assay
negligible
increase
upon
differentiation
infection
compare
mammospheric
transfection
aso
reduce
endogenous
exogenous
activity
compare
cell
error
bar
correspond
mean
sd
target
highly
express
mammospheric
differentiate
adherent
protein
assay
immunoblot
relative
infection
lentivirus
vector
suppress
expression
respectively
mammospheric
cell
transfection
aso
augment
protein
addition
tumor
eight
untreated
patient
five
patient
treat
neoadjuvant
chemotherapy
enrich
sort
cell
growth
mammosphere
tumor
deplete
adherent
growth
exclude
cell
also
reduce
compare
adjacent
normal
breast
tissue
facs
analysis
northern
blot
probe
show
respectively
representative
untreated
table
neoadjuvant
chemotherapy
treat
patient
mean
sd
relative
expression
sample
analyzed
datum
patient
figure
infection
increase
compare
sample
deplete
cell
view
within
article
verify
reduction
mammospheric
cell
perform
northern
blot
probe
recognize
homolog
primer
assay
barely
detect
mammospheric
change
adherence
begin
increase
within
day
increase
far
day
also
express
mammosphere
upregulated
upon
vitro
differentiation
similar
kinetic
therefore
although
rule
possibility
chemotherapy
exposure
alter
property
cell
reduce
consequence
chemotherapy
growth
rather
corollary
capacity
day
expression
differentiate
cell
increase
fold
significantly
different
expression
reduction
mirna
sphere
also
verify
specific
mirna
primer
figure
reduce
fold
fold
mammospheric
compare
differentiate
reduce
significantly
investigate
function
transfected
luciferase
reporter
contain
target
sequence
mammospheric
differentiate
luciferase
activity
suppress
differentiate
suppression
infection
lentivirus
express
enhance
mirna
expression
function
comparably
differentiate
cell
figure
differentiate
cell
antisense
oligonucleotide
aso
significantly
reduce
suppression
luciferase
activity
endogenous
exogenous
figure
transfection
aso
reduce
also
expression
analyzed
specific
primer
figure
close
homology
within
family
single
aso
may
able
inhibit
entire
family
many
member
since
ras
know
target
compare
expression
three
cell
line
protein
highly
express
mammospheric
cell
greatly
reduce
differentiate
cell
ras
protein
detect
cell
show
expressing
shrna
either
gene
mammospheric
reduce
level
differentiate
cell
aso
upregulated
protein
substantially
however
mrna
measure
differ
significantly
among
three
cell
line
show
therefore
silence
ras
expression
inhibit
translation
previously
report
johnson
rather
cleave
mrna
moreover
reduce
mammospheric
cell
lead
ras
overexpression
reduced
clinical
cancer
specimen
reduced
mammosphere
suggest
might
reduce
therefore
examine
expression
northern
blot
select
three
group
patient
specimen
enrich
culture
mammosphere
sort
freshly
isolate
cell
cell
mammosphere
sort
cell
compose
mostly
epc
ponti
patient
table
reduce
compare
either
adherent
cell
tumor
cell
figure
show
northern
blot
representative
patient
receive
chemotherapy
one
figure
depict
mean
standard
deviation
sd
individual
patient
datum
respectively
analysis
expression
normal
adjacent
breast
tissue
high
cancer
cell
deplete
consistent
prior
report
breast
cancer
express
little
normal
breast
tissue
transduction
lentivector
enhance
expression
comparably
cancer
deplete
although
much
patient
receive
chemotherapy
figure
table
reduction
mammosphere
sort
cell
comparable
whether
patient
receive
preoperative
chemotherapy
reduced
cancer
cell
enrich
either
growth
mammosphere
sort
phenotype
also
confirm
show
independent
chemotherapy
exposure
whether
tumor
metastatic
sample
two
patient
group
figure
therefore
reduce
intrinsic
property
epc
reduced
required
maintain
mammosphere
test
whether
important
renewal
study
effect
enforce
expression
mammosphere
assay
cell
infect
form
fold
fewer
mammosphere
uninfected
cell
infect
empty
lentiviruses
mammosphere
formation
also
delay
mammosphere
form
fold
small
cell
control
cell
importantly
mammosphere
passaged
eight
ten
generation
whereas
untransduced
sphere
passaged
least
generation
year
therefore
weaken
capacity
nonadherent
condition
conversely
transfecting
aso
parental
differentiate
cell
enhance
mammosphere
formation
fold
aso
also
greatly
increase
percentage
sp
cell
differentiate
figure
image
image
figure
cell
express
lose
ability
form
mammosphere
proliferate
less
conditions
culture
dissociate
cell
infect
empty
vector
form
fewer
mammosphere
mammosphere
form
develop
much
slowly
reduce
cell
number
compare
untransduced
cell
error
bar
correspond
mean
sd
conversely
differentiate
cell
transfected
control
aso
generate
fold
much
mammosphere
error
bar
correspond
mean
sd
cell
sort
phenotype
breast
tumor
markedly
high
capacity
form
mammosphere
compare
cell
transduction
lentivector
reduce
mammosphere
compare
untransduced
cell
mammosphere
formation
also
significantly
reduce
serial
passage
stable
untransduced
cell
cell
infect
lesser
extent
lentivirus
proliferate
little
vitro
differentiation
untransduced
control
cell
measure
compare
untransduced
view
within
article
expression
also
reduce
mammosphere
form
patient
sort
cancer
cell
patient
infect
percentage
mammosphere
culture
decline
fold
figure
moreover
although
untransduced
cell
maintain
stable
capacity
upon
vitro
passage
number
sphere
form
corresponding
cell
decline
passage
figure
although
mirna
reduce
mammospheric
figure
exogenously
express
mirna
level
alter
mammosphere
formation
figure
moreover
although
identify
target
transduction
mammospheric
reduce
protein
cell
suggest
effective
targeting
may
vary
cellular
context
figure
reduced
maintain
proliferation
inhibits
differentiation
another
property
cell
potential
expand
differentiate
condition
mammospheric
proliferate
half
rate
measure
incorporation
differentiate
condition
proliferation
increase
fold
baseline
peak
day
day
level
somewhat
high
cell
transduced
express
peak
decline
demonstrate
reduce
proliferative
potential
differentiate
precursor
cell
another
hallmark
undifferentiated
state
potential
multilineage
differentiation
mammospheric
express
neither
myoepithelial
luminal
epithelial
figure
day
differentiation
much
cell
express
differentiation
marker
remain
overexpression
significantly
reduce
proportion
lin
cell
mammospheric
differentiate
control
lentiviruses
include
lentivirus
express
see
effect
maintain
lin
population
differentiate
condition
conversely
aso
greatly
increase
percentage
residual
cell
differentiate
figure
similarly
transduction
cell
isolate
patient
cancer
reduce
proportion
cell
fold
figure
therefore
help
maintain
undifferentiated
status
proliferative
potential
mammospheric
cell
cell
line
tumor
silencing
ras
partially
effect
next
examine
whether
effect
reduce
promote
renewal
multilineage
differentiation
attributed
ras
reduce
respectively
level
differentiate
comparably
silence
form
half
many
mammosphere
untransduced
three
time
much
cell
infect
moreover
mammosphere
intermediate
size
cell
versus
cell
untransduced
cell
day
figure
silencing
ras
also
reduce
proliferation
differentiate
condition
much
little
express
figure
day
differentiation
peak
proliferation
silencing
ras
unlike
overexpressing
either
mammospheric
differentiate
reduce
proportion
undifferentiated
cell
lack
ck
figure
contrast
silence
alter
mammosphere
formation
mammospheric
cell
versus
control
vector
figure
slightly
reduce
proliferation
figure
although
much
transduction
however
reduce
proportion
undifferentiated
lin
cell
either
sphere
adherent
condition
figure
moreover
reduction
lin
cell
mammospheric
differentiate
comparable
mediate
express
figure
therefore
reduce
regulate
different
aspect
stemness
silence
multiple
inhibit
renewal
part
regulate
ras
differentiation
silence
image
image
figure
silencing
undifferentiated
subpopulation
proliferation
cell
significantly
alter
mammosphere
formation
culture
dissociate
cell
infect
form
comparable
number
mammosphere
uninfected
cell
cell
infect
lentivector
positive
compare
untransduced
silencing
reduce
proliferation
cell
day
vitro
differentiation
adherent
culture
peak
proliferation
much
transduction
cell
proliferation
measure
compare
untransduced
transduction
vector
similarly
reduce
proportion
lin
cell
cell
cultured
mammosphere
adherent
differentiate
condition
day
compare
vector
transduced
cell
error
bar
correspond
mean
sd
view
within
article
expression
inhibits
tumor
formation
nod
scid
mice
next
assess
effect
enforce
expression
tumor
formation
although
eight
ten
mouse
inoculate
cell
mouse
inject
great
number
cell
form
tumor
significantly
fewer
tumor
develop
mammospheric
cell
moreover
tumor
grow
much
slowly
untransduced
control
tumor
tumor
reach
cm
diameter
day
become
palpable
control
tumor
reach
size
day
similarly
mammospheric
cell
give
rise
fewer
tumor
serially
passaged
vivo
table
suggest
inhibit
capacity
vivo
well
vitro
slightly
reduce
tumorigenesis
much
image
image
figure
mammospheric
cell
tumorigenic
nod
scid
mice
expression
cell
tumor
outgrowth
tumor
volume
measure
mammary
fat
pad
inoculation
leave
middle
right
cell
mammospheric
cell
untransduced
transduced
vector
express
number
legend
indicate
number
mouse
develop
tumor
mammospheric
cell
much
tumorigenic
cell
overexpression
lesser
extent
lead
fewer
tumor
tumor
arise
much
slowly
error
bar
correspond
mean
sd
tumor
grow
mouse
inoculate
cell
similar
histology
hematoxylin
eosin
staining
magnification
tumor
either
untransduced
transduced
vector
high
expression
high
proliferative
index
pcna
staining
tumor
infection
reduce
ras
expression
almost
much
silence
ras
much
effectively
reduce
compare
untransduced
tumor
error
bar
correspond
mean
sd
view
within
article
tissue
structure
cell
morphology
tumor
generate
mammospheric
express
grossly
different
however
much
highly
express
mammospheric
xenograft
tumor
transduction
lentivector
significantly
reduce
tumor
level
tumor
keep
fast
growth
high
proportion
tumor
cell
stain
proliferate
antigen
pcna
transduction
also
significantly
reduce
pcna
staining
xenograft
although
tumor
also
significantly
reduce
pcna
index
effectively
thus
lack
enhance
cell
tumorigenicity
part
modulate
hras
expression
inhibits
tumorigenesis
breast
cancer
cell
assess
whether
reduction
also
important
tumorigenesis
cancer
cell
sort
cell
eight
patient
cancer
evaluate
xenograft
formation
injection
cell
generate
tumor
six
eight
mouse
tumor
develop
mouse
inject
cell
patient
increasing
number
inject
cell
result
tumor
eight
eight
mouse
still
tumor
mouse
receive
cell
lack
phenotype
moreover
cancer
cell
passaged
nod
scid
mouse
cell
serially
transplant
two
far
passage
without
reduce
tumorigenicity
transduction
significantly
reduce
tumorigenicity
also
reduce
tumor
formation
upon
serial
transplantation
therefore
enforce
expression
interfere
tumor
initiation
vivo
renewal
table
incidence
tumor
breast
cancer
cell
serially
nod
scid
mice
cell
tumor
cellspassage
tumor
cellspassage
lin
table
$
compare
untransduced
cell
initial
inoculation
mouse
inoculate
sort
cell
transduced
different
patient
clinical
feature
eight
patient
describe
table
subsequent
passage
cell
isolate
sort
transduced
mouse
inject
tumor
cell
two
patient
whose
transduced
cell
establish
xenograft
view
within
article
tumor
less
likely
metastasize
also
evaluate
whether
enforce
expression
affect
metastasis
examine
lung
liver
xenograft
reach
cm
diameter
size
assess
metastasis
untransduced
xenograft
infection
reduce
number
mouse
lung
metastases
two
ten
mouse
average
lung
weight
figure
metastases
small
also
disperse
among
alveoli
suggest
reduce
clinical
severity
number
lung
tumor
cell
quantify
hhprt
mouse
metastases
also
little
animal
inject
compare
mouse
inoculate
cell
figure
expressing
modestly
significantly
reduce
lung
metastasis
little
effective
image
image
figure
mammospheric
cell
metastasize
lung
liver
unlike
infection
inhibits
metastasis
staining
lung
liver
mouse
implant
cell
either
untransduced
transduced
lentivector
arrow
indicate
focal
metastasis
mean
sd
lung
weight
mouse
group
expression
hhprt
mrna
relative
mouse
gapdh
number
indicate
number
animal
group
ten
lung
liver
metastasis
analysis
exclude
animal
without
metastases
relevant
organ
compare
untransduced
tumor
view
within
article
similarly
liver
expression
ras
silence
reduce
number
mouse
liver
metastasis
respectively
confirm
measure
little
hhprt
mrna
liver
mouse
inoculate
cell
micrometastases
three
ten
mouse
reduction
mouse
inject
cell
four
ten
mouse
respectively
compare
implant
cell
mouse
figure
therefore
reduce
mammospheric
cell
metastasis
lung
liver
reduction
partially
due
change
ras
reduced
metastasis
cell
due
difference
tumor
size
animal
sacrifice
tumor
diameter
reach
cm
result
slow
growth
tumor
alter
metastatic
potential
cell
study
distinguish
possibility
discussion
evidence
cancer
stem
cell
hypothesis
grow
identify
increase
number
malignancy
however
rare
within
tumor
difficult
study
little
know
regulate
critical
ability
renew
initiate
tumor
find
breast
tumor
patient
highly
enrich
cell
property
take
advantage
chemotherapeutic
resistance
generate
highly
malignant
breast
cancer
cell
line
sequential
vivo
passage
nod
scid
mouse
enrich
cell
display
tentatively
define
property
include
enhance
mammosphere
formation
multipotent
differentiation
chemotherapy
resistance
phenotype
based
vitro
mammosphere
form
assay
proportion
sp
cell
estimate
cell
remain
cell
also
largely
epc
mammospheric
cell
fold
much
tumorigenic
nod
scid
mouse
parent
line
metastasize
capable
serial
xenotransplantation
key
property
mammosphere
coincide
obtain
sort
cell
breast
cancer
cell
provide
virtually
unlimited
number
cell
study
similar
approach
vivo
chemotherapy
might
also
select
breast
cancer
line
possibly
tumor
potential
accumulate
specific
mutation
line
relevance
result
obtain
enrich
cell
however
need
confirm
sort
cancer
cell
patient
provide
mean
isolate
large
number
study
regulate
stemness
finding
neoadjuvant
chemotherapy
treatment
select
survival
epc
although
surprising
light
know
resistance
chemotherapy
somewhat
disturbing
selective
outgrowth
little
differentiate
cell
may
one
reason
neoadjuvant
adjuvant
chemotherapy
always
effective
prevent
late
tumor
recurrence
one
contribute
factor
chemotherapy
selection
whether
neoadjuvant
chemotherapy
patient
mouse
increase
expression
drug
efflux
transporter
provide
selective
survival
advantage
increased
expression
support
early
study
take
advantage
drug
efflux
enrich
sp
cell
multiple
mechanism
likely
influence
selective
survival
chemotherapy
include
preferential
activation
dna
repair
pathway
show
glioma
take
advantage
ability
obtain
large
number
cell
study
change
mirna
expression
vitro
differentiation
mammospheric
cell
express
substantially
little
mirna
differentiate
parent
cell
global
reduction
mirna
expression
previously
note
cancer
cell
relative
normal
tissue
investigate
mechanism
global
reduction
mirna
one
possible
contribute
factor
might
reduce
mirna
processing
describe
mouse
embryonic
development
difference
mirna
expression
immediate
consequence
growth
since
adherence
substantially
alter
mirna
expression
within
day
place
differentiate
condition
however
much
mirna
express
parental
line
induce
although
take
long
express
virtually
absent
expression
distinguish
cell
differentiate
progeny
parent
line
moreover
lack
require
renewal
vitro
tumorigenicity
vivo
overexpression
reduce
renewal
proliferative
capacity
convert
highly
malignant
metastasizing
little
malignant
cell
conversely
antagonize
aso
differentiate
enhance
sphere
formation
contrast
overexpressing
oncomirs
differentially
mammosphere
effect
vitro
renewal
although
appear
play
major
role
regulate
stemness
regulate
expression
differentially
express
oncomirs
include
list
well
will
undoubtedly
contribute
regulate
distinct
pathway
require
tumor
initiation
transformation
proliferation
invasion
metastasis
apoptosis
chemo
radiotherapy
resistance
will
good
system
study
role
oncomirs
breast
cancer
initiation
result
suggest
reduce
might
regulate
fate
much
generally
cell
line
expand
vitro
vivo
might
accumulate
mutation
might
make
different
tumor
test
importance
reduction
enrich
obtain
breast
cancer
sort
mammosphere
culture
regardless
isolate
express
substantially
little
corresponding
population
cell
deplete
moreover
express
cell
breast
cancer
reduce
mammosphere
formation
proliferation
vitro
tumor
xenograft
formation
mammosphere
cell
contain
epc
unable
define
exact
point
begin
express
result
suggest
expression
begin
early
stage
differentiation
reduced
intrinsic
property
possibly
epc
consequence
exposure
chemotherapy
growth
mammosphere
enrich
patient
generate
either
sort
growth
condition
similarly
reduce
comparably
derived
cell
expose
chemotherapy
postulate
work
tumor
suppressor
silence
ras
confirm
finding
cell
ras
homolog
express
protein
mrna
correlated
inversely
expression
hras
high
differentiate
moreover
exogenous
significantly
increased
report
breast
cancer
correlate
poor
prognosis
increase
human
breast
cancer
mutation
rare
suggest
possibility
regulation
overexpression
tumor
think
primarily
secondary
chromosomal
translocation
delete
multiple
recognition
site
study
suggest
overexpression
also
secondary
reduce
expression
ras
regulate
different
aspect
stemness
ras
appear
important
renewal
since
silence
ras
reduce
mammosphere
formation
clonal
expansion
tumorigenicity
effect
cell
differentiation
hand
appear
help
maintain
multipotency
since
silence
reduce
proportion
undifferentiated
cell
affect
vitro
renewal
support
overexpressed
embryo
poorly
differentiate
tumor
thus
act
master
regulator
multiple
aspect
stemness
presumably
silence
multiple
target
remain
identify
direct
target
include
gene
implicate
regulation
include
cyclin
comparing
mirna
mrna
expression
cell
may
help
define
mirna
network
additional
target
mrna
comparison
recently
report
regulate
multiple
oncogene
much
one
pathway
therapeutic
mimic
might
attractive
differentiate
resistant
within
breast
cancer
possibly
tumor
much
potent
specifically
silence
one
oncogene
sirna
mimic
potentially
single
agent
combine
conventional
chemo
radiotherapy
since
express
normal
breast
tissue
differentiate
cell
introduce
exogenously
trigger
toxicity
noncancerous
cell
corollary
cancer
stem
cell
hypothesis
metastases
may
also
arise
support
find
cell
phenotype
prevalent
metastatic
pleural
effusion
moreover
xenograft
metastases
reduce
expression
parallel
property
alternate
hypothesis
metastatic
tumor
originate
cell
tumor
undergo
transition
emt
result
suggest
two
contrary
idea
mutually
exclusive
fact
poorly
express
mesenchymal
highly
express
epithelial
tumor
opposite
true
target
highly
express
embryo
mesenchymal
cell
mesenchymal
tumor
therefore
reduce
may
link
emt
gene
map
site
frequent
chromosomal
instability
cancer
poorly
express
lung
colon
cancer
downregulation
breast
tumor
compare
normal
breast
report
previous
microarray
analysis
confirm
present
study
reduce
cancer
compare
adjacent
normal
breast
however
difference
small
compare
fold
reduction
compare
cancer
cell
epc
within
tumor
might
contribute
moderate
reduction
bulk
breast
cancer
cell
reduction
breast
tumor
might
serve
surrogate
frequency
poorly
differentiate
cell
tumor
provide
useful
prognostic
information
likelihood
chemotherapy
response
relapse
fact
high
expression
strongly
correlate
poor
prognosis
advance
ovarian
cancer
despite
evidence
increase
array
cancer
cancer
stem
cell
hypothesis
remain
hypothesis
result
need
consider
light
evidence
possible
phenotypic
heterogeneity
recently
suggest
glioma
heterogeneity
breast
tumor
cell
develop
tumor
initiation
secondary
additional
mutation
epigenetic
change
alternate
possibility
cancer
stem
cell
hypothesis
also
need
keep
mind
recent
study
suggest
might
artifact
xenotransplantation
consist
minority
cell
capable
survive
support
mouse
rather
human
growth
factor
supply
xenogeneic
tumor
microenvironment
fact
mouse
lymphoma
cell
generate
transgenic
mouse
transplant
congenic
mouse
lymphoma
cell
lack
stem
cell
marker
also
form
tumor
however
strong
tentatively
define
xenogeneic
microenvironment
may
also
indicator
ability
seed
congenic
tumor
site
may
multipotency
provide
mean
generate
tumor
support
niche
cell
necessary
sustain
recently
show
human
cell
experimental
procedure
detailed
procedure
provide
supplemental
data
tumor
tumor
obtain
female
patient
breast
carcinoma
include
case
cancer
case
recurrent
breast
cancer
pleural
metastasis
table
twelve
breast
cancer
patient
receive
neoadjuvant
chemotherapy
follow
modified
radical
mastectomy
eight
cancer
case
treat
resection
without
chemotherapy
specimen
obtain
biopsy
bard
biopsy
system
az
seven
patient
neoadjuvant
chemotherapy
pleural
fluid
obtain
pleural
puncture
five
case
recurrent
cancer
pleural
metastasis
sample
immediately
mechanically
digest
collagenase
describe
filter
filter
tumor
cell
sort
staining
cell
deplete
cocktail
lineage
marker
antibody
generation
cell
line
cell
atcc
passaged
nod
scid
mouse
inject
cell
mammary
fat
pad
mouse
epirubicin
mg
kg
pharmacia
inject
tail
vein
weekly
suspension
tumor
xenograft
remove
tumor
reach
cm
diameter
isolate
describe
cell
passaged
nod
scid
mouse
mammosphere
culture
cell
cell
ml
cultured
suspension
supplement
invitrogen
ml
egf
bd
bioscience
bovine
serum
albumin
sigma
ml
insulin
sigma
propagate
sphere
vitro
sphere
collect
gentle
centrifugation
dissociate
single
cell
describe
cultured
generate
mammosphere
next
generation
differentiation
cell
dissociate
sphere
plate
cell
ml
well
plate
precoated
collagen
iv
bd
bioscience
dmem
supplement
fcs
without
growth
factor
passaged
reach
confluence
acknowledgment
thank
robert
clarke
howell
manchester
uk
advice
work
support
natural
science
foundation
china
grant
national
scholar
program
project
ministry
science
technology
china
guangzhou
science
technology
bureau
nih
much
malignancy
neither
initiate
genetic
event
cell
origin
know
cancer
heterogeneous
composition
organize
hierarchy
include
cell
competent
recreate
tumor
transplantation
designate
tumor
initiate
cell
cancer
stem
cell
cell
comprise
bulk
tumor
mass
following
first
hit
whether
occur
within
stem
much
differentiate
cell
secondary
event
genetic
epigenetic
nature
contribute
evolution
malignancy
access
early
step
cancer
formation
impossible
patient
animal
model
provide
window
phase
cancer
development
likely
relevant
human
biology
far
genetic
event
mirror
occur
patient
consider
issue
seek
apply
cancer
epithelial
origin
principle
prove
successful
study
hematopoietic
malignancy
leukemia
childhood
sarcoma
chromosomal
translocation
lead
production
chimeric
protein
serve
initiate
genetic
event
although
gene
rearrangement
associate
leukemia
rare
study
infrequent
event
define
transcription
factor
critical
normal
differentiation
pathway
much
generally
malignancy
lately
contribution
chromosomal
rearrangement
epithelial
cancer
view
minor
recently
chromosomal
rearrangement
involve
ets
family
transcription
factor
identify
case
human
prostate
cancer
tomlins
tomlins
tomlins
furthermore
fusion
gene
identify
lung
cancer
case
observation
prompt
conclusion
regard
involvement
chromosomal
rearrangement
epithelial
cancer
unique
recurrent
chromosomal
translocation
associate
cancer
germ
layer
include
human
secretory
breast
carcinoma
sbc
congenital
congenital
acute
leukemia
produce
fusion
oncogene
encode
chimeric
protein
make
domain
also
know
tel
ets
family
transcription
factor
protein
tyrosine
kinase
ptk
domain
also
know
trk
family
tyrosine
kinase
receptor
consistent
presence
translocation
human
sbc
provide
strong
genetic
epidemiological
support
role
initiation
breast
cancer
breast
cancer
representative
epithelial
malignancy
heterogeneity
genetically
clinically
part
phenotypic
heterogeneity
may
reflect
diverse
cellular
origin
different
subtype
breast
cancer
report
murine
model
human
sporadic
breast
cancer
based
translocation
demonstrate
two
commit
mammary
progenitor
normal
mammary
developmental
hierarchy
serve
target
cell
breast
cancer
addition
perform
microarray
analysis
reveal
transformation
mediate
largely
activation
complex
result
generating
conditional
knockin
allele
generate
knockin
allele
introduce
portion
human
cdna
encode
ptk
domain
find
sbc
patient
exon
mouse
locus
render
fusion
allele
conditional
insertion
floxed
transcriptional
sequence
stopper
figure
upstream
knockin
cdna
result
allele
activate
excision
floxed
stopper
produce
mouse
hybrid
protein
transform
nih
cell
datum
show
therefore
knockin
allele
chimeric
protein
see
patient
image
image
figure
generating
conditional
knockin
allele
schematic
diagram
endogenous
wt
allele
conditional
knockin
allele
activate
allele
upon
excision
floxed
cassette
stopper
fusion
protein
produce
activate
allele
probe
southern
blot
show
x
xhoi
ecorv
noti
vii
viii
exon
poly
signal
sterile
alpha
motif
point
domain
ptk
protein
tyrosine
kinase
domain
southern
blot
screen
confirmation
correctly
targeted
cell
clone
probe
recognize
kb
xhoi
fragment
wt
allele
kb
xhoi
fragment
due
incomplete
digestion
noti
kb
fragment
complete
digestion
knockin
allele
probe
recognize
kb
ecorv
fragment
wt
allele
kb
ecorv
fragment
allele
analysis
show
greatly
elevate
expression
fusion
transcript
cell
note
slightly
leaky
expression
parental
cell
without
excision
stopper
western
blot
show
detection
fusion
protein
tyrosine
phosphorylated
doublet
cell
parental
cell
cell
positive
control
view
within
article
identify
correctly
targeted
cell
clone
southern
blot
find
cell
without
excision
exhibit
slightly
leaky
expression
allele
removal
stopper
greatly
increase
expression
protein
level
fusion
protein
detect
cell
however
expression
readily
visible
cell
thus
conditional
knockin
allele
function
design
endogenous
locus
active
mammary
epithelial
cell
control
endogenous
promoter
first
examine
normally
express
mammary
gland
mg
mouse
strain
generate
carry
locus
cassette
insert
exon
serve
reporter
expression
upon
staining
mg
heterozygous
female
lacz
activity
find
express
ductal
alveolar
mammary
epithelial
cell
mec
figure
supplemental
data
available
article
online
addition
flow
cytometry
analysis
reveal
cell
four
major
mec
subpopulation
define
previously
figure
activation
mammary
gland
lead
mammary
tumor
complete
penetrance
without
activation
wt
littermates
heterozygous
female
rarely
male
develop
mammary
tumor
advance
age
year
possibly
due
stopper
expression
activate
expression
mg
initially
plan
two
commonly
cre
mouse
line
unfortunately
lead
lethal
myeloproliferative
disease
within
several
week
birth
apparently
due
expression
hematopoietic
system
datum
show
much
restrict
expression
endogenous
wap
gene
well
transgene
boulanger
kordon
robinson
robinson
wagner
afford
approach
activation
mg
without
accompany
effect
tissue
mature
mature
nulliparous
female
mouse
cell
present
transiently
minor
subset
estrus
wap
expression
greatly
elevate
differentiate
mec
late
pregnancy
turn
follow
based
expression
pattern
wap
initially
predict
hereafter
wcen
female
mouse
might
require
round
pregnancy
order
express
sufficient
cre
activate
unexpectedly
however
nulliparous
wcen
female
develop
multifocal
mammary
tumor
early
month
age
precede
lobuloalveolar
hyperplasia
parous
wcen
female
develop
similar
multifocal
mammary
tumor
antecedent
alveolar
hyperplasia
significant
difference
tumor
latency
histology
age
wcen
male
also
develop
mammary
tumor
figure
datum
show
image
image
figure
mice
develop
mammary
tumor
antecedent
alveolar
hyperplasia
curve
mammary
gland
mg
wcen
female
ba
bc
exhibit
extensive
lobuloalveolar
hyperplasia
compare
wt
bb
bd
ba
bb
mg
whole
mount
stain
bc
bd
hematoxylin
eosin
mg
section
scale
bar
red
arrow
alveolar
hyperplasia
blue
arrow
duct
accumulation
secretion
within
duct
pcr
analysis
genomic
dna
show
excision
cassette
tumor
location
pcr
primer
indicate
western
blot
analysis
wcen
tumor
cell
positive
control
ip
western
confirm
expression
tumor
cell
histology
section
scale
bar
mammary
tumor
develop
wcen
show
squamous
metaplasia
nulliparous
female
show
primary
mammary
tumor
show
metastasis
lymph
node
eg
eh
male
eg
show
primary
mammary
tumor
eh
show
metastasis
lung
view
within
article
confirm
mammary
tumor
wcen
animal
result
activation
expression
perform
pcr
analysis
genomic
dna
prepare
tumor
organ
wcen
animal
find
stopper
allele
excise
tumor
cell
consistent
also
detect
protein
tumor
tissue
western
blot
previous
study
demonstrate
expression
fusion
protein
cell
lead
constitutive
phosphorylation
akt
well
constitutive
expression
cyclin
feature
also
characterize
mammary
tumor
hereafter
tumor
tumor
heterogeneous
respect
morphology
rate
tumor
progression
figure
datum
show
much
tumor
highly
invasive
transplantable
upon
subcutaneous
injection
immunodeficient
mouse
rate
tumor
follow
transplantation
correlated
apparent
rate
progression
corresponding
primary
tumor
due
relatively
short
latency
tumor
much
wcen
mouse
fail
show
sign
metastasis
occasion
metastases
lymph
node
lung
observe
figure
transient
cell
nulliparous
mammary
gland
target
cell
nulliparous
female
mouse
wap
activate
small
transient
population
mec
estrus
kordon
robinson
robinson
study
hereafter
wclz
female
show
thus
also
mec
fail
persist
wclz
mouse
since
cell
accumulate
nulliparous
wclz
mouse
infer
mec
wap
first
activate
proliferate
extensively
possibly
die
apoptosis
boulanger
henry
wagner
addition
one
infer
cell
equivalent
mammary
stem
cell
mascs
virgin
mouse
since
wcen
nulliparous
female
develop
multifocal
mammary
tumor
penetrance
transient
mec
likely
cell
virgin
express
cre
therefore
activate
expression
cell
might
direct
target
transformation
test
hypothesis
reporter
wcen
background
generate
hereafter
wcenlz
female
predict
presence
hyperplastic
mec
mg
subsequent
development
mammary
tumor
indeed
lacz
staining
primarily
restrict
hyperplastic
alveolar
cell
hyperplastic
mg
moreover
cell
confine
tumor
epithelial
cell
mammary
tumor
thus
genetic
marking
suggest
activation
cre
rescue
otherwise
transient
subpopulation
mec
maintain
progeny
subsequent
step
progression
frank
malignancy
furthermore
reason
wcenlz
tumor
also
mark
lacz
test
transplant
tumor
cell
immunodeficient
mouse
limited
dilution
without
fractionation
typically
tumor
cell
need
form
new
tumor
mouse
contrast
sometimes
even
sort
tumor
cell
sufficient
initiate
new
tumor
host
suggest
evolve
target
cell
enrich
population
tumor
cell
image
image
figure
target
cell
mammary
tumor
transient
mammary
progenitors
rather
mascs
schematic
diagram
experiment
normal
wclz
virgin
mg
contain
transient
wave
mec
wcenlz
mutant
mg
transient
mec
appear
rescue
death
lead
alveolar
hyperplasia
eventually
mammary
tumor
show
whole
mount
wcenlz
mg
tumor
stain
lacz
tissue
section
counterstained
nuclear
fast
red
note
cell
mainly
restrict
alveolar
compartment
scale
bar
flow
cytometry
analysis
wt
mg
wcen
hyperplastic
mg
wcen
tumor
profile
show
already
gate
lin
cell
percentage
positive
cell
representative
experiment
view
within
article
hyperplastic
mammary
gland
tumor
accumulate
cell
characterize
nature
target
cell
examine
surface
marker
previously
mammary
tissue
enrich
stem
progenitor
population
shackleton
stingl
flow
cytometry
analysis
much
tumor
cell
moreover
mg
mature
nulliparous
wcen
female
contain
great
number
cell
wt
control
even
develop
tumor
contrast
shackleton
similar
stingl
subpopulation
alter
wcen
hyperplastic
mg
datum
argue
mammary
tumor
wcen
mouse
unlikely
arise
transformation
mascs
instead
may
derived
commit
mammary
progenitor
mammary
tumor
derived
committed
alveolar
progenitors
hematopoietic
system
developmental
hierarchy
mec
include
mascs
bipotent
ductal
alveolar
progenitor
single
progenitor
mature
luminal
myoepithelial
cell
propose
robinson
position
target
cell
hierarchy
perform
immunostaining
luminal
epithelial
cell
marker
keratin
basal
myoepithelial
cell
marker
keratin
muscle
actin
sma
well
mammary
progenitor
marker
keratin
estrogen
receptor
figure
figure
overall
identify
two
broad
tumor
type
wcen
mouse
majority
tumor
type
exhibit
relatively
glandular
structure
contain
luminal
epithelial
cell
surround
basal
myoepithelial
cell
positive
sometimes
sma
occasionally
basal
myoepithelial
cell
region
luminal
epithelial
cell
figure
figure
much
extreme
case
type
tumor
type
region
within
tumor
contain
large
number
basal
myoepithelial
cell
small
number
luminal
epithelial
cell
little
organize
manner
figure
second
class
tumor
type
exhibit
basal
myoepithelial
cell
contain
predominantly
luminal
epithelial
cell
interestingly
large
number
cell
tumor
also
figure
figure
contrast
much
type
tumor
lack
abnormal
cell
however
type
tumor
contain
small
number
cell
figure
addition
also
identify
additional
subtype
type
tumor
type
exhibit
glandular
structure
luminal
epithelial
cell
surround
basal
myoepithelial
cell
however
many
luminal
cell
also
figure
thus
represent
tumor
feature
type
summary
staining
property
cell
different
type
tumor
provide
figure
majority
type
tumor
contain
cell
whereas
cell
present
type
tumor
figure
however
tumor
type
express
datum
show
figure
interestingly
upon
careful
examination
immunofluorescence
observe
significant
number
cell
addition
luminal
epithelial
cell
figure
image
image
figure
two
major
type
tumor
immunostaining
microarray
analysis
type
bipotent
aa
ae
type
tumor
based
aa
ae
staining
pattern
scale
bar
flow
cytometry
analysis
show
cell
type
tumor
normal
mg
almost
mec
gate
gate
represent
cell
mg
hierarchical
cluster
analysis
wcen
tumor
type
blue
line
together
sample
murine
model
breast
cancer
normal
mg
tumor
cluster
ii
highlight
yellow
line
tumor
highlight
red
line
heat
map
three
representative
gene
cluster
show
heat
map
show
gene
intrinsic
gene
list
show
figure
gene
name
cluster
list
table
heat
map
red
black
green
represent
average
average
average
level
expression
respectively
gray
indicate
datum
record
view
within
article
recently
integrin
show
mark
luminal
progenitor
normal
mg
interestingly
find
type
tumor
abundantly
express
whereas
much
type
tumor
contain
much
fewer
cell
figure
exception
type
tumor
microarray
expression
profile
confirm
type
tumor
express
high
level
follow
type
remain
type
tumor
datum
show
since
type
tumor
exhibit
luminal
appearance
characterize
large
number
cell
ask
whether
cell
might
represent
block
progenitor
fact
flow
cytometry
analysis
reveal
almost
cell
tumor
normal
mg
majority
cell
cell
whereas
luminal
cell
also
detect
small
population
cell
significant
number
also
express
datum
suggest
luminal
progenitor
cell
abnormal
cell
type
type
tumor
probably
represent
luminal
progenitor
block
differentiation
toward
mature
luminal
epithelial
cell
type
tumor
basal
myoepithelial
cell
addition
luminal
cell
part
tumor
epithelial
cell
population
compare
microarray
expression
profile
generate
sort
tumor
epithelial
cell
based
lacz
marker
wcenlz
female
tumor
observe
slight
enrichment
rather
loss
basal
gene
cluster
cluster
define
figure
discuss
sort
tumor
cell
determine
gene
set
enrichment
assay
gsea
datum
show
confirm
basal
myoepithelial
cell
tumor
part
tumor
epithelial
cell
normal
cell
recruit
tumor
due
presence
mix
cell
type
type
tumor
cell
tumor
originate
mascs
bipotent
progenitor
multiple
progenitor
since
genetic
marking
experiment
flow
cytometry
analysis
rule
mascs
target
next
ask
whether
tumor
derived
distinct
progenitor
bipotent
progenitor
clonal
transgenic
line
express
cre
cell
presence
doxycycline
generate
animal
also
carry
conditional
luciferase
reporter
locus
similar
reporter
unexpectedly
find
transgene
exhibit
leaky
cre
expression
nulliparous
female
develop
mammary
tumor
without
doxycycline
tumor
also
feature
cell
luminal
basal
myoepithelial
lineage
figure
since
cre
express
level
without
doxycycline
sometimes
might
excise
stopper
allele
allele
within
cell
tumor
arise
cell
genotype
tumor
epithelial
cell
inherit
allele
unmodified
allele
indeed
tumor
arise
nulliparous
female
detect
excision
locus
locus
figure
since
highly
unlikely
multiple
progenitor
obtain
partial
excision
pattern
describe
give
rise
tumor
pattern
observation
support
clonal
origin
type
tumor
bipotent
progenitor
furthermore
microarray
datum
reveal
compare
normal
mg
type
tumor
express
high
level
alveolar
cell
marker
level
ductal
cell
marker
also
know
carrier
family
member
figure
suggest
alveolar
cellular
origin
contrast
tumor
express
express
level
express
fraction
tumor
cell
consistent
mascs
potential
target
cell
give
rise
ductal
alveolar
cell
figure
taken
together
conclude
target
cell
mammary
tumor
arise
wcen
female
either
commit
bipotent
alveolar
progenitor
type
luminal
alveolar
progenitor
type
progenitor
within
transient
cell
nulliparous
female
mammary
tumor
express
luminal
basal
gene
cluster
compare
tumor
murine
breast
cancer
model
microarray
expression
profile
hierarchical
clustering
based
intrinsic
gene
list
develop
murine
model
breast
cancer
show
figure
figure
general
compare
murine
model
tumor
relatively
homogeneous
cluster
together
however
type
tumor
form
subcluster
separate
type
tumor
contrast
tumor
parous
nulliparous
remain
sample
female
mix
together
form
distinct
subcluster
datum
suggest
initiate
oncogenic
event
cellular
origin
reproductive
history
much
important
determine
phenotype
tumor
type
tumor
express
gene
cluster
include
basal
gene
cluster
strong
cluster
strong
luminal
gene
cluster
similar
tumor
type
tumor
express
cluster
cluster
contrast
tumor
mouse
express
luminal
cluster
note
tumor
much
heterogeneous
tumor
also
divide
two
major
subcluster
one
contain
cluster
luminal
cluster
figure
cluster
contain
basal
cluster
luminal
cluster
though
express
slightly
level
cluster
figure
cluster
ii
difference
may
due
part
different
cell
origin
mascs
much
likely
target
tumor
commit
progenitor
target
signature
associated
mammary
tumorigenesis
understand
mechanism
mammary
tumorigenesis
first
perform
gsea
microarray
expression
profile
unsorted
tumor
compare
normal
mg
gene
set
collection
metabolic
signaling
pathway
gsea
molecular
signature
database
website
unexpectedly
analysis
reveal
pathway
seem
common
tumor
cell
general
reflect
increase
metabolic
activity
proliferation
table
two
possibility
may
account
result
first
pathway
active
normal
mg
tumor
may
reveal
assay
second
noncancerous
cell
tumor
introduce
significant
unsorted
tumor
sample
wcenlz
animal
tumor
epithelial
cell
labeled
lacz
figure
thus
opportunity
mark
tumor
epithelial
cell
separate
stromal
cell
addition
target
cell
wclz
virgin
female
well
premalignant
hyperplastic
mec
wcenlz
female
also
mark
lacz
thus
provide
opportunity
isolate
cell
analysis
generate
microarray
expression
profile
several
sample
either
wcenlz
hyperplastic
mg
develop
visible
tumor
mammary
tumor
arise
wcenlz
female
compare
sort
tumor
cell
sort
hyperplastic
mec
gsea
gene
set
attempt
identify
pathway
upregulated
tumor
progression
top
gene
set
enrich
sort
tumor
cell
derived
comparison
much
informative
comparison
unsorted
tumor
table
compare
table
relate
hypoxia
response
tumor
wnt
signaling
trk
ngf
signaling
tgf
signaling
gene
regulate
evident
validate
effectiveness
approach
also
compare
unsorted
tumor
sort
hyperplastic
mec
thus
comparison
baseline
top
gene
set
enrich
unsorted
tumor
reveal
analysis
similar
compare
normal
mg
table
compare
table
suggest
gsea
sort
tumor
cell
may
reveal
pathway
well
specificity
unsorted
tumor
next
compare
sort
tumor
cell
unsorted
tumor
gsea
gene
set
reason
gene
pathway
upregulated
specifically
tumor
epithelial
cell
far
enrich
comparison
also
potentially
reveal
overall
signature
tumor
epithelial
cell
compartment
compose
pathway
upregulated
initial
transformation
tumor
progression
among
gene
set
enrich
sort
tumor
cell
observe
pathway
relate
gene
regulate
ebp
response
target
wnt
signaling
jnk
signaling
tgf
signaling
table
determine
portion
tumor
signature
acquire
tumor
initiation
ideally
need
sort
normal
target
cell
compare
expression
profile
sort
hyperplastic
mec
unfortunately
lacz
staining
mammary
tissue
fdg
dye
yield
significant
amount
background
staining
even
lacz
tissue
background
staining
difficulty
sort
hyperplastic
mec
tumor
cell
typically
constitute
total
cell
prohibit
sort
small
population
transient
target
cell
estimate
wagner
wagner
smith
sufficient
confidence
overcome
technical
limitation
turn
vitro
model
signaling
unique
oncoprotein
transform
cell
germ
layer
reason
mechanism
transformation
might
conserve
different
cell
type
signaling
nih
cell
study
previously
many
also
observe
tumor
thus
generate
microarray
expression
profile
cell
compare
cell
perform
gsea
gene
set
identify
several
common
gene
set
enrich
cell
sort
tumor
cell
include
pathway
wnttargets
table
compare
table
since
wnttargets
arise
among
gene
set
three
analysis
next
focused
gene
set
compare
core
enrichment
gene
three
analysis
observe
similarity
sort
tumor
cell
compare
unsorted
tumor
cell
compare
control
cell
figure
include
gene
jun
plaur
jun
also
know
encode
component
complex
target
gene
human
colorectal
carcinoma
plaur
encode
upar
transcription
activate
addition
also
upregulated
activity
thus
set
appear
represent
signature
consistent
datum
also
observe
enrichment
gene
set
contain
gene
motif
collection
gsea
database
sort
tumor
cell
cell
table
much
directly
manually
gene
set
target
gene
based
publish
literature
plus
jun
observe
significant
enrichment
sort
tumor
cell
cell
addition
set
identify
additional
target
gene
upregulated
comparison
include
hbegf
growth
factor
typically
function
tumor
suppressor
however
may
also
act
oncogene
fact
overexpression
find
breast
cancer
case
much
malignant
phenotype
note
observe
significant
enrichment
signature
sort
tumor
cell
compare
sort
hyperplastic
mec
figure
figure
suggest
least
part
signature
might
already
acquire
hyperplastic
mec
initial
stage
transformation
image
image
figure
enrichment
target
cell
gsea
show
enrichment
target
gene
sort
tumor
cell
compare
unsorted
tumor
sort
hyperplastic
cell
cell
gene
express
high
level
sort
tumor
cell
highlight
green
line
gene
express
high
level
sort
hyperplastic
mec
cell
indicate
red
arrow
view
within
article
confirm
involvement
complex
transformation
perform
electrophoretic
mobility
shift
assay
emsa
nuclear
lysate
cell
observe
significantly
large
specific
band
shift
create
complex
formation
cell
complex
compose
western
blot
analysis
confirm
significantly
elevate
level
total
phosphorylated
cell
suggest
indeed
major
complex
form
upon
transformation
image
image
figure
upregulation
activation
complex
associated
transformation
emsa
nuclear
lysate
control
kd
transduced
cell
incubation
specific
unlabeled
block
band
shift
lane
nuclear
lysate
produce
significantly
large
band
shift
compare
control
lysate
compare
lane
lane
antibody
specific
destroy
band
shift
produce
nuclear
extract
whereas
antibody
effect
western
blot
analysis
perform
lysate
control
mscvp
cell
cell
possess
tyrosine
phosphorylated
oncoprotein
doublet
elevate
level
phosphorylated
akt
mek
well
elevate
level
total
cyclin
loading
control
immunofluorescence
da
dc
dg
immunohistochemical
dd
df
dj
dl
staining
wt
mg
da
dd
dg
dj
hyperplastic
mg
db
mammary
tumor
dc
df
dl
antibody
da
dc
phosphorylated
dd
df
dg
total
dj
dl
wt
mg
da
dd
dj
nulliparous
female
mouse
wt
mg
dg
lactate
female
scale
bar
immunostaining
three
sbc
case
confirm
presence
activation
complex
scale
bar
view
within
article
validate
upregulation
activation
complex
tumor
perform
immunostaining
antibody
phosphorylated
total
wt
mg
mainly
localized
cytoplasm
figure
hyperplastic
mec
tumor
cell
overall
intensity
staining
increase
much
importantly
significant
nuclear
staining
detect
figure
addition
upregulation
phosphorylation
also
evident
hyperplastic
mec
tumor
cell
wt
mg
figure
suggest
activation
complex
early
event
present
hyperplastic
mec
persist
tumorigenesis
determine
status
human
sbc
stain
three
sbc
case
antibody
show
figure
three
three
sbc
sample
study
detect
nuclear
staining
expression
activation
phosphorylation
suggest
activation
complex
indeed
associate
human
sbc
expression
blocks
transformation
determine
activation
necessary
transformation
employ
lack
transactivation
domain
block
activity
several
different
system
coexpression
cell
block
transformation
morphologically
figure
ectopic
expression
murine
cell
human
cell
lead
large
matrigel
culture
coexpression
show
previously
cell
form
tumor
upon
subcutaneous
injection
immunodeficient
mouse
now
show
expression
cell
significantly
reduce
tumorigenic
property
vivo
compare
microarray
expression
profile
tumor
tumor
gsea
expect
many
gene
set
enrich
sort
tumor
cell
compare
unsorted
tumor
downregulated
tumor
table
importantly
one
gene
set
directly
relate
signaling
image
image
figure
expression
blocks
transformation
expression
cell
confirm
western
blot
analysis
loading
control
total
akt
expression
morphological
transformation
scale
bar
soft
agar
colony
formation
error
bar
mean
sd
cell
western
blot
analysis
control
cell
mscvp
cell
alone
treat
either
mek
inhibitor
inhibitor
treatment
coexpression
significant
effect
upon
cyclin
level
cell
loading
control
total
akt
effect
expression
cell
growth
day
matrigel
culture
scale
bar
effect
expression
human
cell
growth
matrigel
culture
scale
bar
tumor
growth
curve
luciferase
express
cell
inject
subcutaneously
nude
mouse
roi
region
interest
value
sr
comparison
image
mouse
day
day
top
panel
show
cell
transduced
tumor
develop
host
lower
panel
show
three
distinct
population
cell
express
high
medium
level
gfp
respectively
transduced
tumor
develop
host
j
pcr
genotyping
forward
primer
reverse
primer
promoter
viral
vector
confirm
integration
virus
three
population
tumor
primer
set
detect
control
virus
vector
k
expression
level
estimate
indirectly
compare
expression
level
endogenous
total
endogenous
expression
endogenous
detect
pcr
primer
set
locate
region
delete
expression
total
detect
second
primer
set
locate
common
region
flow
cytometry
analysis
show
reduce
number
cell
tumor
compare
control
tumor
representative
experiment
show
view
within
article
lastly
ask
whether
force
expression
primary
tumor
cell
impair
capacity
form
new
tumor
upon
transplantation
develop
protocol
transduce
tumor
cell
ex
vivo
quickly
sort
virally
infect
cell
transplant
mouse
immediately
three
independent
experiment
perform
five
five
mouse
transplant
tumor
cell
transduced
control
virus
empty
vector
lpig
develop
tumor
month
whereas
three
five
mouse
transplant
number
tumor
cell
develop
tumor
within
time
window
one
tumor
derived
tumor
cell
detect
three
distinct
population
tumor
cell
express
high
medium
level
gfp
intriguingly
gfphi
population
significantly
small
two
contrast
majority
tumor
cell
control
lpig
tumor
cell
express
high
level
gfp
individually
sort
distinct
population
cell
confirm
derived
virally
transduced
cell
quantitated
expression
level
compare
virally
transduced
cell
transplantation
input
consistent
gfp
expression
level
gfphi
gfplow
cell
tumor
also
express
high
medium
level
respectively
addition
even
gfphi
tumor
cell
express
much
level
input
finding
suggest
selection
tumor
cell
express
high
level
occur
vivo
upon
staining
antibody
stem
progenitor
marker
find
tumor
contain
fewer
cell
control
tumor
since
mec
may
represent
stem
progenitor
cell
mg
hypothesize
force
expression
tumor
cell
may
reduce
number
tumor
cell
capable
initiate
new
tumor
upon
transplantation
furthermore
one
mouse
transplant
tumor
cell
two
separate
tumor
develop
one
tumor
express
high
level
gfp
express
level
gfp
datum
show
sort
cell
tumor
serially
transplant
number
sort
cell
range
mouse
month
transplantation
mouse
inject
gfplow
thus
also
cell
already
develop
new
tumor
whereas
none
mouse
transplant
gfphi
thus
also
cell
develop
tumor
suggest
high
level
expression
tumor
cell
reduce
number
tumor
cell
capable
form
new
tumor
upon
transplantation
discussion
committed
mammary
progenitors
cell
origin
breast
cancer
central
question
cancer
biology
cellular
origin
cancer
cancer
originate
normal
stem
cell
lose
normal
growth
control
initiate
progenitor
much
differentiate
cell
acquisition
stem
cell
attribute
mutation
current
view
derived
largely
study
leukemia
hematopoietic
system
since
hematopoietic
stem
cell
hscs
endow
argue
transformation
hscs
provide
simple
mean
generate
leukemic
cell
cellular
phenotype
diverse
leukemia
mirror
progenitor
rather
hscs
fact
evidence
patient
mouse
model
favor
progenitor
cell
origin
many
leukemia
see
similarly
although
mascs
often
propose
cell
origin
breast
tumor
cellular
phenotype
human
breast
cancer
easily
reconcile
view
instance
since
mascs
give
rise
luminal
myoepithelial
cell
one
expect
see
mix
cell
type
breast
cancer
mascs
represent
predominant
cellular
origin
yet
much
human
breast
tumor
exhibit
phenotype
luminal
epithelial
cell
suggest
much
differentiate
cell
mg
may
serve
cell
origin
breast
cancer
however
existence
commit
progenitor
normal
mg
remain
directly
demonstrate
likewise
direct
evidence
also
lack
show
cell
target
transformation
lead
breast
cancer
cellular
origin
human
breast
cancer
difficult
establish
murine
model
therefore
represent
alternative
analysis
previous
study
murine
model
propose
mascs
much
differentiate
cell
include
mammary
progenitor
target
breast
cancer
moreover
murine
model
create
overexpression
oncogene
drive
promoter
mmtv
different
oncogene
versus
neu
pymt
appear
preferentially
transform
distinct
population
mec
however
due
exogenous
promoter
thus
oncogene
often
express
level
absence
genetic
marking
thorough
characterization
tumor
cell
type
model
definitively
assign
target
cell
within
normal
mec
developmental
hierarchy
wcen
mouse
transcriptional
control
endogenous
promoter
therefore
express
physiological
level
since
mammary
tumor
develop
nulliparous
wcen
female
penetrance
transient
cell
cell
expression
activate
unique
combination
genetic
marking
experiment
describe
provide
direct
evidence
support
commit
mammary
progenitor
within
transient
cell
target
previous
study
genetic
marking
identify
population
multipotent
mec
term
mec
originate
differentiate
cell
first
pregnancy
lactate
cycle
survive
remodeling
persist
throughout
remainder
life
boulanger
henry
wagner
wagner
smith
recently
population
alveolar
progenitor
cell
similar
identify
nulliparous
mouse
mg
cell
represent
multipotent
progenitor
capable
proliferation
differentiation
luminal
myoepithelial
cell
upon
transplantation
apparently
progenitor
cell
target
wcen
virgin
female
describe
study
study
also
support
existence
epithelial
cell
hierarchy
normal
mg
mammary
tumor
describe
least
two
type
commit
alveolar
progenitor
transient
population
mec
nulliparous
mg
bipotent
alveolar
progenitor
target
type
tumor
luminal
alveolar
progenitor
target
type
tumor
however
exclude
possibility
type
tumor
also
derived
bipotent
progenitor
block
differentiation
give
rise
immature
luminal
cell
favor
luminal
progenitor
rather
bipotent
progenitor
target
cell
support
conclusion
knockout
mg
lead
expansion
luminal
progenitor
concomitant
block
differentiation
suggest
existence
progenitor
normal
mec
hierarchy
type
tumor
observe
region
extensive
basal
epithelial
cell
type
region
immature
luminal
epithelial
cell
surround
basal
myoepithelial
cell
type
well
explain
existence
epithelial
cell
hierarchy
tumor
commit
bipotent
alveolar
progenitor
transform
become
oncogenic
bipotent
progenitor
give
rise
abnormal
progenitor
basal
progenitor
much
case
progenitor
differentiate
type
bipotent
tumor
occasionally
either
influence
microenvironment
acquire
additional
mutation
abnormal
luminal
basal
progenitor
become
far
transform
give
rise
clone
immature
luminal
basal
epithelial
cell
due
block
differentiation
respectively
image
image
figure
mammary
epithelial
cell
hierarchy
normal
mammary
gland
mammary
tumor
female
proposed
target
cell
wcen
female
indicate
red
circle
red
arrow
indicate
tumorigenesis
tumor
initiation
progression
mediate
view
within
article
type
ii
keratin
pair
type
keratin
form
heterodimer
basal
cell
stratified
epithelia
thus
consider
basal
cell
marker
distinguish
basal
myoepithelial
cell
luminal
epithelial
cell
however
study
show
also
stain
subset
luminal
epithelial
cell
addition
basal
myoepithelial
cell
figure
figure
fact
luminal
cell
represent
block
luminal
progenitor
tumor
note
normal
mg
population
figure
study
luminal
cell
also
detect
addition
microarray
analysis
murine
breast
cancer
model
also
show
gene
cluster
distinct
basal
gene
cluster
figure
also
thus
distinct
marker
combination
marker
together
marker
sma
define
subpopulation
cell
murine
mammary
tumor
although
show
transform
commit
alveolar
progenitor
possibility
may
also
transform
mascs
interestingly
describe
due
leaky
expression
allele
without
excision
stopper
thus
independent
wap
promoter
small
number
heterozygous
mouse
develop
mammary
tumor
advance
age
much
tumor
fall
within
one
four
subtype
describe
wcen
female
figure
suggest
target
cell
two
type
mouse
probably
similar
however
genetic
setting
one
certain
bipotent
tumor
type
feature
derived
commit
bipotent
progenitor
similar
wcen
mascs
since
probably
give
rise
tumor
similar
appearance
addition
tumor
feature
four
subtype
also
observe
tumor
either
contain
extensively
basal
cell
contain
mainly
luminal
cell
figure
much
likely
due
long
latency
tumor
develop
mouse
year
compare
several
month
wcen
female
much
differentiate
single
cell
may
transform
accumulate
additional
mutation
extend
time
period
transformation
oncoprotein
complex
transcriptional
complex
compose
heterodimeric
jun
family
protein
pathway
integrate
multiple
growth
signal
transcriptional
level
regulate
several
cellular
process
normal
mg
previous
study
show
pivotal
regulator
postnatal
mg
growth
development
human
breast
cancer
activation
associate
proliferation
angiogenesis
invasive
breast
cancer
overexpression
breast
cancer
cell
induce
cell
cycle
block
inhibit
growth
vitro
vivo
regulate
proliferation
invasiveness
breast
cancer
cell
overexpression
protein
observe
hyperplastic
neoplastic
human
breast
disorder
addition
also
effective
target
dna
vaccine
protect
mouse
breast
cancer
finding
demonstrate
expression
lead
upregulation
activation
complex
several
target
gene
upregulated
cell
tumor
cell
figure
figure
include
hbegf
possibly
cyclin
stimulate
proliferation
cyclin
major
positive
regulator
cell
cycle
progression
induce
although
observe
increase
level
cyclin
sort
tumor
cell
directly
compare
unsorted
tumor
possibly
due
expression
stromal
cell
observe
upregulation
cell
microarray
western
blot
demonstrate
upregulation
tumor
progression
also
detect
high
level
cyclin
expression
tumor
western
blot
intriguingly
microarray
analysis
show
several
target
gene
know
promote
angiogenesis
invasiveness
include
plaur
ctsl
cathepsin
matrix
upregulated
cell
hyperplastic
mec
suggest
invasiveness
program
may
establish
early
transformation
observation
may
partially
account
short
latency
aggressiveness
tumor
mouse
appearance
sbc
child
young
year
age
together
previous
observation
human
breast
cancer
cell
study
support
critical
role
breast
tumorigenesis
invasiveness
focus
transcriptional
complex
target
human
breast
cancer
warrant
modeling
chromosomal
rearrangements
human
epithelial
tumor
provide
pathogenesis
therapy
breast
cancer
model
describe
based
translocation
human
cancer
datum
demonstrate
fusion
oncoprotein
sufficient
initiate
mammary
tumorigenesis
complement
genetic
evidence
human
suggest
translocation
primary
event
disorder
model
induce
small
number
cell
mammary
tissue
tumor
cell
emerge
within
environment
normal
cell
thus
closely
mimic
human
disease
initiate
somatic
mutation
recent
finding
recurrent
gene
fusion
prostate
cancer
lung
cancer
suggest
balanced
chromosomal
rearrangement
epithelial
cancer
may
much
common
important
previously
believe
tomlins
demonstrate
hematopoietic
malignancy
study
gene
rearrangement
contribute
understanding
normal
blood
cell
development
malignancy
addition
study
gene
fusion
kinase
activity
targeted
therapy
cancer
imatinib
fusion
hope
success
modeling
infrequent
translocation
see
human
epithelial
cancer
describe
will
generation
sophisticated
model
chromosomal
arrangement
may
occur
much
commonly
epithelial
tumor
engineer
mouse
permit
experimental
access
early
target
cell
step
transformation
process
may
serve
effective
model
preclinical
testing
experimental
procedure
mice
conditional
knockin
mouse
generate
gene
targeting
detail
provide
supplemental
experimental
procedure
transgenic
mouse
acquire
repository
reporter
mouse
immunodeficient
mouse
maintain
mouse
colony
reporter
kindly
provide
william
study
involve
mouse
approve
children
hospital
boston
institutional
animal
care
committee
perform
accordance
relevant
protocol
human
sbc
sample
sbc
case
accrue
pathology
department
children
women
health
centre
british
columbia
instituto
molecular
da
porto
burnaby
general
hospital
burnaby
canada
informed
consent
obtain
patient
sample
study
ethic
approval
receive
research
ethic
board
university
british
columbia
pathology
immunostaining
lacz
staining
flow
cytometry
standard
protocol
follow
detailed
procedure
provide
supplemental
experimental
procedure
biochemical
cellular
assay
standard
protocol
follow
detail
emsa
western
blot
immunoprecipitation
study
soft
agar
assay
provide
supplemental
experimental
procedure
microarray
data
collection
analysis
microarray
expression
profile
collect
affymetrix
agilent
chip
analyzed
gsea
describe
detail
provide
supplemental
experimental
procedure
microarray
datum
deposit
gene
expression
omnibus
geo
geo
series
accession
number
tumor
affymetrix
chip
cell
tumor
select
tumor
agilent
chip
acknowledgment
thank
william
nicole
help
transgenic
mouse
carol
assistance
cell
targeting
melanie
general
support
cell
sort
discussion
tim
help
microarray
cell
work
support
grant
nci
mouse
model
human
cancer
consortium
department
defense
grant
canadian
institute
health
research
cihr
fund
nci
award
nci
investigator
howard
hughes
medical
institute
support
breast
cancer
development
award
treatment
option
patient
advance
breast
cancer
many
vary
include
endocrine
therapy
chemotherapy
novel
targeted
therapy
patient
may
also
receive
investigational
agent
context
clinical
trial
discretion
physician
treatment
choice
depend
patient
age
menopausal
status
disease
characteristic
endocrine
therapy
usually
treatment
choice
patient
potentially
disease
include
aromatase
inhibitor
anastrozole
letrozole
exemestane
tamoxifen
new
oestrogen
receptor
antagonist
fulvestrant
luteinising
hormone
release
hormone
polychemotherapy
provide
mainstay
treatment
patient
hormone
tumour
well
aggressive
disease
whose
tumour
long
respond
endocrine
past
year
treatment
strategy
early
breast
cancer
change
dramatically
tamoxifen
introduction
novel
contrast
early
breast
cancer
set
consensus
guideline
uniform
guideline
management
patient
advance
disease
currently
lack
guidelines
important
tool
treatment
decision
make
currently
available
advance
breast
cancer
vary
geographically
may
adequately
address
specific
patient
change
clinical
practice
early
disease
set
lack
uniform
guideline
raise
question
optimal
treatment
strategy
patient
subsequently
develop
advance
disease
now
physician
patient
explore
select
much
appropriate
therapy
complex
array
option
available
aim
study
primary
aim
study
establish
level
need
among
breast
cancer
physician
development
new
advance
breast
cancer
treatment
guideline
secondary
aim
assess
impact
disease
recurrence
physician
patient
understanding
goal
treatment
factor
influence
physician
treatment
decision
patient
advance
breast
cancer
understanding
information
source
utilised
role
current
treatment
guideline
process
insight
potential
area
improvement
exist
guideline
method
survey
conduct
breast
cancer
physician
direct
survey
via
european
school
oncology
eso
website
response
analyse
approximately
physician
complete
survey
copy
survey
study
include
supplementary
material
survey
respondent
patient
breast
cancer
survey
respondent
state
fully
qualify
physician
treat
patient
breast
cancer
respondents
ask
confirm
country
region
based
specialist
role
management
patient
breast
cancer
also
ascertain
many
patient
breast
cancer
physician
see
course
usual
year
proportion
patient
early
stage
advance
stage
disease
emotional
impact
disease
recurrence
physician
ask
think
patient
recently
progress
breast
cancer
ask
consider
whether
patient
little
much
distressed
progression
newly
diagnose
early
disease
just
consider
patient
physician
ask
whether
little
much
distressed
patient
diagnose
early
disease
question
also
ask
provide
detail
emotional
impact
little
much
appropriate
stage
onwards
survey
ask
physician
think
specifically
patient
recently
progress
breast
cancer
treatment
goal
factor
influence
treatment
decision
patient
advance
breast
cancer
next
section
physician
ask
rate
list
potential
treatment
goal
patient
options
include
improve
overall
survival
delay
disease
progression
improve
quality
life
achieve
response
physician
ask
specify
information
source
utilised
physician
support
treatment
decision
patient
advance
breast
cancer
physician
ask
rate
list
patient
factor
may
play
role
treatment
decision
make
patient
factor
include
patient
age
menopausal
status
treatment
history
status
human
epidermal
growth
factor
receptor
status
performance
status
size
tumour
degree
nodal
involvement
number
metastases
site
metastases
comorbidity
psychological
state
social
circumstance
distance
hospital
physician
ask
rate
list
treatment
factor
may
play
role
decision
factor
include
treatment
efficacy
side
effect
contraindication
cost
ease
formulation
administration
need
personal
experience
whether
endorse
guideline
part
hospital
policy
question
also
specify
three
additional
factor
role
guideline
treatment
advance
breast
cancer
physician
ask
rate
often
various
information
source
aid
treatment
decision
patient
source
include
work
colleague
opinion
leader
medical
conference
medical
press
lie
press
treatment
guideline
representative
text
book
internet
patient
also
give
option
include
rating
three
additional
information
source
physician
state
never
guideline
ask
aware
treatment
guideline
patient
advance
breast
cancer
list
hear
also
ask
give
reason
guideline
physician
frequently
occasionally
treatment
guideline
ask
name
guideline
physician
except
state
never
guideline
ask
whether
agree
list
reason
guideline
useful
state
currently
guideline
think
may
useful
also
ask
importance
follow
reason
list
reason
guideline
useful
include
confirm
treatment
decision
keep
aware
new
drug
keep
aware
new
clinical
datum
keep
aware
new
dose
regimen
reassure
reassure
patient
justify
approach
remind
available
option
prompt
far
patient
evaluation
protect
legal
action
potential
improvement
exist
treatment
guideline
physician
frequently
occasionally
treatment
guideline
also
ask
rate
importance
list
potential
improvement
exist
guideline
potential
improvement
guideline
include
update
much
frequently
much
specific
particular
group
patient
include
much
clinical
datum
include
well
summary
page
endorse
recognised
international
opinion
leader
endorse
cancer
organisation
eso
easy
find
also
give
option
list
improvement
recommend
result
survey
respondent
patient
breast
cancer
total
questionnaire
complete
half
respondent
european
asia
south
america
remainder
split
north
america
respondents
encompass
area
medical
personnel
involve
treatment
breast
cancer
include
surgeon
oncologist
radiologist
just
respondent
state
much
patient
treat
breast
cancer
overall
approximately
breast
cancer
patient
treat
advance
disease
image
survey
respondent
role
management
breast
cancer
patient
view
within
article
emotional
impact
disease
recurrence
result
survey
show
disappointment
distress
level
great
first
recurrence
first
diagnosis
early
breast
cancer
physician
patient
state
physician
patient
respectively
state
distress
level
little
first
diagnosis
early
breast
cancer
datum
indicate
physician
patient
find
first
recurrence
distressing
difficult
main
reason
give
physician
find
recurrence
much
disappointing
first
diagnosis
raise
question
first
treatment
adequate
patient
result
feeling
personal
failure
disease
now
fewer
treatment
option
available
offer
patient
difficult
tell
patient
disease
recur
physician
develop
close
relationship
patient
stage
physician
find
little
disappointing
first
diagnosis
main
reason
recurrence
always
acknowledge
possibility
similarity
main
reason
give
physician
patient
find
event
much
distressing
first
diagnosis
include
knowledge
now
cure
fear
death
particularly
perceive
death
cancer
unpleasant
patient
confidence
physician
treatment
shake
may
lead
expect
cure
early
breast
cancer
recurrence
shock
feeling
disappointment
anxiety
patient
may
develop
depression
patient
fear
next
treatment
ill
side
effect
poor
quality
life
possible
cure
physician
say
patient
find
little
distressing
first
diagnosis
main
reason
give
patient
tell
recurrence
already
accept
cancer
patient
will
already
tell
expect
recurrence
treatment
goal
factor
influence
treatment
decision
patient
advance
breast
cancer
stage
disease
goal
treat
physician
improve
patient
quality
life
delay
progression
disease
improve
overall
survival
treatment
decision
therefore
centre
efficacy
respondent
potential
side
effect
status
site
metastases
contraindication
status
addition
respond
physician
state
important
treatment
endorse
guideline
image
treatment
goal
physician
treat
patient
advance
breast
cancer
rank
order
importance
view
within
article
table
factor
influence
physician
make
treatment
decision
patient
advance
breast
cancer
importance
response
consider
patient
factor
site
treatment
performance
menopausal
number
psychological
degree
nodal
size
social
distance
home
drug
factor
side
personal
ease
need
formulation
part
hospital
table
oestrogen
receptor
human
epidermal
growth
factor
receptor
view
within
article
information
source
utilised
physician
support
treatment
decision
patient
advance
breast
cancer
role
guideline
much
respondent
currently
available
treatment
guideline
frequently
occasionally
key
source
information
medical
conference
internet
medical
press
much
commonly
guideline
include
formal
publication
national
comprehensive
cancer
network
nccn
guideline
publication
specific
meeting
american
society
clinical
oncology
asco
gallen
san
antonio
breast
cancer
symposium
sabcs
primarily
reminder
available
option
confirm
treatment
decision
table
information
source
utilised
breast
cancer
physician
support
treatment
decision
patient
advance
breast
cancer
source
frequency
response
treatment
medical
medical
work
text
opinion
table
two
physician
give
answer
twice
make
total
responder
question
rather
percentage
adjust
accordingly
view
within
article
image
reason
treatment
guideline
useful
physician
view
within
article
potential
improvement
exist
treatment
guideline
response
suggest
breast
cancer
physician
welcome
improvement
exist
guideline
include
make
easy
find
much
frequent
update
cancer
organisation
opinion
leader
well
specificity
particular
patient
group
addition
respondent
like
see
worldwide
consensus
treatment
option
development
global
guideline
include
specific
recommendation
elderly
bone
metastases
pregnant
woman
male
patient
guidelines
patient
comorbidity
renal
failure
problem
malignancy
also
useful
respond
physician
survey
indicate
preference
easy
access
large
amount
information
many
suggest
interactive
computer
technology
update
image
potential
improvement
exist
treatment
guideline
view
within
article
discussion
conclusion
result
survey
suggest
degree
emotional
impact
breast
cancer
physician
patient
time
first
recurrence
great
first
diagnosis
result
suggest
due
emotional
impact
recurrence
well
dilemma
physician
face
regard
choose
much
appropriate
treatment
patient
advance
breast
cancer
level
distress
great
party
stage
perhaps
patient
situation
survey
suggest
recurrence
mean
death
physician
recurrence
imply
failure
side
question
likely
raise
adequacy
efficacy
previous
treatment
confidence
physician
future
therapy
may
reduce
line
previous
report
result
survey
highlight
treatment
goal
physician
treat
patient
advance
breast
cancer
improve
quality
life
extend
overall
point
along
raise
suggest
great
effort
make
research
treatment
option
patient
advance
breast
cancer
result
trial
disseminate
effectively
perhaps
guideline
addition
new
technology
interactive
computer
program
update
may
help
ensure
physician
fully
able
make
appropriate
inform
decision
regard
optimum
treatment
strategy
patient
advance
breast
cancer
survey
show
treatment
guideline
key
source
information
support
treatment
decision
make
patient
advance
breast
cancer
ranking
alongside
medical
conference
internet
medical
press
approximately
half
survey
respondent
also
list
patient
source
information
may
part
reflect
fact
patient
breast
cancer
often
well
inform
available
treatment
option
thus
may
great
involvement
treatment
process
patient
group
fact
care
show
affect
treatment
adherence
may
also
influence
advance
breast
cancer
guideline
currently
available
include
formal
nccn
publication
regional
guideline
limited
scope
little
consistent
available
early
breast
cancer
respondents
survey
feel
improvement
make
development
uniform
global
guideline
advance
breast
cancer
detail
treatment
recommendation
specific
patient
group
although
limitation
survey
based
relatively
small
sample
size
due
response
interpretation
question
potentially
subjective
appear
result
line
current
field
indeed
since
time
survey
effort
initiate
eso
together
european
breast
cancer
conference
produce
global
metastatic
breast
cancer
mbc
guideline
creation
task
initial
set
recommendation
management
patient
mbc
now
interestingly
article
notion
treatment
mbc
consider
approve
standard
care
particularly
treatment
fail
factor
affect
treatment
choice
view
important
current
survey
broadly
agreement
include
current
recommendation
result
present
survey
reinforce
importance
initiative
development
much
detail
guideline
task
force
await
interest
conflict
interest
author
andrew
receive
honorarium
glaxosmithkline
roche
astrazeneca
novartis
speaker
roche
astrazeneca
novartis
amgen
addition
receive
travel
support
roche
astrazeneca
novartis
amgen
glaxosmithkline
acknowledgement
research
fund
astrazeneca
conduct
collaboration
eso
author
like
thank
mitchell
complete
medical
communication
provide
medical
writing
support
fund
astrazeneca
metastasis
major
death
breast
cancer
patient
well
understanding
underlie
molecular
cellular
mechanism
crucial
development
effective
treatment
metastatic
breast
cancer
metastasis
process
mediate
migration
cancer
cell
primary
site
distant
site
adhesion
circulate
cancer
cell
endothelium
subsequent
migration
critical
step
process
therefore
identify
molecule
mediate
cancer
cell
endothelial
cell
interaction
necessary
design
specific
treatment
prevent
breast
cancer
metastasis
receptor
oxidized
lipoprotein
oxldl
first
identify
scavenger
receptor
binding
uptake
oxldl
endothelial
cell
recently
show
play
important
role
signaling
now
well
accept
strong
link
chronic
inflammation
cancer
progression
metastasis
interestingly
expression
regulate
mediator
one
main
mediator
inflammation
link
many
aspect
tumorigenesis
include
metastasis
give
emerge
role
inflammation
like
test
hypothesis
expression
endothelial
cell
promote
breast
cancer
metastasis
present
study
examine
role
breast
cancer
cell
endothelial
cell
interaction
material
antibody
reagent
goat
mouse
antibody
normal
goat
igg
recombinant
human
recombinant
human
obtain
rd
system
minneapolis
mn
goat
antibody
raise
recombinant
human
oxidized
density
lipoprotein
receptor
extracellular
domain
antibody
select
ability
block
receptor
ligand
interaction
manufacturer
mouse
monoclonal
antibody
select
ability
recognize
human
direct
elisa
western
blot
calcein
order
invitrogen
carlsbad
cambrex
east
nj
rpmi
invitrogen
cell
culture
human
lung
microvascular
endothelial
cell
hlmvecs
obtain
cambrex
grow
supplement
fetal
bovine
serum
fbs
hlmvecs
passage
experiment
cell
obtain
atcc
maintain
culture
medium
rpmi
contain
fetal
bovine
serum
mm
cell
maintain
incubator
air
immunoblotting
immunoblotting
perform
describe
previously
antibody
dilution
analysis
carry
quantity
one
program
biorad
hercules
cell
surface
elisa
expression
cell
surface
measure
cell
surface
immunosorbent
assay
elisa
describe
previously
cell
incubate
mouse
monoclonal
antibody
follow
goat
igg
peroxidase
activity
detect
substrate
solution
pierce
rockford
quantify
read
plate
microplate
reader
nm
stain
secondary
antibody
blank
assay
triplicate
sample
repeat
three
time
adhesion
assay
adhesion
assay
perform
describe
previously
briefly
hlmvecs
seed
grow
well
plate
confluent
cell
disperse
trypsin
solution
wash
serum
free
rpmi
incubate
calcein
molecular
probes
min
calcein
cell
add
confluent
endothelial
monolayer
cell
well
incubate
cell
wash
extensively
pbs
remove
float
cancer
cell
cancer
cell
observe
fluorescent
microscope
count
random
field
magnification
triplicate
sample
migration
assay
assay
perform
describe
lee
previously
hlmvecs
seed
grow
well
transwell
insert
pore
size
corning
confluent
calcein
cell
add
apical
chamber
incubation
cell
upper
face
membrane
scrape
gently
cotton
swab
cell
face
membrane
count
fluorescent
microscope
random
field
magnification
triplicate
sample
statistic
value
express
mean
sem
data
analyzed
analysis
variance
anova
follow
bonferroni
test
value
consider
significant
induce
expression
human
lung
microvascular
endothelial
cell
potent
mediator
explore
role
breast
cancer
cell
endothelial
cell
interaction
first
examine
regulation
expression
human
lung
microvascular
endothelial
cell
study
stimulate
expression
dose
manner
image
expression
human
lung
microvascular
endothelial
cell
dose
response
time
course
expression
hlmvecs
assess
immunoblotting
membrane
strip
blot
antibody
representative
blot
bar
graph
show
change
expression
treatment
result
show
representative
three
independent
experiment
data
present
mean
sem
asterisk
indicate
value
significantly
different
control
cell
treatment
view
within
article
stimulate
surface
expression
human
lung
microvascular
endothelial
cell
type
ii
membrane
protein
cell
surface
exposure
require
function
confirm
treatment
also
lead
increase
surface
expression
plasma
membrane
perform
elisa
specifically
examine
cell
surface
indeed
cell
surface
expression
correlated
expression
hlmvecs
image
stimulate
surface
expression
hlmvecs
hlmvecs
treat
indicate
dependent
surface
expression
quantify
cell
surface
elisa
follow
treatment
describe
section
data
present
mean
sem
asterisk
indicate
value
significantly
different
control
cell
treatment
view
within
article
adhesion
migration
tem
breast
cancer
cell
know
promote
tumor
cell
adhesion
endothelial
cell
next
examine
potential
involvement
breast
cancer
cell
endothelial
cell
interaction
adhesion
breast
cancer
cell
hlmvecs
subsequent
tem
markedly
decrease
presence
either
block
antibody
recombinant
protein
whereas
control
igg
recombinant
protein
significant
effect
cancer
cell
adhesion
tem
image
inhibition
breast
cancer
cell
adhesion
migration
block
antibody
hlmvecs
stimulate
ml
calcein
cell
add
hlmvecs
con
without
treatment
tnf
hlmvecs
tnf
hlmvecs
presence
ml
normal
igg
tnf
hlmvecs
presence
ml
antibody
incubate
adhesion
assay
tem
assay
representative
image
show
cancer
cell
adhesion
endothelial
cell
bar
graph
show
bind
migrate
cell
assess
describe
section
data
present
mean
sem
asterisk
indicate
value
significantly
different
cell
treat
alone
view
within
article
image
inhibition
breast
cancer
cell
adhesion
migration
recombinant
protein
hlmvecs
stimulate
ml
calcein
cell
add
hlmvecs
con
without
treatment
tnf
hlmvecs
tnf
hlmvecs
presence
ml
recombinant
human
tnf
hlmvecs
presence
ml
recombinant
human
incubate
adhesion
assay
tem
assay
representative
image
show
cancer
cell
adhesion
endothelial
cell
bar
graph
show
bind
migrate
cell
assess
describe
section
data
present
mean
sem
asterisk
indicate
value
significantly
different
cell
treat
alone
view
within
article
discussion
vitro
adhesion
assay
leukocyte
able
bind
physiological
stress
binding
specifically
block
antibody
indicate
support
leukocyte
adhesion
demonstrate
breast
cancer
cell
adhesion
endothelial
cell
subsequent
migration
inhibit
block
antibody
recombinant
protein
suggest
may
act
adhesion
molecule
mediate
cancer
cell
endothelial
cell
interaction
therefore
breast
cancer
cell
may
express
specific
surface
molecule
bind
endothelial
study
warrant
identify
ligand
express
breast
cancer
cell
circulating
cancer
cell
leukocyte
suggest
share
family
adhesion
molecule
initial
interaction
vasculature
roll
early
attachment
firm
adhesion
interestingly
study
adhesion
cell
endothelial
cell
completely
inhibit
block
antibody
recombinant
protein
suggest
involvement
adhesion
molecule
link
chronic
inflammation
cancer
well
establish
however
underlie
molecular
mechanism
fully
understand
atherosclerosis
consider
type
chronic
inflammation
early
recruitment
monocyte
lesion
require
activation
endothelial
cell
increase
endothelial
oxldl
scavenger
receptor
primarily
express
endothelial
cell
accumulate
evidence
suggest
expression
associate
condition
hypertension
diabetes
mediator
oxldl
also
show
expression
vitro
thus
finding
regulate
breast
cancer
cell
endothelial
cell
interaction
provide
another
molecular
link
inflammation
metastasis
potential
function
metastasis
much
profound
adhesive
property
indeed
report
play
diverse
role
signaling
endothelial
dysfunction
binding
oxldl
able
reduce
intracellular
oxide
concentration
increase
superoxide
production
endothelial
cell
activation
associate
increase
production
mediator
activation
resultant
cytokine
production
link
signaling
endothelial
cell
furthermore
activation
pkc
show
stimulate
expression
matrix
metalloproteinase
mmp
mmp
recognize
critical
player
metastasis
since
extravasation
intravasation
cancer
cell
critical
step
metastasis
block
cancer
cell
endothelial
cell
interaction
effective
approach
prevent
treat
metastatic
cancer
study
suggest
pathway
may
novel
drug
target
breast
cancer
metastasis
essential
formulation
drug
facilitate
preparation
patient
acceptability
recently
report
several
common
excipient
modulate
activity
efflux
transporter
cremophor
vitamin
tpgs
increase
transport
substrate
inhibit
transport
cell
enhance
intestinal
absorption
rat
model
study
demonstrate
excipient
change
several
drug
administration
inhibit
efflux
transporter
however
extent
inhibition
specificity
excipient
respect
breast
cancer
resistance
protein
bcrp
much
recently
discover
atp
binding
cassette
abc
remain
unclear
bcrp
drug
efflux
transporter
abc
family
express
several
normal
human
tissue
actively
extrude
wide
variety
substrate
cell
bcrp
localized
apical
membrane
intestinal
epithelium
high
mrna
level
protein
efflux
transporter
human
moreover
oral
availability
several
bcrp
substrate
reduce
markedly
bcrp
therefore
bcrp
might
play
similar
role
regulate
drug
absorption
small
intestine
absorption
drug
secrete
efflux
system
might
improve
inhibit
bcrp
action
intestinal
membrane
aim
study
examine
effect
excipient
bcrp
function
fifteen
excipient
currently
pharmaceutical
formulation
employ
test
compound
list
table
estimate
bcrp
inhibitory
effect
various
excipient
vitro
uptake
study
perform
mardin
darby
canine
kidney
mdck
cell
transfected
gene
bcrp
addition
compare
inhibitory
effect
excipient
bcrp
function
vitro
uptake
study
also
perform
cell
express
mitoxantrone
transport
bcrp
substrate
transporter
table
description
test
excipient
structural
characteristic
cmc
cmc
cremophor
castor
cremophor
castor
sorbitan
sorbitan
span
span
span
pluronic
vitamin
polyethylene
glycol
brij
myrj
gelucire
propylene
glycol
glyceryl
triacetate
ethyl
oleate
table
please
refer
methodology
section
detail
view
within
article
material
method
mitoxantrone
purchase
biochemical
usa
donate
glaxosmithkline
uk
novartis
pharma
switzerland
respectively
cremophor
brij
myrj
obtain
louis
usa
span
span
span
propylene
glycol
glyceryl
triacetate
ethyl
oleate
obtain
wako
pure
chemical
industry
osaka
japan
pluronic
vitamin
tpgs
donate
parsippany
nj
usa
wales
uk
respectively
gelucire
cremophor
obtain
france
chemical
tokyo
japan
respectively
chemical
available
commercially
reagent
grade
critical
micelle
concentration
cmc
surfactant
transport
buffer
mm
nacl
mm
mm
kcl
mm
mm
mm
hepes
mm
glucose
mm
ph
measure
automatic
interface
science
japan
method
describe
cmc
value
obtain
plot
surface
tension
versus
concentration
excipient
parent
cell
stably
cell
seed
well
plate
density
cell
well
grow
two
day
dulbecco
modify
eagle
medium
invitrogen
carlsbad
usa
fetal
bovine
serum
antibiotic
antimycotic
solution
parent
cell
infect
recombinant
adenovirus
harboring
gene
green
fluorescent
protein
gfp
bcrp
expression
vector
infection
detail
construction
recombinant
describe
previously
cell
medium
change
second
day
two
day
culture
cell
bcrp
gfp
respectively
uptake
study
intracellular
atp
assay
uptake
study
carry
describe
minor
modification
cell
incubate
transport
buffer
contain
nm
mitoxantrone
inhibition
study
inhibitor
bcrp
inhibitor
appropriate
concentration
excipient
add
incubation
buffer
designate
time
uptake
terminate
cell
wash
lysed
radioactivity
lysate
measure
liquid
counter
coulter
usa
remain
cell
lysate
determine
protein
concentration
method
uptake
study
bcrp
inhibit
effect
endogenous
cell
add
incubation
except
cell
treat
atp
assay
carry
describe
minor
modification
cell
incubate
transport
buffer
contain
mm
sodium
azide
excipient
cell
expose
wash
lysed
atp
lysate
determine
luciferase
assay
atp
fluorescence
kit
ink
tokyo
japan
data
evaluate
analysis
variance
anova
dunnett
multiple
comparison
test
consider
statistically
significant
result
discussion
present
study
provide
evidence
first
time
excipient
may
considerable
impact
function
bcrp
cmc
kind
excipient
show
table
study
perform
little
equal
cmc
excipient
surfactant
abolish
micelle
formation
excipient
regard
excipient
propylene
glycol
glyceryl
triacetate
ethyl
oleate
effect
investigate
time
profile
uptake
mitoxantrone
nm
investigate
bcrp
gfp
cell
control
show
bcrp
cell
demonstrate
markedly
reduce
uptake
mitoxantrone
time
gfp
cell
respectively
image
uptake
mitoxantrone
cell
uptake
mitoxantrone
nm
measure
min
cell
control
cell
measure
uptake
via
bcrp
add
incubation
inhibit
endogenous
cell
point
bar
represent
mean
vertical
bar
show
within
size
limit
significant
difference
view
within
article
uptake
mitoxantrone
presence
kind
excipient
determine
bcrp
gfp
show
increase
uptake
mitoxantrone
time
bcrp
whereas
negligible
effect
gfp
excipient
find
five
cremophor
span
pluronic
brij
markedly
increase
uptake
mitoxantrone
bcrp
cell
little
effective
gfp
suggest
potent
bcrp
inhibitor
image
inhibitory
effect
various
excipient
uptake
mitoxantrone
cell
uptake
mitoxantrone
nm
measure
presence
absence
excipient
positive
control
positive
control
cell
treat
measure
uptake
via
bcrp
add
incubation
inhibit
endogenous
cell
except
cell
treat
value
express
percentage
uptake
absence
excipient
positive
control
column
represent
mean
significant
difference
control
view
within
article
moreover
uptake
mitoxantrone
presence
kind
excipient
also
determine
gfp
show
increase
uptake
mitoxantrone
time
whereas
little
effective
statistically
gfp
ten
excipient
cremophor
cremophor
span
pluronic
vitamin
tpgs
brij
myrj
gelucire
increase
uptake
mitoxantrone
cell
significantly
suggest
inhibit
additionally
excipient
also
increase
uptake
mitoxantrone
gfp
cell
presumably
inhibition
endogenous
cell
line
notably
difference
inhibitory
effect
excipient
bcrp
function
although
detail
unclear
exact
mechanism
excipient
inhibit
efflux
transporter
remain
unknown
report
pluronic
significantly
reduce
intracellular
atp
level
correlate
well
inhibition
efflux
transporter
however
find
significant
change
intracellular
atp
level
bcrp
gfp
cell
five
excipient
inhibit
bcrp
whereas
sodium
azide
markedly
reduce
intracellular
atp
level
cell
line
indicate
reduction
intracellular
atp
level
may
play
minor
role
far
study
need
clarify
mechanism
pluronic
reduce
intracellular
atp
level
cell
differ
previous
finding
might
difference
cell
line
table
intracellular
atp
level
treatment
table
express
mean
excipient
show
parenthesis
significant
difference
view
within
article
conclusion
study
demonstrate
excipient
cremophor
span
pluronic
brij
inhibit
bcrp
well
fact
recent
study
prove
excipient
act
bioavailability
bcrp
substrate
drug
inhibit
intestinal
bcrp
clinical
application
combine
bcrp
well
substrate
excipient
may
provide
potential
strategy
improve
bioavailability
tissue
distribution
acknowledgment
thank
netherlands
cancer
institute
netherlands
provide
parent
cell
glaxosmithkline
supply
novartis
pharma
supply
work
support
part
ministry
education
culture
science
technology
japan
january
california
environmental
protection
agency
calepa
air
resources
board
unanimously
add
secondhand
tobacco
smoke
also
referred
passive
smoking
smoking
environmental
tobacco
smoke
ets
state
list
toxic
air
contaminants
toxic
air
contaminants
include
particulate
formaldehyde
hydrocarbon
board
unanimously
approve
regulation
based
report
assess
exposure
health
effect
secondhand
smoke
california
environmental
protection
agency
report
update
report
health
effect
secondhand
smoke
calepa
prepare
california
environmental
protection
agency
national
institute
health
result
year
process
include
public
scientific
review
state
scientific
review
panel
toxic
air
contaminants
consider
report
calepa
response
public
criticism
require
several
revision
report
unanimously
approve
addition
include
first
measurement
secondhand
smoke
exposure
calepa
add
four
new
entry
list
disease
secondhand
smoke
breast
cancer
young
primarily
premenopausal
woman
never
smoke
induction
adult
delivery
alter
vascular
calepa
find
evidence
breast
cancer
postmenopausal
woman
conclusion
secondhand
smoke
breast
cancer
young
woman
never
smoke
particularly
important
cancer
tend
particularly
aggressive
despite
fact
conclusion
secondhand
smoke
breast
cancer
young
woman
make
lead
government
scientific
agency
modern
version
widely
accept
bradford
hill
criterion
importance
conclusion
include
american
cancer
society
american
cancer
society
american
cancer
society
surgeon
general
department
health
human
services
accept
conclusion
order
provide
assess
calepa
conclusion
compare
evidence
form
basis
surgeon
general
conclusion
secondhand
smoke
lung
cancer
united
state
office
surgeon
general
evidence
calepa
reach
similar
conclusion
breast
cancer
california
environmental
protection
agency
analysis
design
detail
question
whether
passive
active
smoking
breast
cancer
calepa
report
go
great
depth
page
passive
smoking
appendix
page
active
smoking
evaluate
evidence
article
summarize
evidence
recently
publish
report
accessed
web
california
environmental
protection
agency
surgeon
general
united
state
office
surgeon
general
rather
analysis
design
compare
amount
nature
evidence
review
calepa
passive
smoking
lung
cancer
exist
surgeon
general
conclude
passive
smoking
lung
cancer
secondhand
smoke
evidence
breast
cancer
young
primarily
premenopausal
woman
strong
much
consistent
lung
cancer
evidence
method
compare
evidence
epidemiologic
study
cite
surgeon
united
state
office
surgeon
general
cite
calepa
breast
cancer
young
primarily
premenopausal
woman
california
environmental
protection
agency
surgeon
general
give
particular
weight
high
exposure
category
dose
response
result
report
expose
subject
dose
response
result
report
compare
total
number
study
type
study
cohort
case
control
number
study
risk
great
number
study
statistically
significant
increase
risk
expose
among
high
exposure
secondhand
smoke
statistically
significant
test
trend
secondhand
smoke
dose
response
analysis
magnitude
pool
risk
estimate
also
criterion
evidence
report
examine
come
conclusion
causality
result
table
summarize
criterion
evaluate
evidence
amount
nature
evidence
present
report
table
summary
evidence
secondhand
smoke
lung
cancer
surgeon
general
report
united
state
office
surgeon
general
compare
evidence
breast
cancer
young
primarily
premenopausal
woman
california
epa
report
california
environmental
protection
agency
cancer
surgeon
general
report
breast
cancer
young
woman
california
epa
used
update
bradford
hill
criterion
consideration
adjustment
potential
considered
biological
examined
dose
considered
effect
active
examined
total
number
positive
relative
risk
statistically
significant
pooled
risk
risk
ci
case
control
study
spousal
risk
study
expose
specific
case
control
study
dose
response
information
high
exposure
category
study
well
exposure
assessment
expose
table
excludes
report
premenopausal
risk
estimate
say
result
similar
report
overall
risk
estimate
breast
cancer
study
statistically
significant
increase
risk
confidence
level
expose
among
high
exposure
secondhand
smoke
statistically
significant
test
trend
secondhand
smoke
dose
response
analysis
confidence
interval
report
pool
estimate
view
within
article
surgeon
general
calepa
evaluate
evidence
similar
update
version
bradford
hill
criterion
causality
strength
association
consistency
association
coherence
biological
plausibility
dose
response
experimental
evidence
surgeon
general
report
give
special
attention
disease
misclassification
misclassification
subject
personal
smoking
status
exposure
ets
expect
ets
lung
cancer
risk
based
active
smoking
risk
specific
subsections
calepa
report
address
follow
issue
detail
limitation
study
concern
bias
case
control
study
potential
confound
controversy
regard
relative
potency
active
passive
smoking
active
passive
smoking
exposure
misclassification
window
susceptibility
publication
bias
similar
risk
observe
active
passive
smoking
surgeon
general
report
lung
cancer
study
point
estimate
risk
ratio
report
statistically
significant
increase
risk
expose
woman
least
one
high
exposure
category
united
state
office
surgeon
general
summary
include
one
study
statistically
significant
increase
one
histological
subgroup
one
hirayama
cohort
study
report
statistically
significant
elevate
risk
pool
risk
estimate
spousal
exposure
combine
case
control
study
high
exposure
category
study
dose
response
result
confidence
interval
report
united
state
office
surgeon
general
table
table
mammary
carcinogen
tobacco
smoke
aromatic
compound
dibenzo
dibenzo
dibenzo
oxide
dibenzo
chloride
table
source
calepa
report
table
california
environmental
protection
agency
view
within
article
calepa
report
study
point
estimate
breast
cancer
young
premenopausal
woman
sandler
smith
morabia
zhao
johnson
kropp
hanaoka
study
report
statistically
significant
elevation
risk
expose
woman
three
much
study
reach
statistical
significance
exposure
report
significant
elevation
risk
high
exposure
group
hirayama
gammon
statistically
significant
dose
response
relationship
increase
secondhand
smoke
exposure
similar
approach
surgeon
general
report
study
report
statistically
significant
increase
risk
overall
sandler
smith
morabia
zhao
johnson
kropp
hanaoka
high
exposure
hirayama
smith
johnson
kropp
gammon
hanaoka
two
hirayama
hanaoka
four
hirayama
reynolds
hanaoka
cohort
study
report
statistically
significant
elevate
risk
pool
relative
risk
estimate
young
primarily
premenopausal
woman
expose
woman
five
study
much
complete
exposure
assessment
statistically
significant
result
expose
woman
smith
morabia
zhao
johnson
kropp
discussion
evidence
epidemiologic
study
secondhand
smoke
calepa
draw
causal
conclusion
secondhand
smoke
breast
cancer
young
primarily
premenopausal
woman
strong
surgeon
general
conclude
causal
relationship
secondhand
smoke
lung
volume
study
passive
smoking
lung
cancer
increase
since
surgeon
general
report
general
pattern
mostly
case
control
study
show
significantly
elevate
risk
continue
analysis
secondhand
smoke
lung
cancer
iarc
report
examine
study
publish
find
case
control
study
cohort
study
statistically
significant
elevation
risk
measure
secondhand
smoke
iarc
working
group
evaluation
carcinogenic
risk
humans
surgeon
general
review
study
secondhand
smoke
lung
cancer
publish
case
control
cohort
study
find
statistically
significant
increase
risk
department
health
human
services
breast
cancer
calepa
report
high
percentage
study
individually
statistically
significant
much
cohort
evidence
support
increase
risk
surgeon
general
report
draw
causal
conclusion
lung
cancer
report
relied
primarily
case
control
study
reach
conclusion
support
result
cohort
study
evidence
exposure
puberty
first
full
term
pregnancy
particularly
time
many
young
woman
work
waitress
waitresses
high
prevalence
exposure
secondhand
smoke
occupational
group
level
secondhand
smoke
pollution
high
venue
study
waitresses
high
lung
cancer
rate
among
occupational
group
applying
prevalence
exposure
relative
risk
breast
cancer
among
young
primarily
premenopausal
woman
waitress
yield
attributable
risk
breast
cancer
among
occupational
group
doubt
causality
association
argue
confound
may
explain
result
fact
almost
study
breast
cancer
especially
produce
high
risk
estimate
control
much
know
suspect
confounder
breast
cancer
bmi
family
history
hormone
alcohol
status
physical
activity
benign
breast
disease
age
menarche
reproductive
measure
see
calepa
report
california
environmental
protection
agency
miller
see
calepa
table
detail
presentation
confounder
study
section
short
discussion
furthermore
unlikely
factor
true
confounder
risk
associate
tobacco
smoke
exposure
similar
without
control
confounder
discussion
confound
much
extensive
lung
cancer
surgeon
general
report
united
state
office
surgeon
general
biological
plausibility
argument
surgeon
general
report
limited
note
active
smoking
lung
cancer
reasonable
assume
passive
smoking
united
state
office
surgeon
general
calepa
report
present
direct
evidence
identify
mammary
carcinogen
rodent
tobacco
smoke
see
table
california
environmental
protection
agency
calepa
also
present
molecular
epidemiology
consistent
hypothesis
breast
cancer
may
concentrate
woman
genetic
susceptibility
carcinogen
tobacco
smoke
california
environmental
protection
agency
surgeon
general
report
secondhand
smoke
department
health
human
services
calepa
report
california
environmental
protection
agency
present
risk
breast
cancer
associate
secondhand
smoke
find
virtually
elevation
risk
compare
table
surgeon
general
report
table
calepa
report
arrive
different
conclusion
regard
causality
surgeon
general
report
conclude
evidence
suggestive
sufficient
infer
causal
relationship
secondhand
smoke
breast
cancer
conclusion
calepa
report
regular
ets
exposure
relate
breast
cancer
diagnose
young
primarily
premenopausal
woman
association
likely
explain
bias
confound
primary
reason
different
conclusion
converse
biological
plausibility
argument
surgeon
general
make
secondhand
smoke
lung
cancer
since
active
smoking
breast
cancer
passive
smoking
iarc
working
group
evaluation
carcinogenic
risk
humans
american
cancer
society
american
cancer
society
department
health
human
services
statement
active
smoking
associate
increase
risk
breast
cancer
based
pool
analysis
study
compare
breast
cancer
current
smoker
never
smoker
find
increase
risk
well
two
major
consensus
document
surgeon
general
report
active
smoking
department
health
human
services
international
agency
research
tobacco
smoke
iarc
working
group
evaluation
carcinogenic
risk
humans
also
reach
negative
conclusion
regard
link
active
smoking
breast
cancer
consensus
report
active
smoking
publish
iarc
working
group
evaluation
carcinogenic
risk
humans
department
health
human
services
literature
base
conclusion
end
study
active
smoking
breast
cancer
take
care
minimize
inclusion
passive
smoker
reference
group
however
demonstrate
increase
risk
breast
cancer
active
smoker
study
demonstrate
significantly
increase
risk
breast
cancer
associate
active
smoking
similar
increase
risk
associate
secondhand
smoke
fact
link
active
smoking
breast
cancer
widely
understand
calepa
california
environmental
protection
agency
include
discussion
issue
report
section
appendix
calepa
report
six
recent
prospective
cohort
study
find
statistically
significant
increase
breast
cancer
risk
associate
least
measure
active
smoking
california
environmental
protection
agency
fact
risk
associate
active
smoking
much
large
risk
associate
passive
smoking
despite
much
large
dose
smoke
smoker
receive
also
concern
researcher
available
evidence
indicate
like
heart
disease
dose
response
curve
linear
several
possible
explanation
fact
risk
active
passive
smoking
much
different
morabia
california
environmental
protection
agency
johnson
none
consider
definitively
establish
one
explanation
active
smoking
damage
ovary
depress
estrogen
level
associate
breast
cancer
risk
effect
tend
counter
effect
carcinogen
smoke
active
smoker
much
passive
smoker
receive
large
enough
dose
smoke
depress
estrogen
level
another
explanation
relate
idea
woman
genetically
susceptible
cancer
develop
young
age
biological
mechanism
give
rise
lack
linear
dose
response
curve
active
passive
smoking
clearly
important
area
far
basic
research
fact
biology
completely
work
however
never
require
prerequisite
identification
risk
example
take
decade
increase
risk
heart
disease
passive
smoking
first
identify
see
example
glantz
reasonably
complete
understanding
biology
explain
effect
active
passive
smoking
similar
see
example
glantz
indeed
even
though
tobacco
industry
routinely
demand
detail
biological
explanation
determine
causality
ever
since
original
surgeon
general
report
public
health
service
conclude
active
smoking
lung
cancer
man
neither
surgeon
general
calepa
require
every
detail
biology
define
accept
clearly
observe
risk
exist
lung
cancer
secondhand
smoke
breast
cancer
young
primarily
premenopausal
woman
acknowledgment
like
thank
andrew
howard
morrison
wells
feedback
early
draft
glantz
work
support
national
cancer
institute
grant
grant
agency
play
role
conduct
research
preparation
revision
manuscript
breast
cancer
predominant
cancer
woman
western
world
incidence
woman
will
develop
breast
cancer
due
early
detection
extensive
treatment
option
many
patient
breast
cancer
evolve
deadly
form
cancer
chronic
consequence
become
subject
great
interest
patient
physical
psychological
functioning
aspect
measure
health
status
hs
questionnaire
quality
life
qol
another
aspect
refer
satisfaction
different
aspect
life
number
breast
cancer
increase
enormously
recent
year
however
large
number
study
refer
qol
measure
health
status
qol
hs
qol
often
consider
interchangeable
concept
qol
define
world
health
organization
quality
life
group
individual
perception
position
life
context
culture
value
system
live
relation
goal
expectation
standard
word
qol
person
subjective
evaluation
functioning
wide
range
area
review
hughes
identify
frequently
mention
qol
domain
social
relationship
interaction
psychological
personal
satisfaction
employment
autonomy
personal
choice
leisure
personal
competence
community
adjustment
independent
live
skill
residential
environment
community
integration
support
service
receive
individual
social
demographic
indicator
personal
development
fulfillment
social
acceptance
social
status
ecological
fit
physical
material
domain
consider
encompass
life
research
focuses
satisfaction
within
health
relate
domain
physical
functioning
psychological
personal
satisfaction
social
relationship
interaction
measure
hs
measure
impact
disease
health
relate
patient
ask
physical
possibility
social
activity
state
mind
concern
functioning
thus
hs
indicate
whether
limitation
whereas
qol
also
reflect
extent
patient
indicate
bother
limitation
depending
research
question
hs
qol
important
evaluate
breast
cancer
survivor
outcome
interest
possible
long
term
effect
breast
cancer
treatment
function
hs
questionnaire
sufficient
objective
study
satisfaction
function
qol
questionnaire
need
thus
extremely
important
recognize
different
definition
concept
realize
hs
questionnaire
able
answer
research
question
concern
qol
majority
study
concern
breast
cancer
patient
much
one
questionnaire
reach
will
provide
good
insight
woman
test
long
distinction
make
outcome
score
hs
questionnaire
outcome
score
derived
qol
questionnaire
study
carry
demonstrate
difference
qol
hs
world
health
organization
quality
life
questionnaire
qol
questionnaire
rand
health
survey
hs
questionnaire
administer
breast
cancer
survivor
two
hypothesis
study
first
hypothesis
concern
difference
qol
hs
breast
cancer
survivor
assume
breast
cancer
survivor
impair
qol
due
psychological
adjustment
give
situation
whereas
hs
still
impair
continue
negative
effect
breast
cancer
treatment
function
second
hypothesis
concern
correlation
assume
outcome
score
qol
hs
correlate
well
score
two
questionnaire
yield
conclusion
based
previous
study
show
difference
health
status
due
surgical
breast
cancer
survivor
divide
two
treatment
group
breast
conserve
therapy
versus
mastectomy
patient
method
patient
consecutive
patient
diagnose
early
stage
breast
cancer
surgical
treatment
january
december
eligible
study
women
prove
breast
cancer
recurrence
distant
metastases
exclude
since
know
recurrence
breast
cancer
profound
negative
effect
qol
therefore
compromise
result
one
hundred
woman
contact
telephone
ask
want
participate
reason
interested
hard
want
confront
past
reason
one
hundred
woman
agree
participate
return
questionnaire
patient
representative
sample
dutch
early
stage
breast
cancer
patient
treatment
accord
international
guideline
proportion
two
treatment
group
comparable
information
international
cancer
patient
time
since
diagnosis
surgical
treatment
least
month
range
month
reference
population
reference
population
hypothesis
derived
questionnaire
manual
qol
reference
population
exist
healthy
dutch
woman
live
residential
area
include
breast
cancer
reference
population
hs
healthy
dutch
woman
comparable
concern
age
social
questionnaire
qol
assess
world
health
organization
quality
life
assessment
develop
generic
consist
item
assess
facet
qol
within
six
domain
physical
health
psychological
health
level
independence
social
relationship
environment
general
evaluative
facet
overall
quality
life
general
health
develop
simultaneously
center
worldwide
aspect
life
consider
contribute
qol
discuss
focus
group
center
inclusion
facet
eventually
based
consensus
within
culture
among
health
professional
healthy
individual
general
population
person
contact
health
service
disease
response
scale
question
point
scale
score
facet
domain
range
timeframe
evaluation
complete
questionnaire
previous
two
week
reliability
validity
instrument
present
study
cronbach
alpha
domain
range
domain
physical
health
facet
domain
environment
facet
rand
health
survey
dutch
assess
health
status
rand
identical
medical
outcome
study
short
evaluate
health
eight
dimension
physical
functioning
bodily
pain
role
limitation
due
physical
health
problem
role
limitation
due
personal
emotional
problem
general
mental
health
social
functioning
energy
fatigue
general
health
perception
addition
include
single
item
provide
indication
perceive
change
health
rationale
dimension
health
concept
much
frequently
include
health
survey
item
measure
score
per
dimension
adapt
instrument
year
subscale
score
represent
scale
high
score
indicate
good
health
status
timeframe
evaluation
function
previous
four
week
good
reliability
present
study
cronbach
alpha
range
dimension
social
functioning
item
dimension
physical
functioning
item
statistical
procedure
examine
difference
two
treatment
group
breast
conserve
therapy
bct
mastectomy
mtc
regard
clinical
parameter
tumor
surgical
treatment
adjuvant
treatment
demographic
characteristic
child
live
partner
educational
level
test
employ
analysis
variance
perform
examine
difference
bct
mtc
patient
regard
score
qol
separate
domain
dimension
score
overall
qol
domain
qol
dimension
rand
compare
treatment
group
separately
score
exist
reference
population
due
number
test
small
consider
statistically
significant
association
domain
dimension
examine
pearson
correlation
coefficient
analysis
perform
statistical
package
social
science
spss
version
result
characteristic
include
patient
include
woman
comparable
woman
decline
participation
respect
surgical
treatment
tumor
characteristic
however
participant
significantly
young
much
often
receive
chemotherapy
much
often
treat
radiotherapy
characteristic
two
treatment
group
woman
treat
breast
conserve
therapy
removal
tumor
mean
lumpectomy
axillary
lymph
node
dissection
follow
radiation
breast
woman
undergo
mastectomy
removal
breast
tissue
include
nipple
axillary
lymph
node
dissection
concerning
demographic
clinical
feature
difference
age
partner
child
two
treatment
group
level
education
show
significant
difference
compared
bct
group
large
percentage
mtc
group
much
year
education
clinical
feature
show
difference
regard
tumor
size
lymph
node
metastases
adjuvant
treatment
mtc
group
significantly
much
large
tumor
much
lymph
node
metastases
much
often
receive
hormonal
therapy
women
bct
group
treat
much
frequently
radiotherapy
part
conserve
treatment
table
clinical
demographic
feature
bct
mtc
group
include
patient
bct
mtc
age
diagnosis
sd
level
education
yr
tumor
size
cm
cm
metastases
yes
hormone
table
note
view
within
article
quality
life
surgical
treatment
scores
facet
overall
qol
separate
domain
show
significant
difference
two
treatment
group
compared
reference
score
bct
group
score
high
psychological
domain
reference
score
derived
manual
table
scores
bct
mtc
group
different
domain
reference
score
bctmtcreference
scoreresults
overall
qol
general
physical
psychological
bct
level
social
table
comparison
score
significant
result
show
table
note
standard
deviation
bracket
view
within
article
health
status
surgical
treatment
scores
dimension
show
significant
difference
bct
mtc
group
compared
score
reference
population
woman
mtc
group
score
physical
functioning
role
limitation
due
physical
problem
general
health
perception
bct
group
similar
health
status
reference
population
table
scores
bct
mtc
group
different
dimension
reference
score
bctmtcreference
scoreresults
general
health
mtc
physical
mtc
social
role
limitation
mtc
role
limitation
general
mental
energy
bodily
health
table
comparison
score
significant
result
show
table
note
standard
deviation
bracket
view
within
article
correlation
qol
hs
questionnaire
finally
correlation
calculate
following
absolute
correlation
consider
small
medium
high
large
overall
correlation
show
considerable
variety
corresponding
domain
dimension
pair
see
bold
correlation
table
general
health
overall
qol
show
high
level
correlation
qol
physical
domain
show
high
correlation
rand
dimension
energy
fatigue
medium
correlation
dimension
physical
functioning
mental
health
psychological
domain
high
correlation
whereas
social
domain
social
dimension
just
reach
medium
correlation
high
correlation
find
hs
energy
fatigue
qol
physical
domain
represent
common
variance
table
pearson
correlation
individual
domain
separate
dimension
overall
domain
general
social
role
role
mental
energy
bodily
health
table
note
correlation
significant
correlation
significant
level
tail
level
tail
view
within
article
discussion
aim
study
aim
study
determine
whether
score
qol
hs
breast
cancer
survivor
comparable
score
healthy
reference
population
establish
difference
conclusion
reach
apply
qol
questionnaire
compare
hs
questionnaire
previous
study
compare
different
hs
questionnaire
see
whether
result
interchangeable
apply
cancer
study
show
considerable
difference
outcome
questionnaire
far
comparison
qol
hs
questionnaire
breast
cancer
patient
result
concern
qol
difference
find
regard
qol
two
treatment
group
expect
patient
qol
impair
compare
reference
score
bct
group
score
well
qol
psychological
domain
possible
explanation
result
might
psychological
adaptation
several
study
show
benefit
find
diagnosis
breast
cancer
treatment
result
well
psychological
adaptation
thus
well
breast
cancer
survivor
compare
woman
benign
breast
disease
report
poorer
physical
health
function
difference
psychological
stress
greater
positive
psychological
adaptation
improve
life
result
concern
hs
score
hs
dimension
show
significant
difference
two
treatment
group
however
compare
reference
score
mtc
group
score
significantly
ill
general
health
perception
physical
functioning
role
limitation
due
physical
problem
concur
hypothesis
result
study
agreement
previous
study
report
score
comparable
healthy
show
woman
mastectomy
much
likely
score
physical
health
study
outcome
based
outcome
may
conclude
negative
effect
breast
cancer
qol
survivor
recurrence
disease
however
score
show
problem
physical
dimension
mastectomy
group
thus
based
qol
measure
conclude
intervention
need
treatment
aim
physical
emotional
functioning
seem
need
mtc
group
focusing
health
status
difference
outcome
score
study
also
reflect
pearson
correlation
high
correlation
qol
physical
health
hs
energy
fatigue
represent
variance
slightly
much
half
variance
indicate
outcome
measure
interchangeable
example
score
questionnaire
study
social
domain
compare
dimension
social
functioning
physical
limitation
emotional
problem
number
social
activity
social
contact
score
dimension
social
functioning
will
however
patient
may
satisfy
nature
social
contact
since
inquire
number
social
contact
especially
inquire
satisfaction
concern
social
activity
social
support
score
social
domain
may
high
mean
attempt
improve
social
life
patient
based
score
social
functioning
will
probably
contribute
well
qol
patient
feel
socially
impair
literature
overview
study
find
compare
qol
questionnaire
hs
questionnaire
perform
administer
patient
intermittent
patient
follow
liver
study
observe
although
patient
report
significant
impairment
domain
hs
qol
measurement
show
consider
objective
functional
impairment
problem
difference
result
questionnaire
underscore
importance
apply
questionnaire
able
answer
research
question
pose
combination
measure
function
satisfaction
relation
function
satisfaction
study
much
extensive
argue
ideally
combination
hs
qol
measure
provide
different
practice
hardly
ever
useful
study
design
interested
functional
outcome
treatment
also
wish
assess
influence
treatment
qol
study
question
answer
correctly
type
questionnaire
conclusion
breast
cancer
survivor
report
good
qol
illustrate
good
adjustment
diagnosis
treatment
breast
cancer
hs
however
still
impair
four
five
year
woman
receive
mst
based
outcome
feel
conclude
hs
questionnaire
assess
qol
researcher
want
incorporate
adjustment
patient
give
situation
qol
questionnaire
papillary
lesion
breast
encompass
diverse
epithelial
proliferation
include
benign
condition
papillary
ductal
hyperplasia
component
fibrocystic
change
solitary
multiple
papilloma
well
malignant
condition
situ
carcinoma
micropapillary
solid
papillary
invasive
ductal
adenocarcinoma
typical
papillary
component
invasive
ductal
carcinoma
widespread
screening
mammography
much
much
asymptomatic
benign
lesion
discover
require
specific
management
diagnose
biopsy
case
atypical
lesion
current
recommendation
involve
excisional
biopsy
rule
ductal
carcinoma
situ
invasive
carcinoma
relatively
study
limited
number
case
investigate
risk
carcinoma
patient
diagnosis
papilloma
breast
make
ultrasound
biopsy
conduct
study
quantify
risk
investigate
factor
associate
risk
cancer
patient
papilloma
patient
method
patient
retrospective
review
datum
record
january
march
show
papillary
lesion
patient
undergo
surgery
department
obstetrics
hospital
several
clinical
history
distinguish
inclusion
criterion
papilloma
lesion
diagnose
histological
report
preoperative
surgical
patient
separate
patient
preoperative
histology
patient
without
preoperative
histology
much
patient
papilloma
diagnose
preoperative
histology
referred
mammographic
screening
nipple
discharge
main
clinical
symptom
patient
without
preoperative
histology
mean
patient
age
year
range
year
clinically
patient
palpable
lesion
patient
present
nipple
discharge
benign
papilloma
identify
preoperative
biopsy
case
ductography
case
cytology
case
result
surgical
excision
available
patient
table
summary
initial
finding
patient
diagnose
papilloma
table
normal
view
within
article
imaging
bilateral
mammography
craniocaudal
mediolateral
oblique
perform
patient
ultrasonography
perform
radiologist
case
dense
breast
abnormality
detect
mammogram
systematic
case
symptomatic
patient
complementary
ductography
indicate
spontaneous
unilateral
nipple
discharge
present
perform
injection
contrast
medium
gauge
cannula
insert
pathologic
duct
craniocaudal
lateral
view
obtain
spot
compression
magnification
view
realize
area
concern
papilloma
suspect
regular
defect
find
information
regard
radial
location
depth
abnormality
collect
lesion
size
based
great
lesion
dimension
mass
cluster
calcification
imaging
sonography
size
much
patient
mammography
lesion
single
cluster
calcification
biopsy
mass
identify
ultrasonography
perform
sonographic
guidance
gauge
automate
needle
bard
usa
biopsy
microcalcifications
perform
stereotactic
guidance
gauge
biopsy
vab
probe
mammotome
biopsy
ethicon
gauge
biopsy
probe
bard
usa
case
total
excision
targeted
lesion
localize
clip
place
biopsy
ethicon
stereotactic
sampling
microcalcifications
verify
routinely
specimen
lesion
result
concordance
discuss
radiologist
pathologist
physician
result
categorize
isolate
benign
papilloma
atypical
papilloma
papilloma
associate
lesion
atypical
ductal
hyperplasia
adh
atypical
lobular
hyperplasia
alh
lobular
carcinoma
situ
lcis
malignancy
ductal
carcinoma
situ
dcis
invasive
ductal
carcinoma
idc
benign
lesion
fibrocystic
mastosis
benign
lesion
statistical
analysis
operative
report
obtain
patient
technique
surgery
record
histology
abnormal
breast
tissue
patient
papillary
lesion
operate
definitive
histology
compare
preoperative
diagnosis
factor
associate
underestimation
malignancy
evaluate
univariate
analysis
test
student
multivariate
analysis
logistic
regression
analysis
result
preoperative
finding
diagnostic
histologic
imaging
finding
patient
papilloma
pathologic
report
give
table
preoperative
histology
vab
guidance
available
patient
follow
benign
papilloma
mastosis
benign
lesion
papilloma
associate
atypia
papilloma
associate
carcinoma
situ
papilloma
associate
invasive
carcinoma
table
summary
histologic
finding
core
biopsy
surgical
excision
histology
core
surgical
excision
typical
situ
dcis
invasive
typical
benign
papilloma
carcinoma
invasive
table
associated
papilloma
view
within
article
mammography
normal
case
show
microcalcifications
case
mass
case
ultrasound
perform
case
confirm
mammographic
finding
lesion
evaluate
ductography
sign
suggestive
papilloma
present
case
two
patient
palpable
mass
diagnosis
patient
clinical
symptom
nipple
discharge
bloody
case
case
nipple
discharge
analyzed
patient
need
ductography
show
sign
papilloma
case
histology
operative
specimen
surgical
excision
perform
basis
diagnosis
suspect
papilloma
either
clinical
histologic
radiographic
clinical
radiographic
diagnosis
patient
biopsy
patient
histopathologic
finding
surgically
excise
lesion
reveal
benign
papilloma
patient
atypical
papilloma
patient
mastosis
benign
lesion
patient
adh
patient
alh
patient
lcis
patient
dcis
patient
idc
patient
patient
core
biopsy
prior
surgery
correlation
histological
preoperative
diagnosis
histological
result
operative
specimen
report
table
malignancy
find
final
histology
patient
initial
atypia
well
patient
initial
diagnosis
benign
papilloma
fisher
exact
test
patient
biopsy
prior
surgery
residual
lesion
find
case
presume
entirely
excise
core
biopsy
thirty
lesion
diagnose
papilloma
core
biopsy
papilloma
surgical
excision
atypical
lesion
mastosis
dcis
lcis
idc
eight
lesion
diagnose
benign
core
biopsy
prove
papilloma
surgery
one
lesion
originally
diagnose
atypical
papilloma
core
biopsy
prove
dcis
excision
another
lesion
papilloma
associate
adh
core
biopsy
find
idc
excision
risk
factor
malignancy
analyzed
risk
factor
malignancy
associate
papilloma
firstly
whole
population
secondly
patient
preoperative
histological
diagnosis
typical
papilloma
whole
population
patient
age
little
year
find
carcinoma
final
pathology
contrast
patient
age
much
year
patient
carcinoma
final
excisional
pathology
nipple
discharge
presence
microcalcifications
also
find
relate
risk
malignancy
respectively
multivariate
analysis
significant
relationship
presence
malignancy
excision
age
continuous
variable
well
presence
microcalcifications
respectively
factor
study
show
significant
difference
patient
atypical
papilloma
diagnose
preoperative
histology
malignancy
present
surgical
specimen
patient
age
little
year
versus
case
patient
age
much
year
fisher
exact
test
factor
study
nipple
discharge
microcalcifications
mass
show
significant
difference
table
risk
factor
malignancy
associate
papilloma
benign
malignant
rr
univariate
age
nipple
discharge
microcalcifications
mass
table
view
within
article
discussion
finding
papillary
lesion
breast
much
often
encounter
widespread
core
biopsy
initial
diagnosis
mammographic
sonographic
lesion
malignancy
may
much
team
recommend
excision
papilloma
study
among
large
study
concern
surgical
excision
papillary
lesion
report
preinvasive
invasive
carcinoma
find
case
isolate
papilloma
diagnose
preoperative
exam
malignancy
associate
papilloma
case
age
much
year
microcalcifications
associate
high
risk
malignancy
definitive
histology
table
papillary
lesion
diagnose
core
biopsy
surgically
excise
summary
literature
compare
study
author
reference
patient
surgically
excise
surgical
excision
benign
malignant
liberman
philpotts
renshaw
mercado
sydnor
table
papilloma
without
atypia
view
within
article
papilloma
find
duct
breast
compose
layer
myoepithelial
layer
epithelial
layer
much
often
find
woman
year
may
identify
microscopically
may
extensively
may
demonstrate
feature
atypia
tissue
diagnosis
require
since
atypical
hyperplasia
carcinoma
may
present
way
papilloma
much
common
significant
nipple
ductography
helpful
confirm
suspect
diagnosis
case
nipple
discharge
normal
mammographic
sonographic
imaging
impact
radiology
century
mastectomy
segmentectomy
treatment
choice
bloody
nipple
discharge
radiologist
begin
percutaneous
histologic
needle
sampling
breast
late
procedure
follow
development
liberman
conclude
study
include
case
percutaneously
diagnose
benign
intraductal
lesion
long
require
open
surgical
another
study
concern
benign
histologic
finding
philpotts
show
importance
surgical
excision
discordance
radiography
histology
treatment
atypical
hyperplasia
diagnose
core
biopsy
describe
require
surgical
excision
exclude
underestimate
cancer
treatment
papilloma
diagnose
core
biopsy
seem
much
case
malignant
upgrade
lesion
surgery
patient
report
small
study
concern
surgical
excision
comparison
initial
biopsy
recent
study
include
papilloma
benign
papillary
lesion
core
biopsy
mercado
find
patient
atypical
ductal
hyperplasia
dcis
surgery
recommend
surgery
patient
papilloma
sydnor
show
study
underestimation
rate
benign
papilloma
underestimation
carcinoma
significantly
relate
neither
needle
type
number
study
report
high
risk
underestimation
invasive
carcinoma
indicate
surgical
excision
papillary
lesion
diagnose
study
among
patient
initial
diagnosis
papilloma
atypia
find
patient
lcis
patient
malignancy
dcis
invasive
carcinoma
patient
contradict
report
emphasize
need
determine
risk
factor
underestimation
risk
factor
malignancy
renshaw
well
page
find
study
high
risk
underestimation
malignancy
atypical
papilloma
atypia
associate
papilloma
find
initial
core
needle
study
test
age
much
year
presence
nipple
discharge
microcalcifications
mass
potential
risk
factor
malignancy
similar
study
concern
age
patient
study
factor
find
literature
surprisingly
find
age
much
year
well
presence
nipple
discharge
microcalcifications
significantly
relate
risk
malignancy
surgical
excision
significance
nipple
discharge
persist
multivariate
analysis
explain
number
patient
include
study
interesting
complete
study
risk
factor
large
number
patient
similarly
patient
atypia
associate
papilloma
preoperative
histology
preclude
conclusion
risk
malignancy
papilloma
associate
atypia
conclusion
benign
papilloma
associate
malignancy
excisional
surgery
give
rate
carcinoma
find
patient
isolate
papillary
lesion
study
recommend
surgical
excision
papilloma
analyzed
risk
factor
association
malignancy
papilloma
though
microcalcifications
nipple
discharge
find
potential
risk
factor
malignancy
univariate
analysis
differentiate
effectively
benign
malignant
disease
multivariate
analysis
probably
number
patient
study
patient
age
much
year
presence
microcalcifications
find
independently
relate
risk
malignancy
conflict
interest
author
conflict
interest
disclose
acknowledgement
author
thank
nicole
md
retrospective
datum
basis
much
epidemiologic
research
study
breast
cancer
datum
collect
number
factor
often
difficult
obtain
objective
measure
reproductive
history
lifestyle
practice
datum
potentially
prone
number
bias
include
recall
interviewer
instrument
bias
subsequently
lead
misclassification
datum
threaten
validity
study
result
important
aspect
survey
research
measure
extent
bias
assess
quality
datum
absence
objective
measure
validity
datum
assess
however
reliability
measure
thus
indicate
well
study
tool
elicit
response
repeat
measurement
different
setting
different
point
time
epidemiologic
study
reliability
survey
instrument
much
commonly
assess
test
retest
method
response
give
baseline
survey
compare
response
give
survey
questionnaire
many
study
recent
year
implicate
postmenopausal
hormone
therapy
breast
cancer
risk
based
whereas
finding
report
validity
accuracy
assessment
reliability
consistency
lack
literature
part
quality
control
protocol
large
case
control
study
association
breast
cancer
germany
test
retest
evaluate
reliability
woman
number
putative
breast
cancer
risk
factor
include
reproductive
history
family
history
lifestyle
method
study
population
study
subject
participant
marie
study
large
case
control
study
breast
cancer
conduct
two
region
germany
city
hamburg
region
august
september
woman
diagnosis
incident
situ
invasive
breast
cancer
live
one
study
region
either
prospectively
identify
recruit
hospital
clinic
serve
study
region
retrospectively
recruit
hamburg
cancer
registry
diagnosis
date
back
january
women
eligible
case
diagnose
age
year
resident
one
study
region
speak
german
control
case
age
place
residence
interviews
conduct
person
interviewer
structure
study
questionnaire
study
compliance
declaration
helsinki
review
approve
ethic
committee
university
heidelberg
university
current
reliability
study
include
sample
woman
draw
first
year
recruitment
marie
study
context
validation
study
specifically
decline
recontacted
offer
contact
information
medical
practitioner
approximately
woman
recruit
first
year
study
stratified
random
sample
woman
draw
participation
validation
study
sample
stratified
case
control
status
age
year
yes
intention
approximately
targeted
marie
study
sample
draw
random
sample
woman
pool
recontacted
mail
request
participation
total
woman
case
control
respond
positively
result
participation
proportion
september
march
case
control
person
original
interviewer
shorten
version
original
study
questionnaire
reliability
study
questionnaire
design
conduct
little
minute
consist
question
original
questionnaire
deem
much
relevant
main
study
question
include
question
reproductive
history
family
history
lifestyle
original
questionnaire
short
interview
photographic
depiction
know
german
product
memory
aid
question
take
original
questionnaire
except
case
question
allow
smooth
transition
subsequent
question
remain
within
time
limit
necessary
limit
amount
datum
collect
end
second
questionnaire
ask
first
last
phase
rather
phase
statistical
analysis
marie
survey
questionnaire
generate
datum
range
binary
continuous
assess
whether
disagreement
response
first
second
interview
lead
misclassification
datum
include
continuous
datum
categorize
binary
ordinal
except
age
first
live
birth
remain
continuous
category
grouping
based
either
category
literature
level
variation
deem
acceptable
give
variable
age
menarche
year
age
menopause
year
number
pregnancy
week
first
child
family
history
cancer
yes
wine
consumption
convert
ethanol
consumption
gram
day
bicycle
ride
weekend
hour
hour
cigarette
yes
yes
application
form
pill
gel
vaginal
injection
drop
type
monotherapy
estrogen
progestin
combine
estrogen
progestin
therapy
duration
year
measure
test
retest
reliability
overall
stratified
disease
status
proportion
overall
agreement
po
cohen
po
refer
percent
participant
remain
category
first
second
interview
positive
response
number
participant
corresponding
po
test
differential
agreement
case
control
status
fit
logistic
regression
model
variable
agreement
agree
disagree
outcome
variable
disease
status
case
control
independent
difference
agreement
disease
status
calculate
logistic
regression
model
proc
phreg
statistical
analysis
sas
version
sas
institute
cary
po
agreement
weighted
calculate
agree
option
proc
procedure
result
based
first
interview
case
control
similar
regard
age
parity
first
birth
control
slightly
nonsignificantly
much
likely
case
high
education
significant
difference
see
smoking
wine
consumption
mean
interval
first
second
interview
similar
case
control
week
range
week
range
respectively
table
characteristic
reliability
study
participant
case
control
status
case
control
interval
interview
mean
week
range
education
level
obtain
parity
history
history
history
alcohol
table
based
first
interview
distribution
age
region
hormone
therapy
report
sample
stratified
variable
first
birth
cigarette
wine
year
view
within
article
table
show
test
retest
agreement
putative
breast
cancer
risk
factor
include
overall
disease
status
agreement
high
report
po
differ
disease
status
selected
aspect
last
phase
vary
level
reliability
type
monotherapy
combine
therapy
show
strong
agreement
po
follow
form
application
po
duration
therapy
po
control
show
slightly
high
agreement
case
duration
case
po
control
po
difference
reach
statistical
significance
agreement
duration
variable
year
year
year
year
somewhat
binary
variable
nonetheless
remain
high
po
datum
show
table
test
retest
reliability
putative
breast
cancer
risk
factor
lifestyle
factor
positive
responsespo
positive
responsespo
positive
responsespo
control
application
form
type
duration
age
age
last
menstrual
age
first
live
duration
family
history
cancer
wine
consumption
ethanol
day
regular
cigarette
bicycle
ride
hour
weekend
table
postmenopausal
hormone
therapy
po
proportion
overall
agreement
case
much
two
category
compare
weighted
report
logistic
regression
model
dependent
variable
agreement
yes
independent
variable
disease
status
case
control
refer
late
phase
excludes
woman
miss
value
woman
report
never
data
date
first
interview
first
birth
age
year
participants
ask
ever
smoke
regularly
cigarette
per
day
least
month
age
year
nonsport
average
number
hour
per
weekend
view
within
article
women
recall
age
menarche
age
menopause
highly
consistent
po
po
respectively
agreement
interview
nearly
perfect
number
pregnancy
age
first
live
birth
po
po
respectively
although
agreement
duration
first
child
slightly
high
case
control
po
po
respectively
difference
statistically
significant
agreement
ever
first
child
high
difference
disease
status
case
po
control
po
datum
show
family
history
type
cancer
show
equally
strong
agreement
mother
po
sister
po
agreement
independent
participant
disease
status
reliability
variable
represent
lifestyle
factor
strong
wine
consumption
po
cigarette
smoking
po
physical
activity
measure
nonsport
bicycle
ride
weekend
somewhat
overall
agreement
po
however
agreement
essentially
identical
case
control
discussion
overall
study
demonstrate
context
german
case
control
study
datum
obtain
via
two
personal
interview
highly
reliable
regard
variable
consider
possible
risk
factor
breast
cancer
include
datum
agreement
nondifferential
disease
status
study
one
two
examine
test
retest
reliability
date
newcomb
colleague
report
finding
reliability
substudy
part
large
study
breast
cancer
find
high
agreement
case
control
duration
case
correlation
coefficient
icc
control
icc
finding
similarly
high
case
control
categorize
duration
case
control
one
reason
differential
finding
might
methodologic
appear
newcomb
colleague
conduct
full
interview
twice
whereas
shorten
version
original
questionnaire
ask
every
phase
validity
study
marie
agreement
assess
woman
physician
report
overall
agreement
duration
icc
differential
agreement
disease
status
although
reliability
questionnaire
preclude
direct
comparison
validity
study
result
duration
combine
finding
two
study
reinforce
high
quality
marie
study
datum
published
finding
reliability
reproductive
health
factor
examine
uniformly
high
range
finding
age
menarche
parity
age
first
birth
age
last
menstrual
period
corroborate
trend
study
examine
reliability
tend
consider
total
duration
birth
study
consider
overall
agreement
first
second
interview
high
study
line
finding
previous
study
total
duration
range
although
overall
sample
size
large
stratified
family
history
cancer
cancer
type
leave
insufficient
statistical
power
make
stable
estimate
reliability
family
history
specifically
breast
cancer
nonetheless
study
finding
family
history
cancer
agreement
two
previous
study
zhu
colleague
show
strong
reliability
report
family
history
cancer
regard
parent
sibling
whereas
horowitz
colleague
find
high
level
agreement
family
history
breast
cancer
first
degree
relative
third
study
reliability
man
report
family
history
prostate
cancer
find
agreement
answer
question
consistently
one
interview
next
author
suggest
may
due
type
cancer
study
prostate
cancer
little
openly
discuss
family
compare
type
cancer
fact
study
look
exclusively
man
may
also
explain
finding
zhu
associate
horowitz
colleague
current
study
majority
publish
study
assess
reliability
lifestyle
datum
compare
response
current
recent
level
frequency
quantity
fewer
study
publish
finding
recall
lifestyle
datum
distant
past
question
whether
ever
regularly
smoke
participant
study
give
highly
consistent
response
line
finding
previous
reliability
study
smoking
status
agreement
range
relatively
strong
finding
recall
alcohol
consumption
specifically
wine
consume
age
year
confirm
two
study
also
examine
reliability
report
alcohol
consumption
distant
past
colleague
find
recall
high
icc
cohort
woman
year
ask
quantity
frequency
alcohol
consumption
adult
year
study
associate
find
reliability
lifetime
alcohol
consume
recall
decade
range
spearman
however
finding
stratified
sex
age
group
current
study
identify
weekend
bicycle
ride
variable
agreement
overall
although
agreement
nondifferential
disease
status
smoking
alcohol
consumption
reliability
datum
physical
activity
report
literature
generally
refer
current
recent
activity
however
reliability
questionnaire
marie
study
collect
datum
weekend
bicycle
ride
study
colleague
sample
woman
year
ask
recall
hour
per
week
history
physical
activity
distant
past
show
reliability
woman
recall
light
moderate
exercise
include
bicycle
ride
time
period
year
age
relatively
pearson
correlation
coefficient
light
exercise
moderate
exercise
compare
recall
type
physical
activity
according
study
agreement
physical
activity
increase
intensity
regularity
increase
explain
relatively
agreement
see
study
weekend
bicycle
ride
tend
recreational
practiced
little
regularly
transportation
bicycle
ride
recent
study
test
retest
reliability
much
commonly
measure
either
cohen
categoric
variable
icc
continuous
variable
method
hypothesis
testing
criticize
inappropriate
prevalence
value
icc
value
dependent
variance
factor
population
compare
finding
study
comparison
measure
interpret
caution
additional
problem
compare
study
measure
dimension
variable
interest
often
vary
one
survey
instrument
next
example
collect
datum
alcohol
consumption
include
question
current
alcohol
ever
never
alcohol
amount
alcohol
consume
present
recent
past
distant
past
furthermore
whereas
study
result
nondifferential
disease
status
note
good
test
retest
reliability
alone
preclude
possibility
recall
bias
study
several
strength
minimize
high
variability
associate
two
different
interviewer
make
certain
interviewer
first
second
interview
addition
interview
set
remain
far
reducing
potential
variability
result
finally
allow
sufficient
time
pass
interview
minimize
possibility
woman
simply
recall
response
give
first
interview
rather
truly
respond
question
second
time
limitation
study
also
consider
study
protocol
require
second
interview
remain
minute
force
selective
choose
question
original
hour
questionnaire
result
include
first
last
phase
rather
replicate
total
lifetime
make
difficult
compare
result
two
interview
may
responsible
comparatively
agreement
duration
researchers
try
include
phase
second
interview
future
reliability
study
examine
different
life
phase
factor
summary
test
retest
reliability
marie
study
survey
questionnaire
agreement
study
examine
similar
breast
cancer
risk
factor
finding
indicate
marie
survey
instrument
good
quality
likelihood
misclassification
author
like
thank
datum
management
support
previous
find
appropriate
substituents
aromatic
strongly
inhibit
growth
breast
cancer
cell
investigation
mode
action
reveal
tubulin
primary
target
bind
colchicine
binding
site
prevent
polymerization
dimer
functional
microtubules
require
vital
function
cell
include
mitosis
though
compound
active
range
vivo
activity
disappointing
probably
due
presence
metabolically
unstable
aldehyde
function
chemical
modification
functional
group
render
molecule
stable
physiological
condition
one
first
modification
perform
comprise
conversion
aldehyde
function
methyl
imines
oximes
methyl
imines
prove
simply
release
aldehyde
oximes
however
stable
display
activity
somewhat
parent
result
prompt
convert
aldehyde
stable
derivative
study
describe
synthesis
biological
characterization
condensation
product
aldehyde
malononitrile
image
figure
example
agent
inhibit
cell
cycle
progression
different
mechanism
view
within
article
main
objective
study
search
compound
strongly
inhibit
tumor
growth
blockade
cell
cycle
show
antimitotic
agent
inhibition
tubulin
polymerization
accompany
cell
cycle
arrest
blockade
normal
cell
cycle
render
cell
susceptible
apoptosis
cell
cycle
intervention
emerge
interesting
new
strategy
first
approve
drug
inhibit
tumor
growth
cell
cycle
arrest
phase
alkaloid
inhibit
tubulin
much
recently
natural
product
taxane
discover
block
cell
cycle
phase
stabilize
attractive
target
enzyme
control
cell
cycle
large
number
compound
find
inhibit
kinase
especially
since
mainly
interested
indole
derivative
selection
agent
contain
structural
element
present
figure
simple
example
natural
constituent
plant
induce
arrest
cell
cycle
phase
inhibit
growth
breast
cancer
major
reaction
product
also
interfere
cell
cycle
progression
breast
cancer
inhibitor
kinase
cell
cycle
control
phase
also
achieve
whereas
derivative
block
cell
cycle
present
study
convert
block
cell
cycle
phase
inhibition
tubulin
polymerization
determine
activity
breast
cancer
cell
effect
cell
cycle
analyzed
flow
cytometry
since
cell
cycle
arrest
may
lead
apoptotic
cell
death
marker
apoptosis
activation
caspase
determine
two
representative
example
major
goal
study
discovery
potent
antitumor
agent
retain
activity
vivo
thus
one
compound
synthesize
evaluate
mxt
mouse
mammary
tumor
model
result
chemistry
previous
investigation
much
favorable
substitution
pattern
start
respect
antitumor
activity
decide
select
substituents
anticipate
similar
mode
action
propanedinitrile
conversion
aldehyde
corresponding
methylene
propanedinitrile
readily
accomplish
reaction
malononitrile
structural
modification
alter
property
indole
core
much
lead
minor
effect
also
synthesize
analogue
methylene
propanedinitrile
one
group
replace
hydrogen
group
modification
abolish
strongly
decrease
activity
indole
derivative
thus
datum
compound
present
image
figure
synthesis
methylene
propanedinitrile
view
within
article
activity
compound
synthesize
first
evaluate
activity
human
breast
cancer
cell
microplate
assay
one
reference
compound
unsubstituted
methylene
propanedinitrile
strongly
inhibit
growth
cell
value
based
previous
investigation
series
compound
methoxy
group
phenyl
variety
lipophilic
substituents
position
indole
include
alkyl
group
variable
length
test
methoxyphenyl
indole
derivative
strongly
inhibit
growth
cell
value
potency
unsubstituted
indole
significantly
increase
substituents
introduce
add
substantial
amount
lipophilicity
parent
molecule
alkyl
derivative
alkyl
chain
methyl
decrease
value
similar
observation
make
phenylindole
furnish
methyl
ethyl
trifluoromethyl
group
phenyl
value
one
order
magnitude
high
establish
antimitotic
drug
vincristine
methoxy
group
shift
position
activity
decrease
value
polar
character
substituents
indole
moiety
detrimental
potency
value
methoxyphenyl
indole
derivative
drop
one
order
magnitude
ether
function
position
cleave
datum
show
table
effect
methylene
propanedinitrile
human
breast
cancer
cell
table
inhibition
cell
growth
determine
incubation
day
subsequent
crystal
violet
staining
viable
cell
mean
value
two
independent
experiment
replicate
sd
generally
little
analogous
experiment
describe
cell
one
exception
incubation
period
day
determine
view
within
article
image
figure
inhibitory
effect
methoxyphenyl
methylene
propanedinitrile
variable
alkyl
chain
length
growth
breast
cancer
cell
inhibition
cell
growth
determine
incubation
day
subsequent
crystal
violet
staining
viable
cell
vincristine
reference
drug
view
within
article
methylene
propanedinitrile
also
test
activity
breast
cancer
cell
since
similar
activity
observe
cell
line
involvement
estrogen
receptor
present
cell
rule
difference
activity
usually
within
statistical
error
assay
except
small
number
compound
whose
value
differ
factor
much
q
general
preference
sensitivity
two
cell
line
though
slight
tendency
high
value
cell
notice
comparison
inhibitory
effect
methylene
propanedinitrile
corresponding
reveal
latter
much
active
factor
cell
cycle
arrest
previous
study
show
aldehyde
exert
cytotoxic
effect
inhibition
tubulin
polymerization
cell
cycle
arrest
thus
interest
study
effect
methylene
propanedinitrile
cell
cycle
assay
cell
cycle
dependent
dna
content
cell
determine
flow
cytometry
propidium
iodide
permeabilized
cell
first
one
much
active
methylene
propanedinitrile
study
effect
cell
cycle
comparison
corresponding
aldehyde
vincristine
treatment
cell
three
agent
lead
decrease
peak
cell
phase
parallel
increase
number
cell
phase
due
blockade
cell
cycle
phase
change
cell
cycle
distribution
accompany
appearance
significant
quantity
cell
dna
content
cell
fraction
comparison
reveal
exert
effect
require
tenfold
high
concentration
vincristine
even
much
active
block
cell
cycle
concentration
image
figure
flow
cytometry
analysis
cell
cycle
breast
cancer
cell
expose
compound
vincristine
various
concentration
dna
content
quantify
standard
propidium
iodide
procedure
describe
experimental
section
cell
assign
label
label
label
cell
label
respectively
accord
dna
content
view
within
article
five
much
derivative
different
cytostatic
potency
examine
effect
cell
cycle
progression
increase
concentration
already
concentration
significant
fraction
appear
probably
due
apoptotic
process
cell
pool
sometimes
phenomenon
become
evident
cell
cycle
arrest
occur
according
reduce
number
cell
phase
peak
decrease
high
concentration
usually
blockade
cell
cycle
observe
concentration
tenfold
high
value
image
figure
cell
cycle
distribution
cell
treat
methylene
propanedinitrile
panel
panel
panel
various
concentration
vincristine
reference
drug
percentage
cell
cell
show
data
refer
representative
experiment
two
view
within
article
inhibition
tubulin
polymerization
one
possible
explanation
cell
cycle
arrest
inhibition
tubulin
polymerization
functional
microtubules
observe
antimitotic
agent
colchicine
therefore
two
methylene
propanedinitrile
corresponding
test
inhibitory
activity
polymerization
tubulin
isolate
calf
brain
comparison
aldehyde
colchicine
include
assay
cytotoxicity
determine
two
breast
cancer
cell
line
differ
estrogen
receptor
status
vulva
carcinoma
cell
line
characterize
high
level
egf
receptor
progression
tubulin
polymerization
measure
nm
cuvette
period
min
temperature
raise
concentration
colchicine
aldehyde
suppress
tubulin
polymerization
whereas
methylene
propanedinitrile
inactive
datum
cytotoxicity
determine
three
different
cell
line
reveal
inhibition
tumor
cell
growth
derivative
depend
blockade
tubulin
polymerization
respect
methylene
propanedinitrile
resemble
unsubstituted
aldehyde
also
inhibit
cell
growth
without
affect
tubulin
polymerization
relevant
concentration
result
make
alternative
mode
action
latter
compound
likely
table
effect
methylene
propanedinitrile
growth
human
cancer
cell
tubulin
polymerization
cn
cn
table
inhibition
cell
growth
determine
incubation
day
subsequent
crystal
violet
staining
viable
cell
mean
value
four
independent
experiment
replicate
sd
incubation
period
day
incubation
period
day
tubulin
polymerization
presence
inhibitor
control
without
inhibitor
test
view
within
article
activation
caspase
inhibition
cell
growth
indole
derivative
accompany
occurrence
substantial
fraction
cell
cycle
analysis
effect
probably
due
apoptotic
process
induce
phase
observation
accord
microscopic
image
cell
nucleus
take
treatment
show
structure
fragmentation
pattern
nucleus
typical
apoptosis
image
shown
apoptotic
path
cell
death
characterize
release
mitochondria
induction
various
caspase
enzyme
condensation
chromosome
fragmentation
nuclear
study
cleavage
caspase
substrate
biochemical
marker
apoptosis
two
representative
example
methylene
propanedinitrile
test
ability
increase
caspase
activity
within
human
leukemia
cell
compound
induce
caspase
activity
concentration
somewhat
different
effect
cleavage
caspase
substrate
induction
caspase
like
activity
much
strong
observe
reference
antitumor
agent
etoposide
even
etoposide
apply
high
concentration
strongly
enhance
caspase
activity
also
observe
concentration
datum
show
indole
derivative
also
inhibit
growth
cell
treatment
value
nm
nm
respectively
determine
mtt
assay
clinically
anticancer
agent
etoposide
display
value
nm
image
figure
effect
etoposide
caspase
like
panel
caspase
like
panel
activity
cell
exposure
control
show
caspase
activity
beginning
treatment
bar
represent
mean
three
independent
experiment
sd
increase
statistically
significant
view
within
article
although
study
provide
strong
evidence
apoptosis
mechanism
cell
death
title
compound
necrosis
compete
action
rule
therefore
stain
cell
induction
caspase
trypan
blue
procedure
apply
detect
necrotic
although
uptake
trypan
blue
occur
apoptotic
necrotic
staining
cell
trypan
blue
treatment
period
etoposide
show
occurrence
many
cell
take
dye
though
roughly
number
cell
remain
untreated
control
cell
show
hardly
uptake
dye
since
staining
cell
trypan
blue
allow
clear
distinction
make
necrosis
apoptosis
method
require
quantify
number
cell
undergo
apoptosis
count
cell
nuclear
addition
cycloheximide
block
synthesis
protein
require
apoptotic
nevertheless
picture
obtain
light
microscopy
cell
treat
show
similar
morphology
treat
etoposide
see
supplementary
material
inhibition
mxt
mouse
mammary
tumor
preliminary
study
aldehyde
mxt
mouse
mammary
tumor
model
reveal
antitumor
activity
observe
vitro
lose
vivo
lack
vivo
activity
rationalized
presence
metabolically
aldehyde
function
thus
aldehyde
convert
derivative
modify
functional
group
since
indole
derivative
retain
vitro
activity
representative
compound
series
evaluate
vivo
test
model
transplantable
mxt
mouse
mammary
tumor
treatment
start
transplantation
last
two
week
end
treatment
tumor
size
treat
animal
compare
untreated
control
animal
methylene
propanedinitrile
show
significant
inhibition
tumor
growth
effect
comparable
effect
reference
drug
cisplatin
reach
experiment
cisplatin
administer
dose
mg
kg
lead
reduction
body
weight
whereas
animal
show
sign
toxicity
treat
mg
per
body
weight
image
figure
inhibitory
effect
indole
cisplatin
growth
transplant
mxt
mouse
mammary
tumor
two
week
treatment
point
scatter
diagram
represent
tumor
area
one
animal
state
dose
administer
subcutaneously
three
time
per
week
view
within
article
table
effect
cisplatin
growth
mxt
mouse
mammary
tumor
mg
tumor
body
table
dose
kg
body
weight
administer
three
time
per
week
mean
sd
two
week
treatment
tumor
area
treat
animal
tumor
area
control
animal
difference
mean
body
weight
first
last
day
treatment
significant
inhibition
tumor
growth
significant
inhibition
tumor
growth
view
within
article
discussion
aim
study
chemical
modification
antimitotic
derivative
vivo
activity
since
reactive
group
aldehyde
function
conversion
methylene
propanedinitrile
structure
render
molecule
stable
metabolic
transformation
reduce
bioactivity
parent
structure
result
study
show
carbonyl
oxygen
replace
group
without
abolish
activity
cancer
cell
also
interesting
note
different
substituents
methylene
propanedinitrile
similar
influence
antitumor
activity
aldehyde
series
similarity
structure
activity
relationship
indicate
common
mode
action
aldehyde
corresponding
methylene
propanedinitrile
investigate
mode
action
methylene
find
act
different
mechanism
aldehyde
show
inhibit
tubulin
polymerization
action
assume
responsible
strong
antimitotic
effect
aldehyde
fact
propanedinitrile
aldehyde
share
structure
activity
profile
significantly
high
activity
much
aldehyde
rationalized
common
mode
action
type
indole
derivative
encompass
additional
effect
aldehyde
tubulin
polymerization
assumption
support
datum
unsubstituted
aldehyde
methoxy
derivative
show
similar
cytostatic
activity
inhibit
tubulin
polymerization
obviously
methoxy
group
phenyl
play
crucial
role
interaction
tubulin
methoxy
group
locate
position
indole
rather
phenyl
inhibition
tubulin
polymerization
precise
mechanism
methylene
propanedinitrile
inhibit
cell
growth
remain
unclear
agent
block
cell
cycle
phase
drive
cell
apoptotic
cell
death
process
probably
mediate
activation
caspase
caspase
enzyme
activity
strongly
stimulate
concentration
fold
high
much
require
anticancer
drug
etoposide
finding
accord
observe
fragmentation
nuclear
dna
concentration
datum
obtain
growth
inhibitory
effect
indole
rationalized
result
apoptotic
cell
death
follow
cell
cycle
arrest
phase
however
reason
cell
cycle
blockade
evident
interaction
tubulin
find
corresponding
aldehyde
exclude
another
target
consider
egf
receptor
associate
ptk
structure
methylene
propanedinitrile
resemble
however
inhibition
egf
receptor
phosphorylation
cell
cycle
arrest
late
observe
obviously
tyrphostin
require
free
phenolic
hydroxyl
group
action
egf
receptor
also
check
protein
tyrosine
kinase
human
tissue
find
activity
whether
cdk
cyclin
involve
observe
cell
cycle
blockade
remain
investigate
chemical
structure
methylene
propanedinitrile
however
exhibit
hardly
similarity
know
inhibitor
important
aspect
application
agent
anticancer
drug
vivo
activity
one
compound
study
treat
mouse
bear
transplant
mxt
mammary
tumor
significant
inhibition
tumor
growth
achieve
without
obvious
adverse
effect
though
datum
derived
single
experiment
preliminary
character
consider
proof
principle
indole
derivative
exhibit
vivo
activity
remain
optimized
conclusion
series
previously
characterize
antimitotic
agent
high
potency
convert
corresponding
methylene
propanedinitrile
render
stable
possible
metabolic
transformation
aldehyde
function
vitro
assay
activity
various
cell
line
reveal
potency
phenylindole
derivative
decrease
slightly
upon
structural
modification
increase
value
human
breast
cancer
cell
generally
little
factor
though
methylene
propanedinitrile
share
structure
activity
relationship
aldehyde
molecular
target
however
might
different
interfere
polymerization
tubulin
dominant
molecular
action
similar
aldehyde
methylene
propanedinitrile
block
cell
cycle
phase
drive
tumor
cell
apoptosis
demonstrate
strong
increase
caspase
activity
question
whether
necrotic
cell
death
also
play
role
yet
clearly
answer
important
aspect
study
vivo
activity
class
antimitotic
agent
thus
derivative
evaluate
vivo
antitumor
activity
significantly
inhibit
growth
transplant
mxt
mouse
mammary
tumor
dose
mg
kg
body
weight
vivo
activity
parallel
corresponding
aldehyde
biological
characteristic
new
compound
make
interesting
candidate
far
development
anticancer
agent
general
method
melting
point
determine
apparatus
uncorrected
nmr
spectrum
record
spectrometer
bruker
tms
internal
standard
accord
assign
structure
mass
spectrum
obtain
spectrometer
varian
purity
compound
check
analysis
perform
university
regensburg
synthesis
start
aldehyde
describe
previously
preparation
methylene
propanedinitrile
suspension
mmol
acid
mmol
etoh
ml
add
drop
piperidine
mixture
heat
reflux
ml
add
slowly
precipitate
separate
filtration
purify
etoh
column
chromatography
etoac
mixture
methylene
propanedinitrile
yellow
crystal
yield
mp
nmr
arh
calcd
find
methylene
propanedinitrile
yellow
crystal
yield
mp
etoh
nmr
aabb
hz
indole
calcd
find
methoxyphenyl
methylene
propanedinitrile
yellow
crystal
yield
mp
etoh
nmr
dd
hz
hz
aabb
hz
hz
hz
calcd
find
methoxyphenyl
methylene
propanedinitrile
yellow
solid
yield
mp
nmr
dd
hz
hz
hz
aabb
hz
hz
calcd
find
methoxyphenyl
methylene
propanedinitrile
yellow
crystal
yield
mp
etoh
nmr
aabb
hz
calcd
find
methoxyphenyl
methylene
propanedinitrile
orange
crystal
yield
mp
nmr
arh
aabb
hz
arh
calcd
find
methylphenyl
methylene
propanedinitrile
yellow
crystal
yield
mp
etoh
nmr
dd
hz
hz
hz
aabb
hz
calcd
find
methylene
propanedinitrile
yellow
solid
yield
mp
etoh
nmr
aabb
hz
br
calcd
find
methoxyphenyl
methylene
propanedinitrile
yellow
solid
yield
mp
etoh
nmr
ppm
aabb
hz
br
calcd
find
methylene
propanedinitrile
yellow
crystal
yield
mp
etoh
nmr
hz
sext
hz
hz
aabb
hz
hz
hz
calcd
find
methoxyphenyl
methylene
propanedinitrile
yellow
solid
yield
mp
etoh
nmr
hz
hz
aabb
hz
hz
br
calcd
find
methoxyphenyl
methylene
propanedinitrile
yellow
solid
yield
mp
etoh
nmr
hz
sext
hz
hz
hz
aabb
hz
hz
hz
calcd
find
methylene
propanedinitrile
yellow
solid
yield
mp
etoh
nmr
hz
hz
hz
aabb
hz
hz
br
calcd
find
methoxyphenyl
methylene
propanedinitrile
yellow
solid
yield
mp
etoh
nmr
hz
hz
hz
aabb
hz
hz
br
calcd
find
methylphenyl
methylene
propanedinitrile
orange
crystal
yield
mp
etoh
nmr
hz
hz
dd
hz
hz
br
calcd
find
methylene
propanedinitrile
yellow
powder
yield
mp
etoh
nmr
hz
hz
dd
hz
hz
br
z
calcd
find
trifluoromethyl
phenyl
yl
methylene
propanedinitrile
orange
powder
yield
mp
etoh
nmr
hz
hz
dd
hz
hz
hz
br
calcd
find
trifluoromethyl
phenyl
yl
methylene
propanedinitrile
yellow
solid
yield
mp
etoh
nmr
hz
hz
dd
hz
hz
hz
aabb
br
z
calcd
find
trifluoromethyl
phenyl
yl
methylene
propanedinitrile
orange
crystal
yield
mp
etoh
hz
dd
hz
hz
hz
hz
aabb
br
z
calcd
find
material
reagent
bioassays
drug
biochemical
obtain
sigma
germany
except
note
cell
line
breast
cancer
cell
vulva
carcinoma
cell
human
origin
obtain
american
type
culture
collection
atcc
rockville
md
female
mouse
buy
germany
mxt
mammary
tumor
generously
provide
laboratory
experimental
oncology
mass
usa
determination
activity
human
breast
cancer
cell
grow
medium
supplement
mg
gentamycin
sulfate
mg
fetal
calf
serum
fcs
start
experiment
cell
suspension
transfer
well
microplate
well
cell
grow
day
humidify
incubator
medium
replace
one
contain
test
compound
well
control
well
plate
contain
dmf
preparation
stock
solution
initial
cell
density
determine
addition
glutaric
dialdehyde
pbs
well
instead
test
compound
incubation
day
medium
remove
glutaric
dialdehyde
pbs
add
min
solution
aldehyde
decant
cell
stain
treat
min
aqueous
solution
crystal
violet
decant
cell
wash
several
time
water
remove
adherent
dye
addition
etoh
plate
gently
shake
optical
density
well
measure
microplate
nm
human
breast
cancer
cell
similar
procedure
describe
cell
apply
alteration
cell
grow
supplement
sodium
pyruvate
mg
gentamycin
sulfate
mg
phenol
red
fcs
analogous
protocol
apply
vulva
carcinoma
cell
two
modification
concentration
fcs
reduce
incubation
period
day
determination
value
cell
line
mtt
assay
previously
flow
cytometry
cell
grow
confluence
bottom
culture
flask
test
substance
dissolve
dmf
dilute
require
concentration
content
dmf
medium
control
time
dilution
set
concentration
one
culture
flask
cell
expose
test
substance
incubation
time
necessary
obtain
sufficient
number
cell
cell
incubation
cell
trypsinized
centrifuged
excess
serum
contain
medium
min
wash
pbs
pellet
cell
resuspended
ml
pbs
ml
etoh
etoh
pbs
remove
centrifugation
cell
wash
pbs
addition
ml
pbs
ml
dna
extraction
buffer
cell
transfer
eppendorf
cup
ml
incubate
min
room
temperature
centrifuged
cell
stain
ml
propidium
iodide
solution
least
min
room
temperature
analyzed
flow
cytometry
analysis
datum
file
four
parameter
collect
event
sample
flow
rate
adjust
cell
appropriate
accuracy
data
analyzed
software
tubulin
polymerization
isolation
purification
calf
brain
tubulin
cortex
one
two
fresh
calf
brain
pem
buffer
ml
tissue
mg
ml
buffer
solution
homogenize
portion
centrifugation
min
supernatant
carefully
decant
concentration
gtp
atp
adjust
mm
respectively
stir
gently
min
solution
transfer
centrifugation
tube
carefully
sucrose
solution
pem
buffer
solution
contain
mm
gtp
transfer
volume
centrifugation
min
pellet
weigh
suspend
pem
buffer
solution
ml
homogenize
stand
ice
min
suspension
centrifuged
min
supernatant
separate
adjust
mm
gtp
incubation
min
tubulin
centrifugation
min
microtubules
obtain
pellet
yield
range
per
brain
aliquots
freeze
liquid
nitrogen
store
purity
check
polyacrylamide
gel
electrophoresis
tubulin
polymerization
pellet
freeze
microtubules
warm
water
bath
addition
fold
volume
pemg
buffer
homogenize
complete
keep
mixture
min
follow
centrifugation
min
remove
protein
reaction
tube
contain
ml
supernatant
dmso
solution
test
compound
vary
concentration
reaction
mixture
preincubated
min
ice
follow
addition
mm
gtp
solution
pemg
buffer
tube
reaction
mixture
transfer
cuvette
uv
connect
two
different
temperature
controller
first
temperature
inside
cuvette
hold
cuvette
switch
second
temperature
controller
absorption
measure
period
min
nm
absorption
start
reaction
baseline
three
independent
experiment
perform
determination
value
experiment
two
control
reaction
mixture
mean
value
define
reading
generally
within
caspase
induction
human
acute
myeloid
leukemia
cell
maintain
logarithmic
growth
rpmi
supplement
fcs
mg
penicillin
mg
streptomycin
sulfate
apoptosis
induce
treatment
cell
cell
ml
indole
derivative
etoposide
reference
drug
cell
incubate
atmosphere
cell
lysate
prepare
treatment
preparation
extract
step
perform
cell
pelleted
min
wash
pbs
pelleted
min
resuspended
hepes
buffer
mm
hepes
ph
mm
dithiothreitol
dtt
mm
na
edta
chaps
min
incubation
ice
lysate
centrifuged
min
supernatant
remove
take
care
avoid
pellet
fifty
microliter
aliquot
contain
cytosolic
protein
estimate
bradford
method
appropriate
protease
inhibitor
heidelberg
germany
caspase
respectively
dmso
assay
without
inhibitor
min
dilute
assay
buffer
mm
hepes
mm
dtt
mm
na
edta
chaps
sample
freeze
experiment
perform
within
one
week
extract
preparation
caspase
activity
assess
monitoring
cleavage
fluorochrome
tag
synthetic
substrate
respectively
hplc
thaw
lysate
appropriate
substrate
add
final
concentration
respectively
sample
incubate
min
specific
product
quantify
fluorescence
detector
merck
fluorescence
measure
excitation
wavelength
nm
nm
emission
wavelength
nm
release
amc
afc
respectively
control
experiment
datum
show
confirm
release
amc
afc
linear
least
min
condition
specify
estimate
specific
caspase
activity
measurement
blank
substrate
negative
control
substrate
cell
lysate
inhibitor
positive
control
substrate
cell
lysate
perform
result
obtain
fluorescence
unit
peak
area
blank
value
subtract
standard
contain
pmol
amc
pmol
afc
utilize
determine
amount
fluorochrome
release
result
present
amount
amc
afc
release
pmol
min
block
selective
protease
inhibitor
microscopy
cell
cell
density
ml
fcs
rpmi
medium
treat
either
dmf
control
etoposide
cell
photograph
directly
fold
magnification
digital
camera
mount
zeiss
microscope
determination
antitumor
activity
mouse
hormone
resistant
mxt
mouse
mammary
tumor
grow
ovariectomized
female
mouse
transplantation
start
experiment
tumor
piece
serially
transplant
female
mouse
animal
randomly
assign
group
treatment
start
transplantation
compound
suspend
polyethylene
glycol
saline
reference
drug
cisplatin
dissolve
saline
agent
administer
subcutaneously
two
week
treatment
tumor
area
determine
measurement
two
perpendicular
axis
one
across
large
diameter
change
body
weight
start
end
therapy
record
order
detect
obvious
toxicity
acknowledgment
author
thank
marko
university
karlsruhe
helpful
discussion
liebl
university
regensburg
excellent
technical
assistance
reference
note
kaufmann
liebl
gastpar
gross
von
angerer
bioorg
med
chem
article
|
pdf
k
|
view
record
scopus
|
cited
scopus
gastpar
marko
von
angerer
med
chem
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
curr
pharm
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
chem
res
toxicol
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
von
angerer
exp
opin
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
von
angerer
curr
opin
drug
discovery
view
record
scopus
|
cited
scopus
br
cancer
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
med
chem
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
garcia
bjeldanes
firestone
biol
chem
view
record
scopus
|
cited
scopus
cover
hsieh
kim
bjeldanes
firestone
biol
chem
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
hong
firestone
bjeldanes
biochem
pharmacol
article
|
pdf
k
|
view
record
scopus
|
cited
scopus
hong
kim
firestone
bjeldanes
carcinogenesis
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
li
wang
sarkar
sarkar
cancer
res
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
turkson
kim
cheng
muehlbeyer
hippe
eisenbrand
proc
sci
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
lee
lee
song
kim
kim
cho
choi
kim
bioorg
med
chem
article
|
pdf
k
|
view
record
scopus
|
cited
scopus
kim
kim
kim
lee
min
clin
cancer
res
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
eisenbrand
hippe
muehlbeyer
cancer
res
clin
oncol
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
exp
opin
invest
drug
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
med
chem
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
bioorg
med
chem
article
|
pdf
k
|
view
record
scopus
|
cited
scopus
chang
yang
mol
biol
rev
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
bednarski
drug
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
watanabe
view
record
scopus
|
cited
scopus
zhang
ogawa
tanaka
cancer
article
|
pdf
k
|
view
record
scopus
|
cited
scopus
breast
cancer
res
treat
view
record
scopus
|
cited
scopus
levitzki
biochem
pharmacol
abstract
|
pdf
k
|
view
record
scopus
|
cited
scopus
levitzki
exp
cell
res
abstract
|
pdf
k
|
view
record
scopus
|
cited
scopus
bednarski
med
chem
full
text
via
crossref
|
view
record
scopus
|
cited
scopus
supplementary
datum
k
microsoft
word
file
supplementary
datum
view
within
article
corresponding
author
fax
bioorganic
medicinal
chemistry
volume
issue
december
list
|
previous
next
home
browse
search
select
setting
alerts
help
sciencedirect
|
contact
|
terms
&
conditions
|
privacy
policycopyright
elsevier
right
reserve
sciencedirect
register
trademark
elsevier
var
hidediv
collabboxcontent
patient
recurrent
breast
cancer
present
initially
distant
metastases
dm
much
frequent
breast
mortality
figure
show
site
first
breast
cancer
much
common
metastatic
site
approximately
woman
breast
cancer
die
bone
metastases
image
figure
site
first
view
within
article
survival
follow
recurrence
significantly
long
patient
locoregional
recurrence
median
time
year
versus
patient
develop
dm
median
time
year
site
distant
metastasis
affect
prognosis
patient
bone
first
site
metastasis
well
overall
survival
month
versus
month
survival
first
metastases
month
versus
month
patient
visceral
rate
patient
bone
lung
liver
metastases
breast
cancer
express
hormonal
receptor
potentially
endocrine
therapy
essential
management
breast
cancer
patient
adjuvant
endocrine
therapy
trial
tamoxifen
aromatase
inhibitor
report
efficacy
term
survival
dfs
distant
dfs
therapy
able
reduce
risk
breast
cancer
recurrence
especially
reduce
dm
likely
much
significant
beneficial
effect
increase
survival
time
patient
diagnose
early
breast
cancer
review
will
discuss
timing
risk
factor
dm
efficacy
current
reduce
risk
dm
postmenopausal
patient
breast
cancer
timing
recurrence
peak
hazard
period
recurrence
observe
first
year
surgery
risk
ongoing
even
year
diagnosis
zero
rate
recurrence
year
year
year
different
timing
recurrence
observe
hormonal
receptor
positive
negative
breast
cancer
hormone
disease
risk
breast
cancer
relapse
high
first
year
peak
first
third
year
surgery
fifth
year
risk
decrease
dramatically
hormone
disease
peak
relapse
first
third
year
observe
hormone
tumor
fifth
year
risk
remain
high
especially
postmenopausal
hormone
patient
treat
endocrine
therapy
early
recurrence
occur
much
frequently
presence
one
much
follow
factor
large
tumor
size
cm
high
number
involve
axillary
lymph
node
poor
histological
grade
level
estrogen
receptor
human
epidermal
growth
factor
receptor
early
relapse
rate
range
majority
type
breast
cancer
recurrence
predict
factor
overall
survival
site
first
dm
remain
poorly
predictable
although
much
frequent
association
observe
hormonal
receptor
negativity
development
visceral
metastases
lobular
histology
development
surface
recent
datum
indicate
overexpressing
breast
cancer
patient
increase
risk
brain
future
gene
expression
profile
may
well
predict
site
breast
cancer
surgery
young
age
year
vascular
invasion
extensive
situ
carcinoma
associate
high
risk
local
recurrence
mastectomy
vascular
invasion
retain
independent
role
predict
local
local
recurrence
associate
high
risk
develop
dm
patient
develop
local
recurrence
increase
risk
dm
compare
patient
without
local
irrespective
type
recurrence
associate
increase
mortality
patient
early
breast
cancer
effect
mortality
great
patient
distant
recent
retrospective
cohort
study
patient
early
stage
ii
breast
cancer
find
year
patient
recurrence
versus
patient
dm
locoregional
recurrence
compared
group
hazard
ratio
death
high
patient
distant
recurrence
follow
locoregional
recurrence
contralateral
recurrence
group
similar
trend
observe
breast
death
distant
versus
locoregional
another
small
study
patient
find
dm
much
frequent
type
recurrence
eight
isolate
local
recurrence
dm
local
recurrence
dm
associate
year
survival
rate
median
survival
time
isolate
local
first
recurrence
distant
metastatic
first
event
year
table
year
survival
rate
event
follow
local
distant
metastatic
year
survival
ci
year
survival
ci
overall
survival
local
first
event
overall
survival
distant
first
event
table
ci
confidence
interval
view
within
article
impact
adjuvant
endocrine
therapy
distant
metastases
tamoxifen
early
breast
cancer
trialists
collaborative
group
show
median
year
year
adjuvant
tamoxifen
therapy
significantly
reduce
recurrence
mortality
patient
estrogen
tumor
adjuvant
tamoxifen
therapy
reduce
risk
local
recurrence
risk
dm
introduction
aromatase
inhibitor
adjuvant
therapy
improve
result
lead
recommendation
optimal
hormonal
therapy
woman
include
aromatase
inhibitor
initial
therapy
treatment
five
year
tamoxifen
available
option
subgroup
postmenopausal
patient
patient
major
contraindication
aromatase
inhibitor
patient
tolerate
aromatase
inhibitor
aromatase
inhibitor
adjuvant
setting
evaluate
three
different
strategy
initial
therapy
year
diagnosis
upfront
strategy
switch
therapy
switch
year
tamoxifen
switch
strategy
extend
therapy
year
tamoxifen
extend
adjuvant
strategy
study
evaluate
role
adjuvant
therapy
postmenopausal
early
breast
cancer
patient
report
impact
drug
term
distant
metastases
vary
degree
however
difference
define
dm
study
end
point
exist
trial
time
distant
metastases
define
time
random
assignment
distant
recurrence
ignore
local
regional
contralateral
breast
recurrence
second
malignancy
censor
death
without
recurrence
upfront
study
study
switch
strategy
tamoxifen
follow
study
extend
therapy
letrozole
year
switch
strategy
exemestane
intergroup
exemestane
study
ies
event
consider
time
distant
recurrence
include
distant
recurrence
also
death
breast
cancer
death
unknown
metastases
report
type
event
consider
calculate
time
distant
metastases
report
upfront
study
impact
drug
time
distant
metastases
various
trial
report
table
table
efficacy
end
point
adjuvant
trial
compare
tamoxifen
aromatase
inhibitor
year
survival
ci
distant
metastases
ci
ci
value
upfront
strategy
big
switch
strategy
anastrozole
extended
adjuvant
therapy
table
definition
end
point
trial
design
trial
may
vary
respective
risk
reduction
interpret
mind
atac
arimidex
tamoxifen
alone
combination
big
breast
international
group
ci
confidence
interval
hazard
ratio
ies
intergroup
exemestane
study
nr
report
result
observe
patient
hormone
tumor
result
obtain
patient
estrogen
estrogen
tumor
group
ci
value
view
within
article
upfront
strategy
anastrozole
initial
result
arimidex
tamoxifen
alone
combination
trial
report
significantly
improve
dfs
patient
receive
anastrozole
compare
receive
tamoxifen
month
total
distant
metastases
occur
anastrozole
arm
occur
tamoxifen
arm
significant
prolongation
time
dm
overall
population
subset
hormone
patient
significant
risk
reduction
dfs
trend
toward
reduction
incidence
dm
ci
significant
benefit
survival
overall
population
reduction
death
breast
cancer
anastrozole
group
also
significant
upfront
strategy
letrozole
breast
international
group
big
trial
examine
effect
tamoxifen
adjuvant
letrozole
monotherapy
trial
arm
respectively
well
sequential
adjuvant
therapy
tamoxifen
year
follow
letrozole
arm
letrozole
year
follow
tamoxifen
arm
total
year
postmenopausal
woman
breast
median
month
primary
core
analysis
include
patient
monotherapy
arm
sequential
arm
total
dfs
event
occur
patient
receive
letrozole
demonstrate
improvement
dfs
reduction
risk
dm
compare
patient
tamoxifen
another
analysis
big
year
median
report
dm
much
common
type
early
recurrence
occur
event
initial
adjuvant
letrozole
therapy
markedly
reduce
risk
early
dm
dm
event
letrozole
versus
dm
event
tamoxifen
reduction
result
big
obtain
median
month
consider
monotherapy
arm
letrozole
tamoxifen
continue
demonstrate
superiority
letrozole
tamoxifen
dfs
well
reduction
risk
dm
ci
switch
aromatase
inhibitor
therapy
trial
evaluate
switch
strategy
far
subdivide
trial
unplanned
switch
trial
plan
switch
former
trial
study
patient
recurrence
year
tamoxifen
randomized
continue
tamoxifen
switch
trial
plan
switch
big
patient
randomized
either
year
tamoxifen
tamoxifen
follow
diagnosis
consequence
patient
early
recurrence
tamoxifen
count
failure
plan
switch
trial
enter
unplanned
switch
trail
thus
potentially
former
trial
much
favorable
result
final
datum
big
will
indicate
result
plan
switch
trail
will
different
plan
switch
one
among
study
plan
unplanned
switch
datum
anastrozole
exemestane
available
datum
letrozole
sequential
arm
big
expect
anastrozole
pooled
result
three
available
anastrozole
plan
unplanned
switch
therapy
year
tamoxifen
report
recently
publish
patient
switch
anastrozole
significant
improvement
distant
survival
ci
ci
trial
include
variable
design
inclusion
criterion
two
unplanned
switch
study
one
plan
switch
trial
study
result
possibly
unreliable
interpret
cautiously
exemestane
ies
study
classify
unplanned
switch
trial
examine
efficacy
safety
switch
exemestane
follow
year
tamoxifen
adjuvant
therapy
total
year
continue
tamoxifen
much
recent
analysis
ies
conduct
month
demonstrate
improvement
dfs
unadjusted
time
distant
recurrence
overall
patient
population
similarly
improvement
dfs
unadjusted
time
distant
recurrence
unadjusted
observe
patient
extended
adjuvant
therapy
half
breast
cancer
recurrence
death
occur
year
tamoxifen
majority
delay
recurrence
distant
metastatic
event
emphasize
still
need
reduce
risk
potential
strategy
reduce
risk
delay
recurrence
extension
endocrine
therapy
beyond
year
various
trial
compare
versus
year
tamoxifen
analyzed
ebctcg
although
long
treatment
tamoxifen
appear
involve
slightly
recurrence
breast
cancer
mortality
rate
finding
reliably
informative
number
event
hand
mortality
appear
great
among
patient
allocate
long
treatment
although
difference
clearly
significant
versus
year
death
rate
ratio
clinician
prefer
recommend
tamoxifen
beyond
year
least
statistically
reliable
evidence
emerge
recurrence
particularly
mortality
trial
versus
year
tamoxifen
extended
adjuvant
therapy
now
offer
woman
far
protection
delay
relapse
anastrozole
small
austrian
breast
colorectal
cancer
study
group
trial
evaluate
efficacy
extend
adjuvant
anastrozole
compare
treatment
postmenopausal
woman
early
breast
cancer
month
overall
disease
recurrence
reduce
anastrozole
additional
efficacy
result
show
distant
metastatic
recurrence
patient
receive
anastrozole
receive
treatment
preliminary
result
may
suggest
beneficial
effect
anastrozole
extend
adjuvant
setting
however
safety
datum
report
publish
date
letrozole
impact
extend
adjuvant
letrozole
therapy
dm
evaluate
phase
iii
randomized
trial
compare
letrozole
versus
placebo
year
tamoxifen
median
month
year
letrozole
arm
demonstrate
significant
reduction
ci
risk
distant
breast
cancer
subgroup
analysis
also
demonstrate
superiority
letrozole
several
subgroup
include
patient
without
prior
chemotherapy
dfs
letrozole
arm
placebo
arm
difference
arm
observe
overall
survival
versus
respectively
however
survival
advantage
apparent
woman
breast
cancer
group
comprise
approximately
patient
risk
death
reduce
significant
compare
placebo
exemestane
national
surgical
adjuvant
breast
bowel
project
trial
examine
exemestane
versus
placebo
extend
adjuvant
therapy
patient
treat
tamoxifen
year
trial
blind
result
reporting
trial
result
full
accrual
despite
subsequent
crossover
placebo
patient
receive
exemestane
trial
median
month
patient
statistically
significant
improvement
survival
versus
relative
risk
statistically
significant
difference
risk
distant
metastases
event
exemestane
group
versus
event
placebo
group
death
placebo
group
versus
exemestane
group
relative
risk
treatment
strategy
much
effective
reduce
risk
distant
metastases
patient
new
diagnosis
breast
cancer
direct
comparison
upfront
switch
strategy
ongoing
two
randomized
trial
big
tamoxifen
exemestane
adjuvant
multicenter
study
waiting
result
study
oncologist
face
problem
choose
two
strategy
available
datum
suggest
factor
may
help
identify
patient
high
risk
early
relapse
ie
within
first
year
diagnosis
factor
include
predict
novo
resistance
tamoxifen
overexpression
level
associate
highly
aggressive
tumor
large
tumor
size
cm
high
number
metastatic
lymph
node
poor
histological
grading
vascular
invasion
majority
early
relapse
distant
metastases
data
big
trial
show
local
distant
recurrence
respectively
patient
respectively
treatment
letrozole
much
effective
tamoxifen
reduce
early
patient
high
risk
recurrence
receive
upfront
therapy
patient
without
risk
factor
early
relapse
good
upfront
switch
unknown
waiting
result
trial
directly
compare
two
strategy
term
efficacy
tolerability
different
toxicity
profile
tamoxifen
may
help
clinician
choose
two
strategy
individual
patient
newly
diagnose
patient
potential
strategy
plan
extend
therapy
prospective
policy
year
tamoxifen
follow
additional
year
however
high
recurrence
rate
nearly
first
year
tamoxifen
counterbalance
expect
absolute
benefit
observe
extend
therapy
early
first
year
plan
switch
strategy
introduction
already
demonstrate
able
reduce
recurrence
rate
first
year
preferable
delay
introduction
newly
diagnose
patient
much
effective
reduce
risk
distant
metastases
yet
directly
comparative
datum
regard
efficacy
reduce
dm
result
randomized
crossover
study
postmenopausal
woman
show
week
treatment
letrozole
significantly
much
effective
anastrozole
reduce
median
estradiol
level
similarly
crossover
comparison
inhibition
aromatization
significantly
great
letrozole
study
patient
treat
anastrozole
follow
letrozole
vice
versa
mean
percentage
inhibition
aromatase
level
treatment
anastrozole
letrozole
treatment
treatment
anastrozole
suppress
plasma
level
estrone
estradiol
estrone
sulfate
mean
respectively
whereas
treatment
letrozole
corresponding
decrease
respectively
suppression
estrone
estrone
sulfate
significantly
well
treatment
letrozole
compare
anastrozole
respectively
whether
difference
potency
clinically
relevant
know
one
directly
comparative
study
letrozole
versus
anastrozole
patient
treatment
advance
breast
cancer
letrozole
appear
much
effective
anastrozole
term
response
rate
versus
significant
difference
time
progression
primary
end
point
study
ttp
month
treatment
ongoing
trial
compare
different
type
adjuvant
setting
will
clarify
issue
good
conclusion
timing
breast
cancer
recurrence
affect
hormonal
receptor
status
year
peak
recurrence
see
patient
hormone
tumor
well
patient
hormone
tumor
peak
much
pronounce
hormone
tumor
among
hormone
tumor
high
incidence
early
relapse
within
first
year
observe
patient
overexpression
level
high
number
metastatic
axillary
lymph
node
poor
histological
grade
large
tumor
size
presence
vascular
invasion
patient
hormone
tumor
retain
high
risk
recurrence
much
year
diagnosis
majority
breast
cancer
recurrence
dm
represent
much
significant
challenge
threaten
patient
survival
adjuvant
endocrine
therapy
tamoxifen
reduce
risk
breast
cancer
recurrence
include
dm
show
superior
tamoxifen
reduce
recurrence
risk
especially
risk
dm
different
strategy
administer
adjuvant
therapy
able
reduce
risk
dm
wait
result
ongoing
trial
compare
upfront
switch
strategy
patient
new
diagnosis
breast
cancer
individual
risk
early
recurrence
may
help
oncologist
choose
two
strategy
individual
great
risk
early
recurrence
upfront
strategy
may
much
appropriate
switch
strategy
funding
del
receive
honorarium
speaker
activity
astrazeneca
novartis
venturini
receive
honorarium
speaker
activity
novartis
pfizer
hereditary
breast
cancer
account
approximately
breast
cancer
case
often
include
mutation
two
breast
cancer
susceptibility
gene
women
born
mutation
either
significantly
high
risk
develop
breast
ovarian
cancer
woman
general
population
magnitude
risk
woman
former
group
controversial
study
show
mutation
associate
risk
breast
carcinoma
age
year
besides
risk
mutation
tumour
suppressor
gene
increase
risk
early
onset
breast
carcinoma
mutation
carrier
risk
mutation
carrier
develop
breast
cancer
age
year
risk
increase
age
year
cumulative
risk
estimate
age
year
adult
woman
family
identification
mutation
necessary
first
step
towards
improve
treatment
prevention
hereditary
breast
cancer
inherit
way
woman
abnormal
brca
susceptibility
gene
chance
pass
gene
child
women
situation
therefore
confront
reality
child
might
develop
breast
cancer
point
life
child
reach
legal
age
parent
might
raise
question
whether
genetic
testing
breast
cancer
susceptibility
gene
minor
useful
however
unlike
testing
cancer
preventive
therapeutic
strategy
exist
li
syndrome
familial
von
information
one
mutation
status
reach
legal
adult
age
consider
medically
necessary
disease
prevention
early
detection
guidelines
early
detection
breast
cancer
advise
testing
begin
early
age
year
recommend
surveillance
technique
breast
clinical
breast
examination
guideline
also
stress
genetic
testing
offer
moment
health
benefit
expand
offer
time
predictive
genetic
testing
recommend
establish
effective
important
medical
treatment
offer
testing
provide
scope
treatment
essential
degree
prevent
alleviate
outbreak
disease
consequence
outbreak
disease
rationale
behind
option
predictive
testing
minor
disease
delay
person
old
enough
make
inform
choice
addition
early
identification
breast
cancer
susceptibility
gene
minor
associate
psychological
social
ethical
concern
objective
article
provide
systematic
detail
review
attitude
minor
parent
relative
affect
individual
healthcare
professional
towards
predictive
genetic
testing
breast
cancer
will
specifically
investigate
stakeholder
consider
preferred
ideal
age
testing
reason
advance
support
position
will
analyze
whether
position
recommend
review
guideline
share
various
stakeholder
little
know
extent
party
involve
agree
professional
recommendation
concern
cancer
susceptibility
testing
sake
clarity
define
minor
person
reach
legal
age
much
country
year
distinguish
child
adolescent
gradual
development
child
cognitive
skill
moral
reasoning
fact
child
progress
successive
state
development
become
capable
great
participation
decision
welfare
discuss
adolescent
refer
minor
able
participate
decision
individual
minor
decision
make
capacity
discuss
child
refer
minor
consider
unable
data
source
search
database
pubmed
scholar
biological
abstract
index
online
web
science
abstract
one
follow
keyword
attitude
view
survey
questionnaire
response
opinion
belief
interview
perspective
reasoning
focus
group
value
idea
emotion
thought
feeling
actual
search
keyword
truncate
form
combination
term
brca
breast
ovarian
addition
referral
minor
also
examine
follow
keyword
child
childhood
adolescent
infant
young
minor
pediatric
paediatric
relevant
reference
within
pertinent
article
also
consult
search
include
literature
index
study
selection
abstract
retrieve
article
read
study
include
far
consideration
publish
journal
appear
english
report
attitude
minor
parent
relative
affect
individual
healthcare
professional
towards
predictive
genetic
testing
breast
cancer
minor
study
describe
attitude
towards
population
screening
minor
exclude
quantitative
well
qualitative
study
include
data
extraction
synthesis
considerable
heterogeneity
population
study
measure
candidate
article
consider
inappropriate
pool
datum
instead
present
summary
form
result
identify
study
attitude
towards
genetic
testing
hereditary
breast
cancer
minor
study
heterogeneous
variety
study
population
study
design
sample
size
study
measure
quality
study
also
vary
overview
study
present
table
table
describe
attitude
towards
predictive
genetic
testing
breast
cancer
minor
summarize
question
ask
response
question
various
study
distinguish
two
different
situation
case
adolescent
request
genetic
test
brca
case
parent
request
test
child
based
study
provide
overview
argument
testing
case
aim
make
qualitative
appraisal
every
argument
describe
many
person
argument
table
aim
design
method
measure
limitation
study
assess
attitude
towards
predictive
testing
minor
family
history
breast
cancer
datum
rowley
loader
assess
knowledge
attitude
area
obstetrician
towards
dna
testing
genetic
susceptibility
breast
testing
genetic
susceptibility
breast
information
might
biased
respondent
answer
representativeness
sample
assess
attitude
unaffected
relative
woman
breast
ovarian
cancer
regard
ethical
issue
autonomy
confidentiality
relate
surveytelephone
structure
interview
subjects
recruit
contact
affect
relative
identify
patient
list
university
medical
center
washington
hospital
variable
familial
risk
genetic
testing
exposure
knowledge
genetic
testing
optimism
cope
style
attitude
ethical
issue
genetic
sample
comprise
primarily
middle
class
white
education
questionnaire
determine
consumer
provider
want
discuss
breast
cancer
susceptibility
testing
preferred
role
testing
surveyquestionnaire
recruit
ask
name
address
unaffected
relative
woman
list
john
hopkins
maryland
tumor
registry
nurse
practitioner
identify
nurse
practitioner
association
maryland
physician
randomly
select
american
medical
association
physician
variable
question
relate
discussion
describe
determine
view
daughter
increase
risk
develop
breast
cancer
regard
benefit
risk
participate
genetic
susceptibility
research
determine
mother
view
enrolling
daughter
genetic
susceptibility
daughter
interview
separately
much
case
simultaneously
interview
interest
participate
genetic
testing
research
often
high
actual
interest
limitation
generalizability
finding
family
sample
white
study
attitude
toward
testing
child
among
individual
receive
test
result
surveytelephone
interview
woman
approximately
month
receive
genetic
test
genetic
testing
minor
demographic
variable
general
attitude
toward
genetic
testing
general
psychological
distress
distress
breast
ovarian
surgery
history
family
cancer
history
personal
mutation
measurement
sample
representative
term
race
religion
lucassen
houlston
investigate
nature
degree
variation
exist
practice
attitude
towards
genetic
testing
breast
cancer
susceptibility
surveyquestionnaire
send
geneticist
united
kingdom
represent
specialist
consultant
involve
cancer
ask
four
clinical
describe
campbell
ross
study
healthcare
professional
attitude
regard
parental
access
confidentiality
predictive
genetic
testing
interview
record
tape
transcribe
data
examine
ask
respond
family
request
predictive
testing
various
condition
policy
recommendation
well
testing
preference
child
assume
positive
family
history
attitude
towards
question
relate
confidentiality
genetic
sample
sample
convenience
sample
examine
adolescent
attitude
towards
genetic
testing
breast
ask
participate
anonymous
survey
parental
guardian
consent
seek
information
three
hereditary
disorder
provide
afterwards
student
attitude
variable
attitude
towards
genetic
testing
three
different
information
background
insurance
coverage
individual
high
risk
condition
limited
population
suburban
high
school
welkenhuysen
investigate
attitude
midwife
nurse
regard
predictive
testing
hereditary
breast
surveymail
questionnaire
send
sample
midwife
nurse
randomly
select
membership
file
midwife
nurse
variable
opinion
acceptability
predictive
response
rate
nurse
welkenhuysen
investigate
reaction
general
practitioner
gp
nurse
midwife
concern
cancer
risk
surveymail
questionnaire
send
sample
gp
midwife
nurse
randomly
select
membership
file
respective
professional
variable
hypothetical
scenario
involve
breast
cancer
follow
response
rate
nurse
identify
attitude
toward
genetic
questionnaire
subject
three
different
hospital
nurse
medical
student
approach
duty
different
oncology
patient
relative
survey
outpatient
chemotherapy
unit
wait
room
patient
group
approach
wait
outpatient
wait
variable
attitude
towards
genetic
describe
campbell
ross
explore
parental
attitude
belief
genetic
testing
child
condition
present
throughout
life
group
case
vary
degree
controversy
explore
begin
least
focus
group
represent
convenience
sample
respondent
personal
experience
genetic
condition
examine
psychological
family
function
health
attitude
belief
genetic
risk
adolescent
behaviour
form
family
assessment
measure
breast
cancer
genetic
testing
conduct
correlation
make
actual
genetic
risk
small
sample
far
preclude
analysis
subtype
based
family
history
cancer
riordan
loescher
examine
attitude
medical
student
single
university
towards
genetic
testing
surveyquestionnaire
distribute
medical
clinical
demographic
limited
possibly
biased
table
view
within
article
table
summary
find
study
population
sample
size
include
study
size
response
rate
rowley
loader
opinion
divide
appropriateness
offering
testing
daughter
age
year
woman
harbour
strongly
agree
agree
somewhat
neither
agree
disagree
disagree
five
rochester
usa
hospital
area
provider
present
presentation
complete
attitude
questionnaire
much
woman
agree
parent
able
decide
whether
minor
child
genetic
test
agree
strongly
agree
age
year
least
one
relative
breast
ovarian
cancer
personal
history
woman
response
rate
mention
woman
find
susceptibility
test
daughter
physician
nurse
practitioner
think
important
test
daughter
woman
susceptible
inherit
breast
woman
plus
nurse
practitioner
physician
five
consumer
nurse
practitioner
physician
study
observe
mother
daughter
range
reaction
prospect
enrolling
child
adolescent
genetic
susceptibility
research
perception
benefit
risk
fairly
concordant
mother
daughter
daughter
initially
identify
risk
participate
perception
risk
benefit
evolve
course
daughter
breast
cancer
family
recruit
primarily
breast
center
john
hopkins
mother
daughter
interview
study
participant
agree
statement
child
age
year
opportunity
test
gene
mutation
agree
either
respond
sure
depend
either
know
decline
answer
question
among
study
participant
report
child
age
year
individual
note
want
child
test
mutation
endorse
test
mutation
learn
mutation
status
certify
genetic
counsellor
belong
extensive
northern
european
descent
know
mutation
individual
woman
man
participate
response
rate
mention
lucassen
houlston
respondent
prepare
offer
predictive
testing
girl
ask
predictive
test
prepare
know
action
geneticist
united
kingdom
deal
cancer
geneticist
complete
questionnaire
receive
campbell
ross
regarding
access
genetic
testing
breast
cancer
adolescent
family
history
disease
clinician
encourage
testing
prohibit
testing
permit
testing
circumstance
permit
discourage
professional
geneticist
paediatrician
geneticist
different
institution
practice
site
paediatrician
different
institution
practice
site
response
rate
mention
much
girl
want
test
familial
breast
cancer
relative
breast
cancer
significantly
much
willing
test
girl
main
reason
give
girl
genetic
testing
breast
cancer
knowledge
make
nervous
grade
attend
suburban
high
school
student
complete
questionnaire
welkenhuysen
agreement
high
adolescent
request
predictive
test
breast
cancer
median
parent
request
predictive
testing
child
median
nurse
midwife
nurse
midwife
nurse
respond
welkenhuysen
gp
nurse
midwife
argue
daughter
risk
breast
cancer
young
test
hand
gp
midwife
nurse
think
predictive
test
daughter
nurse
midwife
gp
nurse
midwife
gp
midwife
nurse
respond
survey
respondent
increase
cancer
risk
child
choose
individual
three
different
hospital
turkey
include
patient
without
cancer
caregivers
cancer
patient
senior
medical
student
individual
participate
patient
without
cancer
caregivers
cancer
patient
senior
medical
student
nurse
campbell
ross
widespread
interest
focus
group
testing
child
breast
cancer
recruit
individual
suburb
chicago
caucasian
well
intensively
focus
group
comprise
respondent
overall
respondent
male
female
mother
daughter
pair
mother
treat
breast
cancer
adolescent
daughter
mother
take
brca
gene
previous
history
breast
cancer
control
group
without
history
breast
cancer
adolescent
woman
previous
history
breast
cancer
woman
without
history
breast
cancer
riordan
loescher
student
agree
test
breast
cancer
predisposition
agree
test
disorder
student
already
take
genetic
course
little
willing
provide
testing
student
university
student
complete
questionnaire
table
view
within
article
request
genetic
argument
testing
three
main
argument
describe
favour
provide
predictive
genetic
test
hereditary
breast
cancer
upon
request
adolescent
firstly
various
healthcare
professional
argue
adolescent
consider
competent
able
give
consent
treatment
investigation
secondly
various
stakeholder
referred
potential
psychological
benefit
clinical
geneticist
mention
genetic
testing
minor
lead
potential
potential
lifestyle
chance
usage
contraceptive
pill
planning
midwife
nurse
mention
benefit
planning
life
well
remove
uncertainty
prepare
psychologically
especially
mother
breast
cancer
increase
risk
breast
cancer
emphasize
psychological
benefit
might
stem
relief
associate
negative
test
result
thirdly
study
referred
medical
benefit
early
detection
preventive
measure
survey
adolescent
girl
wish
test
state
event
positive
result
submit
frequent
breast
examination
early
mammogram
argument
testing
four
main
argument
describe
genetic
testing
upon
request
adolescent
firstly
healthcare
professional
indicate
require
consent
parent
adolescent
proceeding
genetic
testing
secondly
various
study
referred
potential
negative
psychological
consequence
genetic
testing
breast
cancer
adolescence
clinical
geneticist
fear
testing
affect
adolescent
test
result
positive
various
study
report
respondent
fear
testing
lead
increased
anxiety
stress
adolescent
undergo
testing
also
one
study
report
substantial
concern
potential
stigmatization
thirdly
various
study
report
respondent
feel
immediate
medical
benefit
perform
predictive
genetic
testing
minor
breast
cancer
clinical
geneticist
put
likely
year
become
circumstance
may
dramatically
change
hard
see
immediate
decision
example
life
plan
influence
knowledge
carrier
status
risk
negligible
age
interview
study
mother
breast
cancer
age
year
increase
risk
breast
cancer
question
value
genetic
test
result
absence
effective
intervention
absence
immediate
medical
benefit
clinical
geneticist
advise
much
time
reflection
adolescent
consider
also
young
get
test
clinical
geneticist
referred
fact
testing
might
lead
slope
thin
end
wedge
mature
year
old
parent
request
genetic
test
argument
testing
three
main
argument
describe
favour
perform
genetic
test
upon
request
parent
firstly
study
respondent
referred
advantage
early
detection
start
preventive
measure
breast
clinical
breast
examination
diet
modification
early
age
secondly
midwife
nurse
referred
fact
testing
childhood
remove
uncertainty
prepare
child
psychologically
prepare
child
future
thirdly
midwife
nurse
referred
parent
right
know
health
child
argument
testing
three
main
argument
describe
genetic
testing
inherit
mutation
firstly
study
referred
absence
immediate
medical
benefit
potential
many
healthy
year
medical
implication
may
appear
secondly
midwife
nurse
indicate
know
one
carrier
status
lead
add
psychological
burden
child
parent
dark
future
stigmatization
thirdly
study
referred
personal
autonomy
child
right
know
child
right
decide
later
life
discussion
substantial
proportion
adolescent
interested
learn
whether
risk
familial
breast
cancer
attitude
healthcare
professional
geneticist
well
paediatrician
obstetrician
gynaecologist
testing
adolescent
breast
cancer
example
survey
clinical
geneticist
deal
cancer
genetic
show
respondent
offer
predictive
testing
girl
whose
mother
carry
pathogenic
mutation
mature
age
well
inform
risk
test
percent
respondent
know
action
take
split
opinion
relate
complexity
request
balance
potential
harm
benefit
respondents
stress
adolescent
capacity
often
mature
enough
take
control
healthcare
request
genetic
test
familial
breast
cancer
several
professional
guideline
relate
genetic
testing
minor
already
acknowledge
gradual
development
child
cognitive
skill
moral
reasoning
although
argue
parent
consent
genetic
test
clearly
advisable
adolescent
always
require
example
family
law
reform
act
british
medical
association
bma
recommendation
genetic
testing
document
bma
state
young
people
year
old
presume
competent
give
consent
genetic
testing
without
necessity
obtain
consent
parent
guardian
adult
various
professional
guideline
clearly
recommend
adolescent
predictive
genetic
testing
occur
counselling
wherein
complete
information
provide
disorder
value
limitation
test
result
preventive
therapeutic
option
possible
psychological
impact
test
also
question
whether
test
request
voluntary
come
competent
argument
favour
provide
predictive
genetic
test
disease
adolescent
request
line
general
evolution
medicine
take
account
adolescent
maturity
competence
however
article
include
review
adequately
define
frequently
term
neither
provide
recommendation
assess
psychosocial
maturity
adolescent
well
professional
guideline
regard
predictive
genetic
testing
provide
recommendation
regard
assessment
minor
competence
crucial
importance
health
professional
assess
competence
experience
counsel
young
patient
many
respondent
study
review
probably
request
predictive
genetic
test
inform
potential
risk
test
many
adolescent
interview
study
invitation
participate
genetic
test
breast
cancer
hypothetical
situation
result
careful
assessment
benefit
risk
test
illustrate
interview
study
show
adolescent
respondent
regardless
age
respond
affirmatively
ask
whether
undergo
testing
interview
focused
sample
collection
rather
assessment
risk
benefit
test
addition
study
individual
test
mutation
learn
mutation
status
certify
genetic
counsellor
show
significantly
little
support
testing
survey
study
unaffected
relative
breast
cancer
patient
potential
explanation
find
individual
experience
genetic
counselling
testing
may
much
aware
potential
risk
limitation
counsel
test
might
also
explain
relatively
many
respondent
support
genetic
testing
minor
condition
breast
cancer
although
recommendation
genetic
society
regard
genetic
testing
condition
various
parent
believe
detection
childhood
might
advantageous
start
preventive
measure
might
help
prepare
child
psychologically
future
therefore
parent
often
believe
right
give
consent
genetic
testing
brca
child
study
medical
student
obstetrician
gynaecologist
paediatric
resident
medical
student
resident
practicing
physician
show
various
healthcare
professional
agree
provide
genetic
testing
child
upon
parental
request
review
survey
indicate
various
respondent
apparently
fail
understand
potential
risk
relate
genetic
testing
may
concept
genetic
transmission
neglect
take
account
consider
genetic
testing
minor
review
professional
guideline
indicate
professional
guideline
similarly
formulate
predictive
genetic
testing
disease
perform
person
legal
age
except
case
disorder
preventive
therapeutic
action
initiate
based
rationale
medical
benefit
child
primary
genetic
testing
case
testing
urgent
outbreak
disease
occur
adulthood
therapy
preventive
measure
initiate
time
stress
testing
delay
person
old
enough
decide
cautious
position
towards
testing
minor
adopt
testing
minor
might
harm
create
depression
anxiety
family
perception
child
stigmatize
child
author
also
stress
testing
child
confidentiality
privacy
genetic
information
also
argue
adolescent
disadvantaged
ability
make
complex
potentially
decision
incomplete
brain
maturation
associate
executive
function
finding
underscore
need
genetic
education
counsel
address
request
testing
minor
might
help
bring
expectation
assessment
risk
realistic
level
study
show
patient
healthcare
professional
daily
involvement
clinical
genetic
may
exaggerate
expectation
genetic
testing
due
focus
familial
breast
cancer
result
study
consider
representative
disease
research
show
example
rating
predictive
genetic
testing
adolescent
disease
disease
little
favourable
treatable
disease
make
clear
discuss
adolescent
parental
request
predictive
genetic
test
disorder
various
individual
element
take
consideration
availability
preventive
therapeutic
measure
disease
severity
disease
utility
genetic
test
onset
disorder
psychosocial
ethical
legal
concern
recent
study
also
show
majority
clinical
geneticist
usa
canada
uk
australia
new
zealand
agree
exist
guideline
regard
predictive
genetic
testing
minor
cite
policy
reason
refuse
test
indicate
clinician
make
individual
judgment
oppose
simply
follow
suggest
recommendation
conclusion
systematic
review
analyse
common
argument
favour
predictive
genetic
testing
minor
case
familial
breast
cancer
although
accurate
comparison
various
study
difficult
due
vary
study
population
study
design
sample
size
study
measure
analysis
show
many
respondent
aware
potential
risk
relate
testing
various
respondent
take
position
oppose
position
advance
professional
recommendation
also
observe
lack
representative
study
geneticist
genetic
counsellor
professional
group
issue
much
recommendation
genetic
testing
minor
research
perform
attitude
geneticist
genetic
counsellor
towards
genetic
testing
minor
adherence
professional
guideline
topic
clarke
institute
medical
genetic
cardiff
university
university
hospital
wales
park
cardiff
wales
united
kingdom
richard
senior
social
worker
department
clinical
genetic
children
hospital
westmead
westmead
nsw
australia
acknowledgement
research
contribution
support
network
excellence
eu
treatment
cancer
profound
impact
patient
appearance
body
image
yet
comparison
relative
research
impact
surgery
body
image
see
overview
psychosocial
impact
chemotherapy
receive
relatively
little
attention
chemotherapy
recognize
range
side
effect
include
nausea
fatigue
hair
loss
often
make
patient
feel
ill
way
actual
disease
alopecia
hair
loss
often
rate
one
much
common
fear
traumatic
aspect
chemotherapy
see
batchelor
may
even
consider
treatment
cancer
although
mechanism
prevent
reduce
hair
loss
device
develop
effectiveness
see
batchelor
overview
hair
loss
many
patient
currently
unavoidable
aspect
chemotherapy
treatment
understanding
much
experience
hair
loss
enable
inform
healthcare
practice
well
support
patient
two
different
literature
currently
inform
understanding
quantitative
research
attempt
establish
incidence
severity
different
side
effect
chemotherapy
assess
impact
psychosocial
outcome
body
image
distress
qualitative
study
aim
explore
experience
chemotherapy
include
hair
loss
woman
literature
briefly
review
tell
little
woman
prepare
hair
loss
occur
quantitative
study
hair
loss
much
study
within
nursing
field
concern
document
incidence
severity
side
effect
onset
duration
symptom
extent
perceive
distressing
difficult
alopecia
typically
rank
one
much
side
effect
chemotherapy
along
nausea
fatigue
griffin
lindley
study
suggest
experience
side
effect
difficult
distressing
patient
anticipate
lindley
see
also
knowledge
might
go
way
reassure
receive
chemotherapy
first
time
nonetheless
substantial
number
patient
undergo
chemotherapy
find
hair
loss
difficult
distressing
little
research
explore
psychosocial
impact
side
effect
depression
body
image
carpenter
find
woman
rate
significantly
time
alopecia
although
necessarily
mean
overall
prospective
longitudinal
study
explore
patient
body
image
treatment
complete
hair
loss
hair
find
body
image
poor
treatment
improve
return
level
hair
begin
difficult
tease
whether
difference
body
image
result
alopecia
specifically
much
general
adjustment
cancer
diagnosis
chemotherapy
treatment
suggest
many
woman
experience
range
distressing
side
effect
chemotherapy
treatment
include
alopecia
significant
impact
psychosocial
research
need
explore
psychosocial
impact
chemotherapy
side
effect
cancer
patient
cope
change
qualitative
study
hair
loss
qualitative
study
explore
cancer
patient
predominantly
woman
experience
chemotherapy
include
meaning
hair
loss
social
cultural
aspect
hair
loss
experience
hair
loss
meaning
chemotherapy
treatment
experience
fatigue
although
study
focused
specifically
hair
loss
collectively
identify
number
key
element
experience
alopecia
study
provide
descriptive
account
process
hair
loss
suggest
many
woman
traumatic
patient
describe
hair
fall
clump
pillow
stick
body
shower
clog
hole
shock
hair
loss
occur
confront
two
study
explicitly
briefly
examine
woman
prepare
treatment
side
effect
one
patient
prepare
gathering
information
people
know
nurse
internet
go
shave
hair
buy
wig
even
engage
activity
still
feel
order
manage
cope
alopecia
patient
disguise
camouflage
hair
loss
wig
scarf
rosman
describe
woman
engage
total
camouflage
wig
wear
always
partial
camouflage
decide
wear
wig
presence
people
usually
home
normal
something
take
effort
benefit
protection
study
describe
problem
associate
wig
find
uncomfortable
signal
disease
perpetuate
feeling
abnormal
woman
relieve
effort
abandon
wig
discard
study
focus
meaning
hair
loss
suggest
represent
visible
reminder
illness
woman
look
like
cancer
patient
recognize
hair
loss
also
create
loss
identity
person
mirror
long
look
feel
like
normally
however
woman
hair
loss
accept
inevitable
consequence
price
one
pay
temporary
manageable
aspect
treatment
one
just
get
take
evidence
effectiveness
strength
treatment
qualitative
study
extremely
useful
woman
experience
hair
loss
despite
small
sample
size
coherence
theme
describe
across
study
however
rarely
focus
specifically
process
prepare
hair
loss
study
address
anticipation
preparation
hair
loss
often
one
among
many
theme
focus
theme
detail
sacrifice
favour
provide
overview
chemotherapy
experience
gallagher
william
consequently
despite
utility
study
still
know
little
woman
prepare
effect
chemotherapy
treatment
preparation
might
support
healthcare
worker
summary
hair
loss
often
unavoidable
side
effect
undergo
chemotherapy
treatment
cancer
often
experience
distressing
traumatic
research
suggest
hair
loss
may
also
psychosocial
impact
patient
body
image
little
know
patient
might
much
vulnerable
effect
factor
might
ameliorate
distress
patient
hair
loss
significant
challenge
nurse
physician
yet
little
know
process
prepare
perspective
woman
since
preparation
hair
loss
identify
key
role
healthcare
professional
understanding
much
crucial
period
may
enhance
ability
support
cancer
patient
potentially
difficult
time
paper
datum
interview
woman
prior
commence
chemotherapy
treatment
explore
process
anticipate
prepare
hair
loss
method
datum
paper
form
part
large
study
explore
woman
experience
chemotherapy
wide
study
nineteen
woman
recruit
volunteer
basis
oncology
centre
large
city
south
west
england
study
scrutinize
give
approval
university
west
england
south
west
local
regional
ethic
committee
detail
study
introduce
consultant
specialist
nurse
consultation
prior
chemotherapy
treatment
initial
interview
arrange
telephone
formal
write
consent
obtain
first
interview
woman
diagnosis
breast
cancer
receive
chemotherapy
although
variety
treatment
previously
undergo
surgery
remove
breast
tissue
undergo
radiotherapy
chemotherapy
expect
surgery
late
date
one
woman
first
experience
chemotherapy
woman
age
relationship
marry
exception
one
identify
recognize
limit
volunteer
sample
recognize
small
sample
will
represent
select
set
experience
however
aim
identify
number
key
aspect
prepare
chemotherapy
treatment
explore
depth
women
interview
beginning
treatment
course
chemotherapy
complete
paper
focus
analysis
initial
interview
woman
talk
expectation
chemotherapy
treatment
think
respond
change
appearance
interview
conduct
author
participant
home
exception
two
woman
preferred
interview
hospital
set
last
approximately
one
hour
women
interview
prior
commence
treatment
expectation
concern
chemotherapy
understand
term
chemotherapy
feel
think
might
impact
appearance
anticipate
chemotherapy
will
change
physical
appearance
feeling
body
question
initial
interview
focused
woman
view
create
photographic
record
experience
discuss
resultant
datum
analyzed
adopt
widely
seldom
acknowledge
method
thematic
analysis
identify
analyze
report
pattern
theme
across
datum
set
thematic
analysis
much
common
form
analysis
analysis
ground
theory
search
pattern
theme
across
datum
set
theoretical
framework
mean
see
braun
clarke
accessible
discussion
thematic
analysis
current
study
thematic
analysis
identify
recurrent
pattern
woman
experience
prepare
side
effect
chemotherapy
treatment
analysis
proceed
number
stage
firstly
datum
transcribe
two
researcher
read
transcript
note
initial
observation
secondly
initial
observation
review
develop
initial
code
systematically
apply
datum
set
identify
datum
extract
associate
code
code
review
consistency
datum
extract
datum
extract
coherent
relate
collectively
represent
theme
validity
relation
whole
datum
set
theme
identify
accurately
represent
datum
whole
finally
theme
give
final
definition
name
reflect
content
three
key
theme
identify
discuss
result
discussion
many
woman
study
like
study
chemotherapy
often
see
synonymous
hair
loss
many
woman
find
thought
hair
loss
distressing
even
seem
little
distressed
anxious
lose
hair
still
put
great
deal
think
anticipate
manage
cope
hair
loss
analysis
reveal
three
key
theme
come
term
hair
loss
become
ready
take
control
theme
discuss
turn
hair
loss
woman
like
qualitative
study
report
one
first
reaction
tell
will
need
chemotherapy
distress
anxiety
lose
hair
many
say
bad
thing
treatment
something
just
sort
sit
absolutely
think
chemo
initially
will
first
think
oh
god
go
lose
hair
think
anything
else
think
sick
think
anything
else
god
go
lose
hair
many
concern
feel
like
usual
see
also
gallagher
particularly
true
woman
consider
hair
special
feature
example
woman
describe
hair
security
hide
behind
one
thing
easily
change
enhance
appearance
something
spend
lot
money
something
make
different
woman
upset
understand
distress
think
many
also
concern
hair
loss
make
identifiable
subsequently
lose
privacy
see
also
press
rosman
however
like
rosman
find
woman
react
accept
hair
loss
inevitable
consequence
treatment
even
welcome
opportunity
image
wig
short
reaction
consider
form
affective
rehearsal
gallagher
describe
process
woman
predict
based
personal
experience
response
cancer
meaning
assign
hair
intensity
distress
hair
loss
will
create
women
anticipate
hair
loss
try
different
emotional
reaction
test
opinion
advance
actual
hair
loss
term
inevitability
hair
loss
theme
describe
process
come
accept
hair
loss
likely
inevitable
go
often
unrealistic
hope
hair
might
retain
fear
hair
loss
mean
woman
initially
engage
treatment
want
chemotherapy
want
lose
hair
hope
one
lucky
will
avoid
hair
loss
back
mind
hope
one
person
happen
medical
research
allow
healthcare
professional
predict
fair
amount
certainty
drug
treatment
regimen
produce
great
likelihood
hair
loss
loss
will
occur
women
uncertainty
fear
hope
end
new
deliver
example
one
woman
describe
friend
try
comfort
story
undergo
chemotherapy
experience
hair
loss
consultant
tell
definitely
lose
hair
actually
sit
front
say
name
go
lose
hair
come
term
bit
much
think
almost
think
head
well
maybe
perhaps
might
lucky
perhaps
might
go
thin
actually
look
say
go
lose
hair
might
keep
go
lose
hair
start
come
term
think
now
take
step
positive
something
although
often
see
upset
new
nevertheless
allow
woman
accept
will
lose
hair
start
focusing
prepare
manage
cope
event
becoming
ready
theme
describe
time
energy
emotional
resource
woman
invest
explore
manage
hair
loss
occur
feel
ready
hair
loss
expect
anticipate
event
woman
interview
keen
tell
scarf
wig
obtain
preparation
hair
loss
already
set
one
wig
another
one
come
along
information
availability
wig
receive
nurse
physician
study
note
woman
cut
hair
purchase
wig
william
gallagher
really
explore
woman
engage
activity
mean
woman
study
purchase
proudly
present
evidence
come
term
inevitability
hair
loss
actively
engage
prepare
process
wig
scarf
see
way
become
ready
hair
loss
gathering
resource
hair
loss
finally
happen
go
first
chemo
session
say
wig
lady
want
see
wig
lady
say
oh
see
next
one
say
want
see
today
absolutely
know
cope
three
week
think
hair
go
fall
get
come
see
order
go
color
great
feel
really
happy
say
brilliant
just
like
good
buy
scarf
consequently
hate
need
just
need
ready
really
simply
wig
scarf
enough
help
feel
ready
hair
loss
may
want
try
camouflage
ensure
actually
work
actual
fact
just
test
run
put
wig
four
day
ago
go
nobody
look
twice
nobody
look
twice
think
go
brilliant
gonna
feel
really
good
hair
go
fine
building
notion
affective
rehearsal
see
kind
behavioural
rehearsal
gather
resource
practice
strategy
manage
hair
loss
second
form
behavioural
rehearsal
cut
hair
short
anticipation
really
want
wake
one
morning
find
load
hair
pillow
like
think
get
really
upset
um
whereas
short
um
think
notice
much
gradually
short
also
way
prepare
work
colleague
spouse
child
great
shock
actually
happen
slow
process
rather
shave
process
behavioural
rehearsal
allow
woman
manage
anxiety
hair
loss
loss
privacy
practice
strategy
camouflage
disguise
hair
loss
reassure
material
emotional
resource
cope
hair
loss
happen
prepare
alter
appearance
taking
control
theme
capture
way
woman
talk
engage
strategy
feel
much
control
hair
loss
despite
range
information
available
patient
point
treatment
hair
loss
might
expect
occur
advice
wear
lose
hair
woman
still
perceive
timing
nature
hair
loss
uncertain
since
know
sure
will
happen
shaving
hair
rather
wait
fall
see
way
exert
control
process
start
think
might
take
start
rather
wait
thought
wake
one
morning
find
great
clump
pillow
shower
whatever
think
much
distressing
time
choose
control
hair
loss
able
decide
will
occur
see
important
especially
many
aspect
disease
treatment
side
effect
seem
outside
personal
control
see
shaving
hair
control
definitely
control
aspect
able
control
feel
feel
sick
gonna
feel
sick
nothing
thing
one
thing
decide
hair
go
whether
hide
wig
whether
wear
scarf
whatever
know
woman
think
carefully
control
process
hair
loss
also
control
manage
emotional
reaction
hair
loss
may
distressing
frightening
actively
engage
find
way
alleviate
distress
order
deal
loss
shaving
hair
see
proactive
step
something
individual
decide
go
hair
rather
lose
way
get
back
cancer
well
chemo
go
take
hair
go
anything
hair
loss
will
hair
loss
process
actively
precipitate
rather
passively
await
something
within
control
general
discussion
anticipatory
coping
argue
preparation
see
form
anticipatory
involve
preparation
manage
stressful
consequence
upcoming
event
likely
certain
occur
anticipatory
coping
receive
relatively
little
research
attention
likely
involve
activity
proactive
coping
cope
effort
prevent
potentially
stressful
event
targeted
towards
anticipate
event
activity
include
resource
accumulation
information
initial
appraisal
assessment
impact
event
initial
coping
effort
activity
prevent
minimize
event
feedback
see
taylor
woman
study
actively
accumulate
resource
wig
scarf
many
make
initial
appraisal
event
likely
distressing
consider
impact
might
feeling
interaction
engage
cope
effort
affective
rehearsal
behavioural
rehearsal
seek
feedback
either
front
mirror
front
determine
relative
success
strategy
anticipatory
coping
appear
routine
part
way
woman
respond
new
likely
experience
alopecia
although
study
examine
anticipatory
coping
least
one
suggest
type
cope
may
routine
part
manage
stressful
difficult
event
relate
illness
may
useful
avoid
problem
well
manage
stressful
event
strategy
woman
describe
similarly
useful
enable
deal
stress
lose
hair
well
avoid
problematic
interaction
help
manage
emotional
consequence
hair
loss
argue
cope
research
need
focus
particular
case
hair
loss
rather
broad
cope
chemotherapy
cope
cancer
diagnosis
descriptive
research
one
present
inform
selection
relevant
variable
much
streamlined
research
argue
focus
anticipatory
coping
useful
starting
point
explore
far
individual
difference
efficacy
cope
effort
woman
engage
much
much
anticipatory
coping
experience
little
stress
anxiety
hair
actually
fall
affective
rehearsal
behavioural
rehearsal
important
element
anticipatory
coping
control
research
demonstrate
many
activity
woman
engage
manage
cope
hair
loss
value
allow
woman
control
situation
control
central
concept
psychological
theory
emotional
adjustment
cope
study
explore
different
strategy
individual
cancer
patient
might
order
compensate
lack
control
one
exception
thompson
study
cancer
patient
range
different
diagnosis
find
although
strong
relationship
perception
control
successful
adjustment
control
important
control
daily
emotion
physical
symptom
much
important
control
disease
relationship
medical
care
woman
study
may
control
cancer
side
effect
treatment
find
way
control
shave
hair
fall
cut
short
prepare
see
without
hair
practicing
wear
wig
scarf
important
participant
thompson
study
perceive
control
much
problem
feeling
control
like
find
associate
successful
coping
well
emotional
adjustment
improve
performance
understanding
woman
anticipatory
coping
strategy
enhance
sense
perceive
control
may
important
resource
physician
nurse
much
exist
good
practice
provision
information
side
effect
treatment
leaflet
produce
charity
breast
cancer
provision
indeed
innovative
development
computerized
hair
imaging
software
allow
woman
see
new
without
hair
prior
change
promote
continue
extend
availability
useful
resource
however
much
information
leaflet
recommendation
focus
physical
side
effect
rather
emotional
psychosocial
impact
treatment
example
review
area
batchelor
recommend
health
care
professional
encourage
woman
shave
head
hair
loss
become
pronounce
associate
little
pain
discomfort
promote
quick
similarly
woman
long
hair
encourage
hair
cut
short
disguise
thin
also
minimize
problem
shed
long
hair
may
create
anxiety
research
suggest
cut
shaving
hair
may
serve
additional
function
prepare
loss
hair
control
timing
hair
loss
feel
proactive
fail
consider
psychological
motivation
behind
particular
practice
strategy
healthcare
professional
may
miss
opportunity
help
patient
enhance
feeling
control
suggest
nurse
healthcare
practitioner
consider
way
help
patient
perceive
control
issue
language
control
information
leaflet
interaction
patient
paper
focused
specifically
cope
one
particular
aspect
chemotherapy
identify
range
different
strategy
people
adopt
much
reveal
something
people
adopt
different
strategy
control
information
share
patient
well
understanding
benefit
adopt
different
strategy
well
understanding
range
different
strategy
available
clear
understanding
psychosocial
impact
alter
appearance
due
chemotherapy
treatment
health
care
professional
patient
aid
process
anticipatory
coping
provide
patient
wide
range
resource
strategy
cope
recommend
development
explicit
guidance
healthcare
professional
patient
information
well
reflect
psychosocial
concern
acknowledgement
author
like
thank
woman
volunteer
take
part
study
share
experience
chemotherapy
consultant
oncologist
exercise
participation
treatment
breast
cancer
report
irwin
irwin
irwin
whilst
grow
interest
effect
physical
activity
intervention
upon
quality
life
qol
health
outcome
different
cancer
population
recent
year
trial
provide
detail
information
term
session
weekly
adherence
exercise
intervention
protocol
much
study
simply
mock
mock
segal
document
amount
exercise
cancer
patient
attain
term
overall
intervention
adherence
physical
activity
consequently
tend
provide
snapshot
rather
detail
information
duration
intensity
frequency
exercise
achieve
patient
treat
cancer
data
present
way
capture
dynamic
continuous
nature
exercise
adherence
taking
point
far
although
overall
adherence
rate
exercise
intervention
might
high
number
participant
meet
weekly
exercise
framework
goal
across
intervention
period
may
irwin
irwin
omission
previous
report
problematic
number
reason
difficult
know
type
exercise
intervention
likely
provide
benefit
clear
level
exercise
likely
achievable
woman
recover
breast
cancer
vary
point
exercise
intervention
level
adherence
also
lead
diffusion
treatment
since
patient
will
expose
intervention
intend
therefore
compromise
internal
validity
trial
moreover
high
level
adherence
achieve
effect
report
treatment
control
group
difficult
know
whether
effect
due
poor
adherence
within
study
ineffective
intervention
many
previous
trial
field
involve
exercise
intervention
whereby
cancer
patient
require
either
amount
exercise
complete
week
return
physical
activity
log
report
activity
via
telephone
recall
taylor
courneya
courneya
jones
segal
whilst
number
pragmatic
economic
reason
researcher
might
opt
type
approach
assess
exercise
adherence
raise
substantial
issue
potential
report
bias
thus
much
robust
evidence
require
cancer
patient
often
require
endure
long
difficult
treatment
regimen
treatment
type
vary
patient
possible
therefore
patient
perform
well
exercise
intervention
motivate
healthy
cancer
patient
adherence
exercise
intervention
may
high
relative
little
motivate
counterpart
adherence
may
also
relate
patient
status
current
health
behaviour
review
physical
activity
intervention
support
suggestion
identify
advance
age
gender
educational
level
smoking
overweight
social
support
determinant
poor
intervention
session
attendance
however
determinant
often
derived
study
involve
apparently
healthy
participant
remain
unclear
whether
determinant
apply
patient
woman
treat
breast
cancer
additional
determinant
exercise
breast
cancer
patient
include
type
cancer
treatment
time
since
cancer
treatment
treatment
side
effect
lymphoedema
fatigue
information
document
previous
report
therefore
difficult
know
breast
cancer
patient
likely
risk
exercise
programme
require
additional
support
change
exercise
behaviour
pattern
sheffield
exercise
breast
cancer
trial
sherbert
daley
daley
randomised
control
trial
rct
design
investigate
effect
progressive
supervise
exercise
therapy
intervention
upon
qol
associate
health
outcome
woman
treat
breast
cancer
sherbert
include
intervention
usual
care
group
fully
characterise
treatment
behaviour
study
seek
provide
detail
descriptive
datum
regard
number
woman
able
achieve
different
dose
aerobic
exercise
term
duration
rating
perceive
rpe
heart
rate
course
intervention
also
document
compliance
intervention
adherence
exercise
demonstrate
difficult
challenge
healthy
population
department
health
likely
equally
much
difficult
patient
complete
treatment
cancer
therefore
pattern
adherence
trial
intervention
document
purpose
inform
future
intervention
involve
population
understanding
determinant
exercise
treatment
cancer
one
critical
step
towards
develop
effective
intervention
therefore
study
explore
difference
intervention
session
adherence
accord
patient
route
trial
recruitment
characteristic
health
behaviour
cancer
treatment
regimen
side
effect
treatment
method
trial
design
patient
recruitment
detailed
information
sherbert
report
elsewhere
daley
daley
will
describe
briefly
precontemplation
contemplation
preparation
stage
change
exercise
soc
prochaska
diclemente
woman
age
year
complete
treatment
early
stage
breast
cancer
multiple
arthritis
prevent
exercise
participation
eligible
study
participants
randomised
stratification
hormone
therapy
yes
chemotherapy
treat
yes
receive
exercise
therapy
usual
care
eight
week
south
sheffield
local
research
ethic
committee
provide
ethical
approval
trial
trial
outcome
include
qol
depression
fatigue
physical
activity
aerobic
fitness
body
mass
index
bmi
muscle
function
primary
recruitment
strategy
postal
invitation
letter
patient
treat
oncologist
surgeon
identify
potentially
eligible
patient
hospital
record
secondary
recruitment
strategy
involve
medium
radio
newspaper
advertisement
presentation
member
trial
team
breast
cancer
nurse
trial
awareness
activity
cancer
support
group
word
mouth
exercise
therapy
exercise
therapy
session
take
place
basis
experience
exercise
researcher
educate
master
degree
level
session
last
min
line
previously
publish
guideline
cancer
patient
intervention
behavioural
goal
woman
attend
three
exercise
session
per
week
university
trial
centre
work
towards
accumulate
min
moderate
intensity
exercise
three
day
week
session
participants
encourage
focus
firstly
frequency
exercise
focus
duration
intensity
exercise
session
whilst
exercise
therapy
guide
intervention
framework
patient
encourage
exercise
intensity
comfortable
within
intervention
framework
adherence
intervention
participant
offer
range
aerobic
exercise
activity
step
cycling
walk
rpe
borg
scale
assess
every
min
every
exercise
therapy
session
trial
research
assistant
document
information
activity
log
exercise
therapy
session
incorporate
variety
technique
raise
decisional
balance
goal
set
promote
exercise
behaviour
image
figure
exercise
therapy
intervention
framework
note
exercise
therapy
session
last
total
min
include
min
cool
exercise
behaviour
change
counsel
discussion
view
within
article
equal
contact
group
also
attend
trial
centre
three
time
per
week
eight
week
participate
min
session
however
contrast
exercise
therapy
group
group
every
effort
make
keep
little
approximately
beat
per
minute
limit
aerobic
stimulus
provide
intervention
rpe
maintain
light
intensity
exercise
rpe
record
activity
log
every
session
assess
every
min
session
give
placebo
group
involve
aerobic
exercise
training
feel
necessary
record
every
min
every
min
session
sufficient
type
activity
include
light
body
conditioning
exercise
passive
every
effort
make
avoid
communicate
patient
idea
stretch
body
conditioning
placebo
control
exercise
behavioural
change
advice
give
group
within
session
centre
around
topic
live
condition
allow
much
stringent
test
aerobic
exercise
clinically
meaningful
treatment
equate
social
contact
group
important
since
attention
treatment
effect
usual
care
usual
care
group
encourage
continue
life
normal
invite
take
part
exercise
session
centre
complete
week
assessment
measure
baseline
participant
provide
information
concern
medical
history
specific
cancer
diagnosis
type
hormonal
therapy
type
length
cancer
treatment
presence
lymphoedema
stage
disease
time
since
treatment
information
concern
frequency
exercise
per
week
month
soc
exercise
prochaska
diclemente
bmi
percentage
body
fat
aerobic
fitness
also
assess
baseline
aerobic
fitness
measure
min
single
test
perform
index
multiple
deprivation
office
prime
rank
score
calculate
participant
based
residential
measure
deprivation
encompass
seven
domain
income
employment
health
disability
education
skill
training
barrier
housing
service
live
environment
adherence
define
level
session
participation
achieve
participant
dose
term
duration
rpe
exercise
achieve
participant
session
calculate
weekly
physical
activity
log
maintain
trial
research
assistant
analyses
adherence
rate
calculate
include
woman
randomised
intervention
regardless
compliance
relationship
route
recruitment
participant
characteristic
session
adherence
examine
independent
analysis
variance
analysis
depending
type
datum
since
intervention
involve
attend
supervise
session
dedicate
centre
group
participant
include
determinant
session
adherence
analysis
participants
categorised
accord
particular
characteristic
independent
variable
session
adherence
analysis
see
table
description
category
table
mean
session
adherence
trial
intervention
accord
recruitment
route
select
baseline
lifestyle
treatment
regimen
outcome
session
adherence
route
recruitment
oncologist
letter
community
advertisement
age
year
bmi
normal
weight
overweight
obese
smoking
status
smoker
stage
change
exercise
precontemplation
contemplation
preparation
frequency
physical
activity
never
three
time
per
month
per
week
twice
per
week
index
multiple
deprivation
quartile
little
deprived
quartile
quartile
quartile
much
deprived
missing
treated
chemotherapy
yes
treated
surgery
mastectomy
lumpectomy
treated
radiotherapy
yes
lymphoedema
yes
table
refer
standard
error
includes
intervention
group
analysis
purpose
combine
recruitment
route
cancer
care
support
group
breast
cancer
nurse
medium
advertisement
word
mouth
single
route
recruitment
referred
community
advertisement
view
within
article
result
participants
demographic
trial
recruitment
strategy
eligible
patient
consent
participate
trial
randomised
either
aerobic
exercise
therapy
usual
care
prevalence
characteristic
participant
include
report
accord
lifestyle
treatment
regimen
outcome
find
table
sample
size
sufficient
estimate
prevalence
adherence
little
precision
confidence
interval
session
adherence
dose
exercise
achieve
descriptive
information
rpe
duration
exercise
aerobic
exercise
therapy
group
provide
table
table
respectively
additionally
percentage
woman
achieve
min
min
min
exercise
therapy
across
intervention
period
detail
table
adherence
intervention
acceptable
exercise
therapy
group
respectively
attend
least
session
much
prescribe
session
percentage
woman
achieve
min
aerobic
exercise
per
session
increase
time
range
although
relatively
large
percentage
able
achieve
target
range
attend
session
range
table
describe
amount
exercise
term
intensity
rpe
duration
exercise
achieve
exercise
therapy
participant
table
adherence
exercise
therapy
intervention
exercise
therapy
session
week
week
week
week
week
week
week
week
mean
sd
rpe
mean
sd
duration
session
time
participate
aerobic
exercise
mean
sd
lk
lk
session
percentage
percentage
table
data
based
aggregate
score
session
across
week
aerobic
exercise
session
last
total
min
session
also
include
cool
well
discussion
exercise
behaviour
change
strategy
percentage
based
number
woman
attend
attend
final
exercise
therapy
session
week
session
view
within
article
table
adherence
intervention
week
week
week
week
week
week
week
week
mean
sd
rpe
mean
sd
session
percentage
table
last
min
data
based
aggregate
score
session
across
week
percentage
based
number
woman
attend
final
exercise
placebo
session
week
session
view
within
article
determinants
session
adherence
trial
intervention
significant
difference
route
recruitment
characteristic
health
behaviour
type
treatment
regimen
treatment
side
effect
category
session
adherence
intervention
record
refer
table
discussion
intervention
adherence
clear
complete
trial
type
intervention
need
acceptable
patient
attendance
intervention
session
crucial
patient
acquire
knowledge
skill
regard
core
element
intervention
case
type
behavioural
intervention
benefit
exercise
experience
cancer
patient
regular
participation
study
woman
treat
breast
cancer
achieve
acceptable
level
overall
aerobic
exercise
adherence
percentage
session
adherence
rate
comparable
trial
involve
breast
cancer
patient
type
cancer
courneya
courneya
mock
segal
attend
exercise
therapy
intervention
able
achieve
public
health
recommend
min
moderate
intensity
give
week
session
see
table
highlight
early
however
many
previous
trial
mock
mock
segal
segal
involve
cancer
patient
typically
report
overall
adherence
rate
exercise
intervention
rather
number
participant
adhere
behavioural
goal
intervention
dose
exercise
achieve
participant
within
session
across
week
problematic
since
mask
important
information
lead
inappropriate
conclusion
datum
example
number
session
complete
aerobic
exercise
therapy
group
high
amount
aerobic
exercise
achieve
steadily
increase
imply
intervention
tolerate
acceptable
participant
however
far
inspection
adherence
datum
conclusion
may
somewhat
premature
since
proportion
participant
attend
session
also
increase
time
five
participant
complete
aerobic
exercise
therapy
session
prescribe
taken
together
finding
indicate
support
many
woman
treat
breast
cancer
able
adapt
relatively
quickly
progressive
aerobic
exercise
intervention
many
will
need
even
great
amount
support
offer
trial
facilitate
exercise
behaviour
change
say
indeed
supervise
exercise
programme
may
entirely
appropriate
woman
since
many
likely
family
employment
responsibility
affect
ability
attend
exercise
facility
regular
basis
try
facilitate
participant
visit
centre
offering
participant
opportunity
exercise
various
time
day
include
evening
weekend
provide
dedicate
recent
research
report
breast
cancer
survivor
little
confident
exercise
experience
family
responsibility
consequently
may
much
pragmatic
dynamic
flexible
approach
medium
telephone
support
mail
physical
activity
prompt
may
yield
even
high
exercise
adherence
rate
exercise
dose
record
study
research
examine
preference
woman
treat
breast
cancer
majority
preferred
exercise
moderate
intensity
home
alone
mind
adherence
exercise
therapy
session
towards
end
intervention
might
relate
effect
make
multiple
visit
session
exercise
facility
participant
may
find
difficult
sustain
time
progressive
intensity
dose
exercise
achieve
participant
line
trial
protocol
see
participant
average
intensity
throughout
intervention
however
also
appear
small
discrepancy
rpe
datum
datum
indicate
participant
exercise
intensity
accordance
protocol
whereas
rpe
datum
suggest
participant
perceive
exercise
intensity
exercise
usual
exercise
study
primary
regulator
exercise
intensity
datum
nevertheless
highlight
important
issue
relate
regulation
exercise
intensity
cancer
patient
need
avoid
relying
solely
single
measure
intensity
regulation
previous
trial
attempt
breast
cancer
patient
exercise
based
placebo
condition
condition
additional
complication
patient
blind
group
assignment
like
trial
include
placebo
arm
possible
participant
become
aware
receive
active
treatment
become
receive
alternative
treatment
may
offer
feel
important
include
condition
control
potential
attention
social
effect
might
explain
trial
finding
systematic
review
evidence
exercise
intervention
cancer
patient
identify
need
trial
include
arm
session
adherence
rate
intervention
suggest
able
achieve
authentic
alternative
exercise
therapy
intervention
indeed
session
adherence
marginally
high
exercise
therapy
intervention
group
table
confirm
group
average
remain
little
beat
per
minute
per
intervention
protocol
furthermore
typical
average
rpe
score
across
intervention
period
range
consider
within
exercise
range
far
support
minimal
aerobic
content
intervention
nevertheless
rpe
score
high
expect
particularly
give
participant
corresponding
score
within
range
although
participant
aerobic
output
relatively
body
conditioning
exercise
include
intervention
involve
anaerobic
stimulus
consequently
rpe
score
might
reflect
determinants
exercise
session
adherence
apparently
high
overall
session
adherence
rate
couple
lack
significant
finding
determinant
session
adherence
analysis
suggest
woman
treat
breast
cancer
keen
participate
exercise
intervention
programme
give
opportunity
support
finding
contrast
find
predictor
exercise
adherence
colorectal
cancer
survivor
include
soc
exercise
employment
status
treatment
protocol
rule
possibility
lack
significant
difference
category
participant
session
adherence
result
sample
rather
homogeneous
focus
effort
towards
understanding
health
behaviour
treatment
factor
likely
determinant
exercise
behaviour
population
may
factor
play
much
role
regard
issue
following
study
find
association
social
cognitive
variable
attitude
perception
control
intention
health
behaviour
breast
cancer
patient
might
variable
prove
well
indicator
exercise
adherence
future
research
examine
much
precisely
limitation
strength
sample
size
relatively
modest
large
study
may
well
able
provide
much
precise
estimate
regard
determinant
exercise
adherence
population
participants
sherbert
white
ethnic
origin
therefore
finding
woman
ethnicity
treat
breast
cancer
caution
supervise
nature
intervention
mean
possible
systematically
record
rpe
well
duration
exercise
provide
opportunity
examine
detail
precise
intensity
dose
exercise
achieve
participant
intervention
important
strength
previous
trial
adequate
adherence
critical
examine
efficacy
intervention
obtain
good
session
adherence
indicate
context
rct
supervise
aerobic
exercise
therapy
intervention
acceptable
woman
treat
breast
cancer
research
still
require
tease
potential
determinant
exercise
population
intervention
enhance
regular
exercise
remain
challenge
hope
finding
planning
future
exercise
intervention
trial
involve
breast
cancer
patient
acknowledgement
like
thank
patient
agree
participate
trial
also
like
thank
professor
assistance
patient
recruitment
green
assistance
intervention
source
funding
study
support
grant
cancer
research
uk
comparison
surgery
breast
lesion
diagnosis
percutaneous
sonography
stereotactic
guide
biopsy
fast
little
invasive
much
comfortable
much
additionally
percutaneous
biopsy
prevent
woman
histologic
prove
benign
disease
unnecessary
surgery
accelerate
start
treatment
case
breast
cancer
women
breast
cancer
diagnose
surgical
biopsy
undergo
usually
second
operation
evaluate
axilla
require
complete
tumor
resection
confirmation
histologic
diagnosis
operative
planning
offer
possibility
definite
surgical
treatment
one
step
thus
aim
study
evaluation
likelihood
one
therapeutic
surgery
patient
percutaneously
prove
breast
cancer
different
factor
correlate
one
operation
especially
morphology
lesion
quality
imaging
diagnostic
preoperative
sonographic
stereotactic
guide
localization
material
biopsy
retrospective
study
mean
patient
age
year
range
year
evaluate
datum
clinical
radiological
surgical
report
consecutive
patient
therapeutic
operation
case
breast
cancer
institution
january
december
operation
perform
follow
percutaneously
prove
breast
cancer
patient
woman
undergo
large
core
biopsy
stereotactic
guidance
patient
diagnose
sonographic
guidance
bard
covington
usa
needle
reason
preoperative
biopsy
case
follow
patient
undergo
fine
needle
aspiration
case
technical
approach
possible
due
lesion
position
breast
patient
reject
percutaneous
biopsy
radial
scar
reason
immediate
surgical
biopsy
patient
definite
clinical
radiological
diagnosis
lead
operation
radiologist
choose
method
guidance
aspect
much
reliable
imaging
visibility
decision
action
supervise
prove
head
department
generally
stereotactic
guidance
mass
visualize
sonographically
calcify
lesion
sonographic
guidance
detectable
specimen
perform
confirm
presence
lesion
within
specimen
surgery
stereotactic
biopsy
perform
woman
prone
position
dedicate
table
digital
imaging
imaging
usa
tissue
acquire
stereotactic
guide
biopsy
gauge
biopsy
probe
mammotome
ethicon
oh
usa
median
specimen
acquire
range
specimen
radiography
perform
case
lesion
remove
completely
localize
clip
place
sonographically
guide
biopsy
perform
woman
position
sonographic
equipment
usa
acquire
tissue
gauge
automate
system
median
specimen
acquire
range
preoperative
localization
technique
one
hundred
patient
attempt
breast
conservation
undergo
preoperative
tumor
localization
day
surgery
localization
wire
bard
covington
usa
localization
wire
place
center
lesion
large
lesion
cm
two
even
much
localization
wire
delineate
tumor
localization
define
exact
distance
wire
tumor
equal
mm
stereotactically
sonographically
guide
localization
visible
architecture
distortion
mammogram
perform
end
preoperative
tumor
localization
procedure
personal
consultation
surgeon
take
place
case
sixteen
patient
mastectomy
without
preoperative
localization
primary
surgical
treatment
breast
axillary
surgery
gynecologist
specialized
breast
surgery
therapeutic
procedure
concern
breast
conservation
versus
mastectomy
need
axillary
surgery
versus
sentinel
lymph
node
biopsy
versus
axillary
dissection
decide
surgeon
consultation
radiologist
patient
based
imaging
pathology
report
clinical
finding
patient
preference
multicentricity
tumor
history
therapeutic
radiation
therapy
breast
contraindication
breast
conservation
axillary
dissection
perform
case
invasive
carcinoma
clinical
suspicion
axillary
lymph
node
sentinel
lymph
node
biopsy
case
clinically
sonographically
negative
axilla
finding
additional
surgical
procedure
different
situation
additional
surgery
recommend
institution
require
due
tumor
close
margin
resection
residual
microcalcifications
biopsy
site
case
carcinoma
associate
calcification
due
multifocality
histologic
underestimation
preoperative
biopsy
patient
undergo
preoperative
needle
localization
mastectomy
follow
multidisciplinary
tumor
conference
consensus
surgeon
radiologist
pathologist
patient
basis
histologic
finding
imaging
datum
patient
preference
sentinel
lymph
node
metastases
identify
complete
axillary
dissection
perform
separate
surgical
procedure
pathology
institution
pathologic
analysis
correlation
imaging
definite
histologic
diagnosis
perform
preoperative
percutaneous
biopsy
surgical
specimen
consider
histologic
underestimation
case
lesion
show
atypical
ductal
hyperplasia
adh
percutaneous
biopsy
ductal
carcinoma
situ
dcis
surgery
dcis
percutaneous
biopsy
infiltrate
carcinoma
surgical
specimen
specimen
margin
consider
positive
tumor
extend
mm
case
invasive
carcinoma
mm
case
dcis
ink
margin
sentinel
lymph
node
examine
frozen
section
immunohistochemistry
paraffin
section
sentinel
node
turn
far
axillary
surgery
recommend
sentinel
lymph
node
show
metastases
freeze
section
patient
undergo
axillary
dissection
surgical
procedure
case
malignant
involvement
paraffin
section
immunohistochemistry
axillary
dissection
necessary
data
collection
medical
history
review
retrospectively
determine
number
surgical
procedure
patient
factor
record
include
primary
breast
cancer
treatment
breast
conserve
operation
versus
mastectomy
axillary
surgery
sentinel
lymph
node
biopsy
versus
axillary
dissection
mammographic
sonographic
finding
mammographically
visible
mass
microcalcifications
sonographically
visible
mass
architecture
distortion
lesion
size
core
biopsy
histology
histologic
underestimation
localization
quality
initial
surgical
procedure
datum
enter
computerized
table
excel
microsoft
redmond
far
analysis
statistic
statistical
analysis
patient
perform
sas
software
corporation
cambridge
ma
usa
collect
datum
significance
concern
operation
versus
calculate
mann
whitney
find
whether
tumor
size
potential
predictor
additional
surgical
procedure
significance
level
test
evaluation
power
influence
confidence
interval
calculate
lesion
type
size
surgical
procedure
one
hundred
patient
solitary
unilateral
lesion
multiple
ipsilateral
lesion
multifocal
multicentric
lesion
mammographically
visible
mass
find
patient
microcalcifications
patient
sonographically
visible
mass
detect
patient
whereas
architectural
distortion
find
patient
range
cm
mean
cm
one
hundred
patient
finally
treat
breast
conserve
therapy
patient
mastectomy
histology
reveal
dcis
patient
one
operation
patient
average
tumor
size
cm
range
cm
median
cm
average
tumor
size
cm
range
cm
median
cm
infiltrating
carcinoma
find
patient
axillary
surgery
perform
patient
patient
positive
find
number
surgical
procedure
one
hundred
twelve
patient
undergo
one
operation
patient
undergo
surgical
procedure
patient
three
operation
perform
patient
mastectomy
versus
patient
breast
conserve
therapy
significant
difference
tendency
much
require
case
attempt
breast
conserve
therapy
among
woman
attempt
breast
conservation
definite
treatment
breast
conservation
mastectomy
patient
different
reason
case
due
tumor
close
margin
resection
case
include
residual
microcalcifications
first
surgery
find
multifocal
multicentric
tumor
consecutive
mastectomy
case
additional
axillary
dissection
case
invasive
carcinoma
find
definite
histology
include
patient
positive
sentinel
lymph
node
two
patient
mastectomy
demand
bivariate
analysis
factor
associate
perform
one
operation
according
bivariate
analysis
patient
one
operation
significantly
much
likely
tumor
size
small
mann
whitney
z
table
one
operation
patient
average
tumor
size
cm
range
cm
median
cm
average
tumor
size
cm
range
cm
median
cm
table
bivariate
analysis
factor
associate
perform
nonpalpable
percutaneously
prove
breast
cancer
one
operation
level
significance
multiple
lesion
mass
mammogram
mass
sonography
mammogram
sonographically
visible
architecture
distortion
histologic
underestimation
stereotactically
guide
wire
localization
sonographically
guide
wire
localization
central
localization
wire
table
view
within
article
find
significant
difference
concern
tumor
stage
number
operation
find
much
situ
carcinoma
woman
group
woman
treat
one
surgical
step
versus
ptis
versus
tumor
stage
likelihood
one
operation
significantly
high
versus
almost
comparable
likelihood
one
operation
versus
table
table
association
tumor
stage
number
surgical
procedure
tumor
table
view
within
article
statistical
significance
mann
whitney
z
tumor
size
ptis
tumor
operation
frequency
tendency
little
operation
case
small
situ
tumor
average
tumor
size
cm
patient
one
operation
versus
cm
patient
additional
surgical
procedure
table
case
multiple
lesion
likelihood
significantly
high
patient
treat
first
step
versus
patient
far
operation
necessary
table
one
operation
significantly
much
likely
woman
mammographic
density
versus
patient
sonographically
visible
mass
versus
patient
table
find
significantly
high
frequency
perform
case
microcalcifications
versus
additional
surgical
procedure
necessary
table
significant
difference
concern
sonographically
visible
architectural
distortion
operation
frequency
tendency
much
necessary
case
versus
one
definite
surgical
treatment
one
operation
significantly
much
likely
preoperative
interventional
histologic
diagnosis
confirm
therapeutic
operation
patient
obtain
correct
percutaneously
prove
histologic
diagnosis
seven
case
preoperative
histologic
diagnosis
show
underestimation
situ
lesion
turn
invasive
cancer
therapeutic
operation
two
case
preoperative
histologic
diagnosis
atypical
ductal
hyperplasia
versus
dcis
surgical
specimen
four
patient
unexpected
multifocal
tumor
surgical
specimen
two
patient
histologic
diagnosis
unclear
percutaneous
biopsy
patient
representative
preoperative
diagnosis
treat
one
operation
woman
undergo
patient
localization
wire
position
central
mm
distance
tumor
case
distance
tumor
maximally
mm
woman
undergo
one
operation
stereotactically
guide
wire
localization
patient
undergo
patient
sonographically
guide
wire
localization
treat
one
surgical
step
undergo
second
surgery
find
significant
correlation
number
operation
position
localization
wire
tendency
high
likelihood
one
surgical
step
see
case
central
localization
wire
position
versus
case
centrally
localized
wire
table
discussion
several
different
previous
study
investigator
evaluate
woman
percutaneously
prove
breast
cancer
significantly
high
likelihood
treat
one
operation
patient
breast
cancer
diagnose
surgical
biopsy
case
diagnostic
biopsy
margin
far
axillary
dissection
mastectomy
extensive
tumor
often
require
lot
advantage
make
one
surgical
step
desirable
operation
risk
little
patient
anxiety
well
cosmetic
result
also
increase
cost
efficiency
study
population
woman
treat
definitely
one
surgical
step
mastectomy
breast
conserve
therapy
multivariate
analysis
find
likelihood
significantly
high
perform
one
operation
woman
undergo
mastectomy
preoperative
percutaneous
biopsy
reliable
reveal
histologic
underestimation
among
patient
attempt
breast
conserve
therapy
one
definite
surgical
procedure
perform
significantly
much
often
case
mammographically
sonographically
visible
mass
mass
detectable
mammogram
ultrasound
may
guarantee
much
precise
assessment
extent
tumor
study
likelihood
one
definite
surgical
step
significantly
high
case
small
tumor
publish
previous
study
image
stereotactically
guide
wire
localization
mm
percutaneously
prove
breast
cancer
infiltrate
ductal
carcinoma
associate
dcis
upper
outer
quadrant
right
breast
view
within
article
reason
additional
surgery
much
case
tumor
close
margin
resection
woman
require
far
surgery
patient
study
number
comparable
result
find
resection
margin
patient
undergo
woman
study
general
important
achieve
margin
reduce
risk
local
recurrence
several
study
show
risk
find
margin
resection
significantly
woman
preoperative
percutaneously
prove
breast
cancer
histologically
prove
malignancy
enable
surgeon
much
tissue
study
show
significantly
high
number
necessary
case
dcis
demonstrate
much
difficult
get
margin
case
dcis
case
invasive
tumor
say
obviously
possible
assess
tumor
margin
much
accurate
case
visible
mass
rather
lesion
compose
microcalcifications
mammogram
image
sonographically
guide
wire
localization
multifocal
infiltrate
carcinoma
mm
mm
size
upper
inner
quadrant
right
breast
localization
wire
place
center
lesion
arrow
distance
lesion
mm
breast
conserve
therapy
possible
view
within
article
image
sonographically
guide
wire
localization
mm
percutaneously
prove
breast
cancer
infiltrate
ductal
carcinoma
upper
outer
quadrant
leave
breast
arrow
mark
wire
within
irregular
solid
mass
view
within
article
second
much
common
reason
study
histologic
underestimation
find
percutaneously
prove
biopsy
turn
representative
seven
case
preoperative
percutaneous
biopsy
yield
dcis
however
surgery
reveal
infiltrate
carcinoma
atypical
ductal
hyperplasia
suspect
preoperatively
two
case
come
dcis
surgical
specimen
contrary
result
find
four
case
surgery
reveal
multifocal
tumor
two
case
unclear
preoperative
histologic
diagnosis
literature
rate
underestimation
atypical
ductal
hyperplasia
dcis
study
histologic
underestimation
correlate
significantly
high
likelihood
far
operation
effect
position
localization
wire
surgical
outcome
evaluate
central
position
mm
distance
tumor
case
peripheral
position
maximum
mm
case
find
significant
correlation
number
operation
position
localization
wire
tendency
high
likelihood
one
surgical
step
case
central
localization
wire
versus
central
localization
wire
table
result
support
even
much
peripheral
position
localization
wire
patient
treat
one
surgical
step
presume
good
cooperation
radiologist
surgeon
achieve
one
operation
sonographically
stereotactically
guide
wire
localization
range
previous
study
report
literature
see
option
reduce
operation
frequency
follow
percutaneously
prove
nonpalpable
breast
cancer
especially
case
patient
demand
breast
conserve
therapy
preoperative
planning
right
surgical
procedure
woman
high
importance
cancer
diagnose
much
one
quadrant
breast
conserve
therapy
avoid
histologic
underestimation
result
significantly
little
gauge
gauge
automate
core
biopsy
previous
study
suspect
dcis
gauge
automate
core
biopsy
turn
invasive
carcinoma
operation
suspect
dcis
gauge
biopsy
come
invasive
carcinoma
open
surgery
attempt
well
surgical
result
margin
preoperative
additional
magnetic
resonance
imaging
may
perform
mri
even
avoid
unexpected
multifocal
carcinoma
surgical
specimen
achieve
complete
excision
microcalcifications
patient
percutaneously
prove
breast
cancer
much
one
localization
wire
important
mark
lesion
margin
especially
case
extend
lesion
margin
guarantee
furthermore
selection
patient
sentinel
lymph
node
biopsy
precise
careful
reserve
patient
without
suspect
palpable
lymph
node
without
suspicious
finding
axillary
reduced
frequency
second
step
axillary
dissection
may
provide
intraoperative
histologic
analysis
sentinel
lymph
node
one
nine
woman
suffer
breast
cancer
life
time
many
woman
will
diagnose
stage
nonpalpable
lesion
identify
screening
program
percutaneous
sonographically
guide
automate
core
biopsy
stereotactically
guide
addition
exact
preoperative
wire
localization
tumor
offer
chance
one
definite
surgical
procedure
study
mammographically
sonographically
visible
mass
small
size
tumor
preoperative
percutaneous
biopsy
exact
preoperative
localization
find
important
factor
associate
single
step
procedure
definite
surgical
treatment
find
patient
see
future
goal
far
improvement
preoperative
imaging
technique
define
tumor
margin
much
exactly
much
extensive
preoperative
percutaneous
diagnostic
development
much
powerful
reliable
percutaneous
biopsy
device
reduce
rate
histologic
underestimation
endothelin
family
peptide
potent
property
addition
role
also
involve
acid
synthesis
proliferation
many
cell
type
four
isoform
identify
human
plasma
major
form
act
via
receptor
receptor
eta
etb
etc
identify
bind
eta
etb
also
role
cancer
especially
paracrine
autocrine
mediator
vivo
study
demonstrate
increase
production
several
type
malignant
cell
pancreatic
colon
breast
cancer
cell
line
yamashita
colleague
show
high
concentration
tissue
cancerous
breast
healthy
breast
tissue
receptor
eta
etb
overexpressed
breast
carcinoma
release
breast
cancer
cell
bind
eta
receptor
breast
fibroblast
vivo
vitro
study
show
breast
fibroblast
stimulate
breast
cancer
cell
paracrine
manner
big
precursor
metabolism
circulate
big
measure
healthy
volunteer
suggest
long
big
reflect
activity
endothelin
system
great
sensitivity
human
breast
cancer
cell
contain
endothelin
convert
enzyme
convert
big
study
level
high
breast
cancer
tissue
healthy
breast
tissue
however
knowledge
clinical
significance
serum
big
level
evaluate
breast
cancer
patient
study
investigate
serum
big
level
patient
breast
cancer
whether
big
marker
breast
cancer
patient
method
study
subject
consist
female
patient
age
range
year
median
age
year
histologically
confirm
invasive
ductal
carcinoma
breast
healthy
female
control
age
range
year
median
age
year
subject
breast
cancer
divide
group
accord
clinical
presentation
disease
fourth
group
consist
healthy
control
group
subject
patient
primary
breast
cancer
metastasized
serum
sample
patient
collect
initiation
specific
therapy
surgical
intervention
patient
group
undergo
modify
radical
mastectomy
tumor
classify
accord
system
table
group
subgroup
classify
accord
tumor
size
tumor
size
cm
tumor
size
cm
lymph
node
status
node
negative
node
positive
receptor
status
estrogen
progesterone
receptor
pr
negative
pr
positive
table
table
characteristic
subject
newly
diagnose
nonmetastatic
primary
breast
cancer
group
patientspercent
stage
stage
stage
stage
stage
tumor
size
ln
status
ln
receptor
status
pr
pr
unknown
rx
table
pr
estrogen
receptor
progesterone
receptor
status
view
within
article
group
consist
patient
metastatic
breast
cancer
group
patient
except
metastatic
disease
diagnosis
undergo
modify
radical
mastectomy
receive
adjuvant
chemotherapy
radiotherapy
hormone
therapy
combination
treatment
subject
progressive
disease
serum
sample
collect
initiation
new
chemotherapeutic
regimen
group
patient
accord
site
visceral
metastases
local
bone
metastasis
table
table
characteristic
subject
metastatic
breast
cancer
treat
disease
group
patientspercent
initial
stage
treatment
neoadjuvant
adjuvant
hormonal
metastatic
site
visceral
metastasis
bone
local
metastasis
table
view
within
article
group
consist
patient
undergo
modify
radical
mastectomy
receive
chemotherapy
radiotherapy
hormonal
therapy
combination
treatment
table
cancer
complete
remission
year
group
consist
healthy
control
table
characteristic
subject
whose
breast
cancer
remission
least
year
group
patientspercent
stage
stage
stage
stage
stage
treatment
neoadjuvant
adjuvant
hormonal
table
view
within
article
laboratory
examination
blood
sample
collect
specimen
tube
contain
acid
edta
centrifuged
plasma
supernatant
store
plasma
level
big
measure
enzyme
immunoassay
kit
phoenix
california
usa
statistical
analysis
spss
software
statistical
package
social
science
version
inc
chicago
ill
usa
statistical
analysis
result
express
median
value
standard
deviation
mann
whitney
test
also
difference
among
group
determine
mann
whitney
test
value
little
consider
statistically
significant
result
median
serum
big
level
patient
breast
cancer
ml
statistically
significantly
high
control
ml
table
median
serum
big
level
group
ml
statistically
significantly
high
control
group
patient
group
patient
metastatic
disease
group
ml
ml
ml
respectively
table
patient
primary
tumor
group
serum
big
level
differ
statistical
significance
accord
tumor
size
tumor
size
cm
tumor
size
cm
axillary
node
involvement
lymph
node
ln
receptor
status
receptor
negative
receptor
positive
table
group
median
serum
big
level
statistically
significantly
high
control
table
group
big
level
patient
visceral
metastasis
differ
patient
bone
local
metastasis
statistical
significance
big
level
observe
therapy
patient
control
table
big
level
subject
breast
cancer
patient
control
group
patientsmedian
age
year
big
ml
breast
cancer
table
view
within
article
table
serum
big
level
group
study
group
level
ml
group
tumor
size
tumor
size
axillary
node
axillary
node
pr
pr
group
visceral
bone
local
group
group
table
pr
estrogen
receptor
progesterone
receptor
status
view
within
article
discussion
several
clinical
study
patient
variety
malignancy
suggest
system
influence
tumor
growth
progression
women
breast
cancer
show
exhibit
statistically
significantly
high
expression
woman
without
breast
cancer
staining
ductal
carcinoma
intensity
carcinoma
normal
breast
cancer
although
physiological
role
human
breast
cancer
well
define
increase
tissue
level
implication
tumor
growth
cell
proliferation
act
via
receptor
eta
etb
recently
colleague
detect
elevate
level
primary
breast
cancer
furthermore
breast
carcinoma
eta
receptor
positive
breast
carcinoma
show
etb
receptor
positivity
however
previous
study
show
receptor
presence
show
breast
fibroblast
stromal
cell
mitogenic
factor
breast
fibroblast
hand
breast
fibroblast
stimulate
proliferation
breast
cancer
cell
secrete
insulin
like
growth
factor
ii
mitogenic
breast
cancer
cell
big
biological
precursor
big
know
physiological
activity
recently
demonstrate
human
breast
cancer
cell
express
endothelin
convert
enzyme
convert
big
breast
conversion
big
contribute
growth
breast
fibroblast
big
min
mainly
eliminate
kidney
liver
plasma
big
much
long
man
furthermore
secretion
endothelial
cell
compartment
bind
circulate
level
may
underestimate
local
concentration
thus
investigation
secretory
activity
measurement
big
level
may
well
approach
show
elevate
serum
big
level
female
patient
breast
cancer
find
suggest
presence
tumor
increase
plasma
big
level
yamashita
colleague
find
correlation
factor
prognostic
breast
cancer
tumor
size
lymph
node
hormone
receptor
status
level
study
also
find
association
factor
serum
level
big
subject
breast
cancer
lack
correlation
plasma
tumor
size
explain
difference
production
secretion
rate
individual
tumor
serum
big
level
measure
patient
hepatocellular
cancer
hcc
plasma
level
big
find
elevate
patient
successful
tumor
result
decrease
circulate
big
level
hand
recurrence
hcc
accompany
increase
plasma
big
level
level
big
demonstrate
plasma
patient
colorectal
cancer
principal
source
increase
production
localized
epithelial
cancer
cell
colorectal
cancer
patient
liver
metastases
significantly
high
level
big
localized
disease
contrast
study
patient
primary
nonmetastatic
breast
cancer
high
serum
level
big
patient
metastatic
disease
undergo
mastectomy
receive
chemotherapy
difference
may
due
local
therapy
systemic
antineoplastic
give
treatment
breast
cancer
study
big
level
measure
newly
diagnose
patient
metastatic
disease
initiation
treatment
surgery
chemotherapy
however
present
study
patient
metastatic
disease
already
receive
treatment
disease
serum
sample
collect
diagnosis
metastasis
serum
big
level
patient
little
metastatic
datum
suggest
big
level
seem
change
treatment
affect
metastatic
potential
cancer
cell
stimulate
angiogenesis
recently
colleague
show
breast
cancer
tissue
etb
receptor
expression
correlated
vascular
endothelial
growth
factor
expression
angiogenesis
role
metastasis
demonstrate
study
induce
osteoblastic
metastasis
breast
cancer
cell
line
via
eta
receptor
investigation
blockage
eta
receptor
inhibit
osteoblastic
metastasis
breast
cancer
cell
culture
study
patient
metastatic
breast
cancer
high
serum
big
level
control
however
difference
find
serum
big
level
patient
bone
local
visceral
metastasis
perhaps
small
number
patient
group
addition
role
tumor
growth
metastasis
receptor
may
predict
prognosis
patient
several
type
cancer
patient
cell
lung
carcinoma
expression
associate
poor
prognosis
another
study
patient
breast
cancer
receptor
expression
correlated
disease
free
overall
survival
colleague
suggest
patient
pretreatment
big
level
may
prognostic
posttreatment
failure
patient
advance
carcinoma
conclusion
statistically
significantly
elevate
serum
big
level
find
subject
primary
metastatic
breast
cancer
local
systemic
treatment
may
affect
big
level
patient
breast
cancer
serum
big
level
seem
sensitive
indicator
activation
patient
breast
cancer
study
warrant
elucidate
prognostic
importance
big
female
patient
breast
cancer
since
introduction
mastectomy
ssm
concern
local
control
recurrence
rate
discuss
literature
operation
remove
nipple
areola
complex
skin
overlying
superficial
tumor
previous
surgical
biopsy
site
together
entire
breast
parenchyma
follow
immediate
breast
reconstruction
ibr
ssm
preserve
native
skin
envelope
include
inframammary
fold
facilitate
optimal
breast
reconstruction
superiority
ssm
follow
ibr
compare
reconstruction
method
establish
several
study
term
cosmetic
functional
due
relatively
recent
introduction
ssm
little
extensive
resection
skin
compare
conventional
mastectomy
concern
persist
ssm
might
increase
risk
local
regional
recurrence
limited
number
study
show
increase
local
recurrence
associate
however
many
series
include
either
small
sample
size
short
time
addition
heterogeneous
patient
material
vary
stage
breast
cancer
invasive
noninvasive
aim
study
examine
incidence
local
recurrence
year
consecutive
series
breast
cancer
patient
either
stage
undergo
ssm
ibr
single
institution
addition
study
aim
examine
occurrence
systemic
relapse
association
local
recurrence
patient
method
patient
much
mastectomy
study
period
perform
patient
stage
disease
exclude
study
retrospective
review
consecutive
patient
either
stage
breast
cancer
undergo
ssm
follow
ibr
carry
operation
perform
department
surgery
helsinki
university
central
hospital
end
department
plastic
surgery
breast
surgery
unit
helsinki
university
central
hospital
beginning
patient
record
analyzed
patient
tumor
treatment
characteristic
detail
tumor
characteristic
obtain
pathology
report
whereas
surgical
record
radiology
report
analyzed
datum
pattern
timing
recurrence
american
joint
committee
cancer
ajcc
stage
system
grouping
patient
accord
stage
research
plan
approve
helsinki
university
central
hospital
head
surgery
permission
grant
examination
patient
record
surgery
ssm
perform
breast
surgeon
establish
manner
nipple
areola
complex
together
entire
breast
parenchyma
remove
well
exist
biopsy
scar
skin
overlying
superficial
tumor
periareolar
type
incision
much
commonly
case
superficial
tumor
previous
biopsy
scar
incision
include
nipple
areola
complex
surgical
biopsy
scar
skin
overlying
superficial
tumor
ssm
frequently
combine
axillary
lymph
node
dissection
sentinel
lymph
node
biopsy
generally
dissection
level
ii
axillary
lymph
node
perform
diagnosis
invasive
carcinoma
dcis
suspect
dissection
level
axillary
lymph
node
perform
sentinel
lymph
node
biopsy
perform
onwards
altogether
dissection
level
ii
axillary
lymph
node
perform
patient
level
axillary
clearance
patient
sentinel
lymph
node
biopsy
patient
ssm
follow
ibr
perform
team
reconstructive
plastic
surgeon
reconstruction
method
determine
patient
anatomy
preference
variety
method
four
prostheses
latissimus
dorsi
flap
flap
prostheses
transverse
rectus
tram
microvascular
flap
deep
inferior
epigastric
microvascular
flap
two
superficial
inferior
epigastric
artery
microvascular
flap
adjuvant
systemic
radiotherapy
adjuvant
chemotherapy
radiotherapy
administer
accord
national
guideline
generally
radiotherapy
administer
lymph
node
positive
patient
patient
primary
tumor
much
cm
diameter
altogether
patient
series
receive
radiotherapy
chemotherapy
generally
administer
patient
high
risk
recurrence
thus
lymph
node
positive
patient
patient
primary
tumor
much
cm
diameter
usually
receive
chemotherapy
chemotherapy
also
administer
patient
small
primary
tumor
histological
grade
negative
hormone
receptor
addition
patient
young
year
age
receive
chemotherapy
patient
series
receive
chemotherapy
furthermore
antiestrogen
medication
administer
patient
hormone
receptor
positive
tumor
addition
either
positive
lymph
node
tumor
histological
grade
classification
recurrence
patient
schedule
program
first
clinical
checkup
week
operation
subsequent
clinical
examination
surgeon
oncologist
well
mammography
ultrasound
breast
regional
lymph
node
area
year
recurrence
classify
local
regional
systemic
accord
first
site
recurrence
local
recurrence
include
isolate
skin
subcutaneous
recurrence
since
chest
wall
recurrence
account
regional
recurrence
include
isolate
regional
lymph
node
metastasis
result
patient
tumor
characteristic
patient
tumor
characteristic
describe
table
seventeen
patient
stage
disease
microinvasive
dcis
furthermore
three
patient
dcis
axillary
node
positive
nodal
histology
ductal
carcinoma
metastasis
apparent
invasion
breast
specimen
table
patient
tumor
characteristic
stage
age
range
year
mean
age
year
ductal
lobular
total
table
view
within
article
recurrence
rate
time
recurrence
describe
table
mean
time
series
month
range
month
overall
recurrence
rate
include
systemic
recurrence
isolated
local
recurrence
occur
rate
incidence
isolate
regional
lymph
node
recurrence
combine
locoregional
recurrence
rate
none
patient
stage
disease
recurrence
time
table
recurrence
stage
stage
total
mean
time
month
local
skin
subcutaneous
dcis
ductal
lobular
carcinoma
regional
lymph
node
dcis
ductal
lobular
carcinoma
systemic
dcis
ductal
lobular
table
view
within
article
locoregional
recurrence
isolate
without
sign
synchronous
systemic
disease
mean
interval
locoregional
recurrence
month
range
month
mean
time
detection
locoregional
recurrence
month
range
month
patient
develop
locoregional
recurrence
node
negative
time
primary
surgery
two
stage
patient
disease
consequently
none
patient
receive
chemotherapy
primary
surgery
localization
size
detection
local
recurrence
four
local
recurrence
locate
area
spare
skin
envelope
two
detect
clinical
examination
one
detect
mammography
one
detect
ultrasound
size
three
local
recurrence
mm
one
mm
diameter
treatment
locoregional
recurrence
locoregional
recurrence
treat
salvage
surgery
recurrence
follow
chemotherapy
healthy
margin
obtain
case
salvage
surgery
none
breast
reconstruction
none
patient
develop
new
local
regional
systemic
recurrence
discussion
local
recurrence
rate
breast
cancer
surgeon
gradually
adopt
little
extensive
much
conserve
technique
concern
oncological
safety
new
surgical
approach
raise
especially
ssm
discuss
potentially
increase
local
recurrence
leave
much
breast
skin
intact
nevertheless
despite
vary
surgical
approach
year
much
change
local
recurrence
local
recurrence
rate
locoregional
recurrence
rate
series
well
comparable
result
study
nevertheless
compare
study
straightforward
many
include
patient
stage
disease
also
include
stage
patient
addition
guideline
administer
radiotherapy
differ
somewhat
country
different
indication
radiotherapy
mastectomy
may
affect
local
recurrence
rate
different
study
radiotherapy
show
substantially
reduce
local
recurrence
independent
tumor
table
local
recurrence
lr
rate
ssm
ibr
previously
publish
paper
much
patient
include
month
lr
rate
carlson
newman
table
view
within
article
management
local
recurrence
key
successful
local
recurrence
management
early
detection
follow
salvage
surgery
healthy
margin
subsequent
adjuvant
nevertheless
common
agreement
ssm
ibr
patient
organize
regular
clinical
examination
basis
scheme
substantial
variation
take
place
frequency
span
checkup
well
routine
mammography
routine
system
patient
comprise
mammography
ultrasound
well
clinical
examination
surgeon
oncologist
year
surgery
routine
imaging
support
finding
two
four
local
recurrence
detect
clinical
examination
alone
whereas
one
detect
mammography
one
ultrasound
prognosis
local
recurrence
local
recurrence
mastectomy
generally
regard
indicator
poor
prognosis
although
challenge
study
study
patient
develop
local
recurrence
ssm
later
develop
distant
metastases
die
disease
within
mean
month
local
recurrence
another
study
patient
local
recurrence
ibr
develop
distant
metastases
hand
carlson
show
stage
patient
treat
local
recurrence
ssm
ibr
evidence
disease
end
whereas
true
stage
patient
present
series
patient
treat
local
regional
recurrence
disease
free
end
average
month
detection
treatment
recurrence
excellent
outcome
local
recurrence
treatment
series
might
part
due
fact
five
seven
patient
locoregional
recurrence
early
stage
disease
stage
also
two
stage
patient
node
negative
time
primary
surgery
furthermore
local
recurrence
detect
early
stage
facilitate
radical
salvage
surgery
healthy
margin
additionally
chemotherapy
administer
patient
follow
surgical
treatment
recurrence
conclusion
present
study
conclude
ssm
follow
ibr
seem
sound
procedure
stage
breast
cancer
patient
addition
study
confirm
finding
local
recurrence
always
associate
systemic
relapse
surgery
currently
favored
standard
care
primary
management
patient
early
breast
cancer
breast
conservation
technique
demonstrate
similar
survival
rate
compare
mastectomy
however
surgery
demonstrate
high
level
local
recurrence
radical
local
recurrence
breast
conservative
surgery
much
frequent
patient
without
radiotherapy
usually
occur
tumor
suggest
residual
disease
may
remain
primary
treatment
breast
surgical
procedure
usually
based
breast
palpation
mammography
ultrasound
much
recently
magnetic
resonance
imaging
mri
since
method
may
underestimate
real
extent
disease
ability
distinguish
malignant
tissue
normal
tissue
become
challenge
resection
margin
evaluation
become
important
method
assess
local
cancer
control
however
due
high
multifocality
breast
margin
necessarily
indicate
remain
breast
tissue
much
commonly
radiopharmaceutical
detection
breast
cancer
first
approve
food
drug
administration
fda
scintimammography
drug
affinity
cancer
cell
probably
due
high
metabolism
mitochondrial
concentration
thus
scintimammography
show
overall
sensitivity
specificity
detect
breast
addition
widely
multifocal
multicentric
breast
carcinoma
previous
study
demonstrate
breast
cancer
surgery
localize
occult
breast
carcinoma
guide
since
uptake
high
cancer
cell
breast
normal
cell
may
breast
cancer
surgery
thus
radioguided
surgery
intravenous
associate
breast
magnetic
resonance
imaging
mri
breast
cancer
resection
test
mri
high
definition
image
examination
show
good
correlation
real
tumor
well
mammography
ultrasound
palpation
determine
tumor
context
order
achieve
much
specific
method
estimate
real
extent
disease
reduce
residual
disease
breast
cancer
resection
develop
novel
technique
radioguided
intraoperative
margin
evaluation
rime
thus
aim
study
assess
whether
rime
feasible
technique
whether
may
help
breast
cancer
resection
free
margin
minimize
residual
disease
patient
method
patient
selection
breast
cancer
woman
stage
iia
iiia
schedule
mastectomy
consecutively
select
january
december
women
integral
healthcare
center
university
follow
inclusion
criterion
histologic
diagnosis
invasive
ductal
carcinoma
core
biopsy
incisional
biopsy
unifocal
unilateral
tumor
clinical
examination
recent
mammography
least
month
patient
excisional
biopsy
neoadjuvant
chemotherapy
recurrent
disease
presence
metallic
material
body
exclude
ethic
committee
institution
approve
study
patient
give
inform
consent
scintimammography
two
ten
day
mastectomy
patient
submit
scintimammography
radiolabeling
quality
control
procedure
medical
imaging
massachusetts
usa
carry
accord
manufacturer
instruction
briefly
scintimammography
perform
gamma
camera
sopha
sopha
medical
vision
equip
parallel
hole
collimator
patient
place
prone
position
mci
dose
inject
vein
previously
sterile
plastic
cannula
follow
ml
saline
solution
breast
image
matrix
size
pixels
acquire
lateral
posterior
oblique
view
image
chest
axillary
region
obtain
anterior
view
dynamic
image
breast
tumor
obtain
lateral
view
min
administration
dynamic
image
region
interest
roi
draw
around
tumor
target
normal
tissue
background
bg
time
activity
curve
generate
patient
optimal
time
perform
radioguided
surgery
estimate
based
time
ratio
maximum
image
curve
analyzed
photograph
direct
reading
computer
screen
method
perform
two
nuclear
physician
image
figure
scintimammography
lateral
view
roi
technique
tumor
normal
breast
tissue
view
within
article
image
figure
time
activity
curve
scintimammography
line
represent
tumor
line
represent
normal
breast
tissue
line
show
optimal
time
begin
rime
case
view
within
article
magnetic
resonance
imaging
mri
perform
device
elscint
elscint
haifa
israel
day
scintimammography
patient
patient
position
prone
imaging
table
breast
freely
contain
dedicate
breast
coil
imaging
sequence
fat
saturation
tr
ta
nex
mm
gap
matrix
fat
saturation
tr
ta
nex
mm
gap
matrix
sequence
previous
min
contrast
injection
bolus
mmol
kg
laboratory
argentina
intravenously
inject
upper
vein
prior
sterile
plastic
cannula
sequence
perform
three
plane
coronal
sagittal
axial
sequence
perform
sagittal
plane
size
capture
image
corresponding
tumor
estimate
measurement
three
diameter
take
focus
contrast
uptake
evaluate
well
cancer
involvement
skin
deep
fascia
image
interpret
photograph
film
select
view
radiologist
image
figure
magnetic
resonance
imaging
breast
show
tumor
contrast
administration
sequence
view
within
article
radioguided
intraoperative
margin
evaluation
rime
time
surgery
anesthesia
bolus
mbq
intravenously
inject
describe
patient
optimal
time
begin
radioguided
surgery
estimate
previously
await
firstly
radiation
count
contralateral
breast
without
cancer
measure
probe
guidance
system
france
determine
bg
subsequently
radiation
count
tumor
always
high
normal
tissue
bg
perform
procedure
thereafter
segmentectomy
perform
determine
resection
margin
starting
tumor
site
margin
consider
radiation
count
equivalent
bg
count
thus
tumor
surgically
excise
presence
residual
radioactivity
high
bg
tumor
bed
check
resection
margin
enlarge
residual
radioactivity
detect
always
angle
away
chest
wall
patient
ex
vivo
count
segmentectomy
margin
also
identify
finally
patient
submit
modify
radical
mastectomy
originally
plan
identify
margin
segmentectomy
residual
breast
send
histopathological
analysis
patient
realize
mri
analyzed
tumoral
involvement
skin
deep
fascia
presence
eventual
small
tumor
focus
mri
also
help
performance
rime
histopathology
analysis
tumor
bed
residual
breast
margin
segmentectomy
mark
china
ink
surgical
specimen
cut
section
macroscopic
examination
perform
macroscopically
suspicious
area
much
area
residual
breast
select
inclusion
paraffin
block
area
identify
determine
distance
tumor
segmentectomy
specimen
tumor
bed
residual
breast
specimen
slice
stain
hematoxylin
eosin
examine
optical
microscope
ductal
carcinoma
consider
residual
disease
focus
residual
breast
specimen
statistical
analysis
mean
standard
deviation
median
frequency
describe
outcome
association
presence
residual
disease
margin
status
analyzed
fisher
exact
test
continuous
variable
student
wilcoxon
test
data
analysis
perform
sas
software
version
sas
institute
cary
consider
statistically
significant
result
rime
feasibility
margin
status
clinical
datum
show
table
rime
technique
successfully
perform
patient
principal
tumor
excise
technique
nineteen
patient
histologically
free
margin
segmentectomy
patient
focally
involve
margin
three
involve
margin
situ
ductal
carcinoma
invasive
ductal
carcinoma
mean
minimal
margin
segmentectomy
mm
median
mm
range
significant
difference
patient
without
residual
disease
mean
minimal
margin
value
mm
mm
table
compare
presence
absence
residual
disease
regard
margin
status
table
clinical
characteristic
patient
tumor
age
year
mean
committed
breast
site
tumor
upper
outer
upper
inner
lower
outer
lower
inner
biopsy
clinical
tumor
size
mm
mean
mammographic
tumor
size
mm
mean
clinical
staging
table
view
within
article
table
association
residual
disease
margin
status
segmentectomy
rime
margin
table
fisher
exact
test
view
within
article
disease
residual
rime
promote
absence
residual
disease
patient
twenty
patient
present
residual
disease
situ
ductal
carcinoma
invasive
ductal
carcinoma
mean
size
residual
disease
mm
median
mm
range
segmentectomy
patient
present
residual
radioactivity
high
bg
tumor
bed
resection
margin
enlarge
histopathological
evaluation
reveal
residual
disease
patient
table
demonstrate
distribution
patient
accord
distance
residual
disease
focus
tumor
bed
table
distribution
patient
accord
distance
residual
disease
rd
focus
tumor
bed
distance
tumor
without
table
rd
residual
disease
view
within
article
tumor
segmentectomy
size
mean
tumor
size
mri
mm
sd
median
mm
range
association
tumor
size
detect
clinical
examination
mammography
mri
histopathological
analysis
presence
residual
disease
hand
volume
segmentectomy
realize
rime
patient
without
residual
disease
high
patient
residual
disease
table
table
association
tumor
segmentectomy
size
presence
residual
disease
residual
disease
rd
absence
presence
mean
tumor
size
large
diameter
mm
clinical
tumor
volume
segmentectomy
larger
diameter
mm
volume
table
student
twenty
patient
perform
mri
absence
rd
presence
rd
wilcoxon
test
view
within
article
scintimammography
radiation
count
pathology
outcome
intensity
uptake
scintimammography
high
case
moderate
case
mild
case
median
optimal
time
perform
rime
technique
min
range
min
radiation
count
tumor
range
cps
mean
sd
median
contralateral
breast
bg
range
cps
mean
sd
median
mean
radiation
count
background
tumor
ratio
median
range
patient
demonstrate
focal
uptake
scintimammography
median
number
fragment
examine
microscope
per
patient
range
include
tumor
residual
breast
difference
number
fragment
evaluate
patient
without
residual
disease
discussion
persistence
cancer
cell
residual
breast
conservative
surgery
undesirable
associate
local
recurrence
since
tumor
bed
commonly
site
recurrence
local
recurrence
much
frequent
radiotherapy
suggest
residual
disease
remain
conservative
surgery
moment
diagnostic
technique
guide
complete
excision
cancer
conservative
surgery
technique
intraoperative
intraoperative
pathological
surgical
study
access
tumor
margin
surgical
procedure
since
margin
associate
well
cancer
local
control
however
margin
necessarily
indicate
absence
residual
present
study
patient
margin
however
individual
residual
disease
result
agreement
previous
study
show
presence
residual
carcinoma
patient
free
margin
conservative
rime
several
study
demonstrate
breast
cancer
frequently
multifocal
complicate
complete
resection
cancer
surgery
due
difficulty
identify
small
focus
carcinoma
within
normal
tissue
radioguided
surgery
become
routine
breast
cancer
surgery
technique
sentinel
lymph
node
biopsy
radioguided
occult
lesion
localization
roll
study
employ
radioguided
surgery
intravenous
injection
breast
although
aim
diagnose
rime
help
margin
evaluation
attempt
find
carcinoma
focus
residual
breast
based
high
metabolism
tumor
normal
breast
therefore
rime
technique
employ
rationale
high
affinity
tumor
cell
normal
breast
tissue
allow
differentiation
breast
carcinoma
normal
adjacent
tissue
guidance
currently
concept
also
apply
parathyroid
exact
mechanism
accumulation
tumor
cell
completely
understand
however
seem
associate
high
metabolic
activity
specific
uptake
mitochondria
although
may
theoretically
access
tumor
focus
study
show
small
carcinoma
focus
detect
scintimammography
mri
unfortunately
since
residual
disease
find
patient
rime
technique
also
present
drawback
however
size
carcinoma
residual
focus
small
mean
mm
half
situ
ductal
carcinoma
agreement
present
investigation
study
also
show
tumor
cm
diameter
carcinoma
situ
poorly
detectable
scintimammography
probably
easily
differentiate
small
carcinoma
focus
normal
tissue
due
similarly
radiation
count
hand
mri
able
detect
breast
carcinoma
small
overcome
scintimammography
limitation
although
patient
perform
mri
verify
one
half
present
residual
disease
role
mri
rime
important
evaluate
apparently
mri
omit
technique
however
evaluation
involvement
skin
deep
fascia
tumor
focus
find
rime
essential
factor
associate
residual
disease
veronesi
show
site
local
recurrence
breast
conservative
surgery
restrict
resection
area
datum
accordance
report
recurrence
treat
breast
much
frequently
near
primary
tumor
site
although
study
suggest
residual
disease
remain
close
tumor
bed
distance
focus
tumor
bed
unknown
holland
mastectomy
specimen
find
carcinoma
focus
place
distance
cm
index
tumor
cm
case
mean
rime
show
majority
focus
close
tumor
bed
patient
residual
disease
thus
perform
rime
technique
margin
enlarge
cm
absence
residual
disease
obtain
case
thus
margin
enlarge
cm
patient
remain
without
carcinoma
residual
breast
just
patient
residual
disease
far
margin
patient
present
multicentric
carcinoma
carcinoma
focus
much
cm
tumor
bed
tumor
focus
identify
clinical
examination
mammography
mri
rime
technique
addition
since
focus
residual
carcinoma
rime
small
localized
close
primary
tumor
important
verify
whether
treat
radiotherapy
mainly
high
boost
dose
radiation
margin
resection
status
conservative
surgery
consider
predictor
factor
tumor
local
recurrence
several
suggest
margin
relate
residual
disease
however
study
margin
status
well
tumor
size
associate
residual
disease
additionally
tumor
size
measure
clinical
examination
mammography
mri
histopathologic
examination
statistically
different
patient
without
residual
disease
diagnostic
method
nevertheless
rime
volume
segmentectomy
high
patient
without
residual
carcinoma
result
consistent
prior
observation
milan
trial
ii
demonstrate
well
local
control
disease
much
extensive
surgical
resection
methodological
aspect
important
emphasize
aspect
relate
methodology
study
firstly
patient
palpable
tumor
therefore
resection
also
guide
clinician
sense
fact
rime
application
conservative
surgery
cancer
seem
much
interesting
however
patient
cancer
usually
submit
conservative
surgery
ethical
reason
preliminary
evaluation
rime
effectiveness
carry
patient
therefore
order
determine
quantify
residual
disease
surgery
simulate
rime
patient
large
tumor
mean
size
clinical
exam
mm
schedule
mastectomy
since
previous
study
demonstrate
local
recurrence
rate
increase
increase
tumor
speculate
frequency
residual
disease
select
patient
small
tumor
addition
residual
disease
widely
study
histological
analysis
median
number
fragment
examine
microscope
holland
example
study
multifocal
disease
examine
mean
fragment
per
patient
high
rate
residual
disease
observe
current
study
relate
unusually
meticulous
histological
evaluation
radioactivity
exposure
surgeon
rime
operation
also
observe
show
safe
similar
occur
exposure
sentinel
lymph
node
mapping
finally
since
patient
present
leave
breast
tumor
necessary
angle
probe
away
chest
wall
rime
avoid
count
physiological
uptake
heart
therefore
heart
liver
physiological
uptake
influence
radioguided
surgery
conclusion
study
show
rime
feasible
technique
help
tumor
resection
free
margin
assessment
however
rime
promote
complete
breast
cancer
resection
since
seem
limited
small
focus
tumor
detection
despite
current
study
present
attractive
preliminary
outcome
help
breast
surgery
firstly
patient
rime
make
residual
disease
detection
possible
tumor
removal
undetectable
clinical
examination
technique
margin
management
addition
size
quantity
focus
residual
disease
rime
utilization
reduce
furthermore
rime
disturb
standard
technique
surgery
associate
intraoperative
pathological
margin
finally
far
study
consider
order
refine
rime
evaluate
relevance
finding
surgery
debate
oncologic
safety
breast
conserve
therapy
bct
patient
stage
ii
breast
cancer
veronesi
fisher
publish
result
prospective
randomised
patient
quadrantectomy
may
lead
significant
lack
cosmetic
outcome
may
improve
lumpectomy
however
still
dissatisfied
may
due
bct
patient
unfavourable
cancer
location
last
year
institution
operate
breast
cancer
patient
lumpectomy
technique
cohort
patient
undergo
bct
much
satisfy
result
except
patient
central
caudal
cancer
location
several
oncoplastic
technique
already
describe
improve
cosmetic
outcome
concomitant
breast
reduction
local
parenchyma
flap
moreover
technique
show
increase
size
resection
free
margin
improve
cosmetic
report
hall
findlay
vertical
breast
reduction
improve
cosmetic
outcome
patient
central
breast
cancer
breast
cancer
locate
upper
inner
quadrant
call
land
patient
method
inclusion
criterion
eligibility
patient
histologically
verify
stage
ii
breast
cancer
eligible
combine
bct
hall
findlay
breast
reduction
oncologic
exclusion
criterion
modify
bct
bct
microscopic
resection
free
margin
resection
reasonable
attempt
multicentric
carcinoma
inflammatory
breast
cancer
progressive
disease
neoadjuvant
chemotherapy
contraindication
radiotherapy
patient
preference
exclusion
criterion
small
breast
size
cup
smoking
diabetes
bmi
exclusion
criterion
necessary
immediate
late
breast
reduction
patient
preference
include
patient
centrally
locate
breast
cancer
within
cm
distance
nipple
areola
complex
breast
cancer
quadrant
breast
treat
lumpectomy
concomitant
hall
findlay
breast
operative
procedure
bct
patient
breast
cancer
first
undergo
lumpectomy
microscopically
free
margin
resection
least
mm
resection
free
margin
intraoperative
freeze
section
ensure
cancer
free
resection
margin
patient
positive
margin
definitive
histology
either
treat
mastectomy
depending
extent
residual
cancer
one
drain
place
end
operation
ensure
drainage
wound
seroma
haematoma
patient
sentinel
lymph
node
biopsy
lumpectomy
blue
dye
apply
subcutaneously
axillary
level
ii
dissection
case
cancer
involvement
sentinel
lymph
node
operative
procedure
centrally
locate
breast
cancer
preoperative
marking
show
resection
line
central
lumpectomy
draw
around
nipple
total
length
incision
cm
line
around
nipple
right
breast
areola
complex
nac
plan
medial
dermoglandular
pedicle
reconstructed
skin
lumpectomy
area
show
base
pedicle
measure
least
cm
diameter
exactly
cm
image
figure
preoperative
marking
medial
pedicled
dermoglandular
flap
reconstruction
central
lumpectomy
lumpectomy
incision
cm
length
green
line
around
nipple
close
lumpectomy
around
areola
complex
areola
complex
reconstructed
skin
lumpectomy
defect
cm
diameter
based
medial
pedicled
dermoglandular
flap
base
least
cm
skin
around
areola
complex
deepithelialized
ensure
blood
lumpectomy
defect
fill
areola
end
result
week
postoperative
view
within
article
skin
incision
central
lumpectomy
perform
freeze
section
reveal
negative
resection
margin
tumor
bed
mark
titan
clip
radiotherapy
guidance
thereafter
dermoglandular
flap
design
area
around
deepithelialized
cm
parenchyma
underneath
leave
well
blood
supply
base
flap
cm
long
distance
sternum
base
flap
cm
reconstructed
local
flap
technique
skin
outer
inner
pole
breast
undermine
allow
rotation
breast
closure
inferior
vertical
scar
length
cm
distance
sternum
cm
deepithelialized
flap
rotate
upward
central
lumpectomy
defect
breast
resected
skin
tissue
underneath
help
reduce
give
breast
round
shape
parenchyma
suture
may
necessary
hold
breast
shape
vertical
scar
end
cm
submammary
fold
achieve
distance
submammary
fold
areola
cm
portion
vertical
scar
close
string
suture
result
small
bulky
skin
mass
flatten
first
week
operation
due
skin
undermine
area
technique
avoid
inverted
first
describe
breast
operative
procedure
breast
cancer
land
patient
breast
cancer
different
approach
central
breast
cancer
hall
findlay
technique
lateral
dermoglandular
pedicle
supply
patient
nac
skin
incision
follow
preoperative
marking
green
line
first
skin
undermine
breast
parenchyma
except
area
lateral
dermoglandular
pedicle
ensure
blood
supply
breast
quadrant
resected
include
fascia
patient
nac
supply
lateral
pedicle
construct
surround
skin
resection
margin
histologically
determine
frozen
section
tumor
bed
mark
titan
clip
defect
upper
medial
quadrant
fill
parenchyma
inner
pole
rotation
breast
nac
rotate
new
position
image
figure
preoperative
marking
hall
findlay
breast
reduction
lumpectomy
breast
lump
case
patient
undergo
bilateral
breast
reduction
due
breast
hypertrophy
ptosis
left
breast
lateral
side
patient
supine
lumpectomy
breast
defect
patient
nipple
areola
complex
reduce
cm
diameter
supply
lateral
pedicle
closure
defect
rotation
breast
end
result
week
postoperative
view
within
article
first
year
patient
close
every
month
clinical
examination
laboratory
test
include
tumor
marker
thorax
abdomen
every
month
well
mammogram
plus
ultrasound
per
year
clinical
evaluation
consist
palpation
quality
life
question
arm
mobility
nipple
sensation
breast
sensation
normal
normal
scale
furthermore
patient
ask
judge
cosmetic
result
scale
accord
harris
cosmetic
result
document
breast
symmetry
index
bsi
give
difference
compare
several
length
parameter
one
side
result
operative
procedure
september
september
woman
operate
technique
due
central
breast
cancer
five
patient
operate
single
surgeon
patient
operate
surgeon
four
woman
undergo
secondary
mastectomy
week
first
operation
woman
multicentric
intraductal
breast
cancer
seen
mammogram
intraoperative
freeze
section
woman
hemangiosarcoma
within
tumor
woman
bct
adjuvant
radiotherapy
postoperative
morbidity
haematoma
formation
necessitate
second
operation
treat
conservatively
epidermal
necrosis
cm
nipple
areola
complex
treat
conservatively
outpatient
ward
mean
hospitalization
time
day
demographic
datum
table
show
hormonal
responsive
breast
cancer
median
month
systemic
local
recurrence
cancer
relate
death
table
demographic
datum
patient
central
locate
breast
cancer
mm
ablatio
mm
mm
mm
mm
ablatio
mm
mm
mm
mm
ablatio
mm
table
three
patient
undergo
mastectomy
bct
hall
findlay
breast
reduction
due
multicentric
disease
due
hemangiosarcoma
two
patient
eligible
neoadjuvant
chemotherapy
yield
pathologic
partial
remission
patient
free
disease
median
month
patient
except
chemotherapy
herceptin
adjuvant
therapy
view
within
article
quality
life
patient
breast
cancer
normal
nipple
patient
different
feeling
normal
new
nipple
median
bsi
patient
treat
bct
hall
findlay
breast
reduction
illustrate
cosmetic
result
woman
satisfy
harris
scale
symmetry
satisfy
harris
scale
general
appearance
arm
mobility
normal
patient
breast
reduction
patient
excellent
symmetry
first
operation
breast
cancer
patient
undergo
breast
reduction
hall
findlay
technique
radiation
therapy
one
patient
undergo
immediate
breast
reduction
discussion
general
consideration
oncoplastic
surgery
define
combination
reconstructive
technique
oncologic
recently
clough
present
excellent
cosmetic
oncologic
result
woman
oncoplastic
main
advantage
increase
distance
resection
improve
cosmetic
patient
breast
cancer
may
need
oncoplastic
eligible
patient
usually
unfavourable
relation
size
breast
tumor
medium
large
breast
well
tumor
location
lead
large
visible
scar
deep
breast
defect
bct
perform
respect
patient
centrally
locate
breast
cancer
fulfil
criterion
tumor
location
scar
tissue
defect
may
easily
visible
routine
quadrantectomy
technique
oncoplastic
surgery
may
improve
cosmetic
result
reconstruct
tissue
defect
breast
parenchyma
place
scar
around
nac
central
breast
cancer
resection
nac
necessary
cosmetic
result
poor
standard
bct
perform
thus
much
surgeon
perform
mastectomy
patient
central
breast
cancer
oncoplastic
surgery
may
omit
mastectomy
reconstruct
nac
immediately
study
datum
describe
breast
reduction
technique
vertical
scar
medial
lateral
pedicle
nac
improve
cosmetic
outcome
patient
central
locate
breast
cancer
series
patient
able
achieve
subjective
objective
good
cosmetic
result
oncoplastic
surgery
four
undergo
subsequent
mastectomy
patient
lumpectomy
resection
free
margin
least
mm
local
distant
recurrence
median
month
comparing
hall
findlay
technique
several
oncoplastic
technique
describe
breast
reduction
central
breast
cancer
grisotti
flap
describe
technique
show
perfect
cosmetic
however
case
especially
large
breast
lateral
end
scar
may
exceed
submammary
fold
may
thus
visible
true
breast
reduction
technique
inverted
disadvantage
medial
scar
cross
submammary
fold
show
hypertrophy
case
moreover
much
inverted
technique
necessitate
large
dissection
area
result
increase
morbidity
long
operation
vertical
scar
technique
improve
cosmetic
aspect
regard
scar
along
medial
lateral
side
breast
reduce
scar
visibility
extensive
dissection
may
avoid
reduce
morbidity
especially
radiotherapy
increase
learn
curve
report
simple
central
resection
tumor
immediate
closure
technique
short
operation
time
however
may
possible
small
size
breast
cancer
simple
central
resection
tumor
may
result
little
projection
flat
reconstruction
modify
hall
findlay
technique
describe
central
lumpectomy
defect
fill
breast
parenchyma
result
good
projection
natural
breast
shape
another
advantage
hall
findlay
technique
rate
skin
areola
necrosis
fast
learn
first
case
observe
skin
necrosis
areola
necrosis
complication
necessitate
although
number
small
early
result
indicate
fast
learn
curve
morbidity
rate
several
author
describe
different
oncoplastic
technique
accord
tumor
location
depending
site
pedicle
nac
hall
findlay
breast
reduction
technique
different
pedicle
nac
blood
supply
thus
medial
lateral
pedicle
may
patient
breast
cancer
independent
tumor
location
may
much
important
advantage
technique
oncoplastic
surgeon
regard
hall
findlay
technique
lateral
pedicle
breast
cancer
mean
operation
time
cosmetic
result
good
one
patient
concomitant
breast
reduction
technique
anatomic
clinical
study
demonstrate
main
nerve
branch
reach
nipple
lateral
medial
side
well
cooper
thus
may
important
avoid
superior
inferior
pedicle
preserve
nipple
sensation
nipple
sensation
normal
patient
hall
findlay
technique
series
however
number
statistic
evaluation
technique
breast
cancer
location
round
block
may
result
reduce
nipple
sensation
however
prove
datum
respect
conclusive
remark
conclusion
suggest
hall
findlay
breast
reduction
technique
improve
cosmetic
outcome
bct
safe
improve
cosmetic
result
feasible
breast
cancer
location
may
superior
inverted
technique
due
reduce
dissection
fast
learn
curve
small
centrally
locate
breast
cancer
round
block
technique
grisotti
technique
excellent
alternative
breast
cancer
much
common
malignancy
among
woman
western
society
considerably
high
asia
incidence
rate
increase
steadily
international
difference
incidence
mortality
rate
indicate
important
difference
endogenous
hormonal
lifestyle
environmental
factor
genetic
susceptibility
mammographic
screening
activity
among
country
estrogen
play
major
role
growth
differentiation
normal
breast
tissue
development
progression
breast
cancer
confirm
experimental
clinical
epidemiological
evidence
japanese
woman
whose
diet
rich
isoflavonoids
show
incidence
breast
cancer
may
explain
difference
relative
risk
prevalence
risk
factor
include
dietary
factor
phytoestrogens
natural
compound
derived
plant
exhibit
activity
tham
cassidy
contain
high
amount
isoflavonoids
genistein
mg
like
lignan
find
possess
weak
estrogenic
activity
range
time
little
estradiol
epidemiological
evidence
indicate
soy
intake
associate
risk
breast
cancer
among
woman
lee
prolong
length
menstrual
cycle
hence
identify
natural
compound
act
antagonist
estrogen
breast
tissue
agonist
bone
cardiovascular
tissue
beneficial
licorice
japanese
chinese
much
ingredient
chinese
medicine
human
least
year
appear
early
chinese
medicinal
book
herb
yield
licorice
product
analgesic
agent
agent
licorice
extract
generally
recognize
safe
also
flavoring
agent
tobacco
beverage
licorice
widely
utilize
western
world
glabra
glabra
indigenous
spain
iraq
turkey
japan
north
glabra
contain
glycyrrhizin
flavonoid
isoflavonoids
recent
research
focused
active
component
extract
glabra
term
activity
tham
cassidy
lee
glycyrrhizin
major
licorice
root
constitute
licorice
extract
consider
primary
constituent
herb
glycyrrhizin
also
exhibit
proapoptotic
property
cytotoxicity
hepatocyte
long
treatment
chronic
hepatitis
japan
component
glabrene
isoliquiritigenin
extract
glabra
bind
human
estrogen
receptor
high
affinity
stimulate
proliferation
cell
show
similarity
estradiol
tamir
maggiolini
glabridin
glabra
show
estrogen
effect
concentration
nm
isoliquiritigenin
also
suggest
candidate
agent
treatment
prostate
cancer
hplc
profile
indicate
extract
glabra
rich
flavonoid
isoflavonoids
contain
different
type
phenol
study
indicate
glabra
root
contain
wide
variety
chemical
various
bioactivity
include
cell
proliferation
activity
order
understand
mechanism
component
glabra
root
growth
breast
tumor
cell
investigate
effect
series
analysis
include
srb
pcr
neurite
outgrowth
assay
moreover
expression
profile
perform
cdna
microarray
assay
characterization
phytoestrogen
examine
genetic
response
ise
terasaka
terasaka
reveal
gene
network
provide
significant
functional
mechanism
material
chemical
antibody
glycyrrhizin
purchase
wako
osaka
japan
estradiol
sigma
aldrich
louis
powder
glabra
root
obtain
japan
extract
prepare
boil
powder
water
ici
hydroxytamoxifen
purchase
tocris
cookson
ellisville
stock
mm
solution
compound
dissolve
dmso
vehicle
final
concentration
solvent
culture
medium
exceed
affect
yield
cell
fetal
bovine
serum
fbs
purchase
hyclone
logan
penicillin
streptomycin
solution
trypsin
edta
solution
purchase
life
technology
grand
island
antibody
akt
mapk
recognize
total
akt
total
phosphorylation
protein
respectively
antibody
recognize
phosphorylated
akt
purchase
cell
signaling
technology
beverly
ma
chemical
high
quality
available
commercial
source
cell
culture
rna
extraction
human
breast
cancer
cell
obtain
jcrb
cell
bank
national
institute
health
science
tokyo
japan
cultured
rpmi
medium
invitrogen
supplement
fbs
humidify
atmosphere
air
cell
cultured
phenol
rpmi
medium
contain
fbs
day
treat
nm
control
dmso
vehicle
day
cell
cultured
day
presence
chemical
specific
concentration
mrna
purify
cell
system
promega
madison
quality
mrna
confirm
spectrophotometry
cell
jcrb
cell
bank
maintain
dmem
dulbecco
modify
eagle
medium
contain
fetal
bovine
serum
fbs
horse
serum
hs
mm
glutamine
antibiotic
mixture
penicillin
ml
streptomycin
mg
ml
mg
ml
environment
mm
falcon
plastic
tissue
culture
dish
reagent
tissue
culture
gibco
life
technology
md
srb
assay
srb
assay
perform
accord
mcf
cell
treat
nm
extract
glabra
root
glycyrrhizin
day
transfection
luciferase
assay
reporter
plasmid
construct
contain
promoter
human
estrogen
receptor
gene
examine
estrogenic
activity
procedure
describe
previously
inoue
inoue
four
independent
transfection
perform
treatment
result
express
mean
value
sd
relative
degree
gene
expression
response
extract
analyzed
reverse
chain
reaction
describe
previously
western
blot
total
protein
extract
sds
buffer
sonicated
ice
incubation
min
loading
buffer
total
protein
resolve
sds
page
gel
transfer
onto
nitrocellulose
membrane
millipore
ma
transfer
cell
hercules
ma
detect
probe
membrane
saline
contain
bsa
antibody
dilute
overnight
complex
rabbit
detect
horseradish
goat
antibody
rabbit
igg
cell
signaling
technology
visualize
ecl
plus
western
blotting
detection
system
amersham
pharmacia
biotech
arlington
heights
cool
tokyo
japan
relative
level
total
akt
protein
sample
determine
strip
rabbit
antibody
membrane
follow
membrane
antibody
neurite
outgrowth
assay
cdna
human
gene
expression
vector
promega
cell
transfected
expression
vector
invitrogen
select
neomycin
medium
expression
vector
confirm
western
blot
antibody
tag
control
pccon
cell
transfected
pcer
maintain
phenol
dmem
contain
serum
fbs
hs
mm
antibiotic
pcer
pccon
cell
plate
equal
density
medium
treat
vehicle
ethanol
nm
ethanol
extract
ml
combination
nerve
growth
factor
ngf
ml
sigma
aldrich
neurite
outgrowth
examine
treatment
score
different
condition
treatment
approximately
cell
per
well
examine
neurite
define
cell
bear
neurite
cell
process
outgrowth
long
one
cell
body
length
datum
express
percentage
cell
total
cell
count
experiment
repeat
least
three
time
three
different
region
culture
count
case
datum
statistically
examine
individual
group
difference
spss
software
datum
consider
significant
cdna
microarray
analysis
estrarray
contain
total
gene
consist
gene
calibration
expression
marker
total
gene
show
greater
statistical
stability
study
biologically
independent
dna
microarray
assay
repeat
three
time
extract
glycyrrhizin
estrarray
assay
calculation
correlation
coefficient
dataset
extract
glycyrrhizin
describe
previously
effect
extract
glabra
cell
proliferation
first
examine
effect
extract
glabra
root
growth
cell
cell
treat
nm
extract
glycyrrhizin
various
concentration
ml
extract
glycyrrhizin
growth
examine
srb
assay
result
show
extract
stimulate
cell
growth
range
ml
reach
level
ml
equal
nm
contrast
glycyrrhizin
show
significant
activity
although
weak
activity
addition
broad
range
concentration
pm
mm
examine
glycyrrhizin
srb
assay
yet
significant
activity
detect
datum
show
activity
report
extract
high
concentration
tham
cassidy
lee
probably
due
toxic
effect
minor
component
study
focused
activity
extract
understand
effect
extract
proliferation
breast
cancer
image
effect
extract
glabra
root
proliferation
cell
test
material
add
cell
culture
indicate
concentration
incubation
cell
three
day
cell
proliferation
examine
srb
assay
result
normalize
value
control
experiment
vehicle
normalize
value
proliferation
index
represent
mean
sd
datum
six
independent
experiment
view
within
article
luciferase
activity
examine
effect
reporter
gene
assay
promoter
contain
element
promoter
contain
cap
site
proab
human
estrogen
receptor
gene
respond
compound
xenoestrogen
inoue
inoue
transfected
reporter
plasmid
contain
proab
luciferase
gene
mcf
cell
examine
activity
extract
glycyrrhizin
various
concentration
extract
exhibit
enhance
luciferase
activity
range
ml
reach
maximal
stimulation
level
ml
equal
nm
contrast
glycyrrhizin
show
effect
range
extract
ml
glycyrrhizin
exhibit
high
proliferation
activity
either
srb
reporter
gene
assay
concentration
perform
far
analysis
image
luciferase
gene
assay
extract
glabra
root
cell
vector
dna
treat
either
vehicle
control
nm
extract
glycyrrhizin
indicate
concentration
luciferase
activity
assay
treatment
value
represent
mean
sd
datum
four
independent
view
within
article
transcription
gene
examine
effect
extract
cell
proliferation
quantitative
analysis
gene
gene
examine
signal
gene
find
respond
estrogen
phytoestrogen
ise
zhang
result
show
extract
expression
trefoil
factor
ctsd
cathepsin
lysosomal
aspartyl
protease
effector
rsk
expression
prkcd
protein
kinase
arhgdia
ras
gene
regulation
pattern
similar
statistic
analysis
far
suggest
difference
degree
expression
gene
extract
contrast
expression
profile
gene
induce
glycyrrhizin
different
induce
image
analysis
gene
stimulate
extract
glabra
root
response
gene
examine
cell
treat
extract
glycyrrhizin
relative
expression
index
value
ratio
mrna
level
treatment
gene
examine
trefoil
factor
family
ctsd
lysosomal
aspartyl
protease
prkcd
arhgdia
ras
superfamily
gene
value
represent
mean
sd
datum
three
independent
experiment
view
within
article
activation
akt
proliferation
cell
activation
rapid
signaling
pathway
occur
within
hour
stimulation
promote
cell
proliferation
synergistically
examine
involvement
akt
signaling
mediate
extract
glabra
root
level
phosphorylated
form
total
protein
determine
treatment
cell
ml
extract
compare
treatment
nm
ml
glycyrrhizin
phosphorylation
akt
clearly
detect
response
material
examine
however
phosphorylation
akt
induce
extract
inhibit
cell
estrogen
antagonist
ici
hydroxytamoxifen
exactly
observe
treatment
phosphorylation
akt
activate
glycyrrhizin
inhibit
antagonist
suggest
scheme
pathway
signaling
similar
extract
glycyrrhizin
although
activate
key
player
signaling
contribute
distinct
different
signaling
pathway
image
activation
akt
extract
glabra
inhibition
phosphorylation
ici
ici
hydroxytamoxifen
akt
inhibition
akt
phosphorylation
ici
hydroxytamoxifen
cell
untreated
treat
glycyrrhizin
extract
ml
nm
various
length
time
min
lysed
sds
sample
buffer
protein
sample
electrophoresed
sds
polyacrylamide
gel
transfer
nitrocellulose
membrane
probe
antibody
specific
phosphorylated
akt
level
protein
loading
confirm
antibody
recognize
total
protein
total
akt
protein
inhibition
estrogen
signaling
cell
treat
chemical
min
incubation
cell
ici
hydroxytamoxifen
min
view
within
article
enhancement
neurite
outgrowth
report
estrogen
contribute
neurite
outgrowth
cell
rat
cell
line
manner
examine
extract
similar
ability
enhance
neurite
outgrowth
manner
cell
transfected
vector
pcer
empty
vector
pccon
treat
extract
presence
ngf
large
proportion
cell
newly
sprout
treatment
extract
compare
treatment
glycyrrhizin
contrast
neither
cell
treat
extract
cell
without
treatment
exhibit
enhancement
neurite
outgrowth
datum
suggest
effect
extract
neurite
outgrowth
similar
whereas
glycyrrhizin
effect
image
neurite
outgrowth
stimulate
extract
glabra
root
control
cell
pccon
cell
transfected
expression
vector
pcer
cultured
add
ngf
cell
treat
nm
ml
extract
glycyrrhizin
cultured
pcer
cell
treat
pcer
cell
treat
pcer
cell
treat
pcer
treat
pccon
cell
treat
quantitative
analysis
neurite
outgrowth
show
panel
percentage
cell
least
one
neurite
long
diameter
cell
body
view
within
article
gene
expression
profile
dna
microarray
assay
set
gene
greater
statistical
stability
select
repeat
biologically
independent
assay
ten
time
far
characterization
chemical
similar
expression
profile
obtain
cell
treat
extract
estrarray
whereas
expression
profile
treatment
glycyrrhizin
different
significant
correlation
observe
extract
gene
suggest
presence
estrogenic
activity
extract
interestingly
weak
significant
correlation
detect
extract
glycyrrhizin
although
correlation
glycyrrhizin
result
suggest
glycyrrhizin
modulate
expression
gene
contribute
correlation
extract
glycyrrhizin
different
image
cluster
analysis
gene
expression
profile
glycyrrhizin
extract
glabra
root
cell
cultured
glycyrrhizin
gly
lane
ml
extract
glabra
ex
lane
nm
lane
dna
microarray
analysis
gene
expression
profile
represent
gene
red
gene
green
treatment
glycyrrhizin
extract
glabra
color
scale
indicate
ratio
signal
treatment
signal
vehicle
signal
show
relative
expression
level
gene
top
indicate
relative
degree
similarity
cell
name
gene
group
name
show
right
number
gene
group
show
parenthesis
view
within
article
gene
far
categorize
six
group
specific
function
enzyme
signaling
proliferation
transcription
transport
correlation
analysis
significant
correlation
observe
extract
group
signaling
proliferation
whereas
significant
correlation
glycyrrhizin
furthermore
significant
correlation
observe
extract
glycyrrhizin
signaling
gene
suggest
glycyrrhizin
partly
share
common
signaling
pathway
extract
gene
whose
response
extract
different
glycyrrhizin
list
table
list
consist
total
gene
include
gene
image
correlation
gene
expression
profile
glycyrrhizin
extract
glabra
root
gene
expression
profile
compare
sample
treatment
extract
glycyrrhizin
extract
glycyrrhizin
bar
indicate
correlation
coefficient
total
gene
gene
categorize
six
group
enzyme
signaling
proliferation
transcription
transport
show
view
within
article
table
gene
show
significant
different
response
treatment
glycyrrhizin
extract
glabra
relative
expression
index
unigene
table
gene
unigene
name
accession
number
group
name
show
whose
response
treatment
glycyrrhizin
gly
significantly
different
treatment
estrogen
extract
ex
list
anova
test
perform
gene
see
section
value
relative
expression
index
see
represent
mean
three
independent
experiment
treatment
cell
view
within
article
discussion
demonstrate
extract
glabra
root
share
similarity
cellular
activity
proliferation
morphology
much
likely
mediate
similar
gene
response
transcriptional
signaling
level
signal
mediate
cell
start
binding
presence
various
binding
protein
firstly
activate
rapid
signaling
pathway
pathway
estrogen
signaling
include
phosphorylation
akt
show
member
protein
kinase
activate
growth
factor
peptide
hormone
mediate
signal
various
membrane
receptor
akt
protein
kinase
locate
downstream
phosphoinositide
kinase
k
pathway
activation
akt
inhibit
apoptosis
stimulate
cellular
proliferation
several
chemical
report
activate
akt
cellular
activity
cell
activation
akt
pathway
estrogen
stimulate
growth
factor
receptor
signaling
promote
cell
proliferation
synergistically
dupont
activation
receptor
agent
stimulate
proliferation
cell
pathway
involve
protein
kinase
akt
case
activation
akt
pathway
result
activation
meanwhile
activation
rsk
see
phosphorylation
may
activate
function
phosphorylation
activation
rapid
signaling
pathway
occur
within
hour
stimulation
far
activate
variety
downstream
pathway
cellular
activity
include
transcriptional
activation
suppression
gene
element
example
component
extract
glabra
root
involve
cellular
activity
glycyrrhizin
triterpene
glycoside
major
component
dry
weight
extract
glabra
root
show
wide
range
pharmacological
property
example
result
indicate
glycyrrhizin
induce
expression
gene
proliferation
cell
suggest
estrogenic
activity
extract
due
component
report
glycyrrhizin
bind
directly
mineralocorticoid
receptor
agonist
plasma
concentration
high
enough
compete
aldosterone
cortisol
mineralocorticoid
receptor
armanini
armanini
glycyrrhizin
also
inhibitor
hydroxysteroid
dehydrogenase
involve
conversion
testosterone
concentration
mm
incubation
medium
vitro
glycyrrhizin
stimulate
aromatization
testosterone
estradiol
block
activity
hydroxysteroid
dehydrogenase
armanini
enzyme
involve
synthesis
metabolism
androgen
estrogen
glycyrrhizin
bind
estrogen
androgen
receptor
glycyrrhizin
act
agent
cell
tumor
cell
induce
apoptosis
based
fact
conclude
activation
rapid
signaling
pathway
glycyrrhizin
occur
independently
estrogen
receptor
therefore
estrogenic
activity
extract
due
glycyrrhizin
glabridin
present
extract
much
exhibit
estrogen
effect
concentration
nm
glabridin
show
unique
range
concentration
activity
little
activation
cell
growth
maximum
level
stimulation
observe
importantly
apoptotic
activity
detect
concentration
tamir
dong
datum
show
srb
assay
show
indicate
extract
stimulate
cell
growth
range
ml
reach
maximum
level
ml
roughly
correspond
glabridin
estimate
content
activity
activation
apoptosis
even
concentration
ml
least
glabridin
present
condition
glabridin
induce
apoptosis
tamir
dong
datum
show
hand
extract
significantly
enhance
cell
growth
ml
although
glabridin
equivalent
condition
glabridin
enhance
cell
growth
fact
suggest
although
glabridin
may
contribute
estrogenic
activity
extract
activity
modulate
component
chalcone
isoliquiritigenin
another
component
extract
candidate
treatment
prostate
cancer
exhibit
activity
high
concentration
breast
cancer
cell
show
growth
promote
effect
concentration
maggiolini
however
growth
promote
effect
isoliquiritigenin
nm
suggest
isoliquiritigenin
partly
contribute
estrogenic
activity
component
root
estrogenic
activity
glabrene
genistein
find
extract
concentration
bind
estrogen
receptor
affinity
glabridin
tamir
may
also
influence
estrogenic
activity
extract
therefore
finding
strongly
support
hypothesis
estrogenic
activity
extract
due
cooperation
component
extract
glycyrrhizin
glabridin
isoliquiritigenin
glabrene
genistein
whose
high
concentration
concentration
activity
modulate
weak
cytotoxicity
extract
might
much
beneficial
clinical
application
single
usage
glabridin
isoliquiritigenin
care
breast
cancer
patient
require
variety
medical
discipline
well
effective
coordination
communication
hospital
healthcare
professional
past
several
year
specialist
treat
patient
integrate
change
organization
medical
care
creation
healthcare
network
design
improve
performance
coordination
care
give
way
practice
also
adjust
new
patient
behavior
oncology
often
confront
patient
wish
know
much
information
possible
play
active
role
involve
treatment
medical
decision
concern
recent
year
imbalance
amount
information
hold
doctor
physician
patient
relationship
greatly
reduce
today
information
available
patient
much
equal
basis
french
law
patient
right
access
medical
record
help
speed
trend
patient
medical
record
one
much
important
element
medical
treatment
sharing
information
healthcare
professional
cornerstone
healthcare
information
system
indispensable
tool
organize
summarize
medical
care
track
quality
care
provide
today
effort
make
medical
care
much
efficient
effective
desire
continuity
treatment
hospital
require
various
healthcare
professional
share
information
oncology
experiment
conduct
outside
france
show
allow
patient
play
active
role
sharing
record
increase
level
satisfaction
well
healthcare
professional
treat
cancer
patient
hold
medical
record
may
also
allow
reduce
anxiety
due
lack
information
uncertainty
information
provide
moreover
may
consider
possibly
beneficial
communication
compliance
medical
treatment
various
study
conduct
united
kingdom
united
state
show
contrast
result
seem
depend
type
disease
patient
suffer
stage
illness
motivation
medical
team
involve
expectation
various
party
study
first
phase
research
program
aim
assess
impact
medical
record
hold
cancer
patient
aim
assess
french
breast
cancer
patient
perception
expectation
information
exchange
medical
care
particular
wish
find
opinion
give
medical
record
contain
information
essential
continue
care
patient
method
sample
investigation
focused
volunteer
breast
cancer
patient
aware
diagnosis
disease
limit
age
time
since
diagnosis
make
treat
region
france
million
locate
france
method
investigation
survey
patient
enrolment
last
october
patient
inclusion
hospital
physician
surgeon
oncologist
radiotherapist
work
healthcare
center
involve
treatment
breast
cancer
contact
avoid
selection
bias
sampling
training
patient
inclusion
physician
participate
previous
study
aim
determine
expectation
regard
information
exchange
treatment
breast
cancer
based
number
patient
see
year
declare
first
survey
physician
distribute
questionnaire
either
first
consecutive
breast
cancer
patient
come
consultation
questionnaire
send
physician
physician
allocate
batch
number
questionnaire
enable
number
questionnaire
distribute
determine
questionnaire
return
patient
send
complete
questionnaire
study
coordination
center
envelope
clinical
research
nurse
project
contact
physician
post
phone
order
remind
include
patient
study
questionnaire
item
questionnaire
explore
follow
characteristic
patient
age
family
status
level
education
size
city
residence
disease
duration
person
inform
patient
disease
stage
communication
entourage
organization
treatment
presence
usual
family
practitioner
gynecologist
physician
coordinating
medical
care
frequency
care
motive
late
consultation
existence
summary
medical
record
repeat
investigation
may
perform
patient
participation
treatment
frequency
document
keep
give
healthcare
professional
summary
sheet
table
note
date
upcoming
consultation
satisfaction
desire
involvement
treatment
patient
preference
expectation
medical
record
give
hold
contain
essential
information
continue
treatment
disease
content
type
document
format
paper
electronic
possible
impact
advantage
drawback
scale
end
part
questionnaire
patient
write
comment
wish
one
specific
question
focused
patient
preference
regard
participation
choice
treatment
adapt
method
degner
breast
cancer
patient
rank
five
different
attitude
order
preference
study
patient
give
five
attitude
number
range
statement
agree
much
statement
agree
least
prefer
make
decision
treatment
will
receive
prefer
make
final
decision
treatment
seriously
consider
doctor
opinion
prefer
doctor
share
responsibility
decide
treatment
good
prefer
doctor
make
final
decision
treatment
will
seriously
consider
opinion
prefer
leave
decision
regard
treatment
doctor
table
view
within
article
term
active
relatively
active
collaborative
relatively
passive
passive
will
provide
much
clarity
item
list
order
accord
degner
recommendation
entire
questionnaire
test
beforehand
sample
ten
patient
plan
study
condition
enable
question
adjust
correct
analysis
univariate
bivariate
descriptive
analysis
criterion
perform
enable
study
relationship
patient
perception
concern
treatment
medical
record
characteristic
age
social
status
family
status
size
town
live
stage
disease
time
elapse
since
diagnosis
pearson
test
fisher
exact
test
qualitative
variable
datum
process
spss
software
version
windows
spss
illinois
usa
result
questionnaire
enable
estimate
physician
distribute
questionnaire
total
anonymous
questionnaire
send
patient
patient
participation
rate
estimate
patient
treatment
characteristic
percent
patient
treat
private
healthcare
establishment
public
healthcare
facility
five
division
dpartements
region
france
patient
characteristic
summarize
table
table
show
organization
treatment
course
disease
much
time
general
practitioner
among
usual
primary
care
physician
single
physician
coordinated
medical
care
time
half
case
oncologist
table
characteristic
patient
sample
variablesn
na
age
year
family
status
married
children
including
size
town
residence
education
level
person
give
hospital
general
time
since
diagnosis
stage
disease
type
treatment
receive
entourage
inform
disease
spouse
family
close
table
figure
vary
depending
number
miss
answer
several
possible
answer
view
within
article
table
organization
care
breast
cancer
patient
variablesn
na
usual
primary
care
physician
general
primary
care
primary
care
physician
diagnosis
time
since
last
consultation
one
primary
care
physician
less
reason
last
consultation
one
primary
care
physician
illness
unrelated
illness
relate
including
including
including
cancer
number
consultation
last
month
including
general
including
including
including
including
number
physician
clearly
identify
coordinating
medical
care
including
including
including
including
general
including
summary
record
physician
appointment
sheet
patient
unnecessarily
repeat
investigation
applicable
miss
document
consultation
physician
office
general
table
figure
vary
depending
number
miss
answer
view
within
article
patient
involvement
medical
care
table
show
type
document
patient
hold
pass
healthcare
professional
except
image
report
laboratory
result
patient
almost
never
document
result
exception
laboratory
result
pass
document
various
physician
table
type
document
hold
pass
healthcare
professional
breast
cancer
patient
na
na
na
na
type
document
hold
laboratory
image
surgery
hospitalization
letters
hospital
physician
primary
care
letters
primary
care
physician
hospital
letters
hospital
type
document
pass
image
laboratory
letters
hospital
physician
primary
care
surgery
letters
primary
care
physician
hospital
hospitalization
letters
hospital
table
figure
vary
depending
number
miss
answer
view
within
article
percent
patient
satisfy
involvement
treatment
satisfy
quite
satisfy
one
woman
satisfy
nevertheless
patient
want
level
involvement
remain
want
much
involve
want
little
involve
opinion
matter
woman
survey
answer
question
patient
seem
rather
much
satisfy
satisfy
quite
satisfy
regarding
choice
treatment
state
physician
consult
order
make
decision
whole
patient
relatively
passive
attitude
choose
role
prefer
physician
decide
upon
treatment
take
opinion
serious
consideration
percent
patient
choose
role
collaboration
choose
role
passive
choose
role
relatively
active
opted
role
active
group
together
patient
opted
rather
passive
role
prefer
collaborative
role
rather
active
role
furthermore
active
role
statement
widely
reject
patient
give
role
ranking
statement
agree
least
medical
record
contain
essential
information
cancer
care
according
patient
hypothetical
paper
medical
record
hold
contain
document
essential
treatment
disease
table
show
approval
whatever
type
document
impact
medical
record
current
situation
show
table
patient
mainly
appreciate
usefulness
record
case
emergency
consultation
able
much
information
well
communication
physician
opinion
divide
risk
lose
forget
medical
record
half
patient
agree
proposal
whereas
half
disagree
patient
raise
issue
privacy
table
type
document
breast
cancer
patient
like
include
medical
record
items
desire
share
medical
recordsentirely
agreemostly
agreemostly
disagreeentirely
disagree
na
na
na
na
laboratory
image
hospitalization
surgery
letters
hospital
physician
primary
care
letters
primary
care
physician
hospital
letters
hospital
table
figure
vary
depending
number
miss
answer
view
within
article
table
breast
cancer
patient
point
view
medical
record
compare
current
situation
impact
propose
share
recordsentirely
agreemostly
agreemostly
disagreeentirely
disagree
na
na
na
na
advantages
well
much
communication
hospital
physician
much
communication
much
making
emergency
consultation
physician
avoiding
unnecessary
repeat
able
request
second
medical
risk
lose
risk
forget
problem
privacy
problem
privacy
problem
privacy
insurance
table
figure
vary
depending
number
miss
answer
view
within
article
percent
patient
agree
hold
medical
record
choose
entirely
agree
choose
mostly
agree
wish
able
write
record
choose
entirely
agree
choose
mostly
agree
patient
write
comment
specify
writing
concern
personal
disease
treatment
wish
mention
side
effect
advantage
drawback
treatment
write
question
disease
treatment
patient
wish
hold
medical
record
state
able
read
even
deep
disease
just
soon
forget
disease
enable
well
come
term
patient
unsure
want
read
comment
expect
state
point
write
medical
record
either
speak
physician
keep
personal
diary
support
principle
paper
record
category
preference
regarding
hypothesis
medical
record
make
available
electronic
format
patient
computer
internet
access
percent
drive
drive
table
show
patient
various
opinion
access
record
make
available
electronic
format
table
breast
cancer
patient
attitude
towards
electronic
medical
record
entirely
agreemostly
agreemostly
disagreeentirely
disagree
na
na
na
na
access
record
via
access
record
via
computer
different
access
right
member
table
figure
vary
depending
number
miss
answer
view
within
article
discussion
main
result
investigation
firstly
breast
cancer
patient
satisfy
current
level
involvement
treatment
much
prefer
decision
treatment
make
physician
take
patient
opinion
serious
consideration
secondly
patient
willing
hold
paper
medical
record
contain
information
essential
continue
treatment
disease
record
consider
useful
medical
care
see
possible
mean
help
improve
information
communication
however
patient
express
privacy
lose
forget
medical
record
result
patient
involvement
treatment
consistent
research
although
study
patient
little
satisfy
current
level
involvement
wish
much
actively
involve
medical
care
significant
variation
patient
individual
patient
variation
one
point
time
another
several
factor
may
influence
patient
preference
particular
young
patient
high
level
education
relapse
live
large
city
wish
participate
medical
care
play
active
collaborative
role
psychological
variable
disease
severity
also
find
influence
information
need
decisional
preference
french
law
august
call
creation
personal
medical
record
meet
need
expectation
population
breast
cancer
patient
willingness
hold
medical
record
indeed
patient
will
full
control
record
will
electronic
format
contain
medical
information
will
complete
healthcare
professional
time
new
diagnostic
therapeutic
information
require
order
coordinate
care
study
patient
interest
hold
medical
record
hypothetical
whatever
format
medical
record
paper
electronic
wait
record
become
reality
observe
patient
will
behave
also
take
account
patient
decline
share
medical
record
study
half
patient
consider
write
medical
record
previous
study
cancer
patient
proportion
patient
write
record
much
able
write
medical
record
often
consider
useful
patient
note
reminder
question
ask
physician
late
time
one
first
argument
record
allow
patient
receive
much
information
disease
need
demonstrate
previous
research
perhaps
reason
patient
want
medical
record
contain
nearly
document
offer
test
result
report
letter
confirm
result
australian
study
show
patient
see
hold
medical
record
mean
obtain
information
thus
appear
patient
study
hold
medical
record
mean
find
information
disease
diagnosis
prognosis
chance
recovery
side
effect
may
experience
however
consider
link
exist
patient
desire
obtain
information
desire
participate
one
american
study
cancer
patient
highlight
strong
correlation
preference
patient
want
much
information
possible
desire
participate
show
desire
find
much
information
wish
participate
two
distinct
thing
many
patient
want
much
information
necessarily
want
get
involve
participate
much
result
show
significant
difference
preference
support
principle
paper
medical
record
according
population
patient
medical
record
equally
mean
improve
communication
one
study
conduct
london
patient
confirm
read
record
barrier
physician
patient
break
level
trust
heighten
however
contrary
finding
various
randomized
study
prove
medical
record
significantly
improve
communication
patient
physician
cancer
care
hand
may
much
opportunity
patient
expectation
record
improve
communication
among
physician
meet
european
study
female
cancer
patient
show
great
dissatisfaction
communication
hospital
primary
care
physician
extremely
satisfy
satisfy
dissatisfied
extremely
dissatisfied
moreover
allow
patient
hold
record
show
potentially
beneficial
communication
healthcare
professional
appear
record
little
impact
communication
patient
entourage
result
show
patient
already
share
lot
information
member
entourage
much
case
inform
disease
show
study
namely
france
majority
patient
want
family
fully
inform
study
spouse
partner
child
well
inform
play
important
role
provide
vital
support
cancer
patient
advantage
accord
patient
study
involve
continuity
cancer
care
see
record
contain
vital
medical
information
useful
case
emergency
mean
avoid
repeat
unnecessary
investigation
request
second
opinion
principle
usefulness
record
case
emergency
show
several
time
united
kingdom
patient
study
appreciate
write
information
mean
avoid
medical
history
new
healthcare
professional
meet
meanwhile
french
government
help
address
need
create
cancer
plan
plan
cancer
order
improve
coordination
care
one
key
measure
cancer
plan
creation
share
oncology
record
record
design
mean
pass
information
accessible
physician
patient
thus
patient
will
able
play
active
role
medical
care
desire
ross
demonstrate
study
show
patient
prefer
emphasize
advantage
medical
record
rather
focus
disadvantage
well
appear
unanimously
agree
benefit
record
much
much
divide
opinion
drawback
effect
express
certain
fear
half
believe
record
lose
whereas
half
feel
little
risk
literature
similar
experiment
show
record
rarely
lose
none
lose
recent
study
conduct
united
kingdom
case
another
british
study
carry
breast
cancer
patient
well
lose
record
copy
original
document
safely
keep
healthcare
facility
physician
provide
care
patient
potential
lose
record
raise
issue
privacy
however
accord
majority
patient
study
hold
record
present
threat
privacy
whether
employer
insurance
company
people
entourage
patient
decide
access
record
yet
patient
feel
privacy
vital
issue
french
law
patient
right
access
medical
record
debate
partly
resolve
law
august
one
side
patient
association
argue
direct
access
record
ensure
transparency
medical
care
also
enable
get
second
medical
opinion
necessary
give
piece
evidence
ever
need
assert
right
side
physician
organization
emphasize
risk
expose
patient
highly
technical
medical
information
hard
understand
bear
psychologically
also
fear
patient
employer
insurance
company
force
patient
pass
record
onto
finally
also
fear
rise
number
claim
fact
last
two
argument
lead
physician
censor
information
contain
record
development
information
technology
increasing
healthcare
field
make
share
electronic
medical
record
inevitable
will
likely
encourage
patient
participation
process
benefit
remain
assess
nonetheless
patient
study
seem
ready
hold
medical
record
electronic
format
fewer
half
completely
agree
access
medical
information
via
electronic
mean
american
study
show
little
much
half
patient
interested
medical
record
via
internet
patient
ensure
privacy
prevention
access
personally
identifiable
information
person
integrity
completeness
information
access
information
time
will
guarantee
today
issue
yet
fully
resolve
participation
rate
suggest
patient
interested
approach
concern
directly
good
response
rate
fact
physician
ask
give
survey
consecutive
patient
provide
fair
representativeness
study
sample
many
patient
remission
phase
diagnose
much
month
prior
study
amount
time
pass
since
active
treatment
phase
may
reduce
intensity
reaction
finally
datum
patient
anxiety
since
many
study
show
patient
psychological
state
influence
satisfaction
attitude
quality
life
anxiety
measure
future
experimental
study
conclusion
study
conduct
sample
french
woman
suffer
breast
cancer
observe
overall
satisfaction
care
receive
disease
level
involvement
well
show
certain
number
need
desire
term
patient
information
participation
majority
patient
thus
seem
favor
hold
medical
record
contain
much
information
possible
subject
certain
condition
access
consultation
record
field
will
enable
well
determine
content
way
practice
acknowledgment
author
wish
thank
anonymous
patient
participate
investigation
physician
hand
questionnaire
patient
scientific
council
project
pr
dr
jf
dr
j
dr
x
dr
dr
pr
fn
dr
jm
dr
pr
jm
dr
romestaing
also
like
thank
follow
partner
region
association
physician
union
home
hospital
care
service
healthcare
facility
participate
network
work
make
possible
part
support
french
national
cancer
association
french
hospital
french
ministry
research
french
ministry
health
programme
high
authority
health
young
age
breast
cancer
patient
find
several
large
study
predict
badly
clinical
outcome
compared
old
patient
young
breast
cancer
patient
exhibit
great
proportion
aggressive
pathologic
feature
lymphovascular
space
invasion
high
nuclear
grade
high
proportion
estrogen
receptor
negativity
however
even
pathologic
factor
account
young
age
remain
independent
predictor
ill
outcome
patient
treat
either
therapy
mastectomy
recent
update
large
randomized
trial
highlight
benefit
postmastectomy
radiotherapy
pmrt
outcome
breast
cancer
patient
report
result
report
danish
breast
cancer
cooperative
group
randomized
study
include
postmenopausal
patient
demonstrate
pmrt
associate
improve
locoregional
control
lrc
rate
distant
metastases
patient
treat
adjuvant
chemotherapy
addition
british
colombia
trial
demonstrate
benefit
pmrt
year
rate
lrc
overall
survival
premenopausal
patient
treat
adjuvant
chemotherapy
furthermore
year
result
randomized
trial
early
breast
cancer
trialists
collaborative
group
confirm
pmrt
improve
lrc
regardless
nodal
status
improve
year
patient
data
specific
patient
treat
neoadjuvant
chemotherapy
much
limited
group
previously
examine
affect
pmrt
patient
age
median
age
year
treat
neoadjuvant
chemotherapy
mastectomy
find
addition
improve
lrc
survival
patient
locally
advance
disease
four
much
positive
lymph
node
primary
tumor
stage
iii
disease
despite
evidence
demonstrate
benefit
pmrt
breast
cancer
patient
evaluation
risk
among
patient
year
old
adequately
address
purpose
study
examine
affect
pmrt
young
breast
cancer
patient
year
neoadjuvant
chemotherapy
mastectomy
stage
disease
patient
method
retrospectively
review
patient
year
old
treat
stage
breast
cancer
protocol
neoadjuvant
chemotherapy
mastectomy
patient
clinically
stage
diagnosis
retrospectively
accord
american
joint
committee
cancer
staging
guideline
median
number
recover
axillary
lymph
node
mastectomy
range
total
patient
treat
pmrt
patient
zero
three
positive
lymph
node
surgery
referred
pmrt
patient
four
much
lymph
node
patient
refuse
referred
unknown
reason
patient
treat
pmrt
treatment
volume
period
typically
include
chest
wall
drain
lymphatic
include
supraclavicular
internal
mammary
nodal
region
median
dose
gy
follow
chest
wall
boost
median
dose
gy
patient
undergo
compute
tomography
simulation
planning
optimal
target
coverage
minimal
exposure
lung
heart
chest
wall
usually
treat
medial
lateral
tangent
photon
design
include
entire
chest
wall
separate
supraclavicular
anterior
photon
field
match
superior
border
tangential
field
design
encompass
level
iii
axilla
axillary
apex
electron
field
often
match
medial
tangential
field
particular
care
cover
internal
mammary
nodal
region
respect
critical
structure
include
heart
lung
finally
chest
wall
typically
boost
electron
design
include
mastectomy
scar
adequate
margin
statistical
analysis
distribution
clinical
pathologic
factor
group
patient
compare
test
locoregional
recurrence
lrr
define
disease
recurrence
ipsilateral
chest
wall
ipsilateral
axillary
supraclavicular
infraclavicular
internal
mammary
lymph
node
site
recurrence
score
distant
metastasis
lrr
consider
independent
event
regardless
whether
occur
distant
metastasis
year
actuarial
rate
lrr
calculate
accord
method
comparison
two
patient
group
make
log
rank
test
survival
statistic
measure
date
diagnosis
value
consider
significant
result
patient
characteristic
median
irradiate
nonirradiated
patient
month
respectively
month
patient
combine
range
median
survive
patient
month
table
outline
comparison
disease
characteristic
treatment
group
patient
pmrt
group
statistically
great
percentage
stage
iii
tumor
great
percentage
lymphovascular
space
invasion
stage
disease
also
nonsignificant
trend
toward
much
advance
nodal
stage
find
pmrt
treatment
group
disease
difference
find
group
respect
nuclear
grade
hormone
receptor
status
tamoxifen
margin
status
presence
extracapsular
extension
number
node
sample
relationship
find
volume
outcome
table
patient
tumor
characteristic
characteristicno
clinical
clinical
clinical
pathologic
tumor
size
cm
positive
percentage
positive
node
sample
tumor
margin
free
close
mm
estrogen
progesterone
hormonal
response
neoadjuvant
adjuvant
table
abbreviation
radiotherapy
lvsi
lymphovascular
space
invasion
cr
complete
response
pr
partial
response
nr
response
pd
progressive
disease
data
parenthesis
percentage
view
within
article
locoregional
recurrence
patient
pmrt
group
locoregional
failure
patient
group
lrr
year
lrr
rate
patient
receive
pmrt
compare
patient
receive
pmrt
site
locoregional
failure
include
isolate
chest
wall
patient
isolate
supraclavicular
region
patient
simultaneous
chest
wall
supraclavicular
region
patient
simultaneous
chest
wall
infraclavicular
node
patient
simultaneous
chest
wall
axilla
infraclavicular
supraclavicular
node
patient
image
rate
year
actuarial
locoregional
control
patient
treat
radiotherapy
without
view
within
article
mean
median
time
local
recurrence
patient
month
respectively
table
show
relationship
select
clinical
pathologic
characteristic
patient
treatment
group
lrr
four
patient
clinical
stage
iia
disease
receive
pmrt
patient
also
perineural
invasion
extracapsular
extension
positive
axillary
lymph
node
patient
alive
disease
free
last
visit
addition
pmrt
improve
lrr
clinical
stage
iib
disease
clinical
stage
patient
clinical
stage
iib
disease
present
disease
disease
patient
pathologic
nodal
disease
surgery
much
advance
apparent
initial
clinical
examination
radiographic
study
patient
four
much
lymph
node
patient
tumor
refractory
chemotherapy
receive
pmrt
decline
lose
patient
undergo
pmrt
none
experience
locoregional
failure
however
remain
patient
disease
progression
chemotherapy
receive
pmrt
lrr
patient
clinical
stage
disease
one
three
positive
lymph
node
surgery
therefore
meaningful
analysis
conduct
small
subset
table
actuarial
rate
lrr
accord
clinical
pathologic
factor
lrr
rate
characteristicno
clinical
stage
clinical
stage
clinical
stage
positive
node
table
abbreviation
lrr
locoregional
recurrence
radiotherapy
na
applicable
view
within
article
radiotherapy
also
correlated
reduce
lrr
patient
stratified
accord
stage
stage
survival
patient
locoregional
failure
alive
last
year
actuarial
rate
patient
stage
pmrt
group
group
subset
analysis
survival
clinical
stage
find
stage
iib
patient
pmrt
significantly
improve
compare
receive
pmrt
stage
patient
receive
pmrt
significantly
improve
compare
patient
receive
pmrt
additionally
improve
survival
patient
four
much
positive
node
surgery
patient
lymphovascular
space
invasion
image
rate
year
actuarial
survival
patient
treat
radiotherapy
without
view
within
article
table
actuarial
survival
rate
accord
clinical
pathologic
factor
survival
rate
characteristicno
clinical
stage
clinical
stage
clinical
stage
positive
node
lvsi
table
abbreviation
na
applicable
abbreviation
table
view
within
article
discussion
first
report
evaluate
affect
pmrt
breast
cancer
patient
year
old
diagnosis
treat
neoadjuvant
chemotherapy
mastectomy
datum
find
addition
pmrt
patient
stage
disease
lead
superior
rate
year
lrc
patient
stage
iib
disease
analyzed
separately
improvement
lrc
survival
addition
pmrt
remain
statistically
significant
large
magnitude
benefit
see
pmrt
young
patient
provide
valuable
datum
well
tailor
adjuvant
treatment
decision
difficult
clinical
circumstance
finding
provide
evidence
support
recommendation
adjuvant
patient
guide
physician
counseling
young
patient
young
age
previously
suggest
predictive
factor
ill
outcome
breast
cancer
patient
treat
mastectomy
without
recent
large
retrospective
study
canada
analyzed
patient
disease
one
three
positive
lymph
node
treat
mastectomy
chemotherapy
find
age
year
independent
risk
factor
lrr
mastectomy
hazard
ratio
furthermore
large
five
national
surgical
adjuvant
breast
project
trial
patient
disease
stage
treat
mastectomy
adjuvant
chemotherapy
find
young
patient
great
rate
lrr
without
distant
failure
among
patient
finally
retrospective
report
include
one
institution
include
patient
stage
disease
treat
neoadjuvant
chemotherapy
mastectomy
suggest
young
age
risk
factor
lrr
although
study
suggest
young
age
might
adverse
prognostic
factor
outcome
important
note
report
show
similar
result
furthermore
result
subset
analysis
interpret
cautiously
large
randomized
trial
british
colombia
trial
danish
trial
study
include
premenopausal
patient
recent
show
improvement
lrc
survival
pmrt
breast
cancer
emphasis
place
identify
subset
patient
might
high
risk
local
recurrence
particularly
recommendation
pmrt
routine
consensus
panel
include
american
society
therapeutic
radiology
oncology
american
society
clinical
oncology
national
institute
health
recommend
pmrt
patient
four
much
positive
axillary
node
primary
tumor
however
group
cite
insufficient
evidence
recommend
pmrt
small
primary
tumor
one
three
positive
lymph
node
surgery
patient
potentially
feature
young
age
furthermore
recommendation
regard
patient
receive
neoadjuvant
chemotherapy
yet
example
american
society
clinical
oncology
panel
conclude
insufficient
evidence
make
recommendation
suggestion
whether
patient
treat
preoperative
systemic
therapy
give
pmrt
surgery
date
large
series
breast
cancer
patient
year
treat
neoadjuvant
chemotherapy
mastectomy
without
pmrt
result
suggest
young
patient
stage
disease
derive
large
benefit
lrc
addition
pmrt
reduction
lrr
year
without
pmrt
respectively
improvement
year
without
pmrt
respectively
improve
survival
young
patient
stage
iib
disease
result
seen
previous
report
similarly
treat
patient
age
significant
proportion
patient
clinical
stage
iib
either
stage
disease
four
much
positive
lymph
node
surgery
disease
progression
two
factor
independently
prognostic
local
recurrence
mastectomy
despite
result
suggest
young
age
might
powerful
prognostic
factor
gauge
benefit
pmrt
patient
stage
iib
great
disease
relatively
patient
stage
ii
disease
one
three
positive
lymph
node
therefore
benefit
pmrt
young
patient
group
remain
unclear
one
limitation
analysis
retrospective
nature
retrospective
study
inherently
risk
imbalance
patient
tumor
characteristic
two
cohort
pmrt
pmrt
study
difference
several
factor
much
advance
tumor
characteristic
pmrt
group
yet
improve
locoregional
survival
benefit
emphasize
advantage
pmrt
overcome
negative
pathologic
feature
cohort
second
limitation
study
modest
number
patient
stage
iib
disease
result
need
confirm
large
study
although
large
series
patient
year
treat
neoadjuvant
chemotherapy
mastectomy
without
multivariate
analysis
possible
relatively
limited
number
event
conclusion
addition
pmrt
associate
significant
improvement
lrc
young
patient
year
old
neoadjuvant
chemotherapy
mastectomy
clinical
stage
breast
cancer
help
guide
difficult
treatment
decision
much
woman
treat
breast
cancer
undergo
primary
surgery
often
follow
adjuvant
radiotherapy
reduce
breast
cancer
mortality
surgery
mastectomy
disease
woman
however
reveal
past
regimen
lead
increase
risk
death
heart
disease
particularly
year
presumably
unwanted
irradiation
cardiac
structure
dose
response
curve
cardiac
mortality
produce
model
call
relative
model
conjunction
datum
cardiac
mortality
two
randomized
trial
death
ischemic
heart
disease
report
irradiate
patient
breast
cancer
laterality
dose
response
curve
however
based
cardiac
death
therefore
subject
considerable
uncertainty
pierce
estimate
normal
tissue
complication
probability
cardiac
mortality
seven
postmastectomy
technique
however
investigator
caution
additional
clinical
datum
available
validate
predictive
model
normal
tissue
complication
probability
estimate
well
relative
comparison
technique
rather
absolute
risk
assessment
estimation
cardiac
risk
today
breast
require
development
reliable
dose
response
relationship
turn
require
detail
cardiac
dosimetry
past
regimen
give
woman
datum
present
heart
dosimetry
datum
breast
cancer
available
furthermore
unknown
quantitative
measure
heart
dose
volume
much
relevant
subsequent
heart
disease
risk
study
variety
heart
dose
specification
include
absorb
dose
biologically
effective
dose
bed
cumulative
radiation
effect
estimate
biologic
radiation
dose
published
datum
record
percentage
volume
heart
irradiate
various
dose
limited
information
might
however
important
assess
heart
disease
percentage
volume
heart
irradiate
certain
threshold
dose
might
well
predictor
cardiac
death
instance
mean
heart
dose
bed
information
also
need
concern
effect
irradiate
different
cardiac
structure
especially
coronary
artery
coronary
artery
dose
report
several
technique
irradiation
however
much
study
report
mean
dose
whole
heart
study
method
develop
estimate
cardiac
dose
present
dose
estimate
whole
heart
three
main
coronary
artery
technique
commonly
information
heart
disease
rate
randomized
trial
breast
cancer
observational
study
combination
dose
derive
dose
response
relationship
enable
prediction
likely
cardiac
risk
current
future
breast
cancer
regimen
facilitate
development
treatment
guideline
addition
individual
patient
whose
heart
include
radiation
beam
allow
assessment
cardiac
risk
based
plan
thus
identify
woman
complex
planning
technique
might
justify
reduce
cardiac
dose
method
material
general
method
technique
based
virtual
simulation
compute
tomography
ct
treatment
planning
reconstruct
regimen
previous
decade
treat
breast
chest
wall
locoregional
lymph
node
dose
distribution
calculate
treatment
planning
system
tms
version
netherlands
accurate
within
dose
mm
position
much
situation
show
phantom
measurement
approximately
consecutive
ct
planning
scan
female
patient
database
department
review
patient
supine
arm
rest
similar
position
breast
cancer
previous
decade
scan
one
representative
patient
average
weight
height
choose
detail
calculation
ct
datum
transfer
virtual
simulation
software
package
release
gmbh
darmstadt
germany
patient
surface
contour
define
automated
density
gradient
track
heart
coronary
artery
contour
radiation
oncologist
review
radiologist
cranial
limit
heart
include
right
atrium
exclude
pulmonary
trunk
superior
contour
heart
caudal
myocardial
border
scan
contrast
enhance
therefore
image
coronary
artery
visible
location
infer
visible
reliable
landmark
include
anterior
interventricular
leave
atrioventricular
right
atrioventricular
groove
short
length
leave
main
coronary
artery
contour
include
leave
anterior
descend
lad
coronary
artery
field
border
beam
arrangement
machine
parameter
regimen
define
virtual
simulation
emphasis
surface
reconstruction
function
figure
illustrate
virtual
simulation
reconstruct
leave
internal
mammary
chain
imc
field
image
virtual
simulation
photon
leave
direct
internal
mammary
coronal
sagittal
transverse
compute
tomography
image
edges
radiation
field
show
yellow
heart
outline
top
right
beam
eye
view
show
position
field
red
relative
underlie
heart
bony
bottom
middle
surface
reconstruction
image
show
light
field
yellow
view
within
article
treatment
parameter
patient
outline
export
computerized
treatment
planning
system
dose
distribution
calculate
algorithm
photon
beam
beam
model
collapse
algorithm
former
regimen
latter
selection
case
tissue
inhomogeneity
substantial
agreement
algorithm
calculate
heart
dose
within
much
regimen
within
regimen
regimen
cardiac
dose
volume
histograms
generate
estimate
mean
maximum
dose
percentage
volume
irradiate
different
dose
obtain
heart
lad
right
circumflex
coronary
artery
cardiac
dose
distribution
several
regimen
iridium
wire
implant
also
derived
involve
generate
scale
hard
copy
appropriate
ct
slice
isodose
distribution
iridium
wire
implant
superimpose
manual
planning
technique
incorporating
lung
correction
generate
cardiac
dose
distribution
physical
density
lung
take
orthovoltage
treatment
axial
ct
slice
superior
middle
inferior
level
heart
single
direct
field
apply
dose
assume
bolus
two
applicators
assume
proportion
cardiac
structure
include
within
isodose
line
calculate
plot
dose
volume
histograms
typically
based
three
ct
slice
per
plan
heart
approximately
dose
point
per
ct
slice
three
coronary
artery
small
volume
mean
one
dose
point
per
slice
regimen
bed
calculate
linear
quadratic
model
estimate
ratio
heart
disease
gy
calculation
ratio
gy
orthovoltage
correction
factor
account
enhance
biologic
effectiveness
irradiation
brachytherapy
regimen
reconstructed
typical
boost
tumor
bed
surgery
external
beam
likely
position
surgical
scar
mark
virtual
simulation
isodose
standard
iridium
implant
superimpose
scale
hard
copy
three
sagittal
ct
section
one
expect
center
implant
one
cm
medial
one
cm
lateral
point
iridium
wire
cm
long
position
cm
apart
cm
beneath
skin
specific
technique
reconstructed
detail
trial
early
breast
cancer
collate
trial
publication
protocol
discussion
radiotherapist
work
various
country
onwards
information
technique
commonly
treat
chest
wall
breast
associate
lymphatic
reconstructed
description
target
volume
clinical
definition
field
border
field
arrangement
beam
energy
give
table
illustrate
distance
cm
field
wedge
compensator
tangential
pair
beam
oppose
table
radiotherapy
technique
reconstructed
cardiac
dose
estimation
targetfield
field
chest
wall
breast
tangential
pair
superiorsternal
equivalent
bolus
applicators
kv
cm
inframammary
medialmidline
match
internal
mammary
chain
kv
lateralmidaxillary
line
chest
wall
direct
anterior
border
supraclavicular
fossa
electron
inferiorxyphoid
sternal
junction
medialmidline
lateralmidaxillary
line
chest
wall
internal
mammary
node
tangential
pair
superiorsternal
tangential
beam
angle
downward
cm
inframammary
cm
contralateral
side
midline
lateralmidaxillary
line
chest
wall
internal
mammary
node
field
tangential
pair
superiorsternal
equivalent
bolus
applicators
cm
inframammary
fold
border
contralateral
side
lateralmidaxillary
line
internal
node
direct
anterior
superiorsternal
size
cm
inferiorxyphoid
sternal
kv
cm
medial
border
internal
mammary
node
similar
direct
anterior
superiorsternal
size
cm
inferiorxyphoid
sternal
junction
cm
contralateral
midline
cm
medial
border
mastectomy
scar
boostdirect
anterior
cm
strip
cover
approximate
position
mastectomy
field
approximate
electron
kv
brachytherapy
two
plane
iridium
supraclavicular
fossa
direct
anterior
mv
second
costal
size
cm
beam
laterally
cm
contralateral
side
midline
joint
posterior
axilla
direct
posterior
shape
medial
border
border
supraclavicular
fossa
lateral
wall
bony
thorax
head
table
regimen
illustrate
view
within
article
image
radiotherapy
technique
reconstructed
cardiac
dose
estimation
see
table
additional
detail
include
definition
field
border
imc
internal
mammary
chain
view
within
article
variation
patient
anatomy
two
technique
reconstructed
consecutive
contemporary
breast
cancer
patient
ct
planning
database
patient
angle
breast
board
unlike
representative
patient
position
flat
difference
mean
small
systematic
difference
dose
patient
representative
patient
interpatient
variability
however
comparable
direct
anterior
leave
right
imc
field
leave
tangential
irradiation
reconstructed
consecutive
patient
right
tangential
irradiation
reconstructed
consecutive
patient
little
interpatient
variation
heart
dose
expect
regimen
result
dose
estimate
representative
patient
mean
dose
coronary
artery
maximum
dose
mean
dose
mean
bed
heart
representative
patient
summarize
table
appendix
table
online
give
additional
detail
include
percentage
volume
structure
irradiate
various
dose
mean
bed
maximum
dose
table
heart
coronary
artery
dose
breast
radiotherapy
regimen
mean
dose
gy
maximum
dose
gy
mean
bed
mean
dose
gy
mean
dose
gy
mean
dose
gy
targetfield
dose
chest
wall
breast
tangential
gy
gy
gy
chest
wall
breast
medial
border
match
internal
mammary
field
tangential
gy
gy
gy
chest
wall
direct
gy
chest
wall
internal
mammary
node
tangential
gy
gy
gy
internal
mammary
node
direct
gy
gy
gy
gy
mastectomy
scar
boostdirect
gy
gy
gy
supraclavicular
fossa
direct
gy
gy
posterior
axilla
direct
gy
gy
table
abbreviation
lad
leave
anterior
descend
coronary
artery
right
coronary
artery
cca
circumflex
coronary
artery
bed
biologically
effective
dose
bed
calculate
ratio
arm
elevate
rest
regimen
illustrate
dose
regimen
give
near
gray
uncertainty
involve
manual
planning
dose
give
decimal
place
view
within
article
heart
dose
chest
wall
breast
irradiation
breast
chest
wall
mean
heart
dose
vary
gy
gy
large
dose
result
orthovoltage
irradiation
example
standard
leave
tangential
mean
heart
dose
gy
megavoltage
gy
orthovoltage
irradiation
partly
explain
lateral
scatter
partly
depth
dose
characteristic
orthovoltage
beam
deliver
gy
point
central
axis
give
dose
approximately
gy
multiply
need
tangential
beam
result
dose
distribution
within
breast
chest
wall
within
normal
tissue
nearby
hot
spot
tumor
dose
gy
within
heart
tangential
beam
match
direct
imc
field
medial
tangential
border
cm
midline
heart
therefore
several
centimeters
posterior
field
edge
receive
radiation
dose
tangential
beam
mean
heart
dose
gy
gy
irradiation
wide
tangential
medial
border
cm
contralateral
midline
hence
relatively
large
heart
volume
irradiate
gy
receive
heart
irradiation
respectively
appendix
table
mean
heart
dose
gy
gy
irradiation
respectively
irradiation
leave
breast
chest
wall
part
heart
receive
great
dose
anterior
surface
leave
ventricle
maximum
heart
dose
gy
leave
tangential
irradiation
gy
leave
electron
irradiation
image
axial
compute
tomography
section
show
dose
distribution
leave
tangential
pair
radiotherapy
isodose
line
correspond
percentage
give
dose
three
main
coronary
artery
outline
cm
margin
add
view
within
article
heart
dose
imc
irradiation
imc
locate
anteriorly
space
close
heart
therefore
imc
generally
lead
great
mean
heart
dose
irradiation
target
particularly
treatment
imc
either
direct
anterior
wide
tangential
field
deliver
mean
heart
dose
gy
gy
great
dose
result
leave
direct
anterior
irradiation
heart
volume
irradiate
also
considerable
particularly
direct
anterior
photon
field
deliver
gy
around
around
heart
field
respectively
contrast
direct
electron
imc
irradiation
result
mean
heart
dose
around
gy
heart
volume
around
receive
gy
owing
rapid
decrease
dose
beyond
isodose
image
axial
compute
tomography
section
show
dose
distribution
right
leave
direct
anterior
internal
mammary
field
isodose
line
correspond
percentage
give
dose
three
main
coronary
artery
outline
cm
margin
add
view
within
article
direct
anterior
megavoltage
imc
result
irradiation
different
part
heart
treatment
field
dose
gy
receive
right
atrium
field
similar
dose
receive
leave
ventricle
direct
anterior
imc
match
tangential
irradiation
together
much
total
heart
dose
originate
imc
field
example
gy
deliver
chest
wall
imc
beam
imc
field
contribute
gy
chest
wall
field
gy
heart
dose
give
total
mean
heart
dose
gy
heart
dose
scar
boost
irradiation
mean
heart
dose
boost
irradiation
surgical
scar
gy
photon
beam
deliver
gy
mean
heart
dose
whereas
leave
electron
beam
deliver
gy
rapid
decrease
depth
dose
iridium
wire
implant
previous
decade
deliver
boost
dose
gy
scar
localized
deposition
dose
implant
mean
percent
tumor
dose
gy
receive
heart
irradiation
heart
dose
boost
small
relative
dose
chest
wall
breast
give
dose
example
patient
receive
gy
mv
tangential
leave
chest
wall
follow
gy
electron
scar
boost
receive
total
mean
heart
dose
gy
gy
chest
wall
gy
boost
irradiation
important
determinant
heart
dose
boost
scar
position
relative
heart
likely
vary
patient
patient
dose
present
illustrate
relative
magnitude
cardiac
dose
different
boost
technique
useful
comparison
technique
however
dose
vary
substantially
individual
patient
depending
boost
position
magnitude
uncertainty
assess
section
variability
boost
position
heart
dose
supraclavicular
fossa
axillary
irradiation
supraclavicular
fossa
scf
axillary
field
distant
heart
receive
scatter
radiation
alone
mean
dose
gy
field
scf
axillary
field
even
far
heart
therefore
cardiac
dose
likely
coronary
artery
dose
radiation
dose
receive
cardiac
structure
mainly
determine
location
relative
treatment
field
lad
coronary
artery
anterior
aspect
heart
near
leave
breast
leave
imc
technique
treat
target
lad
dose
exceed
heart
dose
example
leave
mv
tangential
irradiation
deliver
mean
heart
dose
gy
compare
mean
lad
dose
gy
part
lad
receive
gy
appendix
table
lad
penumbra
leave
direct
photon
imc
field
receive
mean
dose
gy
contrast
field
receive
mean
dose
gy
scatter
radiation
right
coronary
artery
locate
anteriorly
right
midline
much
technique
exclude
radiation
field
direct
anterior
imc
irradiation
include
imc
field
leave
mean
dose
gy
gy
irradiation
circumflex
coronary
artery
locate
posterior
myocardium
generally
receive
dose
either
lad
right
coronary
artery
mean
circumflex
dose
tangential
gy
dose
gy
deliver
direct
electron
chest
wall
scar
boost
irradiation
combination
different
regimen
woman
treat
much
one
regimen
direct
imc
match
tangential
breast
field
tangential
breast
plus
boost
mean
dose
regimen
add
calculate
total
mean
dose
cardiac
structure
full
dosimetric
information
include
percentage
volume
structure
irradiate
different
dose
bed
combination
different
regimen
describe
method
reconstruct
different
regimen
dose
plan
variability
heart
dose
dose
table
appendix
table
estimate
representative
patient
average
weight
build
dose
receive
individual
patient
will
vary
depending
individual
characteristic
include
breast
size
extent
breast
surgery
sternal
length
circumstance
linear
accelerator
source
variability
much
case
apply
method
estimate
cardiac
dose
retrospectively
magnitude
likely
effect
cardiac
dose
describe
variation
patient
anatomy
tangential
pair
direct
imc
irradiation
reconstructed
consecutive
patient
ct
planning
database
mean
heart
dose
vary
gy
coefficient
variation
mean
divide
standard
deviation
cv
gy
cv
tangential
pair
gy
cv
gy
cv
imc
thus
regimen
interpatient
variability
heart
dose
also
substantial
variation
different
regimen
image
variability
mean
heart
dose
receive
patient
take
compute
tomography
database
radiotherapy
center
united
kingdom
left
right
internal
mammary
chain
imc
leave
tangential
irradiation
reconstructed
consecutive
patient
right
tangential
irradiation
reconstructed
consecutive
patient
heart
dose
patient
represent
black
dot
view
within
article
presence
breast
tissue
dose
table
appendix
table
patient
breast
tissue
present
irradiation
direct
electron
field
usually
perform
mastectomy
tangential
pair
external
beam
scar
boost
irradiation
either
mastectomy
surgery
technique
reconstructed
representative
patient
breast
tissue
irradiate
side
include
exclude
dose
calculation
decrease
mean
heart
dose
presence
breast
tissue
gy
photon
technique
tangential
pair
scar
boost
irradiation
electron
field
presence
breast
tissue
decrease
mean
heart
dose
gy
leave
right
electron
chest
wall
field
respectively
gy
leave
right
electron
scar
boost
irradiation
respectively
variation
patient
position
cardiac
dose
affect
patient
treatment
position
factor
likely
affect
cardiac
dose
change
either
thoracic
therefore
cardiac
position
relative
radiation
beam
thorax
angle
flat
bed
influence
field
border
representative
patient
thoracic
position
similar
previous
decade
imc
breast
chest
wall
scf
axillary
irradiation
previous
patient
treat
prone
different
position
unlikely
affect
heart
dose
axillary
usually
deliver
scatter
cardiac
irradiation
alone
tangential
irradiation
ipsilateral
arm
position
affect
field
border
right
breast
chest
wall
mostly
involve
scatter
cardiac
dose
leave
tangential
irradiation
effect
change
arm
position
study
contour
system
united
kingdom
left
tangential
reconstructed
volunteer
first
arm
head
support
arm
rest
second
ipsilateral
arm
abduct
contralateral
arm
side
heart
dose
gy
arm
position
gy
arm
position
difficulty
identify
field
border
virtual
simulator
precise
identification
landmark
sternal
notch
sternal
junction
subject
uncertainty
effect
mean
heart
dose
quantify
reconstruct
tangential
pair
direct
imc
field
standard
position
second
move
cm
superiorly
third
move
cm
inferiorly
table
show
difference
mean
heart
dose
result
movement
usually
always
table
mean
heart
dose
breast
radiotherapy
regimen
effect
variability
field
position
heart
dose
mean
heart
dose
gy
field
standard
positionfield
move
superiorly
cmfield
move
inferiorly
cm
targetfield
chest
wall
chest
wall
internal
mammary
internal
mammary
table
variability
likely
minimal
dose
mainly
scatter
radiation
view
within
article
variability
boost
position
iridium
wire
boost
reconstructed
first
centered
nipple
second
move
cm
superiorly
third
cm
inferiorly
table
show
result
difference
mean
heart
dose
reality
position
scar
therefore
boost
well
vary
much
cm
therefore
heart
dose
measurement
subject
high
degree
uncertainty
general
far
inferior
boost
great
heart
dose
however
heart
dose
boost
irradiation
always
relative
technique
give
dose
gy
table
mean
heart
dose
scar
boost
radiotherapy
effect
variability
boost
position
heart
dose
mean
heart
dose
gy
dose
implant
standard
positionfield
implant
move
superiorly
cmfield
implant
move
inferiorly
cm
brachytherapy
wire
direct
anterior
gy
table
view
within
article
different
model
treatment
unit
axillary
scf
irradiation
two
different
make
linear
accelerator
energy
mv
field
choose
usually
distant
heart
therefore
heart
dose
largely
scatter
irradiation
originate
machine
treatment
head
vary
accord
machine
mean
heart
dose
vary
gy
supraclavicular
gy
axillary
field
thus
different
machine
make
little
difference
heart
dose
enable
comparison
different
regimen
beam
energy
datum
one
machine
effect
change
distance
beam
direct
imc
tangential
pair
field
set
distance
cm
difference
distance
result
difference
mean
heart
dose
gy
imc
gy
tangential
pair
irradiation
discussion
present
dose
estimate
breast
cancer
regimen
widespread
worldwide
considerable
variation
cardiac
dose
accord
regimen
example
direct
imc
deliver
heart
dose
lad
dose
whereas
electron
imc
irradiation
deliver
heart
dose
lad
dose
still
deliver
therapeutic
tumor
dose
difference
likely
result
wide
variation
cardiac
dose
worldwide
past
decade
owing
diversity
practice
will
useful
dose
response
relationship
estimate
include
coronary
artery
heart
dose
wide
variety
different
regimen
consistent
publish
estimate
technique
available
comparison
wide
standard
leave
tangential
irradiation
direct
imc
irradiation
estimate
irradiate
heart
volume
usually
consistent
estimate
within
volume
never
much
table
comparison
measure
publish
cardiac
dose
estimate
field
dose
estimate
volume
present
estimate
volume
wide
tangential
pair
breast
internal
mammary
volume
heart
receive
tangential
volume
heart
receive
gagliardi
direct
internal
mammary
chain
volume
heart
receive
direct
internal
mammary
chain
volume
heart
receive
table
calculate
point
cardiac
dose
rather
mean
dose
present
study
therefore
result
comparable
omit
comparison
also
report
heart
coronary
artery
dose
seven
postmastectomy
regimen
mostly
around
year
differ
regimen
reconstructed
study
largely
historical
reported
dose
estimate
publish
dose
volume
histograms
convert
dose
equivalent
fraction
thus
great
degree
uncertainty
present
view
within
article
source
variability
give
regimen
reconstruction
regimen
inevitably
subject
several
source
variability
study
characterize
principal
source
dose
variability
virtual
simulation
ct
planning
breast
cancer
major
source
error
estimate
cardiac
dose
give
individual
likely
variation
patient
anatomy
individual
dose
plan
information
anatomy
patient
outline
rarely
available
therefore
estimate
cardiac
dose
group
patient
treat
early
trial
breast
cancer
dose
estimate
representative
patient
average
weight
build
might
give
good
indication
cardiac
dose
receive
particular
regimen
uncertainty
exist
locate
three
main
coronary
artery
arterial
contrast
ct
planning
however
artery
visible
ct
slice
course
tend
follow
interventricular
atrioventricular
groove
identifiable
ct
addition
accuracy
estimate
limited
normal
movement
heart
lung
thoracic
cage
movement
will
tend
slightly
change
position
heart
relative
radiation
beam
however
ct
planning
scan
reconstruction
acquire
several
minute
include
many
breathing
cycle
original
also
deliver
several
minute
therefore
ct
image
likely
illustrate
change
position
heart
relative
treatment
field
original
thus
average
variation
dose
change
regimen
heart
dose
affect
patient
position
treatment
position
tangential
irradiation
vary
region
ipsilateral
arm
elevate
rest
abduct
leave
tangential
lower
ipsilateral
arm
position
change
mean
heart
dose
gy
volunteer
represent
increase
similar
systematic
change
heart
dose
report
patient
representative
patient
position
leave
tangential
irradiation
deliver
gy
mean
heart
dose
undergo
irradiation
arm
position
heart
dose
might
around
gy
assume
dose
increase
change
arm
position
speculate
mean
lad
dose
great
close
radiation
beam
right
circumflex
coronary
artery
distant
tangential
beam
dose
probably
little
affect
arm
position
dose
estimate
leave
tangential
irradiation
applicable
patient
treat
position
likely
systematically
underestimate
heart
lad
dose
patient
irradiate
ipsilateral
arm
irradiation
lad
coronary
artery
much
breast
cancer
regimen
anterior
part
heart
include
lad
coronary
artery
receive
great
radiation
dose
lad
dose
generally
great
dose
whole
heart
two
coronary
artery
distribution
atherosclerosis
general
population
lad
right
coronary
artery
circumflex
coronary
artery
therefore
great
radiation
dose
receive
coronary
artery
appear
much
prone
atherosclerosis
blockage
lad
atherosclerosis
lead
leave
ventricular
infarction
hence
damage
artery
might
contribute
excess
cardiac
mortality
see
past
breast
cancer
regimen
coronary
arterial
damage
assess
directly
myocardial
perfusion
imaging
assess
myocardial
ischemia
several
study
show
excess
anterior
cardiac
perfusion
defect
area
expect
high
dose
month
year
leave
breast
cancer
one
study
reveal
increase
myocardial
perfusion
defect
region
supply
lad
month
leave
tangential
pair
region
supply
coronary
artery
unclear
whether
damage
lead
clinical
consequence
excess
death
heart
disease
see
need
dose
response
relationship
reliably
assess
cardiac
risk
current
future
regimen
relationship
cardiac
dose
subsequent
cardiac
morbidity
mortality
need
study
successfully
quantify
cardiac
dose
volume
irradiate
much
common
breast
cancer
regimen
demonstrate
wide
range
cardiac
dose
estimate
derived
enable
development
cardiac
dose
response
relationship
datum
early
breast
cancer
trialists
collaborative
group
trial
datum
woman
information
technique
tumor
laterality
outcome
available
acknowledgment
work
arise
involvement
early
breast
cancer
trialists
collaborative
group
thank
early
breast
cancer
trialists
collaborative
group
secretariat
many
collaborator
comment
also
gratefully
acknowledge
professor
david
moore
professor
john
gagliardi
sir
richard
peto
help
work
negative
psychological
state
frequently
associate
diagnosis
treatment
breast
cancer
change
immune
system
may
important
breast
cancer
patient
data
many
study
suggest
chronic
psychological
stress
adversely
affect
immune
function
result
interpret
caution
causality
determine
study
undertake
evaluate
psychological
endocrine
immunological
effect
relaxation
visualization
therapy
rvt
breast
cancer
patient
undergo
radiotherapy
possibility
enhancement
immune
function
psychological
intervention
generate
considerable
interest
significant
evidence
stress
management
intervention
may
positive
psychological
effect
variety
psychosocial
intervention
cancer
education
behavioral
technique
individual
group
therapy
show
reduce
anxiety
depression
enhance
active
coping
style
fact
study
show
decrease
depression
anxiety
regardless
cancer
type
psychological
therapy
cancer
patient
usually
seek
alternative
supportive
therapy
able
help
clinical
treatment
may
strengthen
coping
skill
disease
well
make
participant
treatment
rationale
theory
patient
truly
commit
treatment
improve
quality
life
increase
survival
even
induce
remission
disease
stress
lead
activation
hpa
axis
increase
peripheral
cortisol
know
immunosuppressive
effect
cortisol
may
also
result
depressed
addition
previous
work
show
breast
cancer
associate
increase
cortisol
level
prior
follow
treatment
however
cortisol
level
find
among
recently
diagnose
breast
cancer
patient
history
depression
stress
disorder
ptsd
show
breast
cancer
associate
flatter
circadian
pattern
hpa
axis
function
flatter
daytime
slope
cortisol
associate
fatigue
breast
cancer
patient
predictive
early
mortality
metastatic
breast
cancer
independent
know
prognostic
factor
addition
depression
associate
blunt
stress
reactivity
metastatic
breast
cancer
recent
work
suggest
flatter
daytime
cortisol
slope
among
metastatic
breast
cancer
patient
may
relate
disrupt
feedback
inhibition
hpa
axis
rather
hypersensitivity
response
stimulation
psychological
intervention
aim
reduce
psychological
stress
cortisol
level
lead
improve
immune
function
health
date
study
address
relationship
breast
cancer
randomized
control
relaxation
intervention
patient
advance
breast
cancer
associate
reduce
cortisol
level
patient
increase
cortisol
level
beginning
intervention
increased
lymphocyte
count
reduce
evening
cortisol
level
observe
breast
cancer
patient
follow
week
rvt
recently
randomized
clinical
trial
assess
psychological
behavioral
immune
change
stress
management
intervention
large
sample
breast
cancer
patient
intervention
effective
reduce
anxiety
score
improve
perceive
social
support
dietary
habit
well
maintain
stable
increase
proliferation
measurement
peripheral
hormone
may
sufficient
finally
determine
functional
hormonal
action
target
tissue
glucocorticoid
gc
immunomodulation
orchestrate
specific
binding
gc
intracellular
steroid
receptor
mr
gc
receptor
gr
although
mr
high
affinity
circulate
gc
gr
much
effect
immune
system
mediate
via
gr
presence
receptor
indicate
immune
system
prepare
hpa
axis
activation
subsequent
elevation
endogenous
gc
suggest
elevate
cortisol
level
may
produce
state
acquire
steroid
resistance
enable
lymphocyte
respond
little
intensity
gc
phenomenon
previously
observe
major
depression
chronic
stress
hypothesized
psychological
distress
experience
breast
cancer
patient
associate
reduce
lymphocyte
sensitivity
gc
date
largely
unknown
whether
stress
management
intervention
able
restore
impair
cellular
response
investigate
rvt
capable
attenuate
psychological
distress
stress
anxiety
depression
salivary
cortisol
level
increase
nonspecific
lymphocyte
proliferative
response
finally
investigate
lymphocyte
sensitivity
gc
vitro
explore
functional
hormonal
action
immune
system
method
study
design
study
undertake
design
two
time
point
psychological
endocrine
immunological
datum
obtain
baseline
day
intervention
intervention
include
group
consist
four
patient
salivary
sample
collect
three
time
day
assess
cortisol
level
peripheral
blood
immunological
test
draw
time
day
subjects
total
subject
breast
cancer
stage
ii
undergo
radiotherapy
recruit
radiotherapy
service
luca
hospital
porto
alegre
brazil
randomly
assign
two
group
patient
experimental
group
ii
patient
control
group
radiotherapy
session
never
exceed
min
radiation
exposure
average
min
control
group
participate
rvt
intervention
type
additional
intervention
subject
complete
two
assessment
least
week
chemotherapy
washout
demographic
information
include
age
ethnicity
religion
education
marital
status
occupation
status
obtain
form
create
study
study
protocol
approve
scientific
ethic
committee
porto
alegre
brazil
write
inform
consent
obtain
subject
exclusion
criterion
include
presence
acute
chronic
infection
heart
disease
anorexia
anemia
clinical
depression
ptsd
disease
gc
psychological
profile
psychosocial
variable
assess
mean
structure
clinical
interview
perform
train
investigator
stress
level
assess
inventory
stress
adult
issl
issl
identify
presence
stress
symptom
type
symptom
somatic
psychological
stress
phase
include
alarm
adaptation
exhaustion
exhaustion
include
item
somatic
symptom
item
psychological
symptom
instrument
based
model
stress
symptom
list
scale
specific
phase
stress
score
perform
mean
three
different
stage
relate
duration
week
month
intensity
stress
symptom
sum
physical
well
psychological
symptom
within
stage
result
score
relate
presence
stress
accordingly
follow
criterion
alarm
phase
adaptation
phase
exhaustion
phase
duration
administration
min
state
trait
anxiety
inventory
stai
beck
anxiety
inventory
bai
employ
generic
measure
anxiety
stai
item
assessment
device
include
separate
measure
state
trait
anxiety
duration
administration
min
scores
stai
direct
interpretation
high
score
respective
scale
mean
much
trait
state
anxiety
score
mean
little
find
sensitive
indicator
change
anxiety
experience
patient
counseling
behavior
modification
program
beck
anxiety
inventory
bai
discriminate
anxiety
depression
display
validity
scale
consist
item
describe
common
symptom
anxiety
include
inability
relax
headache
item
consist
four
statement
represent
vary
degree
severity
duration
administration
min
respondent
ask
rate
much
bother
symptom
past
week
point
scale
range
item
summed
obtain
total
score
range
high
score
indicate
high
level
anxious
symptom
anxiety
anxiety
scale
obtain
high
internal
consistency
item
total
correlation
range
beck
depression
inventory
bdi
employ
scale
assess
depression
level
bdi
consist
item
assess
intensity
depression
clinical
normal
patient
item
list
four
statement
arrange
increase
severity
particular
symptom
depression
item
summed
obtain
total
score
range
high
score
indicate
high
level
symptom
depression
depression
duration
administration
min
richardson
reliability
coefficient
scale
always
high
rvt
intervention
detail
rvt
intervention
include
objective
structure
component
content
describe
previously
rvt
intervention
consist
daily
min
structure
group
session
breast
cancer
unit
luca
hospital
porto
alegre
brazil
subject
always
lead
train
investigator
psychologist
time
session
undergo
immediately
follow
radiotherapy
different
room
hospital
rvt
include
relaxation
period
min
subject
induce
create
image
desire
objective
result
include
progressive
muscle
relaxation
guide
meditation
deep
breathing
subjects
guide
create
mental
image
tumor
attack
immune
system
visualize
breast
completely
heal
subjects
perform
rvt
twice
day
home
tape
subject
remind
phone
call
perform
rvt
session
home
collection
salivary
sample
cortisol
measurement
assessment
steroid
saliva
prove
valid
reliable
reflection
unbound
hormone
blood
salivary
cortisol
concentration
reflect
level
present
serum
participants
ask
collect
three
saliva
sample
help
cotton
roll
course
experimental
day
always
meal
venepuncture
sampling
perform
across
day
assess
aspect
circadian
pattern
upon
arrival
laboratory
sample
centrifuged
freeze
salivary
cortisol
sample
analyzed
ria
dpc
brazil
sensitivity
assay
estimate
nm
coefficient
variation
little
result
sampling
time
express
nmol
collection
peripheral
blood
isolation
mononuclear
cell
ten
milliliter
peripheral
blood
collect
venepuncture
morning
sample
store
tube
analysis
sample
always
collect
time
day
minimize
circadian
variation
peripheral
blood
mononuclear
cell
pbmc
isolate
centrifugation
sigma
louis
usa
gradient
min
cell
count
mean
microscopy
viability
always
exceed
judge
ability
exclude
trypan
blue
sigma
cell
culture
steroid
sensitivity
assay
peripheral
sensitivity
hormone
estimate
functional
assay
develop
measure
ability
steroid
suppress
proliferation
vitro
proliferation
evaluate
incubate
pbmc
cell
well
pha
gibco
grand
island
usa
complete
culture
medium
supplement
gentamicin
glutamine
hepes
fetal
calf
serum
sigma
louis
usa
atmosphere
dexamethasone
dex
selective
gc
receptor
agonist
corticosterone
cort
bind
type
steroid
receptor
add
duplicate
well
substance
purchase
sigma
lymphocyte
culture
gc
concentration
range
free
gc
reach
rest
state
stress
pharmacological
treatment
vivo
one
optimum
pha
concentration
steroid
culture
fifty
culture
medium
add
stimulate
culture
spontaneous
without
lectin
culture
mitogen
replace
culture
medium
data
present
percentage
basal
proliferation
pha
without
steroid
cell
proliferation
viability
assay
proliferative
response
determine
modify
colorimetric
assay
last
culture
supernatant
gently
discard
freshly
prepare
mtt
sigma
louis
usa
solution
mg
ml
add
well
dehydrogenase
enzyme
metabolically
active
cell
convert
substrate
formazan
produce
dark
blue
precipitate
cell
culture
incubate
atmosphere
complete
removal
supernatant
dimethyl
sulfoxide
sigma
louis
usa
add
well
optical
density
od
determine
biorad
hercules
usa
elisa
plate
reader
wavelength
nm
proliferation
viability
express
od
culture
statistical
analysis
variable
test
normality
distribution
mean
kolmogorov
smirnov
test
demographic
medical
history
health
behavior
variable
describe
pre
intervention
complete
sample
frequency
descriptive
statistic
difference
proportion
group
test
mean
test
test
compare
pre
post
intervention
psychological
score
also
compute
effect
size
pre
post
intervention
change
observe
outcome
measure
proliferation
cortisol
datum
analyzed
analysis
variance
anova
include
one
variable
control
versus
experimental
one
variable
cortisol
mitogen
steroid
level
area
curve
auc
cortisol
datum
vitro
gc
response
dex
cort
estimate
rule
relationship
variable
investigate
pearson
partial
correlation
control
anxiety
level
baseline
residualized
change
score
calculate
associate
psychological
physiological
outcome
time
significance
level
set
data
analyzed
statistical
package
social
science
spss
chicago
usa
result
subjects
total
subject
breast
cancer
meeting
criterion
recruit
twenty
patient
complete
day
rvt
subject
control
sample
characteristic
show
table
experimental
control
homogeneous
show
similar
sociodemographic
profile
addition
experimental
control
group
similar
health
behavior
subject
drink
coffee
daily
basis
three
regular
smoker
experimental
group
one
patient
experimental
group
ameliorate
follow
third
rvt
session
none
engage
regular
physical
activity
patient
tamoxifen
affect
immune
system
however
datum
change
control
tamoxifen
none
take
contraceptive
drug
hormone
replacement
therapy
table
sociodemographic
characteristic
subject
breast
cancer
undergo
radiotherapy
enrolled
radiotherapy
service
luca
hospital
brazil
distribute
experimental
control
group
control
experimental
value
age
range
year
year
year
education
marital
married
separated
employment
full
table
difference
proportion
group
ethnicity
marital
status
religion
employment
status
test
mean
test
difference
regard
age
year
education
assess
mean
independent
test
view
within
article
psychological
assessment
experimental
control
group
show
similar
stress
depression
score
preintervention
period
baseline
however
patient
experimental
group
much
anxious
subject
control
group
baseline
bai
follow
analysis
thus
control
basal
anxiety
level
psychological
score
change
time
control
group
however
experimental
group
show
significantly
reduce
level
stress
anxiety
depression
score
follow
day
rvt
datum
indicate
efficacy
rvt
program
study
attenuate
emotional
distress
present
radiotherapy
treatment
table
psychological
assessment
baseline
follow
day
rvt
obtain
patient
breast
cancer
undergo
radiotherapy
size
issl
issl
issl
stai
state
stai
trait
table
data
present
preintervention
experimental
preintervention
experimental
preintervention
experimental
preintervention
control
pair
test
view
within
article
cortisol
assessment
study
able
assess
hpa
axis
function
mean
measure
salivary
cortisol
level
across
day
salivary
cortisol
level
differ
significantly
three
sampling
time
cortisol
peak
morning
present
regular
circadian
pattern
group
cortisol
level
differ
experimental
control
group
baseline
also
show
similar
integrate
cortisol
level
auc
cortisol
control
nmol
per
hour
experimental
nmol
per
hour
group
interaction
cortisol
level
group
baseline
indicate
morning
cortisol
level
high
control
compare
experimental
group
although
approach
statistical
significance
cortisol
level
change
time
control
group
rvt
effective
change
cortisol
level
experimental
group
image
pre
post
rvt
intervention
salivary
cortisol
level
obtain
ria
across
day
control
experimental
group
patient
breast
cancer
data
present
rvt
change
cortisol
level
view
within
article
lymphocyte
proliferation
sensitivity
gc
proliferation
evaluate
index
nonspecific
immunity
proliferative
response
differ
significantly
across
three
mitogen
concentration
anova
reveal
experimental
control
group
show
similar
proliferation
baseline
proliferative
response
change
time
control
group
follow
rvt
experimental
group
significant
interaction
group
x
phase
baseline
post
intervention
image
proliferation
response
obtain
pre
post
rvt
control
experimental
group
patient
breast
cancer
pbmc
isolate
cultured
vitro
pha
proliferation
viability
estimate
colorimetric
assay
data
present
mean
response
differ
across
pha
concentration
rvt
produce
significant
change
proliferation
response
view
within
article
also
investigate
functional
gc
immunomodulatory
action
incubate
peripheral
lymphocyte
steroid
dex
cort
produce
significant
suppression
proliferation
baseline
lymphocyte
experimental
group
much
sensitive
cort
dex
although
approach
statistical
significance
latter
change
cellular
sensitivity
dex
cort
time
control
group
rvt
produce
change
sensitivity
dex
cort
interaction
group
x
phase
steroid
image
peripheral
sensitivity
gc
assess
pre
post
rvt
control
experimental
group
patient
breast
cancer
cellular
sensitivity
estimate
ability
gc
suppress
proliferation
glucocorticoid
include
agonist
dexamethasone
gr
natural
steroid
corticosterone
bind
gr
mineralocorticoid
receptor
data
present
percentage
basal
proliferation
without
steroid
dex
cort
produce
significant
suppression
proliferation
rvt
produce
significant
change
cellular
sensitivity
dexamethasone
corticosterone
view
within
article
relationship
psychological
endocrine
immune
variable
first
evaluate
potential
impact
psychological
status
cortisol
immune
measure
significant
correlation
note
baseline
residualized
change
score
calculate
associate
psychological
physiological
outcome
time
pearson
partial
correlation
compute
examine
strength
direction
relationship
cortisol
index
psychological
variable
data
control
basal
anxiety
level
observe
change
score
negatively
correlated
change
cortisol
level
investigate
relationship
cortisol
level
immune
measure
significant
relationship
observe
baseline
particular
morning
cortisol
level
negatively
correlated
proliferation
pha
pha
pha
although
latter
approach
statistical
significance
addition
cortisol
level
inversely
correlated
sensitivity
gc
particular
morning
cortisol
level
correlated
auc
dex
auc
cort
cortisol
level
correlated
auc
cort
auc
dex
although
latter
approach
statistical
significance
therefore
increase
cortisol
level
baseline
associate
reduce
cellular
sensitivity
gc
discussion
breast
cancer
conventional
therapeutic
frequently
associate
psychological
distress
poor
quality
life
investigate
psychological
endocrine
immunological
effect
day
stress
management
intervention
rvt
patient
breast
cancer
undergo
radiotherapy
knowledge
first
report
intervention
attempt
brief
window
radiotherapy
intervention
effective
reduce
psychological
distress
change
cortisol
level
lymphocyte
proliferation
sensitivity
gc
datum
agreement
previous
work
show
attenuation
psychological
distress
patient
cancer
positive
finding
pivotal
importance
consider
depressed
cancer
patient
poor
prognosis
reduce
survival
rate
proactive
attitude
elicit
stress
management
intervention
may
important
step
towards
much
integrative
approach
treat
cancer
patient
negative
burden
stress
anxiety
depression
worsen
quality
life
show
significant
response
rvt
associate
improve
quality
life
breast
cancer
patient
although
previous
work
demonstrate
rvt
capable
ameliorate
psychological
distress
largely
unknown
extent
alteration
translated
physiological
change
evaluate
salivary
cortisol
physiological
marker
hpa
axis
assessment
cortisol
saliva
prove
procedure
reliable
measure
unbound
steroid
circulation
little
affect
alteration
protein
binding
investigation
disorder
however
observe
cortisol
level
remain
unchanged
following
rvt
contrast
previous
study
report
decrease
cortisol
level
follow
stress
management
intervention
breast
cancer
previous
work
evaluate
daytime
salivary
cortisol
breast
prostate
cancer
patient
week
intervention
meditation
method
study
intervention
also
able
attenuate
stress
score
without
change
salivary
cortisol
level
however
observe
intervention
effective
reduce
cortisol
level
patient
high
cortisol
level
baseline
also
similarly
observe
two
intervention
analyzed
serum
cortisol
breast
cancer
study
salivary
cortisol
level
baseline
influence
endocrine
assessment
follow
rvt
datum
show
work
necessary
disentangle
conflict
observation
several
author
demonstrate
relationship
psychological
stress
weaken
immune
system
conversely
show
stress
management
intervention
capable
attenuate
change
impact
stress
immunological
parameter
breast
cancer
immunological
parameter
include
peripheral
cell
count
cytokine
functional
assay
natural
killer
cell
activity
lymphocyte
proliferation
note
much
study
describe
immunological
change
rather
increase
specific
immunological
variable
date
largely
unknown
extent
immunological
change
relate
clinical
benefit
immunological
effect
stress
relaxation
may
part
explain
reduce
release
stress
hormone
catecholamines
gc
increase
peripheral
neuropeptide
opioid
contrast
previous
work
demonstrate
rvt
ineffective
change
proliferation
measurement
peripheral
hormone
may
sufficient
determine
functional
hormonal
action
target
tissue
therefore
investigate
first
time
rvt
effect
peripheral
lymphocyte
sensitivity
gc
vitro
line
unchanged
cortisol
level
sensitivity
gc
also
vary
follow
rvt
taking
together
datum
suggest
rvt
cohort
breast
cancer
patient
unable
translate
psychological
biological
change
might
positive
psychological
change
result
enhance
physiological
parameter
explain
several
methodological
clinical
difference
previous
study
include
type
duration
intervention
sample
size
clinical
feature
psychological
morbidity
indeed
patient
enrolled
study
present
moderate
level
stress
anxiety
depression
score
speculate
patient
worsen
psychological
morbidity
much
benefit
rvt
present
much
intense
attenuation
emotional
burden
also
speculate
timing
intervention
active
treatment
suboptimal
may
much
effective
administer
later
dysallostatic
load
indeed
clinically
significant
distress
often
find
onset
month
follow
completion
cancer
time
dysallostatic
load
expect
much
impact
although
intervention
significantly
short
previous
work
perform
rvt
week
psychological
distress
reduce
similar
magnitude
previous
study
perhaps
long
intervention
may
much
clearly
associate
meaningful
endocrine
immunological
change
regard
observe
significant
increase
white
blood
cell
count
patient
cancer
follow
day
rvt
highlight
however
rvt
consist
daily
group
session
along
extra
session
perform
individually
home
tape
help
patient
strengthen
coping
skill
disease
well
make
participant
treatment
find
significant
relationship
psychological
morbidity
physiological
variable
experimental
group
find
particularly
much
anxious
control
baseline
anxiety
level
positively
correlated
cortisol
level
follow
rvt
compatible
knowledge
activation
hpa
axis
addition
morning
cortisol
level
inversely
correlated
proliferation
sensitivity
gc
baseline
datum
line
knowledge
stress
hormone
modulate
immune
system
make
lymphocyte
much
resistant
gc
chronic
stress
indeed
acquire
steroid
resistance
observe
several
pathology
include
chronic
stress
major
depression
ptsd
overall
finding
lend
far
support
idea
psychological
distress
alter
parameter
exposure
radiation
may
confound
variable
study
indeed
local
radiation
therapy
associate
effect
immune
endocrine
system
immunological
effect
include
blunt
proliferation
change
cellular
trafficking
however
finding
compatible
observation
indeed
cell
experimental
control
subject
similar
proliferation
rate
compare
healthy
control
previously
recruit
laboratory
addition
cortisol
level
also
compatible
salivary
assessment
observe
healthy
subject
however
potential
effect
radiation
stress
hormone
immune
function
discard
consider
may
saturate
limited
effect
rvt
conclusion
study
add
grow
literature
suggest
rvt
effectively
attenuate
psychological
distress
may
thus
improve
quality
life
cancer
patient
undergo
radiotherapy
study
necessary
explore
underlie
physiological
mechanism
involve
attenuation
stress
group
intervention
also
necessary
understand
extent
change
relate
clinical
progress
remission
disease
breast
cancer
relatively
rare
poor
nation
form
part
group
malignancy
account
approximately
one
third
cancer
death
rich
nation
diet
demographic
early
menarche
timing
length
exposure
hormone
chemical
may
account
risk
factor
contribute
disparity
effective
management
encompass
need
understand
nature
breast
cancer
order
accomplish
prevention
improve
treatment
outcome
patient
quality
life
every
stage
disease
fact
woman
still
succumb
breast
cancer
underscore
need
identify
disease
marker
genetic
epigenetic
change
regulate
mammary
epithelial
cell
proliferation
purpose
infectious
association
viral
omit
paper
interested
reader
referred
overview
instead
link
inflammation
malignancy
explore
order
examine
potential
role
infectious
agent
disease
etiology
treatment
virchow
first
postulate
cancer
originate
chronic
site
inflammation
based
certain
irritant
enhance
cell
proliferation
grow
body
clinical
experimental
datum
implicate
virus
infectious
irritant
associate
human
cancer
include
possibly
breast
cancer
relationship
infectious
agent
notably
microbe
breast
cancer
remain
vague
even
though
relationship
establish
number
chronic
disease
hypothesis
breast
cancer
management
identical
cancer
term
need
understand
risk
factor
alleviate
treatment
improve
outcome
include
prevention
cancer
recurrence
capable
evade
immune
system
long
period
time
promote
chronic
inflammatory
response
may
increase
likelihood
cancer
promote
tumor
metastases
correlation
effect
become
blur
consider
criterion
may
suitable
label
certain
virus
microbe
oncogenic
infectious
agent
association
infectious
agent
cancer
little
question
arise
whether
association
significant
proof
causality
ubiquitous
opportunistic
infectious
agent
may
complicate
effort
pinpoint
association
microbe
cancer
however
identification
lesser
indirect
association
may
aid
treatment
patient
subset
link
persistent
hepatitis
virus
infection
increase
risk
liver
cancer
possible
connection
human
mammary
tumor
virus
breast
cancer
microbe
associate
number
chronic
disease
potential
oncogenic
infectious
agent
accurate
detection
may
one
reason
paucity
literature
report
one
establish
association
disease
convincing
evidence
infectious
agent
actually
present
tumor
induce
local
response
present
early
stage
disease
perhaps
prime
immune
response
onset
cancer
promote
metastases
addition
putative
correlation
microbe
cancer
based
understanding
feature
microbe
useful
identification
examination
local
distal
oncogenic
response
nucleic
acid
bacterial
lipopolysaccharides
dead
viable
non
cultivable
microbe
well
strain
variant
may
evade
immune
defense
therapy
implicit
hypothesis
assumption
link
microbe
microbial
component
cancer
onset
well
progression
evidence
association
strong
gastric
neoplasm
breast
malignancy
first
part
paper
focuses
improve
technique
develop
study
help
confirm
refute
case
association
microbe
breast
cancer
second
part
review
novel
microbial
adjuvant
therapy
also
relevance
breast
cancer
treatment
finding
cancer
microbe
normal
cellular
proliferation
program
go
result
cancer
disease
usually
may
involve
exposure
hormone
carcinogen
critical
time
point
course
entire
one
adopt
virchow
cancer
also
disease
chronic
inflammation
exploration
interaction
warrant
order
fully
understand
breast
cancer
etiology
microbe
human
cell
least
ten
one
healthy
person
play
important
largely
role
health
maintenance
disease
consistent
association
helicobacter
pylori
gastric
cancer
provide
direct
evidence
role
certain
microbe
oncogenic
infectious
agent
evidence
microbe
strain
variant
microbial
component
even
present
tumor
molecular
analysis
sequence
enable
sensitive
detection
identification
numerous
microorganism
prostate
cancer
case
breast
cancer
molecular
method
reveal
candidate
endogenous
control
gene
well
association
human
mammary
tumor
virus
disease
molecular
documentation
microbe
match
normal
breast
cancer
tissue
will
important
establish
connection
disease
specific
organism
microbial
component
strain
variant
shift
microbial
distribution
strain
variant
mutant
unknown
factor
breast
cancer
etiology
find
association
cystic
fibrosis
infection
form
colony
one
size
wild
type
counterpart
resistant
antibiotic
certain
nutritional
requirement
case
cancer
deficient
strain
variant
microbe
identify
association
breast
tumor
see
cancer
microbe
text
microbial
variant
medical
relevance
persist
antibiotic
treatment
play
role
relapse
infection
microbe
identification
tumor
call
question
perhaps
many
researcher
look
association
think
stain
tumor
biopsy
early
study
reveal
artifact
stain
typically
detect
infection
biopsy
positive
identification
make
based
microbial
retention
presence
stain
useful
pinpoint
breast
tuberculosis
thick
cell
wall
may
convincing
identification
microbe
tumor
biopsy
recent
immunohistochemical
electron
microscopy
evidence
provide
much
definitive
proof
microbe
present
chronic
disease
model
system
historical
experiment
also
show
obtain
breast
tumor
inject
test
subject
induce
disease
case
although
early
study
include
cultivation
researcher
find
unstable
microbe
difficult
general
cultivate
agar
plate
unless
special
condition
cultivation
remain
gold
standard
confirm
microbial
infection
even
though
microbe
grow
know
medium
two
study
may
enable
genetic
analysis
cancer
microbe
lederberg
show
coli
readily
cultivate
penicillin
selection
growth
presence
microbial
lysate
consist
mainly
peptidoglycan
amino
acid
diaminopimelic
acid
almost
fifty
year
later
expand
upon
finding
show
unstable
coli
deficient
fact
contain
wild
type
peptidoglycan
efficient
require
peptidoglycan
precursor
diaminopimelic
acid
enzyme
catalyzes
synthesis
acid
side
chain
improve
method
isolation
expand
cultivable
microbe
systematic
evaluation
make
model
system
whether
oncogenic
infectious
agent
different
class
microbe
microbial
component
recently
characterize
human
mammary
tumor
virus
new
evidence
emerge
microbe
also
promote
distal
oncogenic
response
pathogenic
gut
microbe
associate
tumor
development
breast
author
recent
study
observe
elevate
level
know
breast
cancer
metastatic
marker
helicobacter
mouse
increased
level
proinflammatory
cytokine
also
observe
mouse
cancer
human
patient
advance
breast
cancer
although
exact
mechanism
gut
bacterium
trigger
inflammation
induce
tumor
remain
unclear
result
point
new
causative
agent
breast
cancer
correlate
separate
finding
drug
lymphocyte
reduce
invasive
pathology
disease
understand
interaction
improve
treatment
vitro
study
microbe
well
microscopic
assessment
presence
absence
microbe
inside
tumor
necessary
step
evaluate
role
infectious
agent
may
breast
cancer
possible
chronic
microbial
infection
involve
adherence
invasion
replication
persistence
may
contribute
host
immune
response
exacerbate
disease
patient
subset
response
may
involve
increase
macrophage
know
play
important
role
breast
cancer
onset
progression
alternatively
microbial
product
lipopolysaccharides
dna
rna
condition
immune
response
alter
probability
cancer
unlike
pylori
microbe
may
associate
cancer
microbe
regard
associate
latent
atypical
chronic
infection
unresponsive
antibiotic
treatment
coli
know
stimulate
number
macrophage
lung
cancer
model
system
putative
breast
cancer
microbe
may
well
stimulate
macrophage
similar
manner
consequence
stimulation
elevated
macrophage
may
produce
free
radical
cellular
damage
hand
recent
study
show
persistence
microbe
inside
outside
cell
provide
support
idea
immune
system
patient
may
compromise
respect
breast
cancer
microbial
variant
microbe
breast
cancer
treatment
side
microbe
may
benefit
breast
cancer
treatment
nausea
vomit
diarrhea
adverse
event
associate
continuous
five
advance
breast
cancer
severe
gastrointestinal
may
lead
dose
reduction
therapy
cessation
adverse
consequence
patient
clinical
trial
fiber
supplementation
significantly
reduce
gastrointestinal
associate
colorectal
cancer
similar
adjuvant
regimen
may
provide
natural
alternative
pharmaceutical
therapy
currently
conjunction
chemotherapy
breast
cancer
addition
symptom
renew
interest
microbe
eradicate
breast
tumor
william
coley
late
demonstrate
efficacy
kill
bacterial
vaccine
destroy
tumor
cell
certain
patient
bone
soft
tissue
sarcoma
immunological
dependence
therapy
fact
patient
enter
clinical
trial
previously
subject
radiotherapy
chemotherapy
know
immunological
outcome
late
cancer
vaccine
study
prove
disappointing
approach
abandon
recent
discovery
anaerobic
microbe
preferentially
colonize
hypoxic
region
tumor
cell
lysis
may
provide
novel
century
twist
mean
improve
upon
coley
toxin
demonstrate
deplete
lethal
toxin
kill
viable
tumor
cell
administer
mouse
show
anaerobic
microbe
grow
hypoxic
region
solid
tumor
addition
find
optimal
efficacy
anaerobic
microbial
therapy
combination
chemotherapy
latter
group
show
intravenous
injection
mouse
treatment
doxorubicin
derivative
enhance
tumor
shrinkage
compare
either
agent
alone
identify
key
enzyme
responsible
improve
treatment
result
combination
therapy
finding
human
may
limited
microbial
component
immunogenic
nevertheless
opportunity
selectively
deliver
one
two
knockout
punch
tumor
microbial
component
specialized
system
represent
powerful
addition
acknowledgment
dr
thaler
davis
thank
insight
encouragement
paper
dedicate
memory
professor
joshua
lederberg
work
support
grant
foundation
therapy
bct
become
widely
accept
treatment
option
management
patient
breast
cancer
conventional
radiotherapeutic
approach
lumpectomy
generally
consist
deliver
gy
entire
breast
employ
wedge
tangential
field
optimized
single
isodose
distribution
without
inhomogeneity
correction
efficacy
empirically
derived
treatment
approach
establish
multiple
clinical
trial
local
control
rate
range
complication
rate
little
despite
apparent
success
conventional
treatment
strategy
far
reduction
acute
chronic
toxicity
possible
within
breast
adjacent
normal
tissue
several
study
demonstrate
significant
dose
inhomogeneity
large
superior
inferior
region
breast
employ
wedge
tangential
region
increase
dose
show
contribute
inferior
cosmetic
result
particularly
woman
several
different
technique
develop
optimize
dose
delivery
radiation
therapy
physical
compensator
design
computerized
tomography
ct
improve
dimensional
dose
distribution
unfortunately
widespread
implementation
remain
impractical
much
institution
addition
customized
compensator
may
increase
scatter
dose
contralateral
breast
second
technique
much
frequently
utilize
application
wedge
correct
vary
tissue
thickness
throughout
breast
eliminate
need
construct
customized
compensator
patient
dimensional
dosimetric
profile
wedge
provide
equivalent
tissue
compensation
customized
filter
intensity
modulate
radiation
therapy
imrt
deliver
multileaf
collimator
mlc
one
way
provide
optimized
dose
distribution
whole
breast
rapid
efficient
imrt
breast
irradiation
treatment
offer
potential
advantage
improve
dose
homogeneity
reduce
dose
lung
heart
reduce
scatter
dose
contralateral
breast
dosimetric
improvement
may
lead
well
cosmetic
result
lower
cardiac
pulmonary
complication
reduce
risk
contralateral
breast
cancer
herein
report
technique
clinical
implementation
imrt
tangential
beam
slide
window
technique
adjuvant
treatment
breast
cancer
december
much
patient
treat
technique
university
pittsburgh
medical
center
cancer
network
also
report
comparison
imrt
plan
plan
randomly
select
patient
method
material
ct
simulation
patient
place
supine
board
scanner
patient
position
arm
hold
handle
head
scanner
couch
drive
make
sure
patient
clear
scanner
patient
clear
arm
position
adjust
radiation
oncologist
breast
tissue
place
radiopaque
wire
around
patient
breast
mark
border
cm
breast
tissue
border
ct
perform
without
intravenous
contrast
axial
ct
image
thorax
acquire
every
mm
include
breast
complete
leave
right
lung
heart
ge
ct
scanner
ge
medical
system
milwaukee
isocenter
locate
axial
image
contain
midline
lateral
marker
measure
one
third
vertical
distance
midline
medial
field
border
apex
breast
ct
datum
transfer
treatment
planning
system
eclipse
planning
system
version
varian
medical
system
palo
alto
via
network
connection
axial
sagittal
coronal
view
planning
system
tangential
field
medial
lateral
border
design
cover
entire
breast
collimator
angle
beam
depth
gantry
angle
adjust
minimize
normal
tissue
dose
ensure
full
coverage
breast
include
tumor
bed
skin
lung
tool
planning
system
radiation
oncologist
contour
heart
leave
breast
cancer
patient
primary
breast
target
volume
tv
define
draw
line
midline
marker
lateral
marker
mm
inside
breast
skin
exclude
lung
heart
target
volume
define
generate
uniform
dose
across
breast
inverse
planning
program
planning
system
contour
perform
axial
ct
slice
figure
show
marker
contour
representative
axial
ct
slice
breast
imrt
image
markers
contour
representative
axial
ct
slice
breast
imrt
view
within
article
inverse
treatment
planning
based
volume
specify
dose
constraint
inverse
treatment
planning
perform
slide
window
technique
employ
module
eclipse
planning
system
planning
process
tangential
field
utilize
dose
constraint
follow
planning
target
volume
receive
gy
much
ipsilateral
lung
receive
much
gy
leave
breast
cancer
constraint
much
heart
receive
much
gy
final
dose
calculation
imrt
plan
perform
inhomogeneity
correction
fluence
map
extend
cm
outside
breast
skin
accommodate
respiratory
motion
chest
imrt
plan
recalculated
new
fluence
map
plan
verification
validation
radiation
oncologist
prior
treatment
delivery
approve
plan
imrt
plan
patient
validate
varian
linear
accelerator
phantom
confirm
dose
delivery
intensity
map
isodose
coronal
image
phantom
plan
compare
film
dosimetry
criterion
adopt
evaluate
isodose
line
gradient
isodose
line
mm
gradient
isodose
line
different
patient
plan
average
dose
deviation
measure
expected
dose
ion
chamber
different
patient
plan
average
dose
deviation
measure
expected
film
patient
setup
verification
treatment
patient
set
treatment
table
linear
accelerator
per
plan
electronic
portal
imaging
perform
start
treatment
confirmation
setup
reproducibility
thereafter
every
week
port
film
image
compare
digitally
reconstructed
radiograph
prior
treatment
entire
treatment
include
patient
setup
beam
delivery
complete
minute
imrt
treatment
take
approximately
amount
time
treatment
wedge
field
due
small
number
field
relatively
modulation
fluence
fact
necessary
therapist
place
wedge
field
dosimetric
comparison
imrt
dosimetric
parameter
calculate
compare
imrt
plan
term
dose
uniformity
reduction
dose
critical
organ
ct
datum
randomly
select
breast
cancer
breast
cancer
retrospective
treatment
planning
study
patient
treat
imrt
beam
arrangement
contour
keep
optimized
distribution
obtain
wedge
different
beam
weight
eclipse
planning
system
inhomogeneity
correction
creation
plan
mix
photon
dose
tv
critical
organ
record
patient
dosimetric
parameter
compare
percent
volume
target
volume
tv
receive
prescription
dose
pd
homogeneity
index
dhi
part
tv
receive
dose
high
little
pd
percent
volume
tv
receive
pd
percent
volume
tv
receive
pd
parameter
heart
percent
volume
heart
receive
gy
mean
dose
ipsilateral
lung
gy
lung
percent
volume
ipsilateral
lung
receive
gy
percent
volume
contralateral
lung
receive
pd
total
monitor
unit
statistical
analysis
spss
statistical
package
spss
chicago
tail
perform
compare
mean
group
result
mean
homogeneity
index
tv
imrt
sd
sd
sd
sd
respectively
sd
sd
sd
sd
respectively
dose
comparison
show
tv
imrt
homogeneity
index
increase
imrt
compare
improvement
dose
homogeneity
statistically
significant
reduction
imrt
compare
respectively
reduction
statistically
significant
mean
dose
heart
imrt
sd
sd
respectively
percent
reduction
dose
imrt
compare
respectively
mean
dose
ipsilateral
lung
imrt
sd
sd
respectively
percent
reduction
dose
imrt
compare
respectively
percent
volume
contralateral
volume
lung
receive
pd
reduce
imrt
compare
reduction
statistically
significant
mean
total
imrt
isodose
distribution
examine
transverse
coronal
sagittal
slice
patient
example
isodose
distribution
plane
show
imrt
one
patient
time
treatment
include
patient
setup
beam
delivery
complete
imrt
timeframe
table
mean
tv
coverage
imrt
technique
sd
sd
difference
imrt
value
dhi
table
sd
standard
deviation
view
within
article
table
percent
volume
organ
irradiate
technique
volume
sd
sd
difference
imrt
value
ipsilateral
total
table
sd
standard
deviation
view
within
article
image
example
isodose
distribution
plane
imrt
one
patient
view
within
article
discussion
breast
radiotherapy
challenge
anatomy
surround
structure
make
inherently
difficult
site
achieve
homogeneous
dose
distribution
site
complex
shape
may
modify
far
surgery
locate
interface
also
important
organ
risk
close
proximity
lung
heart
case
tumor
single
plane
radiotherapy
breast
plan
lead
substantial
dose
inhomogeneity
particularly
woman
large
breast
dose
may
lead
increased
normal
tissue
side
effect
poor
cosmetic
result
significant
psychological
morbidity
patient
imrt
deliver
mlc
one
way
provide
optimized
dose
distribution
whole
breast
rapid
efficient
manner
result
study
suggest
well
dose
homogeneity
reduce
volume
hot
spot
imrt
comparison
also
report
similar
well
dose
homogeneity
may
translate
reduce
skin
toxicity
well
cosmetic
outcome
comparison
conventional
leave
instead
wedge
compensator
also
reduce
scatter
dose
contralateral
breast
part
body
report
previous
study
dose
contralateral
breast
reduce
significantly
imrt
comparison
conventional
present
study
dose
contralateral
lung
significantly
reduce
reflect
reduction
scatter
dose
part
body
similarly
study
physical
wedge
compensation
technique
much
significant
factor
associate
increase
scatter
dose
result
approximately
time
much
exposure
compare
breast
decrease
scatter
dose
potential
reduce
second
malignancy
specifically
young
woman
breast
cancer
treat
radiation
reduction
dose
critical
organ
include
heart
lung
technique
modest
tangential
breast
imrt
technique
beam
go
similar
volume
critical
organ
beam
size
angle
reduce
ability
inverse
planning
optimize
far
reduce
dose
critical
organ
technique
achieve
goal
well
disadvantage
increase
scatter
dose
expose
large
volume
dose
one
way
reduce
heart
dose
critical
remove
region
breast
overlap
heart
target
volume
thus
allow
reduce
heart
dose
result
inferior
coverage
breast
volume
thus
decision
make
treat
physician
based
clinical
information
one
concern
imrt
geographical
target
volume
intrafraction
motion
induce
breathing
study
show
difference
plan
expect
dose
interplay
respiratory
motion
normal
breathing
mlc
motion
imrt
delivery
similar
conventional
tangential
breast
reason
insignificant
respiratory
motion
effect
large
margin
clinically
extend
fluence
map
cm
beyond
breast
volume
gradual
change
beam
intensity
along
motion
direction
thus
tangential
photon
beam
safe
breast
treatment
patient
beam
setup
conventional
treatment
without
need
effect
respiratory
motion
dose
coverage
conclusion
imrt
intact
breast
cancer
slide
window
technique
successfully
implement
clinic
now
successfully
treat
much
patient
technique
cancer
center
network
take
hour
complete
planning
whereas
imrt
take
hour
however
treatment
delivery
time
imrt
compare
conventional
dosimetric
datum
suggest
improve
dose
homogeneity
breast
reduction
dose
lung
heart
imrt
treatment
may
clinical
value
potentially
contribute
improve
cosmetic
result
reduce
late
toxicity
much
decade
now
major
trend
healthcare
rather
relying
clinical
experience
healthcare
professional
encourage
base
clinical
finding
scientific
study
evidence
usually
understand
empirically
based
finding
randomized
clinical
trial
rct
consider
one
much
robust
form
evidence
much
objective
way
eliminate
bias
however
form
evidence
bias
much
difficult
control
observational
case
study
may
much
appropriate
answer
certain
kind
research
question
regardless
research
design
careful
systematic
scientific
determine
effective
diagnostic
procedure
treatment
optimal
patient
care
limited
practice
order
minimize
unnecessary
treatment
control
cost
expectation
healthcare
provider
will
incorporate
evidence
involve
patient
treatment
relatively
recently
expectation
patient
past
treatment
decision
professional
healthcare
provider
much
recently
trend
within
healthcare
transform
patient
role
treatment
one
passive
recipient
one
much
equal
partner
increase
expansion
number
viable
treatment
option
available
exponential
growth
internet
availability
health
information
contribute
great
patient
involvement
healthcare
decision
patient
choice
concept
root
principle
inform
choice
order
principle
healthcare
provider
ensure
patient
reasonably
inform
risk
benefit
procedure
prior
patient
give
consent
afford
opportunity
concern
question
address
scientific
study
determine
risk
benefit
different
treatment
order
patient
inform
regard
treatment
choice
require
reasonable
understanding
advantage
disadvantage
available
treatment
increase
opportunity
oncology
patient
particular
become
involve
variety
therapeutic
option
available
different
cancer
much
oncology
patient
want
involve
attain
preferred
role
lead
well
quality
life
despite
patient
always
assume
preferred
role
cancer
patient
wish
involve
despite
much
opportunity
several
study
report
degree
patient
wish
participate
vary
widely
patient
level
involvement
indicative
desire
information
many
patient
undertake
passive
role
still
want
well
inform
increase
knowledge
satisfaction
treatment
compliance
quality
life
report
positive
outcome
adequate
information
provision
enough
information
link
dissatisfaction
care
reduce
investigator
find
desire
information
temporal
nature
different
kind
information
request
different
time
throughout
disease
trajectory
generally
information
cancer
patient
say
require
much
information
survival
stage
disease
treatment
option
relate
side
effect
literature
widely
refer
desire
information
exhibit
patient
information
need
acknowledge
term
need
inappropriately
describe
occur
term
need
imply
objective
standard
need
assess
actually
determine
patient
express
desire
information
sake
simplicity
however
will
term
need
order
agreement
exist
literature
overwhelmingly
healthcare
practitioner
much
widely
much
preferred
source
information
cancer
patient
although
evidence
electronic
medium
source
cancer
information
increase
significantly
patient
may
also
specially
design
intervention
call
consumer
decision
aid
cda
provide
information
relevant
specific
decision
regard
treatment
option
cda
prior
physician
consultation
one
way
engage
patient
meaningful
discussion
treatment
option
addition
provide
relevant
information
patient
lead
decision
process
risk
benefit
treatment
option
present
format
easy
understand
along
value
clarification
exercise
mean
elicit
patient
personal
preference
regard
different
treatment
option
cda
increasingly
common
method
support
treatment
choice
often
facilitate
decision
process
however
patient
may
access
choose
decision
aid
prior
make
treatment
choice
pierce
study
unaided
process
woman
diagnosis
breast
cancer
diagnosis
cardiovascular
disease
find
several
problematic
aspect
decision
behaviour
decision
aid
design
part
counteract
faulty
decision
behavior
pierce
also
assert
majority
woman
study
make
satisfactory
decision
without
benefit
decision
aid
unaided
decision
based
type
information
evidence
mention
previously
healthcare
practitioner
much
preferred
source
information
patient
face
treatment
choice
however
source
family
friend
medium
internet
also
widely
researchers
examine
source
breast
cancer
patient
report
inconsistent
result
investigator
report
people
source
favored
documentary
source
report
reverse
factor
may
come
play
patient
make
decision
treatment
choose
simple
provision
information
researchers
examine
decision
actually
make
real
world
descriptive
theory
rather
make
theory
discover
people
often
make
decision
appear
rational
choice
frame
outcome
patient
value
whether
patient
ability
motivation
understand
scientific
information
may
play
role
decision
make
decisional
heuristic
adaptive
decision
process
make
decision
complex
situation
information
may
incomplete
difficult
understand
also
emotional
impact
diagnose
cancer
may
lead
patient
base
decision
fear
rather
scientific
evidence
term
theoretical
research
two
particularly
informative
model
oncology
patient
seek
healthcare
information
exist
literature
johnson
produce
comprehensive
model
information
seek
focuses
characteristic
utility
information
channel
source
well
factor
antecedent
information
seek
personal
relevance
background
factor
much
recently
longo
develop
conceptual
model
identify
several
personal
contextual
factor
think
influence
information
seek
factor
roughly
equivalent
johnson
personal
relevance
background
factor
instead
focusing
characteristic
source
longo
model
describe
actual
process
information
seek
information
two
kind
information
identify
one
result
active
information
seek
one
result
passive
receipt
information
two
category
several
phase
information
identify
accord
level
patient
involvement
example
phase
patient
aware
receive
available
information
phase
patient
aware
information
attempt
access
passively
receive
longo
identify
satisfaction
health
outcome
activity
daily
live
adls
empowerment
locus
control
relevant
patient
outcome
conceptual
model
helpful
identify
key
variable
study
help
organize
finding
relate
research
evidence
obtain
empirical
research
systematic
review
exist
literature
either
refute
confirm
model
propose
relationship
thus
either
challenge
strengthen
model
ultimate
goal
produce
much
accurate
representation
truth
longo
model
useful
synthesize
integrate
concept
surround
information
seek
cancer
patient
however
relationship
propose
need
test
refined
intention
determine
whether
influence
factor
relationship
present
longo
model
support
exist
literature
order
resolve
seek
empirical
article
explore
way
breast
cancer
patient
acquire
utilize
information
treatment
paper
author
survey
exist
literature
relate
express
information
need
breast
cancer
patient
face
treatment
choice
mastectomy
lumpectomy
information
source
satisfy
need
outcome
relate
decisional
support
intervention
specifically
summarize
research
relate
follow
various
express
information
need
breast
cancer
patient
term
type
range
quality
quantity
source
information
fill
various
need
within
context
treatment
decision
mastectomy
lumpectomy
question
effect
woman
identify
result
research
evidence
specifically
decision
aid
support
treatment
decision
mastectomy
lumpectomy
method
broadly
speak
aim
systematic
review
synthesize
finding
several
study
address
topic
problem
strategy
limit
bias
random
error
study
put
rigorous
critical
appraisal
process
finding
combine
interpret
finding
diverse
compare
statistically
research
method
dissimilar
much
narrative
approach
undertake
research
question
guide
review
broad
net
literature
result
capture
diverse
set
study
evident
early
process
integrative
review
much
appropriate
strategy
finding
integrative
review
allow
inclusion
diversity
literature
empirical
theoretical
contribute
comprehensive
topic
interest
procedure
review
literature
publish
last
year
conduct
follow
database
cumulative
index
nursing
health
literature
medline
psychinfo
science
citation
index
expanded
social
science
citation
index
arts
citation
index
last
three
web
science
search
limited
article
publish
english
january
march
order
adequately
cover
topic
review
conduct
two
search
relate
one
guide
question
first
search
term
information
seek
information
source
information
seek
behaviour
information
need
information
resource
oncology
cancer
neoplasm
yield
hit
search
far
refined
limit
term
breast
conserve
therapy
bct
lumpectomy
mastectomy
surgery
result
substantial
narrowing
focus
search
consequently
number
hit
reduce
abstract
article
review
determine
eight
article
relevant
topic
review
conduct
second
search
key
search
term
treatment
choice
combination
oncology
cancer
neoplasm
yield
combine
total
hit
search
far
refined
limit
term
decisional
support
decision
aid
cda
consumer
decision
aid
result
substantial
narrowing
focus
search
consequently
number
hit
reduce
abstract
article
review
determine
three
article
relevant
topic
review
acceptance
rejection
article
based
inclusion
exclusion
criterion
list
complete
list
exclude
article
available
author
image
expanded
conceptual
model
health
information
seek
behavior
information
health
care
decision
view
within
article
combined
relevant
article
two
search
number
search
reference
list
search
retain
article
yield
another
article
hand
search
follow
journal
yield
final
three
article
european
journal
cancer
care
medical
decision
making
oncology
nursing
cancer
nursing
patient
education
counseling
article
meet
inclusion
exclusion
criterion
determine
methodological
evaluation
feasible
give
disparate
research
method
among
include
article
result
retrieve
article
sort
three
broad
category
article
study
participant
breast
cancer
patient
within
context
make
treatment
decision
mastectomy
lumpectomy
investigator
first
group
report
study
examine
information
need
second
group
source
information
preferred
third
group
effectiveness
specific
decisional
support
intervention
first
two
group
provide
potential
answer
question
third
group
article
provide
potential
answer
question
table
article
examine
information
need
breast
cancer
patient
toolsranked
information
need
order
high
first
difference
group
topic
quality
amount
reason
bilodeau
degner
rr
reportedinformation
need
item
list
thurstone
pair
comparisondisease
stage
chance
cure
treatment
option
physical
emotional
aspect
side
much
important
old
woman
high
school
education
little
rr
need
item
list
thurstone
pair
cure
spread
disease
treatment
option
family
risk
adverse
attractiveness
much
important
young
woman
much
important
old
woman
family
risk
much
important
woman
family
member
breast
cancer
chance
cure
much
important
want
active
role
dm
chance
cure
much
important
close
time
diagnosis
much
important
far
diagnosis
rr
toronto
informational
need
cancer
disease
treatment
test
physical
high
age
total
score
fewer
information
need
difference
based
marital
status
income
education
rr
toronto
informational
need
cancer
treatment
disease
test
physical
difference
treatment
subgroup
difference
based
marital
status
education
income
young
woman
great
need
information
high
total
score
rr
statement
describe
information
need
seven
overall
ranking
seven
state
hypothesis
relate
decisional
control
active
passive
information
patient
want
receive
detail
information
illness
treatment
passive
patient
want
minimal
information
subgroup
passive
patient
want
detail
information
even
though
wish
take
part
dm
rr
interview
information
seek
sense
control
reduce
anxiety
change
behavior
predict
future
much
woman
want
much
information
possible
rr
reportedinformation
need
item
list
thurstone
pair
comparisondisease
cure
disease
stage
treatment
family
risk
side
woman
year
age
year
information
regard
sexuality
much
important
woman
year
age
old
woman
rate
information
regard
social
life
much
important
young
woman
rr
need
item
list
thurstone
pair
comparisondisease
cure
disease
stage
treatment
change
decisional
control
desire
time
since
diagnosis
woman
intermediate
level
education
rate
information
treatment
option
second
stage
disease
third
priority
table
sample
size
eleven
diagnosis
breast
cancer
view
within
article
table
article
examine
source
information
preferred
breast
cancer
patient
toolsranked
list
influence
source
bilodeau
degner
rr
source
provide
list
source
physician
friend
family
nurse
ranking
preferred
source
physician
nurse
friend
relative
brochure
medical
journal
level
education
medical
journal
overall
people
source
much
write
source
rr
five
specific
item
supply
source
physician
primary
provider
give
nurse
also
mention
american
cancer
society
library
pamphlet
young
woman
satisfy
information
receive
physician
feel
well
inform
hughes
rr
background
inventory
include
list
source
top
three
source
prior
consultation
lie
medium
relative
friend
educational
brochure
also
mention
healthcare
professional
group
receive
information
much
source
bct
group
consultation
author
presume
source
family
medium
rr
rank
preference
physician
family
theme
elicit
trusting
opinion
advice
physician
treatment
decision
appreciate
importance
family
friend
support
rr
factor
list
include
influential
source
percentage
source
surgeon
general
practitioner
family
friend
cancer
foundation
mastectomy
group
name
family
much
frequent
source
bct
group
bct
group
name
gp
much
frequent
source
mastectomy
group
rr
factor
list
include
influential
source
rank
preference
physician
initial
consult
second
third
opinion
family
second
opinion
decline
age
old
age
associate
want
someone
else
make
treatment
decision
young
woman
want
much
information
possible
old
woman
least
likely
discuss
treatment
decision
layperson
bath
rr
source
obtain
focus
group
rank
preference
healthcare
professional
family
friend
organization
support
seek
information
facilitate
cope
sense
control
increase
confidence
help
dm
reason
avoid
information
prevent
worry
avoid
fear
minimize
feeling
negativity
depression
rr
scale
rate
list
source
list
report
percentage
somewhat
helpful
breast
cancer
physician
write
material
physician
write
friend
family
primary
care
physician
woman
year
age
little
likely
receive
write
information
source
physician
family
friend
younger
woman
much
likely
find
write
information
physician
family
friend
somewhat
helpful
rr
scale
rate
list
score
source
surgeon
primary
care
physician
spouse
radiation
oncologist
medical
oncologist
impersonal
source
little
influential
spouse
child
friend
parent
much
influential
mastectomy
group
radiation
oncologist
much
influential
bct
group
davis
rr
respondent
receive
information
specific
source
time
accessed
first
health
professional
book
brochure
pamphlet
internet
hospital
clinic
cancer
organization
percentage
source
helpful
book
brochure
pamphlet
health
professional
spouse
partner
newspaper
magazine
internet
internet
extensively
minority
breast
cancer
patient
woman
find
information
receive
time
diagnosis
adequate
rr
choose
top
three
source
list
eight
source
physician
family
friend
clinic
tie
nurse
medium
clinic
tie
people
source
significantly
much
important
nurse
second
much
frequently
source
bct
group
physician
family
friend
second
much
frequently
source
physician
mastectomy
group
table
view
within
article
table
clinical
trial
consumer
decision
aid
cda
surgical
treatment
breast
cancer
article
year
country
description
audiotape
workbook
value
clarification
review
consultation
surgeon
pilot
pilot
pilot
consecutive
patient
two
surgeonsn
anxiety
knowledge
treatment
option
decisional
conflict
decisional
unaffected
cda
knowledge
level
improve
decisional
conflict
subscale
remain
cda
audiotape
workbook
value
clarification
review
consultation
surgeon
randomization
clinical
trial
datum
collect
baseline
prior
surgery
response
rate
surgeon
contact
patient
pamphlet
information
cda
number
photo
value
anxiety
knowledge
treatment
option
decisional
conflict
decisional
overall
effect
cda
trend
towards
overall
decisional
conflict
reduction
woman
lean
towards
unsure
enrollment
many
positive
comment
form
participant
qualitative
net
interactive
breast
cancer
longitudinal
three
datum
collection
point
three
response
rate
consecutive
datum
collection
month
oral
information
surgeon
site
serve
control
least
style
treatment
preference
decisional
conflict
quality
life
breast
cancer
specific
functioning
symptom
satisfaction
information
general
treatment
specific
dm
process
decision
effect
cdrom
satisfaction
information
treatment
decision
positive
effect
cdrom
satisfaction
information
dm
process
communication
physician
cdrom
group
report
well
general
health
well
physical
functioning
physician
administer
decision
board
slide
door
reveal
information
sequential
fashion
two
information
card
read
response
rate
consecutive
patient
surgeonsn
dm
process
information
provide
decision
make
decision
board
information
present
time
require
complete
physician
satisfaction
dm
decision
board
easy
understand
help
decision
help
patient
think
question
ask
patient
decision
board
recommend
patient
satisfy
information
receive
report
satisfaction
dm
process
physician
find
intervention
helpful
much
consultation
physician
administer
decision
board
slide
door
reveal
information
sequential
fashion
two
information
card
read
cluster
randomized
clinical
trial
surgeon
randomized
surgeon
based
age
surgeon
patient
intervention
usual
practice
usual
practice
surgeon
discuss
treatment
usual
fashion
without
decision
knowledge
decisional
conflict
satisfaction
dm
treatment
choice
anxiety
group
control
group
follow
consultation
high
knowledge
score
decisional
conflict
high
satisfaction
dm
time
difference
month
difference
anxiety
depression
score
intervention
control
group
time
consultation
five
step
intervention
set
mapping
commitment
administer
consultation
control
trial
measurement
three
point
planning
control
arm
intervention
arm
physician
approximately
equal
number
present
consultation
take
part
physician
conduct
surgical
consultation
per
usual
practice
decision
quality
scale
patient
physician
version
item
satisfaction
consultation
scale
patient
physician
version
higher
decision
quality
intervention
control
patient
decision
scale
amount
agreement
patient
physician
fair
control
group
kappa
moderate
intervention
group
kappa
significant
time
administer
intervention
significantly
much
control
table
view
within
article
information
need
study
eight
article
author
discuss
express
informational
need
breast
cancer
patient
within
context
choose
mastectomy
lumpectomy
despite
variety
method
group
investigator
finding
consistent
article
report
overall
desire
information
high
majority
patient
want
much
information
possible
much
request
information
chance
cure
follow
order
stage
disease
treatment
option
family
risk
side
effect
stage
disease
relate
chance
cure
stage
cancer
indication
severity
illness
consequently
curable
next
great
desire
treatment
information
information
available
help
important
reason
satisfying
information
need
report
article
number
factor
find
associate
type
degree
information
need
summarize
table
table
summary
information
need
information
source
finding
article
significant
finding
information
need
age
older
information
social
life
fewer
information
need
younger
need
information
preference
information
physical
attractiveness
sexuality
education
lower
information
preferred
degree
decisional
information
chance
cure
family
history
breast
information
family
risk
time
since
diagnosis
diagnosispreference
information
diagnosispreference
information
chance
cure
actual
role
active
patientspreference
detail
information
passive
patientspreference
minimal
information
subgroup
want
detail
information
source
information
age
younger
second
opinion
much
information
possible
satisfaction
information
receive
physician
written
information
physician
family
friend
somewhat
helpful
older
someone
else
make
decision
less
likely
discuss
treatment
decision
layperson
less
likely
receive
write
information
source
physician
family
friend
less
likely
want
much
information
therapy
choice
less
likely
consult
three
much
physician
treatment
education
higher
medical
journal
involvement
dm
higher
gp
information
source
type
surgery
source
prior
consultation
family
much
frequent
source
spouse
child
friend
much
influential
family
friend
second
much
frequent
source
physician
much
frequent
source
nurse
second
much
frequent
source
physician
radiation
oncologist
much
influential
table
view
within
article
information
source
study
investigator
study
explore
source
information
breast
cancer
patient
access
order
support
choice
two
form
surgical
treatment
preferred
source
rank
either
participant
directly
ranking
determine
based
mean
score
evaluative
scale
overall
one
study
physician
much
preferred
source
follow
closely
healthcare
provider
single
study
mention
internet
world
wide
web
rank
fifth
behind
newspaper
magazine
study
rank
actual
source
participant
ask
either
list
source
rate
degree
influence
scale
choice
treatment
decision
simply
list
source
healthcare
professional
much
frequently
identify
source
great
influence
family
friend
also
highly
rank
one
study
participant
ask
list
source
accessed
first
receive
diagnosis
case
top
three
source
order
physician
book
brochure
pamphlet
internet
age
type
surgery
choose
find
influence
source
choice
finding
one
study
qualitative
method
include
two
theme
consistent
quantitative
study
find
trusting
advice
opinion
physician
treatment
decision
appreciate
importance
support
family
friend
theme
support
notion
interactive
human
source
information
preferred
static
electronic
source
decision
aid
study
several
evaluative
study
decisional
support
intervention
include
mixture
decision
aid
term
purpose
patient
population
diagnosis
six
study
focused
woman
make
treatment
choice
lumpectomy
mastectomy
quantitative
finding
statistically
significant
difference
find
intervention
control
group
study
study
find
difference
qualitative
finding
much
definitive
patient
appreciate
clarity
information
diagram
picture
fact
information
physician
provide
reinforce
overall
patient
physician
reaction
intervention
positive
table
cda
outcome
table
table
intervention
group
compare
control
group
significant
increase
decrease
nr
relationship
measure
report
view
within
article
methodological
rigor
disparate
nature
research
method
among
include
article
preclude
systematic
quality
assessment
perform
article
similar
method
group
together
narrative
assessment
research
rigor
much
common
research
design
investigate
information
need
source
descriptive
design
method
datum
collection
include
questionnaire
interview
individual
focus
group
questionnaire
source
preference
information
need
able
elicit
degree
preference
scale
however
effect
note
especially
information
need
study
patient
designate
every
kind
information
important
technique
four
study
eliminate
problem
allow
information
need
measure
relative
consecutive
convenience
sampling
quantitative
study
give
difficulty
randomizing
patient
vulnerability
population
study
introduce
potential
sampling
bias
sample
majority
study
predominantly
white
woman
attain
much
balanced
sample
sampling
example
may
lead
much
representative
sample
therefore
great
ability
generalize
population
large
one
study
focused
ethnicity
find
subtle
difference
source
high
write
material
suggest
much
heterogeneous
sampling
may
produce
slightly
different
result
sampling
qualitative
study
entirely
appropriate
give
goal
kind
sampling
ensure
special
knowledge
phenomenon
choose
another
factor
time
diagnosis
datum
collection
vary
substantially
among
study
time
diagnosis
month
pass
diagnostic
consultation
datum
collection
make
recall
bias
considerable
threat
give
information
need
find
change
time
one
study
quite
likely
information
need
month
will
comparable
information
need
time
diagnosis
none
study
examine
source
time
data
analysis
consist
either
simple
reporting
frequency
ranking
various
statistical
method
determine
difference
ranking
accord
specific
variable
age
education
choice
surgery
degree
decisional
control
statistically
significant
analysis
individual
level
article
report
result
decisional
support
intervention
various
experimental
design
determine
effectiveness
different
decision
aid
three
article
report
development
pilot
testing
decisional
support
tool
two
study
randomized
control
trial
design
cluster
randomization
physician
randomized
one
study
longitudinal
design
datum
collection
occur
three
point
control
group
receive
either
usual
practice
significantly
scale
version
decisional
support
intervention
statistical
test
determine
difference
group
statistically
significant
test
manova
power
calculation
report
three
study
pilot
one
three
study
underpowered
summary
information
need
source
accessed
satisfy
need
explore
several
study
mainly
descriptive
level
additionally
sampling
method
study
may
limit
generalizability
result
study
examine
decision
aid
outcome
much
rigorous
find
modest
difference
intervention
group
usual
practice
discussion
discussion
review
focused
information
need
identify
breast
cancer
patient
context
make
treatment
choice
source
information
access
satisfy
need
investigator
conduct
systematic
review
literature
examine
information
support
need
breast
cancer
patient
cancer
patient
general
none
focused
specifically
information
need
context
make
treatment
choice
one
systematic
review
source
information
cancer
patient
locate
one
review
examine
information
need
source
tandem
systematic
review
decisional
support
intervention
cancer
treatment
exist
however
none
restrict
examine
consumer
decision
aid
cda
breast
cancer
patient
specifically
review
unique
link
together
three
different
relate
aspect
information
seek
behavior
examine
within
context
specific
patient
population
particular
disease
trajectory
based
review
relationship
information
need
information
source
decisional
support
describe
follow
way
much
patient
wish
involve
treatment
take
part
plan
treatment
need
base
decision
sort
information
requirement
information
express
information
need
need
satisfy
determine
source
accessed
cda
intervention
design
healthcare
professional
help
patient
physician
choose
among
two
much
sound
clinical
option
however
patient
may
aware
access
desire
need
cda
decisional
support
intervention
one
number
information
source
patient
may
base
treatment
decision
well
several
factor
age
education
health
status
may
influence
information
need
priority
information
source
accessed
information
need
overall
ranking
information
need
fairly
consistent
chance
cure
stage
disease
take
precedence
treatment
information
surprising
since
question
much
case
ask
relatively
close
time
diagnosis
cancer
see
threat
life
able
determine
extent
threat
likely
priority
information
need
find
influence
several
factor
albeit
consistently
eight
article
review
age
education
time
since
diagnosis
degree
participation
find
influence
information
need
priority
ranking
example
old
woman
rank
information
sexuality
information
high
young
woman
explain
number
way
older
woman
much
likely
single
therefore
may
lack
sexual
partner
may
increase
sexual
dysfunction
due
hormonal
change
women
already
cope
functional
change
may
concern
change
may
threaten
ability
maintain
independence
result
information
need
regard
take
precedence
sexuality
alternate
explanation
may
old
woman
much
sexual
experience
draw
young
woman
therefore
fewer
information
need
another
factor
find
influence
information
need
time
since
diagnosis
information
concern
chance
cure
stage
disease
much
important
need
breast
cancer
patient
take
high
priority
close
time
diagnosis
surprising
since
degree
threat
feeling
vulnerability
heighten
time
diagnosis
somewhat
time
information
source
choice
source
information
breast
cancer
patient
inform
treatment
choice
consistent
people
source
rank
high
medium
documentary
source
almost
study
physician
much
preferred
source
overall
family
friend
information
resource
also
prevalent
finding
patient
appreciate
human
source
information
interactive
tailor
specific
situation
question
answer
information
gap
fill
human
source
however
differ
term
knowledge
domain
physician
nurse
family
member
different
kind
expertise
study
examine
differentiate
helpful
know
kind
information
seek
family
friend
kind
seek
health
professional
relative
importance
process
factor
find
associate
kind
source
chiefly
age
education
degree
involvement
income
eventual
surgical
choice
example
old
woman
find
much
satisfy
information
receive
physician
young
woman
want
much
information
seek
great
variety
source
speculation
due
change
attitude
towards
medical
old
patient
much
familiar
comfortable
physician
patient
relationship
physician
large
role
therefore
trust
information
doctor
give
good
enough
income
education
impact
source
predictable
way
two
minority
group
study
high
income
associate
computer
consequently
high
ranking
source
higher
education
associate
medical
journal
one
study
expect
overall
traditional
research
dissemination
vehicle
healthcare
journal
patient
patient
considerable
education
however
source
accessed
much
highly
educate
subject
may
much
positive
attitude
towards
research
may
well
able
understand
assess
research
finding
decision
aid
cda
study
examine
review
show
mix
finding
decrease
decisional
conflict
increase
satisfaction
decision
increase
knowledge
score
qualitatively
comment
regard
decision
aid
positive
quantitatively
difference
usual
practice
cda
modest
good
may
suggest
woman
get
information
need
source
get
information
need
physician
without
cda
congruent
finding
study
much
woman
able
make
satisfactory
decision
regard
breast
cancer
treatment
without
decision
aid
longo
model
author
find
certain
aspect
longo
model
support
finding
integrative
review
information
need
literature
variable
age
education
demographic
factor
longo
model
time
since
diagnosis
delivery
care
degree
participation
attitude
intention
behavior
find
influence
kind
information
breast
cancer
patient
desire
longo
model
variable
posit
influence
information
seek
influence
factor
longo
model
culture
language
healthcare
structure
information
seek
support
literature
either
significant
statistical
relationship
find
influence
factor
information
seek
difficult
expensive
measure
example
influence
healthcare
structure
information
seek
require
study
involve
countless
participant
likely
although
information
need
information
seek
argue
information
need
prerequisite
information
seek
order
active
information
seek
occur
need
perceive
may
factor
influence
type
quality
quantity
information
patient
require
also
influence
actively
passively
patient
act
satisfy
information
need
example
woman
high
priority
information
need
actively
seek
priority
need
may
passively
receive
longo
mention
health
outcome
empowerment
locus
control
satisfaction
adls
patient
outcome
affect
information
seek
behavior
information
variable
similar
outcome
measure
cda
study
cda
one
many
different
source
information
fact
find
significantly
increase
satisfaction
information
decision
decision
process
improve
health
outcome
support
relationship
information
seek
patient
consumer
outcome
represent
model
information
seek
locus
control
empowerment
activity
daily
live
support
review
literature
one
weakness
longo
model
address
difference
choice
information
source
vary
personal
age
contextual
proximity
factor
assumption
one
three
type
source
channel
will
indication
model
channel
may
influence
personal
contextual
factor
johnson
comprehensive
model
information
seek
source
characteristic
perceive
source
utility
see
influence
source
choice
review
age
education
degree
involvement
income
find
associate
source
choice
incorporating
characteristic
individual
context
source
include
utility
model
strengthen
help
explain
role
source
choice
affect
outcome
satisfaction
decision
make
suggest
much
refined
version
model
provide
great
insight
understanding
way
consumer
health
information
determine
information
important
information
accessed
recipient
health
information
impact
outcome
satisfaction
suggest
relationship
within
model
support
literature
need
test
develop
suggest
far
research
need
explore
interaction
implication
future
research
begin
understand
information
important
breast
cancer
patient
source
role
cda
provide
information
many
question
regard
information
seek
information
leave
example
source
preferred
quality
information
source
make
attractive
patient
cda
good
way
provide
information
patient
need
make
inform
healthcare
decision
additional
research
design
answer
subsequent
question
will
provide
insight
require
refine
model
health
information
patient
conclusion
women
breast
cancer
face
surgical
treatment
disease
express
desire
information
chance
cure
staging
disease
available
treatment
several
factor
influence
express
desire
include
age
stage
disease
whether
active
passive
participant
source
preferred
accessed
woman
satisfy
information
need
overwhelmingly
interactive
human
source
primarily
study
review
physician
age
education
type
treatment
choose
influence
choice
information
source
qualitative
finding
support
cda
qualitative
finding
much
patient
decisional
support
intervention
find
little
decisional
conflict
high
satisfaction
decision
make
decision
process
high
knowledge
level
study
relation
considerable
cost
produce
decision
aid
benefit
fairly
practice
implication
make
breast
cancer
treatment
decision
know
interactive
human
source
evidence
preferred
far
much
source
treatment
information
high
priority
many
patient
want
much
high
quality
information
possible
increasing
participation
healthcare
patient
necessitate
development
intervention
provide
current
systematically
derived
research
thus
ensure
healthcare
decision
make
based
good
evidence
decision
aid
universally
available
either
patient
conjunction
healthcare
professional
produce
limited
benefit
course
trend
information
need
source
choice
based
demographic
characteristic
imply
member
specific
population
hold
similar
preference
many
author
stress
need
assess
information
need
individual
basis
well
assumption
source
make
young
patient
internet
old
patient
think
physician
opinion
regard
treatment
good
enough
practitioner
need
aware
trend
limited
research
area
focus
determine
reason
certain
source
context
interactive
human
source
preferred
patient
mechanism
evaluate
addition
role
traditional
research
play
patient
well
understanding
concept
surround
source
conceptual
model
provide
solid
foundation
create
much
effective
way
disseminate
information
patient
essential
optimal
acknowledgement
support
foundation
medical
research
canadian
institute
health
research
cihr
graduate
scholarship
vasoactive
intestinal
peptide
vip
pituitary
adenylate
peptide
pacap
receptor
know
show
overexpressed
human
tumor
receptor
two
primary
peptide
high
affinity
first
vip
amino
acid
hydrophobic
peptide
isolate
porcine
intestine
vip
three
lysine
residue
position
two
tyrosine
residue
position
two
arginine
arg
residue
position
essential
residue
terminus
amidated
amino
acid
require
full
biologic
activity
vip
second
pituitary
adenylate
cyclase
polypeptide
pacap
amino
acid
peptide
isolate
bovine
hypothalamus
pacap
find
stimulate
accumulation
intracellular
extracellular
camp
rat
anterior
pituitary
cell
later
isolate
amino
acid
peptide
bovine
hypothalamus
observe
similar
property
share
homology
amino
acid
like
also
amidated
biological
action
vip
pacap
mediate
family
three
receptor
designate
gene
receptor
also
detect
cell
membrane
normal
intestinal
epithelial
cell
albeit
receptor
density
specify
human
tumor
hand
study
reveal
receptor
locate
plasma
membrane
tumor
cell
among
tumor
receptor
find
high
density
high
incidence
include
cancer
breast
prostate
urinary
colon
pancreas
lung
stomach
liver
goal
radiolabeled
specifically
target
receptor
vivo
visualization
human
tumor
labeled
kev
tyrosine
position
taking
consideration
ubiquitous
availability
predominant
world
wide
role
nuclear
medicine
labeled
kev
require
modification
peptide
accommodate
group
additional
amino
acid
chelate
analogue
allow
efficient
imaging
human
breast
cancer
positron
emission
tomography
pet
permit
high
imaging
resolution
lead
visualization
small
tumor
mm
pet
imaging
tumor
labeled
vip
highly
pet
imaging
goal
label
vip
pacap
analogue
another
radionuclide
namely
radionuclide
long
half
life
kev
available
commercially
abundantly
know
chemistry
provide
nearly
quantitative
yield
labeled
compound
prepare
inject
without
far
purification
attempt
develop
analogue
high
receptor
affinity
well
vivo
stability
synthesize
characterize
several
analogue
molecule
based
upon
datum
choose
two
good
additional
analogue
make
total
four
enable
labeling
four
peptide
far
derivatized
describe
material
method
section
purpose
investigation
evaluate
analogue
ascertain
biological
activity
receptor
specificity
compromise
compare
determine
pet
imaging
human
breast
cancer
material
method
three
analogue
vip
peptide
one
pacap
name
molecular
weight
synthesize
labeled
amino
acid
sequence
give
table
evaluate
analogue
functional
activity
receptor
affinity
vitro
blood
clearance
vivo
stability
athymic
nude
mouse
bear
human
breast
cancer
cell
affinity
human
breast
cancer
specimen
ex
vivo
table
amino
acid
sequence
molecular
weight
purity
analogue
name
molecular
weight
amu
molecular
weight
amu
sequence
amino
peptide
bma
bma
bma
table
view
within
article
synthesis
peptide
analogue
analogue
synthesize
harbor
lysine
residue
separate
acid
spacer
chelating
agent
synthesis
hplc
purification
carry
american
peptide
company
sunnyvale
briefly
peptide
synthesize
polyethylene
glycol
peg
resin
via
fmoc
chemistry
peptide
chain
assemble
resin
repetitive
removal
fmoc
protect
group
couple
protect
amino
acid
couple
agent
dic
hobt
piperidine
formamide
dmf
agent
cyclic
peptide
prepare
separately
convert
linear
fragment
lactam
bond
side
chain
make
solution
phase
cyclic
fragment
purify
via
assemble
main
chain
peptide
dic
hobt
couple
side
chain
protect
group
cleave
remove
treat
peptide
resin
acid
tfa
crude
peptide
precipitate
cold
ether
collect
filtration
purify
via
phosphate
acetic
acid
buffer
water
hplc
column
linear
gradient
acetonitrile
pooled
fraction
peptide
verify
mass
amino
acid
analysis
analogue
name
accord
molecular
weight
radiolabeling
peptide
analogue
high
specific
activity
carrier
add
kev
obtain
either
washington
university
school
medicine
louis
columbia
inc
ontario
canada
analogue
mol
glycine
buffer
ph
glass
test
tube
add
mol
hcl
agent
ci
mol
hcl
mixture
vortexed
incubate
minute
radiolabeling
peptide
analogue
study
preparation
cell
binding
assay
available
ten
analogue
ml
glass
test
tube
also
add
mol
hcl
mci
nacl
mol
ph
reaction
mixture
vortexed
incubate
room
temperature
min
add
ml
mol
solution
ph
neutralize
ph
quality
control
radiochemical
purity
labeled
analogue
determine
liquid
chromatography
hplc
shimadzu
corporation
couple
uv
detector
nai
tl
radioactivity
monitor
rate
reverse
phase
column
mm
mm
serve
stationary
phase
two
solvent
acid
tfa
tfa
acetonitrile
mobile
phase
gradient
aqueous
flow
rate
ml
min
min
functional
assay
vip
large
quantity
muscle
relaxant
muscle
relaxant
property
assess
biological
functional
activity
analogue
compare
native
assay
based
binding
vip
specific
receptor
produce
decrease
rest
tension
internal
anal
sphincter
ias
smooth
muscle
effect
different
concentration
analogue
determine
maximum
fall
basal
tension
ias
reach
preparation
smooth
muscle
strip
two
adult
rats
anesthetized
kill
accordance
protocol
approve
institutional
animal
care
committee
distal
anal
canal
dissect
transfer
quickly
krebs
solution
follow
composition
mmol
nacl
kcl
glucose
adhere
blood
vessel
tissue
contain
external
anal
sphincter
remove
sharp
dissection
anal
canal
open
pin
flat
side
dissect
tray
contain
krebs
solution
follow
removal
fine
dissection
ias
circular
smooth
muscle
strip
approximately
mm
wide
cm
long
part
anal
canal
suture
tie
end
muscle
strip
isometric
tension
measurement
measurement
isometric
tension
ias
muscle
strip
transfer
muscle
bath
krebs
solution
continuously
mixture
one
end
muscle
strip
tie
bottom
muscle
bath
end
attach
isometric
force
transducer
model
instruments
ma
isometric
tension
measure
datum
acquisition
system
adinstruments
hill
nsw
australia
record
chart
adinstruments
initially
tension
apply
muscle
strip
muscle
strip
allow
occasional
washing
equilibration
period
strip
develop
steady
tension
strip
develop
steady
tension
relax
response
field
stimulation
optimal
length
base
line
muscle
strip
determine
drug
response
effect
different
concentration
analogue
rest
ias
tension
examine
cumulative
concentration
response
give
concentration
response
curve
derived
muscle
strip
wash
continuously
min
testing
concentration
response
curve
another
agent
maximum
relaxation
smooth
muscle
strip
determine
completely
relax
muscle
strip
mmol
ethylenediaminetetraacetic
acid
edta
percentage
maximum
fall
ias
tone
plot
log
concentration
respective
analogue
value
calculate
concentration
relaxivity
occur
culture
human
breast
cancer
cell
line
estrogen
breast
tumor
cell
american
type
culture
collection
maintain
rpmi
medium
mm
adjust
contain
mm
hepes
mm
sodium
pyruvate
sodium
bicarbonate
glucose
supplement
ml
bovine
insulin
fetal
bovine
serum
air
cell
confluent
detach
wash
resuspended
medium
concentration
approximately
cell
ml
cell
binding
assay
cell
grow
seed
well
sterile
plate
corning
science
cell
cell
well
add
increase
concentration
nm
nm
sample
labeled
peptide
incubate
humidify
incubator
air
incubation
terminate
add
ml
cold
washing
buffer
make
bsa
medium
min
cell
wash
thrice
buffer
supernatant
wash
collect
mark
test
tube
cell
solubilized
naoh
collect
separate
test
tube
procedure
repeat
thrice
solubilized
cell
collect
cell
supernatant
count
radioactivity
gamma
counter
packard
series
meriden
ct
count
datum
permit
calculate
free
radioactivity
ratio
number
peptide
molecule
bind
cell
datum
plot
per
scatchard
kd
value
calculate
guideline
assay
guidance
manual
nih
chemical
genomic
center
procedure
repeat
autoradiography
purpose
study
determine
receptor
specific
differential
uptake
human
breast
cancer
tissue
versus
normal
breast
tissue
freshly
freeze
randomly
choose
histologically
prove
human
breast
cancer
normal
tissue
obtain
institutional
department
pathology
section
mount
clean
glass
slide
store
mount
slide
allow
reach
room
temperature
condensed
dry
approximately
ci
labeled
analogue
solution
dilute
mm
tris
hcl
buffer
ph
contain
mm
mm
bacitracin
mm
layer
tissue
incubate
room
temperature
min
slide
wash
thoroughly
cold
nacl
solution
dry
expose
phosphor
imaging
plate
plate
process
fujifilm
flourescent
image
analyzer
image
gauge
procedure
repeat
breast
cancer
normal
breast
tissue
tissue
incubate
peptide
analogue
analyzed
luminescence
psl
calculate
tumor
normal
tissue
reverse
transcription
real
time
polymerase
chain
reaction
goal
ascertain
human
breast
cancer
normal
tissue
autoradiography
perform
express
receptor
receptor
expression
density
different
tumor
tissue
normal
tissue
tissue
architecture
sample
human
breast
cancer
normal
tissue
disrupt
addition
trizol
vitrogen
life
technology
presence
mm
silica
bead
release
rna
homogenize
rapid
procedure
recommend
manufacturer
biospec
product
rna
extract
total
rna
reverse
transcribe
taqman
assay
reagent
one
hour
result
strand
cdna
dilute
template
pcr
reaction
taqman
master
mix
specific
primer
probe
perform
dna
engine
system
system
follow
cycling
condition
min
cycle
expression
level
determine
cycle
threshold
ct
value
normalize
human
dehydrogenase
gapdh
standard
curve
calculation
blood
clearance
blood
clearance
study
radiolabeled
analogue
perform
mouse
rapid
blood
clearance
radioactivity
may
minimize
back
ground
thereby
enable
well
view
target
tissue
study
carry
four
analogue
group
athymic
nude
mouse
per
analogue
labeled
peptide
ci
administer
lateral
tail
vein
sample
blood
approximately
draw
min
post
administration
facilitate
rapid
reliable
blood
draw
small
incision
make
part
tail
lateral
vein
expose
blood
draw
pressure
apply
stop
far
bleeding
sample
weigh
radioactivity
count
gamma
counter
packard
series
meriden
ct
along
standard
solution
prepare
time
injection
percentage
inject
dose
gram
blood
calculate
mean
sd
time
point
plot
function
time
vivo
stability
objective
assess
vivo
stability
administer
peptide
determine
transchelation
peptide
plasma
protein
analysis
perform
sodium
dodecyl
sulphate
polyacrylamide
gel
electrophoresis
eighteen
percent
tris
glycine
gel
vitrogen
life
technology
labeled
peptide
instance
administer
lateral
tail
vein
athymic
nude
mouse
ml
blood
collect
heparinized
eppendorf
vial
follow
euthanasia
min
serum
collect
centrifugation
rpm
min
tris
glycine
sds
buffer
deionized
water
add
serum
load
well
molecular
weight
standard
facilitate
estimation
molecular
weight
various
protein
band
load
another
well
far
much
labeled
incubate
human
serum
albumin
hsa
incubate
hsa
also
apply
incubation
buffer
carry
explain
finally
incubate
alone
also
apply
maintain
min
analysis
perform
simultaneously
two
gel
one
gel
stain
coomassie
blue
destained
cut
count
radioactivity
associate
protein
band
gamma
counter
gel
autoradiography
expose
gel
phosphor
imaging
plate
stain
coomassie
blue
destained
cut
count
radioactivity
plate
process
fujifilm
flourescent
image
analyzer
image
gauge
synthesis
characterization
amino
acid
sequence
analogue
give
table
together
calculate
observe
molecular
weight
purity
determine
analytical
hplc
radiochemical
purity
radiochemical
purity
labeled
peptide
determine
hplc
respectively
retention
time
vary
represent
typical
hplc
elution
curve
diagonal
line
represent
percent
gradient
labeling
efficiency
respectively
image
hplc
elution
profile
one
reveal
radioactivity
bind
peak
min
uv
peak
also
centered
around
min
diagonal
line
represent
gradient
function
time
view
within
article
functional
assay
response
value
peptide
analogue
respectively
unaltered
datum
suggest
biological
activity
analogue
compare
compromise
table
kd
value
analogue
control
table
view
within
article
image
effect
increase
concentration
analogue
relaxivity
tissue
value
present
view
within
article
cell
binding
assay
dissociation
constant
kd
labeled
peptide
analogue
calculate
find
image
cell
binding
datum
plot
per
scatchard
binding
perform
human
breast
cancer
cell
express
receptor
case
instead
biological
activity
peptide
analogue
influence
tracer
plot
represent
receptor
specific
binding
kd
slope
estimate
nih
chemical
genomic
center
assay
guidance
manual
version
receptor
binding
kd
value
calculate
analogue
give
table
view
within
article
autoradiography
human
breast
cancer
tissue
diagnose
invasive
ductal
carcinoma
high
grade
situ
micropapillary
carcinoma
high
grade
situ
microinvasive
carcinoma
intermediate
grade
tubulolobular
carcinoma
addition
seven
histologically
designate
normal
tumor
normal
radioactivity
ratio
calculate
quantitative
analysis
phosphor
imaging
plate
range
ratio
invasive
ductal
carcinoma
ratio
situ
microinvasive
tumor
tubulolobular
carcinoma
ratio
typical
image
slide
show
table
result
human
breast
cancer
tissue
autoradiography
ratio
tumor
normal
tissue
analogue
invasive
ductal
situ
micropapillary
situ
microinvasive
high
grade
tubulolobular
table
histopathological
report
view
within
article
image
example
digital
autoradiography
normal
breast
cancer
tissue
incubate
image
calculate
tumor
normal
psl
reflect
high
receptor
expression
tumor
tissue
result
consistent
corresponding
analytical
datum
view
within
article
measure
receptor
expression
freshly
freeze
sample
human
breast
cancer
normal
tissue
following
series
run
cancer
tissue
normal
tissue
difference
receptor
expression
tumor
tissue
find
time
great
normal
tissue
histopathology
correlated
tumor
normal
receptor
expression
ratio
follow
invasive
ductal
tumor
tissue
situ
micropapillary
high
grade
situ
microinvasive
reveal
typical
profile
tumor
sample
normal
tissue
image
normal
human
breast
cancer
tissue
reveal
distinct
cycle
difference
tumor
normal
tissue
fewer
cycle
require
amplify
protein
tumor
tissue
compare
normal
tissue
density
receptor
much
tumor
tissue
normal
breast
tissue
view
within
article
blood
clearance
blood
clearance
biphasic
approximately
min
min
min
min
approximately
min
min
min
min
respectively
typical
graph
time
versus
display
image
blood
clearance
study
one
analogue
clearance
curve
biphasic
min
min
view
within
article
vivo
stability
polyacrylamide
gel
analysis
indicate
min
post
injection
approximately
radioactivity
remain
labeled
peptide
remain
radioactivity
associate
protein
molecular
weight
kda
lane
similarly
lane
incubate
hsa
negligible
transchelation
protein
experiment
approximately
free
bind
protein
molecular
weight
kda
lane
represent
separation
protein
visualize
follow
coomassie
blue
staining
molecular
weight
standard
also
autoradiography
various
sample
explain
methodology
figure
legend
quantitative
analysis
radioactivity
distribution
various
protein
band
give
table
image
leave
coomassie
blue
stain
gel
represent
protein
band
approximate
molecular
weight
right
autoradiography
represent
radioactivity
associate
corresponding
protein
lane
vivo
mouse
serum
lane
incubate
hsa
ex
vivo
lane
incubate
hsa
ex
vivo
lane
view
within
article
table
page
analysis
lane
molecular
weight
kda
serum
vivo
table
radioactivity
estimate
molecular
weight
view
within
article
discussion
annually
usa
approximately
million
breast
biopsy
perform
approximately
million
find
benign
pathology
ability
determine
benign
malignant
status
suspect
breast
cancer
mass
find
mammography
may
minimize
number
million
unnecessary
invasive
biopsy
spare
patient
physical
psychological
trauma
well
save
health
care
dollar
although
great
make
imaging
breast
cancer
magnetic
resonance
mri
computerized
tomography
ct
ultrasound
radionuclide
imaging
pet
glucose
modality
suffer
serious
limitation
need
investigate
improve
imaging
probe
might
target
specific
biomarker
thereby
contribute
great
reliability
high
sensitivity
specificity
imaging
malignant
lesion
exclude
benign
pathology
data
abundant
breast
cancer
cell
overexpress
gene
product
cell
surface
receptor
name
endogenous
growth
hormone
peptide
high
affinity
receptor
bind
similarly
vpac
receptor
high
affinity
receptor
however
demonstrate
human
breast
cancer
cell
overexpress
either
receptor
receptor
overexpressed
malignant
cell
cell
morphology
alter
high
density
normal
breast
tissue
cell
receptor
phosphorylated
cell
membrane
datum
render
receptor
highly
useful
biomarker
may
probe
noninvasive
pet
imaging
confirmation
presence
suspect
mass
will
ascertain
malignancy
absence
benign
pathology
investigation
choose
apparently
potent
peptide
analogue
synthesize
characterize
derivatized
radiolabeling
enable
perform
pet
imaging
purpose
investigation
determine
biological
characteristic
probe
compromise
receptor
specificity
receptor
binding
affinity
alter
vivo
stability
diminish
probe
bind
human
breast
tissue
express
receptor
binding
preferential
compare
normal
breast
tissue
datum
strongly
demonstrate
analogue
potent
functionally
stable
analogue
radiolabeling
efficiency
great
require
far
purification
probe
inject
pet
imaging
muscle
relaxant
muscle
relaxivity
assay
ias
smooth
muscle
functional
study
perform
strongly
indicate
biological
activity
none
analogue
compromise
similarly
binding
assay
perform
human
breast
cancer
cell
line
corroborate
datum
equally
affirmatively
vitro
receptor
autoradiography
study
show
time
great
quantity
analogue
bind
breast
cancer
tissue
normal
breast
tissue
study
carry
establish
good
working
technique
always
yield
ratio
datum
indicate
great
number
receptor
express
malignant
cell
normal
datum
confirm
previous
observation
human
analogue
strongly
suggest
analogue
ability
specifically
localize
malignant
breast
lesion
pet
imaging
datum
obtain
confirm
increase
receptor
expression
tumor
tissue
generally
corroborate
autoradiography
datum
range
receptor
expression
vary
depending
size
tissue
abundance
malignant
cell
sample
provide
blood
clearance
datum
mouse
analogue
indicate
rapid
clearance
supportive
early
imaging
clearance
together
internalization
phosphorylation
receptor
will
promote
diagnostic
therapeutic
application
peptide
certain
chelate
show
unstable
vivo
promote
transchelation
protein
may
vivo
application
chelate
case
polyacrylamide
gel
analysis
indicate
approximately
remain
bind
peptide
kda
transchelated
protein
vivo
among
transchelated
approximately
fraction
protein
molecular
weight
kda
include
significant
portion
remain
loading
well
see
approximately
protein
molecular
weight
kda
protein
molecular
weight
kda
approximately
clear
min
rapid
clearance
radioactivity
sample
acquire
min
post
administration
labeled
analogue
blood
draw
min
post
injection
contain
negligible
radioactivity
either
count
autoradiography
obtain
insight
possibility
far
transchelation
serum
protein
incubate
peptide
hsa
vitro
demonstrate
activity
transchelated
protein
lack
transchelation
consistent
strong
chelating
moiety
couple
peptide
urinary
excretion
peptide
analogue
post
injection
negligible
prevent
hplc
confirmation
enzymatic
degradation
peptide
might
eliminate
urine
consider
together
lack
transchelation
serum
protein
lack
urinary
excretion
reasonable
assume
peptide
remain
intact
far
evidence
increase
quantity
radioactivity
accumulate
tumor
time
elapse
vivo
administration
datum
give
stability
far
analysis
perform
urine
collect
mouse
give
previously
show
great
activity
bind
peptide
assumption
radioactivity
bind
normal
organ
relatively
large
size
may
bind
vpac
receptor
express
normal
cell
albeit
density
summary
vitro
limited
vivo
datum
strongly
suggest
four
analogue
potent
biological
activity
compromise
worthy
far
evaluation
investigation
promise
lead
evaluate
utility
pet
imaging
human
breast
cancer
determine
malignant
lesion
benign
one
acknowledgment
work
support
nih
grant
thank
juan
md
department
pathology
advice
assistance
study
pathological
specimen
thank
also
due
phd
department
experimental
therapeutic
biospec
product
breast
cancer
second
much
frequent
death
among
woman
western
world
deregulation
gene
involve
cell
cycle
extracellular
matrix
remodel
cell
adhesion
motility
report
much
invasive
stage
disease
although
early
detection
effective
treatment
modality
breast
cancer
improve
overall
cure
rate
prognosis
breast
cancer
poor
primary
treatment
modality
phenotype
constitute
much
case
cytoreductive
surgery
follow
adjuvant
chemotherapy
radiotherapy
however
need
develop
additional
mode
treatment
important
group
patient
angiogenesis
process
new
blood
vessel
form
exist
vascular
network
essential
requirement
tumour
growth
metastasis
process
involve
proteolysis
basement
membrane
endothelial
cell
migration
proliferation
matrix
remodel
disruption
vascular
basement
membrane
may
facilitate
extravasation
endothelial
cell
lead
formation
sprout
well
intravasation
tumour
cell
vessel
affect
metastatic
spread
malignant
cell
thus
critical
event
cancer
progression
development
ability
invade
surround
tissue
vascular
endothelial
growth
factor
vegf
main
positive
regulator
angiogenesis
bind
receptor
result
endothelial
cell
activation
proliferation
migration
invasion
survival
six
glycosylated
isoform
vegf
placenta
growth
much
extensively
study
implicate
angiogenesis
two
multiple
mature
molecule
main
soluble
biologically
active
form
signal
transduction
vegf
mediate
domain
intracellular
portion
receptor
vegf
initiate
intracellular
signal
cascade
lead
change
expression
gene
promote
endothelial
cell
migration
proliferation
well
produce
increase
permeability
capillary
angiogenesis
key
growth
metastasis
solid
tumour
breast
cancer
high
level
vegf
show
correlate
poor
prognosis
decrease
overall
survival
breast
cancer
patient
addition
vegf
may
function
autocrine
factor
breast
carcinoma
cell
maintain
survival
vasoactive
intestinal
peptide
vip
amino
acid
neuropeptide
belong
large
family
peptide
include
pituitary
adenylate
peptide
pacap
molecule
vip
pleiotropic
peptide
since
express
distinct
subpopulation
much
major
structure
central
peripheral
nervous
system
well
endocrine
paracrine
cell
neuroendocrine
peptide
exert
wide
array
biological
effect
include
endocrine
secretion
immunomodulation
muscle
relaxation
cell
proliferation
differentiation
vip
pacap
bind
high
affinity
receptor
whereas
receptor
bind
pacap
high
affinity
vip
affinity
receptor
couple
stimulatory
nucleotide
binding
protein
result
adenylate
cyclase
activation
little
commonly
signal
pathway
increase
camp
protein
kinase
pka
activation
may
phosphorylate
protein
substrate
lead
increased
oncogene
expression
many
human
cancer
cell
system
study
vip
behave
factor
exert
action
protection
apoptosis
regard
several
evidence
indicate
vip
may
play
important
role
growth
differentiation
function
normal
neoplastic
breast
thus
vip
consider
additional
breast
cancer
growth
factor
context
high
occurrence
gene
expression
report
human
breast
cancer
cell
line
carcinoma
metastasis
aim
present
report
evaluate
possible
implication
vip
angiogenesis
breast
cancer
previous
vitro
study
laboratory
show
vip
increase
vegf
expression
secretion
prostate
tumour
cell
line
lncap
fact
suggest
important
role
vip
proangiogenic
factor
contribute
regulation
tissue
vascularization
prostate
cancer
breast
prostate
cancer
cancer
possess
similar
pathological
entity
exhibit
similar
epidemiological
pattern
hand
vip
regulate
vegf
expression
secretion
lung
cancer
cell
intense
rat
model
induce
angiogenesis
autocrine
paracrine
mechanism
present
study
investigate
vip
effect
upon
vegf
expression
well
mediate
signal
pathway
involve
breast
cancer
cell
line
contribution
understanding
underlie
pathogenesis
disease
progression
main
prerequisite
develop
effective
preventive
therapeutic
strategy
breast
cancer
material
reagent
synthetic
vip
purchase
france
ethyl
alexis
germany
wortmannin
calbiochem
germany
reagent
obtain
sigma
spain
cell
line
breast
carcinoma
cell
line
obtain
american
type
culture
collection
manassas
va
usa
cell
line
cultured
roswell
park
memorial
institute
medium
life
technology
barcelona
spain
supplement
antibiotic
antimycotic
foetal
bovine
serum
fbs
cell
line
cultured
medium
contain
ml
insulin
cell
grow
humidify
air
carbon
atmosphere
split
weekly
trypsin
edta
culture
medium
component
purchase
invitrogen
barcelona
spain
rna
extraction
reverse
transcription
polymerase
chain
reaction
total
rna
extract
cultured
cancer
cell
reagent
biotech
lab
houston
tx
usa
accord
manufacturer
instruction
two
receptor
total
rna
complementary
dna
cdna
murine
leukaemia
virus
reverse
transcriptase
accord
manufacturer
guideline
life
technology
order
rule
genomic
dna
contamination
also
perform
without
reverse
transcriptase
two
vip
receptor
respectively
reaction
pcr
amplification
primer
set
amplify
cdna
human
vip
receptor
vegf
isoform
number
cycle
determine
preliminary
experiment
within
exponential
range
pcr
amplification
negative
control
water
instead
cdna
run
parallel
exclude
different
contamination
pcr
amplification
perform
applied
biosystems
foster
city
usa
cycle
profile
previously
report
last
cycle
final
extension
min
pcr
product
electrophoresed
agarose
gel
stain
ethidium
bromide
uv
light
bands
product
scan
analyzed
imaging
system
gel
spain
experiment
repeat
least
three
time
similar
result
obtain
mrna
level
study
gene
normalize
table
oligonucleotide
primer
analysis
vip
receptor
expression
breast
cancer
cell
product
size
bp
used
semiquantitative
tca
ctc
tgc
agt
ctt
tcc
tct
ttc
cat
tca
gaa
ttc
aag
cca
tcc
tgt
gtg
cct
cgg
ctt
gtc
aca
tx
aag
aaa
atc
cct
gtg
gcg
agt
ctg
tgt
ttt
tgc
tga
tcg
agg
agc
cgg
tct
tca
cag
ggt
cag
tct
ggt
gag
acc
tag
cat
tcg
ctx
gct
tct
gag
gtc
tgc
agg
aag
acc
agg
gtg
ctg
gtc
aag
gac
acc
agg
ctc
agc
ttg
agg
att
cct
atg
tgg
gtc
gtc
cca
gtt
ggt
table
view
within
article
quantitative
quantitative
analysis
carry
rna
sample
sybr
green
pcr
master
mix
applied
biosystems
protocol
accord
manufacturer
instruction
thermal
cycling
condition
min
min
activate
reverse
transcriptase
follow
cycle
min
pcr
reaction
perform
applied
biosystems
pcr
system
sds
specific
primer
show
table
relative
quantification
normalize
result
pcr
represent
ct
value
ct
define
threshold
cycle
number
product
first
detect
fluorescence
amount
target
normalize
endogenous
reference
housekeeping
gene
ct
difference
ct
value
derived
corresponding
gene
sample
assay
gene
ct
represent
difference
pair
sample
differential
ratio
express
ct
quantification
vip
vegf
cell
place
mm
cell
culture
dish
density
cell
complete
medium
control
receive
medium
cell
wash
pbs
harvest
scrape
pbs
pelleted
centrifugation
min
preparation
cytosolic
extract
pack
cell
resuspended
mm
hepes
ph
mm
kcl
mm
edta
mm
egta
mm
dithiothreitol
dtt
mm
phenyl
pmsf
ml
aprotinin
ml
leupeptin
ml
mm
naf
mm
mm
cell
keep
ice
min
add
cytosolic
extract
pelleted
centrifugation
supernatant
store
order
perform
far
assay
vip
level
cytosolic
fraction
determine
enzyme
eia
commercially
available
kit
accord
manufacturer
instruction
phoenix
pharmaceutical
karlsruhe
germany
human
vip
vip
cell
place
well
plate
density
cell
well
complete
medium
control
receive
medium
incubation
period
cell
cell
vip
medium
remove
keep
elisa
assay
vegf
analyzed
human
vegf
rd
system
minneapolis
mn
usa
cyclic
ability
vip
forskolin
elevation
camp
level
determine
human
breast
cancer
cell
cell
cell
well
plate
treat
medium
contain
bovine
serum
albumin
bsa
mg
ml
bacitracin
mm
pmsf
mm
min
treatment
medium
remove
order
measure
intracellular
camp
ethanol
add
transfer
fresh
tube
evaporate
sample
dissolve
phosphate
buffer
store
far
assay
afterwards
camp
level
measure
mean
competitive
binding
assay
statistical
analysis
data
express
mean
statistical
analysis
perform
appropriate
student
two
tail
test
bonferroni
test
multiple
comparison
analysis
variance
anova
consider
significant
vip
mrna
peptide
level
cancer
cell
investigate
expression
vip
mrna
level
semiquantitative
quantitative
protein
level
experiment
photomicrograph
show
illustrate
morphological
appearance
human
breast
cell
line
cell
semiquantitative
analysis
mrna
expression
control
sample
vip
yield
product
expect
size
cell
line
expression
mrna
internal
control
quantitative
show
mrna
level
vip
cell
significantly
cell
evaluation
cytosolic
extract
mrna
translation
corresponding
peptide
mean
eia
reveal
similar
level
immunoreactive
vip
two
cell
line
study
image
morphological
image
breast
cancer
cell
left
expression
vip
mrna
lane
lane
cell
study
semiquantitative
preparation
normalize
accord
expression
mrna
pcr
yield
product
expect
size
bp
vip
lane
bp
molecular
dna
marker
lane
negative
control
right
quantification
vip
mrna
expression
vip
peptide
level
quantification
vip
perform
eia
data
bar
mean
student
test
view
within
article
expression
vip
receptor
semiquantitative
analysis
demonstrate
breast
cancer
cell
express
mrna
mrna
lncap
human
prostate
cancer
cell
line
positive
control
since
show
express
mainly
also
receptor
expression
mrna
internal
control
order
measure
mrna
level
quantitative
also
perform
significantly
high
cell
compare
cell
image
semiquantitative
study
expression
mrna
receptor
lane
lane
human
breast
cancer
cell
lane
positive
control
receptor
human
lncap
cancer
cell
preparation
normalize
accord
expression
mrna
pcr
yield
product
expect
size
bp
receptor
respectively
lane
bp
molecular
dna
marker
lane
negative
control
quantification
mrna
data
bar
mean
student
test
view
within
article
coupling
vip
receptor
camp
system
functionality
vip
receptor
breast
cancer
cell
assess
ability
vip
stimulation
camp
production
response
qualitatively
similar
cell
line
however
vip
treatment
result
maximal
camp
level
cell
time
high
cell
forskolin
diterpene
interact
adenylate
cyclase
direct
manner
also
increase
camp
level
mechanism
case
cell
line
exhibit
similar
pattern
adenylate
cyclase
stimulation
image
adenylate
cyclase
stimulation
breast
cancer
cell
effect
vip
forskolin
data
mean
anova
bonferroni
test
corresponding
control
view
within
article
effect
vip
vegf
mrna
protein
level
cell
stimulate
vip
min
respectively
vegf
mrna
expression
investigate
specific
primer
total
rna
extract
cell
mean
transcript
also
analyzed
control
amplification
reaction
rna
cell
give
three
product
bp
sequenced
show
correspond
respectively
analysis
reveal
increase
expression
vegf
mrna
response
vip
manner
vip
effect
mrna
expression
far
assess
quantitative
control
cell
study
increase
time
period
cell
show
mrna
expression
reach
maximal
similar
level
min
vip
stimulation
cell
respectively
image
effect
vip
expression
vegf
mrna
breast
cancer
cell
semiquantitative
product
vegf
mrna
isoform
mrna
bp
marker
control
template
size
product
expect
correspond
quantification
mrna
data
bar
mean
anova
bonferroni
test
control
group
view
within
article
order
investigate
whether
expression
mrna
accompany
enhancement
protein
production
elisa
perform
cell
level
measure
medium
cell
treat
vip
respectively
result
indicate
vegf
level
maximal
cell
respectively
image
effect
vip
extracellular
vegf
level
cell
incubation
cell
perform
absence
presence
vip
indicate
time
culture
medium
take
measurement
level
elisa
data
mean
student
test
control
group
view
within
article
involvement
phosphoinositide
kinase
pka
pathway
vip
effect
production
protein
kinase
inhibitor
wortmannin
pka
order
determine
whether
pka
signal
pathway
mediate
stimulatory
effect
vip
synthesis
breast
cancer
cell
inhibitor
able
decrease
vip
effect
level
involvement
camp
pka
pathway
far
confirm
observation
stimulatory
effect
forskolin
upon
secretion
cell
line
image
involvement
pka
pathway
vip
effect
production
cell
cell
cultured
vip
absence
presence
pka
wortmannin
inhibitor
culture
medium
take
respectively
level
measure
elisa
effect
forskolin
also
evaluate
data
mean
anova
bonferroni
test
control
vip
view
within
article
discussion
present
study
reveal
vip
induce
vegf
expression
mrna
protein
level
human
breast
cancer
cell
line
proangiogenic
vip
action
initiate
peptide
interaction
receptor
lead
activation
classical
pka
signal
pathway
tumour
growth
dissemination
dependent
angiogenesis
process
broadly
refer
formation
new
capillary
blood
vessel
vessel
study
molecular
mechanism
angiogenesis
show
depend
dynamic
balance
various
regulatory
proangiogenic
antiangiogenic
factor
among
vegf
main
positive
regulator
angiogenesis
show
many
tumour
include
breast
cancer
vegf
expression
serve
prognostic
criterion
breast
cancer
recent
datum
indicate
various
direct
indirect
antiangiogenic
method
therapy
patient
breast
cancer
complementary
standard
therapy
interestingly
vegf
act
patient
breast
cancer
stimulation
angiogenesis
also
autocrine
paracrine
stimulator
cell
proliferation
well
antiapoptotic
factor
tumour
cell
via
induction
expression
vegf
overexpressed
mrna
protein
level
many
human
tumour
well
immortalize
transform
cell
line
vegf
expression
regulate
several
factor
include
hypoxia
cytokine
hormone
modulator
pkc
act
via
intracellular
signal
pathway
however
hormonal
regulation
vegf
synthesis
breast
cancer
cell
sex
steroid
particularly
oestrogen
still
controversial
subject
although
oestrogen
induce
angiogenesis
evidence
existence
mechanism
breast
cancer
datum
allow
inclusion
vip
among
complex
array
factor
exhibit
proangiogenic
activity
result
stimulation
vegf
expression
first
demonstrate
expression
vip
mrna
peptide
level
breast
cancer
cell
whereas
vip
mrna
level
high
cell
corresponding
peptide
level
similar
two
cell
line
apparent
discrepancy
may
explain
term
degree
vip
mrna
instability
cell
present
datum
vip
significance
breast
cancer
cell
extend
previous
observation
vip
presence
human
normal
mammary
gland
appear
role
regulate
milk
secretion
vip
may
act
breast
cancer
cell
study
autocrine
paracrine
mechanism
since
express
receptor
show
mrna
level
value
observe
cell
relate
previous
observation
oestrogen
downregulation
expression
breast
cancer
cell
line
overexpression
receptor
breast
cancer
tissue
cell
line
well
establish
lack
detection
mrna
expression
two
cell
line
study
agree
poor
null
expression
great
majority
frequently
occur
carcinoma
detect
receptor
functional
show
ability
stimulate
camp
production
activation
adenylate
cyclase
much
frequent
signal
pathway
vip
efficiency
couple
receptor
signal
transduction
machinery
well
cell
since
highly
responsive
vip
camp
production
semiquantitative
analysis
breast
cancer
cell
serve
identify
three
product
bp
sequenced
show
correspond
vegf
isoform
amino
acid
agreement
previous
observation
lung
prostate
cancer
cell
addition
vip
lead
increase
expression
vegf
quantitative
analysis
give
maximal
mrna
level
min
vip
addition
cell
whereas
necessary
cell
obtain
similar
response
previous
study
prostate
cancer
lncap
cell
show
vip
effect
vegf
mrna
expression
compatible
present
result
breast
cancer
cell
similar
experimental
condition
differential
response
breast
cancer
progression
relate
observe
difference
camp
production
two
cell
line
study
applicable
vegf
expression
mrna
level
also
protein
level
since
vip
increase
manner
level
extracellular
secrete
cell
maximal
response
respectively
thus
datum
indicate
stimulatory
effect
vip
protein
production
result
increase
vegf
gene
transcription
possibly
consequence
direct
action
promoter
region
vegf
gene
exhibit
several
potential
transcription
factor
binding
site
multiple
regulatory
pathway
vegf
expression
report
different
tumour
include
breast
cancer
observe
upregulation
vegf
expression
breast
cancer
cell
appear
initiate
receptor
result
adenylate
cyclase
stimulation
pka
activation
support
observation
camp
stimulus
diterpene
forskolin
also
increase
vegf
expression
whereas
pka
inhibitor
completely
block
vip
effect
signal
may
also
involve
since
corresponding
kinase
inhibitor
wortmannin
behave
potent
blocking
agent
upon
vip
activity
previous
result
show
vip
upregulated
vegf
expression
manner
lung
prostate
cancer
cell
addition
involvement
protein
kinase
system
observe
prostate
cancer
cell
context
interesting
note
propose
relevance
signal
pathway
regulation
vegf
expression
breast
cancer
cell
also
development
breast
disease
study
find
vip
stimulate
vegf
expression
breast
cancer
cell
act
receptor
involve
least
camp
pka
signal
pathway
two
cell
line
choose
represent
two
different
stage
disease
since
breast
cell
loose
ability
respond
oestrogen
cancer
development
progression
cell
represent
early
stage
breast
cancer
whereas
cell
reflect
advance
stage
disease
present
datum
potential
proangiogenic
role
vip
level
continue
additional
study
ability
vip
induce
angiogenesis
breast
tumour
well
antiangiogenic
activity
available
antagonist
vip
chemotherapeutic
conjugate
contribute
well
knowledge
breast
cancer
progression
well
much
effective
therapeutic
approach
extremely
important
disease
acknowledgement
study
support
grant
fellow
osteoporosis
skeletal
disease
characterize
decrease
bone
strength
alter
bone
architecture
increase
risk
fracture
clinically
define
bone
mineral
density
bmd
standard
deviation
much
mean
bmd
young
adult
woman
bmd
history
fracture
age
three
strong
prognostic
factor
subsequent
high
rate
bone
loss
occur
early
transition
much
bone
lose
rate
bone
loss
slow
approximately
per
year
woman
enter
postmenopausal
general
increase
bone
loss
observe
menopause
attributed
natural
decrease
estrogen
level
estrogen
negative
regulatory
effect
osteoclast
decrease
estrogen
level
will
increase
rate
bone
resorption
thereby
increase
fracture
risk
association
estrogen
elevate
fracture
risk
observe
large
prospective
study
postmenopausal
woman
year
baseline
serum
estrogen
level
woman
hip
vertebral
fracture
compare
serum
estrogen
level
woman
fracture
adjustment
weight
age
woman
undetectable
serum
estradiol
level
approximate
great
risk
hip
vertebral
fracture
woman
detectable
therefore
appear
woman
undetectable
serum
estradiol
concentration
pg
ml
increase
risk
hip
vertebral
fracture
addition
contribution
estrogen
increased
fracture
risk
epidemiologic
study
large
population
postmenopausal
woman
seek
identify
additional
fracture
risk
factor
independent
bmd
status
prospective
study
healthy
postmenopausal
woman
independent
predictor
fracture
include
age
year
prior
fall
leave
strength
maternal
fracture
history
physical
activity
personal
fragility
fracture
history
several
additional
risk
factor
however
include
body
weight
weight
loss
smoking
predict
fracture
risk
independent
another
study
nearly
postmenopausal
woman
identify
risk
factor
contribute
hip
fracture
author
conclude
individual
risk
factor
minimal
effect
fracture
risk
combination
multiple
risk
factor
significantly
increase
fracture
furthermore
woman
study
bmd
multiple
risk
factor
great
risk
suggest
comprehensive
risk
assessment
may
good
identify
woman
risk
fracture
bone
loss
fracture
risk
breast
cancer
therapy
women
breast
cancer
may
already
elevate
risk
fracture
compare
woman
history
cancer
addition
fracture
risk
factor
experience
healthy
postmenopausal
woman
breast
cancer
therapy
may
increase
bone
turnover
bone
loss
furthermore
direct
toxic
effect
chemotherapy
treatment
may
also
contribute
increase
fracture
risk
evidence
high
fracture
risk
breast
cancer
survivor
come
prospective
longitudinal
cohort
study
postmenopausal
woman
enrolled
women
health
initiative
observational
study
fracture
datum
collect
postmenopausal
breast
cancer
survivor
woman
without
breast
cancer
adjust
age
body
weight
ethnicity
region
enrollment
analysis
woman
breast
cancer
increase
risk
fracture
compare
woman
without
breast
another
study
woman
breast
cancer
bone
metastases
nearly
increase
risk
vertebral
fracture
compare
healthy
woman
risk
increase
approximately
fold
woman
recurrent
disease
taken
together
result
clinical
trial
indicate
survivor
breast
cancer
increase
risk
fracture
chemotherapy
treatment
breast
cancer
particular
concern
premenopausal
woman
premature
menopause
may
result
rapid
significant
bone
contrast
premenopausal
woman
experience
bone
loss
secondary
premature
ovarian
failure
postmenopausal
woman
may
experience
direct
negative
effect
chemotherapy
bone
metabolism
retrospective
chart
review
demonstrate
postmenopausal
woman
undergo
chemotherapy
early
breast
cancer
experience
significant
decrease
bmd
compare
woman
receive
moreover
author
study
suggest
observe
bmd
decrease
standard
deviation
patient
receive
chemotherapy
may
result
approximate
increase
risk
addition
chemotherapy
woman
hormone
breast
cancer
may
also
receive
aromatase
inhibitor
part
adjuvant
regimen
although
therapy
demonstrate
significant
improvement
survival
compare
tamoxifen
also
associate
increase
bone
loss
fracture
incidence
estrogen
bone
protective
postmenopausal
woman
depletion
residual
estrogen
therapy
result
significant
bone
loss
anastrozole
tamoxifen
alone
combination
atac
trial
woman
receive
anastrozole
elevate
level
biochemical
marker
bone
turnover
experience
significant
bmd
loss
lumbar
spine
total
hip
year
therapy
bone
loss
continue
throughout
duration
therapy
year
anastrozole
treatment
patient
experience
approximate
bmd
decline
compare
patient
receive
tamoxifen
lumbar
spine
total
hip
fracture
incidence
also
significantly
high
patient
receive
anastrozole
compare
tamoxifen
respectively
image
aromatase
inhibitor
therapy
increase
fracture
woman
breast
cancer
shown
fracture
incidence
patient
receive
aromatase
inhibitor
therapy
tamoxifen
placebo
four
clinical
trial
tamoxifen
alone
exemestane
big
international
group
cancer
institute
canada
clinical
trial
group
permission
view
within
article
increased
bone
loss
fracture
incidence
appear
common
side
effect
therapy
year
therapy
woman
enrolled
breast
international
group
big
study
receive
letrozole
experience
significantly
much
fracture
woman
receive
tamoxifen
women
letrozole
monotherapy
arm
continue
significantly
much
fracture
woman
tamoxifen
monotherapy
arm
year
treatment
similarly
month
result
intergroup
exemestane
study
ies
show
fracture
significantly
much
frequent
woman
switch
exemestane
compare
woman
continue
tamoxifen
overall
result
trial
indicate
patient
will
experience
significant
bone
loss
increase
risk
fracture
thus
treatment
strategy
allow
patient
clinical
benefit
therapy
without
increase
fracture
risk
need
fracture
risk
patient
breast
cancer
clear
many
breast
cancer
therapy
improve
patient
survival
reduce
disease
recurrence
may
also
detrimental
effect
bone
health
unfortunately
guideline
management
bone
health
woman
breast
cancer
fall
behind
currently
available
clinical
trial
datum
outline
american
society
clinical
oncology
asco
guideline
annual
bmd
screening
recommend
patient
high
risk
experience
fracture
however
patient
fall
threshold
osteoporosis
direct
receive
pharmacologic
therapy
zoledronic
acid
setting
osteoporotic
threshold
may
identify
woman
increase
risk
fracture
example
large
observational
study
healthy
postmenopausal
woman
majority
woman
sustain
osteoporotic
fracture
within
year
bmd
testing
great
furthermore
fracture
occur
woman
osteopenic
woman
consider
therapeutic
intervention
threshold
specify
asco
available
datum
intervention
follow
breast
cancer
efficacy
recurrence
tolerability
liberate
trial
suggest
woman
breast
cancer
may
significant
bone
loss
begin
measurement
baseline
lumbar
spine
bmd
indicate
patient
osteoporotic
osteopenic
initiate
treatment
suggest
least
woman
begin
therapy
may
already
considerable
bone
loss
number
therapeutic
option
available
pharmacologic
prevention
postmenopausal
bone
loss
however
several
treatment
may
problematic
context
patient
breast
cancer
particular
therapy
may
promote
tumorigenesis
reduce
effectiveness
adjuvant
chemotherapy
cancer
furthermore
oral
bisphosphonate
administer
dose
indicate
treatment
osteoporosis
may
insufficient
protect
bone
face
bone
loss
accelerate
cancer
treatment
setting
evidence
several
clinical
trial
indicate
much
viable
treatment
option
prevent
bone
loss
aibl
associate
fracture
may
intravenous
bisphosphonate
end
intravenous
bisphosphonate
zoledronic
acid
examine
three
clinical
trial
prevention
aibl
postmenopausal
woman
undergo
therapy
ovarian
ablation
combine
endocrine
therapy
premenopausal
woman
hormone
breast
cancer
result
suppression
estrogen
production
may
increase
risk
bone
loss
fracture
austrian
breast
colorectal
cancer
study
group
trial
compare
goserelin
ovarian
suppression
plus
tamoxifen
anastrozole
premenopausal
woman
breast
cancer
bmd
substudy
trial
patient
receive
endocrine
treatment
without
zoledronic
acid
mg
every
month
bmd
measure
baseline
month
women
receive
endocrine
therapy
without
concurrent
zoledronic
acid
experience
significant
overall
bone
loss
throughout
year
treatment
month
patient
receive
anastrozole
significant
bmd
loss
lumbar
spine
bmd
loss
hip
respectively
compare
baseline
similar
manner
patient
receive
tamoxifen
experience
bmd
loss
spine
hip
respectively
however
bmd
unaffected
endocrine
therapy
woman
receive
concurrent
zoledronic
acid
remain
stable
throughout
month
treatment
furthermore
zoledronic
acid
significantly
decrease
proportion
patient
become
osteopenic
endocrine
therapy
prevent
patient
receive
anastrozole
become
result
demonstrate
premenopausal
woman
receive
endocrine
therapy
breast
cancer
subject
significant
bone
loss
spine
hip
zoledronic
acid
administer
every
month
endocrine
treatment
prevent
cancer
bone
loss
patient
population
image
upfront
zoledronic
acid
prevent
bone
loss
premenopausal
woman
breast
cancer
receive
endocrine
therapy
change
baseline
time
lumbar
spine
patient
treat
month
anastrozole
acid
show
patient
receive
goserelin
reprinted
gnant
zoledronic
acid
prevent
cancer
bone
loss
premenopausal
woman
receive
adjuvant
endocrine
therapy
breast
cancer
report
austrian
breast
colorectal
cancer
study
group
j
clin
oncol
reprinted
permission
american
society
clinical
oncology
view
within
article
postmenopausal
woman
already
significantly
reduce
estrogen
production
therapy
deplete
residual
estrogen
level
thus
increase
bone
loss
fracture
risk
femara
adjuvant
synergy
trial
will
evaluate
mg
zoledronic
acid
administer
every
month
prevention
aibl
patient
breast
cancer
receive
patient
randomized
receive
zoledronic
acid
concomitantly
therapy
upfront
first
sign
significant
bone
loss
fracture
delay
month
study
patient
receive
upfront
zoledronic
acid
experience
bmd
increase
lumbar
spine
hip
woman
delay
group
experience
significant
bmd
loss
respectively
observe
bmd
change
within
group
appear
correlate
change
biochemical
marker
bone
metabolism
serum
level
type
collagen
alkaline
phosphatase
significantly
increase
delay
group
significantly
decrease
upfront
recently
combine
month
datum
present
integrate
analysis
confirm
upfront
zoledronic
acid
prevent
bone
loss
furthermore
result
patient
complete
year
therapy
indicate
upfront
zoledronic
acid
continue
suppress
marker
bone
metabolism
patient
bmd
lumbar
spine
total
hip
delay
additional
trial
will
define
benefit
zoledronic
acid
combine
early
stage
breast
cancer
image
upfront
zoledronic
acid
prevent
aromatase
bone
loss
postmenopausal
woman
breast
cancer
mean
standard
error
mean
percentage
change
bone
mineral
density
lumbar
spine
total
hip
show
month
woman
breast
cancer
administer
upfront
delay
zoledronic
acid
value
correspond
comparison
baseline
month
reprinted
zoledronic
acid
inhibit
adjuvant
bone
loss
postmenopausal
woman
early
breast
cancer
j
clin
oncol
reprinted
permission
american
society
clinical
oncology
view
within
article
conclusion
data
multiple
clinical
trial
indicate
patient
breast
cancer
increase
risk
fracture
compare
healthy
postmenopausal
woman
current
guideline
bone
health
management
patient
breast
cancer
rely
osteoporotic
bmd
treatment
indicator
fail
identify
large
proportion
woman
risk
fracture
addition
risk
factor
experience
healthy
postmenopausal
woman
bmd
age
personal
history
fragility
fracture
family
history
hip
fracture
glucocorticoid
body
mass
index
patient
breast
cancer
expose
numerous
unique
fracture
risk
factor
clearly
breast
cancer
alone
appear
increase
risk
fracture
independent
risk
treatment
include
chemotherapy
hormone
analogue
therapy
profound
negative
effect
bone
health
thereby
increase
fracture
risk
future
bone
health
management
guideline
will
need
include
comprehensive
fracture
risk
assessment
guide
treatment
decision
modern
treatment
breast
cancer
significantly
prolong
patient
survival
therapy
far
extend
survival
beyond
achieve
tamoxifen
one
consequence
improve
survival
increase
need
address
bone
health
issue
patient
clinical
trial
demonstrate
efficacy
zoledronic
acid
prevention
aibl
administer
concurrently
endocrine
therapy
therefore
zoledronic
acid
combination
may
optimize
clinical
outcome
allow
patient
receive
much
effective
treatment
without
increase
fracture
risk
conflict
interest
statement
receive
honorarium
unrestricted
educational
grant
research
funding
follow
company
amgen
astrazeneca
eli
lilly
glaxosmithkline
novartis
pfizer
roche
role
funding
source
article
support
unrestricted
educational
grant
provide
novartis
pharmaceutical
corporation
acknowledgment
financial
support
medical
editorial
assistance
provide
novartis
pharmaceutical
corporation
thank
michael
communication
medical
editorial
assistance
manuscript
interval
cancer
cancer
occur
negative
screening
episode
far
plan
screening
relatively
common
event
accounting
quarter
much
breast
cancer
occur
screen
subject
frequency
radiological
feature
measure
screening
performance
may
allow
comparison
different
programme
although
require
adoption
agree
criterion
definition
identification
radiological
review
screening
mammogram
report
negative
woman
subsequently
develop
consider
quality
control
aspect
recommend
european
uk
guideline
quality
assurance
screening
mammogram
review
classify
define
classification
vary
generally
comprise
true
visible
screening
mammogram
visible
mammography
diagnosis
false
negative
minor
abnormality
possibly
worth
diagnostic
assessment
also
call
minimal
sign
false
negative
clear
definite
abnormality
prompt
diagnostic
assessment
also
call
screening
error
miss
occult
visible
screening
time
diagnosis
according
european
guideline
good
screening
performance
achieve
review
mammogram
classify
miss
cancer
category
strictly
consider
miss
cancer
mammography
finding
subtle
may
prompt
recall
screening
possible
cancer
largely
identify
knowledge
subsequently
detect
study
explore
effect
mammography
review
methodology
classification
different
review
methodology
currently
employ
allow
valid
comparison
within
optimal
review
process
define
european
uk
guideline
although
depending
adopt
method
reviewer
may
facilitate
identify
screening
mammogram
thus
review
method
will
impact
classification
several
aspect
review
process
may
potentially
affect
reviewer
classification
include
case
mix
extent
information
provide
versus
number
reviewer
consensus
yet
little
directly
evaluate
study
compare
review
method
may
impact
classification
relative
miss
present
retrospective
study
mammographic
review
interval
breast
cancer
validate
set
screening
mammogram
compare
review
methodology
multiple
reviewer
aim
study
assess
influence
review
method
include
extent
information
available
time
review
classification
particularly
within
false
negative
spectrum
estimate
associate
variability
classification
evidence
work
discuss
implication
radiological
review
screening
importance
define
standardising
review
methodology
quality
control
measure
screening
practice
material
method
set
mammogram
employ
study
consist
screening
case
negative
screen
report
negative
confirm
repeat
screening
seed
screening
case
report
negative
follow
within
year
ten
case
choose
randomly
case
previously
review
three
experience
involve
review
film
study
ensure
consensus
screening
mammogram
include
study
relate
period
screening
centre
subjects
identification
datum
conceal
film
original
conventional
screen
film
mammogram
digitized
dvd
prepare
display
case
follow
sequence
two
adjacent
oblique
view
follow
full
screen
magnification
upper
half
half
sequence
show
craniocaudal
view
simulate
currently
adopt
report
digital
mammography
workstation
six
radiologist
prior
knowledge
study
film
involve
film
reading
study
different
experience
reading
mammogram
year
total
mammogram
read
compare
effect
review
method
film
reading
perform
three
independent
phase
separate
time
first
phase
review
method
simulate
blind
mask
review
radiologist
invite
look
whole
set
unaware
case
control
mix
ratio
report
opinion
based
three
option
negative
return
screening
screen
need
referral
assessment
minor
abnormality
see
abnormality
see
definitely
worth
diagnostic
assessment
reporting
give
form
indicate
scheme
two
mammography
view
exact
side
site
abnormality
note
approximately
week
second
phase
review
review
method
perform
simulate
partially
inform
review
set
now
include
display
previously
describe
radiologist
aware
reporting
based
approach
phase
final
review
phase
review
method
approximately
week
dvd
provide
simulate
fully
inform
review
include
interval
case
together
diagnostic
mammogram
display
report
approach
remain
constant
report
review
phase
check
one
radiologist
involve
film
reading
study
set
sc
verify
exactly
identify
reviewer
describe
distribution
classification
case
reviewer
review
method
probability
report
minimal
sign
determine
accord
reading
radiologist
review
method
multivariate
analysis
logistic
regression
extra
variation
package
variation
report
negative
control
review
method
determine
accord
kappa
statistic
kappa
design
adjust
expect
chance
agreement
convention
value
respectively
indicative
slight
fair
moderate
substantial
almost
perfect
concordance
result
table
show
distribution
classification
reviewer
review
method
report
average
review
method
range
radiologist
review
method
range
review
method
range
respectively
report
average
review
method
range
radiologist
review
method
range
review
method
range
respectively
table
show
result
multivariate
analysis
probability
classification
minimal
sign
reader
radiologist
reading
modality
effect
significant
association
evident
reader
whereas
significantly
high
probability
classification
evident
review
method
review
method
compare
review
method
table
distribution
classification
interval
cancer
accord
review
method
six
radiologist
review
reading
review
method
minimal
screening
review
method
minimal
screening
review
method
minimal
screening
table
view
within
article
table
radiologist
review
method
effect
classification
interval
cancer
screening
error
minimal
sign
confidence
interval
radiologist
review
method
table
reference
category
view
within
article
table
show
classification
negative
normal
screen
report
review
method
average
reporting
rate
range
radiologist
range
respectively
distribution
report
category
similar
one
reader
minimal
sign
clearly
adopt
threshold
suspicion
average
ppv
report
first
reading
range
radiologist
report
range
table
distribution
classification
negative
screening
case
review
method
radiologist
reading
minimal
screening
table
view
within
article
consistency
report
negative
control
review
method
show
table
overall
reproducibility
slight
minimal
sign
fair
negative
report
table
concordance
kappa
statistic
classify
interval
cancer
negative
control
review
method
review
average
six
reviewer
z
minimal
screening
table
view
within
article
discussion
european
guideline
focus
frequency
rather
review
quality
screening
radiological
review
however
important
evaluate
potentially
improve
performance
radiologist
involve
provide
information
clinical
quality
gather
epidemiological
may
argue
radiological
review
may
approach
programme
perspective
strong
case
make
potential
ability
guide
clinical
research
priority
improve
radiological
surveillance
interval
breast
cancer
adopt
part
clinical
quality
assurance
two
issue
point
first
currently
lack
standardisation
evidence
review
method
may
impact
classification
interval
second
implication
setting
valid
fair
manner
approximate
reasonable
practice
extent
process
inform
blind
expect
effect
classification
reality
one
replicate
exact
condition
screening
practice
experimental
design
claim
replicate
real
screening
instead
comparative
phase
reading
allow
valid
evaluation
difference
classification
phase
within
study
brief
work
provide
far
evidence
two
aspect
radiological
review
interval
breast
cancer
first
extent
information
provide
film
reader
time
review
influence
classification
screening
mammogram
general
much
inform
little
blind
reviewer
much
likely
screen
will
classify
show
abnormality
association
strongly
evident
category
miss
second
show
substantial
variability
reader
classification
blind
inform
review
method
simulate
blind
review
phase
reviewer
unaware
interval
case
unaware
ratio
interval
normal
screen
phase
reviewer
aware
study
interval
case
phase
fully
inform
reviewer
aware
study
interval
case
diagnostic
mammogram
show
phase
blind
review
comparable
reality
since
reader
aware
perform
review
series
seed
cancer
case
much
high
cancer
prevalence
current
screening
much
common
reaction
condition
even
expert
reader
reduce
threshold
suspicion
maximize
sensitivity
miss
cancer
usually
perceive
great
unnecessary
recall
negative
case
much
likely
reason
fair
proportion
normal
screen
classify
abnormal
first
phase
study
reality
screening
reader
prompt
case
will
subsequently
develop
face
large
majority
negative
screen
cancer
will
either
perceive
perceive
judge
warrant
recall
radiological
review
method
close
screening
practice
possible
extremely
important
avoid
overestimation
false
negative
miss
classification
much
review
perform
purpose
latter
seldom
perform
practice
blind
approach
might
major
implication
review
outcome
conclusion
set
unrealistic
standard
radiologist
performance
indeed
screening
process
general
international
screening
environment
raise
increase
issue
clinical
staff
understand
relevance
standard
blind
review
method
expect
broad
interest
service
screening
work
well
study
see
table
show
inform
relative
blind
review
will
lead
much
classify
miss
study
differ
design
allow
compare
phase
increase
extent
information
quantify
relative
difference
classification
interval
case
similar
study
design
duncan
study
fail
demonstrate
increase
false
negative
rate
compare
blind
inform
review
knowledge
cancer
side
site
pattern
table
summary
study
compare
blind
inform
interval
cancer
review
method
include
present
study
proportion
case
review
screening
error
calculate
negative
control
review
screening
error
mix
inform
review
present
moberg
duncan
rijke
table
current
screening
reading
per
day
per
week
seed
case
review
set
interval
cancer
negative
control
negative
control
ratio
review
set
overall
blind
reading
ratio
view
within
article
aim
blind
review
interval
case
seed
screen
negative
series
reproduce
screening
condition
cancer
prevalence
may
addition
fatigue
loss
attention
lead
false
negative
report
course
current
screening
cancer
negative
ratio
cancer
prevalence
reproduce
compromise
find
number
set
allow
sensitivity
estimate
size
set
review
study
choose
ratio
reader
allow
total
reading
assess
average
sensitivity
ratio
mix
negative
control
blind
review
vary
different
study
see
table
high
study
moberg
ratio
study
rijke
ratio
might
expect
excess
concentration
cancer
set
might
influence
reviewer
adjust
threshold
suspicion
towards
high
sensitivity
hypothesis
remain
unproven
compromise
high
cancer
control
case
ratio
reasonable
set
size
explain
despite
relatively
small
sample
size
study
allow
show
significant
difference
report
accord
review
methodology
focused
within
false
negative
spectrum
assess
whether
mammography
review
method
differential
effect
much
subtle
cancer
much
obvious
cancer
miss
although
much
inform
review
method
increase
classification
within
category
fact
much
evident
much
significant
category
feel
reasonable
treat
repeat
measurement
three
reading
film
per
reviewer
independent
measurement
analysis
may
argue
change
classification
case
study
relate
learn
effect
reviewer
much
likely
identify
case
result
sequential
phase
film
reading
keep
memory
previous
reading
although
theoretically
possible
unlikely
account
highly
significant
difference
show
datum
much
likely
due
impact
extra
information
provide
review
method
relative
method
addition
separate
film
reading
phase
week
period
review
radiologist
will
read
large
volume
least
screening
diagnostic
mammogram
study
design
might
lack
comparison
previous
mammogram
old
screen
film
mammogram
instead
much
recent
case
digital
mammogram
comparison
previous
mammogram
common
practice
screening
program
prior
film
available
include
aspect
avoid
complexity
identify
true
effect
review
method
reason
efficiency
consider
several
reading
phase
previous
mammogram
always
routinely
display
current
screening
reading
service
include
previous
mammogram
available
perhaps
show
slight
increase
true
positive
abnormality
recall
investigation
particularly
minimal
sign
slight
decrease
false
positive
recall
substantially
change
overall
finding
conclusion
work
particular
set
mammogram
since
standardised
set
know
outcome
previously
publish
film
soft
copy
reading
dvd
digital
mammogram
several
reason
digital
mammography
yet
show
superior
screen
film
mammography
still
widely
adopt
europe
review
much
incident
interval
still
deal
screen
film
mammogram
proper
evaluation
digital
mammogram
require
set
display
dedicate
workstation
irrespective
reason
compare
phase
reading
within
set
finding
valid
whether
much
recent
film
much
sophisticated
technology
conclusion
provide
evidence
effect
mammography
review
methodology
classification
much
inform
review
mammogram
case
subsequently
identify
much
likely
screening
mammogram
will
classify
miss
category
due
subjective
nature
mammography
interpretation
substantial
variability
radiological
classification
standardising
mammography
review
method
ensure
validity
relative
reasonable
screening
practice
variability
classification
suggest
multiple
reviewer
employ
consensus
approach
disagreement
radiological
review
perform
part
quality
assurance
screening
datum
support
blind
review
method
since
inform
review
significantly
increase
frequency
classify
false
negative
whenever
possible
proportion
negative
control
seed
high
possible
since
much
representative
screening
scenario
reduce
increase
perception
bias
might
occur
prevalence
set
high
allow
much
realistic
classification
interval
breast
cancer
conflict
interest
statement
author
declare
absence
financial
personal
relationship
people
organisation
inappropriately
influence
bias
research
systemic
chemotherapy
treatment
breast
cancer
improve
overall
survival
whether
give
preoperatively
postoperative
adjuvant
newer
chemotherapy
regimen
contain
taxane
far
improve
survival
compare
standard
taxane
expensive
toxic
might
benefit
small
number
patient
therefore
identification
predictive
factor
research
priority
several
neoadjuvant
chemotherapy
trial
report
signature
obtain
tumour
biopsy
take
much
study
describe
signature
predict
clinical
pathological
response
although
one
fail
identify
gene
predict
study
two
weakness
restrict
routine
practice
first
none
attempt
predict
response
patient
randomised
different
regimen
specificity
signature
particular
regimen
remain
unproven
second
many
study
include
mix
population
patient
tumour
patient
tumour
tumour
rate
clinical
pathological
response
neoadjuvant
since
status
dominant
factor
datum
breast
tumour
study
mix
population
lead
confound
gene
gene
link
status
previously
report
signature
predict
response
cell
line
tumour
range
chemotherapeutic
aim
present
study
confirm
ability
signature
predict
response
breast
tumour
chemotherapy
large
series
patient
enrolled
phase
iii
neoadjuvant
trial
method
patient
selection
sample
processing
substudy
restrict
patient
tumour
study
contain
patient
tumour
patient
tumour
easily
confound
gene
link
status
additionally
pathological
complete
response
rare
treatment
either
regimen
patient
tumour
well
selection
patient
will
great
effect
disease
pathological
complete
response
surrogate
measure
chemosensitivity
measure
consistently
predict
well
survival
neoadjuvant
undertake
study
context
prospective
phase
iii
intergroup
trial
neoadjuvant
chemotherapy
european
organisation
research
treatment
cancer
eortc
breast
international
group
big
design
show
figure
trial
compare
treatment
traditional
regimen
regimen
patient
large
operable
tumour
eligible
patient
evidence
distant
metastatic
disease
ie
define
tumour
node
metastasis
tnm
stage
system
histologically
confirm
large
operable
invasive
tumour
tumour
size
node
status
locally
advance
breast
cancer
plan
primary
endpoint
difference
survival
two
group
depending
status
will
report
later
predicting
response
gene
signature
plan
secondary
endpoint
trial
report
substudy
restrict
patient
assess
eortc
datum
centre
april
meet
follow
criterion
tumour
immunohistochemistry
pretreatment
biopsy
completion
plan
chemotherapy
regimen
major
protocol
violation
tumour
much
yield
rna
available
pretreatment
freeze
biopsy
ethical
approval
clinical
trial
associate
translational
project
obtain
participate
institution
patient
give
write
inform
consent
clinical
translational
study
image
image
figure
study
design
eortc
big
trial
epirubicin
cyclophosphamide
plus
docetaxel
surgery
follow
radiotherapy
hormonal
therapy
accord
centre
policy
view
within
article
substudy
patient
randomly
assign
european
regimen
six
cycle
mg
fluorouracil
mg
epirubicin
mg
cyclophosphamide
fec
treatment
three
cycle
mg
docetaxel
follow
three
cycle
mg
epirubicin
plus
mg
docetaxel
tet
completion
chemotherapy
patient
undergo
surgery
mastectomy
depending
locoregional
clinical
response
pathological
complete
response
outcome
measure
define
disappearance
invasive
component
primary
tumour
treatment
much
scatter
tumour
cell
detect
pathologist
resection
specimen
analysis
pathological
complete
response
locally
pathologist
centre
datum
review
centrally
patient
one
incisional
two
core
biopsy
freeze
start
chemotherapy
frozen
section
biopsy
assess
centrally
vb
exclude
study
tumour
cell
content
rna
extract
freeze
section
previously
affymetrix
chip
statistical
analysis
microarray
datum
deposit
gene
expression
omnibus
database
accession
number
affymetrix
file
normalised
robust
average
algorithm
infer
presence
amplicon
gene
region
chromosome
cluster
distance
ward
linkage
method
conversion
datum
probability
pathological
complete
response
university
usa
anthracycline
eortc
clinical
study
epirubicin
since
datum
epirubicin
sensitivity
available
signature
doxorubicin
anthracycline
similar
epirubicin
weight
generate
analysis
apply
expression
value
summed
create
score
convert
probability
apply
function
webappendix
webtable
probability
combine
yield
predict
probability
pathological
complete
response
fec
tet
regimen
previously
receiver
operate
characteristic
roc
curve
test
quality
prediction
dataset
find
ci
area
curve
auc
roc
curve
statistical
significance
discrimination
pathological
complete
response
complete
response
assess
wilcoxon
test
statistical
test
youden
select
threshold
estimation
sensitivity
specificity
positive
predictive
value
ppv
negative
predictive
value
npv
overall
accuracy
sensitivity
specificity
youden
index
express
fraction
roc
analysis
convert
percentage
summary
table
association
clinical
variable
pathological
complete
response
test
univariate
multivariate
logistic
regression
fisher
exact
test
category
ordinal
variable
observation
pool
adjacent
consecutive
category
grade
tumour
size
node
status
binary
estimate
age
signature
cut
median
test
population
fisher
exact
test
age
surrogate
indicator
menopausal
status
median
age
year
continuous
variable
age
signature
logistic
regression
missing
value
grade
assign
separate
category
avoid
decrease
sample
size
logistic
regression
analysis
model
potential
benefit
select
treatment
regimen
accord
predict
probability
pathological
complete
response
individual
regimen
regimen
preference
score
calculate
subtract
predict
probability
pathological
complete
response
tet
predict
probability
pathological
complete
response
fec
simple
scenario
patient
negative
regimen
preference
score
receive
tet
patient
positive
score
receive
fec
zero
threshold
allocation
one
regimen
assume
predict
probability
pathological
complete
response
two
regimen
perfectly
match
unlikely
independently
derived
datum
hypothetical
pathological
complete
response
rate
entire
group
patient
calculate
different
regimen
allocation
threshold
take
account
observe
pathological
complete
response
rate
number
patient
group
threshold
study
register
clinical
trial
site
national
cancer
institute
website
role
funding
source
sponsor
trial
eortc
design
coordinated
trial
funding
source
study
role
design
study
collection
analysis
interpretation
datum
writing
report
md
pf
ap
sm
jrn
rdi
full
access
raw
datum
corresponding
author
full
access
datum
final
responsibility
submit
publication
result
patient
tumour
assess
datum
centre
april
patient
exclude
major
protocol
violation
two
patient
tumour
patient
content
pretreatment
incisional
core
biopsy
patient
poor
quality
rna
little
yield
rna
patient
biopsy
tumour
fec
group
tumour
tet
group
eortc
big
study
test
affymetrix
microarray
clinical
pathological
datum
tumour
show
table
webtable
response
predictor
construct
take
gene
predict
response
cell
line
fluorouracil
cyclophosphamide
docetaxel
epirubicin
give
single
drug
combine
signature
form
genomic
signature
previously
figure
show
predict
probability
pathological
complete
response
fec
tet
calculate
genomic
signature
two
treatment
group
signature
significantly
predict
response
patient
receive
appropriate
drug
assess
ability
signature
identify
responder
roc
analysis
youden
index
identify
threshold
calculation
performance
accuracy
prediction
signature
patient
ci
patient
fec
group
patient
patient
tet
group
table
furthermore
signature
specific
two
regimen
table
figure
show
signature
predict
response
correct
group
ie
fec
signature
predict
response
fec
treatment
tet
signature
predict
response
tet
treatment
group
ie
fec
tet
tet
fec
treatment
regimen
eortc
study
contain
epirubicin
albeit
differ
schedule
total
dose
therefore
small
amount
crossover
predictor
oppose
group
might
anticipate
note
weak
prediction
tet
signature
fec
group
albeit
boundary
ci
auc
barely
exceed
value
random
classifier
none
fec
signature
tet
group
ci
auc
overlap
design
study
call
exposure
tumour
three
cycle
docetaxel
give
combine
anthracycline
plus
taxane
pattern
response
tet
initial
taxane
exposure
explain
fec
predictor
significant
tet
group
study
role
individual
drug
two
group
roc
analysis
assess
performance
predictor
table
webfigure
patient
signature
significantly
associate
response
patient
receive
relevant
drug
consistent
absence
prediction
fec
signature
docetaxel
much
strong
predictor
doxorubicin
tet
group
conclude
signature
predict
pathological
complete
response
build
individual
drug
signature
predict
pathological
complete
response
table
clinical
demographic
characteristic
patient
fec
group
tet
group
age
year
histology
invasive
invasive
tnm
stage
grade
hormone
receptor
status
pr
status
response
table
pcr
pathological
complete
response
receptor
ductal
lobular
cancer
three
patient
pr
oestrogen
receptor
assess
locally
centre
case
little
tumour
cell
stain
positive
pr
immunohistochemistry
deem
negative
case
negative
status
assess
centrally
based
microarray
datum
view
within
article
image
image
figure
prediction
pathological
complete
response
genomic
signature
stratified
trial
group
complete
response
point
individual
patient
complete
response
pathological
complete
response
receive
fec
receive
tet
green
dash
line
show
mean
value
group
black
dash
line
show
maximum
empirical
youden
index
panel
calculate
performance
metric
table
view
within
article
table
performance
metric
genomic
signature
fec
grouptet
group
patient
ci
patient
ci
table
ppv
predict
pathological
complete
response
classification
statistic
optimum
threshold
maximum
empirical
youden
index
ci
show
view
within
article
table
area
roc
curve
genomic
signature
single
agent
signature
group
fec
grouptet
group
auc
ci
ci
fec
tet
table
auc
group
approximate
ci
bootstrap
sample
value
wilcoxon
rank
sum
test
null
hypothesis
difference
view
within
article
image
image
figure
roc
analysis
ability
genomic
signature
discriminate
patient
pathological
complete
response
patient
residual
disease
auc
number
case
location
maximum
empirical
youden
index
green
point
show
view
within
article
clinical
variable
age
diagnosis
node
status
tumour
size
pathological
variable
histological
grade
status
test
ability
predict
pathological
complete
response
fisher
exact
test
table
univariate
logistic
regression
webtable
tumour
size
none
clinical
pathological
variable
show
significant
association
response
tumour
size
patient
tet
group
show
borderline
significant
association
response
significant
bonferroni
correction
comparison
table
comparison
webtable
larger
tumour
much
difficult
treat
tumour
size
classic
prognostic
factor
breast
cancer
fec
tet
signature
test
way
find
significantly
associate
response
odd
ratio
ci
fec
tet
comparison
remain
significant
bonferroni
correction
expect
give
absence
effect
clinical
pathological
variable
univariate
analysis
genomic
signature
remain
significant
formal
multivariate
testing
webtable
table
fisher
exact
test
association
clinical
variable
genomic
signature
pathological
complete
response
group
fec
grouptet
group
ci
ci
size
grade
nodal
status
status
age
old
fec
tet
table
ratio
amplify
status
establish
table
age
analyse
binary
variable
cut
year
surrogate
menopausal
status
signature
binary
variable
cut
median
univariate
multivariate
linear
regression
model
include
age
genomic
signature
continuous
variable
show
webtable
view
within
article
plot
predict
probability
pathological
complete
response
two
regimen
divide
four
quadrant
figure
quadrant
contain
many
patient
respond
well
treatment
triangle
undesirable
taxane
mean
patient
candidate
conventional
fec
treatment
conversely
quadrant
many
patient
fail
respond
treatment
circle
patient
candidate
treatment
new
drug
remain
quadrant
contain
patient
high
predict
probability
pathological
complete
response
one
regimen
quadrant
contain
many
patient
fail
respond
fec
green
circle
high
predict
probability
pathological
complete
response
tet
quadrant
contain
patient
fail
respond
tet
blue
circle
high
predict
probability
pathological
complete
response
fec
inspection
plot
show
divide
diagonal
line
might
form
basis
rule
allocate
patient
different
regimen
patient
diagonal
line
receive
tet
patient
line
receive
fec
diagonal
line
act
regimen
allocation
threshold
select
treatment
least
two
reason
exist
ask
might
happen
threshold
alter
ie
diagonal
line
displace
vertically
first
might
desirable
decrease
number
patient
receive
taxane
second
predict
probability
pathological
complete
response
two
regimen
independently
derived
unlikely
match
precisely
image
image
figure
probability
pathological
complete
response
fec
tet
treatment
complete
response
point
correspond
individual
patient
plot
show
predict
probability
pcr
calculate
microarray
datum
record
value
show
figure
vertical
horizontal
dot
line
draw
threshold
calculate
performance
metric
table
treatment
allocation
model
assign
patient
fec
point
diagonal
line
tet
point
mark
arrow
discuss
text
view
within
article
develop
treatment
allocation
model
figure
study
effect
alter
threshold
first
calculate
regimen
preference
score
simply
predict
probability
pathological
complete
response
fec
treatment
minus
predict
probability
pathological
complete
response
tet
treatment
point
mark
arrow
figure
regimen
preference
score
therefore
treatment
allocation
model
patient
assign
fec
treatment
regimen
preference
score
threshold
diagonal
line
tet
regimen
preference
score
threshold
diagonal
line
diagonal
line
figure
correspond
threshold
zero
figure
patient
mark
arrow
allocate
treatment
tet
regimen
preference
score
zero
ratio
green
triangle
green
circle
diagonal
line
give
pathological
complete
response
rate
fec
treatment
number
multiply
total
number
point
line
give
number
responder
group
allocate
fec
treatment
likewise
ratio
blue
triangle
blue
circle
line
give
pathological
complete
response
rate
tet
treatment
number
multiply
total
number
point
line
give
number
responder
group
allocate
tet
treatment
combine
calculate
hypothetical
pathological
complete
response
rate
group
together
image
image
figure
treatment
allocation
model
complete
response
red
line
show
hypothetical
pathological
complete
response
rate
change
proportion
patient
allocate
treatment
change
view
within
article
line
downward
figure
equivalent
decrease
regimen
allocation
threshold
figure
threshold
lower
ie
diagonal
line
figure
move
vertically
much
patient
assign
fec
treatment
green
dash
line
figure
whereas
raise
much
patient
assign
tet
treatment
blue
dash
line
example
point
mark
arrow
regimen
preference
score
decrease
regimen
allocation
threshold
mean
score
now
threshold
patient
receive
fec
treatment
generally
score
much
likely
patient
receive
tet
treatment
conversely
threshold
much
likely
patient
receive
fec
treatment
red
line
figure
show
hypothetical
pathological
complete
response
rate
change
regimen
allocation
threshold
vary
wide
range
threshold
central
region
hypothetical
pathological
complete
response
rate
red
line
well
pathological
complete
response
rate
note
fec
tet
group
clinical
trial
exact
choice
threshold
broad
range
seem
suggest
procedure
will
robust
peak
red
curve
displace
left
zero
suggest
fec
treatment
safely
much
frequently
treatment
select
signature
describe
conclude
clinical
application
genomic
signature
useful
effect
overall
treatment
success
decrease
number
patient
expose
taxane
discussion
study
confirm
signature
based
cell
line
predict
pathological
complete
response
breast
tumour
chemotherapy
knowledge
first
study
genomic
predictor
two
different
treatment
study
large
cohort
patient
enrolled
multicentre
randomised
phase
iii
clinical
trial
will
require
establish
whether
genomic
signature
also
predict
survival
likely
since
much
previous
study
note
patient
achieve
pathological
complete
response
indeed
long
survival
remain
true
multivariate
finding
report
doxorubicin
signature
instead
epirubicin
signature
drug
anthracycline
similar
activity
expect
change
major
effect
outcome
second
caveat
gene
weight
calculate
datum
obtain
different
affymetrix
platform
study
platform
inevitably
result
loss
performance
since
weight
implicitly
convey
information
dynamic
range
individual
probe
particular
change
platform
might
affect
threshold
performance
measure
auc
roc
curve
useful
measure
performance
change
platform
require
predetermine
threshold
auc
obtain
study
support
conclusion
signature
correctly
predict
response
individual
drug
combination
nonetheless
repeat
study
chip
develop
epirubicin
signature
might
improve
quality
prediction
one
obstacle
widespread
application
genomic
signature
technical
challenge
preserve
freeze
biopsy
routine
clinical
practice
affymetrix
chip
develop
analysis
material
small
modification
protocol
might
need
test
material
alternatively
pcr
technique
develop
measure
expression
gene
genomic
signature
universally
accept
definition
pathological
complete
response
much
stringent
definition
specify
complete
absence
invasive
disease
breast
axilla
definition
difficult
apply
context
multicentre
trial
necessitate
standardisation
local
pathological
assessment
pathological
review
resected
tissue
aim
study
test
whether
chemosensitivity
signature
derived
cell
line
predict
chemosensitivity
patient
pathological
complete
response
define
disappearance
invasive
component
primary
tumour
treatment
much
scatter
tumour
cell
detect
pathologist
resection
specimen
proof
large
mass
tumour
cell
disappear
give
relatively
advance
nature
tumour
study
occur
tumour
cell
sensitive
drug
therefore
occurrence
appropriate
outcome
measure
give
aim
killing
large
number
tumour
cell
desirable
guarantee
survival
patient
possibly
rare
tumour
stem
cell
crucial
determinant
hence
validation
clinical
relevance
signature
report
will
good
show
prediction
improve
survival
patient
large
adjuvant
study
definition
pathological
complete
response
relevant
present
signature
show
predict
sensitivity
tumour
negative
work
will
need
show
whether
signature
different
one
relevant
tumour
express
steroid
hormone
receptor
good
context
adjuvant
study
pathological
complete
response
rate
neoadjuvant
treatment
tumour
indeed
pathological
complete
response
rate
group
neoadjuvant
setting
study
ten
time
large
one
undertake
need
identify
signature
similar
predictive
power
group
treatment
allocation
model
explore
figure
figure
suggest
selection
treatment
regimen
genomic
signature
potential
increase
pathological
complete
response
rate
around
confirm
prospectively
phase
iii
trial
will
major
change
current
paradigm
breast
cancer
treatment
important
caveat
will
apply
patient
tumour
within
group
two
major
class
tumour
different
profile
call
class
genomic
signature
predict
response
class
small
size
group
mean
exclude
possibility
performance
signature
differ
two
group
many
new
drug
study
combination
neoadjuvant
adjuvant
chemotherapy
selective
enrolment
patient
unlikely
benefit
establish
drug
combination
decrease
size
increase
power
trial
npv
genomic
signature
make
feasible
identify
early
stage
patient
unlikely
respond
fec
tet
treatment
hence
much
benefit
new
drug
organising
clinical
trial
basis
important
implication
subsequent
new
drug
test
information
obtain
apply
define
group
albeit
one
poor
outcome
conventional
treatment
whether
right
proceed
way
matter
debate
clearly
think
contributors
mc
tp
pr
eb
jb
dc
hb
participate
recruitment
patient
rdi
participate
tissue
section
rna
extraction
microarray
hybridisation
vb
responsible
pathological
examination
biopsy
hb
manage
clinical
trial
select
patient
inclusion
substudy
pf
md
ap
sm
jrn
participate
statistical
analysis
hb
md
dc
ap
jrn
rdi
participate
design
study
hb
md
dc
jb
ap
rdi
participate
report
author
see
approve
final
version
report
conflict
interest
author
declare
conflict
interest
acknowledgment
thank
patient
doctor
nurse
involve
eortc
study
generous
participation
thank
vos
expert
assistance
datum
management
sample
processing
thank
help
bioinformatics
critical
comment
report
thank
university
dna
array
facility
swiss
institute
bioinformatics
project
support
thank
european
commission
sixth
framework
programme
active
grant
fondation
fondation
swiss
national
science
foundation
molecular
oncology
eortc
translational
research
fund
swedish
cancer
society
king
fifth
fund
swedish
research
council
national
institute
health
american
association
cancer
research
foundation
cancer
research
financial
support
treatment
patient
breast
cancer
adjuvant
systemic
treatment
decrease
risk
develop
distant
metastases
death
around
prognostic
factor
identify
patient
relatively
high
risk
develop
distant
metastases
patient
benefit
much
treatment
main
clinically
prognostic
factor
breast
cancer
age
tumour
diameter
histological
several
commonly
clinicopathological
guideline
develop
basis
prognostic
however
factor
predict
accurately
exact
clinical
behaviour
breast
tumour
therefore
patient
depending
clinicopathological
guideline
advise
adjuvant
systemic
treatment
according
one
study
many
patient
need
treat
one
patient
remain
alive
clinicopathological
guideline
therefore
additional
factor
need
guide
decision
adjuvant
systemic
treatment
gene
prognosis
signature
identify
gene
expression
profile
patient
breast
cancer
select
tissue
bank
netherlands
cancer
five
patient
receive
form
adjuvant
systemic
treatment
three
patient
receive
chemotherapy
two
patient
receive
endocrine
treatment
patient
follow
least
annually
least
year
patient
classify
prognosis
signature
poor
prognosis
odd
ratio
ci
develop
distant
metastasis
within
year
compare
patient
good
signature
seem
much
powerful
prognostic
factor
distant
metastasis
death
current
clinicopathological
factor
seem
strong
independent
prognostic
factor
multivariate
prognostic
value
signature
validate
three
retrospective
study
patient
breast
cancer
van
vijver
study
signature
patient
age
year
good
prognosis
signature
poor
prognosis
signature
buyse
assess
untreated
patient
age
year
good
prognosis
signature
poor
prognosis
signature
study
patient
two
dutch
institute
age
year
good
prognosis
signature
poor
prognosis
signature
van
vijver
group
show
year
overall
survival
patient
cancer
poor
prognosis
signature
versus
patient
good
prognosis
three
study
prognosis
signature
seem
strong
independent
prognostic
factor
comparison
current
clinicopathological
factor
multivariate
analysis
prognosis
signature
patient
might
treat
save
one
life
however
whether
accurate
subject
ongoing
research
major
difficulty
technical
implementation
prognosis
signature
daily
clinical
practice
will
feasibility
collect
breast
tumour
rna
necessary
obtain
prognosis
signature
much
hospital
tumour
sample
routinely
directly
fix
formalin
embed
paraffin
block
however
storage
tissue
way
result
rna
degradation
evaluate
whether
prognosis
signature
suitable
clinical
practice
undertake
microarray
breast
cancer
raster
study
aim
assess
feasibility
implementation
gene
prognosis
signature
diagnostic
test
community
hospital
netherlands
effect
prognosis
signature
adjuvant
systemic
treatment
proportion
patient
poor
versus
good
prognosis
series
unselected
patient
breast
cancer
concordance
risk
predict
prognosis
signature
risk
predict
commonly
clinicopathological
guideline
report
finding
raster
study
method
patient
women
enrolled
study
give
inform
consent
histologically
confirm
unilateral
primary
operable
invasive
adenocarcinoma
breast
clinically
accord
tumour
node
metastases
tnm
stage
system
sixth
edition
age
year
diagnosis
exclusion
criterion
previous
history
malignancy
exception
carcinoma
cervical
dysplasia
neoadjuvant
systemic
treatment
end
accrual
patient
study
coordinator
decide
change
maximum
allow
age
year
ie
year
study
coordinator
protocol
prognostic
value
prognosis
signature
obtain
patient
age
year
time
plan
validation
prognostic
value
patient
age
year
yet
available
central
review
board
netherlands
cancer
institute
approve
amendment
however
patient
include
analysis
report
procedure
participate
study
hospital
uniformly
structure
multidisciplinary
breast
cancer
care
standard
operating
procedure
treat
least
patient
breast
cancer
year
least
one
dedicate
physician
surgeon
pathologist
medical
oncologist
local
coordinator
since
collection
tumour
tissue
surgical
specimen
pathologist
obtain
prognosis
signature
standard
procedure
patient
permission
inform
consent
surgery
need
therefore
patient
enrolled
surgery
ensure
permission
obtain
enrolment
patient
receive
surgery
primary
treatment
immediately
breast
tumour
surgically
remove
store
container
without
preserve
solution
eg
formalin
take
pathology
department
surgeon
process
attend
local
pathologist
surgeon
pathologist
assist
staff
train
procedure
within
surgery
tumour
sample
take
local
pathologist
quality
control
check
rna
accordance
guidance
food
drug
administration
fda
assessment
gene
prognosis
signature
mammaprint
amsterdam
netherlands
purpose
biopsy
punch
mm
diameter
distribute
trial
coordinator
netherlands
cancer
institute
participate
pathology
department
ensure
standardised
tumour
sampling
sample
store
local
pathologist
directly
removal
container
rna
preservation
fluid
name
since
change
austin
tx
usa
send
regular
mail
pathology
department
netherlands
cancer
institute
sample
patient
postoperatively
eligible
analysis
prognosis
signature
send
agendia
laboratory
amsterdam
netherlands
sample
postoperatively
ineligible
patient
store
pathology
department
netherlands
cancer
institute
quality
check
rna
sample
routinely
agendia
laboratory
prognosis
signature
test
surgery
patient
follow
exclude
analysis
disease
define
metastasis
mm
histology
little
invasive
tumour
cell
sample
insufficient
quality
tumour
patient
histology
patient
consider
invasive
breast
cancer
surgery
therefore
ask
participate
raster
study
surgery
definitive
pathological
examination
diagnosis
prove
different
invasive
carcinoma
eg
ductal
carcinoma
situ
cystic
carcinoma
myoepithelial
tumour
malignancy
treat
physician
ascertain
patient
prognosis
corresponding
advice
adjuvant
systemic
treatment
chemotherapy
without
immunotherapy
endocrine
treatment
dutch
institute
healthcare
improvement
cbo
guideline
register
treatment
advice
clinical
registration
form
crf
subsequently
prognosis
signature
result
obtain
weigh
treatment
decision
final
treatment
advice
register
crf
adjuvant
systemic
treatment
advice
discuss
patient
patient
preference
treatment
include
actual
adjuvant
systemic
treatment
give
register
crf
obtain
annually
accrue
patient
april
tumour
sample
analyse
pathology
department
participate
hospital
pathologist
blind
result
prognosis
signature
histological
tumour
grade
accord
status
status
status
establish
participate
hospital
accord
locally
method
according
dutch
guideline
oestrogen
progesterone
receptor
deem
positive
least
tumour
cell
stain
positive
immunohistochemical
assay
sample
deem
score
immunohistochemical
assay
score
immunohistochemical
assay
fluorescent
hybridisation
result
fish
available
fish
result
positive
negative
initial
histopathology
datum
without
central
review
tumour
sample
assessment
treat
physician
statistical
analysis
tumour
sample
receive
netherlands
cancer
institute
freeze
liquid
nitrogen
store
frozen
section
sample
obtain
stain
haematoxylin
eosin
analyse
experience
breast
pathologist
mjvdv
eligible
sample
contain
least
tumour
cell
detail
rna
isolation
microarray
analysis
correlation
microarray
datum
prognosis
signature
previously
microarray
analysis
obtain
prognosis
signature
mammaprint
staff
agendia
laboratory
blind
clinical
pathological
datum
agendia
mammaprint
diagnostic
service
recognised
food
drug
administration
medical
device
mammaprint
array
chip
assess
mrna
expression
gene
triplicate
agilent
santa
usa
oligonucleotide
microarray
sensitivity
gene
signature
initially
set
allow
patient
poor
outcome
series
signature
develop
identify
risk
current
study
good
poor
prognosis
signature
first
identify
prognosis
signature
subsequent
validation
hereafter
risk
assessment
clinicopathological
factor
referred
clinical
risk
clinical
risk
index
include
dutch
cbo
gallen
nottingham
prognostic
index
npi
adjuvant
online
version
study
moderate
high
clinical
risk
indication
adjuvant
systemic
treatment
clinical
guideline
vary
substantially
selection
criterion
patient
receive
adjuvant
systemic
treatment
dutch
cbo
guideline
npi
much
restrictive
select
patient
adjuvant
systemic
treatment
compare
guideline
outline
dutch
cbo
guideline
primarily
based
assumption
adjuvant
chemotherapy
justify
absolute
survival
benefit
much
year
expect
guideline
formally
adapt
lead
minor
change
risk
assessment
adjuvant
systemic
treatment
patient
treat
adaptation
guideline
risk
assessment
adjuvant
systemic
treatment
based
previous
guideline
guideline
clinical
risk
define
age
year
tumour
grade
small
mm
grade
small
mm
tumour
small
mm
grade
risk
define
fewer
mitotic
figure
every
patient
risk
assessment
treatment
adaptation
adapt
guideline
according
guideline
clinical
risk
define
age
year
tumour
grade
mm
small
grade
small
mm
grade
mm
little
additionally
age
year
grade
tumour
mm
little
deem
risk
patient
age
year
deem
high
risk
notably
dutch
cbo
guideline
adjuvant
endocrine
treatment
advise
clinically
patient
tumour
combination
chemotherapy
according
gallen
guideline
clinical
risk
define
positive
status
criterion
tumour
size
cm
small
grade
age
year
tumour
deem
associate
moderate
high
risk
distant
metastasis
death
npi
compute
score
algorithm
cm
status
moderate
high
risk
define
score
great
adjuvant
online
software
calculate
year
survival
probability
based
patient
age
tumour
size
tumour
grade
status
nodal
patient
assign
high
clinical
risk
year
survival
probability
little
estimate
adjuvant
online
software
institutional
approval
study
obtain
centrally
institutional
review
board
netherlands
cancer
institute
locally
institutional
review
board
participate
hospital
prospective
feasibility
study
register
international
standard
randomised
control
trial
register
number
patient
give
write
inform
consent
analysis
report
jmbdm
scl
mjvdv
hvt
centrally
netherlands
cancer
institute
statistical
analysis
calculation
spss
version
difference
group
interest
test
pearson
test
ordinal
variable
age
pathological
stage
tnm
histological
grade
nodal
status
much
two
group
test
trend
test
significant
finding
define
value
level
agreement
assessment
prognosis
signature
express
mean
cohen
kappa
kappa
one
suggest
perfect
agreement
kappa
zero
suggest
agreement
role
funding
source
study
financially
support
dutch
health
care
insurance
board
funding
source
role
study
design
datum
collection
datum
analysis
datum
interpretation
write
report
decision
submit
publication
jmbdm
hvt
mjvdv
scl
access
raw
datum
jmbdm
mjvdv
scl
final
responsibility
decision
submit
publication
result
patient
enrolled
participate
dutch
hospital
exclusion
preoperative
postoperative
patient
protocol
violation
patient
cancer
patient
histology
permit
figure
eligible
patient
remain
patient
another
patient
exclude
sampling
failure
patient
procedure
patient
eligible
patient
prognosis
profile
obtain
image
image
figure
patient
enrolled
exclude
test
gene
signature
carcinoma
situ
note
tumour
small
biopsy
mean
tumour
sample
take
obtain
gene
prognosis
signature
little
tumour
tissue
remain
standard
pathological
examination
view
within
article
mean
age
eligible
patient
year
median
sd
range
mean
tumour
diameter
mm
median
sd
range
note
difference
age
eligible
patient
prognosis
signature
obtain
webtable
contrast
mean
diameter
sd
large
patient
prognosis
signature
obtain
mm
mm
tumour
much
often
grade
patient
tumour
characteristic
patient
prognosis
signature
assess
summarised
table
median
month
range
ten
first
event
occur
consist
three
regional
recurrence
five
distant
metastases
first
event
one
contralateral
breast
cancer
one
second
primary
malignancy
carcinoma
table
characteristic
patient
tumour
analysis
gene
prognosis
signature
gene
prognosis
signature
good
poor
age
type
axillary
histological
tumour
tumour
size
ptnm
histological
good
intermediate
poor
nodal
isolated
tumour
cell
mm
micrometastases
mm
adjuvant
systemic
endocrine
adjuvant
table
procedure
tumour
node
metastases
stage
stage
missing
value
calculation
value
actual
treatment
crf
percentage
might
add
round
view
within
article
patient
series
good
prognosis
signature
patient
poor
prognosis
signature
table
show
association
gene
prognosis
signature
clinical
pathological
characteristic
good
prognosis
signature
infrequently
note
tumour
patient
grade
tumour
patient
tumour
patient
contrast
poor
prognosis
signature
often
find
grade
tumour
patient
lobular
breast
carcinoma
patient
according
dutch
cbo
guideline
patient
high
risk
adjuvant
online
patient
npi
patient
gallen
guideline
patient
clinical
risk
discordant
prognosis
signature
patient
kappa
accord
dutch
cbo
guideline
patient
kappa
accord
adjuvant
online
patient
kappa
accord
npi
patient
kappa
accord
gallen
guideline
table
like
emphasise
comparison
clinicopathological
risk
assessment
prognosis
signature
risk
assessment
theoretical
based
fact
one
method
choose
comparison
show
patient
patient
identify
high
risk
differ
profile
profile
compare
amount
discordance
similar
amount
discordance
finding
clinical
guideline
paper
vary
datum
show
table
gene
prognosis
profile
risk
assessment
accord
clinicopathological
risk
index
gene
prognosis
signature
discordant
finding
ci
kappa
good
poor
clinical
risk
dutch
cbo
guideline
high
clinical
risk
adjuvant
online
high
clinical
risk
npi
guideline
moderate
high
clinical
risk
gallen
guideline
moderate
high
table
number
summed
obtain
discordant
finding
definition
clinical
moderate
high
risk
see
method
data
miss
one
patient
percentage
might
add
round
view
within
article
according
dutch
cbo
guideline
patient
clinical
high
risk
clinical
risk
table
based
guideline
oncologist
recommend
adjuvant
systemic
treatment
patient
chemotherapy
patient
endocrine
therapy
patient
patient
table
figure
recommendation
register
patient
much
adjuvant
systemic
treatment
advise
theoretically
need
accord
dutch
cbo
guideline
patient
little
adjuvant
systemic
treatment
advise
theoretically
need
accord
dutch
cbo
guideline
table
therefore
oncologist
treatment
advice
compliant
clinical
dutch
cbo
guideline
patient
clinical
risk
prognosis
signature
take
account
table
figure
oncologist
recommend
adjuvant
systemic
treatment
patient
chemotherapy
patient
endocrine
treatment
patient
patient
recommendation
register
crf
show
much
patient
recommend
treatment
crf
crf
table
adjuvant
systemic
treatment
advice
formulate
dutch
cbo
guideline
crf
none
chemotherapy
endocrine
treatment
dutch
cbo
guideline
risk
compliance
high
risk
compliant
table
treatment
advice
crf
agree
advice
dutch
cbo
guideline
percentage
might
add
round
view
within
article
image
image
figure
adjuvant
systemic
treatment
recommendation
patient
patient
clinical
risk
based
dutch
cbo
guideline
concordant
prognosis
signature
based
risk
patient
two
method
risk
assessment
discordant
view
within
article
table
adjuvant
systemic
treatment
advice
formulate
dutch
cbo
guideline
prognosis
signature
crf
none
chemotherapy
endocrine
treatment
dutch
cbo
guideline
prognosis
signature
table
treatment
advice
crf
crf
agree
advice
dutch
cbo
guideline
guideline
exist
patient
percentage
might
add
round
view
within
article
clinical
risk
prognosis
signature
patient
preference
treatment
take
account
adjuvant
systemic
treatment
actually
give
patient
register
crf
chemotherapy
patient
endocrine
treatment
patient
give
patient
table
table
figure
patient
much
adjuvant
systemic
treatment
patient
initially
advise
register
crf
based
dutch
cbo
guideline
overall
patient
receive
another
adjuvant
systemic
treatment
combine
dutch
cbo
guideline
prognosis
signature
finding
patient
preference
treatment
crf
compare
treatment
advice
based
dutch
cbo
guideline
register
crf
table
table
adjuvant
systemic
treatment
advice
formulate
dutch
cbo
guideline
prognosis
signature
patient
treatment
preference
crf
none
chemotherapy
endocrine
treatment
dutch
cbo
guideline
prognosis
signature
patient
preference
table
actual
treatment
give
agree
advice
dutch
cbo
guideline
guideline
exist
patient
percentage
might
add
round
view
within
article
table
treatment
advice
dutch
cbo
guideline
crf
versus
actual
treatment
give
crf
crf
none
chemotherapy
endocrine
treatment
crf
none
chemotherapy
endocrine
treatment
table
data
number
patient
percentage
patient
treatment
advice
agree
actual
treatment
give
change
finding
gene
prognosis
signature
patient
receive
much
adjuvant
systemic
treatment
advise
dutch
cbo
guideline
incorporation
prognosis
signature
patient
preference
patient
receive
little
adjuvant
systemic
treatment
advise
dutch
cbo
guideline
incorporation
prognosis
signature
patient
preference
view
within
article
show
figure
patient
risk
assessment
gene
prognosis
signature
give
concordant
finding
advice
adjuvant
systemic
treatment
remain
consequently
increase
adjuvant
systemic
treatment
mainly
note
patient
risk
accord
clinical
dutch
cbo
guideline
discordant
accord
prognosis
signature
figure
based
risk
accord
clinical
dutch
cbo
guideline
form
adjuvant
systemic
treatment
advise
patient
chemotherapy
five
patient
endocrine
treatment
six
patient
patient
webtable
dutch
cbo
guideline
prognosis
signature
find
patient
preference
treatment
consider
patient
actually
receive
adjuvant
systemic
treatment
receive
chemotherapy
patient
receive
endocrine
treatment
receive
webtable
compared
crf
decision
adjuvant
systemic
treatment
change
patient
result
increase
patient
receive
chemotherapy
patient
receive
endocrine
treatment
discussion
finding
study
show
implementation
gene
prognosis
signature
diagnostic
test
feasible
community
hospital
netherlands
postoperatively
patient
exclude
mainly
metastases
generally
invasive
breast
cancer
small
proportion
patient
already
clinically
surgery
consequently
large
proportion
patient
clinically
deem
surgery
pathological
assessment
lymph
node
around
study
patient
surgery
expect
remain
patient
exclude
histology
permit
eg
ductal
carcinoma
situ
without
invasion
assess
pathological
assessment
surgical
specimen
future
exclusion
prevent
collect
freeze
tumour
sample
patient
breast
cancer
standard
clinical
procedure
way
need
prognosis
signature
assess
postoperatively
patient
pathological
tumour
characteristic
know
thereby
prevent
unnecessary
logistical
difficulty
furthermore
much
emphasis
adequate
sampling
tumour
pathological
assessment
decrease
number
tumour
tumour
cell
percentage
start
raster
study
patient
age
year
include
amendment
protocol
end
upper
age
limit
year
however
number
patient
age
year
represent
patient
whole
study
population
undertake
analysis
assess
effect
inclusion
patient
study
finding
prognosis
signature
obtain
eligible
patient
proportion
improve
optimising
require
logistic
however
cell
percentage
specimen
insufficient
rna
quality
always
avoid
tumour
assess
patient
show
good
prognosis
signature
show
poor
prognosis
signature
find
confirm
previous
note
discordance
prognosis
signature
clinical
risk
assessment
patient
regardless
clinical
risk
index
prognosis
signature
combination
dutch
cbo
guideline
adjuvant
systemic
treatment
decision
adjuvant
systemic
treatment
advise
additional
patient
chemotherapy
six
additional
patient
endocrine
treatment
additional
patient
ten
additional
patient
compare
dutch
cbo
guideline
alone
table
increase
mainly
much
patient
receive
endocrine
treatment
endocrine
treatment
add
four
endocrine
treatment
withhold
chemotherapy
add
patient
withhold
patient
net
patient
much
chemotherapy
original
purpose
research
project
improve
selection
patient
high
risk
develop
distant
metastases
thereby
optimising
advice
adjuvant
systemic
treatment
clinical
guideline
differ
substantially
advice
dutch
cbo
guideline
restrictive
recommendation
adjuvant
systemic
treatment
endocrine
chemotherapy
compare
adjuvant
online
gallen
guideline
initially
based
validation
van
vijver
expect
little
chemotherapy
advise
prognosis
signature
clinical
practice
study
much
patient
receive
adjuvant
systemic
treatment
mainly
endocrine
treatment
patient
chemotherapy
patient
finding
explain
fact
van
vijver
gallen
guideline
estimate
effect
prognosis
signature
decision
adjuvant
systemic
treatment
gallen
guideline
classify
patient
current
study
clinically
high
risk
whereas
much
restrictive
dutch
cbo
guideline
classify
clinically
high
risk
prognosis
signature
patient
classify
poor
prognosis
prediction
result
little
treatment
gallen
guideline
much
adjuvant
systemic
treatment
comparison
dutch
cbo
guideline
overall
comparison
risk
assessment
test
patient
clinicopathological
risk
assessment
discordant
prognosis
signature
patient
systemic
adjuvant
treatment
management
differ
recommend
dutch
cbo
guideline
actually
give
based
prognosis
signature
dutch
cbo
guideline
patient
preference
find
might
result
improve
selection
patient
survival
outcome
show
retrospective
furthermore
study
show
combine
prognosis
signature
traditional
prognostic
predictive
factor
give
advice
adjuvant
systemic
treatment
also
know
yet
exact
predictive
value
prognosis
signature
consortium
collaboration
european
organisation
research
treatment
cancer
prognosis
signature
prospectively
study
currently
underway
will
provide
finding
exact
prognostic
predictive
value
prognosis
study
show
patient
tumour
good
prognosis
signature
view
prognosis
signature
need
classify
tumour
poor
prognosis
likelihood
good
prognosis
signature
obviously
prognosis
signature
little
discriminative
value
regard
prognosis
subgroup
additional
prognostic
test
might
need
patient
performance
gene
prognosis
signature
interesting
amplification
adverse
prognostic
factor
however
know
tumour
will
develop
distant
metastases
adequate
locoregional
treatment
study
tumour
good
prognosis
signature
need
chemotherapy
trastuzumab
subgroup
patient
need
study
worldwide
many
patient
breast
cancer
tumour
receive
adjuvant
hormonal
treatment
often
prognostic
test
decide
patient
also
receive
adjuvant
chemotherapy
however
patient
breast
cancer
treat
successfully
without
adjuvant
systemic
treatment
test
improve
selection
patient
will
benefit
adjuvant
systemic
treatment
include
hormonal
treatment
need
urgently
optimum
individualised
treatment
breast
clinical
research
community
will
important
role
process
freeze
store
breast
cancer
tissue
enable
generation
prognostic
predictive
profile
report
show
process
possible
large
number
hospital
gene
recurrence
score
assay
another
prognostic
profile
quantify
likelihood
distant
recurrence
patient
treat
tamoxifen
breast
cancer
tailorx
trial
assigning
individualized
options
treatment
trial
will
assess
whether
gene
frequently
associate
risk
recurrence
woman
breast
cancer
assign
patient
much
appropriate
effective
treatment
comparison
prognostic
value
gene
prognosis
signature
study
gene
recurrence
score
useful
assessment
performance
patient
series
another
interesting
question
physician
choose
base
treatment
decision
prognosis
signature
risk
assessment
discordant
dutch
cbo
guideline
prognosis
signature
additionally
patient
knowledge
prognosis
signature
affect
currently
study
behavioural
analysis
finding
will
publish
later
separate
report
pilot
formal
analysis
however
analysis
plan
conjunction
mindact
microarray
node
negative
disease
may
avoid
chemotherapy
trial
implementation
gene
prognosis
signature
feasible
dutch
community
hospital
fact
freeze
tissue
need
undertake
test
obstacle
clinical
show
study
much
important
question
remain
whether
prognosis
signature
study
will
avoid
unnecessary
adjuvant
systemic
treatment
without
compromise
overall
patient
survival
expect
optimum
adjuvant
systemic
treatment
prognosis
signature
integrate
current
clinicopathological
risk
assessment
contributors
scl
mjvdv
sr
whvh
responsible
study
design
development
protocol
whvh
ensure
jmbdm
coordinated
study
participate
patient
accrual
jmbdm
take
part
datum
collection
jmbdm
hvt
analyse
datum
jmbdm
scl
mjvdv
take
part
datum
interpretation
write
report
author
involve
review
report
medical
involve
paper
mjvdv
scl
contribute
equally
report
principal
raster
study
clinician
enter
patient
participate
study
number
accrue
patient
parenthesis
j
j
j
care
group
j
van
hospital
k
van
hospital
j
van
j
atrium
medical
center
van
den
berry
hospital
nijmegen
j
vries
deventer
hospital
deventer
perre
van
j
van
ten
bokkel
huinink
j
hospital
roumen
k
van
medical
centre
eindhoven
van
stam
spectrum
j
peeters
j
netherlands
cancer
institute
antoni
van
leeuwenhoek
hospital
amsterdam
van
vries
hospital
j
walter
amsterdam
van
graaf
van
van
van
leeuwen
graaf
group
van
leeuwen
j
hospital
k
van
j
hospital
conflict
interest
raster
study
financially
support
dutch
health
care
insurance
board
ljvv
mjvdv
name
application
gene
signature
study
ljvv
employ
agendia
commercial
company
market
gene
signature
mammaprint
employ
agendia
whvh
member
board
agendia
acknowledgment
woman
participate
study
doctor
nurse
datum
manager
participate
hospital
netherlands
enrolled
patient
breast
cancer
much
common
cancer
woman
worldwide
much
epidemiological
study
aetiology
breast
cancer
focused
event
woman
reproductive
year
however
observation
association
intrauterine
exposure
radiation
leukaemia
tumour
association
intrauterine
exposure
diethylstilbestrol
vaginal
adenocarcinoma
suggest
stage
carcinogenesis
might
set
early
perinatal
period
postulate
exposure
high
amount
endogenous
oestrogen
might
contribute
development
breast
cancer
perinatal
factor
might
surrogate
measure
intrauterine
oestrogen
exposure
factor
include
high
intrauterine
exposure
growth
loss
growth
factor
gene
formation
cancer
also
suggest
role
mammary
perinatal
factor
study
association
risk
breast
cancer
include
birthweight
measure
birth
size
parental
age
delivery
gestational
age
twin
membership
radiation
complication
maternal
characteristic
much
perinatal
factor
infection
twin
membership
birthweight
maternal
diethylstilbestrol
maternal
age
associate
alter
concentration
maternal
endogenous
perinatal
factor
might
associate
intrauterine
exposure
growth
birthweight
birth
previously
publish
systematic
review
study
association
birthweight
risk
breast
cancer
publish
april
dec
note
high
birthweight
associate
relative
risk
rr
ci
breast
current
study
available
evidence
association
risk
breast
cancer
maternal
age
paternal
age
gestational
age
birth
length
maternal
treatment
diethylstilbestrol
twin
membership
eclampsia
intrauterine
factor
method
search
strategy
selection
criterion
search
pubmed
study
publish
june
search
strategy
follow
search
term
breast
cancer
combination
birthweight
maternal
age
paternal
age
gestational
age
birth
length
diethylstilbestrol
twin
multiple
birth
radiation
infection
neonatal
jaundice
eclampsia
maternal
diet
maternal
weight
include
study
provide
original
analysis
association
perinatal
factor
invasive
breast
cancer
exclude
review
case
report
study
factor
outcome
identify
study
study
miss
pubmed
search
software
revman
generate
forest
plot
summary
effect
estimate
perinatal
factor
model
weigh
study
inverse
variance
rr
revman
software
log
scale
rr
ci
might
differ
slightly
publish
paper
round
error
summary
total
subtotal
provide
test
statistic
heterogeneity
across
study
degree
freedom
value
statistic
measure
extent
finding
test
overall
effect
z
statistic
value
significant
heterogeneity
across
study
ie
summary
effect
estimate
calculate
attempt
include
datum
identify
paper
perinatal
factor
study
include
still
list
review
table
population
overlap
one
contain
study
include
study
categorical
exposure
variable
compare
high
category
unless
indicate
otherwise
combine
publish
study
face
challenge
different
study
topic
might
provide
different
comparison
example
point
define
extreme
category
might
choose
differently
comparison
generally
possible
without
knowledge
therefore
combine
comparison
extreme
category
across
study
definition
similar
inappropriate
produce
single
estimate
effect
disparate
study
finding
forest
plot
summary
effect
estimate
provide
report
interpret
representation
potential
source
disparity
conflict
review
study
instead
simplified
study
synthesis
prenatal
factor
overall
woman
age
regardless
menopausal
status
menopausal
status
diagnosis
overall
include
study
include
premenopausal
postmenopausal
woman
study
present
analysis
finding
menopausal
status
study
include
menopausal
status
role
funding
source
project
support
fund
susan
komen
cure
funding
source
involvement
datum
collection
analysis
interpretation
overall
study
design
fx
access
raw
datum
fx
final
responsibility
submit
publication
result
publish
study
assess
association
perinatal
factor
risk
breast
cancer
identify
include
analysis
three
study
exclude
analysis
maternal
age
rr
estimate
ci
rr
one
exclude
analysis
maternal
age
stratified
menopausal
status
absence
ci
rr
one
exclude
analysis
gestational
age
study
population
contain
another
update
three
study
diethylstilbestrol
treatment
exclude
study
population
much
recent
one
twin
membership
exclude
rr
provide
however
finding
report
substantial
heterogeneity
study
case
value
heterogeneity
report
publication
bias
assess
funnel
plot
figure
suggest
small
study
null
result
might
miss
birth
length
dizygotic
twin
membership
relation
risk
breast
cancer
image
image
figure
funnel
plot
show
publication
bias
paternal
age
birth
length
twin
membership
dizygotic
twin
membership
eclampsia
relation
risk
breast
cancer
daughter
view
within
article
since
completion
review
birthweight
breast
five
additional
study
publish
topic
include
three
cohort
study
two
case
control
finding
five
study
suggest
increase
risk
breast
cancer
woman
high
birthweight
association
significant
three
birthweight
much
strongly
associate
premenopausal
breast
cancer
two
whereas
strong
association
postmenopausal
breast
cancer
note
finding
study
mostly
consistent
previously
publish
study
lend
support
high
birthweight
risk
factor
breast
cancer
especially
premenopausal
update
integrate
newly
publish
study
generate
summary
rr
associate
high
birthweight
ci
degree
breast
cancer
regardless
menopausal
status
much
plausible
mechanism
underlie
positive
association
maternal
age
risk
breast
cancer
daughter
high
intrauterine
exposure
endogenous
oestrogen
concentration
oestrogen
maternal
blood
pregnancy
show
high
old
identify
case
control
study
assess
association
maternal
age
delivery
daughter
risk
breast
cancer
seven
cohort
study
table
study
assess
association
maternal
age
risk
breast
cancer
daughter
regardless
menopausal
status
daughter
increase
maternal
age
find
associate
increase
risk
breast
cancer
daughter
nine
association
statistically
significant
four
summary
rr
cohort
study
ci
degree
summary
effect
estimate
calculate
case
control
study
significant
heterogeneity
degree
finding
study
separately
assess
premenopausal
breast
cancer
summary
rr
degree
postmenopausal
breast
cancer
summary
rr
degree
also
suggest
high
maternal
age
associate
increase
risk
breast
cancer
daughter
increase
risk
breast
cancer
range
third
decade
year
life
early
fourth
decade
year
table
published
study
maternal
age
delivery
daughter
risk
breast
cancer
trenddaughters
breast
cancer
nage
diagnosis
yearscontrols
population
case
control
study
marchand
age
year
janerich
thompson
parous
daughter
nulliparous
daughter
parous
nulliparous
daughter
pool
year
increase
maternal
sanderson
overall
study
overall
study
ekbom
woman
age
newcomb
patient
control
premenopausal
postmenopausal
weiss
innes
range
hodgson
choi
sd
premenopausal
postmenopausal
park
patient
age
patient
age
cohort
study
colditz
baseline
year
zhang
first
examination
year
hemminki
mogren
include
man
patient
age
mccormack
patient
age
patient
age
xue
baseline
year
table
available
rr
sir
ci
see
webtable
view
within
article
note
daughter
born
old
mother
much
likely
old
father
little
likely
mother
therefore
association
mention
might
confound
paternal
age
birth
order
control
association
high
maternal
age
increase
risk
breast
cancer
daughter
persist
seven
study
include
paternal
age
potential
association
remain
statistically
significant
three
study
study
birth
order
potential
confounder
positive
association
persist
ten
remain
statistically
significant
four
many
exposure
include
gestational
age
birthweight
complication
parental
socioeconomic
factor
year
birth
parental
smoking
twin
membership
maternal
hormone
adjust
adjustment
factor
often
affect
appreciably
effect
estimate
maternal
age
delivery
risk
breast
cancer
high
incidence
autosomal
dominant
disorder
note
child
born
old
father
much
frequent
substitution
high
number
structural
chromosomal
anomaly
suggest
possible
since
number
cell
division
much
large
oogenesis
cell
division
unlike
oogenesis
continue
error
dna
much
likely
occur
paternal
maternal
germ
line
furthermore
activity
apoptosis
germ
cell
response
mutagen
decline
paternal
dna
repair
system
much
efficient
independent
maternal
previous
study
suggest
advance
paternal
age
delivery
might
increase
cancer
risk
accumulation
identify
six
case
control
study
four
cohort
study
table
assess
association
paternal
age
risk
breast
cancer
daughter
older
paternal
age
delivery
associate
high
risk
breast
cancer
daughter
five
seven
study
regardless
menopausal
status
daughter
breast
association
statistically
significant
three
study
figure
summary
rr
degree
finding
two
study
assess
separately
risk
premenopausal
breast
cancer
suggest
positive
association
large
summary
rr
degree
finding
risk
postmenopausal
breast
cancer
report
separately
study
table
published
study
paternal
age
delivery
daughter
risk
breast
cancer
trenddaughters
breast
cancer
nage
daughter
diagnosis
yearscontrols
population
case
control
study
marchand
janerich
newcomb
case
control
premenopausal
post
menopausal
innes
range
hodgson
choi
sd
cohort
study
colditz
baseline
year
zhang
first
assessment
year
hemminki
xue
table
available
rr
sir
ci
see
webtable
view
within
article
image
image
figure
study
paternal
age
daughter
risk
breast
cancer
incidence
ratio
squares
represent
sir
diamonds
represent
summary
sir
line
represent
ci
sir
ci
generate
revman
generic
inversed
variance
method
analysis
rr
breast
cancer
continuous
increment
paternal
age
provide
study
consistently
transform
rr
increase
year
paternal
age
make
comparable
study
categorical
datum
view
within
article
eight
study
control
maternal
age
potential
advance
paternal
age
remain
positively
associate
risk
breast
cancer
six
study
association
significant
two
adjustment
maternal
age
substantially
attenuate
association
paternal
age
daughter
risk
breast
cancer
three
maternal
age
paternal
age
closely
associate
adjustment
might
introduce
consequently
underestimate
effect
maternal
paternal
age
three
study
attempt
resolve
underestimation
analysis
maternal
paternal
age
compare
risk
breast
cancer
across
combination
parental
independent
effect
maternal
age
remain
three
effect
strong
study
adequate
sample
size
combination
independent
effect
paternal
age
suggest
one
little
clear
two
adjustment
birth
order
exposure
make
much
study
adjustment
seem
substantially
change
effect
estimate
paternal
age
extent
increase
postnatal
gonadotropin
depend
extent
maturation
utero
therefore
gestational
age
compared
female
infant
female
infant
born
week
gestation
serum
hormone
fsh
concentration
ten
time
high
serum
luteinising
hormone
three
four
time
high
first
postnatal
raise
postnatal
serum
concentration
gonadotropin
preterm
female
infant
might
lead
ovarian
postulate
increase
concentration
increase
risk
breast
additionally
female
infant
survive
premature
birth
show
much
likely
accelerate
prenatal
growth
enhance
mitotic
division
might
associate
high
risk
breast
cancer
later
gestational
age
preterm
delivery
risk
breast
cancer
later
life
study
eight
case
control
study
four
cohort
study
table
regardless
age
cancer
onset
short
gestational
age
premature
birth
associate
high
risk
breast
cancer
four
study
decrease
risk
breast
cancer
four
association
increase
decrease
attain
statistical
significance
two
study
summary
rr
cohort
study
suggest
association
gestational
age
risk
breast
cancer
rr
degree
finding
case
control
study
significantly
heterogeneous
degree
data
gestational
age
premature
birth
suggest
risk
breast
cancer
opposite
direction
study
assess
premenopausal
woman
separately
summary
rr
degree
study
assess
postmenopausal
woman
separately
summary
rr
degree
finding
significant
table
published
study
gestational
age
delivery
risk
breast
cancer
trendwomen
breast
cancer
nage
diagnosis
yearscontrols
population
case
control
marchand
ekbom
woman
sanderson
study
study
innes
range
park
nested
case
control
woman
age
woman
age
woman
age
case
control
twin
kaijser
woman
age
case
control
twin
hubinette
comparison
woman
age
comparison
cohort
mogren
include
man
ekbom
woman
age
patient
age
kaijser
early
onset
year
troisi
table
available
sir
rr
ci
see
webtable
view
within
article
since
birthweight
positively
associate
risk
breast
cancer
later
negatively
associate
premature
birth
birthweight
probably
negative
confounder
association
gestational
age
risk
breast
cancer
finding
study
control
birthweight
potential
confounder
differ
substantially
finding
study
consider
adjustment
birth
order
family
history
exposure
also
account
without
appreciably
affect
finding
study
review
point
gestational
age
range
week
little
since
gestational
age
highly
correlated
cumulative
intrauterine
exposure
oestrogen
growth
hormone
factor
stratify
study
gestational
age
assess
study
stratum
preferable
however
small
number
available
study
allow
approach
birth
length
strongly
associate
therefore
mechanism
explain
association
birthweight
risk
breast
cancer
might
also
account
effect
birth
length
similar
birthweight
birth
length
positively
associate
oestrogen
concentration
maternal
nonetheless
finding
based
danish
medical
birth
register
suggest
birth
length
positively
associate
height
adulthood
even
adjust
birthweight
whereas
association
birthweight
height
disappear
adjust
birth
length
association
birth
length
establish
risk
factor
breast
cancer
suggest
birth
length
might
affect
risk
breast
cancer
pathway
independent
birthweight
much
closely
involve
regulate
growth
anthropometric
factor
throughout
life
association
long
birth
length
high
risk
assess
four
case
control
four
cohort
study
table
study
premenopausal
postmenopausal
woman
provide
summary
rr
degree
figure
finding
review
study
suggest
long
birth
length
associate
increase
risk
breast
cancer
two
study
association
statistically
significant
figure
two
study
separately
assess
association
premenopausal
postmenopausal
breast
finding
suggest
large
association
premenopausal
woman
breast
cancer
summary
rr
degree
postmenopausal
woman
breast
cancer
summary
rr
degree
table
published
study
birth
length
risk
breast
cancer
trendwomen
breast
cancer
nage
diagnosis
yearscontrols
population
case
control
ekbom
woman
age
vatten
range
nested
case
control
ekbom
woman
age
woman
age
age
case
control
twin
hubinette
woman
age
cohort
range
study
population
woman
age
mccormack
woman
age
vatten
woman
age
median
range
patient
age
patient
age
table
available
ci
see
webtable
view
within
article
image
image
figure
study
birth
length
risk
breast
cancer
incidence
ratio
squares
represent
sir
diamonds
represent
summary
sir
line
represent
ci
sir
ci
generate
revman
generic
inversed
variance
method
analysis
view
within
article
effect
estimate
association
birth
length
risk
breast
cancer
similar
birthweight
risk
breast
birthweight
include
potential
confounder
two
association
birth
length
risk
remain
statistically
significant
one
conversely
association
birthweight
breast
cancer
remove
birth
length
take
account
adjustment
head
one
slightly
attenuate
association
birth
length
risk
breast
cancer
adjustment
perinatal
factor
family
history
breast
cancer
appreciably
change
effect
estimate
none
available
study
assess
role
height
intermediate
variable
diethylstilbestrol
synthetic
oestrogen
develop
support
pregnancy
threaten
miscarriage
premature
labour
according
center
disease
control
prevention
atlanta
usa
estimate
million
pregnant
woman
fetuses
expose
diethylstilbestrol
association
intrauterine
exposure
diethylstilbestrol
adenocarcinoma
food
drug
administration
issue
drug
advise
physician
stop
prescribe
diethylstilbestrol
pregnant
prenatal
exposure
large
amount
oestrogen
might
associate
increase
risk
breast
cancer
later
oestrogen
supplement
diethylstilbestrol
pregnancy
provide
opportunity
study
association
exogenous
oestrogen
exposure
utero
subsequent
risk
breast
cancer
case
control
cohort
study
undertake
assess
association
table
four
study
based
three
exist
cohort
national
cooperative
diethylstilbestrol
randomised
clinical
trial
diethylstilbestrol
undertake
university
chicago
large
private
practice
massachusetts
finding
four
study
find
significant
increase
risk
woman
expose
diethylstilbestrol
utero
statistically
significant
increase
risk
age
year
associate
exposure
diethylstilbestrol
since
exclude
two
early
study
study
assess
cancer
overall
analysis
remain
overall
rr
rr
diagnosis
breast
cancer
postmenopausal
woman
three
study
separately
assess
premenopausal
breast
summary
rr
degree
table
published
study
diethylstilbestrol
exposure
pregnancy
daughter
risk
breast
cancer
trenddaughters
breast
cancer
nage
diagnosis
yearscontrols
population
case
control
study
weiss
sanderson
cohort
study
woman
age
patient
age
patient
age
palmer
woman
age
patient
age
patient
age
palmer
troisi
table
available
rr
ci
see
webtable
view
within
article
several
important
exposure
suggest
potential
confounder
publish
study
association
diethylstilbestrol
risk
breast
cancer
seem
substantially
change
adjustment
factor
include
gestational
age
first
exposure
compared
singleton
pregnancy
twin
pregnancy
might
involve
release
almost
twice
concentration
hormone
include
human
human
placenta
dizygotic
twin
might
expose
large
amount
hormone
monozygotic
presence
two
placenta
oppose
sharing
one
placenta
furthermore
oestrogen
lipophilic
consequently
pass
placenta
enter
fetal
circulation
therefore
dizygotic
twin
pregnancy
might
expose
high
amount
oestrogen
singleton
monozygotic
twin
pregnancy
however
twin
might
expose
hormone
short
time
singleton
twin
usually
deliver
short
gestation
avoid
complication
association
twin
membership
risk
breast
cancer
assess
eight
case
control
study
six
cohort
study
table
five
study
assess
association
regardless
menopausal
status
diagnosis
breast
cancer
positive
association
inverse
association
note
summary
rr
estimate
suggest
twin
membership
associate
decrease
risk
breast
cancer
marginal
statistical
significance
summary
rr
degree
figure
association
record
study
assess
premenopausal
breast
cancer
separately
summary
rr
degree
neither
cohort
case
control
study
note
significant
association
twin
membership
breast
cancer
rr
degree
summary
rr
degree
respectively
also
undertake
separate
study
assess
monozygotic
twin
note
association
twin
membership
breast
cancer
summary
rr
degree
association
record
cohort
study
summary
rr
degree
case
control
study
summary
rr
degree
finding
cohort
study
summary
rr
degree
case
control
study
summary
rr
degree
analyse
dizygotic
twin
separately
suggest
modest
significant
increase
risk
breast
cancer
associate
type
twin
membership
figure
although
combination
cohort
case
control
study
suggest
significant
heterogeneity
finding
degree
table
published
study
twin
membership
risk
breast
cancer
trendwomen
breast
cancer
nage
diagnosis
yearscontrols
population
case
control
hsieh
twin
twin
twin
twin
twin
twin
sanderson
study
study
swerdlow
opposite
ekbom
age
woman
age
swerdlow
national
twin
birth
weiss
innes
age
range
park
age
patient
age
patient
cohort
braun
monozygotic
twin
dizygotic
monozygotic
twin
dizygotic
twin
mogren
include
man
monozygotic
twin
dizygotic
monozygotic
twin
dizygotic
twin
hemminki
twin
table
available
ci
see
webtable
view
within
article
image
image
figure
study
twin
membership
include
monozygotic
dizygotic
risk
breast
cancer
view
within
article
image
image
figure
study
dizygotic
twin
membership
risk
breast
cancer
sir
ci
generate
revman
generic
inversed
variance
method
analysis
summary
estimate
provide
statistically
significant
heterogeneity
view
within
article
two
study
attempt
assess
role
zygosity
twin
development
one
study
compare
risk
breast
cancer
dizygotic
twin
monozygotic
study
compare
risk
twin
twin
estimate
zygosity
finding
show
difference
risk
breast
cancer
accord
zygosity
apart
concentration
hormone
pregnancy
monozygotic
twin
dizygotic
twin
might
differ
aspect
example
dizygotic
twin
much
often
conceive
woman
overweight
woman
old
woman
black
since
risk
breast
cancer
also
associate
maternal
anthropometric
partly
heritable
factor
adjust
review
study
might
confound
association
dizygotic
twin
membership
risk
breast
cancer
past
year
number
multiple
birth
increase
assist
reproductive
phenomenon
might
recent
assess
risk
factor
breast
cancer
daughter
future
study
might
also
question
potential
effect
relevant
parental
characteristic
potential
confounder
analyse
association
multiple
birth
risk
breast
cancer
especially
young
woman
etiology
hypertension
oedema
seizure
eclampsia
without
seizure
unclear
woman
eclampsia
oestrogen
concentration
normal
pregnancy
similar
twin
pregnancy
labour
might
induce
woman
eclampsia
decrease
maternal
fetal
morbidity
mortality
therefore
daughter
born
woman
eclampsia
much
likely
short
gestational
age
cumulative
exposure
pregnancy
hormone
born
normal
pregnancy
maternal
eclampsia
pregnancy
assess
risk
factor
breast
cancer
daughter
five
case
control
study
one
cohort
table
three
study
assess
association
regardless
menopausal
status
two
study
record
decrease
risk
eclampsia
breast
cancer
summary
rr
borderline
significant
heterogeneity
figure
finding
study
analyse
premenopausal
breast
cancer
separately
suggest
overall
association
summary
rr
degree
none
study
study
postmenopausal
breast
cancer
separately
table
published
study
eclampsia
daughter
risk
breast
cancer
sir
ci
breast
cancer
nage
diagnosis
yearscontrols
population
case
control
study
marchand
yes
noor
ekbom
yes
noor
woman
age
sanderson
yes
noor
innes
yes
noor
range
nested
case
control
study
ekbom
yes
noor
age
age
age
cohort
mogren
include
man
table
available
incidence
ratio
comparison
actual
expect
number
daughter
cancer
based
external
reference
view
within
article
image
image
figure
study
maternal
eclampsia
daughter
risk
breast
cancer
sir
ci
generate
revman
generic
inversed
variance
method
analysis
view
within
article
since
mother
eclampsia
pregnancy
much
likely
multiple
pregnancy
high
index
pregnancy
factor
need
control
analysis
might
also
affect
daughter
risk
breast
cancer
two
study
provide
strong
support
inverse
association
risk
breast
cancer
sweden
study
population
partly
overlap
research
warrant
confirm
association
effect
several
perinatal
factor
risk
breast
cancer
also
study
however
currently
available
evidence
sparse
fetuses
especially
sensitive
exposure
ionising
effect
exposure
ionising
radiation
japan
risk
cancer
later
life
assess
however
finding
breast
cancer
report
researchers
study
report
high
incidence
cancer
japanese
age
expose
especially
childhood
cancer
woman
however
increase
persist
another
year
possibly
background
cancer
incidence
increase
population
data
exposure
risk
population
available
rr
breast
cancer
high
woman
expose
radiation
year
age
compare
woman
expose
old
age
risk
breast
cancer
increase
young
age
neonatal
jaundice
also
associate
high
risk
breast
cancer
odd
ratio
however
datum
available
one
study
jaundice
onset
within
first
birth
mainly
infection
although
much
research
need
establish
whether
neonatal
jaundice
associate
increase
risk
breast
cancer
study
suggest
oestrogen
exposure
might
role
high
concentration
oestrogen
measure
infant
probably
due
impair
liver
function
role
maternal
diabetes
risk
breast
cancer
daughter
assess
one
association
note
standardised
incidence
ratio
sir
sanderson
report
increase
risk
breast
cancer
daughter
mother
high
weight
pregnancy
compare
little
kg
kg
kg
since
high
weight
pregnancy
associate
high
find
consistent
increase
risk
breast
cancer
woman
high
sanderson
also
assess
maternal
coffee
consumption
alcohol
intake
report
association
risk
breast
cancer
daughter
discussion
review
study
suggest
increase
birthweight
birth
length
maternal
age
paternal
age
positively
associate
increase
risk
breast
cancer
maternal
twin
membership
associate
decrease
risk
breast
cancer
association
might
modify
menopausal
status
factor
birthweight
birth
length
seem
much
closely
associate
premenopausal
breast
cancer
finding
several
factor
remain
inconclusive
provide
question
far
research
neonatal
jaundice
suggest
associate
breast
cancer
current
datum
sparse
draw
conclusion
monozygotic
twin
membership
dizygotic
twin
membership
seem
associate
different
risk
develop
breast
cancer
ie
risk
monozygotic
twin
modest
increase
risk
dizygotic
twin
finding
inconsistent
underlie
mechanism
remain
unclear
although
gestational
age
associate
risk
breast
cancer
overall
premenopausal
postmenopausal
breast
cancer
might
affect
differently
gestational
age
although
finding
risk
significant
furthermore
role
much
modifiable
perinatal
factor
maternal
weight
maternal
weight
maternal
diet
require
far
study
one
major
challenge
assessment
intrauterine
factor
risk
chronic
disease
later
life
collection
reliable
datum
perinatal
period
scandinavian
datum
birth
registry
birth
record
keep
misclassification
minimum
study
personal
interview
mail
questionnaire
data
birth
record
validate
underlie
mechanism
association
perinatal
factor
risk
breast
cancer
late
life
still
need
elucidate
intrauterine
concentration
endogenous
oestrogen
pregnancy
hormone
involve
association
separate
assessment
breast
cancer
accord
oestrogen
receptor
progesterone
receptor
status
might
provide
additional
datum
datum
currently
sparse
although
several
risk
factor
breast
cancer
identify
restrict
number
breast
cancer
attributable
recognised
risk
scope
research
might
yield
additional
important
information
aetiology
way
prevent
breast
cancer
finding
suggest
entire
woman
life
include
prenatal
experience
might
relevant
future
risk
research
effort
might
focus
ascertain
much
important
window
susceptibility
identify
new
opportunity
prevention
future
study
need
confirm
importance
exposure
risk
breast
cancer
identify
underlie
mechanism
contributors
km
design
study
seek
funding
review
report
provide
statistical
advice
fx
datum
analysis
review
publish
study
write
report
conflict
interest
author
declare
conflict
interest
acknowledgment
preparation
report
support
susan
komen
cure
part
environmental
factor
breast
cancer
science
review
project
lead
spring
institute
investigator
medical
school
roswell
park
cancer
institute
university
southern
california
worldwide
nearly
third
breast
cancer
case
occur
patient
age
year
figure
much
develop
country
proportion
rise
much
despite
grow
level
interest
researcher
regard
age
group
agree
recommendation
currently
exist
specifically
management
breast
cancer
elderly
patient
large
degree
due
paucity
clinical
trial
datum
old
patient
breast
cancer
indeed
many
breast
cancer
clinical
trial
tend
exclude
elderly
individual
mainly
either
basis
age
alone
comorbidity
international
society
geriatric
oncology
siog
create
review
publish
literature
provide
recommendation
diagnosis
treatment
breast
cancer
elderly
individual
report
outline
recommendation
identify
area
exist
evidence
weak
level
evidence
need
good
practice
image
image
figure
breast
cancer
high
incidence
elderly
woman
view
within
article
incidence
general
characteristic
breast
cancer
much
common
cancer
woman
million
new
case
per
year
cancer
woman
europe
north
breast
cancer
lead
cancer
mortality
woman
worldwide
woman
die
disease
crude
incidence
breast
cancer
north
america
per
woman
year
breast
mortality
per
contrast
incidence
per
woman
year
mortality
per
woman
northern
western
age
year
old
crude
incidence
rate
per
woman
north
america
per
northern
western
europe
corresponding
breast
cancer
mortality
figure
per
woman
similar
incidence
mortality
figure
find
south
america
argentina
new
zealand
australia
central
eastern
europe
czech
republic
figure
show
incidence
mortality
breast
cancer
develop
develop
country
image
image
figure
incidence
mortality
breast
cancer
per
woman
develop
develop
view
within
article
age
diagnosis
breast
cancer
associate
much
favourable
tumour
biology
indicate
increased
hormone
sensitivity
attenuate
overexpression
grade
proliferative
index
see
reference
webappendix
however
elderly
patient
much
likely
present
large
much
advance
tumour
recent
report
suggest
involvement
lymph
node
increase
furthermore
seem
major
difference
outcome
patient
age
nevertheless
elderly
patient
little
likely
treat
accord
accept
treatment
consequence
strong
negative
effect
explanation
difference
approach
treatment
complex
include
physician
patient
bias
view
relative
caregivers
psychosocial
issue
cost
proximity
oncology
radiotherapy
centre
despite
fact
breast
cancer
occur
mainly
elderly
patient
population
substantially
clinical
trial
age
significant
predictor
whether
old
patient
breast
cancer
offer
entry
clinical
fact
old
patient
just
likely
young
patient
participate
give
collaboration
comprehensive
geriatric
assessment
paramount
importance
detect
problem
improve
functional
status
possibly
survival
elderly
patient
comorbidity
functional
status
significantly
affect
prognosis
treatment
thorough
consideration
give
overall
health
elderly
patient
proportion
patient
old
year
operable
breast
cancer
die
age
alone
however
barrier
treatment
screening
breast
cancer
elderly
individual
mammography
screening
generally
regard
effective
woman
age
picture
little
clear
woman
year
study
show
association
screening
reduce
breast
cancer
mortality
age
whereas
retrospective
model
study
suggest
potential
survival
benefit
even
patient
year
dutch
experience
mammography
screening
patient
year
biologically
likely
mammography
screening
little
effective
woman
old
year
accuracy
mammography
ie
sensitivity
specificity
detect
cancer
even
increase
advance
age
increase
breast
tissue
however
benefit
screening
need
weigh
presence
concurrent
medical
condition
limit
patient
life
expectancy
limit
patient
ability
tolerate
cancer
treatment
possibility
overdiagnosis
detection
lesion
affect
woman
might
cultural
difference
approach
breast
cancer
screening
europe
preference
centrally
organised
screening
programme
personal
invitation
level
year
generally
accept
much
appropriate
target
group
within
context
term
elderly
take
include
patient
age
year
old
recommendation
mammography
beyond
target
group
age
easily
give
physician
without
specific
medical
indication
north
america
especially
usa
breast
screening
much
commonly
individual
basis
rather
population
based
decision
screening
mammography
patient
age
might
depend
clinical
situation
american
geriatric
society
recommend
screening
individualised
rather
set
guideline
age
recommend
set
upper
age
limit
long
estimate
life
expectancy
year
much
american
cancer
society
advise
continue
breast
cancer
screening
long
individual
good
health
candidate
recommendations
strong
datum
support
oppose
systematic
mammography
woman
year
age
cultural
difference
approach
breast
cancer
screening
take
account
breast
cancer
screening
programme
mammography
screening
age
year
appropriate
individual
patient
decision
individualised
take
account
risk
benefit
screening
patient
preference
physiological
age
life
expectancy
treatment
early
stage
breast
cancer
multidisciplinary
treatment
planning
integrate
local
systemic
therapy
well
sequence
surgery
several
treatment
guideline
practice
standard
develop
surgical
management
patient
breast
cancer
see
reference
webappendix
elderly
population
breast
cancer
mortality
range
alternative
conventional
surgery
include
outpatient
surgery
local
preferably
undertake
family
support
present
past
assumption
elderly
patient
receive
little
aggressive
form
breast
cancer
treatment
reduce
life
expectancy
mean
hormonal
treatment
alone
without
surgery
consider
reasonable
treatment
option
elderly
woman
breast
cancer
limited
life
expectancy
mainly
patient
old
eg
year
effect
omit
surgery
overall
survival
clear
differ
different
study
table
four
trial
compare
tamoxifen
monotherapy
surgery
surgery
alone
arm
currently
regard
suboptimum
term
treatment
since
adjuvant
hormone
treatment
give
group
research
endocrine
therapy
elderly
trial
much
informative
design
surgery
adjuvant
show
benefit
overall
survival
compare
tamoxifen
alone
despite
long
much
importantly
significantly
high
proportion
patient
treat
tamoxifen
alone
experience
local
relapse
subsequent
salvage
breast
cancer
surgery
another
study
show
increase
breast
cancer
mortality
group
surgery
woman
age
year
much
operable
breast
cancer
randomised
surgery
tamoxifen
tamoxifen
increase
breast
cancer
mortality
surgery
hazard
ratio
ci
overall
mortality
confirm
primary
hormonal
treatment
tamoxifen
inferior
surgery
without
hormonal
treatment
local
control
survival
breast
cancer
medically
fit
old
however
surgery
result
significantly
well
overall
table
effect
omit
surgery
overall
survival
local
recurrence
elderly
woman
breast
cancer
patient
surgery
surgery
table
significant
difference
tamoxifen
versus
surgery
tamoxifen
surgery
alone
significant
difference
tamoxifen
versus
surgery
tamoxifen
surgery
alone
significance
report
view
within
article
neoadjuvant
treatment
aromatase
inhibitor
show
well
response
rate
tamoxifen
postmenopausal
patient
breast
specific
datum
compare
aromatase
inhibitor
alone
surgery
combine
aromatase
inhibitor
elderly
patient
approach
warrant
far
investigation
preferably
old
patient
limited
life
expectancy
omission
surgery
unlikely
affect
breast
cancer
specific
mortality
breast
conservation
treatment
breast
conservation
treatment
consist
surgery
lumpectomy
partial
mastectomy
postoperative
radiotherapy
now
recommend
standard
care
patient
age
early
disease
see
reference
webappendix
large
randomised
study
clearly
show
breast
conservation
treatment
similar
efficacy
mastectomy
difference
survival
overall
survival
similar
two
approach
although
significant
increase
local
recurrence
see
breast
conservation
treatment
group
especially
young
patient
much
elderly
woman
primary
breast
cancer
candidate
breast
conservation
treatment
however
available
datum
suggest
old
patient
little
likely
receive
conclusion
large
randomised
trial
breast
conservation
treatment
versus
mastectomy
easily
apply
elderly
patient
woman
age
year
exclude
trial
however
small
study
involve
patient
age
year
older
document
breast
conservation
treatment
comparison
mastectomy
associate
well
preferred
much
elderly
compare
mastectomy
association
microscopically
close
positive
resection
margin
subsequent
risk
breast
tumour
recurrence
conservative
surgery
radiotherapy
controversial
many
retrospective
study
report
significantly
increase
rate
breast
tumour
recurrence
receive
radiotherapy
positive
microscopic
resection
margin
compare
negative
margin
see
reference
webappendix
association
also
report
three
prospective
randomised
trial
analyse
microscopic
margin
status
subsequent
risk
breast
tumour
recurrence
patient
undergo
conservative
surgery
several
factor
associate
risk
breast
tumour
recurrence
patient
positive
margin
series
positive
margin
characterised
focal
associate
risk
breast
tumour
recurrence
compare
much
extensively
involve
patient
consider
candidate
conservative
surgery
radiotherapy
especially
absence
associate
extensive
intraductal
european
organisation
research
treatment
cancer
eortc
trial
effect
positive
margin
local
recurrence
highly
significant
woman
year
however
significance
disappear
old
patient
young
patient
attempt
make
achieve
negative
surgical
margin
achieve
management
close
positive
margin
need
address
multidisciplinary
meeting
depending
patient
age
comorbid
condition
life
expectancy
surgical
discuss
well
additional
radiotherapy
tumour
bed
boost
however
radiotherapy
consider
substitute
adequate
surgery
negative
margin
total
mastectomy
young
patient
total
mastectomy
remain
surgical
option
patient
prefer
breast
conservation
treatment
decline
fit
postoperative
breast
radiotherapy
mastectomy
also
indicate
patient
large
primary
lesion
tumour
approach
breast
conservation
treatment
eg
multicentric
disease
even
large
unifocal
tumour
mastectomy
also
indicate
salvage
treatment
breast
tumour
recurrence
breast
conservation
treatment
cosmetic
result
breast
conservation
likely
poor
axillary
surgery
axillary
lymph
node
dissection
patient
clinical
evidence
involvement
axillary
lymph
node
however
without
clinical
lymph
node
involvement
indication
upfront
axillary
lymph
node
dissection
little
clear
elderly
population
surgery
recently
become
largely
redundant
subgroup
possibility
sentinel
lymph
node
procedure
sentinel
lymph
node
procedure
old
patient
breast
cancer
little
likely
undergo
axillary
lymph
node
dissection
young
patient
several
first
although
generally
consider
safe
procedure
axillary
lymph
node
dissection
associate
postoperative
pain
muscle
weakness
contribute
subsequent
reduction
quality
one
study
however
show
old
patient
experience
fewer
axillary
lymph
node
arm
symptom
young
second
axillary
lymph
node
dissection
consider
stage
rather
therapeutic
procedure
breast
cancer
determine
pathological
nodal
involvement
therefore
dictate
need
adjuvant
treatment
however
axillary
lymph
node
dissection
usually
affect
systemic
treatment
choice
elderly
clinically
patient
tumour
small
third
several
study
show
difference
outcome
old
patient
small
tumour
without
palpable
lymph
node
axillary
lymph
node
dissection
elderly
patient
result
axillary
lymph
node
dissection
will
affect
adjuvant
chemotherapy
decision
include
small
tumour
risk
nodal
involvement
might
appropriate
omit
axillary
lymph
node
dissection
case
factor
quality
life
perception
body
image
weigh
discuss
patient
recent
year
biopsy
sentinel
lymph
node
minimally
invasive
highly
sensitive
reproducible
technique
introduce
alternative
axillary
lymph
node
sentinel
lymph
node
biopsy
show
safe
accurate
method
predict
axillary
status
patient
breast
cancer
see
reference
webappendix
include
age
year
sentinel
lymph
node
biopsy
requirement
axillary
lymph
node
dissection
result
many
sentinel
lymph
node
biopsy
now
widely
consider
acceptable
treatment
option
patient
age
tumour
size
little
cm
clinical
evidence
axillary
elderly
patient
breast
cancer
ideal
candidate
biopsy
sentinel
lymph
node
encourage
undergo
procedure
finding
biopsy
old
patient
breast
cancer
significantly
affect
subsequent
treatment
decision
include
adjuvant
systemic
treatment
controversy
exist
regard
need
complementary
axillary
lymph
node
dissection
positive
sentinel
lymph
node
find
especially
axilla
explore
surgery
risk
macroscopic
disease
limited
microscopic
disease
will
probably
choose
adjuvant
treatment
chemotherapy
van
zee
publish
nomogram
predict
risk
subsequent
nodal
metastasis
basis
result
sentinel
lymph
node
biopsy
tumour
characteristic
nomogram
develop
patient
age
particularly
useful
decide
whether
axillary
lymph
node
dissection
old
patient
recommendations
surgery
patient
breast
cancer
old
year
age
differ
procedure
offer
young
patient
unless
patient
preference
dictate
axillary
lymph
node
dissection
clinical
suspicion
axillary
lymph
node
involvement
tumour
since
adjuvant
treatment
depend
pathological
result
axillary
lymph
node
dissection
biopsy
sentinel
lymph
node
safe
alternative
axillary
lymph
node
dissection
patient
clinically
node
negative
tumour
elderly
patient
tumour
size
little
cm
clinical
evidence
axillary
involvement
offer
sentinel
lymph
node
biopsy
controversy
exist
regard
need
axillary
lymph
node
dissection
positive
sentinel
lymph
node
biopsy
radiotherapy
tolerability
limit
factor
radiotherapy
old
patient
huguenin
show
important
toxicity
woman
age
year
similarly
compare
group
woman
age
year
young
group
show
high
toxicity
woman
age
year
old
will
discuss
radiotherapy
surgery
postmastectomy
surgery
postoperative
radiotherapy
surgery
combine
appropriate
systemic
treatment
show
achieve
reduction
absolute
risk
year
local
recurrence
reduction
year
absolute
breast
cancer
mortality
risk
slight
noticeable
increase
cancer
mortality
woman
receive
radiotherapy
mainly
heart
disease
lung
cancer
probably
relate
old
suboptimum
radiotherapy
regimen
technique
despite
benefit
elderly
patient
continue
receive
radiotherapy
little
frequently
surgery
young
number
randomised
trial
usually
limited
upper
age
limit
year
show
significant
reduction
risk
local
recurrence
postoperative
breast
irradiation
effect
overall
survival
trial
find
age
factor
predict
risk
local
recurrence
whole
breast
irradiation
compare
conservative
surgery
several
study
specifically
assess
benefit
radiotherapy
elderly
patient
large
study
show
decrease
relative
rate
breast
tumour
recurrence
however
absolute
incidence
relapse
well
absolute
benefit
radiotherapy
tend
datum
overall
survival
generally
absent
exception
one
conclude
radiotherapy
avoid
old
whereas
suggest
offer
benefit
term
slight
reduction
local
relapse
rate
improvement
overall
survival
early
breast
cancer
trialists
group
overview
involve
woman
breast
cancer
show
year
risk
local
recurrence
surgery
high
woman
age
year
compare
age
year
age
group
absolute
effect
radiotherapy
surgery
local
recurrence
mainly
conserve
breast
also
great
woman
age
year
old
woman
year
risk
reduction
respectively
although
risk
reduction
still
significant
old
woman
table
postoperative
breast
irradiation
therefore
consider
patient
undergo
surgery
irrespective
age
woman
age
year
risk
recurrence
eg
small
tumour
clear
margin
axillary
positive
plan
receive
endocrine
treatment
absolute
reduction
local
recurrence
tend
slight
mortality
usually
associate
condition
cancer
leukemia
group
trial
woman
age
year
old
breast
cancer
assign
surgery
tamoxifen
alone
breast
radiotherapy
tamoxifen
show
reduction
breast
tumour
recurrence
year
radiotherapy
patient
therefore
depend
multidimensional
assessment
include
absolute
benefit
radiotherapy
comorbidity
life
expectancy
patient
course
radiotherapy
hypofractionation
trial
progress
assess
omission
breast
radiotherapy
risk
old
patient
table
effect
age
radiotherapy
local
recurrence
patient
undergo
year
local
recurrence
risk
absolute
risk
reduction
surgery
plus
radiotherapy
table
woman
age
year
view
within
article
supplementary
dose
boost
radiation
excision
site
surgery
clear
margin
gy
whole
breast
radiation
improve
year
local
recurrence
compare
boost
although
absolute
benefit
decrease
age
relative
effect
reduce
local
recurrence
nearly
half
remain
similar
age
year
reduction
risk
local
recurrence
patient
age
year
favour
boost
table
partial
breast
irradiation
confine
area
around
primary
tumour
explore
prospective
trial
potential
advantage
much
short
overall
treatment
time
table
year
actuarial
local
recurrence
without
supplementary
radiotherapy
patient
undergo
surgery
early
breast
boost
boost
total
population
year
table
view
within
article
postmastectomy
radiotherapy
limited
level
evidence
effect
postmastectomy
radiotherapy
old
patient
large
restrict
patient
young
year
contrast
radiotherapy
surgery
absolute
effect
postmastectomy
radiotherapy
year
risk
local
recurrence
mainly
chest
wall
lymph
node
show
independent
woman
mastectomy
axillary
clearance
disease
reduction
recurrence
average
age
group
however
woman
age
year
include
trial
assess
retrospective
analysis
surveillance
epidemiology
end
result
seer
datum
identify
woman
age
year
old
undergo
mastectomy
invasive
breast
median
year
postmastectomy
radiotherapy
associate
significant
improvement
survival
hazard
ratio
ci
patient
patient
intermediate
risk
much
small
retrospective
cohort
woman
age
year
tumour
four
much
involve
node
referred
canadian
british
columbia
cancer
risk
recurrence
significantly
woman
treat
postmastectomy
radiotherapy
compare
surgery
alone
median
year
multivariate
analysis
histology
omission
postmastectomy
radiotherapy
predict
local
recurrence
increasing
number
involve
node
associate
impair
survival
increase
risk
distant
metastases
retrospective
series
probably
selection
bias
favour
offering
postmastectomy
radiotherapy
patient
high
risk
disease
principle
patient
offer
postmastectomy
chest
wall
radiotherapy
four
much
involve
node
tumour
positive
resection
section
recommendation
based
finding
randomised
control
show
reduction
locoregional
failure
year
survival
advantage
postmenopausal
patient
receive
comprehensive
locoregional
radiotherapy
plus
tamoxifen
versus
tamoxifen
alone
survival
advantage
emerge
year
therefore
old
patient
life
expectancy
little
year
decision
regard
adjuvant
radiotherapy
based
consideration
locoregional
control
patient
tumour
one
three
positive
node
consensus
guideline
american
society
clinical
american
society
therapeutic
national
institute
indicate
insufficient
evidence
recommend
routine
postmastectomy
radiotherapy
additionally
patient
risk
factor
eg
grade
histology
lymphovascular
invasion
role
adjuvant
radiotherapy
uncertain
group
role
adjuvant
postmastectomy
irradiation
currently
explore
uk
medical
research
council
eortc
trial
upper
age
limit
eligibility
recommendations
radiotherapy
surgery
adjuvant
systemic
treatment
decrease
risk
local
relapse
consider
elderly
patient
breast
cancer
absolute
benefit
local
relapse
might
small
elderly
patient
tumour
early
breast
cancer
trialists
collaborative
group
ebctcg
show
difference
proportional
reduction
local
recurrence
risk
effect
radiotherapy
mortality
breast
cancer
little
clear
far
stratification
available
radiotherapy
will
improve
overall
much
much
affect
comorbidity
age
occurrence
distant
metastases
local
unlikely
decision
offer
radiotherapy
will
need
take
account
patient
health
functional
status
risk
mortality
comorbidity
particularly
cardiac
vascular
risk
local
recurrence
principle
postmastectomy
irradiation
indicate
patient
four
much
involve
node
tumour
old
patient
life
expectancy
little
year
decision
whether
implement
adjuvant
radiotherapy
based
consideration
locoregional
control
alone
limited
datum
available
support
systematic
postmastectomy
radiotherapy
patient
one
three
positive
node
risk
factor
additional
dose
radiation
tumour
bed
consider
old
patient
treatment
systemic
treatment
decrease
risk
local
relapse
adjuvant
hormone
treatment
primary
issue
whether
hormone
treatment
necessary
elderly
patient
early
breast
cancer
woman
disease
treatment
decision
based
risk
benefit
analysis
take
account
relapse
rate
within
first
year
potential
reduction
ipsilateral
contralateral
breast
cancer
relapse
patient
life
expectancy
adverse
event
patient
tumour
receive
hormone
treatment
data
show
difference
efficacy
tamoxifen
ebctcg
show
breast
cancer
treatment
year
adjuvant
tamoxifen
reduce
yearly
death
rate
due
breast
cancer
independent
age
compare
hormonal
treatment
figure
another
study
show
adjuvant
tamoxifen
significantly
improve
year
overall
survival
compare
adjuvant
hormone
treatment
woman
age
much
large
phase
iii
trial
investigate
role
aromatase
inhibitor
versus
tamoxifen
sequentially
also
show
differential
effect
age
relative
efficacy
endocrine
treatment
see
reference
webappendix
specific
trial
show
significant
benefit
subgroup
woman
age
year
benefit
lose
significance
threshold
possibly
cancer
death
stress
compete
issue
life
expectancy
estimation
control
even
overall
absolute
benefit
letrozole
year
tamoxifen
similar
different
age
image
image
figure
relative
recurrence
mortality
reduction
per
age
group
adjuvant
tamoxifen
compare
hormonal
view
within
article
young
patient
choice
adjuvant
hormone
treatment
old
patient
determine
risk
relapse
tumour
biology
potential
adverse
event
several
large
randomised
study
compare
efficacy
tolerability
aromatase
inhibitor
tamoxifen
treatment
early
breast
cancer
see
reference
webappendix
study
aromatase
inhibitor
well
tamoxifen
term
survival
although
little
difference
rate
overall
survival
except
trial
upper
age
limit
median
age
year
term
tolerability
treatment
tamoxifen
associate
increase
risk
endometrial
cancer
thromboembolic
event
deep
venous
thrombosis
pulmonary
however
small
increase
mortality
endometrial
cancer
thromboembolic
episode
much
small
mortality
reduction
result
death
avoid
contralateral
breast
cancer
cardiovascular
event
patient
year
note
age
show
relate
alteration
metabolism
tamoxifen
result
high
level
tamoxifen
metabolite
elderly
woman
whether
lead
alter
efficacy
dose
tamoxifen
might
prove
useful
potentially
little
toxic
standard
dose
suggest
several
biological
surrogate
endpoint
study
small
randomised
area
far
investigation
aromatase
inhibitor
much
likely
muscle
pain
osteoporosis
bone
fracture
tamoxifen
consideration
elderly
patient
bone
mineral
density
young
patient
optimum
bisphosphonate
prevent
bone
loss
patient
receive
aromatase
inhibitor
currently
oral
bisphosphonate
much
commonly
treatment
osteoporosis
however
preliminary
datum
suggest
zoledronic
acid
give
intravenously
every
month
also
effective
prevent
bone
general
rule
lack
analysis
safety
profile
aromatase
inhibitor
accord
age
common
even
large
trial
evidence
breast
international
group
trial
risk
cardiovascular
event
slightly
raise
aromatase
inhibitor
compare
tamoxifen
however
since
evidence
report
trial
compare
aromatase
inhibitor
tamoxifen
trial
compare
aromatase
inhibitor
placebo
adjuvant
treatment
speculate
cognitive
impairment
also
describe
association
adjuvant
hormonal
datum
insufficient
confirm
association
compare
relative
effect
aromatase
inhibitor
versus
tamoxifen
cognitive
function
tamoxifen
start
chemotherapy
complete
aromatase
inhibitor
datum
timing
relate
chemotherapy
seem
acceptable
approach
tamoxifen
recommendations
elderly
patient
breast
tumour
benefit
adjuvant
hormone
treatment
evidence
difference
efficacy
tamoxifen
aromatase
inhibitor
aromatase
inhibitor
slightly
much
effective
tamoxifen
elderly
patient
much
vulnerable
adverse
event
safety
important
factor
choose
tamoxifen
aromatase
inhibitor
older
patient
candidate
endocrine
treatment
offer
initial
treatment
aromatase
inhibitor
tamoxifen
initially
treat
tamoxifen
consideration
give
change
aromatase
inhibitor
year
tamoxifen
treatment
adjuvant
chemotherapy
ebctcg
randomised
trial
show
substantial
benefit
adjuvant
chemotherapy
postmenopausal
woman
age
group
compare
large
age
year
age
compare
year
figure
patient
age
year
range
year
significant
due
small
number
image
image
figure
relative
recurrence
mortality
reduction
per
age
group
adjuvant
polychemotherapy
compare
view
within
article
general
patient
tumour
derived
greater
absolute
survival
benefit
compare
patient
tumour
two
independent
study
seer
database
show
adjuvant
chemotherapy
improve
overall
survival
elderly
patient
tumor
benefit
similar
woman
age
year
one
benefit
restrict
patient
breast
cancer
however
absolute
benefit
depend
individual
patient
health
tumour
parameter
status
tumour
size
grade
overexpression
considerable
uncertainty
remain
regard
subgroup
old
woman
much
likely
benefit
tumour
benefit
chemotherapy
reduce
little
obvious
elderly
individual
regimen
clearly
show
improvement
survival
relapse
rate
postmenopausal
patient
age
year
compare
however
whether
benefit
also
hold
true
highly
intermediate
grade
tumour
large
retrospective
review
four
randomised
trial
tumour
positive
positive
negative
oestrogen
receptor
old
young
woman
derived
similar
reduction
breast
cancer
mortality
recurrence
regimen
contain
much
one
phase
iii
trial
specifically
design
elderly
patient
year
age
study
weekly
flat
dose
epirubicin
plus
tamoxifen
improve
survival
compare
tamoxifen
alone
improve
overall
survival
benefit
adjuvant
chemotherapy
addition
hormone
treatment
breast
cancer
likely
high
tumour
clearly
hormone
sensitive
eg
level
hormone
receptor
absence
oestrogen
progesterone
receptor
high
grade
although
conclusive
datum
available
regard
choice
chemotherapy
healthy
old
patient
receive
regimen
young
counterpart
care
warrant
elderly
patient
experience
greater
patient
death
retrospective
yearly
conference
gallen
switzerland
recommend
four
cycle
regimen
six
cycle
cyclophosphamide
methotrexate
fluorouracil
cmf
adequate
treatment
patient
patient
disease
unresponsive
hormone
hormone
response
uncertain
regimen
without
taxane
favour
however
recommendation
referred
general
population
acknowledge
special
consideration
apply
elderly
woman
regimen
show
well
efficacy
cmf
effect
age
potential
toxicity
induce
taxane
add
concurrently
sequentially
anthracycline
likely
challenge
benefit
expect
chemotherapy
therefore
combination
confine
biologically
aggressive
tumour
fit
elderly
woman
regimen
also
replace
anthracycline
rather
add
although
specifically
aim
elderly
patient
recent
study
show
docetaxel
combination
cyclophosphamide
well
term
survival
compare
four
cycle
combination
docetaxel
cyclophosphamide
might
reasonable
alternative
patient
certainly
cardiac
risk
anthracycline
adjuvant
chemotherapy
option
elderly
patient
however
safety
concern
consider
regimen
associate
year
cardiac
failure
rate
woman
age
year
compare
cmf
recipient
control
receive
adjuvant
contrast
cmf
show
little
effective
also
poorly
tolerate
old
compare
mortality
among
woman
age
year
old
international
breast
cancer
study
group
mortality
chemotherapy
also
report
patient
age
year
old
four
consider
choose
adjuvant
chemotherapy
therefore
absence
cardiac
contraindication
four
course
regimen
consider
elderly
docetaxel
cyclophosphamide
might
alternative
certainly
patient
cardiac
regimen
cmf
threshold
dose
efficacy
become
inferior
thus
dose
reduction
avoid
curative
setting
study
adapt
chemotherapy
regimen
limited
toxicity
elderly
patient
ongoing
healthy
elderly
patient
breast
cancer
estimate
survival
year
much
consider
much
aggressive
chemotherapy
regimen
include
anthracycline
taxane
treatment
adjuvant
trastuzumab
concurrent
taxane
chemotherapy
total
duration
year
improve
outcome
significantly
despite
significant
effect
survival
irrespective
age
group
herceptin
adjuvant
hera
trial
patient
age
year
include
large
trial
oncologist
remain
cautious
regard
adjuvant
trastuzumab
elderly
patient
study
patient
cardiac
comorbidity
exclude
national
surgical
adjuvant
breast
bowel
project
study
age
year
independent
predictor
congestive
heart
cardiac
adverse
event
much
concern
old
patient
high
risk
cardiovascular
disease
healthy
elderly
patient
without
cardiac
disease
tumour
consider
trastuzumab
treatment
close
cardiac
monitoring
essential
old
patient
receive
trastuzumab
adjuvant
setting
conclusive
datum
confirm
factor
confer
survival
benefit
elderly
patient
breast
cancer
undergo
chemotherapy
despite
know
benefit
factor
reduce
febrile
neutropenia
many
elderly
patient
high
risk
develop
eortc
american
society
clinical
oncology
asco
guideline
recommend
prophylactic
factor
expect
rate
febrile
neutropenia
high
advise
systematic
prophylactic
factor
elderly
patient
breast
cancer
receive
chemotherapy
risk
febrile
neutropenia
state
age
year
risk
factor
febrile
neutropenia
need
take
consideration
decision
prophylactic
recently
safety
concern
emerge
concern
factor
since
risk
develop
leukaemia
might
concern
confirm
another
recommendations
treatment
adjuvant
chemotherapy
decision
instead
take
account
individual
patient
estimate
absolute
benefit
life
expectancy
treatment
tolerance
preference
older
patient
breast
tumour
potentially
derive
large
benefit
survival
although
specifically
validate
elderly
population
year
decision
adjuvant
online
help
weigh
risk
benefit
adjuvant
treatment
together
patient
absence
cardiac
contraindication
four
course
regimen
usually
preferred
cmf
elderly
patient
breast
cancer
taxanes
add
anthracycline
fit
elderly
woman
docetaxel
cyclophosphamide
cmf
replace
anthracycline
patient
cardiac
risk
absence
cardiac
contraindication
adjuvant
trastuzumab
offer
old
patient
breast
cancer
chemotherapy
indicate
cardiac
monitoring
essential
metastatic
breast
cancer
metastatic
breast
cancer
treatable
curable
therefore
main
aim
treat
elderly
patient
like
young
patient
metastatic
breast
cancer
maintain
quality
life
minimise
symptom
disease
prolong
survival
without
excessive
toxicity
older
woman
much
likely
young
woman
diagnose
much
advance
stage
breast
cancer
due
lack
screening
delay
select
patient
tumour
burden
metastases
especially
bone
metastases
primary
tumour
removal
improve
hormone
treatment
hormone
treatment
treatment
choice
woman
tumour
without
disease
superiority
aromatase
inhibitor
treatment
tamoxifen
show
postmenopausal
whether
true
beyond
age
year
suggest
single
trial
since
benefit
aromatase
inhibitor
tamoxifen
mainly
term
survival
overall
survival
tamoxifen
valuable
alternative
aromatase
inhibitor
adverse
event
cost
concern
patient
initially
respond
hormone
treatment
prolong
stable
disease
significant
benefit
subsequent
line
hormone
treatment
eg
tamoxifen
aromatase
inhibitor
exemestane
anastrozole
letrozole
treatment
option
include
tamoxifen
aromatase
inhibitor
pure
fulvestrant
aromatase
inhibitor
steroidal
aromatase
inhibitor
aromatase
inhibitor
vice
versa
progestin
oestrogen
evidence
form
hormone
treatment
elderly
patient
breast
cancer
metastatic
disease
compare
young
postmenopausal
patient
chemotherapy
women
old
year
age
treat
chemotherapy
metastatic
disease
derive
similar
benefit
young
older
patient
exclude
receive
chemotherapy
advance
breast
cancer
chemotherapy
consider
hormone
refractory
patient
oestrogen
progesterone
receptor
status
available
fully
reliable
one
course
hormone
treatment
might
option
particularly
asymptomatic
patient
without
metastases
prolong
interval
primary
tumour
metastatic
disease
preference
give
chemotherapeutic
drug
safe
profile
weekly
taxane
regimen
new
little
cardiotoxic
anthracycline
formulation
capecitabine
gemcitabine
drug
often
elderly
patient
adapt
dose
compare
young
patient
based
pharmacokinetic
pharmacodynamic
toxicity
alteration
population
level
evidence
specific
dosing
schedule
generally
monotherapy
generally
favour
combination
chemotherapy
since
latter
generally
associate
increase
toxicity
little
survival
compare
sequential
single
drug
choice
chemotherapy
drug
regimen
dependent
individual
patient
characteristic
drug
availability
health
system
since
chemotherapy
situation
palliative
quality
life
paramount
significant
toxicity
generally
acceptable
principle
dose
reduction
elderly
patient
systematically
recommend
consider
based
pharmacological
parameter
alter
accord
observe
essential
population
particular
avoid
debilitating
chemotherapy
regimen
risk
febrile
neutropenia
much
deliver
upfront
growth
factor
alternative
drug
eg
anthracycline
regimen
little
myelosuppression
weekly
dosing
anthracycline
taxane
available
require
prophylactic
administration
factor
particular
attention
pay
supportive
care
since
old
patient
much
likely
develop
neutropenia
young
generally
little
functional
reserve
young
counterpart
bisphosphonates
provide
supportive
albeit
expensive
benefit
many
patient
bone
metastases
starting
bisphosphonate
woman
bone
destruction
imaging
normal
plain
radiograph
consider
reasonable
safety
administration
bisphosphonate
elderly
patient
cancer
also
targeted
treatment
targeted
treatment
show
useful
treatment
breast
cancer
patient
trastuzumab
conjunction
chemotherapy
age
document
risk
factor
congestive
heart
failure
patient
receive
trastuzumab
depend
probably
much
comorbidity
age
study
patient
age
addition
bevacizumab
paclitaxel
treatment
metastatic
breast
cancer
show
improvement
response
datum
specific
risk
benefit
bevacizumab
old
patient
breast
cancer
however
pool
analysis
patient
type
cancer
five
randomised
trial
show
patient
age
year
increase
risk
arterial
thromboembolic
event
particularly
bevacizumab
give
combination
recommendations
goal
treat
metastatic
breast
cancer
old
patient
different
young
patient
much
patient
breast
cancer
hormonal
treatment
first
choice
chemotherapy
consider
patient
disease
choice
chemotherapy
drug
regimen
dependent
individual
patient
characteristic
preference
drug
availability
conclusion
elderly
patient
comprise
large
part
breast
cancer
population
important
specific
consideration
population
recommendation
treatment
breast
cancer
individual
based
evidence
consensus
however
much
available
datum
rely
retrospective
study
subanalyses
general
population
study
far
need
develop
prospective
clinical
trial
old
population
patient
breast
cancer
search
strategy
selection
criterion
medline
choose
primary
source
information
review
search
pubmed
article
publish
march
follow
mesh
term
breast
neoplasm
mammography
radiography
ultrasonography
mastectomy
biopsy
mammoplasty
radiotherapy
chemotherapy
adjuvant
neoadjuvant
therapy
tamoxifen
aromatase
inhibitor
additionally
publication
consider
reviewer
relevant
topic
include
study
design
limited
randomised
control
trial
also
include
review
retrospective
study
cohort
study
abstract
key
international
meeting
abstract
focusing
geriatric
aspect
study
include
elderly
patient
include
formal
publication
study
also
publish
general
study
analyse
elderly
subgroup
include
supplement
available
datum
international
regional
breast
cancer
treatment
guideline
practice
guideline
also
consult
furthermore
although
international
conference
good
clinical
practice
definition
elderly
year
arbitrary
threshold
year
review
first
selection
obtain
sufficient
quantity
datum
author
consider
apply
level
evidence
grade
recommendation
accord
asco
guideline
however
much
study
consist
subanalyses
per
age
group
age
cutoff
heterogeneous
different
study
decide
inappropriate
apply
level
evidence
grade
guideline
consistently
therefore
decide
provide
consensus
recommendation
expert
panel
siog
breast
cancer
elderly
task
force
review
search
finding
agree
study
relevant
sufficiently
power
address
various
topic
discuss
throughout
paper
consensus
reach
among
participant
recommendation
contributors
hw
ma
idea
hw
coordinated
development
recommendation
core
group
different
specialist
develop
first
draft
different
topic
radiotherapy
hw
chemotherapy
hormone
treatment
jf
screening
epidemiology
surgery
manuscript
extensively
review
second
group
expert
different
field
ah
eb
hb
mb
ma
author
approve
final
recommendation
manuscript
conflict
interest
author
declare
conflict
interest
randomised
trial
mammography
screening
figure
show
reduction
mortality
breast
downside
process
include
overdetection
breast
cancer
overdetection
detection
cancer
present
clinically
woman
lifetime
therefore
diagnose
absence
screening
several
study
try
quantify
overdetection
invasive
breast
cancer
mammography
screening
estimate
vary
widely
need
valid
precise
estimate
magnitude
overdetection
attributable
mammography
screening
inform
policy
clinical
practice
woman
participate
screening
although
overdetection
invasive
cancer
ductal
carcinoma
situ
possible
paper
focus
invasive
breast
cancer
image
image
figure
mammography
screening
reduce
death
breast
cancer
photo
science
photo
library
view
within
article
systematic
review
paper
estimate
overdetection
invasive
breast
cancer
mammography
screening
identify
direction
extent
different
study
method
bias
might
affect
estimate
overdetection
method
estimate
overdetection
invasive
breast
cancer
mammography
screening
three
broad
approach
estimation
overdetection
method
method
model
approach
first
two
design
follow
imagine
group
woman
start
screen
continue
screen
year
second
group
woman
age
screen
time
period
ideally
group
form
randomisation
ensure
similarity
risk
assuming
similar
underlie
risk
breast
cancer
two
group
effect
screening
incidence
estimate
compare
screen
unscreened
group
term
average
annual
incidence
cumulative
incidence
figure
image
image
figure
effect
biennial
screening
woman
age
year
incidence
invasive
breast
cancer
absence
overdetection
based
hypothetical
datum
woman
undergo
screening
year
incidence
rate
cumulative
incidence
high
screen
population
unscreened
population
effect
arrow
show
incidence
without
screening
plus
incidence
prevalent
cancer
detect
early
screening
prevalent
cancer
arrowhead
show
incidence
without
screening
plus
incidence
incident
cancer
detect
early
screening
incident
cancer
view
within
article
absence
overdetection
incidence
screen
unscreened
group
will
effect
length
time
diagnosis
advance
account
figure
show
large
increase
incidence
screen
group
first
screening
round
occur
prevalent
cancer
increase
extend
second
third
screening
round
little
perfect
sensitivity
screening
incidence
subsequent
round
also
increase
cancer
might
present
clinically
future
detect
early
screening
incident
cancer
lead
time
therefore
ensure
average
incidence
rate
screen
group
high
unscreened
group
screening
stop
year
age
dip
incidence
occur
screen
group
dip
cancer
diagnose
year
already
detect
early
screening
incidence
appear
year
figure
assume
biennial
screening
screen
woman
screen
year
pattern
see
practice
incidence
age
little
high
screen
unscreened
woman
also
ensure
cumulative
incidence
typically
high
screen
unscreened
group
screening
period
figure
eventually
point
time
screening
stop
cumulative
incidence
breast
cancer
screen
unscreened
group
will
therefore
valid
comparison
cumulative
incidence
screen
unscreened
group
make
several
year
screening
stop
method
investigator
compare
average
annual
incidence
breast
cancer
specify
age
group
certain
period
screen
woman
unscreened
woman
age
overdetection
present
figure
difference
incidence
will
solely
due
lead
time
however
increase
incidence
screen
group
adjustment
lead
time
show
overdetection
figure
image
image
figure
effect
biennial
screening
woman
age
year
incidence
invasive
breast
cancer
presence
overdetection
based
hypothetical
datum
woman
undergo
screening
year
incidence
rate
cumulative
incidence
high
screen
population
unscreened
population
effect
overdetection
arrow
show
incidence
without
screening
plus
incidence
prevalent
cancer
detect
early
screening
prevalent
cancer
plus
incidence
overdetected
prevalent
cancer
arrowhead
show
incidence
without
screening
plus
incidence
incident
cancer
detect
early
screening
incident
cancer
plus
incidence
overdetected
incident
cancer
view
within
article
incidence
screen
woman
simply
observe
screen
population
incidence
rate
unscreened
woman
observe
control
group
randomised
trial
estimate
basis
incidence
screening
population
offer
screening
overdetection
excess
incidence
account
account
exclude
early
screening
round
compare
incidence
rate
screen
woman
incidence
rate
unscreened
woman
screening
programme
well
establish
therefore
remove
much
due
early
detection
prevalent
cancer
also
include
adjustment
lead
time
therefore
account
incident
cancer
figure
latter
component
account
simply
compare
incidence
rate
screen
woman
unscreened
woman
year
old
initial
round
will
however
also
exclude
prevalent
cancer
never
destine
become
clinically
relevant
figure
approach
will
therefore
produce
estimate
overdetection
even
apply
perfectly
without
bias
describe
paper
problem
method
theoretically
well
method
estimation
overdetection
method
method
cumulative
incidence
among
group
woman
screen
example
age
year
year
compare
cumulative
incidence
unscreened
group
time
period
incidence
rate
breast
cancer
dip
several
year
screening
stop
due
effect
screening
figure
surveillance
breast
cancer
group
continue
least
several
year
screening
end
overdetection
cumulative
incidence
time
will
identical
two
group
overdetection
due
screening
will
excess
case
breast
cancer
screen
group
compare
unscreened
group
time
figure
method
cumulative
incidence
unscreened
population
observe
estimate
method
will
include
overdetection
associate
prevalent
cancer
initial
screening
round
incident
cancer
subsequent
round
reason
method
theoretically
much
robust
method
estimation
overdetection
method
modelling
disease
transition
investigator
third
option
based
model
disease
transition
model
range
simple
involve
disease
state
transition
probability
complex
many
disease
stage
state
many
probability
eg
computer
programme
model
natural
history
breast
cancer
model
modelling
approach
trade
complexity
transparency
validity
model
result
example
simple
model
require
fewer
assumption
fewer
datum
requirement
may
much
transparent
however
simplicity
may
lead
inadequate
representation
true
datum
although
complex
model
much
accurately
capture
true
disease
process
generally
much
little
transparent
lack
transparency
hard
assess
whether
prone
bias
discuss
therefore
will
assess
incidence
rate
method
paper
methodological
issue
potential
source
bias
estimate
overdetection
method
biased
estimate
overdetection
high
optimum
method
address
follow
issue
bias
estimation
overdetection
avoid
table
table
methodological
issue
bias
affect
estimate
overdetection
methodological
issue
bias
affect
estimate
estimate
overdetection
solution
different
risk
screen
unscreened
may
high
cancer
risk
screen
unscreened
population
participation
screening
group
high
participation
screen
population
high
screening
unscreened
population
offering
screening
control
group
group
offer
screening
inappropriate
adjustment
last
screen
least
year
statistical
numerical
adjustment
incidence
may
high
screening
round
exclude
statistical
numerical
adjustment
table
view
within
article
risk
screened
unscreened
population
underlie
risk
breast
cancer
well
achieve
datum
randomised
trial
trial
datum
unavailable
observational
datum
adjustment
difference
underlie
risk
screen
unscreened
population
may
make
basis
know
risk
factor
datum
derived
screen
unscreened
population
adjustment
change
time
trend
risk
may
also
need
example
deal
change
breast
cancer
incidence
might
occur
due
increase
hormone
replacement
therapy
estimate
overdetection
might
either
high
depending
adjustment
make
participation
screening
contamination
intervention
control
group
fewer
woman
population
offer
screening
actually
participate
degree
screening
occur
unscreened
group
estimate
overdetection
will
screening
unscreened
group
screening
screen
group
unscreened
control
group
offer
screening
end
trial
observational
study
incidence
control
group
will
raise
overdetection
estimate
will
method
ideally
long
last
screen
control
group
offer
screening
period
estimate
overdetection
will
consideration
inappropriate
adjustment
result
estimate
either
high
depending
whether
method
adjustment
necessary
sufficient
last
screen
example
year
much
allow
decrease
incidence
observe
screen
stop
little
last
screen
will
bias
adjust
statistical
method
otherwise
estimate
overdetection
will
high
note
method
initial
screening
round
exclude
adjustment
make
account
among
incident
cancer
detect
subsequent
screening
round
method
search
strategy
selection
criterion
primary
research
review
article
attempt
estimate
overdetection
invasive
breast
cancer
mammography
screening
publish
english
journal
eligible
inclusion
systematic
review
restrict
review
paper
provide
estimate
breast
cancer
incidence
screen
unscreened
group
able
assess
whether
extent
result
might
affect
bias
search
medline
dec
mesh
term
breast
neoplasm
additional
word
text
search
screening
overdiagnosis
overdetection
search
strategy
yield
report
also
search
reference
list
publish
review
primary
study
strategy
yield
five
additional
report
study
assessment
datum
extraction
one
reviewer
cb
assess
abstract
report
identify
search
study
meet
inclusion
criterion
abstract
deem
possibly
relevant
full
paper
independently
review
two
three
reviewer
decide
inclusion
cb
either
nh
li
data
study
design
source
screen
unscreened
population
time
period
screening
participation
screening
screen
population
degree
screening
unscreened
population
duration
screening
duration
screening
end
method
calculate
overdetection
estimate
overdetection
extract
study
two
three
reviewer
cb
nh
independently
also
assess
presence
source
bias
table
might
affect
report
estimate
overdetection
difference
resolve
consensus
necessary
review
another
reviewer
li
facilitate
comparison
across
study
also
define
standard
measure
overdetection
calculate
follow
result
include
two
review
six
primary
study
systematic
review
figure
two
review
provide
estimate
overdetection
datum
six
publish
randomised
control
trial
mammography
screening
table
six
primary
study
two
study
report
two
estimate
based
different
datum
different
time
remain
four
primary
study
report
one
estimate
overdetection
eight
estimate
overdetection
obtain
total
six
primary
study
table
thus
total
obtain
estimate
overdetection
several
overlap
datum
source
image
image
figure
study
selection
inclusion
review
view
within
article
table
method
datum
source
eight
randomised
control
trial
mammography
screening
estimate
overdetection
method
six
study
estimate
canada
canada
two
health
insurance
canada
canada
two
primary
study
zackrisson
sweden
peeters
netherlands
paci
italy
paci
italy
method
two
study
four
estimate
primary
study
zahl
sweden
zahl
norway
jonsson
sweden
jonsson
sweden
table
control
trial
view
within
article
review
four
primary
study
method
two
primary
study
apply
method
table
study
incidence
rate
cumulative
incidence
invasive
breast
cancer
screen
population
obtain
either
intervention
group
randomised
trial
population
invite
screening
programme
estimate
incidence
unscreened
population
much
complicate
obtain
diverse
method
incidence
control
group
randomised
control
incidence
control
population
without
screening
programme
time
period
screening
offer
another
population
demonstrate
similar
underlie
breast
cancer
incidence
control
population
implementation
screening
programme
adjustment
change
breast
cancer
incidence
time
different
age
distribution
adjust
different
underlie
risk
breast
cancer
control
screen
incidence
control
population
implementation
screening
programme
without
adjustment
change
breast
cancer
incidence
time
different
age
investigator
seven
study
calculate
overdetection
incidence
screen
population
divide
incidence
unscreened
population
relative
risk
calculate
overdetection
incidence
screen
population
minus
incidence
unscreened
population
absolute
risk
difference
variation
calculation
overdetection
estimate
recalculated
standard
estimate
overdetection
datum
report
paper
describe
method
report
result
focus
comparison
standard
estimate
study
optimum
method
deal
methodological
issue
identify
therefore
bias
common
almost
universal
study
table
try
assess
possible
direction
bias
calculation
overdetection
estimation
net
effect
commonly
difficult
upward
downward
bias
study
much
commonly
author
deal
poorly
overdetection
estimate
affect
many
study
bias
create
screening
among
screen
population
participation
screening
among
control
population
acknowledge
estimate
affect
table
presence
methodological
issue
bias
affect
estimate
overdetection
include
study
methodological
issue
bias
affect
estimate
affect
estimate
number
affect
estimate
number
affect
estimate
report
primary
number
affect
estimate
method
method
different
risk
screen
unscreened
participation
screening
group
high
participation
screening
offering
screening
control
group
inappropriate
adjustment
cumulative
incidence
inappropriate
adjustment
incidence
rate
table
applicable
data
reference
data
reference
view
within
article
three
estimate
overdetection
based
datum
trial
zackrisson
table
clearly
estimate
moss
gtzsche
much
high
main
reason
estimate
seem
high
might
author
adequately
deal
least
year
datum
screening
end
therefore
need
statistically
adjust
result
estimate
biased
upwards
gtzsche
estimate
also
high
include
invasive
cancer
ductal
carcinoma
situ
dcis
zackrisson
calculate
overdetection
basis
incidence
many
year
screening
intervention
group
end
therefore
adequately
account
therefore
three
little
biased
estimate
table
three
estimate
however
will
biased
downward
effect
little
participation
screening
woman
offer
screening
screening
woman
control
group
table
assessment
methodological
issue
bias
affect
estimate
overdetection
study
method
studysimilar
cancer
risk
screen
unscreened
groupsparticipation
screening
screening
unscreened
population
group
screen
end
studyappropriate
consideration
group
yearsoverdetection
estimate
report
ci
overdetection
estimate
recalculatedref
screening
end
yearsadjustment
make
inclusion
initial
screen
malmyn
yn
per
woman
malmyn
yn
canada
per
woman
canada
canada
per
woman
canada
stockholmyn
per
woman
stockholmyn
yn
gothenburgyn
per
woman
gothenburgyn
yn
two
per
woman
two
health
insurance
yn
per
woman
yn
per
woman
zackrisson
sweden
yn
peeters
netherlands
yn
yn
paci
italy
paci
italy
table
issue
account
account
applicable
na
arrow
indicate
underestimation
overestimation
overdetection
risk
difference
risk
estimate
calculate
based
breast
cancer
include
dcis
screen
unscreened
woman
least
biased
estimate
view
within
article
moss
gtzsche
estimate
overdetection
canadian
trial
table
trial
offer
screening
control
group
end
intervention
period
report
incidence
much
year
afterwards
therefore
good
source
datum
estimation
overdetection
estimate
gtzsche
based
trial
biased
however
compare
incidence
soon
end
intervention
period
without
accounting
way
estimate
therefore
biased
upwards
moss
datum
appropriately
estimate
avoid
bias
much
woman
age
year
year
respectively
table
moss
gtzsche
datum
stockholm
gothenburg
two
county
trial
table
trial
difficult
estimation
overdetection
people
control
group
offer
screening
end
intervention
period
moss
estimate
biased
downward
acknowledge
problem
calculate
overdetection
control
group
offer
screening
gtzsche
avoid
problem
compare
incidence
screen
offer
control
group
however
introduce
problem
datum
without
adequate
duration
adjust
estimate
also
seriously
overestimate
moss
gtzsche
also
calculate
overdetection
estimate
datum
health
insurance
plan
hip
trial
great
new
york
usa
edinburgh
trial
uk
overdetection
estimate
woman
age
year
hip
trial
woman
age
year
edinburgh
trial
although
datum
hip
trial
available
moss
based
estimate
incidence
year
end
screening
therefore
estimate
biased
upwards
insufficient
duration
adjustment
also
downward
intervention
group
screening
control
group
net
effect
two
bias
probably
overestimation
overdetection
moss
incidence
datum
long
report
hip
investigator
estimate
respect
edinburgh
trial
underlie
risk
control
intervention
group
probably
therefore
estimate
overdetection
based
trial
unreliable
peeters
calculate
overdetection
year
start
screening
programme
nijmegen
netherlands
control
population
woman
age
year
city
time
period
screened
unscreened
group
similar
underlie
risk
overdetection
estimate
include
dcis
woman
age
year
onset
screening
respectively
combine
overdetection
estimate
woman
year
inclusion
dcis
insufficient
duration
screening
cease
adjustment
mean
estimate
likely
biased
upwards
however
also
likely
biased
downward
screen
population
occurrence
screening
control
population
paci
report
two
estimate
overdetection
year
start
screening
programme
italy
overdetection
estimate
woman
age
respectively
estimate
adjust
however
likely
biased
downward
screen
population
occurrence
screening
control
population
substantial
least
one
within
screen
population
cancer
detect
screening
cancer
present
clinically
furthermore
may
bias
unknown
direction
due
difference
underlie
risk
screen
control
population
population
implementation
screening
programme
estimate
method
apply
datum
randomised
control
trial
two
primary
observational
study
report
overdetection
estimate
method
table
little
biased
study
jonsson
based
datum
breast
screening
programme
gradually
introduce
sweden
fully
establish
jonsson
colleague
calculate
overdetection
two
time
point
first
screen
initial
phase
year
first
screen
stabilised
phase
overdetection
estimate
adjustment
lead
time
initial
phase
stabilised
phase
age
group
year
respectively
estimate
calculate
initial
phase
high
due
inclusion
cancer
detect
initial
screening
round
stabilised
phase
estimate
little
biased
initial
screen
exclude
will
also
exclude
overdetected
cancer
potentially
lead
underestimation
overdetection
table
assessment
methodological
issue
bias
affect
estimate
overdetection
include
study
incidence
rate
method
studysimilar
cancer
risk
screen
unscreened
groupsparticipation
screening
screening
unscreened
population
group
screen
end
studyappropriate
consideration
group
yearsoverdetection
estimate
report
rr
ci
overdetection
estimate
recalculatedref
screening
end
yearsadjustment
make
lead
inclusion
initial
screen
zahl
sweden
ynan
zahl
norway
ynan
jonsson
sweden
jonsson
sweden
table
issue
account
account
applicable
na
arrow
indicate
underestimation
overestimation
overdetection
least
biased
estimate
risk
view
within
article
overdetection
estimate
calculate
zahl
also
swedish
programme
datum
woman
age
year
annual
incidence
screen
population
estimate
number
woman
undergo
initial
screening
round
appear
negligible
period
zahl
adjust
calculate
annual
incidence
control
population
year
screening
commence
without
adjustment
change
incidence
time
thus
overdetection
estimate
overestimate
zahl
also
calculate
overdetection
screening
programme
norway
overdetection
estimate
woman
age
year
swedish
comparison
estimate
biased
adjustment
adjustment
change
incidence
control
population
time
comparison
make
many
woman
undergo
initial
screening
round
estimate
might
high
due
inclusion
cancer
detect
initial
screening
round
zahl
also
claim
reduction
breast
cancer
incidence
woman
old
year
age
however
lack
reduction
might
account
screening
woman
age
year
fact
woman
sufficient
time
several
screening
round
reach
year
age
discussion
identify
describe
four
important
bias
might
affect
estimate
overdetection
invasive
breast
cancer
substantially
underlie
breast
cancer
risk
different
screen
unscreened
population
little
participation
screening
screen
population
occurrence
screening
unscreened
population
screening
control
group
end
intervention
screening
period
inadequate
allowance
table
see
bias
consequence
discuss
adequately
paper
address
issue
overdetection
invasive
breast
cancer
researchers
need
consider
estimate
overdetection
discuss
result
light
identify
eight
publication
fulfil
inclusion
criterion
basis
recalculated
estimate
overdetection
report
estimate
overdetection
range
study
however
bias
common
suggest
different
method
different
type
degree
bias
affect
method
explain
much
variability
valid
estimate
show
heterogeneity
attempt
calculate
pool
estimate
theoretically
much
robust
method
estimate
overdetection
approach
datum
randomised
control
trial
much
several
year
screening
stop
control
group
never
screen
zackrisson
canadian
trial
author
method
zackrisson
estimate
age
year
age
year
moss
estimate
age
age
method
adjustment
exclusion
cancer
detect
initial
screening
round
may
also
result
valid
overdetection
estimate
however
estimate
biased
downward
somewhat
omission
initial
screening
round
study
method
based
screening
implementation
therefore
observational
study
rather
randomised
trial
raise
possibility
bias
may
arise
dissimilar
underlie
risk
screen
unscreened
population
study
jonsson
based
datum
year
onwards
initial
screening
round
little
affect
bias
estimate
overdetection
study
age
year
age
year
age
year
age
year
apart
estimate
provide
note
several
group
estimate
overdetection
modelling
obtain
include
study
review
provide
estimate
incidence
separately
screen
unscreened
population
additionally
discuss
introduction
understand
implication
model
output
implicit
explicit
assumption
process
step
model
process
difficult
therefore
assess
whether
extent
overdetection
estimate
affect
bias
identify
outline
duffy
apply
disease
transition
model
approach
calculate
overdetection
datum
swedish
two
county
gothenburg
trial
two
county
trial
overdetection
estimate
ci
first
screen
second
screen
third
screen
woman
age
year
gothenburg
trial
overdetection
estimate
first
screen
second
screen
third
screen
woman
age
year
apply
similar
modelling
approach
calculate
overdetection
datum
copenhagen
screening
programme
denmark
reported
overdetection
estimate
first
screen
second
screen
woman
age
year
group
generate
estimate
incidence
screen
unscreened
population
therefore
possible
overdetection
estimate
accord
definition
one
paper
exclude
svendsen
assess
whether
annual
invasive
breast
cancer
incidence
screen
population
copenhagen
screening
programme
denmark
within
confidence
interval
project
incidence
estimate
population
screening
county
without
screening
programme
overdetection
estimate
report
unable
calculate
svendsen
conclude
second
screening
round
onwards
incidence
invasive
breast
cancer
screen
population
within
ci
project
incidence
absence
screening
conclude
therefore
evidence
overdetection
conclude
little
biased
estimate
overdetection
report
far
zackrisson
based
canadian
trial
jonsson
estimate
range
woman
age
year
woman
age
year
woman
age
year
old
trial
datum
tend
provide
estimate
whereas
much
recent
observational
datum
provide
jonsson
colleague
tend
towards
high
estimate
although
difference
estimate
attributed
largely
study
method
sensitivity
mammography
screening
cancer
will
progress
overdetected
cancer
may
increase
improvement
technology
hypothesis
consistent
recent
datum
new
south
wales
programme
australia
suggest
although
cancer
detection
rate
screening
increase
time
ie
improve
sensitivity
interval
cancer
rate
far
trial
mammography
screening
woman
age
year
progress
future
estimate
overdetection
will
need
based
observational
datum
programme
estimate
make
method
address
avoid
bias
describe
paper
method
datum
randomised
control
trial
long
last
theoretically
much
desirable
method
however
seem
much
unlikely
much
randomised
trial
will
design
implement
trial
control
group
screen
end
screening
intervention
may
possible
although
seem
likely
many
woman
now
undergo
screening
provide
programme
subsequently
implement
country
method
likely
much
practical
apply
datum
current
screening
programme
advantage
require
long
duration
valid
reliable
estimate
might
still
generate
method
provide
bias
identify
paper
adequately
address
basis
review
inadequate
high
quality
evidence
overdetection
invasive
breast
cancer
screening
mammography
estimate
publish
date
biased
much
affect
multiple
source
bias
range
good
estimate
woman
age
year
woman
age
year
woman
age
year
new
study
well
attention
method
urgently
need
quantify
true
extent
overdetection
mammography
screening
programme
conflict
interest
author
declare
conflict
interest
acknowledgment
author
thank
professor
bruce
armstrong
comment
draft
manuscript
study
support
australian
national
health
medical
research
council
program
grant
screening
test
evaluation
breast
cancer
global
public
health
burden
much
one
million
new
case
diagnose
worldwide
much
new
case
diagnose
united
state
year
american
cancer
society
although
increase
proportion
new
breast
cancer
diagnosis
represent
potentially
curable
early
stage
disease
significant
proportion
woman
will
experience
relapse
result
much
breast
death
anticipate
united
state
year
consequently
investigator
strive
delineate
pathophysiology
breast
cancer
develop
therapeutic
innovation
order
minimize
individual
recurrence
risk
optimize
potential
cure
within
last
year
number
insight
therapeutic
innovation
management
early
stage
breast
cancer
report
selected
highlight
will
review
incident
breast
cancer
case
united
state
one
much
highly
breast
study
within
past
year
report
decline
incident
breast
cancer
case
san
antonio
breast
cancer
symposium
sabcs
ravdin
colleague
demonstrate
sharp
decline
incident
breast
cancer
case
among
woman
united
state
compare
although
incidence
new
breast
cancer
diagnosis
remain
stable
decline
annual
incidence
rate
observe
decline
evident
woman
year
age
old
much
pronounce
woman
positive
breast
cancer
compare
disease
trend
ascribed
primarily
early
report
women
health
initiative
whereby
deleterious
effect
hormone
replacement
therapy
report
result
subsequent
decline
hormone
replacement
therapy
prescription
among
woman
united
state
fact
increase
incidence
coronary
artery
disease
incident
breast
cancer
case
hormone
replacement
therapy
report
hrt
decline
end
year
situ
breast
cancer
breast
cancer
either
ductal
lobular
carcinoma
situ
indicator
increase
risk
development
invasive
disease
lesion
potential
target
intervention
aim
reduce
rate
subsequent
development
invasive
cancer
several
relevant
study
report
american
society
clinical
oncology
asco
annual
meeting
one
study
investigator
screen
surveillance
epidemiology
end
result
seer
database
incident
situ
case
diagnose
selected
tumor
patient
characteristic
identify
incident
case
evaluate
outcome
report
represent
dcis
lcis
respectively
approximately
treat
breast
conserve
surgery
bcs
alone
bcs
irradiation
total
mastectomy
difference
survival
demonstrate
woman
treat
bcs
irradiation
compare
total
mastectomy
finding
consistent
result
oxford
overview
three
national
surgical
adjuvant
breast
bowel
project
nsabp
dcis
trial
also
update
year
nsabp
evaluate
bcs
without
irradiation
nsabp
evaluate
bcs
irradiation
follow
tamoxifen
versus
placebo
nsabp
evaluate
bcs
irradiation
follow
tamoxifen
versus
anastrozole
anticipate
majority
observe
recurrence
among
woman
dcis
treat
bcs
ipsilateral
breast
tumor
recurrence
ibtr
addition
radiotherapy
confer
reduction
risk
invasive
ibtr
locoregional
distant
failure
observe
absence
combine
analysis
approximately
ibtr
invasive
however
treat
bcs
experience
breast
death
develop
invasive
ibtr
advances
adjuvant
chemotherapy
optimal
adjuvant
chemotherapy
strategy
woman
early
stage
breast
cancer
yet
determine
ideal
treatment
paradigm
subgroup
woman
derive
significant
benefit
give
treatment
strategy
clearly
identify
offer
treatment
subgroup
derive
significant
benefit
spare
potentially
deleterious
effect
treatment
type
individualized
calculus
illustrate
taxane
example
introduction
taxane
adjuvant
treatment
strategy
represent
therapeutic
innovation
significant
benefit
demonstrate
number
adequately
power
randomized
trial
however
regimen
also
associate
significant
rate
short
toxicity
thus
investigator
strive
characterize
calculus
subgroup
woman
early
stage
breast
cancer
strategy
may
tailor
appropriate
population
chemotherapy
efficacy
adjuvant
regimen
several
independent
study
now
report
improve
outcome
woman
early
stage
breast
cancer
treat
adjuvant
regimen
overall
efficacy
strategy
recently
confirm
pool
analysis
pool
analysis
patient
participate
nine
adjuvant
taxane
trial
significant
disease
free
survival
dfs
benefit
report
overall
rr
lymph
subset
rr
survival
benefit
also
report
overall
rr
lymph
subset
rr
ci
absolute
benefit
dfs
overall
survival
favor
regimen
range
respectively
recently
report
woman
participate
adjuvant
taxane
study
hazard
ratio
favor
regimen
thus
incorporation
taxane
adjuvant
strategy
confer
significant
overall
survival
benefit
whether
subgroup
particularly
woman
disease
derive
benefit
adjuvant
taxane
therapy
remain
uncertain
topic
early
breast
cancer
trialists
collaborative
group
anticipate
evaluation
taxane
formulation
determination
ideal
adjuvant
taxane
formulation
dose
schedule
also
active
area
investigation
eastern
cooperative
oncology
group
ecog
example
evaluate
weekly
versus
weekly
schedule
paclitaxel
mg
dose
versus
mg
dose
respectively
docetaxel
mg
dose
versus
mg
dose
respectively
four
cycle
weekly
cyclophosphamide
conventional
dose
mg
dose
preliminary
result
report
significant
benefit
observe
either
taxane
schedule
however
trend
observe
toward
dfs
benefit
weekly
paclitaxel
administration
ecog
update
woman
eligible
analysis
median
period
month
despite
initial
report
trend
toward
dfs
benefit
weekly
paclitaxel
administration
difference
either
taxane
schedule
time
update
analysis
however
significant
difference
observe
toxicity
profile
regimen
example
incidence
grade
febrile
neutropenia
weekly
docetaxel
arm
versus
study
arm
exploratory
subset
analysis
apparent
benefit
weekly
paclitaxel
regimen
hormone
population
weekly
docetaxel
regimen
hormone
population
exploratory
analysis
although
provocative
hypothesis
generate
interpret
caution
evaluation
taxane
schedule
role
sequencing
adjuvant
anthracycline
taxane
chemotherapy
administration
also
investigate
traditionally
sequential
adjuvant
therapy
plan
anthracycline
typically
administer
prior
taxane
sequencing
convention
recently
challenge
randomized
phase
ii
study
evaluate
cycle
docetaxel
mg
cycle
conventional
dose
mg
upfront
docetaxel
administration
associate
decrease
dose
reduction
superior
relative
dose
intensity
rdi
however
whether
increase
rdi
will
translate
improve
efficacy
uncertain
sequential
versus
concurrent
strategy
also
evaluate
recent
phase
iii
study
patient
operable
breast
cancer
randomized
receive
adjuvant
epirubicin
either
sequentially
concurrently
either
paclitaxel
docetaxel
exploratory
analysis
significant
dfs
difference
study
arm
furthermore
consistent
ecog
superiority
specific
taxane
demonstrate
big
woman
node
positive
breast
cancer
randomized
one
four
arm
cmf
cmf
cmf
docetaxel
result
study
originally
report
asco
although
sequential
arm
prove
superior
arm
dfs
benefit
observe
evaluate
regimen
study
recently
update
cns
substudy
evaluate
incident
brain
metastases
detect
substudy
although
strategy
associate
high
rate
abnormal
cytology
abnormal
mri
difference
cns
relapse
rate
death
taxane
cohort
observe
estrogen
receptor
expression
taxane
efficacy
potential
relationship
estrogen
receptor
expression
taxane
efficacy
evaluate
pool
analysis
patient
participate
two
different
breast
cancer
international
research
group
study
bcirg
pacs
bcirg
concurrent
adjuvant
docetaxel
adriamycin
cyclophosphamide
versus
concurrent
adriamycin
cyclophosphamide
fac
evaluate
year
dfs
versus
versus
benefit
demonstrate
regimen
pacs
cycle
adjuvant
fluorouracil
epirubicin
cyclophosphamide
fec
compare
sequential
regimen
cycle
fec
follow
cycle
docetaxel
show
improve
year
dfs
versus
versus
regimen
recent
analysis
pool
datum
two
study
dfs
benefit
report
cohort
specifically
hazard
ratio
dfs
versus
hazard
ratio
death
versus
cohort
respectively
however
test
interaction
status
chemotherapy
regimen
statistically
significant
give
positivity
prove
predictive
response
chemotherapy
prior
study
investigator
also
explore
predictive
capacity
taxane
responsiveness
analysis
relative
efficacy
docetaxel
appear
significantly
patient
strongly
tumor
compare
tumor
confound
effect
dose
size
number
specific
drug
limit
utility
result
except
say
global
taxane
hormone
receptor
interaction
unlikely
absolute
dose
density
dose
dense
strategy
aim
optimize
cell
kill
sequentially
eradicate
numerically
dominant
rapidly
proliferate
cell
population
follow
much
resistant
cell
since
reporting
significant
survival
benefit
administration
dose
dense
adjuvant
adriamycin
cyclophosphamide
paclitaxel
cancer
leukemia
group
calgb
dose
dense
strategy
evaluate
number
setting
example
ago
trial
dose
dense
epirubicin
paclitaxel
cyclophosphamide
etc
versus
conventional
schedule
follow
recently
report
study
woman
high
risk
early
stage
breast
cancer
randomized
sequential
course
cycle
mg
total
cycle
administer
every
week
support
cycle
weekly
mg
follow
cycle
weekly
mg
median
month
period
dose
dense
strategy
confer
significant
benefit
versus
result
represent
much
impressive
survival
benefit
date
high
risk
population
however
generalizability
result
somewhat
limited
introduction
dose
density
dose
intensity
study
schema
context
study
however
demonstrate
limited
dose
response
relationship
three
active
component
ago
regimen
evaluate
dose
range
study
deliver
functional
dose
three
drug
consequently
one
may
conclude
dose
dense
schedule
much
compensate
decrease
number
drug
administration
another
recently
report
study
national
cancer
institute
canada
ncic
patient
stratified
nodal
status
status
primary
surgery
cycle
oral
cyclophosphamide
epirubicin
fluorouracil
cef
cycle
adriamycin
cyclophosphamide
follow
cycle
paclitaxel
dose
dense
strategy
cycle
epirubicin
cyclophosphamide
follow
cycle
paclitaxel
administer
every
week
time
first
interim
analysis
adjust
year
rfs
cef
regimen
respectively
exploratory
analysis
trend
favoring
observe
compare
cef
among
subgroup
superiority
cef
rfs
compare
conventionally
schedule
equivalence
date
either
former
regimen
lead
author
conclude
taxane
may
indicate
patient
analysis
long
anticipate
table
national
cancer
institute
canada
ncic
schema
per
mg
mg
iv
mg
po
mg
mg
iv
mg
iv
mg
iv
mg
iv
mg
iv
mg
iv
table
cef
oral
cyclophosphamide
adriamycin
cyclophosphamide
paclitaxel
epirubicin
cyclophosphamide
paclitaxel
day
view
within
article
advances
targeted
therapy
trastuzumab
number
pivotal
adjuvant
trastuzumab
herceptin
trial
originally
report
recently
update
hera
woman
high
risk
node
negative
breast
cancer
randomized
observation
year
adjuvant
trastuzumab
year
trastuzumab
primary
chemotherapy
experimental
arm
trastuzumab
administer
initial
dose
mg
kg
mg
kg
every
week
thereafter
significant
year
dfs
benefit
observe
year
adjuvant
trastuzumab
compare
observation
versus
respectively
recent
update
median
year
period
benefit
report
specifically
unadjusted
risk
death
trastuzumab
compare
observation
alone
efficacy
result
year
trastuzumab
treatment
arm
still
similar
result
observe
update
joint
analysis
nsabp
clinical
trial
trastuzumab
administer
concurrently
paclitaxel
four
cycle
weekly
either
weekly
weekly
respectively
total
year
duration
trastuzumab
therapy
update
analysis
perez
colleague
confirm
previously
report
benefit
trastuzumab
therapy
sustain
specifically
median
period
year
report
year
dfs
versus
report
year
versus
favor
trastuzumab
study
arm
another
pivotal
adjuvant
trastuzumab
trial
bcirg
also
update
study
patient
randomized
cycle
follow
cycle
docetaxel
trastuzumab
initiate
docetaxel
administer
total
duration
year
cycle
docetaxel
trastuzumab
tch
administer
concurrently
administer
total
duration
year
result
plan
interim
analysis
report
tch
compare
control
arm
exploratory
analysis
woman
breast
cancer
exhibit
topoisomerase
ii
dna
replication
enzyme
targeted
anthracycline
appear
derive
therapeutic
advantage
therapy
conversely
differential
benefit
therapy
observe
among
woman
without
thus
postulate
woman
without
may
able
forgo
anthracycline
component
regimen
thereby
avoid
risk
cardiotoxicity
associate
recently
report
second
interim
analysis
dfs
benefit
sustain
arm
versus
tch
versus
although
magnitude
benefit
diminish
compare
first
analysis
much
notably
however
second
interim
analysis
previously
report
predictive
capacity
topoisomerase
ii
gene
significantly
diminish
compare
first
interim
analysis
thus
whether
subset
woman
breast
cancer
may
forgo
regimen
associate
risk
cardiotoxicity
remain
uncertain
expression
chemosensitivity
investigator
identify
subset
woman
benefit
specific
chemotherapy
regimen
recent
pool
analysis
subset
analysis
seven
randomized
control
trial
coworkers
report
reduction
relapse
risk
reduction
risk
death
among
adjuvant
woman
breast
cancer
compare
cohort
author
conclude
superiority
adjuvant
chemotherapy
regimen
appear
limited
cohort
observe
residual
effect
chemotherapy
chemotherapy
among
woman
breast
cancer
enhance
sensitivity
breast
cancer
anthracycline
postulate
reflect
part
topoisomerase
ii
although
impact
yet
well
define
effort
reflect
evolve
paradigm
shift
adjuvant
management
strategy
whereby
chemotherapy
recommendation
increasingly
tailor
biology
individual
tumor
importantly
datum
derived
entirely
era
significance
setting
antibody
routinely
administer
uncertain
cardiotoxicity
cardiotoxicity
important
clinical
concern
particularly
trastuzumab
administer
conjunction
anthracycline
number
cardiac
safety
update
pivotal
trastuzumab
trial
recently
report
investigator
report
far
cardiac
event
observe
year
compare
year
cumulative
incidence
cardiac
event
versus
trastuzumab
versus
control
arm
respectively
one
cardiac
death
observe
control
arm
cardiac
event
observe
trastuzumab
study
arm
date
nsabp
investigator
report
similarly
stable
cardiac
incident
rate
versus
year
versus
year
trastuzumab
versus
respectively
investigator
also
propose
clinical
prediction
model
trastuzumab
mediate
cardiac
event
incorporating
age
medication
status
baseline
leave
ventricular
ejection
fraction
result
cardiac
risk
score
aim
predict
cumulative
risk
incident
cardiac
event
therapy
status
determination
significant
controversy
recently
arise
around
status
determination
status
currently
determine
measure
protein
expression
immunohistochemistry
ihc
gene
amplification
fluorescence
situ
hybridization
fish
reasonable
expect
increase
level
trastuzumab
target
namely
receptor
confer
additional
therapeutic
benefit
conversely
reasonable
expect
trastuzumab
therapy
confer
significant
benefit
absence
amplification
overexpression
however
recent
analysis
central
testing
perform
large
randomized
north
american
adjuvant
trastuzumab
trial
nsabp
suggest
benefit
see
adjuvant
trastuzumab
may
confine
patient
ihc
tumor
nsabp
woman
eligible
enrollment
ihc
breast
cancer
determine
centrally
approve
reference
lab
enrolled
patient
tumor
originally
classify
later
prove
central
lab
review
however
consistent
dfs
benefit
observe
every
subset
woman
study
include
woman
status
central
review
rr
finding
may
seem
discordant
prior
study
calgb
demonstrate
benefit
trastuzumab
therapy
woman
breast
cancer
metastatic
setting
latter
study
patient
randomized
local
lab
first
identify
critical
distinction
patient
randomized
adjuvant
trial
first
call
positive
local
lab
later
call
negative
centrally
hence
potential
explanation
nsabp
datum
include
possibility
false
negative
result
central
lab
testing
problem
within
specimen
provide
evaluation
yet
biologic
explanation
issue
fully
elucidate
give
significant
survival
improvement
demonstrate
adjuvant
trastuzumab
trial
reasonable
offer
adjuvant
trastuzumab
woman
whose
breast
cancer
ever
report
even
face
discordant
result
another
lab
facilitate
decision
regard
testing
asco
publish
guideline
topic
early
year
table
testing
rr
nsabp
study
adjuvant
trastuzumab
act
event
act
ci
ihc
ihc
fish
table
reprinted
permission
view
within
article
conclusion
although
incidence
one
type
early
stage
breast
cancer
appear
decline
united
state
optimal
treatment
paradigm
type
yet
determine
able
successfully
cure
woman
early
stage
disease
ongoing
refinement
current
management
strategy
anticipate
recently
successful
variation
regimen
application
dose
dense
strategy
report
furthermore
reassure
stabilization
cumulative
cardiotoxicity
event
adjuvant
setting
long
however
identification
biological
breast
cancer
feature
accurately
predict
responsiveness
conventional
chemotherapy
targeted
therapy
remain
ongoing
area
investigation
hope
far
insight
pathophysiology
breast
cancer
will
permit
far
refinement
adjuvant
systemic
therapy
paradigm
consequence
anticipate
adjuvant
therapy
recommendation
will
become
increasingly
tailor
affect
individual
biology
cancer
cardiotoxicity
various
chemotherapeutic
regimen
side
effect
special
interest
may
life
threaten
therefore
may
necessitate
major
modification
treatment
much
antineoplastic
drug
demonstrate
cardiac
toxicity
group
drug
produce
decrease
myocardial
contractility
relaxation
cardiomyopathy
ii
drug
exacerbate
ischemia
iii
drug
affect
cardiac
conduction
system
anthracycline
doxorubicin
epirubicin
implicate
causative
agent
chemotherapy
induce
cardiomyopathy
incorporation
anthracycline
combination
regimen
increase
response
rate
remission
duration
survival
patient
advance
breast
cancer
clinical
value
limited
patient
due
late
onset
ventricular
dysfunction
subsequent
congestive
heart
failure
chf
although
majority
patient
impair
cardiac
function
due
anthracycline
develop
clinically
overt
chf
within
first
year
discontinuation
chemotherapy
patient
may
take
many
year
among
two
much
commonly
anthracycline
epirubicin
consider
little
cardiotoxic
doxorubicin
exact
mechanism
cardiac
damage
still
unclear
recent
study
show
combination
epirubicin
paclitaxel
highly
effective
regimen
improve
prognosis
patient
metastatic
breast
cancer
although
paclitaxel
cardiac
effect
rare
limited
mainly
disturbance
cardiac
conduction
several
study
demonstrate
combination
two
antineoplastic
drug
increase
risk
cardiac
toxicity
especially
administration
epirubicin
exceed
cumulative
dose
mg
natriuretic
peptide
anp
natriuretic
peptide
bnp
secrete
ventricle
respectively
response
wall
stress
main
biological
action
arterial
suppression
sympathetic
activity
aldosterone
system
inhibition
endothelin
release
also
demonstrate
effect
proanp
probnp
show
sensitive
marker
predict
early
cardiac
dysfunction
plasma
level
significantly
elevate
patient
heart
failure
early
detection
cardiac
dysfunction
patient
receive
cardiotoxic
chemotherapy
major
clinical
importance
evaluation
leave
ventricular
ejection
fraction
lvef
mean
radionucleotide
ventriculography
muga
scan
demonstrate
reliable
index
leave
ventricular
function
ecg
along
clinical
examination
remain
far
routine
procedure
testing
monitoring
cardiac
function
present
study
undertake
order
evaluate
cardiotoxicity
anthracycline
combination
taxane
breast
cancer
patient
elucidate
possible
role
proanp
probnp
early
diagnosis
clinical
heart
failure
administer
treatment
include
either
high
risk
cardiotoxic
regimen
contain
epirubicin
paclitaxel
risk
cardiotoxic
regimen
consist
mitoxantrone
docetaxel
lvef
ecg
well
proanp
plasma
level
assess
patient
order
evaluate
cardiac
function
prospectively
material
study
population
august
december
forty
consecutive
female
patient
histologically
confirm
breast
cancer
enrolled
study
patient
provide
inform
consent
study
approve
scientific
ethical
committee
anticancer
hospital
patient
diagnose
manage
investigation
conform
principle
outline
declaration
helsinki
study
eligibility
criterion
include
ecog
eastern
cooperative
oncology
group
performance
status
ii
lvef
value
determine
muga
scan
iii
normal
renal
serum
creatinine
mg
dl
normal
slightly
abnormal
hepatic
function
aminotransferase
iu
aminotransferase
iu
iv
absence
underlie
cardiac
disease
coronary
artery
disease
arrhythmias
valvular
disease
severe
hypertension
congestive
heart
failure
history
malignant
disease
patient
receive
chemotherapeutic
hormonal
agent
local
radiotherapy
month
prior
study
period
exclude
patient
undergo
either
total
partial
mastectomy
axillary
liver
lung
brain
lymph
node
metastases
diagnose
computed
tomography
scan
bone
metastases
diagnose
bone
scintigraphy
staging
determine
accord
tnm
tumor
node
metastasis
classification
detection
estrogen
receptor
pgr
progesterone
receptor
gene
encode
human
epidermal
growth
factor
receptor
immunohistochemistry
cancer
patient
divide
two
group
accord
administer
treatment
group
include
patient
treat
high
risk
cardiotoxic
regimen
contain
epirubicin
paclitaxel
group
patient
treat
risk
cardiotoxic
regimen
contain
mitoxantrone
docetaxel
comparison
two
much
group
control
group
contain
female
patient
diagnose
heart
failure
group
include
healthy
woman
control
group
match
age
natriuretic
peptide
order
determine
proanp
level
group
venous
blood
draw
sterile
ml
edta
contain
tube
onset
right
end
chemotherapy
concerning
control
group
one
sample
venous
blood
take
sample
centrifuged
rpm
min
serum
separate
store
day
measurement
proanp
level
measure
fmol
ml
enzyme
immunoassay
radionucleotide
ventriculography
lvef
determine
radionucleotide
ventriculography
injection
autologous
lvef
value
consider
abnormal
lvef
decline
baseline
level
great
consider
indicate
significant
cardiac
toxicity
lvef
determine
group
patient
onset
within
one
week
end
chemotherapy
control
group
patient
lvef
value
control
group
normal
lvef
value
high
cardiac
evaluation
ecg
standard
lead
ecg
record
every
three
chemotherapy
cycle
patient
qt
time
correct
heart
rate
qtc
formula
qtc
qt
qtc
time
much
consider
prolong
physical
examination
perform
cancer
patient
chemotherapy
cycle
every
three
month
end
treatment
statistical
analysis
result
express
mean
standard
deviation
normally
distribute
continuous
variable
median
interquartile
range
variable
frequency
categorical
variable
continuous
variable
test
normal
distribution
kolmogorov
smirnov
test
correlation
assess
spearman
test
difference
treatment
assess
wilcoxon
test
comparison
group
study
student
test
normally
distribute
variable
otherwise
kruskal
wallis
test
apply
categorical
datum
compare
fisher
exact
test
appropriate
probability
value
tail
consider
significant
analysis
perform
statistical
software
package
stata
version
stata
result
total
forty
cancer
patient
thirty
three
control
match
sex
age
enrolled
trial
patient
characteristic
list
table
mean
age
study
population
year
sd
difference
demonstrate
regard
age
group
median
period
patient
month
range
table
patient
characteristic
group
agroup
total
age
year
mean
sd
estrogen
receptor
status
progesterone
receptor
status
status
table
view
within
article
group
consist
patient
advance
metastatic
breast
cancer
stage
iiia
iv
treat
six
cycle
epirubicin
mg
give
bolus
intravenous
infusion
paclitaxel
mg
give
intravenous
hourly
infusion
day
one
cycle
repeat
every
three
week
none
group
patient
previously
receive
chemotherapeutic
regimen
contain
anthracycline
two
patient
treat
chest
wall
irradiation
three
chest
wall
irradiation
least
six
month
prior
enrollment
study
metastatic
site
treatment
group
patient
liver
lung
bone
lymph
node
group
consist
patient
residual
disease
surgical
treatment
stage
iia
iib
iiia
receive
six
cycle
chemotherapy
consist
mitoxantrone
mg
intravenously
hour
infusion
docetaxel
mg
intravenously
hour
infusion
well
day
one
cycle
repeat
every
three
week
none
group
patient
metastases
onset
treatment
group
consist
female
patient
new
york
heart
association
classification
ii
iv
heart
failure
mean
age
group
year
sd
group
consist
healthy
woman
mean
age
year
sd
proanp
analysis
group
plasma
level
proanp
increase
fmol
ml
range
fmol
ml
range
whereas
increase
range
fmol
ml
range
contrary
group
value
natriuretic
peptide
treatment
significantly
different
proanp
table
natriuretic
peptide
patient
control
group
group
agroup
anp
bnp
table
view
within
article
among
group
difference
record
initial
proanp
level
completion
chemotherapy
proanp
level
significantly
increase
patient
group
respectively
group
proanp
level
different
respectively
treatment
respectively
group
proanp
level
different
treatment
respectively
chemotherapy
difference
limited
proanp
level
end
chemotherapy
significantly
different
patient
group
control
group
heart
failure
image
comparison
proanp
value
treatment
group
view
within
article
image
comparison
value
treatment
group
view
within
article
statistically
significant
difference
demonstrate
regard
level
natriuretic
peptide
treatment
cancer
patient
healthy
control
group
completion
therapy
proanp
significantly
elevate
group
compare
group
respectively
none
factor
study
grade
pgr
metastases
age
find
significantly
relate
proanp
lvef
analysis
statistically
significant
decrease
lvef
observe
treatment
high
risk
cardiotoxic
regimen
regarding
risk
cardiotoxic
regimen
difference
demonstrate
concern
lvef
change
treatment
image
comparison
lvef
treatment
group
view
within
article
group
three
patient
significant
lvef
decline
baseline
value
respectively
two
much
one
common
three
reach
lvef
value
respectively
five
patient
present
increase
proanp
value
mean
increase
fmol
ml
fmol
ml
respectively
significant
correlation
increase
plasma
proanp
decrease
lvef
increase
decrease
lvef
conversely
group
correlation
proanp
alteration
lvef
value
find
respectively
ecg
analysis
significant
ecg
change
patient
group
study
period
concerning
determination
qtc
time
significant
prolongation
find
follow
concerning
group
twelve
patient
die
due
progressive
metastatic
disease
two
develop
symptom
congestive
heart
failure
peripheral
oedema
admit
hospital
five
seven
day
twelve
month
completion
chemotherapy
respectively
significant
lvef
decline
demonstrate
chemotherapy
case
drop
former
patient
drop
latter
hospitalization
study
show
far
decrease
lvef
first
patient
second
regarding
natriuretic
peptide
level
proanp
increase
chemotherapy
fmol
ml
chemotherapy
concern
former
patient
fmol
ml
latter
one
whereas
level
increase
fmol
ml
fmol
ml
respectively
eight
patient
still
treat
second
third
line
chemotherapeutic
regimen
four
patient
remain
free
disease
since
completion
chemotherapy
none
patient
develop
symptom
congestive
heart
failure
patient
lose
follow
regarding
group
patient
none
die
disease
progression
four
patient
relapse
subsequently
receive
second
line
chemotherapy
evidence
disease
relapse
eight
patient
whereas
two
patient
lose
follow
none
develop
symptom
cardiac
dysfunction
discussion
combination
anthracycline
paclitaxel
first
line
treatment
metastatic
breast
cancer
explore
several
study
show
high
efficacy
superior
level
activity
compare
anthracycline
paclitaxel
single
drug
generally
anthracycline
limited
development
cardiomyopathy
among
much
severe
side
effect
associate
drug
anthracycline
induce
cardiotoxicity
result
irreversible
damage
demonstrate
reduce
contractility
subsequent
clinical
heart
failure
epirubicin
demonstrate
little
cardiotoxicity
doxorubicin
allow
patient
tolerate
high
dose
anthracycline
reduce
cardiotoxicity
combination
epirubicin
paclitaxel
probably
based
upon
limited
interaction
pharmacokinetic
well
cardiotoxic
potential
epirubicin
estimate
risk
chf
report
little
dose
mg
increase
mg
mg
however
meinardi
demonstrate
although
observe
degree
subclinical
cardiotoxicity
chemotherapy
may
short
term
probably
increase
long
term
result
late
development
cardiac
dysfunction
certain
patient
combination
docetaxel
mitoxantrone
associate
increase
risk
cardiotoxicity
development
chf
even
cumulative
dose
mg
mg
respectively
concurrent
administration
two
drug
seem
safe
patient
normal
baseline
cardiac
function
special
concern
necessary
patient
prior
anthracycline
therapy
mediastinal
irradiation
cardiovascular
disease
present
study
clearly
confirm
regimen
represent
much
cardiotoxic
combination
one
although
mean
lvef
remain
within
normal
range
decrease
record
immediately
chemotherapy
meinardi
point
reduction
lvef
much
even
lvef
value
remain
within
normal
limit
well
absolute
lvef
value
may
risk
factor
development
chf
long
term
although
cumulative
dose
epirubicin
mg
mg
observe
drop
lvef
study
indicate
even
dose
epirubicin
contain
regimen
myocardial
damage
express
impairment
systolic
function
although
clinical
value
lvef
referred
limited
sensitivity
specificity
seem
rather
predict
subsequent
occurrence
chf
demonstrate
significant
lvef
decline
chemotherapy
associate
development
chf
two
patient
month
later
concerning
natriuretic
peptide
several
study
demonstrate
anp
bnp
level
find
elevate
patient
heart
failure
cardiac
impairment
proportional
absolute
increment
normal
level
proanp
peptide
suggest
molecule
might
much
sensitive
marker
early
cardiac
dysfunction
bnp
anp
respectively
plasma
proanp
level
report
negatively
correlated
lvef
degree
increase
concentration
correlate
severity
heart
failure
previous
study
show
level
become
elevate
development
chf
even
decline
lvef
occur
present
study
statistically
significant
increase
proanp
find
chemotherapy
group
patient
treat
high
risk
regimen
epirubicin
paclitaxel
also
demonstrate
increase
proanp
level
strongly
relate
decrease
lvef
value
moreover
level
proanp
find
increase
chemotherapy
two
patient
develop
chf
follow
thus
proanp
level
might
sensitive
marker
detection
either
early
cardiotoxicity
agreement
finding
meinardi
report
significant
increase
proanp
level
chemotherapy
regimen
although
none
patient
study
develop
overt
chf
within
one
year
follow
several
finding
mild
cardiotoxicity
detect
indicate
possible
risk
cardiac
dysfunction
late
onset
cardiotoxicity
development
chf
demonstrate
study
follow
period
long
show
anp
level
significantly
increase
child
cancer
receive
chemotherapy
much
impressive
increase
record
group
six
child
include
two
go
chf
without
previous
lvef
decline
several
previous
study
show
increase
bnp
concentration
seem
much
sensitive
anp
detection
leave
ventricular
dysfunction
demonstrate
plasma
bnp
sensitive
specific
identify
heart
failure
positive
predictive
value
identify
leave
ventricular
systolic
dysfunction
study
record
significant
increase
proanp
accordance
lvef
decline
chf
development
although
several
study
show
qtc
time
prolongation
sign
cardiotoxicity
indicate
disturbance
myocardium
probably
predispose
patient
arrhythmias
present
study
neither
qtc
time
prolongation
arrhythmias
record
conclusion
finding
indicate
even
cumulative
dose
epirubicin
cardiac
dysfunction
determine
lvef
decline
proanp
increase
demonstrate
clinically
chf
present
serious
side
effect
proanp
level
might
reliable
sensitive
marker
detection
early
well
late
cardiac
impairment
chemotherapy
latter
fact
great
importance
take
consideration
already
compromise
quality
life
patient
advance
metastatic
disease
acknowledgement
like
thank
md
department
cardiac
surgery
center
valuable
assistance
regard
enzyme
immunoassay
breast
much
frequent
cancer
site
woman
worldwide
predominantly
industrialised
country
western
europe
north
america
incidence
increase
north
america
asia
although
increase
much
pronounce
industrialised
country
however
reversal
incidence
trend
observe
united
state
since
early
woman
depending
study
whereas
incidence
young
woman
remain
france
incidence
breast
cancer
increase
continuously
since
late
per
year
health
professional
france
express
concern
possible
increase
frequency
breast
cancer
among
young
woman
publication
specifically
address
age
group
recently
similar
concern
express
clinician
study
carry
canton
geneva
observe
annual
increase
ci
incidence
breast
cancer
woman
age
observation
confirm
another
study
analyse
datum
cancer
registry
aim
describe
trend
incidence
breast
cancer
young
woman
france
datum
seven
cancer
registry
case
record
seven
registry
compare
observe
old
woman
material
method
incidence
invasive
breast
cancer
tumour
record
seven
french
dpartements
hrault
period
analyse
focusing
woman
represent
total
case
case
patient
age
time
diagnosis
annual
percentage
change
period
estimate
separately
four
age
group
young
woman
woman
just
age
invitation
organised
screening
france
woman
invite
organised
screening
woman
beyond
age
organised
screening
change
estimate
datum
aggregate
annual
age
year
age
group
model
include
linear
time
trend
polynomial
function
age
linearity
time
trend
test
add
polynomial
function
time
order
provide
global
visualisation
trend
breast
cancer
incidence
graphical
approach
report
observe
year
incidence
birth
cohort
also
present
result
incidence
rate
increase
age
group
different
extent
small
increase
find
woman
much
specifically
woman
annual
increase
great
increase
observe
woman
age
increase
almost
per
year
consequently
distribution
number
case
change
period
age
group
represent
total
number
new
breast
cancer
case
period
period
linearity
time
trend
test
change
incidence
woman
age
age
group
variation
much
complex
simply
summarised
annual
percentage
change
particular
decrease
observe
last
period
age
group
indeed
include
woman
age
increase
also
tend
flatten
age
group
table
annual
rate
change
percent
ci
number
case
incidence
rate
age
group
period
age
change
linearity
incidence
rate
per
casesincidence
ratebnumber
casesincidence
ratebnumber
casesincidence
ratebnumber
case
table
result
test
polynomial
function
time
world
age
standardised
rate
view
within
article
image
incidence
accord
age
cohort
view
within
article
present
incidence
rate
observe
accord
birth
cohort
analysis
birth
cohort
make
difficult
context
breast
cancer
due
major
change
diagnostic
practice
however
figure
enable
observe
change
incidence
present
detail
manner
give
age
risk
breast
cancer
increase
birth
cohort
visible
induce
development
screening
woman
age
probably
age
increase
level
among
old
woman
flatten
notice
age
group
last
period
might
result
former
advance
diagnosis
due
screening
age
group
trend
also
see
age
group
discussion
breast
cancer
incidence
increase
france
considerable
difference
regard
age
even
though
moderate
increase
incidence
breast
cancer
young
woman
study
moreover
trend
consistent
whole
period
organised
opportunistic
screening
become
common
france
among
woman
age
thus
difficult
interpret
time
trend
breast
cancer
incidence
age
group
disentangle
combine
effect
development
screening
associate
improvement
diagnostic
technique
many
potential
moderate
risk
young
woman
early
diagnosis
much
uncommon
technically
hard
carry
old
however
trend
incidence
young
woman
compatible
slow
change
diagnostic
practice
difficult
distinguish
effect
possible
change
risk
factor
study
trend
stage
diagnosis
survival
age
group
help
interpret
observe
increase
incidence
another
explanation
likely
improvement
completeness
cancer
registration
period
possibility
difficult
quantify
probably
french
cancer
registry
datum
collect
network
code
european
network
cancer
registry
recommendation
system
prevent
large
number
case
underreported
data
recently
check
extensive
comparison
mortality
without
indicate
special
situation
publication
describe
change
trend
incidence
breast
cancer
young
woman
probably
incidence
relatively
woman
sweden
study
analyse
trend
breast
cancer
incidence
among
young
woman
report
increase
per
year
respectively
age
group
another
study
restrict
woman
age
carry
united
state
year
show
significant
change
breast
cancer
incidence
also
report
stability
incidence
breast
cancer
woman
age
period
usa
observe
significant
though
small
decrease
woman
age
annual
percentage
change
contrary
significant
increase
observe
canton
geneva
switzerland
corresponding
annual
percentage
change
ci
woman
age
sharp
acceleration
annual
increase
ci
proper
explanation
phenomenon
although
increase
magnetic
resonance
imaging
mri
diagnostic
tool
may
partly
explain
increase
result
consider
cautiously
due
small
number
case
patient
age
increase
observe
two
area
even
though
moderate
real
increase
incidence
breast
cancer
young
woman
study
systematic
screening
breast
cancer
among
young
woman
since
age
group
disease
rare
diagnosis
difficult
impact
mortality
establish
breast
cancer
diagnose
young
patient
much
aggressive
detect
old
cancer
responsible
large
proportion
lose
potential
year
prevention
policy
targeted
know
risk
factor
thus
important
breast
cancer
risk
factor
young
woman
numerous
specific
age
group
family
history
breast
cancer
exposure
radiation
particularly
hodgkin
disease
lack
physical
activity
reproductive
factor
late
first
pregnancy
early
onset
menstruation
number
child
oral
contraceptive
alcohol
still
poorly
establish
spontaneous
artificial
termination
pregnancy
smoking
need
substantial
research
development
environmental
exposure
thus
difficult
set
prevention
policy
since
major
risk
factor
breast
cancer
young
woman
many
early
puberty
prevent
however
positive
effect
breast
cancer
incidence
may
follow
awareness
campaign
benefit
healthy
lifestyle
represent
major
health
issue
far
beyond
topic
breast
cancer
risk
associate
new
oral
also
encourage
also
protect
factor
benefit
physical
activity
well
conflict
interest
none
declare
acknowledgement
study
receive
funding
cancer
national
cancer
research
fund
france
recently
increase
body
weight
show
associate
increase
risk
mortality
various
cancer
esophageal
colon
endometrial
renal
breast
cancer
particular
strong
association
adiposity
increase
risk
breast
cancer
postmenopausal
woman
describe
decade
since
much
case
breast
cancer
sex
positive
association
obesity
development
breast
cancer
may
partly
explain
excessive
estrogen
production
adipose
tissue
recently
however
many
study
show
adipose
tissue
huge
endocrine
organ
produce
many
bioactive
product
know
adipocytokine
leptin
kda
protein
product
obese
gene
identify
representative
multiple
biological
action
although
role
leptin
initially
think
maintenance
homeostasis
body
weight
regulate
food
intake
energy
via
effect
show
implicate
modulation
many
process
reproduction
hematopoiesis
angiogenesis
wound
healing
cell
differentiation
proliferation
leptin
exert
physiological
action
leptin
receptor
identify
many
tissue
include
brain
placenta
pancreas
adrenal
gland
hematopoietic
cell
liver
lung
heart
previous
study
demonstrate
express
human
normal
malignant
breast
epithelial
cell
mediate
proliferation
cell
addition
show
leptin
protein
overexpression
correlated
high
risk
tumor
recurrence
human
breast
cancer
result
take
together
suggest
signal
might
promote
carcinogenesis
progression
breast
cancer
neu
receptor
mr
receptor
encode
neu
belong
epidermal
growth
factor
receptor
egfr
family
receptor
tyrosine
kinase
receptor
egfr
family
common
extracellular
domain
single
membrane
span
region
cytoplasmic
protein
tyrosine
kinase
domain
despite
abundance
ligand
identify
egfr
direct
ligand
discover
instead
function
heterodimer
member
egfr
family
upon
interaction
agonistic
ligand
overexpressed
human
breast
cancer
associate
enhance
tumor
aggressiveness
high
risk
relapse
death
currently
attract
great
deal
attention
new
adjuvant
therapy
antibody
trastuzumab
herceptin
prove
effective
treat
certain
breast
cancer
leptin
receptor
belong
cytokine
receptor
superfamily
consist
several
isoform
include
long
short
form
lack
intrinsic
kinase
activity
intracellular
kinase
protein
kinase
mapk
cascade
crucial
activation
downstream
signaling
molecule
however
interaction
two
pathway
signal
malignant
cell
remain
largely
unknown
study
therefore
examine
signal
interaction
consider
correlated
malignant
potential
breast
cancer
material
method
human
recombinant
leptin
purchase
sigma
chemical
louis
egfr
tyrosine
kinase
inhibitor
purchase
biomol
plymouth
pa
tyrosine
kinase
inhibitor
inhibitor
calbiochem
la
jolla
mouse
antihuman
polyclonal
antibody
mab
mouse
kinase
erk
mab
mouse
purchase
santa
cruz
biotechnology
santa
cruz
mouse
antihuman
monoclonal
neu
antibody
lab
vision
rabbit
monoclonal
antibody
purchase
cell
signaling
danvers
ma
cell
culture
human
breast
cancer
cell
purchase
american
type
culture
collection
manassas
va
cell
maintain
dulbecco
modify
eagle
medium
supplement
fetal
calf
serum
sigma
unit
ml
penicillin
ml
streptomycin
grand
island
proliferation
assay
proliferation
assay
perform
previously
describe
briefly
breast
cancer
cell
cell
seed
well
plate
dulbecco
modify
eagle
medium
contain
fatty
bovine
serum
albumin
cell
stimulate
various
concentration
leptin
experiment
cell
pretreated
either
dimethyl
sulfoxide
dmso
control
mol
min
incubation
mts
solution
promega
madison
add
well
additional
culture
number
live
cell
evaluate
measure
absorbance
nm
immunoprecipitation
western
blot
analysis
immunoprecipitation
western
blot
analysis
perform
previously
describe
brief
cell
grow
confluence
cm
dish
leptin
add
culture
stimulation
leptin
various
time
cellular
protein
lysate
ml
tube
obtain
protein
incubate
antibody
tube
immunoprecipitates
collect
protein
immunoprecipitated
protein
electrophoresed
polyacrylamide
gel
min
protein
transfer
onto
immobilon
transfer
membrane
millipore
bedford
ma
sequential
incubation
reconstitute
nonfat
milk
powder
block
nonspecific
site
thereafter
membrane
incubate
various
dilution
mouse
antiphosphotyrosine
mab
horseradish
igg
development
standard
ecl
kit
amersham
buckinghamshire
united
kingdom
cell
pretreated
mol
nmol
mol
min
stimulation
membrane
strip
immunoblotted
antibody
control
phosphorylation
cell
lysate
electrophoresed
polyacrylamide
gel
min
protein
transfer
onto
immobilon
transfer
membrane
sequential
incubation
reconstitute
nonfat
milk
powder
block
nonspecific
site
dilution
rabbit
monoclonal
antibody
horseradish
donkey
igg
prior
development
standard
ecl
kit
amersham
cell
pretreated
min
stimulation
membrane
strip
immunoblotted
antibody
control
statistical
analysis
result
statistically
analyzed
student
consider
statistically
significant
result
leptin
induces
tyrosine
phosphorylation
breast
cancer
cell
line
expression
examine
four
breast
cancer
cell
line
show
express
high
level
western
blot
polyclonal
show
four
cell
line
express
significant
level
protein
although
density
localization
band
vary
among
cell
however
significantly
express
cell
line
therefore
investigate
whether
exogenously
add
leptin
follow
experiment
image
fig
western
blot
leptin
receptor
human
breast
cancer
cell
cell
lysate
blot
mab
polyclonal
antibody
bands
run
around
kda
correspond
form
respectively
view
within
article
first
cell
incubate
ml
leptin
min
phosphorylation
molecule
examine
immunoblotting
antiphosphotyrosine
mab
show
leptin
induce
tyrosine
phosphorylation
phosphorylation
level
increase
early
min
decline
immediately
enhance
phosphorylation
continue
least
min
reverse
experiment
immunoprecipitates
antiphosphotyrosine
show
similar
reactivity
mab
image
leptin
induce
sustain
tyrosine
phosphorylation
cell
serum
starve
incubate
ml
leptin
min
cell
lysis
immunoprecipitated
mab
immunoprecipitates
immunoblotted
antiphosphotyrosine
mab
control
membrane
strip
immunoblotted
cell
lysate
immunoprecipitated
antiphosphotyrosine
antibody
immunoblotted
antibody
view
within
article
next
experiment
cell
express
moderate
level
result
cell
leptin
proliferation
via
phosphorylation
next
examine
effect
exogenous
leptin
proliferation
cell
concentration
ml
show
leptin
increase
proliferation
manner
effect
significant
maximal
ml
leptin
ml
show
significant
proliferative
effect
cell
contrast
much
high
concentration
leptin
ml
significantly
induce
proliferation
cell
image
leptin
stimulate
proliferation
breast
cancer
cell
line
via
activation
cell
preincubated
min
either
dmso
open
bar
mol
shade
bar
cultured
indicate
concentration
leptin
cell
proliferation
measure
mts
assay
data
express
percentage
control
absence
leptin
data
represent
mean
sem
six
different
experiment
view
within
article
however
pretreatment
tyrosine
kinase
inhibitor
significantly
inhibit
effect
leptin
physiological
concentration
mol
totally
abrogate
effect
ml
leptin
contrast
significantly
inhibit
effect
leptin
cell
datum
imply
proliferation
breast
cancer
cell
line
correlated
phosphorylation
significantly
however
proliferation
correlated
phosphorylation
significantly
transactivation
partially
dependent
egfr
elucidate
mechanism
transactivation
next
perform
several
experiment
specific
inhibitor
show
tyrosine
kinase
inhibitor
concentration
mol
strongly
inhibit
tyrosine
phosphorylation
egfr
tyrosine
kinase
inhibitor
nmol
also
reduce
level
tyrosine
phosphorylation
although
inhibition
slightly
little
image
tyrosine
phosphorylation
dependent
egfr
cell
serum
starve
pretreated
nmol
mol
mol
min
stimulate
min
ml
leptin
cell
lysis
immunoprecipitated
mab
immunoprecipitates
immunoblotted
antiphosphotyrosine
mab
membrane
strip
immunoblotted
control
view
within
article
phosphorylation
egfr
family
report
closely
relate
pathway
perform
experiment
specific
inhibitor
show
concentration
mol
partially
inhibit
phosphorylation
suggest
locate
upstream
transactivation
transactivation
induces
erk
mapk
activation
erk
mapk
key
molecule
cellular
response
cell
proliferation
invasion
next
investigate
molecular
interaction
erk
mapk
signaling
pathway
leptin
ml
induce
phosphorylation
erk
mapk
significantly
detect
early
min
stimulation
peak
min
gradually
decline
thereafter
however
pretreatment
mol
strongly
inhibit
phosphorylation
erk
mapk
suggest
phosphorylation
act
upstream
erk
mapk
signaling
pathway
image
erk
mapk
phosphorylation
dependent
cell
serum
starve
incubate
ml
leptin
min
cell
lysis
lysate
immunoblotted
cell
serum
starve
pretreated
mol
dmso
min
stimulate
ml
leptin
min
cell
lysate
immunoblotted
mab
view
within
article
discussion
leptin
produce
mainly
adipose
tissue
play
essential
role
regulate
fat
metabolism
recent
report
demonstrate
leptin
receptor
positively
express
human
normal
malignant
breast
epithelial
cell
addition
leptin
stimulate
proliferation
normal
malignant
breast
epithelial
cell
moreover
clinical
study
show
serum
leptin
level
significantly
elevate
breast
cancer
patient
compare
control
datum
collectively
support
hypothesis
leptin
might
mechanically
involve
development
progression
breast
cancer
however
molecular
mechanism
leptin
signaling
malignant
cell
fully
understand
different
member
receptor
family
become
concept
signal
transduction
tyrosine
phosphorylation
various
receptor
tyrosine
kinase
response
activation
many
receptor
gpcr
designate
transactivation
show
important
physiological
consequence
draw
considerable
attention
recent
year
addition
gpcr
ligand
stimulation
class
cytokine
receptor
growth
hormone
prolactin
report
induce
tyrosine
phosphorylation
egfr
family
member
receptor
structural
similarity
suggest
possible
transactivation
egfr
family
leptin
fact
already
show
leptin
induce
phosphorylation
egfr
esophageal
gastric
cancer
cell
present
study
provide
direct
evidence
exogenous
leptin
induce
phosphorylation
overexpressed
human
breast
cancer
cell
line
phenomenon
previously
report
cell
transfected
present
study
however
additionally
find
exogenous
leptin
induce
phosphorylation
erk
mapk
significantly
inhibit
specific
inhibitor
moreover
treatment
totally
abrogate
effect
leptin
finding
strongly
suggest
transactivation
implicate
effect
leptin
since
expression
clinically
associate
poor
outcome
breast
cancer
think
two
receptor
system
promote
development
progression
breast
cancer
exogenous
leptin
also
induce
phosphorylation
estrogen
receptor
cell
line
moderately
express
result
indicate
leptin
induce
transactivation
cell
experiment
however
treatment
significantly
reduce
effect
leptin
previous
report
suggest
leptin
increase
nuclear
expression
activity
absence
estradiol
result
growth
stimulation
enhancement
growth
stimulation
might
attributed
much
strongly
effect
report
acid
lpa
induce
rapid
transient
expression
well
egfr
however
phosphorylation
show
difference
phosphorylation
study
phosphorylation
detect
minute
continue
least
phosphorylation
detect
several
minute
decline
undetectable
level
min
stimulation
moreover
egfr
inhibitor
totally
abrogate
phosphorylation
lpa
contrast
partially
inhibit
phosphorylation
leptin
result
seem
reasonable
since
activate
form
heterodimer
egfr
much
interestingly
specific
inhibition
partially
inhibit
phosphorylation
leptin
occur
phosphorylation
lpa
inhibition
pattern
exogenous
prolactin
previously
report
breast
cancer
cell
finding
collectively
suggest
ligand
type
cytokine
receptor
transactivation
different
mechanism
gpcr
stimulation
recent
report
suggest
leptin
increase
vegf
expression
pathway
also
stimulate
proliferation
effect
breast
cancer
cell
line
nuclear
expression
estrogen
receptor
also
report
relate
growth
stimulation
fact
suggest
leptin
stimulate
cell
growth
various
signal
cascade
however
result
indicate
adipocytokine
utilize
downstream
signaling
partner
promote
progression
breast
cancer
link
adiposity
breast
cancer
may
closely
relate
overexpression
therefore
reduction
serum
leptin
level
may
clinically
beneficial
especially
patient
breast
cancer
acknowledgment
author
thank
technical
assistance
sentinel
lymph
node
sln
define
first
lymph
node
direct
drainage
pathway
primary
tumor
first
report
perform
sentinel
lymph
node
biopsy
slnb
radioactive
colloid
breast
cancer
patient
since
report
many
study
show
feasibility
accuracy
slnb
breast
cancer
result
prevalence
technique
determine
nodal
staging
breast
cancer
lymphoscintigraphy
lsg
often
perform
slnb
radioactive
colloid
show
drainage
primary
tumor
axillary
node
show
various
number
axillary
node
chakera
report
unsuccessful
sln
mapping
relate
patient
age
body
weight
additionally
injection
site
radiotracer
patient
age
localization
tumor
also
report
failure
visualization
lsg
however
significance
number
axillary
node
still
unclear
study
explore
potential
factor
affect
visualization
axillary
node
lsg
furthermore
discuss
possible
significance
modality
patient
method
study
patient
clinical
stage
breast
cancer
retrospectively
examine
exclusion
criterion
include
pregnancy
neoadjuvant
treatment
diagnostic
surgery
neoadjuvant
chemotherapy
informed
consent
obtain
patient
prior
examination
surgery
patient
undergo
lsg
slnb
isotope
blue
dye
isotope
combination
morning
day
surgery
megabecquerels
radioisotope
laboratory
tokyo
japan
sterile
saline
total
volume
ml
inject
subdermally
four
site
around
tumor
tumor
palpable
patient
undergo
periareolar
injection
injection
radiocolloid
breast
leave
injection
site
lsg
perform
min
injection
anterior
view
image
breast
obtain
visualize
lymph
node
define
area
increase
uptake
axilla
lsg
perform
injection
blue
dye
method
total
ml
dye
osaka
japan
inject
four
site
operate
room
general
anesthesia
min
entire
breast
perform
intraoperative
detection
radioactive
sln
perform
probe
healthcare
japan
tokyo
japan
radioactive
node
identify
discrete
area
radioisotope
uptake
separate
injection
site
count
great
per
clearly
high
background
count
discrete
radioactive
sln
remove
completely
background
count
little
much
radioactive
resected
sln
sln
stain
blue
radioactive
intraoperative
freeze
section
analysis
resected
sln
perform
patient
sln
bisect
along
major
axis
one
section
pair
fix
embed
paraffin
stain
standard
histopathological
procedure
section
pair
send
intraoperative
freeze
section
examination
event
diameter
sln
little
mm
one
section
embed
cut
surface
freeze
stain
hematoxylin
eosin
event
diameter
much
mm
diameter
sln
bisect
along
major
axis
one
section
pair
slice
mm
interval
thereafter
specimen
evaluate
part
freeze
section
examination
patient
whose
intraoperative
histological
result
negative
malignancy
undergo
far
axillary
dissection
follow
case
continue
complete
axillary
dissection
patient
clinically
apparent
positive
node
patient
diagnose
positive
intraoperative
freeze
section
analysis
patient
identification
sln
procedure
patient
undergo
breast
conserve
surgery
mastectomy
specialized
surgeon
regarding
diagnosis
lsg
number
visualize
axillary
node
classify
three
group
patient
nonvisualized
node
patient
one
visualize
node
patient
multiple
visualize
node
among
three
group
patient
compare
clinicopathological
characteristic
result
slnb
image
lymphoscintigraphy
show
node
one
visualize
node
two
visualize
node
three
visualize
node
view
within
article
statistical
analysis
perform
test
qualitative
variable
quantitative
variable
analyzed
one
way
factorial
analysis
variance
spearman
correlation
test
analyze
statistical
correlation
number
visualize
axillary
node
histological
metastatic
node
evaluate
interaction
independent
influence
factor
sln
status
multiple
logistic
regression
model
create
significance
define
result
patient
analyzed
study
april
january
three
patient
bilateral
breast
cancer
include
patient
undergo
bilateral
slnb
total
breast
axillae
retrospectively
evaluate
clinicopathological
characteristic
include
gender
age
tumor
location
tumor
classification
lymph
nodal
status
histological
type
number
histological
positive
node
show
table
cancer
invasive
ductal
carcinoma
ductal
carcinoma
situ
type
mucinous
carcinoma
carcinoma
invasive
lobular
carcinoma
patient
negative
node
patient
positive
node
patient
isolate
tumor
cell
table
clinicopathological
characteristic
breast
cancer
patient
gender
age
mean
range
tumor
location
upper
inner
lower
inner
upper
outer
lower
outer
central
tumor
lymph
node
histologic
type
invasive
ductal
number
histological
positive
node
table
uicc
classification
scheme
tnm
category
dcis
ductal
carcinoma
situ
view
within
article
slnb
procedure
perform
show
table
among
patient
patient
undergo
slnb
isotope
patient
combination
blue
dye
isotope
eleven
patient
inject
periareolar
area
patient
inject
subdermally
around
tumor
significant
difference
exist
biopsy
procedure
among
three
group
table
number
visualized
axillary
node
lymphoscintigraphy
among
different
procedure
sentinel
lymph
node
biopsy
visualize
sln
identification
method
radiocolloid
blue
injection
site
radiocolloid
table
sln
sentinel
lymph
node
view
within
article
result
slnb
show
table
nineteen
patient
delay
image
failure
immediate
image
visualize
nine
patient
node
patient
node
patient
multiple
node
table
result
lymphoscintigraphy
sentinel
lymph
node
biopsy
patient
visualize
axillary
node
lymphoscintigraphy
remove
sln
per
patient
mean
range
success
rate
sln
identification
table
sln
sentinel
lymph
node
view
within
article
regarding
number
node
clinicopathological
characteristic
provide
table
eight
patient
node
primary
tumor
localized
upper
outer
quadrant
breast
patient
node
patient
multiple
node
suffer
lesion
upper
outer
quadrant
seventeen
patient
multiple
node
clinically
positive
node
number
node
associate
clinical
nodal
status
table
clinicopathological
characteristic
among
status
visualized
node
lymphoscintigraphy
visualize
age
mean
range
mean
range
location
upper
inner
lower
inner
upper
outer
lower
outer
central
tumor
size
mm
mean
range
lymph
nodal
status
histologic
type
invasive
ductal
table
uicc
classification
scheme
tnm
category
bmi
index
height
weight
ratio
calculate
body
weight
kg
divide
square
height
dcis
ductal
carcinoma
situ
view
within
article
result
slnb
number
node
give
table
sln
successfully
identify
case
patient
one
multiple
node
successfully
identify
patient
multiple
node
mean
number
dissect
sln
range
significantly
high
nonvisualized
node
node
meanwhile
risk
sln
metastasis
one
resected
sln
two
resected
sln
risk
resected
sln
risk
node
lsg
risk
sln
metastasis
node
risk
node
risk
accordingly
metastasis
find
sln
patient
multiple
visualize
node
lsg
patient
node
patient
nonvisualized
node
metastasis
significant
correlation
see
number
visualize
node
histological
metastatic
table
result
sentinel
lymph
node
biopsy
among
status
visualized
node
lymphoscintigraphy
visualize
success
rate
sln
identification
maximum
radioactivity
content
sln
count
remove
sln
status
positive
rate
number
histological
positive
node
table
sln
sentinel
lymph
node
view
within
article
image
relationship
number
visualize
axillary
node
histological
metastatic
node
significant
correlation
find
number
node
view
within
article
multivariate
analysis
prognostic
factor
sln
status
show
table
univariate
analysis
tumor
size
clinical
lymph
nodal
status
number
node
significant
respectively
multivariate
analysis
number
visualize
axillary
node
lsg
significant
independent
factor
table
multivariate
analysis
prognostic
factor
sln
status
ci
tumor
lymph
node
status
referent
table
sln
sentinel
lymph
node
hazard
ratio
ci
confidence
interval
number
visualize
axillary
node
lymphoscintigraphy
view
within
article
discussion
slnb
emerge
minimally
invasive
alternative
axillary
lymph
node
dissection
nodal
staging
breast
cancer
preoperative
lsg
often
carry
slnb
radioactive
colloid
enable
physician
surgeon
see
migration
root
primary
tumor
axillary
node
regarding
clinical
availability
lsg
report
discuss
significance
nonvisualization
axillary
node
however
significance
number
visualize
node
unclear
therefore
study
retrospectively
evaluate
clinical
factor
potentially
involve
visualization
status
axillary
node
lsg
table
factor
affecting
successful
mapping
lymphoscintigraphy
author
colloid
injection
site
radiotracer
localization
tumor
chakera
ah
albumin
body
weight
injection
site
radiotracer
goyal
albumin
bmi
tumor
size
localization
tumor
sln
identification
rate
remove
sln
yf
colloid
size
lymph
node
metastasis
colloid
sln
identification
rate
remove
sln
radioactivity
content
sln
table
bmi
index
height
weight
ratio
calculate
body
weight
kg
divide
square
height
rate
nonvisualized
case
lymphoscintigraphy
factor
associate
fail
axillary
mapping
lymphoscintigraphy
view
within
article
case
successful
obtain
result
acceptable
compare
previous
report
table
difference
due
type
amount
isotope
study
albumin
colloid
much
report
report
show
well
accumulation
compare
albumin
additionally
study
megabecquerels
radiocolloid
fold
amount
previous
report
previous
report
report
follow
clinical
factor
significant
nonvisualization
axillary
node
age
body
weight
localization
tumor
tumor
size
several
explanation
exist
instance
demonstrate
patient
node
old
patient
node
suggest
diffusion
rate
radiotracer
slow
old
patient
additionally
goyal
report
obese
woman
bmi
much
likely
negative
sln
visualization
potentially
due
fatty
lymph
node
reduce
capacity
concentrate
radiotracer
however
study
neither
patient
age
bmi
significantly
correlated
number
node
result
might
also
affect
type
radioisotope
inject
dose
radioactive
agent
moreover
study
obese
woman
bmi
fewer
six
regarding
location
tumor
patient
nonvisualized
node
tumor
frequently
locate
upper
outer
quadrant
breast
compare
one
much
node
much
patient
radioisotope
inject
subdermally
around
tumor
accordingly
radioactivity
injection
site
upper
outer
quadrant
breast
may
axillary
node
patient
inject
periareolar
area
patient
nonvisualized
axillary
node
might
decrease
result
study
show
patient
node
sln
surgery
hand
six
nine
case
nonvisualized
node
show
sln
surgery
among
six
case
two
case
detect
sln
blue
method
four
case
detect
sln
single
method
suggest
even
case
sln
still
detect
surgery
support
previous
report
patient
multiple
node
number
dissect
sln
significantly
high
compare
nonvisualized
one
visualize
node
accordingly
suggest
several
number
sln
leave
patient
multiple
node
slnb
carry
much
carefully
moreover
patient
multiple
node
show
high
rate
histological
positive
sln
interestingly
number
metastatic
node
significantly
correlated
node
regarding
sln
status
multivariate
analysis
number
node
significant
independent
factor
reason
result
clearly
understand
however
previous
study
suggest
radiocolloid
accumulate
lymph
node
retention
associate
status
macrophage
line
nodal
accordingly
speculate
following
lymph
node
metastasis
occur
compromise
therefore
migration
colloid
node
occur
eventually
number
node
increase
taken
together
patient
number
metastatic
node
lsg
demonstrate
much
lymph
node
however
far
observation
carry
validate
explanation
include
technical
aspect
procedure
conclusion
preoperative
lsg
effective
evaluate
sln
status
status
associate
number
dissect
sln
moreover
result
lsg
potentially
reflect
histological
nodal
status
contribute
possible
improvement
successful
slnb
acknowledgment
author
thank
george
wu
university
advice
revision
manuscript
past
year
increase
knowledge
molecular
alteration
involve
development
dissemination
tumour
describe
new
target
new
drug
effective
least
vitro
however
character
much
cytostatic
cytotoxic
make
clinical
development
difficult
new
drug
classical
clinical
trial
design
based
objective
decrease
tumour
size
fail
several
author
advise
need
change
design
trial
concept
minimum
inhibitory
dose
efficacy
maximum
tolerable
dose
molecular
activity
serum
histological
marker
clinical
datum
rate
progression
improvement
quality
life
currently
introduce
methodology
clinical
among
change
perhaps
consider
much
relevant
evaluation
time
variable
clinical
however
limitation
usefulness
whatever
version
expression
overall
survival
survival
ttp
survival
follow
relapse
lie
high
variability
measurement
consequence
interaction
factor
breast
cancer
time
clinical
evolution
disease
heterogeneous
well
know
metastatic
stage
patient
succumb
within
month
survive
several
clinical
observation
confirm
study
tumour
several
year
specific
evaluation
clinical
evolution
breast
cancer
clinical
factor
histological
much
recently
molecular
biology
factor
show
predict
time
survival
follow
interval
histology
grade
disease
site
number
metastases
adjuvant
treatment
receive
variable
highlight
factor
know
predictive
clinical
evolution
disease
employ
design
clinical
trial
essentially
stratification
objective
eliminate
minimise
effect
know
predictive
factor
prior
randomisation
patient
various
treatment
arm
however
need
highlight
even
within
trial
objective
variable
select
stratification
purpose
different
far
factor
often
consider
independent
variable
despite
among
well
hence
objective
present
study
create
model
take
account
predictive
variable
apply
model
grouping
patient
respect
similar
time
patient
method
data
collection
characteristic
patient
patient
datum
obtain
database
spanish
group
investigation
breast
cancer
geicam
hold
datum
participate
spanish
hospital
access
datum
permission
spanish
agency
personnel
data
protection
commitment
maintain
datum
select
patient
diagnose
via
histology
metastatic
breast
cancer
receive
treatment
advance
disease
cancer
breast
consider
series
patient
quality
collate
datum
confirm
extensive
randomised
audit
program
statistical
analysis
collect
demographic
datum
variable
potentially
predictive
survival
follow
relapse
ttp
age
hormonal
status
pre
post
menopausal
time
initial
diagnosis
time
recurrence
type
histology
grade
differentiation
expression
hormonal
receptor
tumour
size
cm
number
metastatic
axillary
node
adjuvant
treatment
receive
without
anthracycline
interval
number
site
metastases
table
clinical
datum
derived
patient
database
characteristicn
age
stage
axilla
node
involvement
ratio
histology
grade
hormonal
receptor
hormonal
status
diagnosis
status
relapse
interval
adjuvant
chemotherapy
without
site
recurrence
lung
nodule
mastectomy
skin
involvement
table
view
within
article
dependent
variable
progression
month
initial
date
therapeutic
intervention
metastatic
disease
include
local
distance
recurrence
date
progression
treatment
statistical
analysis
univariate
analysis
perform
possible
variable
predictive
include
survival
curve
evaluate
accord
procedure
kaplan
comparison
curve
perform
variable
statistical
value
introduce
subsequent
multivariate
analysis
perform
cox
regression
analysis
proportional
establish
system
score
take
account
value
coefficient
obtain
variable
reach
statistical
significance
regression
model
score
variable
establish
divide
coefficient
coefficient
see
table
validation
model
score
procedure
perform
overall
patient
sample
relevant
datum
available
calculation
probability
progression
follow
treatment
construct
table
establish
principal
variable
event
progression
first
therapy
line
period
time
select
first
year
interval
spss
package
version
windows
chicago
throughout
role
funding
source
geicam
group
act
sponsor
study
design
collection
analysis
interpretation
datum
writing
report
decision
submit
paper
publication
result
analysis
involve
mature
patient
series
time
current
analysis
total
event
progression
therapy
median
month
ci
metastatic
disease
univariate
analysis
univariate
analysis
perform
accord
method
kaplan
meier
variable
variable
reach
statistical
significance
age
hormonal
status
time
relapse
interval
axilla
node
involvement
tumour
treatment
presence
hormonal
receptor
tumour
size
ratio
number
affect
lymph
node
divide
tumour
size
cm
grade
differentiation
receipt
anthracycline
adjuvant
treatment
presence
relapse
single
metastases
site
response
treatment
table
univariate
analysis
progression
ci
hormonal
status
diagnosis
involvement
tumour
size
ratio
ta
differentiation
grade
hormonal
receptor
adjuvant
chemotherapy
anthracycline
anthracycline
interval
hormonal
status
relapse
metastatic
site
single
multiple
response
therapy
stable
evaluable
table
ratio
number
affect
lymph
node
size
tumour
cm
view
within
article
multivariate
analysis
cox
regression
model
variable
reach
statistical
probability
univariate
analysis
include
variable
show
independent
predictive
value
ttp
metastatic
site
visceral
local
recurrence
distance
interval
hormonal
receptor
table
multivariate
cox
regression
analysis
metastases
metastases
hormonal
receptor
ratio
interval
dfi
table
view
within
article
model
score
assign
score
variable
taking
account
absolute
value
equation
obtain
cox
regression
model
hence
least
value
reference
assign
value
point
rest
score
obtain
divide
value
variable
reference
involvement
score
point
table
construction
model
score
function
value
obtain
cox
regression
analysis
see
text
detail
metastases
single
hormonal
receptor
ratio
interval
dfi
table
view
within
article
test
usefulness
score
system
model
apply
patient
relevant
datum
available
patient
three
class
establish
point
calculate
novo
ttp
class
observe
follow
median
ttp
score
scale
score
month
score
month
score
month
image
validation
score
model
patient
sample
progression
analysis
score
segregate
three
category
point
statistically
significant
difference
three
category
table
figure
percentage
probability
progression
first
year
present
interval
three
category
view
within
article
survival
table
survival
table
employ
calculate
probability
progression
follow
treatment
interval
month
month
period
discussion
date
development
agent
demonstration
activity
based
capacity
much
little
reduce
tumour
size
one
important
consequence
phase
ii
clinical
trial
proceed
phase
iii
large
sample
study
subject
arrival
drug
devoid
cytoreductive
capacity
methodology
trial
based
intend
response
reduction
tumour
size
become
little
satisfactory
author
highlight
need
change
methodology
evaluate
much
effectively
utility
new
drug
one
change
propose
fundamental
objective
new
clarify
time
variable
variation
survival
follow
relapse
ttp
however
phase
ii
phase
iii
clinical
trial
variable
single
objective
evaluation
effectiveness
need
tool
determine
priori
increment
time
variable
consider
beneficial
require
clear
knowledge
factor
predict
natural
history
disease
breast
cancer
time
variable
subject
wide
variation
well
document
clinical
factor
metastatic
site
interval
presence
symptom
relate
metastatic
disease
adjuvant
treatment
anthracycline
histological
factor
hormonal
receptor
grade
differentiation
capacity
predict
factor
process
stratification
patient
introduce
phase
iii
clinical
however
employ
independent
variable
without
take
account
exist
reduce
validity
trial
methodology
score
employ
apply
situation
author
already
present
study
model
apply
extend
series
patient
derived
different
hospital
long
period
characteristic
observe
relation
frequency
site
metastatic
disease
similar
publish
variable
reach
statistical
significance
available
majority
patient
undergo
intervention
breast
cancer
thus
endow
model
ease
possible
time
evaluate
different
clinical
guideline
operate
different
hospital
different
value
derived
however
randomly
compare
datum
different
hospital
group
hospital
find
difference
indeed
moment
progression
time
variable
well
recognised
clinical
history
frequency
clinical
visit
evaluation
disease
stage
homogeneous
one
hospital
compare
another
finding
publish
patient
series
regard
median
progression
confirm
patient
series
sufficiently
representative
real
situation
author
highlight
need
extensive
historical
measure
tool
take
account
predictive
factor
present
study
provide
solution
problem
reliably
predict
clinical
evolution
disease
clinical
predictive
model
incorporate
future
analysis
new
predictive
response
factor
new
concept
breast
cancer
disease
different
phenotype
basal
like
conclusion
new
scoring
model
possible
group
patient
metastatic
breast
cancer
accord
predict
ttp
useful
tool
time
select
stratify
patient
entry
new
randomised
clinical
trial
study
currently
underway
determine
sensitivity
specificity
model
well
usefulness
clinical
trial
evaluate
new
drug
neoadjuvant
chemotherapy
nac
current
standard
form
treatment
management
locally
advance
breast
cancer
nac
lead
increase
rate
surgery
bct
among
patient
breast
however
several
group
report
high
recurrence
rate
patient
treat
bct
preoperative
planning
determination
incision
line
often
much
difficult
tumour
nac
position
lesion
image
obtain
prone
mri
differ
operative
position
due
mammary
deformation
effect
difficult
confirm
tumour
spread
precisely
operative
acquire
mr
image
operative
position
tumour
respond
well
nac
procedure
designate
naked
image
projection
reproduction
method
nipr
project
initial
tumour
image
onto
skin
breast
operation
patient
method
patient
january
march
breast
cancer
patient
undergo
supine
oblique
mri
operative
position
bcs
foundation
health
promotion
twenty
patient
ductal
carcinoma
situ
dcis
remain
invasive
ductal
carcinoma
period
patient
undergo
conventional
bcs
nac
twenty
dcis
patient
diagnose
core
needle
biopsy
vacnb
metallic
marker
put
place
landmark
supine
mri
subsequent
bcs
case
disease
stage
accord
american
joint
committee
cancer
clinical
staging
guideline
national
comprehensive
cancer
network
nccn
tumour
metastasis
tnm
classification
report
initial
tumour
size
cm
determine
mammography
mmg
ultrasound
compute
tomography
ct
initial
case
regional
lymph
node
nodal
involvement
assess
aspiration
biopsy
patient
metastases
inflammatory
tumour
exclude
study
core
biopsy
tumour
perform
prior
nac
obtain
adequate
tumour
tissue
histological
diagnosis
determination
histological
grade
hormone
receptor
status
overexpression
human
epidermal
growth
factor
receptor
intend
treatment
patient
invasive
ductal
carcinoma
four
cycle
combination
doxorubicin
cyclophosphamide
every
week
follow
weekly
paclitaxel
time
dose
tumour
response
nac
assess
accord
guideline
response
evaluation
criteria
solid
tumour
recist
response
therapy
measure
classify
follow
complete
reduction
enhance
lesion
within
breast
term
complete
response
cr
partial
response
pr
deem
occur
tumour
reduce
size
least
progressive
disease
pd
define
increase
tumour
size
least
case
surgery
perform
within
day
last
cycle
chemotherapy
guidelines
bct
remain
uniform
study
period
lack
extensive
microcalcifications
initial
tumour
size
large
one
quadrant
absence
collagen
vascular
disease
contraindication
radiation
therapy
fifteen
patient
undergo
bcs
nipr
treatment
nac
conventional
bcs
perform
dye
application
protocol
nac
informed
consent
obtain
patient
prior
participation
study
oblique
supine
mri
nipr
procedure
procedure
patient
lie
equivalent
position
patient
raise
arm
surgical
side
adopt
posture
operation
record
site
nipple
move
result
raise
arm
create
coordinate
axis
mri
image
centre
nipple
fix
oral
medicine
capsule
tape
nipple
four
site
cm
nipple
vertical
horizontal
direction
skin
surface
nipr
procedure
mr
examination
perform
mr
unit
philip
medical
system
best
netherlands
coil
mri
perform
three
different
time
induction
chemotherapy
treatment
regimen
just
operation
sequence
sense
sensitivity
encode
technology
sense
factor
image
repetition
time
time
transverse
plane
image
factor
transverse
plane
fat
suppression
selective
partial
inversion
recovery
spir
echo
image
transverse
plane
obtain
section
thickness
mm
gap
mm
acquisition
matrix
field
view
fov
mm
dynamic
mr
image
obtain
fat
suppression
selective
partial
inversion
recovery
spir
repetition
time
time
contrast
material
injection
start
immediately
first
set
obtain
magnevist
schering
osaka
japan
administer
ml
kg
body
weight
rate
ml
follow
ml
saline
vein
two
set
dynamic
image
obtain
serially
mnemonic
system
mri
mnemonic
image
projection
method
maximal
intensity
procedure
mip
image
mr
image
five
oral
capsule
marker
initial
tumour
spread
metallic
clip
generate
transparent
sheet
radial
coordinate
axis
centre
nipple
draw
match
marker
initial
tumour
spread
image
nac
show
metallic
clip
vacnb
present
signal
mr
image
day
surgery
patient
reproduce
posture
adopt
mr
scan
treatment
planning
room
mnemonic
image
project
skin
breast
transparent
sheet
time
projection
table
position
location
mnemonic
image
display
actual
size
image
maximum
intensity
image
initial
tumour
lesion
scale
full
size
transparent
sheet
view
within
article
image
oblique
supine
position
reproduce
posture
adopt
mri
scan
surgery
treatment
planning
room
view
within
article
image
mnemonic
initial
tumour
image
project
full
size
skin
breast
view
within
article
verification
reproducibility
mri
scan
position
first
perform
nipr
dcis
microscopically
localized
calcification
evaluate
reproducibility
mr
imaging
position
operative
position
metallic
clip
insert
landmark
later
bcs
dcis
patient
metallic
clip
visualize
nipr
technique
reproduce
projection
skin
patient
breast
signal
site
mark
skin
breast
metallic
mapping
button
place
projection
site
subsequently
operative
position
obtain
confirm
deployment
metallic
clip
mapping
button
discrepancies
position
metallic
button
metallic
clip
place
reproduce
site
measure
scan
linear
distance
measure
calculate
projection
discrepancy
metallic
clip
image
image
metallic
clip
mapping
button
verification
reproducibility
mri
scan
position
operative
enlarge
image
show
metallic
clip
mapping
button
view
within
article
verification
utility
nipr
surgical
resection
line
establish
accord
contour
initial
tumour
project
reproduce
nipr
technique
conventional
method
cm
initial
tumour
lesion
estimate
residual
tumour
detect
surgical
resection
line
determine
reference
dye
application
prone
mri
ct
image
specimen
extract
surgery
subject
scan
radiologist
breast
surgeon
check
resected
specimen
operate
room
additional
excision
perform
operation
case
calcify
lesion
tumour
observe
within
cm
excision
margin
rapid
examination
mammary
gland
positive
cancer
cell
specimen
photograph
digitized
area
resected
specimen
calculate
nih
image
excision
specimen
area
additional
excision
rate
analyse
initial
additional
specimen
subject
pathological
examination
additional
excision
define
additional
specimen
obtain
operation
find
compose
healthy
breast
tissue
following
definitive
surgery
excise
specimen
fix
formalin
cut
multiple
serial
section
approximately
mm
thickness
embed
paraffin
tissue
block
stain
hematoxylin
eosin
evaluate
pathologist
positive
margin
define
presence
invasive
intraductal
carcinoma
within
mm
excision
margin
additional
excision
consider
pathological
margin
status
positive
initial
specimen
excision
specimen
area
additional
excision
rate
patient
undergo
nipr
compare
result
patient
undergo
cm
final
pathological
examination
indicate
positive
margin
patient
routinely
undergo
attempt
obtain
negative
margin
statistical
comparison
group
perform
welch
mann
whitney
comparison
consider
statistically
significant
result
metallic
clip
vacnb
detect
mip
image
supine
mri
detect
case
possible
measure
distance
mapping
button
metallic
clip
show
table
median
distance
vacnb
metallic
clip
mapping
button
dcis
patient
mm
according
location
median
distance
follow
upper
inner
quadrant
mm
inner
quadrant
mm
upper
outer
quadrant
mm
outer
quadrant
mm
central
position
mm
nipr
demonstrate
location
metallic
clip
within
little
mm
case
observation
confirm
high
degree
reproducibility
mri
scan
position
position
operation
table
difference
mammotome
metallic
marker
mapping
button
difference
mm
z
direct
mean
range
mean
range
mean
range
table
transparent
sheet
coordinate
axis
describe
centre
nipple
therefore
image
projection
lesion
near
nipple
central
position
error
dcis
ductal
carcinoma
situ
inner
quadrant
outer
quadrant
upper
inner
quadrant
upper
outer
quadrant
central
position
view
within
article
table
list
clinical
characteristic
patient
receive
nac
nipr
cm
group
nipr
group
include
four
case
disease
case
cm
group
nac
clinical
cr
pr
observe
patient
respectively
nipr
group
patient
respectively
cm
group
median
period
nipr
cm
month
range
month
range
month
case
local
relapse
distant
metastasis
either
group
table
pretreatment
clinical
characteristic
response
neoadjuvant
chemotherapy
age
mean
yr
range
yr
follow
median
tumour
category
clinical
response
table
sd
stable
disease
pr
partial
response
cr
complete
response
view
within
article
average
area
excise
specimen
case
range
range
respectively
nipr
group
value
range
range
respectively
cm
group
welch
image
average
area
excise
specimen
naked
image
projection
reproduction
method
nipr
conventional
method
cm
view
within
article
rate
nipr
cm
group
respectively
specimen
show
residual
dcis
none
case
nipr
group
require
additional
excision
based
scrape
cytology
initial
operation
additional
excision
require
case
cm
group
mann
whitney
case
additional
excision
cm
group
negative
margin
initial
specimen
permanent
sectioning
residual
tumour
additional
specimen
pathological
margin
status
positive
case
nipr
group
case
cm
group
difference
group
significant
table
comparison
additional
intraoperative
excision
cm
nipr
table
sequential
additional
excision
perform
case
tumour
calcify
lesion
detect
within
mm
cm
conventional
method
nipr
naked
initial
image
projection
reproduction
method
view
within
article
table
comparison
pathological
margin
status
cm
nipr
negative
positive
total
table
positive
margin
define
presence
invasive
intraductal
carcinoma
within
mm
surgical
margin
cm
conventional
method
nipr
naked
initial
image
projection
reproduction
method
view
within
article
discussion
due
simultaneous
nac
bcs
widely
perform
patient
breast
cancer
however
increase
rate
positive
margin
due
focus
minimize
residual
cancer
report
bcs
nac
especially
case
tumour
respond
well
tumour
shrinkage
viable
tumour
focus
may
remain
distance
central
residual
tumour
preoperative
planning
determination
optimal
incision
line
much
difficult
tumour
nac
overcome
difficulty
localization
tumour
site
patient
respond
well
nac
result
tumour
necessary
surgeon
accurately
recognize
residual
tumour
initial
tumour
site
breast
mri
report
high
sensitivity
rate
identification
residual
tumour
tissue
particularly
compare
imaging
technique
ct
mmg
patient
study
preoperatively
mri
often
contrast
medium
rate
uptake
contrast
enable
suspicious
area
breast
far
distinguish
synchronous
tumour
show
uptake
contrast
material
breast
mri
may
improve
preoperative
evaluation
extent
disease
accurate
preoperative
measurement
tumour
size
mri
limit
rate
positive
margin
procedure
however
one
problem
associate
mr
image
breast
planning
bcs
deformation
breast
place
patient
prone
position
suggest
supine
oblique
position
mri
much
useful
surgical
planning
prone
kaufmann
emphasize
schematic
photography
mass
localization
beginning
nac
helpful
localization
initial
tumour
method
report
placement
metallic
marker
platinum
coil
position
size
tumour
skin
breast
prepare
transparent
grid
breast
tumour
feel
necessary
excise
initial
tumour
lesion
prior
nac
avoid
risk
residual
tumour
cell
develop
new
bcs
procedure
call
nipr
mri
scan
perform
prior
nac
patient
position
adopt
surgery
procedure
initial
image
project
reproduce
skin
breast
just
operation
project
image
set
surgical
excision
line
bcs
perform
mammary
resection
vertical
mammary
surface
lesion
usually
perform
reconstruction
lesion
operation
often
difficult
therefore
image
tumour
project
breast
two
dimension
method
success
procedure
depend
reproducibility
posture
mri
position
position
nipr
show
reproducibility
posture
mri
position
position
nipr
useful
patient
dcis
facilitate
detection
metallic
clip
surgical
treatment
case
also
confirm
mmg
concordant
nipr
discrepancies
relative
position
mapping
button
metallic
clip
place
reproduce
site
measure
median
discrepancy
linear
distance
mapping
button
metallic
clip
mm
sibylle
report
rate
bcs
patient
treat
high
rate
compare
present
study
nipr
may
explain
difference
preoperative
planning
sibylle
perform
resection
tumour
nac
treat
initial
tumour
site
nac
selection
criterion
remain
controversial
present
standardized
protocol
type
extension
bcs
nac
case
clinical
cr
negative
imaging
residual
tumour
mmg
placement
metallic
marker
primary
tumour
site
facilitate
localization
surgery
metallic
clip
indicate
location
tumour
reveal
initial
tumour
extent
therefore
difficult
determine
extent
excision
accurately
addition
metallic
clip
detect
rate
separate
remove
several
author
report
useful
tool
operative
setting
also
poorly
palpable
breast
tumour
however
may
able
clearly
distinguish
fibrosis
residual
cm
involve
excision
unnecessarily
large
volume
breast
tissue
study
cm
find
five
case
among
six
additional
excision
specimen
addition
additional
excision
nipr
nipr
procedure
enable
precise
excision
adequate
amount
breast
tissue
compare
cm
success
depend
identification
initial
tumour
location
reproducibility
patient
posture
surgery
nipr
significantly
reduce
excision
specimen
area
compare
cm
facilitate
resection
adequate
amount
tissue
preoperative
planning
superior
cosmetic
outcome
consider
factor
reduce
resection
area
improve
cosmetic
result
resected
tissue
volume
cosmetic
outcome
inversely
moreover
procedure
may
enable
operation
mri
image
therefore
mr
imaging
improve
residual
tumour
detect
mr
imaging
chemotherapy
may
resected
nipr
procedure
may
decrease
mammary
resection
area
aim
mri
study
project
extent
initial
tumour
compare
size
post
nac
tumour
onto
breast
operative
position
time
surgery
aim
estimation
nipr
surgical
excision
line
assess
supine
mri
combination
nipr
modality
mmg
useful
determine
surgical
resection
line
near
future
unfortunately
analysis
focused
practical
procedure
surgery
nac
datum
regard
local
failure
survival
discuss
short
period
study
procedure
report
involve
dedicate
breast
coil
study
one
case
initial
tumour
spread
nac
detect
supine
mri
ct
mmg
prone
mri
breast
coil
may
detect
disease
supine
mri
direct
comparison
diagnosis
spread
oblique
supine
prone
mri
scan
breast
coil
patient
require
nipr
supine
mri
safe
simple
technique
useful
localization
tumour
spread
prior
bcs
well
initial
lesion
furthermore
procedure
may
relieve
stress
surgeon
perform
operation
breast
cancer
patient
nac
however
due
small
number
case
include
present
study
possible
come
definitive
conclusion
regard
management
bcs
nac
prospective
study
large
number
patient
require
clarify
result
great
detail
conflict
interest
statement
none
declare
rare
hereditary
condition
demonstrate
high
cancer
risk
hypersensitivity
response
exposure
agent
ultraviolet
ionize
radiation
characterize
processing
dna
damage
recognize
individual
risk
cancer
may
relate
genetically
determine
difference
ability
cell
identify
repair
dna
damage
suggest
individual
genetically
susceptible
cancer
manifest
exhibit
increase
dna
radiosensitivity
radiosensitivity
extensively
study
breast
cancer
patient
show
unselected
group
breast
cancer
case
find
radiosensitive
study
scott
colleague
author
also
find
healthy
control
radiosensitive
deficient
dna
repair
capacity
propose
predispose
factor
familial
breast
cancer
sporadic
breast
cancer
case
genomic
instability
also
describe
various
hereditary
cancer
include
breast
cancer
finding
suggest
radiosensitivity
actually
potential
predispose
condition
breast
cancer
mutation
penetrance
gene
may
gene
involve
dna
damage
processing
repair
development
assay
definition
parameter
potential
identify
cancer
prone
individual
topic
prime
interest
field
cancer
recent
implication
cancer
relate
gene
processing
regulation
processing
dna
damage
make
measurement
induction
repair
various
form
dna
damage
attractive
putative
predictor
cancer
predisposition
despite
current
information
consensus
yet
reach
cellular
assay
breast
cancer
risk
datum
report
literature
contradictory
investigator
find
high
sensitivity
reduce
repair
capacity
peripheral
blood
cell
breast
cancer
patient
expose
gamma
uv
light
evaluate
determination
chromosome
aberration
mn
dna
fragmentation
mean
comet
assay
find
significant
difference
two
end
point
chromosomal
aberration
dna
repair
now
optimum
method
prediction
radiosensitivity
good
parameter
find
largely
context
assess
inherent
cellular
radiosensitivity
damage
induction
repair
parameter
various
experimental
approach
detection
dna
strand
break
example
filter
elution
constant
field
gel
electrophoresis
gel
electrophoresis
pfge
comet
assay
parameter
much
frequently
analyzed
test
system
initial
dna
damage
residual
dna
damage
remain
period
repair
repair
rate
comet
assay
already
recognize
among
much
sensitive
method
available
measure
dna
strand
break
far
advantage
speed
simplicity
fact
observation
make
level
single
cell
also
tool
investigate
fundamental
aspect
dna
damage
cellular
response
damage
alkaline
comet
assay
resolve
break
frequency
thousand
per
cell
distance
break
order
da
definitely
well
beyond
range
fragment
size
conventional
electrophoresis
suitable
alkaline
comet
assay
detect
single
double
dna
strand
break
whereas
neutral
condition
detect
mainly
break
neutral
alkaline
method
detect
level
dna
damage
assess
rejoin
break
respectively
present
study
induction
dna
damage
repair
leukocyte
breast
cancer
patient
healthy
volunteer
compare
vitro
exposure
gamma
ray
alkaline
neutral
comet
assay
material
study
subject
blood
cell
irradiation
breast
cancer
patient
age
year
mean
age
recruit
imam
general
hospital
mastectomy
none
treat
chemotherapy
radiotherapy
healthy
volunteer
age
year
mean
age
select
match
group
study
approve
ethical
committee
school
medical
science
tarbiat
modares
university
patient
give
inform
write
consent
donor
complete
write
questionnaire
obtain
information
relate
life
style
dietary
habit
medical
history
exposure
chemical
physical
agent
heparinized
venous
blood
add
ml
micro
tube
contain
ml
rpmi
medium
gibco
brl
supplement
fetal
calf
serum
gibco
brl
diluted
blood
irradiate
ice
gamma
ray
dose
rate
gy
min
generate
source
canada
compare
dna
damage
breast
cancer
patient
control
cell
irradiate
gy
alkaline
version
gy
neutral
version
radiation
dose
select
dose
response
curve
construct
healthy
individual
show
intermediate
level
damage
cell
construct
dose
response
curve
sample
obtain
healthy
cancer
individual
dna
damage
analyse
immediately
dose
range
gy
irradiation
dna
repair
assess
gy
irradiation
alkaline
gy
neutral
version
keep
cell
start
experiment
cryopreserved
lymphocyte
healthy
individual
internal
standard
assay
several
experimental
date
slide
preparation
irradiation
sample
centrifuged
supernatant
pour
pelleted
cell
mix
agarose
agarose
pbs
free
cell
mixture
add
window
make
slide
iran
precoated
normal
agarose
merck
immediately
cover
coverslip
slide
place
tray
keep
min
ice
coverslip
remove
alkaline
comet
assay
slide
submerse
alkaline
lysis
solution
sodium
chloride
mm
edta
mm
tris
base
dimethylsulfoxide
sodium
sarcosinate
triton
merck
germany
ph
lysis
follow
step
slide
freshly
prepare
alkaline
solution
naoh
mm
edta
merck
germany
ph
horizontal
gel
electrophoresis
tank
paya
pajouhesh
iran
min
electrophoresis
cm
min
slide
wash
three
time
neutralization
buffer
mm
tris
buffer
ph
rinse
ethanol
min
air
dry
neutral
comet
assay
slide
submerse
min
lysis
solution
sodium
chloride
mm
edta
mm
tris
base
dimethylsulfoxide
sodium
sarcosinate
triton
merck
germany
ph
lysis
slide
rinse
three
time
tbe
buffer
mm
tris
mm
edta
mm
boric
acid
merck
germany
ph
min
slide
keep
horizontal
gel
electrophoresis
tank
paya
pajouhesh
iran
contain
tbe
buffer
electrophoresis
cm
min
slide
wash
water
min
rinse
ethanol
min
air
dry
staining
microscopic
analysis
experimental
parameter
cell
stain
ethidium
bromide
merck
ml
coverslip
make
magnification
nikon
microscope
equip
wavelength
band
nm
barrier
filter
attach
ccd
camera
image
randomly
select
cell
analyzed
code
slide
comet
analyzed
visual
classification
describe
damage
assign
five
class
based
visual
aspect
comet
consider
extent
dna
migration
accord
criterion
establish
comets
bright
head
tail
classify
class
cell
dna
migration
comet
small
head
long
diffuse
tail
classify
class
severely
damage
cell
comets
intermediate
appearance
classify
class
damage
score
calculate
based
follow
equation
adopt
range
arbitrary
unit
corresponding
situation
range
damage
comet
comet
extremely
damage
dd
dd
dna
damage
score
number
class
comet
total
number
score
comet
weighting
factor
class
comet
one
may
suspect
visual
classification
may
inferior
computerized
analysis
tail
moment
analysis
image
capture
ccd
camera
however
clearly
show
statistical
difference
visual
quantification
image
analysis
computer
tail
moment
quantification
method
quantification
dna
damage
comet
assay
several
author
furthermore
present
study
method
give
satisfactory
result
cell
whereas
computerized
analysis
require
expensive
equipment
also
software
visual
analysis
standard
microscope
however
verify
validity
result
obtain
visual
analysis
picture
cell
incubation
time
irradiation
capture
ccd
camera
repair
study
analyzed
automatically
casp
software
casp
version
casp
tool
image
analysis
comet
assay
develop
work
either
color
image
comet
show
kinetic
repair
similar
significantly
different
obtain
visual
analysis
comet
four
experimental
parameter
evaluate
characterize
cellular
radiation
effect
baseline
dna
damage
detectable
cell
irradiate
induce
dna
damage
measure
directly
irradiation
dd
net
dna
damage
calculate
subtract
baseline
dna
damage
dna
damage
measure
directly
irradiation
repair
capacity
also
estimate
quantitatively
irradiation
standardization
follow
equation
adopt
make
divide
actual
value
obtain
irradiate
sample
value
obtain
control
cell
include
electrophoresis
run
statistical
analysis
statistical
analysis
carry
graph
pad
prism
software
version
difference
mean
initial
dna
damage
group
test
significance
unpaired
student
analyze
result
residual
dna
damage
group
mann
whitney
also
figure
draw
sigma
plot
windows
version
comparison
initial
radiosensitivity
breast
cancer
patient
healthy
volunteer
result
show
figure
present
range
assay
parameter
observe
study
subject
well
median
percentile
cell
cancer
patient
exhibit
noticeably
high
baseline
amount
dna
fragmentation
mean
value
background
dna
damage
statistically
different
breast
cancer
patient
healthy
individual
alkaline
neutral
version
image
box
plot
show
baseline
induce
dna
damage
dd
net
induce
dna
damage
dd
control
breast
cancer
patient
bc
measure
alkaline
neutral
comet
assay
exposure
gy
gamma
ray
box
extend
percentile
percentile
horizontal
line
median
dot
line
mean
value
whisker
present
datum
addition
value
locate
outside
borderline
mark
whisker
present
point
view
within
article
induced
dna
damage
high
breast
cancer
patient
healthy
control
fail
reach
statistical
significance
net
induce
dna
damage
show
nearly
identical
median
solid
line
mean
value
dot
line
control
patient
addition
similar
range
distribution
find
result
control
patient
mark
boundary
box
represent
percentile
patient
result
lie
within
range
healthy
control
consider
show
normal
cellular
reaction
addition
patient
exhibit
little
damage
irradiate
cell
mark
range
also
classify
normal
datum
patient
however
differ
considerably
normal
range
patient
exhibit
result
lie
outside
percentile
healthy
individual
consider
abnormal
experimental
marker
show
highly
sensitive
cellular
reaction
gamma
ray
regarding
background
damage
cell
control
breast
cancer
patient
value
high
basal
cut
point
alkaline
version
control
breast
cancer
patient
value
high
basal
cut
point
neutral
version
induced
damage
dd
irradiate
cell
yield
control
breast
cancer
patient
value
high
induce
cut
point
alkaline
version
control
breast
cancer
patient
value
high
induce
cut
point
neutral
version
regarding
net
induce
dd
damage
control
breast
cancer
patient
value
high
net
induce
cut
point
alkaline
version
control
breast
cancer
patient
value
high
net
induce
cut
point
neutral
version
statistical
analysis
show
relationship
age
dna
damage
breast
cancer
patient
healthy
control
regard
baseline
induce
net
induce
version
comet
assay
comparison
dose
response
relationship
breast
cancer
patient
healthy
volunteer
show
dose
response
curve
five
breast
cancer
patient
mean
age
year
range
five
healthy
control
mean
age
year
range
alkaline
neutral
condition
comet
assay
immediately
irradiation
initial
yield
dna
damage
cancer
patient
control
increase
radiation
dose
electrophoresis
demonstrate
mark
difference
observe
initial
dna
damage
analyzed
lymphocyte
different
healthy
people
cancer
patient
particularly
true
dose
gy
reduction
variability
observe
gy
primarily
due
fact
dose
exceed
gy
marginal
additional
increase
amount
dna
tail
comet
obtain
experimental
condition
statistical
analysis
show
difference
dose
response
curve
breast
cancer
patient
healthy
volunteer
version
comet
assay
image
dose
response
curve
dna
migration
obtain
blood
sample
five
healthy
donor
full
line
five
breast
cancer
patient
break
line
process
immediately
vitro
exposure
alkaline
neutral
comet
assay
datum
point
represent
mean
sd
induce
dna
damage
view
within
article
study
repair
kinetic
order
investigate
rejoin
dna
break
change
residual
dna
damage
five
breast
cancer
patient
five
healthy
volunteer
exposure
gamma
ray
gy
alkaline
gy
neutral
condition
show
difference
repair
capacity
blood
lymphocyte
group
variability
much
mark
among
show
result
obtain
automatic
analysis
tail
moment
repair
kinetic
dna
damage
alkaline
neutral
comet
assay
study
statistical
analysis
show
significant
difference
olive
tail
moment
normal
individual
breast
cancer
patient
incubation
time
irradiation
see
kinetic
repair
much
similar
different
obtain
visual
analysis
comet
show
version
comet
assay
damage
little
efficiently
repair
among
patient
among
control
image
repair
kinetic
lymphocyte
five
healthy
donor
five
breast
cancer
patient
vitro
exposure
gy
gamma
ray
alkaline
gy
neutral
comet
assay
standardization
make
divide
actual
value
obtain
irradiate
sample
value
obtain
control
cell
include
electrophoresis
run
repair
assess
incubation
time
datum
point
represent
mean
sd
standardized
residual
dna
damage
view
within
article
image
repair
kinetic
lymphocyte
five
healthy
donor
five
breast
cancer
patient
vitro
exposure
gy
gamma
ray
alkaline
gy
neutral
comet
assay
olive
tail
moment
calculate
casp
image
analysis
software
assess
repair
dna
damage
incubation
time
post
irradiation
datum
point
represent
mean
sd
olive
tail
moment
view
within
article
discussion
alkaline
comet
assay
dna
break
ssb
describe
peripheral
blood
lymphocyte
breast
cancer
patient
information
concern
occurrence
break
dsb
patient
date
attempt
make
study
occurrence
induction
type
dna
strand
break
peripheral
blood
leukocyte
breast
cancer
patient
alkaline
comet
assay
detect
mostly
ssb
also
dsb
easily
repair
patient
without
defect
mechanism
pose
major
threat
genomic
integrity
neutral
comet
assay
detect
mostly
dna
break
dsb
important
direct
consequence
treat
cell
ionize
radiation
variety
evidence
point
toward
dsb
key
damage
type
link
lethality
particular
link
dsb
chromosome
turn
closely
correlate
cell
death
cell
type
strongly
supportive
concept
alkaline
neutral
comet
assay
result
show
patient
high
baseline
value
control
result
also
line
finding
alkaline
neutral
version
comet
assay
measure
baseline
dna
damage
untreated
sporadic
breast
cancer
patient
author
also
observe
high
baseline
value
breast
cancer
patient
alkaline
condition
comet
assay
find
also
agreement
study
chromosomal
aberration
micronucleus
test
study
endpoint
study
also
report
high
level
baseline
dna
damage
blood
lymphocyte
cancer
case
benign
control
contrast
finding
alkaline
comet
assay
author
find
background
dna
damage
peripheral
blood
lymphocyte
breast
cancer
patient
similar
control
individual
consistent
datum
lymphocyte
patient
multiple
tumor
lung
cancer
breast
cancer
also
report
exhibit
range
dna
damage
control
cell
persistent
basal
dna
damage
may
reflect
high
exposure
carcinogen
deficient
dna
repair
irradiation
vitro
version
comet
assay
reveal
difference
among
group
term
induce
dd
net
induce
dd
level
dna
damage
although
trend
toward
increase
induce
dna
damage
level
dd
cell
cancer
patient
fail
reach
statistical
significance
may
part
due
strong
variability
author
find
similar
induction
dna
damage
peripheral
blood
mononuclear
cell
breast
cancer
patient
control
individual
result
also
line
finding
alkaline
comet
assay
reveal
difference
cryopreserved
lymphocyte
breast
cancer
patient
control
subject
similarly
difference
reveal
comet
assay
cell
control
subject
patient
brca
mutation
irradiation
gy
vitro
contrast
result
increase
dna
damage
level
observe
blood
lymphocyte
breast
cancer
patient
range
value
obtain
healthy
control
set
cut
point
determine
range
normal
radiation
reaction
see
section
cut
point
case
mark
dna
damage
identify
clearly
alkaline
neutral
version
comet
assay
show
number
breast
cancer
patient
exhibit
result
lie
outside
percentile
control
much
healthy
individual
regard
net
induce
dna
damage
alkaline
neutral
breast
cancer
patient
alkaline
neutral
control
result
agreement
report
study
hand
result
disagree
find
increase
level
basal
dna
damage
cell
breast
cancer
patient
compare
healthy
control
reason
discrepancy
finding
study
understand
might
reside
patient
control
cohort
cancer
stage
treatment
prior
blood
sampling
arbitrary
determine
value
experimental
protocol
well
variability
study
select
range
value
obtain
healthy
control
point
researcher
cytogenetic
end
point
preferred
choose
mean
sd
control
point
point
compute
receiver
operating
characteristic
roc
analysis
corresponding
good
accuracy
test
minimal
false
positive
result
larger
study
necessary
show
parameter
control
reasonable
identification
subject
damage
dose
response
curve
dna
migration
obtain
just
irradiation
show
increase
dna
damage
function
radiation
dose
statistical
analysis
show
difference
group
context
conclude
group
analogous
response
analyzed
immediately
exposure
researcher
report
dose
response
cell
unselected
bc
patient
similar
control
group
micronucleus
assay
comet
assay
choice
sampling
time
follow
irradiation
study
repair
capacity
normal
cell
obtain
cancer
patient
based
previous
study
much
study
incubation
time
much
mainly
study
residual
dna
damage
peripheral
blood
cell
woman
carry
mutation
find
difference
residual
dna
damage
control
cell
carry
brca
mutation
first
min
min
sampling
interval
therefore
line
study
incubation
time
select
study
repair
dna
damage
version
comet
assay
quantitative
estimation
repair
capacity
blood
lymphocyte
show
much
damage
healthy
group
repair
within
whereas
breast
cancer
patient
reveal
datum
show
breast
cancer
donor
analyzed
study
deficient
damage
repair
difference
residual
break
among
breast
cancer
patient
control
irradiation
observe
alkaline
neutral
condition
comet
assay
result
line
finding
researcher
describe
difference
residual
dna
damage
different
interval
post
irradiation
among
breast
cancer
patient
healthy
control
alkaline
comet
assay
however
contrast
result
study
report
difference
residual
dna
damage
breast
cancer
patient
control
although
report
claim
sensitivity
fibroblast
measure
either
colony
assay
dsb
rejoin
capacity
major
parameter
determine
extent
acute
reaction
radiotherapy
breast
cancer
patient
report
show
impair
dna
repair
involve
development
late
irradiation
effect
suggest
individual
exhibit
severely
reduce
dna
repair
capacity
follow
development
late
clinical
symptom
repair
may
link
increase
susceptibility
cancer
influence
change
characteristic
lymphocyte
population
tumor
development
comet
assay
alkaline
condition
detect
ssb
dsb
damage
ssb
irradiation
almost
rejoin
consider
dna
damage
detect
neutral
condition
irradiation
ascribed
residual
dsb
several
report
literature
indicate
dna
break
rate
rejoin
measure
intrinsic
radiosensitivity
tumor
cell
general
gy
produce
ssb
per
cell
dsb
little
total
dna
damage
induce
immediately
irradiation
therefore
comet
assay
neutral
condition
much
sensitive
detection
dsb
per
gy
process
dna
break
rejoin
contain
fast
component
slow
component
induce
ssb
rejoin
several
minute
many
cell
line
dsb
rejoin
min
fast
component
slow
component
irradiation
suggest
remain
damage
measure
much
excellent
index
restoration
ability
dna
damage
show
rejoin
dsb
mammalian
cell
line
number
residual
dsb
change
neutral
filter
elution
however
pfge
number
dsb
induce
radiation
show
decrease
slightly
irradiation
experimental
result
dna
damage
alkaline
condition
decrease
slightly
irradiation
breast
cancer
patient
decline
control
value
gy
irradiation
neutral
condition
healthy
donor
present
considerable
reduction
damage
patient
high
residual
damage
even
exposure
even
dsb
complex
type
rejoin
consider
dsb
happen
slow
component
dna
repair
conclusion
find
difference
initial
dna
damage
breast
cancer
patient
healthy
control
comet
assay
alkaline
neutral
condition
find
difference
residual
dna
damage
alkaline
neutral
condition
therefore
suggest
amount
residual
dna
damage
irradiation
putative
predictor
cancer
predisposition
cellular
radiosensitivity
acknowledgement
work
support
research
department
tarbiat
modares
university
author
wish
express
thank
personnel
imam
general
hospital
help
sample
collection
patient
healthy
individual
voluntary
contribution
blood
donation
help
advice
irradiation
sample
increased
cardiovascular
mortality
radiotherapy
breast
cancer
bc
first
notice
scandinavian
british
trial
find
later
confirm
trial
randomizing
postoperative
study
leave
right
comparison
result
concern
mortality
datum
patient
treat
either
postmastectomy
postlumpectomy
irradiation
except
one
study
exclusively
examine
postlumpectomy
datum
available
regard
cardiac
morbidity
among
patient
treat
therapy
one
modeling
study
dose
volume
effect
suggest
irradiate
volume
heart
derived
measure
maximum
distance
posterior
field
border
heart
contour
view
tangential
treatment
beam
also
call
maximum
heart
distance
mhd
enable
retrospective
analysis
volume
effect
date
study
publish
examine
individual
dose
volume
effect
relation
incidence
cvd
image
fig
simulator
film
show
measurement
maximum
heart
distance
dorsal
field
border
tangential
breast
field
mediolateral
much
distant
heart
contour
arrow
view
within
article
present
study
assess
effect
tangential
breast
irradiation
cvd
incidence
compare
bc
patient
subsequently
evaluate
whether
increase
mhd
associate
great
risk
cvd
patient
irradiate
leave
side
method
material
data
collection
include
patient
stage
bc
treat
therapy
five
institution
ziekenhuis
eindhoven
erasmus
mc
daniel
den
hoed
cancer
center
clinic
netherlands
cancer
institute
university
hospital
leuven
patient
treat
radiation
field
breast
tangent
treat
adjuvant
chemotherapy
exclude
patient
bilateral
bc
secondary
malignant
tumor
time
diagnosis
bc
oncologic
record
collect
follow
datum
date
bc
diagnosis
laterality
tumor
histology
axillary
lymph
node
status
date
treatment
modality
primary
bc
recurrent
disease
type
surgery
radiation
field
history
cardiac
disease
diagnosis
bc
date
diagnosis
cardiac
event
cardiovascular
risk
factor
date
much
recent
medical
information
date
death
primary
death
accord
international
classification
disease
edition
radiotherapy
information
include
number
fraction
total
dose
beam
energy
boost
irradiation
risk
factor
smoking
hypertension
hypercholesterolemia
diabetes
mellitus
record
date
diagnosis
bc
end
smoking
score
positive
patient
smoke
end
stop
smoking
little
year
end
hypertension
hypercholesterolemia
diabetes
mellitus
score
positive
state
medical
information
treat
patient
update
information
least
january
specific
cardiac
diagnosis
risk
factor
well
vital
status
send
questionnaire
general
practitioner
gp
netherlands
belgium
nearly
resident
gp
receive
medical
attend
physician
registry
consult
information
date
death
information
incomplete
patient
collect
cardiac
datum
patient
record
gp
patient
record
complete
information
least
january
available
patient
patient
die
acute
cardiac
event
without
prior
evidence
cardiac
disease
date
death
record
date
diagnosis
cardiac
event
measurement
maximum
heart
distance
three
investigator
train
measure
maximum
heart
distance
mhd
pilot
study
patient
level
agreement
establish
result
follow
policy
mhd
measure
independently
two
investigator
perpendicular
distance
dorsal
field
border
much
distant
part
heart
contour
visible
simulator
film
result
average
little
mm
difference
find
case
large
disagreement
two
observer
consensus
reach
treatment
breast
irradiation
give
oppose
beam
dose
gy
fraction
gy
patient
megavoltage
equipment
mv
case
eleven
percent
patient
treat
machine
boost
give
patient
statistical
analysis
overall
cumulative
probability
death
estimate
function
time
since
start
treatment
method
cox
proportional
hazard
model
quantify
effect
laterality
mhd
score
cvd
risk
take
account
several
covariate
age
treatment
cardiovascular
risk
factor
cox
model
fit
commercial
statistical
software
spss
chicago
test
student
test
compare
categoric
continuous
variable
respectively
role
funding
source
sponsor
study
role
study
design
datum
collection
datum
analysis
datum
interpretation
write
report
author
final
responsibility
decision
submit
publication
result
patient
include
study
median
since
start
year
range
year
median
age
diagnosis
bc
year
distribution
cardiac
risk
factor
different
bc
patient
except
diabetes
mellitus
occur
much
often
case
history
cvd
bc
diagnosis
report
much
often
bc
patient
table
table
patient
characteristic
breast
cancer
laterality
bcp
median
age
median
risk
factor
cvd
diabetes
smoking
former
current
cvd
bc
table
abbreviation
bc
breast
cancer
cvd
cardiovascular
disease
value
number
percentage
unless
otherwise
note
view
within
article
overall
bc
survival
different
comparison
overall
cardiovascular
mortality
patient
treat
leave
side
right
side
render
hazard
ratio
confidence
interval
ci
adjust
age
bc
diagnosis
history
cvd
diabetes
mellitus
mortality
ischemic
heart
disease
nonsignificantly
increase
ci
datum
show
image
fig
overall
survival
survival
breast
cancer
laterality
view
within
article
image
fig
survival
cardiovascular
disease
laterality
cox
regression
analysis
adjust
age
breast
cancer
diagnosis
history
cardiovascular
disease
diabetes
mellitus
view
within
article
table
death
bcp
breast
cardiovascular
myocardial
heart
sudden
table
abbreviation
bc
breast
cancer
value
number
percentage
international
classification
disease
edition
code
view
within
article
increased
morbidity
cvd
statistically
significantly
associate
irradiation
leave
side
ci
adjust
age
diagnosis
bc
history
cvd
diabetes
mellitus
median
time
event
year
increase
cvd
incidence
observe
category
ischemic
heart
disease
marginally
significantly
increase
risk
ci
also
category
heart
disease
ci
consist
pericarditis
valvular
dysfunction
cardiomyopathy
congestive
heart
failure
statistically
significant
difference
risk
cardiovascular
disease
patient
irradiate
beam
treat
linear
accelerator
apart
irradiation
independent
risk
factor
increase
cardiovascular
morbidity
previously
diagnose
cvd
high
blood
pressure
hypercholesterolemia
diabetes
mellitus
risk
continue
smoking
marginally
significantly
increase
exclusion
patient
history
cvd
analysis
render
similar
result
respect
risk
cvd
ci
table
cardiovascular
morbidity
laterality
cox
regression
analysis
bc
bc
ci
cardiovascular
ischemic
heart
heart
table
abbreviation
bc
breast
cancer
hazard
ratio
ci
confidence
interval
value
number
percentage
unless
otherwise
note
adjusted
age
bc
diagnosis
history
cardiovascular
disease
diabetes
mellitus
international
classification
disease
edition
code
international
classification
disease
edition
code
view
within
article
image
fig
survival
free
cardiovascular
disease
laterality
adjust
age
breast
cancer
diagnosis
history
cardiovascular
disease
diabetes
mellitus
view
within
article
table
cox
regression
analysis
potential
risk
factor
cvd
ci
radiotherapy
leave
right
hypertension
yes
diabetes
mellitus
yes
hypercholesterolemia
yes
smoking
current
unknown
history
cvd
yes
table
abbreviation
hazard
ratio
ci
confidence
interval
cvd
cardiovascular
disease
adjusted
age
hypertension
diabetes
mellitus
hypercholesterolemia
smoking
history
cvd
view
within
article
simulator
film
need
mhd
measurement
miss
patient
bc
maximum
heart
distance
measure
patient
bc
evaluable
case
disagreement
mm
difference
two
observer
occur
case
concordance
eventually
reach
case
mean
mhd
mm
range
mm
examine
effect
mhd
measure
irradiate
heart
volume
cvd
risk
significant
trend
increase
risk
great
mhd
observe
patient
mhd
mm
seem
high
risk
ischemic
heart
disease
compare
patient
small
mhd
measurement
although
number
small
reach
statistical
significance
table
cardiovascular
morbidity
mhd
measurement
cox
regression
analysis
ischemic
heart
heart
cardiovascular
disease
eventshr
ci
eventshr
ci
eventshr
ci
table
abbreviation
mhd
maximum
heart
distance
hazard
ratio
ci
confidence
interval
adjusted
age
history
cardiovascular
disease
diabetes
mellitus
event
ischemic
heart
disease
patient
miss
mhd
measurement
event
heart
disease
patient
miss
mhd
measurement
event
cardiovascular
disease
patient
miss
mhd
measurement
view
within
article
discussion
large
multicenter
study
focused
exclusively
patient
treat
postlumpectomy
breast
tangential
observe
increase
incidence
cvd
bc
compare
bc
irrespective
volume
heart
radiation
field
respect
mortality
cvd
show
statistically
nonsignificant
increase
risk
similar
magnitude
cardiotoxic
effect
result
know
since
publication
late
side
effect
treatment
patient
hodgkin
lymphoma
many
cardiac
disorder
describe
result
irradiation
coronary
artery
disease
valvular
insufficiency
pericarditis
cardiomyopathy
basic
feature
particular
tissue
damage
heart
fibrosis
occur
way
cardiovascular
mortality
comparison
irradiate
nonirradiated
patient
first
indication
possible
negative
effect
irradiation
treatment
bc
see
oslo
stockholm
trial
randomizing
postmastectomy
irradiation
clear
excess
mortality
myocardial
infarction
mi
notice
irradiate
group
cardiotoxic
effect
due
various
cardiac
disease
also
find
two
british
trial
first
eight
postmastectomy
trial
show
increase
mortality
approximately
irradiate
group
whereas
update
report
excess
mortality
seem
confine
heart
disease
relative
risk
rr
irradiate
nonirradiated
patient
overview
early
breast
cancer
trialists
collaborative
group
also
report
increase
cardiovascular
mortality
irradiate
group
rr
late
publication
absolute
reduction
bc
mortality
year
absolute
increase
mortality
result
net
positive
effect
adjuvant
dutch
late
effect
bc
study
excess
cardiovascular
mortality
result
find
postmastectomy
population
rr
patient
treat
postlumpectomy
cardiovascular
mortality
elevate
suggest
much
favorable
result
improve
technique
left
right
comparison
respect
cardiovascular
mortality
left
right
comparison
make
several
study
estimate
cardiac
mortality
irradiation
much
study
concern
mix
population
patient
treat
postmastectomy
postlumpectomy
study
surveillance
epidemiology
end
result
seer
registry
cardiovascular
mortality
ratio
patient
irradiation
irradiate
right
side
year
respectively
however
patient
treat
breast
conservation
cohort
second
decade
treatment
limited
allow
firm
conclusion
regard
postlumpectomy
group
addition
radiation
treatment
regimen
include
different
target
volume
time
period
study
furthermore
information
available
many
patient
also
treat
internal
mammary
field
radiation
internal
mammary
node
leave
even
right
side
may
considerable
radiation
dose
heart
another
mortality
analysis
laterality
perform
swedish
cancer
registry
show
excess
mi
mortality
year
survivor
irradiate
bc
leave
side
rr
one
study
patient
ontario
cancer
registry
exclusively
postlumpectomy
irradiation
analyzed
high
risk
mortality
mi
observe
irradiate
patient
bc
rr
adjust
age
bc
diagnosis
absolute
excess
cardiac
mortality
due
irradiation
bc
treatment
estimate
small
render
many
study
underpowered
regard
small
difference
surprising
several
study
come
opposite
conclusion
excess
cardiovascular
mortality
cardiovascular
morbidity
bc
study
present
datum
incidence
cardiovascular
event
study
cardiovascular
morbidity
number
event
will
large
enable
statistically
much
powerful
analysis
indeed
although
find
significant
leave
right
difference
cvd
mortality
difference
cvd
morbidity
significant
correspond
recent
finding
harris
make
leave
right
comparison
patient
treat
postlumpectomy
find
excess
cardiac
mortality
patient
treat
leave
side
however
incidence
coronary
artery
disease
increase
patient
bc
year
survival
free
mi
patient
treat
bc
respectively
study
patient
additional
radiation
field
internal
mammary
field
chemotherapy
adjuvant
doxorubicin
two
study
recently
report
datum
cvd
incidence
bc
evaluate
risk
ischemic
heart
disease
valvular
heart
disease
congestive
heart
failure
conduction
abnormality
find
statistically
significant
difference
cardiac
morbidity
radiation
among
patient
treat
mean
year
however
dutch
late
effect
bc
study
hand
median
almost
year
report
increase
risk
mi
valvular
dysfunction
congestive
heart
failure
administer
breast
irradiation
associate
increase
risk
cardiovascular
disease
number
patient
study
treat
breast
tangential
probably
small
detect
potential
difference
risk
volume
effect
risk
cvd
gagliardi
develop
normal
tissue
complication
probability
model
mi
based
datum
patient
treat
early
stockholm
trial
model
clear
volume
effect
see
analysis
ct
scan
however
model
based
limited
number
patient
treat
relatively
old
radiation
technique
assume
irradiate
heart
volume
estimate
measure
mhd
irradiation
beam
show
however
dose
volume
relationship
heart
disease
establish
mhd
measurement
study
maximum
heart
distance
may
good
indicator
actual
irradiate
heart
volume
organ
motion
play
role
simulator
film
snapshot
much
accurate
information
come
actual
treatment
film
megavoltage
imaging
megavoltage
imaging
datum
suggest
mhd
somewhat
overestimate
simulator
film
however
datum
seem
exclude
large
difference
mhd
category
support
hypothesis
dose
volume
effect
dose
level
gy
limitation
study
far
know
large
study
risk
cvd
patient
treat
breast
tangential
treatment
adjuvant
chemotherapy
may
act
independent
risk
factor
cvd
exclude
also
information
radiation
regimen
administer
end
radiation
field
treat
case
local
recurrence
contralateral
bc
unlike
much
study
approach
gp
actively
collect
information
ischemic
heart
disease
also
type
heart
disease
well
cardiac
risk
factor
nearly
complete
potentially
long
enough
detect
difference
cvd
risk
irradiation
analysis
laterality
advantage
least
possible
chance
introduce
bias
indeed
distribution
patient
characteristic
treat
patient
similar
cardiac
risk
factor
except
diabetes
mellitus
previously
diagnose
cvd
consider
chance
finding
adjust
cox
regression
analysis
unfortunately
considerable
number
irradiation
mhd
measure
simulator
film
miss
however
patient
characteristic
group
different
conclusion
concern
increase
cardiovascular
morbidity
associate
leave
irradiation
remain
case
without
mhd
measurement
exclude
boost
give
case
study
population
exact
information
term
cardiac
dose
boost
obtain
however
two
institution
boost
give
iridium
implant
one
institution
implant
electron
photon
boost
two
institution
patient
detailed
information
cardiac
volume
irradiate
high
dose
photon
boost
miss
number
patient
probably
estimate
majority
patient
boost
moderately
contribute
total
heart
dose
approximately
gy
boost
give
almost
case
consider
confound
factor
finding
even
mhd
mm
much
cardiotoxic
effect
occur
compare
may
indicate
dose
relevant
mhd
category
irradiate
heart
volume
expose
dose
prescribe
dose
gy
may
considerable
unfortunately
datum
clearance
value
heart
contour
field
border
negative
mhd
look
volume
effect
dose
level
datum
suggest
cardiac
result
radiation
finding
may
point
direction
need
confirm
alternatively
relevant
exposure
parameter
also
radiation
dose
leave
anterior
descend
coronary
artery
warrant
far
research
lack
knowledge
radiation
parameter
determine
excess
cvd
risk
relate
fact
nature
heart
damage
poorly
understand
coronary
artery
disease
seem
obvious
explanation
explain
increase
risk
type
heart
disease
observe
datum
according
prospective
single
photon
emission
compute
tomography
study
patient
treat
bc
tangential
beam
induce
persist
localized
myocardial
perfusion
defect
compatible
microvascular
damage
result
wall
motion
disturbance
may
explain
spectrum
heart
disease
irradiation
find
study
many
limited
coronary
artery
disease
conclusion
nowadays
many
patient
treat
therapy
invasive
bc
often
ductal
carcinoma
situ
increased
risk
cvd
postlumpectomy
breast
tangential
confirm
carefully
weigh
benefit
adjuvant
modern
sophisticated
technique
treat
target
volume
much
precisely
spare
normal
tissue
much
effectively
study
need
establish
dose
level
cardiotoxic
side
effect
occur
meanwhile
suggest
application
technique
radiotherapeutic
treatment
bc
acknowledgment
author
thank
velde
datum
management
therapy
preferred
management
strategy
appropriately
select
patient
ductal
carcinoma
situ
dcis
invasive
breast
cancer
ibc
multiple
randomized
control
trial
establish
importance
adjuvant
breast
radiotherapy
conservative
surgery
dcis
ibc
conventional
breast
deliver
whole
ipsilateral
breast
two
tangential
field
megavoltage
photon
usually
wedge
improve
dose
homogeneity
conventional
breast
result
moderate
degree
acute
skin
toxicity
approximately
one
third
one
half
patient
usually
limited
brisk
erythema
patchy
moist
desquamation
breast
whereas
much
severe
acute
toxicity
uncommon
late
toxicity
may
include
fat
necrosis
lymphedema
skin
fibrosis
moderate
ill
grade
late
toxicity
uncommon
increased
frequency
acute
late
skin
effect
associate
increase
breast
dose
inhomogeneity
resultant
hot
spot
conventional
breast
significant
portion
breast
tissue
may
receive
prescription
dose
potential
hot
spot
imrt
explore
technique
improve
breast
dose
homogeneity
decrease
hot
spot
dose
normal
tissue
imrt
treatment
technique
drive
planning
allow
modulation
beam
intensity
within
treatment
field
obtain
highly
conformal
dose
delivery
breast
imrt
area
active
research
recent
year
several
publication
show
feasibility
dosimetric
superiority
conventional
plan
decrease
acute
side
effect
breast
imrt
compare
conventional
crt
potential
decrease
late
complication
however
publish
clinical
outcome
patient
treat
breast
imrt
sparse
emory
clinic
atlanta
begin
imrt
adjuvant
breast
forward
plan
treatment
two
tangential
field
combination
dynamic
multileaf
collimator
dmlc
enhance
dynamic
wedge
edws
change
inverse
plan
imrt
technique
simultaneous
integrate
boost
resection
cavity
report
clinical
outcome
patient
treat
initial
imrt
technique
comparison
cohort
patient
treat
period
crt
edws
method
material
patient
evaluation
treatment
record
emory
clinic
evaluate
identify
patient
stage
iii
breast
cancer
receive
adjuvant
breast
conservative
surgery
january
december
patient
distant
metastatic
disease
presentation
treat
mastectomy
include
institutional
review
board
approval
obtain
retrospective
analysis
patient
crt
cohort
treat
institution
period
transition
breast
imrt
breast
imrt
adopt
one
physician
physician
end
imrt
treatment
planning
capacity
increase
adopt
physician
breast
imrt
become
standard
treatment
patient
crt
cohort
treat
first
institutional
breast
imrt
whereas
receive
crt
discretion
attend
radiation
oncologist
based
non
factor
include
treatment
planning
capacity
patient
undergo
standard
staging
evaluation
diagnosis
surgical
pathological
report
review
verify
stage
standardized
sixth
edition
american
joint
committee
cancer
patient
routinely
schedule
multidisciplinary
interval
history
physical
examination
breast
imaging
accord
recognize
schedule
surgery
patient
undergo
conservative
surgery
accord
standard
practice
surgical
oncologist
close
positive
margin
perform
accordance
patient
surgeon
preference
margin
categorize
positive
pathology
report
note
presence
tumor
cell
ink
margin
specimen
close
tumor
cell
present
within
cm
ink
margin
negative
tumor
cell
least
cm
ink
margin
chemotherapy
patient
sufficient
risk
distant
metastasis
offer
adjuvant
chemotherapy
generally
doxorubicin
cyclophosphamide
accordance
consensus
guideline
time
preoperative
chemotherapy
generally
offer
facilitate
breast
conservation
patient
tumor
size
location
make
surgery
unlikely
without
decrease
tumor
size
patient
clinically
lymph
node
sentinel
lymph
node
biopsy
axillary
nodal
dissection
generally
perform
initiation
neoadjuvant
chemotherapy
radiation
radiation
therapy
typically
initiate
week
completion
surgery
chemotherapy
compute
tomography
ct
scan
obtain
treatment
planning
patient
cm
slice
several
centimeters
caudal
breast
patient
undergo
scanning
supine
position
ipsilateral
arm
abduct
stabilization
bar
larger
breast
woman
board
generally
discretion
attend
radiation
oncologist
time
simulation
radiopaque
wire
place
mark
tangential
field
border
superior
inferior
field
border
place
cm
beyond
clinically
palpable
breast
tissue
medial
border
set
midline
sternum
lateral
border
along
line
radiopaque
wire
also
cover
surgical
scar
assist
plan
boost
crt
crt
medial
lateral
tangential
field
create
encompass
entire
breast
follow
standard
technique
field
collimation
adjust
follow
slope
chest
wall
gantry
angle
adjust
make
deep
tangential
border
eliminate
divergence
lung
deep
edge
tangential
beam
pass
medial
lateral
border
set
simulation
cranial
caudal
tangent
field
border
tangent
set
cranial
caudal
wire
marker
additional
adjustment
collimator
gantry
rotation
make
necessary
limit
volume
lung
field
anterior
border
tangent
give
cm
flash
beyond
breast
supraclavicular
field
prescribe
match
line
set
level
caudal
edge
junction
adjustment
couch
position
tangential
field
make
multileaf
collimator
create
superior
tangential
block
match
line
prevent
divergence
tangent
supraclavicular
field
treat
supraclavicular
field
anterior
block
field
set
match
line
angle
field
treat
photon
dose
gy
fraction
typically
prescribe
depth
cm
posterior
axillary
field
rarely
reserve
patient
incomplete
axillary
dissection
gross
extranodal
disease
ipsilateral
internal
mammary
node
treat
cadplan
treatment
planning
software
varian
medical
system
palo
alto
plan
dose
gy
tangential
field
standard
fractionation
fraction
photon
mv
mv
energy
edws
typically
wedge
angle
every
patient
optimize
dose
homogeneity
edws
medial
lateral
tangent
field
nearly
every
patient
correction
tissue
inhomogeneity
make
boost
accord
treat
physician
preference
target
boost
surgical
cavity
cm
margin
define
simulation
ct
correlated
physical
examination
location
surgical
scar
boost
deliver
electron
sufficient
energy
isodose
line
cover
depth
cavity
define
ct
technique
boost
dose
gy
fraction
cumulative
total
dose
gy
imrt
patient
treat
imrt
tangential
field
identical
describe
breast
crt
except
field
collimation
rotate
allow
dmlc
movement
longitudinal
plane
patient
cadplan
software
imrt
treatment
algorithm
develop
account
irregular
breast
surface
plane
isocenter
generate
fluence
map
convert
leaf
sequence
file
delivery
dmlc
software
account
contour
irregularity
longitudinal
plane
much
patient
generation
imrt
plan
edws
identical
tangential
field
deliver
portion
dose
without
imrt
compensation
improve
dose
homogeneity
combination
dmlc
edws
effectively
consider
surface
contour
irregularity
edws
craniocaudal
dmlc
plane
crt
plan
correction
tissue
inhomogeneity
make
dose
fractionation
schedule
imrt
plan
crt
plan
treatment
policy
apply
rare
posterior
axillary
field
treatment
internal
mammary
node
supraclavicular
field
prescribe
technique
crt
boost
prescribe
accord
treat
physician
preference
manner
patient
treat
conventional
tangent
initial
evaluation
imrt
technique
involve
qualitative
comparison
isodose
distribution
multiple
axial
ct
slice
compare
isodose
distribution
conventional
tangent
edws
imrt
technique
judge
superior
crt
one
plan
later
run
majority
patient
treat
imrt
assessment
toxicity
treatment
acute
toxicity
assess
physician
check
least
weekly
documentation
acute
radiation
toxicity
focus
weekly
note
final
treatment
summary
first
visit
occur
month
completion
treatment
note
review
description
pain
physical
examination
finding
include
skin
erythema
dry
moist
desquamation
breast
edema
acute
toxicity
retrospectively
grade
accord
radiation
therapy
oncology
group
rtog
criterion
based
bad
toxicity
describe
interval
start
treatment
week
completion
individual
scoring
toxicity
component
erythema
desquamation
edema
perform
separate
note
make
occurrence
breast
cellulitis
antibiotic
therapy
prescribe
table
rtog
ctc
grade
criterion
acute
radiation
dermatitis
rtog
acute
radiation
morbidity
criterion
skin
nci
ctc
version
acute
radiation
dermatitis
criterion
change
faint
dull
erythema
epilation
dry
desquamation
decrease
erythema
dry
desquamation
bright
erythema
patchy
moist
desquamation
moderate
brisk
erythema
patchy
moist
desquamation
mostly
confine
skin
fold
moderate
edema
moist
desquamation
skin
fold
pit
moist
desquamation
cm
diameter
confine
skin
fold
pit
edema
hemorrhage
necrosis
ulceration
full
thickness
may
include
induce
minor
trauma
table
abbreviation
rtog
radiation
therapy
oncology
group
nci
ctc
national
cancer
institute
common
toxicity
criteria
view
within
article
patient
chart
also
review
report
late
toxicity
potentially
relate
include
radiation
pneumonitis
clinically
appreciable
fat
necrosis
lymphedema
development
second
malignancy
statistical
analysis
time
calculate
onset
definitive
therapy
either
date
first
definitive
surgery
start
date
neoadjuvant
chemotherapy
treat
preoperative
chemotherapy
site
first
failure
consider
analysis
one
follow
category
ipsilateral
breast
tumor
recurrence
ibtr
contralateral
breast
tumor
recurrence
cbtr
distant
metastasis
dm
overall
survival
survival
dss
freedom
ibtr
cbtr
dm
calculate
method
comparison
treatment
group
make
test
estimate
report
standard
error
patient
synchronous
bilateral
breast
cancer
score
cbtr
include
number
risk
cbtr
similarly
patient
metachronous
bilateral
breast
cancer
late
breast
cancer
score
cbtr
include
number
risk
subsequent
cbtr
patient
synchronous
metachronous
bilateral
breast
cancer
include
analysis
dss
freedom
dm
second
malignancy
fisher
exact
test
test
comparison
categorical
variable
treatment
group
univariate
analysis
variable
associate
ibtr
dm
whereas
test
test
difference
continuous
variable
value
consider
statistically
significant
statistical
analysis
perform
stata
version
software
college
park
tx
result
patient
characteristic
total
breast
treat
patient
imrt
crt
included
analysis
patient
synchronous
patient
metachronous
bilateral
breast
cancer
patient
characteristic
list
table
period
evaluation
estrogen
progesterone
receptor
status
perform
infrequently
patient
dcis
hormonal
receptor
status
know
patient
dcis
patient
dcis
treat
crt
much
often
receive
adjuvant
hormonal
therapy
treat
imrt
otherwise
patient
characteristic
well
balanced
group
table
patient
characteristic
patient
dcis
age
breast
stage
grade
estrogen
receptor
progesterone
receptor
lymphovascular
invasion
margin
plns
na
pcr
adj
adj
breast
dose
gy
boost
total
dose
gy
age
breast
tumor
size
cm
grade
necrosis
margin
adj
breast
dose
gy
boost
total
dose
gy
table
abbreviation
imrt
radiotherapy
crt
conventional
radiotherapy
ibc
invasive
breast
cancer
dcis
ductal
carcinoma
situ
neu
gene
amplification
protein
overexpression
plns
number
involve
lymph
node
evaluation
pathologic
lymph
node
evaluation
extranodal
extension
involve
lymph
node
na
ctx
neoadjuvant
chemotherapy
pcr
rate
pathologic
complete
response
neoadjuvant
chemotherapy
adj
ctx
adjuvant
chemotherapy
adj
adjuvant
hormonal
therapy
value
express
number
percent
unless
note
otherwise
view
within
article
chemotherapy
patient
ibc
receive
preoperative
receive
adjuvant
chemotherapy
statistically
significant
difference
chemotherapy
crt
imrt
patient
group
group
much
common
adjuvant
chemotherapy
regimen
four
cycle
second
much
common
regimen
four
cycle
follow
four
cycle
taxane
among
patient
treat
preoperative
chemotherapy
four
cycle
much
common
regimen
group
radiation
therapy
median
dose
whole
breast
gy
median
total
dose
gy
imrt
crt
patient
group
much
patient
receive
boost
tumor
cavity
significant
difference
boost
patient
treat
imrt
crt
median
year
range
month
patient
treat
imrt
year
range
month
treat
crt
patient
alive
last
much
year
patient
treat
imrt
patient
treat
crt
patient
lose
represent
patient
alive
last
patient
treat
imrt
patient
treat
crt
patient
censor
last
acute
toxicity
percent
patient
sufficient
datum
permit
grade
acute
toxicity
acute
skin
toxicity
report
patient
treat
imrt
grade
grade
grade
case
grade
dermatitis
patient
treat
crt
case
grade
dermatitis
grade
grade
grade
dermatitis
case
grade
greater
acute
toxicity
either
treatment
group
imrt
associate
statistically
significant
decrease
acute
skin
toxicity
rtog
grade
compare
crt
breast
cellulitis
occur
patient
treat
imrt
treat
crt
late
toxicity
second
malignancy
radiation
pneumonitis
develop
treat
imrt
treat
conventional
ipsilateral
lymphedema
see
patient
treat
imrt
describe
crt
degree
clinically
appreciable
fat
necrosis
note
patient
treat
crt
patient
treat
imrt
one
patient
treat
crt
undergo
mastectomy
extensive
fat
necrosis
year
instance
rib
fracture
note
patient
assessment
breast
cosmesis
insufficient
grade
comparison
treatment
arm
year
rate
second
malignancy
exclude
skin
cancer
patient
treat
imrt
patient
treat
crt
survival
local
distant
failure
curve
patient
ibc
show
note
throughout
text
patient
ibc
year
rate
cohort
treat
imrt
cohort
treat
crt
year
dss
rate
patient
treat
imrt
treat
crt
year
rate
freedom
ibtr
imrt
crt
ipsilateral
recurrence
infiltrate
cancer
year
rate
freedom
cbtr
imrt
crt
six
instance
cbtr
five
infiltrate
cancer
one
situ
year
rate
freedom
dm
treat
imrt
treat
crt
image
curve
patient
invasive
breast
cancer
ibc
show
freedom
ipsilateral
breast
tumor
recurrence
ibtr
freedom
contralateral
breast
tumor
recurrence
cbtr
number
patient
remain
risk
report
yearly
interval
treatment
group
imrt
radiotherapy
view
within
article
curve
patient
dcis
show
patient
dcis
year
rate
treat
imrt
crt
year
rate
freedom
ibtr
patient
treat
imrt
crt
two
four
instance
ibtr
infiltrate
cancer
year
rate
freedom
cbtr
imrt
crt
contralateral
recurrence
infiltrate
cancer
instance
dm
dss
rate
patient
dcis
image
curve
patient
ductal
carcinoma
situ
dcis
show
freedom
ipsilateral
breast
tumor
recurrence
freedom
contralateral
breast
tumor
recurrence
number
patient
remain
risk
report
yearly
interval
treatment
group
imrt
radiotherapy
view
within
article
univariate
analysis
univariate
analysis
multiple
variable
perform
patient
ibc
dcis
patient
ibc
variable
assess
age
stage
grade
estrogen
receptor
status
progesterone
receptor
status
neu
status
lymphovascular
invasion
qualitative
margin
negative
close
positive
number
positive
lymph
node
menopausal
status
extranodal
extension
preoperative
chemotherapy
pathologic
tumor
response
preoperative
chemotherapy
adjuvant
chemotherapy
adjuvant
dose
whole
breast
boost
dose
total
dose
rtog
grade
acute
skin
toxicity
ibc
negative
progesterone
receptor
status
adjuvant
chemotherapy
associate
development
ibtr
whereas
increase
number
positive
lymph
node
associate
development
dm
patient
ibc
acute
skin
toxicity
rtog
grade
year
risk
ibtr
significantly
different
estimate
toxicity
rtog
grade
patient
dcis
variable
assess
age
tumor
size
presence
necrosis
qualitative
margin
menopausal
status
adjuvant
breast
dose
boost
dose
total
dose
rtog
grade
acute
skin
toxicity
patient
dcis
presence
close
cm
positive
margin
associate
great
risk
ibtr
year
risk
ibtr
patient
dcis
acute
skin
toxicity
rtog
grade
significantly
different
risk
ibtr
estimate
grade
toxicity
discussion
acute
toxicity
adjuvant
breast
establish
efficacious
treatment
generally
well
tolerate
however
even
moderate
acute
skin
toxicity
see
breast
negatively
impact
patient
quality
life
provide
improve
technique
may
decrease
toxicity
one
randomized
trial
two
retrospective
analysis
show
ability
breast
imrt
decrease
acute
skin
toxicity
compare
crt
experience
confirm
significant
decrease
acute
toxicity
rtog
grade
breast
imrt
many
early
breast
imrt
report
technique
two
tangential
field
identical
crt
therefore
decrease
acute
toxicity
attributed
imrt
rather
difference
target
definition
beam
geometry
mechanism
decrease
acute
skin
toxicity
breast
imrt
likely
combination
treatment
planning
delivery
factor
imrt
planning
similar
tangential
beam
previously
show
several
investigator
improve
dose
homogeneity
decrease
hot
spot
especially
inframammary
fold
whereas
imrt
treatment
delivery
especially
dmlc
result
modest
decrease
surface
buildup
dose
limitation
planning
software
period
report
preclude
rigorous
quantitative
dosimetric
comparison
crt
imrt
planning
technique
previous
study
evaluate
acute
toxicity
breast
variety
score
system
include
rtog
criterion
study
national
cancer
institute
common
toxicity
criteria
ctc
radiation
dermatitis
radiation
dermatitis
little
difference
two
score
system
list
table
limitation
score
system
elucidate
clinically
meaningful
difference
toxicity
discuss
continue
facilitate
comparison
among
study
rtog
criterion
acute
skin
reaction
addition
physical
examination
finding
incorporate
component
pain
score
tender
erythema
grade
potentially
result
much
grade
event
patient
physical
examination
finding
otherwise
code
grade
incorporating
pain
rtog
criterion
arguably
well
reflect
severity
radiation
dermatitis
single
assessment
whereas
ctc
evaluate
pain
skin
reaction
separately
magnitude
absolute
decrease
moderate
badly
acute
skin
toxicity
imrt
range
series
report
consecutive
cohort
study
patient
treat
crt
wedge
patient
treat
imrt
ctc
version
acute
radiation
dermatitis
grade
high
significantly
decrease
crt
imrt
frequency
grade
high
toxicity
crt
cohort
high
may
relate
planning
patient
series
crt
patient
undergo
ct
simulation
treatment
planning
decrease
acute
toxicity
imrt
seen
analysis
close
absolute
decrease
moist
desquamation
report
investigator
late
toxicity
difference
report
occurrence
radiation
pneumonitis
lymphedema
fat
necrosis
treatment
arm
analysis
find
sufficiently
descriptive
consistent
assessment
late
cosmesis
make
far
comparison
treatment
arm
retrospective
toxicity
score
recognize
limitation
study
data
available
nearly
every
patient
permit
score
several
important
category
acute
late
toxicity
include
radiation
dermatitis
cellulitis
lymphedema
pneumonitis
fat
necrosis
presence
absence
routinely
note
however
documentation
often
consistently
describe
possible
side
effect
treatment
include
overall
cosmesis
chronic
breast
pain
fibrosis
preclude
confident
assessment
frequency
severity
effect
assume
decrease
late
toxicity
will
parallel
decrease
acute
toxicity
achieve
imrt
result
randomized
control
trial
compare
imrt
crt
woman
show
significant
decrease
late
change
breast
appearance
assess
serial
photography
year
change
note
treat
imrt
treat
crt
significant
association
development
late
change
increase
dose
inhomogeneity
clinical
outcome
absence
alter
fractionation
dose
escalation
therapeutic
change
imrt
expect
improve
local
control
outcome
patient
adjuvant
breast
however
possibility
outcome
imrt
ignore
imrt
unique
potential
include
great
difficulty
verify
treatment
delivery
potentially
increase
effect
intrafraction
motion
setup
error
theoretical
concern
increase
risk
malignancy
dmlc
imrt
treatment
delivery
technique
result
modest
decrease
surface
buildup
dose
compare
conventional
field
possible
decrease
dose
superficial
subcutaneous
breast
tissue
adversely
affect
local
control
study
report
clinical
outcome
large
number
long
date
patient
treat
breast
imrt
find
significant
difference
dss
difference
rate
ibtr
cbtr
dm
second
malignancy
patient
treat
imrt
crt
evidence
patient
little
severe
acute
skin
toxicity
experience
great
rate
local
failure
note
absence
difference
study
proof
treatment
equivalence
two
technique
share
identical
treatment
field
dose
fractionation
difference
local
control
likely
little
power
study
detect
similarly
imrt
increase
risk
second
malignancy
contralateral
breast
cancer
increase
expect
small
require
much
large
study
long
potentially
detect
however
randomized
study
breast
imrt
conventional
treatment
look
mature
experience
imrt
find
clinical
outcome
evaluate
possible
effect
future
direction
one
advantage
breast
imrt
technique
describe
preservation
conventional
treatment
field
volume
decrease
eliminate
possibility
difference
treatment
efficacy
newer
breast
imrt
technique
include
current
institutional
technique
often
volume
contour
show
considerable
variability
among
individual
institution
early
imrt
technique
design
improve
breast
dose
homogeneity
make
direct
contribution
normal
tissue
avoidance
limitation
treatment
planning
software
current
software
relatively
simple
breast
imrt
technique
also
incorporate
normal
tissue
avoidance
breast
imrt
technique
similar
initial
technique
show
achieve
homogenous
target
coverage
equivalent
well
normal
tissue
spare
one
third
planning
time
much
complicate
imrt
technique
advantages
much
sophisticated
breast
imrt
technique
include
superior
dosimetry
inclusion
internal
mammary
node
desire
ability
shorten
treatment
course
delivery
simultaneous
integrate
tumor
bed
boost
far
hypofractionation
breast
imrt
technique
offer
possibility
much
convenient
even
well
tolerate
treatment
risk
late
toxicity
however
remain
see
whether
change
target
fractionation
will
affect
outcome
patient
adjuvant
breast
initial
breast
imrt
technique
find
difference
clinical
outcome
compare
cohort
treat
crt
improve
therapeutic
ratio
breast
imrt
may
remove
many
exist
barrier
proper
adjuvant
breast
without
compromise
fundamental
principle
irradiation
conclusion
patient
treat
tangential
breast
imrt
dmlc
edws
experience
decrease
significant
acute
skin
toxicity
show
excellent
outcome
dss
ibtr
cbtr
dm
second
malignancy
rate
similar
cohort
treat
crt
absence
randomized
datum
patient
treat
new
breast
imrt
technique
indicate
table
table
table
toxicity
acute
dermatitis
rtog
grade
dermatitis
rtog
grade
breast
late
radiation
fat
second
table
abbreviation
imrt
radiotherapy
rtog
radiation
therapy
oncology
group
view
within
benefit
adjuvant
radiotherapy
chest
wall
controversial
many
year
recently
publish
datum
show
regimen
produce
moderate
definite
reduction
breast
cancer
mortality
also
overall
mortality
benefit
postmastectomy
independent
effect
systemic
treatment
also
show
study
danish
breast
cancer
cooperative
group
british
columbia
study
however
first
report
find
advantage
overall
survival
year
one
explanation
increase
non
breast
death
particularly
cardiac
disease
relationship
old
radiation
technique
two
oppose
tangential
photon
beam
common
technique
postmastectomy
chest
wall
electron
beam
chest
wall
also
routinely
already
show
technique
yield
locoregional
control
survival
overall
survival
rate
similar
standard
photon
beam
important
problem
junction
internal
mammary
chain
imc
field
supraclavicular
field
chest
wall
electron
beam
field
computed
tomography
ct
localization
imc
study
already
rule
develop
define
field
limit
electron
beam
chest
wall
without
lymph
node
irradiation
institut
curie
year
purpose
study
report
late
improvement
technique
assess
early
toxicity
method
material
year
electron
postmastectomy
adjuvant
irradiation
chest
wall
institut
curie
thousand
patient
treat
institut
curie
postmastectomy
adjuvant
irradiation
indicate
lymph
tumor
initial
presentation
patient
treat
neoadjuvant
chemotherapy
indication
remain
even
histologic
examination
show
complete
tumor
response
lymph
node
tumor
mm
clinically
multiple
tumor
vascular
invasion
young
patient
prescribe
dose
gy
fraction
chest
wall
regional
lymph
node
treat
photon
supraclavicular
axillary
region
mix
technique
imc
area
boost
give
mastectomy
scar
new
technique
dosimetric
improvement
standard
technique
without
change
treatment
volume
chest
wall
lymph
node
area
prescribe
dose
dose
distribution
calculate
treatment
planning
software
isis
technologie
diffusion
paris
france
dose
calculation
perform
calculation
parameter
new
standard
technique
study
design
study
split
two
part
new
electron
radiation
technique
design
compare
standard
one
dosimetric
study
early
skin
toxicity
new
technique
evaluate
prospectively
first
patient
radiation
therapy
oncology
group
criterion
report
clinical
study
treatment
planning
institut
curie
standard
technique
since
treatment
plan
perform
ct
slice
acquire
simulator
ct
varian
much
adapt
patient
anatomy
five
ct
slice
perform
chest
wall
area
central
axis
cm
inside
superior
inferior
limit
unavailability
ct
scanner
department
anatomic
datum
take
simulator
ct
scanner
allow
ideal
patient
position
angle
breast
board
thorax
important
electron
avoid
distance
effect
patient
arm
craniocaudal
direction
angle
chest
wall
beam
either
contralateral
breast
dorsal
muscle
important
irregularity
chest
wall
present
much
slice
acquire
one
ct
slice
acquire
supraclavicular
clinical
target
volume
chest
wall
include
breast
bed
mastectomy
scar
cm
margin
imc
supraclavicular
area
since
electron
beam
irradiation
standard
postmastectomy
treatment
setup
facility
direct
face
field
convincing
reason
choose
lymph
node
irradiation
institut
curie
previously
describe
mix
photon
electron
beam
imc
area
technique
choice
avoid
unnecessary
irradiation
heart
ratio
gy
gy
photon
electron
dose
supraclavicular
area
irradiate
photon
patient
lie
angle
breast
board
angle
bring
thorax
patient
horizontal
position
irradiation
consist
three
separate
field
chest
wall
imc
supraclavicular
field
technique
angle
chest
wall
beam
separate
anterior
imc
field
gap
mm
systematically
junction
chest
wall
imc
field
chest
wall
supraclavicular
field
generous
cm
margin
add
ensure
target
volume
entirely
encompass
homogeneous
part
electron
beam
ensure
sufficient
skin
dose
mm
bolus
systematically
electron
energy
choose
isodose
gy
situate
costal
wall
depth
energy
available
treatment
machine
saturne
varian
routinely
chest
wall
irradiation
mev
energy
mev
necessary
patient
treat
photon
mix
photon
electron
avoid
late
skin
complication
patient
treatment
plan
optimized
adapt
individual
patient
anatomy
dose
distribution
central
axis
plane
chest
wall
give
isodose
situate
costal
wall
depth
skin
receive
dose
prescribe
dose
evaluate
dose
imc
dose
point
imc
reference
point
position
depth
lung
interface
cm
laterally
medial
line
central
transverse
plane
imc
target
volume
previously
show
ct
scan
study
despite
mm
gap
imc
chest
wall
field
much
case
gy
observe
image
patient
position
standard
postmastectomy
field
chest
wall
electron
internal
mammary
chain
photon
electron
supraclavicular
node
photon
view
within
article
image
standard
technique
dose
distribution
prescribe
total
dose
view
within
article
treatment
planning
new
irradiation
technique
new
irradiation
technique
recently
implement
institution
approval
board
radiation
oncology
chest
wall
imc
volume
now
include
one
unique
field
gantry
angle
vertical
simulation
radiation
oncologist
determine
clinical
volume
chest
wall
irradiate
also
delineate
imc
target
volume
electron
energy
choose
isodose
costal
wall
depth
mm
bolus
place
bolus
modify
two
dimension
five
chest
wall
ct
slice
imc
chest
wall
well
cover
isodose
gy
image
postmastectomy
field
new
technique
chest
wall
electron
internal
mammary
chain
electron
photon
boost
supraclavicular
node
photon
view
within
article
image
dose
distribution
prescribe
dose
new
technique
view
within
article
beam
distance
variation
imc
often
clinical
practice
layer
mm
bolus
material
standard
technique
imc
irradiate
mix
field
separate
chest
wall
field
bolus
area
simulation
new
technique
chest
wall
include
imc
area
radiation
oncologist
delineate
imc
old
field
need
part
bolus
remove
corresponding
size
old
imc
field
imc
reference
point
receive
dose
per
fraction
inferior
gy
part
bolus
remove
imc
region
electron
go
deep
nodal
area
boost
imc
complete
dose
total
gy
well
spare
skin
additional
dose
deliver
imc
boost
field
deliver
photon
mv
treat
fraction
prescribe
maximal
dose
twice
weekly
depending
complement
dose
deliver
image
bolus
shape
position
part
bolus
remove
obtain
well
dose
distribution
internal
mammary
chain
missing
portion
correspond
internal
mammary
chain
field
standard
technique
edges
beveled
avoid
variation
transition
view
within
article
lateral
external
part
chest
wall
distance
effect
also
present
moreover
chest
wall
always
thick
region
lead
lateral
chest
wall
become
much
conformal
also
need
boost
portion
chest
wall
standard
technique
plan
also
include
dosimetric
defect
previous
retrospective
study
show
recurrence
area
therefore
decide
complement
dose
part
chest
wall
reference
isodose
gy
enter
ipsilateral
lung
second
layer
cm
bolus
material
place
ct
slice
need
bolus
prepare
dosimetrist
two
layer
bolus
need
protect
lung
beam
eye
view
show
projection
bolus
layer
bolus
sagittal
laser
position
mark
patient
skin
bolus
layer
ensure
reproducible
every
fraction
edge
bolus
produce
hot
cold
spot
subcutaneous
area
beneath
bolus
edge
beveled
image
new
technique
two
thickness
bolus
position
reproducibility
dose
distribution
view
within
article
dosimetric
comparison
standard
technique
dosimetry
study
include
first
patient
treat
new
technique
evaluate
dosimetric
advantage
technique
perform
second
treatment
plan
patient
standard
technique
treatment
plan
standard
new
technique
report
maximal
dose
treat
volume
dose
receive
imc
reference
point
depth
isodose
measure
posterior
border
sternum
medial
plane
central
axis
slice
depth
isodose
measure
posterior
border
sternum
laterally
sternum
ipsilateral
edge
central
axis
slice
maximal
depth
isodose
ipsilateral
lung
central
axis
slice
prospective
clinical
study
datum
patient
treat
new
technique
prospectively
record
early
toxicity
assess
weekly
accord
radiation
therapy
oncology
group
classification
radiation
therapy
oncology
group
grade
follow
grade
skin
reaction
grade
faint
dull
erythema
epilation
dry
desquamation
decrease
grade
tender
bright
erythema
patchy
moist
desquamation
moderate
edema
grade
confluent
moist
desquamation
skin
fold
pit
edema
grade
ulceration
hemorrhage
necrosis
result
dosimetric
study
chest
wall
dose
gy
prescribe
technique
standard
technique
imc
dose
deliver
photon
gy
electron
gy
new
technique
depending
conformation
patient
necessary
add
dose
gy
imc
photon
boost
standard
technique
different
gantry
angle
imc
chest
wall
create
hot
spot
show
table
summarize
main
dosimetric
difference
new
technique
standard
technique
table
dosimetric
comparison
new
standard
technique
patient
technique
standard
technique
maximal
dose
gy
mean
imc
dose
mean
depth
isodose
cm
medial
plane
mean
depth
isodose
cm
mean
depth
isodose
cm
lung
mean
table
abbreviation
imc
internal
mammary
chain
sd
standard
deviation
dose
chest
wall
gy
dose
receive
imc
reference
point
distance
posterior
border
sternum
isodose
curve
distance
posterior
lateral
border
sternum
isodose
curve
maximal
depth
isodose
curve
lung
view
within
article
maximal
dose
find
five
slice
gy
new
technique
gy
standard
technique
hot
spot
standard
technique
plan
situate
overlap
imc
chest
wall
field
mean
dose
imc
reference
point
gy
gy
new
standard
plan
respectively
medial
plane
isodose
cm
sternum
new
technique
cm
standard
plan
lateral
border
sternum
isodose
also
deep
standard
plan
isodose
cm
depth
homolateral
lung
new
plan
deep
cm
cm
standard
plan
clinical
prospective
study
date
patient
treat
study
follow
three
patient
develop
grade
reaction
grade
grade
grade
reaction
end
two
patient
undergo
concomitant
one
experience
grade
one
grade
reaction
median
radiation
dose
gy
range
gy
duration
day
range
day
discussion
standard
electron
irradiation
technique
year
institut
curie
study
report
early
evaluation
improvement
choice
field
based
pattern
local
regional
recurrence
much
mastectomy
series
demonstrate
local
recurrence
develop
chest
wall
especially
mastectomy
scar
second
much
common
site
supraclavicular
region
show
advance
disease
presentation
positive
lymph
node
chemotherapy
predict
clinically
significant
rate
locoregional
recurrence
therefore
postmastectomy
irradiation
chest
wall
supraclavicular
region
recommend
patient
four
much
positive
lymph
node
already
show
optimal
dose
offer
great
chance
locoregional
control
breast
cancer
cost
locoregional
morbidity
appear
gy
fraction
different
technique
irradiation
chest
wall
regional
lymph
node
numerous
study
confirm
postmastectomy
electron
beam
chest
wall
irradiation
effective
photon
beam
chest
wall
irradiation
local
control
overall
survival
also
demonstrate
technique
little
toxic
study
confirm
find
report
dosimetric
improvement
standard
technique
dosimetric
comparison
institution
new
breast
cancer
patient
treat
every
year
postmastectomy
patient
challenge
therefore
change
technique
without
involve
practice
dosimetrist
therapist
improvement
need
standard
technique
produce
hot
spot
conformal
enough
already
note
unavailability
ct
scanner
department
anatomic
datum
preferably
take
simulator
ct
show
patient
model
reconstructed
five
slice
comparable
ct
acquisition
regard
beam
placement
dosimetric
optimization
however
important
irregularity
present
chest
wall
much
ct
slice
perform
treatment
planning
software
isis
electron
algorithm
similar
radiation
concept
originally
develop
photon
beam
account
distance
effect
throughout
field
well
penumbra
change
depth
however
heterogeneity
correction
calculate
equivalent
depth
method
therefore
reason
decide
clinic
dose
distribution
show
heterogeneity
correction
particular
attention
dose
distribution
within
chest
wall
choice
energy
bolus
shaping
get
isodose
costal
wall
new
technique
one
unique
electron
beam
include
chest
wall
imc
target
volume
demonstrate
well
dose
homogeneity
standard
technique
treat
imc
separately
mix
photon
electron
choose
different
electron
energy
imc
chest
wall
one
unique
field
new
treatment
plan
depth
modulation
perform
change
bolus
thickness
cm
change
shape
craniocaudal
direction
well
represent
five
ct
slice
possible
design
bolus
datum
simulator
ct
slice
shaping
bolus
associate
choice
energy
step
mev
improve
conformality
dose
distribution
plan
five
ct
slice
treatment
planning
time
noticeably
increase
thus
possible
apply
new
planning
method
mastectomy
patient
allow
benefit
much
conformal
plan
adapt
individual
anatomy
moreover
simplified
treatment
delivery
suppress
imc
field
boost
deliver
much
twice
weekly
standard
linear
accelerator
saturne
linear
accelerator
produce
electron
energy
step
mev
imply
much
effort
optimize
plan
mix
electron
energy
much
complex
bolus
dose
distribution
five
simulator
ct
slice
result
planning
time
compare
full
dosimetry
imply
much
variation
contour
chest
wall
patient
however
benefit
ct
scan
bolus
limitation
practice
possible
derive
dose
volume
histograms
heart
lung
however
dose
distribution
electron
strongly
dependent
algorithm
date
heterogeneity
correction
inaccuracy
calculation
model
make
get
conformal
homogeneous
dose
distribution
skin
costal
wall
however
position
isodose
relative
sternum
homolateral
lung
routinely
assess
limit
unnecessary
heart
lung
irradiation
new
technique
result
well
spare
underlie
normal
tissue
isodose
cm
shallow
heart
isodose
cm
little
deep
lung
measurement
relative
measurement
compare
two
treatment
plan
patient
another
important
point
early
tolerance
similar
previously
report
finding
evaluation
standard
technique
series
patient
treat
institut
curie
report
grade
early
skin
reaction
patient
grade
patient
grade
patient
conclusion
report
describe
improvement
standard
postmastectomy
electron
beam
technique
chest
wall
new
technique
provide
improve
target
homogeneity
conformality
compare
standard
technique
treatment
well
tolerate
rate
early
toxicity
event
translational
regulation
play
key
role
cancer
development
progression
impact
tumor
cell
proliferation
growth
response
stress
hypoxia
stimulation
mitogenic
signal
cell
hormone
receptor
ability
translation
machinery
load
ribosome
onto
mrna
via
cap
primary
point
control
stratify
mrna
cap
dependent
highly
regulate
mrna
utilize
internal
ribosome
entry
site
ires
within
untranslated
region
thereby
translation
inhibition
hypoxia
mrna
acquire
ribosome
initiate
translation
interaction
initiation
complex
comprise
protein
scaffold
protein
formation
interaction
mrna
ability
facilitate
translation
initiation
control
protein
major
form
maintain
inactive
state
kinase
mtor
activate
stress
hypoxia
mtor
activity
reduce
holcik
sonenberg
hypophosphorylated
activate
thereby
suppress
mrna
translation
promote
translation
mrna
many
ires
mrna
think
initiate
subset
factor
mediate
interaction
importantly
cellular
mrna
utilize
dual
mechanism
initiation
cap
ires
include
orchestrate
angiogenesis
hypoxia
response
transcription
factor
inhibition
apoptosis
among
tumor
progression
require
development
tumor
vasculature
generally
induce
response
tumor
hypoxia
process
know
angiogenic
switch
tumor
angiogenesis
rate
limit
tumor
growth
regulate
multiple
level
gene
control
include
mrna
translation
angiogenesis
also
think
dynamic
tumor
volume
expand
hypoxia
increase
trigger
additional
vascularization
elevate
expression
vegf
proangiogenic
factor
partially
restore
oxygen
grow
tumor
edge
repeat
tumor
continue
grow
show
strongly
overexpressed
majority
human
large
advance
tumor
breast
know
locally
advance
breast
cancer
labc
breast
cancer
cell
tumor
model
show
together
overexpressed
function
switch
facilitate
mrna
translation
promote
translation
mrna
promote
tumor
survival
angiogenesis
datum
suggest
addition
tumor
model
overexpression
increase
mrna
translation
second
translational
control
pathway
exist
stimulate
mrna
translation
select
mrna
involve
tumorigenesis
result
expression
level
translation
initiation
factor
breast
cancer
first
examine
immunohistochemistry
ihc
expression
level
key
factor
comprise
regulate
mrna
initiation
complex
normal
breast
specimen
pretreatment
tumor
biopsy
invasive
ductal
carcinoma
much
common
form
breast
cancer
woman
antibody
study
optimized
ihc
background
staining
primary
antibody
omit
datum
show
immunoblot
analysis
equal
amount
protein
extract
normal
breast
epithelium
posttreatment
labc
surgical
tumor
specimen
demonstrate
strong
specific
binding
respective
target
level
moderately
elevate
strongly
elevate
tumor
cm
size
tumor
figure
table
supplemental
data
available
article
online
significantly
increase
thereafter
far
increase
tumor
size
cm
thus
moderately
elevate
much
half
small
invasive
ductal
carcinoma
strongly
elevate
roughly
surprisingly
negative
regulator
mrna
translation
markedly
overexpressed
tumor
cm
size
increase
among
small
tumor
large
tumor
cm
labc
tumor
figure
table
initiation
factor
also
strongly
increase
labc
tumor
compare
small
tumor
figure
table
future
report
will
present
clinical
association
overexpression
tumor
lymph
node
involvement
disease
progression
disease
parameter
level
initiation
factor
unchanged
normal
tumor
breast
tissue
far
pursue
study
involve
increase
expression
associate
large
tumor
size
image
image
figure
representative
level
protein
synthesis
factor
breast
tumor
specimen
examined
study
ihc
analysis
representative
specimen
normal
breast
epithelium
labc
tumor
show
data
representative
patient
specimen
report
table
three
core
punch
per
specimen
immunoblot
analysis
demonstrate
specificity
antibody
binding
equal
protein
amount
fresh
normal
breast
epithelial
tissue
posttreatment
surgical
resection
tumor
show
ihc
level
representative
normal
breast
epithelium
tumor
specimen
show
view
within
article
determine
phosphorylation
status
tumor
cell
ihc
due
unacceptable
background
staining
variability
due
tissue
processing
difference
staining
report
generally
without
match
datum
abundance
kremer
however
decrease
mtor
phosphorylation
surrogate
loss
mtor
activity
determine
hypoxic
region
tumor
ihc
also
suggest
likely
activate
hypoxic
growing
edge
tumor
datum
show
suggest
dynamic
role
mtor
activity
cancer
development
large
labc
tumor
specimen
study
highly
hypoxic
show
increased
abundance
figure
increased
expression
promotes
translation
vegf
mrna
hypoxia
human
breast
cancer
specimen
examine
suggest
significant
association
overexpression
large
tumor
size
breast
cancer
address
possible
function
determine
function
increase
expression
protein
synthesis
hypoxia
angiogenesis
tumor
formation
panel
transform
invasive
ductal
carcinoma
cell
line
line
consist
cell
immortalize
human
breast
epithelial
cell
cell
early
primary
breast
cancer
cell
cell
late
highly
transform
breast
cancer
cell
immunoblot
analysis
equal
amount
protein
equal
number
cell
demonstrate
fold
increase
level
fold
high
level
increase
transformation
similar
human
tumor
specimen
level
fold
highly
transform
cell
compare
little
transform
cell
line
retain
activation
change
core
member
initiation
complex
include
poly
binding
protein
datum
show
protein
show
therefore
breast
cancer
cell
line
examine
functional
importance
increase
expression
translation
angiogenesis
tumor
formation
image
image
figure
analysis
global
protein
synthesis
mrna
translation
elevated
level
increasingly
transformed
cell
line
immunoblot
comparison
immortalize
cell
transform
cell
transform
cell
expression
level
identify
factor
cell
treat
rapamycin
ml
overall
protein
synthesis
activity
overexpression
mutant
global
protein
synthetic
rate
determine
labeling
normal
hypoxic
condition
student
test
two
side
endogenous
secrete
vegf
protein
level
normoxic
hypoxic
hx
condition
cell
line
determine
elisa
normalize
equal
level
vegf
mrna
vegf
mrna
level
cell
normoxic
hypoxic
mrna
level
determine
result
cell
line
similar
datum
show
gene
silence
silence
cell
shrna
nonspecific
control
shrna
express
lentivirus
vector
level
find
cell
level
cell
determine
immunoblot
vegf
synthesis
dependence
vegf
protein
level
determine
elisa
cell
normalize
equal
mrna
level
show
overall
protein
synthesis
level
reduction
level
protein
synthesis
determine
incorporation
silence
normoxic
hypoxic
condition
vector
control
overexpressing
cell
data
study
derived
least
three
independent
experiment
standard
error
mean
calculate
least
three
independent
experiment
result
achieve
pair
student
test
view
within
article
breast
cancer
cell
engineer
stably
overexpress
fold
similar
human
labc
tumor
based
ihc
datum
show
tag
deletion
mutant
bind
fail
enhance
mrna
translation
hypoxia
overexpression
mutant
little
effect
overall
normoxic
protein
synthesis
rate
cell
line
compare
equal
protein
amount
cell
largely
resistant
moderate
strong
hypoxia
downregulation
protein
synthesis
render
much
sensitive
overexpression
however
overexpression
hypoxic
cell
upregulated
vegf
mrna
translation
fold
compare
fold
control
increase
normalize
equal
vegf
mrna
level
vegf
mrna
level
increase
cell
hypoxia
regardless
mutant
protein
overexpression
similar
vegf
mrna
result
find
cell
datum
show
overexpression
increase
mrna
translation
hypoxia
fold
cell
slightly
cell
possibly
due
level
little
transform
cell
indeed
stable
reduction
level
gene
silence
immortalize
cell
eliminate
strong
translation
vegf
mrna
overexpressing
cell
figure
reduce
overall
protein
synthesis
normal
oxygen
silence
far
impair
protein
synthesis
hypoxia
compare
control
cell
mrna
translation
hypoxia
also
much
strongly
stimulate
overexpression
cell
figure
expression
slightly
fold
increase
sustain
overexpressing
cell
hypoxia
figure
consistent
result
elevated
level
comprise
translation
switch
increased
expression
provide
switch
mrna
translation
activate
hypoxia
investigate
possibility
cell
overexpressing
transfected
plasmid
express
bicistronic
mrna
reporter
contain
renilla
luciferase
downstream
firefly
luciferase
control
either
emcv
ires
sequence
describe
previously
translation
rate
normoxia
hypoxia
determine
quantify
level
two
different
form
luciferase
normalize
equal
mrna
level
increased
level
stimulate
translation
direct
vegf
ires
fold
hypoxia
impair
translation
fold
proof
translation
element
show
control
study
mrna
express
without
stable
hairpin
upstream
either
element
deletion
ires
figure
hypoxia
also
alter
size
mrna
datum
show
hairpin
block
luciferase
translation
ires
element
normoxic
hypoxic
condition
whereas
deletion
ires
block
luciferase
translation
hypoxia
image
image
figure
overexpression
mrna
translation
switch
bicistronic
vector
contain
ires
vegf
emcv
test
translation
dual
luciferase
reporter
system
normoxic
hypoxic
hx
condition
quantification
result
express
rate
ires
translation
show
right
result
control
versus
experimental
group
determine
student
test
two
side
vector
express
rfp
gfp
bicistronic
reporter
mrna
hypoxic
control
cell
visualize
confocal
microscopy
quantify
ten
independent
field
cell
integrity
initiation
complex
normoxia
increase
hypoxia
overexpression
protein
complexes
purify
cap
chromatography
protein
detect
immunoblot
analysis
lower
resolution
concentrate
associate
well
quantitation
typical
result
show
representative
study
least
three
independent
experiment
vegf
expression
level
normoxia
hypoxia
level
determine
elisa
secrete
factor
normalize
equal
vegf
mrna
level
describe
legend
figure
standard
error
mean
calculate
least
three
independent
experiment
result
achieve
pair
student
test
view
within
article
increased
level
also
stimulate
translation
fold
emcv
ires
control
viral
ires
fold
impair
respective
translation
activity
ires
translation
sustain
increase
hypoxia
inhibition
protein
synthesis
overexpression
figure
alternatively
splice
mrna
form
detect
datum
show
directly
visualize
translation
switch
cap
ires
mediate
vector
control
overexpressing
cell
transfected
plasmid
express
bicistronic
mrna
luciferase
open
reading
frame
replace
red
fluorescent
protein
rfp
vegf
green
fluorescent
protein
gfp
compared
vector
control
cell
cell
express
fold
increase
level
vegf
gfp
compare
rfp
hypoxia
figure
right
panel
increased
expression
therefore
act
switch
promote
translation
increased
level
trigger
disassembly
initiation
complexes
moderate
oxygen
depletion
integrity
initiation
complex
investigate
condition
increase
deprivation
oxygen
control
overexpressing
cell
protein
associate
retention
analyzed
immunoblot
analysis
control
cell
initiation
complex
disrupt
largely
disrupt
cell
overexpressing
initiation
complex
almost
fully
disrupt
increased
expression
therefore
decrease
fold
level
deprivation
require
provoke
strong
disassembly
complex
normalize
equal
mrna
level
overexpressing
cell
increase
vegf
protein
synthesis
fold
oxygen
deprivation
require
control
cell
yield
small
fold
increase
increased
expression
promotes
vegf
mrna
translation
tumor
vascularization
tumor
angiogenesis
model
examine
effect
vegf
expression
tumor
vascularization
angiogenesis
model
system
cell
overexpressing
vector
control
implant
chick
chorioallantoic
membrane
cam
chick
embryo
allow
grow
day
figure
upper
panel
angiogenesis
cam
time
measurement
vascularization
cam
tumor
derived
overexpressing
cell
show
fold
high
density
vascularization
compare
vector
control
mutant
figure
result
obtain
cell
engineer
express
similarly
increase
level
express
level
show
much
modest
increase
tumor
angiogenesis
figure
versus
significant
effect
angiogenesis
cell
image
image
figure
overexpression
promotes
tumor
angiogenesis
vascular
vegf
expression
representative
tumor
grow
cam
show
photograph
situ
corresponding
vector
control
overexpression
vector
alone
mutant
cell
vascular
area
tumor
grow
cam
cell
line
without
overexpression
determine
describe
experimental
procedure
morphometric
analysis
tumor
vasculature
cam
study
make
visible
immunofluorescence
staining
fluorescein
isothiocyanate
fitc
lycopersicon
lectin
vector
lab
follow
fluorescence
photography
immunoblot
analysis
protein
level
level
obtain
equal
amount
cam
tumor
protein
tumor
mass
weight
tumor
increase
expression
mutant
cell
cam
tumor
weight
quantify
mean
value
sem
shown
derived
least
three
independent
experiment
standard
error
mean
calculate
least
three
independent
experiment
result
achieve
pair
student
test
view
within
article
situ
staining
lectin
visualize
luminal
surface
blood
vessel
demonstrate
vessel
tumor
overexpressing
significantly
large
much
irregularly
shape
leaky
compare
vector
control
tumor
much
vegf
cam
tumor
time
tumor
derived
level
tumor
cam
determine
immunoblot
analysis
equal
amount
cam
protein
lysate
demonstrate
fold
increase
level
sample
electrophoretic
analysis
protein
indicate
hypophosphorylated
activate
form
cam
tumor
consistent
ability
downregulate
translation
sequestration
tumor
growth
cam
show
overexpressing
cell
tumor
almost
large
day
growth
compare
vector
mutant
control
figure
whereas
cell
tumor
increase
compare
control
cell
tumor
thus
increase
expression
promote
angiogenesis
vascular
density
conjunction
increase
level
importance
promote
tumor
angiogenesis
also
investigate
breast
cancer
cell
silence
expression
expression
reduce
stable
transform
lentivirus
shrna
vector
without
effect
level
reduction
result
decrease
overall
protein
synthesis
rate
datum
show
consistent
result
figure
compared
control
tumor
implant
cam
chick
embryo
tumor
angiogenesis
reduce
silence
silence
silence
also
much
significantly
reduce
vegf
production
tumor
growth
compare
silence
consistent
importance
vegf
mrna
translation
image
image
figure
effect
tumor
growth
angiogenesis
vegf
expression
cell
stably
reduce
expression
transformation
shrna
lentivirus
vector
implant
cam
tumor
grow
day
tumor
excise
equal
amount
protein
examine
immunoblot
analysis
show
top
representative
tumor
grow
cam
control
silence
cell
photograph
situ
bottom
tumor
vasculature
make
visible
immunofluorescence
staining
lectin
describe
legend
figure
vascular
density
tumor
grow
cam
shown
determine
describe
experimental
procedure
level
vegf
expression
secrete
cam
determine
assay
equal
amount
cam
extract
elisa
tumor
growth
determine
compare
excise
weight
volume
tumor
mg
normalize
vector
control
tumor
set
data
study
derived
least
three
independent
experiment
comprise
five
egg
per
tumor
cell
line
vector
control
overexpressing
cell
implant
subcutaneously
flank
nude
mouse
implantation
day
exogenous
estrogen
pellet
tumor
photograph
situ
excise
day
ihc
carry
section
typical
result
show
tumor
cell
volume
determine
day
three
independent
trial
eight
mouse
per
group
control
overexpressing
tumor
grow
mouse
week
express
rfp
gfp
bicistronic
reporter
mrna
tumor
excise
freeze
section
prepare
visualize
confocal
microscopy
merge
rfp
gfp
image
show
data
quantify
ten
independent
field
cell
display
ratio
gfp
rfp
tumor
vasculature
visualize
texas
tumor
vasculature
endothelium
mice
inject
stain
sacrifice
min
later
tumor
vasculature
visualize
embed
section
confocal
microscopy
quantify
arrow
indicate
blood
vessel
erythrocytes
standard
error
mean
calculate
least
three
independent
experiment
result
achieve
pair
student
test
view
within
article
increased
expression
promotes
tumor
growth
translation
angiogenesis
animal
model
study
next
determine
whether
expression
vegf
increase
tumor
angiogenesis
growth
mouse
tumor
model
female
mouse
week
age
implant
subcutaneously
flank
equal
number
vector
control
overexpressing
cell
primary
tumor
growth
promote
fold
period
week
figure
tumor
small
within
week
study
far
datum
show
neither
unmodified
overexpressing
cell
form
tumor
mouse
datum
show
tumor
excise
embed
paraffin
thin
section
analyzed
ihc
large
tumor
continue
overexpress
strongly
increase
expression
show
change
level
compare
vector
control
level
vegf
mrna
translation
visualize
tumor
prior
transfection
vector
overexpressing
cell
vector
express
bicistronic
vegf
mrna
describe
early
tumor
grow
period
week
excise
visualize
confocal
microscopy
gfp
rfp
ratio
measure
level
translation
direct
vegf
ires
quantify
overexpressing
tumor
synthesize
fold
high
level
gfp
drive
vegf
ires
compare
rfp
drive
find
vector
control
cell
normalize
mrna
level
datum
therefore
demonstrate
switch
translation
tumor
growth
tumor
cell
overexpressing
tumor
vasculature
visualize
injection
conjugate
dextran
bind
endothelial
vasculature
component
analysis
tumor
section
confocal
microscopy
demonstrate
fold
increase
small
blood
vessel
density
overexpressing
tumor
compare
control
see
contain
erythrocytes
overexpression
therefore
promote
increase
mrna
translation
expense
mrna
translation
associate
increase
tumor
growth
angiogenesis
animal
model
discussion
several
key
mrna
tumorigenesis
dual
translation
mrna
utilize
ires
mechanism
important
effect
hypoxia
restrict
mrna
translation
thus
mrna
encode
angiogenic
factor
vegf
fgf
mediator
hypoxia
response
among
possess
alternate
mean
initiate
translation
hypoxic
condition
previously
show
survival
breast
tumor
cell
stress
condition
hypoxia
involve
increase
vegf
mrna
translation
via
activation
mtor
pathway
study
suggest
although
increase
result
induction
vegf
transcription
selective
vegf
translation
considerably
increase
hypoxia
activation
overexpressed
consequent
reduction
protein
synthesis
promotion
mrna
translation
also
previously
show
human
chromosome
position
include
gene
amplify
human
breast
prostate
cancer
possibly
explain
overexpression
observe
large
tumor
key
finding
study
increase
expression
cell
trigger
angiogenesis
response
much
high
level
oxygen
great
sequestration
suppression
increase
mrna
translation
scenario
associate
increase
sustain
translation
via
ires
dual
function
mrna
hypoxia
include
orchestrate
angiogenesis
vegf
hypoxia
response
however
translation
mrna
also
increase
translation
overexpression
promote
tumor
growth
angiogenesis
well
holcik
sonenberg
indeed
collectively
work
suggest
may
two
pathway
translational
control
may
involve
cancer
progression
suggest
increase
expression
stronger
mrna
translation
may
one
mechanism
one
also
likely
require
uncoupling
hypoxia
inhibition
mrna
translation
transformation
second
pathway
suggest
involve
increase
expression
promote
great
level
mrna
translation
hypoxia
function
absence
uncoupling
hypoxia
inhibition
mrna
translation
maintenance
expression
mrna
translation
condition
likely
critical
development
large
tumor
observe
mouse
promote
tumor
cell
survival
overexpression
increase
tumor
cell
proliferation
rate
datum
show
suggest
preservation
tumor
cell
viability
underlie
least
part
large
increase
tumor
size
observe
animal
importantly
model
translational
control
cancer
cap
dependent
ires
dependent
derived
largely
animal
model
system
point
statistically
associate
change
observe
translation
factor
level
human
tumor
specimen
nevertheless
several
group
now
observe
elevate
level
human
prostate
head
neck
gastrointestinal
cancer
kremer
martin
effect
overexpression
study
also
odd
report
engineer
overexpressed
find
inhibitory
cell
growth
transformation
study
level
overexpression
much
high
likely
explain
inhibitory
effect
even
normoxic
condition
much
physiological
level
typically
function
growth
inhibitor
stress
activation
finding
support
molecular
mechanism
translation
drive
translation
promote
hypoxia
level
require
tumor
promote
strong
translation
tumor
cell
proliferation
absence
hypoxia
observe
lymphoma
tumor
model
solid
tumor
high
level
also
expect
promote
tumor
survival
angiogenesis
particularly
hypoxia
inhibition
mrna
translation
either
disruption
hypoxia
signaling
pathway
tumor
cell
specific
integrin
mean
contrast
elevate
reduce
level
oxygen
depletion
require
trigger
inhibition
thereby
preserve
tumor
cell
viability
promote
strong
mrna
translation
mediate
need
mention
activation
hypoxia
study
equivalent
treatment
cell
rapamycin
mtor
inhibitor
block
tumor
growth
function
antiangiogenic
agent
del
bufalo
thomas
rapamycin
inhibition
mtor
effect
cell
apart
activation
include
inhibition
cell
growth
inhibition
vegf
stimulation
vascular
endothelial
cell
yu
impair
akt
activity
arrest
fact
note
rapamycin
strongly
downregulate
vegf
production
block
expression
level
transcription
del
bufalo
thomas
consistent
result
figure
summary
show
overexpression
model
system
promote
switch
translation
mediate
hypoxia
result
selective
translation
mrna
vegf
promote
tumor
angiogenesis
survival
experimental
procedure
ihc
immunoblot
vegf
elisa
analysis
expression
study
quantitative
subcutaneous
tumor
model
cam
analysis
tumor
growth
angiogenesis
incorporation
assay
cell
line
cell
culture
antibody
plasmid
transfection
describe
supplemental
experimental
procedure
tissue
specimen
specimen
consist
primary
breast
cancer
specimen
stage
iii
include
factor
specimen
obtain
archival
paraffin
block
breast
cancer
patient
age
year
treat
school
medicine
nyusm
sample
select
code
specimen
protocol
approve
nyusm
institutional
review
board
include
tumor
specimen
identify
stage
iii
invasive
ductal
carcinoma
tumor
specimen
obtain
pretreatment
surgical
resection
small
tumor
pretreatment
tumor
core
biopsy
except
immunoblot
study
figure
obtain
fresh
posttreatment
surgically
resected
tumor
specimen
fresh
normal
breast
tissue
obtain
mammoplasty
reduction
surgery
final
breast
cancer
diagnosis
confirm
pathologic
evaluation
pretreatment
tumor
size
determine
surgical
pathology
small
tumor
clinically
caliper
measurement
large
tumor
cm
tumor
cm
tissue
microarray
develop
describe
three
mm
mm
thick
circular
punch
per
tumor
specimen
choose
pathologist
blind
study
design
specimen
stain
hematoxylin
eosin
confirm
diagnosis
series
include
control
normal
breast
tissue
select
common
specimen
provide
consistent
interpretation
pack
section
cell
line
engineer
specific
factor
morphometric
analysis
tumor
vasculature
tumor
vasculature
cam
study
make
visible
staining
fluorescein
isothiocyanate
fitc
lycopersicon
lectin
vector
lab
describe
briefly
freeze
section
fix
permeabilized
triton
block
incubate
slide
mount
view
confocal
fluorescent
microscopy
zeiss
scope
percent
vascular
area
mean
fluorescent
vasculature
density
tumor
derived
image
describe
vivo
vessel
labeling
conduct
describe
briefly
texas
dextran
mol
wt
molecular
probes
prepare
mg
ml
pbs
inject
tail
vein
weight
mouse
sacrifice
min
later
tumor
rapidly
excise
fix
formalin
paraffin
embed
section
visualize
immunofluorescence
microscopy
statistical
analysis
statistical
analysis
laboratory
research
result
compare
difference
control
experimental
group
utilize
student
test
see
supplemental
experimental
procedure
ihc
statistical
analysis
show
supplemental
acknowledgment
thank
member
lab
helpful
discussion
critique
work
work
support
grant
department
defense
breast
cancer
research
program
breast
cancer
research
foundation
foundation
american
cancer
society
susan
komen
breast
cancer
research
foundation
monoclonal
chimeric
humanised
human
antibody
therapy
become
increasingly
available
treat
various
form
human
malignancy
variety
disease
entity
breast
colon
cancer
antibody
therapy
show
improve
overall
survival
well
time
disease
progression
particularly
combine
chemotherapy
review
mechanism
behind
activity
mediate
monoclonal
antibody
depend
target
induce
growth
receptor
interfere
signal
transduction
antibody
direct
neu
epidermal
receptor
may
also
induce
cellular
cytotoxicity
adcc
antibody
direct
epithelial
cellular
adhesion
molecule
primarily
act
adcc
also
know
clinic
antigen
transmembrane
express
ductal
cell
surface
normal
glandular
epithelia
variety
epithelial
cancer
cancer
cell
also
glycosylated
expose
variable
number
domain
peptide
core
make
good
target
immunotherapy
demonstrate
antibody
response
breast
ovarian
colon
lung
pancreatic
cancer
patient
healthy
woman
natural
humoral
immune
response
favourable
prognostic
factor
naturally
occur
antibody
lead
cap
cluster
cell
surface
unmask
cell
surface
molecule
involve
cell
adhesion
limit
tumour
invasion
redistribution
also
expose
cell
surface
receptor
involve
immune
recognition
process
enable
recognition
destruction
tumour
cell
antigen
specific
humanised
specific
monoclonal
antibody
mediate
vitro
tumour
cell
kill
currently
evaluate
clinical
trial
potential
immunotherapy
breast
cancer
serum
level
correlate
tumour
load
progression
affect
mediate
tumour
cell
kill
analyse
effect
present
sera
cancer
patient
well
pbmc
characteristic
vitro
mediate
adcc
increase
efficacy
treatment
addition
cytokine
effect
antibody
concentration
investigate
discuss
material
patient
serum
sample
serum
level
serial
serum
sample
obtain
ovarian
breast
cancer
patient
collect
store
analyse
level
capacity
inhibit
adcc
cancer
antigen
serum
level
determine
advia
centaur
assay
bayer
corporation
usa
perform
fully
automate
advia
centaur
system
assay
based
mab
direct
dominant
repeat
sequence
capture
antigen
mab
direct
carbohydrate
tracer
level
recommend
manufacturer
exclude
normal
population
ml
isolation
peripheral
blood
mononuclear
cell
pbmc
natural
killer
nk
cell
purification
peripheral
blood
mononuclear
cell
pbmc
different
healthy
donor
isolate
obtain
blood
bank
amsterdam
netherlands
density
gradient
centrifugation
oslo
norway
number
cell
determine
pbmc
cryopreserved
separate
batch
nk
cell
enrichment
perform
negative
depletion
nk
cell
isolation
kit
ii
germany
accord
manufacture
recommendation
adcc
assay
humanised
mab
provide
london
uk
highly
purify
human
igg
amsterdam
netherlands
control
antibody
breast
tumour
cell
line
cultured
imdm
plus
fcs
target
cell
line
donor
pbmc
thaw
cultured
overnight
modify
dulbecco
medium
imdm
gibco
paisley
scotland
supplement
foetal
calf
serum
fcs
gibco
paisley
scotland
experiment
iu
ml
ml
ml
iu
ml
add
culture
pbmc
medium
concentration
cell
ml
target
cell
label
ci
mbq
amersham
buckinghamshire
uk
cell
wash
twice
ml
medium
medium
concentration
cell
ml
fifty
microlitres
target
cell
seed
well
culture
plate
costar
cambridge
ma
usa
cell
incubate
mab
control
antibody
final
concentration
ml
unless
otherwise
specify
alternatively
serum
sample
add
min
incubation
pbmc
seed
culture
plate
cell
ratio
plate
incubate
another
release
supernatant
determine
automatic
gamma
counter
measurement
carry
triplicate
spontaneous
maximal
release
determine
percentage
release
specific
release
define
specific
release
release
without
flow
cytometry
label
mouse
clone
corresponding
murine
igg
control
antibody
amsterdam
netherlands
well
mouse
clone
pharmingen
becton
dickinson
san
jose
usa
determination
pbmc
surface
marker
expression
flow
cytometry
expression
analyse
nk
cell
healthy
donor
cultured
complete
medium
without
patient
sera
purify
rd
system
minneapolis
mn
usa
follow
rabbit
immunoglobulin
dako
glostrup
denmark
mica
expression
analyse
mica
clone
rd
system
minneapolis
mn
usa
follow
polyclonal
goat
immunoglobulin
dako
glostrup
denmark
cell
incubate
antibody
min
analyse
facscan
datum
analysis
perform
cellquest
software
bd
bioscience
san
jose
usa
fc
receptor
fcr
block
effector
cell
overnight
monoclonal
antibody
clone
clone
clone
control
mouse
igg
pharmingen
becton
dickinson
san
jose
usa
block
pbmc
incubate
overnight
antibody
ml
adcc
perform
presence
antibody
statistic
normality
distribution
datum
confirm
kolmogorov
smirnov
test
q
q
plot
pearson
correlation
test
perform
analyse
relation
cell
number
tumour
cell
kill
analyse
influence
serum
level
adcc
test
investigate
influence
different
cytokine
ability
mediate
adcc
value
consider
significant
datum
analyse
spss
software
nk
cell
number
polymorphism
determine
level
adcc
based
develop
vitro
assay
study
whether
antibody
mediate
adcc
adcc
perform
human
breast
cancer
cell
line
target
cell
human
peripheral
blood
mononuclear
cell
effector
cell
humanised
show
killing
cell
maximal
killing
concentration
range
ml
show
presence
ml
tumour
cell
kill
vary
widely
healthy
donor
test
tumour
cell
kill
responder
donor
pbmc
improve
increase
concentration
ml
datum
show
percentage
nk
cell
within
pbmc
correlated
ability
mediate
adcc
table
also
positive
correlation
fcriii
positive
cell
table
correlation
find
tumour
cell
kill
percentage
cell
cytotoxic
lymphocyte
cell
monocyte
show
image
differential
adcc
mediate
pbmc
healthy
donor
ml
view
within
article
table
adcc
correlation
pbmc
characteristic
specific
killing
cell
pbmc
pbmc
pbmc
pbmc
pbmc
pbmc
pbmc
pbmc
pbmc
pbmc
pbmc
pbmc
pbmc
table
view
within
article
adcc
mediate
primarily
fcriii
show
involve
adcc
blocking
assay
carry
confirm
mechanism
model
indeed
adcc
block
effector
cell
two
different
monoclonal
antibody
antibody
fcrii
fcri
image
adcc
depend
fcriii
antibody
different
fcr
fcriii
clone
clone
fcrii
fcri
block
mediate
adcc
effector
cell
incubate
overnight
ml
mab
fc
receptor
adcc
perform
ml
view
within
article
proportion
nk
cell
component
contribute
observe
difference
tumour
cell
kill
pbmc
different
donor
pbmc
high
responder
enrich
equal
number
nk
cell
analyse
adcc
assay
enriched
nk
cell
high
responder
induce
specific
killing
enrich
nk
cell
responder
induce
specific
killing
result
suggest
observe
difference
high
responder
may
also
due
intrinsic
characteristic
nk
cell
rather
just
number
nk
cell
elucidate
expression
level
fcriii
investigate
two
different
antibody
one
clone
bind
high
affinity
cell
individual
homozygous
fcriiia
polymorphism
difference
expression
find
clone
table
expression
level
determine
clone
correlated
capacity
mediate
adcc
table
suggest
role
fcriiia
polymorphism
adcc
image
level
adcc
depend
partly
proportion
nk
cell
pbmc
expression
adcc
perform
ml
donor
pbmc
high
pbmc
pbmc
responder
corresponding
enrich
nk
cell
obtain
negative
selection
one
representative
experiment
four
perform
show
expression
pbmc
pbmc
analyse
flow
cytometry
two
mab
clone
view
within
article
next
investigate
whether
addition
nk
cell
activate
cytokine
enhance
adcc
mediate
also
high
responder
previously
demonstrate
increase
adcc
addition
confirm
extend
finding
study
effect
cytokine
well
adcc
fold
enhancement
tumour
cell
kill
observe
pbmc
differential
effect
image
enhance
adcc
pbmc
four
different
donor
responder
high
response
cultured
day
presence
prior
perform
adcc
increase
cytotoxicity
due
cytokine
treatment
cytotoxicity
ratio
cytokine
treat
untreated
calculate
follow
tumour
cell
lysis
cytokine
treat
pbmc
tumour
cell
lysis
pbmc
ratio
indicate
tumour
cell
kill
high
pbmc
untreated
pbmc
view
within
article
high
antigen
serum
level
inhibit
purify
tumour
cell
inhibit
adcc
frequently
elevate
serum
patient
breast
ovarian
cancer
test
tumour
agent
analyse
effect
serum
antigen
level
adcc
high
responder
pbmc
see
killing
cell
line
without
antibody
always
affect
addition
contain
patient
sera
indicate
natural
antibody
may
present
serum
sufficient
mediate
vitro
adcc
mediate
however
strongly
inhibit
presence
serum
contain
ml
specific
lysis
however
addition
serum
contain
level
ml
effect
tumour
cell
kill
versus
specific
lysis
serum
sample
level
upper
limit
normal
ml
adcc
inhibition
little
inhibition
cytotoxicity
high
serum
sample
level
ml
inhibition
tumour
cell
kill
high
level
serum
overcome
increase
serum
dilution
thus
decrease
concentration
however
possible
inhibit
factor
also
dilute
therefore
investigate
whether
inhibit
effect
serum
contain
high
level
also
resolve
add
increase
level
antigen
completely
block
tumour
cell
kill
mediate
concentration
ml
kill
kill
presence
however
presence
increase
concentration
inhibition
target
cell
kill
antigen
decrease
ml
completely
abrogate
ml
image
high
serum
level
inhibit
adcc
overcome
add
increase
concentration
example
adcc
pbmc
presence
serum
ml
high
ml
level
correlation
level
percentage
inhibition
mediate
tumour
cell
kill
graph
divide
four
quadrant
leave
normal
level
ml
little
inhibition
upper
leave
normal
level
much
inhibition
right
normal
level
ml
little
inhibition
upper
right
normal
level
much
inhibition
symbol
correspond
serum
sample
various
level
take
different
time
point
four
patient
breast
cancer
one
patient
ovarian
cancer
open
circle
correspond
single
sample
individual
patient
breast
ovarian
cancer
adcc
assay
perform
ml
high
responder
pbmc
effector
high
serum
sample
ml
obtain
patient
breast
cancer
serially
dilute
level
ml
dilution
test
adcc
assay
perform
ml
one
representative
experiment
three
perform
adcc
inhibition
overcome
increase
concentration
white
bar
depict
mediate
tumour
cell
kill
absence
serum
killing
optimal
mab
concentration
ml
black
bar
depict
tumour
cell
kill
presence
serum
sample
high
level
ml
obtain
patient
breast
cancer
one
representative
experiment
three
perform
show
view
within
article
discussion
clinical
success
monoclonal
antibody
specifically
targeting
tumour
cell
create
great
interest
immunotherapy
trastuzumab
monoclonal
antibody
targeting
extracellular
domain
neu
protein
result
trial
compare
adjuvant
chemotherapy
alone
combination
trastuzumab
woman
surgically
remove
breast
cancer
show
benefit
disease
free
survival
overall
survival
trastuzumab
treat
patient
contrary
neu
express
breast
cancer
virtually
breast
adenocarcinoma
due
repeat
extracellular
sequence
present
multiple
region
per
molecule
ensure
antibody
binding
even
express
tumour
specific
antibody
therefore
much
widely
applicable
therapeutic
agent
lead
cap
cluster
surface
tumour
cell
expose
cell
surface
receptor
involve
immune
recognition
process
enable
recognition
destruction
tumour
cell
antigen
specific
indeed
previously
show
mediate
adcc
positive
cell
line
nk
cell
fcriii
play
important
role
mediate
tumour
cell
kill
two
different
allotypes
fcriiia
describe
polymorphism
report
affect
binding
donor
positive
polymorphism
well
clinical
response
treatment
rituximab
increase
clinical
response
explain
high
affinity
rituximab
result
increase
nk
cell
mediate
lysis
positive
cell
fcriiia
specific
clone
display
strong
binding
pbmc
individual
homozygous
fcriiia
polymorphism
show
correlation
high
fcriiia
expression
antibody
mediate
adcc
correlation
observe
antibody
bind
equally
strong
fcriiia
allotypes
datum
strongly
suggest
fcriiia
polymorphism
may
also
influence
adcc
dna
type
analysis
carry
confirm
observation
currently
numerous
effort
ongoing
improve
efficacy
therapeutic
antibody
vitro
molecular
fc
region
one
possibility
improve
affinity
mab
fcriiia
thereby
enhance
adcc
furthermore
combination
therapy
nk
cell
activate
cytokine
may
increase
adcc
previously
show
augment
adcc
indeed
system
stimulation
pbmc
ifn
increase
adcc
moreover
demonstrate
patient
treat
antibody
combination
exhibit
increase
vitro
adcc
show
addition
rituximab
therapy
treatment
lymphoma
result
nk
cell
expansion
correlate
clinical
response
also
observe
adcc
activity
increase
maintain
respond
stable
disease
patient
however
vivo
relevance
vitro
result
need
far
confirmation
different
serum
sample
vary
level
demonstrate
inhibit
adcc
serum
level
upper
limit
normal
ml
inhibit
adcc
serum
sample
level
differ
among
cancer
patient
consider
define
therapeutic
dose
one
way
confirm
inhibit
effect
perform
adcc
remove
sera
unfortunately
possible
remove
patient
sera
without
dilute
sera
however
tumour
cell
kill
restore
high
concentration
antibody
concentration
ml
overcome
vitro
inhibition
tumour
cell
kill
extremely
high
level
ml
strongly
suggest
indeed
inhibit
adcc
concentration
achieve
serum
administration
dose
level
mg
kg
vivo
concentration
lie
well
within
tolerable
dose
consider
exceed
mg
kg
nevertheless
care
need
extrapolate
finding
vitro
set
vivo
situation
dynamic
force
circulate
blood
may
influence
antigen
antibody
interaction
serum
sample
inhibit
adcc
even
though
level
normal
limit
another
possible
inhibitory
factor
soluble
form
class
chain
mica
ligand
nk
cell
receptor
soluble
mica
release
tumour
cell
inhibit
expression
effector
function
immune
cell
patient
progressive
malignant
tumour
mica
express
target
cell
adcc
assay
block
inhibit
kill
suggest
play
role
adcc
however
demonstrate
impairment
expression
nk
cell
incubation
serum
sample
inhibit
adcc
suggest
case
soluble
ligand
play
role
adcc
inhibition
datum
show
conclusion
vitro
result
indicate
number
nk
cell
nk
cell
activate
cytokine
polymorphism
high
serum
level
influence
adcc
high
concentration
lie
within
dose
recently
test
phase
clinical
trial
compensate
elevate
serum
level
optimal
effect
treatment
might
see
serum
level
early
stage
patient
contrast
advance
disease
patient
screening
patient
high
level
nk
cell
bear
polymorphism
adjust
dosage
circulate
level
nk
cell
activate
cytokine
may
increase
efficacy
treatment
compared
conventional
external
beam
radiation
brachytherapy
offer
different
much
localized
therapeutic
approach
allow
radiotherapy
short
distance
radioisotope
place
near
malignant
tissue
site
resection
little
adverse
effect
adjacent
healthy
organ
two
type
device
currently
breast
cancer
system
catheter
surgically
insert
tumor
bed
system
utilize
end
catheter
surgically
place
tumor
bed
despite
advantage
offer
brachytherapy
relatively
complicate
placement
removal
procedure
utilization
biodegradable
implant
load
radioisotope
may
spare
need
surgical
procedure
removal
brachytherapy
hardware
device
provide
much
efficient
therapy
virtue
proximity
site
surgery
also
contribute
improvement
quality
life
patient
previous
study
show
vivo
feasibility
safety
brachytherapy
platform
rapid
slow
crosslinked
chitosan
hydrogel
implant
rat
model
due
property
particle
produce
product
afford
local
moderate
radiotherapy
site
implantation
minimal
damage
distant
tissue
highly
hydrophobic
commonly
adrenal
scintigraphy
good
radioactive
component
biodegradable
device
release
rate
solely
dependent
rate
platform
degradation
biocompatibility
crosslinked
chitosan
implant
assess
rat
find
safe
absorbable
surgical
suture
conspicuous
biodegradable
implant
breast
cancer
patient
undergo
surgery
replace
external
beam
radiation
apply
week
remain
breast
tissue
prevent
local
recurrence
overall
objective
present
study
challenge
hypothesis
locoregional
tumor
recurrence
either
reduce
prevent
implantation
biodegradable
implant
adjacent
site
tumor
resection
much
specifically
study
goal
prepare
chitosan
ct
implant
load
study
effect
load
ct
hydrogel
ct
primary
therapy
tumor
progression
implantation
adjacent
tumor
study
ability
ct
prevent
tumor
recurrence
adjuvant
therapy
minimal
residual
disease
model
characterize
degradation
kinetic
ct
vivo
trace
possible
adverse
effect
toxicity
ct
implant
implantation
site
distant
organ
material
material
unless
state
otherwise
material
purchase
sigma
louis
analytical
grade
water
reverse
preparation
ct
gel
ct
mg
dissolve
ml
acetic
acid
frutarom
israel
ct
solution
heat
ml
glutaraldehyde
solution
water
add
ct
gel
form
immediately
rinse
least
three
fresh
portion
pbs
mm
ph
residue
detect
detection
perform
spectrophotometrically
nm
monomeric
nm
dimer
water
content
gel
average
preparation
ct
hydrogel
ct
mg
dissolve
ml
acetic
acid
frutarom
israel
one
ml
suspension
mci
cis
international
france
disperse
ct
solution
carry
trace
remove
describe
procedure
lead
initial
amount
onto
gel
surface
rest
remove
rinsing
perform
irradiation
detect
rinse
water
ct
gel
cut
small
cube
contain
ci
determine
dose
calibrator
capintec
crc
capintec
instruments
nj
usa
implant
immediately
mouse
dose
design
accord
previous
report
sodium
salt
intravenous
injection
treatment
breast
cancer
cell
xenograft
mouse
model
cell
line
metastatic
mammary
mouse
tumor
atcc
cultured
humidify
atmosphere
air
dulbecco
modified
eagle
medium
supplement
fetal
bovine
serum
biological
industry
israel
penicillin
mg
biological
industry
israel
streptomycin
mg
biological
industry
israel
cell
harvest
wash
pbs
concentrate
cell
ml
pbs
tumor
progression
disease
study
respectively
animal
regulation
anesthesia
euthanasia
study
conduct
accord
principles
laboratory
animal
care
nih
publication
revision
mutual
committee
animal
welfare
hebrew
university
jerusalem
medicine
university
medical
center
review
approve
study
protocol
female
week
balb
mouse
obtain
laboratory
israel
study
mouse
keep
constant
environmental
condition
light
dark
cycle
standard
laboratory
chow
tap
water
anesthesia
perform
intraperitoneal
injection
mg
kg
body
weight
ketamine
ml
usa
euthanasia
mouse
carry
cervical
dislocation
effect
ct
tumor
progression
primary
therapy
model
suspension
cell
ml
mouse
subcutaneously
sc
inject
back
sixty
mouse
scheme
tumor
become
visually
apparent
one
week
cell
injection
two
week
cell
injection
mouse
divide
three
group
group
operation
perform
hydrogel
implant
treatment
group
group
hydrogel
implant
mouse
study
possible
effect
vehicle
naive
hydrogel
group
ct
implant
mouse
implantation
procedure
perform
cm
incision
back
anesthetized
mouse
place
hydrogel
encapsulate
tumor
close
skin
stainless
steel
staple
week
implantation
three
mouse
group
sacrifice
tumor
remove
weigh
addition
multiple
biopsy
specimen
tumor
bed
lung
heart
liver
spleen
kidney
fix
formalin
embed
paraffin
subject
histopathological
analysis
remain
mouse
follow
death
occur
survival
analysis
conduct
kaplan
meier
product
limit
method
image
scheme
schematic
presentation
experimental
primary
therapy
surgical
adjuvant
therapy
protocol
employ
cell
ct
implant
sc
subcutaneous
view
within
article
effect
ct
prevent
tumor
recurrence
adjuvant
therapy
model
aim
section
study
construct
model
minimal
residual
disease
lead
tumor
recurrence
follow
surgical
therapy
examine
impact
ct
scheme
placement
tumor
recurrence
rate
sixty
mouse
divide
three
study
group
describe
implantation
procedure
perform
cm
incision
back
anesthetized
mouse
mount
hydrogel
surgical
cavity
inject
suspension
cell
ml
cell
mouse
close
skin
stainless
steel
staple
week
mouse
group
sacrifice
multiple
biopsy
specimen
tumor
bed
lung
heart
liver
spleen
kidney
fix
formalin
embed
paraffin
subject
histopathological
analysis
remain
mouse
follow
death
occur
survival
analysis
conduct
kaplan
meier
product
limit
method
histological
analysis
specimen
tumor
bed
lung
heart
liver
spleen
kidney
previously
collect
rinse
pbs
formaldehyde
pbs
dehydrated
ethanol
embed
paraffin
block
section
stain
hematoxylin
eosin
imaging
estimation
biological
elimination
hydrogel
verify
localization
ct
hydrogel
cube
radioactive
hydrogel
implant
subcutaneously
back
four
mouse
scintigraphy
perform
day
implantation
mouse
image
min
anesthesia
camera
elscint
haifa
israel
collimator
data
analyzed
program
ge
healthcare
region
interest
draw
focus
total
number
count
region
obtain
data
obtain
imaging
study
calculate
elimination
hydrogel
site
implantation
oxidative
degradation
gel
vitro
verify
previous
histological
observation
gel
color
change
time
associate
degradation
process
suggest
oxidation
process
involve
implant
elimination
hydrogel
cube
mm
incubate
elevate
concentration
mm
potassium
permanganate
water
min
gel
retrieve
wash
twice
water
incubate
separately
ml
aqueous
hematoxylin
mg
ml
eosin
mg
ml
solution
room
temperature
concentration
remain
dye
incubation
medium
measure
nm
hematoxylin
nm
eosin
fraction
percent
initial
amount
dye
onto
gel
calculate
effect
ct
tumor
progression
primary
therapy
model
tumor
growth
rate
vary
among
different
study
group
growth
rate
untreated
group
group
day
far
tumor
progression
observe
day
tumor
progression
rate
treatment
group
implant
ct
fold
slow
day
first
day
time
rate
day
day
rate
observe
group
far
tumor
progression
observe
day
photograph
solid
tumor
microphotographs
metastatic
spread
take
day
hydrogel
implantation
show
metastatic
spread
detect
lung
ct
treat
group
week
metastases
detect
lung
control
group
metastatic
spread
detect
day
heart
liver
spleen
kidney
group
image
tumor
progression
express
tumor
weight
mouse
open
square
naive
hydrogel
open
circle
treatment
group
implantation
ct
group
fill
circle
shown
mean
value
different
experiment
sem
view
within
article
image
representative
image
whole
solid
tumor
take
sacrifice
mouse
back
leave
take
lung
mouse
right
day
injection
cell
neoadjuvant
therapy
model
study
magnification
top
panel
naive
control
implant
lower
panel
ct
implant
note
metastatic
cell
lung
naive
control
mouse
view
within
article
survival
analysis
reveal
mortality
initiate
day
hydrogel
implantation
end
day
naive
hydrogel
group
treatment
group
implant
ct
mortality
initiate
day
complete
day
hydrogel
implantation
image
survival
analysis
tumor
progression
break
line
naive
hydrogel
solid
line
ct
bold
solid
line
implantation
group
neoadjuvant
therapy
model
time
scale
relate
day
gel
implantation
view
within
article
preventive
effect
ct
tumor
recurrence
adjuvant
therapy
model
mortality
naive
hydrogel
group
occur
day
cell
injection
however
study
group
implant
ct
mortality
occur
population
last
day
cell
injection
percent
group
confirm
detail
pathological
analysis
survival
maintain
end
study
day
mouse
sacrifice
subject
histopathological
analysis
image
survival
analysis
tumor
progression
break
line
naive
hydrogel
solid
line
ct
bold
solid
line
implantation
group
surgical
adjuvant
therapy
model
time
scale
relate
day
gel
implantation
cell
injection
view
within
article
depict
tumor
progression
week
cell
injection
two
control
group
compare
healthy
subcutaneous
tissue
evidence
disease
treatment
group
minor
calcification
part
muscle
fiber
implantation
bed
addition
metastatic
spread
detect
lung
liver
control
group
metastatic
spread
detect
organ
treatment
group
metastatic
spread
detect
heart
kidney
spleen
group
image
representative
image
whole
mouse
specimen
take
tumor
bed
liver
lung
mouse
sacrifice
day
injection
cell
surgical
adjuvant
therapy
model
study
top
panel
naive
control
implant
lower
panel
ct
implant
note
tumor
cell
metastatic
cell
lung
liver
naive
hydrogel
treat
mouse
tumor
bed
liver
lung
upper
panel
panel
view
within
article
estimation
biological
elimination
kinetic
hydrogel
total
elimination
rate
site
implantation
determine
imaging
study
amount
radioactivity
q
time
implantation
calculate
accord
follow
equation
image
representative
scintigraphy
image
show
activity
decay
lack
body
distribution
decay
activity
site
implantation
express
negative
value
natural
logarithm
radioactive
fraction
remain
time
solid
line
total
elimination
include
biological
elimination
line
calculate
decay
radioisotope
view
within
article
initial
amount
radioactivity
total
elimination
constant
transformation
equation
negative
value
natural
logarithm
radioactivity
fraction
time
yield
follow
equation
ln
q
derived
imaging
study
change
remain
fraction
radioactivity
time
solid
line
total
radioactivity
elimination
consist
typical
radioactive
decay
constant
biological
elimination
constant
calculate
follow
equation
biological
elimination
calculate
accord
total
elimination
constant
derived
imaging
study
find
day
radioactive
decay
constant
calculate
isotope
find
day
plot
break
line
radioactive
decay
constant
total
decay
constant
give
value
biological
elimination
constant
day
derived
biological
elimination
day
oxidative
degradation
hydrogel
vitro
show
incubate
gel
cube
solution
increase
concentration
permanganate
result
concentration
dependent
decrease
eosin
staining
concomitant
increase
hematoxylin
staining
indicate
direct
correlation
extent
permanganate
drive
oxidation
process
image
hematoxylin
open
circle
eosin
close
circle
onto
cube
ct
hydrogel
oxidation
increase
concentration
shown
mean
measurement
view
within
article
discussion
biodegradable
platform
radioisotope
delivery
local
radiotherapy
suggest
past
carriers
particulate
nature
inject
intravenously
targeting
hepatic
malignancy
direct
inject
directly
solid
tumor
study
present
study
different
approach
suggest
implant
radioactive
biodegradable
hydrogel
adjacent
tumor
tumor
bed
primary
therapy
adjuvant
therapy
follow
surgical
resection
virtue
design
derived
therapy
regimen
propose
replace
conventional
brachytherapy
machinery
prevention
locoregional
recurrence
moreover
contrast
targeting
approach
attempt
concentrate
malignant
tissue
approach
suggest
local
post
resection
irradiation
mean
prevent
minimal
residual
disease
common
postoperative
complication
concept
demonstrate
study
employ
polysaccharide
based
hydrogel
load
offer
proof
concept
xenograft
mouse
model
relevant
breast
cancer
purpose
chitosan
ct
employ
biodegradable
platform
ct
natural
polysaccharide
biocompatibility
biodegradation
property
variety
medical
application
substitution
scaffold
wound
healing
accelerator
without
embed
fibroblast
expand
time
ct
biodegradation
crosslinked
biocompatibility
specific
composite
test
find
superior
absorbable
suture
hydrogel
load
obtain
biodegradable
radioactive
matrix
ct
implantation
adjacent
solid
tumor
able
delay
progression
two
week
assess
monitor
tumor
weight
neoadjuvant
therapy
model
finding
interesting
since
mouse
model
know
metastatic
rapid
complete
mortality
even
treat
external
beam
radiation
median
survival
time
treatment
group
day
fold
long
two
control
group
day
treatment
external
beam
radiation
model
extend
survival
fold
compare
control
group
survival
rate
woman
undergo
surgery
follow
adjuvant
radiotherapy
woman
undergo
mastectomy
however
year
local
recurrence
rate
high
follow
breast
conservation
reduce
external
beam
radiation
therapy
compare
follow
mastectomy
context
study
finding
regard
effect
regional
irradiation
accomplish
implantation
ct
adjuvant
therapy
model
profound
model
mimic
minimal
residual
disease
tumor
bed
associate
locoregional
systemic
recurrence
study
find
survival
survival
mouse
treat
ct
compare
total
mortality
survival
mouse
untreated
group
treat
naive
control
tumor
detect
macroscopically
microscopically
tumor
bed
ct
group
day
compare
two
control
group
large
tumor
develop
site
cell
injection
addition
detail
histopathological
analysis
multiple
specimen
take
tumor
bed
lung
liver
group
show
evidence
tumor
surgical
site
distant
metastasis
contrast
tumor
surgical
site
well
lung
liver
metastasis
present
control
group
efficacy
local
radiation
therapy
prevention
distant
metastasis
formation
minimal
residual
disease
model
great
importance
warrant
far
study
tumor
type
presence
minimal
disease
follow
surgical
resection
malignant
tumor
major
problem
result
local
systemic
recurrence
month
year
follow
surgery
addition
efficient
therapy
will
eliminate
minimal
residual
disease
surgical
site
may
prove
great
importance
cancer
therapy
previous
study
demonstrate
localization
lack
systemic
distribution
radioactivity
implantation
ct
despite
increase
rate
hydrogel
degradation
due
incorporation
radioactive
isotope
imaging
present
study
enable
calculation
kinetic
vivo
release
radioisotope
hydrogel
release
detect
measure
amount
radioactivity
decrease
time
implantation
site
latter
result
two
parallel
process
radioisotope
decay
biological
elimination
isotope
elimination
result
one
much
follow
process
release
hydrogel
due
degradation
hydrogel
release
hydrogel
dissociation
follow
diffusion
hydrogel
last
possibility
little
likely
occur
due
chemical
stability
physiological
condition
plain
diffusion
rule
due
entrap
hydrogel
already
show
previous
study
thus
biological
elimination
radioactivity
site
implantation
result
degradation
hydrogel
lead
release
first
order
kinetic
characterize
day
imaging
calculate
elimination
rate
compound
entrap
biomaterial
much
convenient
accurate
gravimetric
method
require
animal
sacrifice
implant
retrieval
moreover
imaging
method
unlike
gravimetric
method
reflect
structural
change
biomaterial
may
release
mass
loss
biomaterial
previous
study
show
hydrogel
degradation
accompany
change
nature
staining
indicate
redox
mechanism
elucidate
point
oxidized
gel
vitro
follow
staining
degradation
product
color
change
observe
verify
hypothesis
find
may
indicate
addition
biodegradation
gel
also
attributed
oxidation
process
reactive
oxygen
species
generate
local
irradiation
radioisotope
entrap
gel
matrix
conclude
application
ct
biodegradable
hydrogel
implant
treatment
mammary
mouse
tumor
model
show
delay
tumor
progression
primary
therapy
model
much
importantly
prevent
tumor
recurrence
metastatic
spread
minimal
residual
disease
model
biodegradable
implant
compose
crosslinked
ct
load
radioisotope
may
alternative
brachytherapy
procedure
acknowledgement
result
report
include
project
partial
fulfillment
phd
degree
requirement
hebrew
university
jerusalem
study
present
part
gordon
conference
drug
carriers
medicine
biology
usa
study
support
research
grant
science
foundation
research
grant
united
state
israel
science
foundation
robert
fund
endowment
affiliate
david
bloom
center
pharmacy
viral
vector
one
major
vehicle
gene
therapy
get
sequence
express
proper
host
cell
adenovirus
adv
linear
dna
virus
widely
clinical
application
advantage
produce
high
high
transduction
efficiency
proliferate
quiescent
cell
adv
infection
cell
mediate
binding
fiber
protein
cell
membrane
protein
know
adenovirus
receptor
car
primary
receptor
member
immunoglobulin
receptor
superfamily
recently
role
integrin
secondary
receptor
heparin
sulfate
third
receptor
receptor
adenovirus
binding
report
car
receptor
still
major
route
adenoviral
infection
although
adv
many
advantage
yet
clinical
application
follow
restriction
one
major
limitation
associate
gene
therapy
via
viral
vector
require
repeat
treatment
due
development
humoral
immune
response
vector
host
adv
general
lack
replication
ability
require
repetitive
administration
consequently
provoke
serious
innate
adaptive
immune
response
liver
toxicity
another
confront
adv
mediate
gene
therapy
distribution
tissue
vivo
gene
transfer
relatively
broad
tissue
expression
car
issue
impose
increase
risk
toxicity
due
vector
dissemination
cell
increase
unwanted
side
effect
immunogenic
toxicity
moreover
administer
locally
repeatedly
maintain
sustainable
effect
today
well
know
immune
response
dose
dependent
rise
neutralize
antibody
primary
administration
avoiding
neutralization
adv
antibody
much
efficient
strategy
mask
surface
adv
attachment
poly
ethylene
glycol
peg
peg
modification
technique
diminish
protein
protein
interaction
therapeutic
protein
cell
vivo
moreover
pegylation
provide
prolong
circulation
time
bloodstream
shield
adv
immune
response
employ
spacer
link
targeting
moiety
however
pegylated
adv
peg
adv
still
rely
transduction
site
via
viral
infection
mechanism
hence
pegylation
result
limited
binding
internalization
adv
consequently
inefficient
gene
delivery
objective
cell
moreover
peg
adv
show
significantly
expression
level
adv
resolve
problem
surface
peg
adv
modify
targeting
moiety
peptide
protein
folate
ligand
grant
retargeting
well
know
human
epidermal
growth
factor
receptor
neu
invasive
breast
cancer
expression
similar
primary
tumor
corresponding
metastasis
contrary
expression
normal
tissue
level
thus
neu
monoclonal
antibody
mab
interest
potential
targeting
moiety
viral
vector
breast
cancer
cell
herceptin
trastuzumab
recombinant
neu
mab
specifically
bind
membrane
region
neu
high
affinity
inhibit
signal
transduction
cell
proliferation
moreover
approve
therapeutic
agent
breast
cancer
fda
show
significant
activity
single
agent
combination
traditional
cytotoxic
chemotherapy
treatment
neu
metastatic
breast
cancer
patient
report
aim
demonstrate
effectiveness
formulation
adv
spacer
peg
peg
adv
conjugate
one
terminal
group
peg
molecule
conjugate
surface
adv
contain
gfp
gene
enhancement
specificity
efficacy
comparatively
evaluate
extent
gfp
transduction
neu
positive
cell
cell
neu
deficient
cell
retargeting
strategy
intracellular
delivery
system
depict
morphology
size
conjugation
efficiency
prepare
peg
adv
characterize
transmission
electron
microscopy
tem
dynamic
light
dls
zeta
potential
fast
performance
liquid
chromatography
fplc
respectively
moreover
targeting
characteristic
prepare
peg
adv
confirm
flow
cytometry
extent
immune
response
elicit
surface
modify
adv
also
analyzed
determine
amount
release
macrophage
cell
image
schematic
representation
peg
adv
conjugate
retargeting
adenoviral
vector
neu
cell
peg
adv
transduce
cell
via
incorporate
heparin
pathway
view
within
article
material
material
adv
carry
gfp
gene
herceptin
kda
obtain
cancer
center
poly
ethylene
glycol
derivative
peg
cooh
mw
purchase
dithiobis
dtssp
purchase
pierce
rockford
edc
nhs
purchase
sigma
louis
cell
culture
medium
material
product
grand
island
cell
purchase
atcc
manassas
va
chemical
analytical
grade
generation
adenovirus
express
gfp
adv
type
express
gfp
control
cytomegalovirus
cmv
promoter
region
adenovirus
adv
express
gfp
propagate
cell
purify
density
purification
purified
preparation
mm
saline
pbs
sucrose
finally
store
number
viral
particle
calculate
measurement
optical
density
nm
unit
equivalent
viral
particle
per
milliliter
preparation
peg
adv
particle
ml
adv
contain
gfp
gene
store
saline
pbs
sucrose
adv
dithiobis
dtssp
molar
ratio
sodium
phosphate
buffer
ph
contain
nacl
respectively
reaction
carry
min
room
temperature
poly
ethylene
glycol
derivative
peg
cooh
mw
add
solution
molar
ratio
reaction
room
temperature
reaction
peg
adv
terminate
addition
excess
free
product
purify
centricon
membrane
tube
amicon
mw
cutoff
remove
free
peg
residue
purify
peg
adv
store
synthetic
scheme
peg
adv
conjugate
show
peg
modification
ratio
determine
fluorescamine
assay
calculate
percent
immobilization
peg
surface
adv
amount
surface
amine
group
peg
immobilization
determine
image
synthetic
scheme
peg
adv
conjugate
view
within
article
synthesis
peg
adv
conjugate
prepare
peg
adv
reactivate
edc
nhs
molar
ratio
sodium
phosphate
buffer
ph
contain
nacl
activate
min
room
temperature
reactant
centricon
membrane
tube
amicon
mw
cutoff
remove
free
edc
nhs
residue
add
solution
molar
ratio
reaction
carry
excess
free
add
terminate
reaction
finally
intact
particle
purify
size
exclusion
chromatography
amersham
sweden
purify
peg
adv
store
synthetic
scheme
peg
adv
conjugate
show
quantity
conjugation
determine
protein
assay
bradford
method
preparation
peg
adv
conjugate
peg
adv
existence
conjugate
peg
adv
colloidal
gold
particle
labeled
peg
adv
conjugate
colloidal
gold
particle
nm
synthesize
report
prepare
gold
particle
conjugate
igg
south
san
francisco
complex
bind
peg
adv
briefly
prepare
gold
particle
adjust
ph
dilute
incubate
colloidal
gold
particle
solution
room
temperature
bsa
solution
add
stabilize
colloidal
gold
particle
mixture
incubate
additional
min
remove
centrifugation
repeat
suspend
sodium
phosphate
buffer
ph
contain
nacl
bsa
conjugate
incubate
peg
adv
characterization
peg
adv
conjugate
identification
peg
adv
conjugate
confirm
fplc
mono
cation
exchange
column
system
laboratory
consist
fraction
mm
tube
uv
detector
monitor
inject
column
start
buffer
buffer
distil
water
peg
adv
load
onto
column
eluted
loading
buffer
buffer
mm
tris
buffer
ph
elution
achieve
ml
linear
gradient
flow
rate
ml
min
finally
column
wash
nacl
run
perform
room
temperature
measurement
average
size
surface
charge
size
surface
charge
adv
peg
adv
peg
adv
measure
dls
analyzer
japan
argon
ion
laser
operate
nm
light
source
size
adv
peg
adv
peg
adv
express
mean
diameter
transmission
electron
microscopy
tem
image
characterization
morphology
surface
morphology
adv
peg
adv
peg
adv
peg
adv
observe
tem
operate
kv
transmission
electron
microscopy
nikon
japan
measurement
cell
transduction
neu
positive
breast
cancer
cell
neu
deficient
brain
cancer
cell
cultured
dulbecco
modified
eagle
medium
dmem
supplement
fetal
bovine
serum
fbs
penicillin
streptomycin
iu
ml
respectively
cell
maintain
humidify
incubator
cell
well
cell
well
cell
well
cell
seed
well
plate
cell
infect
adv
peg
adv
peg
adv
day
cell
observe
fluorescence
microscopy
olympus
olympus
optical
tokyo
japan
metamorph
imaging
system
molecular
devices
usa
flow
cytometry
perform
quantitative
measurement
gfp
expression
level
adv
peg
adv
peg
adv
infect
cell
cell
seed
plate
infection
cell
density
cell
well
respectively
infection
cell
raise
cell
dissociation
solution
sigma
louis
usa
wash
pbs
three
time
pbs
wash
pbs
add
perform
flow
cytometry
analysis
facscan
sunnyvale
usa
cellquest
software
evaluation
immune
response
murine
raw
macrophage
cell
seed
plate
adv
peg
adv
peg
adv
infection
cell
density
well
contain
dmem
supplement
fbs
iu
ml
penicillin
sodium
ml
streptomycin
sulfate
culture
medium
replace
ml
fresh
medium
contain
vps
adv
peg
adv
peg
adv
level
release
culture
medium
determine
elisa
rd
mn
result
discussion
show
prepare
peg
adv
conjugate
peg
conjugate
adv
via
group
adv
surface
primary
amine
group
peg
peg
modification
ratio
fluorescamine
assay
show
much
purify
peg
adv
edc
nhs
couple
agent
protein
assay
prove
much
molecule
conjugate
peg
adv
complex
resultant
peg
adv
conjugate
confirm
fplc
output
separate
difference
linear
gradient
separation
perform
mono
cation
exchange
column
first
individual
characteristic
peak
adv
min
min
identify
respectively
characteristic
peak
peg
adv
observe
min
similar
one
adv
slight
surface
charge
difference
adv
peg
adv
fplc
datum
resultant
peg
adv
show
uncharged
impurity
include
small
molecule
eluted
first
follow
adv
peg
adv
peg
adv
image
ion
exchange
chromatograms
peg
adv
peak
indicate
uncharged
impurity
include
small
molecule
adv
peg
adv
peg
adv
view
within
article
morphology
adv
peg
adv
peg
adv
peg
adv
observe
tem
tem
image
identify
size
pegylated
adv
slightly
increase
comparison
adv
due
presence
peg
size
difference
due
existence
observe
moreover
clearly
identify
gold
particle
labeled
imply
peg
adv
complex
average
size
size
distribution
adv
peg
adv
peg
adv
also
determine
dls
show
average
size
adv
peg
adv
peg
adv
nm
respectively
result
also
confirm
tem
image
size
pegylated
adv
increase
due
volume
peg
chain
surface
adv
surface
charge
value
adv
peg
adv
peg
adv
mv
respectively
surface
charge
peg
mv
reference
hence
high
positive
surface
charge
peg
adv
due
presence
peg
chain
expect
conjugation
peg
produce
value
mv
surface
charge
peg
adv
compare
mv
naked
adv
result
also
confirm
peg
surface
adv
image
transmission
electron
microscopy
tem
image
adv
peg
adv
peg
adv
peg
adv
view
within
article
image
size
distribution
zeta
potential
adv
peg
adv
peg
adv
view
within
article
investigate
transduction
efficiency
adv
peg
adv
peg
adv
prepare
conjugation
molar
ratio
concentration
vps
cell
vps
cell
vps
cell
infect
cell
line
respectively
comparative
gfp
expression
level
measure
fluorescence
intensity
analysis
gfp
intensity
datum
clearly
demonstrate
transduction
efficiency
peg
adv
depended
neu
expression
level
infect
cell
gfp
intensity
cell
exhibit
high
value
follow
one
cell
however
increase
gfp
intensity
observe
cell
imply
affinity
peg
adv
neu
positive
breast
cancer
cell
predominant
image
fluorescence
microscope
image
cell
follow
incubation
adv
peg
adv
peg
adv
view
within
article
quantify
gfp
intensity
virus
transduction
perform
flow
cytometry
analysis
brain
cancer
cell
intensity
peak
peg
adv
hardly
shift
right
due
negative
character
upon
neu
comparison
gfp
intensity
peak
peg
adv
neu
positive
cell
line
shift
much
right
moreover
gfp
intensity
peg
adv
observe
significantly
enhance
compare
peg
adv
gfp
expression
percent
level
peg
adv
reduce
naked
adv
cell
line
respectively
contrast
peg
adv
exhibit
naked
adv
cell
line
respectively
moreover
increase
gfp
expression
level
cell
line
observe
peg
adv
peg
adv
result
also
clearly
reveal
peg
adv
successfully
neu
express
cell
noteworthy
result
indicate
transduction
efficiency
peg
adv
neu
positive
cancer
cell
significantly
enhance
via
neu
specific
targeting
route
image
transduction
efficiency
flow
cytometry
analysis
adv
peg
adv
peg
adv
view
within
article
evaluate
pegylation
might
attenuate
production
macrophage
cell
proinflammatory
cytokine
infect
raw
macrophage
cell
viral
particle
vps
adv
peg
adv
peg
adv
vitro
respectively
macrophage
cell
possible
source
cytokine
produce
injection
adv
vector
release
cell
important
cytokine
relate
extent
immune
response
raw
cell
infect
two
vps
dose
release
culture
supernatant
release
concentration
measure
case
vps
treatment
adv
peg
adv
peg
adv
infect
raw
cell
release
concentration
pg
pg
pg
respectively
also
case
vps
treatment
concentration
detect
pg
pg
pg
respectively
noteworthy
result
show
concentration
peg
adv
peg
adv
decrease
compare
adv
moreover
result
exhibit
dependency
concentration
viral
particle
dose
virus
infect
raw
cell
however
although
expression
treat
peg
adv
decrease
compare
adv
much
increase
peg
adv
examine
result
seem
herceptin
immunogenic
characteristic
antibody
size
composition
component
image
proinflammatory
cytokine
expression
release
macrophage
cell
infection
adv
peg
adv
peg
adv
view
within
article
nevertheless
reduce
amount
release
macrophage
cell
suggest
pegylation
adv
minimize
adverse
immune
response
problem
often
associate
adv
gene
therapy
previous
work
demonstrate
pegylation
adv
effectively
mask
viral
surface
shield
adv
vector
immune
system
conclusion
datum
suggest
antibody
conjugate
pegylation
adv
reduce
innate
immune
response
resolve
problem
adv
far
plan
examine
efficacy
immunogenic
system
vivo
mouse
model
consequently
result
transduction
efficiency
clearly
demonstrate
affinity
peg
adv
conjugate
target
cell
significantly
enhance
ensure
minimize
unwanted
side
effect
immunogenic
toxicity
alone
increase
sustainable
effect
peg
envelop
conclusion
synthesize
peg
adv
conjugate
retargeting
gene
therapy
breast
cancer
cell
conjugate
vector
find
feasible
overcome
limitation
factor
associate
immune
response
targeting
adenoviral
gene
delivery
peg
adv
capable
enhance
transduction
efficiency
onto
breast
cancer
cell
via
neu
targeting
moiety
also
envelop
peg
surface
adv
reduce
extent
immune
response
study
may
render
target
specific
gene
delivery
adenoviral
vector
many
clinical
application
study
synergistic
efficacy
therapeutic
antibody
gene
therapy
via
peg
adv
breast
cancer
treatment
vivo
level
prospect
acknowledgment
work
support
national
core
research
center
technology
republic
recent
study
treatment
breast
cancer
demonstrate
local
control
may
affect
survival
wide
free
margin
warrant
part
breast
large
glandular
resection
affect
final
result
compromise
basic
purpose
conservative
surgery
techniques
commonly
employ
aesthetic
surgery
introduce
oncological
treatment
perform
mirror
quadrantectomy
produce
good
final
result
might
improve
oncological
start
oncoplastic
surgery
technique
currently
offer
patient
oncological
result
describe
study
patient
method
retrospective
study
woman
affect
breast
cancer
suitable
breast
conservation
size
position
tumour
treat
conventional
technique
compromise
final
result
cancer
two
bilateral
remove
november
december
case
perform
bilateral
breast
reduction
inferior
superior
combine
pedicle
patient
involve
study
submit
specific
consent
process
counsel
regard
advantage
limitation
oncoplastic
operation
surgical
methodology
planning
evaluate
breast
shape
size
degree
ptosis
position
lesion
tumour
locate
inferior
pole
breast
treat
superior
pedicle
technique
cancer
upper
pole
quadrant
breast
excise
inferior
pedicle
reduction
small
medium
size
breast
tumour
location
require
periareolar
approach
table
population
mean
tumour
size
receptor
status
infiltrating
ductal
infiltrating
lobular
grading
nodal
status
table
view
within
article
operation
perform
single
oncoplastic
surgeon
without
assistance
specialist
plastic
surgeon
resection
accurately
plan
final
shape
assess
photographic
examination
figure
figure
figure
figure
image
figure
mirror
quadrantectomy
inferior
pedicle
breast
reduction
view
within
article
image
figure
mirror
quadrantectomy
inferior
pedicle
breast
reduction
result
view
within
article
image
figure
mirror
quadrantectomy
superior
pedicle
breast
reduction
view
within
article
image
figure
mirror
quadrantectomy
superior
pedicle
breast
reduction
result
view
within
article
specimen
remove
perform
pathologist
assure
least
cm
macroscopic
complete
cavity
margin
eventually
second
specimen
new
orientation
send
permanent
section
margin
consider
free
microscopic
evidence
either
situ
invasive
cancer
within
mm
resection
infiltrate
excise
new
margin
free
indicate
metallic
clip
leave
improve
identification
tumour
bed
following
surgical
treatment
chemotherapy
require
patient
undergo
radiation
gy
deliver
whole
breast
plus
boost
gy
tumour
bed
radiotherapy
employ
series
oncological
perform
annual
clinical
examination
bilateral
mammography
blood
test
clinical
suspicion
occur
bone
scan
liver
scan
chest
ct
scan
employ
detect
distant
disease
result
population
woman
two
bilateral
cancer
undergo
mirror
quadrantectomy
follow
month
range
median
age
year
woman
six
patient
positive
family
history
breast
cancer
least
one
first
degree
relative
affect
case
subdivide
accord
ptnm
classification
single
case
detect
final
pathological
examination
majority
patient
free
disease
axilla
table
surgical
technique
inferior
superior
table
view
within
article
estrogen
progesterone
receptor
status
investigate
case
double
positive
double
negative
pgr
one
case
estrogen
receptor
express
receptor
grade
report
woman
sample
oncological
surgical
outcome
obtain
complete
excision
mm
free
margin
patient
mm
margin
sample
three
case
margin
mm
negative
two
patient
dcis
focus
margin
also
case
new
margin
negative
patient
second
general
margin
occult
cancer
identify
healthy
breast
specimen
single
case
local
recurrence
month
surgical
treatment
woman
receive
far
treatment
second
excision
currently
alive
free
disease
five
patient
deceased
metastatic
breast
cancer
one
currently
alive
bone
metastasis
investigate
characteristic
patient
distant
recurrence
find
median
age
median
survival
diagnosis
month
two
patient
bilateral
synchronous
disease
four
patient
five
three
estrogen
receptor
negative
two
pn
positive
concern
complication
report
five
case
skin
suffer
one
case
partial
nipple
necrosis
treat
local
nipple
removal
never
require
discussion
local
control
affect
survival
original
breast
cancer
metastatic
disease
inception
revise
year
trial
year
demonstrate
small
significant
decrease
death
due
breast
cancer
patient
treat
lumpectomy
radiation
compare
undergo
lumpectomy
alone
subset
also
report
high
local
recurrence
rate
advantage
partially
offset
mortality
similar
report
confirm
veronesi
compare
quadrantectomy
radiation
find
slightly
high
although
significant
mortality
rate
patient
receive
evidence
provide
recent
early
breast
cancer
trialists
cooperative
group
report
quarter
isolate
recurrence
will
death
breast
cancer
happen
otherwise
year
local
control
determinant
survival
percentage
affect
woman
large
free
margin
resection
recommend
founder
breast
conservative
oncoplastic
surgery
allow
wide
excision
improve
local
control
oncoplastic
concept
based
possibility
perform
large
resection
accord
breast
reduction
technique
compare
resection
margin
quadrantectomy
oncoplastic
surgery
confirm
mm
free
margin
obtain
much
frequently
technique
conclusion
keep
report
kaur
also
find
oncoplastic
resection
associate
large
volume
breast
tissue
excise
increase
rate
free
margin
study
report
close
margin
rate
often
report
series
far
completion
surgery
never
require
never
observe
focal
involvement
margin
possibly
due
pathologic
follow
simultaneous
resection
reach
least
cm
free
opinion
secondary
surgery
avoid
prevent
psychological
complication
also
far
excision
oncoplastic
technique
become
challenge
study
report
oncological
result
oncoplastic
surgery
recently
rietjens
series
case
median
month
report
rate
local
recurrence
comparison
make
historical
study
breast
conservation
milan
trial
report
recurrence
rate
tumour
little
specifically
series
author
observe
local
recurrence
lesion
cm
rietjens
also
observe
local
recurrence
oncoplastic
surgery
reach
mastectomy
milan
trial
rate
study
increase
conventional
quadrantectomy
even
year
result
although
interesting
accordance
report
clough
describe
year
local
recurrence
rate
involve
one
case
local
recurrence
lady
receive
inferior
pedicle
breast
reduction
lobular
carcinoma
breast
histopathology
high
likelihood
behaviour
might
determine
disease
lady
treat
far
excision
currently
alive
free
disease
sampling
occult
breast
cancer
mirror
quadrantectomy
allow
sampling
breast
detect
occult
disease
suggest
report
breast
cancer
specimen
breast
reduction
rate
confirm
recent
series
study
occult
breast
cancer
find
probably
sample
however
opposite
breast
exploration
still
opinion
interesting
opportunity
occult
disease
breast
oncoplastic
surgery
limitation
although
oncoplastic
surgery
provide
cosmetic
outcome
likely
prove
effective
oncological
procedure
currently
far
become
gold
standard
conservative
treatment
several
reason
may
explain
difficulty
first
cosmetic
procedure
require
plastic
surgery
expertise
hand
much
surgeon
deal
breast
cancer
plastic
surgeon
hand
culturally
unaware
basic
oncological
skill
oncoplastic
surgery
challenge
also
expensive
often
double
time
conventional
quadrantectomy
generalized
likely
dramatically
increase
wait
list
affect
national
health
service
indication
restrict
lesion
whose
size
location
compromise
acceptable
cosmetic
result
bilateral
reduction
small
cancer
large
breast
consider
unless
increase
oncological
effectiveness
will
definitively
demonstrate
finally
complex
glandular
become
challenge
breast
radiotherapist
breast
radiologist
deal
mammogram
multidisciplinary
oncological
approach
never
experience
difficulty
field
conclusion
breast
oncoplastic
surgery
experience
good
tool
warrant
local
control
breast
localized
disease
require
dedicate
expertise
opinion
practiced
multidisciplinary
integrate
cancer
center
mirror
quadrantectomy
model
although
extremely
effective
likely
become
standard
care
much
efficient
technique
test
conflict
interest
author
declare
financial
personal
relationship
people
organisation
inappropriately
influence
bias
work
acknowledgement
author
acknowledge
miss
cooperation
effective
scientific
writing
north
american
black
cohosh
relate
cimicifuga
species
century
across
many
culture
variety
health
benefit
native
american
black
cohosh
agent
related
asian
cimicifuga
species
china
japan
analgesic
agent
well
treat
infectious
disease
recent
year
black
cohosh
united
state
europe
relieve
symptom
associate
female
medical
condition
particularly
menopause
root
rhizome
plant
contain
major
class
compound
triterpene
glycoside
show
extract
enrich
triterpene
glycoside
specific
triterpene
glycoside
isolate
black
cohosh
possess
anticancer
activity
watanabe
einbond
hostanska
hostanska
precise
mechanism
nature
active
component
yet
know
purpose
study
determine
nature
active
anticancer
component
black
cohosh
relate
cimicifuga
species
effect
triterpene
glycoside
actein
morphology
human
breast
cancer
cell
image
structure
actein
view
within
article
material
method
chemical
reagent
solvent
reagent
reagent
grade
water
distil
deionized
black
cohosh
fraction
purify
component
dissolve
dimethylsulfoxide
dmso
sigma
louis
prior
addition
cell
culture
triterpene
glycoside
dissolve
dmso
ml
ml
db
dilute
ethanol
add
aqueous
medium
final
concentration
ethanol
plant
material
cimigenol
triterpene
glycoside
relate
cimicifuga
species
kind
gift
ye
guangzhou
china
documentation
material
study
describe
ye
zhang
zhang
naturex
south
hackensack
nj
generously
provide
black
cohosh
extract
contain
triterpene
glycoside
black
cohosh
raw
material
collect
united
state
natural
dry
naturally
air
identify
scott
new
york
botanical
lot
raw
material
compare
authentic
sample
hplc
sample
deposit
naturex
table
composition
triterpene
glycoside
enrich
extract
black
cohosh
triterpene
glycoside
acetyl
shengmanol
acetyl
shengmanol
cimigenol
isoferulic
table
view
within
article
extraction
isolation
procedure
black
cohosh
root
rhizome
lot
number
south
hackensack
nj
extract
etoh
water
ethanol
remove
reduce
pressure
concentrate
extract
partition
methylene
chloride
water
provide
fraction
triterpene
glycoside
tg
methylene
chloride
tg
water
methylene
chloride
remove
reduce
pressure
concentrate
fraction
far
partition
water
tg
fraction
obtain
phase
table
effect
purify
triterpene
glycoside
cimicifuga
species
cell
proliferation
overexpressing
human
breast
cancer
cell
cimigenol
table
cell
treat
increase
concentration
cimicifuga
component
number
viable
cell
determine
coulter
counter
similar
result
obtain
additional
study
view
within
article
cell
culture
negative
overexpressing
positive
cell
obtain
atcc
manassas
va
cell
grow
dulbecco
modify
eagle
medium
dmem
gibco
brl
life
technology
rockville
md
contain
fetal
bovine
serum
fbs
gibco
brl
cell
transfected
full
length
cdna
coding
region
fold
increase
}
kind
gift
dennis
slamon
angeles
cell
maintain
rpmi
supplement
fbs
plus
glutamine
gibco
rockville
md
proliferation
assay
coulter
counter
assay
determine
growth
inhibitory
activity
human
breast
cancer
cell
expose
increase
concentration
black
cohosh
extract
contain
triterpene
glycoside
purify
triterpene
glycoside
cimicifuga
species
number
viable
cell
determine
coulter
counter
assay
cell
seed
cell
per
well
well
plate
cm
diameter
later
medium
replace
fresh
medium
without
indicate
test
material
triplicate
number
attach
viable
cell
count
later
model
coulter
counter
coulter
electronic
fl
value
calculate
previously
describe
cell
viability
calculate
compare
cell
count
treat
sample
relative
cell
count
dmso
dmso
ethanol
control
convert
percentage
mtt
assay
mtt
assay
determine
sensitivity
actein
cell
seed
cell
well
well
plate
allow
attach
medium
replace
fresh
medium
contain
dmso
compound
cell
treat
incubate
mtt
reagent
absorbance
read
nm
colony
formation
assay
effect
actein
ability
cell
form
colony
determine
colony
formation
assay
cell
seed
cell
per
well
well
plate
later
medium
replace
fresh
medium
contain
dmso
compound
triplicate
cell
treat
actein
medium
replace
fresh
medium
contain
actein
incubate
day
incubation
medium
remove
cell
wash
twice
pbs
cell
fix
ml
ethanol
min
ethanol
remove
sample
allow
dry
room
temperature
colony
stain
min
ml
giemsa
solution
rinse
tap
water
allow
dry
room
temperature
cell
growth
assay
datum
express
deviation
control
treat
cell
compare
student
indirect
immunofluorescence
microscopy
cell
effect
actein
cell
structure
examine
compare
fluorescent
microscopy
cell
nucleus
actin
filament
stain
accord
method
cell
allow
attach
coverslip
well
plate
mm
diameter
treat
dmso
control
actein
ml
wash
dmem
fix
pbs
contain
formaldehyde
triton
min
room
temperature
cell
next
wash
pbs
second
wash
pbs
replace
ml
well
pbs
contain
unit
ml
texas
phalloidin
stain
actin
filament
ml
dapi
stain
nucleus
cell
incubate
min
room
temperature
protect
light
sample
visualize
nikon
microscope
image
obtain
cool
ccd
device
camera
chip
scientific
instruments
junction
nj
metamorph
software
universal
imaging
pa
result
growth
inhibitory
activity
extract
black
cohosh
previous
experiment
indicate
fraction
purify
component
black
cohosh
inhibit
growth
human
breast
cancer
cell
cell
test
overexpressing
human
breast
cancer
cell
much
sensitive
growth
inhibitory
effect
ethyl
acetate
fraction
purify
triterpene
glycoside
actein
black
cohosh
cell
overexpress
fgf
receptor
mutant
negative
result
previous
experiment
test
growth
inhibitory
activity
extract
black
cohosh
root
rhizome
contain
different
percent
triterpene
glycoside
human
breast
cancer
cell
order
explore
nature
active
component
cell
expose
increase
concentration
agent
number
viable
cell
determine
coulter
counter
assay
show
extract
concentration
triterpene
glycoside
result
inhibition
cell
growth
value
concentration
inhibition
cell
proliferation
extract
triterpene
glycoside
ml
extract
triterpene
glycoside
value
ml
value
ml
obtain
purify
triterpene
glycoside
actein
percent
polyphenol
isoferulic
acid
respective
three
fraction
image
effect
extract
enrich
triterpene
glycoside
actein
cell
proliferation
overexpressing
human
breast
cancer
cell
cell
treat
increase
concentration
extract
contain
triterpene
glycoside
actein
number
viable
cell
determine
coulter
counter
similar
result
obtain
additional
study
view
within
article
growth
inhibitory
activity
compound
cimicifuga
species
previous
experiment
indicate
black
cohosh
triterpene
glycoside
test
actein
much
potent
characterize
nature
active
component
test
effect
series
triterpene
glycoside
relate
cimicifuga
species
cell
proliferation
much
strongly
act
component
acetyl
group
position
ml
compare
ml
parent
compound
lack
acetyl
residue
compound
epi
derivative
compound
exhibit
efficacy
similar
ml
actein
equal
ml
exhibit
activity
comparable
cimigenol
value
ml
compound
acetyl
derivative
possess
next
high
activity
value
ml
compound
cimigenol
hydroxyl
derivative
compound
exhibit
little
growth
inhibitory
activity
value
ml
ml
respectively
compound
cimigenol
possess
several
residue
also
little
active
value
ml
colony
formation
assay
ascertain
anticancer
potential
actein
test
effect
actein
ability
cell
form
colony
colony
small
average
actein
treat
cell
value
ml
ml
respectively
image
effect
actein
ability
cell
form
colony
cell
treat
increase
concentration
actein
number
colony
determine
colony
formation
assay
view
within
article
effect
actein
human
breast
cancer
cell
determine
whether
sensitivity
correlate
expression
compare
effect
actein
genetically
match
pair
human
breast
cancer
cell
transfected
full
length
cdna
coding
region
find
transfected
cell
value
ml
much
sensitive
parental
cell
value
ml
image
effect
actein
cell
proliferation
human
breast
cancer
cell
cell
treat
increase
concentration
actein
number
viable
cell
determine
mtt
assay
similar
result
obtain
additional
study
view
within
article
fluorescent
microscopy
effect
actein
human
breast
cancer
cell
observe
two
effect
actein
cell
structure
fluorescent
microscopy
fewer
cell
mitosis
cell
treat
actein
ml
distribution
actin
filament
alter
treatment
actein
cell
untreated
cell
actin
primarily
beneath
cell
membrane
whereas
actein
treat
cell
actin
disperse
cytoplasm
also
present
around
nucleus
furthermore
nucleus
characteristic
apoptotic
cell
image
fluorescence
microscopy
cell
treat
actein
cell
treat
actein
ml
fix
methanol
stain
dna
actin
observe
indirect
fluorescence
microscopy
describe
material
method
cell
dapi
stain
actin
stain
leave
dmso
right
ml
actein
cell
dapi
stain
actin
stain
leave
dmso
right
ml
actein
magnification
view
within
article
discussion
study
examine
growth
inhibitory
activity
extract
purify
component
cimicifuga
species
human
breast
cancer
cell
result
support
hypothesis
growth
inhibitory
effect
black
cohosh
human
breast
cancer
cell
primarily
due
triterpene
glycoside
fraction
additional
unpublished
study
test
activity
individual
component
black
cohosh
caffeic
acid
polyphenol
fraction
value
polyphenol
acid
acid
isoferulic
acid
great
cell
although
polyphenol
much
active
cell
cell
display
weak
activity
cell
line
present
previous
result
indicate
percent
inhibition
cell
proliferation
relate
triterpene
glycoside
content
back
cohosh
isoferulic
content
however
exclude
role
polyphenolic
fraction
component
result
contradict
finding
caffeic
acid
ester
cae
fraction
much
active
triterpene
glycoside
fraction
human
breast
cancer
cell
difference
result
due
different
experimental
procedure
incubation
medium
fact
polyphenol
triterpene
glycoside
differ
molecular
weight
thus
perform
assay
medium
able
find
increase
activity
cae
fraction
crystal
violet
early
apoptosis
assay
acetyl
group
position
appear
important
growth
inhibitory
activity
triterpene
glycoside
compound
consistent
finding
acetyl
derivative
acid
acid
}
acetate
derivative
also
much
active
parent
compound
since
colony
colony
formation
assay
small
average
cell
actein
appear
decrease
rate
cell
proliferation
actein
appear
cytostatic
well
cytotoxic
activity
may
play
role
action
actein
since
cell
transfected
appear
much
sensitive
growth
inhibitory
effect
actein
parental
cell
consistent
finding
cell
much
sensitive
cell
test
possible
great
sensitivity
transfected
cell
may
reflect
part
difference
growth
rate
transfected
parental
cell
find
treatment
cell
actein
alter
cell
structure
since
actin
filament
aggregate
around
cell
nucleus
nucleus
appear
effect
consistent
actein
induce
apoptosis
aggregation
actin
around
nucleus
occur
response
cell
stress
result
corroborate
result
previous
study
indicate
growth
inhibitory
effect
actein
extract
black
cohosh
associate
activation
specific
stress
response
pathway
apoptosis
einbond
einbond
taken
together
result
indicate
triterpene
glycoside
actein
relate
compound
may
useful
prevention
treatment
human
breast
cancer
acknowledgment
thank
park
park
chen
excellent
technical
assistance
guidance
dennis
slamon
gift
cell
